PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Arden, SR; Sinor, JD; Potthoff, WK; Aizenman, E				Arden, SR; Sinor, JD; Potthoff, WK; Aizenman, E			Subunit-specific interactions of cyanide with the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONS IN-VITRO; REDOX MODULATORY SITE; INTRACELLULAR CALCIUM CONCENTRATIONS; CORTICAL-NEURONS; NMDA RECEPTOR; PYRROLOQUINOLINE QUINONE; OXIDIZED GLUTATHIONE; HIPPOCAMPAL CULTURES; MEDIATED RESPONSES; ZINC INHIBITION	Cyanide can potentiate N-methyl-D-aspartate receptor-mediated physiological responses in neurons. Here we show that this phenomenon may be attributable to a subunit-specific chemical modification of the receptor directly by the toxin. N-Methyl-D-aspartate (30 mu M)-induced whole cell responses in mature (22-29 days in vitro) rat cortical neurons were potentiated nearly a-fold by a 3-5-min treatment with 2 mM potassium cyanide, as did a similar treatment with 4 mM dithiothreitol. A 1-min incubation with the thiol oxidant 5,5'-dithio-bis(a-nitrobenzoic acid) (0.5 mM) readily reversed the potentiation induced by either cyanide or dithiothreitol. Cyanide did not increase further currents previously potentiated by dithiothreitol nor was it able to potentiate responses during brief co-application with the agonist. Transient expression studies in Chinese hamster ovary cells with wild-type and mutated recombinant N-methyl-D-aspartate subunits (NR) demonstrated that cyanide selectively potentiated NR1/NR2A receptors, presumably via the chemical reduction of NR2A. In contrast, currents mediated by NR1/NR2B receptors were somewhat diminished by the metabolic inhibitor. Some of the effects of cyanide on NR1/NR2B receptors may be mediated by the formation of a thiocyanate adduct with a cysteine residue located in NR1. Cyanide thus is able to distinguish chemically between two different N-methyl-D-aspartate receptor subtypes and produce diametrically opposing functional effects.	Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Aizenman, E (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, E1456-BST,3500 Terrace St, Pittsburgh, PA 15261 USA.		Aizenman, Elias/K-2726-2012	Aizenman, Elias/0000-0001-9610-4194	NINDS NIH HHS [NS29365] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029365] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIZENMAN E, 1995, NEUROSCI LETT, V189, P57, DOI 10.1016/0304-3940(95)11442-Y; AIZENMAN E, 1992, J NEUROSCI, V12, P2362; AIZENMAN E, 1990, NEURON, V5, P841, DOI 10.1016/0896-6273(90)90343-E; AIZENMAN E, 1994, NEUROSCI LETT, V168, P189, DOI 10.1016/0304-3940(94)90447-2; AIZENMAN E, 1989, NEURON, V2, P1257, DOI 10.1016/0896-6273(89)90310-3; AIZENMAN E, 1992, BRAIN RES, V585, P28, DOI 10.1016/0006-8993(92)91187-J; BOECKMAN FA, 1994, NEUROSCI LETT, V173, P189, DOI 10.1016/0304-3940(94)90180-5; Boeckman FA, 1996, J PHARMACOL EXP THER, V279, P515; Brimecombe JC, 1997, P NATL ACAD SCI USA, V94, P11019, DOI 10.1073/pnas.94.20.11019; CAI ZW, 1992, NEUROCHEM RES, V17, P803, DOI 10.1007/BF00969016; CATSIMPOOLAS N, 1964, J BIOL CHEM, V239, P4132; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chen NS, 1997, MOL PHARMACOL, V51, P1015, DOI 10.1124/mol.51.6.1015; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CORNELL NW, 1972, ANAL BIOCHEM, V47, P203, DOI 10.1016/0003-2697(72)90293-X; DUBINSKY JM, 1991, J NEUROSCI, V11, P2545; EMERSON D, 1993, J BACTERIOL, V175, P7819, DOI 10.1128/JB.175.24.7819-7827.1993; Ferreira IL, 1997, BRAIN RES, V768, P157, DOI 10.1016/S0006-8993(97)00634-3; GILBERT KR, 1991, NEUROSCI LETT, V133, P11, DOI 10.1016/0304-3940(91)90045-U; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOZLAN H, 1994, J NEUROPHYSIOL, V72, P3017, DOI 10.1152/jn.1994.72.6.3017; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; KANTHASAMY AG, 1994, TOXICOL APPL PHARM, V126, P156, DOI 10.1006/taap.1994.1102; Kaplin AI, 1996, J NEUROSCI, V16, P2002; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; LEHNINGER A, 1978, BIOCHEMISTRY-US, P477; MICHAELS RL, 1990, J NEUROSCI, V10, P283; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; Paoletti P, 1997, J NEUROSCI, V17, P5711; PATEL MN, 1992, TOXICOL APPL PHARM, V115, P124, DOI 10.1016/0041-008X(92)90375-3; PATEL MN, 1993, NEUROTOXICOLOGY, V14, P35; PATEL MN, 1991, NEUROSCI LETT, V131, P42, DOI 10.1016/0304-3940(91)90332-N; PATEL MN, 1994, NEUROCHEM RES, V19, P1319, DOI 10.1007/BF01006824; PAUWELS PJ, 1989, MOL PHARMACOL, V36, P525; PECCI L, 1980, BIOCHIM BIOPHYS ACTA, V623, P348, DOI 10.1016/0005-2795(80)90262-7; Sinor J. D., 1997, Society for Neuroscience Abstracts, V23, P930; Sinor JD, 1997, BRAIN RES, V747, P297, DOI 10.1016/S0006-8993(96)01237-1; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; SULLIVAN JM, 1994, NEURON, V13, P929, DOI 10.1016/0896-6273(94)90258-5; Sun PW, 1997, J PHARMACOL EXP THER, V280, P1341; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; TANG LH, 1993, J PHYSIOL-LONDON, V465, P303, DOI 10.1113/jphysiol.1993.sp019678; TANG LH, 1993, NEURON, V11, P857, DOI 10.1016/0896-6273(93)90115-8; VANAMAN TC, 1970, J BIOL CHEM, V245, P3565; WAGNER PD, 1975, BIOCHEMISTRY-US, V14, P1900, DOI 10.1021/bi00680a015; Wo ZG, 1996, MOL PHARMACOL, V50, P770; ZEEVALK GD, 1992, J NEUROCHEM, V59, P1211, DOI 10.1111/j.1471-4159.1992.tb08430.x; ZHONG J, 1994, MOL PHARMACOL, V45, P846	51	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21505	21511		10.1074/jbc.273.34.21505	http://dx.doi.org/10.1074/jbc.273.34.21505			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705279	hybrid			2022-12-27	WOS:000075492600013
J	Singh, S; Tang, HK; Lee, JY; Saunders, GF				Singh, S; Tang, HK; Lee, JY; Saunders, GF			Truncation mutations in the transactivation region of PAX6 result in dominant-negative mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX-CONTAINING GENE; DNA-BINDING ACTIVITY; SMALL EYE SEY; PAIRED DOMAIN; ANIRIDIA GENE; EYELESS GENE; PROTEINS; MOUSE; CELLS; TRANSCRIPTION	PAX6 is a transcription factor with two DNA-binding domains (paired box and homeobox) and a proline-serine-threonine (PST)-rich transactivation domain. PAX6 regulates eye development in animals ranging from jellyfish to Drosophila to humans. Heterozygous mutations in the human PAX6 gene result in various phenotypes, including aniridia, Peter's anomaly, autosomal dominant keratitis, and familial foveal dysplasia, It is believed that the mutated allele of PAX6 produces an inactive protein and aniridia is caused due to genetic haploinsufficiency, However, several truncation mutations have been found to occur in the C-terminal half of PAX6 in patients with Aniridia resulting in mutant proteins that retain the DNA-binding domains but have lost most of the transactivation domain, It is not clear whether such mutants really behave as loss-of-function mutants as predicted by haploinsufficiency. Contrary to this theory, our data showed that these mutants are dominant-negative in transient transfection assays when they are coexpressed with wild-type PAX6. We found that the dominant-negative effects result from the enhanced DNA binding ability of these mutants. Kinetic studies of binding and dissociation revealed that various truncation mutants have 3-5-fold higher affinity to various DNA-binding sites when compared with the wild-type PAX6, These results provide a new insight into the role of mutant PAX6 in causing aniridia.	Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Saunders, GF (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Biochem & Mol Biol, Box 117, Houston, TX 77030 USA.	saunders@odin.mdacc.tmc.edu			NCI NIH HHS [CA16672] Funding Source: Medline; NEI NIH HHS [EY09675, EY10608] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY010608, R01EY009675] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; Azuma N, 1996, NAT GENET, V13, P141, DOI 10.1038/ng0696-141; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; DAVIS A, 1993, HUM MOL GENET, V2, P2093, DOI 10.1093/hmg/2.12.2093; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Desplan C, 1997, CELL, V91, P861, DOI 10.1016/S0092-8674(00)80475-4; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Glaser T., 1995, MOL GENETICS OCULAR, P51; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1993, HUM MOL GENET, V2, P915; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JORDAN T, 1992, NAT GENET, V1, P328, DOI 10.1038/ng0892-328; LYONS LA, 1992, GENOMICS, V13, P925, DOI 10.1016/0888-7543(92)90002-A; MARTHA A, 1994, AM J HUM GENET, V54, P801; MARTHA AD, 1994, HUM MUTAT, V3, P297, DOI 10.1002/humu.1380030319; MATSUO T, 1993, NAT GENET, V3, P299, DOI 10.1038/ng0493-299; MINTZHITTNER HA, 1992, AM J OPHTHALMOL, V114, P700, DOI 10.1016/S0002-9394(14)74048-6; NELSON LB, 1984, SURV OPHTHALMOL, V28, P621, DOI 10.1016/0039-6257(84)90184-X; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Saunders GF, 1998, HUM MUTAT, pS207; Schedl A, 1996, CELL, V86, P71, DOI 10.1016/S0092-8674(00)80078-1; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; Tang HK, 1997, HUM MOL GENET, V6, P381, DOI 10.1093/hmg/6.3.381; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TON CCT, 1992, GENOMICS, V13, P251, DOI 10.1016/0888-7543(92)90239-O; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Vogan KJ, 1996, MOL CELL BIOL, V16, P6677; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILKIE AOM, 1994, J MED GENET, V31, P89, DOI 10.1136/jmg.31.2.89; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Xu ZP, 1997, J BIOL CHEM, V272, P3430, DOI 10.1074/jbc.272.6.3430; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0	54	68	74	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21531	21541		10.1074/jbc.273.34.21531	http://dx.doi.org/10.1074/jbc.273.34.21531			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705283	hybrid			2022-12-27	WOS:000075492600017
J	Camper, L; Hellman, U; Lundgren-Akerlund, E				Camper, L; Hellman, U; Lundgren-Akerlund, E			Isolation, cloning, and sequence analysis of the integrin subunit alpha 10, a beta 1-associated collages binding integrin expressed on chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; LEUKOCYTE ADHESION GLYCOPROTEIN; HUMAN ARTICULAR CHONDROCYTES; SMOOTH-MUSCLE CELLS; MOLECULAR-CLONING; CYTOPLASMIC DOMAINS; TISSUE DISTRIBUTION; DEPENDENT ADHESION; LAMININ RECEPTOR; MESSENGER-RNA	We have found that chondrocytes express a novel collagen type II-binding integrin, a new member of the beta 1-integrin family. The integrin alpha subunit, which has a M(r) of 160 kDa reduced, was isolated from bovine chondrocytes by collagen type II affinity purification. The human homologue was obtained by screening a human chondrocyte library with a bovine cDNA probe. Cloning and cDNA sequence analysis of the human integrin alpha subunit designated alpha 10 show that it shares the general structure of other integrin alpha subunits, The predicted amino acid sequence consists of a 1167-amino acid mature protein, including a signal peptide (22 amino acids), a long extracellular domain (1098 amino acids), a transmembrane domain (25 amino acids), and a short cytoplasmic domain (22 amino acids). The extracellular part contains a 7-fold repeated sequence, an I-domain (199 amino acids) and three putative divalent cation-binding sites. The deduced amino acid sequence of alpha 10 is 35% identical to the integrin subunit (alpha 2 and 37% identical to the integrin subunit alpha 1. Northern blot analysis shows a single mRNA of 5.4 kilobases in chondrocytes. A peptide antibody against the predicted sequence of the cytoplasmic domain of alpha 10 immunoprecipitated two proteins with masses of 125 and 160 kDa from chondrocyte lysates under reducing conditions. The peptide antibody specifically stained chondrocytes in tissue sections of human articular cartilage, showing that alpha 10 beta 1 is expressed in cartilage tissue.	Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, S-22100 Lund, Sweden; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Ludwig Institute for Cancer Research	Camper, L (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Cell & Matrix Biol, POB 94, S-22100 Lund, Sweden.	lisbet.camper@medkem.lu.se	Haglund, Lisbet/N-3095-2013	Haglund, Lisbet/0000-0002-1288-2149				ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOTTGER BA, 1989, DIFFERENTIATION, V41, P158, DOI 10.1111/j.1432-0436.1989.tb00743.x; BRIESEWITZ R, 1993, J BIOL CHEM, V268, P2989; CALDERWOOD DA, 1995, BIOCHEM SOC T, V23, P504; Camper L, 1997, J CELL BIOL, V138, P1159, DOI 10.1083/jcb.138.5.1159; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; COLOMBATTI A, 1993, MATRIX, V13, P297, DOI 10.1016/S0934-8832(11)80025-9; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; deMelker AA, 1997, BIOCHEM J, V328, P529, DOI 10.1042/bj3280529; DURR J, 1993, EXP CELL RES, V207, P235, DOI 10.1006/excr.1993.1189; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FORSBERG E, 1994, EXP CELL RES, V213, P183, DOI 10.1006/excr.1994.1189; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; HAUSELMANN HJ, 1992, MATRIX, V12, P116; Hellman U, 1997, SPRING LAB MAN, P97; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOLMVALL K, 1995, EXP CELL RES, V221, P496, DOI 10.1006/excr.1995.1401; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; LANGUINO LR, 1989, BLOOD, V73, P734; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE CH, 1995, CELL GROWTH DIFFER, V6, P347; MILLER EJ, 1972, BIOCHEMISTRY-US, V11, P4903, DOI 10.1021/bi00776a005; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; PONCZ M, 1987, J BIOL CHEM, V262, P8476; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P16580, DOI 10.1074/jbc.271.28.16580; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SALTER DM, 1992, BRIT J RHEUMATOL, V31, P231; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHNAPP LM, 1995, J CELL SCI, V108, P537; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAKADA Y, 1991, J CELL BIOL, V115, P257, DOI 10.1083/jcb.115.1.257; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Towbin H, 1992, Biotechnology, V24, P145; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; TUCKWELL DS, 1994, CELL ADHES COMMUN, V2, P385, DOI 10.3109/15419069409004450; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WOODS VL, 1994, ARTHRITIS RHEUM, V37, P537, DOI 10.1002/art.1780370414; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773	64	189	211	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20383	20389		10.1074/jbc.273.32.20383	http://dx.doi.org/10.1074/jbc.273.32.20383			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685391	hybrid			2022-12-27	WOS:000075305400068
J	Fiskerstrand, T; Riedel, B; Ueland, PM; Seetharam, B; Pezacka, EH; Gulati, S; Bose, S; Banerjee, R; Berge, RK; Refsum, H				Fiskerstrand, T; Riedel, B; Ueland, PM; Seetharam, B; Pezacka, EH; Gulati, S; Bose, S; Banerjee, R; Berge, RK; Refsum, H			Disruption of a regulatory system involving cobalamin distribution and function in a methionine-dependent human glioma cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; TRANSCOBALAMIN-II RECEPTOR; HOMOCYSTEINE REMETHYLATION; HUMAN-PLACENTA; EXPRESSION; METABOLISM; SYNTHASE; DEFICIENT; ENZYME; RAT	Cobalamin metabolism and function were investigated at the levels fi om transcobalamin II (TCII) receptor to the cobalamin-dependent enzymes, methionine synthase and methylnalonyl-CoA mutase, in a methionine-dependent (P60) and a methionine-independent (P60H) glioma cell line. Using P60H as reference, the P60 cells cultured in a methionine medium had slightly lower TCII receptor activity and normal total cobalamin content, a moderately reduced microsomal and mitochondrial cobalamin(LII) reductase activity but only trace amounts of the methylcobalamin and adenosylcobalamin cofactors. When transferred to a homocysteine medium without methionine, P60H cells showed a slightly enhanced TCII receptor activity, but the other cobalamin-related functions were essentially unchanged. In contrast, the methionine-dependent P60 cells responded to homocysteine medium with a nearly g-fold enhancement of TCII receptor expression and a doubling of both the hydroxycobalamin content and the microsomal reductase activity. The mitochondrial reductase and the cobalamin-related processes further down the pathway did not change markedly. In both cell lines, TCII receptor activity was further increased when growth in homocysteine medium was combined with N2O exposure. These data suggest that low methionine and/or high homocysteine exert a positive feedback control on TCII receptor activity. The concurrent increase in hydroxycobalamin content and in microsomal reductase activity are either subjected to similar regulation or secondary to increased cobalamin transport, This regulatory network is most prominent in the methionine-dependent P60 cells harboring a disruption of the network in the proximity of cobalamin(III) reductase.	Univ Bergen, Dept Pharmacol, N-5021 Bergen, Norway; Univ Bergen, Dept Clin Biochem, N-5021 Bergen, Norway; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Vet Affairs Med Ctr, Milwaukee, WI 53226 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Bergen; University of Bergen; Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Lincoln	Fiskerstrand, T (corresponding author), Univ Bergen, Dept Pharmacol, N-5021 Bergen, Norway.		Ueland, Per M/C-7340-2013; Refsum, Helga/A-4073-2010	Ueland, Per Magne/0000-0002-1903-0571	NIDDK NIH HHS [DK 45776, DK-50052] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK045776, R01DK050052] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKSLEN LA, 1988, ANTICANCER RES, V8, P797; AMAGASAKI T, 1990, BLOOD, V76, P1380; BOSE S, 1995, BIOCHEM J, V310, P923, DOI 10.1042/bj3100923; Bose S, 1997, METHOD ENZYMOL, V281, P281; BOSE S, 1995, J BIOL CHEM, V270, P8152, DOI 10.1074/jbc.270.14.8152; CARDINALE GJ, 1969, ARCH BIOCHEM BIOPHYS, V131, P92, DOI 10.1016/0003-9861(69)90108-8; CHRISTENSEN B, 1992, J PHARMACOL EXP THER, V261, P1096; DRUMMOND JT, 1994, BIOCHEMISTRY-US, V33, P3742, DOI 10.1021/bi00178a034; FENTON WA, 1978, ARCH BIOCHEM BIOPHYS, V189, P441, DOI 10.1016/0003-9861(78)90232-1; FISKERSTRAND T, 1994, CANCER RES, V54, P4899; Fiskerstrand T, 1997, INT J CANCER, V72, P301, DOI 10.1002/(SICI)1097-0215(19970717)72:2<301::AID-IJC17>3.3.CO;2-0; Gulati S, 1997, J BIOL CHEM, V272, P19171, DOI 10.1074/jbc.272.31.19171; HALL CA, 1987, J CELL PHYSIOL, V133, P187, DOI 10.1002/jcp.1041330125; HOFFMAN RM, 1985, ANTICANCER RES, V5, P1; Jacobsen D., 1979, Vitamin B12, P663; KENNEDY DG, 1990, BRIT J NUTR, V64, P721, DOI 10.1079/BJN19900074; KOLHOUSE JF, 1991, J BIOL CHEM, V266, P23010; KOLHOUSE JF, 1980, J BIOL CHEM, V255, P2708; LITEPLO RG, 1991, J CELL PHYSIOL, V149, P332, DOI 10.1002/jcp.1041490222; MELLMAN I, 1979, J BIOL CHEM, V254, P1847; MELLMAN I, 1997, P NATL ACAD SCI USA, V74, P916; PEZACKA EH, 1993, BIOCHIM BIOPHYS ACTA, V1157, P167, DOI 10.1016/0304-4165(93)90061-C; RIEDEL B, 1995, CLIN CHEM, V41, P1164; ROSENBLATT DS, 1990, BIOESSAYS, V12, P331, DOI 10.1002/bies.950120705; SELIGMAN PA, 1978, J BIOL CHEM, V253, P1766; VANKAPEL J, 1983, CLIN CHIM ACTA, V131, P211, DOI 10.1016/0009-8981(83)90090-6; Watanabe F, 1996, J NUTR, V126, P2947, DOI 10.1093/jn/126.12.2947; WATANABE F, 1994, BIOSCI BIOTECH BIOCH, V58, P556, DOI 10.1271/bbb.58.556; WATKINS D, 1989, AM J MED GENET, V34, P427, DOI 10.1002/ajmg.1320340320; WEISSBACH H, 1963, J BIOL CHEM, V238, P3318	30	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20180	20184		10.1074/jbc.273.32.20180	http://dx.doi.org/10.1074/jbc.273.32.20180			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685364	hybrid			2022-12-27	WOS:000075305400041
J	Song, J; Murakami, H; Tsutsui, H; Tang, XR; Matsumura, M; Itakura, K; Kanazawa, I; Sun, K; Yokoyama, KK				Song, J; Murakami, H; Tsutsui, H; Tang, XR; Matsumura, M; Itakura, K; Kanazawa, I; Sun, K; Yokoyama, KK			Genomic organization and expression of a human gene for myc-associated zinc finger protein (MAZ)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KI-RAS PROMOTER; C-MYC; INSITU HYBRIDIZATION; NUCLEAR FACTOR; RECEPTOR GENE; START SITES; TRANSCRIPTION; CELLS; SEQUENCES; BINDS	We have cloned and characterized the genomic structure of the human gene for Myc-associated zinc finger protein (MAZ), which is located on chromosome 16p11.2. This gene is transcribed as an mRNA of 2.7 kilobases (kb) that encodes a 60-kDa MAZ protein. A 40-kb cosmid clone was isolated that includes the promoter, five exons, four introns, and one 3'-untranslated region. All exon-intron junction sequences conform to the GT/AG rule. The promoter region has features typical of a housekeeping gene: a high G + C content (88.44%); a high frequency of CpG dinucleotides, in particular within the region 0.5 kb upstream of the site of initiation of translation; and the absence of canonical TATA and CAAT boxes. An S1 nuclease protection assay demonstrated the presence of multiple sites for initiation of transcription around a site 174 nucleotides (nt) upstream of the ATG codon and such expression was reflected by the promoter activity of a MAZ promoter/CAT (chloramphenicol acetyltransferase) reporter gene. Cis-acting positive and negative elements controlling basal transcription of the human MAZ gene were found from nucleotides (nt) -383 to -248 and nt -2500 to -948. Moreover, positive and negative autoregulatory elements were also identified in the regions from nt -248 to -189 and from nt -383 to -248 after co-transfection of HeLa cells with plasmids that carried the MAZ promoter/CAT construct and the MAZ-expression vector. Our results indicate that the 5'-end flanking sequences are responsible for the promoter activities of the MAZ gene.	RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 305, Japan; China Med Univ, Dept Med Genet, Shenyang 110001, Peoples R China; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 305, Japan; City Hope Natl Med Ctr, Beckman Res Inst, Dept Mol Genet, Duarte, CA 91010 USA; Univ Tokyo, Fac Med, Inst Brain Res, Dept Neurol, Tokyo 113, Japan	RIKEN; China Medical University; University of Tsukuba; City of Hope; Beckman Research Institute of City of Hope; University of Tokyo	Yokoyama, KK (corresponding author), RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, 3-1-1 Koyadai, Tsukuba, Ibaraki 305, Japan.	kazunari@rtc.riken.go.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BONHAM K, 1993, ONCOGENE, V8, P1973; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EVANS T, 1988, J MOL BIOL, V199, P61, DOI 10.1016/0022-2836(88)90379-8; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOU LH, 1983, METHOD ENZYMOL, V100, P60; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JORCYK CL, 1990, ONCOGENE, V6, P323; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KAWAI J, 1989, J IMMUNOL, V142, P312; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; Komatsu M, 1997, ONCOGENE, V15, P1123, DOI 10.1038/sj.onc.1201283; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOYANONAKAGAWA N, 1994, MOL CELL BIOL, V14, P5099, DOI 10.1128/MCB.14.8.5099; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAVROTHALASSITIS GJ, 1990, ONCOGENE, V5, P1337; MOBERG KH, 1992, ONCOGENE, V7, P411; MOBERG KH, 1991, J CELL PHYSIOL, V148, P75, DOI 10.1002/jcp.1041480110; OZAWA K, 1992, GENOMICS, V12, P214, DOI 10.1016/0888-7543(92)90368-3; Parks CL, 1997, J VIROL, V71, P9600, DOI 10.1128/JVI.71.12.9600-9607.1997; Parks CL, 1996, J BIOL CHEM, V271, P4417; PATEL M, 1990, ONCOGENE, V5, P201; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; PYRC JJ, 1992, BIOCHEMISTRY-US, V31, P4102, DOI 10.1021/bi00131a029; Sambrook D.J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; Tsutsui H, 1996, BIOCHEM BIOPH RES CO, V226, P801, DOI 10.1006/bbrc.1996.1432	51	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20603	20614		10.1074/jbc.273.32.20603	http://dx.doi.org/10.1074/jbc.273.32.20603			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685418	hybrid			2022-12-27	WOS:000075305400095
J	Chapline, C; Cottom, J; Tobin, H; Hulmes, J; Crabb, J; Jaken, S				Chapline, C; Cottom, J; Tobin, H; Hulmes, J; Crabb, J; Jaken, S			A major, transformation-sensitive PKC-binding protein is also a PKC substrate involved in cytoskeletal remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; RAT EMBRYO FIBROBLASTS; REF52 CELLS; IDENTIFICATION; FAMILY; SRC	Protein kinase C (PKC) plays a major role in regulating cell growth, transformation, and gene expression; however, identifying phosphorylation events that mediate these responses has been difficult. We expression-cloned a group of PKC-binding proteins and identified a high molecular weight, heat-soluble protein as the major PKC-binding protein in REF52 fibroblasts (Chapline, C., Mousseau, B., Ramsay, K., Duddy, S., Li, Y., Kiley, S. C., and Jaken, S. (1996) J. Biol. Chem. 271, 6417-6422). In this study, we demonstrate that this PKC-binding protein, clone 72, is also a PKC substrate in vitro and in vivo. Using a combination of phosphopeptide mapping, Edman degradation, and electrospray mass spectrometry, serine residues 283, 300, 507, and 515 were identified as the major in vitro PKC phosphorylation sites in clone 72. Phosphorylation state-selective antibodies were raised against phosphopeptides encompassing each of the four phosphorylation sites. These antibodies were used to determine that phorbol esters stimulate phosphorylation of serines 283, 300, 507, and 515 in cultured cells, indicating that clone 72 is directly phosphorylated by PKC in living cells. Phosphorylated clone 72 preferentially accumulates in membrane protrusions and ruffles, indicating that PKC activation and clone 72 phosphorylation are involved in membrane-cytoskeleton remodeling. These data lend further evidence to the model that PKCs directly interact with, phosphorylate, and modify the functions of a group of substrate proteins, STICKs (substrates that interact with C-kinase).	Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA		Jaken, S (corresponding author), Adirondack Biomed Res Inst, 10 Old Barn Rd, Lake Placid, NY 12946 USA.				NCI NIH HHS [CA53841, CA/GM50152] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053841] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CRABB JW, 1991, J BIOL CHEM, V266, P16674; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; FUJISE A, 1994, J BIOL CHEM, V269, P31642; HUDDLESTON MJ, 1993, J AM SOC MASS SPECTR, V4, P710, DOI 10.1016/1044-0305(93)80049-5; HYATT SL, 1994, BIOCHEMISTRY-US, V33, P1223, DOI 10.1021/bi00171a023; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; LIAO L, 1994, BIOCHEMISTRY-US, V33, P1229, DOI 10.1021/bi00171a024; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Mochly-Rosen D, 1998, FASEB J, V12, P35; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Wertz SL, 1996, BIOCHEMISTRY-US, V35, P11104, DOI 10.1021/bi961248x; West K.A., 1992, TXB APPL AUTOMATIC P, P233, DOI [10.1016/B978-0-12-058756-8.50029-8, DOI 10.1016/B978-0-12-058756-8.50029-8]	24	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19482	19489		10.1074/jbc.273.31.19482	http://dx.doi.org/10.1074/jbc.273.31.19482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677369	hybrid			2022-12-27	WOS:000075125200021
J	Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A				Ordentlich, A; Barak, D; Kronman, C; Ariel, N; Segall, Y; Velan, B; Shafferman, A			Functional characteristics of the oxyanion hole in human acetylcholinesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE; SUBSTRATE-SPECIFICITY; SERINE PROTEASES; SUBTILISIN BPN'; ANIONIC SITE; ACTIVE-SITE; RESIDUES; INHIBITION; BINDING; MUTAGENESIS	The contribution of the oxyanion hole to the functional architecture and to the hydrolytic efficiency of human acetylcholinesterase (HuAChE) was investigated through single replacements of its elements, residues Gly-121, Gly-122 and the adjacent residue Gly-120, by alanine, All three substitutions resulted in about 100-fold decrease of the bimolecular rate constants for hydrolysis of acetylthiocholine; however, whereas replacements of Gly-120 and Gly-121 affected only the turnover number, mutation of residue Gly-122 had an effect also on the Michaelis constant. The differential behavior of the G121A and G122A enzymes was manifested also toward the transition state analog m-(N,N,N-trimethylammonio)trifluoroacetophenone (TMTFA), organophosphorous inhibitors, carbamates, and toward selected noncovalent active center ligands, Reactivity of both mutants toward TMTFA was 2000-11,000-fold lower than that of the wild type HuAChE; however, the G121A enzyme exhibited a rapid inhibition pattern, as opposed to the slow binding kinetics shown by the G122A enzyme. For both phosphates (diethyl phosphorofluoridate, diisopropyl phosphorofluoridate, and paraoxon) and phosphonates (sarin and soman), the decrease in inhibitory activity toward the G121A enzyme was very substantial (2000-6700-fold), irrespective of size of the alkoxy substituents on the phosphorus atom, On the other hand, for the G122A HuAChE the relative decline in reactivity toward phosphonates (500-460-fold) differed from that toward the phosphates (12-95-fold). Although formation of Michaelis complexes with substrates does not seem to involve significant interaction with the oxyanion hole, interactions with this motif are a major stabilizing element in accommodation of covalent inhibitors like organophosphates or carbamates. These observations and molecular modeling suggest that replacements of residues Gly-120 or Gly-121 by alanine alter the structure of the oxyanion hole motif, abolishing the H-bonding capacity of residue at position 121. These mutations weaken the interaction between HuA-ChE and the various ligands by 2.7-5.0 kcal/mol. In contrast, variations in reactivity due to replacement of residue Gly-122 seem to result from steric hindrance at the active center acyl pocket.	Israel Inst Biol Res, Dept Biochem & Mol Biol, IL-70450 Ness Ziona, Israel; Israel Inst Biol Res, Dept Organ Chem, IL-70450 Ness Ziona, Israel		Shafferman, A (corresponding author), Israel Inst Biol Res, Dept Biochem & Mol Biol, IL-70450 Ness Ziona, Israel.							ALDRICH WN, 1972, ENZYME INHIBITORS SU, P245; ASHANI Y, 1994, MOL PHARMACOL, V45, P555; BARAK D, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P195; BARAK D, 1994, J BIOL CHEM, V269, P6296; BOURNE N, 1984, J AM CHEM SOC, V106, P7591, DOI 10.1021/ja00336a046; BRADY K, 1990, BIOCHEMISTRY-US, V29, P7608, DOI 10.1021/bi00485a010; BRAXTON S, 1991, J BIOL CHEM, V266, P11797; BRODBECK U, 1979, BIOCHIM BIOPHYS ACTA, V567, P357, DOI 10.1016/0005-2744(79)90122-0; CARTER P, 1990, PROTEINS, V7, P335, DOI 10.1002/prot.340070405; Cousin X, 1998, NUCLEIC ACIDS RES, V26, P226, DOI 10.1093/nar/26.1.226; Cygler M, 1997, METHOD ENZYMOL, V284, P3; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DING XC, 1994, BIOCHEMISTRY-US, V33, P9285, DOI 10.1021/bi00197a032; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FORSBERG A, 1984, EUR J BIOCHEM, V140, P153, DOI 10.1111/j.1432-1033.1984.tb08079.x; Fuxreiter M, 1998, J AM CHEM SOC, V120, P183, DOI 10.1021/ja972326m; GERLT JA, 1993, BIOCHEMISTRY-US, V32, P11943, DOI 10.1021/bi00096a001; GIBNEY G, 1990, P NATL ACAD SCI USA, V87, P7546, DOI 10.1073/pnas.87.19.7546; GRAY PJ, 1987, TOXICOL APPL PHARM, V91, P140, DOI 10.1016/0041-008X(87)90201-8; GROCHULSKI P, 1994, BIOCHEMISTRY-US, V33, P3494, DOI 10.1021/bi00178a005; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; HOSEA NA, 1995, BIOCHEMISTRY-US, V34, P11528, DOI 10.1021/bi00036a028; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021; KEMP JR, 1990, TOXICOL APPL PHARM, V104, P264; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KRONMAN C, 1992, GENE, V121, P29; LoewensteinLichtenstein Y, 1996, MOL PHARMACOL, V50, P1423; MASSOULLIE J, 1992, MULTIDISCIPLINARY AP, P286; MENARD R, 1992, BIOL CHEM H-S, V373, P393, DOI 10.1515/bchm3.1992.373.2.393; Millard CB, 1995, BIOCHEMISTRY-US, V34, P15925, DOI 10.1021/bi00049a007; Monard C., 1961, B SOC CHIM FR, P1084; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; NAIR HK, 1993, J AM CHEM SOC, V115, P9939, DOI 10.1021/ja00075a009; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Ordentlich A, 1996, J BIOL CHEM, V271, P11953, DOI 10.1074/jbc.271.20.11953; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; RICH DH, 1989, COMPUTER AIDED DRUG, P185; RYU SM, 1991, CHEM RES TOXICOL, V4, P517, DOI 10.1021/tx00023a004; SAUNDERS BC, 1948, J CHEM SOC, P695, DOI 10.1039/jr9480000695; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; SOREQ H, 1990, P NATL ACAD SCI USA, V87, P9688, DOI 10.1073/pnas.87.24.9688; Stojan J, 1997, BBA-PROTEIN STRUCT M, V1337, P75, DOI 10.1016/S0167-4838(96)00154-9; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; VASILYEV VV, 1994, J MOL STRUC-THEOCHEM, V304, P129; VELAN B, 1991, J BIOL CHEM, V266, P23977; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; Wlodek ST, 1997, J AM CHEM SOC, V119, P8159, DOI 10.1021/ja970395v	56	119	123	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19509	19517		10.1074/jbc.273.31.19509	http://dx.doi.org/10.1074/jbc.273.31.19509			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677373	hybrid			2022-12-27	WOS:000075125200025
J	Pei, L				Pei, L			Molecular cloning of a novel transcriptional repressor protein of the rat type 1 vasoactive intestinal peptide receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; PREINITIATION COMPLEX; BINDING-PROTEIN; DNA-LIGASE; EXPRESSION; DOMAIN; DROSOPHILA; ELEMENT; SEQUENCE; SUBUNIT	This study demonstrates that the transcriptional repressor sequence of the rat vasoactive intestinal peptide receptor (VIPR) gene constitutes a 42-base pair core element that is the binding site for a nuclear protein. We showed that this element was able to confer transcriptional repression to a heterologous promoter and that deletion or point mutations within this element resulted in loss of transcriptional repression. Southwestern blot analysis indicated that the VIPR repressor element interacts specifically with a nuclear protein of about 72 kDa, By screening a rat lung expression library coupled with rapid amplification of cDNA ends polymerase chain reactions, we isolated a cDNA clone (designated as VIPR-RP) that contains an open reading frame of 656 amino acids. VIPR-RP is 78% identical to a previously characterized protein, differentiation-specific element-binding protein, which is a member of a family of proteins including components of the DNA replication factor C complex. However, VIPR-RP cDNA encodes for a much smaller protein than differentiation-specific element-binding protein because of a frameshift, VIPR-RP mRNA is expressed in multiple tissues, including lung, liver, brain, heart, kidney, spleen, and testis, VIPR-RP protein specifically interacts with the VIPR repressor element as demonstrated by gel shift assays. Transfection of VIP-RP expression vector into Cos cells resulted in transcriptional repression of a reporter construct containing multiple copies of the VIPR repressor element. These results indicate that VIPR-RP is a novel transcriptional repressor protein that regulates VIPR expression.	Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Endocrinol, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pei, L (corresponding author), Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Div Endocrinol, 8700 Beverly Blvd,D-3066, Los Angeles, CA 90048 USA.				NIDDK NIH HHS [DK-02346] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002346] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BROWN NL, 1995, CELL, V80, P879, DOI 10.1016/0092-8674(95)90291-0; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; LAUER G, 1991, J BACTERIOL, V173, P5047, DOI 10.1128/jb.173.16.5047-5053.1991; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LUCKOW B, 1994, MOL CELL BIOL, V14, P1626, DOI 10.1128/MCB.14.3.1626; MCGEHEE RE, 1995, MOL ENDOCRINOL, V9, P487, DOI 10.1210/me.9.4.487; Pei L, 1997, REGUL PEPTIDES, V71, P153, DOI 10.1016/S0167-0115(97)01012-4; PEI L, 1995, BIOCHEM J, V308, P719, DOI 10.1042/bj3080719; Pei L, 1996, J BIOL CHEM, V271, P20879; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHARK KB, 1992, FEMS MICROBIOL LETT, V96, P19, DOI 10.1111/j.1574-6968.1992.tb05387.x; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	25	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19902	19908		10.1074/jbc.273.31.19902	http://dx.doi.org/10.1074/jbc.273.31.19902			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677428	hybrid			2022-12-27	WOS:000075125200080
J	Chandok, MR; Sopory, SK				Chandok, MR; Sopory, SK			ZmcPKC70, a protein kinase C-type enzyme from maize - Biochemical characterization, regulation by phorbol 12-myristate 13-acetate and its possible involvement in nitrate reductase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; ESTER RECEPTOR; CALCIUM; PHOSPHORYLATION; CALMODULIN; PLANTS; DIACYLGLYCEROL; PURIFICATION; PROTOPLASTS	The crucial enzyme in diacylglycerol-mediated signaling is protein kinase C (PKC). In this paper we provide evidence for the existence and role of PKC in maize. A protein of an apparent molecular mass of 70 kDa was purified. The protein showed kinase activity that was stimulated by phosphatidylserine and oleyl acetyl glycerol (OAG) in the presence of Ca(2+). Phorbol 12-myristate 13-acetate (PMA) replaced the requirement of GAG. [(3)H]PMA. binding to the 70-kDa protein was competed by unlabeled PMA and OAG but not by 4 alpha-PMA, an inactive analog. The kinase phosphorylates histone H1 at serine residue(s), and this activity was inhibited by H-7 and staurosporine. These properties suggest that the 70-kDa protein is a conventional serine/threonine protein kinase C (cPKC). Polyclonal antibodies raised against the polypeptide precipitate the enzyme activity and immunostained the protein on Western blots. The antibodies also cross-reacted with a protein of expected size from sorghum, rice, and tobacco. A rapid increase in the protein level was observed in maize following PMA treatments. In order to assign a possible role of PKC in gene regulation, the nitrate reductase transcript level was investigated. The transcript level increased by PMA, not by 4 alpha-PMA treatments, and the increase wa.s inhibited by H-7 but not by okadaic acid. The data sham the existence and possible function of PKC in higher plants.	Jawaharlal Nehru Univ, Sch Life Sci, Ctr Plant Mol Biol, New Delhi 110067, India; Int Ctr Genet Engn & Biotechnol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Chandok, MR (corresponding author), Univ Munich, Inst Bot, Menzinger Str 67, D-80638 Munich, Germany.							ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BOSSEN ME, 1990, PHYSIOL PLANTARUM, V80, P55; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVIARIO D, 1995, PLANT MOL BIOL, V27, P953, DOI 10.1007/BF00037023; Chandok MR, 1996, MOL GEN GENET, V251, P599, DOI 10.1007/BF02173650; CHANDOK MR, 1992, PHYTOCHEMISTRY, V31, P2255, DOI 10.1016/0031-9422(92)83259-2; Chandok MR, 1996, J PLANT BIOCHEM BIOT, V5, P7, DOI 10.1007/BF03262971; CHANDOK MR, 1994, FEBS LETT, V356, P39, DOI 10.1016/0014-5793(94)01213-X; CHEN ZT, 1994, PLANT J, V6, P729, DOI 10.1046/j.1365-313X.1994.6050729.x; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DASGUPTA M, 1994, PLANT PHYSIOL, V104, P961, DOI 10.1104/pp.104.3.961; DROBAK BK, 1996, MEMBRANES SPECIALIZE, P195; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; ELLIOTT DC, 1987, BIOCHEM BIOPH RES CO, V145, P1043, DOI 10.1016/0006-291X(87)91541-5; ELLIOTT DC, 1987, PHYTOCHEMISTRY, V26, P2929, DOI 10.1016/S0031-9422(00)84565-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HARMON AC, 1990, PLANT BIOL, V9, P319; HARMON AC, 1987, PLANT PHYSIOL, V83, P830, DOI 10.1104/pp.83.4.830; HARMON AC, 1996, MEMBRANES SPECIALIZE, P137; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HASS BCJ, 1991, J PLANT PHYSL, V138, P350; HEPLER PK, 1985, ANNU REV PLANT PHYS, V36, P397, DOI 10.1146/annurev.pp.36.060185.002145; HUANG KP, 1988, J BIOL CHEM, V263, P14839; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JACON S, 1987, P NATL ACAD SCI USA, V84, P4418; Katagiri T, 1996, PLANT MOL BIOL, V30, P647, DOI 10.1007/BF00049339; KAWASAKI T, 1993, GENE, V129, P183, DOI 10.1016/0378-1119(93)90267-7; KOMATSU S, 1993, PLANT SCI, V94, P127, DOI 10.1016/0168-9452(93)90014-Q; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE Y, 1991, P NATL ACAD SCI USA, V88, P2127, DOI 10.1073/pnas.88.6.2127; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; LONGERAN TA, 1990, PLANT PHYSIOL, V93, P110; MA H, 1993, TRENDS GENET, V9, P228, DOI 10.1016/0168-9525(93)90075-S; Marks F., 1996, PROTEIN PHOSPHORYLAT; MARKS R, 1996, PROTEIN PHOSPHORYLAT, P81; Martell A. E., 1971, SPECIAL PUBLICATION, V17; MERRIL CR, 1983, METHOD ENZYMOL, V96, P230; MORELLO L, 1993, BIOCHEM BIOPH RES CO, V197, P55, DOI 10.1006/bbrc.1993.2440; MUTO S, 1985, FEBS LETT, V193, P88, DOI 10.1016/0014-5793(85)80085-5; NAMORI T, 1994, BIOCHEM BIOPH RES CO, V203, P311; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1986, FEBS LETT, V195, P33, DOI 10.1016/0014-5793(86)80124-7; PARK MH, 1990, BIOCHEM BIOPH RES CO, V169, P1185, DOI 10.1016/0006-291X(90)92021-Q; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PEARS C, 1995, J BIOSCIENCE, V20, P311, DOI 10.1007/BF02703836; POLYA GM, 1993, PLANT PHYSIOL, V101, P545, DOI 10.1104/pp.101.2.545; POOVAIAH BW, 1987, CRC CR REV PLANT SCI, V6, P47, DOI 10.1080/07352688709382247; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; RAGHURAM N, 1995, PLANT MOL BIOL, V29, P25, DOI 10.1007/BF00019116; RANJEVA R, 1987, ANNU REV PLANT PHYS, V38, P73, DOI 10.1146/annurev.pp.38.060187.000445; Roberts DM, 1993, CURR OPIN CELL BIOL, V5, P242, DOI 10.1016/0955-0674(93)90110-C; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SASAKI T, 1994, PLANT J, V6, P615, DOI 10.1046/j.1365-313X.1994.6040615.x; SATIEL AR, 1987, BIOCHEM J, V241, P759; SCHAAP D, 1989, FEBS LETT, V243, P351, DOI 10.1016/0014-5793(89)80160-7; SCHAAP D, 1990, EUR J BIOCHEM, V191, P431, DOI 10.1111/j.1432-1033.1990.tb19139.x; SCHAFER A, 1998, FEBS LETT, V187, P35; SCHALLER GE, 1992, BIOCHEMISTRY-US, V31, P1721, DOI 10.1021/bi00121a020; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SIMPSON GG, 1994, BBA-MOL CELL RES, V1222, P306, DOI 10.1016/0167-4889(94)90183-X; Sopory S K, 1996, Subcell Biochem, V26, P345; STONE JM, 1995, PLANT PHYSIOL, V108, P451, DOI 10.1104/pp.108.2.451; Subramaniam R, 1997, PLANT CELL, V9, P653, DOI 10.1105/tpc.9.4.653; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; URAO T, 1994, PLANT PHYSIOL, V105, P1461, DOI 10.1104/pp.105.4.1461; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572	75	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19235	19242		10.1074/jbc.273.30.19235	http://dx.doi.org/10.1074/jbc.273.30.19235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668112	hybrid			2022-12-27	WOS:000074974700079
J	Fernandez, CJ; Warren, G				Fernandez, CJ; Warren, G			In vitro synthesis of sulfated glycosaminoglycans coupled to inter-compartmental Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							CELL-FREE SYSTEM; GDP-DISSOCIATION INHIBITOR; EMBRYO EPIPHYSEAL CARTILAGE; MOUSE MASTOCYTOMA-CELLS; ADP-RIBOSYLATION FACTOR; COP-COATED VESICLES; BETA-D-XYLOSIDES; RAT-LIVER GOLGI; ENDOPLASMIC-RETICULUM; CHONDROITIN SULFATE	We have used isolated rat liver Gels membranes to reconstitute the synthesis of sulfated glycosaminoglycans (GAGs) onto the membrane-permeable, external acceptor xyloside. Biosynthetic labeling of GAGs with [S-35]sulfate in vitro is shown to have an absolute requirement for ATP and cytosolic proteins and is inhibited by dismantling the Golgi apparatus with okadaic acid or under mitotic conditions suggesting that intercompartmental transport between Golgi cisternae is a prerequisite for the successful completion of the initiation, polymerization, and sulfation of GAGs. Accordingly, we show that in vitro synthesis of S-35-GAGs utilizes the same machinery employed in Golgi transport events in terms of vesicle budding (ADP-ribosylation factor and coatomer), docking (Rabs), targeting (SNAREs), and fusion (N-ethylmaleimide-sensitive factor). This provides compelling evidence that GAGs synthesis is linked to Golgi membrane traffic and suggests that it can be used as a complementation-independent method to study membrane transport in Golgi preparations from any source. We have applied this system to show that intra-Golgi traffic requires the function of the Golgi target-SNARE, syntaxin 5.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England	Cancer Research UK	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	g.warren@icrf.icnet.uk						ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Beeley J. G., 1985, GLYCOPROTEIN PROTEOG; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BREWER CB, 1995, J CELL SCI, V108, P789; CALABRO A, 1994, J BIOL CHEM, V269, P22764; CARRINO DA, 1994, MATRIX BIOL, V14, P121, DOI 10.1016/0945-053X(94)90002-7; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; COLLINS RN, 1992, J BIOL CHEM, V267, P24906; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; ETCHISON JR, 1995, J BIOL CHEM, V270, P756, DOI 10.1074/jbc.270.2.756; Fernandez CJ, 1997, MOL BIOL CELL, V8, P2171, DOI 10.1091/mbc.8.11.2171; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407; FRANSSON LA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P287, DOI 10.1016/0167-4889(92)90149-6; GALLIGANI L, 1975, J BIOL CHEM, V250, P5400; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HOPPE W, 1985, EUR J BIOCHEM, V152, P91, DOI 10.1111/j.1432-1033.1985.tb09167.x; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOBAYASHI T, 1989, J BIOL CHEM, V264, P5966; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KREINER T, 1990, CELL REGUL, V1, P415, DOI 10.1091/mbc.1.5.415; KUGE O, 1994, J CELL BIOL, V125, P51, DOI 10.1083/jcb.125.1.51; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LIDHOLT K, 1988, BIOCHEM J, V254, P571, DOI 10.1042/bj2540571; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LUCOCQ J, 1991, J CELL SCI, V100, P753; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MILLER SG, 1992, METHOD ENZYMOL, V219, P234; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OKAYAMA M, 1973, J BIOCHEM-TOKYO, V74, P1069; PEREZ M, 1986, BIOCHIM BIOPHYS ACTA, V864, P213, DOI 10.1016/0304-4157(86)90012-2; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PRESTON SF, 1985, J CELL BIOL, V101, P1086, DOI 10.1083/jcb.101.3.1086; PRINZ R, 1980, BIOCHIM BIOPHYS ACTA, V630, P402, DOI 10.1016/0304-4165(80)90289-5; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; RATCLIFFE A, 1985, J CELL BIOL, V101, P2355, DOI 10.1083/jcb.101.6.2355; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1987, J BIOL CHEM, V262, P12502; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHWANINGER R, 1991, J BIOL CHEM, V266, P13055; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SCOTT J. E., 1960, METHODS BIOCHEM ANAL, V8, P145; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, V1, P509; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; STEIN GS, 1994, CELL BIOL LAB HDB, V1, P282; STUART RA, 1993, J BIOL CHEM, V268, P4050; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUGUMARAN G, 1992, J BIOL CHEM, V267, P8802; SUGUMARAN G, 1992, BIOCHEM BIOPH RES CO, V183, P357, DOI 10.1016/0006-291X(92)90488-7; SUGUMARAN G, 1991, J BIOL CHEM, V266, P9565; SUGUMARAN G, 1990, J BIOL CHEM, V265, P18284; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VELASCO A, 1988, EUR J CELL BIOL, V47, P241; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WONGPALMS S, 1995, ARCH BIOCHEM BIOPHYS, V319, P383, DOI 10.1006/abbi.1995.1308; Yang DH, 1996, HISTOCHEM J, V28, P33, DOI 10.1007/BF02331425; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	104	12	13	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19030	19039		10.1074/jbc.273.30.19030	http://dx.doi.org/10.1074/jbc.273.30.19030			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668084	hybrid			2022-12-27	WOS:000074974700051
J	Grothe, K; Hanke, C; Momayezi, M; Kissmehl, R; Plattner, H; Schultz, JE				Grothe, K; Hanke, C; Momayezi, M; Kissmehl, R; Plattner, H; Schultz, JE			Functional characterization and localization of protein phosphatase type 2C from Paramecium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; COMPLEX; CALCINEURIN; CLONING; CELLS	me cloned a protein phosphatase 2C gene from Paramecium (PtPP2C), which codes for one of the smallest PP2C isoforms (Klumpp, S,, Hanke, C,, Donella-Deana, A., Beyer, A., Kellner, R., Pinna, L. A., and Schultz, J. E. (1994) J. Biol. Chem. 269, 32774-32780). After mutation of 9 ciliate Q codons (TAA) to CAA PtPP2C was expressed as an active protein in Escherichia coli, The catalytic core region contains 284 amino acids as defined by C- and N-terminal deletions, The C terminus from amino acid 200-300 of PP2C isoforms has only about 20% similarity, To demonstrate that the carboxy end is in fact needed for activity, we generated an enzymatically active PtPP2C containing a C-terminally located tobacco etch virus-protease site. Upon proteolytic truncation enzyme activity was lost, i.e. the C terminus of PP2C is indispensable for enzyme activity. During these experiments isoleucine 214 was fortuitously identified to be essential for PP2C catalysis, Mutation of the hydrophobic amino acid to glycine in the ciliate or bovine isoforms resulted in inactive protein. Because Ile(214) is in a loop region without defined secondary structure, our data clearly go beyond the x-ray structure, The functional equivalence of the 180 amino acid long C terminus from the bovine PP2C with the 100 amino acid long carboxy end of the PtPP2C was demonstrated by producing an active chimera, i,e, the PP2C from Paramecium has no obvious regions which may be specifically involved in subcellular localization or substrate recognition. Using antibodies against recombinant PtPP2C we localized the enzyme by immunogold labeling in the cytosol and nucleus and very distinctly on the ciliary microtubule/dynein complex, The data suggest a role for PtPP2C in the regulation of dyneins, i,e, in cellular cargo transport and ciliary motility.	Univ Tubingen, Inst Pharmazeut, D-72076 Tubingen, Germany; Univ Konstanz, Fak Biol, D-78434 Constance, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Konstanz	Schultz, JE (corresponding author), Univ Tubingen, Inst Pharmazeut, Morgenstelle 8, D-72076 Tubingen, Germany.	Joachim.Schultz@uni-tuebingen.de						Bork P, 1996, PROTEIN SCI, V5, P1421, DOI 10.1002/pro.5560050720; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Dick T, 1997, GENE, V199, P139, DOI 10.1016/S0378-1119(97)00359-4; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Jung G., 1985, ANGEW CHEM, V97, P883, DOI 10.1002/ange.19850971032; KANESHIRO ES, 1979, J PROTOZOOL, V26, P147, DOI 10.1111/j.1550-7408.1979.tb02754.x; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KISSMEHL R, 1998, IN PRESS HISTOCHEM C; Klumpp S, 1998, J NEUROSCI RES, V51, P328, DOI 10.1002/(SICI)1097-4547(19980201)51:3<328::AID-JNR6>3.0.CO;2-I; KLUMPP S, 1994, J BIOL CHEM, V269, P32774; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; Marley AE, 1996, BIOCHEM J, V320, P801, DOI 10.1042/bj3200801; MCGOWAN CH, 1988, METHOD ENZYMOL, V159, P416; Momayezi M, 1996, J HISTOCHEM CYTOCHEM, V44, P891, DOI 10.1177/44.8.8756761; ROBINSON MK, 1994, MOL CELL BIOL, V14, P3634, DOI 10.1128/MCB.14.6.3634; SCHLECHT S, 1993, NATURWISSENSCHAFTEN, V80, P9, DOI 10.1007/BF01139751; SCHROEDER CC, 1990, J CELL BIOL, V111, P2553, DOI 10.1083/jcb.111.6.2553	22	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19167	19172		10.1074/jbc.273.30.19167	http://dx.doi.org/10.1074/jbc.273.30.19167			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668103	Green Published, hybrid			2022-12-27	WOS:000074974700070
J	Lefkowitz, RJ				Lefkowitz, RJ			G protein-coupled receptors III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							BETA-2-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; SUBCELLULAR-DISTRIBUTION; PHOSPHORYLATION SITES; RHODOPSIN KINASE; SEQUESTRATION; ACTIVATION; BINDING; MECHANISM; MUTANT		Duke Univ, Med Ctr, Dept Med Cardiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Dept Med Cardiol, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021					BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1994, J BIOL CHEM, V269, P8721; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KOENIG JA, 1997, TRENDS PHARMACOL SCI, V18, P176; Krueger KM, 1997, J BIOL CHEM, V272, P5; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TSUGA H, 1994, J BIOL CHEM, V269, P32522; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wilde A, 1996, J CELL BIOL, V135, P635, DOI 10.1083/jcb.135.3.635; XIAO RP, 1995, MOL PHARMACOL, V47, P322; YU SS, 1993, J BIOL CHEM, V268, P337; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	47	869	886	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18677	18680		10.1074/jbc.273.30.18677	http://dx.doi.org/10.1074/jbc.273.30.18677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668034	hybrid			2022-12-27	WOS:000074974700001
J	Stancato, LF; Yu, CR; Petricoin, EF; Larner, AC				Stancato, LF; Yu, CR; Petricoin, EF; Larner, AC			Activation of Raf-1 by interferon gamma and oncostatin M requires expression of the Stat1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ALPHA-INTERFERON; GENE-EXPRESSION; ACTIVE STAT1; RECEPTOR; PROTEIN; PATHWAY	A primary signaling cascade responsible for the ex pression of cytokine-stimulated immediate early genes involves the activation of the Jak/Stat pathway. In addition to being tyrosine-phosphorylated, several signal transducers and activators of transcription (Stats), including Stat1 alpha, Stat3, and Stat4, are phosphorylated on a conserved serine residue, which is a consensus phosphorylation site for mitogen-activated protein kinases (MAPKs), Serine phosphorylation of Stat1 alpha is required for maximal transcriptional activation of early response genes by interferon gamma (IFN gamma) as well as the antiviral and antigrowth actions of this cytokine. Incubation of cells with either IFN gamma or oncostatin M (OSM) activates Raf-1, a serine/threonine kinase responsible for the ultimate activation of p42 MAPK. To examine whether any of the signaling components that are required for activation of the Jak/Stat pathway are also necessary for activation of Raf-1 by IFNs and OSM, we examined activation of Raf-1 in cell lines that are deficient in either Stat1 alpha or Stat2. Unexpectedly, incubation of Stat1-deficient, but not Stat2-deficient cells with IFN gamma or OSM for 5 min displayed no increase in Raf-1 activity. In peripheral blood lymphocytes Raf-1 was associated with Stat1, and this interaction was disrupted after incubation of cells with IFN gamma, Stat1-negative cells reconstituted with either Stat1 alpha or Stat1 alpha with a point mutation in the site where it is serine-phosphorylated displayed normal activation of Raf-1 by IFN gamma and OSM, However, activation of Raf-1 was not observed in lines that expressed Stat1 alpha containing a mutation in its tyrosine phosphorylation site or in its SH2 domain. These results provide the first example of a novel role of Stat1 alpha not as a transcription factor, but as a protein which may function to scaffold signaling components required for activation of the distinct Raf/MEK/MAPK signaling cascade.	NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Lab, NIH, Frederick, MD 21701 USA; Ctr Biol Evaluat & Res, Div Cytokine Biol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)	Larner, AC (corresponding author), Cleveland Clin Fdn, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL CANCER INSTITUTE [R01CA077366] Funding Source: NIH RePORTER; NCI NIH HHS [CA77366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; DENT P, 1995, MOL CELL BIOL, V15, P4125; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Sakatsume M, 1996, J IMMUNOL, V156, P4160; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Stancato LF, 1997, MOL CELL BIOL, V17, P3833, DOI 10.1128/MCB.17.7.3833; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	20	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18701	18704		10.1074/jbc.273.30.18701	http://dx.doi.org/10.1074/jbc.273.30.18701			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668040	hybrid			2022-12-27	WOS:000074974700007
J	Grkovic, S; Brown, MH; Roberts, MJ; Paulsen, IT; Skurray, RA				Grkovic, S; Brown, MH; Roberts, MJ; Paulsen, IT; Skurray, RA			QacR is a repressor protein that regulates expression of the Staphylococcus aureus multidrug efflux pump QacA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESISTANCE GENE; KANAMYCIN RESISTANCE; THERMAL INACTIVATION; TRANSPORT PROTEINS; LAC REPRESSOR; BINDING; VECTORS; TRANSCRIPTION; PLASMID	The Staphylococcus aureus QacA protein is a multidrug transporter that confers resistance to a broad range of antimicrobial agents via proton motive force dependent efflux of the compounds. Primer extension analysis was performed to map the transcription start points of the qacA and divergently transcribed qacR mRNAs. Each gene utilized a single promoter element, the locations of which were confirmed by site-directed mutagenesis. Fusions of the qacA and qacR promoters to a chloramphenicol acetyl transferase reporter gene were used to demonstrate that QacR is a trans-acting repressor of qacA transcription that does not autoregulate its own expression. An inverted repeat overlapping the qacA transcription start site was shown to be the operator sequence for control of qacA gene expression. Removal of one half of the operator prevented QacR-mediated repression of the qacA promoter. Purified QacR protein bound specifically to this operator sequence in DNase I-footprinting experiments. Importantly, addition of diverse QacA substrates was shown to induce qacA expression in vivo, as well as inhibit binding of QacR to operator DNA in vitro, by using gel-mobility shift assays. QacR therefore appears to interact directly with structurally dissimilar inducing compounds that are substrates of the QacA multidrug efflux pump.	Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia	University of Sydney	Skurray, RA (corresponding author), Univ Sydney, Sch Biol Sci, Macleay Bldg A12, Sydney, NSW 2006, Australia.		Paulsen, Ian T/K-3832-2012; Brown, Melissa/V-2296-2017	Paulsen, Ian T/0000-0001-9015-9418; Brown, Melissa/0000-0001-6461-7550				AHMED M, 1993, J BIOL CHEM, V268, P11086; AHMED M, 1994, J BIOL CHEM, V269, P28506; ARAMAKI H, 1995, J BACTERIOL, V177, P3120, DOI 10.1128/jb.177.11.3120-3127.1995; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSIUS J, 1984, GENE, V27, P151, DOI 10.1016/0378-1119(84)90136-7; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Doran JL, 1997, CLIN DIAGN LAB IMMUN, V4, P23, DOI 10.1128/CDLI.4.1.23-32.1997; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; GUILFOILE PG, 1992, J BACTERIOL, V174, P3659, DOI 10.1128/JB.174.11.3659-3666.1992; HAGMAN KE, 1995, MICROBIOL-SGM, V141, P611, DOI 10.1099/13500872-141-3-611; Hames B. D., 1981, GEL ELECTROPHORESIS; HILLEN W, 1994, ANNU REV MICROBIOL, V48, P345, DOI 10.1146/annurev.mi.48.100194.002021; HINRICHS W, 1994, SCIENCE, V264, P418, DOI 10.1126/science.8153629; JOBLING MG, 1990, NUCLEIC ACIDS RES, V18, P5315, DOI 10.1093/nar/18.17.5315; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; KATO S, 1992, FEBS LETT, V308, P175, DOI 10.1016/0014-5793(92)81269-R; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LI XZ, 1995, ANTIMICROB AGENTS CH, V39, P1948, DOI 10.1128/AAC.39.9.1948; LOMOVSKAYA O, 1995, J BACTERIOL, V177, P2328, DOI 10.1128/jb.177.9.2328-2334.1995; Lucas CE, 1997, J BACTERIOL, V179, P4123, DOI 10.1128/jb.179.13.4123-4128.1997; LYON BR, 1984, MOL GEN GENET, V193, P554, DOI 10.1007/BF00382099; Markham PN, 1996, J BACTERIOL, V178, P1473, DOI 10.1128/jb.178.5.1473-1475.1996; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; PERRY LJ, 1987, PROTEIN ENG, V1, P101, DOI 10.1093/protein/1.2.101; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; ROUCH DA, 1990, MOL MICROBIOL, V4, P2051, DOI 10.1111/j.1365-2958.1990.tb00565.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shaw W V, 1975, Methods Enzymol, V43, P737; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P6140, DOI 10.1021/bi00441a002; SHEWCHUK LM, 1989, BIOCHEMISTRY-US, V28, P2331, DOI 10.1021/bi00431a052; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; STARK MJR, 1987, GENE, V51, P255, DOI 10.1016/0378-1119(87)90314-3; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; TENNENT JM, 1985, ANTIMICROB AGENTS CH, V27, P79, DOI 10.1128/AAC.27.1.79; TOMAZIC SJ, 1988, J BIOL CHEM, V263, P3086; Volkin D B, 1995, Methods Mol Biol, V40, P35; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zheleznova EE, 1997, PROTEIN SCI, V6, P2465	49	152	161	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18665	18673		10.1074/jbc.273.29.18665	http://dx.doi.org/10.1074/jbc.273.29.18665			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660841	hybrid			2022-12-27	WOS:000074828500096
J	Parker, AE; Van de Weyer, I; Laus, MC; Oostveen, I; Yon, J; Verhasselt, P; Luyten, WHML				Parker, AE; Van de Weyer, I; Laus, MC; Oostveen, I; Yon, J; Verhasselt, P; Luyten, WHML			A human homologue of the Schizosaccharomyces pombe rad1(+) checkpoint gene encodes an exonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; DNA-DAMAGE; USTILAGO-MAYDIS; REC1 GENE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; INSITU HYBRIDIZATION; ALLELIC DELETION; REPAIR	In the fission yeast Schizosaccharomyces pombe the rad1(+) gene is required for both the DNA damage-dependent and the DNA replication-dependent cell cycle checkpoints. We have identified a human homologue of the S. pombe rad1(+) gene, designated Hrad1, as well as a mouse homologue: Mrad1. Two Hrad1 alternative splice variants with different open reading frames have been identified; one codes for a long form, Hrad1A, and the other encodes a short form because of N-terminal truncation, Hrad1B. Hrad1A has 60% identity to the S. pombe rad1(+) sequence at the DNA level and 49% identity and 72% similarity at the amino acid level. Northern blot analysis indicates elevated levels of expression in testis and cancer cell lines. Chromosomal localization by fluorescence in situ hybridization indicates that Hrad1 is located on chromosome 5p13.2-13.3. This region is subject to loss of heterozygosity in several human cancers. Hrad1 also shares homology with the Saccharomyces cerevisiae RAD17 and Ustilago maydis REC1 proteins. REC1 has previously been characterized as a 3' --> 5' exonuclease with a C-terminal domain essential for cell cycle checkpoint function. We have expressed and purified polyhistidine-tagged fusions of Rrad1A and Hrad1B and show that HisHrad1A has 3' --> 5' exonuclease activity, whereas HisHrad1B lacks such activity. The biological functions of the two proteins remain to be determined.	Janssen Res Fdn, Dept Expt Mol Biol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Appl Mol Biol, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson	Luyten, WHML (corresponding author), Janssen Res Fdn, Dept Expt Mol Biol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	wluyten@janbe.jnj.com						ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BHAT KM, 1991, BIOCHEM BIOPH RES CO, V176, P371, DOI 10.1016/0006-291X(91)90934-Y; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CARR AM, 1994, INT J RAD BIOL S, V66, P133; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Demetrick DJ, 1996, CYTOGENET CELL GENET, V73, P104, DOI 10.1159/000134318; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAWN MT, 1995, CANCER RES, V55, P3721; Heng H H, 1994, Methods Mol Biol, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HOLDEN DW, 1991, CURR GENET, V20, P145, DOI 10.1007/BF00312777; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANTERSMOLER G, 1995, MOL BIOL CELL, V6, P1793, DOI 10.1091/mbc.6.12.1793; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LONG KE, 1994, GENE, V148, P155, DOI 10.1016/0378-1119(94)90250-X; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; NASIM A, 1975, GENETICS, V79, P573; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; ONEL K, 1995, MOL CELL BIOL, V15, P5329; Onel K, 1996, GENETICS, V143, P165; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANDHEZ Y, 1997, SCIENCE, V277, P1497; Siede W, 1996, NUCLEIC ACIDS RES, V24, P1669, DOI 10.1093/nar/24.9.1669; SUNNERHAGEN P, 1990, MOL CELL BIOL, V10, P3750, DOI 10.1128/MCB.10.7.3750; THELEN MP, 1994, J BIOL CHEM, V269, P747; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	49	92	97	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18332	18339		10.1074/jbc.273.29.18332	http://dx.doi.org/10.1074/jbc.273.29.18332			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660799	hybrid			2022-12-27	WOS:000074828500054
J	Saharinen, J; Taipale, J; Monni, O; Keski-Oja, J				Saharinen, J; Taipale, J; Monni, O; Keski-Oja, J			Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX MICROFIBRILS; SMOOTH-MUSCLE CELLS; TGF-BETA; PERICELLULAR MATRIX; MOLECULAR-CLONING; 8-CYSTEINE REPEAT; ENDOTHELIAL-CELLS; MARFAN-SYNDROME; MESSENGER-RNA; FIBRILLIN	Transforming growth factor beta (TGF-beta s) are secreted by most cell types as latent high molecular weight complexes consisting of TGF-beta and its latency associated peptide (LAP) propeptide dimers, covalently linked to latent TGF-beta-binding proteins (LTBPs), Currently, three different LTBPs are known (LTBPs 1, 2, and 3), all with highly similar protein domain structure consisting of epidermal growth factor-like and 8-Cys repeats. The 3rd 8-Cys repeat of LTBP-1 mediates its association with TGF-beta 1 . LAP. By using an expressed sequence tag homologous to the 3rd 8-Cys repeat of human LTBP-1 as a probe, a novel cDNA similar to known LTBPs was cloned from human heart cDNA Library. This cDNA was named LTBP-4 and found to exist in at least four different forms, generated by alternative splicing at the amino terminus and at the central epidermal growth factor repeat domain. One of the alternative amino-terminal forms contained an RGD sequence, indicating possible cell-surface interactions with integrins. LTBP-4 gene was localized to chromosomal position 19q13.1-19q13.2. The major LTBP-4 mRNA form is about 5.1 kilobase pairs in size and is predominantly expressed in the heart, aorta, uterus, and small intestine. Immunoblotting analysis indicated that LTBP-4 was secreted from cultured human lung fibroblasts both in a free form and in a disulfide bound complex with a TGF-beta.LAP-like protein. Both LTBP-4 forms were also found to be deposited in the extracellular matrix. The matrix-associated LTBP-4 was susceptible to proteolytic release with plasmin. LTBP-4 is a new member of the growing LTBP-fibrillin family of proteins and offers an alternative means for the secretion and targeted matrix deposition of TGF-beta s or related proteins.	Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Dermatol & Venereol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki	Keski-Oja, J (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; BENEZRA M, 1993, BLOOD, V81, P3324; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAVIS C G, 1990, New Biologist, V2, P410; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; EKLOV S, 1993, CANCER RES, V53, P3193; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; Hyytiainen M, 1998, J BIOL CHEM, V273, P20669, DOI 10.1074/jbc.273.32.20669; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P441, DOI 10.1177/39.4.2005373; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MCCARTNEYFRANCIS NL, 1994, J LEUKOCYTE BIOL, V55, P401, DOI 10.1002/jlb.55.3.401; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOREN A, 1994, J BIOL CHEM, V269, P32469; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; OLOFSSON A, 1992, J BIOL CHEM, V267, P19482; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Pfaff M, 1996, FEBS LETT, V384, P247, DOI 10.1016/0014-5793(96)00325-0; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; Sambrook J., 2002, MOL CLONING LAB MANU; SATO Y, 1993, J CELL BIOL, V123, P1249, DOI 10.1083/jcb.123.5.1249; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; TSUJI T, 1990, P NATL ACAD SCI USA, V87, P8835, DOI 10.1073/pnas.87.22.8835; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	45	108	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18459	18469		10.1074/jbc.273.29.18459	http://dx.doi.org/10.1074/jbc.273.29.18459			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660815	hybrid			2022-12-27	WOS:000074828500070
J	Zwollo, P; Rao, S; Wallin, JJ; Gackstetter, ER; Koshland, ME				Zwollo, P; Rao, S; Wallin, JJ; Gackstetter, ER; Koshland, ME			The transcription factor NF-kappa B/p50 interacts with the blk gene during B cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR BSAP; 3'ALPHA ENHANCER; CHAIN GENE; DIFFERENTIATION; PROTEIN; BINDING; PROMOTER; SUBUNIT; PROLIFERATION	The B cell-specific transcription factor Pax-5 has been shown previously to interact with the promoter of the blk gene in vitro, blk encodes a tyrosine kinase associated with the B cell receptor, which is expressed during the early but not the final stages of B cell development. To investigate whether Pax-5 regulates expression of the blk gene in vivo during B cell development and/or activation, Pax-5a was overexpressed in B cell lines. Increases in blk promoter activity using a chloramphenicol acetyltransferase reporter gene system suggested a role for Pax-5a as a transcriptional activator. Subsequent site-specific mutagenesis studies showed that mutations of the Pax-5 binding site on blk significantly alter promoter activity, although results suggested that other factors could bind to this region as well. Using mobility shift assays, we detected an inducible transcription factor that interacts strongly with a sequence overlapping the Pax-5 site on the blk promoter and identified this as a homodimer of NF-kappa B/p50, a member of the NF-kappa B/Rel family of transcription factors. This factor was present at high levels in lipopolysaccharide-activated normal B cells and in plasma cell lines but either at low levels or undetectable levels in resting normal B cells or pre-B or mature B cell lines. In contrast, lipopolysaccharide induction of a pre B cell line (703/Z) induced a complex that contained both NF-kappa B/p50 and p65. These studies suggest that different NF-kappa B complexes are able to interact with a sequence overlapping the Pax-5 site on the blk promoter and that the relative levels of "bound" factor influence levels of bit expression. Since p50 homodimers and p50/p65 heterodimers of the NF-kappa B complex should have opposing effects on blk transcription, this could provide a mechanism to differentially regulate blk expression during B cell development and activation.	Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA; Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	William & Mary; University of California System; University of California Berkeley	Zwollo, P (corresponding author), Coll William & Mary, Dept Biol, Millington Hall, Williamsburg, VA 23187 USA.			Wallin, Jeffrey/0000-0002-5952-3813				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; DYMECKI SM, 1992, J BIOL CHEM, V267, P4815; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HAGMAN J, 1996, GENE DEV, V7, P2198; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KEHRL JH, 1994, IMMUNOL TODAY, V15, P432, DOI 10.1016/0167-5699(94)90273-9; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Michaelson JS, 1996, J IMMUNOL, V156, P2349; NEURATH MF, 1995, P NATL ACAD SCI USA, V92, P5336, DOI 10.1073/pnas.92.12.5336; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; OKABE T, 1992, EUR J IMMUNOL, V22, P37, DOI 10.1002/eji.1830220107; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; Snapper CM, 1996, J IMMUNOL, V156, P183; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Usui T, 1997, J IMMUNOL, V158, P3197; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961; XU LZ, 1992, INT IMMUNOL, V4, P875, DOI 10.1093/intimm/4.8.875; YAO XR, 1993, P NATL ACAD SCI USA, V90, P7946, DOI 10.1073/pnas.90.17.7946; ZWOLLO P, 1994, J BIOL CHEM, V269, P15310; Zwollo P, 1997, J BIOL CHEM, V272, P10160, DOI 10.1074/jbc.272.15.10160	31	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18647	18655		10.1074/jbc.273.29.18647	http://dx.doi.org/10.1074/jbc.273.29.18647			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660839	hybrid			2022-12-27	WOS:000074828500094
J	Saha, C; Nigam, SK; Denker, BM				Saha, C; Nigam, SK; Denker, BM			Involvement of G alpha(i2) in the maintenance and biogenesis of epithelial cell tight junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTRACELLULAR CALCIUM; ALPHA-SUBUNITS; IDENTIFICATION; MORPHOGENESIS; TERMINUS; NEPHRON	yPolarized epithelial cells have highly developed tight junctions (TJ) to maintain an impermeant barrier and segregate plasma membrane functions, but the mechanisms that promote TJ formation and maintain its integrity are only partially defined. Treatment of confluent monolayers of Madin-Darby canine kidney (MDCK) cells with AlF4- (activator of heterotrimeric G protein alpha subunits) results in a 3-4-fold increase in transepithelial resistances (TER), a reliable indicator of TJ integrity. MOCK cells transfected with activated G alpha(0) (Q205L) have acclerated TJ formation (Denker, B. M., Saha, C., Khawaja, S., and Nigam, S. J. (1996) J. Biol. Chem. 271, 25750-25753). G alpha(i2) has been localized within the tight junction, and a role for G alpha(i2) in the formation and/or maintenance of the tight junction was studied by transfection of MDCK cells with vector without insert (PC), wild type G alpha(i2), or a GTPase-deficient mutant (constitutively activated), Q205L alpha(i2). Tryptic conformational analysis confirmed expression of a constitutively active G alpha(i2) in Q205L alpha(i2)-MDCK cells, and confocal microscopy showed a similar pattern of G alpha(i2) localization in the three cell lines. Q205L alpha(i2)-MDCK cells had significantly higher base-line TER values than wild type G alpha(i2)- or PC-MDCK cells (1187 +/- 150 versus 576 +/- 89 (G alpha(i2)); 377 +/- 52 Omega . cm(2) (PC)), and both G alpha(i2)- and Q205L alpha(i2)-transfected cell lines more rapidly develop TER in the Ca2+ switch, a model widely used to study the mechanisms of junctional assembly. Treatment of cells with AlF4- during the Ca2+ switch had little effect on the kinetics of TER development in G alpha(i2)- or Q205L alpha(i2)-MDCK cells, but PC cells reached half-maximal TER significantly sooner in the presence of AlF4- (similar times to G alpha(i2)-transfected cells). Base-line TER values obtained after the switch were significantly higher for all three cell lines in the presence of AlF4-. These findings indicate that G alpha(i2) is important for both the maintenance and development of the TJ, although additional G alpha subunits are likely to play a role.	Harvard Univ, Inst Med, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Denker, BM (corresponding author), Harvard Univ, Inst Med, Sch Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	bdenker@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055223, R29GM055223] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53507] Funding Source: Medline; NIGMS NIH HHS [GM55223] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; CEREIJIDO M, 1993, J CELL SCI, P127; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; DENKER BM, 1992, J BIOL CHEM, V267, P9998; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DENKER BM, 1995, BIOCHEMISTRY-US, V34, P5544, DOI 10.1021/bi00016a028; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Dodane V, 1996, J MEMBRANE BIOL, V149, P199, DOI 10.1007/s002329900020; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hamilton SE, 1997, BIOCHEM BIOPH RES CO, V234, P1, DOI 10.1006/bbrc.1997.6569; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Saitou M, 1998, J CELL BIOL, V141, P397, DOI 10.1083/jcb.141.2.397; SENKFOR SI, 1993, J CLIN INVEST, V92, P786, DOI 10.1172/JCI116651; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; STEVENSON BR, 1984, J CELL BIOL, V98, P1209, DOI 10.1083/jcb.98.4.1209; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, SEMIN NEPHROL, V15, P315; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072	30	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21629	21633		10.1074/jbc.273.34.21629	http://dx.doi.org/10.1074/jbc.273.34.21629			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705295	hybrid			2022-12-27	WOS:000075492600029
J	Winkler, DG; Cutler, RE; Drugan, JK; Campbell, S; Morrison, DK; Cooper, JA				Winkler, DG; Cutler, RE; Drugan, JK; Campbell, S; Morrison, DK; Cooper, JA			Identification of residues in the cysteine-rich domain of Raf-1 that control Ras binding and Raf-1 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PLASMA-MEMBRANE; PROTEIN-KINASE; MAP KINASE; TYROSINE PHOSPHORYLATION; HA-RAS; ACTIVATION; 14-3-3-PROTEINS; TRANSFORMATION; COMPLEX	We have identified mutations in Raf-l that increase binding to Ras. The mutations were identified making use of three mutant forms of Ras that have reduced Raf-l binding (Winkler, D. G., Johnson, J. C., Cooper, J, A., and Vojtek, A. B. (1997) J. Biol, Chem. 272, 24402-24409). One mutation in Raf-l, N64L, suppresses the Ras mutant R41Q but not other Ras mutants, suggesting that this mutation structurally complements the Ras R41Q mutation. Missense substitutions of residues 143 and 144 in the Raf-l cysteine-rich domain were isolated multiple times. These Raf-l mutants, R143Q, R143W, and K144E, were general suppressors of three different Ras mutants and had increased interaction with non-mutant Ras. Each was slightly activated relative to wild-type Raf-1 in a transformation assay. In addition, two mutants, R143W and K144E, were active when tested for induction of germinal vesicle breakdown in Xenopus oocytes. Interestingly, all three cysteine-rich domain mutations reduced the ability of the Raf-1 N-terminal regulatory region to inhibit Xenopus oocyte germinal vesicle breakdown induced by the C-terminal catalytic region of Raf-l, We propose that a direct or indirect regulatory interaction between the N- and C-terminal regions of Raf-l is reduced by the R143W, R143Q, and K144E mutations, thereby increasing access to the Ras-binding regions of Raf-l and increasing Raf-l activity.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; NCI, Mol Basis Carcinogenesis Lab, ABL Basic Res, Frederick Canc Res & Dev Ctr, Frederick, MD 20702 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of North Carolina; University of North Carolina Chapel Hill	Cooper, JA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N A2025,POB 9024, Seattle, WA 98109 USA.			campbell, sharon/0000-0003-0311-409X	NATIONAL CANCER INSTITUTE [R01CA070308, F32CA066281, R01CA054786] Funding Source: NIH RePORTER; NCI NIH HHS [CA70308, CA66281, CA54786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; CORMACK BP, 1993, SCIENCE, V262, P244, DOI 10.1126/science.8211143; Cutler RE, 1997, EMBO J, V16, P1953, DOI 10.1093/emboj/16.8.1953; CUTLER RE, 1998, IN PRESS P NATL ACAD; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DIAZ R, 1997, MOL CELL BIOL, V17, P4509; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FINNEY RE, 1993, CURR BIOL, V3, P805, DOI 10.1016/0960-9822(93)90214-9; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Rommel C, 1996, ONCOGENE, V12, P609; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Winkler DG, 1997, J BIOL CHEM, V272, P24402, DOI 10.1074/jbc.272.39.24402; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21578	21584		10.1074/jbc.273.34.21578	http://dx.doi.org/10.1074/jbc.273.34.21578			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705288	hybrid, Green Published			2022-12-27	WOS:000075492600022
J	Dobritzsch, D; Konig, S; Schneider, G; Lu, GG				Dobritzsch, D; Konig, S; Schneider, G; Lu, GG			High resolution crystal structure of pyruvate decarboxylase from Zymomonas mobilis - Implications for substrate activation in pyruvate decarboxylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE DEPENDENT ENZYME; THIAMIN DIPHOSPHATE; BREWERS-YEAST; TRANSKETOLASE; EQUILIBRIUM; SCATTERING; OXIDASE; RING; ION; PDC	The crystal structure of tetrameric pyruvate decarboxylase from Zymomonas nobilis has been determined at 1.9 Angstrom resolution and refined to a crystallographic R-factor of 16.2% and R-free of 19.7%, The subunit consists of three domains, all of the alpha/beta type. Two of the subunits form a tight dimer with an extensive interface area. The thiamin diphosphate binding site is located at the subunit-subunit interface, and the cofactor, bound in the V conformation, interacts with residues from the N-terminal domain of one subunit and the C-terminal domain of the second subunit, The S-fold symmetry generates the second thiamin diphosphate binding site in the dimer, Two of the dimers form a tightly packed tetramer with pseudo 222 symmetry. The interface area between the dimers is much larger in pyruvate decarboxylase from Z, mobilis than in the yeast enzyme, and structural differences in these parts result in a completely different packing of the subunits in the two enzymes. In contrast to other pyruvate decarboxylases, the enzyme from Z, mobilis is not subject to allosteric activation by the substrate. The tight packing of the dimers in the tetramer prevents large rearrangements in the quaternary structure as seen in the yeast enzyme and locks the enzyme in an activated conformation. The architecture of the cofactor binding site and the active site is similar in the two enzymes. However, the x-ray analysis reveals subtle but significant structural differences in the active site that might be responsible for variations in the biochemical properties in these enzymes.	Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Martin Luther Universitat Halle Wittenberg, Fachbereich Biochem Biotechnol 1, Inst Biochem, D-06099 Halle, Germany	Karolinska Institutet; Martin Luther University Halle Wittenberg	Lu, GG (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Doktorsringen 9, S-17177 Stockholm, Sweden.	guoguang@alfa.mbb.ki.se	Dobritzsch, Doreen/H-7334-2018; Koenig, Stephan/GRX-2480-2022	Schneider, Gunter/0000-0003-0622-5713				ARJUNAN P, 1986, J MOL BIOL, V355, P590; BABURINA I, 1994, BIOCHEMISTRY-US, V33, P5630, DOI 10.1021/bi00184a035; BRINGERMEYER S, 1986, ARCH MICROBIOL, V146, P105, DOI 10.1007/BF00402334; BRINGERMEYER S, 1988, BIOCATALYSIS, V1, P321; BRUHN H, 1995, EUR J BIOCHEM, V234, P650, DOI 10.1111/j.1432-1033.1995.650_b.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONWAY T, 1987, J BACTERIOL, V169, P949, DOI 10.1128/jb.169.3.949-954.1987; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DIEFENBACH RJ, 1991, BIOCHEM J, V276, P439, DOI 10.1042/bj2760439; Dietrich A, 1997, FEBS LETT, V400, P42, DOI 10.1016/S0014-5793(96)01326-9; DUCLOS JM, 1974, BIOCHEMISTRY-US, V13, P5358, DOI 10.1021/bi00723a016; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FUREY W, 1996, BIOCH PHYSL THIAMIN, P103; HOLZER H, 1956, BIOCHEM Z, V327, P331; HUBNER G, 1988, BIOMED BIOCHIM ACTA, V47, P9; HUBNER G, 1990, FEBS LETT, V266, P17, DOI 10.1016/0014-5793(90)81495-A; HUBNER G, 1978, EUR J BIOCHEM, V92, P175, DOI 10.1111/j.1432-1033.1978.tb12735.x; JONES TA, 1992, P CCP4 STUD WEEK WAR, P99; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P100; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KLEJWEGT G, 1994, ACTA CRYSTALLOGR S D, V50, P178; KONIG S, 1992, BIOCHEMISTRY-US, V31, P8726; KONIG S, 1990, BIOMED BIOCHIM ACTA, V49, P465; KONIG S, 1993, EUR BIOPHYS J BIOPHY, V22, P185; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; Lobell M, 1996, J AM CHEM SOC, V118, P1867, DOI 10.1021/ja951830t; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; Lu GG, 1997, FEBS LETT, V403, P249, DOI 10.1016/S0014-5793(97)00057-4; MICZKA G, 1992, BIOTECHNOL APPL BIOC, V15, P192; MULLER YA, 1993, STRUCTURE, V1, P95, DOI 10.1016/0969-2126(93)90025-C; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEALE AD, 1987, NUCLEIC ACIDS RES, V15, P1753, DOI 10.1093/nar/15.4.1753; NEALE AD, 1987, J BACTERIOL, V169, P1024, DOI 10.1128/jb.169.3.1024-1028.1987; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; POHL M, 1995, BIOTECHNOL APPL BIOC, V22, P95; REYNEN M, 1988, J BACTERIOL, V170, P3310, DOI 10.1128/jb.170.7.3310-3313.1988; Schenk G, 1997, EUR J BIOCHEM, V248, P63, DOI 10.1111/j.1432-1033.1997.t01-1-00063.x; SUN SX, 1995, J AM CHEM SOC, V117, P7317, DOI 10.1021/ja00133a004; ZOLTEWICZ JA, 1980, J ORG CHEM, V45, P2104, DOI 10.1021/jo01299a015; 1994, ACTA CRYSTALLOGR S D, V50, P760	44	149	163	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20196	20204		10.1074/jbc.273.32.20196	http://dx.doi.org/10.1074/jbc.273.32.20196			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685367	hybrid			2022-12-27	WOS:000075305400044
J	Hayakawa, T; Noda, M; Yasuda, K; Yorifuji, H; Taniguchi, S; Miwa, I; Sakura, H; Terauchi, Y; Hayashi, J; Sharp, GWG; Kanazawa, Y; Akanuma, Y; Yazaki, Y; Kadowaki, T				Hayakawa, T; Noda, M; Yasuda, K; Yorifuji, H; Taniguchi, S; Miwa, I; Sakura, H; Terauchi, Y; Hayashi, J; Sharp, GWG; Kanazawa, Y; Akanuma, Y; Yazaki, Y; Kadowaki, T			Ethidium bromide-induced inhibition of mitochondrial gene transcription suppresses glucose-stimulated insulin release in the mouse pancreatic beta-cell line beta HC9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS; B-CELLS; POTASSIUM CHANNEL; K+ CHANNELS; SECRETION; DNA; EXPRESSION; MUTATION; ISLETS; RAT	Recently, a mitochondrial mutation was found to be associated with maternally inherited diabetes mellitus (Kadowaki, T., Kadowaki, H., Mori, Y., Tobe, K., Sakuta, R., Suzuki, Y., Tanabe, Y, Sakura, H., Awata, T., Goto, Y., Hayakawa, T., Matsuoka, K., Kawamori, R., Kamada, T., Horai, S., Nonaka, I., Hagura, R., Akanuma, Y., and Yazaki, Y. (1994) N. Engl. J. Med. 330, 962-968). In order to elucidate its etiology, we have investigated the involvement of mitochondrial function in insulin secretion. Culture of the pancreatic beta-cell line, beta HC9, with low dose ethidium bromide (EB) (0.4 mu g/ml) for 2-6 days resulted in a substantial decrease in the transcription level of mitochondrial DNA (to 10-20% of the control cells) without changing its copy number, whereas the transcription of nuclear genes was grossly unaffected. Electron microscopic analysis revealed that treatment by EB caused morphological changes only in mitochondria and not in other organelles such as nuclei, endoplasmic reticula, Golgi bodies, or secretory granules. When the cells were treated with EB for 6 days, glucose (20 mM) could no longer stimulate insulin secretion, while glibenclamide (1 mu M) Still did. When EB was removed after 3- or B-day treatment, mitochondrial gene transcription recovered within 2 days, and the profiles of insulin secretion returned to normal within 7 days. Studies with fura-2 indicated that in EB-treated cells, glucose (20 mM) failed to increase intracellular Ca2+ while the effect of glibenclamide (1 mu M) was maintained. Our system provides a unique way to investigate the relationship between mitochondrial function and insulin secretion.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Jichi Med Sch, Omiya Med Ctr, Omiya, Saitama 330, Japan; Asahi Life Fdn, Inst Diabet Care & Res, Chiyoda Ku, Tokyo 100, Japan; Natl Def Med Coll, Dept Anat 2, Tokorozawa, Saitama 359, Japan; Meijo Univ, Fac Pharm, Dept Pathobiochem, Tenpaku Ku, Nagoya, Aichi 468, Japan; Univ Tsukuba, Inst Biol Sci, Ibaraki, Osaka 305, Japan; Cornell Univ, Coll Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA	University of Tokyo; Jichi Medical University; Asahi Life Foundation; National Defense Medical College - Japan; Meijo University; University of Tsukuba; Cornell University	Yasuda, K (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Terauchi, Yasuo/AAO-4347-2020	NODA, Mitsuhiko/0000-0003-0413-4631				ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BRUN T, 1993, J BIOL CHEM, V268, P18905; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; CORDELL B, 1979, CELL, V18, P533, DOI 10.1016/0092-8674(79)90070-9; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; DUNNE MJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P67, DOI 10.1016/0304-4157(91)90012-L; EFRAT S, 1993, DIABETES, V42, P901, DOI 10.2337/diabetes.42.6.901; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAYAKAWA T, 1979, J GEN APPL MICROBIOL, V25, P255, DOI 10.2323/jgam.25.255; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; HOSOKAWA H, 1995, DIABETES, V44, P1328, DOI 10.2337/diabetes.44.11.1328; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KADOWAKI H, 1993, LANCET, V341, P893, DOI 10.1016/0140-6736(93)93101-6; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LENZEN S, 1982, J BIOL CHEM, V257, P6631; LENZEN S, 1986, BIOSCIENCE REP, V6, P163, DOI 10.1007/BF01115002; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; LORY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MEDA P, 1990, J CLIN INVEST, V86, P759, DOI 10.1172/JCI114772; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; MISLER S, 1992, PFLUG ARCH EUR J PHY, V421, P289, DOI 10.1007/BF00374842; MIWA I, 1995, ENZYME PROTEIN, V48, P135; Noda M, 1996, DIABETES, V45, P1766, DOI 10.2337/diabetes.45.12.1766; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SAKURADA M, 1993, ENDOCRINOLOGY, V132, P2659, DOI 10.1210/en.132.6.2659; Sambrook J., 2002, MOL CLONING LAB MANU; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Terauchi Y, 1995, J BIOL CHEM, V270, P30253, DOI 10.1074/jbc.270.51.30253; TRUS MD, 1981, DIABETES, V30, P911, DOI 10.2337/diabetes.30.11.911; TSUURA Y, 1993, DIABETES, V42, P1446, DOI 10.2337/diabetes.42.10.1446; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WELSH M, 1985, J BIOL CHEM, V260, P3590; ZYBLER E, 1969, J MOL BIOL, V44, P195	47	89	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20300	20307		10.1074/jbc.273.32.20300	http://dx.doi.org/10.1074/jbc.273.32.20300			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685380	hybrid			2022-12-27	WOS:000075305400057
J	Yonetani, T; Tsuneshige, A; Zhou, YX; Chen, XS				Yonetani, T; Tsuneshige, A; Zhou, YX; Chen, XS			Electron paramagnetic resonance and oxygen binding studies of alpha-nitrosyl hemoglobin - A novel oxygen carrier having no-assisted allosteric functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE HEMOGLOBIN; HYBRID HEMOGLOBINS; TREATED RATS; PHOTO-DISSOCIATION; ERYTHROCYTES; SUBUNITS; EQUILIBRIUM; SPECTRUM; HEMES; MODEL	alpha-Nitrosyl hemoglobin, alpha(Fe-NO)(2)beta(Fe)(2), which is frequently observed upon reaction of deoxy hemoglobin with limited quantities of NO in vitro as well as in vivo, has been synthetically prepared, and its reaction with O-2 has been investigation by EPR and thermodynamic equilibrium measurements. alpha-Nitrosyl hemoglobin is relatively stable under aerobic conditions and undergoes reversible O-2 binding at the heme sites of its beta-subunits. Its O-2 binding is coupled to the structural/functional transition between T- (low affinity extreme) and R- thigh affinity) states. This transition is linked to the reversible cleavage of the heme Fe-proximal His bonds in the alpha(Fe-NO) subunits and is sensitive to allosteric effectors, such as protons, 2,3-biphosphoglycerate, and inositol hexaphosphate. In fact, alpha(Fe-NO)(2)beta(Fe)(2) is exceptionally sensitive to protons, as it exhibits a highly enhanced Bohr effect. The total Bohr effect of alpha-nitrosyl hemoglobin is comparable to that of normal hemoglobin, despite the fact that the oxygenation process involves only two ligation steps. All of these structural and functional evidences have been further confirmed by examining the reactivity of the sulfhydryl group of the Cys(beta 93) toward 4,4'-dipyridyl disulfide of several alpha-nitrosyl hemoglobin derivatives over a wide pH range, as a probe for quaternary structure. Despite the halved O-2-carrying capacity, alpha-nitrosyl hemoglobin is fully functional (cooperative and allosterically sensitive) and could represent a versatile low affinity O-2 carrier with improved features that could deliver O-2 to tissues effectively even after NO is sequestered at the heme sites of the alpha-subunits. It is concluded that the NO bound to the heme sites of the alpha-subunits of hemoglobin acts as a negative allosteric effector of Hb and thus might play a role in O-2/CO2 transport in the blood under physiological conditions.	Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19194 USA	University of Pennsylvania	Yonetani, T (corresponding author), Univ Penn, Med Ctr, Dept Biochem & Biophys, B605 Richards Bldg 6089,3700 Hamilton Walk, Philadelphia, PA 19194 USA.	yonetant@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14508] Funding Source: Medline; NIGMS NIH HHS [GM48130] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMPULSKI RS, 1969, ANAL BIOCHEM, V32, P163, DOI 10.1016/0003-2697(69)90118-3; Barrick D, 1997, NAT STRUCT BIOL, V4, P78, DOI 10.1038/nsb0197-78; BERMAN M, 1971, ARCH BIOCHEM BIOPHYS, V145, P236; BUCCI E, 1965, J BIOL CHEM, V240, pP551; CANTILENA LR, 1992, J LAB CLIN MED, V120, P902; CHAMULITRAT W, 1994, MOL PHARMACOL, V46, P391; DRABKIN DL, 1946, J BIOL CHEM, V164, P703; ERIKSSON LEG, 1994, BIOCHEM BIOPH RES CO, V203, P176, DOI 10.1006/bbrc.1994.2165; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FUJII M, 1993, J BIOL CHEM, V268, P15386; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P197, DOI 10.1098/rspb.1965.0066; GRASSETTI DR, 1967, ARCH BIOCHEM BIOPHYS, V119, P41, DOI 10.1016/0003-9861(67)90426-2; HAYASHI N, 1966, J BIOL CHEM, V241, P79; HENRY Y, 1973, J MOL BIOL, V73, P469, DOI 10.1016/0022-2836(73)90094-6; HILLE R, 1979, J BIOL CHEM, V254, P2110; HUANG TH, 1979, J BIOL CHEM, V254, P1467; HUOT AE, 1992, BIOCHEM BIOPH RES CO, V182, P151, DOI 10.1016/S0006-291X(05)80124-X; IMAI K, 1972, BIOCHEMISTRY-US, V11, P114, DOI 10.1021/bi00751a020; IMAI K, 1977, BIOCHIM BIOPHYS ACTA, V490, P1564; Imai K., 1982, ALLOSTERIC EFFECTS H; KON H, 1975, BIOCHIM BIOPHYS ACTA, V379, P103, DOI 10.1016/0005-2795(75)90012-4; Kosaka H, 1996, BIOCHEM BIOPH RES CO, V218, P749, DOI 10.1006/bbrc.1996.0133; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NAGAI K, 1978, BIOCHIM BIOPHYS ACTA, V532, P17, DOI 10.1016/0005-2795(78)90443-9; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P2033, DOI 10.1073/pnas.77.4.2033; ODA H, 1975, ARCH ENVIRON HEALTH, V30, P453, DOI 10.1080/00039896.1975.10666749; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RALOFF J, 1995, SCI NEWS, V148, P247; REIN H, 1972, FEBS LETT, V24, P24, DOI 10.1016/0014-5793(72)80817-2; ROMBERG RW, 1970, BIOCHEMISTRY-US, V18, P5387; ROSE EJ, 1983, J AM CHEM SOC, V105, P2866, DOI 10.1021/ja00347a056; Scheidt W.R., 1987, METAL COMPLEXES TETR, V64, P1, DOI DOI 10.1007/BFB0036789; SCHEIDT WR, 1975, J AM CHEM SOC, V97, P17, DOI 10.1021/ja00834a005; SHIBAYAMA N, 1987, BIOCHEMISTRY-US, V26, P2194, DOI 10.1021/bi00382a019; SHIGA T, 1969, BIOCHEMISTRY-US, V8, P378, DOI 10.1021/bi00829a052; SHIMAZU M, 1984, INORG CHIM ACTA, V91, P210; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; SUZUKI T, 1965, BIOCHEM BIOPH RES CO, V19, P691, DOI 10.1016/0006-291X(65)90312-8; SZABO A, 1976, BIOCHEMISTRY-US, V15, P4427, DOI 10.1021/bi00665a013; TAKETA F, 1978, J BIOL CHEM, V253, P5448; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; TSUNESHIGE A, 1993, J BIOL CHEM, V268, P23031; Tsuneshige A, 1998, BIOPHYS J, V74, pA81; Tsuneshige A, 1998, BIOPHYS J, V74, pA80; WANG QZ, 1991, LIFE SCI, V49, pPL55, DOI 10.1016/0024-3205(91)90251-6; WAYLAND BB, 1974, J AM CHEM SOC, V96, P6037, DOI 10.1021/ja00826a013; YOSHIMURA T, 1997, CARDIOVASCULAR DIS G, V3, P1	50	121	126	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20323	20333		10.1074/jbc.273.32.20323	http://dx.doi.org/10.1074/jbc.273.32.20323			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685383	hybrid			2022-12-27	WOS:000075305400060
J	Zhu, T; Beckingham, K; Ikebe, M				Zhu, T; Beckingham, K; Ikebe, M			High affinity Ca2+ binding sites of calmodulin are critical for the regulation of myosin I beta motor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDIVIDUAL CA2+-BINDING SITES; CALCIUM-BINDING; MUSCLE MYOSIN; LIGHT-CHAINS; DOMAIN; CONFORMATION; MUTATIONS	We coexpressed myosin IP heavy chain with three different calmodulin mutants in which the two Ca2+-binding sites of the two N-terminal domain (E12Q), C-terminal domain (E34Q), or all four sites (E1234Q) are mutated in order to define the importance of these Ca2+ binding sites to the regulation of myosin Tp. The! calmodulin mutated at the two Ca2+ binding sites in N-terminal domain and C-terminal domain lost its lower affinity Ca2+ binding site and higher affinity Ca2+ binding site, respectively, We found that, based upon the change in the actin-activated ATPase activities and actin translocating activities, myosin I beta with E12Q calmodulin has the regulatory characteristics similar to myosin IP containing wild-type calmodulin, while myosin IP with E34Q or E1234Q calmodulin lose all Ca2+ regulation. While the increase in myosin IP ATPase activity paralleled the dissociation of 1 mol of calmodulin from myosin Ip heavy chain for both wild type (above pCa 5) and E12Q calmodulin (above pCa 6), the Ca2+ level required for the inhibition of actin-translocating activity of myosin Ip was lower than that required for dissociation of calmodulin, suggesting that the conformational change induced by the binding of Ca2+ at the high affinity site but not the dissociation of calmodulin is critical for the inhibition of the motor activity. Our results suggest that the regulation of unconventional myosins by Ca2+ is directly mediated by the Ca2+ binding to calmodulin, and that the C-terminal pair of Ca2+-binding sites are critical for this regulation.	Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA	University of Massachusetts System; University of Massachusetts Worcester; Rice University	Ikebe, M (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, Worcester, MA 01655 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056218, P01HL047530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 56218, HL 47530] Funding Source: Medline; NIAMS NIH HHS [AR 41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARYLKO B, 1992, P NATL ACAD SCI USA, V89, P490, DOI 10.1073/pnas.89.2.490; BECKINGHAM K, 1991, J BIOL CHEM, V266, P6027; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COLUCCIO LM, 1994, J CELL SCI, V107, P2279; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Hasson T, 1996, J BIOL CHEM, V271, P16431, DOI 10.1074/jbc.271.28.16431; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KELLER CH, 1982, CALCIUM CELL FUNCTIO, V3, P103; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; LINSE S, 1991, J BIOL CHEM, V266, P8050; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Mukherjea P, 1996, PROTEIN SCI, V5, P468; POLLARD DP, 1991, ANNU REV PHYSIOL, V53, P653; REIZES O, 1994, P NATL ACAD SCI USA, V91, P6349, DOI 10.1073/pnas.91.14.6349; RUPPERT C, 1993, J CELL BIOL, V120, P1393, DOI 10.1083/jcb.120.6.1393; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SHERR EH, 1993, J CELL BIOL, V120, P1405, DOI 10.1083/jcb.120.6.1405; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Swindells MB, 1996, NAT STRUCT BIOL, V3, P501, DOI 10.1038/nsb0696-501; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; Zhu T, 1996, BIOCHEMISTRY-US, V35, P513, DOI 10.1021/bi952053c; ZHU T, 1994, FEBS LETT, V339, P31, DOI 10.1016/0014-5793(94)80378-1	31	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20481	20486		10.1074/jbc.273.32.20481	http://dx.doi.org/10.1074/jbc.273.32.20481			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685403	hybrid			2022-12-27	WOS:000075305400080
J	Lee, Y; Sayre, LM				Lee, Y; Sayre, LM			Reaffirmation that metabolism of polyamines by bovine plasma amine oxidase occurs strictly at the primary amino termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-AMINOPROPIONITRILE; MONOAMINE-OXIDASE; SPERMIDINE; MODEL	Oxidation of the biologically important polyamines spermine and spermidine by plasma amine oxidase (PAO) was specified many years ago to occur at the terminal primary rather than internal secondary amine positions. However, the finding of sequential enzymatic conversion of spermine to spermidine and then to putrescine (1,4-butanediamine) is superficially suggestive of metabolism at the secondary amine positions, and a recent publication (Houen, G., Beck, K., and Jensen, A. L. (1994) Acta Chem. Scand 48, 52-60) claimed that the original interpretation of preferential "terminal" deamination does not stand up to scrutiny with modern methods of analysis. We herein demonstrate that the findings cited in support of secondary amine deamination can arise artifactually from spontaneous elimination/addition reactions following initial metabolism at the terminal positions of 3-(aminopropyl)amines. We further find no evidence for the ability of PAO to metabolize the secondary amine position in homospermidine, which is devoid of such complicating side reactions. Our results support the original claimed specificity of PAO for the primary amino termini of polyamines, all of which are consistent with the general finding that the quinone-dependent copper amine oxidases specifically metabolize primary amines.	Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University	Sayre, LM (corresponding author), Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.		Sayre, Lawrence M/C-8224-2011		NIGMS NIH HHS [GM 48812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI O, 1966, AGR BIOL CHEM TOKYO, V30, P1202, DOI 10.1080/00021369.1966.10858750; ANTHONY DC, 1989, J NEUROPATH EXP NEUR, V48, P348, DOI 10.1097/00005072-198905000-00148; BACHRACH U, 1960, BIOCHIM BIOPHYS ACTA, V40, P545, DOI 10.1016/0006-3002(60)91401-3; BACHRACH U, 1986, ANAL BIOCHEM, V152, P423, DOI 10.1016/0003-2697(86)90429-X; BERGERON RJ, 1981, SYNTHESIS-STUTTGART, P732; DING CZ, 1993, J MED CHEM, V36, P1711, DOI 10.1021/jm00064a004; FERNANDEZ S, 1991, SYNTHESIS-STUTTGART, P713; HASSE K, 1963, BIOCHEM Z, V337, P69; HOUEN G, 1994, ACTA CHEM SCAND, V48, P52, DOI 10.3891/acta.chem.scand.48-0052; JAKOBY WB, 1959, J BIOL CHEM, V234, P2145; Klinman JP, 1996, J BIOL CHEM, V271, P27189, DOI 10.1074/jbc.271.44.27189; KUTTAN R, 1971, BIOCHEMISTRY-US, V10, P361, DOI 10.1021/bi00779a001; LEE YH, 1995, J AM CHEM SOC, V117, P3096, DOI 10.1021/ja00116a014; Lee YH, 1996, J AM CHEM SOC, V118, P7241, DOI 10.1021/ja9543210; MONDOVI B, 1983, METHOD ENZYMOL, V94, P314; RAIMONDI L, 1985, AGENTS ACTIONS, V16, P95, DOI 10.1007/BF01983110; TABOR CW, 1956, J PHARMACOL EXP THER, V116, P139; TABOR CW, 1970, J BIOL CHEM, V245, P5424; TABOR CW, 1964, FED PROC, V23, P385; TABOR CW, 1964, J BIOL CHEM, V239, P2194; TABOR H, 1972, ADV ENZYMOL RAMB, V36, P203; TANG SS, 1983, J BIOL CHEM, V258, P4331; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i; WILMARTH KR, 1991, J TOXICOL ENV HEALTH, V32, P415, DOI 10.1080/15287399109531493	24	37	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19490	19494		10.1074/jbc.273.31.19490	http://dx.doi.org/10.1074/jbc.273.31.19490			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677370	hybrid			2022-12-27	WOS:000075125200022
J	Short, DB; Trotter, KW; Reczek, D; Kreda, SM; Bretscher, A; Boucher, RC; Stutts, MJ; Milgram, SL				Short, DB; Trotter, KW; Reczek, D; Kreda, SM; Bretscher, A; Boucher, RC; Stutts, MJ; Milgram, SL			An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; GUANYLATE KINASES; EPITHELIAL-CELLS; EXPRESSION; DOMAIN; FAMILY; EZRIN; TIGHT; GENE; ZO-1	The function of the cystic fibrosis transmembrane conductance regulator (CFTR) as a Cl- channel in the apical membrane of epithelial cells is extensively documented. However, less is known about the molecular determinants of CFTR residence in the apical membrane, basal regulation of its Cl- channel activity, and its reported effects on the function of other transporters. These aspects of CFTR function likely require specific interactions between CFTR and unknown proteins in the apical compartment of epithelial cells. Here we report that CFTR interacts with the recently discovered protein, EBP50 GERM-binding phosphoprotein 50). EBP50 is concentrated at the apical membrane in human airway epithelial cells, in vivo, and CFTR and EBP50 associate in in vitro binding assays. The CFTR-EBP50 interaction requires the COOH-terminal DTRL sequence of CFTR and utilizes either PDZ1 or PDZ2 of EBP50, although binding to PDZ1 is of greater affinity. Through formation of a complex, the intel action between CFTR and EBP50 may influence the stability and/or regulation of CFTR Cl- channel function in the cell membrane and provides a potential mechanism through which CFTR can affect the activity of other apical membrane proteins.	Univ N Carolina, Dept Physiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cornell University	Milgram, SL (corresponding author), Univ N Carolina, Dept Physiol, CB 7545, Chapel Hill, NC 27599 USA.	milg@med.unc.edu			NHLBI NIH HHS [P50 HL42384] Funding Source: Medline; NIDDK NIH HHS [R29DK50744] Funding Source: Medline; NIGMS NIH HHS [GM36652] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK050744] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036652] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRANT SR, 1995, AM J PHYSIOL, V269, P198; Bretscher A, 1997, J CELL SCI, V110, P3011; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1996, AM J PHYSIOL, V270, P259; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Gee SH, 1998, J NEUROSCI, V18, P128; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; Greger R, 1996, J MOL MED-JMM, V74, P527; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hanrahan JW, 1996, J EXP ZOOL, V275, P283; HARRIS A, 1995, QJM-INT J MED, V88, P229; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KUVER R, 1994, BIOCHEM BIOPH RES CO, V203, P1457, DOI 10.1006/bbrc.1994.2348; MCNICHOLAS CM, 1997, AM J PHYSIOL, V273, P843; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Myszka DG, 1996, PROTEIN SCI, V5, P2468, DOI 10.1002/pro.5560051209; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Niethammer M, 1996, J NEUROSCI, V16, P2157; ORAT AG, 1995, AM J PHYSIOL, V268, pC1552; Ponting CP, 1997, PROTEIN SCI, V6, P464; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RECZEK D, 1998, J BIOL CHEM, V273, P18378; RIORDAN JR, 1989, SCIENCE, V245, P1066; SARKADI B, 1992, J BIOL CHEM, V267, P2087; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; SONGYANG Z, 1997, SCIENCE, V275, P7376; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WILLOTT E, 1992, AM J PHYSIOL, V262, pC1119, DOI 10.1152/ajpcell.1992.262.5.C1119; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7; Xia XM, 1998, J NEUROSCI, V18, P2360; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	50	393	398	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19797	19801		10.1074/jbc.273.31.19797	http://dx.doi.org/10.1074/jbc.273.31.19797			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677412	Green Published, hybrid			2022-12-27	WOS:000075125200064
J	Weitkamp, B; Jurk, K; Beinbrech, G				Weitkamp, B; Jurk, K; Beinbrech, G			Projectin-thin filament interactions and modulation of the sensitivity of the actomyosin ATPase to calcium by projectin kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIN-LIKE PROTEINS; CRAYFISH CLAW MUSCLE; SKELETAL-MUSCLE; INSECT FLIGHT; MOLLUSCAN TWITCHIN; STRIATED-MUSCLE; BINDING PROTEIN; LIGHT-CHAIN; TROPONIN-I; MYOSIN	The insect muscle protein projectin (900 kDa) belongs to a novel family of cytoskeleton-associated protein kinases (titin, twitchin, and projectin) that are members of the immunoglobulin superfamily, The functions of these kinases are still unknown although recent data suggest a role in modulating muscle activity and generating passive elasticity, An important question is what are the in vivo substrates for these enzymes. We found a thin filament-associated 30 kDa protein that acts as an in vitro substrate for projectin kinase from Locusta migratoria, However, we did not find activators for projectin kinase, Neither calcium, calcium with calmodulin, nor cAMP activated the in vitro activity of projectin kinase, Binding studies revealed a strong interaction between projectin and thin filaments comparable with that of the projectin-myosin interaction. That an interaction might be possible in vivo is suggested by immunological studies showing that projectin is attached to the surface of myosin filaments. Since the molecular weights indicate that the 30 kDa protein might be troponin I, which is known to play a central role in modulating cardiac contractile activity, we studied whether phosphorylation of this protein by projectin changes the calcium sensitivity of the actomyosin ATPase. We found a significant increase in the calcium sensitivity. Thus, our results indicate the existence of a novel mechanism of regulation of muscle activity by a cytoskeleton-associated kinase.	Univ Munster, Inst Anim Physiol, D-48143 Munster, Germany	University of Munster	Weitkamp, B (corresponding author), Inst Arterioskleroseforsch, Domagkstr 3, D-48149 Munster, Germany.	jurk162@uni-muenster.de	Jurk, Kerstin/AAT-7768-2020					AYMESOUTHGATE A, 1995, J CELL BIOL, V128, P393, DOI 10.1083/jcb.128.3.393; BARBAS JA, 1991, GENE DEV, V5, P132, DOI 10.1101/gad.5.1.132; BEALL CJ, 1991, J CELL BIOL, V114, P941, DOI 10.1083/jcb.114.5.941; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BUSS JE, 1977, FEBS LETT, V73, P101, DOI 10.1016/0014-5793(77)80025-2; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; ETLINGER JD, 1976, J CELL BIOL, V68, P123, DOI 10.1083/jcb.68.1.123; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; GAUTEL M, 1995, EMBO J, V14, P1952, DOI 10.1002/j.1460-2075.1995.tb07187.x; GRANGE RW, 1993, CAN J APPL PHYSIOL, V18, P229, DOI 10.1139/h93-020; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; HEROLD PE, 1994, P NATL ACAD SCI USA, V91, P10144; HOROWITS R, 1986, NATURE, V323, P160, DOI 10.1038/323160a0; HOROWITS R, 1989, J CELL BIOL, V109, P2169, DOI 10.1083/jcb.109.5.2169; HU DH, 1990, J MUSCLE RES CELL M, V11, P497, DOI 10.1007/BF01745217; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUXELY HE, 1965, SCI AM, V213, P18; KATO M, 1992, BIOCHEM J, V281, P339, DOI 10.1042/bj2810339; KAWAMURA Y, 1994, J MUSCLE RES CELL M, V15, P623, DOI 10.1007/BF00121070; KELLER CS, 1995, CURR OPIN CELL BIOL, V7, P32, DOI 10.1016/0955-0674(95)80042-5; Kellermayer MSZ, 1996, FEBS LETT, V380, P281, DOI 10.1016/0014-5793(96)00055-5; KENDRICK-JONES J, 1970, Journal of Molecular Biology, V54, P313, DOI 10.1016/0022-2836(70)90432-8; KOLSCH B, 1995, NATURWISSENSCHAFTEN, V82, P239; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKEY A, 1990, EMBO J, V9, P3459, DOI 10.1002/j.1460-2075.1990.tb07554.x; LEHMAN W, 1975, J GEN PHYSIOL, V66, P1, DOI 10.1085/jgp.66.1.1; LEHMAN W, 1974, J GEN PHYSIOL, V63, P553, DOI 10.1085/jgp.63.5.553; LEI JY, 1994, J BIOL CHEM, V269, P21078; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANABE T, 1993, J MUSCLE RES CELL M, V14, P654, DOI 10.1007/BF00141562; MAROTO M, 1992, J MOL BIOL, V224, P287, DOI 10.1016/0022-2836(92)90994-U; NISHITA K, 1990, J BIOCHEM-TOKYO, V108, P677, DOI 10.1093/oxfordjournals.jbchem.a123262; Ohtani Y, 1996, TISSUE CELL, V28, P1, DOI 10.1016/S0040-8166(96)80038-3; OJIMA T, 1995, FISHERIES SCI, V61, P871, DOI 10.2331/fishsci.61.871; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PORTZEHL H, 1964, BIOCHIM BIOPHYS ACTA, V79, P581, DOI 10.1016/0926-6577(64)90224-4; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; ROCKSTEIN M, 1951, ANAL CHEM, V23, P1500, DOI 10.1021/ac60058a044; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; TOHTONG R, 1995, NATURE, V374, P650, DOI 10.1038/374650a0; VANDENBOOM R, 1995, AM J PHYSIOL, V37, P596; VIBERT P, 1993, J MUSCLE RES CELL M, V14, P598, DOI 10.1007/BF00141557; VIGOREAUX JO, 1991, J MUSCLE RES CELL M, V12, P340, DOI 10.1007/BF01738589; ZIEGLER C, 1994, COMP BIOCHEM PHYS A, V109, P823, DOI 10.1016/0300-9629(94)90230-5	48	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19802	19808		10.1074/jbc.273.31.19802	http://dx.doi.org/10.1074/jbc.273.31.19802			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677413	hybrid			2022-12-27	WOS:000075125200065
J	Andersen, CB; Roth, RA; Conti, M				Andersen, CB; Roth, RA; Conti, M			Protein kinase B/Akt induces resumption of meiosis in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; CYCLIC-AMP PHOSPHODIESTERASE; MOLECULAR-CLONING; PHOSPHATIDYLINOSITOL 3-KINASE; CAMP-PHOSPHODIESTERASE; SER/THR KINASE; INSULIN; AKT; PHOSPHORYLATION; ADIPOCYTES	The activation of protein kinase B/Akt is thought to be a critical step in the phosphoinositide 3-kinase pathway that regulates cell growth and differentiation. Because insulin-like growth factor 1 stimulates the resumption of meiosis in Xenopus laevis oocytes via phosphoinositide 3-kinase activation, we investigated the Akt involvement in this process. Injection of mRNA coding for a constitutively active Akt in Xenopus oocytes induced germinal vesicle breakdown (GVBD) to the same extent as progesterone or insulin treatment. Injection of mRNA coding for the wild type Akt kinase was less effective in stimulating GVBD, whereas Akt bearing a lysine mutation in the catalytic domain that abolishes the kinase activity had no effect, A mutant Akt lacking a membrane-targeting sequence did not induce GVBD, despite high levels of expression and activity, As previously reported for insulin, induction of GVBD by Akt was prevented by incubating the oocytes with cilostamide, an inhibitor specific for the type 3 phosphodiesterase (PDE8), suggesting that the activity of a PDE is required for Akt action. That an increase in PDE activity in the oocyte is sufficient to induce meiotic resumption was demonstrated by expression of an active PDE protein. In addition, the constitutively active Akt caused a S-fold increase in the activity of the endogenous PDE. These data demonstrate that Akt is in the pathway controlling resumption of meiosis in the Xenopus oocyte and that regulation of the activity of a PDE3 is a step distal to the kinase activation.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University; Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.				NICHD NIH HHS [P50 HD31398, HD20788] Funding Source: Medline; NIDDK NIH HHS [DK34976] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD031398, R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALESSI BR, 1997, CURR BIOL, V7, P261; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; DEUTERREINHARD M, 1997, MOL CELL BIOL, V17, P2259; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; HU Q, 1995, SCIENCE, V268, P1008; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; MALLER JL, 1986, J CYCLIC NUCL PROT, V11, P543; MALLER JL, 1979, J BIOL CHEM, V254, P579; Rahn T, 1996, J BIOL CHEM, V271, P11575, DOI 10.1074/jbc.271.19.11575; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; SADLER SE, 1991, MOL ENDOCRINOL, V5, P1939, DOI 10.1210/mend-5-12-1939; SADLER SE, 1989, J BIOL CHEM, V264, P856; SADLER SE, 1987, J BIOL CHEM, V262, P10644; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETTE C, 1994, J BIOL CHEM, V269, P18271; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226; Walter SA, 1997, MOL BIOL CELL, V8, P2157, DOI 10.1091/mbc.8.11.2157; WIERSMA A, 1998, 11 INT WORKSH DEV FU, P15; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219	35	71	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18705	18708		10.1074/jbc.273.30.18705	http://dx.doi.org/10.1074/jbc.273.30.18705			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668041	hybrid			2022-12-27	WOS:000074974700008
J	Beau, I; Groyer-Picard, MT; Le Bivic, A; Vannier, B; Loosfelt, H; Milgrom, E; Misrahi, M				Beau, I; Groyer-Picard, MT; Le Bivic, A; Vannier, B; Loosfelt, H; Milgrom, E; Misrahi, M			The basolateral localization signal of the follicle-stimulating hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; POLYMERIC IMMUNOGLOBULIN RECEPTOR; LYSOSOMAL ACID-PHOSPHATASE; TRANSFECTED MDCK CELLS; GROWTH-FACTOR RECEPTOR; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; ALPHA(2A)-ADRENERGIC RECEPTOR; INTERNALIZATION SIGNAL; THYROTROPIN RECEPTOR	The follicle-stimulating hormone receptor (FSHR) is physiologically localized in the basolateral compartment of the membrane of Sertoli cells. This localization is also observed when the receptor is experimentally expressed in Madin-Darby canine kidney cells. We thus used in vitro mutagenesis and transfection into these polarized cells to delineate the basolateral localization signal of the receptor. The signal was localized in the C-terminal tail of the intracellular domain (amino acids 678-691) at a marked distance of the membrane. Mutation of individual amino acids highlighted the importance of Tyr(684) and Leu(689). The 14-amino acid sequence was grafted onto the p75 neurotrophin receptor and redirected this apical protein to the basolateral cell membrane compartment, Deletion of amino acids 677-695 did not modify the internalization of the FSHR, showing that the basolateral localization signal of the FSHR is not colinear with its internalization signal.	Assistance Publ Hop Paris, Hop Bicetre, Inst Federat Rech 21, INSERM,U135,Unite Hormones Genes & Reprod, F-94275 Le Kremlin Bicetre, France; Fac Sci Luminy, Lab Genet & Physiol Dev, Unite Mixte Rech 9943, F-13288 Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; UDICE-French Research Universities; Aix-Marseille Universite	Misrahi, M (corresponding author), Assistance Publ Hop Paris, Hop Bicetre, Inst Federat Rech 21, INSERM,U135,Unite Hormones Genes & Reprod, 3Eme Niveau,78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.		Beau, Isabelle/M-4423-2017	Beau, Isabelle/0000-0002-3352-6813; Vannier, Brigitte/0000-0002-6870-507X				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; Beau I, 1997, J BIOL CHEM, V272, P5241, DOI 10.1074/jbc.272.8.5241; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; Dym M, 1970, Biology Reprod., V3, P308; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GHINEA N, 1994, J CELL BIOL, V125, P87, DOI 10.1083/jcb.125.1.87; GHINEA N, 1992, J CELL BIOL, V118, P1347, DOI 10.1083/jcb.118.6.1347; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LeGall AH, 1997, J BIOL CHEM, V272, P4559, DOI 10.1074/jbc.272.7.4559; Lin S, 1997, J BIOL CHEM, V272, P26300, DOI 10.1074/jbc.272.42.26300; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; LUO H, 1993, AM J PHYSIOL, V265, pC193, DOI 10.1152/ajpcell.1993.265.1.C193; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MCGREGOR MJ, 1989, PROTEIN ENG, V2, P521, DOI 10.1093/protein/2.7.521; MEDURI G, 1992, ENDOCRINOLOGY, V131, P366, DOI 10.1210/en.131.1.366; Meduri G, 1996, J ENDOCRINOL, V148, P435, DOI 10.1677/joe.0.1480435; MISRAHI M, 1997, PHARMACOTHERAPEUTICS, V128, P33; MISRAHI M, 1998, IN PRESS BAILLIERES; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAYMOND JR, 1993, AM J PHYSIOL, V264, pF9, DOI 10.1152/ajprenal.1993.264.1.F9; RODRIGUEZBOULAN E, 1993, J CELL SCI, P9; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; Saunders C, 1996, J BIOL CHEM, V271, P995, DOI 10.1074/jbc.271.2.995; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; Simoni M, 1997, ENDOCR REV, V18, P739, DOI 10.1210/er.18.6.739; Song Y, 1997, FASEB J, V11, P93, DOI 10.1096/fasebj.11.1.9034171; STULTZ CM, 1993, PROTEIN SCI, V2, P305; TALOR Z, 1982, J CLIN INVEST, V69, P1136, DOI 10.1172/JCI110549; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Vannier B, 1996, BIOCHEMISTRY-US, V35, P1358, DOI 10.1021/bi952290f; VASSART G, 1994, ENDOCRINE REV MONOGR, V3, P77; Wozniak M, 1996, J BIOL CHEM, V271, P5017; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; YEH TC, 1994, DIABETES, V43, P1297, DOI 10.2337/diabetes.43.11.1297	54	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18610	18616		10.1074/jbc.273.29.18610	http://dx.doi.org/10.1074/jbc.273.29.18610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660834	hybrid			2022-12-27	WOS:000074828500089
J	Du, SY; Bird, TH; Bauer, CE				Du, SY; Bird, TH; Bauer, CE			DNA binding characteristics of RegA - A constitutively active anaerobic activator of photosynthesis gene expression in Rhodobacter capsulatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PUF OPERON; RHIZOBIUM-MELILOTI; OXYGEN REGULATION; PHOSPHORYLATION; PROTEIN; PROMOTER; SYSTEM; OMPR; IDENTIFICATION	In the purple non-sulfur bacterium Rhodobacter capsulatus, RegA and RegB comprise a two-component regulatory system that is required for maximal anaerobic transcription of key photosynthesis genes. RegB is a sensor kinase that uses ATP to phosphorylate its cognate response regulator, RegA, The mechanism under which RegA similar to P influences transcription of target genes has been unclear given that past attempts to demonstrate DNA binding activity by isolated RegA have failed. This led to a model invoking a role for RegA similar to P as an intermediate in a more complex multicomponent phosphoryl transfer cascade. In the present study, we describe the isolation of a mutant version of RegA (RegA*) which promotes high level expression of photosynthesis genes independent of RegB. DNase I footprint analyses show that purified RegA* binds to the promoters of the puf and puc operons at locations that are consistent with RegA functioning as a transcriptional activator for these operons. We conclude that RegA functions, like most members of the response regulator family, as a DNA-binding protein that directly affects the expression of its target genes.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.	cbauer@bio.indiana.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040941, R29GM040941, K04GM000618, R37GM040941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40941, GM00618, R01 GM040941, R37 GM040941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; BAILALOV I, 1996, BIOCHEMISTRY-US, V35, P11053; BAUER C, 1993, TRENDS GENET, V9, P56, DOI 10.1016/0168-9525(93)90188-N; BAUER CE, 1988, J BIOL CHEM, V263, P4820; Bauer CE, 1996, CELL, V85, P5, DOI 10.1016/S0092-8674(00)81074-0; BAUER CE, 1995, ANOXYGENIC PHOTOSYNT, P1221; BAUER CE, 1987, PROGR PHOTOSYNTHESIS, V4, P699; Bird TH, 1996, J MOL BIOL, V256, P436, DOI 10.1006/jmbi.1996.0099; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; COHENBAZIRE G, 1957, J CELL COMPAR PHYSL, V49, P25, DOI 10.1002/jcp.1030490104; ERASO JM, 1994, J BACTERIOL, V176, P32, DOI 10.1128/JB.176.1.32-43.1994; HAN DC, 1994, MOL MICROBIOL, V12, P23, DOI 10.1111/j.1365-2958.1994.tb00991.x; INOUE K, 1995, BIOCHEMISTRY-US, V34, P391, DOI 10.1021/bi00002a002; Jiang ZY, 1997, J BACTERIOL, V179, P5720, DOI 10.1128/jb.179.18.5720-5727.1997; KLUG G, 1991, MOL GEN GENET, V226, P167, DOI 10.1007/BF00273600; MARRS BL, 1980, METHOD ENZYMOL, V69, P29; Maxam A M, 1980, Methods Enzymol, V65, P499; MOSLEY CS, 1994, J BACTERIOL, V176, P7566, DOI 10.1128/JB.176.24.7566-7573.1994; NAKASHIMA K, 1991, J BIOL CHEM, V266, P10775; NARRO ML, 1990, J BACTERIOL, V172, P4549, DOI 10.1128/jb.172.8.4549-4554.1990; PONNAMPALAM SN, 1995, J BACTERIOL, V177, P2990, DOI 10.1128/jb.177.11.2990-2997.1995; Ponnampalam SN, 1997, J BIOL CHEM, V272, P18391, DOI 10.1074/jbc.272.29.18391; Qian YL, 1996, J BACTERIOL, V178, P12, DOI 10.1128/jb.178.1.12-18.1996; RE SD, 1994, NUCLEIC ACIDS RES, V22, P1555; ROGGIANI M, 1993, J BACTERIOL, V175, P3181; SCOLNIK PA, 1984, NATURE, V307, P289, DOI 10.1038/307289a0; SGANGA MW, 1992, CELL, V68, P945, DOI 10.1016/0092-8674(92)90037-D; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; STRAUCH MA, 1995, J BACTERIOL, V177, P4532, DOI 10.1128/jb.177.15.4532-4536.1995; STUDIER FW, 1990, METHOD ENZYMOL, V53, P450; Tiwari RP, 1996, MICROBIOL-UK, V142, P1693, DOI 10.1099/13500872-142-7-1693; TSUZUKI M, 1994, J MOL BIOL, V242, P607, DOI 10.1006/jmbi.1994.1610; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VOLZ K, 1991, J BIOL CHEM, V266, P15511; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WEINSTEIN M, 1993, GENE, V134, P145, DOI 10.1016/0378-1119(93)90088-K; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; Xu K, 1996, MOL MICROBIOL, V19, P145, DOI 10.1046/j.1365-2958.1996.358882.x; YOUNG DA, 1989, MOL GEN GENET, V218, P1, DOI 10.1007/BF00330558	40	70	72	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18509	18513		10.1074/jbc.273.29.18509	http://dx.doi.org/10.1074/jbc.273.29.18509			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660820	hybrid			2022-12-27	WOS:000074828500075
J	Kiselev, SL; Kustikova, OS; Korobko, EV; Prokhortchouk, EB; Kabishev, AA; Lukanidin, EM; Georgiev, GP				Kiselev, SL; Kustikova, OS; Korobko, EV; Prokhortchouk, EB; Kabishev, AA; Lukanidin, EM; Georgiev, GP			Molecular cloning and characterization of the mouse tag7 gene encoding a novel cytokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DOMAIN-CONTAINING RECEPTOR; MESSENGER-RNA EXPRESSION; DEATH-DOMAIN; FACTOR-ALPHA; FACTOR-BETA; CELL-LINES; TNF-ALPHA; LYMPHOTOXIN	Cloning of the mouse tag7 gene encoding a novel cytokine is described. The Tag7 protein consists of 182 amino acids. Genomic organization of the tag7 gene and its promoter region remind those of the genes of the tumor necrosis factor locus, although the tag7 gene is not linked to this locus. The gene is located on chromosome 7 at the area that corresponds to band 7A3, which has genetic linkage with lupus-like disease in mouse models, tag7 transcription is essential for lymphoid organs, It is also detected in certain areas of lungs, brain, and intestine and in some tumors. Tag7 protein is detectable in both cell-associated and soluble forms. The soluble form of Tag7 triggers apoptosis in mouse L929 cells in vitro and does not involve NF-kappa B activation. The relationship between Tag7 and tumor necrosis factor family of ligands is discussed.	Inst Gene Biol, Moscow 117334, Russia; Danish Canc Soc, DK-2100 Copenhagen, Denmark	Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences; Danish Cancer Society	Kiselev, SL (corresponding author), Inst Gene Biol, 3415 Vavilova St, Moscow 117334, Russia.		Prokhortchouk, Egor/I-9108-2014; Korobko, Elena/AAP-1193-2021; Kiselev, Sergey/AAO-1247-2020	Korobko, Elena/0000-0002-9752-9714; kiselev, sergey/0000-0001-7921-6987				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; COLOMBO MP, 1992, CANCER RES, V52, P4853; DEKOSSODO S, 1992, J EXP MED, V176, P1259, DOI 10.1084/jem.176.5.1259; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GARDNER SM, 1987, J IMMUNOL, V139, P476; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ISHIBASHI K, 1991, BLOOD, V77, P2451; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; KLAUS GGB, 1988, LYMPHOCYTES PRACTICA, P15; KONO DH, 1994, P NATL ACAD SCI USA, V91, P10168, DOI 10.1073/pnas.91.21.10168; KOROBKO EV, IN PRESS CELL DEATH; Kruger-Krasagakes S, 1995, Recent Results Cancer Res, V139, P155; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; MOREL L, 1994, IMMUNITY, V1, P219, DOI 10.1016/1074-7613(94)90100-7; NEDOSPASOV SA, 1986, NUCLEIC ACIDS RES, V14, P7713, DOI 10.1093/nar/14.19.7713; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PEKAREK LA, 1993, CANCER RES, V53, P1978; POKHOLOK DK, 1995, P NATL ACAD SCI USA, V92, P674, DOI 10.1073/pnas.92.3.674; RUBIN BY, 1986, J EXP MED, V164, P1350, DOI 10.1084/jem.164.4.1350; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPIES T, 1986, P NATL ACAD SCI USA, V83, P8699, DOI 10.1073/pnas.83.22.8699; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPRIGGS DR, 1988, J CLIN INVEST, V81, P455, DOI 10.1172/JCI113341; TAKASUKA N, 1991, J IMMUNOL, V146, P3824; TAKASUKA N, 1995, J IMMUNOL, V154, P4803; TIAN QS, 1991, CELL, V67, P629, DOI 10.1016/0092-8674(91)90536-8; VAN MEIR EG, 1995, GLIA, V15, P264, DOI 10.1002/glia.440150308; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211	38	61	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18633	18639		10.1074/jbc.273.29.18633	http://dx.doi.org/10.1074/jbc.273.29.18633			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660837	hybrid			2022-12-27	WOS:000074828500092
J	Yang, PR; Kansra, S; Pimental, RA; Gilbreth, M; Marcus, S				Yang, PR; Kansra, S; Pimental, RA; Gilbreth, M; Marcus, S			Cloning and characterization of shk2 a gene encoding a novel p21-activated protein kinase from fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH SYNDROME PROTEIN; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CELL-GROWTH; RHO-FAMILY; SEXUAL-DIFFERENTIATION; SIGNAL TRANSDUCTION; SMALL GTPASES; HOMOLOG; CDC42	We describe the characterization of a novel gene, shk2, encoding a second p21(cdc42/rac)-activated protein kinase (PAK) homolog in fission yeast. Like other known PAKs, Shk2 binds to Cdc42 in vivo and in vitro. While overexpression of either shk2 or cdc42 alone does not impair growth of wild type fission yeast cells, cooverexpression of the two genes is toxic and leads to highly aberrant cell morphology, providing evidence for functional interaction between Cdc42 and Shk2 proteins in vivo. Fission yeast shk2 null mutants are viable and exhibit no obvious phenotypic defects, Overexpression of shk2 restores viability and normal morphology but not full mating competence to fission yeast cells carrying a shk1 null mutation. Additional genetic data suggest that Shk2, like Cdc42 and Shk1, participates in Ras-dependent morphological control and mating response pathways in fission yeast. We also show that overexpression of byr2, a gene encoding a Stell/MAPK kinase kinase homolog, suppresses the mating defect of cells partially defective for shk1 function, providing evidence of a link between PAKs and mitogen-activated protein kinase signaling in fission yeast. Taken together, our results suggest that Shk2 is partially overlapping in function with Shk1, with Shk1 being the dominant protein in function.	Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Marcus, S (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	smarcus@mdacc.tmc.edu			NCI NIH HHS [T32CA09299, P30CA16672] Funding Source: Medline; NIGMS NIH HHS [R01GM53239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009299, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C, 1993, EXPT FISSION YEAST L; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Hotchin NA, 1996, CANCER SURV, V27, P311; HUGHES DA, 1993, NATURE, V364, P349, DOI 10.1038/364349a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Mosch HU, 1996, P NATL ACAD SCI USA, V93, P5352, DOI 10.1073/pnas.93.11.5352; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rose MD., 1990, METHODS YEAST GENETI; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Sipiczki M, 1989, MOL BIOL FISSION YEA, P431; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; XU HP, 1992, MOL BIOL CELL, V3, P721, DOI 10.1091/mbc.3.7.721; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	47	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18481	18489		10.1074/jbc.273.29.18481	http://dx.doi.org/10.1074/jbc.273.29.18481			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660817	hybrid			2022-12-27	WOS:000074828500072
J	Ridderstrom, M; Cameron, AD; Jones, TA; Mannervik, B				Ridderstrom, M; Cameron, AD; Jones, TA; Mannervik, B			Involvement of an active-site Zn2+ ligand mechanism of human glyoxalase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIOSEPHOSPHATE ISOMERASE; PSEUDOMONAS-PUTIDA; GENE DUPLICATION; PROTEIN MODELS; REFINEMENT; CLONING; EXPRESSION; SEGMENTS; YEAST; METAL	The Zn2+ ligands glutamate 99 and glutamate 172 in the active site of human glyoxalase I were replaced, each in turn, by glutamines by site-directed mutagenesis to elucidate their potential significance for the catalytic properties of the enzyme. To compensate for the loss of the charged amino acid residue, another of the metal ligands, glutamine 33, was simultaneously mutated into glutamate. The double mutants and the single mutants Q33E, E99Q, and E172Q were expressed in Escherichia coli, purified on an S-hexylglutathione matrix, and characterized. Metal analysis demonstrated that mutant Q33E/E172Q contained 1.0 mel of zinc/mol of enzyme subunit, whereas mutant Q33E/E99Q contained only 0.3 mol of zinc/mol of subunit, No catalytic activity could be detected with the double mutant Q33E/E172Q (<10(-8) of the wild-type activity). The second double mutant Q33E/E99Q had 1.5% of the specific activity of the wild-type enzyme, whereas the values for mutants Q33E and E99Q were 1.3 and 0.1%, respectively; the E172Q mutant had less than 10(-5) times the specific activity of the wild-type. The crystal structure of the catalytically inactive double mutant Q33E/E172Q demonstrated that Zn2+ was bound without any gross changes or perturbations. The results suggest that the metal ligand glutamate 172 is directly involved in the catalytic mechanism of the enzyme, presumably serving as the base that abstracts a proton from the hemithioacetal substrate.	Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden; Uppsala Univ, Ctr Biomed, Dept Mol Biol, S-75124 Uppsala, Sweden	Uppsala University; Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Ctr Biomed, Dept Biochem, Box 576, S-75123 Uppsala, Sweden.	bengt.mannervik@biokem.uu.se	Cameron, Alexander/L-7288-2013	Cameron, Alexander/0000-0001-8776-3518				ARONSSON AC, 1981, BIOCHEM J, V197, P67, DOI 10.1042/bj1970067; ARONSSON AC, 1978, BIOCHEM BIOPH RES CO, V81, P1235, DOI 10.1016/0006-291X(78)91268-8; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; BJORNESTEDT R, 1992, BIOCHEM J, V282, P505; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR SYSTEM CRYSTA; Cameron AD, 1997, EMBO J, V16, P3386, DOI 10.1093/emboj/16.12.3386; Clugston SL, 1997, GENE, V186, P103, DOI 10.1016/S0378-1119(96)00691-9; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Espartero J, 1995, PLANT MOL BIOL, V29, P1223, DOI 10.1007/BF00020464; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLUM MW, 1978, ANAL BIOCHEM, V85, P586, DOI 10.1016/0003-2697(78)90258-0; KIM NS, 1993, J BIOL CHEM, V268, P11217; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LAN Y, 1995, J BIOL CHEM, V270, P12957, DOI 10.1074/jbc.270.22.12957; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LU TF, 1994, GENE, V150, P93, DOI 10.1016/0378-1119(94)90864-8; Mannervik B., 1980, ENZYMATIC BASIS DETO, VVolume 2, P263; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; RACKER E, 1951, J BIOL CHEM, V190, P685; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; Ridderstrom M, 1996, BIOCHEM J, V314, P463; Ridderstrom M, 1996, BIOCHEM J, V316, P1005, DOI 10.1042/bj3161005; Ridderstrom M, 1997, BIOCHEM J, V328, P231, DOI 10.1042/bj3280231; SELLIN S, 1982, J BIOL CHEM, V257, P23; SELLIN S, 1987, BIOCHEMISTRY-US, V26, P6779, DOI 10.1021/bi00395a030; SELLIN S, 1983, J BIOL CHEM, V258, P2091; SELLIN S, 1982, BIOCHEMISTRY-US, V21, P4850, DOI 10.1021/bi00263a004; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Vander Jagt D.L., 1989, GLUTATHIONE CHEM, P597	37	66	68	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21623	21628		10.1074/jbc.273.34.21623	http://dx.doi.org/10.1074/jbc.273.34.21623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705294	hybrid			2022-12-27	WOS:000075492600028
J	Geisler, C; Dietrich, J; Nielsen, BL; Kastrup, J; Lauritsen, JPH; Odum, N; Christensen, MD				Geisler, C; Dietrich, J; Nielsen, BL; Kastrup, J; Lauritsen, JPH; Odum, N; Christensen, MD			Leucine-based receptor sorting motifs are dependent on the spacing relative to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; COATED PIT ADAPTINS; FACTOR-II RECEPTOR; CYTOPLASMIC DOMAIN; CARBOXYL-TERMINUS; INVITRO BINDING; INVARIANT CHAIN; DOWN-REGULATION; INTERNALIZATION; CD3-GAMMA	Many integral membrane proteins contain leucine-based motifs within their cytoplasmic domains that mediate internalization and intracellular sorting. Two types of leucine-based motifs have been identified. One type is dependent on phosphorylation, whereas the other type, which includes an acidic amino acid, is constitutively active. In this study, we have investigated how the spacing relative to the plasma membrane affects the function of both types of leucine-based motifs, For phosphorylation-dependent leucine-based motifs, a minimal spacing of 7 residues between the plasma membrane and the phospho-acceptor was required for phosphorylation and thereby activation of the motifs. For constitutively active leucine-based motifs, a minimal spacing of 6 residues between the plasma membrane and the acidic residue was required for optimal activity of the motifs. In addition, we found that the acidic residue of leucine-based motifs must be located amino-terminal to the dileucine sequence for proper function of the motifs and that residues surrounding the motifs affect the activity of the motifs, Thus, our observations suggest that the position, the exact sequence, and surrounding residues are major determinants of the function of leucine-based receptor sorting motifs.	Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, DK-2200 Copenhagen, Denmark	University of Copenhagen	Geisler, C (corresponding author), Univ Copenhagen, Panum Inst, Inst Med Microbiol & Immunol, Bldg 18-3,Blegdamsvej 3C, DK-2200 Copenhagen, Denmark.	cgtcr@biobase.dk	Bartels, Mette Damkjær/AAY-5809-2020; Geisler, Carsten/A-7056-2012	Bartels, Mette Damkjær/0000-0002-8187-3684; Geisler, Carsten/0000-0002-8472-0771				BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BREMNES B, 1994, J CELL SCI, V107, P2021; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; GEISLER C, 1992, J IMMUNOL, V148, P2437; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HAHN WC, 1993, GENE, V127, P267, DOI 10.1016/0378-1119(93)90731-H; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ORR JW, 1994, J BIOL CHEM, V269, P8383; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Sheikh H, 1996, J BIOL CHEM, V271, P12185, DOI 10.1074/jbc.271.21.12185; SHIN JY, 1991, J BIOL CHEM, V266, P10658; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537	34	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21316	21323		10.1074/jbc.273.33.21316	http://dx.doi.org/10.1074/jbc.273.33.21316			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694892	hybrid			2022-12-27	WOS:000075386100085
J	O'Neill, H; Mayhew, SG; Butler, G				O'Neill, H; Mayhew, SG; Butler, G			Cloning and analysis of the genes for a novel electron-transferring flavoprotein from Megasphaera elsdenii - Expression and characterization of the recombinant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZORHIZOBIUM-CAULINODANS ORS571; PEPTOSTREPTOCOCCUS-ELSDENII; PARACOCCUS-DENITRIFICANS; SECONDARY STRUCTURE; ADENINE-DINUCLEOTIDE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; NEURAL NETWORKS; FIXABC REGION; IDENTIFICATION	The genes that encode the two different subunits of the novel electron-transferring flavoprotein (ETF) from Megasphaera elsdenii were identified by screening a partial genomic DNA library with a probe that was generated by amplification of genomic sequences using the polymerase chain reaction. The cloned genes are arranged in tandem with the coding sequence for the beta-subunit in the position 5' to the alpha-subunit coding sequence. Amino acid sequence analysis of the two subunits revealed that there are two possible dinucleotide-binding sites on the alpha-subunit and one on the beta-subunit. Comparison of M. elsdenii ETF amino acid sequence to other ETFs and ETF-like proteins indicates that while homology occurs with the mitochondrial ETF and bacterial ETFs, the greatest similarity is with the putative ETFs from clostridia and with fixAB gene products from nitrogen-fixing bacteria. The recombinant ETF was isolated from extracts of Escherichia coli. It is a heterodimer with subunits identical in size to the native protein. The isolated enzyme contains approximately I mol of FAD, but like the native protein it binds additional flavin to ave a total of about 2 mol of FAD/dimer. It serves as an electron donor to butyryl-CoA dehydrogenase, and it also has NADH dehydrogenase activity.	Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland	University College Dublin	Mayhew, SG (corresponding author), Natl Univ Ireland Univ Coll Dublin, Dept Biochem, Dublin 4, Ireland.	stephen.g.mayhew@ucd.ie		Butler, Geraldine/0000-0002-1770-5301; O'Neill, Hugh/0000-0003-2966-5527				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARIGONI F, 1991, MOL GEN GENET, V225, P514, DOI 10.1007/BF00261695; BALDWIN RL, 1964, BIOCHIM BIOPHYS ACTA, V92, P421, DOI 10.1016/0926-6569(64)90001-X; Bastiaens P I, 1991, J Fluoresc, V1, P95, DOI 10.1007/BF00865205; BECKER DF, 1993, BIOCHEMISTRY-US, V32, P10736, DOI 10.1021/bi00091a026; BEDZYK LA, 1993, J BIOL CHEM, V268, P20211; *BIOS TECHN, 1993, INS 2 VERS W 3 0 US; BROCKMAN HL, 1975, J BACTERIOL, V124, P1447, DOI 10.1128/JB.124.3.1447-1453.1975; BYRON CM, 1989, BIOCHEMISTRY-US, V28, P8582, DOI 10.1021/bi00447a047; CHEN DW, 1994, J BIOL CHEM, V269, P32120; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; ELSDEN SR, 1956, J BACTERIOL, V72, P681, DOI 10.1002/path.1700720235; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; FINOCCHIARO G, 1993, EUR J BIOCHEM, V213, P1003, DOI 10.1111/j.1432-1033.1993.tb17847.x; GHISLA S, 1976, EUR J BIOCHEM, V63, P373, DOI 10.1111/j.1432-1033.1976.tb10239.x; Ghisla S, 1980, Methods Enzymol, V66, P241; GOODMAN SI, 1994, EUR J BIOCHEM, V219, P277, DOI 10.1111/j.1432-1033.1994.tb19939.x; GORNALL AG, 1949, J BIOL CHEM, V177, P751; GUBLER M, 1989, MOL MICROBIOL, V3, P141, DOI 10.1111/j.1365-2958.1989.tb01803.x; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; IHARA S, 1987, ANAL BIOCHEM, V166, P349, DOI 10.1016/0003-2697(87)90584-7; JORNVALL H, 1977, EUR J BIOCHEM, V72, P443, DOI 10.1111/j.1432-1033.1977.tb11268.x; KAMINSKI PA, 1988, MOL GEN GENET, V214, P496, DOI 10.1007/BF00330486; LADD JN, 1959, BIOCHEM J, V71, P16, DOI 10.1042/bj0710016; LADD JN, 1959, BIOCHEM J, V71, P364, DOI 10.1042/bj0710364; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOEHR JP, 1990, PEDIATR RES, V27, P311, DOI 10.1203/00006450-199003000-00024; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P303, DOI 10.1016/0005-2744(71)90208-7; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MCKIE JH, 1991, FEBS LETT, V279, P5, DOI 10.1016/0014-5793(91)80236-V; ONEILL HM, 1995, BIOCHEM SOC T, V23, pS379, DOI 10.1042/bst023379s; ONUALAIN EM, 1989, THESIS U COLLEGE DUB; ONUALLAIN EM, 1986, BIOCHEM SOC T, V14, P440, DOI 10.1042/bst0140440; ONUALLAIN EM, 1987, FLAVINS FLAVOPROTEIN, P361; PACE CP, 1987, BIOCHIM BIOPHYS ACTA, V911, P267, DOI 10.1016/0167-4838(87)90067-7; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; Sharkey CT, 1997, ACTA CRYSTALLOGR D, V53, P461, DOI 10.1107/S0907444997000139; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; TSAI MH, 1995, RES MICROBIOL, V146, P397, DOI 10.1016/0923-2508(96)80285-3; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; Weidenhaupt M, 1996, ARCH MICROBIOL, V165, P169, DOI 10.1007/s002030050312; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2811; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON K, 1994, CURRENT PROTOCOLS MO; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	61	25	27	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21015	21024		10.1074/jbc.273.33.21015	http://dx.doi.org/10.1074/jbc.273.33.21015			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694853	hybrid			2022-12-27	WOS:000075386100046
J	Geraghty, DS; Sucic, HB; Chen, J; Pederson, DS				Geraghty, DS; Sucic, HB; Chen, J; Pederson, DS			Evidence that partial unwrapping of DNA from nucleosomes facilitates the binding of heat shock factor following DNA replication in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RESPONSE ELEMENT; TRANSCRIPTION FACTOR; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; POSITIONING SEQUENCES; PROMOTER; GENE; REPRESSION; PROTEIN	In the yeast Saccharomyces cerevisiae, heat shock transcription factor (HSF) binds heat shock element (HSE) DNA shortly after DNA replication, independently of its activation by heat shock. To determine if HSF binding occurs before newly replicated DNA is packaged into nucleosomes, we inserted an HSE into a DNA segment that normally forms a positioned nucleosome in vivo. Transcription from constructs designed to create steric competition between binding of HSF and histone H2A-H2B dimers was generally poor, suggesting that nucleosome assembly precedes and inhibits HSF binding. However, one such construct was as transcriptionally active as a nucleosome-free control. Structural analyses suggested that similar to 40 base pairs of DNA, including the HSE, had unwrapped from the 3' edge of the histone octamer, allowing HSF to bind; similar to 100 base pairs remained in association with the histone octamer, with the same translational and rotational orientation as was seen for the poorly transcribed constructs. Modeling studies suggest that the active and inactive constructs differ from one another in the ease with which the HSE and flanking sequences can adopt the curvature needed to form a stable nucleosome. These differences may influence the probability of DNA unwrapping from already assembled nucleosomes and the subsequent binding of HSF.	Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Pederson, DS (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, Stafford Bldg,Rom 302, Burlington, VT 05405 USA.	dpederso@zoo.uvm.edu						ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; Blomquist P, 1996, J BIOL CHEM, V271, P153, DOI 10.1074/jbc.271.1.153; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CHEN JJ, 1993, J BIOL CHEM, V268, P7442; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; COCKELL M, 1983, J MOL BIOL, V170, P423, DOI 10.1016/S0022-2836(83)80156-9; CUNNIFF NFA, 1993, J BIOL CHEM, V268, P8317; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Erkine AM, 1996, MOL CELL BIOL, V16, P7004; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FLICK KE, 1994, J BIOL CHEM, V269, P12475; FRAGOSO G, 1995, GENE DEV, V9, P1933, DOI 10.1101/gad.9.15.1933; Gasser R, 1996, J MOL BIOL, V258, P224, DOI 10.1006/jmbi.1996.0245; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; GROSS DS, 1993, EMBO J, V12, P3931, DOI 10.1002/j.1460-2075.1993.tb06071.x; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HANSEN JC, 1991, J BIOL CHEM, V266, P4276; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Holmes SG, 1996, GENE DEV, V10, P1021, DOI 10.1101/gad.10.8.1021; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1995, CURR OPIN CELL BIOL, V7, P371, DOI 10.1016/0955-0674(95)80092-1; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Q, 1995, MOL CELL BIOL, V15, P4375; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; MORSE RH, 1987, NUCLEIC ACIDS RES, V15, P10311, DOI 10.1093/nar/15.24.10311; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PATTERTON HG, 1995, NUCLEIC ACIDS RES, V23, P4170, DOI 10.1093/nar/23.20.4170; PEDERSON DS, 1984, NUCLEIC ACIDS RES, V12, P8489, DOI 10.1093/nar/12.22.8489; PEDERSON DS, 1994, MOL CELL BIOL, V14, P189, DOI 10.1128/MCB.14.1.189; PEDERSON DS, 1986, P NATL ACAD SCI USA, V83, P7206, DOI 10.1073/pnas.83.19.7206; PEDERSON DS, 1990, EMBO J, V9, P1873, DOI 10.1002/j.1460-2075.1990.tb08313.x; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Protacio RU, 1997, J MOL BIOL, V274, P708, DOI 10.1006/jmbi.1997.1440; PTASHNE M, 1987, GENETIC SWITCH, P109; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; RANDALL SK, 1992, J BIOL CHEM, V267, P14259; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; Svaren J, 1996, CURR OPIN GENET DEV, V6, P164, DOI 10.1016/S0959-437X(96)80046-3; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; THOMA F, 1985, NATURE, V315, P250, DOI 10.1038/315250a0; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; van Holde KE., 1989, SPRINGER SERIES MOL; VENTER U, 1994, EMBO J, V13, P4848, DOI 10.1002/j.1460-2075.1994.tb06811.x; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; WALLRATH LL, 1994, BIOESSAYS, V16, P165, DOI 10.1002/bies.950160306; Wolffe Alan P., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P167; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xu M, 1998, MOL CELL BIOL, V18, P1201, DOI 10.1128/MCB.18.3.1201	78	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20463	20472		10.1074/jbc.273.32.20463	http://dx.doi.org/10.1074/jbc.273.32.20463			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685401	hybrid			2022-12-27	WOS:000075305400078
J	Hresko, RC; Heimberg, H; Chi, MMY; Mueckler, M				Hresko, RC; Heimberg, H; Chi, MMY; Mueckler, M			Glucosamine-induced insulin resistance in 3T3-L1 adipocytes is caused by depletion of intracellular ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED ADIPOCYTES; GLYCOGEN-SYNTHASE ACTIVITY; GLUTAMINE-FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; HEXOSAMINE BIOSYNTHESIS; TRANSPORT SYSTEM; TRANSGENIC MICE; PHOSPHATIDYLINOSITOL 3-KINASE; SUBSTRATE PHOSPHORYLATION; INDUCED DESENSITIZATION; DIFFERENTIAL REGULATION	Glucosamine, which enters the hexosamine pathway downstream of the rate-limiting step, has been routinely used to mimic the insulin resistance caused by high glucose and insulin. We investigated the effect of glucosamine on insulin-stimulated glucose transport in 3T3-L1 adipocytes. The Delta-insulin (insulin-stimulated minus basal) value for S-deoxyglucose uptake was dramatically inhibited with increasing concentrations of glucosamine with an ED50 of 1.95 mM. Subcellular fractionation experiments demonstrated that reduction in insulin-stimulated 2-deoxyglucose uptake by glucosamine was due to an inhibition of translocation of both Glut 1 and Glut 4 from the low density microsomes (LDM) to the plasma membrane. Analysis of the insulin signaling cascade revealed that glucosamine impaired insulin receptor autophosphorylation, insulin receptor substrate (IRS-1) phosphorylation, IRS-l-associated PI 3-kinase activity in the LDM, and AKT-1 activation by insulin. Measurement of intracellular ATP demonstrated that the effects of glucosamine were highly correlated with its ability to reduce ATP levels. Reduction of intracellular ATP using azide inhibited Glut 1 and Glut 4 translocation from the LDM to the plasma membrane, insulin receptor autophosphorylation, and IRS-1 tyrosine phosphorylation. Additionally, both the reduction in intracellular ATP and the effects on insulin action caused by glucosamine could be prevented by the addition of inosine, which served as an alternative energy source in the medium. We conclude that direct administration of glucosamine can rapidly lower cellular ATP levels and affect insulin action in fat cells by mechanisms independent of increased intracellular UDP-N-acetylhexosamines and that increased metabolism of glucose via the hexosamine pathway may not represent the mechanism of glucose toxicity in fat cells.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Free Univ Brussels, Diabet Res Ctr, B-1090 Brussels, Belgium	Washington University (WUSTL); Universite Libre de Bruxelles; Vrije Universiteit Brussel	Mueckler, M (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Mueckler, Mike M/F-6115-2012	Heimberg, Harry/0000-0003-1954-7375	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050332, R01DK038495] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38495, DK50332] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BACKER JM, 1992, J BIOL CHEM, V267, P1367; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Buse MG, 1996, J BIOL CHEM, V271, P23197, DOI 10.1074/jbc.271.38.23197; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN H, 1997, MOL CELL ENDOCRINOL, V135, P66; CROOK ED, 1993, DIABETES, V42, P1289, DOI 10.2337/diabetes.42.9.1289; CROOK ED, 1995, DIABETES, V44, P314, DOI 10.2337/diabetes.44.3.314; Crook ED, 1996, DIABETES, V45, P322, DOI 10.2337/diabetes.45.3.322; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Filippis A, 1998, BIOCHEM J, V330, P405, DOI 10.1042/bj3300405; FLORESRIVEROS JR, 1989, J BIOL CHEM, V264, P21557; GARVEY WT, 1987, J BIOL CHEM, V262, P189; GULVE EA, 1994, J BIOL CHEM, V269, P18366; Hawkins M, 1997, J BIOL CHEM, V272, P4889, DOI 10.1074/jbc.272.8.4889; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOHANSKI RA, 1986, BIOCHEM BIOPH RES CO, V134, P1312, DOI 10.1016/0006-291X(86)90393-1; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LIMA FB, 1994, DIABETES, V43, P53, DOI 10.2337/diabetes.43.1.53; MARSHALL BA, 1994, AM J PHYSIOL-ENDOC M, V267, pE738, DOI 10.1152/ajpendo.1994.267.5.E738; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; MERCER RW, 1981, BIOCHIM BIOPHYS ACTA, V648, P63, DOI 10.1016/0005-2736(81)90124-3; Miles PDG, 1998, DIABETES, V47, P395, DOI 10.2337/diabetes.47.3.395; PASSONNEAU JV, 1993, ENZYMATIC ANAL PRACT, P10; PIPER RC, 1991, AM J PHYSIOL, V260, P570; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RICHTER EA, 1988, BIOCHEM J, V252, P733, DOI 10.1042/bj2520733; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Thomson MJ, 1997, J BIOL CHEM, V272, P7759, DOI 10.1074/jbc.272.12.7759; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; TRAXINGER RR, 1991, J BIOL CHEM, V266, P10148; TRAXINGER RR, 1989, J BIOL CHEM, V264, P20910; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Wang HY, 1997, J BIOL CHEM, V272, P25731, DOI 10.1074/jbc.272.41.25731	42	114	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20658	20668		10.1074/jbc.273.32.20658	http://dx.doi.org/10.1074/jbc.273.32.20658			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685425	hybrid			2022-12-27	WOS:000075305400102
J	Kang, S; Liang, L; Parker, CD; Collawn, JF				Kang, S; Liang, L; Parker, CD; Collawn, JF			Structural requirements for major histocompatibility complex class II invariant chain endocytosis and lysosomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN RECEPTOR; DI-LEUCINE MOTIF; MACROPHAGE FC-RECEPTORS; CYTOPLASMIC DOMAIN; RAPID INTERNALIZATION; INTRACELLULAR-TRANSPORT; CARBOXYL-TERMINUS; CELL-SURFACE; MOLECULES; SIGNAL	The invariant chain (Ii) targets newly synthesized major histocompatibility complex class II complexes to a lysosome-like compartment. Previously, we demonstrated that both the cytoplasmic tail (CT) and transmembrane (TM) domains of Ii were sufficient for this targeting and that the CT contains two di-leucine signals, (3)DQRDLI(8) and (12)EQLPML(17) (Odorizzi, C, G., Trowbridge, I. S,, Xue, L., Hopkins, C. R., Davis, C. D., and Collawn, J. F, (1994) J. Cell Biol. 126, 317-330). In the present study, we examined the relationship between signals required for endocytosis and those required for lysosomal targeting by analyzing Ii-transferrin receptor chimeras in quantitative transport assays. Analysis of the Ii CT signals indicates that although 3DQRDLI8 is necessary and sufficient for endocytosis, either dileucine signal is sufficient for lysosomal targeting. Deletions between the two signals reduced endocytosis without affecting lysosomal targeting. Transplantation of the DQRDLI sequence in place of the EQLPML signal produced a chimera that trafficked normally, suggesting that this di-leucine sequence coded for an independent structural motif. Structure-function analysis of the Ii TM region showed that when Ii TM residues 11-19 and 20-29 were individually substituted for the corresponding regions in the wild-type transferrin receptor, lysosomal targeting was dramatically enhanced, whereas endocytosis remained unchanged. Our results therefore demonstrate that the structural requirements for Ii endocytosis and lysosomal targeting are different.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, BHSB 392,UAB Stn, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Collawn, James/0000-0002-2528-2759; Kang, Sunghyun/0000-0003-1542-9750	NIDDK NIH HHS [R29-DK47339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047339] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; ARNESON LS, 1995, J CELL BIOL, V129, P1217, DOI 10.1083/jcb.129.5.1217; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BREMNES B, 1994, J CELL SCI, V107, P2021; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1991, EMBO J, V10, P3247, DOI 10.1002/j.1460-2075.1991.tb04888.x; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FernandezBorja M, 1996, INT IMMUNOL, V8, P625, DOI 10.1093/intimm/8.5.625; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HUGHES SH, 1990, J REPROD FERTIL, P39; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMB CA, 1992, J IMMUNOL, V148, P3478; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MACHAMER CE, 1993, MOL BIOL CELL, V4, P695, DOI 10.1091/mbc.4.7.695; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MELLMAN I, 1984, J CELL BIOL, V98, P1163, DOI 10.1083/jcb.98.4.1163; MOTTA A, 1995, J BIOL CHEM, V270, P27165, DOI 10.1074/jbc.270.45.27165; NEWCOMB JR, 1993, J IMMUNOL, V151, P4153; ODORIZZI CG, 1994, J CELL BIOL, V126, P317, DOI 10.1083/jcb.126.2.317; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; OGATA S, 1994, J BIOL CHEM, V269, P5210; OMARY MB, 1981, J BIOL CHEM, V256, P2888; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PYTOWSKI B, 1995, J BIOL CHEM, V270, P9067, DOI 10.1074/jbc.270.16.9067; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ AL, 1986, J BIOL CHEM, V261, P5225; Simonsen A, 1997, J CELL SCI, V110, P597; SPIRO RC, 1989, J IMMUNOL, V143, P2589; SWIER K, 1995, J IMMUNOL, V155, P630; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; UKKONEN P, 1986, J EXP MED, V163, P952, DOI 10.1084/jem.163.4.952; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	60	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20644	20652		10.1074/jbc.273.32.20644	http://dx.doi.org/10.1074/jbc.273.32.20644			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685423	hybrid			2022-12-27	WOS:000075305400100
J	Plescia, J; Conte, MS; VanMeter, G; Ambrosini, G; Altieri, DC				Plescia, J; Conte, MS; VanMeter, G; Ambrosini, G; Altieri, DC			Molecular identification of the cross-reacting epitope on alpha(m)beta(2) integrin I domain recognized by anti-alpha(IIb)beta(3) monoclonal antibody 7E3 and its involvement in leukocyte adherence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE CORONARY SYNDROMES; LIGAND-BINDING; RECEPTOR CD11B/CD18; BETA(3) SUBUNIT; ARTERY DISEASE; ADHESION; FIBRINOGEN; MAC-1; PATHOGENESIS; INHIBITION	The monoclonal antibody (mAb) 7E3 directed to the platelet integrin alpha(IIb)beta(3) was tested for its cross-reactivity with the homologous leukocyte integrin alpha(M)beta(2),. Nested recombinant fragments of alpha(M) I domain were expressed as glutathione S-transferase fusion proteins and analyzed for antibody recognition. In enzyme-linked immunosorbent assay, mAb 7E3 bound alpha(M) I domain fragments containing the amino-terminal sequence Cys(128)-Ser(172) whereas the carboxyl-terminal region Leu(173)-Pro(291) was ineffective. A synthetic peptide designated R1.1 and duplicating the alpha(M) sequence G(127)CPQEDSDIAFLIDGSGSIIPHDF(150) bound mAb 7E3, In contrast, the adjacent alpha(M) region F(150)RRMKEFVSTVMEQLKKSKTLFS(172) or a control peptide with a scrambled R1.1 sequence was not recognized by mAb 7E3, Binding of mAb 7E3 to alpha(M) I domain blocked monocyte and neutrophil adhesion to immobilized fibrinogen and fibrinogen-dependent leukocyte-endothelium bridging, indistinguishably from bona fide anti-beta(2) mAb IB4. In contrast, leukocyte binding to stable transfectants expressing intercellular adhesion molecule-1 was not affected by mAb 7E3, Balloon-mediated injury of iliofemoral arteries in rabbits resulted in prominent deposition of fibrinogen and increased monocyte adhesion to the injured vessel, in a reaction inhibited by mAb 7E3, but unaffected by control mAb 14E11. Through its cross-reactivity between alpha(IIb)beta(3) and alpha(M)beta(2), mAb 7E3 may initiate a new class of integrin antagonists, capable of simultaneously targeting platelet and leukocyte adhesion mechanisms in vascular injury.	Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Vasc Surg,Harvard Inst Med, Boston, MA 02115 USA	Yale University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Altieri, DC (corresponding author), Yale Univ, Sch Med, Dept Pathol, Boyer Ctr Mol Med, BCMM 436B,295 Congress Ave, New Haven, CT 06536 USA.	dario.altieri@yale.edu			NHLBI NIH HHS [R01 HL43773, HL54131] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773, R01HL054131, R37HL054131] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1991, J IMMUNOL, V147, P1891; ALTIERI DC, 1995, SEMIN CELL BIOL, V6, P269, DOI 10.1006/scel.1995.0036; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; ARNAOUT MA, 1990, BLOOD, V75, P1037; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302; COLLER BS, 1994, SEMIN HEMATOL, V31, P301; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; CONTE MS, 1994, CIRCULATION, V89, P2161, DOI 10.1161/01.CIR.89.5.2161; DeNichilo MO, 1996, J IMMUNOL, V156, P284; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Duperray A, 1997, J BIOL CHEM, V272, P435; FAN ST, 1991, J CLIN INVEST, V87, P50, DOI 10.1172/JCI115000; Frebelius S, 1996, ARTERIOSCL THROM VAS, V16, P1292, DOI 10.1161/01.ATV.16.10.1292; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GINSBERG MH, 1995, THROMB HAEMOSTASIS, V74, P352; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Hatton MWC, 1996, ARTERIOSCL THROM VAS, V16, P1147, DOI 10.1161/01.ATV.16.9.1147; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MARCUS AJ, 1995, THROMB HAEMOSTASIS, V74, P213; MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; Mesri M, 1998, J BIOL CHEM, V273, P744, DOI 10.1074/jbc.273.2.744; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PEREZ RL, 1995, J IMMUNOL, V154, P1879; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Simon DI, 1997, ARTERIOSCL THROM VAS, V17, P528, DOI 10.1161/01.ATV.17.3.528; SKOGEN WF, 1988, BLOOD, V71, P1475; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; VEDDER NB, 1990, P NATL ACAD SCI USA, V87, P2643, DOI 10.1073/pnas.87.7.2643; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	44	29	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20372	20377		10.1074/jbc.273.32.20372	http://dx.doi.org/10.1074/jbc.273.32.20372			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685389	hybrid			2022-12-27	WOS:000075305400066
J	Smolenski, A; Bachmann, C; Reinhard, K; Honig-Liedl, P; Jarchau, T; Hoschuetzky, H; Walter, U				Smolenski, A; Bachmann, C; Reinhard, K; Honig-Liedl, P; Jarchau, T; Hoschuetzky, H; Walter, U			Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RICH FOCAL ADHESION; VASP IN-VITRO; HUMAN-PLATELETS; PURIFICATION; EXPRESSION; SUBSTRATE; CLONING; DOMAIN	The development and functional analysis of a monoclonal antibody (16C2) are reported; the antibody recognizes vasodilator-stimulated phosphoprotein (VASP; an established substrate of both cAMP- and cGMP-dependent protein kinase) only when serine 239 is phosphorylated. VASP serine 239 represents one of the best characterized cGMP-dependent protein kinase phosphorylation sites in vitro and in intact cells, Experiments with purified, recombinant human VASP and various VASP constructs with mutated phosphorylation sites (S157A, S239A, T278A) and experiments with intact cells (human/rat platelets and other cells) treated with cyclic nucleotide-elevating agents demonstrated the specificity of the monoclonal antibody 16C2. Quantitative analysis of the VASP shift from 46 to 50 kDa (indicating VASP serine 157 phosphorylation) and the appearance of VASP detected by the 16C2 monoclonal antibody (VASP serine 239 phosphorylation) in human platelets stimulated by selective protein kinase activators confirmed that serine 239 is the VASP phosphorylation site preferred by cGMP-dependent protein kinase in intact cells. Immunofluorescence experiments with human platelets treated with cGMP analogs showed that the 16C2 monoclonal antibody also detects VASP serine 239 phosphorylation in situ at established intracellular localization sites. Analysis of VASP serine 239 phosphorylation by the 16C2 antibody appears to be the best method presently available to measure cGMP-dependent protein kinase activation in intact cells. Also, the 16C2 antibody promises to be an excellent tool for the evaluation of VASP function in intact cells.	Inst Klin Biochem & Pathobiochem, Med Univ Klin, D-97080 Wurzburg, Germany; NanoTools Antikorpertech, D-79211 Denzlingen, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg	Walter, U (corresponding author), Inst Klin Biochem & Pathobiochem, Med Univ Klin, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	uwalter@klin-biochem.uni-wuerzburg.de	Walter, ulrich/W-2478-2017	Walter, ulrich/0000-0001-6784-2307; Smolenski, Albert/0000-0001-9210-9406				ABEL K, 1995, FEBS LETT, V370, P184, DOI 10.1016/0014-5793(95)00817-S; BUTT E, 1992, BIOCHEM PHARMACOL, V43, P2591, DOI 10.1016/0006-2952(92)90148-C; BUTT E, 1994, J BIOL CHEM, V269, P14509; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; FISCUS RR, 1988, METHOD ENZYMOL, V159, P150; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1989, EUR J BIOCHEM, V185, P41, DOI 10.1111/j.1432-1033.1989.tb15079.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lincoln T M, 1995, Adv Pharmacol, V34, P305; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NOLTE C, 1991, J BIOL CHEM, V266, P14808; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REINHARD M, 1998, IN PRESS GUIDEBOOK C; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SMOLENSKI A, 1998, IN PRESS NAUNYNSCHMI; WALDMANN R, 1987, EUR J BIOCHEM, V167, P441, DOI 10.1111/j.1432-1033.1987.tb13357.x; WALTER U, 1980, J BIOL CHEM, V255, P3757; Zimmer M, 1996, GENOMICS, V36, P227, DOI 10.1006/geno.1996.0457	33	275	288	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20029	20035		10.1074/jbc.273.32.20029	http://dx.doi.org/10.1074/jbc.273.32.20029			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685341	hybrid			2022-12-27	WOS:000075305400018
J	Gueckel, R; Enenkel, C; Wolf, DH; Hilt, W				Gueckel, R; Enenkel, C; Wolf, DH; Hilt, W			Mutations in the yeast proteasome beta-type subunit pre3 uncover position-dependent effects on proteasomal peptidase activity and in vivo function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; SACCHAROMYCES-CEREVISIAE; CATABOLITE INACTIVATION; MULTIFUNCTIONAL PROTEINASE; HYDROLYZING ACTIVITY; UBIQUITIN PATHWAY; INVIVO FUNCTION; CELL-DIVISION; DEGRADATION; PROTEOLYSIS	Proteasomes are highly complex proteases responsible for selective protein degradation in the eukaryotic cell. 26 S proteasomes consist of two regulatory 19 S cap complexes and the 20 S proteasome, which acts as the proteolytic core module. We isolated six mutants of the yeast Saccharomyces cerevisiae containing mutations in the 20 S proteasome P-type subunit Pre3. Three mutations (pre3-2, pre3-3, and pre3-5) which reside at the active site cleft of the Pre3 subunit solely caused reduction of the proteasomal peptidylglutamyl peptide-hydrolyzing activity but did not lead to detectable defects in protein degradation nor to any other phenotype. However, the pre3-2 mutation strengthened phenotypes induced by other 20 S proteasomal mutations, indicating that the peptidylglutamyl peptide-hydrolyzing activity has to fulfill some rescue functions. The other three mutations (pre3-1,pre3-4 and pre3-6) are located at diverse sites of the Pre3 protein and caused multiple defects in proteasomal peptide cleaving activities. pre3-1 and pre3-6 mutants exhibited significant defects in proteasomal protein degradation; they accumulated ubiquitinated proteins and stabilized defined substrate proteins as, e.g. fructose-1,6-bisphosphatase. In addition, pre3-1 and pre3-6 mutant cells exhibited pleiotropic phenotypes as temperature sensitivity and cell cycle-related effects.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany; Humboldt Univ, Inst Biochem, D-10117 Berlin, Germany	University of Stuttgart; Humboldt University of Berlin	Hilt, W (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	hilt@po.uni-stuttgart.de						Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; Ausubel FA, 1990, CURRENT PROTOCOLS MO; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; CENTOLA M, 1994, MOL CELL BIOL, V14, P1510, DOI 10.1128/MCB.14.2.1510; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; Deshaies RJ, 1997, CURR OPIN GENET DEV, V7, P7, DOI 10.1016/S0959-437X(97)80103-7; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FRIEDMAN H, 1994, P NATL ACAD SCI USA, V91, P2031, DOI 10.1073/pnas.91.6.2031; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Gerlinger UM, 1997, MOL BIOL CELL, V8, P2487, DOI 10.1091/mbc.8.12.2487; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guthrie C, 1991, METHODS ENZYMOL, V194; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HILT W, 1993, J BIOL CHEM, V268, P3479; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; JOHNSTON GC, 1980, MOL GEN GENET, V178, P357, DOI 10.1007/BF00270484; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MCCUSKER JH, 1988, GENETICS, V119, P303; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; WAGNER JC, 1992, EUR J BIOCHEM, V203, P571, DOI 10.1111/j.1432-1033.1992.tb16585.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	58	20	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19443	19452		10.1074/jbc.273.31.19443	http://dx.doi.org/10.1074/jbc.273.31.19443			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677364	hybrid			2022-12-27	WOS:000075125200016
J	Matsuguchi, T; Lilly, MB; Kraft, AS				Matsuguchi, T; Lilly, MB; Kraft, AS			Cytoplasmic domains of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor beta chain (h beta c) responsible for human GM-CSF-induced myeloid cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE KINASE; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; EXPRESSION CLONING; NEURITE OUTGROWTH; GROWTH-FACTOR; STEEL FACTOR; ACTIVATION; INTERLEUKIN-6; SUBUNIT	Granulocyte-macrophage colony-stimulating factor (GM-CSF) regulates differentiation, survival, and proliferation of myeloid progenitor cells. The biologic actions; of GM-CSF are mediated by its binding to the alpha and beta subunits of the GM-CSF receptor (GM-CSFR alpha and beta c, respectively). To determine whether identical regions of the beta c protein mediate both cell growth and differentiation, we expressed cDNA constructs encoding the human wild-type (897 amino acids) and truncated beta c (h beta c) subunits along with the wild-type human GM-CSFR alpha subunit in the murine WT19 cell line, an FDC-P1-derived cell line that differentiates toward the monocytic lineage in response to murine GM-CSF. Whereas the WT19 cell line carrying the C-terminal deleted h beta c subunit of 627 amino acids was still able to grow in human GM-CSF (hGM-CSF), 681 amino acids of the hpc were necessary for cell differentiation. The addition of hGM-CSF to WT19 cell lines containing the h beta c627 subunit stimulated the phosphorylation of ERK (extracellular signal-regulated kinase) and induced the tyrosine-phosphorylation of SHP-2 and STAT5, suggesting that the activation of these molecules is insufficient to mediate the induction of differentiation. A point mutation of tyrosine 628 to phenylalanine (Y628F) within h beta c681 abolished the ability of hGM-CSF to induce differentiation. Our results indicate that the signals required for hGM-CSF-induced differentiation and cell growth are mediated by different regions of the h beta c subunit.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA; Univ Washington, Div Med Oncol, Seattle, WA 98108 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Kraft, AS (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Med Oncol, 4200 E 9th Ave, Denver, CO 80262 USA.				NCI NIH HHS [CA45672] Funding Source: Medline; NIDDK NIH HHS [DK44741] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA045672, R01CA045672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BALDWIN GC, 1992, DEV BIOL, V151, P352, DOI 10.1016/0012-1606(92)90175-G; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EMERSON SG, 1989, BLOOD, V74, P49; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HALLEK M, 1994, LEUKEMIA, V8, P740; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Ihara S, 1996, J BIOCHEM, V120, P865; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Matsuguchi T, 1997, J BIOL CHEM, V272, P17450, DOI 10.1074/jbc.272.28.17450; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Melemed AS, 1997, BLOOD, V90, P3462, DOI 10.1182/blood.V90.9.3462; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; OCHI A, 1983, P NATL ACAD SCI-BIOL, V80, P6351, DOI 10.1073/pnas.80.20.6351; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Piekorz RP, 1997, CYTOKINE, V9, P639, DOI 10.1006/cyto.1997.0221; PIESS M, 1997, BLOOD, V89, P3175; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Smith A, 1997, EMBO J, V16, P451, DOI 10.1093/emboj/16.3.451; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; Wakao H, 1997, BIOCHEM BIOPH RES CO, V234, P198, DOI 10.1006/bbrc.1997.6486; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Woldman I, 1997, J IMMUNOL, V159, P877; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	15	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19411	19418		10.1074/jbc.273.31.19411	http://dx.doi.org/10.1074/jbc.273.31.19411			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677359	hybrid			2022-12-27	WOS:000075125200011
J	Nikolic, Z; Laube, B; Weber, RG; Lichter, P; Kioschis, P; Poustka, A; Mulhardt, C; Becker, CM				Nikolic, Z; Laube, B; Weber, RG; Lichter, P; Kioschis, P; Poustka, A; Mulhardt, C; Becker, CM			The human glycine receptor subunit alpha 3 - GLRA3 gene structure, chromosomal localization, and functional characterization of alternative transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-SUBUNIT; ACETYLCHOLINE-RECEPTORS; BINDING SUBUNIT; SPASMODIC MOUSE; SPASTIC MOUSE; MUTATION; HYPEREKPLEXIA; EXPRESSION; PHOSPHORYLATION	The neuronal glycine receptor is a ligand-gated chloride channel composed of ligand binding cu and structural beta polypeptides. Homology screening of a human fetal brain cDNA library resulted in the identification of two alternative splice variants of the glycine receptor alpha 3 subunit, The amino acid sequence predicted for the alpha 3L variant was largely identical to the corresponding rat subunit, In contrast, the novel splice variant alpha 3K lacked the coding sequence for 15 amino acids located within the cytoplasmic loop connecting transmembrane spanning region 3 (TM3) and TM4, Using P1 artificial chromosome (PAC) clones, the structure of the GLRA3 gene was elucidated and its locus assigned to human chromosomal bands 4q33-q34 by fluorescence in situ hybridization. Two transcripts of 2.4 and 9 kilobases, corresponding to alpha 3L and alpha 3K, respectively, were identified and found to be widely distributed throughout the human central nervous system. Structural analysis of the GLRAB gene revealed that the alpha 3K transcript resulted from a complex splice event where excision of the novel exon 8A comprising the alternative sequence of 45 base pairs coincides with the persistence of a large intronic sequence in the S'-untranslated region. Functional expression in KEK 293 cells of alpha 3L and alpha 3K subunits resulted in the formation of glycine-gated chloride channels that differed significantly in desensitization behavior, thus defining the cytoplasmic loop as an important determinant of channel inactivation kinetics.	Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany; Max Planck Inst Hirnforsch, D-60528 Frankfurt, Germany; Deutsch Krebsforschungszentrum, Abt Org Komplexer Genome, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Abt Mol Genomanalyse, D-69120 Heidelberg, Germany	University of Erlangen Nuremberg; Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Becker, CM (corresponding author), Univ Erlangen Nurnberg, Inst Biochem, Fahrstr 17, D-91054 Erlangen, Germany.		Weber, Ruthild/E-2906-2015	Weber, Ruthild/0000-0001-6610-1080				Becker C. M., 1995, NEUROSCIENTIST, V1, P130; BECKER CM, 1988, EMBO J, V7, P3717, DOI 10.1002/j.1460-2075.1988.tb03255.x; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Brune W, 1996, AM J HUM GENET, V58, P989; Buckanovich RJ, 1997, MOL CELL BIOL, V17, P3194, DOI 10.1128/MCB.17.6.3194; BUCKWALTER MS, 1994, HUM MOL GENET, V3, P2025, DOI 10.1093/hmg/3.11.2025; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DERRY JMJ, 1991, GENOMICS, V10, P593, DOI 10.1016/0888-7543(91)90441-G; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; GRENNINGLOH G, 1990, EMBO J, V9, P771, DOI 10.1002/j.1460-2075.1990.tb08172.x; Handford CA, 1996, MOL BRAIN RES, V35, P211; HOFFMAN PW, 1994, J NEUROSCI, V14, P4185; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; KINGSMORE SF, 1994, MAMM GENOME, V5, P831, DOI 10.1007/BF00292030; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; Kling C, 1997, NEUROSCIENCE, V78, P411, DOI 10.1016/S0306-4522(96)00567-2; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; KUHSE J, 1990, J BIOL CHEM, V265, P22317; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; MALOSIO ML, 1991, EMBO J, V10, P2401, DOI 10.1002/j.1460-2075.1991.tb07779.x; MATZENBACH B, 1994, J BIOL CHEM, V269, P2607; Milani N, 1996, AM J HUM GENET, V58, P420; MILANI N, 1998, IN PRESS GENOMICS; Monani U, 1996, GENOME RES, V6, P1200, DOI 10.1101/gr.6.12.1200; MULHARDT C, 1994, NEURON, V13, P1003, DOI 10.1016/0896-6273(94)90265-8; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; REES MI, 1994, HUM MOL GENET, V3, P2175, DOI 10.1093/hmg/3.12.2175; RUIZGOMEZ A, 1991, J BIOL CHEM, V266, P559; RYAN SG, 1994, NAT GENET, V7, P131, DOI 10.1038/ng0694-131; Sambrook J., 2002, MOL CLONING LAB MANU; SAUL B, 1994, FEBS LETT, V350, P71, DOI 10.1016/0014-5793(94)00736-5; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHIANG R, 1995, ANN NEUROL, V38, P85, DOI 10.1002/ana.410380115; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SONTHEIMER H, 1989, NEURON, V2, P1491, DOI 10.1016/0896-6273(89)90195-5; UETZ P, 1994, FEBS LETT, V339, P302, DOI 10.1016/0014-5793(94)80435-4; VAELLO ML, 1994, J BIOL CHEM, V269, P2002; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H	40	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19708	19714		10.1074/jbc.273.31.19708	http://dx.doi.org/10.1074/jbc.273.31.19708			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677400	hybrid			2022-12-27	WOS:000075125200052
J	Barber, LA; Spandau, DF; Rathman, SC; Murphy, RC; Johnson, CA; Kelley, SW; Hurwitz, SA; Travers, JB				Barber, LA; Spandau, DF; Rathman, SC; Murphy, RC; Johnson, CA; Kelley, SW; Hurwitz, SA; Travers, JB			Expression of the platelet-activating factor receptor results in enhanced ultraviolet B radiation-induced apoptosis in a human epidermal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FACTOR PAF; HUMAN KERATINOCYTES; HUMAN NEUTROPHILS; RELEASE; ACETYLHYDROLASE; IDENTIFICATION; STIMULATION; ENDOTOXIN	Recent studies have demonstrated that ultraviolet B radiation (UVB) damages human keratinocytes in part by inducing oxidative stress and cytokine production. Severe UVB damage to the keratinocyte can also result in apoptosis or programmed cell death, Although the lipid mediator platelet-activating factor (PAF) is synthesized in response to epidermal cell damage and epidermal cells express PAF receptors, it is not known whether PAF is involved in UVB-induced epidermal cell apoptosis, These studies examined the role of the PAF system in UVB-induced epidermal cell apoptosis using a novel model system created by retroviral-mediated transduction of the PAF receptor-negative human epidermal cell line KB with the human PAF receptor (PAF-R). Expression of the PAF-R in KB cells did not affect base-line growth or apoptosis, yet resulted in a decrease in the lag time between treatment of the cells and the induction of apoptosis following irradiation with 400 J/m(2) UVB, This effect was inhibited by pretreatment with the PAF-R antagonists WEB 2086 and A-85783, confirming involvement of the PAF-R in this process, At lower doses (100-200 J/m(2)) of UVB, only RR cells that expressed the PAF-R became apoptotic. Treatment of PAF-R-expressing EB clones with the metabolically stable PAF-R agonist 1-hexadexyl-2-N-methylcarbamoyl-3-gIycerophosphocholine (CPAF) alone did not induce apoptosis but augmented the degree of apoptosis observed if CPAF was used in combination with lower doses (200 J/m(2)) of UVB irradiation. interestingly, UVB irradiation was found to stimulate PAF synthesis only in PAF-R-expressing KB cell clones. The antioxidants N-acetyl cysteine, 1,1,3,3-tetramethyl-2-thiourea, and vitamin E inhibited both WE-induced PAF biosynthesis as well as the augmentation of WE-induced apoptosis in PAF-R-expressing HE clones, suggesting the possibility that UVB stimulates the production of oxidized lipid species with PAF-R agonistic activity in this model system. Thus, these studies indicate that a component of UVB-induced epidermal cell cytotoxicity can be modulated by PAF-R activation through the production of PAF and PAF-like species.	Indiana Univ, Sch Med, Dept Dermatol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Jewish Health	Travers, JB (corresponding author), Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, HB Wells Ctr Pediat Res, Rm 2659,702 Barnhill Dr, Indianapolis, IN 46202 USA.	jtravers@wpo.iupui.edu	Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Travers, Jeffrey/0000-0001-7232-1039	NHLBI NIH HHS [HL43403] Funding Source: Medline; NIAMS NIH HHS [K08AR1993] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLOATTI G, 1994, J PHARMACOL EXP THER, V269, P766; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; ARENDS MJ, 1990, AM J PATHOL, V136, P593; AZZOUZI BE, 1993, BIOCHEM BIOPH RES CO, V190, P320; BAULDRY SA, 1991, BIOCHIM BIOPHYS ACTA, V1084, P178; CAMUSSI G, 1987, J EXP MED, V166, P1390, DOI 10.1084/jem.166.5.1390; CASALSTENZEL J, 1987, BRIT J DERMATOL, V118, P475; Cotton J, 1997, RADIAT RES, V147, P148, DOI 10.2307/3579415; CUNDELL DR, 1995, NATURE, V377, P435, DOI 10.1038/377435a0; EAGLE H, 1955, P SOC EXP BIOL MED, V89, P362; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; Ferro TJ, 1997, AM J PHYSIOL-LUNG C, V272, pL979, DOI 10.1152/ajplung.1997.272.5.L979; GRANDEL KE, 1985, NEW ENGL J MED, V313, P405, DOI 10.1056/NEJM198508153130702; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; LEVESQUE JP, 1986, P NATL ACAD SCI USA, V83, P6494, DOI 10.1073/pnas.83.17.6494; LEWIS MS, 1988, J CLIN INVEST, V82, P2045, DOI 10.1172/JCI113825; MALLET AI, 1985, BIOCHEM BIOPH RES CO, V126, P192, DOI 10.1016/0006-291X(85)90590-X; MATSUMOTO K, 1995, BLOOD, V86, P1437, DOI 10.1182/blood.V86.4.1437.bloodjournal8641437; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MIWA M, 1988, J CLIN INVEST, V82, P1983, DOI 10.1172/JCI113818; Murphy RC, 1996, ADV EXP MED BIOL, V416, P51; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; OFLAHERTY JT, 1994, BBA-LIPID LIPID MET, V1210, P209, DOI 10.1016/0005-2760(94)90123-6; PEI Y, 1998, IN PRESS J IMMUNOL; Pinckard RN, 1996, J LEUKOCYTE BIOL, V59, P219, DOI 10.1002/jlb.59.2.219; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; Roth M, 1996, J EXP MED, V184, P191, DOI 10.1084/jem.184.1.191; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SHENG YH, 1995, CURR EYE RES, V14, P341, DOI 10.3109/02713689508999931; SHEPPARD GS, 1994, J MED CHEM, V37, P2011, DOI 10.1021/jm00039a015; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; Stewart MS, 1996, J INVEST DERMATOL, V106, P1086, DOI 10.1111/1523-1747.ep12339344; STOLL LL, 1993, AM J PHYSIOL, V264, pC885, DOI 10.1152/ajpcell.1993.264.4.C885; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; Toledano BJ, 1997, J IMMUNOL, V158, P3705; TRAVERS JB, 1990, BIOCHIM BIOPHYS ACTA, V1042, P193, DOI 10.1016/0005-2760(90)90007-K; TRAVERS JB, 1995, J INVEST DERMATOL, V105, P816, DOI 10.1111/1523-1747.ep12326581; Travers JB, 1996, J INVEST DERMATOL, V107, P88, DOI 10.1111/1523-1747.ep12298295; TRIGGIANI M, 1991, BIOCHIM BIOPHYS ACTA, V1084, P41, DOI 10.1016/0005-2760(91)90053-K; WILCOX RW, 1987, LIPIDS, V22, P800, DOI 10.1007/BF02535534; ZIMMERMAN GA, 1995, J NUTR, V125, P16615	49	64	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18891	18897		10.1074/jbc.273.30.18891	http://dx.doi.org/10.1074/jbc.273.30.18891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668065	hybrid			2022-12-27	WOS:000074974700032
J	Duina, AA; Kalton, HM; Gaber, RF				Duina, AA; Kalton, HM; Gaber, RF			Requirement for Hsp90 and a CyP-40-type cyclophilin in negative regulation of the heat shock response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATION; STEROID-RECEPTOR; BINDING-PROTEIN; HSP70; THERMOTOLERANCE; GROWTH; INVIVO; KINASE; GENES	The heat shock response is a highly conserved mechanism that allows cells to withstand a variety of stress conditions. Activation of this response is characterized by increased synthesis of heat shock proteins (HSPs), which protect cellular proteins from stress-induced denaturation, Heat shock transcription factors (HSFs) are required for increased expression of HSPs during stress conditions and can be found in complexes containing components of the Hsp90 molecular chaperone machinery, raising the possibility that Hsp90 is involved in regulation of the heat shock response. To test this, we have assessed the effects of mutations that impair activity of the Hsp90 machinery on heat shock related events in Saccharomyces cerevisiae. Mutations that either reduce the level of Hsp90 protein or eliminate Cpr7, a CyP-40-type cyclophilin required for full Hsp90 function, resulted in increased HSF-dependent activities. Genetic tests also revealed that Hsp90 and Cpr7 function synergistically to repress gene expression from HSF-dependent promoters. Conditional loss of Hsp90 activity resulted in both increased HSF-dependent gene expression and acquisition of a thermotolerant phenotype. Our results reveal that Hsp90 and Cpr7 are required for negative regulation of the heat shock response under both stress and nonstress conditions and establish a specific endogenous role for the Hsp90 machinery in S. cerevisiae.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Gaber, RF (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	r-gaber@nwu.edu						BARNES CA, 1990, J BACTERIOL, V172, P4352, DOI 10.1128/jb.172.8.4352-4358.1990; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHENG LI, 1993, BIOCHEM BIOPH RES CO, V195, P201, DOI 10.1006/bbrc.1993.2030; CRAIG EA, 1984, CELL, V38, P841, DOI 10.1016/0092-8674(84)90279-4; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; Duina AA, 1996, SCIENCE, V274, P1713, DOI 10.1126/science.274.5293.1713; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; Kaiser C., 1994, METHODS YEAST GENETI; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; MAGER WH, 1993, BIOCHEM J, V290, P1; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nathan DF, 1997, P NATL ACAD SCI USA, V94, P12949, DOI 10.1073/pnas.94.24.12949; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	39	119	123	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18974	18978		10.1074/jbc.273.30.18974	http://dx.doi.org/10.1074/jbc.273.30.18974			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668076	hybrid			2022-12-27	WOS:000074974700043
J	Fay, PJ; Koshibu, K				Fay, PJ; Koshibu, K			The A2 subunit of factor VIIIa modulates the active site of factor IXa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; COAGULATION FACTOR-X; A1/A3-C1-C2 DIMER; CATALYZED PROTEOLYSIS; PROCOAGULANT ACTIVITY; BINDING-SITE; FACTOR XASE; PROTEIN-C; A2-SUBUNIT; ACTIVATION	Factor VIIIa, the protein cofactor for factor Ma, is comprised of Al, A2, and A3-C1-C2 subunits. Isolated subunits of factor VIIIa were examined for their ability to accelerate the factor IXa-catalyzed activation of factor X. The A2 subunit enhanced the k(cat) for this conversion by 100-fold whereas the K-m for factor X was unaffected. The apparent K-d for the interaction of A2 subunit with factor Ma was similar to 300 nM. Similar results were obtained using purified A2 expressed as the isolated domain in Chinese hamster ovary cells, although this material was less stable than the factor VIIIa-derived material. Isolated Al and A3-C1-C2 subunits showed no effect on the rate of factor X conversion. A2 subunit increased the fluorescence anisotropy of fluorescein-Phe-Phe-Arg-factor IXa (Delta r = 0.015) and markedly increased anisotropy in the presence of factor X (Delta r = 0.057), suggesting that it contributes to the orientation of the factor Ma active site and its relation to substrate. A synthetic peptide to A2 residues 558-565 inhibited the A2-dependent enhancement of factor X activation with an IC50 = 40 mu M, a value similar to its K-i for inhibition of the intrinsic factor Xase (105 mu M). These results indicate that the isolated A2 subunit modulates the active site of factor Ma and identifies a functional role for this subunit in factor VIIIa.	Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med & Dent,Dept Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Vasc Med Unit, Sch Med & Dent,Dept Med, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.			Koshibu, Kyoko/0000-0002-9809-0299	NHLBI NIH HHS [HL 38199, HL 30616] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano K, 1998, BLOOD, V91, P538, DOI 10.1182/blood.V91.2.538.538_538_548; Boedeker Berthold G. D., 1992, Transfusion Medicine Reviews, V6, P256, DOI 10.1016/S0887-7963(92)70177-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Gilbert GE, 1997, BIOCHEMISTRY-US, V36, P10768, DOI 10.1021/bi970537y; JESTY J, 1990, J BIOL CHEM, V265, P17539; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MANN KG, 1990, BLOOD, V76, P1; Mathur A, 1997, J BIOL CHEM, V272, P23418, DOI 10.1074/jbc.272.37.23418; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; PITTMAN DD, 1992, BLOOD, V79, P389; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; Regan LM, 1996, J BIOL CHEM, V271, P3982; REGAN LM, 1994, J BIOL CHEM, V269, P9445; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	40	94	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19049	19054		10.1074/jbc.273.30.19049	http://dx.doi.org/10.1074/jbc.273.30.19049			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668086	hybrid			2022-12-27	WOS:000074974700053
J	Foos, G; Garcia-Ramirez, JJ; Galang, CK; Hauser, CA				Foos, G; Garcia-Ramirez, JJ; Galang, CK; Hauser, CA			Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-EXPRESSION; ONCOGENIC ACTIVITY; DOMAIN PROTEIN; NUCLEAR TARGET; BINDING-SITES; MAP KINASE; CELLS; ACTIVATION; PROMOTER	Ets transcription factors are important downstream targets of oncogenic Ras. The transcriptional activity of several Ets family members is regulated by Ras, and interfering with Ets-dependent transcription by expression of just the Ets2 DNA binding domain can inhibit or reverse Ras-mediated cellular transformation. To better understand the role of Ets proteins in Ras transformation, we have now analyzed the effects of stably expressing a variety of Ets2 constructs in Ras-transformed NIH3T3 (DT) cells. Expression of only the Ets2 transactivation domains, which also inhibits Ras or Neu/ErbB-2-mediated activation of Ets-dependent transcription, strongly inhibited anchorage-independent growth, but did not revert the transformed DT cell morphology, Unexpectedly, high expression of full-length Ets2, a transcriptional activator, broadly reversed the transformed properties of DT cells, including anchorage-independent growth, transformed morphology, and tumorigenicity, but did not impair attached cell growth. Increasing full-length Ets2 transcriptional activity by fusing it to the VP16 transactivation domain enhanced its ability to reverse DT cell transformation. Mutational analysis revealed that the mitogen-activated protein kinase phosphorylation site required for Ras-mediated activation, Ets2(T72), was not essential for Ets2 reversion activity. The distinct reversion activities of the highly expressed Ets2 transactivation domains or full-length Ets2, along with the specific reversion activity by Ets2 constructs that either inhibit or activate Ets-dependent transcription, suggests multiple roles for Ets factors in cellular transformation. These results indicate that several distinct approaches for modulating Ets activity may be useful for intervention in human cancers.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Hauser, CA (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Garcia-Ramirez, Jose J/L-2153-2014	Garcia-Ramirez, Jose J/0000-0002-8348-3727	NATIONAL CANCER INSTITUTE [R01CA063130] Funding Source: NIH RePORTER; NCI NIH HHS [CA63130] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Funaoka K, 1997, BIOCHEM BIOPH RES CO, V236, P79, DOI 10.1006/bbrc.1997.6909; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GALANG CK, 1994, ONCOGENE, V9, P2913; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Giovane A, 1997, MOL CELL BIOL, V17, P5667, DOI 10.1128/MCB.17.10.5667; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KIVINEN L, 1993, ONCOGENE, V8, P2703; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; Liu AY, 1997, PROSTATE, V30, P145, DOI 10.1002/(SICI)1097-0045(19970215)30:3<145::AID-PROS1>3.0.CO;2-L; LJUNGDAHL S, 1997, FEBS LETT, V249, P648; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Michieli P, 1996, ONCOGENE, V12, P775; MIN SY, 1994, CELL GROWTH DIFFER, V5, P563; Neznanov N, 1997, J BIOL CHEM, V272, P27549, DOI 10.1074/jbc.272.44.27549; NEZNANOV NS, 1993, MOL CELL BIOL, V13, P1815, DOI 10.1128/MCB.13.3.1815; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHagan RC, 1996, ONCOGENE, V13, P1323; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rees S, 1996, BIOTECHNIQUES, V20, P102; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Venanzoni MC, 1996, ONCOGENE, V12, P1199; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Yang BS, 1996, MOL CELL BIOL, V16, P538	60	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18871	18880		10.1074/jbc.273.30.18871	http://dx.doi.org/10.1074/jbc.273.30.18871			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668063	hybrid			2022-12-27	WOS:000074974700030
J	Liu, XP; Miller, MJS; Joshi, MS; Sadowska-Krowicka, H; Clark, DA; Lancaster, JR				Liu, XP; Miller, MJS; Joshi, MS; Sadowska-Krowicka, H; Clark, DA; Lancaster, JR			Diffusion-limited reaction of free nitric oxide with erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELLS; OXYGEN-UPTAKE; HEMOGLOBIN; COEFFICIENTS; RATS	Concentration changes of nitric oxide (NO) were monitored using an NO-sensitive electrode in phosphate-buffered saline (PBS) with either free oxyhemoglobin (oxyHb) or red blood cells (RBCs), In aerated PBS, the half-life of 0.9 mu M NO is greater than 4 min. NO is undetectable (<50 nM) when added to a solution of oxyHb because the reaction of NO with oxyHb is rapid. The disappearance rate of NO in PBS containing RBCs is rapid, compared with PBS, but it is much slower (by a factor of approximately 650) than with an equivalent solution of free oxyHb, The half-life of NO is inversely proportional to the concentration of RBCs, independent of oxyHb concentration inside RBCs, and the disappearance rate of NO is first order in NO concentration and first order in the concentration of RBCs, After all the oxyHb reacts with NO to form methemoglobin, the disappearance rate of NO slows greatly, These data indicate that the reaction of NO with oxyhemoglobin within RBCs is limited by the diffusion of NO into the cell, which has also been shown previously for the reaction of O-2 with deoxyhemoglobin, Experimental data show that the half-life of NO in the presence of 2.1 x 10(6) RBCs/ml is 4.2 s, From this value, we estimate that the half-life of NO in whole blood (5 x 10(9) RBCs/ml) will be 1.8 ms, A simple analytical expression for the half-life of NO in PBS with RBCs was derived in this study based on a spherical diffusion model. The calculated half-life of NO from the expression is in good agreement with the experimental values.	Louisiana State Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA; Louisiana State Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Louisiana State Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System; Louisiana State University System	Lancaster, JR (corresponding author), Louisiana State Univ, Sch Med, Dept Physiol, 1901 Perdido St, New Orleans, LA 70112 USA.	jlanca@lsumc.edu	Liu, Xiaoping/A-4516-2008	Liu, Xiaoping/0000-0002-7516-382X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031885] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA028842] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA28842] Funding Source: Medline; NICHD NIH HHS [HD31885] Funding Source: Medline; NIDDK NIH HHS [DK46995] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abassi Z, 1997, J LAB CLIN MED, V129, P603, DOI 10.1016/S0022-2143(97)90194-3; Bard A. J., 1980, ELECTROCHEMICAL METH; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; CHIEN JCW, 1969, J AM CHEM SOC, V91, P2166, DOI 10.1021/ja01036a085; COIN JT, 1979, J BIOL CHEM, V254, P1178; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FARMER MC, 1988, BIOMATER ARTIF CELL, V16, P289, DOI 10.3109/10731198809132578; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P445, DOI 10.1111/j.1476-5381.1989.tb12616.x; Hakim TS, 1996, PHYSIOL MEAS, V17, P267, DOI 10.1088/0967-3334/17/4/004; Hartridge H, 1927, J PHYSIOL-LONDON, V52, P232, DOI 10.1113/jphysiol.1927.sp002354; Hermann L, 1865, ARCH ANAT PHYSL LPZ, P469; HUXLEY VH, 1983, MICROVASC RES, V26, P89, DOI 10.1016/0026-2862(83)90058-4; HUXLEY VH, 1981, J PHYSIOL-LONDON, V316, P75, DOI 10.1113/jphysiol.1981.sp013773; JAFFE ER, 1964, RED BLOOD CELL, P397; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KILBOURN RG, 1994, BIOCHEM BIOPH RES CO, V199, P155, DOI 10.1006/bbrc.1994.1208; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; LANCASTER JR, 1992, AM SCI, V80, P248; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LIU XP, 1990, J ELECTROANAL CHEM, V294, P289, DOI 10.1016/0022-0728(90)87152-A; Loscalzo J, 1997, J LAB CLIN MED, V129, P580, DOI 10.1016/S0022-2143(97)90191-8; Malinski T, 1996, METHOD ENZYMOL, V268, P58; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MEULEMANS A, 1994, NEUROSCI LETT, V171, P89, DOI 10.1016/0304-3940(94)90612-2; MULDOON S, 1996, ARTIF CELL BLOOD SUB, V24, P392; NICOLSON P, 1951, PROC R SOC SER B-BIO, V138, P241, DOI 10.1098/rspb.1951.0020; NORTON JM, 1990, BIORHEOLOGY, V27, P21; RABINOVICI R, 1995, CRIT CARE MED, V23, P801, DOI 10.1097/00003246-199505000-00004; Rudolph AS, 1997, J APPL PHYSIOL, V82, P1826, DOI 10.1152/jappl.1997.82.6.1826; Sandoval M, 1997, GASTROENTEROLOGY, V113, P1480, DOI 10.1053/gast.1997.v113.pm9352850; SCHULTZ SC, 1993, J LAB CLIN MED, V122, P301; SHAW AW, 1977, J CHEM SOC FARAD T 1, V73, P1239, DOI 10.1039/f19777301239; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; VANASSENDELFT OW, 1975, ANAL BIOCHEM, V69, P43, DOI 10.1016/0003-2697(75)90563-1; VANDEGRIFF KD, 1984, BIOPHYS J, V45, P825, DOI 10.1016/S0006-3495(84)84226-5; WADE RS, 1990, CHEM RES TOXICOL, V3, P289, DOI 10.1021/tx00016a002; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680; ZUCK TF, 1994, CRIT REV CL LAB SCI, V31, P295, DOI 10.3109/10408369409084678	39	403	410	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18709	18713		10.1074/jbc.273.30.18709	http://dx.doi.org/10.1074/jbc.273.30.18709			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668042	hybrid			2022-12-27	WOS:000074974700009
J	Ikeda, S; Biswas, T; Roy, R; Izumi, T; Boldogh, I; Kurosky, A; Sarker, AH; Seki, S; Mitra, S				Ikeda, S; Biswas, T; Roy, R; Izumi, T; Boldogh, I; Kurosky, A; Sarker, AH; Seki, S; Mitra, S			Purification and characterization of human NTH1, a homolog of Escherichia coli endonuclease III - Direct identification of Lys-212 as the active nucleophilic residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; 8-OXOGUANINE DNA GLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; POLYMERASE-BETA; MAMMALIAN-CELLS; CLONING; PROTEIN; RECONSTITUTION; EXPRESSION; SEQUENCE	The human endonuclease III (hNTH1), a homolog of the Escherichia coli enzyme (Nth), is a DNA glycosylase with abasic (apurinic/apyrimidinic (AP)) lyase activity and specifically cleaves oxidatively damaged pyrimidines in DNA. Its cDNA was cloned, and the full-length enzyme (304 amino acid residues) was expressed as a glutathione S-transferase fusion polypeptide in E. coli. Purified wild-type protein with two additional amino acid residues and a truncated protein with deletion of 22 residues at the NH, terminus were equally active and had absorbance maxima at 280 and 410 nm, the latter due to the presence of a [4Fe-4S]cluster, as in E. coli Nth. The enzyme cleaved thymine glycol-containing form I plasmid DNA and a dihydrouracil (DHU)-containing oligonucleotide duplex. The protein had a molar extinction coefficient of 5.0 x 10(4) and a pi of 10. With the DHU-containing oligonucleotide duplex as substrate, the K-m was 47 nM, and k(cat) was similar to 0.6/min, independent of whether DHU paired with G or A. The enzyme carries out p-elimination and forms a Schiff base between the active site residue and the deoxyribose generated after base removal. The prediction of Lys-212 being the active site was confirmed by sequence analysis of the peptide-oligonucleotide adduct, Furthermore, replacing Lys-212 with Gin inactivated the enzyme. However, replacement with Arg-212 yielded an active enzyme with about 85-fold lower catalytic specificity than the wild-type protein. DNase I footprinting with hNTH1 showed protection of 10 nucleotides centered around the base lesion in the damaged strand and a stretch of 15 nucleotides (with the G opposite the lesion at the 5'-boundary) in the complementary strand. Immunological studies showed that HeLa cells contain a single hNTH species of the predicted size, localized in both the nucleus and the cytoplasm.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Okayama Univ, Sch Med, Dept Biol Mol, Inst Mol & Cellular Biol, Okayama 700, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Okayama University	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Route 1079, Galveston, TX 77555 USA.				NATIONAL CANCER INSTITUTE [R01CA053791] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029261] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53791] Funding Source: Medline; NIEHS NIH HHS [ES08457] Funding Source: Medline; NINDS NIH HHS [NS 29261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aburatani H, 1997, CANCER RES, V57, P2151; ASAHARA H, 1989, BIOCHEMISTRY-US, V28, P4444, DOI 10.1021/bi00436a048; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Augeri L, 1997, BIOCHEMISTRY-US, V36, P721, DOI 10.1021/bi9625511; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; BREIMER LH, 1984, J BIOL CHEM, V259, P5543; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; Eide L, 1996, P NATL ACAD SCI USA, V93, P10735, DOI 10.1073/pnas.93.20.10735; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; HATAHET Z, 1994, J BIOL CHEM, V269, P18814; Hazra TK, 1997, BIOCHEMISTRY-US, V36, P5769, DOI 10.1021/bi963085i; Hilbert TP, 1997, J BIOL CHEM, V272, P6733, DOI 10.1074/jbc.272.10.6733; KATCHER HL, 1983, BIOCHEMISTRY-US, V22, P4071, DOI 10.1021/bi00286a013; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUHNLEIN U, 1976, P NATL ACAD SCI USA, V73, P1169, DOI 10.1073/pnas.73.4.1169; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; MELAMEDE RJ, 1994, BIOCHEMISTRY-US, V33, P1255, DOI 10.1021/bi00171a028; Mitra S, 1997, MOL CELLS, V7, P305; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; OHANDLEY S, 1995, BIOCHEMISTRY-US, V34, P2528, DOI 10.1021/bi00008a017; RoldanArjona T, 1996, NUCLEIC ACIDS RES, V24, P3307, DOI 10.1093/nar/24.17.3307; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SEKI S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P287, DOI 10.1016/0167-4781(92)90027-W; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	40	211	217	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21585	21593		10.1074/jbc.273.34.21585	http://dx.doi.org/10.1074/jbc.273.34.21585			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705289	hybrid			2022-12-27	WOS:000075492600023
J	Schneider, A; Smith, RWP; Kautz, AR; Weisshart, K; Grosse, F; Nasheuer, HP				Schneider, A; Smith, RWP; Kautz, AR; Weisshart, K; Grosse, F; Nasheuer, HP			Primase activity of human DNA polymerase alpha-primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER EMBRYOS; SPECIES-SPECIFIC REPLICATION; CALF THYMUS; IN-VITRO; MAMMALIAN PRIMASE; DIVALENT-CATIONS; ZINC MOTIF; PURIFICATION; BACTERIOPHAGE-T7; SUBUNIT	DNA polymerase alpha-primase consists of four subunits, p180, p68, p58, and p48, and comprises two essential enzymatic functions. To study the primase activity of the complex, we expressed cDNAs encoding for the human p58 and p48 subunits either as single proteins or together using Escherichia coli expression vectors, Coexpression of both primase subunits allowed the purification of a heterodimer in high yields that revealed stable primase activity. Purified recombinant p48 subunit showed enzyme activity, whereas purified p58 did not. In contrast to the heterodimer, the primase activity of p48 was unstable. The activity of p48 could be stabilized by the addition of the divalent cations Mg2+ and Mn2+ but not Zn2+. On a poly(dC) template the primase activity was hardly influenced by the monovalent cation potassium. However, by using poly(dT) as a template the recombinant p48 activity was sensitive to salt, whereas recombinant p58-p48 and the bovine DNA polymerase alpha-primase purified from thymus were less sensitive to the addition of monovalent cations, A complex of bacterially expressed primase and baculovirus-expressed p180 and p68 was assembled in vitro and shown to support replication of simian virus 40 DNA in a cell-free system.	Inst Mol Biotechnol, Biochem Abt, D-07745 Jena, Germany; Inst Mol Biotechnol, Abt Mol Cytol & Elektronenmikroskopie, D-07745 Jena, Germany		Nasheuer, HP (corresponding author), Inst Mol Biotechnol, Biochem Abt, Beutenbergstr 11, D-07745 Jena, Germany.	nasheuer@imb-jena.de	Smith, Richard/J-8117-2019; Nasheuer, Heinz P./B-9025-2008	Smith, Richard/0000-0002-6475-6910; Nasheuer, Heinz Peter/0000-0002-9218-9079				BAKKENIST CJ, 1994, J BIOL CHEM, V269, P26759; BICKLER SW, 1992, BIOTECHNIQUES, V13, P64; BISWAS EE, 1987, BIOCHEMISTRY-US, V26, P5377, DOI 10.1021/bi00391a024; BONET ML, 1992, INT J BIOCHEM, V24, P839; Boudker O, 1997, J MOL BIOL, V272, P770, DOI 10.1006/jmbi.1997.1263; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUCKNER A, 1995, MOL CELL BIOL, V15, P1716; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; CONAWAY RC, 1982, P NATL ACAD SCI-BIOL, V79, P2523, DOI 10.1073/pnas.79.8.2523; Copeland WC, 1997, PROTEIN EXPRES PURIF, V9, P1, DOI 10.1006/prep.1996.0665; COPELAND WC, 1993, J BIOL CHEM, V268, P26179; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; FOIANI M, 1989, J BIOL CHEM, V264, P2189; GROSSE F, 1985, J BIOL CHEM, V260, P1881; GROSSE F, 1981, BIOCHEMISTRY-US, V20, P5470, DOI 10.1021/bi00522a019; HARTMANN GR, 1988, BIOL CHEM H-S, V369, P775; HINE AV, 1994, P NATL ACAD SCI USA, V91, P12327, DOI 10.1073/pnas.91.25.12327; HOLMES AM, 1986, J BIOL CHEM, V261, P1924; HUBSCHER U, 1983, EMBO J, V2, P133, DOI 10.1002/j.1460-2075.1983.tb01394.x; JAZWINSKI SM, 1985, J BIOL CHEM, V260, P4995; KAGUNI LS, 1983, J BIOL CHEM, V258, P9037; Kohn WD, 1997, J MOL BIOL, V267, P1039, DOI 10.1006/jmbi.1997.0930; KONIG H, 1983, EUR J BIOCHEM, V135, P435, DOI 10.1111/j.1432-1033.1983.tb07670.x; Kornberg A., 1991, DNA REPLICATION; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; Madern D, 1997, EUR J BIOCHEM, V249, P607, DOI 10.1111/j.1432-1033.1997.00607.x; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PRUSSAK CE, 1989, J BIOL CHEM, V264, P4957; Rodriguez M, 1996, BIOCHEM MOL BIOL INT, V38, P783; ROTH YF, 1987, EUR J BIOCHEM, V165, P473, DOI 10.1111/j.1432-1033.1987.tb11463.x; Salas M., 1996, MECH PRIMING DNA SYN, P131; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; SEKIYA F, 1995, J BIOL CHEM, V270, P14325, DOI 10.1074/jbc.270.24.14325; SHEAFF RJ, 1993, BIOCHEMISTRY-US, V32, P3027, DOI 10.1021/bi00063a014; Sriram M, 1997, STRUCTURE, V5, P403, DOI 10.1016/S0969-2126(97)00197-4; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; Stadlbauer F, 1996, MOL CELL BIOL, V16, P94; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TABOR S, 1987, J BIOL CHEM, V262, P15330; TSENG BY, 1983, J BIOL CHEM, V258, P9845; VISHWANATHA JK, 1986, NUCLEIC ACIDS RES, V14, P8467, DOI 10.1093/nar/14.21.8467; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WANG TSF, 1996, DNA REPLICATION EUKA, P461; WILSON FE, 1985, J BIOL CHEM, V260, P8173	51	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21608	21615		10.1074/jbc.273.34.21608	http://dx.doi.org/10.1074/jbc.273.34.21608			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705292	hybrid			2022-12-27	WOS:000075492600026
J	Bovolenta, C; Testolin, L; Benussi, L; Lievens, PMJ; Liboi, E				Bovolenta, C; Testolin, L; Benussi, L; Lievens, PMJ; Liboi, E			Positive selection of apoptosis-resistant cells correlates with activation of dominant-negative STAT5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; INTERFERON-ALPHA; HOMEOBOX GENE; TRANSCRIPTION; EXPRESSION; PATHWAY; INTERLEUKIN-3; PROTEIN	The STATE activation has important roles in cell differentiation, cell cycle control, and development. However, the potential implications of STATE in the control of apoptosis remain unexplored. To evaluate any possible link between the erythropoietin receptor (EpoR) JAK2/STAT5 transduction pathway and apoptosis, we have investigated apoptosis-resistant cells (ApoR) that arose from positive selection of the erythroid-committed Ba/F3EpoR cells triggered to apoptosis by ectopic expression of the HOX-B8 homeotic gene, We show that JAK2 is normally activated by Epo in both Ba/F3EpoR and ApoR cells, In contrast, both STAT5a and STAT5b isoforms are uniquely activated in a C-truncated form (86 kDa) only in ApoR cells. Analysis of ApoR and Ba/F3EpoR subclones confirmed that the switch to the truncated STATE isoform coincides with apoptosis survival and that ApoR do not derive from preexisting cells with a shortened STATE. In addition, ApoR cells die in the absence of Epo, This indicates that resistance to apoptosis is not because of a general defect in the apoptotic pathway of ApoR cells. Furthermore, we show that the 86-kDa STATE protein presents a dominant-negative (DN) character. We hypothesize that the switch to a DN STATE may be part of a mechanism that allows ApoR cells to be selectively advantaged during apoptosis. In conclusion, we provide evidence for a functional correlation between a naturally occurring DN STATE and a biological response.	Univ Verona, Inst Biol Chem, I-37134 Verona, Italy; Univ Verona, Inst Anat, I-37134 Verona, Italy; Inst Neurol Sci C Besta, I-20137 Milano, Italy	University of Verona; University of Verona	Liboi, E (corresponding author), Univ Verona, Inst Biol Chem, I-37134 Verona, Italy.	LIBEL@borgoroma.univr.it	BENUSSI, LUISA/K-4409-2016	BENUSSI, LUISA/0000-0003-2836-8141				Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6394; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bovolenta C, 1996, FEBS LETT, V386, P239, DOI 10.1016/0014-5793(96)00453-X; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Krishnaraju K, 1997, BLOOD, V90, P1840, DOI 10.1182/blood.V90.5.1840; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LAWRENCE HJ, 1992, BLOOD, V80, P2445; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MICHAELSON J, 1991, APOPTOSIS MOL BASIS, P31; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERKINS AC, 1993, EMBO J, V12, P3835, DOI 10.1002/j.1460-2075.1993.tb06062.x; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; REN HY, 1994, J BIOL CHEM, V269, P19633; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; Wang DM, 1996, MOL CELL BIOL, V16, P6141	43	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20779	20784		10.1074/jbc.273.33.20779	http://dx.doi.org/10.1074/jbc.273.33.20779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694822	hybrid			2022-12-27	WOS:000075386100015
J	Yu, DH; Qu, CK; Henegariu, O; Lu, XL; Feng, GS				Yu, DH; Qu, CK; Henegariu, O; Lu, XL; Feng, GS			Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC FAMILY KINASES; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; C-SRC; EXTRACELLULAR-MATRIX; RAS PATHWAY; NEURAL-TUBE; MAP KINASE; PHOSPHORYLATION	Shp-2, a widely expressed cytoplasmic tyrosine phosphatase with two SH2 domains, is believed to participate in signal relay downstream of growth factor receptors, We show here that this phosphatase also plays an important role in the control of cell spreading, migration, and cytoskeletal architecture. Fibroblast cells lacking a functional Shp-2 were impaired in their ability to spread and migrate on fibronectin compared with wild-type cells. Furthermore, Shp-2 mutant cells displayed an increased number of focal adhesions and condensed F-actin aggregation at the cell periphery, properties reminiscent of focal adhesion kinase (FAK)-deficient cells. This is consistent with our previous observations in vivo that mice homozygous for the Shp-2 mutation died at midgestation with similar phenotype to FAK and fibronectin-deficient embryos, having severe defects in mesodermal patterning, particularly the truncation of posterior structures. Biochemical analysis demonstrated that FAK dephosphorylation was significantly reduced in Shp-2 mutant cells in suspension. Furthermore, regulated association of Src SH2 domain with FAH and paxillin during cell attachment and detachment on fibronectin was disrupted in Shp-2 mutant cells. This report defines a unique role of the Shp-2 tyrosine phosphatase in cell motility, which might guide the design of a new strategy for pharmaceutical interference of tumor metastasis.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 1044 W Walnut St,Rm 302, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard JD, 1996, DEVELOPMENT, V122, P1137; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FURUTA Y, 1995, ONCOGENE, V11, P1989; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MILARSKI KL, 1994, J BIOL CHEM, V269, P2123; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; Nojima Y, 1996, Hum Cell, V9, P169; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; QU CK, 1998, IN PRESS ONCOGENE, V15; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Vuori K, 1996, MOL CELL BIOL, V16, P2606; XIAO S, 1994, J BIOL CHEM, V269, P21244; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	49	339	341	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21125	21131		10.1074/jbc.273.33.21125	http://dx.doi.org/10.1074/jbc.273.33.21125			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694867	hybrid			2022-12-27	WOS:000075386100060
J	Henry, KW; Yuan, XJ; Koszewski, NJ; Onda, H; Kwiatkowski, DJ; Noonan, DJ				Henry, KW; Yuan, XJ; Koszewski, NJ; Onda, H; Kwiatkowski, DJ; Noonan, DJ			Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; GLUCOCORTICOID RECEPTOR; CO-REPRESSOR; TRANSACTIVATION PROPERTIES; SIGNALING PATHWAYS; PROTEIN IMPORT; X-RECEPTOR; BINDING; PHOSPHORYLATION	Tuberous sclerosis (TSC) is a genetic disorder that results in the development of hamartomatous lesions in a variety of organ systems. Both the prevalence of the disease and the often devastating consequences of these tumors pose a serious health and medical care problem. The disease has been mapped to two distinct genetic loci in humans, and although the genes (TSC1 and TSC2) for both loci have recently been cloned, their function remains an enigma. Data presented here demonstrates that TSC2 protein can bind and selectively modulate transcription mediated by members of the steroid receptor superfamily of genes. These data place TSC2 into a growing list of nuclear receptor coregulators and strengthen the expanding body of evidence that these coregulators may play critical roles in cellular differentiation.	Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Brigham & Womens Hosp, Div Expt Med & Oncol, Boston, MA 02115 USA	University of Kentucky; University of Kentucky; Harvard University; Brigham & Women's Hospital	Noonan, DJ (corresponding author), Univ Kentucky, Dept Biochem, Lexington, KY 40536 USA.							Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALLEGRETTO EA, 1993, J BIOL CHEM, V268, P26625; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BERGER TS, 1992, J STEROID BIOCHEM, V41, P733, DOI 10.1016/0960-0760(92)90414-E; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CONSORTIUM TT, 1997, SCIENCE, V277, P805; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; FRYER AE, 1987, LANCET, V1, P659; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gomez MR, 1988, TUBEROUS SCLEROSIS; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENRY K, 1995, TOXICOL APPL PHARM, V132, P317, DOI 10.1006/taap.1995.1113; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOUSLEY PR, 1983, J BIOL CHEM, V258, P4630; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWIATKOWSKI DJ, 1994, ARCH DERMATOL, V130, P348, DOI 10.1001/archderm.130.3.348; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEFEBVRE P, 1995, J BIOL CHEM, V270, P10806, DOI 10.1074/jbc.270.18.10806; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NELLIST M, 1993, CELL, V75, P1305; ONATE SA, 1995, SCIENCE, V270, P1354; OSBORNE JP, 1991, ANN NY ACAD SCI, V615, P125; PIKE JW, 1985, BIOCHEM BIOPH RES CO, V131, P378, DOI 10.1016/0006-291X(85)91813-3; POVEY S, 1994, ANN HUM GENET, V58, P107, DOI 10.1111/j.1469-1809.1994.tb01881.x; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; Tsuchiya H, 1996, CANCER RES, V56, P429; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	55	107	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20535	20539		10.1074/jbc.273.32.20535	http://dx.doi.org/10.1074/jbc.273.32.20535			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685410	hybrid			2022-12-27	WOS:000075305400087
J	Nakajima, T; Morita, K; Tsunoda, H; Imajoh-Ohmi, S; Tanaka, H; Yasuda, H; Oda, K				Nakajima, T; Morita, K; Tsunoda, H; Imajoh-Ohmi, S; Tanaka, H; Yasuda, H; Oda, K			Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE II-ALPHA; CELL-CYCLE ARREST; WILD-TYPE P53; AFFINITY PURIFICATION; E1A-INDUCED APOPTOSIS; IONIZING-RADIATION; TUMOR-SUPPRESSOR; PROTEIN LIGASE; DEGRADATION; INDUCTION	The human epidermoid carcinoma-derived cell line MA1, established by introduction of the adenovirus E1A 12 S cDNA linked to the hormone-inducible promoter, elicits apoptosis after induction of EIA,,, in response to dexamethasone. E1A expression caused accumulation of wild type p53 more than 10-fold within 24 h after dexamethasone treatment. The cell lines that express E1A mutants containing a deletion either in the amino terminus or the conserved region 1 were unable to accumulate p53, p53 accumulated was degraded efficiently in vitro in the S10-0 extract (S10-0) prepared from MA1 cells in an ATP and ubiquitin-dependent manner, but not in S10-24 prepared after treatment with dexamethasone for 24 h, The p53 polyubiquitination activity in S100-0 was calcium-dependent and reduced greatly in S100-24, Ubiquitin affinity chromatography revealed that p53 ubiquitination activity in eluates thought to contain ubiquitin-conjugating enzymes decreased greatly in S100-24 as compared with S100-0, The accumulation of p53 was accompanied by the increase in the level of Mdm2, which has been shown to degrade p53 through binding to it. The high p53 level, however, was maintained until the late stage of the apoptotic process, These results indicate that the stabilization of p53 by E1A occurs through modification of a ubiquitin-specific enzyme(s) in the ubiquitin-proteasome pathway.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 108, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Tokyo 19203, Japan	Tokyo University of Science; University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Nakajima, T (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan.	nakajima@rs.noda.sut.ac.jp						ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; BAE IS, 1995, CANCER RES, V55, P2387; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1996, CANCER RES, V56, P2649; MAKI M, 1989, J BIOL CHEM, V264, P18866; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nakajima T, 1996, J BIOL CHEM, V271, P24842, DOI 10.1074/jbc.271.40.24842; NAKAJIMA T, 1995, ONCOGENE, V10, P651; Nakajima T, 1997, BIOCHEM BIOPH RES CO, V239, P823, DOI 10.1006/bbrc.1997.7561; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	66	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20036	20045		10.1074/jbc.273.32.20036	http://dx.doi.org/10.1074/jbc.273.32.20036			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685342	hybrid			2022-12-27	WOS:000075305400019
J	Simmons, DT; Roy, R; Chen, L; Gai, DH; Trowbridge, PW				Simmons, DT; Roy, R; Chen, L; Gai, DH; Trowbridge, PW			The activity of topoisomerase I is modulated by large T antigen during unwinding of the SV40 origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-40 DNA-REPLICATION; LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; POLYMERASE-ALPHA-PRIMASE; CORE ORIGIN; PROTEIN-A; STRUCTURAL-CHANGES; PURIFIED PROTEINS; BINDING DOMAIN; VIRAL ORIGIN	When simian virus 40 (SV40) large T antigen binds to the virus origin of replication, it forms a double hexamer that functions as a helicase to unwind the DNA bidirectionally. We demonstrate in this report that T antigen can unwind and release an origin DNA single strand of less than full length in the presence of purified human topoisomerase I. The sites nicked by topoisomerase I in the strands released by T antigen during DNA unwinding were localized primarily to the "late" side of the origin, and the template for lagging strand synthesis was preferred significantly over the one for leading strand synthesis. Importantly, these sites were, for the most part, different from the sites nicked by topoisomerase I in the absence of T antigen. These data indicate that T antigen activates topoisomerase I nicking at discrete sites and releases these nicked strands during unwinding. We hypothesize that a single molecule of topoisomerase I can form a functional complex with a double hexamer of T antigen to simultaneously relax and unwind double-stranded origin-containing DNA.	Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA	University of Delaware	Simmons, DT (corresponding author), Univ Delaware, Dept Biol Sci, Newark, DE 19716 USA.				NCI NIH HHS [CA36118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEEN MD, 1984, BIOCHIM BIOPHYS ACTA, V782, P304, DOI 10.1016/0167-4781(84)90066-6; BOROWIEC JA, 1988, EMBO J, V7, P3149, DOI 10.1002/j.1460-2075.1988.tb03182.x; BOROWIEC JA, 1988, P NATL ACAD SCI USA, V85, P64, DOI 10.1073/pnas.85.1.64; BOROWIEC JA, 1991, J VIROL, V65, P1228, DOI 10.1128/JVI.65.3.1228-1235.1991; Bullock PA, 1997, VIROLOGY, V227, P460, DOI 10.1006/viro.1996.8347; Chen L, 1997, J VIROL, V71, P8743, DOI 10.1128/JVI.71.11.8743-8749.1997; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVEY JM, 1989, CANCER RES, V49, P5016; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8267, DOI 10.1073/pnas.84.23.8267; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEB S, 1987, J VIROL, V61, P2143, DOI 10.1128/JVI.61.7.2143-2149.1987; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; GJORUP OV, 1994, P NATL ACAD SCI USA, V91, P12125, DOI 10.1073/pnas.91.25.12125; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; GUTIERREZ C, 1990, MOL CELL BIOL, V10, P1719, DOI 10.1128/MCB.10.4.1719; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; MADDEN KR, 1992, CANCER RES, V52, P525; MALKAS LH, 1990, BIOCHEMISTRY-US, V29, P6362, DOI 10.1021/bi00479a004; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MATSUMOTO T, 1990, P NATL ACAD SCI USA, V87, P9712, DOI 10.1073/pnas.87.24.9712; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; MURAKAMI Y, 1986, P NATL ACAD SCI USA, V83, P2869, DOI 10.1073/pnas.83.9.2869; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; POMMIER Y, 1998, IN PRESS BIOCHEMISTR; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; ROBERTS JM, 1989, P NATL ACAD SCI USA, V86, P3939, DOI 10.1073/pnas.86.11.3939; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; Simmons DT, 1996, VIROLOGY, V222, P365, DOI 10.1006/viro.1996.0433; Simmons DT, 1998, VIROLOGY, V242, P435, DOI 10.1006/viro.1997.9024; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1988, CANCER CELL, V6, P105; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; Weisshart K, 1996, J VIROL, V70, P3509, DOI 10.1128/JVI.70.6.3509-3516.1996; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WUNKIM K, 1993, J VIROL, V67, P7608, DOI 10.1128/JVI.67.12.7608-7611.1993; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	50	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20390	20396		10.1074/jbc.273.32.20390	http://dx.doi.org/10.1074/jbc.273.32.20390			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685392	hybrid			2022-12-27	WOS:000075305400069
J	Singh, I; Pahan, K; Khan, M; Singh, AK				Singh, I; Pahan, K; Khan, M; Singh, AK			Cytokine-mediated induction of ceramide production is redox-sensitive - Implications to proinflammatory cytokine-mediated apoptosis in demyelinating diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; NEUTRAL SPHINGOMYELINASE; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTIVATION; PATHWAY; CELLS; GENE; DIFFERENTIATION	The present study underlines the importance of reactive oxygen species in cytokine-mediated degradation of sphingomyelin (SM) to ceramide, Treatment of rat primary astrocytes with tumor necrosis factor-alpha (TNF-alpha) Or interleukin-1 beta led to marked alteration in cellular redox (decrease in intracellular GSH) and rapid degradation of SM to ceramide. Interestingly, pretreatment of astrocytes with N-acetylcysteine (NAC), an antioxidant and efficient thiol source for glutathione, prevented cytokine-induced decrease in GSH and degradation of sphingomyelin to ceramide, whereas treatment of astrocytes with diamide, a thiol-depleting agent, alone caused degradation of SM to ceramide. Moreover, potent activation of SM hydrolysis and ceramide generation were observed by direct addition of an oxidant like hydrogen peroxide or a prooxidant like aminotriazole. Similar to NAG, pyrrolidinedithiocarbamate, another antioxidant, was also found to be a potent inhibitor of cytokine-induced degradation of SM to ceramide indicating that cytokine-induced hydrolysis of sphingomyelin is redox-sensitive, Besides astrocytes, NAC also blocked cytokine-mediated ceramide production in rat primary oligodendrocytes, microglia, and C-6 glial cells. Inhibition of TNF-alpha- and diamide-mediated depletion of GSH, elevation of ceramide level, and DNA fragmentation (apoptosis) in primary oligodendrocytes by NAG, and observed depletion of GSH, elevation of ceramide level, and apoptosis in banked human brains from patients with neuroinflammatory diseases (e.g. X-adrenoleukodystrophy and multiple sclerosis) suggest that the intracellular level of GSH may play a critical role in the regulation of cytokine-induced generation of ceramide leading to apoptosis of brain cells in these diseases.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA	Medical University of South Carolina	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.		Singh, Ashok/HGF-2506-2022		NINDS NIH HHS [NS-37766, NS-34741, NS-22576] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS037766, R01NS034741, R01NS022576] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Brugg B, 1996, J NEUROCHEM, V66, P733; CHATTERJEE S, 1993, ADV LIPID RES, V26, P25; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; GANSER AL, 1988, DEV NEUROSCI-BASEL, V10, P99, DOI 10.1159/000111961; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Guilian D, 1986, J NEUROSCI, V6, P2163; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KANTEY H, 1995, J BIOL CHEM, V270, P23780; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Laight DW, 1997, BRIT J PHARMACOL, V120, P1477, DOI 10.1038/sj.bjp.0701078; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LAZO O, 1991, J NEUROCHEM, V56, P1343, DOI 10.1111/j.1471-4159.1991.tb11431.x; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McGuinness MC, 1997, J NEUROIMMUNOL, V75, P174, DOI 10.1016/S0165-5728(97)00020-9; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; POWERS JM, 1992, J NEUROPATH EXP NEUR, V51, P630, DOI 10.1097/00005072-199211000-00007; PRIESS J, 1986, J BIOL CHEM, V261, P8597; RUDICK RA, 1992, ARCH NEUROL-CHICAGO, V49, P265, DOI 10.1001/archneur.1992.00530270079022; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHERTZER HG, 1995, CHEM RES TOXICOL, V8, P431, DOI 10.1021/tx00045a015; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; SPENCE MW, 1993, ADV LIPID RES, V26, P3; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIKU ML, 1990, J IMMUNOL, V145, P690; TSUKADA N, 1991, J NEUROL SCI, V104, P230, DOI 10.1016/0022-510X(91)90315-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEIGMAN K, 1992, CELL, V78, P1005; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wiessner C, 1996, ACTA NEUROCHIR SUPPL, V66, P1; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	49	179	181	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20354	20362		10.1074/jbc.273.32.20354	http://dx.doi.org/10.1074/jbc.273.32.20354			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685387	hybrid			2022-12-27	WOS:000075305400064
J	Swinnen, JV; Alen, P; Heyns, W; Verhoeven, G				Swinnen, JV; Alen, P; Heyns, W; Verhoeven, G			Identification of diazepam-binding inhibitor/acyl-CoA-binding protein as a sterol regulatory element-binding protein-responsive gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CELL-LINE LNCAP; INDUCED INSULIN-SECRETION; AMINO-ACID SEQUENCE; ACYL-COA; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; BENZODIAZEPINE RECEPTOR; ANDROGEN REGULATION; SYNTHASE PROMOTER	Diazepam-binding inhibitor/acyl-CoA-binding protein (DBI/ACBP), a highly conserved 10-kDa polypeptide, has been implicated in various physiological processes including gamma-aminobutyric acid type A receptor binding, acyl-CoA binding and transport, steroidogenesis, and peptide hormone release. Both in LNCaP prostate cancer cells and 3T3-L1 preadipocytes, the expression of DBI/ACBP is stimulated under conditions that promote lipogenesis (treatment with androgens and insulin, respectively) and that involve the activation of sterol regulatory element-binding proteins (SREBPs), Accordingly, we investigated whether DBI/ACBP expression is under the direct control of SREBPs, Analysis of the human and rat DBI/ACBP promoter revealed the presence of a conserved sterol regulatory element (SRE)-like sequence. Gel shift analysis confirmed that this sequence is able to bind SREBPs, In support of the functionality of SREBP binding, coexpression of SREBP-1a with a DBI/ACBP promoter-reporter gene resulted in a 50-fold increase in transcriptional activity in LNCaP cells. Disruption of the SRE decreased basal expression and abolished SREBP-1a-induced transcriptional activation. In agreement with the requirement of a co-regulator for SREBP function, transcriptional activation by SREBP-1a overexpression was severely diminished when a neighboring NF-Y site was mutated. Cholesterol depletion or androgen treatment, conditions that activate SREBP function in LNCaP cells, led to an increase in DBI/ACBP mRNA expression and SRE-dependent transcriptional activation. These findings indicate that the promoter for DBI/ACBP contains a functional SRE that allows DBI/ACBP to be coregulated with other genes involved in lipid metabolism.	Catholic Univ Louvain, Fac Med, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Catholic Univ Louvain, Fac Med, Div Biochem, B-3000 Louvain, Belgium	KU Leuven; Universite Catholique Louvain; Universite Catholique Louvain	Swinnen, JV (corresponding author), LEGENDO, Onderwijs Navorsing, Herestr 49, B-3000 Louvain, Belgium.	johan.swinnen@med.kuleuven.ac.be	Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077				AGERBERTH B, 1993, EUR J BIOCHEM, V216, P623, DOI 10.1111/j.1432-1033.1993.tb18182.x; APFEL R, 1992, MELANOMA RES, V2, P327, DOI 10.1097/00008390-199212000-00006; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BISHOP RW, 1992, J LIPID RES, V33, P549; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; BORBONI P, 1991, NEUROPHARMACOLOGY, V30, P1399, DOI 10.1016/S0028-3908(11)80008-0; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; BROWN AS, 1991, BIOCHEM BIOPH RES CO, V180, P609; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHEN ZW, 1988, EUR J BIOCHEM, V174, P239, DOI 10.1111/j.1432-1033.1988.tb14088.x; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; DESTEFANIS P, 1995, REGUL PEPTIDES, V56, P153, DOI 10.1016/0167-0115(95)00002-S; Devos A, 1997, MOL ENDOCRINOL, V11, P1033, DOI 10.1210/me.11.8.1033; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; FERRERO P, 1984, NEUROPHARMACOLOGY, V23, P1359, DOI 10.1016/0028-3908(84)90061-3; FERRERO P, 1986, P NATL ACAD SCI USA, V83, P827, DOI 10.1073/pnas.83.3.827; GARNIER M, 1993, ENDOCRINOLOGY, V132, P444, DOI 10.1210/en.132.1.444; Guan GM, 1997, J BIOL CHEM, V272, P10295; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; GUIDOTTI A, 1983, P NATL ACAD SCI-BIOL, V80, P3531, DOI 10.1073/pnas.80.11.3531; HALL PF, 1988, INT CONGR SER, V799, P253; HANSEN HO, 1991, BIOCHEM J, V277, P341, DOI 10.1042/bj2770341; Herzig KH, 1996, P NATL ACAD SCI USA, V93, P7927, DOI 10.1073/pnas.93.15.7927; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KNUDSEN J, 1989, BIOCHEM J, V262, P513, DOI 10.1042/bj2620513; KOLMER M, 1993, P NATL ACAD SCI USA, V90, P8439, DOI 10.1073/pnas.90.18.8439; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; Magana MM, 1997, J LIPID RES, V38, P1630; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; MANDRUP S, 1992, J MOL BIOL, V228, P1011, DOI 10.1016/0022-2836(92)90888-Q; MANDRUP S, 1993, BIOCHEM J, V290, P369, DOI 10.1042/bj2900369; MEHTA KD, 1991, J BIOL CHEM, V266, P10415; MIKKELSEN J, 1987, BIOCHEM J, V245, P857, DOI 10.1042/bj2450857; MOGENSEN IB, 1987, BIOCHEM J, V241, P189, DOI 10.1042/bj2410189; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; OSTENSON CG, 1994, EUR J ENDOCRINOL, V131, P201, DOI 10.1530/eje.0.1310201; OSTENSON CG, 1990, REGUL PEPTIDES, V29, P143, DOI 10.1016/0167-0115(90)90077-A; PAPADOPOULOS V, 1995, J STEROID BIOCHEM, V53, P103, DOI 10.1016/0960-0760(95)00027-W; Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7; RASMUSSEN JT, 1994, BIOCHEM J, V299, P165, DOI 10.1042/bj2990165; RASMUSSEN JT, 1993, BIOCHEM J, V292, P907, DOI 10.1042/bj2920907; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SMITH JR, 1988, J BIOL CHEM, V263, P18480; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; Swinnen JV, 1996, DNA CELL BIOL, V15, P197, DOI 10.1089/dna.1996.15.197; Swinnen JV, 1996, MOL CELL ENDOCRINOL, V118, P65, DOI 10.1016/0303-7207(96)03767-7; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; SWINNEN JV, 1994, MOL CELL ENDOCRINOL, V104, P153, DOI 10.1016/0303-7207(94)90118-X; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Swinnen JV, 1997, CANCER RES, V57, P1086; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; YANAGIBASHI K, 1988, ENDOCRINOLOGY, V123, P2075, DOI 10.1210/endo-123-4-2075	62	57	60	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19938	19944		10.1074/jbc.273.32.19938	http://dx.doi.org/10.1074/jbc.273.32.19938			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685328	hybrid			2022-12-27	WOS:000075305400005
J	Tong, L; Warren, TC; Lukas, S; Schembri-King, J; Betageri, R; Proudfoot, JR; Jakes, S				Tong, L; Warren, TC; Lukas, S; Schembri-King, J; Betageri, R; Proudfoot, JR; Jakes, S			Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURES; MOLECULAR-REPLACEMENT; PEPTIDE; P56(LCK); INHIBITORS; MIMETICS; DESIGN	The crystal structure of human p56(lck) SH2 domain in complex with an inhibitor containing the singly charged p-(carboxymethyl)phenylalanine residue (cmF) as a phosphotyrosine (Tyr(P) or pY) replacement has been determined at 1.8 Angstrom resolution. The binding mode of the acetyl-cmF-Glu-Glu-Ile (cmFEEI) inhibitor is very similar to that of the pYEEI inhibitor, confirming that the cmFEEI inhibitor has a similar mechanism of SH2 domain inhibition despite its significantly reduced potency. Observed conformational differences in the side chain of the cmF residue can be interpreted in terms of maintaining similar interactions with the SH2 domain as the Tyr(P) residue. The crystal structure of the free p56(lck) SH2 domain has been determined at 1.9 Angstrom resolution and shows an open conformation for the BC loop and an open phosphotyrosine binding pocket, in contrast to earlier studies on the src SH2 domain that showed mostly closed conformation. The structural information presented here suggests that the carboxymethyl-phenylalanine residue may be a viable Tyr(P) replacement and represents an attractive starting point for the design and development of SH2 domain inhibitors with better pharmaceutical profiles.	Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA	Boehringer Ingelheim	Tong, L (corresponding author), Columbia Univ, Dept Biol Sci, 1212 Amsterdam Ave, New York, NY 10027 USA.	tong@como.bio.columbia.edu		Proudfoot, John/0000-0002-5922-2228; Tong, Liang/0000-0002-0563-6468				BRUGGE JS, 1993, SCIENCE, V260, P918, DOI 10.1126/science.8388123; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Charifson PS, 1997, BIOCHEMISTRY-US, V36, P6283, DOI 10.1021/bi970019n; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GILMER T, 1994, J BIOL CHEM, V269, P31711; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; MIKOL V, 1995, J MOL BIOL, V246, P344, DOI 10.1006/jmbi.1994.0089; MORELOCK MM, 1995, J MED CHEM, V38, P1309, DOI 10.1021/jm00008a009; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oligino L, 1997, J BIOL CHEM, V272, P29046, DOI 10.1074/jbc.272.46.29046; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Plummer MS, 1997, J MED CHEM, V40, P3719, DOI 10.1021/jm970402q; Shahripour A, 1996, BIOORG MED CHEM LETT, V6, P1209, DOI 10.1016/0960-894X(96)00208-9; TILLEY JW, 1991, J MED CHEM, V34, P1125, DOI 10.1021/jm00107a037; TONG L, 1993, J APPL CRYSTALLOGR, V26, P748, DOI 10.1107/S0021889893005631; Tong L, 1996, ACTA CRYSTALLOGR A, V52, P782, DOI 10.1107/S010876739600548X; Tong L, 1996, J MOL BIOL, V256, P601, DOI 10.1006/jmbi.1996.0112; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; YE B, 1995, J MED CHEM, V38, P4270, DOI 10.1021/jm00021a016; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	43	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20238	20242		10.1074/jbc.273.32.20238	http://dx.doi.org/10.1074/jbc.273.32.20238			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685372	hybrid			2022-12-27	WOS:000075305400049
J	Chandra, NC; Spiro, MJ; Spiro, RG				Chandra, NC; Spiro, MJ; Spiro, RG			Identification of a glycoprotein from rat liver mitochondrial inner membrane and demonstration of its origin in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-MANNOSIDASE; N-LINKED OLIGOSACCHARIDES; FRACTION; PROTEINS; PATHWAY; CELLS; GRADIENT; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; LOCALIZATION	Employing antisera against various subfractions of rat liver mitochondria (mitoplast, inner membrane, intermembrane, and matrix) as well as metabolically radiolabeled BRL-3A rat liver cells, we undertook a search for the presence of glycoproteins in this major cellular compartment for which little information in regard to glycoconjugates was available. Subsequent to [S-35]methionine labeling of BRL-3A cells, a peptide:N-glycosidase-sensitive protein (45 kDa) was observed by SDS-polyacrylamide gel electrophoresis of the inner membrane immunoprecipitate, which was reduced to a molecular mass of 42 kDa by this enzyme. The 45-kDa protein was readily labeled with [2-H-3]mannose, and indeed the radioactivity of the inner membrane immunoprecipitate was almost exclusively present in this component. Moreover, antisera directed against mitochondrial NADH-ubiquinone oxidoreductase (complex I) or F1F0-ATPase (complex V) also precipitated a 45-kDa protein from BRL-3A cell lysates as the predominant mannose-radiolabeled constituent. Endo-beta-N-acetylglu-cosaminidase completely removed the radiolabel hom this glycoprotein, and the released oligosaccharides were of the partially trimmed polymannose type (Glc(1)Man(9)GlcNAc to Man(8)GlcNAc). Cycloheximide as well as tunicamycin resulted in total inhibition of radiolabeling of the inner membrane glycoprotein and moreover, pulse-chase studies employing metrizamide density gradient centrifugation demonstrated that the glycoprotein was initially present in the endoplasmic reticulum (ER) and subsequently appeared in a mitochondrial location. Early movement of the glycoprotein to the mitochondria after synthesis in the;ER was also evident from the limited processing undergone by its N-linked oligosaccharides; this stood in contrast to lysosomal glycoproteins in which we noted extensive conversion to complex oligosaccharides. Our findings suggest that the 45-kDa glycoprotein migrates from ER to mitochondria by the previously observed contact sites between the two organelles. Furthermore, the presence of this glycoprotein in at least two major mitochondrial multienzyme complexes would be consistent with a role in mitochondrial translocations.	Joslin Diabet Ctr, Elliott P Joslin Res Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Biol Chem, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Spiro, RG (corresponding author), Joslin Diabet Ctr, Elliott P Joslin Res Lab, 1 Joslin Pl, Boston, MA 02215 USA.				NIDDK NIH HHS [DK17325, DK17477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017325, R01DK017477] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Baginski ES, 1974, METH ENZYMOL; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P485; Bharadwaj M, 1996, BIOCHEM J, V313, P193, DOI 10.1042/bj3130193; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRILES EB, 1977, J BIOL CHEM, V252, P1107; Camici O, 1997, MOL CELL BIOCHEM, V175, P71, DOI 10.1023/A:1006889328983; CHAN TL, 1970, J CELL BIOL, V45, P291, DOI 10.1083/jcb.45.2.291; CRETIN F, 1991, BIOCHIM BIOPHYS ACTA, V1058, P141, DOI 10.1016/S0005-2728(05)80230-0; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GLEW RH, 1973, J BIOL CHEM, V248, P3137; GLOVER LA, 1992, BIOCHEM J, V284, P609, DOI 10.1042/bj2840609; GODELAINE D, 1981, J BIOL CHEM, V256, P161; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HAN AL, 1989, ARCH BIOCHEM BIOPHYS, V275, P166, DOI 10.1016/0003-9861(89)90360-3; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Haucke V, 1997, MOL CELL BIOL, V17, P4024, DOI 10.1128/MCB.17.7.4024; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; KNECHT E, 1988, J HISTOCHEM CYTOCHEM, V36, P1433, DOI 10.1177/36.11.3171166; KOLDOVSKY O, 1971, BIOCHEM J, V125, P697, DOI 10.1042/bj1250697; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.bi.59.070190.001555; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; RICKWOOD D, 1975, FEBS LETT, V50, P102, DOI 10.1016/0014-5793(75)80467-4; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; ROTH J, 1983, J HISTOCHEM CYTOCHEM, V31, P987, DOI 10.1177/31.8.6190857; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SCHNAITMAN C, 1967, J CELL BIOL, V32, P719, DOI 10.1083/jcb.32.3.719; SCHNAITMAN C, 1968, J CELL BIOL, V38, P158, DOI 10.1083/jcb.38.1.158; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; SOTTOCASA G, 1972, BIOCHEM BIOPH RES CO, V47, P808, DOI 10.1016/0006-291X(72)90564-5; SOTTOCASA GL, 1971, FEBS LETT, V17, P100, DOI 10.1016/0014-5793(71)80574-4; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; TOLLESHAUG H, 1985, EUR J BIOCHEM, V153, P223, DOI 10.1111/j.1432-1033.1985.tb09290.x; TOMITA Y, 1985, BIOCHIM BIOPHYS ACTA, V842, P176, DOI 10.1016/0304-4165(85)90200-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VANCE JE, 1991, J BIOL CHEM, V266, P89; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WENG SA, 1993, J BIOL CHEM, V268, P25656; Wieme R.J., 1974, METHOD ENZYMAT AN, V2, P618; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WONG TK, 1982, J BIOL CHEM, V257, P6614	58	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19715	19721		10.1074/jbc.273.31.19715	http://dx.doi.org/10.1074/jbc.273.31.19715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677401	hybrid			2022-12-27	WOS:000075125200053
J	Kawai, H; Sango, K; Mullin, KA; Proia, RL				Kawai, H; Sango, K; Mullin, KA; Proia, RL			Embryonic stem cells with a disrupted GD3 synthase gene undergo neuronal differentiation in the absence of b-series gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO DIFFERENTIATION; NERVOUS-SYSTEM; EXPRESSION; METABOLISM; BRAIN	The dramatic changes in the expression of GD3 and other b-series gangliosides during neuronal development and morphogenesis have led to a widely held belief that these gangliosides may be necessary for neuronal differentiation. To determine directly if GD3 and b-series gangliosides are required for neuronal differentiation, we have produced embryonic stem (ES) cells with both alleles of the GD3 synthase gene (GD3S) disrupted by successive rounds of gene targeting. The double-targeted ES cells were deficient in GD3 synthase activity and did not synthesize b-series gangliosides. Despite this deficit, the GD3S(-/-) ES cells could be induced to undergo neuronal differentiation. Neuronally differentiated wild-type and GD3S(-/-) ES cells formed a complex neurite network around the embryoid bodies, Both types of neuronal cells expressed the axon-specific cytoskeletal proteins, neurofilament-M, and growth-associated protein-43 as well as the dendrite-specific marker, microtubule-associated protein-a. Our results indicate that GD3 synthase and b-series gangliosides are not necessary for the neuronal differentiation of uncommitted precursor cells.	NIDDK, Sect Biochem Genet, Genet & Biochem Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Proia, RL (corresponding author), NIDDK, Sect Biochem Genet, Genet & Biochem Branch, NIH, Bldg 10,Rm 9D-20,10 Ctr Dr,MSC 1810, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270				ARIGA T, 1995, BIOCHEMISTRY-US, V34, P11500, DOI 10.1021/bi00036a024; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BOUVIER JD, 1989, J NEUROCHEM, V52, P460, DOI 10.1111/j.1471-4159.1989.tb09143.x; Brigande JV, 1998, J NEUROCHEM, V70, P871; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GOLDMAN JE, 1984, J NEUROIMMUNOL, V7, P179, DOI 10.1016/S0165-5728(84)80017-X; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; IRVINE RA, 1994, COMP BIOCHEM PHYS B, V109, P603, DOI 10.1016/0305-0491(94)90123-6; KASAHARA K, 1994, ANAL BIOCHEM, V218, P224, DOI 10.1006/abio.1994.1164; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Li RX, 1997, J BIOL CHEM, V272, P1349, DOI 10.1074/jbc.272.2.1349; Liu H, 1997, GLYCOBIOLOGY, V7, P1067, DOI 10.1093/glycob/7.8.1067; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Osanai T, 1997, BIOCHEM BIOPH RES CO, V241, P327, DOI 10.1006/bbrc.1997.7817; PENG I, 1986, J CELL BIOL, V102, P252, DOI 10.1083/jcb.102.1.252; PERCY AK, 1991, J NEUROCHEM, V56, P1461, DOI 10.1111/j.1471-4159.1991.tb02038.x; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSNER H, 1985, DEV BRAIN RES, V18, P85, DOI 10.1016/0165-3806(85)90252-4; ROSNER H, 1992, NEUROCHEM INT, V20, P339, DOI 10.1016/0197-0186(92)90048-V; SANDBERG PO, 1980, EXP CELL RES, V130, P393, DOI 10.1016/0014-4827(80)90017-8; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; Takamiya K, 1996, P NATL ACAD SCI USA, V93, P10662, DOI 10.1073/pnas.93.20.10662; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; TSUJI S, 1985, J BIOCHEM-TOKYO, V97, P969, DOI 10.1093/oxfordjournals.jbchem.a135140; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; Yamamoto A, 1996, J NEUROCHEM, V66, P26; YU RK, 1994, PROG BRAIN RES, V101, P31	37	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19634	19638		10.1074/jbc.273.31.19634	http://dx.doi.org/10.1074/jbc.273.31.19634			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677390	hybrid			2022-12-27	WOS:000075125200042
J	Bemark, M; Olsson, H; Heinegard, D; Leanderson, T				Bemark, M; Olsson, H; Heinegard, D; Leanderson, T			Purification and characterization of a protein binding to the SP6 Kappa promoter - A potential role for CArG-box binding factor-A in Kappa transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ALPHA-ACTIN GENE; SINGLE-STRAND; FACTOR BSAP; ATTACHMENT REGIONS; UPSTREAM ELEMENT; 3'ALPHA ENHANCER; NUCLEAR MATRIX; C-MYC; NF-HB	A protein interacting with an AT-rich region that is a positive control element within the SP6 kappa promoter was purified and identified as CArG-box binding factor-A The purified protein was shown to interact specifically with the coding strand of single-stranded DNA and, with lower affinity, with double-stranded DNA.A mutation that inhibited binding of the protein to the AT-rich region also aborted the transcriptional stimulatory effect of the region. Two Ets proteins, PU.1 and elf-1, that have previously been shown to bind to an adjacent DNA element were shown to physically interact with CArG-box binding factor-A An antiserum raised against the protein recognized two different forms indicating either that different splice-forms of CArG-box binding factor-A are expressed, or that the protein is subject to post-translational modification.	Lund Univ, Dept Cellular & Mol Biol, Immunol Grp, S-22007 Lund, Sweden; Lund Univ, Dept Cellular & Mol Biol, Connect Tissue Biol Grp, S-22007 Lund, Sweden	Lund University; Lund University	Leanderson, T (corresponding author), Lund Univ, Dept Cellular & Mol Biol, Immunol Grp, POB 7031, S-22007 Lund, Sweden.	Tomas.Leandersson@immuno.lu.se	Bemark, Mats/B-2578-2019	Bemark, Mats/0000-0001-7416-9819; Olsson, Henric/0000-0002-5101-8871				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ANDRAKE M, 1988, P NATL ACAD SCI USA, V85, P7942, DOI 10.1073/pnas.85.21.7942; ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; Bemark M, 1998, IMMUNOGENETICS, V47, P183, DOI 10.1007/s002510050347; Bemark M, 1997, EUR J IMMUNOL, V27, P1308, DOI 10.1002/eji.1830270603; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P14, DOI 10.1002/jcb.240520104; CALVIO C, 1995, RNA, V1, P724; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; Davie JR, 1995, INT REV CYTOL, V162A, P191; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HOGBOM E, 1991, NUCLEIC ACIDS RES, V19, P4347, DOI 10.1093/nar/19.16.4347; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KADONAGA JT, 1991, METHOD ENZYMOL, V208, P10; KAMADA S, 1992, GENE, V119, P229, DOI 10.1016/0378-1119(92)90276-U; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LEONARD MW, 1991, MOL CELL BIOL, V11, P6128, DOI 10.1128/MCB.11.12.6128; LOU Y, 1995, MOL CELL BIOL, V15, P4115; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MICHELOTTI GA, 1996, MOL CELL BIOL, V16, P1656; NELSEN B, 1992, INT REV CYTOL, V133, P121, DOI 10.1016/S0074-7696(08)61859-8; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; NEURATH MF, 1994, J IMMUNOL, V153, P730; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; Sambrook L., 1989, MOL CLONING LAB MANU; SCHABLE KF, 1993, BIOL CHEM H-S, V374, P1001; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SIGVARDSSON M, 1995, MOL CELL BIOL, V15, P1343; Sigvardsson M, 1996, J IMMUNOL, V156, P3788; SIGVARDSSON M, 1995, EUR J IMMUNOL, V25, P298, DOI 10.1002/eji.1830250150; SIGVARDSSON M, 1994, MOL IMMUNOL, V31, P1005, DOI 10.1016/0161-5890(94)90095-7; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SMIDT MP, 1995, NUCLEIC ACIDS RES, V23, P2389, DOI 10.1093/nar/23.13.2389; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; Tansey WP, 1997, CELL, V88, P729, DOI 10.1016/S0092-8674(00)81916-9; TAY N, 1992, J VIROL, V66, P6841, DOI 10.1128/JVI.66.12.6841-6848.1992; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371	57	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18881	18890		10.1074/jbc.273.30.18881	http://dx.doi.org/10.1074/jbc.273.30.18881			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668064	hybrid			2022-12-27	WOS:000074974700031
J	Davletov, B; Perisic, O; Williams, RL				Davletov, B; Perisic, O; Williams, RL			Calcium-dependent membrane penetration is a hallmark of the C2 domain of cytosolic phospholipase A2 whereas the C2A domain of synaptotagmin binds membranes electrostatically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-ENVELOPE; TRANSLOCATION; DELTA; A(2)	C2 domains have been identified in a wide range of intracellular proteins, including lipid modifying enzymes, protein kinases, GTPases, and proteins involved int membrane trafficking.Many C2 domains bind membranes in a calcium-dependent manner. The first C2 domain from synaptotagmin I (SytIC2A) and the C2 domain from cytosolic phospholipase A2 (cPLA2C2) are among the best characterized C2 domains in terms of their structures and calcium binding. Here we demonstrate that the protein-lipid interaction is dramatically different for these two domains. Photolabeling with 3-(trifluoromethyl)-3-(m-[I-125]iodophenyl)diazirine ([I-125]TID) in the presence of phospholipid vesicles indicates that cPLA2C2 penetrates into the hydrophobic region of the membrane. Hydrophobic surfaces on cPLA2C2 are exposed even in the absence of calcium, but only in its presence does the domain penetrate into the nonpolar core of the membrane. The interaction of SytIC2A with phospholipid membranes is primarily electrostatic with binding being abolished in 500 mM NaCl. Because soluble phospholipid head group analogues do not compete with binding of either SytIC2A or cPLA2C2 to vesicles, it is likely that membrane binding by these domains involves multiple interactions.	Univ Cambridge, Ctr Mrc, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; University of Cambridge	Davletov, B (corresponding author), Univ Cambridge, Ctr Mrc, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275; Perisic, Olga/0000-0002-3842-2896; Williams, Roger/0000-0001-7754-4207	Medical Research Council [MC_U105184308] Funding Source: Medline; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; Grobler JA, 1998, BIOCHEMISTRY-US, V37, P5020, DOI 10.1021/bi972952w; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Ponting CP, 1996, PROTEIN SCI, V5, P162; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968	22	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19093	19096		10.1074/jbc.273.30.19093	http://dx.doi.org/10.1074/jbc.273.30.19093			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668093	hybrid			2022-12-27	WOS:000074974700060
J	Naver, H; Scott, MP; Golbeck, JH; Olsen, CE; Scheller, HV				Naver, H; Scott, MP; Golbeck, JH; Olsen, CE; Scheller, HV			The eight-amino acid internal loop of PSI-C mediates association of low molecular mass iron-sulfur proteins with the P700-F-X core in photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCOCCUS-SP PCC-6301; CLOSTRIDIUM-PASTEURIANUM FERREDOXIN; REACTION-CENTER COMPLEX; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; MODIFIED LIGANDS; 8-KDA SUBUNIT; CENTER-A; CENTER-B; F-A	The PSI-C subunit of photosystem I (PS I) shows similarity to soluble 2[4Fe-4S] ferredoxins. PSI-C contains an eight residue internal loop and a 15 residue C-terminal extension which are absent in the ferredoxins. The eight-residue loop has been shown to interact with PSI-A/PSI-B (Naver, H., Scott, M. P., Golbeck, J. H., Moller, B. L., and Scheller, H. V. (1996) J. Biol. Chem. 271, 8996-9001). Four mutant proteins were constructed. Two were modified barley PSI-C proteins, one lacking the loop and the C terminus (PSI-C-core) and one where the loop replace the C-terminal extension (PSI-CcoreLc-term). Two were modified Clostridium pasteurianum ferredoxins, one with the loop of barley PSI-C and one with both the loop and the C terminus of PSI-C. Wild-type proteins and the mutants were used to reconstitute barley P700-F-X cores lacking PSI-C, -D, and-E. Western blotting showed that PSI-CcoreLc-term binds to PS I, whereas PSI-C-core does not. Without PSI-D the PSI-CcoreLc-term mutant accepts electrons from F-X in contrast to PSI-C mutants without the loop. Flash photolysis of P700-F, cores reconstituted with C. pasteurianum ferredoxin showed that only the ferredoxin mutants with the loop accepted electrons from F-X. From this, it is concluded that the loop of PSI-C is necessary and sufficient for the association between PS I and PSI-C, and that the loop is functional as an interaction domain even when positioned at the C terminus of PSI-C or on a low molecular mass, soluble ferredoxin.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, DK-1871 Frederiksberg C, Denmark; Royal Vet & Agr Univ, Dept Chem, DK-1871 Frederiksberg, Denmark; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Copenhagen; University of Copenhagen; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Nebraska System; University of Nebraska Lincoln	Scheller, HV (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Biochem Lab, 40 Thorvaldsensvej, DK-1871 Frederiksberg C, Denmark.	scheller@biobase.dk	Scheller, Henrik/AAH-4770-2020; Olsen, Carl E/H-3031-2014; Scheller, Henrik V/A-8106-2008	Scheller, Henrik/0000-0002-6702-3560; Olsen, Carl E/0000-0002-2275-0596; Scheller, Henrik V/0000-0002-6702-3560; Naver, Helle/0000-0002-7364-3862				ADMAN FT, 1972, J BIOL CHEM, V248, P3987; ALIVERTI A, 1995, FEBS LETT, V368, P220, DOI 10.1016/0014-5793(95)00648-S; ANDERSEN B, 1993, PIGMENT PROTEIN COMP, P383; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; Buchanan BB, 1971, METHOD ENZYMOL, V23, P413, DOI [10.1016/S0076-6879(71)23115-3, DOI 10.1016/S0076-6879(71)23115-3]; CHITNIS PR, 1995, PHOTOSYNTH RES, V44, P23, DOI 10.1007/BF00018294; CHITNIS PR, 1989, J BIOL CHEM, V264, P18374; DIAZQUINTANA, 1998, BIOCHEMISTRY, V37, P3429; DUNN PPJ, 1988, PLANT MOL BIOL, V11, P311, DOI 10.1007/BF00027388; ELLEFSON WL, 1980, METHOD ENZYMOL, V69, P223; Fischer N, 1998, EMBO J, V17, P849, DOI 10.1093/emboj/17.4.849; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Fromme P, 1996, CURR OPIN STRUC BIOL, V6, P473, DOI 10.1016/S0959-440X(96)80112-6; GOLBECK JH, 1986, BIOCHIM BIOPHYS ACTA, V849, P16, DOI 10.1016/0005-2728(86)90091-5; GOLBECK JH, 1987, BIOCHIM BIOPHYS ACTA, V895, P167, DOI 10.1016/S0304-4173(87)80002-2; Golbeck JH, 1994, MOL BIOL CYANOBACTER, P319; GRAVES MC, 1985, P NATL ACAD SCI USA, V82, P1653, DOI 10.1073/pnas.82.6.1653; HERMAN PL, 1994, PLANT PHYSIOL, V104, P1459, DOI 10.1104/pp.104.4.1459; HOJ PB, 1987, J BIOL CHEM, V262, P12676; HOJ PB, 1986, J BIOL CHEM, V261, P14292; Jung YS, 1996, J BIOL CHEM, V271, P31135, DOI 10.1074/jbc.271.49.31135; Jung YS, 1997, J BIOL CHEM, V272, P8040, DOI 10.1074/jbc.272.12.8040; Jung YS, 1995, PHOTOSYNTH RES, V46, P249, DOI 10.1007/BF00020437; Kamlowski A, 1997, BBA-BIOENERGETICS, V1319, P199, DOI 10.1016/S0005-2728(96)00162-4; Kjaer B, 1996, PHOTOSYNTH RES, V47, P33, DOI 10.1007/BF00017751; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; LI N, 1991, BIOCHEMISTRY-US, V30, P7863, DOI 10.1021/bi00245a028; MEHARI T, 1995, J BIOL CHEM, V270, P28108; Moulis JM, 1995, BIOCHEMISTRY-US, V34, P16781, DOI 10.1021/bi00051a028; Naver H, 1996, J BIOL CHEM, V271, P8996, DOI 10.1074/jbc.271.15.8996; NAVER H, 1995, PHYSIOL PLANTARUM, V95, P19, DOI 10.1111/j.1399-3054.1995.tb00802.x; NAVER H, 1995, PHOTOSYNTHESIS LIGHT, V2, P155; OHOKA H, 1988, J BIOCHEM-TOKYO, V103, P962, DOI 10.1093/oxfordjournals.jbchem.a122394; PARRETT KG, 1989, BIOCHIM BIOPHYS ACTA, V973, P324, DOI 10.1016/S0005-2728(89)80439-6; PARRETT KG, 1990, BIOCHIM BIOPHYS ACTA, V1015, P341, DOI 10.1016/0005-2728(90)90039-7; Rodday SM, 1996, BIOCHEMISTRY-US, V35, P11832, DOI 10.1021/bi9612834; ROUSSEAU F, 1993, EMBO J, V12, P1755, DOI 10.1002/j.1460-2075.1993.tb05823.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLER HV, 1989, CARLSBERG RES COMMUN, V54, P11, DOI 10.1007/BF02910468; Scheller HV, 1997, PHYSIOL PLANTARUM, V100, P842, DOI 10.1034/j.1399-3054.1997.1000410.x; SCOTT MP, 1992, RES PHOTOSYNTHESIS, V1, P593; SCROFANI SDB, 1994, BIOCHEMISTRY-US, V33, P14486, DOI 10.1021/bi00252a015; SERRANO A, 1982, ANAL BIOCHEM, V126, P109, DOI 10.1016/0003-2697(82)90115-4; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tjus SE, 1998, PLANT PHYSIOL, V116, P755, DOI 10.1104/pp.116.2.755; ZANETTI G, 1987, EUR J BIOCHEM, V169, P143, DOI 10.1111/j.1432-1033.1987.tb13591.x; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; ZHAO JD, 1990, FEBS LETT, V276, P175, DOI 10.1016/0014-5793(90)80536-R	49	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18778	18783		10.1074/jbc.273.30.18778	http://dx.doi.org/10.1074/jbc.273.30.18778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668051	hybrid			2022-12-27	WOS:000074974700018
J	Balch, SG; McKnight, AJ; Seldin, MF; Gordon, S				Balch, SG; McKnight, AJ; Seldin, MF; Gordon, S			Cloning of a novel C-type lectin expressed by murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; CA2+-DEPENDENT ANIMAL LECTINS; NATURAL-KILLER-CELL; SITE-DIRECTED MUTAGENESIS; ACTIVATION ANTIGEN CD69; IMMUNOGLOBULIN-E; MESSENGER-RNA; SUGAR LIGANDS; GENE FAMILIES; MOUSE NKR-P1	We report the cloning of a novel macrophage-restricted C-type lectin by differential display polymerase chain reaction. This molecule, named mouse macrophage C-type lectin, is a 219-amino acid, type II transmembrane protein with a single extracellular C-type lectin domain. Northern blot analysis indicates that it is expressed in cell lines and normal mouse tissues in a macrophage-restricted manner. The cDNA and genomic sequences of mouse macrophage C-type lectin indicate that it is related to the Group II animal C-type lectins. The mel gene locus has been mapped between the genes for the interleukin-17 receptor and CD4 on mouse chromosome 6, the same chromosome as the mouse natural killer cell gene complex.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Calif Davis, Dept Biol Chem, Rowe Program Genet, Davis, CA 95616 USA; Univ Calif Davis, Dept Med, Davis, CA 95616 USA	University of Oxford; University of California System; University of California Davis; University of California System; University of California Davis	Balch, SG (corresponding author), Kansas State Univ, Coll Vet Med, 101 Trotter Hall, Manhattan, KS 66506 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00734] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Alschul S F, 1990, J Mol Biol, V215, P403; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BLACKBURN CC, 1983, J BIOL CHEM, V258, P1180; Brown MG, 1997, GENOMICS, V42, P16, DOI 10.1006/geno.1997.4721; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIORDA R, 1991, J IMMUNOL, V147, P1701; GORDON S, 1996, WEIERS HDB EXPT IMMU, V4, P153; GORDON S, 1997, LUNG MACROPHAGES DEN, P3; GORDON S, 1996, OXFORD TXB MED, V1, P84; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; HAMANN J, 1993, J IMMUNOL, V150, P4920; HOYLE GW, 1991, J BIOL CHEM, V266, P1850; HU ZZ, 1994, BBA-MOL CELL RES, V1220, P333, DOI 10.1016/0167-4889(94)90158-9; IOBST ST, 1994, J BIOL CHEM, V269, P15512; IOBST ST, 1994, J BIOL CHEM, V269, P15505; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE SH, 1985, J EXP MED, V161, P475, DOI 10.1084/jem.161.3.475; LEENEN PJ, 1993, MACROPHAGES RELATED, P29; LEUNG JO, 1985, J BIOL CHEM, V260, P2523; LEWIS CE, 1992, MACROPHAGE NATURAL I; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McKnight AJ, 1998, ADV IMMUNOL, V68, P271, DOI 10.1016/S0065-2776(08)60562-3; ODA S, 1989, J BIOCHEM-TOKYO, V105, P1040, DOI 10.1093/oxfordjournals.jbchem.a122763; ODA S, 1988, J BIOCHEM-TOKYO, V104, P600, DOI 10.1093/oxfordjournals.jbchem.a122518; RICE P, 1996, PROGRAM MANUAL EGCG; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; RUSSELL ME, 1994, J CLIN INVEST, V94, P722, DOI 10.1172/JCI117391; SAKAMAKI T, 1995, J LEUKOCYTE BIOL, V57, P407, DOI 10.1002/jlb.57.3.407; SANTIS AG, 1994, EUR J IMMUNOL, V24, P1692, DOI 10.1002/eji.1830240735; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SPILSBURY K, 1995, BLOOD, V85, P1620, DOI 10.1182/blood.V85.6.1620.bloodjournal8561620; SUTER U, 1987, NUCLEIC ACIDS RES, V15, P7295, DOI 10.1093/nar/15.18.7295; VERCELLI D, 1989, NATURE, V338, P649, DOI 10.1038/338649a0; WATSON ML, 1994, METH MOL G, V5, P369; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WONG S, 1991, J IMMUNOL, V147, P1417; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803	52	61	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18656	18664		10.1074/jbc.273.29.18656	http://dx.doi.org/10.1074/jbc.273.29.18656			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660840	hybrid			2022-12-27	WOS:000074828500095
J	Anton, IM; Lu, WG; Mayer, BJ; Ramesh, N; Geha, RS				Anton, IM; Lu, WG; Mayer, BJ; Ramesh, N; Geha, RS			The Wiskott-Aldrich syndrome protein-interacting protein (WIP) binds to the adaptor protein Nck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAINS; SH2 DOMAIN; NUCLEOTIDE EXCHANGE; TYROSINE; KINASE; PHOSPHORYLATION; PROFILIN; CELLS; THYMOSIN-BETA-4; ORGANIZATION	Nck is a ubiquitous adaptor molecule composed of three Src homology 3 (SH3) domains followed by a single SH2 domain, Nck links, via its SH2 domain, tyrosine-phosphorylated receptors to effector proteins that contain SH3-binding proline-rich sequences. In this report, we demonstrate that recombinant Nck precipitates endogenous WIP, a novel proline-rich protein that interacts with the Wiskott-Aldrich syndrome protein (WASP), from BJAB cell lysates, Nck binds through its second SH3 domain to WIP, and Nck binds to WIP at a site (amino acids 321-415) that differs from the WASP-binding site (amino acids 416-488), WIP has been shown to associate with the actin polymerization regulatory protein profilin and to induce actin polymerization and cytoskeletal reorganization in lymphoid cells. We demonstrate the presence of profilin in Nck precipitates suggesting that Nck may couple extracellular signals to the cytoskeleton via its interaction with WIP and profilin.	Harvard Univ, Div Immunol, Childrens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Geha, RS (corresponding author), Harvard Univ, Div Immunol, Childrens Hosp, Sch Med, Enders 8,300 Longwood Ave, Boston, MA 02115 USA.	geha@al.tch.harvard.edu	Anton, Ines M/G-6090-2015	Anton, Ines M/0000-0002-2935-5919	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI037130] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59561-01] Funding Source: Medline; NIAID NIH HHS [AI-37130] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; DONNELLY SFH, 1993, MOL MICROBIOL, V10, P585, DOI 10.1111/j.1365-2958.1993.tb00930.x; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; LAWE DC, 1997, 0NCOGENE, V14, P223; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matuoka K, 1997, BIOCHEM BIOPH RES CO, V239, P488, DOI 10.1006/bbrc.1997.7492; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; Purich DL, 1997, BIOCHEM BIOPH RES CO, V231, P686, DOI 10.1006/bbrc.1997.6158; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	33	113	114	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20992	20995		10.1074/jbc.273.33.20992	http://dx.doi.org/10.1074/jbc.273.33.20992			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694849	hybrid			2022-12-27	WOS:000075386100042
J	Hukovic, N; Panetta, R; Kumar, U; Rocheville, M; Patel, YC				Hukovic, N; Panetta, R; Kumar, U; Rocheville, M; Patel, YC			The cytoplasmic tail of the human somatostatin receptor type 5 is crucial for interaction with adenylyl cyclase and in mediating desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; AGONIST-INDUCED DESENSITIZATION; PROTEIN-COUPLED RECEPTORS; CARBOXYL-TERMINUS; STIMULATED INTERNALIZATION; PEPTIDE RECEPTOR; PITUITARY-CELLS; MESSENGER-RNA; NPX(N)Y MOTIF; 2 ISOFORMS	We have investigated the role of the cytoplasmic tail (C-tail) of the human somatostatin receptor type 5 (hSSTR5) in regulating receptor coupling to adenylyl cyclase (AC) and in mediating agonist-dependent desensitization and internalization responses. Mutant receptors with progressive C-tail truncation (Delta 347, Delta 338, Delta 328, Delta 318), Cys(320) --> Ala substitution (to block palmitoylation), or Tyr(304) --> Ala substitution of a putative NPXYY internalization motif were stably expressed in Chinese hamster ovary K1 cells. Except for the Tyr(304) --> Ala mutant, which showed no binding, all other mutant receptors exhibited binding characteristics (K-d and B-max) and G protein coupling comparable with wild type (wt) hSSTR5. The C-tail truncation mutants displayed progressive reduction in coupling to AC, with the Delta 318 mutant showing complete loss of effector coupling. Agonist pretreatment of wt hSSTR5 led to uncoupling of AC inhibition, whereas the desensitization response of the C-tail deletion mutants was variably impaired. Compared with internalization (66% at 60 min) of wt hSSTR5, truncation of the C-tail to 318, 328, and 338 residues reduced receptor internalization to 46, 46, and 23%, respectively, whereas truncation to 347 residues slightly improved internalization (72%). Mutation of Cys(320) --> Ala induced a reduction in AC coupling, desensitization, and internalization. These studies show that the C-tail of hSSTR5 serves a multifunctional role in mediating effector coupling, desensitization, and internalization. Whereas coupling to AC is dependent on the length of the C-tail, desensitization and internalization require specific structural domains. Furthermore, internalization is regulated through both positive and negative molecular signals in the C-tail and can be dissociated from the signaling and acute desensitization responses of the receptor.	McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Neurol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Neurosurg, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Pharmacol & Therapeut, Montreal, PQ H3A 1A1, Canada; Montreal Neurol Inst, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University	Patel, YC (corresponding author), McGill Univ, Royal Victoria Hosp, Fraser Labs, Dept Med, Room M3-15,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							AMHERDT M, 1989, J CLIN INVEST, V84, P412, DOI 10.1172/JCI114181; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BENYA RV, 1994, MOL PHARMACOL, V46, P495; Bonifacino JS, 1996, P ASSOC AM PHYSICIAN, V108, P285; BOUVIER M, 1995, BIOCHEM SOC T, V23, P577, DOI 10.1042/bst0230577; BRUNO JF, 1994, BIOCHEM BIOPH RES CO, V202, P1738, DOI 10.1006/bbrc.1994.2136; CHABRY J, 1995, J BIOL CHEM, V270, P2439, DOI 10.1074/jbc.270.6.2439; DAY R, 1995, ENDOCRINOLOGY, V136, P5232, DOI 10.1210/en.136.11.5232; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Greenwood MT, 1997, MOL PHARMACOL, V52, P807, DOI 10.1124/mol.52.5.807; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; HOFLAND LJ, 1995, ENDOCRINOLOGY, V136, P3698, DOI 10.1210/en.136.9.3698; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; IRIE A, 1994, EUR J BIOCHEM, V224, P161, DOI 10.1111/j.1432-1033.1994.tb20007.x; Jockers R, 1996, J BIOL CHEM, V271, P9355, DOI 10.1074/jbc.271.16.9355; KAWATE N, 1994, J BIOL CHEM, V269, P30651; Kumar U, 1997, ENDOCRINOLOGY, V138, P4473, DOI 10.1210/en.138.10.4473; Lamberts SWJ, 1996, NEW ENGL J MED, V334, P246, DOI 10.1056/NEJM199601253340408; Laporte SA, 1996, MOL PHARMACOL, V49, P89; MOREL G, 1985, ENDOCRINOLOGY, V116, P1615, DOI 10.1210/endo-116-4-1615; NG GYK, 1995, P NATL ACAD SCI USA, V92, P10157, DOI 10.1073/pnas.92.22.10157; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; NUSSENZVEIG DR, 1993, J BIOL CHEM, V268, P2389; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Patel YC, 1997, TRENDS ENDOCRIN MET, V8, P398, DOI 10.1016/S1043-2760(97)00168-9; PATEL YC, 1994, J BIOL CHEM, V269, P1506; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PRESKY DH, 1988, J BIOL CHEM, V263, P714; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506; RODRIGUEZ MC, 1992, MOL ENDOCRINOL, V6, P327, DOI 10.1210/me.6.3.327; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Schulein R, 1996, BIOCHEM J, V313, P611, DOI 10.1042/bj3130611; SLICE LW, 1994, J BIOL CHEM, V269, P21755; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SULLIVAN SJ, 1988, ENDOCRINOLOGY, V122, P1137, DOI 10.1210/endo-122-3-1137; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; Tolbert LM, 1998, J NEUROCHEM, V70, P113; VANETTI M, 1993, FEBS LETT, V331, P260, DOI 10.1016/0014-5793(93)80349-Y; XU Y, 1995, ENDOCRINOLOGY, V136, P5070, DOI 10.1210/en.136.11.5070	45	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21416	21422		10.1074/jbc.273.33.21416	http://dx.doi.org/10.1074/jbc.273.33.21416			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694905	hybrid			2022-12-27	WOS:000075386100098
J	Seimiya, H; Tsuruo, T				Seimiya, H; Tsuruo, T			Functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of monoblastoid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CHROMOSOMAL LOCALIZATION; HOMOPHILIC BINDING; MOLECULAR-CLONING; HL-60 CELLS; U937 CELLS; MOTH-EATEN; KINASE-C; RECEPTOR; EXPRESSION	A large family of protein tyrosine phosphatases (PTPs) bidirectionally regulate intracellular signaling pathways by reversing agonistic or antagonistic phosphorylation events derived from the action of protein tyrosine kinases. Receptor-like PTP PTP-U2 is expressed during phorbol ester-induced differentiation of monoblastoid leukemia U937 cells. We found that the shorter isoform, PTP-U2S, was expressed at an earlier phase in the course of differentiation and the longer isoform, PTP-U2L, was induced at a later phase. In the presence of 12-O-tetradecanoylphorbol-13-acetate, ectopic expression of PTP-U2L in U937 cells enhanced several characteristics of terminally differentiated cells. Most striking was that PTP-U2L enhanced apoptosis of the differentiated cells, which was only partially inhibited by caspase inhibitor Z-Asp-CH2-DCB. The catalytically inactive mutant PTP-U2L(C --> S) still retained the ability to enhance the differentiation but retained the ability to enhance the following apoptosis of the cells to a lesser extent. These data indicate a functional involvement of PTP-U2L in apoptosis subsequent to terminal differentiation of U937 cells. Since terminally differentiated blood cells often undergo apoptosis, the data also suggest that PTP-U2L might be involved in physiological turnover of hematopoietic cells in vivo.	Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Japanese Foundation for Cancer Research; University of Tokyo	Tsuruo, T (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, 1-37-1 Kami Ikebukoro, Tokyo 1708455, Japan.	hseimiya@jfcr.or.jp		Seimiya, Hiroyuki/0000-0003-3314-9736				Adachi M, 1996, CELL, V85, P15; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLUMBERG PM, 1988, CANCER RES, V48, P1; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BUTLER TM, 1990, CANCER RES, V50, P6323; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; FRANK DA, 1988, CANCER RES, V48, P4299; FRANK DA, 1988, CANCER RES, V48, P52; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; GUNJI H, 1991, CANCER RES, V51, P741; HONDA H, 1994, BLOOD, V84, P4186, DOI 10.1182/blood.V84.12.4186.bloodjournal84124186; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KEENE P, 1987, BRIT J HAEMATOL, V67, P25, DOI 10.1111/j.1365-2141.1987.tb02291.x; KHARBANDA S, 1994, J BIOL CHEM, V269, P872; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Naito M, 1997, BLOOD, V89, P2060, DOI 10.1182/blood.V89.6.2060; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PIXLEY FJ, 1995, J BIOL CHEM, V270, P27339, DOI 10.1074/jbc.270.45.27339; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; SAP J, 1994, MOL CELL BIOL, V14, P1; SEIMIYA H, 1995, ONCOGENE, V10, P1731; SEIMIYA H, 1993, CELL GROWTH DIFFER, V4, P1033; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; SEIMIYA H, 1995, ONCOGENE, V11, P2047; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; XIAO S, 1994, J BIOL CHEM, V269, P21244; Yahagi Y, 1996, NEUROSCI LETT, V211, P125, DOI 10.1016/0304-3940(96)12738-5; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	52	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21187	21193		10.1074/jbc.273.33.21187	http://dx.doi.org/10.1074/jbc.273.33.21187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694875	hybrid			2022-12-27	WOS:000075386100068
J	Thewke, DP; Panini, SR; Sinensky, M				Thewke, DP; Panini, SR; Sinensky, M			Oleate potentiates oxysterol inhibition of transcription from sterol regulatory element-1-regulated promoters and maturation of sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOUNSATURATED FATTY-ACIDS; COENZYME-A REDUCTASE; CHOLESTEROL-METABOLISM; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; TRANSGENIC MICE; 25-HYDROXYCHOLESTEROL; EXPRESSION; RECEPTOR; SREBP-2	Activation of genes containing SRE-1 (sterol regulatory element 1) sequences is known to be under the regulation of sterols through modulation of the proteolytic maturation of SREBPs (SRE-1-binding proteins). Previous work has demonstrated SREBP-mediated transcriptional activation of genes encoding enzymes of sterol and fatty acid biosynthesis. Because synthesis of both sterols and C18 fatty acids are required for cell growth, in the absence of exogenous supplements of these lipids, we examined the hypothesis that fatty acid can also be regulatory in SREBP maturation. Our data indicate that C18 fatty acids can potentiate the biological activities of a typical, regulatory sterol: 25-hydroxycholesterol. Inhibition of C18 fatty acid synthesis in cells cultured in serum-free medium renders them resistant to killing by 25-hydroxycholesterol. Repression of expression of reporter constructs driven by promoters bearing SRE-1 element(s) by 25-hydroxycholesterol is increased by C18 fatty acid supplementation. C18 fatty acids also increase the inhibitory effect of 25-hydroxycholesterol on proteolytic maturation and nuclear localization of SREBPs, Furthermore, we also show that C18 fatty acid supplementation can enhance the inhibitory effect of 25-hydroxycholesterol on sterol and fatty acid biosynthesis, These results demonstrate that maximal down-regulation of SREBP maturation and the consequent repression of SRE-1 promoters occurs in response to both a regulatory sterol and fatty acid.	E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Johnson City, TN 37614 USA	East Tennessee State University	Sinensky, M (corresponding author), E Tennessee State Univ, Dept Biochem & Mol Biol, James H Quillen Coll Med, Box 70581, Johnson City, TN 37614 USA.							BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Bollag D.M., 1991, PROTEIN METHODS; Brindley D. N, 1991, BIOCH LIPIDS LIPOPRO, P171; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; CHANG TY, 1976, P NATL ACAD SCI USA, V73, P24, DOI 10.1073/pnas.73.1.24; CHIN J, 1981, J BIOL CHEM, V256, P6304; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; GOLDSTEIN JL, 1975, J BIOL CHEM, V250, P8487; Griffin ME, 1996, QJM-MON J ASSOC PHYS, V89, P211; GRUNDY SM, 1989, J NUTR, V119, P529, DOI 10.1093/jn/119.4.529; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; LEONARD S, 1988, BIOCHIM BIOPHYS ACTA, V947, P101, DOI 10.1016/0304-4157(88)90021-4; LIMANEK JS, 1978, P NATL ACAD SCI USA, V75, P5452, DOI 10.1073/pnas.75.11.5452; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; PANINI SR, 1990, J BIOL CHEM, V265, P14118; RUDEL LL, 1990, J LIPID RES, V31, P1873; Rudney Harry, 1993, Current Opinion in Lipidology, V4, P230, DOI 10.1097/00041433-199306000-00009; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sakai J, 1997, J BIOL CHEM, V272, P20213, DOI 10.1074/jbc.272.32.20213; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; SINENSKY M, 1982, J CELL PHYSIOL, V113, P314, DOI 10.1002/jcp.1041130220; SINENSKY M, 1980, P NATL ACAD SCI-BIOL, V77, P6621, DOI 10.1073/pnas.77.11.6621; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TABAS I, 1986, J BIOL CHEM, V261, P3147; TAM SP, 1992, ATHEROSCLEROSIS, V95, P137, DOI 10.1016/0021-9150(92)90017-B; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247	31	65	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21402	21407		10.1074/jbc.273.33.21402	http://dx.doi.org/10.1074/jbc.273.33.21402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694903	Green Published, hybrid			2022-12-27	WOS:000075386100096
J	Wu, XL; Spiro, C; Owen, WG; McMurray, CT				Wu, XL; Spiro, C; Owen, WG; McMurray, CT			cAMP response element-binding protein monomers cooperatively assemble to form dimers on DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CREB; LEUCINE ZIPPER DOMAIN; NUCLEAR FACTOR CREB; X-RAY STRUCTURE; CYCLIC-AMP; SOMATOSTATIN GENE; BASIC REGION; COILED-COIL; PHOSPHORYLATION; FOS	We have analyzed the properties of cAMP response element-binding protein (CREB) in solution with emphasis on dimerization and effects of phosphorylation. Using a purified CREB fusion protein, a novel dye-label technique, and sedimentation equilibrium analysis, we directly and conclusively demonstrate that, unlike Jun and Fos, CREB dimerization is DNA-dependent. CREB exists primarily as a monomer in solution and cooperatively assembles on DNA to form dimers. Sedimentation equilibrium analysis also indicates that dimerization is unaffected by cAMP-dependent protein kinase-phosphorylation or by the symmetry of the cAMP-responsive element binding site. Filter binding assays reveal that CREB binding is unaffected by phosphorylation regardless of the symmetry of the cAMP-responsive element binding site. Our results suggest that structurally similar members of the same bZIP superfamily may differ significantly in their regulation at the level of dimerization.	Mayo Clin & Mayo Fdn, Dept Pharmacol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Grad Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McMurray, CT (corresponding author), Mayo Clin & Mayo Fdn, Dept Pharmacol, 200 1St St Sw, Rochester, MN 55905 USA.	mcmurray.cynthia@mayo.edu			NIDDK NIH HHS [DK 43694] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; Carroll AS, 1997, GENE DEV, V11, P2227, DOI 10.1101/gad.11.17.2227; COHEN DR, 1990, ONCOGENE, V5, P929; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; DAVIES GF, 1995, ARCH BIOCHEM BIOPHYS, V323, P477, DOI 10.1006/abbi.1995.0070; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HURST HC, 1995, PROTEIN PROFILE, V2, P105; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAJEWSKI W, 1994, MOL CELL BIOL, V14, P7204, DOI 10.1128/MCB.14.11.7204; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE JC, 1974, ARCH BIOCHEM BIOPHYS, V165, P268, DOI 10.1016/0003-9861(74)90164-7; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MESELSON M, 1957, P NATL ACAD SCI USA, V43, P581, DOI 10.1073/pnas.43.7.581; Metallo SJ, 1997, NAT STRUCT BIOL, V4, P115, DOI 10.1038/nsb0297-115; Moitra J, 1997, BIOCHEMISTRY-US, V36, P12567, DOI 10.1021/bi971424h; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Pal S, 1997, P NATL ACAD SCI USA, V94, P5556, DOI 10.1073/pnas.94.11.5556; PAPPOULAS O, 1988, CURRENT PROTOCOLS MO; Parker D, 1996, MOL CELL BIOL, V16, P694; Press W. H., 1992, NUMERICAL RECIPES C, V2nd, P656; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUBERT F, 1990, NUCLEIC ACIDS RES, V18, P3427; SCHUERMANN M, 1991, NUCLEIC ACIDS RES, V19, P739, DOI 10.1093/nar/19.4.739; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; SUEOKA N, 1959, NATURE, V183, P1429, DOI 10.1038/1831429a0; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tully T, 1997, P NATL ACAD SCI USA, V94, P4239, DOI 10.1073/pnas.94.9.4239; van Holde K. E., 1985, PHYSICAL BIOCH, P110; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YUN Y, 1990, MOL ENDOCRINOL, V4, P931, DOI 10.1210/mend-4-6-931	59	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20820	20827		10.1074/jbc.273.33.20820	http://dx.doi.org/10.1074/jbc.273.33.20820			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694827	hybrid			2022-12-27	WOS:000075386100020
J	Le, H; Browning, KS; Gallie, DR				Le, H; Browning, KS; Gallie, DR			The phosphorylation state of the wheat translation initiation factors eIF4B, eIF4A, and eIF2 is differentially regulated during seed development and germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; CASEIN KINASE-II; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; CONTROLLED REPRESSOR; ALPHA-SUBUNIT; GERM; BINDING; CELLS; YEAST	The translation initiation factors (eIF) 4B and eIF2 are phosphoproteins whose phosphorylation state differs between mature seed and leaves, We examined the isoforms of eIF4B and the alpha and beta subunits of eIF2 during the development and germination of wheat seed to determine whether the differences in their phosphorylation state are because of tissue-specific regulation or occur concomitant with changes in protein synthetic activity during development. eIF2 alpha underwent phosphorylation through several intermediate isoforms that correlated with the increase and subsequent reduction in protein synthetic activity characteristic of seed development. eIF2 beta and eIF4B, present as highly phosphorylated isoforms during early seed development, underwent dephosphorylation during late development. eIF4B was rapidly phosphorylated within 20 h of germination, whereas eIF2 alpha did not undergo dephosphorylation until 48-60 h of growth. A third factor, eIF4A, was predominantly nonphosphorylated throughout most of seed development and germination. These observations suggest that the phosphorylation state of eIF2 alpha, eIF2 beta, and eIF4B is developmentally regulated in a way that correlates with the changes in protein synthetic activity but that some differences were also observed.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of California System; University of California Riverside; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu						ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; BENNE R, 1980, EUR J BIOCHEM, V104, P109, DOI 10.1111/j.1432-1033.1980.tb04406.x; BENNETT MD, 1973, PHILOS T R SOC B, V266, P39, DOI 10.1098/rstb.1973.0036; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; CHEN D, 1968, AGROCHIMICA, V12, P389; CLARKE RD, 1987, MOL CELL BIOCHEM, V74, P129; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; DELSENY M, 1994, STRESS INDUCED GENE, P25; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; EVERS AD, 1970, ANN BOT-LONDON, V34, P547, DOI 10.1093/oxfordjournals.aob.a084390; FENG L, 1994, MOL CELL BIOL, V14, P5139, DOI 10.1128/MCB.14.8.5139; GALLIE DR, 1995, PLANT PHYSIOL, V108, P1703, DOI 10.1104/pp.108.4.1703; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; GREENE FC, 1985, CEREAL CHEM, V62, P398; GREENE FC, 1983, PLANT PHYSIOL, V71, P40, DOI 10.1104/pp.71.1.40; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; JEFFREY IW, 1990, BIOCHIMIE, V72, P751, DOI 10.1016/0300-9084(90)90160-I; KRAMER G, 1981, CURR TOP CELL REGUL, V20, P185; Lasko P., 1995, Molecular Biology of the Cell, V6, p80A; LAX SR, 1986, J BIOL CHEM, V261, P5632; Le H, 1997, EUR J BIOCHEM, V243, P350, DOI 10.1111/j.1432-1033.1997.0350a.x; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARCUS A, 1964, P NATL ACAD SCI USA, V51, P1075, DOI 10.1073/pnas.51.6.1075; MARCUS A, 1966, PLANT PHYSIOL, V41, P1167, DOI 10.1104/pp.41.7.1167; MEHTA HB, 1986, J BIOL CHEM, V261, P6705; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; Metz AM, 1997, ARCH BIOCHEM BIOPHYS, V342, P187, DOI 10.1006/abbi.1997.0119; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; PATHAK VK, 1988, MOL CELL BIOL, V8, P993, DOI 10.1128/MCB.8.2.993; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROMERO DP, 1986, MOL CELL BIOL, V6, P1044, DOI 10.1128/MCB.6.4.1044; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SEAL SN, 1983, J BIOL CHEM, V258, P573; SPIEGEL S, 1975, NATURE, V256, P228, DOI 10.1038/256228a0; TERCELAFORGUE T, 1987, PHYSIOL PLANTARUM, V69, P105, DOI 10.1111/j.1399-3054.1987.tb01952.x; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8	49	34	38	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20084	20089		10.1074/jbc.273.32.20084	http://dx.doi.org/10.1074/jbc.273.32.20084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685349	hybrid			2022-12-27	WOS:000075305400026
J	Gervais, JLM; Seth, P; Zhang, H				Gervais, JLM; Seth, P; Zhang, H			Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CELL-CYCLE; S-PHASE; ICE/CED-3 PROTEASE; GROWTH ARREST; P21; PCNA; DEATH; SUPPRESSION; REPLICATION	Activation of the p53-mediated DNA dams.ge response induces either G(1) cell cycle arrest or apoptosis. The Gr, cell cycle arrest is in part caused by the p53-dependent transcriptional activation of the CDK inhibitor, p21(Cip1/)Waf1. We report here that human p21 protein is rapidly induced but selectively cleaved during the apoptotic response to gamma-irradiation. Such an event occurred early, well before the morphological appearance of apoptosis. Ectopical expression of p53 in tumor cells alone could induce p21 expression, followed by p21 cleavage and apoptosis, The cleavage of pal could be reproduced in extracts prepared from irradiated cells or by recombinant caspase-3, suggesting that a caspase-like activity is responsible for this cleavage, p21 binds independently to both CDK2 and proliferation cell nuclear antigen (PCNA). Our studies indicated that p21 cleavage by the caspase-like activity specifically abolished its interaction with PCNA, suggesting that p21 cleavage may interfere with normal PCNA-dependent repair. Our data suggest that pal may serve as a critical checkpoint regulator for both cell cycle arrest and apoptosis during the p53-mediated DNA damage response. Manipulation of the checkpoint regulators involved in cell cycle arrest and apoptosis may thus provide a novel strategy to cancer therapy.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; NCI, Med Breast Canc Sect, Med Branch, NIH, Bethesda, MD 20892 USA	Yale University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, H (corresponding author), Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA.	hui.zhang@yale.edu						Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DEN C, 1995, CELL, V82, P675; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	34	200	206	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19207	19212		10.1074/jbc.273.30.19207	http://dx.doi.org/10.1074/jbc.273.30.19207			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668108	hybrid			2022-12-27	WOS:000074974700075
J	Raben, N; Nagaraju, K; Lee, E; Kessler, P; Byrne, B; Lee, L; LaMarca, M; King, C; Ward, J; Sauer, B; Plotz, P				Raben, N; Nagaraju, K; Lee, E; Kessler, P; Byrne, B; Lee, L; LaMarca, M; King, C; Ward, J; Sauer, B; Plotz, P			Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; CELLS; EXPRESSION; THERAPY; MODELS; ENZYME; MOUSE; HEART; CDNA; SITE	We have used gene targeting to create a mouse model of glycogen storage disease type II, a disease in which distinct clinical phenotypes present at different ages. As in the severe human infantile disease (Pompe Syndrome), mice homozygous for disruption of the acid alpha-glucosidase gene (6(neo)/6(neo)) lack enzyme activity and begin to accumulate glycogen in cardiac and skeletal muscle lysosomes by 3 weeks of age, with a progressive increase thereafter. By 3.5 weeks of age, these mice have markedly reduced mobility and strength. They grow normally, however, reach adulthood, remain fertile, and, as in the human adult disease, older mice accumulate glycogen in the diaphragm. By 8-9 months of age animals develop obvious muscle wasting and a weak, waddling gait. This model, therefore, recapitulates critical features of both the infantile and the adult forms of the disease at a pace suitable for the evaluation of enzyme or gene replacement. In contrast, in a second model, mutant mice with deletion of exon 6 (Delta 6/Delta 6), like the recently published acid cu-glucosidase knockout with disruption of exon 13 (Bijvoet, A. G., van de Kamp, E. H., Kroos, M., Ding, J. H., Yang, B. Z., Visser, P., Bakker, C. E., Verbeet, M. P., Oostra, B. A., Reuser, A. J. J., and van der Ploeg, A. T. (1998) Hum. Mel. Genet. 7, 53-62), have unimpaired strength and mobility (up to 6.5 months of age) despite indistinguishable biochemical and pathological changes. The genetic background of the mouse strains appears to contribute to the differences among the three models.	NIAMS, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21218 USA; Univ Miami, Sch Med, Dept Mol Genet & Microbiol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL 33101 USA; NIMH, Clin Neurosci Branch, Bethesda, MD 20892 USA; NCI, Anim Sci Branch, Off Lab Anim Resources, NIH, Bethesda, MD 20892 USA; NIDDK, Biochem & Metab Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Johns Hopkins University; University of Miami; University of Miami; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Raben, N (corresponding author), NIAMS, Arthrit & Rheumatism Branch, NIH, Bldg 10,Rm 9N244,9000 Rockville Pike, Bethesda, MD 20892 USA.	rabenn@arb.niams.nih.gov	Nagaraju, Kanneboyina/AAV-7684-2021; Nagaraju, Kanneboyina/ABA-6525-2021					Adams EM, 1997, HUM MUTAT, V10, P128, DOI 10.1002/(SICI)1098-1004(1997)10:2<128::AID-HUMU5>3.0.CO;2-G; Bijvoet AGA, 1996, BBA-GENE STRUCT EXPR, V1308, P93, DOI 10.1016/0167-4781(96)00093-0; Bijvoet AGA, 1998, HUM MOL GENET, V7, P53, DOI 10.1093/hmg/7.1.53; Erickson RP, 1996, BIOESSAYS, V18, P993, DOI 10.1002/bies.950181209; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; Hirschhorn R., 1995, METABOLIC MOL BASES, P2443; Kessler PD, 1996, P NATL ACAD SCI USA, V93, P14082, DOI 10.1073/pnas.93.24.14082; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; KROOS MA, 1995, J MED GENET, V32, P836, DOI 10.1136/jmg.32.10.836-a; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; MARTINIUK F, 1986, P NATL ACAD SCI USA, V83, P9641, DOI 10.1073/pnas.83.24.9641; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Pauly DF, 1998, GENE THER, V5, P473, DOI 10.1038/sj.gt.3300609; RABEN N, 1995, MUSCLE NERVE, pS70; REUSER AJJ, 1995, MUSCLE NERVE, pS61; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; VANDERPLOEG AT, 1988, PEDIATR RES, V24, P90, DOI 10.1203/00006450-198807000-00021; VANDERPLOEG AT, 1988, J NEUROL, V235, P392; VANDERPLOEG AT, 1991, J CLIN INVEST, V87, P513, DOI 10.1172/JCI115025; VanHove JLK, 1996, P NATL ACAD SCI USA, V93, P65, DOI 10.1073/pnas.93.1.65; Wilson JM, 1996, J CLIN INVEST, V97, P1138, DOI 10.1172/JCI118527; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975; Zaretsky JZ, 1997, HUM GENE THER, V8, P1555, DOI 10.1089/hum.1997.8.13-1555	23	213	238	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19086	19092		10.1074/jbc.273.30.19086	http://dx.doi.org/10.1074/jbc.273.30.19086			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668092	hybrid			2022-12-27	WOS:000074974700059
J	Wu, HH; Momand, J				Wu, HH; Momand, J			Pyrrolidine dithiocarbamate prevents p53 activation and promotes p53 cysteine residue oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; PROTEIN S-THIOLATION; DNA-BINDING FUNCTION; CELL-CYCLE; NUCLEAR-LOCALIZATION; GROWTH ARREST; DIHYDRORHODAMINE 123; E6 ONCOPROTEIN; INTACT-CELLS; WILD-TYPE	Pyrrolidine dithiocarbamate (PDTC) is a thiol compound widely used to study the activation of redox-sensitive transcription factors. Although normally used as an antioxidant, PDTC has been shown to exert pro oxidant activity on proteins both in vitro and in vivo. Be cause p53 redox status has been shown to alter its DNA binding capability, we decided to test the effect of PDTC on p53 activation. In this communication, we report that PDTC inhibits the activation of temperature sensitive murine p53(Val-135) (TSp53) in the transformed rat embryo fibroblast line, Al-5, as well as wild-type human p53 in the normal diploid fibroblast line, WS1neo. In A1-5 cells, PDTC abrogated UV- and temperature shift-induced TSp53 nuclear translocation and p53-mediated transactivation of MDM2. PDTC also blocked UV-induced accumulation of wild-type p53 in WS1neo cells. Continual presence of PDTC was required for its effect as both W-induced nuclear translocation and accumulation resumed after PDTC removal. We next investigated whether PDTC treatment altered the p53 redox state. We found that PDTC increased p53 cysteine residue oxidation in vivo. This represents the first direct evidence showing that the p53 redox state can be altered in vivo and that increased oxidation correlates with its inability to perform its downstream functions.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Cell & Tumor Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Momand, J (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Cell & Tumor Biol, Duarte, CA 91010 USA.		Momand, Jamil/F-8154-2012					BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAYER EA, 1987, ANAL BIOCHEM, V161, P262, DOI 10.1016/0003-2697(87)90450-7; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Dasgupta G, 1997, EXP CELL RES, V237, P29, DOI 10.1006/excr.1997.3766; DOVER R, 1994, J CELL SCI, V107, P1181; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GERWECK LG, 1984, ADV EXP MED BIOL, V180, P269; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; HEYDUK T, 1986, BIOCHIM BIOPHYS ACTA, V874, P337, DOI 10.1016/0167-4838(86)90033-6; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEONARDO AD, 1994, GENE DEV, V8, P2540; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALZMAN W, 1984, MOL CELL BIOL, V4, P1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, CELL GROWTH DIFFER, V8, P941; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; Orrenius S, 1996, BIOCHEM SOC T, V24, P1032, DOI 10.1042/bst0241032; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; RENZING J, 1995, ONCOGENE, V10, P1865; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Saucedo LJ, 1998, CELL GROWTH DIFFER, V9, P119; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; THOMAS JA, 1986, ANAL BIOCHEM, V157, P32, DOI 10.1016/0003-2697(86)90192-2; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vichi P, 1997, EMBO J, V16, P7444, DOI 10.1093/emboj/16.24.7444; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	68	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18898	18905		10.1074/jbc.273.30.18898	http://dx.doi.org/10.1074/jbc.273.30.18898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668066	Green Published, hybrid			2022-12-27	WOS:000074974700033
J	Habib, T; Hejna, JA; Moses, RE; Decker, SJ				Habib, T; Hejna, JA; Moses, RE; Decker, SJ			Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; KINASE; RECEPTOR; WORTMANNIN; ACTIVATION; INHIBITOR; CELLS; GRB2; SHC	Antibodies raised against the 51C/SHIP2 inositol polyphosphate 5'-phosphatase were used to examine the effects of growth factors and insulin on the metabolism of this protein. Immunoblot analysis revealed that the 51C/SHIP2 protein was widely expressed in fibroblast and nonhematopoietic tumor cell lines, unlike the SHIP protein, which was found only in cell lines of hematopoietic origin. The 51C/SHIP2 antiserum precipitated a protein of approximately 145 kDa along with an activity which hydrolyzed phosphatidylinositol 3,4,5-trisphosphate to phosphatidylinositol 3,4-bisphosphate. Tyrosine phosphorylation of the 51C/SHIP2 protein occurred in response to treatment of cells with epidermal growth (EGF), platelet-derived growth factor (PDGF), nerve growth factor (NGF), insulin-like growth factor-1 (IGF-1), or insulin. EGF and PDGF induced transient tyrosine phosphorylation of 51C/SHIP2, with maximal tyrosine phosphorylation occurring at 5-10 min following treatment and returning to near basal levels within 20 min, In contrast, treatment of cells with NGF, IGF-1, or insulin resulted in prolonged tyrosine phosphorylation of 51C/SHIP2 protein, with 40-80% maximal phosphorylation sustained for up to 2 h following agonist treatment. The kinetics of activation of the Akt/PKB protein kinase by the various factors correlated well with the kinetics of tyrosine phosphorylation of 51C/SHIP2, EGF, NGF, and PDGF stimulated the association of 51C/SHIP2 protein with the Shc adapter protein; however, no Shc could be detected in 51C/SHIP2-immune precipitates from cells treated with IGF-1 or insulin. The data suggest that 51C/SHIP2 may play a significant role in regulation of phosphatidylinositol 3'-kinase signaling by growth factors and insulin.	Parke Davis Pharmaceut Res Div, Dept Cell Biol, Ann Arbor, MI 48105 USA; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Pfizer; Oregon Health & Science University	Decker, SJ (corresponding author), Parke Davis Pharmaceut Res Div, Dept Cell Biol, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.	deckers@aa.wl.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Barthel A, 1998, BIOCHEM BIOPH RES CO, V243, P509, DOI 10.1006/bbrc.1998.8134; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DeuterReinhard M, 1997, MOL CELL BIOL, V17, P2559, DOI 10.1128/MCB.17.5.2559; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; FUKUI Y, 1991, ONCOGENE, V6, P407; GIRUIATO S, 1997, J BIOL CHEM, V272, P26857; GUINEBAULT C, 1995, J BIOL CHEM, V268, P13773; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; HEJNA JA, 1995, GENOMICS, V29, P285, DOI 10.1006/geno.1995.1247; HU Q, 1995, SCIENCE, V370, P527; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; OKADA T, 1994, J BIOL CHEM, V269, P3568; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1997, SCIENCE, V387, P673; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	41	107	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18605	18609		10.1074/jbc.273.29.18605	http://dx.doi.org/10.1074/jbc.273.29.18605			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660833	hybrid			2022-12-27	WOS:000074828500088
J	Bellido, T; O'Brien, CA; Roberson, PK; Manolagas, SC				Bellido, T; O'Brien, CA; Roberson, PK; Manolagas, SC			Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines - A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; CYCLIN-DEPENDENT KINASES; HUMAN-MELANOMA CELLS; SIGNAL-TRANSDUCTION; BONE-MARROW; ONCOSTATIN-M; P21; INDUCTION; EXPRESSION; RECEPTORS	The cyclin-dependent kinase inhibitor p21(WAF1,CIP1,SDI1) plays a critical role in cell differentiation, and it has been shown to confer resistance to apoptosis. Based on this, and on evidence that activation of the gp130/signal transducer and activator of transcription (STAT) signal transduction pathway by interleukin (IL)-6 type cytokines promotes differentiation and prevents apoptosis in osteoblastic cells, we have investigated the possibility that p21 is a downstream effector of this signaling pathway in osteoblasts. We report that either oncostatin M (OSM) or IL-6 plus soluble IL-6 receptor increased the levels of p21 mRNA and protein in the osteoblast-like human osteosarcoma cell line MG63 and stimulated the activity of a 2.4-kilobase pair segment of the human p21 gene promoter. Further, nuclear extracts from cytokine-stimulated MG63 cells formed protein-DNA complexes with a 19-base pair nucleotide fragment of the p21 promoter containing a single STAT response element. The identity of the binding proteins as Stat3 and Stat1 was demonstrated with specific antibodies. In addition, and in support of a mediating role of STATs in the activation of the p21 promoter, overexpression of Stat3 potentiated the cytokine effect on the p21 promoter; whereas a dominant negative Stat3, or a mutation of the STAT response element on the promoter, significantly reduced the cytokine effect. Finally, antisense oligonucleotides complementary to p21 mRNA inhibited OSM-induced stimulation of alkaline phosphatase expression and antagonized the protective effect of OSM on anti-Fas-induced apoptosis. These results demonstrate that p21 is a downstream effector of gp130/Stat3 activation and a critical mediator of the pro-differentiating and anti-apoptotic effects of IL-6 type cytokines on human osteoblastic cells.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; McClellan Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center	Bellido, T (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, Ctr Osteoporosis & Metab Bone Dis, 4301 W Markham,Mail Slot 587, Little Rock, AR 72205 USA.	tmbellido@life.uams.edu	O'Brien, Charles A./AAL-5078-2020		NIAMS NIH HHS [R29AR43453] Funding Source: Medline; NIA NIH HHS [P01AG/AMS13918] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLAN EH, 1990, J CELL PHYSIOL, V145, P110, DOI 10.1002/jcp.1041450116; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIMBLE JM, 1994, J CELL BIOCHEM, V54, P122, DOI 10.1002/jcb.240540113; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HEREMANS H, 1978, ONCOLOGY, V35, P246, DOI 10.1159/000225298; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; JILKA RL, 1997, J BONE MINER RES, V12, pS455; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Majeska Robert J., 1996, P1229; MALIK N, 1995, MOL CELL BIOL, V15, P2349; Manolagas Stavros C., 1996, P701; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; METCALF D, 1989, P NATL ACAD SCI USA, V86, P5948, DOI 10.1073/pnas.86.15.5948; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Poluha W, 1996, MOL CELL BIOL, V16, P1335; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Stuart A., 1987, KENDALLS ADV THEORY; TAGUCHI T, 1998, IN PRESS P ASS AM PH; TAKAHASHI K, 1995, J BONE MINER RES, V10, pS317; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WARE CB, 1995, DEVELOPMENT, V121, P1283	49	189	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21137	21144		10.1074/jbc.273.33.21137	http://dx.doi.org/10.1074/jbc.273.33.21137			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694869	hybrid			2022-12-27	WOS:000075386100062
J	Kelly, D; Kim, SJ; Rizzino, A				Kelly, D; Kim, SJ; Rizzino, A			Transcriptional activation of the type II transforming growth factor-beta receptor gene upon differentiation of embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY ELEMENT; SERINE THREONINE KINASE; ENDODERM-LIKE CELLS; EARLY MOUSE EMBRYOS; RNA POLYMERASE-II; TGF-BETA; NF-Y; MICROSATELLITE INSTABILITY; GROWTH-FACTOR-BETA-2 GENE; EXPRESSION CLONING	Previously, it has been shown that differentiation of embryonal carcinoma (EC) cells turns on the expression of functional transforming growth factor type-beta receptors, Here, we show that the type II receptor (T beta R-II) gene is activated at the transcriptional level when EC cells differentiate. We show that the differentiated cells, but not the parental EC cells, express transcripts for T beta R-II, In addition, the expression of T beta R-II promoter/ reporter gene constructs are elevated dramatically when EC cells differentiate and we identify at least two positive and two negative regulatory regions in the 5' flanking region of the T beta R-II gene. Moreover, we identify a cAMP response element/activating transcription factor site that acts as a positive cis-regulatory element in the T beta R-II promoter, and we demonstrate that the transcription factor ATF-1 binds to this site and strongly stimulates the expression of the T beta R-II promoter/reporter gene constructs when ATF-1 is overexpressed in EC-derived differentiated cells, Equally important, we identify a negative regulatory element in a 53-base pair region that had previously been shown to inhibit strongly the expression of T beta R-II promoter/reporter gene constructs, Specifically, we demonstrate that this region, which contains an inverted CCAAT box motif, binds the transcription factor complex NF-Y (also referred to as CBF) in vitro. Furthermore, expression of a dominant-negative NF-YA mutant protein, which prevents DNA binding by NF-Y, enhances TPR-II promoter expression. Together, these studies suggest that the transcription factors ATF-1 and NF-Y play important roles in the regulation of the T beta R-II gene.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; NCI, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.				NATIONAL CANCER INSTITUTE [T32CA009476, P30CA036727, R01CA074771] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09476, CA 36727, CA 74771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BOUCHER PD, 1993, J BIOL CHEM, V268, P17384; BOUCHER PD, 1995, MOL CELL BIOL, V15, P5144; BRYANS M, 1995, BIOCHEM BIOPH RES CO, V211, P5619; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CAMPBELL WJ, 1990, IN VITRO CELL DEV B, V26, P1181; deJonge RR, 1997, ONCOL RES, V9, P89; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Guo YP, 1997, INT J CANCER, V71, P573, DOI 10.1002/(SICI)1097-0215(19970516)71:4<573::AID-IJC11>3.3.CO;2-1; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HASAN S, 1994, J BIOL CHEM, V269, P25042; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HINKLEY C, 1992, MOL CELL BIOL, V12, P4400, DOI 10.1128/MCB.12.10.4400; HUMPHRIES DE, 1994, BIOCHEM BIOPH RES CO, V203, P1020, DOI 10.1006/bbrc.1994.2284; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KAARTINEN V, 1995, NAT GENET, V11, P409; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; KELLY D, 1990, CYTOTECHNOLOGY, V4, P227, DOI 10.1007/BF00563783; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; KELLY D, 1989, DIFFERENTIATION, V41, P34, DOI 10.1111/j.1432-0436.1989.tb00729.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEYKALLESE.M, 1996, IN VITRO CELL BIOL, V33, P294; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lamb KA, 1997, MOL REPROD DEV, V48, P301; Lazzereschi D, 1997, CANCER RES, V57, P2071; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MORIUCHI H, 1995, VIROLOGY, V214, P256, DOI 10.1006/viro.1995.9932; MUMMERY CL, 1990, DEV BIOL, V137, P161, DOI 10.1016/0012-1606(90)90017-D; MunozAntonia T, 1996, CANCER RES, V56, P4831; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11578; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PARIA BC, 1992, DEV BIOL, V151, P91, DOI 10.1016/0012-1606(92)90216-4; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEVELOPMENT, V110, P609; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; REITH W, 1994, J BIOL CHEM, V269, P20020; RIZZINO A, 1988, DEV BIOL, V130, P411, DOI 10.1016/0012-1606(88)90337-5; RIZZINO A, 1983, EXP CELL RES, V143, P143, DOI 10.1016/0014-4827(83)90116-7; RIZZINO A, 1980, P NATL ACAD SCI-BIOL, V77, P457, DOI 10.1073/pnas.77.1.457; RIZZINO A, 1985, IN VITRO CELL DEV B, V21, P531; RIZZINO A, 1987, CANCER RES, V47, P4386; RIZZINO A, 1989, GROWTH FACTORS MAMMA; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO; ROSENTHAL N, 1987, METHODS ENZYMOLOGY G; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHOLTZ B, 1995, MOL REPROD DEV, V41, P140, DOI 10.1002/mrd.1080410204; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAPIRO IM, 1990, SOMAT CELL MOLEC GEN, V16, P1, DOI 10.1007/BF01650475; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SLAGER HG, 1991, DEV BIOL, V145, P205, DOI 10.1016/0012-1606(91)90120-R; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TIESMAN J, 1989, IN VITRO CELL DEV B, V25, P1193; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	77	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21115	21124		10.1074/jbc.273.33.21115	http://dx.doi.org/10.1074/jbc.273.33.21115			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694866	hybrid			2022-12-27	WOS:000075386100059
J	Ozbek, S; Grotzinger, J; Krebs, B; Fischer, M; Wollmer, A; Jostock, T; Mullberg, J; Rose-John, S				Ozbek, S; Grotzinger, J; Krebs, B; Fischer, M; Wollmer, A; Jostock, T; Mullberg, J; Rose-John, S			The membrane proximal cytokine receptor domain of the human interleukin-6 receptor is sufficient for ligand binding but not for gp130 association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; CRYSTAL-STRUCTURE; SIGNAL-TRANSDUCTION; BIOLOGICAL FUNCTION; ESCHERICHIA-COLI; TERMINAL DOMAIN; IL-6 RECEPTOR; ONCOSTATIN-M; EXPRESSION; CELLS	Interleukin-6 (IL-6) belongs to the family of the "four-helix bundle" cytokines. The extracellular parts of their receptors consist of several Ig- and fibronectin type III-like domains. Characteristic of these receptors is a cytokine-binding module consisting of two such fibronectin domains defined by a set of four conserved cysteines and a tryptophan-serine-X-tryptophan-serine (WSXWS) sequence motif. On target cells, IL-6 binds to a specific IL-6 receptor (IL-6R), and the complex of IL-6 IL-GR associates with the signal transducing protein gp130. The IL-GR consists of three extracellular domains. The NH2-terminal Ig-like domain is not needed for ligand binding and signal initiation. Here we have investigated the properties and functional role of the third membrane proximal domain. The protein can be efficiently expressed in bacteria, and the refolded domain is shown to be sufficient for IL-6 binding. When complexed with IL-6, however, it fails to associate with the gp130 protein. Since the second and the third domain together with IL-6 can bind to gp130 and induce signaling, our data demonstrate the ligand binding function of the third domain and point to an important role of the second domain in complex formation with gp130 and signaling.	Johannes Gutenberg Univ Mainz, Med Klin 1, Abt Pathophysiol, D-55101 Mainz, Germany; Rhein Westfal TH Aachen Klinikum, Inst Biochem, D-52057 Aachen, Germany	Johannes Gutenberg University of Mainz; RWTH Aachen University; RWTH Aachen University Hospital	Rose-John, S (corresponding author), Johannes Gutenberg Univ Mainz, Med Klin 1, Abt Pathophysiol, Obere Zahlbacher Str 63, D-55101 Mainz, Germany.	rosejohn@mail.uni-mainz.de	Özbek, Suat/D-3701-2014; Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279; Ozbek, Suat/0000-0003-2569-3942				ANAGUCHI H, 1995, J BIOL CHEM, V270, P27845, DOI 10.1074/jbc.270.46.27845; Baumann H, 1996, J IMMUNOL, V157, P284; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EHLERS M, 1994, J IMMUNOL, V153, P1744; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; Grotzinger J, 1997, PROTEINS, V27, P96; GRUBE BJ, 1994, J BIOL CHEM, V269, P20791; Ichihara M, 1997, BLOOD, V90, P165; Krebs B, 1998, J BIOL CHEM, V273, P2858, DOI 10.1074/jbc.273.5.2858; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; LEEBEEK FWG, 1992, J BIOL CHEM, V267, P14832; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MullerNewen G, 1997, EUR J BIOCHEM, V247, P425, DOI 10.1111/j.1432-1033.1997.00425.x; NEUBAUER P, 1995, BIOTECHNOL BIOENG, V47, P139, DOI 10.1002/bit.260470204; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SALVATI AL, 1995, J BIOL CHEM, V270, P12242, DOI 10.1074/jbc.270.20.12242; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; WARD LD, 1994, J BIOL CHEM, V269, P23286; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21374	21379		10.1074/jbc.273.33.21374	http://dx.doi.org/10.1074/jbc.273.33.21374			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694899	hybrid			2022-12-27	WOS:000075386100092
J	Parthasarathy, N; Gotow, LF; Bottoms, JD; Kute, TE; Wagner, WD; Mulloy, B				Parthasarathy, N; Gotow, LF; Bottoms, JD; Kute, TE; Wagner, WD; Mulloy, B			Oligosaccharide sequence of human breast cancer cell heparan sulfate with high affinity for laminin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; LIPOPROTEIN-LIPASE; BINDING; PROTEOGLYCAN; CHAINS; PROTEIN; DOMAIN; GLYCOSAMINOGLYCANS; SYNDECAN-1; MEMBRANES	Laminin-1 is a basement membrane glycoprotein implicated in tumor-host adhesion, which involves the cell-binding domain(s) of laminin-l and tumor cell surface heparan sulfate (HS), The specific tumor cell surface HS oligosaccharide sequences that are necessary for binding to laminin-l have not been characterized. To identify this laminin-binding oligosaccharide sequence, Glc-NSO4-rich oligosaccharides terminating with [H-3]2,5-anhydromannitol (AMan(R)) residues were isolated from human breast cancer cell (MCF-7)-derived HS through hydrazinolysis/high pH (4.0) nitrous acid treatment/[H-3]NaBH4 reduction. These oligosaccharides were chromatographed on a laminin-l affinity column, A high affinity dodecasaccharide was isolated and characterized. Disaccharide analysis yielded IdoA(2-SO4) --> AMan(R)(6-SO4) as the only disaccharide upon treatment of this dodecasaccharide with nitrous acid at low pH (1.5), The sequence of laminin-binding high affinity oligosaccharide is therefore [IdoA(2-SO4 --> GlcNSO(4)(6-SO4)](5)[IdoA(2-SO4) --> AMan(R)(6-SO4)]. Low affinity dodecasaccharides composed of [IdoA(2-SO4) --> GlcNSO(4)(6-SO4)](5), [IdoA(2-SO4) --> GlcNSO(4)] were also isolated by laminin-l affinity chromatography, Molecular modeling studies indicate that a heparin-binding peptide sequence corresponding to amino acid residues 3010-3031 (KQNCLSSRASFRGCVRNLRLSR) in the G domain of laminin-l, modeled as a right-handed alpha-helix, carries an array of basic residues well placed to bind to clusters of sulfate groups on the high affinity dodecasaccharide.	Wake Forest Univ, Sch Med, Comparat Med Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England	Wake Forest University; Wake Forest University; National Institute for Biological Standards & Control	Parthasarathy, N (corresponding author), Wake Forest Univ, Sch Med, Comparat Med Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.	npartha@wfubmc.edu						ARUMUGHAM RG, 1988, CONNECT TISSUE RES, V18, P135, DOI 10.3109/03008208809008065; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BIENKOWSKI MJ, 1985, SEMIN THROMB HEMOST, V11, P86, DOI 10.1055/s-2007-1004363; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V343, P92, DOI 10.1006/abbi.1997.0147; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HASCALL VC, 1994, METHOD ENZYMOL, V230, P390; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KATO M, 1994, J BIOL CHEM, V269, P18881; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; OIKE Y, 1980, BIOCHEM J, V191, P193, DOI 10.1042/bj1910193; PARTHASARATHY N, 1982, ARCH BIOCHEM BIOPHYS, V213, P504, DOI 10.1016/0003-9861(82)90576-8; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PEJLER G, 1987, J BIOL CHEM, V262, P5036; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; RAHMOUNE H, 1996, BIOCHEM SOC T, V24, P355; RODEN L, 1980, BIOCH GLYCOPROTEINS; SALMIVIRTA M, 1994, EXP CELL RES, V215, P180, DOI 10.1006/excr.1994.1330; SALMIVIRTA M, 1995, EXPERIENTIA, V51, P863, DOI 10.1007/BF01921737; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SHEN GQ, 1995, ARCH BIOCHEM BIOPHYS, V321, P83, DOI 10.1006/abbi.1995.1371; Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; TURNBULL JE, 1993, BIOCHEM SOC T, V21, P477, DOI 10.1042/bst0210477; YURCHENCO PD, 1990, ANN NY ACAD SCI, V580, P195, DOI 10.1111/j.1749-6632.1990.tb17929.x	37	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21111	21114		10.1074/jbc.273.33.21111	http://dx.doi.org/10.1074/jbc.273.33.21111			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694865	hybrid			2022-12-27	WOS:000075386100058
J	Zhou, ZF; Gong, QM; Epstein, ML; January, CT				Zhou, ZF; Gong, QM; Epstein, ML; January, CT			HERG channel dysfunction in human long QT syndrome - Intracellular transport and functional defects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; QUALITY-CONTROL; MISSENSE MUTATION; SECRETORY PATHWAY; MOLECULAR-BASIS; PROTEIN; RESIDUES; FAMILY	Mutations in HERG are associated with human chromosome 7-linked congenital long QT (LQT-2) syndrome. We used electrophysiological, biochemical, and immunohistochemical methods to study the molecular mechanisms of HERG channel dysfunction caused by LQT-2 mutations. Wild type HERG and LQT-2 mutations were studied by stable and transient expression in HEK 293 cells. We found that some mutations (Y611H and V822M) caused defects in biosynthetic processing of HERO channels with the protein retained in the endoplasmic reticulum. Other mutations (I593R and G628S) were processed similarly to wild type HERO protein, but these mutations did not produce functional channels. In contrast, the T474I mutation expressed HERO current but with altered gating properties. These findings suggest that the loss of HERG channel function in LQT-2 mutations is caused by multiple mechanisms including abnormal channel processing, the generation of nonfunctional channels, and altered channel gating.	Univ Wisconsin, Dept Med, Cardiol Sect, Madison, WI 53792 USA; Univ Wisconsin, Dept Anat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	January, CT (corresponding author), Univ Wisconsin, Hosp & Clin, Dept Med Cardiol, Room H6-352,600 Highland Ave, Madison, WI 53792 USA.	ctj@medicine.wisc.edu						Benson DW, 1996, CIRCULATION, V93, P1791, DOI 10.1161/01.CIR.93.10.1791; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; EBELING W, 1974, EUR J BIOCHEM, V47, P91, DOI 10.1111/j.1432-1033.1974.tb03671.x; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JANUARY CT, 1997, ELECTROCARDIOLOGY 96, P231; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Mohammad S, 1997, AM J PHYSIOL-HEART C, V273, pH2534, DOI 10.1152/ajpheart.1997.273.5.H2534; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; Nie L, 1998, BIOPHYS J, V74, pA213; PLANELLSCASES R, 1995, P NATL ACAD SCI USA, V92, P9422, DOI 10.1073/pnas.92.20.9422; Priori Silvia G., 1997, Circulation, V96, pI212; Rampe D, 1997, FEBS LETT, V417, P28, DOI 10.1016/S0014-5793(97)01249-0; Riezman H, 1997, SCIENCE, V278, P1728, DOI 10.1126/science.278.5344.1728; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Satler CA, 1998, HUM GENET, V102, P265, DOI 10.1007/s004390050690; SCHULTEIS CT, 1995, BIOCHEMISTRY-US, V34, P1725, DOI 10.1021/bi00005a029; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Shi WM, 1997, J NEUROSCI, V17, P9423; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Tanaka T, 1997, CIRCULATION, V95, P565, DOI 10.1161/01.CIR.95.3.565; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Vesely Mark R., 1997, Circulation, V96, pI56; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1998, BIOPHYS J, V74, pA26	41	305	313	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21061	21066		10.1074/jbc.273.33.21061	http://dx.doi.org/10.1074/jbc.273.33.21061			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694858	hybrid			2022-12-27	WOS:000075386100051
J	Cao, WH; Garcia-Blanco, MA				Cao, WH; Garcia-Blanco, MA			A serine/arginine-rich domain in the human U1 70k protein is necessary and sufficient for ASF/SF2 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; 5' SPLICE-SITE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SR PROTEINS; PREMESSENGER RNA; 5'-SPLICE-SITE RECOGNITION; DROSOPHILA-MELANOGASTER; ASSEMBLY PATHWAY; SNRNP PROTEIN; IDENTIFICATION	Critical protein-protein interactions among pre-mRNA splicing factors determine splicing efficiency and specificity. The serine/arginine proteins, a family of factors characterized by the presence of an RNA recognition motif and an arginine/serine domain, are essential for constitutive splicing and required for some alternative splicing decisions. ASF/SF2, SC35, and other members of the serine/arginine family, interact with the 70k protein of the U1 small nuclear ribonucleoprotein. The binding of this protein with ASF/SF2 is thought to enhance recognition of the 5' splice site of pre-mRNAs by the U1 small nuclear ribonucleoprotein. It has been clearly documented that the arginine/serine domain of ASF/SF2 is responsible for binding to the U1 70k protein. In this manuscript we characterize the segment in the human UI 70k protein that is both necessary and sufficient for ASF/SF2 binding. A domain within this segment, which begins with Arg(240) and ends with Asp(270), was shown to bind specifically to the arginine/serine domain of ASF/ SF2 using a yeast two-hybrid system and a far Western assay. Mutational analysis of this segment suggested that several arginines are critical for the interaction with ASF/SFS and for phosphorylation by SRPK1, Inspection of the sequence of the Arg(248) to Asp(270) region suggested this as an arsnine/serine-like domain in U1 70k protein, and the data presented in this manuscript strongly support this view. Inspection of the human U1 70k protein sequence, comparison with homologues in other animal species, and mutational analysis indicated the importance of the sequence Arg-Arg-Arg-Ser-Arg-Ser-Arg-Asp, which is found repeated twice in the region from Arg(248) to Asp(270) in the human protein.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Levine Sci Res Ctr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Levine Sci Res Ctr, Dept Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Levine Sci Res Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Levine Sci Res Ctr, Box 3686, Durham, NC 27710 USA.							AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BILLINGS PB, 1982, J IMMUNOL, V128, P1176; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Cao WH, 1997, RNA, V3, P1456; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIDELL RA, 1995, VIROLOGY, V209, P347, DOI 10.1006/viro.1995.1266; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, P NATL ACAD SCI USA, V87, P3338, DOI 10.1073/pnas.87.9.3338; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; HILLEREN PJ, 1995, MOL CELL BIOL, V15, P6341; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MOUNT SM, 1983, CELL, V33, P509, DOI 10.1016/0092-8674(83)90432-4; PETZER S, 1997, RNA, V3, P344; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROSCIGNO RF, 1995, RNA, V1, P692; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; SUNE C, 1995, J VIROL, V69, P3098; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	49	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20629	20635		10.1074/jbc.273.32.20629	http://dx.doi.org/10.1074/jbc.273.32.20629			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685421	hybrid			2022-12-27	WOS:000075305400098
J	Pease, JE; Wang, J; Ponath, PD; Murphy, PM				Pease, JE; Wang, J; Ponath, PD; Murphy, PM			The N-terminal extracellular segments of the chemokine receptors CCR1 and CCR3 are determinants for MIP-1 alpha and eotaxin binding, respectively, but a second domain is essential for efficient receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; AMINO TERMINUS; HIV-1 ENTRY; LIGAND; CHEMOATTRACTANT; RANTES; CXC; SELECTIVITY	CCR1 and CCR3 are seven-transmembrane domain G protein-coupled receptors specific for members of the CC chemokine subgroup of leukocyte chemoattractants, Both have been implicated in the inflammatory response, and CCR3, through its expression on eosinophils, basophils, and Th2 lymphocytes, may be especially important in allergic inflammation. CCR1 and CCR3 are 54% identical in amino acid sequence and share some ligands but not others. In particular, macrophage inflammatory protein la (MIP-la) is a ligand for CCR1 but not CCR3, and eotaxin is a ligand for CCR3 but not CCR1. To map ligand selectivity determinants and to guide rational antagonist design, we analyzed CCR1: CCR3 chimeric receptors, When expressed in mouse pre-B cells, chimeras in which the N-terminal extracellular segments were switched were both able to bind both MIP-1 alpha and eotaxin, but in each case, binding occurred via separate sites. Nevertheless, neither MIP-1 alpha nor eotaxin were effective agonists at either chimeric receptor in either calcium flux or chemotaxis assays. These data are consistent with a multi-site model for chemokine-chemokine receptor interaction in which one or more subsites determine chemokine selectivity, but others are needed for receptor activation. Agents that bind to the N-terminal segments of CCR1 and CCR3 may be useful in blocking receptor function.	Univ Sheffield, Krebs Inst, Sheffield S10 2TN, S Yorkshire, England; NIAID, Host Def Lab, Bethesda, MD 20892 USA; LeukoSite Inc, Cambridge, MA 02142 USA	University of Sheffield; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Ponath, PD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, Exhibit Rd, London SW7 2AZ, England.		Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341				Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225; Alkhatib G, 1997, J BIOL CHEM, V272, P19771, DOI 10.1074/jbc.272.32.19771; Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420; ARAI H, 1997, P NATL ACAD SCI USA, V94, P14485; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berger EA, 1997, AIDS, V11, pS3; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673; COMBADIERE C, 1995, J BIOL CHEM, V270, P30235; COMBADIERE C, 1995, J BIOL CHEM, V270, P29671; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GAU JL, 1997, J EXP MED, V185, P1959; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; Gerard C, 1997, J CLIN INVEST, V100, P2022, DOI 10.1172/JCI119734; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LU ZH, 1995, J BIOL CHEM, V270, P26239; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186; MURPHY PM, 1996, CYTOKINE GROWTH F R, V12, P593; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PEASE JE, 1998, IN PRESS SEMIN IMMUN; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Su SB, 1996, J LEUKOCYTE BIOL, V60, P658, DOI 10.1002/jlb.60.5.658; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373	44	91	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19972	19976		10.1074/jbc.273.32.19972	http://dx.doi.org/10.1074/jbc.273.32.19972			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685332	hybrid			2022-12-27	WOS:000075305400009
J	Ruckman, J; Green, LS; Beeson, J; Waugh, S; Gillette, WL; Henninger, DD; Claesson-Welsh, L; Janjic, N				Ruckman, J; Green, LS; Beeson, J; Waugh, S; Gillette, WL; Henninger, DD; Claesson-Welsh, L; Janjic, N			2 '-fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF(165)) - Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; HIGH-AFFINITY; CELL MITOGEN; IN-VIVO; CHEMICAL MODIFICATION; HAMMERHEAD RIBOZYMES; MESSENGER-RNAS; TUMOR-GROWTH; MOUSE MODEL; FACTOR-B	Vascular endothelial growth factor (VEGF) has been implicated in the pathological induction of new blood vessel growth in a variety of proliferative disorders. Using the SELEX process (Systematic evolution of ligands by exponential enrichment), we have isolated 2'-F-pyrimidine RNA oligonucleotide ligands (aptamers) to human VEGF(165). Representative aptamers from three distinct sequence families were truncated to the minimal sequence capable of high affinity binding to VEGF (23-29 nucleotides) and were further modified by replacement of 2'-O-methyl for 2'-OH at all ribopurine positions where the substitution was tolerated. Equilibrium dissociation constants for the interaction of VEGF with the truncated, 2'-O-methyl-modified aptamers range between 49 and 130 pM, These aptamers bind equally well to murine VEGF(164), do not bind to VEGF(121) or the smaller isoform of placenta growth factor (PlGF(129)), and show reduced, but significant affinity for the VEGF(165)/PlGF(129) heterodimer. Cysteine 137 in the exon 7-encoded domain of VEGF(165) forms a photo-inducible cross-link to a single uridine residue in each of the three aptamers. The aptamers potently inhibit the binding of VEGF to the human VEGF receptors, KDR and Flt-1, expressed by transfected porcine aortic endothelial cells. Furthermore, one of the aptamers is able to significantly reduce intradermal VEGF-induced vascular permeability in vivo.	NeXstar Pharmaceut Inc, Boulder, CO 80301 USA; Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden		Ruckman, J (corresponding author), NeXstar Pharmaceut Inc, Boulder, CO 80301 USA.							ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; Brown L F, 1997, EXS, V79, P233; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; DETMAR M, 1994, J EXP MED, V180, P1141, DOI 10.1084/jem.180.3.1141; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; EATON BE, 1995, CHEM BIOL, V2, P633, DOI 10.1016/1074-5521(95)90023-3; EILINGTON A, 1990, NATURE, V346, P818; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; Green LS, 1996, BIOCHEMISTRY-US, V35, P14413, DOI 10.1021/bi961544+; GREEN LS, 1995, CHEM BIOL, V2, P683, DOI 10.1016/1074-5521(95)90032-2; GUSCHLBAUER W, 1980, NUCLEIC ACIDS RES, V8, P1421, DOI 10.1093/nar/8.6.1421; JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028; JENISON RD, 1998, IN PRESS ANTISENSE N, V8; Joukov V, 1996, EMBO J, V15, P290; KAKIUCHI N, 1982, J BIOL CHEM, V257, P1924; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOCH AE, 1994, J IMMUNOL, V152, P4149; KONIGSBERG W, 1969, METHOD ENZYMOL, V13, P185; Kubik MF, 1997, J IMMUNOL, V159, P259; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LESNIK EA, 1993, BIOCHEMISTRY-US, V32, P7832, DOI 10.1021/bi00081a031; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; Meisenheimer KM, 1997, CRIT REV BIOCHEM MOL, V32, P101, DOI 10.3109/10409239709108550; Melnyk O, 1996, CANCER RES, V56, P921; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER PS, 1993, NUCLEOS NUCLEOT, V12, P785, DOI 10.1080/07328319308018549; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Norris CL, 1996, J AM CHEM SOC, V118, P5796, DOI 10.1021/ja9607852; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Pagratis NC, 1997, NAT BIOTECHNOL, V15, P68, DOI 10.1038/nbt0197-68; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERSHEIM M, 1983, BIOCHEMISTRY-US, V22, P256, DOI 10.1021/bi00271a004; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yoshiji H, 1996, CANCER RES, V56, P2013	75	569	648	2	102	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20556	20567		10.1074/jbc.273.32.20556	http://dx.doi.org/10.1074/jbc.273.32.20556			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685413	hybrid			2022-12-27	WOS:000075305400090
J	Swanson, KD; Reigh, C; Landreth, GE				Swanson, KD; Reigh, C; Landreth, GE			ATP-stimulated activation of the mitogen-activated protein kinases through ionotrophic P2X2 purinoreceptors in PC12 cells - Difference in purinoreceptor sensitivity in two PC12 cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM INFLUX; PHEOCHROMOCYTOMA CELLS; NOREPINEPHRINE RELEASE; EXTRACELLULAR ATP; P-2 RECEPTORS; GROWTH-FACTOR; MAP KINASE; CHANNELS; ASTROCYTES; SECRETION	Extracellular purine nucleotides elicit a diverse range of biological responses through binding to specific cell surface receptors, The ionotrophic P2X subclass of purinoreceptors respond to ATP by stimulation of calcium ion permeability; however, it is unknown how P2X purinoreceptor activation is linked to intracellular signaling pathways. We report that stimulation of PC12 cells with ATP results in the activation of the mitogen-activated protein (MAP) kinases ERK1 and ERK2 and was wholly dependent upon extracellular calcium ions. Treatment of the cells with adenosine, AMP, ADP, UTP, or alpha,beta-methylene ATP was without effect; however, MAP kinase activation was abolished by pretreatment with suramin and reactive blue 2, The calcium-activated tyrosine kinase, Pyk2, acts as an upstream regulator of the MAP kinases and became tyrosine phosphorylated following treatment of the cells with ATP, We have ruled out the involvement of depolarization-mediated calcium influx because specific blockers of voltage-gated calcium channels did not affect MAP kinase activation. These data provide direct evidence that calcium influx through P2X2 receptors results in the activation of the MAP kinase cascade, Finally, we demonstrate that a different line of PC12 cells respond to ATP through P2Y2 purinoreceptors, providing an explanation for the conflicting findings of purine nucleotide responsiveness in PC12 cells.	Case Western Reserve Univ, Alzheimers Res Lab, Sch Med, Dept Neurol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Alzheimers Res Lab, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Landreth, GE (corresponding author), Case Western Reserve Univ, Alzheimers Res Lab, Sch Med, Dept Neurol, E504,10900 Euclid Ave, Cleveland, OH 44106 USA.				NIA NIH HHS [AG-00105] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRY VA, 1994, J CELL SCI, V107, P451; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brake AJ, 1996, ANNU REV CELL DEV BI, V12, P519, DOI 10.1146/annurev.cellbio.12.1.519; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Giniatullin R, 1996, BRIT J PHARMACOL, V119, P1045, DOI 10.1111/j.1476-5381.1996.tb15776.x; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; INOUE K, 1991, BRIT J PHARMACOL, V102, P581, DOI 10.1111/j.1476-5381.1991.tb12216.x; INOUE K, 1989, NEUROSCI LETT, V106, P294, DOI 10.1016/0304-3940(89)90179-1; KIM WK, 1994, J BIOL CHEM, V269, P6471; King BF, 1996, NEUROSCIENCE, V74, P1187, DOI 10.1016/0306-4522(96)00209-6; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; Michel AD, 1996, N-S ARCH PHARMACOL, V354, P562; NEARY JT, 1994, NEUROREPORT, V5, P1617, DOI 10.1097/00001756-199408150-00019; NEARY JT, 1994, J NEUROCHEM, V63, P490; Neary JT, 1996, TRENDS NEUROSCI, V19, P13, DOI 10.1016/0166-2236(96)81861-3; NIKODIJEVIC B, 1994, CELL MOL NEUROBIOL, V14, P27, DOI 10.1007/BF02088587; RHOADS AR, 1993, J NEUROCHEM, V61, P1657, DOI 10.1111/j.1471-4159.1993.tb09800.x; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SELA D, 1991, J BIOL CHEM, V266, P17990; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Vulchanova L, 1996, P NATL ACAD SCI USA, V93, P8063, DOI 10.1073/pnas.93.15.8063; [No title captured]	30	66	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19965	19971		10.1074/jbc.273.32.19965	http://dx.doi.org/10.1074/jbc.273.32.19965			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685331	hybrid			2022-12-27	WOS:000075305400008
J	Aberdam, E; Bertolotto, C; Sviderskaya, EV; de Thillot, V; Hemesath, TJ; Fisher, DE; Bennett, DC; Ortonne, JP; Ballotti, R				Aberdam, E; Bertolotto, C; Sviderskaya, EV; de Thillot, V; Hemesath, TJ; Fisher, DE; Bennett, DC; Ortonne, JP; Ballotti, R			Involvement of microphthalmia in the inhibition of melanocyte lineage differentiation and of melanogenesis by agouti signal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING-HORMONE-RECEPTOR; TRANSCRIPTION FACTOR; HUMAN HOMOLOG; MELANOCORTIN RECEPTORS; INVERSE AGONISTS; TYROSINASE GENE; IN-VITRO; MOUSE; LOCUS; MICE	In mouse follicular melanocytes, production of eumelanins (brown-black pigments) and pheomelanins (yellow-brownish pigments) is under the control of two intercellular signaling molecules that exert opposite actions, alpha-melanocyte-stimulating hormone (alpha MSH) which preferentially increases the synthesis of eumelanins, and agouti signal protein (ASP) whose expression favors the production of hair containing pheomelanins. In this study, we report that ASP does not only affect mature melanocytes but can also inhibit the differentiation of melanoblasts. We show that both alpha MSH and forskolin promote the differentiation of murine melanoblasts into mature melanocytes and that ASP inhibits this process. We present evidence that the expression of a specific melanogenic transcription factor, microphthalmia, and its binding to an M box regulatory element, is inhibited by ASP. We also show that, in B16 murine melanoma cells, ASP inhibits alpha MSH-stimulated expression of tyrosinase, tyrosine-related proteins 1 and 2 through an inhibition of the transcription activity of their respective promoters. Further, ASP inhibits alpha MSH-induced expression of the microphthalmia gene and reduces the level of microphthalmia in the cells. Our data demonstrate that ASP can regulate both melanoblast differentiation and melanogenesis, pointing out the key role of microphthalmia in the control of these processes.	Fac Med, INSERM, U385, F-06107 Nice 2, France; Harvard Univ, Sch Med, Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; St Georges University London	Ballotti, R (corresponding author), Fac Med, INSERM, U385, Ave Valombrose, F-06107 Nice 2, France.		Sviderskaya, Elena V/D-2419-2009; Bertolotto-Ballotti, Corine/O-2155-2016; Bertolotto, Corine/AAF-6634-2021; Bennett, Dorothy C/C-2418-2008; BALLOTTI, Robert/F-8825-2013	Bertolotto, Corine/0000-0001-6971-7753; Bennett, Dorothy C/0000-0002-3639-7527; BALLOTTI, Robert/0000-0002-7322-4908				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; BLANCHARD SG, 1995, BIOCHEMISTRY-US, V34, P10406, DOI 10.1021/bi00033a012; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BURCHILL SA, 1986, J ENDOCRINOL, V109, P15, DOI 10.1677/joe.0.1090015; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; Graham A, 1997, PIGM CELL RES, V10, P298, DOI 10.1111/j.1600-0749.1997.tb00689.x; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES AE, 1994, NAT GENET, V7, P509, DOI 10.1038/ng0894-509; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; HUNT G, 1994, J ENDOCRINOL, V140, pR1, DOI 10.1677/joe.0.140R001; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JIMENEZCERVANTES C, 1994, J BIOL CHEM, V269, P17993; JIMENEZCERVANTES C, 1993, PIGM CELL RES, V6, P394, DOI 10.1111/j.1600-0749.1993.tb00621.x; KOBAYASHI T, 1995, J CELL SCI, V108, P2301; KWON HY, 1994, P NATL ACAD SCI USA, V91, P9760, DOI 10.1073/pnas.91.21.9760; LEDOUARIN NM, 1992, INT REV CYTOL, V138, P269, DOI 10.1016/S0074-7696(08)61591-0; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Pozvek G, 1997, MOL PHARMACOL, V51, P658, DOI 10.1124/mol.51.4.658; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Siegrist W, 1996, BIOCHEM BIOPH RES CO, V218, P171, DOI 10.1006/bbrc.1996.0030; STEINGRIMSSON E, 1994, NAT GENET, V8, P50; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; TAKEUCHI T, 1989, Journal of Investigative Dermatology, V92, p239S, DOI 10.1111/1523-1747.ep13075730; TAMATE HB, 1984, SCIENCE, V224, P1241, DOI 10.1126/science.6328651; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Weilbaecher KN, 1998, J EXP MED, V187, P775, DOI 10.1084/jem.187.5.775; WESTPHAL RS, 1994, MOL PHARMACOL, V46, P937; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; WILSON BD, 1995, HUM MOL GENET, V4, P223, DOI 10.1093/hmg/4.2.223; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1995, ONCOGENE, V10, P123; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733	43	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19560	19565		10.1074/jbc.273.31.19560	http://dx.doi.org/10.1074/jbc.273.31.19560			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677380	hybrid			2022-12-27	WOS:000075125200032
J	Andersson, L; Freeman, MW				Andersson, L; Freeman, MW			Functional changes in scavenger receptor binding conformation are induced by charge mutants spanning the entire collagen domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HELICAL PEPTIDE MODEL; HAMSTER OVARY CELLS; ALZHEIMERS-DISEASE; LIGAND-BINDING; IN-VITRO; EXPRESSION; PROTEINS; SITE; DEGRADATION	Macrophage scavenger receptors are trimeric integral membrane proteins that bind a diverse array of negatively charged ligands, They have been shown to play a role in the pathogenesis of atherosclerosis and in host responses to microbial infections. Earlier mutational studies demonstrated that the distal segment of the collagen domain of the receptor was critically important for high affinity ligand binding activity. In this study, mutations spanning the entire collagen domain were generated and binding was assayed in transfected cells, as well as in assays employing a secreted, receptor fusion protein, Many of the distal, positively charged C-terminal residues in the type II collagen domain of the receptor, previously reported to be essential for binding at 37 degrees C, were found not to be critical for binding at 4 degrees C, Conversely, more proximally charged residues of the collagen receptor that have not been previously mutated were shown to have substantial effects on binding that were also temperature-dependent. These data suggest that scavenger receptor ligand recognition depends on more complex conformational interactions, involving charged residues throughout the entire collagen domain, than was previously recognized.	Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Nessel Gene Therapy Ctr, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Freeman, MW (corresponding author), Massachusetts Gen Hosp, Lipid Metab Unit, GRJ 1328, Boston, MA 02114 USA.				NHLBI NIH HHS [HL 45098] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL145098, R01HL045098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACTON S, 1993, J BIOL CHEM, V268, P3530; ANACHI RB, 1995, FEBS LETT, V368, P551, DOI 10.1016/0014-5793(95)00738-U; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; ASHKENAS J, 1993, J LIPID RES, V34, P983; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; Christie RH, 1996, AM J PATHOL, V148, P399; DANIEL TO, 1983, J BIOL CHEM, V258, P4606; DEJAGER S, 1993, J CLIN INVEST, V92, P894, DOI 10.1172/JCI116664; DOI T, 1993, J BIOL CHEM, V268, P2126; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Harlow E, 1988, ANTIBODIES LAB MANUA; HODGES RS, 1988, J BIOL CHEM, V263, P11768; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MAYER WE, 1995, GENE, V164, P267, DOI 10.1016/0378-1119(95)94092-Z; Mielewczyk SS, 1996, BIOCHEMISTRY-US, V35, P11396, DOI 10.1021/bi960706z; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PENMAN M, 1991, J BIOL CHEM, V266, P23985; RESNICK D, 1993, J BIOL CHEM, V268, P3538; Resnick D, 1996, J BIOL CHEM, V271, P26924, DOI 10.1074/jbc.271.43.26924; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; Starling GC, 1997, TISSUE ANTIGENS, V49, P1, DOI 10.1111/j.1399-0039.1997.tb02702.x; Tanaka T, 1996, PROTEIN ENG, V9, P307, DOI 10.1093/protein/9.3.307; Yamamoto K, 1997, FEBS LETT, V414, P182, DOI 10.1016/S0014-5793(97)01006-5	33	45	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19592	19601		10.1074/jbc.273.31.19592	http://dx.doi.org/10.1074/jbc.273.31.19592			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677385	hybrid			2022-12-27	WOS:000075125200037
J	Genschel, J; Littman, SJ; Drummond, JT; Modrich, P				Genschel, J; Littman, SJ; Drummond, JT; Modrich, P			Isolation of MutS beta from human cells and comparison of the mismatch repair specificities of MutS beta and MutS alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TUMOR-CELLS; ENDOMETRIAL CANCER; NUCLEAR EXTRACTS; COLON-CANCER; MSH3 GENE; DNA; BINDING; HETERODIMER; MUTATIONS	A human MSH2-human MSH3 (hMSH2 . hMSH3) complex of approximately 1:1 stoichiometry (human MutS beta (hMutS beta)) has been demonstrated in several human tumor cell lines and purified to near homogeneity, In vitro, hMutS beta supports the efficient repair of insertion/deletion (I/D) heterologies of 2-8 nucleotides, is weakly active on a single-nucleotide I/D mispair, and is not detectably active on the eight base-base mismatches, Human MutS alpha (hMutS alpha), a heterodimer of hMSH2 and hMSH6, efficiently supports the repair of single-nucleotide IID mismatches, base-base mispairs, and all substrates tested that were repaired by hMutS beta, Thus, the repair specificities of hMutS alpha and hMutS beta are redundant with respect to the repair of I/D heterologies of 2-8 nucleotides. The hMutSa level in repair-proficient HeLa cells (1.5 mu g/mg nuclear extract) is approximately 10 times that of hMutS beta. In HCT-15 colorectal tumor cells, which do not contain hMSH6 and consequently lack hMutS alpha, the hMutS beta level is elevated severalfold relative to that in HeLa cells and is responsible for the repair of I/D mismatches that has been observed in this cell line. LoVo tumor cells, which are genetically deficient in hMSH2, lack both hMutS alpha and hMutS beta, and hMSH3 and hMSH6 levels are less than 4% of those found in repair-proficient cells. Coupled with previous findings (J. T. Drummond, J, Genschel, E. Wolf, and P. Modrich (1997) Proc. Natl. Acad Sci. U.S.A. 94, 10144-10149), these results suggest that hMSH2 partitions between available pools of hMSH3 and hMSH6 and indicate that hMSH2 positively modulates hMSH6 and hMSH3 levels, perhaps by stabilization of the polypeptides upon heterodimer formation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Med Oncol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University	Modrich, P (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NATIONAL CANCER INSTITUTE [K08CA071554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA71554] Funding Source: Medline; NIGMS NIH HHS [GM45190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Akiyama Y, 1997, CANCER RES, V57, P3920; Alani E, 1996, MOL CELL BIOL, V16, P5604; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; FANG WH, 1993, J BIOL CHEM, V268, P11838; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FUJII H, 1989, J BIOL CHEM, V264, P10057; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Greene CN, 1997, MOL CELL BIOL, V17, P2844, DOI 10.1128/MCB.17.5.2844; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; INOKUCHI K, 1995, BIOCHEM BIOPH RES CO, V214, P171, DOI 10.1006/bbrc.1995.2271; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LINTON JP, 1989, MOL CELL BIOL, V9, P3058, DOI 10.1128/MCB.9.7.3058; Malkhosyan S, 1996, MUTAT RES-DNAGING G, V316, P249, DOI 10.1016/S0921-8734(96)90007-7; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; SU SS, 1988, J BIOL CHEM, V263, P6829; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Umar A, 1997, CANCER RES, V57, P3949; Yamamoto H, 1998, CANCER RES, V58, P997	44	320	325	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19895	19901		10.1074/jbc.273.31.19895	http://dx.doi.org/10.1074/jbc.273.31.19895			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677427	hybrid			2022-12-27	WOS:000075125200079
J	Liu, Y; Ray, SK; Yang, XQ; Luntz-Leybman, V; Chiu, IM				Liu, Y; Ray, SK; Yang, XQ; Luntz-Leybman, V; Chiu, IM			A splice variant of E2-2 basic helix-loop-helix protein represses the brain-specific fibroblast growth factor 1 promoter through the binding to an imperfect E-box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; DEVELOPING NERVOUS-SYSTEM; TRANSCRIPTION FACTOR; RAT-BRAIN; MOLECULAR-CLONING; GENE-EXPRESSION; PRONEURAL GENE; TISSUES; LOCALIZATION; ENHANCERS	We previously demonstrated that a cis-element (-489 to -467) in the brain-specific fibroblast growth factor (FGF)-1 promoter (FGF-1.B) binds multiple nuclear factors, and this binding enhances transcriptional activity of this promoter. Here we report the isolation of three cDNA clones, VL1, VL2 and VL3, from a human brain stem cDNA expression library using four tandem repeats of the 26-base pair sequence (-492 to -467) as the probe. These cDNA clones represent the variant of bHLH protein E2-2/SEF2-1 in having 12 additional nucleotides encoding the amino acids RSRS, The glutathione S-transferase (GST) fusion proteins of VL1, VL2, and VL3 immunologically react with anti-E2-2 antibody and anti-GST-VL2 antibody. Electrophoretic mobility shift assay and methylation interference assay revealed that the GST fusion proteins specifically bind to an imperfect E-box sequence (GACCTG) present in the :26-base pair sequence, Transient expression of the full-length E2-2 without RSRS in U1240MG glioblastoma cells resulted in repression of FGF-I,B promoter activity. We further showed a significant repression of promoter activity (>40 fold) by E2-2 (lacking the amino acid sequence RSRS) when the E47 reporter construct, containing a hexameric E-box site, was used. In contrast, the E2-2 variant containing the RSRS sequence has no significant effect on either the FGF-1 promoter or E47 promoter, These results suggest that the relative abundance of the two splice variants of E2-2 in brain could be an important determinant for the expression of FGF-1.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, 480 W 9th Ave, Columbus, OH 43210 USA.		Yang, Xiaoqi/E-2070-2011; Chiu, Ing-Ming/B-1534-2008; yang, xin/HGU-9981-2022		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAZAWA C, 1995, J BIOL CHEM, V270, P8730, DOI 10.1074/jbc.270.15.8730; Alam KY, 1996, J BIOL CHEM, V271, P30263, DOI 10.1074/jbc.271.47.30263; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; BEAN AJ, 1991, P NATL ACAD SCI USA, V88, P10237, DOI 10.1073/pnas.88.22.10237; BEGLEY CG, 1992, P NATL ACAD SCI USA, V89, P38, DOI 10.1073/pnas.89.1.38; CHIU IM, 1990, ONCOGENE, V5, P755; CHOTANI MA, 1995, NUCLEIC ACIDS RES, V23, P434, DOI 10.1093/nar/23.3.434; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DU XY, 1994, J NEUROSCI, V14, P7688; ECKENSTEIN FP, 1994, BIOCHEM PHARMACOL, V47, P103, DOI 10.1016/0006-2952(94)90442-1; GOBEL V, 1992, CELL GROWTH DIFFER, V3, P143; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARA Y, 1994, BRAIN RES, V664, P101, DOI 10.1016/0006-8993(94)91959-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JARMAN AP, 1993, CELL, V73, P1307, DOI 10.1016/0092-8674(93)90358-W; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; Pscherer A, 1996, EMBO J, V15, P6680, DOI 10.1002/j.1460-2075.1996.tb01058.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STOCK A, 1992, J NEUROSCI, V12, P4688; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WANG WP, 1991, ONCOGENE, V6, P1521; WANG WP, 1991, DNA CELL BIOL, V10, P771, DOI 10.1089/dna.1991.10.771; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; WEINER HL, 1989, P NATL ACAD SCI USA, V86, P2683, DOI 10.1073/pnas.86.8.2683; WILCOX BJ, 1991, NEURON, V6, P397, DOI 10.1016/0896-6273(91)90248-X	42	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19269	19276		10.1074/jbc.273.30.19269	http://dx.doi.org/10.1074/jbc.273.30.19269			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668116	hybrid			2022-12-27	WOS:000074974700083
J	Matsuo, E; Mori, H; Shimoike, T; Ito, K				Matsuo, E; Mori, H; Shimoike, T; Ito, K			Syd, a SecY-interacting protein, excludes SecA from, the SecYE complex with an altered secY24 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI PREPROTEIN TRANSLOCASE; ESCHERICHIA-COLI; MEMBRANE; MACHINERY; RECONSTITUTION; COMPONENTS; EXPORT; ATP; OVERPRODUCTION; MUTATIONS	Syd is an Escherichia coli cytosolic protein that interacts with SecY, Overproduction of this protein causes a number of protein translocation-related phenotypes, including the strong toxicity against the secY24 mutant cells. Previously, this mutation was shown to impair the interaction between SecY and SecE, the two fundamental subunits of the membrane-embedded part of protein translocase. We have now studied in vitro the mechanisms of the Syd-directed inhibition of protein translocation, Pro-OmpA translocation into inverted membrane vesicles (IMVs) prepared from the secY24 mutant cells as well as the accompanied translocation ATPase activity of SecA were rapidly inhibited by purified Syd protein. In the course of protein translocation, high affinity binding of preprotein-bearing SecA to the translocase on the IMV is followed by ATP-driven insertion of the 80-kDa SecA segment into the membrane. Our experiments using I-125-labeled SecA and the secY24 mutant IMV showed that Syd abolished both the high affinity SecA binding and the SecA insertion. Syd was even able to release the inserted form of SecA that had been stabilized by a nonhydrolyzable ATP analog. Syd affected markedly the proteolytic digestion pattern of the IMV-integrated SecY24 protein, suggesting that Syd exerts its inhibitory effect by interacting directly with the SecY24 protein. In accordance with this notion, a SecY24 variant with a second site mutation (secY249) resisted the Syd action both in vivo and in vitro. Thus, Syd acts against the SecY24 form of translocase, in which SecY-SecE interaction has been compromised, to exclude the SecA motor protein from the SecYE channel complex.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp		Mori, Hiroyuki/0000-0002-0429-1269				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1990, BIOCHEM BIOPH RES CO, V167, P711, DOI 10.1016/0006-291X(90)92083-C; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; BABA T, 1994, P NATL ACAD SCI USA, V91, P4539, DOI 10.1073/pnas.91.10.4539; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; HANADA M, 1994, J BIOL CHEM, V269, P23625; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Homma T, 1997, FEBS LETT, V408, P11, DOI 10.1016/S0014-5793(97)00376-1; Ito K, 1996, GENES CELLS, V1, P337, DOI 10.1046/j.1365-2443.1996.34034.x; JOLY JC, 1994, P NATL ACAD SCI USA, V91, P4703, DOI 10.1073/pnas.91.11.4703; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Matsuo E, 1998, MOL GEN GENET, V258, P240, DOI 10.1007/s004380050728; MATSUYAMA S, 1992, BIOCHIM BIOPHYS ACTA, V1122, P77, DOI 10.1016/0167-4838(92)90130-6; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Sato K, 1997, J BIOL CHEM, V272, P20082, DOI 10.1074/jbc.272.32.20082; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SHIMOIKE T, 1992, MOL MICROBIOL, V6, P1205, DOI 10.1111/j.1365-2958.1992.tb01559.x; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; Taura T, 1997, BIOCHIMIE, V79, P517, DOI 10.1016/S0300-9084(97)82744-7; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429	34	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18835	18840		10.1074/jbc.273.30.18835	http://dx.doi.org/10.1074/jbc.273.30.18835			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668058	hybrid			2022-12-27	WOS:000074974700025
J	Michaelson, LV; Lazarus, CM; Griffiths, G; Napier, JA; Stobart, AK				Michaelson, LV; Lazarus, CM; Griffiths, G; Napier, JA; Stobart, AK			Isolation of a Delta(5)-fatty acid desaturase gene from Mortierella alpina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSOMAL PREPARATIONS; HISTIDINE-RESIDUES; SYNECHOCYSTIS; CYTOCHROME-B5; ARABIDOPSIS; TEMPERATURE; EXPRESSION; CLONING; ENZYME	Arachidonic acid (C20:4 Delta(5,8,11,14)) is a polyunsaturated fatty acid synthesized by the Delta(6)-fatty acid desaturation of di-homo-gamma-linolenic acid (C20:3 Delta(8,11,14)). I, mammals, it is known to be a precursor of the prostaglandins and the leukotrienes but it is also accumulated. by the filamentous fungus Mortierella alpina. We have isolated a cDNA encoding the Delta(5)-fatty acid desaturase from M. alpina via a polymerase chain reaction-based strategy using primers designed to the conserved histidine box regions of microsomal desaturases, and confirmed its function by expression in the yeast Saccharomyces cerevisiae. Analysis of the lipids from the transformed yeast demonstrated the accumulation of arachidonic acid. The M. alpina Delta(5)-desaturase is the first example of a cloned Delta(5)-desaturase, and differs from other fungal desaturases previously characterized by the presence of an N-terminal domain related to cytochrome b(5).	Univ Bristol, Sch Biol Sci, Bristol BS8 1UG, Avon, England; Hort Res Int, Wellesbourne CV35 9EF, Warwick, England; Univ Bristol, Dept Agr Sci, Inst Arable Crops Res, Long Ashton Res Stn, Bristol BS41 9AF, Avon, England	University of Bristol; University of Warwick; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Rothamsted Research; University of Bristol	Michaelson, LV (corresponding author), Univ Bristol, Sch Biol Sci, Woodland Rd, Bristol BS8 1UG, Avon, England.	louise.michaelson@bristol.ac.uk	Lazarus, Colin M/B-9474-2011	Griffiths, Gareth/0000-0002-7507-6945; Napier, Johnathan/0000-0003-3580-3607; Michaelson, Louise/0000-0001-5621-4495				Anamnart S, 1997, GENE, V184, P299, DOI 10.1016/S0378-1119(96)00621-X; ARONDEL V, 1992, SCIENCE, V258, P1353, DOI 10.1126/science.1455229; AVELANGEMACHEREL MH, 1995, FEBS LETT, V361, P111, DOI 10.1016/0014-5793(95)00163-4; DAILEY HA, 1980, J BIOL CHEM, V255, P5184; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Gill I, 1997, TRENDS BIOTECHNOL, V15, P470, DOI 10.1016/S0167-7799(97)01077-9; Horrobin D.F., 1990, REV CONT PHYSL, V1, P1; HORROBIN DF, 1992, PROG LIPID RES, V31, P167; Jackson FM, 1998, EUR J BIOCHEM, V252, P513, DOI 10.1046/j.1432-1327.1998.2520513.x; JACKSON FM, 1998, IN PRESS J GEN MICRO; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; Napier JA, 1998, BIOCHEM J, V330, P611; Napier JA, 1997, BIOCHEM J, V328, P717; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; REDDY AS, 1993, PLANT MOL BIOL, V22, P293, DOI 10.1007/BF00014936; Sambrook J., 2002, MOL CLONING LAB MANU; Sayanova O, 1997, P NATL ACAD SCI USA, V94, P4211, DOI 10.1073/pnas.94.8.4211; SCHMIDT H, 1994, PLANT MOL BIOL, V26, P631, DOI 10.1007/BF00013749; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; SHIMIZU S, 1988, BIOCHEM BIOPH RES CO, V150, P335, DOI 10.1016/0006-291X(88)90525-6; SMITH MA, 1994, PLANT MOL BIOL, V25, P527, DOI 10.1007/BF00043880; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SMITH MA, 1992, BIOCHEM J, V287, P141, DOI 10.1042/bj2870141; SPERLING P, 1995, EUR J BIOCHEM, V232, P798, DOI 10.1111/j.1432-1033.1995.0798a.x; Tanaka T, 1996, LIPIDS, V31, P1173, DOI 10.1007/BF02524292	27	136	170	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19055	19059		10.1074/jbc.273.30.19055	http://dx.doi.org/10.1074/jbc.273.30.19055			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668087	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000074974700054
J	Schmidt, C; Stehling, P; Schnitzer, J; Reutter, W; Horstkorte, R				Schmidt, C; Stehling, P; Schnitzer, J; Reutter, W; Horstkorte, R			Biochemical engineering of neural cell surfaces by the synthetic N-propanoyl-substituted neuraminic acid precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY A2B5; SIALIC ACIDS; NEURITE OUTGROWTH; GROWTH-FACTOR; RAT; DIFFERENTIATION; LINE; TRANSPLANTATION; MIGRATION; INTEGRIN	Sialylation of glycoproteins and glycolipids plays an important role during development, regeneration, and pathogenesis of diseases, During times of intense plasticity within the nervous system, such as development and regeneration, sialylation of neural cells is distinct from the time of its maintenance, In this study, a synthetic precursor of neuraminic acid, N-propanoylmannosamine (N-propanoyl neuraminic acid precursor (P-NAP)), is applied to the culture medium of oligodendrocyte progenitor cells, microglia, astrocytes, and neurons from neonatal rat brains to alter sialylation of glycoconjugates within these cells. P-NAP is metabolized and incorporated as N-propanoyl neuraminic acid into glycoproteins of the cell membrane. P-NAP stimulates the proliferation of astrocytes and microglia but not of oligodendrocyte progenitor in vitro. However, P-NAP increases the number of oligodendrocyte progenitor cells expressing the early oligodendroglial surface marker A2B5 epitope. In the presence of P-NAP, cerebellar neurons (but not astrocytes) in microexplant cultures start to express the oligodendroglial progenitor marker A2B5 epitope, which is normally undetectable on these cells. The controls, which were performed in the absence of any additive or in the presence of the physiological precursor of neuraminic acid, N-acetylmannosamine, did not show any increase in A2B5 expression.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Horstkorte, R (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.		Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				ASHTON FA, 1990, BRAIN RES, V529, P349, DOI 10.1016/0006-8993(90)90850-B; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CAMERON RS, 1991, GLIA, V4, P124, DOI 10.1002/glia.440040204; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DUBOIS C, 1990, J BIOL CHEM, V265, P2797; EISENBARTH GS, 1984, P NATL ACAD SCI USA, V75, P4913; FISCHER G, 1986, J NEUROSCI, V6, P605; FRANK MM, 1992, CURR OPIN IMMUNOL, V4, P14, DOI 10.1016/S0952-7915(92)90117-W; FREDMAN P, 1984, ARCH BIOCHEM BIOPHYS, V233, P661, DOI 10.1016/0003-9861(84)90492-2; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARA S, 1987, ANAL BIOCHEM, V164, P138, DOI 10.1016/0003-2697(87)90377-0; KAYSER H, 1992, FEBS LETT, V301, P137, DOI 10.1016/0014-5793(92)81233-C; KAYSER H, 1992, J BIOL CHEM, V267, P16934; KEPPLER OT, 1995, J BIOL CHEM, V270, P1308, DOI 10.1074/jbc.270.3.1308; KLUGE A, 1992, EUR J CELL BIOL, V59, P12; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; Mahal LK, 1997, SCIENCE, V276, P1125, DOI 10.1126/science.276.5315.1125; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; Park TU, 1997, BIOCHEM BIOPH RES CO, V234, P686, DOI 10.1006/bbrc.1997.6700; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; RATHJEN FG, 1984, EMBO J, V3, P1; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; Schmidt C, 1997, GLIA, V20, P284; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VIGNAIS L, 1993, INT J DEV NEUROSCI, V11, P603, DOI 10.1016/0736-5748(93)90049-J; WARRINGTON AE, 1993, J NEUROSCI RES, V34, P1, DOI 10.1002/jnr.490340102; Wieser JR, 1996, FEBS LETT, V395, P170, DOI 10.1016/0014-5793(96)01029-0; Wolswijk Guus, 1995, P149	32	72	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19146	19152		10.1074/jbc.273.30.19146	http://dx.doi.org/10.1074/jbc.273.30.19146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668100	hybrid			2022-12-27	WOS:000074974700067
J	Yeagley, D; Agati, JM; Quinn, PG				Yeagley, D; Agati, JM; Quinn, PG			A tripartite array of transcription factor binding sites mediates cAMP induction of phosphoenolpyruvate carboxykinase gene transcription and its inhibition by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER-REGULATORY REGION; PROTEIN-KINASE-A; GLYCOGEN-SYNTHASE KINASE-3-BETA; RESPONSE ELEMENT; GTP GENE; FACTOR CREB; PHOSPHATIDYLINOSITOL 3'-KINASE; MULTIHORMONAL REGULATION; PHOSPHORYLATED CREB; CELL-CYCLE	Transcription of the phosphoenolpyruvate carboxykinase (PEPCH) gene is induced upon activation of protein kinase A by cAMP and phosphorylation of Ser-133 in the transcription factor, cAMP-response element binding protein (CREB), and this induction is inhibited by insulin, We show here that insulin does not act by dephosphorylating CREB or by affecting heterologous kinases that phosphorylate Ser-129 or Ser-142 in CREB, In addition, insulin inhibition of minimal PEPCK promoter activity induced by CREB-GAL4 + protein kinase A was equivalent to inhibition of basal transcription, and thus cAMP-independent. On the other hand, nearly complete insulin inhibition is observed with the full PEPCK promoter (-600/+69), indicating that other factors are involved, The additional promoter elements required for induction by protein kinase A lie within -271 nucleotides of the start site and correspond to putative binding sites for activator protein-1 and CAAT/enhancer-binding protein (C/EBP), first identified by Roesler et al. (Roesler, W. J., McFie, P. J., and Puttick, D. M., (1993) J. Biol. Chem, 268, 3791-3796), This tripartite array of binding sites for CREB, C/EBP, and activator protein-1 (AP-1) factors forms a cAMP response unit that, together with the minimal promoter, can mediate both induction by cAMP and inhibition by insulin, Thus, for the PEPCH gene with a single CREB site, the CREB.CBP.RNA polymerase II complex cannot mediate either induction by cAMP or inhibition by insulin.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Quinn, PG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.				NIDDK NIH HHS [DK49600] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049600] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agati JM, 1998, J BIOL CHEM, V273, P18751, DOI 10.1074/jbc.273.30.18751; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; Budworth PR, 1997, MOL ENDOCRINOL, V11, P1669, DOI 10.1210/me.11.11.1669; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CHU DTW, 1988, J BIOL CHEM, V263, P13007; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1988, ADV SEC MESS PHOSPH, V21, P75; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; DENTON RM, 1992, BIOCHEM SOC T, V20, P659, DOI 10.1042/bst0200659; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HANSON RW, 1972, AM J CLIN NUTR, V25, P1010; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HURST HC, 1990, MOL CELL BIOL, V10, P6192, DOI 10.1128/MCB.10.12.6192; Klemm DJ, 1998, J BIOL CHEM, V273, P917, DOI 10.1074/jbc.273.2.917; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LIU J, 1991, MOL CELL BIOCHEM, V104, P89; LIU JS, 1991, J BIOL CHEM, V266, P19095; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1988, MOL CELL BIOL, V8, P3467, DOI 10.1128/MCB.8.8.3467; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1989, J BIOL CHEM, V264, P9657; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALKER DH, 1992, MOL BIOL CELL, V3, P687, DOI 10.1091/mbc.3.6.687; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WHITE MF, 1994, J BIOL CHEM, V269, P1; WYNSHAWBORIS A, 1986, J BIOL CHEM, V261, P9714; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597	72	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18743	18750		10.1074/jbc.273.30.18743	http://dx.doi.org/10.1074/jbc.273.30.18743			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668047	hybrid			2022-12-27	WOS:000074974700014
J	Dufour, C; Weinberger, RP; Schevzov, G; Jeffrey, PL; Gunning, P				Dufour, C; Weinberger, RP; Schevzov, G; Jeffrey, PL; Gunning, P			Splicing of two internal and four carboxyl-terminal alternative exons in nonmuscle tropomyosin 5 pre-mRNA is independently regulated during development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CYTOSKELETAL TROPOMYOSIN; FUNCTIONAL DOMAINS; PREMESSENGER RNA; GENE-EXPRESSION; SR PROTEINS; CDNA CLONES; ISOFORMS; FIBROBLAST; MUSCLE	Four nonmuscle tropomyosin isoforms have been reported to be produced from the rat Tm5 gene by alternative splicing (Beisel, K, W., and Kennedy, J. E, (1994) Gene (Amst,) 145, 251-256), In order to detect additional isoforms that might be expressed from that gene, we used reverse transcriptase-polymerase chain reaction assays and evaluated the presence of all product combinations of two alternative internal exons (6a and 6b) and four carboxyl-terminal exons (9a, 9b, 9c, and 9d) in developing and adult rat brain. We identified five different combinations for exon 9 (9a + 9b, 9a + 9c, 9a + 9d, 9c, and 9d), and the exon combinations 9a + 9c and 9a + 9d were previously unreported. Each of these combinations existed with both exon 6a and exon 6b, Thus, the rat brain generates at least 10 different isoforms from the Tm5 gene. Northern blot hybridization with alternative exon specific probes revealed that these isoforms were also expressed in a number of different adult rat tissues, although some exons are preferentially expressed in particular tissues. Studies of regulation of the 10 different Tm5 isoform mRNAs during rat brain development indicated that no two isoforms are coordinately accumulated. Furthermore, there is a developmental switch in the use of exon 6a to exon 6b from embryonic to adult isoforms, TM5 protein isoforms show a differential localization in the adult cerebellum.	New Childrens Hosp, Oncol Res Unit, Parramatta, NSW 2124, Australia; Childrens Med Res Inst, Cell Biol Unit, Wentworthville, NSW 2145, Australia; Childrens Med Res Inst, Dev Neurobiol Unit, Wentworthville, NSW 2145, Australia; Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia	Children's Medical Research Institute - Australia; Children's Medical Research Institute - Australia; University of Sydney	Gunning, P (corresponding author), New Childrens Hosp, Oncol Res Unit, Clin Sci Bldg,POB 3515, Parramatta, NSW 2124, Australia.		Schevzov, Galina/G-5117-2013; Gunning, Peter W/E-9058-2010	Schevzov, Galina/0000-0002-0793-2279; Gunning, Peter/0000-0003-0833-3128				BEISEL NW, 1994, GENE, V145, P251; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; FU XD, 1995, RNA, V1, P663; GALLEGO ME, 1992, MOL CELL BIOL, V12, P5415, DOI 10.1128/MCB.12.12.5415; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; GRAHAM IR, 1992, MOL CELL BIOL, V12, P3872, DOI 10.1128/MCB.12.9.3872; GUNNING P, 1990, DEV BIOL, V138, P443, DOI 10.1016/0012-1606(90)90210-A; Gunning P, 1997, ANAT EMBRYOL, V195, P311, DOI 10.1007/s004290050050; HAILSTONES D, 1994, THESIS U SYDNEY SYDN; Hammell RL, 1996, J BIOL CHEM, V271, P4236; Hammell RL, 1997, J BIOL CHEM, V272, P22409, DOI 10.1074/jbc.272.36.22409; HANNAN AJ, 1995, MOL CELL NEUROSCI, V6, P397, DOI 10.1006/mcne.1995.1030; HARADA Y, 1995, J BIOCHEM-TOKYO, V118, P780, DOI 10.1093/oxfordjournals.jbchem.a124980; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; ISHAKAWA R, 1989, J BIOL CHEM, V264, P7490; Kislauskis EH, 1997, J CELL BIOL, V136, P1263, DOI 10.1083/jcb.136.6.1263; LEAVITT J, 1987, MOL CELL BIOL, V7, P2467, DOI 10.1128/MCB.7.7.2467; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LIN CH, 1995, RNA, V1, P234; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; MACLEOD AR, 1988, MOL CELL BIOL, V8, P433, DOI 10.1128/MCB.8.1.433; MACLEOD AR, 1986, NUCLEIC ACIDS RES, V14, P8413, DOI 10.1093/nar/14.21.8413; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RIO DC, 1993, CURR OPIN GENET DEV, V3, P574, DOI 10.1016/0959-437X(93)90093-5; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sambrook J., 2002, MOL CLONING LAB MANU; Schevzov G, 1997, MOL CELL NEUROSCI, V8, P439, DOI 10.1006/mcne.1997.0599; SCHEVZOV G, 1993, J CELL BIOL, V121, P811, DOI 10.1083/jcb.121.4.811; SINGER RH, 1993, CURR BIOL, V3, P719, DOI 10.1016/0960-9822(93)90079-4; TAKENAGA K, 1990, BIOCHIM BIOPHYS ACTA, V1087, P101, DOI 10.1016/0167-4781(90)90129-P; TemmGrove CJ, 1996, CELL MOTIL CYTOSKEL, V33, P223, DOI 10.1002/(SICI)1097-0169(1996)33:3<223::AID-CM6>3.0.CO;2-B; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; WANG YC, 1992, J BIOL CHEM, V267, P2728; WANG YC, 1992, J BIOL CHEM, V267, P12004; WARREN KS, 1995, J CELL BIOL, V129, P697, DOI 10.1083/jcb.129.3.697; Weinberger R, 1996, J NEUROSCI, V16, P238; YAMAWAKIKATAOKA Y, 1987, J BIOL CHEM, V262, P10791; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	53	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18547	18555		10.1074/jbc.273.29.18547	http://dx.doi.org/10.1074/jbc.273.29.18547			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660825	hybrid			2022-12-27	WOS:000074828500080
J	Mamane, Y; Hellauer, K; Rochon, MH; Turcotte, B				Mamane, Y; Hellauer, K; Rochon, MH; Turcotte, B			A linker region of the yeast zinc cluster protein Leu3p specifies binding to everted repeat DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZN(2)CYS(6) BINUCLEAR CLUSTER; UPSTREAM ACTIVATION SITES; SACCHAROMYCES-CEREVISIAE; CYC7 GENE; HAP1; SEQUENCE; TRANSCRIPTION; ELEMENTS; COMPLEX; GAL4	Feast zinc cluster proteins form a major class of yeast transcriptional regulators. They usually bind as homodimers to target DNA sequences, with each monomer recognizing a CGG triplet, Orientation and spacing between the CGG triplet specifies the recognition sequence for a given zinc cluster protein. For instance, Gal4p binds to inverted CGG triplets spaced by 11 base pairs whereas Ppr1p recognizes a similar motif but with a spacing of 6 base pairs. Hap1p, another member of this family, binds to a direct repeat consisting of two CGG triplets. Other members of this family, such as Leu3p, also recognize CGG triplets but when oriented in opposite directions, an everted repeat. This implies that the two zinc clusters of Leu3p bound to an everted repeat must be oriented in opposite directions to those of Gal4p or Ppr1p bound to inverted repeats. In order to map the domain responsible for proper orientation of the zinc clusters of Leu3p, we constructed chimeric proteins between Leu3p and Ppr1p and tested their binding to a Leu3p and a Ppr1p site, Our results show that the linker region, which bridges the zinc cluster to the dimerization domain, specifies binding of Leu3p to an everted repeat. We propose that the Leu3p linker projects the two zinc clusters of a Leu3p homodimer in opposite directions allowing binding to everted repeats.	McGill Univ, Royal Victoria Hosp, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Med, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; Gray WM, 1996, MOL CELL BIOL, V16, P347; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; Ha N, 1996, NUCLEIC ACIDS RES, V24, P1453, DOI 10.1093/nar/24.8.1453; HALVORSEN YDC, 1991, MOL CELL BIOL, V11, P1777, DOI 10.1128/MCB.11.4.1777; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Holmberg S, 1996, GENETICS, V144, P467; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; Karpichev IV, 1997, MOL CELL BIOL, V17, P69, DOI 10.1128/MCB.17.1.69; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; Liang SD, 1996, MOL CELL BIOL, V16, P3773; LODI T, 1991, MOL CELL BIOL, V11, P3762, DOI 10.1128/MCB.11.7.3762; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARMORSTEIN R, 1994, GENE DEV, V8, P2504, DOI 10.1101/gad.8.20.2504; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; PFEIFER K, 1987, CELL, V49, P19, DOI 10.1016/0092-8674(87)90751-3; PREZANT T, 1987, MOL CELL BIOL, V7, P3252, DOI 10.1128/MCB.7.9.3252; REECE RJ, 1993, SCIENCE, V261, P909, DOI 10.1126/science.8346441; REMBOUTSIKA E, 1994, MOL CELL BIOL, V14, P5547, DOI 10.1128/MCB.14.8.5547; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; Seraphin B, 1996, NUCLEIC ACIDS RES, V24, P3276, DOI 10.1093/nar/24.16.3276; SIDDIQUI AH, 1989, MOL CELL BIOL, V9, P4706, DOI 10.1128/MCB.9.11.4706; SIKORSKI RS, 1989, GENETICS, V122, P19; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VASHEE S, 1993, J BIOL CHEM, V268, P24699; WINKLER H, 1988, EMBO J, V7, P1799, DOI 10.1002/j.1460-2075.1988.tb03011.x; Zhang L, 1996, EMBO J, V15, P4676, DOI 10.1002/j.1460-2075.1996.tb00844.x; ZHANG L, 1994, GENE DEV, V8, P2110, DOI 10.1101/gad.8.17.2110; ZITOMER RS, 1987, MOL CELL BIOL, V7, P2212, DOI 10.1128/MCB.7.6.2212	41	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18556	18561		10.1074/jbc.273.29.18556	http://dx.doi.org/10.1074/jbc.273.29.18556			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660826	hybrid			2022-12-27	WOS:000074828500081
J	Bishop, DK; Ear, U; Bhattacharyya, A; Calderone, C; Beckett, M; Weichselbaum, RR; Shinohara, A				Bishop, DK; Ear, U; Bhattacharyya, A; Calderone, C; Beckett, M; Weichselbaum, RR; Shinohara, A			Xrcc3 is required for assembly of Rad51 complexes in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; X-RAY RESISTANCE; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; DNA-REPAIR; HOMOLOGOUS RECOMBINATION; ESCHERICHIA-COLI; RECA HOMOLOGS; IONIZING-RADIATION	Rad51 is a member of a family of eukaryotic proteins related to the bacterial recombinational repair protein RecA, Rad51 protein localizes to multiple subnuclear foci in Chinese hamster ovary cells. Subnuclear Rad51 foci are induced by ionizing radiation or the DNA crosslinking agent cisplatin. Formation of these foci is likely to reflect assembly of a multimeric form of Rad51 that promotes DNA repair. Formation of damage-induced Rad51 foci does not occur in the Chinese hamster ovary cell line irs1SF, which is sensitive to DNA damaging agents. The Rad51 focus formation defect of irs1SF cells is corrected by a construct that encodes the repair protein Xrcc3. Xrcc3 is a human homolog of Rad51 previously isolated by virtue of its ability to correct the radiation sensitivity of irs1SF cells. Changes in the steady state level of Rad51 protein do not account for the irs1SF defect nor do they account for the appearance of foci following DNA damage. These results suggest that Xrcc3 is required for the assembly or stabilization of a multimeric form of Rad51 during DNA repair. Cell Lines defective in two different components of DNA protein kinase formed Rad51 foci in response to damage, indicating DNA protein kinase is not required for damaged-induced mobilization of Rad51.	Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600055, Japan	University of Chicago; University of Chicago Medical Center; Osaka University	Bishop, DK (corresponding author), Univ Chicago, Med Ctr, Dept Radiat & Cellular Oncol, 5841 S Maryland Ave MC1105, Chicago, IL 60637 USA.	dbishop@midway.uchicago.edu						ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Blunt T, 1996, P NATL ACAD SCI USA, V93, P10285, DOI 10.1073/pnas.93.19.10285; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; Errami A, 1996, MOL CELL BIOL, V16, P1519; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P435; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; KRASIN F, 1977, J MOL BIOL, V116, P81, DOI 10.1016/0022-2836(77)90120-6; Li MJ, 1996, P NATL ACAD SCI USA, V93, P10222, DOI 10.1073/pnas.93.19.10222; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LIU N, 1995, AM J HUM GENET S, V57, P147; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSS GM, 1995, CANCER RES, V55, P1235; Sato S, 1995, DNA Res, V2, P147, DOI 10.1093/dnares/2.3.147; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STAHL FW, 1994, GENETICS, V138, P241; Stassen NY, 1997, CURR GENET, V31, P144, DOI 10.1007/s002940050189; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tashiro S, 1996, ONCOGENE, V12, P2165; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Thompson L. H., 1996, Environmental and Molecular Mutagenesis, V27, P68; THOMPSON LH, 1980, MUTAT RES, V74, P21, DOI 10.1016/0165-1161(80)90188-0; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Yamamoto A, 1996, MOL GEN GENET, V251, P1	56	235	239	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21482	21488		10.1074/jbc.273.34.21482	http://dx.doi.org/10.1074/jbc.273.34.21482			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705276	hybrid			2022-12-27	WOS:000075492600010
J	Pillutla, RC; Yue, ZY; Maldonado, E; Shatkin, AJ				Pillutla, RC; Yue, ZY; Maldonado, E; Shatkin, AJ			Recombinant human mRNA cap methyltransferase binds capping enzyme RNA polymerase IIo complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; GUANYLYLTRANSFERASE; PROTEIN; CELLS; GENE; 5'-TRIPHOSPHATASE; TRANSCRIPTION; PROMOTER; REOVIRUS	Guanine N-7 methylation is an essential step in the formation of the m(7)GpppN cap structure that is characteristic of eukaryotic mRNA 5' ends. The terminal 7-methylguanosine is recognized by cap-binding proteins that facilitate key events in gene expression including mRNA processing, transport, and translation. Here we describe the cloning, primary structure, and properties of human RNA (guanine-7-)methyltransferase. Sequence alignment of the 476-amino acid human protein with the corresponding yeast ABD1 enzyme demonstrated the presence of several conserved motifs known to be required for methyltransferase activity. We also identified a Drosophila open reading frame that encodes a putative RNA (guanine-7-)methyltransferase and contains these motifs. Recombinant human methyltransferase transferred a methyl group from S-adenosylmethionine to GpppG 5'ends, which are formed on RNA polymerase II transcripts by the sequential action of RNA 5'-triphosphatase and guanylyltransferase activities in the bifunctional mammalian capping enzyme. Binding studies demonstrated that the human cap methyltransferase associated with recombinant capping enzyme. Consistent with selective capping of RNA polymerase II transcripts, methyltransferase also formed ternary complexes with capping enzyme and the elongating form of RNA polymerase II.	Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 7, Chile	Universidad de Chile	Shatkin, AJ (corresponding author), Ctr Adv Biotechnol & Med, 679 Hoes Ln, Piscataway, NJ 08854 USA.	shatkin@mbcl.rutgers.edu						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; CORY S, 1975, J MOL BIOL, V99, P519, DOI 10.1016/S0022-2836(75)80170-7; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; ENSINGER MJ, 1976, J BIOL CHEM, V251, P5283; FRIDERICI K, 1976, BIOCHEMISTRY-US, V15, P5234, DOI 10.1021/bi00669a006; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; HAGLER J, 1992, SCIENCE, V255, P983, DOI 10.1126/science.1546295; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Lewis JD, 1997, EUR J BIOCHEM, V247, P461, DOI 10.1111/j.1432-1033.1997.00461.x; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MAO XD, 1995, MOL CELL BIOL, V15, P4167; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; MIZUMOTO K, 1987, PROG NUCLEIC ACID RE, V34, P1, DOI 10.1016/S0079-6603(08)60491-2; Morley SJ, 1997, RNA, V3, P1085; Moss B., 1996, FIELDS VIROLOGY, P2637; PERRY RP, 1976, CELL, V8, P433, DOI 10.1016/0092-8674(76)90156-2; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; SCHIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; SRIPATI CE, 1976, J BIOL CHEM, V251, P2898; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; YAGI Y, 1983, EMBO J, V2, P611, DOI 10.1002/j.1460-2075.1983.tb01471.x; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	38	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21443	21446		10.1074/jbc.273.34.21443	http://dx.doi.org/10.1074/jbc.273.34.21443			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705270	hybrid			2022-12-27	WOS:000075492600004
J	Blanchard, F; Raher, S; Duplomb, L; Vusio, P; Pitard, V; Taupin, JL; Moreau, JF; Hoflack, B; Minvielle, S; Jacques, Y; Godard, A				Blanchard, F; Raher, S; Duplomb, L; Vusio, P; Pitard, V; Taupin, JL; Moreau, JF; Hoflack, B; Minvielle, S; Jacques, Y; Godard, A			The mannose 6-phosphate/insulin-like growth factor II receptor is a nanomolar affinity receptor for glycosylated human leukemia inhibitory factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; 6-PHOSPHATE RECEPTOR; HUMAN INTERLEUKIN; BINDING-SITES; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; G-PROTEINS; DA CELLS; GP130; EXPRESSION	Comparison of the binding properties of non-glycosylated, glycosylated human leukemia inhibitory factor (LIF) and monoclonal antibodies (mAbs) directed at gp190/LIF-receptor beta subunit showed that most of the low affinity (nanomolar) receptors expressed by a variety of cell lines are not due to gp190, These receptors bind glycosylated LIF produced in Chinese hamster ovary cells (CHO LIF) (K-d, = 6.9 nM) but not Escherichia coli-derived LIF or CHO LIF treated with endoglycosidase F, CHO LIF binding to these receptors is neither affected by anti-gp190 mAbs nor by anti-gp130 mAbs and is specifically inhibited by low concentrations of mannose 6-phosphate (Man-6-P) (IC50 = 40 mu M), suggesting that they could be related to Man-B-P receptors, The identity of this LIF binding component with the Man-6-P/insulin-like growth factor-II receptor (Man-6-P/IGFII-R) was supported by several findings. (i) It has a molecular mass very similar to that of the Man-6-P/IGFII-R (270 kDa); (ii) the complex of LIF cross linked to this receptor is immunoprecipitated by a polyclonal anti-Man-6-P/IGFII-R antibody; (iii) this antibody inhibits LIF and IGFII binding to the receptor with comparable efficiencies; (iv) soluble Man-6-P/IGFII-R purified from serum binds glycosylated LIF (K-d = 4.3 nM) but not E. coli LIF. The potential role of Man-6-P/IGFII-R in LIF processing and biological activity is discussed.	Inst Biol, INSERM, U463, Grp Rech Cytokines Recepteurs Transduct, F-44035 Nantes 01, France; Inst Biol, IFR26, F-44035 Nantes, France; Univ Bordeaux 2, CNRS, UMR 5540, F-33076 Bordeaux, France; Inst Pasteur Lille, Inst Biol, EP CNRS 525, F-59021 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Jacques, Y (corresponding author), Inst Biol, INSERM, U463, Grp Rech Cytokines Recepteurs Transduct, 9 Quai Moncousu, F-44035 Nantes 01, France.		Minvielle, Stéphane/K-8251-2015; Blanchard, Frederic/AAS-1930-2021; Blanchard, Frederic/K-8018-2015; HOFLACK, Bernard/AAZ-6668-2020	Blanchard, Frederic/0000-0003-1055-2573; Blanchard, Frederic/0000-0003-1055-2573; Minvielle, Stephane/0000-0003-1389-312X; Duplomb, Laurence/0000-0002-5715-3759				Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; CHEREL M, 1995, BLOOD, V86, P2534; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DEGROOTE D, 1994, J IMMUNOL METHODS, V167, P253, DOI 10.1016/0022-1759(94)90094-9; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; FELDMAN EL, 1991, BRAIN RES, V562, P111, DOI 10.1016/0006-8993(91)91194-6; FERRARA N, 1992, P NATL ACAD SCI USA, V89, P698, DOI 10.1073/pnas.89.2.698; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; GASCAN H, 1989, J BIOL CHEM, V264, P21509; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GODARD A, 1992, J BIOL CHEM, V267, P3214; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; Hankins GR, 1996, ONCOGENE, V12, P2003; HERZOG V, 1987, EMBO J, V6, P555, DOI 10.1002/j.1460-2075.1987.tb04790.x; Heymann D, 1996, CYTOKINE, V8, P197, DOI 10.1006/cyto.1996.0028; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; Hudson KR, 1996, J BIOL CHEM, V271, P11971, DOI 10.1074/jbc.271.20.11971; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JACQUES Y, 1996, CYTOKINES, P349; Kandror KV, 1996, J BIOL CHEM, V271, P21703, DOI 10.1074/jbc.271.36.21703; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOBATA A, 1992, EUR J BIOCHEM, V209, P483, DOI 10.1111/j.1432-1033.1992.tb17313.x; KOMFELD S, 1992, ANNU REV BIOCHEM, V61, P307; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LOBEL P, 1987, P NATL ACAD SCI USA, V84, P2233, DOI 10.1073/pnas.84.8.2233; LUDWIG T, 1991, J CELL BIOL, V115, P1561, DOI 10.1083/jcb.115.6.1561; MOREAU JF, 1988, NATURE, V336, P690, DOI 10.1038/336690a0; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MURAYAMA Y, 1990, J BIOL CHEM, V265, P17456; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PAREKH RB, 1992, EUR J BIOCHEM, V203, P135, DOI 10.1111/j.1432-1033.1992.tb19838.x; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; SAKANO KI, 1991, J BIOL CHEM, V266, P20626; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; VAN SJ, 1989, J EXP MED, V169, P363; WARD LD, 1994, J BIOL CHEM, V269, P23286; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	54	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20886	20893		10.1074/jbc.273.33.20886	http://dx.doi.org/10.1074/jbc.273.33.20886			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694835	hybrid			2022-12-27	WOS:000075386100028
J	Chen, XZ; Shayakul, C; Berger, UV; Tian, W; Hediger, MA				Chen, XZ; Shayakul, C; Berger, UV; Tian, W; Hediger, MA			Characterization of a rat Na+-dicarboxylate cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; GLUCOSE COTRANSPORTER; SUCCINATE TRANSPORT; CITRATE TRANSPORT; RENAL METABOLISM; VOLTAGE-CLAMP; VESICLES; ACID; PH; MICROENVIRONMENT	The metabolism of Krebs cycle intermediates is of fundamental importance for eukaryotic cells. In the kidney, these intermediates are transported actively into epithelial cells. Because citrate is a potent inhibitor for calcium stone formation, excessive uptake results in nephrolithiasis due to hypocitraturia. We report the cloning and characterization of a rat kidney dicarboxylate transporter (SDCT1). In situ hybridization revealed that SDCT1 mRNA is localized in 53 segments of kidney proximal tubules and in enterocytes lining the intestinal villi. Signals were also detected in lung bronchioli, the epididymis, and liver, When expressed in Xenopus oocytes, SDCT1 mediated electrogenic, sodium-dependent transport of most Krebs cycle intermediates (K-m = 20-60 ELM), including citrate, succinate, mu-ketoglutarate, and oxaloacetate. Of note, the acidic amino acids L- and D-glutamate and aspartate were also transported, although with lower affinity (K-m = 2-18 mM). Transport of citrate was pH-sensitive. At pH 7.5, the K-m for citrate was high (0.64 mM), whereas at pH 5.5, the K-m was low (57 mu M). This is consistent with the concept that the -2 form of citrate is the transported species. In addition, maximal currents at pH 5.5 were 70% higher than those at pH 7.5, and our data show that the -3 form acts as a competitive inhibitor. Simultaneous measurements of substrate-evoked currents and tracer uptakes under voltage-clamp condition, as well as a thermodynamic approach, gave a Na+ to citrate or a Na+ to succinate stoichiometry of 3 to 1. SDCT1-mediated currents were inhibited by phloretin. This plant glycoside also inhibited the SDCT1-specific sodium leak in the absence of substrate, indicating that at least one Na+ binds to the transporter before the substrate. The data presented provide new insights into the biophysical characteristics and physiological implications of a cloned dicarboxylate transporter.	Harvard Univ, Brigham & Womens Hosp, Inst Med, Div Renal, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Hediger, MA (corresponding author), Harvard Univ, Brigham & Womens Hosp, Inst Med, Div Renal, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	mhediger@rics.bwh.harvard.edu		Hediger, Matthias/0000-0003-1946-027X	NIDDK NIH HHS [DK43171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER S, 1972, J LAB CLIN MED, V79, P505; ANAIZI NH, 1986, AM J PHYSIOL, V251, pF547, DOI 10.1152/ajprenal.1986.251.3.F547; ASPLIN JR, 1996, KIDNEY, P1893; BARACNIETO M, 1984, AM J PHYSIOL, V247, pF282, DOI 10.1152/ajprenal.1984.247.2.F282; BARUCH SB, 1975, MED CLIN N AM, V59, P569, DOI 10.1016/S0025-7125(16)32009-0; BRENNAN TS, 1986, AM J PHYSIOL, V251, pF683, DOI 10.1152/ajprenal.1986.251.4.F683; BURCKHARDT G, 1984, PFLUG ARCH EUR J PHY, V401, P254, DOI 10.1007/BF00582592; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Chen XZ, 1997, BIOPHYS J, V73, P2503, DOI 10.1016/S0006-3495(97)78278-X; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Chen XZ, 1996, BIOPHYS J, V71, P2544, DOI 10.1016/S0006-3495(96)79447-X; FUKUHARA Y, 1983, AM J PHYSIOL, V245, pF374, DOI 10.1152/ajprenal.1983.245.3.F374; HAMM LL, 1990, KIDNEY INT, V38, P728, DOI 10.1038/ki.1990.265; HINTON BT, 1990, J ANDROL, V11, P498; HINTON BT, 1995, MICROSC RES TECHNIQ, V30, P67, DOI 10.1002/jemt.1070300106; HIRAYAMA B, 1986, PFLUG ARCH EUR J PHY, V407, pS174, DOI 10.1007/BF00584948; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; JENKINS AD, 1985, AM J PHYSIOL, V249, pF590, DOI 10.1152/ajprenal.1985.249.4.F590; JORGENSEN KE, 1983, AM J PHYSIOL, V244, pF686, DOI 10.1152/ajprenal.1983.244.6.F686; KEIL M, 1979, ANDROLOGIA, V11, P385; Khatri IA, 1996, BBA-GENE STRUCT EXPR, V1309, P58, DOI 10.1016/S0167-4781(96)00138-8; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; LEVI M, 1991, AM J PHYSIOL, V261, pF767, DOI 10.1152/ajprenal.1991.261.5.F767; Melnick JZ, 1996, J CLIN INVEST, V98, P2381, DOI 10.1172/JCI119051; NICAR MJ, 1983, UROLOGY, V21, P8, DOI 10.1016/0090-4295(83)90113-9; NIETH H, 1966, NATURE, V209, P1244, DOI 10.1038/2091244a0; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PAK CYC, 1987, MINER ELECTROL METAB, V13, P257; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHELL RE, 1985, J PHYSIOL-LONDON, V360, P95, DOI 10.1113/jphysiol.1985.sp015605; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; Segel IH., 1975, ENZYME KINETICS, P227; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMPSON DP, 1983, AM J PHYSIOL, V244, pF223, DOI 10.1152/ajprenal.1983.244.3.F223; ULLRICH KJ, 1984, PFLUG ARCH EUR J PHY, V400, P241, DOI 10.1007/BF00581554; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WRIGHT EM, 1982, P NATL ACAD SCI-BIOL, V79, P7514, DOI 10.1073/pnas.79.23.7514; WRIGHT EM, 1985, ANNU REV PHYSIOL, V47, P127; WRIGHT SH, 1983, J BIOL CHEM, V258, P5456; WRIGHT SH, 1982, J BIOL CHEM, V257, P1773; WRIGHT SH, 1982, BIOCHIM BIOPHYS ACTA, V684, P287, DOI 10.1016/0005-2736(82)90019-0; WRIGHT SH, 1980, J MEMBRANE BIOL, V57, P73, DOI 10.1007/BF01868987; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF432, DOI 10.1152/ajprenal.1987.253.3.F432; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	48	101	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20972	20981		10.1074/jbc.273.33.20972	http://dx.doi.org/10.1074/jbc.273.33.20972			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694847	hybrid			2022-12-27	WOS:000075386100040
J	Liang, C; Rong, LW; Gotte, M; Li, XG; Quan, YD; Kleiman, L; Wainberg, MA				Liang, C; Rong, LW; Gotte, M; Li, XG; Quan, YD; Kleiman, L; Wainberg, MA			Mechanistic studies of early pausing events during initiation of HIV-1 reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER BINDING-SITE; YEAST TY1 RETROTRANSPOSON; NUCLEOCAPSID PROTEIN; NUCLEOTIDE-SEQUENCE; DNA-SYNTHESIS; TRANSFER-RNA; SECONDARY STRUCTURE; TRNA(3)(LYS); ELONGATION	We have investigated the role of sequences that surround the primer binding site (PBS) in the reverse transcriptase-mediated initiation of (-) strand DNA synthesis in human immunodeficiency virus type I. In comparisons of reverse transcription initiated from either the cognate primer tRNALys.3 or a DNA primer D-Lys.3, bound to PBS sequences, we observed that a +3 pausing site occurred in both circumstances, However, the initiation reaction with tRNALys.3 was also characterized by a pausing event after incorporation of the first nucleotide, Alteration of sequences at the 5'-end instead of the 3'-end of the PBS resulted in elimination of the +3 pausing site, suggesting that this site was template sequence-dependent. In contrast, the pausing event at the +1 nucleotide position was still present in experiments that employed either of these mutated RNA templates. The mutations at the 5'-end of the PBS also caused a severely diminished rate of initiation and the strong arrest of reactions at the fl stage when tRNALys.3 was used as primer. Therefore, we propose that the ct pausing event is an initiation-specific event in regard to reactions primed by tRNALys.3 and that sequences at the 5'-end of the PBS may facilitate the release of reverse transcription from initiation to elongation.	McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3A 2B4, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Wainberg, MA (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.							ALYAR A, 1994, J VIROL, V68, P611; ALYAR A, 1992, J VIROL, V66, P2464; Berkhout B, 1997, NUCLEIC ACIDS RES, V25, P4013, DOI 10.1093/nar/25.20.4013; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; Essink BBO, 1996, J MOL BIOL, V264, P243, DOI 10.1006/jmbi.1996.0638; Friant S, 1996, NUCLEIC ACIDS RES, V24, P441, DOI 10.1093/nar/24.3.441; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; HARADA F, 1979, J BIOL CHEM, V254, P979; HARADA F, 1975, J BIOL CHEM, V250, P3487; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Isel C, 1998, NUCLEIC ACIDS RES, V26, P1198, DOI 10.1093/nar/26.5.1198; ISEL C, 1993, J BIOL CHEM, V268, P25269; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; KATI WM, 1992, J BIOL CHEM, V267, P25988; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Lanchy JM, 1996, BIOCHIMIE, V78, P1087, DOI 10.1016/S0300-9084(97)86734-X; Li XG, 1997, J VIROL, V71, P6003, DOI 10.1128/JVI.71.8.6003-6010.1997; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; Liang C, 1997, J VIROL, V71, P5750, DOI 10.1128/JVI.71.8.5750-5757.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; SKALKA A, 1993, REVERSE TRANSCRIPTAS; Skripkin E, 1996, NUCLEIC ACIDS RES, V24, P509, DOI 10.1093/nar/24.3.509; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1993, CELL, V75, P1071, DOI 10.1016/0092-8674(93)90317-J; WILHELM M, 1994, NUCLEIC ACIDS RES, V22, P4560, DOI 10.1093/nar/22.22.4560; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	39	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21309	21315		10.1074/jbc.273.33.21309	http://dx.doi.org/10.1074/jbc.273.33.21309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694891	hybrid			2022-12-27	WOS:000075386100084
J	Rui, LY; Carter-Su, C				Rui, LY; Carter-Su, C			Platelet-derived growth factor (PDGF) stimulates the association of SH2-B beta with PDGF receptor and phosphorylation of SH2-B beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; INSULIN-RECEPTOR; SH2 DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; TRYPTOPHAN-HYDROXYLASE; PROTEIN; IDENTIFICATION; ACTIVATION	We recently identified SH2-B beta as a JAK2-binding protein and substrate involved in the signaling of receptors for growth hormone and interferon-gamma. In this work, we report that SH2-B beta also functions as a signaling molecule for platelet-derived growth factor (PDGF). SH2-B beta fused to glutathione S-transferase (GST) bound PDGF receptor (PDGFR) from PDGF-treated but not control cells. GST fusion protein containing only the SH2 domain of SH2-B beta also bound PDGFR from PDGF-treated cells. An Arg to Glu mutation within the FLVRQS motif in the SH2 domain of SH2-B beta inhibited GST-SH2-B beta binding to tyrosyl-phosphorylated PDGFR. The N-terminal truncated SH2-B beta containing the entire SH2 domain interacted directly with tyrosyl-phosphorylated PDGFR from PDGF-treated cells but not unphosphorylated PDGFR from control cells in a Far Western assay. These results suggest that the SH2 domain of SH2-B beta is necessary and sufficient to mediate the interaction between SH2-B beta and PDGFR. PDGF stimulated coimmunoprecipitation of endogenous SH2-B beta with endogenous PDGFR, in both 3T3-F442A and NIH3T3 cells. PDGF stimulated the rapid and transient phosphorylation of SH2-B beta on tyrosines and most likely on serines and/or threonines. Similarly, epidermal growth factor stimulated the phosphorylation of SH2-B beta; however, phosphorylation appears to be predominantly on serines and/or threonines. In response to PDGF, SH2-B beta associated with multiple tyrosyl-phosphorylated proteins, at least one of which (designated p84) does not bind to PI]GFR. Taken together, these data strongly argue that, in response to PDGF, SH2-B beta directly interacts with PDGFR and is phosphorylated on tyrosine and most likely on serines and/or threonines, and acts as a signaling protein for PDGFR.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.				NIAMS NIH HHS [P60-AR20557] Funding Source: Medline; NIDDK NIH HHS [P60-DK-20572, DK 34171, R01 DK034171] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, P60DK020572, R01DK034171] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Craparo A, 1997, J BIOL CHEM, V272, P11663; FURUKAWA Y, 1993, BIOCHEM BIOPH RES CO, V194, P144, DOI 10.1006/bbrc.1993.1796; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Ichimura T, 1997, FEBS LETT, V413, P273, DOI 10.1016/S0014-5793(97)00910-1; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; INUI H, 1994, J BIOL CHEM, V269, P30546; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; Ma HP, 1996, AM J PHYSIOL-RENAL, V271, pF994, DOI 10.1152/ajprenal.1996.271.5.F994; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Ruusala A, 1998, J CELL SCI, V111, P111; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TANTI JF, 1994, J BIOL CHEM, V269, P6051; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHU GC, 1993, J BIOL CHEM, V268, P1775	36	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21239	21245		10.1074/jbc.273.33.21239	http://dx.doi.org/10.1074/jbc.273.33.21239			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694882	hybrid			2022-12-27	WOS:000075386100075
J	Carman, CV; Som, T; Kim, CM; Benovic, JL				Carman, CV; Som, T; Kim, CM; Benovic, JL			Binding and phosphorylation of tubulin by G protein-coupled receptor kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ASSOCIATION; ACTIVATION; PURIFICATION; MICROTUBULES; EXPRESSION; MEMBRANES; ISOTYPE; ALPHA	Although the beta-adrenergic receptor kinase (beta ARK) mediates agonist-dependent phosphorylation and desensitization of G protein-coupled receptors, recent studies suggest additional cellular functions. During our attempts to identify novel beta ARK interacting proteins, we found that the cytoskeletal protein tubulin could specifially bind to a beta ARR-coupled affinity column. In vitro analysis demonstrated that beta ARK and G protein-coupled receptor kinase-5 (GRK5) mere able to stoichiometrically phosphorylate purified tubulin dimers with a preference for beta-tubulin and, under certain conditions, the beta III-isotype. Examination of the GRK/tubulin binding characteristics revealed that tubulin dimers and assembled microtubules bind GRKs, whereas the catalytic domain of beta ARK contains the primary tubulin binding determinants. In vivo interaction of GRK and tubulin was suggested by the following: (i) co-purification of beta ARK with tubulin from brain tissue; (ii) co-immunoprecipitation of beta ARR and tubulin from COS-l cells; and (iii) co-localization of beta ARK and GRK5 with microtubule structures in COS-l cells. In addition, GRK-phosphorylated tubulin was found preferentially associated with the microtubule fraction during in vitro assembly assays suggesting potential functional significance. These results suggest a novel link between the cytoskeleton and GRKs that may be important for regulating GRK and/or tubulin function.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Mol Pharmacol & Biochem, 233 S 10th St, Philadelphia, PA 19107 USA.		Carman, Christopher/L-8108-2016; Carman, Christopher V./AAX-8995-2020	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548	NATIONAL CANCER INSTITUTE [T32CA009662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09662] Funding Source: Medline; NIGMS NIH HHS [GM47419, GM44944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Choi DJ, 1997, J BIOL CHEM, V272, P17223, DOI 10.1074/jbc.272.27.17223; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; HARGREAVES AJ, 1986, NATURE, V323, P827, DOI 10.1038/323827a0; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KELLY WG, 1983, J CELL BIOL, V97, P1197; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; MANDELKOW EM, 1992, CELL MOTIL CYTOSKEL, V22, P235, DOI 10.1002/cm.970220403; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; NARISHIGE T, 1997, CIRCULATION, V96, P495; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; ONORATO JJ, 1995, J BIOL CHEM, V270, P21346, DOI 10.1074/jbc.270.36.21346; Pedrotti B, 1996, FEBS LETT, V388, P131, DOI 10.1016/0014-5793(96)00520-0; PFEFFER SR, 1983, J CELL BIOL, V97, P40, DOI 10.1083/jcb.97.1.40; Ping PP, 1997, AM J PHYSIOL-HEART C, V273, pH707, DOI 10.1152/ajpheart.1997.273.2.H707; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; ROYCHOWDHURY S, 1994, BIOCHEMISTRY-US, V33, P9800, DOI 10.1021/bi00198a052; Roychowdhury S, 1997, J BIOL CHEM, V272, P31576, DOI 10.1074/jbc.272.50.31576; RuizGomez A, 1997, J BIOL CHEM, V272, P9601; SATO H, 1997, J CELL BIOL, V139, P163; Saunders C, 1997, J BIOL CHEM, V272, P19035, DOI 10.1074/jbc.272.30.19035; SERRANO L, 1987, J CELL BIOL, V105, P1731, DOI 10.1083/jcb.105.4.1731; SERRANO L, 1989, EXP CELL RES, V181, P263, DOI 10.1016/0014-4827(89)90200-0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; TSUTSUI H, 1994, CIRCULATION, V90, P533, DOI 10.1161/01.CIR.90.1.533; WANG N, 1990, J BIOL CHEM, V265, P1239; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1868; WHATLEY VJ, 1994, J BIOL CHEM, V269, P19546; YAMAMOTO H, 1985, J NEUROCHEM, V44, P759, DOI 10.1111/j.1471-4159.1985.tb12880.x	45	108	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20308	20316		10.1074/jbc.273.32.20308	http://dx.doi.org/10.1074/jbc.273.32.20308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685381	hybrid			2022-12-27	WOS:000075305400058
J	Foster, LC; Arkonac, BM; Sibinga, NES; Shi, CW; Perrella, MA; Haber, E				Foster, LC; Arkonac, BM; Sibinga, NES; Shi, CW; Perrella, MA; Haber, E			Regulation of CD44 gene expression by the proinflammatory cytokine interleukin-1 beta in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; EXTRACELLULAR-MATRIX; GAMMA-INTERFERON; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; ATHEROSCLEROTIC PLAQUES; ADHESION MOLECULE-1; ACTIVATION; HYALURONATE; TRANSCRIPTION	The CD44 gene codes for a family of alternatively spliced, multifunctional adhesion molecules that participate in extracellular matrix binding, lymphocyte activation, cell migration, and tumor metastasis. In a mouse model of transplant-associated arteriosclerosis, CD44 protein was induced in the neointima of allografted vessels and colocalized with a subset of proliferating vascular smooth muscle cells (SMC). To elucidate the molecular mechanisms regulating CD44 expression in this model, we investigated the regulation of CD44 gene expression by interleukin (IL)-1 beta. Treatment of rat aortic SMC with IL-1 beta resulted in a 5.3-fold increase in cell surface CD44 expression. Northern analysis showed that IL-1 beta promoted a dose- and time-dependent induction of CD44 mRNA which reached 6.6-fold after 48 h, and nuclear run-on analysis showed that IL-1 beta increased the rate of CD44 gene transcription within 8 h of stimulation. In transient reporter gene transfection experiments in rat aortic SMC, a 1.4-kilobase fragment of the mouse CD44 5'-flanking sequence mediated this response to IL-1 beta, Regulation of CD44 gene expression by the proinflammatory cytokine IL-1 beta may contribute to SMC phenotypic modulation in the pathogenesis of arteriosclerosis.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Perrella, MA (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.	perrella@cvlab.harvard.edu	Sibinga, Nicholas/GOJ-8544-2022	Sibinga, Nicholas/0000-0003-4838-910X				ALHO AM, 1989, J CELL BIOL, V108, P1557, DOI 10.1083/jcb.108.4.1557; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; COUFFINHAL T, 1994, CIRC RES, V74, P225, DOI 10.1161/01.RES.74.2.225; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GAY CG, 1991, P NATL ACAD SCI USA, V88, P296, DOI 10.1073/pnas.88.1.296; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Gunthert U, 1993, Curr Top Microbiol Immunol, V184, P47; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANSSON GK, 1991, CIRCULATION, V84, P1266, DOI 10.1161/01.CIR.84.3.1266; HOFMANN M, 1993, CANCER RES, V53, P1516; Jain M, 1996, J CLIN INVEST, V97, P596, DOI 10.1172/JCI118455; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; LEIBSON HJ, 1984, NATURE, V309, P799, DOI 10.1038/309799a0; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; MOLOSSI S, 1995, J CELL PHYSIOL, V163, P19, DOI 10.1002/jcp.1041630104; MOYER CF, 1991, AM J PATHOL, V138, P951; NILSSON J, 1993, CARDIOVASC RES, V27, P1184, DOI 10.1093/cvr/27.7.1184; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; PACE JL, 1983, J IMMUNOL, V130, P2011; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; PIERRES A, 1992, EUR J IMMUNOL, V22, P413, DOI 10.1002/eji.1830220219; PORRECA E, 1993, ATHEROSCLEROSIS, V99, P71, DOI 10.1016/0021-9150(93)90052-V; RAINES EW, 1993, BRIT HEART J, V69, pS30; Riessen R, 1996, CIRCULATION, V93, P1141, DOI 10.1161/01.CIR.93.6.1141; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHI CW, 1994, CIRC RES, V75, P199, DOI 10.1161/01.RES.75.2.199; Shi CW, 1996, P NATL ACAD SCI USA, V93, P4051, DOI 10.1073/pnas.93.9.4051; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SIDMAN CL, 1984, NATURE, V309, P801, DOI 10.1038/309801a0; SKINNER MP, 1994, AM J PATHOL, V145, P1070; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; STJOHN T, 1990, CELL, V60, P45, DOI 10.1016/0092-8674(90)90714-P; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zhang M, 1997, J BIOL CHEM, V272, P14139, DOI 10.1074/jbc.272.22.14139; ZHOU DFH, 1989, J IMMUNOL, V143, P3390	48	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20341	20346		10.1074/jbc.273.32.20341	http://dx.doi.org/10.1074/jbc.273.32.20341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685385	hybrid			2022-12-27	WOS:000075305400062
J	O'Bryan, JP; Lambert, QT; Der, CJ				O'Bryan, JP; Lambert, QT; Der, CJ			The Src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN; AUTOPHOSPHORYLATION SITES; TYROSINE PHOSPHATASE; PHOSPHORYLATION; ASSOCIATION; KINASE; TRANSDUCTION; ACTIVATION; PATHWAYS; ASSAYS	Upon ligand activation, the epidermal growth factor receptor (EGFR) becomes tyrosine-phosphorylated, thereby recruiting intracellular signaling protei:ns such as Shc. EGFR binding of Shc proteins results in their tyrosine phosphorylation and subsequent activation of the Ras and Erk pathways. Shc interaction wi th activated receptor tyrosine kinases is mediated by two distinct phosphotyrosine interaction domains, an NH2-terminal phosphotyrosine binding (PTB) domain and a COOH-terminal Src homology 2 (SH2) domain. The relative importance of these two domains for EGFR binding was examined by determining if expression of the isolated SH2 or PTB domain of ShcC would inhibit EGFR signaling. The SH2 domain potently inhibited numerous aspects of EGFR signaling including activation of Erb2 and the Elk-1 transcription factor as well as EGFR-dependent transformation. Furthermore, the SH2 domain inhibited focus formation by the Neu oncoprotein, another EGFR family member. Surprisingly, inhibition of the EGFR by the SH2 domain did not involve stable association with the receptor. In contrast, the PTB domain associated quite well with the receptor yet had little effect on EGFR signaling. Although the EGFR cytoplasmic tail contains consensus binding sites for the PTB and SH2 domains of ShcC, and both domains of ShcC interact with the receptor in vitro, the SH2 domain is more potent for inhibiting receptor function in vivo. However, inhibition is not due to stable association with the receptor, suggesting that the SH2 domain is binding to a heretofore unknown protein(s) necessary for proper EGFR function.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	O'Bryan, JP (corresponding author), NIEHS, NIH, POB 12233,Bldg Rm 101-F332,MD F3-06, Res Triangle Pk, NC 27709 USA.	obryan@niehs.nih.gov		O'Bryan, John/0000-0001-5386-1080; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R29CA076570, F32CA068733] Funding Source: NIH RePORTER; NCI NIH HHS [CA76570, CA42978, CA68733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BONFINI L, 1996, TRENDS BIOCHEM SCI, V21, P259; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gotoh N, 1995, ONCOGENE, V11, P2525; HABIB T, 1994, J BIOL CHEM, V269, P25243; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; LI NX, 1994, ONCOGENE, V9, P3457; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nakamura T, 1996, ONCOGENE, V13, P1111; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OBryan JP, 1996, J BIOL CHEM, V271, P11787, DOI 10.1074/jbc.271.20.11787; Okabayashi Y, 1996, J BIOL CHEM, V271, P5265; Okada S, 1997, J BIOL CHEM, V272, P28042, DOI 10.1074/jbc.272.44.28042; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; SOLER C, 1994, ONCOGENE, V9, P2207; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Xu YR, 1997, J BIOL CHEM, V272, P13463, DOI 10.1074/jbc.272.21.13463; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; YOUMING X, 1995, ONCOGENE, V10, P2409; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119	43	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20431	20437		10.1074/jbc.273.32.20431	http://dx.doi.org/10.1074/jbc.273.32.20431			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685397	Green Published, hybrid			2022-12-27	WOS:000075305400074
J	Poussin, C; Foti, M; Carpentier, JL; Pugin, J				Poussin, C; Foti, M; Carpentier, JL; Pugin, J			CD14-dependent endotoxin internalization via a macropinocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LPS-BINDING-PROTEIN; MONOCYTE DIFFERENTIATION ANTIGEN; LIPOPOLYSACCHARIDE LPS; SIGNAL-TRANSDUCTION; BACTERIAL LIPOPOLYSACCHARIDE; HUMAN-NEUTROPHILS; MEMBRANE DOMAINS; EPITHELIAL-CELLS; CD14; RECEPTOR	Gram-negative bacterial endotoxin (a lipopolysaccharide (LPS)) specifically binds to CD14, a glycosylphosphatidyl inositol (GPI)-anchored surface myeloid glycoprotein. This interaction leads to cell activation, but it also promotes LPS internalization and detoxification, In this work, we investigated the route of LPS and CD14 internalization and the relevance of CD14 GPI anchor in the endocytic pathway. In promonocytic THP-1 cells transfected with a GPI or a chimeric integral form of CD14, we showed by differential buoyancy in sucrose density gradients that these two forms of CD14 were sorted to different plasma membrane subdomains. However, both forms of CD14 associated preferentially with the same surface microfilament-enriched microvilli or ruffles. Electron microscopic studies indicated that CD14 internalized via macropinocytosis, a process resembling that of phagocytosis, different from "classical" receptor-mediated endocytic pathways, such as clathrin-coated pits or caveolae. With cell warming, the CD14-enriched ruffles fused and formed large vesicles. Later, these vacuoles made stacks and condensed into phago-lysosomes. CD14 was specifically associated with all of these structures, Radiolabeled LPS internalization paralleled CD14 internalization. Confocal microscopic studies confirmed the co-localization of LPS and CD14 both at the cell surface and in endosomal compartments. The microfilament-disrupting, macropinocytosis blocking agent cytochalasin D inhibited LPS and CD14 internalization but did not prevent LPS-dependent activation, indicating that these two processes are dissociated.	Univ Hosp Geneva, Dept Med, Div Med Intens Care, CH-1211 Geneva 14, Switzerland; Univ Geneva, Fac Med, Dept Morphol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Pugin, J (corresponding author), Univ Hosp Geneva, Dept Med, Div Med Intens Care, 24 r Micheli du Crest, CH-1211 Geneva 14, Switzerland.			Foti, Michelangelo/0000-0001-7199-4135				ALLISON AC, 1971, NATURE-NEW BIOL, V232, P153; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; BAMEZAI A, 1989, J IMMUNOL, V143, P3107; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CARPENTIER JL, 1991, CELL REGUL, V2, P41, DOI 10.1091/mbc.2.1.41; CARPENTIER JL, 1993, J CELL BIOL, V122, P1243, DOI 10.1083/jcb.122.6.1243; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Detmers PA, 1996, J IMMUNOL, V157, P5589; DETMERS PA, 1987, J CELL BIOL, V105, P1137, DOI 10.1083/jcb.105.3.1137; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FRA AM, 1994, J BIOL CHEM, V269, P30745; FRANCIS CL, 1993, NATURE, V364, P639, DOI 10.1038/364639a0; GALLAY P, 1993, J IMMUNOL, V150, P5086; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Grassme HUC, 1996, INFECT IMMUN, V64, P1621; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HAZIOT A, 1988, J IMMUNOL, V141, P547; HOREJSI V, 1988, FOLIA BIOL-PRAGUE, V34, P23; Ilangumaran S, 1996, ANAL BIOCHEM, V235, P49, DOI 10.1006/abio.1996.0090; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; KANG YH, 1990, J LEUKOCYTE BIOL, V48, P316, DOI 10.1002/jlb.48.4.316; Kitchens RL, 1998, J IMMUNOL, V160, P1920; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; KRIEGSMANN J, 1993, CELL MOL BIOL, V39, P791; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; OSHEA JJ, 1985, J IMMUNOL, V135, P1325; PETERSON PK, 1995, INFECT IMMUN, V63, P1598, DOI 10.1128/IAI.63.4.1598-1602.1995; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RITTER TE, 1995, P NATL ACAD SCI USA, V92, P3824, DOI 10.1073/pnas.92.9.3824; Schiff DE, 1997, J LEUKOCYTE BIOL, V62, P786, DOI 10.1002/jlb.62.6.786; Shibata Y, 1996, J IMMUNOL, V156, P772; SIMMONS DL, 1989, BLOOD, V73, P284; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; TAUSK F, 1989, J IMMUNOL, V143, P3295; TOBIAS PS, 1993, J IMMUNOL, V150, P3011; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; Wang Ping-Yuan, 1995, Journal of Inflammation, V47, P126; WRIGHT SD, 1991, CURR OPIN IMMUNOL, V3, P83, DOI 10.1016/0952-7915(91)90082-C; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	49	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20285	20291		10.1074/jbc.273.32.20285	http://dx.doi.org/10.1074/jbc.273.32.20285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685378	hybrid			2022-12-27	WOS:000075305400055
J	Yokoyama, K; Muneyuki, E; Amano, T; Mizutani, S; Yoshida, M; Ishida, M; Ohkuma, S				Yokoyama, K; Muneyuki, E; Amano, T; Mizutani, S; Yoshida, M; Ishida, M; Ohkuma, S			V-ATPase of Thermus thermophilus is inactivated during ATP hydrolysis but can synthesize ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; APPARENT NEGATIVE COOPERATIVITY; NUCLEOTIDE BINDING-SITES; MEMBRANE-BOUND ATPASE; VACUOLAR H+-ATPASE; BOVINE HEART; SULFOLOBUS-ACIDOCALDARIUS; ESCHERICHIA-COLI; CATALYTIC SITES; BACILLUS PS3	The ATP hydrolysis of the V-1-ATPase of Thermus thermophilus have been investigated with an ATP-regenerating system at 25 degrees C, The ratio of ATPase activity to ATP concentration ranged from 40 to 4000 mu M; from this, an apparent K-m of 240 +/- 24 mu M and a V-max of 5.2 +/-0.5 units/mg were deduced. An apparent negative cooperativity, which is frequently observed in case of F-1-ATPases, was not observed for the V-1-ATPase, Interestingly, the rate of hydrolysis decayed rapidly during ATP hydrolysis, and the ATP hydrolysis finally stopped. Furthermore, the inactivation of the V-1-ATPase was attained by a prior incubation with ADP-Mg. The inactivated V-1-ATPase contained 1.5 mol of ADP/mol of enzyme. Difference absorption spectra generated from addition of ATP-Mg to the isolated subunits revealed that the A subunit can bind ATP-Mg, whereas the B subunit cannot. The inability to bind ATP-Mg is consistent with the absence of Walker motifs in the B subunit, These results indicate that the inactivation of the V-1-ATPase during ATP hydrolysis is caused by entrapping inhibitory ADP-Mg in a catalytic site. Light-driven ATP synthesis by bacteriorhodopsin-VoV1-ATPase proteoliposomes was observed, and the rate of ATP synthesis was approximately constant. ATP synthesis occurred in the presence of an ADP-Mg of which concentration was high enough to induce complete inactivation of ATP hydrolysis of VoV1-ATPase, This result indicates that the ADP-Mg-inhibited form is not produced in ATP synthesis reaction.	Kanazawa Univ, Fac Pharmaceut Sci, Dept Biochem, Kanazawa, Ishikawa 920, Japan; Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan; Tokyo Univ Fishers, Lab Biochem Marine Resources, Minato Ku, Tokyo 108, Japan	Kanazawa University; Tokyo Institute of Technology	Yokoyama, K (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, Dept Biochem, 13-1 Takara Machi, Kanazawa, Ishikawa 920, Japan.	yokoken@kenroku.kanazawa-u.ac.jp	ISHIDA, Masami/O-1909-2014; Yokoyama, Ken/AAJ-3582-2020	Yokoyama, Ken/0000-0002-6813-1096				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; ARAI K, 1993, J BIOL CHEM, V268, P5649; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CROSS RL, 1982, J BIOL CHEM, V257, P2101; EBEL RE, 1975, J BIOL CHEM, V250, P191; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRESSER MJ, 1982, J BIOL CHEM, V257, P2030; HISABORI T, 1992, J BIOL CHEM, V267, P4551; HONER ZU, 1997, J BACTERIOL, V179, P1274; INATOMI K, 1986, J BACTERIOL, V167, P837, DOI 10.1128/jb.167.3.837-841.1986; Jault JM, 1996, J BIOL CHEM, V271, P28818, DOI 10.1074/jbc.271.46.28818; JAULT JM, 1993, J BIOL CHEM, V268, P1558; JAULT JM, 1994, J BIOL CHEM, V269, P319; KAKINUMA Y, 1990, FEBS LETT, V271, P97, DOI 10.1016/0014-5793(90)80381-R; KATO Y, 1995, BBA-BIOENERGETICS, V1231, P275, DOI 10.1016/0005-2728(95)00087-Y; KIBAK H, 1993, J BIOL CHEM, V268, P23325; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; LUBBEN M, 1989, J BACTERIOL, V171, P6106; MATSUDA C, 1994, BIOCHEM BIOPH RES CO, V200, P671, DOI 10.1006/bbrc.1994.1503; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MCKAY A, 1982, ARCH MICROBIOL, V131, P43, DOI 10.1007/BF00451497; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MUKOHATA Y, 1986, J BIOCH, V101, P1; MUNEYUKI E, 1988, FEBS LETT, V234, P455, DOI 10.1016/0014-5793(88)80137-6; Muneyuki E, 1996, J BIOCHEM-TOKYO, V120, P940; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; MUNEYUKI E, 1994, BBA-BIOENERGETICS, V1188, P108, DOI 10.1016/0005-2728(94)90028-0; NANBA T, 1987, J BIOCHEM-TOKYO, V102, P591, DOI 10.1093/oxfordjournals.jbchem.a122092; OESTERHELT D, 1973, P NATL ACAD SCI USA, V70, P2853, DOI 10.1073/pnas.70.10.2853; OSHIMA T, 1974, INT J SYST BACTERIOL, V24, P102, DOI 10.1099/00207713-24-1-102; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; VASILYEVA E, 1997, J BIOL CHEM, V272, P12775; VASILYEVA EA, 1982, BIOCHEM J, V202, P9, DOI 10.1042/bj2020009; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; YOKOYAMA K, 1990, J BIOL CHEM, V265, P21946; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494	45	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20504	20510		10.1074/jbc.273.32.20504	http://dx.doi.org/10.1074/jbc.273.32.20504			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685406	hybrid			2022-12-27	WOS:000075305400083
J	Burgers, PMJ; Gerik, KJ				Burgers, PMJ; Gerik, KJ			Structure and processivity of two forms of Saccharomyces cerevisiae DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-C; S-PHASE; EPSILON; PURIFICATION; TEMPLATE; ANALOG; ORIGIN; ERRORS	Yeast DNA polymerase delta (Pol delta) consists of three subunits encoded by the POL3, POL31, and POL32 genes. Each of these genes was cloned under control of the galactose-inducible GAL1-10 promoter and overexpressed in various combinations. Overexpression of all three genes resulted in a 30-fold overproduction of Pol delta, which was identical in enzymatic properties to Pol delta isolated from a wild-type yeast strain. Whereas overproduction of POL3 together with POL32 did not lead to an identifiable Pol3p.Pol32p complex, a chromatographically distinct and novel complex was identified upon overproduction of POL3 and POL31, This two-subunit complex, designated Pol delta*:, is structurally and functionally analogous to mammalian Pol delta. The properties of Pol delta* and Pol delta were compared. A gel filtration analysis showed that Pol delta* is a heterodimer (Pol3p.Pol31p) and Pol delta a dimer of a heterotrimer, (Pol3p.Pol31p.Pol32p)(2). In the absence of proliferating cell nuclear antigen (PCNA), Pol delta* showed a processivity of 2-3 on poly(dA) oligo(dT) compared with 5-10 for Pol delta. In the presence of PCNA, both enzymes were fully processive on this template. DNA replication by Pol delta* on a natural DNA template was dependent on PCNA and on replication factor C. However, Pol delta*-mediated DNA synthesis proceeded inefficiently and was characterized by frequent pause sites. Reconstitution of Pol delta was achieved upon addition of Pol32p to Pol delta.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, J BIOL CHEM, V263, P917; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1988, J BIOL CHEM, V263, P925; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Giot L, 1997, GENETICS, V146, P1239; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; Hindges R, 1997, BIOL CHEM, V378, P345; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MURAKAMI Y, 1993, J BIOL CHEM, V268, P11008; NG L, 1993, J BIOL CHEM, V268, P13571; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108; Shcherbakova PV, 1996, GENETICS, V142, P717; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; YODER BL, 1991, J BIOL CHEM, V266, P22689; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	34	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19756	19762		10.1074/jbc.273.31.19756	http://dx.doi.org/10.1074/jbc.273.31.19756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677406	hybrid			2022-12-27	WOS:000075125200058
J	Zhang, CJ; Cavenagh, MM; Kahn, RA				Zhang, CJ; Cavenagh, MM; Kahn, RA			A family of Arf effectors defined as suppressors of the loss of Arf function in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; GTPASE-ACTIVATING PROTEIN; STATIONARY-PHASE; CHOLERA-TOXIN; TRANSPORT; COFACTOR; REENTRY; DNA	Arf proteins are ubiquitous, eukaryotic regulators of virtually every step of vesicular membrane traffic. ADP-ribosylation factors are essential in yeast and the lethality resulting from either overexpression or underexpression (deletion) of Arf genes has previously been ascribed to dysregulation of the secretory process. We have identified a family of four genes (Suppressors of Arf t(s), SAT) as high copy suppressors of a loss of function allele of ARF1 (arf1-3), Those proteins with SAT activity were found to contain a minimal consensus motif, including a C2C2H2 cluster with a novel and specific spacing. Genetic interactions between members of this family and with ARF1 are consistent with each sharing a common cellular pathway, Included in this family is Gcs1, a protein previously described (Poon, P. P., Wang, X., Rotman, M., Huber, I., Cukierman, E., Cassel, D., Singer, R. A. and Johnston, G. C. (1996) Proc. Natl. Acad, Sci. U. S. A. 93, 10074-10077) to possess Arf GTPase-activating protein (GAP) activity, demonstrating a direct interaction between Arf and at least one of these suppressors, The suppression of the loss of Arf function by overexpression of Gcs1 and demonstration of direct, preferential binding of Gcs1 to the activated form of Arf (Arf GTP) lead us to conclude that the biological role of Gcs1 is as an effector of the essential function of Arf in mitotic growth, rather than a down-regulator as implied by the biochemical (Arf GAP) activity. Suppression of the growth defect of al arf1(-3) cells was observed under conditions that did not alter the secretory defect associated with arf1(-) mutation, indicating that the essential role of Arf in eukaryotes can be distinguished from role(s) in the secretory pathway and appear to employ distinct pathways and effectors.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Emory University	Kahn, RA (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	rkahn@bimcore.emory.edu	Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [GM55823] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055823] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DREBOT MA, 1987, P NATL ACAD SCI USA, V84, P7948, DOI 10.1073/pnas.84.22.7948; FILIPAK M, 1992, CURR GENET, V22, P471, DOI 10.1007/BF00326412; HammondsOdie LP, 1996, J BIOL CHEM, V271, P18859, DOI 10.1074/jbc.271.31.18859; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Leung DW, 1989, TECHNIQUE, V1, P11; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; RUDGE SA, 1998, IN PRESS MOL BIOL CE; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1974, METHODS YEAST GENETI; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	28	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19792	19796		10.1074/jbc.273.31.19792	http://dx.doi.org/10.1074/jbc.273.31.19792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677411	hybrid			2022-12-27	WOS:000075125200063
J	Khwaja, A; Lehmann, K; Marte, BM; Downward, J				Khwaja, A; Lehmann, K; Marte, BM; Downward, J			Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MET RECEPTOR; C-MET; R-RAS; PROTEIN CAUSES; MDCK CELLS; TRANSFORMATION; MORPHOGENESIS	Hepatocyte growth factor/scatter factor (HGF/SF) treatment of the Madin-Darby canine kidney epithelial cell line causes scattering of cells grown in monolayer culture and the formation of branching tubules by cells grown in collagen gels. HGF/SF causes prolonged activation of both the mitogen-activated protein (MAP) kinase extracellular signal-regulated kinase 2 (ERK2) and the phosphoinositide 3-OH kinase (PI 3-kinase) target protein kinase B (PKB)/ Akt; inhibition of either the MAP kinase pathway by the MAP kinase/ERK kinase inhibitor PD98059 or the PI 3-kinase pathway by LY294002 blocks HGF/SF induction of scattering, although in morphologically distinct ways. Expression of constitutively activated PI 3-kinase, Pas, or R-Ras will cause scattering, but activated Raf will not, indicating that activation of the MAP kinase pathway is not sufficient for this response. Downstream of PI 3-kinase, activated PKB/Akt and Pac are both unable to induce scattering, implicating a novel pathway. Scattering induced by Pas or PI 3-kinase is sensitive to PD98059, as well as to LY294002, suggesting that basal MAP kinase activity is required, but not sufficient, for the scattering response. Induction of MDCk cell tubulogenesis in collagen gels by HGF/SF is inhibited by PD98059; expression of activated Pas and Raf causes disorganized growth in this system, but activated PI 3-kinase or R-Ras causes branching tubule formation similar to that seen with HGF/SF treatment. These data indicate that multiple signaling pathways acting downstream of Met and Pas are needed for these morphological effects; scattering is induced primarily by the PI 3-kinase pathway, which acts through effecters, other than PKB/Akt or Pac and requires at least basal MAP kinase function. Elevated PI 3-kinase activity induces tubulogenesis, but total inhibition and excess activation of the MAP kinase pathway both oppose this effect.	Imperial Canc Res Fund, London WC2A 3PX, England	Cancer Research UK	Downward, J (corresponding author), Imperial Canc Res Fund, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@icrf.icnet.uk	Khwaja, Asim/C-1509-2008	Downward, Julian/0000-0002-2331-4729				BARDELLI A, 1992, ONCOGENE, V7, P1973; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CLARK P, 1994, J CELL SCI, V107, P1265; COX AD, 1994, ONCOGENE, V9, P3281; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LU PJ, 1995, J CELL BIOL, V129, P1363, DOI 10.1083/jcb.129.5.1363; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; SAEZ R, 1994, ONCOGENE, V9, P2977; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	52	200	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18793	18801		10.1074/jbc.273.30.18793	http://dx.doi.org/10.1074/jbc.273.30.18793			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668053	hybrid			2022-12-27	WOS:000074974700020
J	Zhang, ZS; Devarajan, P; Dorfman, AL; Morrow, JS				Zhang, ZS; Devarajan, P; Dorfman, AL; Morrow, JS			Structure of the ankyrin-binding domain of alpha-Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B PROTEINS; ALPHA-SUBUNIT; PLASMA-MEMBRANE; MOLECULAR-CLONING; SPECTRIN; RECEPTOR; IDENTIFICATION; NA,K-ATPASE; BETA; NA+,K+-ATPASE	The ankyrin 33-residue repeating motif, an L-shaped structure with protruding beta-hairpin tips, mediates specific macromolecular interactions with cytoskeletal, membrane, and regulatory proteins. The association between ankyrin and alpha-Na,K-ATPase, a ubiquitous membrane protein critical to vectorial transport of ions and nutrients, is required to assemble and stabilize Na,K-ATPase at the plasma membrane. alpha-Na,K-ATPase binds both red cell ankyrin (Ank(R) a product of the ANK1 gene) and Madin-Darby canine kidney cell ankyrin (Ank(G), a product of the ANK3 gene) utilizing residues 142-166 (SYYQEAKSSKIMESFK NMVPQQALV) in its second cytoplasmic domain Fusion peptides of glutathione S-transferase incorporating these 25 amino acids bind specifically to purified ankyrin (K-d = 118 +/- 50 nM). The three-dimensional structure (2.6 Angstrom) of this minimal ankyrin-binding motif, crystallized as the fusion protein, reveals a 7-residue loop with one charged hydrophilic face capping a double beta-strand, Comparison with ankyrin-binding sequences in p53, CD44, neurofascin/L1, and the inositol 1,4,5-trisphosphate receptor suggests that the valency and specificity of ankyrin binding is achieved by the interaction of 5-7-residue surface loops with the beta-hairpin tips of multiple ankyrin repeat units.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA	Yale University; Yale University	Morrow, JS (corresponding author), Yale Univ, Sch Med, Dept Pathol, 333 Cedar St, New Haven, CT 06510 USA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Beck KA, 1997, J CELL SCI, V110, P1239; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P7257, DOI 10.1074/jbc.270.13.7257; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DAVIS JQ, 1993, J CELL BIOL, V121, P121, DOI 10.1083/jcb.121.1.121; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; DEVARAJAN P, 1996, MEMBRANE PROTEIN CYT, P97; DEVARAJAN P, 1997, MOL BIOL CELL S, V8, P305; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; DONAHUE JP, 1994, P NATL ACAD SCI USA, V91, P12178, DOI 10.1073/pnas.91.25.12178; FERRANTE AW, 1995, P NATL ACAD SCI USA, V92, P1911, DOI 10.1073/pnas.92.6.1911; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; INOUE J, 1993, ONCOGENE, V8, P2067; JONES TA, 1996, MANUAL O VERSION 5 1; JORDAN C, 1995, J BIOL CHEM, V270, P29971; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KERR L D, 1992, Current Opinion in Cell Biology, V4, P496, DOI 10.1016/0955-0674(92)90017-7; Leveillard Thierry, 1993, Gene Expression, V3, P135; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MORROW JS, 1989, J CELL BIOL, V108, P455, DOI 10.1083/jcb.108.2.455; MORROW JS, 1997, HDB PHYSIOL 14, P485; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson W J, 1990, Semin Cell Biol, V1, P359; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; ZHANG H, 1992, PLANT CELL, V4, P1575, DOI 10.1105/tpc.4.12.1575; ZHANG Z, 1997, AM CRYSTAL ASS NEWSL, V24, P129	43	76	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18681	18684		10.1074/jbc.273.30.18681	http://dx.doi.org/10.1074/jbc.273.30.18681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668035	hybrid			2022-12-27	WOS:000074974700002
J	Knaus, UG; Wang, Y; Reilly, AM; Warnock, D; Jackson, JH				Knaus, UG; Wang, Y; Reilly, AM; Warnock, D; Jackson, JH			Structural requirements for PAK activation by Rac GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; P21-ACTIVATED KINASE PAK1; RESPIRATORY BURST OXIDASE; NEUTROPHIL NADPH OXIDASE; CELL-CYCLE PROGRESSION; ACTIN STRESS FIBERS; TARGET PROTEINS; CDC42 GTPASES; TRANSFORMATION; RHO	The Rho family GTPases, Rad and Rac2, regulate a variety of cellular functions including cytoskeletal reorganization, the generation of reactive oxygen species, G(1) cell cycle progression and, in concert with Ras, oncogenic transformation, Among the many putative protein targets identified for Rac (and/or Cdc42), the Ser/Thr kinase pal-activated kinase (PAK) is a prime candidate for mediating some of Rac's cellular effects, This report shows that Rad binds to and stimulates the kinase activity of PAK1 approximately 2- and 4-5-fold, respectively, better than Rac2. Mutational analysis was employed to determine the structural elements on Rac and PAK that are important for optimal binding and activation. The most notable difference between the highly homologous Rac isomers is the composition of their C-terminal polybasic domains, Mutation of these six basic residues in Rac1 to neutral amino acids dramatically decreased the ability of Rad to bind PAK1 and almost completely abolished its ability to stimulate PAK activity. Moreover, replacing the highly charged polybasic domain of Rad with the less charged domain of Rac2 (and vice versa) completely reversed the PAK binding/activation properties of the two Rac isomers, Thus, polybasic domain differences account for the disparate abilities of Rac1 and Rac2 to activate PAK, PAH proteins also contain a basic region, consisting of three contiguous lysine residues (Lys(66)-Lys(67)-Lys(68)), which lies outside of the previously identified Cdc42/Rac-binding domain. Mutation of these Lys residues to neutral residues decreased PAK binding to activated Rad and Rac2 (but not Cdc42) and greatly reduced PAK1 activation by Rad, Rac2, and Cdc42 proteins in vivo, In contrast, mutation of lysines 66-68 to basic Arg residues did not decrease (and in some cases enhanced) the ability of Rac1, Rac2, and Cdc42 to bind and activate PAK1. Our studies suggest that the polybasic domain of Rac is a novel effector domain that may allow the two Rac isomers to activate different effector proteins. In addition, our results indicate that a basic region in PAK is required for PAR activation and that binding of Rac/Cdc42 to PAK is not sufficient for kinase activation.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Knaus, UG (corresponding author), Scripps Res Inst, Dept Immunol IMM14, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	uknaus@scripps.edu			NATIONAL CANCER INSTITUTE [R01CA054298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NCI NIH HHS [CA54298] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brzeska H, 1997, P NATL ACAD SCI USA, V94, P1092, DOI 10.1073/pnas.94.4.1092; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P261, DOI 10.1091/mbc.4.3.261; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOSEPH G, 1995, J BIOL CHEM, V270, P29079, DOI 10.1074/jbc.270.49.29079; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KNAUS UG, 1992, J BIOL CHEM, V267, P23575; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KRECK ML, 1994, J BIOL CHEM, V269, P4161; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAUZON PT, 1984, J BIOL CHEM, V259, P541; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	44	96	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21512	21518		10.1074/jbc.273.34.21512	http://dx.doi.org/10.1074/jbc.273.34.21512			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705280	hybrid			2022-12-27	WOS:000075492600014
J	Hou, YM; McInnes, B; Hinek, A; Karpati, G; Mahuran, D				Hou, YM; McInnes, B; Hinek, A; Karpati, G; Mahuran, D			A Pro(504)-> Ser substitution in the beta-subunit of beta-hexosaminidase a inhibits alpha-subunit hydrolysis of G(M2) ganglioside, resulting in chronic Sandhoff disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; GM2 ACTIVATOR PROTEIN; ADULT FORM; GM2-GANGLIOSIDOSIS-B1 VARIANT; SUBSTRATE-SPECIFICITY; JEWISH FAMILY; HEXB GENE; MUTATION; IDENTIFICATION; EXPRESSION	The G(M2) gangliosidoses are caused by mutations in the genes encoding the alpha- (Tay-Sachs) or beta- (Sandhoff) subunits of heterodimeric beta-hexosaminidase A (Hex A), or the G(M2) activator protein (AB variant), a substrate-specific co-factor for Hex A. Although the active site associated with the hydrolysis of G(M2) ganglioside, as well as part of the binding site for the ganglioside-activator complex, is associated with the alpha-subunit, elements of the beta-subunit are also involved. Missense mutations in these genes normally result in the mutant protein being retained in the endoplasmic reticulum and degraded. The mutations associated with the B1-variant of Tay-Sachs are rare exceptions that directly affect residues in the alpha-active site. We have previously reported two sisters with chronic Sandhoff disease who were heterozygous for the common HEXB deletion allele, Cells from these patients had higher than expected levels of mature beta-protein and residual Hex A activity, similar to 20%. We now identify these patients' second mutant allele as a C1510T transition encoding a beta-Pro(504) --> Ser substitution, Biochemical characterization of Hex A from both patient cells and cotransfected CHO cells demonstrated that this substitution (a) decreases the level of heterodimer transport out of the endoplasmic reticulum by similar to 45%, (b) lowers its heat stability, (c) does not affect its K-m, for neutral or charged artificial substrates, and (d) lowers the ratio of units of ganglioside/units of artificial substrate hydrolyzed by a factor of 3. We concluded that the beta-Pro(504) --> Ser mutation directly affects the ability of Hex A to hydrolyze its natural substrate but not its artificial substrates, The effect of the mutation on ganglioside hydrolysis, combined with its effect on intracellular transport, produces chronic Sandhoff disease.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 2C4, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McGill University; McGill University	Mahuran, D (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	hex@sickkids.on.ca	Hinek, Aleksander/V-8790-2019		Canadian Institutes of Health Research [10435] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; Ashkenas J, 1997, AM J HUM GENET, V61, P267, DOI 10.1086/514865; BIKKER H, 1988, NUCLEIC ACIDS RES, V16, P8198, DOI 10.1093/nar/16.16.8198; BOLHUIS PA, 1993, BIOCHIM BIOPHYS ACTA, V1182, P142, DOI 10.1016/0925-4439(93)90134-M; BROWN CA, 1991, J BIOL CHEM, V266, P15855; BROWN CA, 1989, J BIOL CHEM, V264, P21705; BROWN CA, 1993, AM J HUM GENET, V53, P497; DAZZO A, 1984, J BIOL CHEM, V259, P1070; DeGasperi R, 1996, NEUROLOGY, V47, P547, DOI 10.1212/WNL.47.2.547; DEGASPERI R, 1995, BIOCHEM MOL MED, V56, P31, DOI 10.1006/bmme.1995.1053; DREYFUS JC, 1977, AM J HUM GENET, V29, P287; Fernandes Maria, 1992, Human Molecular Genetics, V1, P759, DOI 10.1093/hmg/1.9.759; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; Gravel R. A., 1995, METABOLIC MOL BASIS, P2839; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HENG HHQ, 1993, GENOMICS, V18, P429, DOI 10.1006/geno.1993.1491; Hinek A, 1996, EXP CELL RES, V225, P122, DOI 10.1006/excr.1996.0163; Hou YM, 1996, BIOCHEMISTRY-US, V35, P3963, DOI 10.1021/bi9524575; Hou YM, 1996, AM J HUM GENET, V59, P52; KLIMA H, 1993, BIOCHEM J, V292, P571, DOI 10.1042/bj2920571; KYTZIA HJ, 1983, EMBO J, V2, P1201, DOI 10.1002/j.1460-2075.1983.tb01567.x; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINEKUGEL P, 1992, HUM GENET, V88, P513, DOI 10.1007/BF00219337; LI SC, 1995, J BIOL CHEM, V270, P24246, DOI 10.1074/jbc.270.41.24246; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHURAN DJ, 1990, J BIOL CHEM, V265, P6794; MAHURAN DJ, 1991, BIOCHIM BIOPHYS ACTA, V1096, P87, DOI 10.1016/0925-4439(91)90044-A; MCINNES B, 1992, J CLIN INVEST, V90, P306, DOI 10.1172/JCI115863; MEIER EM, 1991, J BIOL CHEM, V266, P1879; NAKAI H, 1991, CYTOGENET CELL GENET, V56, P164, DOI 10.1159/000133077; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; NEOTE K, 1990, J CLIN INVEST, V86, P1524, DOI 10.1172/JCI114871; NOVAK A, 1979, J LIPID RES, V20, P678; ODOWD BF, 1986, J BIOL CHEM, V261, P2680; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; Pennybacker M, 1996, J BIOL CHEM, V271, P17377, DOI 10.1074/jbc.271.29.17377; PROIA RL, 1984, J BIOL CHEM, V259, P3350; RedonnetVernhet I, 1996, BBA-MOL BASIS DIS, V1317, P127, DOI 10.1016/S0925-4439(96)00044-0; RUBIN M, 1988, J NEUROL SCI, V87, P103, DOI 10.1016/0022-510X(88)90058-5; SANDHOFF K, 1995, METABOLIC MOL BASES, V2, P2427; Sandhoff K, 1989, METABOLIC BASIS INHE, VII, P1807; SmiljanicGeorgijev N, 1997, BBA-PROTEIN STRUCT M, V1339, P192, DOI 10.1016/S0167-4838(97)00002-2; TANAKA A, 1990, AM J HUM GENET, V46, P329; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tse R, 1996, BIOCHEMISTRY-US, V35, P7599, DOI 10.1021/bi960246+; Tse R, 1996, BIOCHEMISTRY-US, V35, P10894, DOI 10.1021/bi960503a; WU YY, 1994, J BIOL CHEM, V269, P16276	48	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21386	21392		10.1074/jbc.273.33.21386	http://dx.doi.org/10.1074/jbc.273.33.21386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694901	hybrid			2022-12-27	WOS:000075386100094
J	Ishaq, M; Zhang, YM; Natarajan, V				Ishaq, M; Zhang, YM; Natarajan, V			Activation-induced down-regulation of retinoid receptor RXR alpha expression in human T lymphocytes - Role of cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARBITRARILY PRIMED PCR; DIFFERENTIAL DISPLAY; MONOCLONAL-ANTIBODIES; INDUCED APOPTOSIS; GENE-EXPRESSION; MESSENGER-RNA; ACID; PROTEIN; INHIBITION; INTERLEUKIN-2	A 5.4-kilobase mRNA, the expression of which is downregulated after treatment of human peripheral blood mononuclear cells (PBMCs) with various T cell-activating agents, was isolated using an mRNA differential display method. Nucleotide sequence analysis identified the 5' end of this RNA as human retinoid receptor RXR alpha mRNA. Here, we report the nucleotide sequence of 3.6 kilobases of this RNA, which represents the 3' end of RXR alpha mRNA, the sequence of which has not been previously described. Activated PBMCs also expressed lower levels of RXR alpha protein, and a DNA binding assay showed that the activation-induced loss of RXRa mRNA and protein expression correlated with the loss of DNA binding activity of this protein. We present evidence that the transition from G(0)/G(1) to S phase of the cell cycle results in the down-regulation of RXR alpha expression and that cell cycle inhibitors, which block the cells in G(1) phase, prevent this down-regulation. The decrease in the levels of RXR alpha mRNA was found to be regulated at the posttranscriptional level and involved new protein synthesis. These observations indicate that the levels of RXR alpha expression in T lymphocytes are coupled to cell cycle progression, and there is tight regulatory control of RXR alpha expression during the transition from G(0)/G(1) to S phase of the cell cycle.	NCI, Frederick Canc Res & Dev Ctr, Mol Cell Biol Lab, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Mol Retrovirol, SAIC Frederick, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Ishaq, M (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Mol Cell Biol Lab, SAIC Frederick, Frederick, MD 21702 USA.				NCI NIH HHS [N01-CO-5600] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BHARGAVA AK, 1993, P NATL ACAD SCI USA, V90, P10260, DOI 10.1073/pnas.90.21.10260; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHANG TW, 1981, P NATL ACAD SCI-BIOL, V78, P1805, DOI 10.1073/pnas.78.3.1805; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; IMBODEN JB, 1985, IMMUNOL TODAY, V6, P328, DOI 10.1016/0167-5699(85)90129-X; IWATA M, 1992, J IMMUNOL, V149, P3302; KURRLE R, 1991, TRANSPLANT P, V23, P272; KVANTA A, 1992, CELL SIGNAL, V4, P275, DOI 10.1016/0898-6568(92)90067-I; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; MAKOVER D, 1991, ONCOGENE, V6, P455; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARTH JD, 1987, EMBO J, V6, P2727, DOI 10.1002/j.1460-2075.1987.tb02566.x; MCCALLUM FS, 1985, BIOCHEM J, V232, P725, DOI 10.1042/bj2320725; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Prashar Y, 1996, P NATL ACAD SCI USA, V93, P659, DOI 10.1073/pnas.93.2.659; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEN RQ, 1995, P NATL ACAD SCI USA, V92, P6778, DOI 10.1073/pnas.92.15.6778; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; TERADA N, 1995, J IMMUNOL, V155, P3418; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; VONWUSSOW P, 1981, J IMMUNOL, V127, P1197; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	41	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21210	21216		10.1074/jbc.273.33.21210	http://dx.doi.org/10.1074/jbc.273.33.21210			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694878	hybrid			2022-12-27	WOS:000075386100071
J	Thiriet, C; Hayes, JJ				Thiriet, C; Hayes, JJ			Functionally relevant histone-DNA interactions extend beyond the classically defined nucleosome core region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE TRANSCRIPTION FACTOR; RIBOSOMAL-RNA GENE; CHROMATIN STRUCTURE; FACTOR ACCESS; ZINC FINGERS; FACTOR-IIIA; XENOPUS; BINDING; ACETYLATION; COMPLEX	We demonstrate that core histones can affect the accessibility of a DNA element positioned outside of the classically defined nucleosome core region. The distance between a well positioned nucleosome and the binding site for the 5 S-specific transcription factor TFIIIA was systematically varied and the relative binding affinity for TFIIIA determined. We found that core histone-DNA interactions attenuate the affinity of TFIIIA for its cognate DNA element by a factor of 50-100-fold even when the critical binding region lies well outside of the classically defined nucleosome core region. These results have implications for the validity of parallels drawn between the accessibility of general nucleases to DNA sequences in chromatin and the activity of actual sequence-specific DNA binding factors.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Hayes, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA.	jjhs@uhura.cc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; BURKHOFF AM, 1987, CELL, V48, P935, DOI 10.1016/0092-8674(87)90702-1; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DELRIO S, 1991, NUCLEIC ACIDS RES, V19, P6197; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; GRUNSTEIN M, 1997, NATURE, V389, P149; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; Howe LW, 1998, MOL CELL BIOL, V18, P1156, DOI 10.1128/MCB.18.3.1156; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; Li Q, 1997, METHODS, V12, P96, DOI 10.1006/meth.1997.0451; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; RAMSAY N, 1986, J MOL BIOL, V189, P179, DOI 10.1016/0022-2836(86)90389-X; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; Tsukiyama T, 1997, CURR OPIN GENET DEV, V7, P182, DOI 10.1016/S0959-437X(97)80127-X; TULLIUS TD, 1987, TRENDS BIOCHEM SCI, V12, P297, DOI 10.1016/0968-0004(87)90145-9; URA K, 1994, J BIOL CHEM, V269, P27171; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; van Holde KE., 1989, SPRINGER SERIES MOL; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1993, METH MOL G, V2, P314; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; Wong JM, 1998, EMBO J, V17, P520, DOI 10.1093/emboj/17.2.520; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O	44	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21352	21358		10.1074/jbc.273.33.21352	http://dx.doi.org/10.1074/jbc.273.33.21352			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694896	hybrid			2022-12-27	WOS:000075386100089
J	Yarovoi, SV; Lun, XP; Picard, N; Rungta, D; Rideout, D; Pfahl, M				Yarovoi, SV; Lun, XP; Picard, N; Rungta, D; Rideout, D; Pfahl, M			Selective activation of an apoptotic retinoid precursor in macrophage cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; ACID RECEPTOR-ALPHA; BREAST-CANCER CELLS; MOBILIZING PHOSPHOLIPASE-A2; CARCINOMA CELLS; N-(4-HYDROXYPHENYL)RETINAMIDE; INHIBITION; INDUCTION; ANALOGS; LIGANDS	Advances in the understanding of the retinoid signaling mechanism has allowed the discovery of highly selective retinoids that activate only one specific receptor class, subtype, or signaling pathway. These novel compounds lack certain of the common retinoid toxicities and therefore suggest promising new approaches for therapeutic applications. We describe here a new compound, 6-[3-(l-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid methyl ester (MX84), that is selectively activated in macrophages, leading to killing of only macrophage monocyte type cells in vitro. We provide evidence that MX84 is an inactive precursor that is converted into an active apoptosis-inducing retinoid in macrophages. The macrophage activity is also secreted, and our data suggest that the secreted activity is a phospholipase D type activity. Our observation may lead to the development of molecules that are highly macrophage-selective apoptosis inducers in vivo and that could represent important novel therapeutics against diseases caused by excessive macrophage activity.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; Maxia Pharmaceut Inc, San Diego, CA 92121 USA		Pfahl, M (corresponding author), Sidney Kimmel Canc Ctr, 10835 Altman Row, San Diego, CA 92121 USA.				NCI NIH HHS [CA55681] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APFEL C, 1992, P NATL ACAD SCI USA, V89, P7129, DOI 10.1073/pnas.89.15.7129; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Beard RL, 1996, J MED CHEM, V39, P3556, DOI 10.1021/jm960386h; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Darmon M., 1991, SEMINARS DEV BIOL, V2, P219; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; DELIA D, 1993, CANCER RES, V53, P6036; DIVINCI A, 1994, INT J CANCER, V59, P422, DOI 10.1002/ijc.2910590322; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; GRATAS C, 1993, ANTICANCER RES, V13, P1239; GRAUPNER G, 1991, BIOCHEM BIOPH RES CO, V179, P1554, DOI 10.1016/0006-291X(91)91750-7; GROSS RW, 1995, J BIOL CHEM, V270, P14855, DOI 10.1074/jbc.270.25.14855; Hsieh TC, 1995, BIOCHEM MOL BIOL INT, V37, P499; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; JONG L, 1993, J MED CHEM, V36, P2605, DOI 10.1021/jm00070a003; KISS Z, 1995, BBA-LIPID LIPID MET, V1259, P105, DOI 10.1016/0005-2760(95)00148-6; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; MARTIN B, 1992, SKIN PHARMACOL, V5, P57; Morris-Kay G., 1992, RETINOIDS NORMAL DEV; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; NACCACHE PH, 1993, LAB INVEST, V69, P19; Oridate N, 1997, INT J CANCER, V70, P484, DOI 10.1002/(SICI)1097-0215(19970207)70:4<484::AID-IJC21>3.0.CO;2-E; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; PONZONI M, 1995, CANCER RES, V55, P853; POWIS G, 1992, CANCER RES, V52, P2835; ROBERTS AB, 1984, RETINOIDS, V2, P209; SHADENDORF D, 1996, J CELL BIOL, V135, P1889; SHAO ZM, 1995, ONCOGENE, V11, P493; STACEY KJ, 1993, IMMUNOL CELL BIOL, V71, P75, DOI 10.1038/icb.1993.8; Supino R, 1996, INT J CANCER, V65, P491, DOI 10.1002/(SICI)1097-0215(19960208)65:4<491::AID-IJC17>3.0.CO;2-D; Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972; TANAKA Y, 1989, ARCH BIOCHEM BIOPHYS, V272, P210, DOI 10.1016/0003-9861(89)90212-9; Wang TTY, 1996, CANCER LETT, V107, P65, DOI 10.1016/0304-3835(96)04344-3; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WILCOX RW, 1987, LIPIDS, V22, P800, DOI 10.1007/BF02535534; XIE MS, 1994, BIOCHEM J, V297, P547, DOI 10.1042/bj2970547	46	4	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20852	20859		10.1074/jbc.273.33.20852	http://dx.doi.org/10.1074/jbc.273.33.20852			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694831	hybrid			2022-12-27	WOS:000075386100024
J	Sasaki, N; Shimada, T; Sutoh, K				Sasaki, N; Shimada, T; Sutoh, K			Mutational analysis of the switch II loop of Dictyostelium myosin II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; MOTOR DOMAIN; PHENOTYPIC SELECTION; DISCOIDEUM; ACTIN; SUBFRAGMENT-1; INVITRO; BINDING; IDENTIFICATION; EXPRESSION	A loop comprising residues 454-459 of Dictyostelium myosin II is structurally and functionally equivalent to the switch II loop of the G-protein family. The consensus sequence of the "switch II loop" of the myosin family is DIXGFE, In order to determine the functions of each of the conserved residues, alanine scanning mutagenesis was carried out on the Dictyostelium myosin II heavy chain gene. Examination of in vivo and in vitro motor functions of the mutant myosins revealed that the I455A and S456A mutants retained those functions, whereas the D454A, G457A, F458A and E459A mutants lost them, Biochemical analysis of the latter myosins showed that the 6457A and E459A mutants lost the basal ATPase activity by blocking of the isomerization and hydrolysis steps of the ATPase cycle, respectively. The F458A mutant, however, lost the actin-activated ATPase activity without loss of the basal ATPase activity. These results are discussed in terms of the crystal structure of the Dictyostelium myosin motor domain.	Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 153, Japan	University of Tokyo	Sutoh, K (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Komaba 3-8-1, Tokyo 153, Japan.	cksutoh@komaba.ecc.u-tokyo.acjp						BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DELOZANNE A, 1985, P NATL ACAD SCI USA, V82, P6807, DOI 10.1073/pnas.82.20.6807; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MANSTEIN DJ, 1989, EMBO J, V8, P923, DOI 10.1002/j.1460-2075.1989.tb03453.x; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; OHALLORAN TJ, 1990, P NATL ACAD SCI USA, V87, P8110, DOI 10.1073/pnas.87.20.8110; Onishi H, 1997, BIOCHEMISTRY-US, V36, P3767, DOI 10.1021/bi9630772; PATTERSON B, 1995, GENETICS, V140, P505; Patterson B, 1996, GENETICS, V143, P801; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; RUPPEL KM, 1994, J BIOL CHEM, V269, P18773; RUPPEL KM, 1990, ANN NY ACAD SCI, P147; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; TAN JL, 1991, J BIOL CHEM, V266, P16044; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; YOUNT RG, 1995, BIOPHYS J, V68, pS44	36	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20334	20340		10.1074/jbc.273.32.20334	http://dx.doi.org/10.1074/jbc.273.32.20334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685384	hybrid			2022-12-27	WOS:000075305400061
J	Silverstein, AM; Grammatikakis, N; Cochran, BH; Chinkers, M; Pratt, WB				Silverstein, AM; Grammatikakis, N; Cochran, BH; Chinkers, M; Pratt, WB			P50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; STEROID-RECEPTOR COMPLEXES; ROUS-SARCOMA VIRUS; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; FK506-BINDING PROTEIN; POLYCLONAL ANTIBODY; ESTROGEN-RECEPTOR; TERMINAL REGION; IMMUNOPHILIN	Several protein kinases (e.g. pp60(src), v-Raf) exist in heterocomplexes with hsp90 and a 50-kDa protein that is the mammalian homolog of the yeast cell cycle control protein Cdc37. In contrast, unliganded steroid receptors exist in heterocomplexes with hsp90 and a tetratri-copeptide repeat (TPR) domain protein, such as an immunophilin. Although p50(cdc37) and TPR domain proteins bind directly to hsp90, p50(cdc37) is, not present in native steroid receptor.hsp90 heterocomplexes. To obtain some insight as to how v-Raf selects predominantly hsp90.p50(cdc37) heterocomplexes, rather than hsp90 TPR protein heterocomplexes, we have examined the binding of p50(cdc37) to hsp90 and to Raf. We show that p50(cdc37) exists in separate hsp90 heterocomplexes from the TPR domain proteins and that intact TPR proteins compete for p50(cdc37) binding to hsp90 but a protein fragment containing a TPR domain does not. This suggests that the binding site for p50(cdc37) Lies topologically adjacent to the TPR acceptor site on the surface of hsp90. Also, we show that p50(cdc37) binds directly to v-Raf, with the catalytic domain of Raf being sufficient. We propose that the combination of exclusive binding of p50(cdc37) versus a TPR domain protein to hsp90 plus direct binding of p50(cdc37) to Raf allows the protein kinase to select for the dominant hsp90 p50(cdc37) composition that is observed with a variety of protein kinase heterocomplexes immunoadsorbed from cytosols.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	University of Michigan System; University of Michigan; Tufts University; Oregon Health & Science University	Pratt, WB (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.			Cochran, Brent/0000-0002-7598-5604	NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047063] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NHLBI NIH HHS [HL47063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chen MS, 1996, J BIOL CHEM, V271, P32315, DOI 10.1074/jbc.271.50.32315; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; Dey B, 1996, MOL BIOL CELL, V7, P1405, DOI 10.1091/mbc.7.9.1405; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; ERHART JC, 1988, ONCOGENE, V3, P595; GRAMMATIKAKIS N, 1995, J BIOL CHEM, V270, P16198, DOI 10.1074/jbc.270.27.16198; GRAMMATIKAKIS N, 1996, M CELL CYCL COLD SPR, P72; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; KIEFFER LJ, 1993, J BIOL CHEM, V268, P12303; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Nair SC, 1997, MOL CELL BIOL, V17, P594, DOI 10.1128/MCB.17.2.594; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; REXIN M, 1991, J BIOL CHEM, V266, P24601; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, J BIOL CHEM, V268, P24270; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	53	109	114	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20090	20095		10.1074/jbc.273.32.20090	http://dx.doi.org/10.1074/jbc.273.32.20090			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685350	hybrid			2022-12-27	WOS:000075305400027
J	Tamai, I; Ohashi, R; Nezu, J; Yabuuchi, H; Oku, A; Shimane, M; Sai, Y; Tsuji, A				Tamai, I; Ohashi, R; Nezu, J; Yabuuchi, H; Oku, A; Shimane, M; Sai, Y; Tsuji, A			Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUVENILE VISCERAL STEATOSIS; BORDER-MEMBRANE-VESICLES; JVS MOUSE; DEFICIENCY; EXPRESSION; CLONING; DEFECT; KIDNEY; CARDIOMYOPATHY; FIBROBLASTS	Primary carnitine deficiency, because of a defect of the tissue plasma membrane carnitine transporters, causes critical symptoms. However, the transporter has not been molecularly identified. In this study, we screened a human kidney cDNA library and assembled a cDNA-encoding OCTN2 as a homologue of the organic cation transporter OCTN1, and then we examined the function of OCTN2 as a carnitine transporter. OCTN2-cDNA encodes a polypeptide of 557 amino acids with 75.8% similarity to OCTN1. Northern blot analysis showed that OCTN2 is strongly expressed in kidney, skeletal muscle, heart, and placenta in adult humans. When OCTN2 was expressed in HEK293 cells, uptake of L-[H-3]carnitine was strongly enhanced in a sodium-dependent manner with K-m value of 4.34 mu M, whereas typical substrates for previously known organic cation transporters, tetraethylammonium and guanidine, were not good substitutes. OCTN2-mediated L-[H-3]carnitine transport was inhibited by the D-isomer, acetyl-D,L-carnitine, and gamma-butyrobebaine with high affinity and by glycinebetaine with lower affinity, whereas choline, beta-hydroxybutyric acid, gamma-aminobutyric acid, lysine, and taurine were not inhibitory. Because the observed tissue distribution of OCTN2 is consistent with the reported distribution of carnitine transport activity and the functional characteristics of OCTN2 coincide with those reported for plasma membrane carnitine transport, we conclude that OCTN2 is a physiologically important, high affinity sodium-carnitine cotransporter in humans.	Kanazawa Univ, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9200934, Japan; Chugai Res Inst Mol Med Inc, Ibaraki, Osaka 3004101, Japan	Kanazawa University	Tsuji, A (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		TAMAI, Ikumi/D-8412-2015; SAI, Yoshimichi/L-3828-2015	SAI, Yoshimichi/0000-0003-2954-1532				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; CARTER AL, 1995, J CHILD NEUROL, V10, P3; Chun JK, 1997, PHARMACEUT RES, V14, P936, DOI 10.1023/A:1012164203648; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; ENGEL AG, 1981, NEUROLOGY, V31, P819, DOI 10.1212/WNL.31.7.819; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Gorboulev V, 1997, DNA CELL BIOL, V16, P871, DOI 10.1089/dna.1997.16.871; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; Hashimoto N, 1998, BIOCHEM PHARMACOL, V55, P1729, DOI 10.1016/S0006-2952(97)00670-9; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HORIUCHI M, 1993, FEBS LETT, V326, P267, DOI 10.1016/0014-5793(93)81805-A; HORIUCHI M, 1994, BBA-MOL BASIS DIS, V1226, P25, DOI 10.1016/0925-4439(94)90054-X; HUTH PJ, 1981, J NEUROCHEM, V36, P715, DOI 10.1111/j.1471-4159.1981.tb01647.x; KISPAL G, 1987, BIOCHIM BIOPHYS ACTA, V896, P96, DOI 10.1016/0005-2736(87)90360-9; KOIZUMI T, 1988, LAB ANIM, V22, P83, DOI 10.1258/002367788780746511; KULLAKUBLICK GA, 1995, GASTROENTEROLOGY, V109, P1274, DOI 10.1016/0016-5085(95)90588-X; KUWAJIMA M, 1991, BIOCHEM BIOPH RES CO, V174, P1090, DOI 10.1016/0006-291X(91)91532-H; Kuwajima M, 1996, BIOCHEM BIOPH RES CO, V223, P283, DOI 10.1006/bbrc.1996.0885; MOLSTAD P, 1978, BIOCHIM BIOPHYS ACTA, V512, P557, DOI 10.1016/0005-2736(78)90165-7; Okuda M, 1996, BIOCHEM BIOPH RES CO, V224, P500, DOI 10.1006/bbrc.1996.1056; PONS R, 1995, J CHILD NEUROL, V10, P8; Prasad PD, 1996, BBA-BIOMEMBRANES, V1284, P109, DOI 10.1016/0005-2736(96)00126-5; PRITCHARD JB, 1993, PHYSIOL REV, V73, P765, DOI 10.1152/physrev.1993.73.4.765; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; REBOUCHE CJ, 1977, BIOCHIM BIOPHYS ACTA, V471, P145, DOI 10.1016/0005-2736(77)90402-3; REBOUCHE CJ, 1984, ARCH BIOCHEM BIOPHYS, V235, P393, DOI 10.1016/0003-9861(84)90212-1; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHAW RD, 1983, AM J PHYSIOL, V245, pG376, DOI 10.1152/ajpgi.1983.245.3.G376; STANLEY CA, 1991, ANN NEUROL, V30, P709, DOI 10.1002/ana.410300512; STIEGER B, 1995, BIOCHEM J, V309, P643, DOI 10.1042/bj3090643; Tamai I, 1997, FEBS LETT, V419, P107, DOI 10.1016/S0014-5793(97)01441-5; TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; VARY TC, 1982, AM J PHYSIOL, V242, pH585, DOI 10.1152/ajpheart.1982.242.4.H585; Vivo D, 1990, INT PEDIAT, V5, P134; Walter JH, 1996, ARCH DIS CHILD, V74, P475, DOI 10.1136/adc.74.6.475; Zhang L, 1997, MOL PHARMACOL, V51, P913, DOI 10.1124/mol.51.6.913	38	562	578	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20378	20382		10.1074/jbc.273.32.20378	http://dx.doi.org/10.1074/jbc.273.32.20378			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685390	hybrid			2022-12-27	WOS:000075305400067
J	Chen, Y; Shyu, JF; Santhanagopal, A; Inoue, D; David, JP; Dixon, SJ; Horne, WC; Baron, R				Chen, Y; Shyu, JF; Santhanagopal, A; Inoue, D; David, JP; Dixon, SJ; Horne, WC; Baron, R			The calcitonin receptor stimulates Shc tyrosine phosphorylation and Erk1/2 activation - Involvement of G(i), protein kinase C, and calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3',5'-CYCLIC ADENOSINE-MONOPHOSPHATE; HETEROTRIMERIC G-PROTEINS; CYTOSOLIC-FREE CALCIUM; BETA-GAMMA-SUBUNITS; MAP KINASE; SIGNAL-TRANSDUCTION; PARATHYROID-HORMONE; PHOSPHOLIPASE-C; RAT OSTEOCLASTS; PATHWAY	While it is web established that adenylyl cyclase and phospholipase C-beta are two proximal signal effecters for the calcitonin receptor, the more distal signaling pathways are less well characterized. G protein-coupled receptors can activate Erk1/2 by G(s)-, G(i)-, or G(q)-dependent signaling pathways, depending on the specific receptor and cell type examined. Since the calcitonin receptor can couple to all three of these G proteins, the ability of calcitonin to activate Erk1/2 was investigated. Calcitonin induced time- and concentration-dependent increases in Shc tyrosine phosphorylation, Shc-Grb2 association and Erk1/2 phosphorylation and activation in a HEK 293 cell line that stably expresses the rabbit calcitonin receptor Cia isoform. Pertussis toxin, which inactivates G(i), and calphostin C, a protein kinase C inhibitor, each partially inhibited calcitonin-induced Shc tyrosine phosphorylation, Shc-Grb2 association, and Erk1/2 phosphorylation. In contrast, neither forskolin nor H89, a protein kinase A inhibitor, had a significant effect on basal or calcitonin-stimulated Erk1/2 phosphorylation. Our results suggest that the calcitonin receptor induces Shc phosphorylation and Erk1/2 activation in HEK293 cells by parallel G(i)- and PRO-dependent mechanisms. The calcitonin-induced elevation of cytosolic free Ca2+ was required for Erk1/2 phosphorylation, since preventing any change in cytosolic free Ca2+ by chelating both cytosolic and extracellular Ca2+ abolished the response. However, the change in Ca2+ that is induced by calcitonin is not sufficient to account for the calcitonin-induced Erk1/2 phosphorylation, since treatment with 100 nM ionomycin or 10 mu M thapsigargin, each of which induced elevations of Ca2+ comparable to those induced by calcitonin, induced significantly less Erk1/2 phosphorylation than that induced by calcitonin. Erk1/2 may have important roles as downstream effecters mediating cellular responses to calcitonin stimulation.	Yale Univ, Sch Med, Dept Orthoped, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA; Univ Western Ontario, Fac Med & Dent, Div Oral Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Fac Med & Dent, Dept Physiol, London, ON N6A 5C1, Canada	Yale University; Yale University; Yale University; Western University (University of Western Ontario); Western University (University of Western Ontario)	Horne, WC (corresponding author), Yale Univ, Sch Med, Dept Orthoped, POB 208044, New Haven, CT 06520 USA.		Dixon, S. Jeffrey/G-3657-2013	Dixon, S. Jeffrey/0000-0001-9162-1686	NIDCR NIH HHS [DE-04724] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE004724, R01DE004724] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Azria M., 1989, CALCITONINS PHYSL PH; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; Chen YH, 1996, EMBO J, V15, P1037, DOI 10.1002/j.1460-2075.1996.tb00441.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORCE T, 1992, AM J PHYSIOL, V262, pF1110, DOI 10.1152/ajprenal.1992.262.6.F1110; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HORNE WC, 1994, TRENDS ENDOCRIN MET, V5, P395, DOI 10.1016/1043-2760(95)92521-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MALGAROLI A, 1989, J BIOL CHEM, V264, P14342; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; Offermanns S, 1996, CANCER SURV, V27, P177; Parrizas M, 1997, J BIOL CHEM, V272, P154; PEREZ M, 1997, J BONE MINER RES, V12, pS323; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shyu JF, 1996, J BIOL CHEM, V271, P31127, DOI 10.1074/jbc.271.49.31127; SU YJ, 1992, ENDOCRINOLOGY, V131, P1497, DOI 10.1210/en.131.3.1497; TETI A, 1995, J BIOL CHEM, V270, P16666, DOI 10.1074/jbc.270.28.16666; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZAIDI M, 1990, J ENDOCRINOL, V126, P473, DOI 10.1677/joe.0.1260473	46	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19809	19816		10.1074/jbc.273.31.19809	http://dx.doi.org/10.1074/jbc.273.31.19809			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677414	hybrid			2022-12-27	WOS:000075125200066
J	Huang, Y; Putney, JW				Huang, Y; Putney, JW			Relationship between intracellular calcium store depletion and calcium release-activated calcium current in a mast cell line (RBL-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTRY	The kinetic relationship between depletion of endoplasmic reticulum calcium stores and the activation of a calcium release-activated calcium current (I-crac) was investigated in the RBL-1 mast cell line. The inositol trisphosphate receptor activator, inositol 2,4,5-trisphosphate ((2,4,5)IP3), the sarcoplasmic-endoplasmic reticulum calcium ATPase inhibitor, thapsigargin, and the calcium ionophore, ionomycin, were used to deplete stored calcium. For (2,4,5)IP3 and thapsigargin, a significant delay was observed between the initiation of calcium store depletion and the activation of I-crac. However, for ionomycin, little or no delay was observed. This may indicate that a specialized subcompartment of the endoplasmic reticulum functions as a regulator of calcium entry and that this compartment is relatively resistant to depletion by (2,4,5)IP3 and thapsigargin but not to depletion by ionomycin. For all three calcium-depleting agents, the rate of development of I-crac. once initiated, was relatively constant, suggesting an all-or-none mechanism. However, there were also clear experimental situations in which submaximal, graded depletion of stored calcium resulted in submaximal activation of I-crac. This complex behavior could also result from the existence of a specific subcompartment of endoplasmic reticulum regulating I-crac. The kinetic behavior of this compartment may not be accurately reflected by the kinetics of calcium changes in the bulk of endoplasmic reticulum. These findings add to the growing body of evidence suggesting specialization of the endoplasmic reticulum calcium stores with regard to the control of capacitative calcium entry.	NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Calcium Regulat Sect, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019	Putney, James W/0000-0002-3379-4789				BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0	14	67	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19554	19559		10.1074/jbc.273.31.19554	http://dx.doi.org/10.1074/jbc.273.31.19554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677379	hybrid			2022-12-27	WOS:000075125200031
J	Renn, SCP; Tomkinson, B; Taghert, PH				Renn, SCP; Tomkinson, B; Taghert, PH			Characterization and cloning of tripeptidyl peptidase II from the fruit fly, Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUST SCHISTOCERCA-GREGARIA; NUCLEOTIDE-SEQUENCE; MUSCA-DOMESTICA; DYE-BINDING; NEUROPEPTIDES; ENDOPEPTIDASE; PURIFICATION; SUBTILISIN; PROTEINS; CDNA	We describe the characterization, cloning, and genetic analysis of tripeptidyl peptidase II (TPP II) from Drosophila melanogaster. Mammalian TPP II removes N-terminal tripeptides, has wide distribution, and has been identified as the cholecystokinin-degrading peptidase in rat brain. Size exclusion and ion exchange chromatography produced a 70-fold purification; of dTPP II activity from Drosophila tissue extracts. The substrate specificity and the inhibitor sensitivity of dTPP II is comparable to that of the human enzyme. In. particular, dTPP II is sensitive to butabindide, a specific inhibitor of the rat cholecystokinin-inactivating activity. We isolated a 4309-base pair dTPP II cDNA which predicts a 1354-amino acid protein. The deduced human and Drosophila TPP II proteins display 38% overall identity. The catalytic triad, its spacing, and the sequences that surround it are highly conserved; the C-terminal end of dTPP II contains a 100-amino acid insert not found in the mammalian proteins. Recombinant dTPP II displays the predicted activity following expression in HEK cells. TPP II maps to cytological position 49F4-7; animals deficient for this interval show reduced TPP II activity.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Swedish Univ Agr Sci, Ctr Biomed, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Washington University (WUSTL); Swedish University of Agricultural Sciences	Taghert, PH (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.				NINDS NIH HHS [NS-21749] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021749] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashburner M., 1989, DROSOPHILA LAB MANUA, P37; BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BULL AL, 1956, J EXP ZOOL, V132, P467, DOI 10.1002/jez.1401320306; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CORNEL MJ, 1995, J BIOL CHEM, V270, P13613, DOI 10.1074/jbc.270.23.13613; Csuhai E, 1995, PROG BRAIN RES, V104, P131; DOEBBER TW, 1978, ENDOCRINOLOGY, V103, P1794, DOI 10.1210/endo-103-5-1794; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ISAAC RE, 1987, BIOCHEM J, V245, P365, DOI 10.1042/bj2450365; ISAAC RE, 1988, BIOCHEM J, V255, P843, DOI 10.1042/bj2550843; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; LAMANGO NS, 1994, BIOCHEM J, V299, P651, DOI 10.1042/bj2990651; LAMANGO NS, 1993, INSECT BIOCHEM MOLEC, V23, P801, DOI 10.1016/0965-1748(93)90068-4; LASKO PF, 1988, GENETICS, V120, P495; MATSAS R, 1984, BIOCHEM J, V223, P433, DOI 10.1042/bj2230433; MORGAN TH, 1938, CARNEGIE I WASH YB, V37, P298; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nassel DR, 1996, CURR OPIN NEUROBIOL, V6, P842, DOI 10.1016/S0959-4388(96)80036-5; OBRIEN MA, 1994, ZOOL SCI, V11, P633; ONDETTI MA, 1982, ANNU REV BIOCHEM, V51, P283, DOI 10.1146/annurev.bi.51.070182.001435; PAGE AE, 1993, ARCH BIOCHEM BIOPHYS, V306, P354, DOI 10.1006/abbi.1993.1523; PETERS K, 1989, CURR MICROBIOL, V18, P171, DOI 10.1007/BF01569566; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; ROSEN J, 1991, J BIOL CHEM, V266, P3827; Sambrook J., 2002, MOL CLONING LAB MANU; SMOLLER DA, 1991, CHROMOSOMA, V100, P487, DOI 10.1007/BF00352199; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMKINSON B, 1991, BIOMED BIOCHIM ACTA, V50, P727; TOMKINSON B, 1987, P NATL ACAD SCI USA, V84, P7508, DOI 10.1073/pnas.84.21.7508; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; Tomkinson B, 1995, NEUROCHEM RES, V20, P1443, DOI 10.1007/BF00970592; Tomkinson B, 1997, FEBS LETT, V405, P277, DOI 10.1016/S0014-5793(97)00173-7; TOMKINSON B, 1990, BIOCHEM J, V267, P149, DOI 10.1042/bj2670149; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; TURNER AJ, 1985, BIOCHEM PHARMACOL, V34, P1347, DOI 10.1016/0006-2952(85)90669-0; Voorhorst WGB, 1996, J BIOL CHEM, V271, P20426, DOI 10.1074/jbc.271.34.20426; WILSON C, 1993, NEUROCHEM RES, V18, P743, DOI 10.1007/BF00966768; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU CT, 1989, MOL GEN GENET, V218, P559, DOI 10.1007/BF00332424; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	46	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19173	19182		10.1074/jbc.273.30.19173	http://dx.doi.org/10.1074/jbc.273.30.19173			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668104	hybrid, Green Submitted			2022-12-27	WOS:000074974700071
J	Roos, J; Kelly, RB				Roos, J; Kelly, RB			Dap160, a neural-specific Eps15 homology and multiple SH3 domain-containing protein that interacts with Drosophila dynamin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; NERVE-TERMINALS; COATED PITS; AMPHIPHYSIN; POLYPEPTIDES; TRANSMISSION; PURIFICATION; ENDOCYTOSIS; BINDING; TARGETS	The discovery of overlapping hot spots of dynamin (Estes, P. S., Roos, J., van der Bliek, A., Kelly, R. B., Krishnan, K. S., and Ramaswami, M. (1996) J. Neurosci. 16, 5443-5456) and the heterotetrameric adaptor 2 complex (Gonzalez-Gaitan, M,, and Jackle, H. (1997) Cell 88, 767-776) in Drosophila nerve terminals led to the concept of zones of active endocytosis close to sites of active exocytosis. The proline-rich domain of Drosophila dynamin was used to identify and purify a third component of the endocytosis zones. Dap160 (dynamin-associated protein 160 kDa) is a membrane-associated, dynamin-binding protein of 160 kDa that has four putative src homology 3 domains and an Eps15 homology domain, motifs frequently found in proteins associated with endocytosis, The binding capacities of the four putative src homology 3 domains were examined individually and in combination and shown to bind known proteins that contained proline-rich domains. Each binding site, however, was different in its preference for binding partners. We suggest that Dap160 is a scaffolding protein that helps anchor proteins required for endocytosis at sites where they are needed in the Drosophila nerve terminal.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kelly, RB (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015927] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15927] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews J, 1996, GENETICS, V143, P1699; BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DOYLE K, 1996, PROMEGA PROTOCOLS AP, P184; Estes PS, 1996, J NEUROSCI, V16, P5443; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; GASS GV, 1996, J NEUROGENET, V10, P169; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; GRIECO F, 1992, BIOTECHNIQUES, V13, P856; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hosaka M, 1998, J BIOL CHEM, V273, P1425, DOI 10.1074/jbc.273.3.1425; Iannolo G, 1997, CANCER RES, V57, P240; ITO N, 1985, DROSOPHILA INFORMATI, V69, P81; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; KOENIG JH, 1989, J NEUROSCI, V9, P3844; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; Mellman I, 1996, CURR OPIN CELL BIOL, V8, P497, DOI 10.1016/S0955-0674(96)80026-3; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Nemoto Y, 1997, J BIOL CHEM, V272, P30817, DOI 10.1074/jbc.272.49.30817; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; REICHMUTH C, 1995, MOL BRAIN RES, V32, P45, DOI 10.1016/0169-328X(95)00058-Z; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Stewart BA, 1996, J NEUROSCI, V16, P3877; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEGOOR J, 1995, P NATL ACAD SCI USA, V92, P5739, DOI 10.1073/pnas.92.12.5739	45	175	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19108	19119		10.1074/jbc.273.30.19108	http://dx.doi.org/10.1074/jbc.273.30.19108			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668096	hybrid			2022-12-27	WOS:000074974700063
J	Urbani, A; Bazzo, R; Nardi, MC; Cicero, DO; De Francesco, R; Steinkuhler, C; Barbato, G				Urbani, A; Bazzo, R; Nardi, MC; Cicero, DO; De Francesco, R; Steinkuhler, C; Barbato, G			The metal binding site of the hepatitis C virus NS3 protease - A spectroscopic investigation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; N-15 NMR-SPECTROSCOPY; HYDROGEN-BONDING INTERACTIONS; ALPHA-LYTIC PROTEASE; NON-B-HEPATITIS; SERINE-PROTEASE; ACTIVE-SITE; NON-A; TAUTOMERIC EQUILIBRIA; HETERONUCLEAR NMR	The NS3 region of the hepatitis C virus encodes for a serine protease activity, which is necessary for the processing of the nonstructural region of the viral polyprotein, The minimal domain with proteolytic activity resides in the N terminus, where a structural tetradentate zinc binding site is located. The ligands being been identified by x-ray crystallography as being three cysteines (Cys(97), Cys(99), and Cys(145)) and one histidine residue (His(149)), which is postulated to coordinate the metal through a water molecule. In this article, we present an analysis of the role of metal coordination with respect to enzyme activity and folding. Using NMR spectroscopy, the resonances of His149 were assigned based on their isotropic shift in a Co(II)-substituted protein. Data obtained with N-15-labeled NS3 protease were compatible with the involvement of the delta-N of His(149) in metal coordination. pH titration experiments showed that the cooperative association of at least two protons is required in the protonation process of His149. Changes in the NMR signals of this residue between pH 7 and 5 are interpreted as evidence for a structural change at the metal binding site, which switches from a "closed" to an "open" conformation. Site-directed mutagenesis of His149 has shown the importance of this residue in the metal incorporation pathway and for achieving an active fold. The metal coordination of the protease was also investigated by circular dichroism and electronic absorption spectroscopies using a Co(II)-substituted enzyme. We show evidence for rearrangements of the metal coordination geometry induced by complex formation with an NS4A peptide cofactor. No such changes were observed upon binding to a substrate peptide. Also, CN- and N-3(-) induced Co(II) ligand field perturbations, which went along with an 1.5-fold enhancement of protease activity.	Ist Ric Biol Mol P Angeletti, I-00040 Pomezia, Rome, Italy	Merck & Company	Steinkuhler, C (corresponding author), Ist Ric Biol Mol P Angeletti, Via Pontina Km 30600, I-00040 Pomezia, Rome, Italy.	Steinkuhler@irbm.it	Cicero, Daniel/AAV-5203-2021; Barbato, Gaetano/G-4904-2011; De Francesco, Raffaele/J-6003-2012	Barbato, Gaetano/0000-0001-9840-6858; De Francesco, Raffaele/0000-0001-8754-5123				BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1988, BIOCHEMISTRY-US, V27, P7689, DOI 10.1021/bi00420a018; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BALACCO G, 1994, J CHEM INF COMP SCI, V34, P1235, DOI 10.1021/ci00022a003; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; BERTINI I, 1978, J AM CHEM SOC, V100, P4873, DOI 10.1021/ja00483a038; Bertini I, 1984, Adv Inorg Biochem, V6, P71; BERTINI I, 1981, J AM CHEM SOC, V103, P7784, DOI 10.1021/ja00416a016; Bianchi E, 1997, BIOCHEMISTRY-US, V36, P7890, DOI 10.1021/bi9631475; BLOMBERG F, 1977, J AM CHEM SOC, V99, P8149, DOI 10.1021/ja00467a005; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CLORE GM, 1991, J AM CHEM SOC, V113, P4350, DOI 10.1021/ja00011a059; CLORE GM, 1992, BIOCHEMISTRY-US, V21, P4048; DeFrancesco R, 1996, BIOCHEMISTRY-US, V35, P13282, DOI 10.1021/bi9616458; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FAILLA C, 1995, J VIROL, V69, P1769, DOI 10.1128/JVI.69.3.1769-1777.1995; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; FESHT A, 1985, ENZYME STRUCTURE MEC, P143; GOOLEY PR, 1993, BIOCHEMISTRY-US, V32, P13098, DOI 10.1021/bi00211a020; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HIROMI I, 1979, KINETICS FAST ENZYME, P99; HOLMQUIST B, 1986, METHOD ENZYMOL, V130, P270; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; KRIZEK BA, 1991, J AM CHEM SOC, V113, P4518, DOI 10.1021/ja00012a021; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Landro JA, 1997, BIOCHEMISTRY-US, V36, P9340, DOI 10.1021/bi963054n; Lesk AM, 1996, J MOL BIOL, V258, P501, DOI 10.1006/jmbi.1996.0264; Lian L. Y., 1993, NMR MACROMOLECULES P, P153; LIN C, 1995, J VIROL, V69, P4373, DOI 10.1128/JVI.69.7.4373-4380.1995; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; MARET W, 1993, METHOD ENZYMOL, V226, P52; MENGLI C, 1997, NAT STRUCT BIOL, V7, P567; MERKLE DL, 1991, J AM CHEM SOC, V113, P5450, DOI 10.1021/ja00014a045; Mori A, 1997, BIOCHEM BIOPH RES CO, V231, P738, DOI 10.1006/bbrc.1997.6180; MUNOWITZ M, 1982, J AM CHEM SOC, V104, P1192, DOI 10.1021/ja00369a007; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; PELTON JG, 1993, PROTEIN SCI, V2, P543; Pieroni L, 1997, J VIROL, V71, P6373, DOI 10.1128/JVI.71.9.6373-6380.1997; ROBERTS JD, 1982, J AM CHEM SOC, V104, P3945, DOI 10.1021/ja00378a027; Schmiedeskamp M, 1997, PROTEIN SCI, V6, P1835, DOI 10.1002/pro.5560060904; SCHUSTER II, 1979, J ORG CHEM, V44, P3864, DOI 10.1021/jo01336a025; SHUYUARN F, 1992, VIROLOGY, V186, P725; SOMMERGRUBER W, 1989, VIROLOGY, V169, P68, DOI 10.1016/0042-6822(89)90042-1; Steinkuhler C, 1996, J VIROL, V70, P6694; Stempniak M, 1997, J VIROL, V71, P2881, DOI 10.1128/JVI.71.4.2881-2886.1997; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Tomei L, 1996, J GEN VIROL, V77, P1065, DOI 10.1099/0022-1317-77-5-1065; Urbani A, 1997, J BIOL CHEM, V272, P9204; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANDIJK AA, 1992, BIOCHEMISTRY-US, V31, P9063, DOI 10.1021/bi00152a050; Vila AJ, 1996, J AM CHEM SOC, V118, P7291, DOI 10.1021/ja9601346; WITANOWSKI M, 1972, TETRAHEDRON, V28, P637, DOI 10.1016/0040-4020(72)84027-4	58	55	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18760	18769		10.1074/jbc.273.30.18760	http://dx.doi.org/10.1074/jbc.273.30.18760			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668049	hybrid, Green Published			2022-12-27	WOS:000074974700016
J	Sundaram, M; Yao, SYM; Ng, AML; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD				Sundaram, M; Yao, SYM; Ng, AML; Griffiths, M; Cass, CE; Baldwin, SA; Young, JD			Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; FUNCTIONAL-CHARACTERIZATION; CLONING; NITROBENZYLTHIOINOSINE; EXPRESSION; ADENOSINE; PROTEIN; BINDING; ANALOGS; SYSTEM	We have recently isolated cDNAs from human placenta and rat jejunum encoding the prototypic human and rat equilibrative nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporters hENT1 and rENT1. The two proteins (456 and 457 residues, M-r 50,000) are 78% identical in amino acid sequence and contain 11 potential transmembrane segments (TMs) with a large putative extracellular loop between TMs 1 and 2 and a large cytoplasmic loop between TMs 6 and 7, When expressed in Xenopus oocytes, recombinant hENT1 and rENT1 transport both purine and pyrimidine nucleosides, including adenosine, and are inhibited by nanomolar concentrations of NBMPR. hENT1 is also potently inhibited by coronary vasodilator drugs (dipyridamole, dilazep, and draflazine), whereas rENT1 is insensitive to inhibition by these compounds (dipyridamole IC,, values 190 nM (hENT1) and greater than or equal to 10 mu M (rENT1) at 10 mu M uridine). In the present study, we have generated reciprocal chimeras between hENT1 and rENT1, using splice sites at residues 99 (end of TM. 2) and 231 (end of TM 6), to identify structural domains of hENT1 responsible for transport inhibition by vasoactive compounds. Transplanting the amino-terminal half of hENT1 into rENT1 converted rENT1 into a dipyridamole/dilazep-sensitive transporter, whereas the amino-terminal half of rENT1 rendered hENT1 dipyridamole/dilazep-insensitive, Domain swaps within the amino-terminal halves of hENT1 and rENT1 identified residues 100-231 (incorporating TMs 3-6) of hENT1 as the major site of vasodilator interaction. Since these drugs function as competitive inhibitors of nucleoside transport and NBMPR binding, TMs 3-6 are likely to form part of the substrate-binding site.	Univ Alberta, Dept Physiol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Oncol, Membrane Transport Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Leeds	Young, JD (corresponding author), Univ Alberta, Dept Physiol, Membrane Transport Res Grp, 7-55 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; CLUMECK N, 1993, J ANTIMICROB CHEMOTH, V32, P133, DOI 10.1093/jac/32.suppl_A.133; CRAIG JE, 1994, MOL MICROBIOL, V11, P1159, DOI 10.1111/j.1365-2958.1994.tb00392.x; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fang X, 1996, BIOCHEM J, V317, P457, DOI 10.1042/bj3170457; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; JACOBSON KA, 1990, PURINES CELLULAR SIG, P20; JARVIS SM, 1982, J PHYSIOL-LONDON, V324, P31, DOI 10.1113/jphysiol.1982.sp014099; JARVIS SM, 1986, MOL PHARMACOL, V30, P659; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; SHI MM, 1986, BIOCHEM J, V240, P879, DOI 10.1042/bj2400879; SIVAPRASADARAO A, 1993, BIOCHEM J, V296, P209, DOI 10.1042/bj2960209; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	25	83	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21519	21525		10.1074/jbc.273.34.21519	http://dx.doi.org/10.1074/jbc.273.34.21519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705281	hybrid			2022-12-27	WOS:000075492600015
J	Velasco, G; Geelen, MJH; del Pulgar, TG; Guzman, M				Velasco, G; Geelen, MJH; del Pulgar, TG; Guzman, M			Malonyl-CoA-independent acute control of hepatic carnitine palmitoyltransferase I activity - Role of Ca2+ calmodulin-dependent protein kinase II and cytoskeletal components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; INTERMEDIATE FILAMENTS; RAT HEPATOCYTES; OKADAIC ACID; BETA-OXIDATION; PHOSPHORYLATION; MITOCHONDRIA; LIVER; CARBOXYLASE; CELLS	The mechanism of malonyl-CoA-independent acute control of hepatic carnitine palmitoyltransferase I (CPT-I) activity was investigated. In a first series of experiments, the possible involvement of the cytoskeleton in the control of CPT-I activity was studied. The results of these investigations can be summarized as follows. (i) Very mild treatment of permeabilized hepatocytes with trypsin produced around 50% stimulation of CPT-I activity. This effect was absent in cells that had been pretreated with okadaic acid (OA) and seemed to be due to the action of trypsin on cell component(s) distinct from CPT-I, (ii) Incubation of intact hepatocytes with 3,3'-iminodipropionitrile, a disrupter of intermediate filaments, increased CPT-I activity in a non-additive manner with respect to OA, Taxol, a stabilizer of the cytoskeleton, prevented the OA- and 3,3'-iminodipropionitrile-induced stimulation of CPT-I, (iii) CPT-I activity in isolated mitochondria was depressed in a dose-dependent fashion by the addition of a total cytoskeleton fraction and a cytokeratin-enriched cytoskeletal fraction, the latter being 3 times more potent than the former. In a second series of experiments, the possible link between Ca2+/calmodulin-dependent protein kinase II (Ca2+/CM-PKII) and the cytoskeleton was studied in the context of CPT-I regulation. The data of these experiments indicate that (i) purified Ca2+/CM-PKII activated CPT-I in permeabilized hepatocytes but not in isolated mitochondria, (ii) purified Ca2+/CM-PKII abrogated the inhibition of CPT-I of isolated mitochondria induced by a cytokeratin-enriched fraction, and (iii) the Ca2+/CM-PKII inhibitor KN-62 prevented the OA-induced phosphorylation of cytokeratins in intact hepatocytes, Results thus support a novel mechanism of short-term control of hepatic CPT-I activity which may rely on the cascade Ca2+/CM-PKII activation --> cytokeratin phosphorylation --> CPT-I de-inhibition.	Univ Utrecht, Vet Biochem Lab, NL-3508 TD Utrecht, Netherlands; Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; Univ Utrecht, Inst Biomembranes, NL-3508 TD Utrecht, Netherlands	Utrecht University; Complutense University of Madrid; Utrecht University	Geelen, MJH (corresponding author), Univ Utrecht, Vet Biochem Lab, POB 80-176, NL-3508 TD Utrecht, Netherlands.	mgeelen@biochem.dgk.ruu.nl	Gomez del Pulgar, Teresa/GXV-5256-2022; Velasco, Guillermo/H-5260-2012; Velasco, Guillermo/AAU-9189-2020	Velasco, Guillermo/0000-0002-1994-2386; Velasco, Guillermo/0000-0002-1994-2386; Guzman, Manuel/0000-0001-7475-118X				ALMAHBOBI G, 1992, EXP CELL RES, V200, P361, DOI 10.1016/0014-4827(92)90184-A; AVRUCH J, 1978, J BIOL CHEM, V253, P4754; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BERNIERVALENTIN F, 1982, J BIOL CHEM, V257, P7092; BEYNEN AC, 1981, BIOCHIM BIOPHYS ACTA, V665, P1, DOI 10.1016/0005-2760(81)90224-1; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; CADRIN M, 1992, CELL SIGNAL, V4, P715, DOI 10.1016/0898-6568(92)90052-A; COLLIER NC, 1993, J CELL BIOCHEM, V52, P297, DOI 10.1002/jcb.240520306; DeLoof A, 1996, INT REV CYTOL, V166, P1; Drynan L, 1996, BIOCHEM J, V317, P791, DOI 10.1042/bj3170791; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; ECKERT BS, 1986, CELL MOTIL CYTOSKEL, V6, P15, DOI 10.1002/cm.970060104; FEULLOLEY M, 1994, AM JPHYSL, V266, pE202; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; FONTAINE EM, 1995, BIOCHEM BIOPH RES CO, V213, P138, DOI 10.1006/bbrc.1995.2108; FORGACS G, 1995, J CELL SCI, V108, P2131; FRASER F, 1997, BIOCHEM J, V323, P411; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Geelen MJH, 1997, BIOCHEM BIOPH RES CO, V233, P253, DOI 10.1006/bbrc.1997.6437; Gualix J, 1996, J BIOL CHEM, V271, P1957, DOI 10.1074/jbc.271.4.1957; GUZMAN M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P227, DOI 10.1016/0005-2760(93)90224-W; GUZMAN M, 1995, BIOCHEM J, V311, P853, DOI 10.1042/bj3110853; GUZMAN M, 1992, BIOCHEM J, V287, P487, DOI 10.1042/bj2870487; GUZMAN M, 1994, BIOCHEM J, V300, P693, DOI 10.1042/bj3000693; GUZMAN M, 1996, AM J PHYSIOL, V270, pG710; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HAYSTEAD TAJ, 1988, EUR J BIOCHEM, V175, P339, DOI 10.1111/j.1432-1033.1988.tb14202.x; HENEGOUWEN PMP, 1992, EXP CELL RES, V199, P90; HOLEN I, 1992, BIOCHEM J, V284, P633, DOI 10.1042/bj2840633; HOLLAND R, 1984, EUR J BIOCHEM, V140, P325, DOI 10.1111/j.1432-1033.1984.tb08105.x; Inagaki M, 1997, J BIOCHEM, V121, P407; KASHFI K, 1992, BIOCHEM J, V282, P909, DOI 10.1042/bj2820909; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122; Linden M, 1996, BIOCHEM BIOPH RES CO, V218, P833, DOI 10.1006/bbrc.1996.0148; MCGARRY JD, 1977, J CLIN INVEST, V60, P265, DOI 10.1172/JCI108764; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; OHTA T, 1992, CARCINOGENESIS, V13, P2443, DOI 10.1093/carcin/13.12.2443; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Spurway TD, 1997, BIOCHEM J, V323, P119, DOI 10.1042/bj3230119; STROMER MH, 1990, CELL MOTIL CYTOSKEL, V17, P11, DOI 10.1002/cm.970170104; Toivola DM, 1997, J CELL SCI, V110, P23; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Velasco G, 1997, BIOCHEM J, V321, P211, DOI 10.1042/bj3210211; Velasco G, 1996, BIOCHEM BIOPH RES CO, V224, P754, DOI 10.1006/bbrc.1996.1095; Velasco G, 1997, ARCH BIOCHEM BIOPHYS, V337, P169, DOI 10.1006/abbi.1996.9784; VELASCO G, 1998, IN PRESS BIOCH PHARM; Zammit V.A., 1994, DIABETES REV, V2, P132	54	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21497	21504		10.1074/jbc.273.34.21497	http://dx.doi.org/10.1074/jbc.273.34.21497			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705278	hybrid			2022-12-27	WOS:000075492600012
J	Valasek, L; Trachsel, H; Hasek, J; Ruis, H				Valasek, L; Trachsel, H; Hasek, J; Ruis, H			Rpg1, the Saccharomyces cerevisiae homologue of the largest subunit of mammalian translation initiation factor 3, is required for translational activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; GLOBIN MESSENGER-RNA; FACTOR EIF-3; SHUTTLE VECTORS; PRT1 PROTEIN; YEAST; COMPLEX; CELLS; PURIFICATION; MECHANISM	Eukaryotic initiation factor 3 (eIF3) consists of at least eight subunits and plays a key role in the formation of the 43 S preinitiation complex by dissociating 40 and 60 S ribosomal subunits, stabilizing the ternary complex, and promoting mRNA binding to 40 S ribosomal subunits. The product of the Saccharomyces cerevisiae RPG1 gene has been described as encoding a protein required for passage through the G(1) phase of the cell cycle and exhibiting significant sequence similarity to the largest subunit of human eIF3. Here we show that under nondenaturing conditions, Rpg1p copurifies with a known yeast eIF3 subunit, Prt1p. An anti-Rpg1p antibody co-immunoprecipitates Prt1p, and an antibody directed against the Myc tag of a tagged version of Prt1p co-immunoprecipitates Rpg1p, demonstrating that both proteins are present in the same complex. A cell-free translation system derived from the temperature-sensitive rpg1-1 mutant strain becomes inactivated by incubation at 37 degrees C, and its activity can be restored by the addition of the Rpg1-containing protein complex. Finally, the rpg1-1 temperature-sensitive mutant strain shows a dramatic reduction of the polysome/monosome ratio upon shift to the restrictive temperature. These data show that Rpg1p is an authentic eIF3 subunit and plays an important role in the initiation step of translation.	Inst Biochem & Mol Zellbiol, Vienna Bioctr, A-1030 Vienna, Austria; Ludwig Boltzmann Forschungsstelle Biochem, A-1030 Vienna, Austria; Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Vienna Biocenter (VBC); Ludwig Boltzmann Institute; University of Bern; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Ruis, H (corresponding author), Inst Biochem & Mol Zellbiol, Vienna Bioctr, Dr Bohrgasse 9, A-1030 Vienna, Austria.	hr@abc.univie.ac.at	Valášek, Leoš Shivaya/I-5743-2014; Hasek, Jiri/H-2427-2014	Valášek, Leoš Shivaya/0000-0001-8123-8667; Hasek, Jiri/0000-0001-6634-2386				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; Altmann M, 1997, METHODS, V11, P343, DOI 10.1006/meth.1996.0432; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; BENNE R, 1978, J BIOL CHEM, V253, P3078; BURKE DJ, 1991, MOL CELL BIOL, V11, P3691, DOI 10.1128/MCB.11.7.3691; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOUMANS H, 1980, BIOCHIM BIOPHYS ACTA, V608, P39, DOI 10.1016/0005-2787(80)90131-8; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; HANNIG EM, 1995, BIOESSAYS, V17, P915, DOI 10.1002/bies.950171103; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Jirincova H, 1998, FOLIA BIOL-PRAGUE, V44, P73; Johnson KR, 1997, J BIOL CHEM, V272, P7106, DOI 10.1074/jbc.272.11.7106; Koller HT, 1996, YEAST, V12, P53, DOI 10.1002/(SICI)1097-0061(199601)12:1<53::AID-YEA886>3.0.CO;2-M; KOVACS D, 1993, SOCIOL RURALIS, V33, P100, DOI 10.1111/j.1467-9523.1993.tb00951.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIPKE PN, 1976, J BACTERIOL, V127, P610, DOI 10.1128/JB.127.1.610-618.1976; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Merrick WC., 1996, TRANSLATION CONTROL, P31; MERRIL CR, 1990, NATURE, V343, P779, DOI 10.1038/343779a0; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MOLDAVE K, 1988, GENETICS TRANSLATION, P271; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Polymenis M, 1997, GENE DEV, V11, P2522, DOI 10.1101/gad.11.19.2522; Sherman F, 1986, LAB COURSE MANUAL ME; Si K, 1997, P NATL ACAD SCI USA, V94, P14285, DOI 10.1073/pnas.94.26.14285; SIKORSKI RS, 1989, GENETICS, V122, P19; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1980, P NATL ACAD SCI-BIOL, V77, P770, DOI 10.1073/pnas.77.2.770; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; WESTERMANN P, 1986, FEBS LETT, V205, P171, DOI 10.1016/0014-5793(86)80891-2; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	44	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21253	21260		10.1074/jbc.273.33.21253	http://dx.doi.org/10.1074/jbc.273.33.21253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694884	hybrid			2022-12-27	WOS:000075386100077
J	Halsted, CH; Ling, EH; Luthi-Carter, R; Villanueva, JA; Gardner, JM; Coyle, JT				Halsted, CH; Ling, EH; Luthi-Carter, R; Villanueva, JA; Gardner, JM; Coyle, JT			Folylpoly-gamma-glutamate carboxypeptidase from pig jejunum - Molecular characterization and relation to glutamate carboxypeptidase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANTIGEN; PTEROYLPOLYGLUTAMATE HYDROLASE; MESSENGER-RNA; GENE; EXPRESSION; CLONING; ACID; DNA; AMINOPEPTIDASE; PURIFICATION	Jejunal folylpoly-gamma-glutamate carboxypeptidase hydrolyzes dietary folates prior to their intestinal absorption. The complete folylpoly-gamma-glutamate carboxypeptidase cDNA was isolated from a pig jejunal cDNA library using an amplified homologous probe incorporating primer sequences from prostate-specific membrane antigen, a protein capable of folate hydrolysis, The cDNA encodes a 751-amino acid polypeptide homologous to prostate-specific membrane antigen and rat brain N-acetylated alpha-linked acidic dipeptidase. PC3 transfectant membranes exhibited activities of folylpoly-gamma-carboxypeptidase and N-acetylated alpha-linked acidic dipeptidase, while immunoblots using monoclonal antibody to native folylpoly-gamma-glutamate carboxypeptidase identified a glycoprotein at 120 kDa and a polypeptide at 84 kDa, The kinetics of native folylpoly-gamma-carboxypeptidase were expressed in membranes of PC3 cells transfected with either pig folylpoly-gamma-carboxypeptidase or human prostate-specific membrane antigen. Folylpoly-gamma-carboxypeptidase transcripts were identified at 2.8 kilobase pairs in human and pig jejunum, human and rat brain, and human prostate cancer LNCaP cells. Thus, pig folylpoly-gamma-carboxypeptidase, rat N-acetylated alpha-linked acidic dipeptidase, and human prostate-specific membrane antigen appear to represent varied expressions of the same gene in different species and tissues. The discovery of the jejunal folylpoly-gamma-carboxypeptidase gene provides a framework for future studies on relationships among these proteins and on the molecular regulation of intestinal folate absorption.	Univ Calif Davis, Sch Med, Dept Internal Med, Davis, CA 95616 USA; Univ Calif Davis, Ctr Engn Plants Resistance Pathogens, Davis, CA 95616 USA; Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA	University of California System; University of California Davis; University of California System; University of California Davis; Harvard University; Harvard Medical School	Halsted, CH (corresponding author), Univ Calif Davis, Sch Med, Dept Internal Med, TB 156, Davis, CA 95616 USA.	chhalsted@ucdavis.edu			NIDDK NIH HHS [DK-45301, DK-35747] Funding Source: Medline; NIMH NIH HHS [MH-57201] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747, R01DK045301] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; Bzdega T, 1997, J NEUROCHEM, V69, P2270; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Carter RE, 1996, P NATL ACAD SCI USA, V93, P749, DOI 10.1073/pnas.93.2.749; CHANDLER C J, 1986, P539; CHANDLER CJ, 1991, AM J PHYSIOL, V260, pG865, DOI 10.1152/ajpgi.1991.260.6.G865; CHANDLER CJ, 1986, J BIOL CHEM, V261, P928; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DIXON KH, 1994, J BIOL CHEM, V269, P17; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Halsted C., 1990, FOLIC ACID METABOLIS, P23; ISRAELI RS, 1993, CANCER RES, V53, P227; ISRAELI RS, 1994, CANCER RES, V54, P1807; KRUMDIECK CL, 1970, ANAL BIOCHEM, V35, P123, DOI 10.1016/0003-2697(70)90017-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEK J, 1995, BRIT J CANCER, V72, P583, DOI 10.1038/bjc.1995.377; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; Luthi-Carter R, 1998, J PHARMACOL EXP THER, V286, P1020; Maras B, 1996, EUR J BIOCHEM, V236, P843, DOI 10.1111/j.1432-1033.1996.00843.x; Matsudaira P, 1989, PRACTICAL GUIDE PROT; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; Nguyen TT, 1997, GASTROENTEROLOGY, V112, P783, DOI 10.1053/gast.1997.v112.pm9041240; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Pinto JT, 1996, CLIN CANCER RES, V2, P1445; Rawlings ND, 1997, BBA-PROTEIN STRUCT M, V1339, P247, DOI 10.1016/S0167-4838(97)00008-3; RINKERSCHAEFFER CW, 1995, GENOMICS, V30, P105, DOI 10.1006/geno.1995.0019; ROBINSON MB, 1987, J BIOL CHEM, V262, P14498; Said HM, 1996, BBA-BIOMEMBRANES, V1281, P164, DOI 10.1016/0005-2736(96)00005-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Silver DA, 1997, CLIN CANCER RES, V3, P81; SLUSHER BS, 1992, J COMP NEUROL, V315, P217; SU SL, 1995, CANCER RES, V55, P1441; TROYER JK, 1995, INT J CANCER, V62, P552, DOI 10.1002/ijc.2910620511; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; VanHoozen CM, 1996, BIOCHEM J, V319, P725; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WANG TTY, 1986, J BIOL CHEM, V261, P3551; Yao R, 1996, P NATL ACAD SCI USA, V93, P10134, DOI 10.1073/pnas.93.19.10134	44	80	85	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20417	20424		10.1074/jbc.273.32.20417	http://dx.doi.org/10.1074/jbc.273.32.20417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685395	hybrid, Green Submitted			2022-12-27	WOS:000075305400072
J	Joseph, B; Orlian, M; Furneaux, H				Joseph, B; Orlian, M; Furneaux, H			p21(waf1) mRNA contains a conserved element in its 3 '-untranslated region that is bound by the Elav-like mRNA-stabilizing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; CYCLIN-DEPENDENT KINASES; AU-RICH ELEMENTS; P53-INDEPENDENT INDUCTION; DROSOPHILA-MELANOGASTER; GROWTH-FACTOR; CELLS; EXPRESSION; DIFFERENTIATION; P21	The Elav-like proteins are specific mRNA-binding proteins that regulate mRNA stability. The neuronal members of this family (HuD, HuC, and Hel-N1) are required for neuronal differentiation. In this report, using purified HuD protein we have localized a high affinity HuD binding site to a 42-nucleotide region within a U-rich tract in the 3'-untranslated region p21(wafl) mRNA. The binding of HuD to this site is readily displaced by an RNA oligonucleotide encoding the HuD binding site of c-fos. The sequence of this binding site is well conserved in human, mouse, and rat p21(wafl) mRNA. p21(wafl) is an inhibitor of cyclin-dependent kinases and proliferating cell nuclear antigen and induces cell cycle arrest at G(1)/S, a requisite early step in cell differentiation. The identification of an Elav-like protein binding site in the 3'-untranslated region of p21(wafl) provides a novel link between the induction of differentiation, mRNA stability, and the termination of the cell cycle.	Mem Sloan Kettering Canc Ctr, Mol Neurooncol Lab, Program Mol Pharmacol & Therapeut, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Furneaux, H (corresponding author), Mem Sloan Kettering Canc Ctr, Mol Neurooncol Lab, Program Mol Pharmacol & Therapeut, 1275 York Ave, New York, NY 10021 USA.			furneaux, henry/0000-0003-2212-1017	NCI NIH HHS [P30-CA08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Chung SM, 1997, J BIOL CHEM, V272, P6593, DOI 10.1074/jbc.272.10.6593; DALMAU J, 1992, AM J PATHOL, V141, P881; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARPER JW, 1993, CELL, V75, P805; HOMYK T, 1985, J NEUROGENET, V2, P309, DOI 10.3109/01677068509102326; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KING PH, 1994, J NEUROSCI, V14, P1943; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Li XS, 1996, CANCER RES, V56, P5055; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHAO ZM, 1995, ONCOGENE, V11, P493; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; Yan GZ, 1997, J NEUROSCI, V17, P6122; YAN GZ, 1995, J NEUROSCI, V15, P6200; Zeng YX, 1996, ONCOGENE, V12, P1557; ZHANG W, 1995, CANCER RES, V55, P668	36	103	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20511	20516		10.1074/jbc.273.32.20511	http://dx.doi.org/10.1074/jbc.273.32.20511			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685407	hybrid			2022-12-27	WOS:000075305400084
J	Sattlegger, E; Hinnebusch, AG; Barthelmess, IB				Sattlegger, E; Hinnebusch, AG; Barthelmess, IB			cpc-3, the Neurospora crassa homologue of yeast GCN2, encodes a polypeptide with juxtaposed eIF2 alpha kinase and histidyl-tRNA synthetase-related domains required for general amino acid control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; FACTOR-2-ALPHA EIF-2-ALPHA KINASE; ARGININE BIOSYNTHETIC ENZYMES; CROSS-PATHWAY REGULATION; PROTEIN-KINASE; INITIATION FACTOR-2-ALPHA; SACCHAROMYCES-CEREVISIAE; TRANSLATIONAL CONTROL; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI	Based on characteristic amino acid sequences of kinases that phosphorylate the alpha subunit of eukaryotic translation initiation factor 2 (eIF2 alpha kinases), degenerate oligonucleotide primers were constructed and used to polymerase chain reaction-amplify from genomic DNA of Neurospora crassa a sequence encoding part of a putative protein kinase. With this sequence an open reading frame was identified encoding a predicted polypeptide with juxtaposed eIF2 alpha kinase and histidyl-tRNA synthetase-related domains. The 1646 amino acid sequence of this gene, called cpc-3, showed 35% positional identity over almost the entire sequence with GCN2 of yeast, which stimulates translation of the transcriptional activator of amino acid biosynthetic genes encoded by GCN4, Strains disrupted for cpc-3 were unable to induce increased transcription and derepression of amino acid biosynthetic enzymes in amino acid-deprived cells. The cpc-3 mutation did not affect the ability to up-regulate mRNA levels of cpc-1, encoding the GCN4 homologue and transcriptional activator of amino acid biosynthetic genes in N. crassa, but the mutation abolished the dramatic increase of CPC1 protein level in response to amino acid deprivation, These findings suggest that cpc-3 is the functional homologue of GCN2, being required for increased translation of cpc-1 mRNA in amino acid-starved cells.	NICHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA; Leibniz Univ Hannover, Inst Appl Genet, D-30419 Hannover, Germany	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Leibniz University Hannover	Sattlegger, E (corresponding author), NICHD, Lab Eukaryot Gene Regulat, NIH, Bldg 6A,Rm B1A-05, Bethesda, MD 20892 USA.	esattlegger@aghmac1.nichd.nih.gov						Aberg A, 1997, BIOCHEMISTRY-US, V36, P3084, DOI 10.1021/bi9618373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arnez JG, 1997, P NATL ACAD SCI USA, V94, P7144, DOI 10.1073/pnas.94.14.7144; ARNEZ JG, 1995, EMBO J, V14, P4143, DOI 10.1002/j.1460-2075.1995.tb00088.x; BARTHELMESS IB, 1982, GENET RES, V39, P169, DOI 10.1017/S0016672300020863; BRUCHEZ JJP, 1993, FUNGAL GENETICS NEWS, V40, P85; CARSIOTIS M, 1974, J BACTERIOL, V119, P893, DOI 10.1128/JB.119.3.893-898.1974; CARSIOTIS M, 1974, J BACTERIOL, V119, P889, DOI 10.1128/JB.119.3.889-892.1974; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CATCHESIDE DEA, 1991, FUNGAL GENET NEWSL, V38, P71; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CHOW TYK, 1993, FUNGAL GENET NEWSLET, V40, P25; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; DAVIS RH, 1979, GENETICS, V93, P557; DAVIS RH, 1962, ARCH BIOCHEM BIOPHYS, V97, P185, DOI 10.1016/0003-9861(62)90063-2; DAVIS RH, 1979, METHOD ENZYMOL, V57, P79; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1986, URFS ORFS PRIMER ANA, P15; EBBOLE DJ, 1991, MOL CELL BIOL, V11, P928, DOI 10.1128/MCB.11.2.928; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FLAVELL RB, 1968, J BACTERIOL, V95, P1063, DOI 10.1128/JB.95.3.1063-1068.1968; FLINT HJ, 1986, MOL GEN GENET, V203, P110, DOI 10.1007/BF00330391; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; GRANT CM, 1994, MOL CELL BIOL, V14, P606, DOI 10.1128/MCB.14.1.606; GURR SJ, 1981, GENE STRUCTURE EUKAR, P93; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HILTON JL, 1965, ARCH BIOCHEM BIOPHYS, V112, P544, DOI 10.1016/0003-9861(65)90093-7; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1984, P NATL ACAD SCI-BIOL, V81, P6442, DOI 10.1073/pnas.81.20.6442; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; HOPE IA, 1985, CELL, V43, P177, DOI 10.1016/0092-8674(85)90022-4; ICELY PL, 1991, J BIOL CHEM, V266, P16073; IRELAN J, 1993, FUNGAL GENET NEWSL, V40, P24; JACOBS M, 1990, NUCLEIC ACIDS RES, V18, P1653, DOI 10.1093/nar/18.6.1653; KOLANUS J, 1990, MOL GEN GENET, V223, P443, DOI 10.1007/BF00264452; KRUGER D, 1990, CURR GENET, V18, P211, DOI 10.1007/BF00318383; KRUGER D, 1996, THESIS U HANNOVER GE; Lee S.B., 1988, FUNGAL GENET REP, V35, P23, DOI [10.4148/1941-4765.1531, DOI 10.4148/1941-4765.1531]; LUO ZG, 1995, MOL CELL BIOL, V15, P5235; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MELLOR H, 1994, J BIOL CHEM, V269, P10201; MELLOR H, 1994, BBA-GENE STRUCT EXPR, V1219, P693, DOI 10.1016/0167-4781(94)90229-1; METZENBERG RL, 1995, FUNGAL GENET NEWSLET, V42, P82; METZENBERG RL, 1984, NEUROSPORA NEWSL, V31, P35; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MULLER F, 1995, MOL GEN GENET, V248, P162, DOI 10.1007/BF02190797; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Qiu HF, 1998, MOL CELL BIOL, V18, P2697, DOI 10.1128/MCB.18.5.2697; QU SM, 1994, GENE, V140, P239, DOI 10.1016/0378-1119(94)90550-9; RABEN N, 1992, NUCLEIC ACIDS RES, V20, P1075, DOI 10.1093/nar/20.5.1075; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Robertson HD, 1996, BIOCHIMIE, V78, P909, DOI 10.1016/S0300-9084(97)86712-0; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; ROUSSOU I, 1988, MOL CELL BIOL, V8, P2132, DOI 10.1128/MCB.8.5.2132; Rudinger J, 1997, BIOORGAN MED CHEM, V5, P1001, DOI 10.1016/S0968-0896(97)00061-8; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Ruhlmann A, 1997, BIOCHEM BIOPH RES CO, V237, P192, DOI 10.1006/bbrc.1997.7108; SACHS MS, 1996, MYCOTA BIOCH MOL BIO, V4, P315; SAMBROOK J, 1989, MOL CLONING LABORATO, pE34; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; SATTLEGGER E, 1996, THESIS U HANNOVER GE; Sokolovsky V., 1990, FUNGAL GENET NEWSLET, V37, P41; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4867; Wang P, 1998, FUNGAL GENET BIOL, V23, P81, DOI 10.1006/fgbi.1997.1023; Wanke C, 1997, MOL MICROBIOL, V23, P23, DOI 10.1046/j.1365-2958.1997.1741549.x; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579; WEK SA, 1995, MOL CELL BIOL, V15, P4497; Yan W, 1996, BIOCHEMISTRY-US, V35, P6559, DOI 10.1021/bi952889f; ZABAROVSKY ER, 1990, NUCLEIC ACIDS RES, V18, P5912; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989; [No title captured]	86	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20404	20416		10.1074/jbc.273.32.20404	http://dx.doi.org/10.1074/jbc.273.32.20404			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685394	hybrid			2022-12-27	WOS:000075305400071
J	Vojtek, AB; Der, CJ				Vojtek, AB; Der, CJ			Increasing complexity of the Ras signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTIVATION; TRANSFORMATION; GTPASES; CASCADE; IDENTIFICATION; SUFFICIENT; MEDIATE; BINDING; CDNAS; P21		Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan	Der, CJ (corresponding author), Univ N Carolina, Dept Pharmacol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.			Der, Channing/0000-0002-7751-2747				AFAR DE, J IMMUNITY, V6, P773; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; Clark G. J., 1993, GTPASES BIOL, DOI 10.1007/978-3-642-78267-1_18; COLICELLI J, 1991, P NATL ACAD SCI USA, V88, P2913, DOI 10.1073/pnas.88.7.2913; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DATTA SR, 1997, CELL, V91, P2318; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; delPeso L, 1997, SCIENCE, V278, P687; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Han LM, 1997, P NATL ACAD SCI USA, V94, P4954, DOI 10.1073/pnas.94.10.4954; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Matsuo T, 1997, DEVELOPMENT, V124, P2671; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TODA T, 1987, ONCOGENES CANCER, P253; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WINKLER DG, 1997, J BIOL CHEM, V272, P24400; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZOHN IE, 1998, IN PRESS ONCOGENE	51	470	477	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19925	19928		10.1074/jbc.273.32.19925	http://dx.doi.org/10.1074/jbc.273.32.19925			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685325	hybrid, Green Published			2022-12-27	WOS:000075305400002
J	Gjoerup, O; Lukas, J; Bartek, J; Willumsen, BM				Gjoerup, O; Lukas, J; Bartek, J; Willumsen, BM			Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-CYCLE PROGRESSION; ABL TYROSINE KINASE; ACTIN STRESS FIBERS; S-PHASE ENTRY; DEREGULATED EXPRESSION; ONCOGENIC RAS; TRANSFORMATION; G(1); RHO	The Rho family of GTPases plays an important and diverse role in reorganization of the actin cytoskeleton, transcriptional regulation, and multiple aspects of cell growth. Our study has examined their potential links to the cell cycle machinery. We find that constitutively active mutants of Rac and Cdc42, but not Rho, are potent inducers of E2F transcriptional activity in NIH 3T3 fibroblasts. Furthermore, activated Rac and Cdc42, but again not Rho, are capable of inducing cyclin D1 accumulation and pRB hyperphosphorylation in serum-deprived cells, outlining one route leading to enhanced E2F-mediated transcription. The inhibitory effect of the cyclin-dependent kinase inhibitors, p16(ink4), p21(cip1), and p27(cip) on Rac/Cdc42-mediated E2F transcription corroborates a role for PRE family members and their functional inactivation by cyclin dependent kinases in generating E2F activity. While the up-regulation of E2F transcriptional activity by Rac or Cdc42, not Rho, suffices for entry into S phase and DNA synthesis in Rat-1 R12 cells, this is clearly not the case in NIH 3T3, where additional requirements must exist.	Univ Copenhagen, Dept Cellular & Mol Biol, DK-1353 Copenhagen K, Denmark; Danish Canc Soc, Div Canc Biol, DK-2100 Copenhagen, Denmark	University of Copenhagen; Danish Cancer Society	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Cellular & Mol Biol, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.		Willumsen, Berthe M/H-1903-2012; Bartek, Jiri/G-5870-2014	Willumsen, Berthe M/0000-0002-2277-6999; Lukas, Jiri/0000-0001-9087-506X				Afshari CA, 1997, ONCOGENE, V14, P3029, DOI 10.1038/sj.onc.1201157; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen Y, 1996, J BIOL CHEM, V271, P19637, DOI 10.1074/jbc.271.33.19637; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fan JG, 1997, ONCOGENE, V14, P2595, DOI 10.1038/sj.onc.1201105; FILMUS J, 1994, ONCOGENE, V9, P3627; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lukas J, 1996, MOL CELL BIOL, V16, P6917; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Michieli P, 1996, ONCOGENE, V12, P775; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; NEVINS JR, 1992, SCIENCE, V258, P424; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Renshaw MW, 1996, CURR BIOL, V6, P76, DOI 10.1016/S0960-9822(02)00424-4; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269; Winston JT, 1996, ONCOGENE, V12, P127; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	54	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18812	18818		10.1074/jbc.273.30.18812	http://dx.doi.org/10.1074/jbc.273.30.18812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668055	hybrid			2022-12-27	WOS:000074974700022
J	Huijbregts, RPH; de Kroon, AIPM; de Kruijff, B				Huijbregts, RPH; de Kroon, AIPM; de Kruijff, B			Rapid transmembrane movement of newly synthesized phosphatidylethanolamine across the inner membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT-SYSTEM; AMINO-ACIDS; PHOSPHATIDYLSERINE DECARBOXYLASE; ASYMMETRIC DISTRIBUTION; ENDOPLASMIC-RETICULUM; ACTIVE-TRANSPORT; PLASMA-MEMBRANE; PHOSPHOLIPIDS; PROTEIN; VESICLES	For the first time the transmembrane movement of an endogenously synthesized phospholipid across the inner membrane of E. coli is reported. [C-14]phosphatidylethanolamine (PE) was biosynthetically introduced into inner membrane vesicles from the PE deficient strain AD93, by reconstitution with the enzyme phosphatidylserine (PS) synthetase, Upon addition of wild type cell lysate containing PS synthetase, and the metabolic substrates CTP and [C-14]serine to inside-out vesicles from AD93, [C-14]PS was synthesized, which was for the most part converted into [C-14]PE. [C-14]PE was introduced in right-side out vesicles by enclosing PS synthetase and CTP in the vesicle lumen and adding [C-14]serine. The newly synthesized [C-14]PE immediately equilibrated over both membrane leaflets (t(1/2) less than one min), as determined by its accessibility toward the amino-reactive chemical fluorescamine. In both inside-out and right-side out vesicles, a 35-65% distribution was found of the newly synthesized PE over the cytoplasmic and periplasmic leaflet, respectively, The transport process of PE was not influenced by the presence of ATP or the proton motive force in inside out vesicles. Pretreatment of both types of vesicles with sulfhydryl reagents, or of right-side out vesicles with proteinase K, did not affect the rate and extent of the transmembrane distribution of the newly synthesized PE.	Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands	Utrecht University	Huijbregts, RPH (corresponding author), Univ Utrecht, Ctr Biomembranes & Lipid Enzymol, Inst Biomembranes, Dept Biochem Membranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		de Kroon, Anton I/O-4119-2016	de Kroon, Anton/0000-0003-1209-756X				BISHOP DG, 1977, EUR J BIOCHEM, V80, P381, DOI 10.1111/j.1432-1033.1977.tb11893.x; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bogdanov M, 1996, J BIOL CHEM, V271, P11615, DOI 10.1074/jbc.271.20.11615; BOGDANOV M, 1995, J BIOL CHEM, V270, P732, DOI 10.1074/jbc.270.2.732; CARTER JR, 1968, J LIPID RES, V9, P748; CHEN CC, 1986, J BIOL CHEM, V261, P2599; CHEN L, 1985, J BACTERIOL, V161, P973, DOI 10.1128/JB.161.3.973-980.1985; COLLEAU M, 1991, CHEM PHYS LIPIDS, V57, P29, DOI 10.1016/0009-3084(91)90046-E; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; deCock H, 1996, EMBO J, V15, P5567, DOI 10.1002/j.1460-2075.1996.tb00941.x; DEVRIJE T, 1987, BIOCHIM BIOPHYS ACTA, V900, P63, DOI 10.1016/0005-2736(87)90278-1; DONOHUEROLFE AM, 1980, P NATL ACAD SCI-BIOL, V77, P1867, DOI 10.1073/pnas.77.4.1867; Dowhan W, 1997, ANNU REV BIOCHEM, V66, P199, DOI 10.1146/annurev.biochem.66.1.199; DOWHAN W, 1992, METHOD ENZYMOL, V209, P348; DOWHAN W, 1974, J BIOL CHEM, V249, P3079; GELDWERTH D, 1993, J CLIN INVEST, V92, P308, DOI 10.1172/JCI116568; HAMA H, 1988, J BACTERIOL, V170, P2236, DOI 10.1128/jb.170.5.2236-2239.1988; HAMA H, 1987, BIOCHIM BIOPHYS ACTA, V905, P231, DOI 10.1016/0005-2736(87)90451-2; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; Hrafnsdottir S, 1997, BIOCHEMISTRY-US, V36, P4969, DOI 10.1021/bi962513h; Huijbregts RPH, 1996, BBA-BIOMEMBRANES, V1280, P41, DOI 10.1016/0005-2736(95)00272-3; Huijbregts RPH, 1997, MOL MEMBR BIOL, V14, P35, DOI 10.3109/09687689709048168; KANFER J, 1964, J BIOL CHEM, V239, P1720; KONINGS WN, 1971, J BIOL CHEM, V246, P5857; KREBS JJR, 1979, J BIOL CHEM, V254, P5308; LANGLEY KE, 1979, P NATL ACAD SCI USA, V76, P6245, DOI 10.1073/pnas.76.12.6245; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P5212, DOI 10.1021/bi00669a003; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; LOMBARDI FJ, 1972, J BIOL CHEM, V247, P7844; MUHLRADT PF, 1975, EUR J BIOCHEM, V51, P343, DOI 10.1111/j.1432-1033.1975.tb03934.x; MULLER M, 1984, P NATL ACAD SCI-BIOL, V81, P7421, DOI 10.1073/pnas.81.23.7421; OSBORN MJ, 1972, J BIOL CHEM, V247, P3062; Possot OM, 1997, MOL MICROBIOL, V24, P457, DOI 10.1046/j.1365-2958.1997.3451726.x; RAETZ CRH, 1972, J BIOL CHEM, V247, P2008; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; RAETZ CRH, 1974, J BIOL CHEM, V249, P5038; RAWYLER A, 1984, BIOCHIM BIOPHYS ACTA, V769, P330, DOI 10.1016/0005-2736(84)90314-6; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIETVELD AG, 1994, J BIOL CHEM, V269, P28670; RIETVELD AG, 1995, EMBO J, V14, P5506, DOI 10.1002/j.1460-2075.1995.tb00237.x; Rilfors L, 1984, MEMBRANE FLUIDITY, P205; ROSEMAN M, 1975, BIOCHEMISTRY-US, V14, P4826, DOI 10.1021/bi00693a008; ROTHMAN JE, 1977, P NATL ACAD SCI USA, V74, P1821, DOI 10.1073/pnas.74.5.1821; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Saha SK, 1996, BIOSCI BIOTECH BIOCH, V60, P111; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; Tang XJ, 1996, SCIENCE, V272, P1495, DOI 10.1126/science.272.5267.1495; TAVERNIER E, 1995, BIOCHIMIE, V77, P174, DOI 10.1016/0300-9084(96)88122-3; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	54	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18936	18942		10.1074/jbc.273.30.18936	http://dx.doi.org/10.1074/jbc.273.30.18936			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668071	hybrid			2022-12-27	WOS:000074974700038
J	Porter, DJT; Short, SA; Hanlon, MH; Preugschat, F; Wilson, JE; Willard, DH; Consler, TG				Porter, DJT; Short, SA; Hanlon, MH; Preugschat, F; Wilson, JE; Willard, DH; Consler, TG			Product release is the major contributor to k(cat) for the hepatitis C virus helicase-catalyzed strand separation of short duplex DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP HELICASE; ADENINE-NUCLEOTIDE BINDING; INDUCED DIMERIZATION; KINETIC MECHANISM; NS3 PROTEIN; NUCLEIC-ACID; GP41 FORMS; ASSAY; HYDROLYSIS; ENZYME	Hepatitis C virus (HCV) helicase catalyzes the ATP-dependent strand separation of duplex RNA and DNA containing a 3' single-stranded tail. Equilibrium and velocity sedimentation centrifugation experiments demonstrated that the enzyme was monomeric in the presence of DNA and ATP analogues. Steady-state and pre-steady-state kinetics for helicase activity were monitored by the fluorescence changes associated with strand separation of F21:HF31 that was formed from a 5'-hexachlorofluorescein-tagged 31-mer (HF31) and a complementary 3'-fluorescein-tagged 21-mer (F21). k(cat) for this reaction was 0.12 s(-1). The fluorescence change associated with strand separation of F21:HF31 by excess enzyme and ATP was a biphasic process. The time course of the early phase (duplex unwinding) suggested only a few base pairs (similar to 2) were disrupted concertedly. The maximal value of the rate constant (k(eff)) describing the late phase of the reaction (strand separation) was 0.5 s(-1), which was 4-fold greater than k(cat). Release of HF31 from E.HF31 in the presence of ATP (0.21 s(-1)) was the major contributor to k(cat). At saturating ATP and competitor DNA concentrations, the enzyme unwound 44% of F21:HF31 that was initially bound to the enzyme (low processivity). These results are consistent with a passive mechanism for strand separation of F21:HF31 by HCV helicase.	Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Porter, DJT (corresponding author), Glaxo Wellcome Inc, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.							ABDELMONEM M, 1976, EUR J BIOCHEM, V65, P441, DOI 10.1111/j.1432-1033.1976.tb10359.x; Ali JA, 1997, SCIENCE, V275, P377, DOI 10.1126/science.275.5298.377; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; Bjornson KP, 1996, BIOCHEMISTRY-US, V35, P2268, DOI 10.1021/bi9522763; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUKH J, 1994, P NATL ACAD SCI USA, V91, P8239, DOI 10.1073/pnas.91.17.8239; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Cohn E., 1943, PROTEINS AMINO ACIDS, P157; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; Dong F, 1996, J BIOL CHEM, V271, P19625, DOI 10.1074/jbc.271.32.19625; DURSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; Eggleston AK, 1996, NUCLEIC ACIDS RES, V24, P1179, DOI 10.1093/nar/24.7.1179; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; Gwack Y, 1996, BIOCHEM BIOPH RES CO, V225, P654, DOI 10.1006/bbrc.1996.1225; HOUSTON P, 1994, P NATL ACAD SCI USA, V91, P5471, DOI 10.1073/pnas.91.12.5471; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MAGRIN S, 1994, HEPATOLOGY, V19, P273; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Raney KD, 1996, J BIOL CHEM, V271, P14074, DOI 10.1074/jbc.271.24.14074; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; SEGL IH, 1993, ENZYME KINETICS, P564; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; WONG I, 1992, J BIOL CHEM, V267, P7596; Wong I, 1996, BIOCHEMISTRY-US, V35, P5726, DOI 10.1021/bi952959i; YO N, 1997, NAT STRUCT BIOL, V4, P463	39	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18906	18914		10.1074/jbc.273.30.18906	http://dx.doi.org/10.1074/jbc.273.30.18906			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668067	hybrid			2022-12-27	WOS:000074974700034
J	Venkatachalam, KV; Akita, H; Strott, CA				Venkatachalam, KV; Akita, H; Strott, CA			Molecular cloning, expression, and characterization of human bifunctional 3 '-phosphoadenosine 5 '-phosphosulfate synthase and its functional domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATED ENZYME INTERMEDIATE; SULFATE ACTIVATION LOCUS; ATP SULFURYLASE; SACCHAROMYCES-CEREVISIAE; PENICILLIUM-CHRYSOGENUM; ARABIDOPSIS-THALIANA; NUCLEOTIDE-SEQUENCE; RAT CHONDROSARCOMA; ESCHERICHIA-COLI; APS KINASE	The universal sulfonate donor, 3'-phosphoadenosine 5'-phosphosulfate (PAPS), is synthesized by the concerted action of ATP sulfurylase and adenosine 5'-phosphosulfate (APS) kinase, which in animals ale fused into a bifunctional protein. The cDNA for human PAPS synthase (hPAPSS) along with polymerase chain reaction products corresponding to several NH2- and COOH-terminal fragments were cloned and expressed in COS-l cells. A 1-268-amino acid fragment expressed APS kinase activity, whereas a 220-623 fragment evinced ATP sulfurylase activity. The 1-268 fragment and full-length hPAPSS (1-623) exhibited hyperbolic responses against APS substrate with equivalent K-m values (0.6 and 0.4 mu M, respectively). The 1-268 fragment demonstrated Michaelis-Menten kinetics against ATP as substrate (K-m 0.26 mM); however, full-length hPAPSS exhibited a sigmoidal response (apparent K-m 1.5 mM) suggesting cooperative binding. Catalytic efficiency (V-mac/K-m) of the 1-268 fragment was 64-fold higher than. full-length hPAPSS for ATP, The kinetic data suggest that the COOH-terminal domain of hPAPSS exerts a regulatory role over APS kinase activity located in that NH2-terminal domain of this bifunctional protein. In addition, the 1-268 fragment and full-length hPAPSS were overexpressed in Escherichia coli and column purified, Purified full-length hPAPSS, in contrast to the! COS-l cell-expressed cDNA construct, exhibited a hyperbolic response curve against ATP suggesting that hPAPSS is perhaps modified in vivo.	NICHD, Sect Steroid Regulat Endocrinol & Reprod, Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strott, CA (corresponding author), NICHD, Sect Steroid Regulat Endocrinol & Reprod, Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	cheastro@box-c.nih.gov		Venkatachalam, K.V./0000-0001-6692-9099				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ARZ HE, 1994, BBA-GENE STRUCT EXPR, V1218, P447, DOI 10.1016/0167-4781(94)90203-8; BANDURSKI RS, 1956, J AM CHEM SOC, V78, P6408, DOI 10.1021/ja01605a028; BORGESWALMSLEY MI, 1995, MOL GEN GENET, V247, P423; CHEREST H, 1987, MOL GEN GENET, V210, P307, DOI 10.1007/BF00325699; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FAROOQUI AA, 1980, INT J BIOCHEM, V12, P529, DOI 10.1016/0020-711X(80)90003-8; FOSTER BA, 1994, J BIOL CHEM, V269, P19777; GREGORY JD, 1960, ANNU REV BIOCHEM, V29, P347, DOI 10.1146/annurev.bi.29.070160.002023; Harlow E., 1988, ANTIBODIES LAB MANUA; Huxtable RJ, 1986, BIOCH SULFUR, P293; KITAGAWA T, 1976, J BIOCH, V79, P223; KORCH C, 1991, MOL GEN GENET, V229, P96, DOI 10.1007/BF00264218; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEUSTEK T, 1994, PLANT PHYSIOL, V105, P897, DOI 10.1104/pp.105.3.897; LEYH TS, 1988, J BIOL CHEM, V263, P2409; LEYH TS, 1992, J BIOL CHEM, V267, P10405; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; LI H, 1995, J BIOL CHEM, V270, P29453, DOI 10.1074/jbc.270.49.29453; LYLE S, 1994, BIOCHEMISTRY-US, V33, P5920, DOI 10.1021/bi00185a032; LYLE S, 1994, BIOCHEMISTRY-US, V33, P6822, DOI 10.1021/bi00188a010; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; RENOSTO F, 1989, J BIOL CHEM, V264, P9433; ROBBINS PW, 1956, J AM CHEM SOC, V78, P6409, DOI 10.1021/ja01605a029; ROBBINS PW, 1958, J BIOL CHEM, V233, P681; ROSENTHAL E, 1995, GENE, V165, P243, DOI 10.1016/0378-1119(95)00450-K; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATISHCHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P11684, DOI 10.1021/bi00162a003; SATISHCHANDRAN C, 1989, J BIOL CHEM, V264, P15012; SCHWEDOCK JS, 1994, J BACTERIOL, V176, P7055, DOI 10.1128/JB.176.22.7055-7064.1994; SEGAL IH, 1987, METHOD ENZYMOL, V143, P334; SERE PA, 1987, ANNU REV BIOCHEM, V56, P89; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VIEILLE C, 1990, MOL PLANT MICROBE IN, V3, P389, DOI 10.1094/MPMI-3-389; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	37	51	56	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19311	19320		10.1074/jbc.273.30.19311	http://dx.doi.org/10.1074/jbc.273.30.19311			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668121	hybrid			2022-12-27	WOS:000074974700088
J	Gerke, C; Kraft, A; Sussmuth, R; Schweitzer, O; Gotz, F				Gerke, C; Kraft, A; Sussmuth, R; Schweitzer, O; Gotz, F			Characterization of the N-acetylglucosaminyltransferase activity involved in the biosynthesis of the Staphylococcus epidermidis polysaccharide intercellular adhesin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULASE-NEGATIVE STAPHYLOCOCCI; AZORHIZOBIUM-CAULINODANS; SACCHAROMYCES-CEREVISIAE; TRANSPOSON MUTANTS; ESCHERICHIA-COLI; SYNTHASE GENE; PROTEIN; IDENTIFICATION; STREPTOCOCCUS; ACCUMULATION	The polysaccharide intercellular adhesin (PIA) is an important factor in the colonization of medical devices by Staphylococcus epidermidis. The genes encoding PIA production are organized in the icaADBC (intercellular adhesion) operon. To study the function of the individual genes, we have established an in vitro assay with UDP-N-acetylglucosamine, the substrate for PIA biosynthesis, and analyzed the products by thin-layer chromatography and mass spectrometry. IcaA alone exhibited a low N-acetylglucosaminyltransferase activity and represents the catalytic enzyme. Coexpression of icaA with icaD led to a significant increase in activity. The newly identified icaD gene is located between icaA and icaB and overlaps both genes, N-Acetylglucosamine oligomers produced by IcaAD reached a maximal length of 20 residues. Only when icaA and icaD were expressed together with icaC were oligomer chains that react with PIA-specific antiserum synthesized. IcaA and IcaD are located in the cytoplasmic membrane, and IcaC also has all the structural features of an integral membrane protein. These results indicate a close interaction between IcaA, IcaD, and IcaC. Tunicamycin and bacitracin did not affect the in vitro synthesis of PIA intermediates or the complete PIA biosynthesis in vivo, suggesting that a undecaprenyl phosphate carrier is not involved. IcaAD represents a novel protein combination among P-glycosyltransferases.	Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Max Planck Inst Entwicklungsbiol, Biochem Abt, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Gotz, F (corresponding author), Univ Tubingen, Inst Organ Chem, Waldhauser Str 7018, D-72076 Tubingen, Germany.	friedrich.goetz@uni-tuebingen.de		Sussmuth, Roderich/0000-0001-7027-2069; Gerke, Christiane/0000-0001-9446-8031				ARAKI Y, 1980, J BIOCHEM-TOKYO, V88, P469, DOI 10.1093/oxfordjournals.jbchem.a132994; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; Din AB, 1996, MOL GEN GENET, V250, P214; GEREMIA RA, 1994, P NATL ACAD SCI USA, V91, P2669, DOI 10.1073/pnas.91.7.2669; GOTZ F, 1987, FEMS MICROBIOL LETT, V40, P285, DOI 10.1016/0378-1097(87)90391-0; GOTZ F, 1990, J APPL BACTERIOL S, P49; Heilmann C, 1996, INFECT IMMUN, V64, P277, DOI 10.1128/IAI.64.1.277-282.1996; Heilmann C, 1996, MOL MICROBIOL, V20, P1083, DOI 10.1111/j.1365-2958.1996.tb02548.x; Heilmann C, 1997, MOL MICROBIOL, V24, P1013, DOI 10.1046/j.1365-2958.1997.4101774.x; Heilmann C, 1998, ZBL BAKT-INT J MED M, V287, P69; HOLTJE JV, 1975, J BACTERIOL, V124, P1067; Hussain M, 1997, INFECT IMMUN, V65, P519, DOI 10.1128/IAI.65.2.519-524.1997; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWICKA A, 1984, ZBL BAKT-INT J MED M, V258, P256, DOI 10.1016/S0176-6724(84)80043-7; LUDWICKA A, 1984, ZBL BAKT-INT J MED M, V256, P479, DOI 10.1016/S0174-3031(84)80024-4; LUGTENBE.EJ, 1972, J BACTERIOL, V109, P326, DOI 10.1128/JB.109.1.326-335.1972; MACK D, 1994, INFECT IMMUN, V62, P3244, DOI 10.1128/IAI.62.8.3244-3253.1994; Mack D, 1996, J BACTERIOL, V178, P175, DOI 10.1128/jb.178.1.175-183.1996; MARMUR J, 1961, J MOL BIOL, V3, P202; MERGAERT P, 1995, J BIOL CHEM, V270, P29217, DOI 10.1074/jbc.270.49.29217; MULLER E, 1993, INFECT IMMUN, V61, P551, DOI 10.1128/IAI.61.2.551-558.1993; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; *NEW ENGL BIOL, 1990, PROT FUS PUR SYST MA; ORLEAN P, 1987, J BIOL CHEM, V262, P5732; PASCUAL A, 1986, EUR J CLIN MICROBIOL, V5, P518, DOI 10.1007/BF02017694; Peschel A, 1996, J BACTERIOL, V178, P531, DOI 10.1128/jb.178.2.531-536.1996; PETERS G, 1981, ZBL BAKT MIK HYG B, V173, P293; ROSS P, 1991, MICROBIOL REV, V55, P35, DOI 10.1128/MMBR.55.1.35-58.1991; RUPP ME, 1994, CLIN INFECT DIS, V19, P231, DOI 10.1093/clinids/19.2.231; Sambrook J., 2002, MOL CLONING LAB MANU; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; SCHUMACHERPERDREAU F, 1994, FEMS MICROBIOL LETT, V117, P71; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; SPAINK HP, 1994, MOL MICROBIOL, V13, P821, DOI 10.1111/j.1365-2958.1994.tb00474.x; SUGAHARA K, 1979, J BIOL CHEM, V254, P6252; TIMMERMAN CP, 1991, INFECT IMMUN, V59, P4187, DOI 10.1128/IAI.59.11.4187-4192.1991; TOJO M, 1988, J INFECT DIS, V157, P713, DOI 10.1093/infdis/157.4.713; Tokuyasu K, 1996, BIOSCI BIOTECH BIOCH, V60, P1598, DOI 10.1271/bbb.60.1598; Veenstra GJC, 1996, J BACTERIOL, V178, P537, DOI 10.1128/jb.178.2.537-541.1996; WIELAND KP, 1995, GENE, V158, P91, DOI 10.1016/0378-1119(95)00137-U; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130; Ziebuhr W, 1997, INFECT IMMUN, V65, P890, DOI 10.1128/IAI.65.3.890-896.1997; [No title captured]	47	341	361	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18586	18593		10.1074/jbc.273.29.18586	http://dx.doi.org/10.1074/jbc.273.29.18586			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660830	hybrid			2022-12-27	WOS:000074828500085
J	Derfoul, A; Robertson, NM; Lingrel, JB; Hall, DJ; Litwack, G				Derfoul, A; Robertson, NM; Lingrel, JB; Hall, DJ; Litwack, G			Regulation of the human Na/K-ATPase beta 1 gene promoter by mineralocorticoid and glucocorticoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; RESPONSE ELEMENT; NA,K-ATPASE; EXPRESSION; ISOFORM; DNA; CORTICOSTEROIDS; COACTIVATOR; SUPERFAMILY; UPSTREAM	Expression of the human Na/K-ATPase beta 1 subunit is regulated by a mineralocorticoid- and glucocorticoid-responsive elements. Here we identified an MR and GR responsive element, at positions -650 to -630, within the beta 1 gene promoter that is required for both MR and GR activation. Independent expression of MR and GR activated by aldosterone or triamcinolone acetonide (TA) leads to significant transactivation of the beta 1 pro meter. Yet coexpression of both receptors activated by aldosterone plus TA or cortisol results in a much lower induction, indicating that coexpression of MR and GR is inhibitory. Gel shift mobility assay using an oligonucleotide including the al-base pair MRE/GRE with whole cell extracts prepared from CV-1 cells overexpressing MR or GR showed specific MR and GR binding to this sequence. Additionally, antibodies to both MR and GR effectively supershifted the protein-DNA complexes, indicating that these receptors bound to the DNA sequence. Finally, the 21-base pair MRE/GRE was capable of activating transcription from a heterologous promoter in response to both aldosterone and TA. Together these data indicate that the 21-base pair sequence represents a true MRE/GRE and that optimal activation of the human Na/K-ATPase beta 1 promoter is controlled by mineralocorticoid and glucocorticoid hormones, It appears that an interaction of MR with GR on the beta 1 promoter effectively down-regulates transcription.	Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	Jefferson University; University System of Ohio; University of Cincinnati	Litwack, G (corresponding author), Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Bluemle Life Sci Bldg,Rm 350,233 S 10th St, Philadelphia, PA 19107 USA.				NCI NIH HHS [CA67032] Funding Source: Medline; NIDDK NIH HHS [DK 44441] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067032] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1991, J BIOL CHEM, V266, P18072; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Bamberger CM, 1997, J STEROID BIOCHEM, V60, P43, DOI 10.1016/S0960-0760(96)00167-7; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EVANS RM, 1989, NEURON, V2, P1105, DOI 10.1016/0896-6273(89)90177-3; EWART HS, 1995, AM J PHYSIOL, pC295; FENG JI, 1993, NUCLEIC ACIDS RES, V21, P2619, DOI 10.1093/nar/21.11.2619; FUNDER JW, 1990, TRENDS ENDOCRIN MET, V1, P145, DOI 10.1016/1043-2760(90)90026-Y; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORISBERGER JD, 1991, ANNU REV PHYSIOL, V53, P565, DOI 10.1146/annurev.physiol.53.1.565; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; IKEDA U, 1991, J BIOL CHEM, V266, P12058; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; LANE LK, 1989, GENOMICS, V5, P445, DOI 10.1016/0888-7543(89)90008-6; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LINGREL JB, 1994, RENAL PHYSIOL BIOCH, V17, P198; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Liu WH, 1996, MOL ENDOCRINOL, V10, P1399, DOI 10.1210/me.10.11.1399; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; ONATE SA, 1995, SCIENCE, V270, P1354; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Verrey F, 1996, MINER ELECTROL METAB, V22, P279; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WHORWOOD CB, 1994, ENDOCRINOLOGY, V135, P901, DOI 10.1210/en.135.3.901; WHORWOOD CB, 1995, J MOL ENDOCRINOL, V15, P93, DOI 10.1677/jme.0.0150093	30	64	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20702	20711		10.1074/jbc.273.33.20702	http://dx.doi.org/10.1074/jbc.273.33.20702			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694812	hybrid			2022-12-27	WOS:000075386100005
J	Kurashima, K; Szabo, EZ; Lukacs, G; Orlowski, J; Grinstein, S				Kurashima, K; Szabo, EZ; Lukacs, G; Orlowski, J; Grinstein, S			Endosomal recycling of the Na+/H+ exchanger NHE3 isoform is regulated by the phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; GROWTH-FACTOR; GLUCOSE-TRANSPORT; INTRACELLULAR PH; MOLECULAR-CLONING; PROTEIN-KINASE; NA/H EXCHANGER; WORTMANNIN; CELLS; INHIBITOR	The NHE3 isoform of the Na+/H+ exchanger localizes to both the plasmalemmal and endosomal compartments in polarized epithelial and transfected Chinese hamster ovary (AP-1) cells. It is unclear how the distribution of NHE3 between these compartments is regulated. In this study, we examined the potential involvement of phosphatidylinositol 3'-kinase (PI3-K) in regulating the activity and distribution of NHE3, as this lipid kinase has been implicated in modulating vesicular traffic in the endosomal recycling pathway. Wortmannin and LY294002, both potent inhibitors of PI3-K, markedly inhibited NHE3-mediated Ht extrusion across the plasma membrane in a concentration- and time-dependent manner. The subcellular distribution of the antiporters was monitored by transfecting epitope-tagged NHE3 into AP-1 cells. In parallel with the inhibition of transport, PIS-K antagonists induced a pronounced loss of NHE3 from the cell surface and its accumulation in an intracellular compartment, as assessed by immunofluorescence microscopy and enzyme-linked immunosorbent assays. Further analysis using cells transfected with antiporters bearing an external epitope tag revealed that the redistribution reflected primarily a decrease in the rate of recycling of intracellular NHE3 to the cell surface. The wortmannin-induced inhibition and redistribution of NHE3 were prevented when cells were incubated at 4 degrees C, consistent with the known temperature dependence of the endocytic process. These observations demonstrate that NHE3 activity is controlled by dynamic endocytic and recycling events that are modulated by PI3-K.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Hosp Sick Children, Div Cell Biol, Cell Biol Programme, Res Inst, Toronto, ON M5G 1X8, Canada	McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Grinstein, S (corresponding author), Hosp Sick Children, Div Cell Biol, Cell Biol Programme, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.on.ca		Orlowski, John/0000-0001-7371-175X; Lukacs, Gergely/0000-0003-0900-0675				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Biemesderfer D, 1997, AM J PHYSIOL-RENAL, V273, pF289, DOI 10.1152/ajprenal.1997.273.2.F289; BORON WF, 1986, ANNU REV PHYSIOL, V48, P377; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; FIELD M, 1989, NEW ENGL J MED, V321, P879; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; Kurashima K, 1997, J BIOL CHEM, V272, P28672, DOI 10.1074/jbc.272.45.28672; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; MA YH, 1994, J BIOL CHEM, V269, P30734; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; OKADA T, 1994, J BIOL CHEM, V269, P3568; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SCHWARTZ MA, 1991, EXP CELL RES, V195, P533, DOI 10.1016/0014-4827(91)90407-L; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Spiro DJ, 1996, MOL BIOL CELL, V7, P355, DOI 10.1091/mbc.7.3.355; SueAQuan AK, 1997, J CELL PHYSIOL, V172, P94, DOI 10.1002/(SICI)1097-4652(199707)172:1<94::AID-JCP11>3.0.CO;2-O; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YANO H, 1993, J BIOL CHEM, V268, P25846; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	48	147	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20828	20836		10.1074/jbc.273.33.20828	http://dx.doi.org/10.1074/jbc.273.33.20828			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694828	hybrid			2022-12-27	WOS:000075386100021
J	Maechler, P; Kennedy, ED; Wang, HY; Wollheim, CB				Maechler, P; Kennedy, ED; Wang, HY; Wollheim, CB			Desensitization of mitochondrial Ca2+ and insulin secretion responses in the beta cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-ISLETS; CYTOSOLIC CA2+; ALPHA-TOXIN; INS-1 CELLS; B-CELLS; GLUCOSE; METABOLISM; CHANNELS; DEHYDROGENASE; AEQUORIN	The role of mitochondria in the desensitization of insulin secretion was investigated. In rat pancreatic beta cells, both insulin secretion and mitochondrial [Ca2+] increases were desensitized following two challenges with the mitochondrial substrate methyl succinate, In the beta cell line INS-1, similar results were observed when a B-min interval separated two 5-min pulses. In contrast, ATP generation monitored in luciferase-expressing INS-1 cells was stimulated to the same extent during both exposures to methyl succinate. Succinate, like alpha-glycerophosphate, activates the electron transport chain at complex II. As a consequence, the mitochondrial membrane hyperpolarizes, promoting ATP synthesis and Ca2+ influx into the mitochondria through the uniporter. The mitochondrial desensitization was further studied in permeabilized INS-1 cells. Increasing extramitochondrial [Ca2+] from 100 to 500 nM enhanced succinate oxidation 4-fold. At 500 nM Ca2+, 1 mM succinate caused a blunted mitochondrial [Ca2+] increase upon the second, compared with the first, stimulation. These effects were mimicked by alpha-glycerophosphate, and there was cross-desensitization between the two compounds. Succinate hyperpolarized the mitochondrial membrane during both the first and second applications. This suggests that the uniporter itself, rather than the respiratory chain, is desensitized. These results emphasize the key role of the mitochondria not only in the stimulation of insulin secretion, but also in its desensitization.	Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Wollheim, CB (corresponding author), Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland.			Maechler, Pierre/0000-0002-2005-1433				Anello M, 1996, DIABETES, V45, P502, DOI 10.2337/diabetes.45.4.502; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Boden G, 1996, AM J PHYSIOL-ENDOC M, V270, pE251, DOI 10.1152/ajpendo.1996.270.2.E251; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GILON P, 1993, J BIOL CHEM, V268, P22265; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HANSFORD RG, 1985, REV PHYSIOL BIOCH P, V102, P1, DOI 10.1007/BFb0034084; IDAHL LA, 1995, BIOCHEM J, V312, P287, DOI 10.1042/bj3120287; JONAS JC, 1994, BIOCHEM J, V301, P523, DOI 10.1042/bj3010523; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Kilpatrick ED, 1998, DIABETES, V47, P606, DOI 10.2337/diabetes.47.4.606; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; Litsky ML, 1997, BIOCHEMISTRY-US, V36, P7071, DOI 10.1021/bi970180y; MacDonald MJ, 1996, ARCH BIOCHEM BIOPHYS, V326, P79, DOI 10.1006/abbi.1996.0049; MACDONALD MJ, 1988, DIABETES, V37, P997, DOI 10.2337/diabetes.37.7.997; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Magnus G, 1997, AM J PHYSIOL-CELL PH, V273, pC717, DOI 10.1152/ajpcell.1997.273.2.C717; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391; NESHER R, 1987, ENDOCRINOLOGY, V121, P1017, DOI 10.1210/endo-121-3-1017; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Nilsson T, 1996, BIOCHEM J, V314, P91, DOI 10.1042/bj3140091; Nusse O, 1998, EMBO J, V17, P1279, DOI 10.1093/emboj/17.5.1279; OHTA M, 1990, J BIOL CHEM, V265, P17525; PALMER M, 1993, J BIOL CHEM, V268, P11959; PRALONG WF, 1994, J BIOL CHEM, V269, P27310; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROBERTSON RP, 1994, DIABETES, V43, P1085, DOI 10.2337/diabetes.43.9.1085; Rutter GA, 1996, P NATL ACAD SCI USA, V93, P5489, DOI 10.1073/pnas.93.11.5489; SATIN LS, 1994, BIOPHYS J, V66, P141, DOI 10.1016/S0006-3495(94)80759-3; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Sekine N, 1997, DIABETES, V46, P1424, DOI 10.2337/diabetes.46.9.1424; SENER A, 1990, BIOCHIM BIOPHYS ACTA, V1019, P42, DOI 10.1016/0005-2728(90)90122-K; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; TZAGOLOFF A, 1982, MITOCHONDRIA, P62; VOEST D, 1995, BIOCHEMISTRY-US, P538; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; [No title captured]	51	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20770	20778		10.1074/jbc.273.33.20770	http://dx.doi.org/10.1074/jbc.273.33.20770			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694821	hybrid, Green Published			2022-12-27	WOS:000075386100014
J	Tomita, T; Tokuhiro, S; Hashimoto, T; Aiba, K; Saido, TC; Maruyama, K; Iwatsubo, T				Tomita, T; Tokuhiro, S; Hashimoto, T; Aiba, K; Saido, TC; Maruyama, K; Iwatsubo, T			Molecular dissection of domains in mutant presenilin 2 that mediate overproduction of amyloidogenic forms of amyloid beta peptides - Inability of truncated forms of PS2 with familial Alzheimer's disease mutation to increase secretion of A beta 42*	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLGA GERMAN FAMILIES; PRECURSOR PROTEIN; MISSENSE MUTATIONS; MAMMALIAN-CELLS; WILD-TYPE; IN-VIVO; GENE; EXPRESSION; PATHOGENESIS; APOPTOSIS	Mutations in presenilin (PS) 1 or PS2 genes account for the majority of early-onset familial Alzheimer's disease, and these mutations have been shown to increase production of species of amyloid beta peptide (A beta) ending at residue 42, i.e. the most amyloidogenic form of A beta. To gain insight into the molecular mechanisms whereby mutant PS induces overproduction of A beta 42, we constructed cDNAs encoding mutant and/or truncated forms of PS2 and examined the secretion of A beta 42 hom COS or neuro2a cells transfected with these genes. Cells expressing full-length PS2 harboring both N141I and M239V mutations in the same polypeptide induced overproduction of A beta 42, although the levels of A beta 42 were comparable with those in cells engineered to express PS2 with one or the other of these PS2 mutations. In contrast, cells engineered to express partially truncated PS2 (eliminating the COOH-terminal third of PS2 while retaining the endoproteolytic NH2-terminal fragment) and harboring a N141I mutation, as well as cells expressing COOH-terminal fragments of PS2, did not overproduce A beta 42, and the levels of A beta 42 were comparable with those in cells that expressed full-length, wild-type PS2 or fragments thereof. These data indicate that: (i) the A beta 42-promoting effects of mutant PS2 proteins reach the maximum level with a given single amino acid substitution tie. N141I or M239V); and (ii) the expression of full-length mutant PS2 is required for the overproduction of A beta 42. Hence, cooperative interactions of NH2- and COOH-terminal fragments generated from full-length mutant PS2 may be important for the overproduction of A beta 42 that may underlie familial Alzheimer's disease.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 130033, Japan; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan; Natl Inst Physiol Sci, Neurochem Lab, Okazaki, Aichi 4448585, Japan	University of Tokyo; RIKEN; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 130033, Japan.		Saido, Takaomi C/N-5472-2015; Sado, Takaomi/AAN-2759-2021; Tomita, Taisuke/L-5427-2015; Hashimoto, Tadafumi/A-7723-2013	Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Tomita, Taisuke/0000-0002-0075-5943; Hashimoto, Tadafumi/0000-0001-5442-4800				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Baba M, 1998, AM J PATHOL, V152, P879; Baumeister R, 1997, Genes Funct, V1, P149; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1998, IN PRESS NEUROBIOL D; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Crook R, 1997, ANN NEUROL, V42, P124, DOI 10.1002/ana.410420121; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Janicki S, 1997, J CELL BIOL, V139, P485, DOI 10.1083/jcb.139.2.485; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kwok JBJ, 1997, NEUROREPORT, V8, P1537, DOI 10.1097/00001756-199704140-00043; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; LEVYLEHAD, 1995, SCIENCE, V269, P973; Mann DMA, 1997, ANN NEUROL, V41, P52, DOI 10.1002/ana.410410110; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; SAIDO TC, 1994, J BIOL CHEM, V269, P15253; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shirotani K, 1997, BIOCHEM BIOPH RES CO, V240, P728, DOI 10.1006/bbrc.1997.7730; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, J BIOL CHEM, V272, P7977, DOI 10.1074/jbc.272.12.7977; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	44	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21153	21160		10.1074/jbc.273.33.21153	http://dx.doi.org/10.1074/jbc.273.33.21153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694871	hybrid			2022-12-27	WOS:000075386100064
J	Um, S; Harbers, M; Benecke, A; Pierrat, B; Losson, R; Chambon, P				Um, S; Harbers, M; Benecke, A; Pierrat, B; Losson, R; Chambon, P			Retinoic acid receptors interact physically and functionally with the T : G mismatch-specific thymine-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; NUCLEAR HORMONE RECEPTORS; ACTIVATION FUNCTION AF-2; HUMAN ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; X RECEPTOR; STEROID-RECEPTORS; CRYSTAL-STRUCTURE; REPAIR ENZYME; PROTEIN HMG-1	The pleiotropic effects of retinoids are mediated by nuclear receptors that are activated by 9-cis- or all-trans-retinoic acid to function as ligand-dependent transcription factors. In a yeast one-hybrid screen for proteins capable of interacting with native retinoic acid receptor (RAR), we have isolated the T:G mismatch-specific thymine-DNA glycosylase (TDG), which initiates the repair of T:G mismatches caused by spontaneous deamination of methylated cytosines. Here, we report that TDG can interact with RAR and the retinoid X receptor (RXR) in a ligand-independent manner, both in yeast and in vitro. Mapping of the binding sites revealed interaction with a region of the ligand binding domain harboring alpha-helix 1 in both RAR and RXR. In transient transfection experiments, TDG potentiated transactivation by RXR from a direct repeat element spaced by one nucleotide (DR1) and by RXR/RAR heterodimers from a direct repeat element spaced by five nucleotides (DR5). In vitro, TDG enhanced RXR and RXR/RAR binding to their response elements. These data indicate that TDG is not only a repair enzyme, but could also function in the control of transcription.	ULP, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), ULP, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, BP 163, F-67404 Illkirch Graffenstaden, France.		Benecke, Arndt G./T-1079-2019	Harbers, Matthias/0000-0002-5613-7220				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHEN ZP, 1994, J BIOL CHEM, V269, P25770; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLEAVER JE, 1995, CELL, V80, P825, DOI 10.1016/0092-8674(95)90283-X; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Friedberg EC, 1996, ANNU REV BIOCHEM, V65, P15; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEERY DM, 1994, NUCLEIC ACIDS RES, V22, P726, DOI 10.1093/nar/22.5.726; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jones PA, 1997, P NATL ACAD SCI USA, V94, P2103, DOI 10.1073/pnas.94.6.2103; Jones PA, 1996, CANCER RES, V56, P2463; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; OLSEN LC, 1989, EMBO J, V8, P3121, DOI 10.1002/j.1460-2075.1989.tb08464.x; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; ONATE SA, 1995, SCIENCE, V270, P1354; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Prendergast P, 1996, MOL ENDOCRINOL, V10, P393, DOI 10.1210/me.10.4.393; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229; Verrier CS, 1997, MOL ENDOCRINOL, V11, P1009, DOI 10.1210/me.11.8.1009; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	72	103	105	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20728	20736		10.1074/jbc.273.33.20728	http://dx.doi.org/10.1074/jbc.273.33.20728			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694815	hybrid			2022-12-27	WOS:000075386100008
J	Kawamura, S; Abe, Y; Ueda, T; Masumoto, K; Imoto, T; Yamasaki, N; Kimura, M				Kawamura, S; Abe, Y; Ueda, T; Masumoto, K; Imoto, T; Yamasaki, N; Kimura, M			Investigation of the structural basis for thermostability of DNA-binding protein HU from Bacillus stearothermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE ELECTROSTATIC INTERACTIONS; HISTONE-LIKE PROTEIN; ESCHERICHIA-COLI; SALT BRIDGES; STABILITY; SPECTROSCOPY; SUBTILIS; SITE; HBSU	Site-directed mutagenesis was used to identify amino acid residues essential for the thermostability of the DNA-binding protein HU from the thermophile Bacillus stearothermophilus (BstHU), Two mutants, BstHU-A27S and BsfHU-V42I, in which Ala(27) and Val(42) in BstHU were replaced by the corresponding amino acids Ser(27) and Ile(42), respectively, in the homologue from a mesophile B. subtilis (BsuHU), were less stable than the wild-type BstHU (63.9 degrees C), showing T-m values of 58.4 degrees C and 60.1 degrees C, respectively, as estimated by circular dichroism (CD) analysis at pH 7.0. The denaturation of two mutants was further characterized using differential scanning calorimetry; the T-m values obtained by calorimetric analysis were in good agreement with those estimated by CD analysis. The results suggest that Ala(27) and Val(42) are partly responsible for enhancing the thermostability of BstHU, When considered together with previous results, it is revealed that Gly(15), Ala(27), Glu(34), Lys(38), and Val(42) are essential for the thermostability of thermophilic protein BstHU, Moreover, five thermostabilizing mutations were simultaneously introduced into BsuHU, which resulted in a quintuple mutant with a T-m value of 71.3 degrees C, which is higher than that of BstHU, and also resulted in insusceptibility to proteinase digestion.	Kyushu Univ, Biochem Lab, Fac Agr, Fukuoka 81281, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Fukuoka 81281, Japan	Kyushu University; Kyushu University	Kimura, M (corresponding author), Kyushu Univ, Biochem Lab, Fac Agr, Fukuoka 81281, Japan.	mkimura@agr.kyushu-u.ac.jp	Abe, Yoshito/AAH-6141-2021; Abe, Yoshito/D-8370-2012	Abe, Yoshito/0000-0002-0016-8490; Abe, Yoshito/0000-0002-0016-8490				AKASAKO A, 1995, BIOCHEMISTRY-US, V34, P8115, DOI 10.1021/bi00025a018; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DRICA K, 1987, MICROBIOL REV, V51, P301; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; Hosaka H, 1997, STRUCTURE, V5, P1199, DOI 10.1016/S0969-2126(97)00270-0; HWANG DS, 1992, J BIOL CHEM, V267, P23083; IMBER R, 1987, EUR J BIOCHEM, V165, P547, DOI 10.1111/j.1432-1033.1987.tb11474.x; Imoto T, 1997, CELL MOL LIFE SCI, V53, P215, DOI 10.1007/PL00000593; IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0; Kawamura S, 1997, J BIOCHEM-TOKYO, V121, P448; Kawamura S, 1996, BIOCHEMISTRY-US, V35, P1195, DOI 10.1021/bi951581l; KAWAMURA S, 1995, BIOSCI BIOTECH BIOCH, V59, P126, DOI 10.1271/bbb.59.126; LAVOIE BD, 1994, J BIOL CHEM, V269, P15571; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; OGASAHARA K, 1985, EUR J BIOCHEM, V150, P17, DOI 10.1111/j.1432-1033.1985.tb08979.x; Querol E, 1996, PROTEIN ENG, V9, P265, DOI 10.1093/protein/9.3.265; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; TANAKA I, 1984, NATURE, V310, P376, DOI 10.1038/310376a0; TRAVERS AA, 1994, CELL, V77, P167, DOI 10.1016/0092-8674(94)90306-9; Vieille C, 1996, TRENDS BIOTECHNOL, V14, P183, DOI 10.1016/0167-7799(96)10026-3; VIS H, 1994, BIOCHEMISTRY-US, V33, P14858, DOI 10.1021/bi00253a025; VIS H, 1995, J MOL BIOL, V254, P692, DOI 10.1006/jmbi.1995.0648; Vogt G, 1997, J MOL BIOL, V269, P631, DOI 10.1006/jmbi.1997.1042; WADA M, 1989, GENE, V76, P345, DOI 10.1016/0378-1119(89)90174-1; WELFLE H, 1993, EUR J BIOCHEM, V217, P849, DOI 10.1111/j.1432-1033.1993.tb18313.x; WELFLE H, 1992, EUR J BIOCHEM, V204, P1049, DOI 10.1111/j.1432-1033.1992.tb16727.x; WHITE SW, 1989, PROTEINS, V5, P281, DOI 10.1002/prot.340050405; WILSON KS, 1990, PROTEIN ENG, V4, P11, DOI 10.1093/protein/4.1.11	30	34	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19982	19987		10.1074/jbc.273.32.19982	http://dx.doi.org/10.1074/jbc.273.32.19982			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685334	hybrid			2022-12-27	WOS:000075305400011
J	Law, GL; Itoh, H; Law, DJ; Mize, GJ; Merchant, JL; Morris, DR				Law, GL; Itoh, H; Law, DJ; Mize, GJ; Merchant, JL; Morris, DR			Transcription factor ZBP-89 regulates the activity of the ornithine decarboxylase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TUMOR SUPPRESSOR WT1; GENE-EXPRESSION; C-MYC; BINDING; GROWTH; CELLS; ACTIVATION; REPRESSION; SITE	Appropriate cellular levels of polyamines are required for cell growth and differentiation. Ornithine decarboxylase is a key regulatory enzyme in the biosynthesis of polyamines, and precise regulation of the expression of this enzyme is required, according to cellular growth state, A variety of mitogens increase the level of ornithine decarboxylase activity, and, in most cases, this elevation is due to increased levels of mRNA. A GC box in the proximal promoter of the ornithine decarboxylase gene is required for basal and induced transcriptional activity, and two proteins, Spl and NF-ODC1, bind to this region in a mutually exclusive manner, Using a yeast one-hybrid screening method, ZBP-89, a DNA-binding protein, was identified as a candidate for the protein responsible for NF-ODC1 binding activity. Three lines of evidence verified this identification; ZBP-89 co-purified with NF-ODC1 binding activity, ZBP-89 antibodies specifically abolished NF-ODC1 binding to the GC box, and binding affinities of 12 different double-stranded oligonucleotides were indistinguishable between NF-ODC1, in nuclear extract, and in vitro translated ZBP-89, ZBP-89 inhibited the activation of the ornithine decarboxylase promoter by Spl in Schneider's Drosophila line 2, consistent with properties previously attributed to NF-ODC1.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Akita Univ, Sch Med, Dept Biochem, Akita 010, Japan; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Washington; University of Washington Seattle; Akita University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011; Merchant, Juanita/AAF-8277-2019	Merchant, Juanita/0000-0002-6559-8184	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045729, R01DK045729] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08229] Funding Source: Medline; NIDDK NIH HHS [DK45729] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABMAYR SM, 1991, CURRENT PROTOCOLS MO; ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ABRAHAMSEN MS, 1991, PERSPECTIVES CELL RE, P107; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BLACK O, 1982, CANC LETT, V1, P87; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; BRASIER AR, 1991, CURRENT PROTOCOLS MO; CAO XM, 1993, J BIOL CHEM, V268, P16949; CONTURSI C, 1995, J BIOL CHEM, V270, P26570, DOI 10.1074/jbc.270.44.26570; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HEBY O, 1981, DIFFERENTIATION, V9, P1; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; JAGGI R, 1988, J STEROID BIOCHEM, V29, P457, DOI 10.1016/0022-4731(88)90179-3; JOHNSON AC, 1992, J BIOL CHEM, V267, P1689; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; LAW GL, 1995, POLYAMINES REGULATIO, P5; LI RS, 1994, J BIOL CHEM, V269, P7941; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; MOSHIER JA, 1993, CANCER RES, V53, P2618; OSTROWSKI J, 1993, NUCLEIC ACIDS RES, V21, P1045, DOI 10.1093/nar/21.4.1045; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PEGG AE, 1988, CANCER RES, V48, P759; PENA A, 1993, J BIOL CHEM, V268, P27277; SEILER N, 1990, CANCER RES, V50, P5077; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Taniuchi T, 1997, BIOCHEM BIOPH RES CO, V233, P154, DOI 10.1006/bbrc.1997.6310; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YOSHIDA M, 1992, CANCER RES, V52, P6671	46	73	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19955	19964		10.1074/jbc.273.32.19955	http://dx.doi.org/10.1074/jbc.273.32.19955			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685330	hybrid			2022-12-27	WOS:000075305400007
J	Liu, QY; Wang, JC				Liu, QY; Wang, JC			Identification of active site residues in the "GyrA" half of yeast DNA topoisomerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; 2-GATE MECHANISM; FLP RECOMBINASE; CLEAVAGE; TRANSPORT; TYROSINE; PROTEIN; ENZYME; REPLICATION; FRAGMENT	Site-directed mutagenesis was carried out at 10 highly conserved polar residues within the C-terminal half of yeast DNA topoisomerase II, which corresponds to the A subunit of bacterial DNA gyrase, to identify amino acid side chains that augment the active site tyrosine Tyr-782 in the breakage and rejoining of DNA strands. Complementation tests show that alanine substitution at Arg-690, Asp-697, Lys-700, Arg-704, or Arg-781, but not at His-735, His-736, Glu-738, Gln-750, or Asn-828, inactivates the enzyme in vivo. Measurements of DNA relaxation and cleavage by purified mutant enzymes show that these activities are abolished in the R690A mutant and are much reduced in the mutants D697A, K700A, R704A, and R781A. When a Y782F polypeptide with a phenylalanine substituting for the active site tyrosine was expressed in cells that also express the R690A polypeptide, the resulting heterodimeric yeast DNA topoisomerase II was found to nick plasmid DNA, Thus in a dimeric wild-type enzyme, Tyr-782 in one protomer and Arg-690 in the other cooperate in trans in the catalysis of DNA cleavage. For the residues D697A, K700A, R704A, and R781A, their locations in the crystal structures of type II DNA topoisomerase fragments suggest that Arg-781 and Lys-700 might be involved in anchoring the 5' and 3' sides of the broken DNA, respectively, and the roles of Asp-697 and Arg-704 are probably less direct.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Wang, JC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.				NIGMS NIH HHS [GM24544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024544, R37GM024544] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BERGER JM, 1995, STRUCTURAL DETERMINA; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Cabral JHM, 1997, NATURE, V388, P903, DOI 10.1038/42294; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CARON PR, 1994, DNA TOPOISOMERASES T, P271; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHAMPOUX JJ, 1981, J BIOL CHEM, V256, P4805; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1979, P NATL ACAD SCI USA, V76, P8289; GOTO T, 1984, CELL, V36, P1073, DOI 10.1016/0092-8674(84)90057-6; Jayaram M, 1997, SCIENCE, V276, P49, DOI 10.1126/science.276.5309.49; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; LIU L, 1994, DNA TOPOISOMERASES T; LIU LF, 1983, J BIOL CHEM, V258, P5365; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; LYNN RM, 1989, PROTEINS, V6, P231, DOI 10.1002/prot.340060305; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MORRISON A, 1979, CELL, V17, P175, DOI 10.1016/0092-8674(79)90305-2; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; REESE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROWE TC, 1984, J BIOL CHEM, V259, P9177; SANDER M, 1983, J BIOL CHEM, V258, P8421; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; STETLER GL, 1979, P NATL ACAD SCI USA, V76, P3737, DOI 10.1073/pnas.76.8.3737; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; TSE YC, 1980, J BIOL CHEM, V255, P5560; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	47	45	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20252	20260		10.1074/jbc.273.32.20252	http://dx.doi.org/10.1074/jbc.273.32.20252			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685374	hybrid			2022-12-27	WOS:000075305400051
J	Rodriguez-Cousino, N; Solorzano, A; Fujimura, T; Esteban, R				Rodriguez-Cousino, N; Solorzano, A; Fujimura, T; Esteban, R			Yeast positive-stranded virus-like RNA replicons - 20 S and 23 S RNA terminal nucleotide sequences and 3 ' end secondary structures resemble those of RNA coliphages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; REPLICATION; POLYMERASE; IDENTIFICATION; FORM; FAMILY	Saccharomyces cerevisiae strains carry single-stranded RNAs called 20 S RNA and 23 S RNA. These RNAs and their double-stranded counterparts, W and T dsRNAs, have been cloned and sequenced, A few nucleotides at both ends, however, remained unknown, These RNAs do not encode coat proteins but their own RNA-dependent RNA polymerases that share a high degree of conservation to each other. The polymerases are also similar to the replicases of RNA coliphages, such as Q beta, Here we have determined the nucleotide sequences of W and T dsRNAs at both ends using reverse transcriptase polymerase chain reaction-generated cDNA clones, We confirmed the terminal sequences by primer-extension and RNase protection experiments. Furthermore, these analyses demonstrated that W and T dsRNAs and their single-stranded RNA counterparts (i) are linear molecules, (ii) have identical nucleotide sequences at their ends, and (iii) have no poly(A) tails at their 3' ends. Both 20 S and 23 S RNAs have GGGGC at the 5' ends and the complementary 5-nucleotides sequence, GCCCC-OH, at their 3' ends. S1 and V1 secondary structure-mapping of the 3' ends of 20 S and 23 S RNAs shows the presence of a stem-loop structure that partially overlaps with the conserved 3' end sequence. Nucleotide sequences and stem-loop structures similar to those described here have been found at the 3' ends of RNA coliphages, These data, together with the similarity of the RNA-dependent RNA polymerases encoded among these RNAs and RNA coliphages, suggest that 20 S and 23 S RNAs are plus-strand single-stranded virus-like RNA replicons in yeast.	Univ Salamanca, Dept Genet & Microbiol, Inst Microbiol Bioquim, CSIC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Esteban, R (corresponding author), Univ Salamanca, Dept Genet & Microbiol, Inst Microbiol Bioquim, CSIC, Edificio Dept Avda Campo Charro S-N, E-37007 Salamanca, Spain.		Rodríguez-Cousiño, Nieves/K-6465-2014; Fujimura, Tsutomu/K-5807-2014; Esteban, Rosa/K-4356-2014	Rodríguez-Cousiño, Nieves/0000-0002-6458-3677; Fujimura, Tsutomu/0000-0002-9457-6769; Esteban, Rosa/0000-0001-6804-7209; Solorzano, Alicia/0000-0003-0072-3463				ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BOEKE JD, 1991, MOL CELLULAR BIOL YE, P193; BRUENN JA, 1993, NUCLEIC ACIDS RES, V21, P5667, DOI 10.1093/nar/21.24.5667; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; CIGAN AM, 1987, GENE, V59, P1; ELSHERBEINI M, 1987, P NATL ACAD SCI USA, V84, P4293, DOI 10.1073/pnas.84.12.4293; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN LM, 1993, THESIS U SALAMANCA S; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; Flores R, 1995, VIRUS TAXONOMY, P495; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; GarciaCuellar MP, 1997, RNA, V3, P27; HANNIG EM, 1985, NUCLEIC ACIDS RES, V13, P4379, DOI 10.1093/nar/13.12.4379; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; Koonin EV, 1992, SEMIN VIROL, V3, P327; Lamb Robert A., 1996, P605; MAIZELS N, 1993, RNA WORLD, P577; Maniatis T., 1982, MOL CLONING LAB MANU; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MATSUMOTO Y, 1991, J BIOL CHEM, V266, P12779; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; Patton JT, 1996, J VIROL, V70, P3961, DOI 10.1128/JVI.70.6.3961-3971.1996; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; PRIANO C, 1987, COLD SPRING HARB SYM, V52, P321, DOI 10.1101/SQB.1987.052.01.037; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; WEJKSNORA PJ, 1978, J BACTERIOL, V134, P246, DOI 10.1128/JB.134.1.246-260.1978; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; WIDNER WR, 1991, MOL CELL BIOL, V11, P2905, DOI 10.1128/MCB.11.5.2905; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	40	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20363	20371		10.1074/jbc.273.32.20363	http://dx.doi.org/10.1074/jbc.273.32.20363			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685388	hybrid			2022-12-27	WOS:000075305400065
J	Adachi, M; Mikami, B; Katsube, T; Utsumi, S				Adachi, M; Mikami, B; Katsube, T; Utsumi, S			Crystal structure of recombinant soybean beta-amylase complexed with beta-cyclodextrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; SWEET-POTATO; EXPRESSION; PROTEIN; CLONING; CRYSTALLIZATION; SUBSTRATE; ISOZYMES; BINDING	In order to study the interaction of soybean beta-amylase with substrate, we solved the crystal structure of beta-cyclodextrin-enzyme complex and compared it with that of alpha-cyclodextrin-enzyme complex. The enzyme was expressed in Escherichia coli at a high level as a soluble and catalytically active protein. The purified recombinant enzyme had properties nearly identical: to those of native soybean beta-amylase and formed the same crystals as the native enzyme. The crystal structure of recombinant enzyme complexed with beta-cyclodextrin was refined at 2.07-Angstrom resolution with a final crystallographic R value of 15.8% (R-free = 21.1%). The root mean square deviation in the position of C-alpha atoms between this recombinant enzyme and the native enzyme was 0.22 Angstrom. These results indicate that the expression system established here is suitable for studying structure-function relationships of beta-amylase, The conformation of the bound beta-cyclodextrin takes an ellipsoid shape in contrast to the circular shape of the bound alpha-cyclodextrin. The cyclodextrins shared mainly two glucose binding sites, 3 and 4. The glucose residue 4 was slightly shifted hom the maltose binding site. This suggests that the binding site of the cyclodextrins is important for its holding of a cleaved substrate, which enables the multiple attack:mechanism of beta-amylase.	Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan	Kyoto University	Mikami, B (corresponding author), Kyoto Univ, Food Sci Res Inst, Uji, Kyoto 6110011, Japan.	mikami@soya.food.kyoto-u.ac.jp						BAILEY JM, 1957, BIOCHEM J, V67, P540, DOI 10.1042/bj0670540; BAILEY JM, 1957, J BIOL CHEM, V226, P1; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEONG CG, 1995, PROTEINS, V21, P105, DOI 10.1002/prot.340210204; FRENCH D, 1961, NATURE, V190, P445, DOI 10.1038/190445a0; FRENCH D, 1950, J AM CHEM SOC, V72, P1866, DOI 10.1021/ja01160a537; FRENCH D, 1961, ENZYMES, V4, P345; IMBERTY A, 1988, J MOL BIOL, V201, P365, DOI 10.1016/0022-2836(88)90144-1; JI ES, 1990, AGR BIOL CHEM TOKYO, V54, P3065, DOI 10.1080/00021369.1990.10870425; KATSUBE T, 1995, PLANT PHYSIOL, V109, P722; KAWAZU T, 1987, J BACTERIOL, V169, P1564, DOI 10.1128/jb.169.4.1564-1570.1987; KIM CS, 1990, PROTEIN ENG, V3, P725, DOI 10.1093/protein/3.8.725; KITAMOTO N, 1988, J BACTERIOL, V170, P5848, DOI 10.1128/jb.170.12.5848-5854.1988; KREIS M, 1987, EUR J BIOCHEM, V169, P517, DOI 10.1111/j.1432-1033.1987.tb13640.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MARSHALL JJ, 1973, EUR J BIOCHEM, V33, P494, DOI 10.1111/j.1432-1033.1973.tb02708.x; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P1, DOI 10.1111/j.1432-1033.1990.tb15454.x; MIKAMI B, 1982, AGR BIOL CHEM TOKYO, V46, P943, DOI 10.1080/00021369.1982.10865177; MIKAMI B, 1986, J BIOCHEM-TOKYO, V100, P513, DOI 10.1093/oxfordjournals.jbchem.a121741; MIKAMI B, 1993, BIOCHEMISTRY-US, V32, P6836, DOI 10.1021/bi00078a006; MIKAMI B, 1994, BIOCHEMISTRY-US, V33, P7779, DOI 10.1021/bi00191a005; MONROE JD, 1991, PLANT PHYSIOL, V97, P1599, DOI 10.1104/pp.97.4.1599; MORITA Y, 1975, J BIOCHEM-TOKYO, V77, P343, DOI 10.1093/oxfordjournals.jbchem.a130731; MORITA Y, 1976, J BIOCHEM, V79, P591, DOI 10.1093/oxfordjournals.jbchem.a131102; NITTA Y, 1989, J BIOCHEM-TOKYO, V105, P573, DOI 10.1093/oxfordjournals.jbchem.a122706; NITTA Y, 1983, J BIOCHEM-TOKYO, V93, P1195, DOI 10.1093/oxfordjournals.jbchem.a134245; NOMURA K, 1986, J BIOCHEM-TOKYO, V100, P1175, DOI 10.1093/oxfordjournals.jbchem.a121821; RHODES C, 1987, NUCLEIC ACIDS RES, V15, P3934, DOI 10.1093/nar/15.9.3934; RORAT T, 1991, THEOR APPL GENET, V83, P257, DOI 10.1007/BF00226260; SAENGER W, 1983, BIOCHEM SOC T, V11, P136, DOI 10.1042/bst0110136; SHARFF AJ, 1993, BIOCHEMISTRY-US, V32, P10553, DOI 10.1021/bi00091a004; SIGGENS KW, 1987, MOL MICROBIOL, V1, P86, DOI 10.1111/j.1365-2958.1987.tb00531.x; SIGGENS KW, 1988, MOL MICROBIOL, V1, P170; STEINER T, 1994, J AM CHEM SOC, V116, P5122, DOI 10.1021/ja00091a014; SUGANUMA T, 1980, AGR BIOL CHEM TOKYO, V44, P1111, DOI 10.1080/00021369.1980.10864080; THOMA JA, 1960, J AM CHEM SOC, V82, P3329, DOI 10.1021/ja01498a025; THOMA JA, 1971, ENZYMES, V5, P115; TOTSUKA A, 1994, EUR J BIOCHEM, V221, P649, DOI 10.1111/j.1432-1033.1994.tb18777.x; Totsuka A, 1996, EUR J BIOCHEM, V240, P655, DOI 10.1111/j.1432-1033.1996.0655h.x; TOTSUKA A, 1993, EUR J BIOCHEM, V214, P787, DOI 10.1111/j.1432-1033.1993.tb17981.x; Utsumi S, 1992, Adv Food Nutr Res, V36, P89, DOI 10.1016/S1043-4526(08)60105-9; YOSHIDA N, 1991, J BIOCHEM-TOKYO, V110, P196, DOI 10.1093/oxfordjournals.jbchem.a123556; YOSHIGI N, 1995, J BIOCHEM, V118, P562, DOI 10.1093/oxfordjournals.jbchem.a124946; YOSHIGI N, 1994, BIOSCI BIOTECH BIOCH, V58, P1080, DOI 10.1271/bbb.58.1080	48	45	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19859	19865		10.1074/jbc.273.31.19859	http://dx.doi.org/10.1074/jbc.273.31.19859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677422	hybrid			2022-12-27	WOS:000075125200074
J	Heist, EK; Srinivasan, M; Schulman, H				Heist, EK; Srinivasan, M; Schulman, H			Phosphorylation at the nuclear localization signal of Ca2+/calmodulin-dependent protein kinase II blocks its nuclear targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-DEPENDENT KINASE; MULTIFUNCTIONAL CAM KINASE; CENTRAL-NERVOUS-SYSTEM; CELL-CYCLE; TRANSCRIPTION FACTOR; HIPPOCAMPAL SLICES; FOS TRANSCRIPTION; RAT-BRAIN; EXPRESSION; ACTIVATION	Translocation of protein kinases with broad: substrate specificities between different subcellular compartments by activation of signaling pathways is an established mechanism to direct the activity of these enzymes toward particular substrates. Recently, we identified two isoforms of Ca2+/calmodulin-dependent protein kinase II (CaM kinase II), which are targeted to the nucleus by an alternatively spliced nuclear localization signal (NLS). Here we report that cotransfection with constitutively active mutants of CaM kinase I or CaM kinase IV specifically blocks nuclear targeting of CaM kinase II as a result of phosphorylation of a Ser immediately adjacent to the NLS of CaM kinase II. Both CaM kinase I and CaM kinase IV are able to phosphorylate this Ser residue in vitro, and mutagenesis studies suggest that this phosphorylation is both necessary and sufficient to block nuclear targeting. Furthermore, we provide experimental evidence that introduction of a negatively charged residue at this phosphorylation site reduces; binding of the kinase to an NLS receptor in vitro, thus providing a mechanism that may explain the blockade of nuclear targeting that me have observed in situ.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.	schulman@cmgm.stanford.edu			NIGMS NIH HHS [GM40600, 5T32 GM07365, GM 30179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040600, T32GM007365, R37GM030179, R01GM030179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; BACSKAI BJ, 1993, SCIENCE, V260, P222, DOI 10.1126/science.7682336; BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; EDMAN CF, 1994, BIOCHIM BIOPHYS ACTA, V1221, P90; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KURET J, 1984, BIOCHEMISTRY-US, V23, P5495, DOI 10.1021/bi00318a018; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Linden D J, 1993, Curr Opin Neurobiol, V3, P401, DOI 10.1016/0959-4388(93)90133-J; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; Nakamura Y, 1996, NEUROSCI LETT, V204, P61, DOI 10.1016/0304-3940(96)12317-X; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONEILL RE, 1995, VIROLOGY, V206, P116, DOI 10.1016/S0042-6822(95)80026-3; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PLANASSILVA MD, 1992, EMBO J, V11, P507, DOI 10.1002/j.1460-2075.1992.tb05081.x; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	63	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19763	19771		10.1074/jbc.273.31.19763	http://dx.doi.org/10.1074/jbc.273.31.19763			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677407	hybrid			2022-12-27	WOS:000075125200059
J	Sakai, T; Peyruchaud, O; Fassler, R; Mosher, DF				Sakai, T; Peyruchaud, O; Fassler, R; Mosher, DF			Restoration of beta(1)A integrins is required for lysophosphatidic acid-induced migration of beta(1)-null mouse fibroblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ADHESION; FIBRONECTIN; PROLIFERATION; MODULATION; INVASION; BINDING; ENCODES; GENE	Cells lacking the beta(1) integrin subunit or expressing beta(1)A with certain cytoplasmic mutations have poor directed cell migration to platelet-derived growth factor or epidermal growth factor, ligands of receptor tyrosine kinases (Sakai, T., Zhang, Q., FHssler, 8, and Mosher, D. F, (1998) J. Cebl Biol. 141, 527-538). We investigated the effect of expression of beta(1)A integrins on lysophosphatidic acid (LPA)-induced migration of fibroblastic cells derived from beta(1)-null mouse embryonic stem cells. These cells expressed edg-2, a G-protein-linked receptor for LPA, as well as the related edg-1 receptor. Cells expressing wild type beta(1)A demonstrated enhanced cell migration across filters coated with gelatin or adhesive proteins in response to LPA, whereas beta(1)-deficient cells lacked LPAinduced cell migratory ability. Checkerboard analyses indicated that LPA causes both chemotaxis and chemokinesis of beta(1)-replete cells. Cells expressing beta(1)A with mutations of prolines or tyrosines in conserved cytoplasmic NPXY motifs, threonine in the inter-motif sequence, or a critical aspartic acid in the extracellular domain had low migratory responses to LPA. These findings indicate that active beta(1)A integrin is required for cell migration induced by LPA and that the cytoplasmic domain of ligated beta(1)A interacts with pathways that are common to both receptor tyrosine kinase and G-protein-linked receptor signaling.	Univ Wisconsin, Dept Med, Med Sci Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Lund Univ, Dept Expt Pathol, S-22185 Lund, Sweden	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Lund University	Mosher, DF (corresponding author), Univ Wisconsin, Dept Med, Med Sci Ctr, 1300 Univ Ave,4285B, Madison, WI 53706 USA.	dfmosher@facstaff.wisc.edu		Peyruchaud, Olivier/0000-0002-5393-4945	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644, R01HL054462] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462, HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Bornfeldt KE, 1996, TRENDS CARDIOVAS MED, V6, P143, DOI 10.1016/1050-1738(96)00038-2; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HLA T, 1990, J BIOL CHEM, V265, P9308; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imamura F, 1996, INT J CANCER, V65, P627, DOI 10.1002/(SICI)1097-0215(19960301)65:5<627::AID-IJC12>3.0.CO;2-4; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LaFlamme SE, 1997, MATRIX BIOL, V16, P153, DOI 10.1016/S0945-053X(97)90003-2; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SAKAI T, 1995, INT J CANCER, V63, P720, DOI 10.1002/ijc.2910630519; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; STOKES CL, 1991, J THEOR BIOL, V152, P377, DOI 10.1016/S0022-5193(05)80201-2; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WILKINSON PC, 1988, METHOD ENZYMOL, V162, P3; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; ZETTER BR, 1990, NEW ENGL J MED, V322, P605; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447	43	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19378	19382		10.1074/jbc.273.31.19378	http://dx.doi.org/10.1074/jbc.273.31.19378			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677354	hybrid			2022-12-27	WOS:000075125200006
J	Zhang, XN; Spudich, JL				Zhang, XN; Spudich, JL			HtrI is a dimer whose interface is sensitive to receptor photoactivation and His-166 replacements in sensory rhodopsin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; SINGLE CYTOPLASMIC DOMAIN; METHYL-ACCEPTING PROTEIN; COILED-COIL INTERACTIONS; COLI ASPARTATE RECEPTOR; ESCHERICHIA-COLI; BACTERIAL CHEMOTAXIS; HALOBACTERIUM-HALOBIUM; TRANSDUCER; CHEMORECEPTOR	Single cysteine substitutions were introduced into three positions of otherwise cysteineless HtrI, a phototaxis transducer found in Halobacterium salinarum that transmits signals from the photoreceptor sensory rhodopsin I (SRI) to a cytoplasmic pathway controlling the cell's motility. Oxidative cross-linking of the monocysteine HtrI mutants in membrane suspensions resulted in dimer forms evident in SDS-polyacrylamide gels. The rate of cross-linking of I64C on the cytoplasmic side of HtrI was accelerated by SRI binding in the dark and further increased by SRI photoactivation. Several residue replacements of His-166 in SRI accelerated the cross-linking rate of I64C in the dark and His-166 mutants that exhibit "inverted signaling" (mediating repellent instead of the normally attractant response to orange light) inverted the light effect on the cross-linking rate of I64C, Secondary structure prediction of HtrI indicates a coiled coil structure in the cytoplasmic region following TM2, a dimerization domain found in a diverse group of proteins. We conclude that 1) HtrI exists as a dimer both in the absence of SRI and in the SRI-HtrI complex, 2) binding of SRI in the dark increases reactivity of the two cysteines at position I64C in the dimer by increasing their proximity or mobility, 3) light activation of wild-type SRI further increases their reactivity, 4) His-166 replacements in the SRI receptor have conformational effects on the structure of HtrI at position 64, and 5) inverted signaling by His-166 mutants likely results from an inverted conformational change at this region induced by SRI photoactivation.	Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System	Spudich, JL (corresponding author), Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA.				NIGMS NIH HHS [R01-GM27750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHEN BW, 1994, BIOTECHNIQUES, V17, P657; Chen XM, 1997, BIOCHEMISTRY-US, V36, P11858, DOI 10.1021/bi970911u; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; CLINE SW, 1987, J BACTERIOL, V169, P1341, DOI 10.1128/jb.169.3.1341-1344.1987; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gardina PJ, 1996, SCIENCE, V274, P425, DOI 10.1126/science.274.5286.425; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; HODGES RS, 1981, J BIOL CHEM, V256, P1214; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Hughson AG, 1996, P NATL ACAD SCI USA, V93, P11546, DOI 10.1073/pnas.93.21.11546; Jung KH, 1996, P NATL ACAD SCI USA, V93, P6557, DOI 10.1073/pnas.93.13.6557; Jung KH, 1998, J BACTERIOL, V180, P2033, DOI 10.1128/JB.180.8.2033-2042.1998; KIM SH, 1992, COLD SPRING HARB SYM, V57, P17, DOI 10.1101/SQB.1992.057.01.004; KRAH M, 1994, EMBO J, V13, P2150, DOI 10.1002/j.1460-2075.1994.tb06491.x; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P3486, DOI 10.1073/pnas.90.8.3486; LEE GF, 1995, P NATL ACAD SCI USA, V92, P3391, DOI 10.1073/pnas.92.8.3391; LEE GF, 1994, J BIOL CHEM, V269, P29920; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; OLSON KD, 1993, BIOPHYS J, V65, P2578, DOI 10.1016/S0006-3495(93)81295-5; OLSON KD, 1995, P NATL ACAD SCI USA, V92, P3185, DOI 10.1073/pnas.92.8.3185; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; Perazzona B, 1996, J BACTERIOL, V178, P6475, DOI 10.1128/jb.178.22.6475-6478.1996; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SARKAR G, 1990, NUCLEIC ACIDS RES, V18, P7465, DOI 10.1093/nar/18.24.7465; SEIDEL R, 1995, P NATL ACAD SCI USA, V92, P3036, DOI 10.1073/pnas.92.7.3036; SPUDICH EN, 1993, J BIOL CHEM, V268, P16095; STOCK JB, 1996, ESCHERICHIA COLI SAL, P123; STODDARD BL, 1992, BIOCHEMISTRY-US, V31, P11978, DOI 10.1021/bi00163a004; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; Tatsuno I, 1996, SCIENCE, V274, P423, DOI 10.1126/science.274.5286.423; YAO VJ, 1992, P NATL ACAD SCI USA, V89, P11915, DOI 10.1073/pnas.89.24.11915; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P8230, DOI 10.1073/pnas.93.16.8230; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P4649, DOI 10.1073/pnas.93.10.4649; Zhang XN, 1997, BIOPHYS J, V73, P1516, DOI 10.1016/S0006-3495(97)78183-9	50	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19722	19728		10.1074/jbc.273.31.19722	http://dx.doi.org/10.1074/jbc.273.31.19722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677402	hybrid			2022-12-27	WOS:000075125200054
J	Beninga, J; Rock, KL; Goldberg, AL				Beninga, J; Rock, KL; Goldberg, AL			Interferon-gamma can stimulate post-proteasomal trimming of the N terminus of an antigenic peptide by inducing leucine aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ENDOPLASMIC-RETICULUM; LYMPHOCYTES-T; MHC; DEGRADATION; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION	Most antigenic peptides presented on major histocompatibility complex class I molecules are generated during protein breakdown by proteasomes, whose specificity is altered by interferon-gamma (IFN-gamma). When extended versions of the ovalbumin-derived epitope SIINFEKL are expressed in vivo, the correct C terminus is generated by proteasomal cleavage, but distinct cytosolic protease(s) generate its N terminus. To identify the other protease(s) involved in antigen processing, we incubated soluble extracts of HeLa cells with the 11-mer QLESIINFEKL, which in vivo is processed to the antigenic 8-mer (SIINFEKL) by a proteasome-independent pathway. This 11-mer was converted to the 9-mer by sequential removal of the N-terminal residues, but surprisingly the extract showed little or no endopeptidase or carboxypeptidase activity against this precursor. After treatment of cells with IFN-gamma, this N-terminal trimming was severalfold faster and proceeded to the antigenic 8-mer. The IFN-treated cells also showed greater aminopeptidase activity against many model fluorogenic substrates. Upon extract fractionation, three bestatin-sensitive aminopeptidase peaks were detected, One was induced by IFN-gamma and was identified immunologically as leucine aminopeptidase (LAP). Purified LAP, like the extracts of IFN-gamma-treated cells, processed the 11-mer peptide to SIINFEKL. Thus, IFN-gamma not only promotes proteasomal cleavages that determine the C termini of antigenic peptides, but also can stimulate formation of their N termini by inducing LAP. This enzyme appears to catalyze the trimming of the N terminus of this and presumably other proteasome-derived precursors. Thus, susceptibility to LAP may be an important influence on the generation on immunodominant epitopes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01655 USA	Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	agoldber@bcmp.med.harvard.edu						AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; ANON LC, 1997, J IMMUNOL, V158, P2535; Bacik I, 1997, J EXP MED, V186, P479, DOI 10.1084/jem.186.4.479; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; Cerundolo V, 1997, EUR J IMMUNOL, V27, P336, DOI 10.1002/eji.1830270148; COUX O, 1996, ANNU REV BIOCHEM, V65, P1; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DICK LR, 1994, J IMMUNOL, V152, P3884; DICK TP, 1996, NATURE, V365, P262; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; ELLIOTT T, 1995, J EXP MED, V181, P1481, DOI 10.1084/jem.181.4.1481; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; GACZYNSKA M, 1994, P NATL ACAD SCI USA, V91, P9213, DOI 10.1073/pnas.91.20.9213; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GRANT EP, 1995, J IMMUNOL, V155, P3750; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; HARDING CV, 1995, J IMMUNOL, V155, P1767; HARRIS CA, 1992, J BIOL CHEM, V267, P6865; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; MA CP, 1992, J BIOL CHEM, V267, P10515; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V2; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROELSE J, 1994, J EXP MED, V180, P1591, DOI 10.1084/jem.180.5.1591; SNYDER HL, 1994, J EXP MED, V180, P2389, DOI 10.1084/jem.180.6.2389; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; TISLJAR U, 1993, BIOL CHEM H-S, V374, P91; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UDAKA K, 1993, P NATL ACAD SCI USA, V90, P11272, DOI 10.1073/pnas.90.23.11272; UENAKA A, 1994, J EXP MED, V180, P1599, DOI 10.1084/jem.180.5.1599; VANENDERT PM, 1995, J EXP MED, V182, P1883, DOI 10.1084/jem.182.6.1883; VANKAER L, 1994, IMMUNITY, V1, P533, DOI 10.1016/1074-7613(94)90043-4; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	50	236	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18734	18742		10.1074/jbc.273.30.18734	http://dx.doi.org/10.1074/jbc.273.30.18734			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668046	hybrid			2022-12-27	WOS:000074974700013
J	Pepio, AM; Fan, XT; Sossin, WS				Pepio, AM; Fan, XT; Sossin, WS			The role of C2 domains in Ca2+-activated and Ca2+ independent protein kinase Cs in Aplysia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; TRANSFERASE FUSION PROTEINS; PHOSPHATIDYL-L-SERINE; SENSORY NEURONS; PRESYNAPTIC FACILITATION; TRANSMITTER RELEASE; REGULATORY DOMAIN; MIXED MICELLES; LIPID-BINDING; ACTIVATION	In the nervous system of the marine mollusk Aplysia there are two protein kinase C (PKC) isoforms, the Ca2+-activated PKC Apl I and the Ca2+-independent PKC Apl II. PKC Apl I, but not PKC Apl II is activated by a shortterm application of the neurotransmitter serotonin, This may be explained by the fact that purified PKC Apl II requires a higher mole percentage of phosphatidylserine to stimulate enzyme activity than does PKC Apl I. In order to understand the molecular basis for this difference, we have compared the ability of lipids to interact with the purified kinases and with regulatory domain fusion proteins derived from the kinases using a variety of assays including kinase activity, phorbol dibutyrate binding, and Liposome binding. We found that a C2 domain fusion protein derived from PKC Apl I binds to lipids constitutively, while a C2 domain fusion protein derived from PKC Apl II does not. In contrast, fusion proteins containing the C1 domains of PRC Apl I and PKC Apl II showed only small differences in lipid interactions. Thus, while the presence of a C2 domain assists lipid-mediated activation of PKC Apl I, it inhibits activation of PKC Apl II.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Sossin, WS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Univ Ave, Montreal, PQ H3A 2B4, Canada.	mdws@musica.mcgill.ca						BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Edwards AS, 1997, BIOCHEMISTRY-US, V36, P15615, DOI 10.1021/bi9718752; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; ELIOT LS, 1993, NATURE, V361, P634, DOI 10.1038/361634a0; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEE MH, 1992, BIOCHEMISTRY-US, V31, P5176, DOI 10.1021/bi00137a013; MALENKA RC, 1987, BRAIN RES, V403, P198, DOI 10.1016/0006-8993(87)90145-4; Mosior M, 1996, P NATL ACAD SCI USA, V93, P1907, DOI 10.1073/pnas.93.5.1907; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NEWTON AC, 1989, J BIOL CHEM, V264, P14909; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1991, PROGR BRAIN RES, V89, P125; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; PIOMELLI D, 1987, J NEUROSCI, V7, P3675; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; QUEST AFG, 1995, METHOD ENZYMOL, V252, P153; RON D, 1994, J BIOL CHEM, V269, P21395; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Sossin W S, 1994, Learn Mem, V1, P189; SOSSIN WS, 1992, J NEUROSCI, V12, P1160; Sossin WS, 1996, J NEUROCHEM, V67, P220; Sossin WS, 1996, J NEUROSCI, V16, P10; SUGITA S, 1992, J NEUROPHYSIOL, V68, P643, DOI 10.1152/jn.1992.68.2.643	43	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19040	19048		10.1074/jbc.273.30.19040	http://dx.doi.org/10.1074/jbc.273.30.19040			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668085	hybrid			2022-12-27	WOS:000074974700052
J	Chaudhry, AZ; Vitullo, AD; Gronostajski, RM				Chaudhry, AZ; Vitullo, AD; Gronostajski, RM			Nuclear factor I (NFI) isoforms differentially activate simple versus complex NFI-responsive promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; HUMAN PAPILLOMAVIRUS TYPE-16; ADENOVIRUS DNA-REPLICATION; STEROID-HORMONE RECEPTORS; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; BINDING PROTEINS; MMTV PROMOTER; SYNERGISTIC INTERACTION; MAMMALIAN-CELLS	Promoter-specific differences in the function of transcription factors play a central role in the regulation of gene expression. We have measured the maximal transcriptional activation potentials of nuclear factor I (NFI) proteins encoded by each of the four identified NFI genes (NFI-A, -B, -C, and -X) by transient transfection in JEG-3 cells using two model NFI-dependent promoters: 1) a simple chimeric promoter containing a single NFI-binding site upstream of the adenovirus major late promoter (NFI-Ad), and 2) the more complex mouse mammary tumor virus long terminal repeat promoter. The relative activation potentials for the NFI isoforms differed between the two promoters, with NFI-X being the strongest activator of NFI-Ad and NFI-B being the strongest activator of the MMTV promoter. To determine if these promoter-specific differences in activation potential were due to the presence of glucocorticoid response elements (GREs), we added GREs upstream of the NFI-binding site in NFI-Ad. NFI-X remains the strongest activator of the GRE containing simple promoter, indicating that differences in relative activation potential are not due solely to the presence of GREs. Since NFI proteins bind to DNA as dimers, we assessed the activation potentials of NFI heterodimers. Here, we show that NFI heterodimers have intermediate activation potentials compared with homodimers, demonstrating one potential mechanism by which different NFI proteins can regulate gene expression.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NN1 14, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Gronostajski, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol NN1 14, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Vitullo, Alfredo/F-9744-2015	Vitullo, Alfredo/0000-0002-4833-5147; Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048796] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34908] Funding Source: Medline; NIDDK NIH HHS [DK48796] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; AMEMIYA K, 1992, J BIOL CHEM, V267, P14204; AOYAMA A, 1990, BIOCHEM BIOPH RES CO, V167, P648, DOI 10.1016/0006-291X(90)92074-A; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; APT D, 1993, J VIROL, V67, P4455, DOI 10.1128/JVI.67.8.4455-4463.1993; ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Gorman C., 1985, DNA CLONING, V2; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GRONOSTAJSKI RM, 1987, NUCLEIC ACIDS RES, V15, P5545, DOI 10.1093/nar/15.14.5545; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KNOX JJ, 1991, MOL CELL BIOL, V11, P2946, DOI 10.1128/MCB.11.6.2946; Krebs CJ, 1996, J NEUROCHEM, V66, P1354; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; Kunzler M, 1996, FEMS MICROBIOL REV, V19, P117; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; Liu YC, 1997, J BIOL CHEM, V272, P10739; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; OCONNOR M, 1995, VIROLOGY, V207, P77, DOI 10.1006/viro.1995.1053; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; RUPP RAW, 1987, NUCLEIC ACIDS RES, V15, P9707, DOI 10.1093/nar/15.23.9707; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TOOHEY MG, 1990, J VIROL, V64, P4477, DOI 10.1128/JVI.64.9.4477-4488.1990; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966	58	53	53	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18538	18546		10.1074/jbc.273.29.18538	http://dx.doi.org/10.1074/jbc.273.29.18538			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660824	hybrid			2022-12-27	WOS:000074828500079
J	Kawaguchi, S; Kuramitsu, S				Kawaguchi, S; Kuramitsu, S			Thermodynamics and molecular simulation analysis of hydrophobic substrate recognition by aminotransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ASPARTATE; AMINO-ACID AMINOTRANSFERASE; ALPHA-CHYMOTRYPSIN CATALYSIS; TYROSINE AMINOTRANSFERASE; ACTIVE-SITE; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURES; LIGAND-BINDING; LYTIC PROTEASE; CLOSED-FORM	Aromatic amino acid aminotransferase (AroAT) and aspartate aminotransferase (AspAT) are known as dual-substrate enzymes, which can bind acidic and hydro phobic substrates in the same pocket (Kawaguchi, S,, Nobe, Y., Yasuoka, J., Wakamiya, T,, Kusumoto, S,, and Kuramitsu, S, (1997) J, Biochem, (Tokyo) 122, 55-63), In order to elucidate the mechanism of hydrophobic substrate recognition, kinetic and thermodynamic analyses using substrates with different hydrophobicities were performed. They revealed that 1) amino acid substrate specificity (k(max)/K(d)) depended on the affinity for the substrate (1/K(d)) and 2) binding of the hydrophobic side chain was enthalpy-driven, suggesting that van der Waals interactions between the substrate-binding pocket and hydrophobic substrate predominated, Three-dimensional structures of AspAT and AroAT bound to alpha-aminoheptanoic acid were built using the homology modeling method, A molecular dynamic simulation study suggested that the outward-facing position of the Arg(292) Side chain was the preferred state to a greater extent in AroAT than AspAT, which would make the hydrophobic substrate bound state of the former more stable. Furthermore, AroAT appeared to have a more flexible conformation than AspAT. Such flexibility would be expected to reduce the energetic cost of conformational rearrangement induced by substrate binding. These two mechanisms (positional preference of Arg and flexible conformation) may account for the high activity of AroAT toward hydrophobic substrates.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan	Osaka University	Kawaguchi, S (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	kuramitu@bio.sci.osaka-u.ac.jp						Akasako A, 1997, J BIOL CHEM, V272, P18686, DOI 10.1074/jbc.272.30.18686; BIGLER TL, 1993, PROTEIN SCI, V2, P786, DOI 10.1002/pro.5560020509; CREIGHTON TE, 1993, DPROTEINS, P217; DOROVSKA VN, 1972, FEBS LETT, V23, P122, DOI 10.1016/0014-5793(72)80299-0; DOROVSKATARAN V, 1982, BIOCHIM BIOPHYS ACTA, V702, P37, DOI 10.1016/0167-4838(82)90025-5; DUNKER AK, 1998, PAC S BIOCOMPUT, V3, P471; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; Faergeman NJ, 1996, BIOCHEMISTRY-US, V35, P14118, DOI 10.1021/bi960545z; FERSHT A, 1985, ENZYME STRUCTURE MEC, P311; FERSHT A, 1985, ENZYME STRUCTURE MEC, P389; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; HANSCH C, 1970, J PHARM SCI, V59, P731, DOI 10.1002/jps.2600590602; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P12229, DOI 10.1021/bi00096a036; HAYASHI H, 1995, J BIOCHEM-TOKYO, V118, P463, DOI 10.1093/oxfordjournals.jbchem.a124931; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; Helms V, 1996, BIOCHEMISTRY-US, V35, P1485, DOI 10.1021/bi951817l; HUANG K, 1995, PROTEIN SCI, V4, P1985, DOI 10.1002/pro.5560041004; INOUE Y, 1989, J BIOL CHEM, V264, P9673; IWASAKI M, 1994, J BIOCHEM-TOKYO, V115, P156, DOI 10.1093/oxfordjournals.jbchem.a124293; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JAGER J, 1992, FEBS LETT, V306, P234, DOI 10.1016/0014-5793(92)81007-9; JENKINS WT, 1966, J BIOL CHEM, V241, P5667; JENKINS WT, 1985, TRANSAMINASES, P216; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KARPLUS M, 1983, ANNU REV BIOCHEM, V52, P263, DOI 10.1146/annurev.bi.52.070183.001403; Kasper P, 1996, EUR J BIOCHEM, V240, P751, DOI 10.1111/j.1432-1033.1996.0751h.x; Kawaguchi S, 1997, J BIOCHEM-TOKYO, V122, P55; KIICK DM, 1983, BIOCHEMISTRY-US, V22, P375, DOI 10.1021/bi00271a022; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4457, DOI 10.1021/bi9521102; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; KURAMITSU S, 1985, J BIOCHEM, V97, P1259, DOI 10.1093/oxfordjournals.jbchem.a135173; KURAMITSU S, 1985, BIOCHEM BIOPH RES CO, V133, P134, DOI 10.1016/0006-291X(85)91851-0; Lu WY, 1997, J MOL BIOL, V266, P441, DOI 10.1006/jmbi.1996.0781; MACE JE, 1995, J MOL BIOL, V251, P116, DOI 10.1006/jmbi.1995.0420; MACE JE, 1995, J MOL BIOL, V254, P720, DOI 10.1006/jmbi.1995.0650; MALASHKEVICH VN, 1995, J MOL BIOL, V247, P111, DOI 10.1006/jmbi.1994.0126; MALASHKEVICH VN, 1995, NAT STRUCT BIOL, V2, P548, DOI 10.1038/nsb0795-548; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MEHTA PK, 1993, EUR J BIOCHEM, V214, P549, DOI 10.1111/j.1432-1033.1993.tb17953.x; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MIYAHARA I, 1994, J BIOCHEM, V116, P1001, DOI 10.1093/oxfordjournals.jbchem.a124620; MIYAZAWA K, 1994, J BIOCHEM, V115, P568, DOI 10.1093/oxfordjournals.jbchem.a124377; MORTON A, 1995, BIOCHEMISTRY-US, V34, P8564, DOI 10.1021/bi00027a006; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NISHIKAWA K, 1972, J PHYS SOC JPN, V32, P1331, DOI 10.1143/JPSJ.32.1331; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1750, DOI 10.1002/pro.5560040910; ONUFFER JJ, 1995, PROTEIN SCI, V4, P1743, DOI 10.1002/pro.5560040909; Oue S, 1997, J BIOCHEM-TOKYO, V121, P161; PERONA JJ, 1995, BIOCHEMISTRY-US, V34, P1489, DOI 10.1021/bi00005a004; PFISTER K, 1985, J BIOL CHEM, V260, P1414; PFISTER K, 1978, P NATL ACAD SCI USA, V75, P145, DOI 10.1073/pnas.75.1.145; Rader SD, 1997, PROTEIN SCI, V6, P1375, DOI 10.1002/pro.5560060701; Rhee S, 1997, J BIOL CHEM, V272, P17293, DOI 10.1074/jbc.272.28.17293; SANDBERG WS, 1991, P NATL ACAD SCI USA, V88, P1706, DOI 10.1073/pnas.88.5.1706; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SEVILLE M, 1988, BIOCHEMISTRY-US, V27, P8344, DOI 10.1021/bi00422a009; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SMITH DL, 1989, BIOCHEMISTRY-US, V28, P8161, DOI 10.1021/bi00446a030; SUGINOHARA K, 1991, INT UNION B, V199, P195; Tanford C., 1980, HYDROPHOBIC EFFECT F, V2; Vacca RA, 1997, J BIOL CHEM, V272, P21932, DOI 10.1074/jbc.272.35.21932; WANGIKAR PP, 1995, BIOCHEMISTRY-US, V34, P12302, DOI 10.1021/bi00038a026; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; Wynn R, 1997, PROTEIN SCI, V6, P1621; YANO T, 1991, J BIOL CHEM, V266, P6079; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	71	10	10	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18353	18364		10.1074/jbc.273.29.18353	http://dx.doi.org/10.1074/jbc.273.29.18353			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660802	hybrid			2022-12-27	WOS:000074828500057
J	Messageot, F; Carlier, D; Rossignol, JM				Messageot, F; Carlier, D; Rossignol, JM			The C terminus of the hepatitis B virus antigen precursor is required for a tunicamycin-sensitive step that promotes efficient secretion of the antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PRECORE PROTEIN; VIRAL REPLICATION; CORE PROTEIN; INTRACELLULAR-TRANSPORT; BINDING-SPECIFICITY; SELECTIVE PROTEINS; BETA-GALACTOSIDASE; ESCHERICHIA-COLI; SIGNAL SEQUENCE	The Hepatitis B virus encodes the secreted e antigen (HBe) whose function in the viral life cycle is unknown. HBe derives from a 25-kDa precursor that is directed to the secretory pathway. After cleavage of the signal sequence, the resulting 22-kDa protein (P22) is processed in a post-endoplasmic reticulum compartment to mature HBe by removal of the 34-amino acid C-terminal domain. The efficiency of HBe secretion is specifically decreased in cells grown in the presence of tunicamycin, an inhibitor of N-glycosylation, Inasmuch as HBe precursor is not N-glycosylated, our data suggest that a cellular tunicamycin-sensitive protein increases the intracellular transport through the HBe secretory pathway. The study of the secretion of HBe derived hom C-terminal-truncated precursors demonstrates that the tunicamycin sensitive secretion absolutely requires a part of the C-terminal region that is removed to form mature HBe, indicating that the cellular tunicamycin-sensitive protein increases the efficiency of the intracellular transport of P22. We have also shown that the Escherichia coli beta-galactosidase can be secreted when fused to the HBe precursor signal sequence and that the P22 C-terminal domain renders the secretion of this reporter protein also tunicamycin-sensitive.	CNRS, UPR 9053, Lab Genet Virus, F-98118 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Rossignol, JM (corresponding author), CNRS, UPR 9053, Lab Genet Virus, Ave Terrasse, F-98118 Gif Sur Yvette, France.							Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Buckwold VE, 1996, J VIROL, V70, P5845, DOI 10.1128/JVI.70.9.5845-5851.1996; CARLIER D, 1994, J GEN VIROL, V75, P171, DOI 10.1099/0022-1317-75-1-171; CARLIER D, 1995, J GEN VIROL, V76, P1041, DOI 10.1099/0022-1317-76-4-1041; CHANG C, 1987, J VIROL, V61, P3322, DOI 10.1128/JVI.61.10.3322-3325.1987; CHEN HS, 1992, J VIROL, V66, P5682, DOI 10.1128/JVI.66.9.5682-5684.1992; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GANEM D, 1996, VIROLOGY, P2703; GARCIA PD, 1988, J CELL BIOL, V106, P1093, DOI 10.1083/jcb.106.4.1093; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guidotti LG, 1996, J VIROL, V70, P7056, DOI 10.1128/JVI.70.10.7056-7061.1996; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; Herbert Daniel N., 1995, Cell, V81, P425; HERMAN GE, 1986, NUCLEIC ACIDS RES, V14, P7130, DOI 10.1093/nar/14.17.7130; HOLLINGER FB, 1996, VIROLOGY, P2738; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JEANJEAN O, 1989, VIROLOGY, V170, P99, DOI 10.1016/0042-6822(89)90356-5; JUNKER M, 1987, NUCLEIC ACIDS RES, V15, P10117, DOI 10.1093/nar/15.24.10117; Klappa P, 1997, EUR J BIOCHEM, V248, P37, DOI 10.1111/j.1432-1033.1997.t01-1-00037.x; LAMBERTS C, 1993, J VIROL, V67, P3756, DOI 10.1128/JVI.67.7.3756-3762.1993; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Scaglioni PP, 1997, J VIROL, V71, P345, DOI 10.1128/JVI.71.1.345-353.1997; SCHLICHT HJ, 1987, J VIROL, V61, P3701, DOI 10.1128/JVI.61.12.3701-3709.1987; SCHLICHT HJ, 1991, J VIROL, V65, P3489, DOI 10.1128/JVI.65.7.3489-3495.1991; SCHLICHT HJ, 1991, J VIROL, V65, P6817, DOI 10.1128/JVI.65.12.6817-6825.1991; SCHODEL F, 1993, J BIOL CHEM, V268, P1332; TONG S, 1991, VIROLOGY, V181, P733, DOI 10.1016/0042-6822(91)90908-T; WANG J, 1991, J VIROL, V65, P5080, DOI 10.1128/JVI.65.9.5080-5083.1991; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; WASENAUER G, 1992, J VIROL, V66, P5338, DOI 10.1128/JVI.66.9.5338-5346.1992	43	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18594	18598		10.1074/jbc.273.29.18594	http://dx.doi.org/10.1074/jbc.273.29.18594			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660831	hybrid			2022-12-27	WOS:000074828500086
J	Junemann, S; Heathcote, P; Rich, PR				Junemann, S; Heathcote, P; Rich, PR			On the mechanism of quinol oxidation in the bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C REDUCTASE; IRON-SULFUR PROTEIN; INHIBITOR; UBIQUINONE; SITE; UBIHYDROQUINONE; OXIDOREDUCTASE; ANTIMYCIN; ELECTRON; BINDING	The question of whether significant levels of a semiquinone can be generated in the Q(o) site of the be, complex under conditions of oxidant-induced reduction is relevant to the mechanism of bifurcation of electron transfer in this site. It has already been reported that beef heart submitochondrial particles under such conditions exhibit an EPR-detectable semiquinone, which is distinct from Q(i)((.) over bar) and which was attributed to a semiquinone in the Q(o) site (de Vries, S., Albracht, S. P. J., Berden, J. A., and Slater, E. C. (1981) J. Biol. Chem. 256, 11996-11998). However, we show here that this signal, which can be generated to a level of around 0.1 per bc(1) monomer, is insensitive to the Q(o) site inhibitors myxothiazol, E-beta-methoxyacrylate-stilbene, and stigmatellin, indicating that it does not arise from a Q(o)((.) over bar) species. Based on sensitivities to inhibitors of other Q sites, up to 60% of the signal may arise from semiquinones of complexes I and II. We further show that the iron-sulfur center remains EPR silent under oxidant-induced reduction conditions. Overall, the results indicate that, under conditions of oxidant-induced reduction, the Q(o) site is occupied primarily by quinol with the iron-sulfur center oxidized, or, possibly, by an antiferromagnetically coupled semiquinone/reduced iron-sulfur center pair, which are EPR silent. This is discussed in relation to proposed mechanisms of quinol oxidation in the Q(o) site, and we describe a minimal intermediate-controlled bifurcation model based on rate constants by which bifurcated electron transfer at the Q(o) site might occur.	UCL, Glynn Lab Bioenerget, Dept Biol, London WC1E 6BT, England; Queen Mary Univ London, Sch Biol Sci, London E1 4NS, England	University of London; University College London; University of London; Queen Mary University London	Rich, PR (corresponding author), UCL, Glynn Lab Bioenerget, Dept Biol, Gower St, London WC1E 6BT, England.	prr@ucl.ac.uk	Heathcote, Peter/B-3749-2011		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Brandt U, 1996, FEBS LETT, V387, P1, DOI 10.1016/0014-5793(96)00436-X; Clark W. M., 1960, OXIDATION REDUCTION; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; DEVRIES S, 1981, J BIOL CHEM, V256, P1996; Ding H, 1995, BIOCHEMISTRY-US, V34, P15979, DOI 10.1021/bi00049a012; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Hartzell C R, 1978, Methods Enzymol, V53, P54; LEE IY, 1972, BIOCHIM BIOPHYS ACTA, V283, P395, DOI 10.1016/0005-2728(72)90257-5; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; MALKIN R, 1981, FEBS LETT, V131, P169, DOI 10.1016/0014-5793(81)80912-X; MIKI T, 1992, ARCH BIOCHEM BIOPHYS, V293, P61, DOI 10.1016/0003-9861(92)90365-4; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Moody A. J., 1997, BIOELECTROCHEMISTRY, P419; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; RIESKE JS, 1976, BIOCHIM BIOPHYS ACTA, V456, P195, DOI 10.1016/0304-4173(76)90012-4; SLATER EC, 1973, BIOCHIM BIOPHYS ACTA, V301, P129, DOI 10.1016/0304-4173(73)90002-5; SLATER EC, 1980, NATURE, V288, P717, DOI 10.1038/288717a0; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; WIKSTROM MK, 1972, BIOCHIM BIOPHYS ACTA, V283, P403, DOI 10.1016/0005-2728(72)90258-7; WILLIAMSSMITH DL, 1978, BIOCHEM J, V170, P365, DOI 10.1042/bj1700365; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	27	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21603	21607		10.1074/jbc.273.34.21603	http://dx.doi.org/10.1074/jbc.273.34.21603			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705291	hybrid			2022-12-27	WOS:000075492600025
J	Spalding, TA; Burstein, ES; Henderson, SC; Ducote, KR; Brann, MR				Spalding, TA; Burstein, ES; Henderson, SC; Ducote, KR; Brann, MR			Identification of a ligand-dependent switch within a muscarinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SITE-DIRECTED MUTAGENESIS; RANDOM SATURATION MUTAGENESIS; ACETYLCHOLINE-RECEPTOR; CONSTITUTIVE ACTIVATION; TRANSMEMBRANE HELICES; ANTAGONIST BINDING; RHODOPSIN; SUBTYPES; EXPRESSION	G-protein-coupled receptors spontaneously switch between active and inactive conformations. Agonists stabilize the active conformation, whereas antagonists stabilize the inactive conformation. In a systematic search for residues that participate in receptor function, several regions of the m5 muscarinic receptor were randomly mutated and tested for their functional properties. Mutations spanning one face of transmembrane 6 (TM6) were found to induce high levels of receptor activity in the absence of agonists (constitutive activity). The same face of TM6 contained several residues crucial for receptor activation by agonists and one residue identified as a contact site for both agonists and antagonists. In addition, one mutation induced agonist-like responses from the receptor when exposed to classical antagonists. These results suggest that TMB is a switch that defines the activation state of the receptor, and that ligand interactions with TM6 stabilize the receptor in either an active or an inactive conformation.	ADADIA Pharmaceut Inc, San Diego, CA 92121 USA; Univ Vermont, Dept Psychiat, Mol Neuropharmacol Sect, Burlington, VT 05405 USA; Univ Vermont, Dept Pharmacol, Mol Neuropharmacol Sect, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Spalding, TA (corresponding author), ADADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	tspalding@acadia-pharm.com			NIGMS NIH HHS [R01 GM52737] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052737] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BLUML K, 1994, J BIOL CHEM, V269, P18870; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; BRANN MR, 1993, LIFE SCI, V52, P405, DOI 10.1016/0024-3205(93)90295-E; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Burstein ES, 1998, BIOCHEMISTRY-US, V37, P4052, DOI 10.1021/bi972132j; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, MOL PHARMACOL, V51, P312, DOI 10.1124/mol.51.2.312; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FRASER CM, 1989, MOL PHARMACOL, V36, P840; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HILF G, 1992, EUR J PHARM-MOLEC PH, V225, P245, DOI 10.1016/0922-4106(92)90026-R; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Jakubik J, 1995, FEBS LETT, V377, P275, DOI 10.1016/0014-5793(95)01360-1; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; MATSUI H, 1995, MOL PHARMACOL, V47, P88; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SPALDING TA, 1994, J BIOL CHEM, V269, P4092; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WESS J, 1990, MOL PHARMACOL, V38, P517; WESS J, 1991, EMBO J, V10, P3729, DOI 10.1002/j.1460-2075.1991.tb04941.x; WESS J, 1993, EMBO J, V12, P331, DOI 10.1002/j.1460-2075.1993.tb05661.x	35	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21563	21568		10.1074/jbc.273.34.21563	http://dx.doi.org/10.1074/jbc.273.34.21563			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705286	hybrid			2022-12-27	WOS:000075492600020
J	Grima, J; Wong, CCS; Zhu, LJ; Zong, SD; Cheng, CY				Grima, J; Wong, CCS; Zhu, LJ; Zong, SD; Cheng, CY			Testin secreted by Sertoli cells is associated with the cell surface, and its expression correlates with the disruption of Sertoli-germ cell junctions but not the inter-Sertoli tight junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ANDROGEN-BINDING-PROTEIN; RAT TESTIS; DEVELOPMENTAL-CHANGES; EXTRACELLULAR-MATRIX; SEMINIFEROUS TUBULE; OCCLUDING JUNCTIONS; SPERMATID BINDING; ENDOTHELIAL-CELLS; CANCER METASTASIS	Testin is a testosterone-responsive Sertoli cell secretory product. In the present study, we demonstrated that the amount of testin secreted by Sertoli cells in vitro was comparable with several other Sertoli cell secretory products. However, virtually no testin was found in the luminal fluid and cytosols of the testis and epididymis when the intercellular junctions were not previously disrupted, suggesting that secreted testin may be reabsorbed by testicular cells in vivo. Studies using Sertoli cells with and without a cell surface cross-inker and radioiodination in conjunction with immunoprecipitation illustrated the presence of two polypeptides of 28 and 45 kDa, which constitute a binding protein complex that anchors testin onto the cell surface, The 28- and 45-kDa peptide appear to be residing on and inside the cell surface, respectively. Immunogold EM studies illustrated testin was abundantly localized on the Sertoli cell side of the ectoplasmic specialization (a modified adherens junction) surrounding developing spermatids. In contrast, very few testin gold particles were found at the site of inter-Sertoli tight junctions. When the inter-Sertoli tight junctions were formed or disrupted, no significant change in testin expression was noted. This is in sharp contrast to the disruption of Sertoli-germ cell junctions, which is accompanied by a surge in testin expression. These results demonstrate the usefulness of testin in examining Sertoli-germ cell interactions.	Populat Council, New York, NY 10021 USA; Univ Hong Kong, Dept Zool, Hong Kong, Hong Kong	Population Council; University of Hong Kong	Cheng, CY (corresponding author), Populat Council, 1230 York Ave, New York, NY 10021 USA.	yan@popcbr.rockefeller.edu		Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [HD-13541] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Aravindan GR, 1996, J CELL PHYSIOL, V168, P123; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BILLIG H, 1995, ENDOCRINOLOGY, V136, P5, DOI 10.1210/en.136.1.5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Byers S., 1993, SERTOLI CELL, P461; BYERS S, 1993, SERTOLI CELL, P431; CAMERON DF, 1991, J CELL SCI, V100, P623; CHENG CY, 1986, J ANDROL, V7, P175; CHENG CY, 1984, ENDOCRINOLOGY, V114, P1386, DOI 10.1210/endo-114-4-1386; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CHENG CY, 1987, J BIOL CHEM, V262, P12768; CHENG CY, 1993, BIOCHEM BIOPH RES CO, V191, P224, DOI 10.1006/bbrc.1993.1206; Chung SSW, 1998, ENDOCRINOLOGY, V139, P1853, DOI 10.1210/en.139.4.1853; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; Diamond J M, 1977, Physiologist, V20, P10; EDDY EM, 1981, GAMETE RES, V4, P333, DOI 10.1002/mrd.1120040407; ENDERS GC, 1988, J CELL SCI, V90, P105; ENDERS GC, 1993, SERTOLI CELL, V90, P105; ENDERS GC, 1993, SERTOLI CELL, P488; ENG F, 1994, J ANDROL, V15, P311; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FRITZ IB, 1993, SERTOLI CELL, P217; Galdieri M, 1981, J ANDROL, V5, P249; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GRIMA J, 1990, ENDOCRINOLOGY, V126, P2989, DOI 10.1210/endo-126-6-2989; Grima J, 1997, J BIOL CHEM, V272, P6499, DOI 10.1074/jbc.272.10.6499; GRIMA J, 1992, MOL CELL ENDOCRINOL, V89, P127, DOI 10.1016/0303-7207(92)90219-V; GRIMA J, 1995, BIOL REPROD, V52, P340, DOI 10.1095/biolreprod52.2.340; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; HOWARDS SS, 1975, FERTIL STERIL, V26, P13; HUCHKINS C, 1978, ANAT REC, V190, P905; JEGOU B, 1993, ENDOCRINOLOGY, V132, P2557, DOI 10.1210/en.132.6.2557; KERR JB, 1992, J REPROD FERTIL, V95, P825, DOI 10.1530/jrf.0.0950825; LARSEN WJ, 1988, TISSUE CELL, V20, P809, DOI 10.1016/0040-8166(88)90025-0; LI AHY, 1994, BIOL REPROD, V50, P1287, DOI 10.1095/biolreprod50.6.1287; MARTINEZPALOMO A, 1980, J CELL BIOL, V87, P736, DOI 10.1083/jcb.87.3.736; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; McNeil Paul L., 1993, Trends in Cell Biology, V3, P302, DOI 10.1016/0962-8924(93)90012-P; MCNEIL PL, 1992, AM J PATHOL, V140, P1097; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; MELDOLESI J, 1978, J CELL BIOL, V79, P156, DOI 10.1083/jcb.79.1.156; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; Mruk D, 1997, J ANDROL, V18, P612; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; NICOLSON GL, 1982, BIOCHIM BIOPHYS ACTA, V695, P113, DOI 10.1016/0304-419X(82)90020-8; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; ONODA M, 1990, BIOL REPROD, V43, P672, DOI 10.1095/biolreprod43.4.672; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PEDERSEN RA, 1988, PHYSL REPROD, V1, P187; PINEAU C, 1993, J ANDROL, V14, P87; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RUSSELL LD, 1987, ENDOCRINOLOGY, V120, P1615, DOI 10.1210/endo-120-4-1615; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; STAHLER MS, 1991, ENDOCRINOLOGY, V128, P2805, DOI 10.1210/endo-128-6-2805; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TRYGGVASON K, 1987, BIOCHIM BIOPHYS ACTA, V907, P191, DOI 10.1016/0304-419X(87)90006-0; WIEBE JP, 1984, CONTRACEPTION, V29, P291, DOI 10.1016/S0010-7824(84)80009-8; WIEBE JP, 1984, LIFE SCI, V34, P1747, DOI 10.1016/0024-3205(84)90574-5; WRIGHT WW, 1989, ANN NY ACAD SCI, V564, P173, DOI 10.1111/j.1749-6632.1989.tb25896.x; YU QC, 1992, AM J PATHOL, V141, P1349; Zhu LJ, 1997, BIOL REPROD, V56, P1330, DOI 10.1095/biolreprod56.5.1330; ZIPARO E, 1980, AM J ANAT, V159, P385, DOI 10.1002/aja.1001590404; ZONG SD, 1992, BIOL REPROD, V47, P568, DOI 10.1095/biolreprod47.4.568; ZONG SD, 1994, BIOL REPROD, V51, P843, DOI 10.1095/biolreprod51.5.843	69	94	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21040	21053		10.1074/jbc.273.33.21040	http://dx.doi.org/10.1074/jbc.273.33.21040			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694856	hybrid			2022-12-27	WOS:000075386100049
J	Mizushima, T; Takaki, T; Kubota, T; Tsuchiya, T; Miki, T; Katayama, T; Sekimizu, K				Mizushima, T; Takaki, T; Kubota, T; Tsuchiya, T; Miki, T; Katayama, T; Sekimizu, K			Site-directed mutational analysis for the ATP binding of DnaA protein - Functions of two conserved amino acids (Lys-178 and Asp-235) located in the ATP-binding domain of DnaA protein in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; REPLICATION ORIGIN; INITIATOR PROTEIN; IN-VITRO; AFFINITY; MUTANTS; SECA; SEQUENCES; TOPOLOGY	DnaA protein, the initiator of chromosomal DNA replication in Escherichia coli, is activated by binding to ATP in vitro. We introduced site-directed mutations into two amino acids of the protein conserved among various ATP-binding proteins and examined functions of the mutated DnaA proteins, in vitro and in vivo. Both mutated DnaA proteins (Lys-178 --> Ile or Asp-235 --> Asn) lost the affinity for both ATP and ADP but did maintain binding activity for oriC. Specific activities in an oriC DNA replication system in vitro were less than one-tenth those of the wild-type protein. Assay of the generation of oriC sites sensitive to P1 nuclease, using the mutated DnaA proteins, revealed a defect in induction of the duplex opening at oriC. On the other hand, expression of each mutated DnaA protein in the temperature-sensitive dnaA46 mutant did not complement the temperature sensitivity. We suggest that Lys-178 and Asp-235 of DnaA protein are essential for the activity needed to initiate oriC DNA replication in vitro and in vivo and that ATP binding to DnaA. protein is required for DNA replication-related functions.	Kyushu Univ, Fac Pharmaceut Sci, Fukuoka 8128582, Japan; Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan	Kyushu University; Okayama University	Sekimizu, K (corresponding author), Kyushu Univ, Fac Pharmaceut Sci, Fukuoka 8128582, Japan.	sekimizu@bisei.pharm.kyushu-u.ac.jp		Katayama, Tsutomu/0000-0001-9994-1684				BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1988, J BIOL CHEM, V263, P10633; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; Kubota T, 1997, BIOCHEM BIOPH RES CO, V232, P130, DOI 10.1006/bbrc.1997.6244; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MATSUYAMA S, 1995, ADV CELL MOL BIOL M, V4, P61; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Mizushima T, 1996, J BIOL CHEM, V271, P3633; Mizushima T, 1996, J BIOL CHEM, V271, P25178, DOI 10.1074/jbc.271.41.25178; Mizushima T, 1997, J BIOL CHEM, V272, P21195, DOI 10.1074/jbc.272.34.21195; Mizushima T, 1996, BIOCHEMISTRY-US, V35, P11512, DOI 10.1021/bi953088f; Sato K, 1996, J BIOL CHEM, V271, P17439, DOI 10.1074/jbc.271.29.17439; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SHINPUKU T, 1995, BIOCHEM BIOPH RES CO, V212, P84, DOI 10.1006/bbrc.1995.1939; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; VANDERWOLK JPW, 1995, J BIOL CHEM, V270, P18975, DOI 10.1074/jbc.270.32.18975; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOLK JV, 1993, MOL MICROBIOL, V8, P31; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; YUNG BYM, 1989, J BIOL CHEM, V264, P6146	29	45	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20847	20851		10.1074/jbc.273.33.20847	http://dx.doi.org/10.1074/jbc.273.33.20847			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694830	hybrid			2022-12-27	WOS:000075386100023
J	Molloy, DP; Milner, AE; Yakub, IK; Chinnadurai, G; Gallimore, PH; Grand, RJA				Molloy, DP; Milner, AE; Yakub, IK; Chinnadurai, G; Gallimore, PH; Grand, RJA			Structural determinants present in the c-terminal binding protein binding site of adenovirus early region 1A proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; ZINC-FINGER; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; CRYSTAL-STRUCTURE; WATER SOLUTION; E1A PROTEINS; PEPTIDE; DOMAIN; TRANSFORMATION	The C-terminal binding protein (CtBP) has previously been shown to bind to a highly conserved six-amino acid motif very close to the C terminus of adenovirus early region 1A (Ad EIA) proteins. We have developed an enzyme-linked immunosorbent assay that has facilitated the screening of synthetic peptides identical or similar to the binding site on Ad E1A for their ability to bind CtBP and thus inhibit its interaction with Ad12 Elk It has been shown that amino acids both C-terminal and N-terminal to the original proposed binding site contribute to the interaction of peptides with CtBP, Single amino acid substitutions across the binding site appreciably alter the K-d of the peptide for CtBP, indicative of a marked reduction in the affinity of the peptide for CtBP, The solution structures of synthetic peptides equivalent to the C termini of both Ad5 and Ad12 E1A and two substituted forms of these have been determined by proton NMR spectroscopy. Both the Ad12 and Ad5 peptides dissolved in trifluoroethanol/water mixtures were found to adopt regular secondary structural conformations seen as a series of beta-turns. An Ad12 peptide bearing a substitution that resulted in only very weak binding to CtBP (Ad12 L258G) was found to be random coil in solution, However, a second mutant (Ad12 V256K), which bound to CtBP rather more strongly (although not as well as the wild type), adopted a conformation similar to that of the wild type, We conclude that secondary structure (beta-turns) and an appropriate series of amino acid side chains are necessary for recognition by CtBP.	Univ Birmingham, Inst Canc Studies, Canc Res Campaign, Birmingham B15 2TA, W Midlands, England; St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	University of Birmingham; Saint Louis University	Molloy, DP (corresponding author), Univ Birmingham, Inst Canc Studies, Canc Res Campaign, Birmingham B15 2TA, W Midlands, England.	D.P.Molloy@cancer.bham.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ACKARYA KR, 1991, J MOL BIOL, V221, P571; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; FILARDO EJ, 1994, J BIOL CHEM, V269, P4641; GARRATT RC, 1985, FEBS LETT, V188, P59, DOI 10.1016/0014-5793(85)80874-7; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; GOURNARIDES JS, 1994, BIOPOLYMERS, V34, P709; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUI F, 1990, CELL, V61, P1217; LUI F, 1994, NATURE, V368, P520; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Malinski JA, 1996, J BIOL CHEM, V271, P12919, DOI 10.1074/jbc.271.22.12919; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; Mitra SN, 1997, BIOPOLYMERS, V41, P97, DOI 10.1002/(SICI)1097-0282(199701)41:1<97::AID-BIP9>3.0.CO;2-Y; MORAN E, 1994, SEMIN VIROL, V5, P327, DOI 10.1006/smvy.1994.1037; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAIDER F, 1992, BIOPOLYMERS, V32, P335, DOI 10.1002/bip.360320407; PEI R, 1989, J VIROL, V63, P3499, DOI 10.1128/JVI.63.8.3499-3506.1989; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RICHARDSON JS, 1988, PROTEINS, V4, P229, DOI 10.1002/prot.340040402; ROSEN S, 1985, PROBL COMMUNISM, V34, P1; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Saudek V., 1994, BRUKER REPORT, V140/94, P6; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHIN HC, 1993, BIOCHEMISTRY-US, V32, P6356, DOI 10.1021/bi00076a008; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; Smith KJ, 1996, J BIOL CHEM, V271, P16703, DOI 10.1074/jbc.271.28.16703; SMITH LJ, 1994, STRUCTURE, V2, P703, DOI 10.1016/S0969-2126(00)00071-X; SOLLERBRANT K, 1996, NUCLEIC ACIDS RES, V24, P3347; SWIFT HJ, 1991, ACTA CRYSTALLOGR B, V47, P535, DOI 10.1107/S0108768191001970; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WINKLER FK, 1991, J MOL BIOL, V217, P235, DOI 10.1016/0022-2836(91)90536-F; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; Wuthrich K, 1986, NMR NUCL ACIDS PROTE; YAO J, 1994, J MOL BIOL, V243, P754, DOI 10.1016/0022-2836(94)90045-0	54	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20867	20876		10.1074/jbc.273.33.20867	http://dx.doi.org/10.1074/jbc.273.33.20867			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694833	hybrid			2022-12-27	WOS:000075386100026
J	Sheikh, S; O'Handley, SF; Dunn, CA; Bessman, MJ				Sheikh, S; O'Handley, SF; Dunn, CA; Bessman, MJ			Identification and characterization of the Nudix hydrolase from the Archaeon, Methanococcus jannaschii, as a highly specific ADP-ribose pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTT; MOLECULAR-CLONING; MUTAGENIC SUBSTRATE; CATALYTIC DOMAIN; DNA-SYNTHESIS; SEQUENCE; PROTEINS; PURIFICATION; FAMILY; MUTATOR	The MJ1149 gene from the Archaeon, Methanococcus jannaschii, has been cloned and expressed in Escherichia coli, The 19-kDa protein containing the Nudix box, GX(5)EX(7)REUXEEXGU, has been purified and identified as a highly specific enzyme catalyzing the Mg2+-dependent hydrolysis of ADP-ribose according to the equation: ADP-ribose + H2O --> AMP + ribose-5-phosphate. The enzyme retains full activity when heated to 80 degrees C, and the rate of hydrolysis is 15-fold higher at 75 degrees C than at 37 degrees C in keeping with the thermophilicity of the organism. This is the first Nudix hydrolase identified from the Archaea, indicating that the family of enzymes containing the Nudix signature sequence is represented in all three kingdoms.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	zoot@jhu.edu		Dunn, Christopher/0000-0001-7899-0110; O'Handley, Suzanne/0000-0001-8373-0065	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA M, 1987, MOL GEN GENET, V206, P9, DOI 10.1007/BF00326530; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Cleland W W, 1979, Methods Enzymol, V63, P103; COX EC, 1969, J BACTERIOL, V100, P390, DOI 10.1128/JB.100.1.390-397.1969; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Hankin S, 1997, INT J BIOCHEM CELL B, V29, P317, DOI 10.1016/S1357-2725(96)00153-7; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HILZ H, 1986, P NATL ACAD SCI USA, V83, P6267, DOI 10.1073/pnas.83.17.6267; HONJO T, 1968, J BIOL CHEM, V243, P3553; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Maksel D, 1998, BIOCHEM J, V329, P313, DOI 10.1042/bj3290313; MATHEW N, 1995, BIOCHEM J, V311, P717, DOI 10.1042/bj3110717; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MOSS J, 1994, MOL CELL BIOCH FOCUS, V138; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; OLIVERA BM, 1989, ADP RIBOSE TRANSFER, P353; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; WITTENBERG J, 1953, J BIOL CHEM, V202, P431	35	53	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20924	20928		10.1074/jbc.273.33.20924	http://dx.doi.org/10.1074/jbc.273.33.20924			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694840	hybrid			2022-12-27	WOS:000075386100033
J	Timpel, C; Strahl-Bolsinger, S; Ziegelbauer, K; Ernst, JF				Timpel, C; Strahl-Bolsinger, S; Ziegelbauer, K; Ernst, JF			Multiple functions of Pmt1p-mediated protein O-mannosylation in the fungal pathogen Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; ENDOTHELIAL-CELLS; HYPHAL FORMATION; GENE FAMILY; GLYCOSYLATION; MUTANTS; MANNOSYLTRANSFERASE; VIRULENCE; GROWTH; OLIGOSACCHARIDES	Protein mannosylation by Pmt proteins initiates O-glycosylation in fungi, We have identified the PMT1 gene and analyzed the function of Pmt1p in the fungal human pathogen Candida albicans. Mutants defective in PMT1 alleles lacked Pmt in vitro enzymatic activity, showed reduced growth rates, and tended to for-m cellular aggregates. In addition, multiple specific deficiencies not known in Saccharomyces cerevisiae (including defective hyphal morphogenesis; supersensitivity to the antifungal agents hygromycin B, G418, clotrimazole, and calcofluor white; and reduced adherence to Caco-2 epithelial cells) were observed in pmt1 mutants. PMT1 deficiency also led to faster electrophoretic mobility of the Als1p cell wall protein and to elevated extracellular activities of chitinase. Homozygous pmt1 mutants were avirulent in a mouse model of systemic infection, while heterozygous PMT1/pmt1 strains showed reduced virulence. The results indicate that protein O-mannosylation by Pmt proteins occurs in different fungal species, where PMT1 deficiency can lead to defects in multiple cellular functions.	Univ Dusseldorf, Inst Mikrobiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Biol Med Forschungszentrum, D-40225 Dusseldorf, Germany; Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany; Bayer AG, Lehrstuhl Zellbiol & Pflanzenphysiol, D-42117 Wuppertal, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; University of Regensburg; Bayer AG	Ernst, JF (corresponding author), Univ Dusseldorf, Inst Mikrobiol, Univ Str 1-26-12, D-40225 Dusseldorf, Germany.	joachim.ernst@uni-duesseldorf.de						BACHER A, 1992, EXP CELL RES, V200, P97, DOI 10.1016/S0014-4827(05)80076-X; BALLOU L, 1991, P NATL ACAD SCI USA, V88, P3209, DOI 10.1073/pnas.88.8.3209; BECKER JM, 1995, INFECT IMMUN, V63, P4515, DOI 10.1128/IAI.63.11.4515-4518.1995; Bourdineaud JP, 1998, MOL MICROBIOL, V27, P85, DOI 10.1046/j.1365-2958.1998.00660.x; BRETTHAUER RK, 1975, ARCH BIOCHEM BIOPHYS, V167, P151, DOI 10.1016/0003-9861(75)90451-8; BULAWA CE, 1995, P NATL ACAD SCI USA, V92, P10570, DOI 10.1073/pnas.92.23.10570; Chiba A, 1997, J BIOL CHEM, V272, P2156; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DELBRUCK S, 1993, MOL MICROBIOL, V10, P859, DOI 10.1111/j.1365-2958.1993.tb00956.x; ELORZA MV, 1994, ARCH MICROBIOL, V161, P145, DOI 10.1007/s002030050034; Finck M, 1996, GLYCOBIOLOGY, V6, P313, DOI 10.1093/glycob/6.3.313; FONZI WA, 1993, GENETICS, V134, P717; Fratti RA, 1996, INFECT IMMUN, V64, P4714, DOI 10.1128/IAI.64.11.4714-4718.1996; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; GOLD MH, 1976, BIOCHEMISTRY-US, V15, P1808, DOI 10.1021/bi00654a004; GOW NAR, 1994, P NATL ACAD SCI USA, V91, P6216, DOI 10.1073/pnas.91.13.6216; Guerreiro P, 1996, YEAST, V12, P273, DOI 10.1002/(SICI)1097-0061(19960315)12:3<273::AID-YEA898>3.0.CO;2-1; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAYETTE MP, 1992, J CLIN MICROBIOL, V30, P411, DOI 10.1128/JCM.30.2.411-417.1992; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HOYER LL, 1995, MOL MICROBIOL, V15, P39, DOI 10.1111/j.1365-2958.1995.tb02219.x; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KELLY R, 1988, MOL GEN GENET, V214, P24, DOI 10.1007/BF00340174; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LEHLE L, 1995, GLYCOPROTEINS, P475; LETOUBLON R, 1974, FEBS LETT, V46, P214, DOI 10.1016/0014-5793(74)80371-6; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; MartinBlanco E, 1996, P NATL ACAD SCI USA, V93, P6048, DOI 10.1073/pnas.93.12.6048; MCCREATH KJ, 1995, P NATL ACAD SCI USA, V92, P2544, DOI 10.1073/pnas.92.7.2544; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; Odds FC., 1988, CANDIDA CANDIDOSIS; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; ROTROSEN D, 1985, J INFECT DIS, V152, P1264, DOI 10.1093/infdis/152.6.1264; ROUSSET M, 1986, BIOCHIMIE, V68, P1035, DOI 10.1016/S0300-9084(86)80177-8; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Sherman F., 1986, METHODS YEAST GENETI; Stoldt VR, 1997, EMBO J, V16, P1982, DOI 10.1093/emboj/16.8.1982; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; STRAHLBOLSINGER S, 1991, EUR J BIOCHEM, V196, P185, DOI 10.1111/j.1432-1033.1991.tb15802.x; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; Vai M, 1996, YEAST, V12, P361, DOI 10.1002/(SICI)1097-0061(19960330)12:4<361::AID-YEA920>3.0.CO;2-T; WESTON A, 1993, EUR J BIOCHEM, V215, P845, DOI 10.1111/j.1432-1033.1993.tb18101.x; ZHU JD, 1985, BIO-TECHNOL, V3, P451, DOI 10.1038/nbt0585-451	56	140	144	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20837	20846		10.1074/jbc.273.33.20837	http://dx.doi.org/10.1074/jbc.273.33.20837			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694829	hybrid			2022-12-27	WOS:000075386100022
J	Dorner, C; Ciossek, T; Muller, S; Moller, NPH; Ullrich, A; Lammers, R				Dorner, C; Ciossek, T; Muller, S; Moller, NPH; Ullrich, A; Lammers, R			Characterization of KIF1C, a new kinesin-like protein involved in vesicle transport from the Golgi apparatus to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTEROGRADE AXONAL-TRANSPORT; TYROSINE-PHOSPHATASE; BREFELDIN-A; CYTOPLASMIC DYNEIN; HEAVY-CHAIN; IN-VIVO; RETROGRADE TRANSPORT; SYNAPTIC VESICLES; MEMBRANE-BINDING; 2-HYBRID SYSTEM	Kinesins comprise a large family of microtubule-based motor proteins, of which individual members mediate specific types of motile processes. Using the ezrin domain of the protein-tyrosine phosphatase PTPD1 as a bait in a yeast two-hybrid screen, we identified a new kinesin-like protein, KIF1C. KIF1C represents a member of the Unc104 subfamily of kinesin-like proteins that are involved in the transport of mitochondria or synaptic vesicles in axons, Like its homologues, the 1103-amino acid protein KIF1C consists of an amino-terminal motor domain followed by a U104 domain and probably binds to target membranes through carboxyl-terminal sequences. Interestingly, KIF1C was tyrosine-phosphorylated after peroxovanadate stimulation when overexpressed in 293 or NIH3T3 fibroblasts or in native C2C12 cells. Using immunofluorescence, we found that KIF1C is localized primarily at the Golgi apparatus. In brefeldin A-treated cells, the Golgi membranes and KIF1C redistributed to the endoplasmic reticulum (ER). This brefeldin A-induced flow of Golgi membranes into the ER was inhibited in cells transiently overexpressing catalytically inactive KIF1C. In conclusion, our data suggest an involvement of tyrosine phosphorylation in the regulation of the Golgi to ER membrane flow and describe a new kinesin-like motor protein responsible for this transport.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Lammers, R (corresponding author), Univ Tubingen, Med Klin 4, Otfried Muller Str 10, D-72076 Tubingen, Germany.	rrlammer@med.uni-tuebingen.de						AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Allan V, 1996, SEMIN CELL DEV BIOL, V7, P335, DOI 10.1006/scdb.1996.0043; Alphey L, 1997, J CELL BIOL, V138, P395, DOI 10.1083/jcb.138.2.395; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Furlong RA, 1996, GENOMICS, V33, P421, DOI 10.1006/geno.1996.0217; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; Hanlon DW, 1997, NEURON, V18, P439, DOI 10.1016/S0896-6273(00)81244-1; Hirokawa N, 1996, TRENDS CELL BIOL, V6, P135, DOI 10.1016/0962-8924(96)10003-9; HOLLENBECK PJ, 1993, J NEUROCHEM, V60, P2265, DOI 10.1111/j.1471-4159.1993.tb03513.x; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; Moore JD, 1996, BIOESSAYS, V18, P207, DOI 10.1002/bies.950180308; MURPHY DB, 1989, J CELL BIOL, V109, P80; Nakagawa T, 1997, P NATL ACAD SCI USA, V94, P9654, DOI 10.1073/pnas.94.18.9654; NAKATA T, 1995, J CELL BIOL, V131, P1039, DOI 10.1083/jcb.131.4.1039; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; OKADA Y, 1995, J NEUROSCI, V15, P3053; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P265, DOI 10.1016/S0968-0004(00)89040-4; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	60	103	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20267	20275		10.1074/jbc.273.32.20267	http://dx.doi.org/10.1074/jbc.273.32.20267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685376	hybrid			2022-12-27	WOS:000075305400053
J	Gromer, S; Arscott, LD; Williams, CH; Schirmer, RH; Becker, K				Gromer, S; Arscott, LD; Williams, CH; Schirmer, RH; Becker, K			Human placenta thioredoxin reductase - Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-DERIVED FACTOR; GLUTATHIONE-REDUCTASE; ESCHERICHIA-COLI; MECHANISM; PURIFICATION; SELENOCYSTEINE; LYMPHOCYTES; MUTAGENESIS; EXPRESSION; ENZYME	Human thioredoxin reductase is a pyridine nucleotide-disulfide oxidoreductase closely related to glutathione reductase but differing from the latter in having a Cys-SeCys (selenocysteine) sequence as an additional redox center. Because selenoproteins cannot be expressed yet in heterologous systems, we optimized the purification of the protein from placenta with respect to final yield (1-2 mg from one placenta), specific activity (42 units/mg), and selenium content (0.94 +/- 0.03 mol/mol subunit). The steady state kinetics showed that the enzyme operates by a ping-pong mechanism; the value of k(cat) was 3330 +/- 882 min(-1), and the K-m values were 18 mu M for NADPH and 25 mu M for Escherichia coli thioredoxin. The activation energy of the reaction was found to be 53.2 kJ/mol, which allows comparisons of the steady state data with previous pre-steady state measurements. In its physiological, NADPH-rednced form, the enzyme is strongly inhibited by organic gold compounds that are widely used in the treatment of rheumatoid arthritis; for auranofin, the K-i was 4 nM when measured in the presence of 50 mu M thioredoxin. At 1000-fold higher concentrations, that is at micromolar levels, the drugs also inhibited human glutathione reductase and the selenoenzyme glutathione peroxidase.	Heidelberg Univ, Ctr Biochem, D-69120 Heidelberg, Germany; Univ Michigan, Med Ctr, Dept Vet Affairs, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48105 USA	Ruprecht Karls University Heidelberg; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schirmer, RH (corresponding author), Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	schirmer.@urz.uni-heidelberg.de			NIGMS NIH HHS [GM21444] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersson M, 1996, J BIOL CHEM, V271, P10116, DOI 10.1074/jbc.271.17.10116; [Anonymous], 1989, COENZYMES COFACTORS; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; BERRY A, 1989, BIOCHEMISTRY-US, V28, P1264, DOI 10.1021/bi00429a047; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Beutler E, 1984, RED CELL METABOLISM, P74; BUCHELER US, 1992, NUCLEIC ACIDS RES, V20, P3127, DOI 10.1093/nar/20.12.3127; CHAUDIERE J, 1984, J INORG BIOCHEM, V20, P313, DOI 10.1016/0162-0134(84)85030-8; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; GROMER S, 1998, THESIS HEIDELBERG U; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; KAIM W, 1991, BIOANORGANISCHE CHEM, P325; Larsen PR, 1997, BIOCHEM SOC T, V25, P588, DOI 10.1042/bst0250588; LENNON BW, 1995, BIOCHEMISTRY-US, V34, P3670, DOI 10.1021/bi00011a023; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MASSEY V, 1960, BIOCHEM J, V77, P341, DOI 10.1042/bj0770341; MOORE EC, 1964, J BIOL CHEM, V239, P3453; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; OBLONG JE, 1993, BIOCHEMISTRY-US, V32, P7271, DOI 10.1021/bi00079a025; RIETVELD P, 1994, BIOCHEMISTRY-US, V33, P13888, DOI 10.1021/bi00250a043; Saito I, 1996, ARTHRITIS RHEUM, V39, P773, DOI 10.1002/art.1780390509; SCHALLREUTER KU, 1990, BIOCHIM BIOPHYS ACTA, V1054, P14, DOI 10.1016/0167-4889(90)90199-N; SCOTT AJ, 1976, REG SCI URBAN ECON, V6, P147, DOI 10.1016/0166-0462(76)90024-7; SEWELL DL, 1995, CLIN MICROBIOL REV, V8, P389, DOI 10.1128/CMR.8.3.389; SIMON TM, 1981, CANCER RES, V41, P94; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282; WILLIAMS CH, 1995, FASEB J, V9, P1267, DOI 10.1096/fasebj.9.13.7557016; WILLIAMS CH, 1967, J BIOL CHEM, V242, P5226; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; ZVAIFLER NJ, 1983, AM J MED, V75, P3, DOI 10.1016/0002-9343(83)90469-2	39	447	453	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20096	20101		10.1074/jbc.273.32.20096	http://dx.doi.org/10.1074/jbc.273.32.20096			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685351	hybrid			2022-12-27	WOS:000075305400028
J	Lackmann, M; Oates, AC; Dottori, M; Smith, FM; Do, C; Power, M; Kravets, L; Boyd, AW				Lackmann, M; Oates, AC; Dottori, M; Smith, FM; Do, C; Power, M; Kravets, L; Boyd, AW			Distinct subdomains of the EphA3 receptor mediate ligand binding and receptor dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EPIDERMAL GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; FACTOR PDGF RECEPTORS; SIGNAL-TRANSDUCTION; INSULIN-RECEPTOR; CELL LINES; IN-VITRO; GENE; EXPRESSION	Eph receptor tyrosine kinases and their ligands (ephrins) are highly conserved protein families implicated in patterning events during development, particularly in the nervous system. In a number of functional studies, strict conservation of structure and function across distantly related vertebrate species has been confirmed. In this study we make use of the observation that soluble human EphA3 (HEK) exerts a dominant negative effect on somite formation and axial organization during zebrafish embryogenesis to probe receptor function. Based on exon structure we have dissected the extracellular region of EphA3 receptor into evolutionarily conserved subdomains and used kinetic BIAcore analysis, mRNA injection into zebrafish embryos, and receptor transphosphorylation analysis to study their function. We show that ligand binding is restricted to the N-terminal region encoded by exon III, and we identify an independent, C-terminal receptor-dimerization domain. Recombinant proteins encoding either region in isolation can function as receptor antagonists in zebrafish. We propose a two-step mechanism of Eph receptor activation with distinct ligand binding and ligand-independent receptor-receptor oligomerization events.	Royal Brisbane Hosp, Queensland Inst Med Res, Bancroft Ctr, Brisbane, Qld 4029, Australia; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Branch, Melbourne, Vic 3050, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Boyd, AW (corresponding author), Royal Brisbane Hosp, Queensland Inst Med Res, Bancroft Ctr, Brisbane, Qld 4029, Australia.	andrewBo@qimr.edu.au	Boyd, Andrew/G-2083-2010	Dottori, Mirella/0000-0003-0598-4195				BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BOYD AW, 1992, J BIOL CHEM, V267, P3262; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; Brennan C, 1997, DEVELOPMENT, V124, P655; Cerretti DP, 1995, MOL IMMUNOL, V32, P1197, DOI 10.1016/0161-5890(95)00108-5; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Connor RJ, 1995, ONCOGENE, V11, P2429; Cooper HM, 1995, ONCOGENE, V11, P2243; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; FJOSE A, 1994, DEVELOPMENT, V120, P71; Flanagan JG, 1997, CELL, V90, P403; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HERREN B, 1993, J BIOL CHEM, V268, P15088; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; Lackmann M, 1996, P NATL ACAD SCI USA, V93, P2523, DOI 10.1073/pnas.93.6.2523; Lackmann M, 1997, J BIOL CHEM, V272, P16521, DOI 10.1074/jbc.272.26.16521; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LEVYTOLEDANO R, 1994, EMBO J, V13, P835, DOI 10.1002/j.1460-2075.1994.tb06326.x; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; OLDBERG A, 1986, J BIOL CHEM, V261, P2113; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; SAJJADI FG, 1991, NEW BIOL, V3, P769; SALVARIS E, 1992, LEUKEMIA RES, V16, P655, DOI 10.1016/0145-2126(92)90016-Z; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; UENO H, 1993, J BIOL CHEM, V268, P22814; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; Weinberg ES, 1996, DEVELOPMENT, V122, P271; WESTERFIELD M, 1995, ZEBRAFISH BOOK; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Xu QL, 1996, NATURE, V381, P319, DOI 10.1038/381319a0; Xu QL, 1995, DEVELOPMENT, V121, P4005	62	83	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20228	20237		10.1074/jbc.273.32.20228	http://dx.doi.org/10.1074/jbc.273.32.20228			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685371	hybrid			2022-12-27	WOS:000075305400048
J	Shetty, KM; Kurada, P; O'Tousa, JE				Shetty, KM; Kurada, P; O'Tousa, JE			Rab6 regulation of rhodopsin transport in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RETINAL-DEGENERATION; ENDOPLASMIC-RETICULUM; PHOTORECEPTOR CELLS; VESICULAR TRANSPORT; OUTER SEGMENT; OPSIN GENE; GOLGI; MEMBRANE; MUTATION	Rab6 is a GTP binding protein that regulates vesicular trafficking within the Golgi and post-Golgi compartments. We overexpressed wild-type, a GTPase defective (Q71L), and a guanine nucleotide binding defective (N125I) Rab6 protein in Drosophila photoreceptors to assess the in vivo role of Rab6 in the trafficking of rhodopsin and other proteins. Expression of Drab6(Q71L) greatly reduced the steady state levels of two rhodopsins, Rh1 and Rh3, whereas Drab6(wt) and Drab6(N125I) showed weaker effects. Analysis of a strain carrying Rh1 rhodopsin under a heat shock promoter showed that Drab6(Q71L), but not Drab6(wt) or Drab6(N125I), prevents the maturation of rhodopsin beyond an immature 40 kDa form. Drab6(Q71L) is a GTPase defective mutant, indicating that anterograde transport of rhodopsin requires Rab6 GTPase function. The three Drab6 strains had no effect on the expression of several other photoreceptor proteins. The Drab6(Q71L) photoreceptors show marked histological defects at young ages and degenerate over a two week time span. These results establish that rhodopsin is transported via a Rab6 regulated pathway and that defects in trafficking pathways lead to retinal degeneration.	Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University of Notre Dame	O'Tousa, JE (corresponding author), Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.			O'Tousa, Joseph/0000-0001-9754-6816	NEI NIH HHS [EY06808] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; Blest A. D., 1980, EFFECTS CONSTANT LIG, P217; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; DERETIC D, 1993, J CELL SCI, V106, P803; FEILER R, 1992, J NEUROSCI, V12, P3862; HUBER A, 1994, EUR J CELL BIOL, V63, P219; Ivessa NE, 1997, J BIOL CHEM, V272, P20828, DOI 10.1074/jbc.272.33.20828; JASMIN BJ, 1992, NEUROSCIENCE, V49, P849, DOI 10.1016/0306-4522(92)90361-5; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; Kurada P, 1998, VISUAL NEUROSCI, V15, P693, DOI 10.1017/S0952523898154093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LEONARD DS, 1992, J NEUROBIOL, V23, P605, DOI 10.1002/neu.480230602; Magee Tony, 1992, Trends in Cell Biology, V2, P318, DOI 10.1016/0962-8924(92)90172-J; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; MISMER D, 1987, GENETICS, V116, P565; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; OZAKI K, 1993, NEURON, V10, P1113, DOI 10.1016/0896-6273(93)90059-Z; Pak W.L., 1979, P67; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PORTER JA, 1992, J CELL BIOL, V116, P683, DOI 10.1083/jcb.116.3.683; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SAPP RJ, 1991, EXP EYE RES, V53, P73, DOI 10.1016/0014-4835(91)90147-7; Satoh AK, 1997, FEBS LETT, V404, P65, DOI 10.1016/S0014-5793(97)00094-X; Satoh AK, 1997, J CELL SCI, V110, P2943; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; SUNG CH, 1994, J NEUROSCI, V14, P5818; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TIXIERVIDAL A, 1993, J CELL SCI, V105, P935; VIHTELIC TS, 1993, J CELL BIOL, V122, P1013, DOI 10.1083/jcb.122.5.1013; WASHBURN T, 1992, GENETICS, V130, P585; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	49	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20425	20430		10.1074/jbc.273.32.20425	http://dx.doi.org/10.1074/jbc.273.32.20425			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685396	hybrid			2022-12-27	WOS:000075305400073
J	Yang, WP; Levesque, PC; Little, WA; Conder, ML; Ramakrishnan, P; Neubauer, MG; Blanar, MA				Yang, WP; Levesque, PC; Little, WA; Conder, ML; Ramakrishnan, P; Neubauer, MG; Blanar, MA			Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARYBDOTOXIN; INHIBITOR; K(V)LQT1; PROTEINS; FORM	Benign familial neonatal convulsions (BFNC), a class of idiopathic generalized epilepsy, is an autosomal dominantly inherited disorder of newborns. BFNC has been linked to mutations in two putative K+ channel genes, KCNQ2 and KCNQ3, Amino acid sequence comparison reveals that both genes share strong homology to KvLQT1, the potassium channel encoded by KCHQ1, which is responsible for over 50% of inherited long QT syndrome. Here we describe the cloning, functional expression, and characterization of K+ channels encoded by KCNQ2 and KCNQ3 cDNAs, Individually, expression of KCNQ2 or KCNQ3 in Xenopus oocytes elicits voltage-gated, rapidly activating K+-selective currents similar to KCNQ1, However, unlike KCNQ1, KCNQ2 and KCNQ3 currents are not augmented by coexpression with the KCNQ1 beta subunit, KCNE1 (minK, IsK). Northern blot analyses reveal that KCNQ2 and KCNQ3 exhibit similar expression patterns in different regions within the brain. Interestingly, coexpression of KCNQ2 and KCNQ3 results in a substantial synergistic increase in current amplitude. Coexpression of KCNE1 with the two channels strongly suppressed current amplitude and slowed kinetics of activation. The pharmacological and biophysical properties of the K+ currents observed in the coinjected oocytes differ somewhat from those observed after injecting either KCNQ2 or KCNQ3 by itself. The functional interaction between KCNQ2 and KCNQ3 provides a framework for understanding how mutations in either channel can cause a form of idiopathic generalized epilepsy.	Bristol Myers Squibb Pharmaceut Res Inst, Dept Cardiovasc Drug Discovery, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Appl Genom, Princeton, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb	Blanar, MA (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Dept Cardiovasc Drug Discovery, Mail Code F12-01,Route 206 & Provinceline Rd, Princeton, NJ 08543 USA.							Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Biervert C, 1998, SCIENCE, V279, P403, DOI 10.1126/science.279.5349.403; Charlier C, 1998, NAT GENET, V18, P53, DOI 10.1038/ng0198-53; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Deal KK, 1996, PHYSIOL REV, V76, P49, DOI 10.1152/physrev.1996.76.1.49; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Shalaby FY, 1997, CIRCULATION, V96, P1733, DOI 10.1161/01.CIR.96.6.1733; Singh NA, 1998, NAT GENET, V18, P25, DOI 10.1038/ng0198-25; Snyder AP, 1996, FIELD ANAL CHEM TECH, V1, P49; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; SUGG EE, 1990, J BIOL CHEM, V265, P18745; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yang WP, 1997, P NATL ACAD SCI USA, V94, P4017, DOI 10.1073/pnas.94.8.4017	14	161	170	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19419	19423		10.1074/jbc.273.31.19419	http://dx.doi.org/10.1074/jbc.273.31.19419			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677360	hybrid			2022-12-27	WOS:000075125200012
J	Asker, N; Axelsson, MAB; Olofsson, SO; Hansson, GC				Asker, N; Axelsson, MAB; Olofsson, SO; Hansson, GC			Dimerization of the human MUC2 mucin in the endoplasmic reticulum is followed by a N-glycosylation-dependent transfer of the mono- and dimers to the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; INTESTINAL MUCIN; O-GLYCOSYLATION; CELLS; BIOSYNTHESIS; RAT; LIPOPROTEINS; OLIGOMERIZATION; IDENTIFICATION; SECRETION	Pulse-chase experiments in the colon cell line LS 174T combined with subcellular fractionation by sucrose density gradient centrifugation showed that the initial dimerization of the MUC2 apomucin started directly after translocation of the apomucin into the rough endoplasmic reticulum as detected by calnexin reactivity. As the mono- and dimers were chased, O-glycosylated MUC2 mono- and dimers were precipitated using an O-glycosylation-insensitive antiserum against the N-terminal domain of the MUC2 mucin. These O-glycosylated species were precipitated from the fractions that comigrated with the galactosyltransferase activity during the subcellular fractionation, indicating that not only MUC2 dimers but also a significant amount of monomers are transferred into the Golgi apparatus. Inhibition of N-glycosylation with tunicamycin treatment slowed down the rate of dimerization and introduced further oligomerization of the MUC2 apomucin in the endoplasmic reticulum, Results of two-dimensional gel electrophoresis demonstrated that these oligomers (putative tri- and tetramers) were stabilized by disulfide bonds. The non-N-glycosylated species of the MUC2 mucin were retained in the endoplasmic reticulum because no O-glycosylated species were precipitated after inhibition by tunicamycin. This suggests that N-glycans of MUC2 are necessary for the correct folding and dimerization of the MUC2 mucin.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Gothenburg	Hansson, GC (corresponding author), Gothenburg Univ, Dept Med Biochem, Med Gatan 9A, S-41390 Gothenburg, Sweden.		Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869				ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; Axelsson MAB, 1998, J BIOL CHEM, V273, P18864, DOI 10.1074/jbc.273.30.18864; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; DEKKER J, 1989, J BIOL CHEM, V264, P10431; DEKKER J, 1990, J BIOL CHEM, V265, P18116; Forstner Janet F., 1994, P1255; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; KLOMP LWJ, 1994, BIOCHEM J, V304, P737, DOI 10.1042/bj3040737; KLOMP LWJ, 1994, BIOCHEM J, V304, P693, DOI 10.1042/bj3040693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCOOL DJ, 1994, BIOCHEM J, V302, P111, DOI 10.1042/bj3020111; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; OHARA S, 1994, BIOCHEM J, V297, P509, DOI 10.1042/bj2970509; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1984, J CELL BIOL, V99, P2123, DOI 10.1083/jcb.99.6.2123; YAO ZM, 1991, J BIOL CHEM, V266, P3300	22	105	106	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18857	18863		10.1074/jbc.273.30.18857	http://dx.doi.org/10.1074/jbc.273.30.18857			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668061	hybrid			2022-12-27	WOS:000074974700028
J	Murga, C; Laguinge, L; Wetzker, R; Cuadrado, A; Gutkind, JS				Murga, C; Laguinge, L; Wetzker, R; Cuadrado, A; Gutkind, JS			Activation of Akt/protein kinase B by G protein-coupled receptors - A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinase gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ACTIVATION; PATHWAY; CELLS; INHIBITION; APOPTOSIS; SIGNALS; AKT; RAS	The serine/threonine protein kinase Akt has recently been shown to be implicated in the pathway leading to cell survival in response to serum and growth factors in a variety of cellular systems. However, the existence of a biochemical route connecting this kinase to the large family of receptors that signal through heterotrimeric G proteins is yet to be explored. in this study, we set out to investigate whether GTP-binding protein (G protein)coupled receptors (GPCRs) can stimulate Akt activity and survival pathways and, if so, to define the mechanism(s) whereby this class of cell surface receptors could regulate Akt function. Using ectopic expression of GPCRs in COS-7 cells as a model, we have observed that both mi and m2 muscarinic acetylcholine receptors, representative of those GPCRs coupled to G, and Gi proteins, respectively, can readily activate an epitope-tagged form of Akt kinase and prevent W-induced apoptosis. We have also found that the pathway connecting G proteins to Akt implicates signals emanating from G alpha(q), G alpha(i) and beta gamma dimers, but not from G alpha(s) Or G alpha(12), in each case acting through a pathway that involves a phosphatidylinositol-3-OH kinase activity. Moreover, our findings suggest a role for a novel py-sensitive complex, p101.phosphatidylinositol-3-OH kinase-gamma, in the transduction of signals leading to Akt stimulation and cell survival by GPCRs and open new avenues for research on the function of the large family of G protein-linked receptors in the regulation of anti-apoptotic pathways.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Univ Jena, Fac Med, Max Planck Res Unit Mol Cell Biol, D-07747 Jena, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Friedrich Schiller University of Jena; Max Planck Society	Gutkind, JS (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		Murga, Cristina/E-1965-2014; Gutkind, J. Silvio/A-1053-2009; Wetzker, Reinhard/AAD-8713-2019; Gutkind, J. Silvio/J-1201-2016	Murga, Cristina/0000-0002-8964-4077; Gutkind, J. Silvio/0000-0002-5150-4482; Cuadrado, Antonio/0000-0002-4039-7140; Cuadrado, Antonio/0000-0002-3444-9012				BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boudewijn MT, 1995, NATURE, V376, P599; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LINDENBOIM L, 1995, J NEUROCHEM, V64, P2491; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; YAN GM, 1995, MOL PHARMACOL, V47, P248	32	291	294	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19080	19085		10.1074/jbc.273.30.19080	http://dx.doi.org/10.1074/jbc.273.30.19080			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668091	hybrid			2022-12-27	WOS:000074974700058
J	Tsai, TY; Lee, YHW				Tsai, TY; Lee, YHW			Roles of copper ligands in the activation and secretion of Streptomyces tyrosinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLAUCESCENS TYROSINASE; TRANSACTIVATOR MELC1; NEUROSPORA-CRASSA; GENE; PROTEIN; EXPRESSION; APOTYROSINASE; ANTIBIOTICUS; SEQUENCE; BINDING	The expression of the melanin operon (melC) of Streptomyces antibioticus requires the chaperone-like protein MelC1 for the incorporation of two copper ions (designated as Cu-A and Cu-B) and the secretion of the apotyrosinase (MelC2) via a transient binary complex formation between these two proteins. To: investigate whether the copper ligand of tyrosinase is involved in this MelC1 MelC2 binary complex function, six single substitution mutations were introduced into the Cu-A and CUB sites. These mutations led to differential effects on the stability, copper content, and export function of binary complexes but a complete abolishment of tyrosinase activity. The defects in the tyrosinase activity in mutants were not because of the impairment of the formation of MelC1 MelC2 complex but rather the failure of MelC2 to be discharged from the copper-activated binary complex. Moreover, the impairments on the discharge of the mutant MelC2 from all the mutant binary complexes appeared to result from the structural changes in their apoforms or copper-activated forms of the complexes, as evidenced by the fluorescence emission and circular dichroism spectral analysis. Therefore, each of six copper ligands in Streptomyces tyrosinase binuclear copper sites plays a pivotal role in the final maturation and the discharge of tyrosinase from the binary complex but has a less significant role in its secretion.	Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan.			Lee Wu, Yan-Hwa/0000-0001-7299-7354				BELTRAMINI M, 1982, BIOCHEM J, V205, P173, DOI 10.1042/bj2050173; BELTRAMINI M, 1982, FEBS LETT, V142, P219, DOI 10.1016/0014-5793(82)80138-5; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN LY, 1992, J BIOL CHEM, V267, P20100; CHEN LY, 1993, J BIOL CHEM, V268, P18710; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRY DC, 1983, BIOCHEMISTRY-US, V22, P4949, DOI 10.1021/bi00290a011; GIEBEL LB, 1991, GENOMICS, V9, P435, DOI 10.1016/0888-7543(91)90409-8; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HINTERMANN G, 1985, MOL GEN GENET, V200, P422, DOI 10.1007/BF00425726; Hopwood D.A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; Huber M., 1986, P265; HUBER M, 1988, BIOCHEMISTRY-US, V27, P5610, DOI 10.1021/bi00415a032; HUBER M, 1985, BIOCHEMISTRY-US, V24, P6038, DOI 10.1021/bi00343a003; JACKMAN MP, 1991, BIOCHEM J, V274, P707, DOI 10.1042/bj2740707; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KERTESZ D, 1972, BIOCHEM BIOPH RES CO, V49, P1208, DOI 10.1016/0006-291X(72)90597-9; KUPPER U, 1989, J BIOL CHEM, V264, P17250; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YHW, 1988, GENE, V65, P71, DOI 10.1016/0378-1119(88)90418-0; Lee YHW, 1996, ADV INORG BIOCHEM, P223; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; LERCH K, 1980, NATURE, V284, P368, DOI 10.1038/284368a0; LEU WM, 1989, GENE, V84, P267; LEU WM, 1992, J BIOL CHEM, V267, P20108; LIAW LL, 1995, BIOCHEM BIOPH RES CO, V214, P447, DOI 10.1006/bbrc.1995.2307; LINZEN B, 1985, SCIENCE, V229, P519, DOI 10.1126/science.4023698; MASON HS, 1965, ANNU REV BIOCHEM, V34, P595, DOI 10.1146/annurev.bi.34.070165.003115; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schmid F., 1990, PROTEIN STRUCTURE PR, P251; TAKASE M, 1992, GENE, V121, P359; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; YONG G, 1990, BIOCHEMISTRY-US, V29, P9684, DOI 10.1021/bi00493a025	39	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19243	19250		10.1074/jbc.273.30.19243	http://dx.doi.org/10.1074/jbc.273.30.19243			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668113	hybrid			2022-12-27	WOS:000074974700080
J	Meerovitch, K; Wing, S; Goltzman, D				Meerovitch, K; Wing, S; Goltzman, D			Proparathyroid hormone-related protein is associated with the chaperone protein BiP and undergoes proteasome-mediated degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE; ENDOPLASMIC-RETICULUM; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; APOLIPOPROTEIN B100; PEPTIDE PRODUCTION; SECRETORY PROTEIN; ER DEGRADATION; HEAVY-CHAIN; CELL-DEATH; PATHWAY	Parathyroid hormone-related peptide (PTHrP) is an important causal factor for hypercalcemia associated with malignancy. In addition to the endocrine functions attributed to secretory forms of the peptide, PTHrP also plays a local role as a mediator of cellular growth and differentiation presumably at least in part through intracellular pathways. In studying the post-translational regulation of PTHrP, we observed that PTHrP was conjugated to multiple ubiquitin moieties. We report here that the proteasome is responsible for the degradation of the endoplasmic reticulum-associated precursor, pro-PTHrP. Cells expressing prepro-PTHrP and exposed to lactacystin accumulate pro-PTHrP assessed by anti-pro specific antibodies. Brefeldin A-treated cells also accumulate pro-PTHrP suggesting that degradation does not occur in the endoplasmic reticulum (ER) lumen. Subcellular fractionation of both lactacystin and brefeldin A-treated cells indicated that accumulated pro-PTHrP resides in microsomal fractions with a portion of the protein exposed to the cytosolic side of the ER membrane as assessed by protease protection experiments. Immunoprecipitation and Western blot analysis identified pro-PTHrP in association with the ER molecular chaperone protein BiP. We conclude that pro-PTHrP from the ER can gain access to the cytoplasmic side of the ER membrane where it can undergo ubiquitination and degradation by the proteasome.	McGill Univ, Calcium Res Lab, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Polypeptide Lab, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University	Goltzman, D (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amizuka N, 1996, ENDOCRINOLOGY, V137, P5055, DOI 10.1210/en.137.11.5055; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BONIFACINO JS, 1994, CELL PROTEOLYTIC SYS; BROADUS AE, 1994, PARATHYROIDS; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLTZMAN D, 1997, ENDOCRINE NEOPLASMS; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO;2-F; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KAISER SM, 1994, MOL ENDOCRINOL, V8, P139, DOI 10.1210/me.8.2.139; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LI X, 1993, CANCER RES, V53, P2980; LIU B, 1993, ENDOCRINOLOGY, V132, P1658, DOI 10.1210/en.132.4.1658; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; McGee TP, 1996, J BIOL CHEM, V271, P25630, DOI 10.1074/jbc.271.41.25630; Meerovitch K, 1997, J BIOL CHEM, V272, P6706, DOI 10.1074/jbc.272.10.6706; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RABBANI SA, 1995, ENDOCRINOLOGY, V136, P5416, DOI 10.1210/en.136.12.5416; RIVETT AJ, 1993, BIOCHEM J, V291, P1; Roberts BJ, 1997, J BIOL CHEM, V272, P9771; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	49	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21025	21030		10.1074/jbc.273.33.21025	http://dx.doi.org/10.1074/jbc.273.33.21025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694854	hybrid			2022-12-27	WOS:000075386100047
J	Muhlbauer, SK; Eichacker, LA				Muhlbauer, SK; Eichacker, LA			Light-dependent formation of the photosynthetic proton gradient regulates translation elongation in chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED PEA-CHLOROPLASTS; SPINACH-CHLOROPLASTS; PHOTOSYSTEM-I; ELECTRON-TRANSPORT; PROTEIN-SYNTHESIS; MESSENGER-RNAS; BINDING; ACCUMULATION; D1; PLASTOQUINONE	Upon transfer of lysed chloroplasts from darkness to light, the accumulation of membrane and stromal chloroplast proteins is strictly regulated at the level of translation elongation. In darkness, translation elongation is retarded even in the presence of exogenously added ATP and dithiothreitol. In the light, addition of the electron transport inhibitor 3-(3,4-dichlorophenyl)-1,1-dimethyl urea inhibits translation elongation even in the presence of ATP. This inhibition can be overcome by addition of artificial electron donors in the presence of light, but not in darkness. Electron flow between photo-system II and I induced by far red light of 730 nm is sufficient for the activation of translation elongation. This activation can also be obtained by electron donors to photosystem I, which transport protons into the thylakoid lumen, Release of the proton gradient by uncouplers prevents the Light-dependent activation of translation elongation. Also, the induction of translation activation is switched off rapidly upon transfer from light to darkness. Hence, we propose that the formation of a photosynthetic proton gradient across the thylakoid membrane activates translation elongation in chloroplasts.	Univ Munich, Dept Bot, D-80638 Munich, Germany	University of Munich	Eichacker, LA (corresponding author), Univ Munich, Dept Bot, Menzinger Str 67, D-80638 Munich, Germany.							ALLEN CA, 1995, REDOX REP, V1, P119, DOI 10.1080/13510002.1995.11746969; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; BERRY JO, 1988, P NATL ACAD SCI USA, V85, P4190, DOI 10.1073/pnas.85.12.4190; BHAYA D, 1984, PLANT PHYSIOL, V75, P832, DOI 10.1104/pp.75.3.832; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; Eichacker LA, 1996, J BIOL CHEM, V271, P32174, DOI 10.1074/jbc.271.50.32174; GAL A, 1990, J BIOL CHEM, V265, P19742; HAEHNEL W, 1977, BIOCHIM BIOPHYS ACTA, V459, P418, DOI 10.1016/0005-2728(77)90043-3; HATTORI T, 1986, ARCH BIOCHEM BIOPHYS, V244, P630; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; INAGAKI N, 1992, FEBS LETT, V300, P5, DOI 10.1016/0014-5793(92)80152-7; IZAWA S, 1978, BIOCHEM BIOPH RES CO, V83, P1171, DOI 10.1016/0006-291X(78)91518-8; Izawa S., 1980, METHODS ENZYMOL    C, P413; JUNGE W, 1977, ANNU REV PLANT PHYS, V28, P503, DOI 10.1146/annurev.pp.28.060177.002443; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; KIM JM, 1991, J BIOL CHEM, V266, P14931; KIRK MM, 1985, CELL, V41, P419, DOI 10.1016/S0092-8674(85)80015-5; Klaff P, 1995, PHOTOSYNTH RES, V46, P235, DOI 10.1007/BF00020436; KLEIN RR, 1986, J BIOL CHEM, V261, P1138; Kuroda H, 1996, PLANT CELL PHYSIOL, V37, P754, DOI 10.1093/oxfordjournals.pcp.a029010; MCCARTY RE, 1980, METHOD ENZYMOL, V69, P719; MICHAELS A, 1990, BIOCHEM BIOPH RES CO, V170, P1082, DOI 10.1016/0006-291X(90)90503-F; ORLICH G, 1980, EUR J BIOCHEM, V111, P525, DOI 10.1111/j.1432-1033.1980.tb04968.x; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; TANAKA A, 1994, PLANTA, V192, P92; TANIGUCHI M, 1993, FEBS LETT, V317, P57, DOI 10.1016/0014-5793(93)81491-H; vanWijk KJ, 1996, FEBS LETT, V388, P89, DOI 10.1016/0014-5793(96)00540-6; WOOD PM, 1976, EUR J BIOCHEM, V61, P337, DOI 10.1111/j.1432-1033.1976.tb10027.x	30	55	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20935	20940		10.1074/jbc.273.33.20935	http://dx.doi.org/10.1074/jbc.273.33.20935			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694842	hybrid			2022-12-27	WOS:000075386100035
J	Sheridan, SD; Benham, CJ; Hatfield, GW				Sheridan, SD; Benham, CJ; Hatfield, GW			Activation of gene expression by a novel DNA structural transmission mechanism that requires supercoiling-induced DNA duplex destabilization in an upstream activating sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; SUPERHELICAL DNA; GEL-ELECTROPHORESIS; ILVGMEDA OPERON; RICH REGIONS; TRANSCRIPTION; PROTEIN; PROMOTER; TRANSITIONS	We have previously demonstrated that integration host factor (IHF)-mediated activation of transcription from the ilvP(G) promoter of Escherichia coli requires a supercoiled DNA template and occurs in the absence of specific interactions between IHF and RNA polymerase. In this report, we describe a novel, supercoiling-dependent, DNA structural transmission mechanism for this activation. We provide theoretical evidence for a supercoiling-induced DNA duplex destabilized (SIDD) structure in the A + T-rich, ilvP(G) regulatory region between base pair positions +1 and -160, We show that the region of this SIDD sequence immediately upstream of an IHF binding site centered at base pair position -92 is, in fact, destabilized by superhelical stress and that this duplex destabilization is inhibited by IHF binding. Thus, in the presence of IHF, the negative superhelical twist normally absorbed by this DNA structure in the promoter distal half of the SIDD sequence is transferred to the downstream portion of the SIDD sequence containing the ilvP(G) promoter site. This IHF-mediated translocation of superhelical energy facilitates duplex destabilization in the -10 region of the downstream ilvP(G) promoter and activates transcription by increasing the rate of open complex formation.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; CUNY Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA	University of California System; University of California Irvine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Hatfield, GW (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Benham, Craig J/G-1512-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55073, GM07311, GM47012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1992, J BIOL CHEM, V267, P1776; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Barton MC, 1997, P NATL ACAD SCI USA, V94, P7257, DOI 10.1073/pnas.94.14.7257; BENHAM CJ, 1979, P NATL ACAD SCI USA, V76, P3870, DOI 10.1073/pnas.76.8.3870; BENHAM CJ, 1992, J MOL BIOL, V225, P835, DOI 10.1016/0022-2836(92)90404-8; BENHAM CJ, 1990, J CHEM PHYS, V92, P6294, DOI 10.1063/1.458353; BENHAM CJ, 1993, P NATL ACAD SCI USA, V90, P2999, DOI 10.1073/pnas.90.7.2999; Benham CJ, 1996, J MOL BIOL, V255, P425, DOI 10.1006/jmbi.1996.0035; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; BOWATER RP, 1994, NUCLEIC ACIDS RES, V22, P2042, DOI 10.1093/nar/22.11.2042; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; Fyfe JAM, 1998, J BACTERIOL, V180, P2152, DOI 10.1128/JB.180.8.2152-2159.1998; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; HIGGINS NP, 1989, J BIOL CHEM, V264, P3035; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; NISHI T, 1986, GENE, V44, P29, DOI 10.1016/0378-1119(86)90039-9; PAGEL JM, 1992, J MOL BIOL, V224, P919, DOI 10.1016/0022-2836(92)90460-2; PALECEK E, 1992, METHOD ENZYMOL, V212, P139; Parekh BS, 1996, J BIOL CHEM, V271, P20258, DOI 10.1074/jbc.271.34.20258; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PRUSS GJ, 1989, CELL, V56, P521, DOI 10.1016/0092-8674(89)90574-6; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; Sambrook J., 2002, MOL CLONING LAB MANU; SHINDO H, 1995, BIOL PHARM BULL, V18, P1328; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STECK TR, 1993, MOL MICROBIOL, V10, P473, DOI 10.1111/j.1365-2958.1993.tb00920.x; VANRIJN PA, 1988, NUCLEIC ACIDS RES, V16, P4595, DOI 10.1093/nar/16.10.4595; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	36	77	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21298	21308		10.1074/jbc.273.33.21298	http://dx.doi.org/10.1074/jbc.273.33.21298			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694890	hybrid			2022-12-27	WOS:000075386100083
J	Dimitriadis, EK; Prasad, R; Vaske, MK; Chen, L; Tomkinson, AE; Lewis, MS; Wilson, SH				Dimitriadis, EK; Prasad, R; Vaske, MK; Chen, L; Tomkinson, AE; Lewis, MS; Wilson, SH			Thermodynamics of human DNA ligase I trimerization and association with DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; DOMAIN; IDENTIFICATION; RESIDUES; BINDING; SITE	The interaction between human DNA polymerase beta (pol beta) and DNA Ligase I, which appear to be responsible for the gap filling and nick ligation steps in short patch or simple base excision repair, has been examined by affinity chromatography and analytical ultracentrifugation. Domain mapping studies revealed that complex formation is mediated through the non-catalytic N-terminal domain of DNA ligase I and the N-terminal 8-kDa domain of pol beta that interacts with the DNA template and excises 5'-deoxyribose phosphate residue. Intact pol beta, a 39-kDa bi-domain enzyme, undergoes indefinite self-association, forming oligomers of many sizes. The binding sites for self-association reside within the C-terminal 31-kDa domain. DNA ligase I undergoes self-association to form a homotrimer, At temperatures over 18 degrees C, three pol beta monomers attached to the DNA ligase I trimer, forming a stable heterohexamer, In contrast, at lower temperatures (<18 degrees C), pol beta and DNA ligase I formed a stable 1:1 binary complex only. In agreement with the domain mapping studies, the 8-kDa domain of pol beta interacted with DNA ligase I, forming a stable 3:3 complex with DNA ligase I at all temperatures, whereas the 31-kDa domain of pol beta did not. Our results indicate that the association between pol beta and DNA ligase I involves both electrostatic binding and an entropy-driven process. Electrostatic binding dominates the interaction mediated by the 8-kDa domain of pol beta, whereas the entropy-driven aspect of interprotein binding appears to be contributed by the 31-kDa domain.	NIEHS, LSB, NIH, Res Triangle Pk, NC 27709 USA; NIH, Biomed Engn & Phys Sci Program, Bethesda, MD 20892 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; University of Texas System; University of Texas Health San Antonio	Wilson, SH (corresponding author), NIEHS, LSB, NIH, POB 12233,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047251, R29GM047251] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047251, GM47251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beard WA, 1995, METHOD ENZYMOL, V262, P98; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; CHUN PW, 1995, J BIOL CHEM, V270, P13925; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dimitriadis EK, 1997, PROG COLL POL SCI S, V107, P20; Eykhoff P., 1974, SYSTEM IDENTIFICATIO; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; KIM SJ, 1994, J MOL BIOL, V244, P224, DOI 10.1006/jmbi.1994.1720; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mackey ZB, 1997, MOL CELL BIOL, V17, P989, DOI 10.1128/MCB.17.2.989; MANUKIAN EB, 1986, MODERN CONCEPTS THEO; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Papoulis A., 1991, PROBABILITY RANDOM V; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; PRASAD R, 1993, J BIOL CHEM, V268, P22746; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Rao C.R., 1965, LINEAR STAT INFERENC, V2nd; RON D, 1992, BIOTECHNIQUES, V13, P866; Samson LD, 1992, ESSAYS BIOCHEM, V27, P69; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SRIVASTAVA DK, 1998, IN PRESS J BIOL CHEM, V273; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	33	60	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20540	20550		10.1074/jbc.273.32.20540	http://dx.doi.org/10.1074/jbc.273.32.20540			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685411	hybrid			2022-12-27	WOS:000075305400088
J	Drissi, H; Lasmoles, F; Le Mellay, V; Marie, PJ; Lieberherr, M				Drissi, H; Lasmoles, F; Le Mellay, V; Marie, PJ; Lieberherr, M			Activation of phospholipase C-beta 1 via G alpha(q/11) during calcium mobilization by calcitonin gene-related peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ALPHA-SUBUNITS; CYCLIC-AMP FORMATION; BETA-GAMMA-SUBUNITS; SIGNAL-TRANSDUCTION; ADENYLATE-CYCLASE; COS-7 CELLS; C ISOZYMES; RECEPTOR; GQ; IDENTIFICATION	Interaction of calcitonin gene-related peptide (CGRP) with its receptors leads to stimulation of adenylyl cyclase and/or phospholipase C (PLC), While regulation of adenylyl cyclase is thought to involve the G-protein G(s), it is not known whether activation of PLC results from coupling the receptor to G(q) family proteins or whether beta gamma subunits released from receptor-activated G(s) activate PLC. We used human bone cells OHS-4 bearing CORP receptors in which CORP activates only the PLC signaling pathway to determine how CORP acts. CORP increased the concentration of intracellular calcium ([Ca2+](i)) within 5 s via a Ca2+ influx through voltage-gated calcium channels and by mobilizing calcium from the endoplasmic reticulum. The activation of effecters, like PLC coupled to G-proteins, is the early event in the pathway leading to inositol 1,4,5-trisphosphate formation, which is responsible for Ca2+ mobilization. Western blotting demonstrated a range of PLC-beta isoforms (beta 1, beta 3, beta 4, but not beta 2) and G-proteins (G alpha(q/11) and G alpha(s)). Only phospholipase C-beta 1 is involved in the mobilization of Ca2+ from the endoplasmic reticulum of Fura-2-loaded confluent OHS-4 cells and the formation of inositol 1,4,5-trisphosphate by CORP; PLC-gamma have no effect. Activation of PLC-beta 1 by CORP involves the G alpha(q/11) subunit, which is insensitive to pertussis toxin, but not G beta gamma subunits. We therefore believe that CORP causes the activation of two separate G-proteins.	INRA, CNRS, UPR 1524, F-78350 Jouy En Josas, France; Hop Lariboisiere, INSERM, U349, Paris, France	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Lieberherr, M (corresponding author), INRA, CNRS, UPR 1524, Batiment 221, F-78350 Jouy En Josas, France.	lieberhe@diamant.jouy.inra.fr		drissi, hicham/0000-0002-3322-281X				Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIRNBAUMER L, 1995, J RECEPT SIGNAL TR R, V15, P213; BJURHOLM A, 1992, J BONE MINER RES, V7, P1011; BLEASDALE JE, 1989, ADV PROSTAG THROMB L, V19, P590; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DEFTOS LJ, 1989, BONE MINERAL RES, V6, P267; Drissi H, 1997, J BONE MINER RES, V12, pF391; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; FARLEY JR, 1993, METABOLISM, V42, P97, DOI 10.1016/0026-0495(93)90179-R; FOURNIER B, 1991, J CELL BIOL, V114, P577, DOI 10.1083/jcb.114.3.577; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GOLTZMAN D, 1985, SCIENCE, V227, P1343, DOI 10.1126/science.2983422; GRAY DW, 1991, BRIT J PHARMACOL, V107, P691; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Han ZQ, 1997, J MOL ENDOCRINOL, V18, P267, DOI 10.1677/jme.0.0180267; HOFMANN SL, 1982, J BIOL CHEM, V257, P4359; JAMES SR, 1994, BIOCHEM J, V304, P359, DOI 10.1042/bj3040359; JOSEPH SK, 1989, ARCH BIOCHEM BIOPHYS, V273, P1, DOI 10.1016/0003-9861(89)90156-2; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KAWASE T, 1995, BONE, V16, pS379, DOI 10.1016/8756-3282(95)00016-7; KOZASA T, 1993, P NATL ACAD SCI USA, V90, P9176, DOI 10.1073/pnas.90.19.9176; KUPPE A, 1990, BIOCHIM BIOPHYS ACTA, V1047, P41, DOI 10.1016/0005-2760(90)90258-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUFER R, 1989, J BIOL CHEM, V264, P2683; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; MICHELANGELI VP, 1986, CALCIFIED TISSUE INT, V39, P44, DOI 10.1007/BF02555739; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NELSON MT, 1990, NATURE, V344, P770, DOI 10.1038/344770a0; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OLIVEIRA L, 1994, TRENDS PHARMACOL SCI, V15, P170, DOI 10.1016/0165-6147(94)90137-6; Parsons AM, 1997, SYNAPSE, V26, P235, DOI 10.1002/(SICI)1098-2396(199707)26:3<235::AID-SYN5>3.3.CO;2-#; POYNER DR, 1992, PHARMACOL THERAPEUT, V56, P32; PRENTKI M, 1986, FEBS LETT, V197, P285, DOI 10.1016/0014-5793(86)80343-X; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STANGL D, 1993, ENDOCRINOLOGY, V132, P744, DOI 10.1210/en.132.2.744; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THIEBAUD D, 1991, J BONE MINER RES, V6, P1137; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UI M, 1990, ADP RIBOSYLATING TOX, P45; Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756-3282(96)00017-8; WU DQ, 1992, J BIOL CHEM, V267, P1811	57	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20168	20174		10.1074/jbc.273.32.20168	http://dx.doi.org/10.1074/jbc.273.32.20168			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685362	hybrid			2022-12-27	WOS:000075305400039
J	Frank, O; Schwanbeck, R; Wisniewski, JR				Frank, O; Schwanbeck, R; Wisniewski, JR			Protein footprinting reveals specific binding modes of a high mobility group protein I to DNAs of different conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IFN-BETA GENE; 4-WAY JUNCTION DNA; HMG-I; VIRUS INDUCTION; RNA-POLYMERASE; CDC2 KINASE; EXPRESSION; HMG-I(Y); DOMAINS; CDNA	The high mobility group proteins I and Y (HMGI/Y) are abundant components of chromatin. They are thought to derepress chromatin, affect the assembly and activity of the transcriptional machinery, and associate with constitutive heterochromatin during mitosis. HMGI/Y protein molecules contain three potential DNA-binding. motifs (AT-hooks), but the extent of contacts between DNA and the entire protein has not been determined, We have used a protein-footprinting procedure to map regions of the Chironomus HMGI protein molecule that are involved in contacts with DNA, We find that in the presence of double-stranded DNA all AT-hook motifs are protected against hydroxyl radical proteolysis. In contrast, only two motifs were protected in the presence of four-wag junction DNA. Large regions that flank the AT-hook motifs were found to be strongly protected against proteolysis in complexes with interferon-beta promoter DNA, suggesting amino acid residues outside the AT-hooks considerably contribute to DNA binding.	Univ Gottingen, Zool Inst Entwicklungsbiol 3, D-37073 Gottingen, Germany	University of Gottingen	Wisniewski, JR (corresponding author), Univ Gottingen, Zool Inst Entwicklungsbiol 3, Humboldtallee 34A, D-37073 Gottingen, Germany.	jwisnie@gwdg.de	Schwanbeck, Ralf/A-2648-2008	Schwanbeck, Ralf/0000-0003-0925-929X				ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; Bagga R, 1997, GENE DEV, V11, P629, DOI 10.1101/gad.11.5.629; Baichoo N, 1997, BIOCHEMISTRY-US, V36, P10830, DOI 10.1021/bi970714v; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Berner JM, 1997, ONCOGENE, V14, P2935, DOI 10.1038/sj.onc.1201135; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; Bornstein P, 1977, Methods Enzymol, V47, P132; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CLAUS P, 1994, J BIOL CHEM, V269, P33042; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Ghidelli S, 1997, CHROMOSOMA, V105, P369, DOI 10.1007/BF02529752; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; Greiner DP, 1996, P NATL ACAD SCI USA, V93, P71, DOI 10.1073/pnas.93.1.71; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk E, 1997, J BIOL CHEM, V272, P19763, DOI 10.1074/jbc.272.32.19763; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Hill DA, 1997, NUCLEIC ACIDS RES, V25, P3523, DOI 10.1093/nar/25.17.3523; Huth JR, 1997, NAT STRUCT BIOL, V4, P657, DOI 10.1038/nsb0897-657; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1990, EXP CELL RES, V187, P60; LEHN DA, 1988, BIOCHEM INT, V16, P963; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; Nicolas FJ, 1996, P NATL ACAD SCI USA, V93, P6881, DOI 10.1073/pnas.93.14.6881; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; RAM TG, 1993, CANCER RES, V53, P2655; Reeves R, 1996, BIOCHEMISTRY-US, V35, P5063, DOI 10.1021/bi952424p; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwanbeck R, 1997, J BIOL CHEM, V272, P27476, DOI 10.1074/jbc.272.43.27476; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tkachenko A, 1997, CANCER RES, V57, P2276; VANHOLDE K, 1994, CHROMATIN STRUCTURE, P1; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Wisniewski JR, 1997, EUR J BIOCHEM, V243, P151, DOI 10.1111/j.1432-1033.1997.0151a.x; Wisniewski JR, 1996, INT J DEV BIOL, V40, P177; XIAO D, 1997, CBHUNG KUO I HSUEH K, V18, P79; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649	50	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20015	20020		10.1074/jbc.273.32.20015	http://dx.doi.org/10.1074/jbc.273.32.20015			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685339	hybrid			2022-12-27	WOS:000075305400016
J	Gokmen-Polar, Y; Fields, AP				Gokmen-Polar, Y; Fields, AP			Mapping of a molecular determinant for protein kinase C beta(II) isozyme function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; NUCLEAR-MEMBRANE; MIXED MICELLES; LEUKEMIA-CELLS; LAMIN-B; CALCIUM; PHOSPHATIDYLSERINE; DIFFERENTIATION; DIACYLGLYCEROL	In human erythroleukemia (K562) cells, the highly related protein kinase C (PRC) alpha and PKC beta(II) isozymes serve distinct functions in cellular differentiation and proliferation, respectively. Previous studies using two domain switch PRC chimera revealed that the catalytic domains of PHC alpha and beta(II) contain molecular determinants important for isozyme-specific function (Walker, S. D,, Murray, N, R,, Burns, D, J,, and Fields, A. P, (1995) Proc. Natl, Acad, Sci. U.S.A. 92, 9156-9160), We have now analyzed a panel of PKC chimeras to determine the specific region within the catalytic domain important for PKC beta(II) function. A cellular assay for PKC beta(II) function was devised based on the finding that PKC beta(II) selectively translocates to the nucleus and phosphorylates nuclear lamin B in response to the PKC activator bryostatin, This response is strictly dependent upon expression of PKC beta(II) or a PKC chimera that functions like PKC beta(II). We demonstrate that a PKC alpha/beta(II) chimera containing only the carboxyl-terminal 13 amino acids from PRC beta(II) (beta(II) V5) is capable of nuclear translocation and lamin B phosphorylation. These results are consistent with our recent observation that the PRC beta(II) V5 region binds to phosphatidylglycerol (PG), a potent and selective PRC beta(II) activator present in the nuclear membrane (Murray, N, R,, and Fields, A. P, (1998) J. Biol. Chem. 273, 11514-11520). Soluble beta(II) V5 peptide selectively inhibits PG-stimulated PKC beta(II) activity in a dose-dependent fashion, indicating that PG-mediated activation of PKC beta(II) involves interactions with the beta(II) V5 region of the enzyme. We conclude that beta(II) V5 is a major determinant for PKC beta(II) nuclear function and suggest a model in which binding of PG to the beta(II) V5 region stimulates nuclear PKC beta(II) activity during G(2) phase of the cell cycle.	Univ Texas, Med Branch, Sealy Ctr Oncol & Haematol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Fields, AP (corresponding author), Univ Texas, Med Branch, Sealy Ctr Oncol & Haematol, Med Res Bldg,Rm 9-104,301 Univ Blvd, Galveston, TX 77555 USA.		Gokmen-Polar, Yesim/AAX-4001-2021	Gokmen-Polar, Yesim/0000-0001-9927-4893	NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NCI NIH HHS [CA56869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; CLEMENS MJ, 1992, J CELL SCI, V103, P881; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Fields A P, 1995, Prog Cell Cycle Res, V1, P271; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KIKKAWA U, 1989, ANN REV BIOCH, V58, P32; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Murray NR, 1998, J BIOL CHEM, V273, P11514, DOI 10.1074/jbc.273.19.11514; MURRAY NR, 1997, PROTEIN KINASE C MOL; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; RATAN RR, 1988, J CELL BIOL, V107, P993, DOI 10.1083/jcb.107.3.993; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Sun B, 1997, J BIOL CHEM, V272, P26313, DOI 10.1074/jbc.272.42.26313; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156	38	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20261	20266		10.1074/jbc.273.32.20261	http://dx.doi.org/10.1074/jbc.273.32.20261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685375	hybrid			2022-12-27	WOS:000075305400052
J	Hammami-Hauasli, N; Schumann, H; Raghunath, M; Kilgus, O; Luthi, U; Luger, T; Bruckner-Tuderman, L				Hammami-Hauasli, N; Schumann, H; Raghunath, M; Kilgus, O; Luthi, U; Luger, T; Bruckner-Tuderman, L			Some, but not all, glycine substitution mutations in COL7A1 result in intracellular accumulation of collagen VII, loss of anchoring fibrils, and skin blistering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIC EPIDERMOLYSIS-BULLOSA; GENE COL7A1; EPIDERMAL JUNCTION; MUTANT COLLAGEN; HELIX FORMATION; NC-2 DOMAIN; CONFORMATION; ORGANIZATION; PROCOLLAGEN; EXPRESSION	COL7A1 gene mutations cause dystrophic epidermolysis bullosa, a skin blistering disorder. The phenotypes result from defects of collagen VII, the major component of the anchoring fibrils at the dermo-epidermal junction; however, the molecular mechanisms underlying the phenotypes remain elusive. We investigated naturally occurring COL7A1 mutations and showed that some, but not all, glycine substitutions in collagen VII interfered with biosynthesis of the protein in a dominant-negative manner. Three point mutations in exon 73 caused glycine substitutions G2006D, G2034R, and G2015E in the triple helical domain of collagen VII and interfered with its folding and secretion. Confocal laser scanning studies and semiquantitative immunoblotting determined that dystrophic epidermolysis bullosa keratinocytes retained up to 2.5-fold more procollagen VII within the rough endoplasmic reticulum than controls. Limited proteolytic digestions of mutant procollagen VII produced aberrant fragments and revealed reduced stability of the triple helix. In contrast, the glycine substitution G1519D in another segment of the triple helix affected neither procollagen VII secretion nor anchoring fibril function and remained phenotypically silent. These data demonstrate that collagen VII presents a remarkable exception among collagens in that not all glycine substitutions within the triple helix exert dominant-negative interference and that the biological consequences of the substitutions probably depend on their position within the triple helix.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Hamburg, Dept Dermatol, D-22587 Hamburg, Germany; Univ Zurich, Cent Lab Electron Microscopy, CH-8091 Zurich, Switzerland	University of Munster; University of Hamburg; University of Zurich	Bruckner-Tuderman, L (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.		Raghunath, Michael/E-6483-2010; Raghunath, Michael/M-2727-2019	Raghunath, Michael/0000-0002-2138-6614; 				BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNERTUDERMAN L, 1988, DERMATOLOGICA, V176, P57, DOI 10.1159/000248673; BRUCKNERTUDERMAN L, 1987, EUR J BIOCHEM, V165, P607, DOI 10.1111/j.1432-1033.1987.tb11483.x; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; BrucknerTuderman L, 1996, BIOCHEM CELL BIOL, V74, P729, DOI 10.1139/o96-079; BURGESON RE, 1993, J INVEST DERMATOL, V101, P252, DOI 10.1111/1523-1747.ep12365129; BYRS P, 1993, CONNECTIVE TISSUE IT, P317; Christiano A M, 1996, Exp Dermatol, V5, P1, DOI 10.1111/j.1600-0625.1996.tb00086.x; Christiano AM, 1996, AM J HUM GENET, V58, P671; CHRISTIANO AM, 1994, GENOMICS, V21, P160, DOI 10.1006/geno.1994.1238; Dunnill MGS, 1996, J INVEST DERMATOL, V107, P171, DOI 10.1111/1523-1747.ep12329570; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gardella R, 1996, AM J HUM GENET, V59, P292; GEDDEDAHL T, 1996, PRINCIPLES PRACTICE, V1, P1225; GREENSPAN DS, 1993, HUM MOL GENET, V2, P273, DOI 10.1093/hmg/2.3.273; HammamiHauasli N, 1997, J INVEST DERMATOL, V109, P384, DOI 10.1111/1523-1747.ep12336264; HILAL L, 1993, NAT GENET, V5, P287, DOI 10.1038/ng1193-287; HINTNER H, 1981, J INVEST DERMATOL, V76, P113, DOI 10.1111/1523-1747.ep12525447; HOVNANIAN A, 1994, AM J HUM GENET, V55, P289; HOVNANIAN S, 1997, AM J HUM GENET, V61, P599; Kivirikko S, 1996, J INVEST DERMATOL, V106, P1300, DOI 10.1111/1523-1747.ep12349019; Kon A, 1997, J INVEST DERMATOL, V108, P224, DOI 10.1111/1523-1747.ep12335324; Kon A, 1997, J INVEST DERMATOL, V109, P684, DOI 10.1111/1523-1747.ep12338093; KONIG A, 1994, J INVEST DERMATOL, V102, P105, DOI 10.1111/1523-1747.ep12371741; KONIG A, 1992, J CELL BIOL, V117, P679, DOI 10.1083/jcb.117.3.679; Lee JYY, 1997, J INVEST DERMATOL, V108, P947; LEIGH IM, 1987, EPITHELIA, V1, P17; MCGRATH JA, 1993, J INVEST DERMATOL, V100, P366, DOI 10.1111/1523-1747.ep12471830; OLSEN BR, 1995, CURR OPIN CELL BIOL, V7, P720, DOI 10.1016/0955-0674(95)80115-4; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Schumann H, 1997, AM J HUM GENET, V60, P1344, DOI 10.1086/515463; Shimizu H, 1996, J INVEST DERMATOL, V106, P119, DOI 10.1111/1523-1747.ep12329600; SONNENBERG A, 1991, EXP CELL RES, V197, P234, DOI 10.1016/0014-4827(91)90428-W; STEINMANN B, 1995, SCIENCE, V267, P258, DOI 10.1126/science.7809634; Steinmann Beat, 1993, P351; Terracina M, 1997, J INVEST DERMATOL, V109, P405; TIDMAN MJ, 1985, J INVEST DERMAOTL, V88, P448; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; Winberg JO, 1997, HUM MOL GENET, V6, P1125, DOI 10.1093/hmg/6.7.1125	42	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19228	19234		10.1074/jbc.273.30.19228	http://dx.doi.org/10.1074/jbc.273.30.19228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668111	hybrid			2022-12-27	WOS:000074974700078
J	Hata, Y; Duh, E; Zhang, K; Robinson, GS; Aiello, LP				Hata, Y; Duh, E; Zhang, K; Robinson, GS; Aiello, LP			Transcription factors Sp1 and Sp3 alter vascular endothelial growth factor receptor expression through a novel recognition sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE ENHANCER ELEMENTS; BOVINE RETINAL PERICYTES; PERMEABILITY FACTOR; IN-VIVO; FACTOR VEGF; GENE-EXPRESSION; TYROSINE KINASE; DEVELOPMENTAL EXPRESSION; DIABETIC-RETINOPATHY; SIGNAL-TRANSDUCTION	Kinase domain receptor (KDR) is a high affinity, endothelial cell-specific, autophosphorylating tyrosine kinase receptor for vascular endothelial growth factor, This transcriptionally regulated receptor is a critical mediator of endothelial cell (EC) growth and vascular development. In this study, we identify a DNA element modulating KDR promoter activity and evaluate the nuclear binding proteins accounting for a portion of the cell-type specificity of the region. KDR promoter luciferase activity was retained within -85/+296 and was 10-30-fold higher in EC than non-EC, Electrophoretic mobility shift assays demonstrated specific nuclear protein binding to -85/-64, and single point mutations suggested important binding nucleotides between -79/-68 with five critical bases between -74/-70 (5'-CTCCT-3'). DNA-protein complexes were displaced by Spl consensus sequence oligodeoxynucleotides and supershifted by Sp1- and Sp3-specific antibodies. Spl and Sp3 protein in EC nuclear extracts bound the -79/-68 region even when all surrounding classic Spl recognition sites were removed. Spl protein in nuclear extracts was 4-24-fold higher in EC than non-EC, whereas Sp3 was 3-7-fold higher. Sp1/Sp3 ratios in EC were 2-10-fold higher. Overexpression of Spl protein increased KDR promoter activity 3-fold in both EC and non-EC, whereas simultaneous co-expression of Sp3 attenuated this response. An Spl consensus sequence cis element "decoy" reduced EC KDR promoter activity and mRNA expression by 85 and 69%, respectively. An antisense phosphorothioate oligodeoxynucleotide to Spl inhibited Spl and KDR protein expression by 66 and 68%, respectively, without changing Sp3 protein expression. These data illustrate that Spl and Sp3 modulate KDR promoter activity through a novel recognition binding sequence. However, since Spl-mediated promoter activation is attenuated by Sp3, endothelial selective KDR promoter activity may be partially regulated by variations in the Sp1/Sp3 ratio.	Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA 02215 USA; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02215 USA; Hybridon Inc, Cambridge, MA 02139 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Aiello, LP (corresponding author), Joslin Diabet Ctr, Beetham Eye Inst, 1 Joslin Pl, Boston, MA 02215 USA.	aiello@joslab.harvard.edu	Zhang, Kang/Y-2740-2019	Zhang, Kang/0000-0002-4549-1697	NATIONAL EYE INSTITUTE [R29EY010827] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10827] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473; AIELLO LP, 1994, P NATL ACAD SCI USA, V91, P6231, DOI 10.1073/pnas.91.13.6231; AIELLO LP, 1995, ARCH OPHTHALMOL-CHIC, V113, P1538, DOI 10.1001/archopht.1995.01100120068012; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; FAVARD C, 1991, BIOL CELL, V73, P1, DOI 10.1016/0248-4900(91)90002-5; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Lutty GA, 1996, ARCH OPHTHALMOL-CHIC, V114, P971, DOI 10.1001/archopht.1996.01100140179011; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILLER JW, 1994, AM J PATHOL, V145, P574; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MURATA T, 1995, OPHTHALMIC RES, V27, P48, DOI 10.1159/000267567; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Noti JD, 1996, MOL CELL BIOL, V16, P2940; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PIERCE JC, 1992, METHOD ENZYMOL, V216, P549; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Robinson GS, 1996, P NATL ACAD SCI USA, V93, P4851, DOI 10.1073/pnas.93.10.4851; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SAFFER JD, 1990, GENE DEV, V4, P659, DOI 10.1101/gad.4.4.659; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SEETHARAM L, 1995, ONCOGENE, V10, P135; SENGER DR, 1986, CANCER RES, V46, P5629; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; Strawn LM, 1996, CANCER RES, V56, P3540; Takagi H, 1996, DIABETES, V45, P1016, DOI 10.2337/diabetes.45.8.1016; Takagi H, 1996, INVEST OPHTH VIS SCI, V37, P1311; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; Tilton RG, 1997, J CLIN INVEST, V99, P2192, DOI 10.1172/JCI119392; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VINORES SA, 1995, AM J PATHOL, V147, P1289; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMADA T, 1995, J CLIN INVEST, V96, P1230, DOI 10.1172/JCI118156; YU CY, 1990, MOL CELL BIOL, V10, P282, DOI 10.1128/MCB.10.1.282	76	118	120	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19294	19303		10.1074/jbc.273.30.19294	http://dx.doi.org/10.1074/jbc.273.30.19294			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668119	hybrid, Green Published			2022-12-27	WOS:000074974700086
J	Obaishi, H; Nakanishi, H; Mandai, K; Satoh, K; Satoh, A; Takahashi, K; Miyahara, M; Nishioka, H; Takaishi, K; Takai, Y				Obaishi, H; Nakanishi, H; Mandai, K; Satoh, K; Satoh, A; Takahashi, K; Miyahara, M; Nishioka, H; Takaishi, K; Takai, Y			Frabin, a novel FGD1-related actin filament-binding protein capable of changing cell shape and activating c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY; CDC42HS; CASCADE; RAC1	We purified from rat brain a novel F-actin-binding protein with a M-r of about 105,000 (p105), which was estimated by SDS-polyacrylamide gel electrophoresis. We cloned its cDNA from a rat brain cDNA library and characterized it, p105 was a protein of 766 amino acids and showed a calculated M-r of 86,449. p105 consisted of one F-actin-binding domain at the N-terminal region, one Dbl homology domain and one pleckstrin homology domain at the middle region, and one cysteine-rich domain at the C-terminal region. This domain organization of p105 was similar to that of FGD1, which has been determined to be the genetic locus responsible for facio-genital dysplasia or Aarskog-Scott syndrome. We therefore named p105 frabin (FGD1-related F-actin-binding protein). Frabin bound along the sides of F-actin and showed F-actin-cross-linking activity. Overexpression of frabin in Swiss 3T3 cells and COS7 cells induced cell shape change and c-Jun N-terminal kinase activation, respectively, as described for FGD1. Because FGD1 has been shown to serve as a GDP/GTP exchange protein for Cdc42 small G protein, it is likely that frabin is a direct linker between Cdc42 and the actin cytoskeleton.	Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, Takai Biotimer Project, ERATO, JCR Pharmaceut Co Ltd,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Biochem & Mol Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Mandai, Kenji/0000-0002-0115-6635; Nakanishi, Hiroyuki/0000-0002-9765-0266				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; FRASER AB, 1975, BIOCHEMISTRY-US, V14, P2207, DOI 10.1021/bi00681a025; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PASTERIS NG, 1994, CELL, V79, P669; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169	24	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18697	18700		10.1074/jbc.273.30.18697	http://dx.doi.org/10.1074/jbc.273.30.18697			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668039	hybrid			2022-12-27	WOS:000074974700006
J	Pajor, AM; Hirayama, BA; Loo, DDF				Pajor, AM; Hirayama, BA; Loo, DDF			Sodium and lithium interactions with the Na+/dicarboxylate cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANES; SUCCINATE TRANSPORT; XENOPUS OOCYTES; KINETICS	The two-electrode voltage clamp was used to study the currents associated with transport of succinate by the cloned Na+/dicarboxylate cotransporter, NaDC-1, expressed in Xenopus oocytes, The presence of succinate induced inward currents which were dependent on the concentrations of succinate and sodium,;md on the membrane potential. At -50 mV, the K-0.5(succinate) was 180 mu M and the K-0.5(Na+) was 19 mM. The Hill coefficient was 2.3, which is consistent with a transport stoichiometry of 3 Na+:1 divalent anion substrate. Currents wt:re induced in NaDC-1 by a range of di- and tricarboxylates, including citrate, methylsuccinate, fumarate, and tricarbally-late. Although Na+ is the preferred cation, Li+ was also able to support transport. The K-0.5(succinate) was approximately 10-fold higher in Li+ compared with Na+. In the presence of Na+, however, Li+ was a potent inhibitor of transport. Millimolar concentrations of Li+ resulted in decreases in apparent succinate affinity and in the I-max(succinate). Furthermore, lithium inhibition under saturating sodium concentrations showed hyperbolic kinetics, suggesting that one of the three cation binding sites in NaDC-1 has a higher affinity for Li+ than Na+. We conclude that NaDC-1 is an electrogenic anion transporter that accepts either Na+ or Li+ as coupling cations. However, NaDC-1 contains a single high affinity binding site for Li+ that, when occupied,. results in transport inhibition, which may account for its potent inhibitory effects on renal dicarboxylate transport.	Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of Arizona; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Pajor, AM (corresponding author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.	Pajor@biosci.arizona.edu			NIDDK NIH HHS [DK46269, DK02429] Funding Source: Medline; NIGMS NIH HHS [GM52094] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K02DK002429, R01DK046269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM052094] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai LQ, 1997, AM J PHYSIOL-GASTR L, V273, pG267, DOI 10.1152/ajpgi.1997.273.2.G267; BOND PA, 1974, BRIT J PHARMACOL, V50, P283, DOI 10.1111/j.1476-5381.1974.tb08574.x; BOND PA, 1972, BRIT J PHARMACOL, V46, P116, DOI 10.1111/j.1476-5381.1972.tb06854.x; Cao YW, 1997, J NEUROSCI, V17, P2257; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Forster IC, 1997, J MEMBRANE BIOL, V160, P9, DOI 10.1007/s002329900291; FUKUHARA Y, 1983, AM J PHYSIOL, V245, pF374, DOI 10.1152/ajprenal.1983.245.3.F374; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HAMM LL, 1990, KIDNEY INT, V38, P728, DOI 10.1038/ki.1990.265; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HIRAYAMA B, 1986, PFLUGERS ARCH, V407, P174; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; KANAI Y, 1994, J BIOL CHEM, V269, P20599; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MARKOVICH D, 1993, P NATL ACAD SCI USA, V90, P8073, DOI 10.1073/pnas.90.17.8073; Murer H, 1992, HDB PHYSL, V2, P2165, DOI DOI 10.1002/CPHY.CP080247); Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; SCHELL RE, 1985, J PHYSIOL-LONDON, V360, P95, DOI 10.1113/jphysiol.1985.sp015605; Segel I.H., 1975, ENZYME KINETICS; WRIGHT EM, 1982, P NATL ACAD SCI-BIOL, V79, P7514, DOI 10.1073/pnas.79.23.7514; WRIGHT SH, 1983, J BIOL CHEM, V258, P5456; WRIGHT SH, 1982, BIOCHIM BIOPHYS ACTA, V684, P287, DOI 10.1016/0005-2736(82)90019-0	28	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18923	18929		10.1074/jbc.273.30.18923	http://dx.doi.org/10.1074/jbc.273.30.18923			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668069	hybrid			2022-12-27	WOS:000074974700036
J	Shirra, MK; Hansen, U				Shirra, MK; Hansen, U			LSF and NTF-1 share a conserved DNA recognition motif yet require different oligomerization states to form a stable protein-DNA complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CP2; CRYSTAL-STRUCTURE; VIRUS TYPE-1; OPERATOR COMPLEX; BINDING-PROTEINS; B/HLH/Z DOMAIN; ACTIVATION; REGION; DIMER; RESOLUTION	The mammalian transcription factor LSF (also known as CP2 and LBP-1c) binds as a homo-oligomer to directly repeated elements in viral and cellular promoters. LSF and the Drosophila transcription factor NTF-1 (also known as Elf-1 and Grainyhead) share a similar DNA binding region, which is unlike any established DNA binding motifs. However, we demonstrate that dimeric NTF-1 can bind an LSF half-site, whereas LSF cannot. To characterize further the DNA binding and oligomerization characteristics of LSF, truncation mutants were used to demonstrate that between 234 and 320 amino acids of LSF are required for high affinity DNA binding. Mixing of a truncation mutant with full-length LSF in a DNA binding assay established that the form of LSF that binds DNA is larger than a dimer. Unexpectedly, one C-terminal deletion derivative, partially defective in oligomerization properties, could occupy odd numbers of adjacent, tandem LSF half-sites, unlike full-length LSF. The numbers of DNA-protein complexes formed on multiple half-sites with this mutant indicated that LSF binds DNA as a tetramer, although cross-linking experiments confirmed a previous report concluding that LSF is primarily dimeric in solution. The DNA binding and oligomerization properties of LSF support models depicting novel mechanisms to prevent continual, adjacent binding by a protein that recognizes directly repeated DNA sequences.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Hansen, U (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.			Hansen, Ulla/0000-0001-9803-4185	NCI NIH HHS [CA38038, T32 CA09361] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009361, R01CA038038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Bellorini M, 1996, MOL CELL BIOL, V16, P503; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DYNLACHT BD, 1989, GENE DEV, V3, P1677, DOI 10.1101/gad.3.11.1677; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; JONES KA, 1988, GENE DEV, V2, P1101, DOI 10.1101/gad.2.9.1101; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; Lenouvel F, 1997, J BIOL CHEM, V272, P15521, DOI 10.1074/jbc.272.24.15521; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MALIM MH, 1989, J VIROL, V63, P3213, DOI 10.1128/JVI.63.8.3213-3219.1989; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; SHIRRA MK, 1995, THESIS HARVARD U; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; SUZUKI M, 1993, EMBO J, V12, P3221, DOI 10.1002/j.1460-2075.1993.tb05991.x; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WALKER J, 1993, MOL BIOCHEM PARASIT, V61, P255, DOI 10.1016/0166-6851(93)90071-5; WU FK, 1988, EMBO J, V7, P2117, DOI 10.1002/j.1460-2075.1988.tb03051.x; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; ZHONG FM, 1994, J BIOL CHEM, V269, P21269	47	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19260	19268		10.1074/jbc.273.30.19260	http://dx.doi.org/10.1074/jbc.273.30.19260			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668115	hybrid			2022-12-27	WOS:000074974700082
J	Siddhanta, U; Presta, A; Fan, BC; Wolan, D; Rousseau, DL; Stuehr, DJ				Siddhanta, U; Presta, A; Fan, BC; Wolan, D; Rousseau, DL; Stuehr, DJ			Domain swapping in inducible nitric-oxide synthase - Electron transfer occurs between flavin and heme groups located on adjacent subunits in the dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE NO SYNTHASE; SPECTRAL CHARACTERIZATION; CATALYTIC ACTIVITY; IRON REDUCTION; L-ARGININE; BINDING; ENZYME; CALMODULIN; SUBSTRATE; BRAIN	Cytokine-inducible nitric-oxide (NO) synthase (iNOS) contains an oxygenase domain that binds heme, tetrahydrobiopterin, and L-arginine, and a reductase domain that binds FAD, FMN, calmodulin, and NADPH, Dimerization of two oxygenase domains allows electrons to transfer from the flavins to the heme irons, which enables O-2 binding and NO synthesis from L-arginine. In an iNOS heterodimer comprised of one full-length subunit and an oxygenase domain partner, the single reductase domain transfers electrons to only one of two hemes (Siddhanta, U., Wu, C., Abu-Soud, H. M., Zhang, J., Ghosh, D. K., and Stuehr, D. J. (1996) J. Biol. Chem. 271, 7309-7312). Here, we characterize a pair of heterodimers that contain an L-Arg binding mutation (E371A) in either the full-length or oxygenase domain subunit to identify which heme iron becomes reduced. The E371A mutation prevented L-Arg binding to one oxygenase domain in each heterodimer but did not affect the L-Arg affinity of its oxygenase domain partner and did not prevent heme iron reduction in any case. The mutation prevented NO synthesis when it was located in the oxygenase domain of the adjacent subunit but had no effect when in the oxygenase domain in the same subunit as the reductase domain. Resonance Raman characterization of the heme-L-Arg interaction confirmed that E371A only prevents L-Arg binding in the mutated oxygenase domain. Thus, flavin-to-heme electron transfer proceeds exclusively between adjacent subunits in the heterodimer. This implies that domain swapping occurs in an iNOS dimer to properly align reductase and oxygenase domains for NO synthesis.	Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	Cleveland Clinic Foundation; Yeshiva University; Albert Einstein College of Medicine	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, NN-1,9500 Euclid Ave, Cleveland, OH 44195 USA.			Wolan, Dennis/0000-0001-9879-8353	NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM54806] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Gachhui R, 1996, J BIOL CHEM, V271, P20594, DOI 10.1074/jbc.271.34.20594; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; Mayer B, 1997, NITRIC OXIDE-BIOL CH, V1, P50, DOI 10.1006/niox.1996.0102; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Morita H, 1997, J BACTERIOL, V179, P7812, DOI 10.1128/jb.179.24.7812-7815.1997; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Presta A, 1997, NITRIC OXIDE-BIOL CH, V1, P74, DOI 10.1006/niox.1996.0110; PRESTA A, 1998, IN PRESS J AM CHEM S; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; Salerno JC, 1996, BIOCHEMISTRY-US, V35, P7626, DOI 10.1021/bi960607l; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; SU ZZ, 1995, J BIOL CHEM, V270, P29117, DOI 10.1074/jbc.270.49.29117; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; Wang J., 1996, METHODS NITRIC OXIDE, P427; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WOLGEL SA, 1990, METHOD ENZYMOL, V188, P95; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891; XIE QW, 1994, J BIOL CHEM, V269, P28500	56	170	171	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18950	18958		10.1074/jbc.273.30.18950	http://dx.doi.org/10.1074/jbc.273.30.18950			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668073	hybrid			2022-12-27	WOS:000074974700040
J	Milev, P; Monnerie, H; Popp, S; Margolis, RK; Margolis, RU				Milev, P; Monnerie, H; Popp, S; Margolis, RK; Margolis, RU			The core protein of the chondroitin sulfate proteoglycan phosphacan is a high-affinity ligand of fibroblast growth factor-2 and potentiates its mitogenic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; CENTRAL-NERVOUS-SYSTEM; TYROSINE-PHOSPHATASE; EXTRACELLULAR VARIANT; NEUROCAN; BRAIN; TISSUE	Using a radioligand binding assay we have demonstrated that phosphacan, a chondroitin sulfate proteoglycan of nervous tissue that also represents the extracellular domain of a receptor-type protein tyrosine phosphatase, shows saturable, reversible, high-affinity binding (K-d similar to 6 nM) to fibroblast growth factor-a (FGF-S), Binding was reduced by only similar to 35% following chondroitinase treatment of the proteoglycan, indicating that the interaction is mediated primarily through the core protein rather than the glycosaminoglycan chains. Immunocytochemical studies also showed an overlapping localization of FGF-S and phosphacan in the developing central nervous system. At concentrations of 10 mu g protein/ml, both native phosphacan and the core protein obtained by chondroitinase treatment potentiated the mitogenic effect of FGF-2 (5 ng/ml) on NIH/3T3 cells by 75-90%, which is nearly the same potentiation as that produced by heparin at an equivalent concentration. Although studies on the role of proteoglycans in mediating the binding and mitogenic effects of FGF-S have previously focused on cell surface heparan sulfate, our results indicate that the core protein of a chondroitin sulfate proteoglycan may also regulate the access of FGF-S to cell surface signaling receptors in nervous tissue.	NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA; SUNY Hlth Sci Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA	New York University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Margolis, RU (corresponding author), NYU, Med Ctr, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.				NIMH NIH HHS [MH-00129] Funding Source: Medline; NINDS NIH HHS [NS-09348, NS-13876] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013876, R01NS009348] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baird Andrew, 1994, Current Opinion in Neurobiology, V4, P78, DOI 10.1016/0959-4388(94)90035-3; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CADAY CG, 1990, DEV BRAIN RES, V52, P241, DOI 10.1016/0165-3806(90)90240-Y; GIORDANO S, 1992, DEV BIOL, V152, P293, DOI 10.1016/0012-1606(92)90136-5; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; Margolis RK, 1996, PERSPECT DEV NEUROBI, V3, P273; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MEYERPUTTLITZ B, 1995, J NEUROCHEM, V65, P2327; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MILEV PV, 1992, J BIOTECHNOL, V22, P299, DOI 10.1016/0168-1656(92)90148-3; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; RAUCH U, 1991, J BIOL CHEM, V266, P14785; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SENSENBRENNER M, 1993, PROG NEUROBIOL, V41, P683, DOI 10.1016/0301-0082(93)90031-M; SUZU S, 1994, BLOOD, V83, P3113, DOI 10.1182/blood.V83.11.3113.bloodjournal83113113	20	83	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21439	21442		10.1074/jbc.273.34.21439	http://dx.doi.org/10.1074/jbc.273.34.21439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705269	hybrid			2022-12-27	WOS:000075492600003
J	Vandorpe, DH; Shmukler, BE; Jiang, LW; Lim, B; Maylie, J; Adelman, JP; de Franceschi, L; Cappellini, MD; Brugnara, C; Alper, SL				Vandorpe, DH; Shmukler, BE; Jiang, LW; Lim, B; Maylie, J; Adelman, JP; de Franceschi, L; Cappellini, MD; Brugnara, C; Alper, SL			cDNA cloning and functional characterization of the mouse Ca2+-gated K+ channel, mIK1 - Roles in regulatory volume decrease and erythroid differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SICKLE-CELL DISEASE; ACTIVATED POTASSIUM CHANNELS; HUMAN RED-CELLS; XENOPUS-OOCYTES; ANION-EXCHANGER; IN-VITRO; CALCIUM; CLOTRIMAZOLE; DEHYDRATION; INHIBITION	We have cloned from murine erythroleukemia (MEL) cells, thymus, and stomach the cDNA encoding the Ca2+-gated K+ (K-Ca) channel, mIK1, the mouse homolog of hIK1 (Ishii, T. M., Silvia, C., Hirschberg, B., Bond, C. T., Adelman, J. P., and Maylie, J. (1997) Proc. Natl. Acad. Sci.(U. S. A. 94, 11651-11656), mIK1 mRNA was detected at varied levels in many tissue types. mIK1 K-Ca channel activity expressed in Xenopus oocytes closely resembled the K-Ca of red cells (Grardos channel) and MEL cells in its single channel conductance, lack of voltage-sensitivity of activation, inward rectification, and Ca2+ concentration dependence. mIK1 also resembled the erythroid channel in its pharmacological properties, mediating whole cell and unitary currents sensitive to low nM concentrations of both clotrimazole (CLT) and its des-imidazolyl metabolite, 2-chlorophenyl-bisphenyl-methanol, and to low nM concentrations of iodocharybdotoxin, Whereas control oocytes subjected to hypotonic swelling remained swollen, mIK1 expression conferred on oocytes a novel, Ca2+-dependent, CLT-sensitive regulatory volume decrease response. Hypotonic swelling of voltage-clamped mIK1-expressing oocytes increased outward currents that were Ca2+-dependent, CLT-sensitive, and reversed near the K+ equilibrium potential. mIK1 mRNA levels in ES cells increased steadily during erythroid differentiation in culture, in contrast to other K-Ca mRNAs examined. Low nanomolar concentrations of CLT inhibited proliferation and erythroid differentiation of peripheral blood stem cells in Liquid culture.	Beth Israel Med Ctr, Mol Med Unit, Boston, MA 02215 USA; Beth Israel Med Ctr, Renal Unit, Boston, MA 02215 USA; Beth Israel Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Inst Med, Boston, MA 02215 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Univ Verona, Dept Internal Med, I-37100 Verona, Italy; Univ Verona, Dept Gen Pathol, I-37100 Verona, Italy; Univ Milan, IRCCS, Maggiore Hosp, Dept Internal Med, I-20122 Milan, Italy; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Oregon Health & Science University; Oregon Health & Science University; University of Verona; University of Verona; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Alper, SL (corresponding author), Beth Israel Med Ctr, Mol Med Unit, RW763,Beth Israel Deaconess Med Ctr E Campus,330, Boston, MA 02215 USA.	salper@bih.harvard.edu	Brugnara, Carlo/A-8041-2010; CAPPELLINI, MARIA DOMENICA/B-4475-2017	Brugnara, Carlo/0000-0001-8192-8713; CAPPELLINI, MARIA DOMENICA/0000-0001-8676-6864	NHLBI NIH HHS [HL15157] Funding Source: Medline; NIDDK NIH HHS [DK51059, DK47636] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047636, R01DK051059] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; ARCANGELI A, 1987, BIOCHEM BIOPH RES CO, V146, P1450, DOI 10.1016/0006-291X(87)90812-6; ARMSBY CC, 1995, AM J PHYSIOL-CELL PH, V268, pC894, DOI 10.1152/ajpcell.1995.268.4.C894; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; Brugnara C, 1997, Curr Opin Hematol, V4, P122; BRUGNARA C, 1995, J PHARMACOL EXP THER, V273, P266; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; Brugnara C, 1995, Ann N Y Acad Sci, V763, P262, DOI 10.1111/j.1749-6632.1995.tb32411.x; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; BULBARELLI A, 1998, IN PRESS BLOOD; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; Chernova MN, 1997, BBA-BIOMEMBRANES, V1329, P111, DOI 10.1016/S0005-2736(97)00090-4; Chernova MN, 1997, J GEN PHYSIOL, V109, P345, DOI 10.1085/jgp.109.3.345; CHRISTOPHERSEN P, 1991, J MEMBRANE BIOL, V119, P75, DOI 10.1007/BF01868542; De Franceschi L., 1997, Blood, V90, p264A; DeFranceschi L, 1997, J CLIN INVEST, V100, P1847, DOI 10.1172/JCI119713; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; DEUTSCH C, 1991, J BIOL CHEM, V266, P3668; Devor DC, 1997, AM J PHYSIOL-CELL PH, V273, pC531, DOI 10.1152/ajpcell.1997.273.2.C531; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; FIBACH E, 1989, BLOOD, V73, P100; Franco RS, 1996, BLOOD, V88, P4359; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GRYGORCZYK R, 1983, CELL CALCIUM, V4, P499, DOI 10.1016/0143-4160(83)90025-8; GRYGORCZYK R, 1984, BIOPHYS J, V45, P693, DOI 10.1016/S0006-3495(84)84211-3; GRYGORCZYK R, 1985, EUR BIOPHYS J BIOPHY, V12, P57, DOI 10.1007/BF00260428; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guillemot JC, 1996, BLOOD, V88, P2722, DOI 10.1182/blood.V88.7.2722.bloodjournal8872722; HALPERIN JA, 1989, J CLIN INVEST, V83, P1466, DOI 10.1172/JCI114039; HAMIL OP, 1981, J PHYSL, V319, P97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hartzell HC, 1996, J GEN PHYSIOL, V108, P157, DOI 10.1085/jgp.108.3.157; Hatton CJ, 1996, AM J PHYSIOL-CELL PH, V271, pC85, DOI 10.1152/ajpcell.1996.271.1.C85; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Jiang LW, 1997, AM J PHYSIOL-CELL PH, V272, pC191, DOI 10.1152/ajpcell.1997.272.1.C191; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KELLY SM, 1995, COMP BIOCHEM PHYS A, V111, P681, DOI 10.1016/0300-9629(95)00046-A; Kennedy M, 1997, NATURE, V386, P488, DOI 10.1038/386488a0; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEINDERS T, 1992, BIOCHIM BIOPHYS ACTA, V1112, P67, DOI 10.1016/0005-2736(92)90255-K; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Li Q, 1996, J BIOL CHEM, V271, P18651, DOI 10.1074/jbc.271.31.18651; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; MCDOUGALL A, 1995, CURR BIOL, V5, P318, DOI 10.1016/S0960-9822(95)00062-5; MOZZARELLI A, 1987, SCIENCE, V237, P500, DOI 10.1126/science.3603036; OHNISHI ST, 1989, BIOCHIM BIOPHYS ACTA, V1010, P199; PARKER I, 1994, CELL CALCIUM, V15, P276, DOI 10.1016/0143-4160(94)90067-1; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; Rufo PA, 1996, J CLIN INVEST, V98, P2066, DOI 10.1172/JCI119012; Rufo PA, 1997, J CLIN INVEST, V100, P3111, DOI 10.1172/JCI119866; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Shirihai O, 1996, PFLUG ARCH EUR J PHY, V431, P632, DOI 10.1007/s004240050045; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; Zolotarev AS, 1996, AM J PHYSIOL-GASTR L, V271, pG311, DOI 10.1152/ajpgi.1996.271.2.G311	66	174	181	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21542	21553		10.1074/jbc.273.34.21542	http://dx.doi.org/10.1074/jbc.273.34.21542			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705284	hybrid			2022-12-27	WOS:000075492600018
J	Noll, M; Petrukhin, K; Lutsenko, S				Noll, M; Petrukhin, K; Lutsenko, S			Identification of a novel transcription regulator from Proteus mirabilis, PMTR, revealed a possible role of YJAI protein in balancing zinc in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ENCODES; METAL; TRANSPORTER; RESISTANCE; SEQUENCE; CADMIUM	Zinc is an essential trace element required for structural integrity and functional activity of numerous proteins, yet mechanisms by which cells regulate zinc concentration are poorly understood. Here, we identified a gene from Proteus mirabilis that encodes a 135-amino acid residue protein, PMTR (P. mirabilis transcription regulator), a new member of the MerR family of transcription activators. Transformation of Escherichia coli with PMTR-carrying vectors specifically increases cell tolerance to zinc, suggesting the role of PMTR in zinc homeostasis. In response to zinc, PMTR-containing cells robustly accumulate a 12-kDa protein, the amount of which correlates with the cells' ability to grow at high zinc concentrations. The 12-kDa protein is not induced in the presence of Ni2+, Co2+, Cd2+, Mn2+, or Fe2+, indicating that the PMTR-dependent expression of the 12-kDa protein is specifically regulated by zinc. The 12-kDa protein was identified as the C-terminal fragment off. coli protein YJAI, and was shown to contain two zinc-binding motifs, Metal-affinity chromatography and Zn-65 blotting assay confirmed the ability of the 12-kDa protein to bind zinc specifically (zinc > cobalt much greater than cadmium). We propose that YJAI is an important component of the zinc-balancing mechanism in E. coli, the up-regulation of which with PMTR results in an increased tolerance to zinc.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Lutsenko, S (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.			Petrukhin, Konstantin/0000-0002-5545-6924				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BROCKLEHURST K, 1997, ASBMB FALL S; CHANG LW, 1990, J TOXICOL SCI, V4, P125; COLEMAN JE, 1992, ANNU REV BIOCHEM, V61, P897, DOI 10.1146/annurev.bi.61.070192.004341; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; FEINBERG H, 1993, J CHEM INF COMP SCI, V33, P501, DOI 10.1021/ci00013a030; Goyer RA, 1997, ANNU REV NUTR, V17, P37, DOI 10.1146/annurev.nutr.17.1.37; Hagenmaier S, 1997, J BACTERIOL, V179, P2073, DOI 10.1128/jb.179.6.2073-2076.1997; HARRIS TJR, 1986, MOL BIOL MED, V3, P272; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; HOGSTRAND C, 1996, J EXP BIOL, V199, P2453; HOLMES DJ, 1993, EMBO J, V12, P3183, DOI 10.1002/j.1460-2075.1993.tb05987.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKANO Y, 1991, J BIOCHEM-TOKYO, V109, P223; NIES DH, 1992, PLASMID, V27, P17, DOI 10.1016/0147-619X(92)90003-S; NOLL M, 1998, P 4 WORLD C FOODB IN; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; UNDERWOOD EJ, 1981, J HUM NUTR, V35, P37; UPHOFF TS, 1990, J BACTERIOL, V172, P1206, DOI 10.1128/jb.172.3.1206-1216.1990; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P8166, DOI 10.1021/bi960574+; Zhao H, 1996, J BIOL CHEM, V271, P23203, DOI 10.1074/jbc.271.38.23203; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	28	40	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21393	21401		10.1074/jbc.273.33.21393	http://dx.doi.org/10.1074/jbc.273.33.21393			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694902	hybrid			2022-12-27	WOS:000075386100095
J	Exton, JH				Exton, JH			Small GTPases minireview series	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material									Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, 221 Kirkland Hall, Nashville, TN 37232 USA.								0	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19923	19923		10.1074/jbc.273.32.19923	http://dx.doi.org/10.1074/jbc.273.32.19923			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685324	hybrid			2022-12-27	WOS:000075305400001
J	Rosenberg, K; Olsson, H; Morgelin, M; Heinegard, D				Rosenberg, K; Olsson, H; Morgelin, M; Heinegard, D			Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH PLATE CARTILAGE; RAY-EMISSION SRIXE; ELECTRON-MICROSCOPY; ARTICULAR-CARTILAGE; BINDING-SITE; II COLLAGEN; CALCIUM; THROMBOSPONDIN; DECORIN; COMP	Cartilage and tendon extracellular matrices are composed of collagens, proteoglycans, and a number of noncollagenous proteins. Cartilage oligomeric matrix protein (COMP) is a prominent such protein, structurally related to the thrombospondins. We found that native COMP binds to collagen I/II and procollagen I/II and that the interaction is dependent on the divalent cations Zn2+ or Ni2+, whereas Ca2+, Mg2+, and Mn2+ did not promote binding. Using a solid phase assay, Scatchard analysis identified one class of binding site with a dissociation constant (K-d) close to 1.5 nM in the presence of Zn2+. The results were confirmed by studies using surface plasmon resonance. Furthermore, metal chelate chromatography demonstrated that COMP bound Zn2+ and Ni2+. Electron microscopy showed that the interaction occurred at four defined sites on the 300-nm collagen and procollagen molecules. Two were located close to each end, and two at 126 and 206 nm, respectively, from the C-terminal, COMP interacted via its C-terminal globular domain and significantly only in the presence of Zn2+.	Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden	Lund University	Heinegard, D (corresponding author), Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, POB 94, S-22100 Lund, Sweden.	Dick.Heinegard@medkem.lu.se		Olsson, Henric/0000-0002-5101-8871				ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; CHATEAUVERT JMD, 1989, J RHEUMATOL, V16, P1098; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; Ekman S, 1997, CALCIFIED TISSUE INT, V60, P547, DOI 10.1007/s002239900278; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; GALVIN NJ, 1987, J CELL BIOL, V104, P1413, DOI 10.1083/jcb.104.5.1413; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HARGEST TE, 1985, J HISTOCHEM CYTOCHEM, V33, P275, DOI 10.1177/33.4.3980981; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KUHN K, 1987, STRUCTURE FUNCTION C, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1986, ANN NY ACAD SCI, V485, P273, DOI 10.1111/j.1749-6632.1986.tb34589.x; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; Maroudas, 1979, ADULT ARTICULAR CART, P219; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; PRITZKER KPH, 1987, J RHEUMATOL, V14, P806; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RIZZO R, 1995, J EXP ZOOL, V273, P82, DOI 10.1002/jez.1402730111; ROSENBERG L, 1991, J BIOL CHEM, V266, P7016; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STENFLO J, 1991, ANN NY ACAD SCI, V614, P11, DOI 10.1111/j.1749-6632.1991.tb43688.x; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VITTUR F, 1992, BIOCHEM BIOPH RES CO, V188, P1010, DOI 10.1016/0006-291X(92)91332-K; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Zaia J, 1997, J BIOL CHEM, V272, P14120, DOI 10.1074/jbc.272.22.14120	52	264	277	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20397	20403		10.1074/jbc.273.32.20397	http://dx.doi.org/10.1074/jbc.273.32.20397			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685393	hybrid			2022-12-27	WOS:000075305400070
J	Clottes, E; Burchell, A				Clottes, E; Burchell, A			Three thiol groups are important for the activity of the liver microsomal glucose-6-phosphatase system - Unusual behavior of one thiol located in the glucose-6-phosphate translocase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; GLUCOSE 6-PHOSPHATASE; PHOSPHOHYDROLASE COMPONENT; MEMBRANE INTEGRITY; RAPID KINETICS; TRANSPORT; PERMEABILITY; IDENTIFICATION; ACTIVATION; EXPRESSION	Liver microsomal glucose-6-phosphatase (Glc-6-Pase) is a multicomponent system involving both substrate and product carriers and a catalytic subunit, We have investigated the inhibitory effect of N-ethylmaleimide (NEM), a rather specific sulfhydryl reagent, on rat liver Glc-6-Pase activity. Three thiol groups are important for Glc-6-Pase system activity. Two of them are located in the glucose-g-phosphate (Glc-6-P) translocase, and one is located in the catalytic subunit, The other transporters (phosphate and glucose) are not affected by NEM treatment. The NEM alkylation of the catalytic subunit sulfhydryl residue is prevented by preincubating the disrupted microsomes with saturating concentrations of substrate or product. This suggests either that the modified cysteine is located in the protein active site or that substrate binding hides the thiol group via a conformational change in the enzyme structure. Two other thiols important for the Glc-6-Pase system activity are located in the Glc-6-P translocase and are more reactive than the one located in the catalytic subunit. The study of the NEM inhibition of the translocase has provided evidence of the existence of two distinct areas in the protein that can behave independently, with conformational changes occurring during Glc-6-P binding to the transporter. The recent cloning of a human putative Glc-6-P carrier exhibiting homologies with bacterial phosphoester transporters, such as Escherichia coli UhpT (a Glc-6-P translocase), is compatible with the fact that two cysteine residues are important for the bacterial Glc-6-P transport.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland	University of Dundee	Burchell, A (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland.	aburchell@ninewells.dundee.ac.uk	Clottes, Eric/C-6088-2011; Burchell, Ann/B-7475-2008					Arion W J, 1976, J Biol Chem, V251, P4891; Arion WJ, 1998, J BIOL CHEM, V273, P6223, DOI 10.1074/jbc.273.11.6223; ARION WJ, 1980, J BIOL CHEM, V255, P396; ARION WJ, 1983, J BIOL CHEM, V258, P2661; ARION WJ, 1984, BIOCHEM J, V220, P835, DOI 10.1042/bj2200835; ARION WJ, 1975, MOL CELL BIOCHEM, V6, P75, DOI 10.1007/BF01732001; ARION WJ, 1976, J BIOL CHEM, V251, P4901; ARION WJ, 1980, J BIOL CHEM, V255, P387; ARION WJ, 1972, J BIOL CHEM, V247, P2551; BERTELOOT A, 1991, J BIOL CHEM, V266, P5497; BERTELOOT A, 1995, J BIOL CHEM, V270, P21098, DOI 10.1074/jbc.270.36.21098; BLAIR JNR, 1988, BIOCHIM BIOPHYS ACTA, V964, P161, DOI 10.1016/0304-4165(88)90162-6; BREWER CF, 1967, ANAL BIOCHEM, V18, P248, DOI 10.1016/0003-2697(67)90007-3; BURCHELL A, 1988, FEBS LETT, V242, P153, DOI 10.1016/0014-5793(88)81005-6; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; BURCHELL A, 1992, BIOESSAYS, V14, P395, DOI 10.1002/bies.950140609; COLILLA W, 1973, BIOCHIM BIOPHYS ACTA, V309, P328, DOI 10.1016/0005-2744(73)90031-4; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; FOSTER JD, 1991, BIOCHIM BIOPHYS ACTA, V1118, P91, DOI 10.1016/0167-4838(91)90445-6; FULCERI R, 1992, BIOCHEM J, V286, P813, DOI 10.1042/bj2860813; GARLAND RC, 1976, MOL CELL BIOCHEM, V12, P23, DOI 10.1007/BF01731900; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; HEMRICKA W, 1997, FEBS LETT, V409, P17; Hill BC, 1998, ARCH BIOCHEM BIOPHYS, V350, P273, DOI 10.1006/abbi.1997.0528; Kimura T, 1997, J BIOL CHEM, V272, P580; Kishnani PS, 1997, BIOCHEM MOL MED, V61, P168, DOI 10.1006/bmme.1997.2600; KNIGHT P, 1978, BIOCHEM J, V175, P1023, DOI 10.1042/bj1751023; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LANGE AJ, 1980, J BIOL CHEM, V255, P8381; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcolongo P, 1996, BIOCHEM BIOPH RES CO, V219, P916, DOI 10.1006/bbrc.1996.0333; MEISSNER G, 1988, METHOD ENZYMOL, V157, P417; Nordlie R C, 1974, Curr Top Cell Regul, V8, P33; NORDLIE RC, 1985, ENZYMES BIOL MEMBR, V2, P349; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P93; Pan CJ, 1998, J BIOL CHEM, V273, P6144, DOI 10.1074/jbc.273.11.6144; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Petrov VV, 1997, J BIOL CHEM, V272, P1688, DOI 10.1074/jbc.272.3.1688; SHULZE HU, 1986, J BIOL CHEM, V261, P16571; SINGH J, 1981, BIOCHIM BIOPHYS ACTA, V678, P477, DOI 10.1016/0304-4165(81)90129-X; STDENIS JF, 1994, J CLIN ENDOCR METAB, V79, P955, DOI 10.1210/jc.79.4.955; STETTEN MR, 1967, BIOCHIM BIOPHYS ACTA, V139, P138, DOI 10.1016/0005-2744(67)90120-9; VALKILI B, 1981, BIOCHEM J, V194, P319; WADA N, 1993, J BIOL CHEM, V268, P14003; WALLIN BK, 1972, BIOCHEM BIOPH RES CO, V48, P694, DOI 10.1016/0006-291X(72)90404-4; Woltjer RL, 1997, BIOCHEMISTRY-US, V36, P9911, DOI 10.1021/bi963007v; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973; ZAKIM D, 1990, J BIOL CHEM, V265, P201	50	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19391	19397		10.1074/jbc.273.31.19391	http://dx.doi.org/10.1074/jbc.273.31.19391			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677356	hybrid			2022-12-27	WOS:000075125200008
J	Hobba, GD; Lothgren, A; Holmberg, E; Forbes, BE; Francis, GL; Wallace, JC				Hobba, GD; Lothgren, A; Holmberg, E; Forbes, BE; Francis, GL; Wallace, JC			Alanine screening mutagenesis establishes tyrosine 60 of bovine insulin-like growth factor binding protein-2 as a determinant of insulin-like growth factor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR IGF BINDING; FACTOR (IGF)-BINDING PROTEINS; FACTOR-I; FACTOR BINDING-PROTEIN-4; CHEMICAL MODIFICATION; ANALOGS; SITES; AFFINITY; SEQUENCE; RECEPTOR	The determinants of insulin-like growth factor (IGF) binding to its binding proteins (IGFBPs) are poorly characterized in terms of important residues in the IGFBP molecule. We have previously used tyrosine iodination to implicate Tyr-60 in the IGF-binding site of bovine IGFBP-2 (Hobba, G. D., Forbes, B. E., Parkinson, E. J., Francis, G;. L., and Wallace, J. C, (1996) J. Biol. Chem. 271, 30529-30536). In this report, we show that the mutagenic replacement of Tyr-60 with either Ala or Phe reduced the affinity of bIGFBP-2 for IGF-I (4.0- and 8.4-fold, respectively) and for IGF-II (3.5- and 4.0-fold, respectively). Although adjacent residues Val-59, Thr-61, Pro-62, and Arg-63 are well conserved in IGFBP family members, Ala substitution for these residues did not reduce the IGF affinity of bIGFBP-2. Kinetic analysis of the bIGFBP-2 mutants on IGF biosensor chips in the BIAcore instrument revealed that Tyr-60 --> Phe bIG-FBP-2 bound to the IGF-I surface 3.0-fold more slowly than bIGFBP-2 and was released 2.6-fold more rapidly than bIGFBP-2. We therefore propose that the hydroxyl group of Tyr-60 participates in a hydrogen bond that is important for the initial complex formation with IGF-I and the stabilization of this complex. In contrast, Tyr-60 --> Ala bIGFBP-2 associated with the IGF-I surface 5.0-fold more rapidly than bIGFBP-2 but exhibited an 18.4-fold more rapid release from this surface compared with bIGFBP-2. Thus both the aromatic nature and the hydrogen bonding potential of the tyrosyl side chain of Tyr-60 are important structural determinants of the IGF-binding site of bIGFBP-2.	Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Cooperat Res Ctr Tissue Growth & Repair, Adelaide, SA 5005, Australia; CSIRO, Div Human Nutr, Adelaide, SA 5000, Australia; Pharmacia & Upjohn AB, Metab Dis Res, S-11287 Stockholm, Sweden	University of Adelaide; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Pfizer; Pharmacia Corporation	Wallace, JC (corresponding author), Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia.	jwallace@biochem.adelaide.edu.au	, John/AAP-5150-2020; Forbes, Briony/R-1838-2019	Forbes, Briony/0000-0003-4360-9927				ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Arai T, 1996, J BIOL CHEM, V271, P6099, DOI 10.1074/jbc.271.11.6099; BACH LA, 1993, J BIOL CHEM, V268, P9246; BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; BALLARD FJ, 1994, INT CONGR SER, V1056, P131; BAXTER RC, 1994, HORM RES, V42, P140, DOI 10.1159/000184186; BINOUX M, 1991, MODERN CONCEPTS INSU, P329; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; Bowles MR, 1997, ANAL BIOCHEM, V244, P133, DOI 10.1006/abio.1996.9888; CASCIERI MA, 1994, HORM RES, V41, P80, DOI 10.1159/000183965; CHERNAUSEK SD, 1995, J BIOL CHEM, V270, P11377, DOI 10.1074/jbc.270.19.11377; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; EDWARDS PR, 1995, ANAL BIOCHEM, V231, P210, DOI 10.1006/abio.1995.1522; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; FRANCIS GL, 1993, BIOCHEM J, V293, P713, DOI 10.1042/bj2930713; FRANCIS GL, 1988, BIOCHEM J, V251, P95, DOI 10.1042/bj2510095; Godel H., 1992, LC GC INT, V5, P44; GYLLENSTEN UB, 1989, BIOTECHNIQUES, V7, P700; Heding A, 1996, J BIOL CHEM, V271, P13948, DOI 10.1074/jbc.271.24.13948; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; JONES JI, 1993, J BIOL CHEM, V268, P1125; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landale EC, 1995, GROWTH FACTORS, V12, P245, DOI 10.3109/08977199509028963; LeRoith D, 1997, NEW ENGL J MED, V336, P633, DOI 10.1056/NEJM199702273360907; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; MALY P, 1988, J BIOL CHEM, V263, P7068; Manes S, 1997, ENDOCRINOLOGY, V138, P905, DOI 10.1210/en.138.3.905; MCCUSKER RH, 1991, ENDOCRINOLOGY, V129, P939, DOI 10.1210/endo-129-2-939; MOSS JA, 1991, J BIOL CHEM, V266, P909; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; OH Y, 1997, J BIOL CHEM, V271, P30322; Parker A, 1996, J BIOL CHEM, V271, P13523, DOI 10.1074/jbc.271.23.13523; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROGHANI M, 1991, J CLIN ENDOCR METAB, V73, P658, DOI 10.1210/jcem-73-3-658; SATO A, 1993, INT J PEPT PROT RES, V41, P433; SOMMER A, 1991, MODERN CONCEPTS INSU, P329; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TORRES AM, 1995, J MOL BIOL, V248, P385, DOI 10.1006/jmbi.1995.0229; TUNON P, 1984, J BIOCHEM BIOPH METH, V9, P171, DOI 10.1016/0165-022X(84)90008-3; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7	48	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19691	19698		10.1074/jbc.273.31.19691	http://dx.doi.org/10.1074/jbc.273.31.19691			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677398	hybrid			2022-12-27	WOS:000075125200050
J	Lee, H; Kim, HT; Yun, Y				Lee, H; Kim, HT; Yun, Y			Liver-specific enhancer II is the target for the p53-mediated inhibition of hepatitis B viral gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS HBX PROTEIN; RNA POLYMERASE-II; BINDING-PROTEIN; TRANSCRIPTION INITIATION; DNA-BINDING; WILD-TYPE; X-GENE; CORE PROMOTER; 2ND ENHANCER; P53	Here, we established the inhibitory mechanism of p53 on hepatitis B viral gene expression using HepG2 cells. Our results are as follows, First, p53 down-regulated the activities of all four promoters of hepatitis B virus (HBV), suggestive of the presence of a common element mediating the p53-dependent transcriptional repression. Second, employing the 5'-deletion constructs of the pregenomic/core promoter, the liver-specific enhancer II region was localized as a target for the p53-mediated transcriptional repression. Third, in a detailed analysis of the enhancer II region, the 5'-proximal 31-base pair region was defined as a p53-repressible element. Throughout the study, p53-mediated repression was rescued upon coexpression of the X-gene product, HBx. Finally, in an electrophoretic mobility shift assay, the defined p53-repressible element did not bind purified p53 directly, but shifted three bands in HepG2 nuclear extract, two of which was supershifted upon addition of p53 monoclonal antibody. These results display a novel mechanism of p53 dependent transcriptional repression in which p53 negatively regulates the viral-specific DNA enhancer through protein to protein interaction with an enhancer-binding protein. At the same time, the results indicate that p53 plays a defensive role against HBV by transcriptionally repressing the HBV core promoter through liver-specific enhancer II and HBx is required to counteract this inhibitory function of p53.	Mogam Biotechnol Res Inst, Signal Transduct Lab, Kyunggido 449910, South Korea		Yun, Y (corresponding author), Mogam Biotechnol Res Inst, Signal Transduct Lab, 341 Pojungri, Kyunggido 449910, South Korea.							AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; CATTANEO R, 1983, NATURE, V305, P336, DOI 10.1038/305336a0; CHEN IH, 1995, J VIROL, V69, P3647, DOI 10.1128/JVI.69.6.3647-3657.1995; CHIRILLO P, 1997, P NATL ACAD SCI USA, V92, P11215; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; JAMEEL S, 1986, MOL CELL BIOL, V6, P710, DOI 10.1128/MCB.6.2.710; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LOPEZCABRERA M, 1990, P NATL ACAD SCI USA, V87, P5069, DOI 10.1073/pnas.87.13.5069; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MALPIECE Y, 1983, NUCLEIC ACIDS RES, V11, P4645, DOI 10.1093/nar/11.13.4645; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RALL LB, 1983, MOL CELL BIOL, V3, P1766, DOI 10.1128/MCB.3.10.1766; RANEY AK, 1990, J VIROL, V64, P2360, DOI 10.1128/JVI.64.5.2360-2368.1990; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAUL Y, 1985, EMBO J, V4, P427, DOI 10.1002/j.1460-2075.1985.tb03646.x; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; SU H, 1992, P NATL ACAD SCI USA, V89, P2708, DOI 10.1073/pnas.89.7.2708; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG Y, 1990, J VIROL, V64, P3977, DOI 10.1128/JVI.64.8.3977-3981.1990; YAGINUMA K, 1993, J VIROL, V67, P2559, DOI 10.1128/JVI.67.5.2559-2565.1993; YEE JK, 1989, SCIENCE, V246, P658, DOI 10.1126/science.2554495; YUH CH, 1993, J VIROL, V67, P142, DOI 10.1128/JVI.67.1.142-149.1993; YUH CH, 1992, J VIROL, V66, P4073, DOI 10.1128/JVI.66.7.4073-4084.1992; YUH CH, 1990, J VIROL, V64, P4281, DOI 10.1128/JVI.64.9.4281-4287.1990	42	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19786	19791		10.1074/jbc.273.31.19786	http://dx.doi.org/10.1074/jbc.273.31.19786			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677410	hybrid			2022-12-27	WOS:000075125200062
J	Nagiec, MM; Skrzypek, M; Nagiec, EE; Lester, RL; Dickson, RC				Nagiec, MM; Skrzypek, M; Nagiec, EE; Lester, RL; Dickson, RC			The LCB4 (YOR171c) and LCB5 (YLR260w) genes of Saccharomyces encode sphingoid long chain base kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREVISIAE; SPHINGOSINE-1-PHOSPHATE; RECEPTOR; SPHINGOLIPIDS; STRAINS; YEAST	Sphingolipid long chain bases (LCBs) and phosphorylated derivatives, particularly sphingosine l-phosphate, are putative signaling molecules. To help elucidate the physiological roles of LCB phosphates, we identified two Saccharomyces cerevisiae genes, LCB4 (YOR171c) and LCB5 (YLR260w), which encode LCB kinase activity. This conclusion is based upon the synthesis of LCB kinase activity in Escherichia coli expressing either LCB gene. LCB4 encodes most (97%) Saccharomyces LCB kinase activity, with the remainder requiring LCB5. Log phase Icb4-deleted yeast cells make no LCB phosphates, showing that the Lcb4 kinase synthesizes all detectable LCB phosphates under these growth conditions. The Lcb4 and Lcb5 proteins are paralogs with 53% amino acid identity but are not related to any known protein, thus revealing a new class of lipid kinase, Two-thirds of the Lcb4 and one-third of the Lcb5 kinase activity are in the membrane fraction of yeast cells, a puzzling finding in that neither protein contains a membrane-localization signal. Both enzymes can use phytosphingosine, dihydrosphingosine, or sphingosine as substrate. LCB4 and LCBB should be useful for probing the functions of LCB phosphates in S. cerevisiae, Potential mammalian cDNA homologs of the LCB kinase genes may prove useful in helping to understand the function of sphingosine l-phosphate in mammals.	Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Dickson, RC (corresponding author), Univ Kentucky, Med Ctr, Dept Biochem, 800 Rose St, Lexington, KY 40536 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041302] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BURNS N, 1998, MICROBIAL GENOME MET, P61; Choi OH, 1996, NATURE, V380, P634; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; Crowther GJ, 1997, ARCH BIOCHEM BIOPHYS, V337, P284, DOI 10.1006/abbi.1996.9799; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LESTER RL, 1993, ADV LIPID RES, V26, P253; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; PATTON JL, 1992, J BACTERIOL, V174, P7180, DOI 10.1128/jb.174.22.7180-7184.1992; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Rius RA, 1997, FEBS LETT, V417, P173, DOI 10.1016/S0014-5793(97)01277-5; SABA DJ, 1997, J BIOL CHEM, V272, P26087; SIKORSKI RS, 1989, GENETICS, V122, P19; Skrzypek M, 1997, J BACTERIOL, V179, P1513, DOI 10.1128/jb.179.5.1513-1520.1997; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; WOLFE HW, 1997, NATURE, V387, P708; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; ZUHERINGDORF DM, 1997, FEBS LETT, V410, P34	33	138	148	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19437	19442		10.1074/jbc.273.31.19437	http://dx.doi.org/10.1074/jbc.273.31.19437			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677363	hybrid			2022-12-27	WOS:000075125200015
J	Raman, C; Kuo, A; Deshane, J; Litchfield, DW; Kimberly, RP				Raman, C; Kuo, A; Deshane, J; Litchfield, DW; Kimberly, RP			Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOCYTES-T; ANTIGEN RECEPTOR; B-CELL; SIGNAL-TRANSDUCTION; MEMBRANE GLYCOPROTEIN; NEGATIVE REGULATION; COMPLEX; SUBSTRATE; ACTIVATION; TYROSINE	The transmembrane protein CD5, expressed on all T cells and the B1 subset of B cells, modulates antigen receptor-mediated activation. We used the yeast two-hybrid system to identify proteins that interact with its cytoplasmic domain and play a role in CD5 proximal signaling events. We found that the beta subunit of the serine/threonine kinase casein kinase 2 (CK2) interacts specifically with the cytoplasmic domain of CD5. Coimmunoprecipitation experiments showed activation-independent association of CK2 with CD5 in human and murine B and T cell lines and murine splenocytes. The interaction of CK2 holoenzyme with CD5 is mediated by the amino terminus of the regulatory subunit beta. CK2 binds and phosphorylates CD5 at the CK2 motifs flanked by Ser(459) and Ser(461). Cross-linking of CD5 bads to the activation of CD5-associated CK2 in a murine B-lymphoma cell line and a human T-leukemia cell line and is independent of net recruitment of CK2 to CD5. In contrast, CK2 is not activated following cross-linking of the B cell receptor complex or the T cell receptor complex. This direct regulation of CK2 by a cell surface receptor provides a novel pathway for control of cell activation that could play a significant role in regulation of CD5-dependent antigen receptor activation in T and B cells.	Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	University of Alabama System; University of Alabama Birmingham; Western University (University of Western Ontario)	Raman, C (corresponding author), Univ Alabama Birmingham, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.	craman@uab.edu	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620; Kimberly, Robert/0000-0002-5330-3086	PHS HHS [P60-38520-08] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBEROLAILA J, 1993, J IMMUNOL, V151, P4423; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Appleyard GD, 1998, CLIN EXP IMMUNOL, V111, P225; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; Bikah G, 1996, SCIENCE, V274, P1906, DOI 10.1126/science.274.5294.1906; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CEUPPENS JL, 1986, J IMMUNOL, V137, P1816; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVIES AA, 1992, P NATL ACAD SCI USA, V89, P6368, DOI 10.1073/pnas.89.14.6368; FABB SA, 1993, IMMUNOGENETICS, V38, P241, DOI 10.1007/BF00211525; FILHOL O, 1992, J BIOL CHEM, V267, P20577; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GaryGouy H, 1997, J IMMUNOL, V159, P3739; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARDY RR, 1989, CURR OPIN IMMUNOL, V2, P189, DOI 10.1016/0952-7915(89)90187-8; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUANG HJS, 1987, P NATL ACAD SCI USA, V84, P204, DOI 10.1073/pnas.84.1.204; IMBODEN JB, 1990, J CLIN INVEST, V85, P130, DOI 10.1172/JCI114402; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; JUNE CH, 1987, J IMMUNOL, V138, P2782; KANTOR A, IMMUNOL TODAY, V12, P388; KIPPS TJ, 1989, ADV IMMUNOL, V47, P117, DOI 10.1016/S0065-2776(08)60663-X; KROESEN BJ, 1995, CANCER RES, V55, P4409; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P812, DOI 10.1002/eji.1830240406; LEDBETTER JA, 1985, J IMMUNOL, V135, P2331; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Litchfield DW, 1996, BIOCHEM CELL BIOL, V74, P541, DOI 10.1139/o96-458; LUO W, 1992, J IMMUNOL, V148, P1630; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; OSMAN N, 1993, EUR J IMMUNOL, V23, P1173, DOI 10.1002/eji.1830230530; OSMAN N, 1992, EUR J IMMUNOL, V22, P2995, DOI 10.1002/eji.1830221135; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; Pospisil R, 1996, J EXP MED, V184, P1279, DOI 10.1084/jem.184.4.1279; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RAMAN C, 1992, J IMMUNOL, V149, P3858; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RETH M, 1995, IMMUNOL TODAY, V16, P310; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; SEN J, 1990, J IMMUNOL, V144, P2925; Simarro M, 1997, J IMMUNOL, V159, P4307; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; Suzuki H, 1997, J EXP MED, V186, P17, DOI 10.1084/jem.186.1.17; TARAKHOVSKY A, 1995, SCIENCE, V269, P535, DOI 10.1126/science.7542801; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; VAN DE VELDE H, 1991, NATURE, V351, P662; VANDENBERGHE P, 1993, IMMUNOLOGY, V78, P210; VERMEER LA, 1994, EUR J IMMUNOL, V24, P585, DOI 10.1002/eji.1830240314; VERWILGHEN J, 1993, J IMMUNOL, V150, P835; YU Q, 1990, NUCLEIC ACIDS RES, V18, P5296, DOI 10.1093/nar/18.17.5296	64	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19183	19189		10.1074/jbc.273.30.19183	http://dx.doi.org/10.1074/jbc.273.30.19183			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668105	hybrid			2022-12-27	WOS:000074974700072
J	Rodriguez-Fernandez, JL; Rozengurt, E				Rodriguez-Fernandez, JL; Rozengurt, E			Bombesin, vasopressin, lysophosphatidic acid, and sphingosylphosphorylcholine induce focal adhesion kinase activation in intact Swiss 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION PATHWAYS; STRESS FIBER FORMATION; GROWTH-FACTOR; RAPIDLY STIMULATE; ACTIN CYTOSKELETON; DNA-SYNTHESIS; MAP KINASE; CROSS-TALK; PHOSPHORYLATION	Treatment of quiescent Swiss 3T3 cells with bombesin rapidly increased focal adhesion kinase (FAR)-associated tyrosine kinase activity in immune complexes. The effect was rapid (maximum at 2.5 min) and dose dependent (half-maximum response at 0.05 nM). Addition of vasopressin, lysophosphatidic acid, and sphingosylphosphorylcholine also elicited a rapid increase in FAT-associated tyrosine kinase activity. Addition of the selective Src inhibitor pyrazolopyrimidine directly to the in vitro kinase assay potently inhibited Src kinase activity induced by bombesin but did not :effect the kinase activity of FATE measured by autophosphorylation or by synthetic substrate phosphorylation in paralell assays. In addition, Src activity was not detected in FATE immunoprecipitates using an optimal Src peptide substrate. Thus, agonist-induced tyrosine kinase activity measured in FATE immunoprecipitates is mediated by FATE activation rather than by co-immunoprecipitating Src. Bombesin-induced FATE activation is not dependent either on protein kinase C or Ca2+ mobilization but was completely blocked by treatment with cytochalasin D or by placing the cells in suspension. These findings indicate that FATE activation requires an intact actin cytoskeleton. Our results demonstrate that agonists that act via 7-transmembrane domain receptors stimulate FATE kinase activation.Treatment of quiescent Swiss 3T3 cells with bombesin rapidly increased focal adhesion kinase (FAR)-associated tyrosine kinase activity in immune complexes. The effect was rapid (maximum at 2.5 min) and dose dependent (half-maximum response at 0.05 nM). Addition of vasopressin, lysophosphatidic acid, and sphingosylphosphorylcholine also elicited a rapid increase in FAT-associated tyrosine kinase activity. Addition of the selective Src inhibitor pyrazolopyrimidine directly to the in vitro kinase assay potently inhibited Src kinase activity induced by bombesin but did not :effect the kinase activity of FATE measured by autophosphorylation or by synthetic substrate phosphorylation in paralell assays. In addition, Src activity was not detected in FATE immunoprecipitates using an optimal Src peptide substrate. Thus, agonist-induced tyrosine kinase activity measured in FATE immunoprecipitates is mediated by FATE activation rather than by co-immunoprecipitating Src. Bombesin-induced FATE activation is not dependent either on protein kinase C or Ca2+ mobilization but was completely blocked by treatment with cytochalasin D or by placing the cells in suspension. These findings indicate that FATE activation requires an intact actin cytoskeleton. Our results demonstrate that agonists that act via 7-transmembrane domain receptors stimulate FATE kinase activation.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Imperial Canc Res Fund, London WC2A 3PX, England; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cancer Research UK; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall,Rm 11-124, Los Angeles, CA 90095 USA.		Rodriguez-Fernandez, Jose Luis/Q-5021-2019	Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425				ALBERT DA, 1992, P NATL ACAD SCI USA, V89, P1597, DOI 10.1073/pnas.89.5.1597; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Charlesworth A, 1996, ONCOGENE, V12, P1337; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LACH EB, 1995, CELL GROWTH DIFFER, V6, P1427; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Mann DJ, 1997, ONCOGENE, V14, P1759, DOI 10.1038/sj.onc.1201134; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROZENGURT E, 1988, PROG NUCLEIC ACID RE, V35, P261, DOI 10.1016/S0079-6603(08)60616-9; ROZENGURT E, 1991, EUR J CLIN INVEST, V21, P123, DOI 10.1111/j.1365-2362.1991.tb01801.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1995, CANCER SURV, V24, P81; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Seckl MJ, 1996, J BIOL CHEM, V271, P29453, DOI 10.1074/jbc.271.46.29453; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24334, DOI 10.1074/jbc.270.41.24334; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Withers DJ, 1997, J BIOL CHEM, V272, P2509; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, J BIOL CHEM, V262, P3947; Zhou Songyang, 1995, Nature (London), V373, P536	71	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19321	19328		10.1074/jbc.273.30.19321	http://dx.doi.org/10.1074/jbc.273.30.19321			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668122	hybrid			2022-12-27	WOS:000074974700089
J	Schmidt, PP; Rova, U; Katterle, B; Thelander, L; Graslund, A				Schmidt, PP; Rova, U; Katterle, B; Thelander, L; Graslund, A			Kinetic evidence that a radical transfer pathway in protein R2 of mouse ribonucleotide reductase is involved in generation of the tyrosyl free radical	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HERPES-SIMPLEX VIRUS; ESCHERICHIA-COLI; ELECTRON-TRANSFER; RADICAL-DIIRON(III) COFACTOR; MOSSBAUER SPECTROSCOPIES; 3-DIMENSIONAL STRUCTURE; FE2+ REACTION; SUBUNIT; EPR	Class I ribonucleotide reductases consist of two subunits, R1 and R2, The active site is located in B1; active R2 contains a diferric center and a tyrosyl free radical (Tyr(.)), both essential for enzymatic activity. The proposed mechanism for the enzymatic reaction includes the transport of a reducing equivalent, i.e. electron or hydrogen radical, across a 35-Angstrom distance between Tyr(.) in R2 and the active site in R1, which are connected by a hydrogen-bonded chain of conserved, catalytically essential amino acid residues. Asp(266) and Trp(103) in mouse R2 are part of this radical transfer pathway. The differic/Tyr(.) site in R2 is reconstituted spontaneously by mixing iron-free apoR2 with Fe(II) and O-2. The reconstitution reaction requires the delivery of an external reducing equivalent to form the diferric/Tyr(.) site. Reconstitution kinetics were investigated in mouse ape-wild type R2 and the three mutants D266A, W103Y, and W103F by rapid freeze-quench electron paramagnetic resonance with greater than or equal to 4 Fe(II)/R2 at various reaction temperatures. The kinetics of Tyr(.) formation in D266A and W103Y is on average 20 times slower than in wild type R2, More strikingly, Tyr(.) formation is completely suppressed in W103F, No change in the reconstitution kinetics was found starting from Fe(II)-preloaded proteins, which shows that the mutations do not affect the rate of iron binding. Our results are consistent with a reaction mechanism using Asp266 and Trp(103) for delivery of the external reducing equivalent. Further, the results with W103F suggest that an intact hydrogen-bonded chain is crucial for the reaction, indicating that the external reducing equivalent is a H-.. Finally, the formation of Tyr(.) is not the slowest step of the reaction as it is in Escherichia coli R2, consistent with a stronger interaction between Tyr(.) and the iron center in mouse R2, A new electron paramagnetic resonance visible intermediate named mouse X, strikingly similar to species X found in E. coli R2, was detected only in small amounts under certain conditions. We propose that it may be an intermediate in a side reaction leading to a diferric center without forming the neighboring Tyr ..	Univ Stockholm, Dept Biophys, S-10691 Stockholm, Sweden; Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden	Stockholm University; Umea University; Stockholm University	Graslund, A (corresponding author), Univ Stockholm, Dept Biophys, S-10691 Stockholm, Sweden.							ABERG A, 1993, BIOCHEMISTRY-US, V32, P9845; ATTA M, 1994, J AM CHEM SOC, V116, P6429, DOI 10.1021/ja00093a051; Ballou D P, 1978, Methods Enzymol, V54, P85; BENDER CJ, 1989, J AM CHEM SOC, V111, P8076, DOI 10.1021/ja00203a002; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; Davydov R, 1996, BIOCHEMISTRY-US, V35, P5571, DOI 10.1021/bi952836y; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Edmondson DE, 1996, INORG CHIM ACTA, V252, P399, DOI 10.1016/S0020-1693(96)05427-8; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; GERFEN GJ, 1993, J AM CHEM SOC, V115, P6420, DOI 10.1021/ja00067a071; Graslund A, 1996, ANNU REV BIOPH BIOM, V25, P259; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; Katterle B, 1997, J BIOL CHEM, V272, P10414; Kauppi B, 1996, J MOL BIOL, V262, P706, DOI 10.1006/jmbi.1996.0546; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; OCHIAI EI, 1990, J BIOL CHEM, V265, P15758; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; Schmidt PP, 1996, J BIOL CHEM, V271, P23615, DOI 10.1074/jbc.271.39.23615; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; THELANDER L, 1994, MET IONS BIOL SYST, V30, P109; Tong WH, 1996, J AM CHEM SOC, V118, P2107, DOI 10.1021/ja952764y; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; van Dam PJ, 1998, J AM CHEM SOC, V120, P5080, DOI 10.1021/ja9737127; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; [No title captured]	38	52	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21463	21472		10.1074/jbc.273.34.21463	http://dx.doi.org/10.1074/jbc.273.34.21463			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705274	hybrid			2022-12-27	WOS:000075492600008
J	Sakakibara, M; Inoue, H; Yoshioka, T				Sakakibara, M; Inoue, H; Yoshioka, T			Evidence for the involvement of inositol trisphosphate but not cyclic nucleotides in visual transduction in Hermissenda eye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMULUS VENTRAL PHOTORECEPTORS; INVERTEBRATE PHOTORECEPTORS; PHOSPHOLIPASE-C; SQUID PHOTORECEPTORS; ION CHANNELS; EXCITATION; LIGHT; DROSOPHILA; CALCIUM; PHOTOTRANSDUCTION	Although several second messengers are known to be involved in invertebrate photoresponses, the mechanism underlying invertebrate phototransduction remains unclear. In the present study, brief injection of inositol trisphosphate into Hermissenda photoreceptors induced a transient Na+ current followed by burst activity, which accurately reproduced the native photoresponse. Injection of Ca2+ did not induce a significant change in the membrane potential but potentiated the native photoresponse, Injection of a Ca2+ chelator decreased the response amplitude and increased the response latency. Injection of cGMP induced a Ca2+-dependent, transient depolarization with a short latency. cAMP injection evoked Na+-dependent action potentials without a rise in membrane potential. Taken together, these results suggest that phototransduction in Hermissenda is mediated by Na+ channels that are directly activated by inositol trisphosphate without mobilization of cytosolic Ca2+.	Tokai Univ, Dept Biol Sci & Technol, Sch High Technol Human Welf, Numazu 41003, Japan; Waseda Univ, Dept Mol Neurobiol, Sch Human Sci, Tokorozawa, Saitama 359, Japan	Tokai University; Waseda University	Sakakibara, M (corresponding author), Tokai Univ, Dept Biol Sci & Technol, Sch High Technol Human Welf, Numazu 41003, Japan.							Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; ALKON DL, 1973, J GEN PHYSIOL, V61, P444, DOI 10.1085/jgp.61.4.444; ALKON DL, 1972, J GEN PHYSIOL, V60, P631, DOI 10.1085/jgp.60.6.631; ALKON DL, 1978, J NEUROPHYSIOL, V41, P1328, DOI 10.1152/jn.1978.41.5.1328; ALKON DL, 1976, J GEN PHYSIOL, V67, P197, DOI 10.1085/jgp.67.2.197; ALKON DL, 1985, BIOPHYS J, V48, P983, DOI 10.1016/S0006-3495(85)83861-3; BACIGALUPO J, 1991, P NATL ACAD SCI USA, V88, P7938, DOI 10.1073/pnas.88.18.7938; BACIGALUPO J, 1995, J NEUROSCI, V15, P7196; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BOLSOVER SR, 1985, J PHYSIOL-LONDON, V364, P381, DOI 10.1113/jphysiol.1985.sp015751; BROWN JE, 1992, EXP EYE RES, V54, P403, DOI 10.1016/0014-4835(92)90052-T; BROWN JE, 1984, J PHYSIOL-LONDON, V353, P523, DOI 10.1113/jphysiol.1984.sp015349; BROWN JE, 1984, NATURE, V311, P160, DOI 10.1038/311160a0; BROWN JE, 1987, BIOCHEM J, V247, P293, DOI 10.1042/bj2470293; DENNIS M J, 1967, Journal of Neurophysiology (Bethesda), V30, P1439; DETWILER PB, 1976, J PHYSIOL-LONDON, V256, P691, DOI 10.1113/jphysiol.1976.sp011346; ETCHEBERRIGARAY R, 1991, J EXP BIOL, V156, P619; FADDIS MN, 1993, J GEN PHYSIOL, V101, P909, DOI 10.1085/jgp.101.6.909; FEIN A, 1984, NATURE, V311, P157, DOI 10.1038/311157a0; FENG JJ, 1991, BRAIN RES, V552, P291, DOI 10.1016/0006-8993(91)90094-C; FRANK TM, 1991, J GEN PHYSIOL, V97, P697, DOI 10.1085/jgp.97.4.697; GOMEZ MD, 1995, NEURON, V15, P607, DOI 10.1016/0896-6273(95)90149-3; GROSSMAN Y, 1981, COMP BIOCHEM PHYS A, V68, P487, DOI 10.1016/0300-9629(81)90079-7; HARDIE RC, 1995, J NEUROSCI, V15, P889; HARDIE RC, 1993, NATURE, V366, P113, DOI 10.1038/366113a0; HATT H, 1994, P NATL ACAD SCI USA, V91, P6264, DOI 10.1073/pnas.91.14.6264; Honda E, 1995, BRAIN RES, V703, P79, DOI 10.1016/0006-8993(95)01072-6; INOUE H, 1985, BIOCHEM BIOPH RES CO, V132, P513, DOI 10.1016/0006-291X(85)91163-5; JOHNSON EC, 1986, NATURE, V324, P468, DOI 10.1038/324468a0; JOHNSON EC, 1995, J NEUROSCI, V15, P6586; LEVY S, 1985, J GEN PHYSIOL, V85, P805, DOI 10.1085/jgp.85.6.805; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; NAGY K, 1991, Q REV BIOPHYS, V24, P165, DOI 10.1017/S0033583500003401; NOMURA K, 1990, J MEMBRANE BIOL, V115, P241, DOI 10.1007/BF01868639; ODAY PM, 1989, J GEN PHYSIOL, V93, P473, DOI 10.1085/jgp.93.3.473; PAK WL, 1991, PHOTOCHEM PHOTOBIOL, V53, P871, DOI 10.1111/j.1751-1097.1991.tb09901.x; PAYNE R, 1986, J GEN PHYSIOL, V88, P107, DOI 10.1085/jgp.88.1.107; PAYNE R, 1986, J GEN PHYSIOL, V87, P243, DOI 10.1085/jgp.87.2.243; PAYNE R, 1986, J GEN PHYSIOL, V88, P127, DOI 10.1085/jgp.88.1.127; SAIBIL HR, 1984, FEBS LETT, V168, P213, DOI 10.1016/0014-5793(84)80248-3; SAKAKIBARA M, 1994, BIOCHEM BIOPH RES CO, V202, P299, DOI 10.1006/bbrc.1994.1927; SHIN JH, 1993, NEURON, V11, P845, DOI 10.1016/0896-6273(93)90114-7; SOMASUNDARAM B, 1995, J BIOL CHEM, V270, P16638, DOI 10.1074/jbc.270.28.16638; STEIVE H, 1992, VISION RES, V32, P403; SZUTS EZ, 1986, BIOCHEM J, V240, P929, DOI 10.1042/bj2400929; TAKEDA T, 1982, VISION RES, V22, P303, DOI 10.1016/0042-6989(82)90130-4; THIO CL, 1993, J NEUROSCI, V13, P4889; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; UKHANOV KY, 1995, J GEN PHYSIOL, V105, P95, DOI 10.1085/jgp.105.1.95; WECKSTROM M, 1988, ACTA PHYSIOL SCAND, V132, P103, DOI 10.1111/j.1748-1716.1988.tb08303.x; WOOD SF, 1989, J BIOL CHEM, V264, P12970; YOSHIOKA T, 1983, BIOCHEM BIOPH RES CO, V111, P567, DOI 10.1016/0006-291X(83)90344-3; YOSHIOKA T, 1983, BIOCHIM BIOPHYS ACTA, V755, P50, DOI 10.1016/0304-4165(83)90271-4	53	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20795	20801		10.1074/jbc.273.33.20795	http://dx.doi.org/10.1074/jbc.273.33.20795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694824	hybrid			2022-12-27	WOS:000075386100017
J	Eckhardt, M; Gotza, B; Gerardy-Schahn, R				Eckhardt, M; Gotza, B; Gerardy-Schahn, R			Mutants of the CMP-sialic acid transporter causing the Lec2 phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MANNOSIDASE-II; MOLECULAR-CLONING; ENDOPLASMIC-RETICULUM; GLYCOSYLATION MUTANTS; GOLGI-APPARATUS; SIALYLATION; TOPOGRAPHY; EXPRESSION; DEFICIENT; GALACTOSE	Chinese hamster ovary (CHO) mutants belonging to the Lec2 complementation group are unable to translocate CMP-sialic acid to the lumen of the Golgi apparatus. Complementation cloning in these cells has recently been used to isolate cDNAs encoding the CMP-sialic acid transporter from mouse and hamster. The present study was carried out to determine the molecular defects leading to the inactivation of CMP-sialic acid transport, To this end, CMP-sialic acid transporter cDNAs derived from five independent clones of the Lec2 complementation group, were analyzed. Deletions in the coding region were observed for three clones, and single mutants were found to contain an insertion and a point mutation. Epitope-tagged variants of the wild-type transporter protein and of the mutants were used to investigate the effect of the structural changes on the expression and subcellular targeting of the transporter proteins. Mutants derived from deletions showed reduced protein expression and in immunofluorescence showed a diffuse staining throughout the cytoplasm in transiently transfected cells, while the translation product derived from the point mutated cDNA (G189E) was expressed at the level of the wild-type transporter and co-localized with the Golgi marker cu-mannosidase ll. This mutation therefore seems to directly affect the transport activity. Site-directed mutagenesis was used to change glycine 189 into alanine, glutamine, and isoleucine, respectively. While the G189A mutant was able to complement CMP-sialic acid transport-deficient Chinese hamster ovary mutants, the exchange of glycine 189 into glutamine or isoleucine dramatically affected the transport activity of the CMP-sialic acid transporter.	MHH, Inst Med Mikrobiol, D-30625 Hannover, Germany	Hannover Medical School; University of Hamburg; University Medical Center Hamburg-Eppendorf	Gerardy-Schahn, R (corresponding author), MHH, Inst Med Mikrobiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	rgs@mikrobio.h.shuttle.de						Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; BRILES EB, 1977, J BIOL CHEM, V252, P1107; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Gorelik E, 1997, CANCER RES, V57, P332; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HARVEY BE, 1992, CANCER RES, V52, P1775; HARVEY BE, 1993, BIOCHEM BIOPH RES CO, V190, P571, DOI 10.1006/bbrc.1993.1086; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; Ishida N, 1996, J BIOCHEM, V120, P1074; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; ROST B, 1995, PROTEIN SCI, V4, P521; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITOH O, 1992, J BIOL CHEM, V267, P5700; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTER UV, 1989, EUR J BIOCHEM, V181, P249, DOI 10.1111/j.1432-1033.1989.tb14719.x; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; Tabuchi M, 1997, BIOCHEM BIOPH RES CO, V232, P121, DOI 10.1006/bbrc.1997.6239; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VERBERT A, 1987, BIOCHIMIE, V69, P91, DOI 10.1016/0300-9084(87)90240-9	35	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20189	20195		10.1074/jbc.273.32.20189	http://dx.doi.org/10.1074/jbc.273.32.20189			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685366	hybrid			2022-12-27	WOS:000075305400043
J	Hyytiainen, M; Taipale, J; Heldin, CH; Keski-Oja, J				Hyytiainen, M; Taipale, J; Heldin, CH; Keski-Oja, J			Recombinant latent transforming growth factor beta-binding protein 2 assembles to fibroblast extracellular matrix and is susceptible to proteolytic processing and release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE MICROFIBRILS; FACTOR-LIKE DOMAINS; MARFAN-SYNDROME; CALCIUM-BINDING; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; TGF-BETA; FIBRILLIN; COMPONENT; GENE	Latent transforming growth factor P-binding protein 2 (LTBP-2) belongs to the fibrillin-LTBP gene family and is a component of 10-nm microfibrils. LTBP-2 consists mainly of domains of 8-cysteine and EGF-Like repeats linked by proline-rich regions. To characterize the biochemical properties of LTBP-2, its assembly to the extracellular matrix, and its proteolytic release from the matrix, LTBP-2 was expressed recombinantly in Chinese hamster ovary cells and purified to homogeneity under nondenaturing conditions. Purified LTBP-2 bound calcium and was glycosylated at the central domain of EGF-like repeats. Antibodies made against the recombinant LTBP-2 decorated fibrillar structures in fibroblast extracellular matrix. Treatment of matrices with plasmin or elastase released a soluble similar to 160-kDa LTBP-2 fragment. Processing of LTBP-2 was studied by treating purified LTBP-2 with plasmin or porcine pancreatic elastase. LTBP-2 was processed with these proteases initially to a similar to 160-kDa fragment, and with higher concentrations to a protease-resistant similar to 120-kDa fragment. Processing sites were localized by amino acid sequencing to proline-rich regions at the N-terminal part of LTBP-2, suggesting that the matrix binding sites locate to the N-terminal similar to 500 amino acids of LTBP-2. Purified and biotinylated LTBP-2 could be assembled to fibrillar structures in fibroblast extracellular matrix during cell cultivation, indicating that LTBP-2 assembly to the matrix is not strictly linked to cells that make it and suggesting that microfibril assembly may involve soluble intermediates.	Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	University of Helsinki; Ludwig Institute for Cancer Research	Keski-Oja, J (corresponding author), Univ Helsinki, Haartman Inst, Dept Virol, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.							DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; DAVIS EC, 1994, J CELL SCI, V107, P727; DAVIS EC, 1993, CELL TISSUE RES, V272, P211, DOI 10.1007/BF00302726; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KIELTY CM, 1994, FEBS LETT, V351, P85, DOI 10.1016/0014-5793(94)00818-3; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MOREN A, 1994, J BIOL CHEM, V269, P32469; Nakajima Y, 1997, J CELL BIOL, V136, P193, DOI 10.1083/jcb.136.1.193; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; Olofsson A, 1995, J BIOL CHEM, V270, P31294, DOI 10.1074/jbc.270.52.31294; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Peters D. M. P., 1994, EXTRACELLULAR MATRIX, P315; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Saharinen J, 1996, EMBO J, V15, P245, DOI 10.1002/j.1460-2075.1996.tb00355.x; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Sakamoto H, 1996, J BIOL CHEM, V271, P4916; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; Taipale J, 1996, J HISTOCHEM CYTOCHEM, V44, P875, DOI 10.1177/44.8.8756760; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YIN WS, 1995, J BIOL CHEM, V270, P10147, DOI 10.1074/jbc.270.17.10147; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	43	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20669	20676		10.1074/jbc.273.32.20669	http://dx.doi.org/10.1074/jbc.273.32.20669			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685426	hybrid			2022-12-27	WOS:000075305400103
J	Zambrano, N; Minopoli, G; de Candia, P; Russo, T				Zambrano, N; Minopoli, G; de Candia, P; Russo, T			The Fe65 adaptor protein interacts through its PID1 domain with the transcription factor CP2/LSF/LBP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BINDING DOMAIN; DNA-BINDING; IN-VITRO; MOTIF; SHC; PHOSPHORYLATION; ASSOCIATION; DISTINCT	The neural protein Fe65 possesses three putative protein-protein interaction domains: one WRY domain and two phosphotyrosine interaction/phosphotyrosine binding domains (PID1 and PID2); the most C-terminal of these domains (PHD2) interacts in vivo with the Alzheimer's beta-amyloid precursor protein, whereas the WW domain binds to Mena, the mammalian homolog of Drosophila-enabled protein. By the interaction trap procedure, we isolated a cDNA clone encoding a possible ligand of the N-terminal PID/PTB domain of Fe65 (PID1), Sequence analysis of this clone revealed that this ligand corresponded to the previously identified transcription factor CP2/LSF/LBP1, Co-immunoprecipitation experiments demonstrated that the interaction between Fe65 and CP2/LSF/LBP1 also takes place in vivo between the native molecules. The localization of both proteins was studied using fractionated cellular extracts. These experiments demonstrated that the various isoforms of CP2/LSF/LBP1 are differently distributed among subcellular fractions. At least one isoform, derived from alternative splicing (LSF-ID), is present outside the nucleus; Fe65 was found in both fractions. Furthermore, transfection experiments with an HA-tagged CP2/LSF/LBP1 cDNA demonstrated that Fe65 interacts also with the nuclear form of CP2/LSF/LBP1. Considering that the analysis of Fe65 distribution in fractionated cell extracts demonstrated that this protein is present both in nuclear and non-nuclear fractions, we examined the expression of Fe65 deletion mutants in the two fractions. This analysis allowed us to observe that a small region N-terminal to the WW domain is phosphorylated and is necessary for the presence of Fe65 in the nuclear fraction.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Naples Federico II	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.		Russo, Tommaso/K-1331-2016; de Candia, Paola/Z-1498-2019; de Candia, Paola/HGC-8826-2022; Zambrano, Nicola/B-9352-2014	Russo, Tommaso/0000-0003-4426-0106; de Candia, Paola/0000-0003-4767-446X; de Candia, Paola/0000-0003-4767-446X; Zambrano, Nicola/0000-0001-9395-3481	Telethon [E.0522] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAM LP, 1993, FEBS LETT, V322, P56, DOI 10.1016/0014-5793(93)81110-L; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; FIORE F, 1995, CELL CYCLE MATERIALS, P211; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Giambarella U, 1997, EMBO J, V16, P4897, DOI 10.1093/emboj/16.16.4897; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; ONODA K, 1993, J BIOL CHEM, V268, P4106; PARADA CA, 1995, J BIOL CHEM, V270, P2274, DOI 10.1074/jbc.270.5.2274; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; QUINTO I, 1993, J BIOL CHEM, V268, P26719; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Volker JL, 1997, GENE DEV, V11, P1435, DOI 10.1101/gad.11.11.1435; WINEY M, 1993, J CELL BIOL, V122, P743, DOI 10.1083/jcb.122.4.743; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399	43	137	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20128	20133		10.1074/jbc.273.32.20128	http://dx.doi.org/10.1074/jbc.273.32.20128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685356	hybrid			2022-12-27	WOS:000075305400033
J	Boss, V; Abbott, KL; Wang, XF; Pavlath, GK; Murphy, TJ				Boss, V; Abbott, KL; Wang, XF; Pavlath, GK; Murphy, TJ			The cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) proteins are expressed in vascular smooth muscle cells - Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase c-coupled cell surface receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GENE; CALCINEURIN; FOS; DEPHOSPHORYLATION; TRANSDUCTION; MECHANISM; COMPLEX; KINASE; FAMILY	Expression of the antigen-regulated, cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) is not restricted to lymphoid cells, as thought initially, but the physiological inducers of NFAT-mediated transcription in non-lymphoid cells are unknown. Here, cultured vascular smooth muscle cells (VSMC) are shown to express two isoforms of the NFAT family endogenously, which are localized differentially in cells under resting conditions. Using a retroviral NFAT-specific luciferase reporter, we show that VSMC support previously unrecognized complexities in NEAT-mediated transcription, including evidence for negative regulation by Ca2+ signaling and positive regulation through co-activation of adenylyl cyclase and Ca2+ mobilization, The VSMC mitogen platelet derived growth factor-BE (PDGF-EB) induces NFAT-mediated transcription in VSMC, Thrombin and angiotensin II, which activate G alpha(q)-coupled receptors, are significantly weaker inducers of NFAT-mediated luciferase expression than is PDGF-BB, However, co-stimulation studies show that G alpha(q) receptor agonists augment the NEAT-mediated transcriptional response to PDGF-BB, This synergy can be explained in part by augmented intracellular Ca2+ transients elicited by multiple agonist challenges. These data indicate that agonists for phospholipase C-coupled receptors stimulate NFAT-mediated transcription in VSMC differentially, and that NEAT can function to integrate co-activating signals in the extracellular environment.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Grad Div Biol & Biomed Sci, Grad Program Mol Therapeut & Toxicol, Atlanta, GA 30322 USA	Emory University; Emory University	Murphy, TJ (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rm 5031,OW Rollins Res Bldg, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043410, P30AR042687] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52801] Funding Source: Medline; NIAMS NIH HHS [AR43410, AR42687] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEDI H, 1995, CARDIOVASC RES, V30, P544, DOI 10.1016/0008-6363(95)00092-5; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; BRAISER AR, 1989, BIOTECHNIQUES, V7, P1116; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL GW, 1995, BLOOD, V86, P2689; Condie R, 1996, J BIOL CHEM, V271, P13175, DOI 10.1074/jbc.271.22.13175; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; FIRST MR, 1994, J AM SOC NEPHROL, V4, P30; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JACKSON CL, 1992, HYPERTENSION, V20, P713, DOI 10.1161/01.HYP.20.6.713; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1993, J IMMUNOL, V151, P837; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; KRAISS LW, 1993, J CLIN INVEST, V92, P338, DOI 10.1172/JCI116572; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Nickenig G, 1996, MOL PHARMACOL, V50, P743; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PAVLATH GK, 1989, SOMAT CELL MOLEC GEN, V15, P191, DOI 10.1007/BF01534870; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Weiss DL, 1996, MOL CELL BIOL, V16, P228; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; WILCOX JN, 1994, HAEMOSTASIS THROMBOS, P1139; WU J, 1995, MOL CELL BIOL, V15, P4337	43	96	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19664	19671		10.1074/jbc.273.31.19664	http://dx.doi.org/10.1074/jbc.273.31.19664			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677394	hybrid			2022-12-27	WOS:000075125200046
J	Phelan, SA; Loeken, MR				Phelan, SA; Loeken, MR			Identification of a new binding motif for the paired domain of Pax-3 and unusual characteristics of spacing of bipartite recognition elements on binding and transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR ALVEOLAR RHABDOMYOSARCOMA; DNA-BINDING; WAARDENBURG SYNDROME; BOX GENE; PROTEIN; SEQUENCES; DROSOPHILA; FUSION; EXPRESSION; MUTATIONS	Pax-3, a transcription factor that is required for development of the embryonic neural tube, neural crest, and semitic derivatives, contains two DNA-binding domains, a paired domain, and a paired-type homeodomain. Although Pax-3 binds to sequences related to the e5 element of the Drosophila even-skipped gene, the sequence requirements of an optimal Pax-3 response element have not been well characterized. Using both DNA-binding domains and a pool of random oligonucleotides, we identified a new paired box consensus motif, "GT-TAT," which was located 1, 4, 5, 8, or 13 base pairs downstream of the homeobox binding motif, "ATTA." Binding analysis of these sequences demonstrated that the distance between recognition elements for the homeodomain and the paired domain affects affinity. Specifically, spacing elements 1 or 13 base pairs apart from each other conferred low affinity Pax-3 binding, whereas intermediate spacing (5 or 8 bass pairs) conferred high affinity binding. Contrary to previous reports, oligonucleotides deleted for either the ATTA or the GTTAT could also be bound by Pax-5, although both sites were necessary for maximal affinity. Finally, transient transfections demonstrated that Pax-3 trans-activation correlated with binding affinity. Because the Pax-3-responsive genes identified to date contain almost exclusively low affinity binding sequences, our analysis indicates that they may be responsive to Pax-3 only when cellular levels are high.	Joslin Diabet Ctr, Mol Biol Sect, Boston, MA 02215 USA; Harvard Univ, Sch Med, Div Med Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Loeken, MR (corresponding author), Joslin Diabet Ctr, Mol Biol Sect, 1 Joslin Pl, Boston, MA 02215 USA.		Loeken, Mary R./AAC-2450-2022	Loeken, Mary R./0000-0002-8056-9816	NCI NIH HHS [CA50599] Funding Source: Medline; NIDDK NIH HHS [T32 DK07260, DK36836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007260, P30DK036836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, NUCLEIC ACIDS RES, V22, P3131, DOI 10.1093/nar/22.15.3131; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FAINSOD A, 1991, NUCLEIC ACIDS RES, V19, P4005, DOI 10.1093/nar/19.14.4005; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; Jun S, 1996, DEVELOPMENT, V122, P2639; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MIURA M, 1989, GENE, V75, P31; NORBY PL, 1992, NUCLEIC ACIDS RES, V20, P6317, DOI 10.1093/nar/20.23.6317; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; Phelan SA, 1997, DIABETES, V46, P1189, DOI 10.2337/diabetes.46.7.1189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TASSABEHJI M, 1993, NAT GENET, V3, P26, DOI 10.1038/ng0193-26; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P594; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0	44	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19153	19159		10.1074/jbc.273.30.19153	http://dx.doi.org/10.1074/jbc.273.30.19153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668101	hybrid, Green Published			2022-12-27	WOS:000074974700068
J	Rossi, R; Barra, D; Bellelli, A; Boumis, G; Canofeni, S; Di Simplicio, P; Lusini, L; Pascarella, S; Amiconi, G				Rossi, R; Barra, D; Bellelli, A; Boumis, G; Canofeni, S; Di Simplicio, P; Lusini, L; Pascarella, S; Amiconi, G			Fast-reacting thiols in rat hemoglobins can intercept damaging species in erythrocytes more efficiently than glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MIXED DISULFIDES; BLOOD; OXIDATION; STABILITY; REAGENTS; EXCHANGE; BINDING; CHAINS; CELLS; GSH	The S-conjugation rates of the free-reacting thiols present on each component of rat hemoglobin with 5,5-dithio-bis(2,2-nitrobenzoic acid) (DTNB) have been studied under a variety of conditions. On the basis of their reactivity with DTNB (0.5 mn), three classes of thiols have been defined as follows: fast reacting (fHbSH), with t(1/2) <100 ms; slow reacting (sHbSH), with t(1/2) 30-50 s; and very slow reacting (vsHbSH), with t(1/2) 180-270 s, Under paraphysiological conditions, fHbSH (identified with Cys-125 beta(H3)) conjugates with DTNB 100 times faster than glutathione and similar to 4000 times more rapidly than (v)sHbSH (Cys-13 alpha(All) and Cys-93 beta(F9)). Such characteristics of fHbSH reactivity that are independent of the quaternary state of hemoglobin are mainly due to the following: (i) its low pK (similar to 6.9, the cysteinyl anion being stabilized by a hydrogen bond with Ser-123 beta(H1)) and (ii) the large exposure to the solvent (as measured by analysis of a model of the molecular surface) and make these thiols the kinetically preferred groups in rat erythrocytes for S-conjugation. In addition, because of the high cellular concentration (8 mM, i.e. four times that of glutathione), fHbSHs are expected to intercept damaging species in erythrocytes more efficiently than glutathione, thus adding a new physiopathological role (direct involvement in cellular strategies of antioxidant defense) to cysteinyl residues in proteins.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Siena, Ist Clin Malattie Nervose & Mentali, Sez Farmacol, I-53100 Siena, Italy; CNR, Ctr Biol Mol, I-00185 Rome, Italy	Sapienza University Rome; University of Siena; Consiglio Nazionale delle Ricerche (CNR)	Amiconi, G (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	amigino@axrma.uniromal.it	Bellelli, Andrea/D-2785-2009; Rossi, Ranieri/C-8743-2011; Barra, Donatella/D-1236-2011	Rossi, Ranieri/0000-0002-0187-4530; BOUMIS, Giovanna/0000-0001-5323-7288				AMICONI G, 1989, J BIOL CHEM, V264, P17745; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V2, P202; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTLER E, 1975, RED CELL METABOLISM, P105; BIRCHMEIER W, 1973, BIOCHEMISTRY-US, V12, P3667, DOI 10.1021/bi00743a015; BRIGELIUS R, 1983, BIOCHEM PHARMACOL, V32, P2529, DOI 10.1016/0006-2952(83)90014-X; CHIANCONE E, 1970, J BIOL CHEM, V245, P4105; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; CHUA CG, 1975, BIOCHEM J, V149, P259, DOI 10.1042/bj1490259; CONDO SG, 1981, EUR J BIOCHEM, V116, P243, DOI 10.1111/j.1432-1033.1981.tb05325.x; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; DATTA MC, 1981, HEMOGLOBIN, V5, P701, DOI 10.3109/03630268108991838; DISIMPLICIO P, 1994, BBA-GEN SUBJECTS, V1199, P245; DISIMPLICIO P, 1998, NITRIC OXIDE CELL PR; DISIMPLICIO P, 1988, CLIN CHEM ENZYMOL CO, V1, P71; DISIMPLICIO P, 1996, BIOCHIM BIOPHYS ACTA, V1289, P257; FERRANTI P, 1993, INT J BIOCHEM, V25, P1943, DOI 10.1016/0020-711X(88)90329-1; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; GAREL MC, 1986, J BIOL CHEM, V261, P4704; GARRICK LM, 1975, BIOCHEM J, V149, P245, DOI 10.1042/bj1490245; GARRICK LM, 1978, BIOCHEM J, V173, P321, DOI 10.1042/bj1730321; Giardina B, 1981, Methods Enzymol, V76, P417; GIBSON QH, 1973, J BIOL CHEM, V248, P1281; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GROSSMAN SJ, 1988, J PHARMACOL EXP THER, V244, P118; GUIDOTTI G, 1965, J BIOL CHEM, V240, P3924; HALLAWAY BE, 1980, ARCH BIOCHEM BIOPHYS, V203, P332, DOI 10.1016/0003-9861(80)90184-8; HALLIWELL B, 1989, FREE RADICAL BIO MED, P9; HUBBARD SJ, 1993, NACCESS RELEASE 2 1; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOSOWER NS, 1977, EUR J BIOCHEM, V77, P529, DOI 10.1111/j.1432-1033.1977.tb11695.x; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; KOSOWER NS, 1989, COENZYMES COFACTOR B, V3, P319; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUZZATTO L, 1987, CELL BIOCHEM FUNCT, V5, P101, DOI 10.1002/cbf.290050204; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; NIKETIC V, 1992, INT J BIOCHEM, V24, P503, DOI 10.1016/0020-711X(92)90046-4; OKONJO KO, 1993, J PROTEIN CHEM, V12, P33, DOI 10.1007/BF01024911; PACKER L, 1995, METHOD ENZYMOL, V252, pR13; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; ROSSI R, 1995, BBA-GEN SUBJECTS, V1243, P230, DOI 10.1016/0304-4165(94)00133-I; SIES H, 1993, EUR J BIOCHEM, V215, P213, DOI 10.1111/j.1432-1033.1993.tb18025.x; Sies H., 1982, METABOLIC COMPARTMEN, P205; Starke DW, 1997, FREE RADICAL BIO MED, V23, P373, DOI 10.1016/S0891-5849(97)00009-9; STEIN S, 1971, J BIOL CHEM, V246, P5287; TAYLOR JF, 1966, J BIOL CHEM, V241, P241; TERADA T, 1993, BIOCHEM MOL BIOL INT, V29, P1009; TONDO CV, 1971, AN ACAD BRAS CIENC, V43, P651; TORCHINSKY YM, 1981, SULPHUR PROTEINS; Waring R.H., 1996, BIOL INTERACTIONS SU, P145; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294	58	62	62	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19198	19206		10.1074/jbc.273.30.19198	http://dx.doi.org/10.1074/jbc.273.30.19198			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668107	hybrid, Green Published			2022-12-27	WOS:000074974700074
J	Tomita, S; Kirino, Y; Suzuki, T				Tomita, S; Kirino, Y; Suzuki, T			A basic amino acid in the cytoplasmic domain of Alzheimer's beta-amyloid precursor protein (APP) is essential for cleavage of APP at the alpha-site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DISEASE; PHOSPHORYLATION; MUTATION; OCCURS; CELLS; GENE; CDNA; COMPARTMENT; DERIVATIVES	In Alzheimer's disease (AD), the beta-amyloid peptide (A alpha) is thought to be produced as a result of the aberrant metabolism of beta-amyloid precursor protein (APP). We report that the APP cytoplasmic domain contains a novel and important signal for APP metabolism. A single amino acid mutation that changed arginine at amino acid 747 of APP770 (corresponding to position 672 of APP695) to a non-basic amino acid greatly increased the production of intracellular APP carboxyl-terminal fragment(s) cleaved at beta-site(s) (CTF beta), but did not result in increased secretion of A beta 40 and A beta 42. This was not due to a simple intracellular accumulation of CTF beta resulting from a lack of gamma-secretase. CTF beta derived from this mutant APP was generated and degraded as efficiently as CTF beta derived from wild-type APP. This result indicates that the increase in the quantity of CTF beta does not always give rise to more A beta production, as was previously suggested by studies of a familial AD mutation of APP, These findings suggest that APP carrying the substitution mutation at this basic amino acid may be metabolized by another protein secretory pathway. Although these results have not completely elucidated why CTF beta derived from the mutant APP escapes from subsequent cleavage by gamma-secretase, analysis of the processing pathway of this mutant APP should provide insights into the pathogenesis of the sporadic type of AD.	Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, 7-3-1 Hong, Tokyo 113, Japan.		Suzuki, Toshiharu/B-5342-2013					BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESAUVAGE F, 1989, SCIENCE, V245, P651, DOI 10.1126/science.2569763; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; NORSTEDT C, 1993, J BIOL CHEM, V268, P608; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; SUZUKI T, 1992, NEUROSCIENCE, V48, P755, DOI 10.1016/0306-4522(92)90264-3; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; YAMAMOTO K, 1992, J BIOCHEM-TOKYO, V111, P87, DOI 10.1093/oxfordjournals.jbchem.a123724	42	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19304	19310		10.1074/jbc.273.30.19304	http://dx.doi.org/10.1074/jbc.273.30.19304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668120	hybrid			2022-12-27	WOS:000074974700087
J	Kolupaeva, VG; Pestova, TV; Hellen, CUT; Shatsky, IN				Kolupaeva, VG; Pestova, TV; Hellen, CUT; Shatsky, IN			Translation eukaryotic initiation factor 4G recognizes a specific structural element within the internal ribosome entry site of encephalomyocarditis virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; MOUTH-DISEASE VIRUS; SECONDARY STRUCTURE; MUTATIONAL ANALYSIS; COMPLEX-FORMATION; FACTOR EIF-4A; REGION; DOMAIN; SEQUENCE; SUFFICIENT	A complex of eukaryotic initiation factors (eIFs) 4A, 4E, and 4G (collectively termed eIF4F) plays a key role in recruiting mRNAs to ribosomes during translation initiation. The site of ribosomal entry onto most mRNAs is determined by interaction of the 5'-terminal cap with eIF4E; eIFs 4A and 4G may facilitate ribosomal entry by modifying mRNA structure near the cap and by interacting with ribosome-associated factors. eIF4G recruits uncapped encephalomyocarditis virus (EMCV) mRNA to ribosomes without the involvement of eIF4E by binding directly to the similar to 450-nucleotide long EMCV internal ribosome entry site (IRES). We have used chemical and enzymatic probing to map the eIF4G binding site to a structural element within the J-K domain of the EMCV IRES that consists of an oligo(A) loop at the junction of three helices. The oligo(A) loop itself is not sufficient to form stable complexes with eIF4G since alteration of its structural context abolished its interaction with eIF4G. Addition of wild type or trans-dominant mutant forms of eIF4A to binary IRES.eIF4G complexes did not further alter the pattern of chemical/enzymatic modification of the IRES.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physiochem Biol, Moscow 119899, Russia; SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA	Lomonosov Moscow State University; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Shatsky, IN (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physiochem Biol, Moscow 119899, Russia.	shatsky@ins.genebee.msu.su	Shatsky, Ivan N/A-5331-2012		NIAID NIH HHS [R01 AI051340] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BOROVJAGIN AV, 1991, NUCLEIC ACIDS RES, V19, P4999, DOI 10.1093/nar/19.18.4999; BROWN EA, 1991, J VIROL, V65, P5828, DOI 10.1128/JVI.65.11.5828-5838.1991; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; deQuinto SL, 1997, J VIROL, V71, P4171; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Haghighat A, 1997, J BIOL CHEM, V272, P21677, DOI 10.1074/jbc.272.35.21677; Hellen CUT, 1995, CURR TOP MICROBIOL, V203, P31; Hoffman MA, 1996, J VIROL, V70, P6425, DOI 10.1128/JVI.70.9.6425-6430.1996; HOFFMAN MA, 1995, J VIROL, V69, P4399, DOI 10.1128/JVI.69.7.4399-4406.1995; HYYPIA T, 1992, P NATL ACAD SCI USA, V89, P8847, DOI 10.1073/pnas.89.18.8847; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jackson RJ, 1995, RNA, V1, P985; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; Kaminski A, 1998, RNA, V4, P626, DOI 10.1017/S1355838298971898; Kolupaeva VG, 1996, RNA, V2, P1199; KUHN R, 1990, J VIROL, V64, P4625; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; MADER S, 1995, MOL CELL BIOL, V15, P4990; MartinezSalas E, 1996, J VIROL, V70, P992; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEYER K, 1995, J VIROL, V69, P2819, DOI 10.1128/JVI.69.5.2819-2824.1995; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; PILIPENKO EV, 1989, NUCLEIC ACIDS RES, V17, P5701, DOI 10.1093/nar/17.14.5701; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; VANDERVELDEN A, 1995, VIROLOGY, V214, P82, DOI 10.1006/viro.1995.9952; Witherell GW, 1995, VIROLOGY, V214, P660, DOI 10.1006/viro.1995.0081; Wutz G, 1996, J GEN VIROL, V77, P1719, DOI 10.1099/0022-1317-77-8-1719; YAN RQ, 1992, J BIOL CHEM, V267, P23226; YODERHILL J, 1993, J BIOL CHEM, V268, P5566	40	155	162	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18599	18604		10.1074/jbc.273.29.18599	http://dx.doi.org/10.1074/jbc.273.29.18599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660832	hybrid			2022-12-27	WOS:000074828500087
J	Crabb, JW; Nie, ZQ; Chen, Y; Hulmes, JD; West, KA; Kapron, JT; Ruuska, SE; Noy, N; Saari, JC				Crabb, JW; Nie, ZQ; Chen, Y; Hulmes, JD; West, KA; Kapron, JT; Ruuska, SE; Noy, N; Saari, JC			Cellular retinaldehyde-binding protein ligand interactions - GLN-210 and LYS-221 are in the retinoid binding pocket	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	68th Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology	APR, 1996	FT LAUDERDALE, FLORIDA	Assoc Res Vis & Ophthalmol			SITE-DIRECTED MUTAGENESIS; BOVINE RETINA; X-RECEPTORS; ACID; RHODOPSIN; CLONING; GENE; DETERMINANTS; TRANSDUCIN; CRALBP	Cellular retinaldehyde-binding protein (CRALBP) carries Il-cis-retinal and/or Il-cis-retinol as endogenous ligands in the retinal pigment epithelium (RPE) and Muller cells of the retina and has been linked with autosomal recessive retinitis pigmentosa, Ligand interactions determine the physiological role of CRALBP in the RPE where the protein is thought to function as a substrate carrier for Il-cis-retinol dehydrogenase in the synthesis of Il-cis-retinal for visual pigment regeneration. However, CRALBP is also present in optic nerve and brain where its natural ligand and function are not yet known. We have characterized the interactions of retinoids with native bovine CRALBP, human recombinant CRALBP (rCRALBP) and five mutant rCRALBPs. Efforts to trap and/or identify a Schiff base in the dark, under a variety of reducing, denaturing, and pH conditions were unsuccessful, suggesting the lack of covalent interactions between CRALBP and retinoid. Buried and solvent-exposed lysine residues were identified in bovine CRALBP by reductive methylation of the holoprotein followed by denaturation and reaction with [H-3]acetic anhydride, Radioactive lysine residues were identified by Edman degradation and electrospray mass spectrometry following proteolysis and purification of modified peptides, Human rCRALBP mutants K152A, K221A, and K294A were prepared to investigate possible retinoid interactions with buried or partially buried lysines. Two other rCRALBP mutants, I162V and Q210R, were also prepared to identify substitutions altering the retinoid binding properties of a random mutant. The structures of all the mutants were verified by amino acid and mass spectral analyses and retinoid binding properties evaluated by W-visible and fluorescence spectroscopy. AU of the mutants bound Il-cis-retinal essentially like the wild type protein, indicating that the proteins were not grossly misfolded, Three of the mutants bound 9-cis-retinal like the wild type protein; however, Q210R and K221A bound less than stoichiometric amounts of the g-cis-isomer and exhibited lower affinity for this retinoid relative to wild type rCRALBP. Residues Gin-210 and Lys-221 are located within a region of CRALBP exhibiting sequence homology with the ligand binding cavity of yeast phosphatidylinositol-transfer protein, The data implicate Gin-210 and Lys-221 as components of the CRALBP retinoid binding cavity and are discussed in the context of ligand interactions in structurally or functionally related proteins with known crystallographic structures.	Adirondack Biomed Res Inst, Lake Placid, NY 12946 USA; Univ Washington, Dept Biochem & Ophthalmol, Seattle, WA 98195 USA; Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	University of Washington; University of Washington Seattle; Cornell University	Crabb, JW (corresponding author), Adirondack Biomed Res Inst, 10 Old Barn Rd, Lake Placid, NY 12946 USA.	jcrabb@cell-science.org			NATIONAL EYE INSTITUTE [P30EY001730] Funding Source: NIH RePORTER; NEI NIH HHS [EY02317, EY01730, EY06603] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507; CHEN Y, 1994, TECHNIQUES PROTEIN C, V5, P371; CHENG L, 1991, J BIOL CHEM, V266, P24404; CRABB JW, 1988, J BIOL CHEM, V263, P18678; Crabb JW, 1998, METH MOL B, V89, P91; Crabb JW, 1998, PROTEIN SCI, V7, P746, DOI 10.1002/pro.5560070324; CRABB JW, 1988, J BIOL CHEM, V263, P18688; Crabb JW, 1996, INVEST OPHTH VIS SCI, V37, P3691; CRABB JW, 1991, J BIOL CHEM, V266, P16674; CRABB JW, 1997, CURRENT PROTOCOLS PR, V7; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FUTTERMAN S, 1977, J BIOL CHEM, V252, P3267; INTRES R, 1994, J BIOL CHEM, V269, P25411; JACOBY IV, 1993, BIOCHEMISTRY-US, V32, P872; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; KAPRON JT, 1995, PROTEIN SCI S2, V4, P147; KAPRON JT, 1997, PROTEIN SCI, V6, P1; Kennedy BN, 1998, J BIOL CHEM, V273, P5591, DOI 10.1074/jbc.273.10.5591; KENNEDY BN, 1998, INVEST OPHTH VIS SCI, V39, P539; Kersten S, 1996, BIOCHEMISTRY-US, V35, P3816, DOI 10.1021/bi952737k; LONGSTAFF C, 1985, BIOCHEMISTRY-US, V25, P6311; Luck LA, 1997, TECH PROT CHEM, V8, P439, DOI 10.1016/S1080-8914(97)80044-0; Maw MA, 1997, NAT GENET, V17, P198, DOI 10.1038/ng1097-198; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; Norris AW, 1998, METH MOL B, V89, P123; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; Ong David E., 1994, P283; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SAARI JC, 1994, BIOCHEMISTRY-US, V33, P3106, DOI 10.1021/bi00176a045; Saari JC, 1997, GLIA, V21, P259; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SAARI JC, 1988, EXP EYE RES, V46, P569, DOI 10.1016/S0014-4835(88)80013-7; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; Saari John C., 1994, P351; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; STUBBS GW, 1979, J BIOL CHEM, V254, P8529; ZHANG JH, 1992, PROTEINS, V13, P87, DOI 10.1002/prot.340130202; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	45	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20712	20720		10.1074/jbc.273.33.20712	http://dx.doi.org/10.1074/jbc.273.33.20712			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694813	hybrid			2022-12-27	WOS:000075386100006
J	Gimenez-Roqueplo, AP; Celerier, J; Lucarelli, G; Corvol, P; Jeunemaitre, X				Gimenez-Roqueplo, AP; Celerier, J; Lucarelli, G; Corvol, P; Jeunemaitre, X			Role of N-glycosylation in human angiotensinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HUMAN RENIN; LINKED OLIGOSACCHARIDES; RAT ANGIOTENSINOGEN; HUMAN HYPERTENSION; EXPRESSION; PROTEIN; PLASMA; RADIOIMMUNOASSAY; HETEROGENEITY	Human angiotensinogen, the specific substrate of renin, is a heterogeneous glycoprotein constitutively secreted by the liver. Different glycosylation levels may be responsible for its heterogeneity. It contains four putative asparagine-linked glycosylation sites (Asn-X-Ser/Thr), Systematic site-directed mutagenesis (Asn replaced with Gin) of these four sites was undertaken, and 11 (single, double, triple, and quadruple (N-4)) mutants were produced in COS-7 and/or CHO-K1 cells and characterized. All of the sites were N-glycosylated with preferential glycosylation of the Asn(14) and the Asn(271). The suppression of the Asn(14) glycosylation site led to 5 times lower K-m and a 10 times lower k(cat). Angiotensinogen heterogeneity was much lower for the N-4 mutant protein, which produced a single form at 48 kDa. Pulse-chase experiments showed slight intracellular retention (15%) of the deglycosylated protein after 24 h, Interestingly, the N-4 mutant had a higher catalytic efficiency (k(cat)/K-m = 5.0 versus 1.6 mu M-1 . s(-1)) than the wild-type protein. The thermal stability of the N-4 protein was unaffected by deglycosylation, suggesting that it was correctly folded. This deglycosylated recombinant human angiotensinogen could be of value for x-ray crystallography studies.	Coll France, INSERM U36, Chair Med Expt & Endocrinol Renale, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France	Gimenez-Roqueplo, AP (corresponding author), Coll France, INSERM U36, Chair Med Expt & Endocrinol Renale, 3 Rue Ulm, F-75005 Paris, France.	jeunemaitre@hbroussais.fr	GIMENEZ-ROQUEPLO, Anne-Paule/T-6752-2018; JEUNEMAITRE, Xavier/AAQ-4853-2021	GIMENEZ-ROQUEPLO, Anne-Paule/0000-0002-4816-670X; JEUNEMAITRE, Xavier/0000-0001-5925-381X				CAMPBELL CJ, 1987, BIOCHEM J, V243, P121, DOI 10.1042/bj2430121; CAMPBELL DJ, 1984, ENDOCRINOLOGY, V114, P776, DOI 10.1210/endo-114-3-776; CLOUSTON W M, 1988, Genomics, V2, P240, DOI 10.1016/0888-7543(88)90008-0; Cohen P, 1996, J CLIN ENDOCR METAB, V81, P3505, DOI 10.1210/jc.81.10.3505; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; CUMIN F, 1987, BIOCHIM BIOPHYS ACTA, V913, P10, DOI 10.1016/0167-4838(87)90226-3; DO YS, 1984, J BIOL CHEM, V262, P1037; DOOLITTLE RF, 1983, SCIENCE, V222, P417, DOI 10.1126/science.6604942; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FENG W, 1995, J BIOL CHEM, V270, P11851, DOI 10.1074/jbc.270.20.11851; FERNLEY RT, 1986, EUR J BIOCHEM, V154, P597, DOI 10.1111/j.1432-1033.1986.tb09440.x; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; GENAIN C, 1984, J CLIN ENDOCR METAB, V59, P478, DOI 10.1210/jcem-59-3-478; GimenezRoqueplo AP, 1996, J BIOL CHEM, V271, P9838, DOI 10.1074/jbc.271.16.9838; GOULD AB, 1971, CARDIOVASC RES, V5, P86, DOI 10.1093/cvr/5.1.86; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HILGENFELDT U, 1987, MOL CELL ENDOCRINOL, V51, P211, DOI 10.1016/0303-7207(87)90030-X; HILGENFELDT U, 1988, MOL CELL ENDOCRINOL, V56, P91, DOI 10.1016/0303-7207(88)90012-3; INOUE I, 1995, J BIOL CHEM, V270, P11430, DOI 10.1074/jbc.270.19.11430; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; Kaetzel DM, 1996, BBA-PROTEIN STRUCT M, V1298, P250, DOI 10.1016/S0167-4838(96)00136-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mathews S, 1996, PROTEIN EXPRES PURIF, V7, P81, DOI 10.1006/prep.1996.0012; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; MOFFETT RB, 1987, BIOCHIM BIOPHYS ACTA, V912, P73; NAGASE M, 1994, BIOSCI BIOTECH BIOCH, V58, P1884, DOI 10.1271/bbb.58.1884; OKHUBO H, 1983, P NATL ACAD SCI USA, V80, P2196; PRINTZ MP, 1977, J BIOL CHEM, V252, P1654; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROITSCH T, 1989, EUR J BIOCHEM, V181, P525, DOI 10.1111/j.1432-1033.1989.tb14755.x; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SKEGGS LT, 1963, J EXP MED, V118, P73, DOI 10.1084/jem.118.1.73; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TEWKSBURY DA, 1981, BIOCHEM BIOPH RES CO, V99, P1311, DOI 10.1016/0006-291X(81)90762-2; TEWKSBURY DA, 1990, HYPERTENSION PATHOPH, P1197; THIBONNIER M, 1994, J BIOL CHEM, V269, P3304; vanBerkel PHC, 1996, BIOCHEM J, V319, P117, DOI 10.1042/bj3190117; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WEI L, 1988, BIOCHEM BIOPH RES CO, V156, P1103, DOI 10.1016/S0006-291X(88)80746-0	42	32	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21232	21238		10.1074/jbc.273.33.21232	http://dx.doi.org/10.1074/jbc.273.33.21232			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694881	hybrid			2022-12-27	WOS:000075386100074
J	Graham, JE; Richardson, JP				Graham, JE; Richardson, JP			rut sites in the nascent transcript mediate rho-dependent transcription termination in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRO MESSENGER-RNA; ESCHERICHIA-COLI; BACTERIOPHAGE-LAMBDA; HELICASE ACTIVITY; DNA INTERACTIONS; PROTEIN; ANTITERMINATION; BINDING; SEQUENCE; REQUIREMENT	The in vitro function of the coliphage lambda tR1 Rho-dependent terminator is governed primarily by a tripartite upstream sequence element designated rut. To determine the contribution of the different components of the rut site to terminator function in the normal context of coupled translation of the nascent cro message, tR1 variants lacking different rut site sequences were tested for terminator function in vivo. Intact rutA and rutB sequences were both necessary for efficient termination. However, deletion of the upstream rutA was far more detrimental than deletion of rutB. The intervening boxB, which encodes a short RNA stem and loop, could be deleted without reducing termination or detectably altering Rho's interaction with the corresponding cro transcript. The relative importance of these sequence elements was also the same in a minimal in vitro termination assay system. Rut sequences are therefore essential for terminator function in vivo and rutA contributes substantially more to tR1 function than does rutB. The relative contribution of these elements can be ascribed to differences in Rho's binding affinity for the encoded transcripts. If other cellular factors also bind the rut element RNA, they do not alter the relative contribution of its two regions to Rho-dependent transcription termination in vivo.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.	jrichard@bio.indiana.edu			NIAID NIH HHS [AI01042] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIFANO P, 1991, CELL, V64, P553; ANDREWS C, 1985, J BIOL CHEM, V260, P5826; CERUZZI MAF, 1985, J BIOL CHEM, V260, P9412; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; COURT D, 1980, J MOL BIOL, V138, P231, DOI 10.1016/0022-2836(80)90285-5; DAMBLY-CHAUDIERE C, 1983, Journal of Molecular and Applied Genetics, V2, P45; DAS A, 1993, ANNU REV BIOCHEM, V62, P893; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; FRIEDMAN DI, 1995, MOL MICROBIOL, V18, P191, DOI 10.1111/j.1365-2958.1995.mmi_18020191.x; FRIEDMAN DI, 1988, BACTERIOPHAGES, V2, P263; GALLUPPI G, 1976, RNA POLYMERASE, P657; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GREENBLATT J, 1993, NATURE, V364, P401, DOI 10.1038/364401a0; HART CM, 1991, J BIOL CHEM, V266, P24140; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; JAEGER JA, 1990, METHODS ENZYMOL, V183, P281; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LERNER CG, 1990, NUCLEIC ACIDS RES, V18, P4631, DOI 10.1093/nar/18.15.4631; LINN T, 1990, J BACTERIOL, V172, P1077, DOI 10.1128/jb.172.2.1077-1084.1990; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; Miller J. H., 1972, EXPT MOL GENETICS, pXVI; MILLER JH, 1992, SHORT COURSE BACTERI, P268; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; PATTERSON TA, 1994, J MOL BIOL, V236, P217, DOI 10.1006/jmbi.1994.1131; QIAN L, 1991, BIOTECHNIQUES, V10, P736; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; Richardson LV, 1996, J BIOL CHEM, V271, P21597, DOI 10.1074/jbc.271.35.21597; ROBERT J, 1987, CELL, V51, P483, DOI 10.1016/0092-8674(87)90644-1; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHNEIDER D, 1993, FASEB J, V7, P201, DOI 10.1096/fasebj.7.1.7678562; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; STEINMETZ EJ, 1994, P NATL ACAD SCI USA, V91, P1401, DOI 10.1073/pnas.91.4.1401; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7980, DOI 10.1021/bi963179s; WARREN F, 1984, P NATL ACAD SCI-BIOL, V81, P3612, DOI 10.1073/pnas.81.12.3612; Washburn RS, 1996, J MOL BIOL, V260, P347, DOI 10.1006/jmbi.1996.0405; ZALATAN F, 1992, J BIOL CHEM, V267, P19082; ZALATAN F, 1993, J BIOL CHEM, V268, P17051; ZOU LL, 1991, J BIOL CHEM, V266, P10201	51	27	28	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20764	20769		10.1074/jbc.273.33.20764	http://dx.doi.org/10.1074/jbc.273.33.20764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694820	hybrid			2022-12-27	WOS:000075386100013
J	Rane, MJ; Arthur, JM; Prossnitz, ER; McLeish, KR				Rane, MJ; Arthur, JM; Prossnitz, ER; McLeish, KR			Activation of mitogen-activated protein kinases by formyl peptide receptors is regulated by the cytoplasmic tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HUMAN NEUTROPHILS; SIGNAL-TRANSDUCTION; HL-60 CELLS; BETA-2-ADRENERGIC RECEPTOR; CHEMOATTRACTANT RECEPTOR; LEUCYL-PHENYLALANINE; COUPLED RECEPTORS; PHYSICAL COMPLEX; C5A RECEPTOR	Wild type formyl peptide receptors (FPRwt) and receptors deleted of the carboxyl-terminal 45 amino acids (FPRdel) were stably expressed in undifferentiated HL-60 promyelocytes. Expression of FPRwt reconstituted N-formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated extracellular signal-regulated kinase (ERK) and p38 kinase activity. Expression of FPRdel resulted in a 2-5-fold increase in basal ERK and p38 kinase activity, whereas FMLP failed to stimulate either mitogen-activated protein kinase (MAPK). Pertussis toxin abolished FMLP stimulation of both MAPKs in FPRwt cells but had no effect on either basal or FMLP-stimulated MAPK activity in FPRdel cells. FMLP stimulated a concentration-dependent increase in guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) binding in membranes from FPRwt but not FPRdel cells. GTP gamma S inhibited FMLP binding to FPRwt but not FPRdel membranes. Photoaffinity labeling with azidoanilide-[gamma-P-32]GTP in the presence or absence of FMLP showed increased labeling only in FPRwt membranes. Immunoprecipitation of alpha(i2) and alpha(q/11) from solubilized, photolabeled membranes showed that FPRwt were coupled to alpha(i2) but not to alpha(q/11). FPRwt cells demonstrated calcium mobilization following stimulation with FMLP, whereas FPRdel cells showed no increase in intracellular calcium. We conclude that the carboxyl-terminal tail of FPRs is necessary for ligand-mediated activation of G(i) proteins and MAPK cascades. Deletion of the carboxyl-terminal tail results in constitutive activation of ERK and p38 kinase through a G(i2)-independent pathway.	Univ Louisville, Kidney Dis Program, Hlth Sci Ctr, Dept Med, Louisville, KY 40202 USA; Univ Louisville, Hlth Sci Ctr, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Vet Affairs Med Ctr, Louisville, KY 40202 USA; Univ New Mexico, Hlth Sci Ctr, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA	University of Louisville; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of New Mexico; University of New Mexico's Health Sciences Center	McLeish, KR (corresponding author), Univ Louisville, Kidney Dis Program, Hlth Sci Ctr, Dept Med, 615 S Floyd St, Louisville, KY 40202 USA.		Prossnitz, Eric R./B-4543-2008; McLeish, Kenneth R./B-9819-2013	McLeish, Kenneth R./0000-0002-7816-3286; Arthur, John/0000-0003-4342-4762; Prossnitz, Eric/0000-0001-9190-8302	NIAID NIH HHS [AI36357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036357, R01AI036357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALI H, 1994, J BIOL CHEM, V269, P24557; AMATRUDA TT, 1995, J BIOL CHEM, V270, P28010; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Arthur JM, 1997, AM J PHYSIOL-RENAL, V273, pF129, DOI 10.1152/ajprenal.1997.273.1.F129; Avdi NJ, 1996, J BIOL CHEM, V271, P33598, DOI 10.1074/jbc.271.52.33598; BOMMAKANTI RK, 1993, J LEUKOCYTE BIOL, V54, P572, DOI 10.1002/jlb.54.6.572; BOMMAKANTI RK, 1992, J BIOL CHEM, V267, P7576; BOMMAKANTI RK, 1995, BIOCHEMISTRY-US, V34, P6720, DOI 10.1021/bi00020a017; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GIERSCHIK P, 1989, EUR J PHARM-MOLEC PH, V172, P481, DOI 10.1016/0922-4106(89)90031-X; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; JACOBS AA, 1995, J LEUKOCYTE BIOL, V57, P679, DOI 10.1002/jlb.57.4.679; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MCLEISH KR, 1989, BIOCHEM J, V260, P427, DOI 10.1042/bj2600427; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nick JA, 1997, J CLIN INVEST, V99, P975, DOI 10.1172/JCI119263; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; Okamoto Y, 1997, J BIOL CHEM, V272, P21589, DOI 10.1074/jbc.272.34.21589; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Prossnitz ER, 1997, J BIOL CHEM, V272, P15213, DOI 10.1074/jbc.272.24.15213; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1993, J IMMUNOL, V151, P5704; Rane MJ, 1997, J IMMUNOL, V159, P5070; Sambrook J., 2002, MOL CLONING LAB MANU; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SCHEPERS TM, 1992, J BIOL CHEM, V267, P159; SCHREIBER RE, 1994, J BIOL CHEM, V269, P326; Shi LC, 1996, J NEUROCHEM, V67, P1478; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; Xie W, 1997, J BIOL CHEM, V272, P24948, DOI 10.1074/jbc.272.40.24948; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	42	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20916	20923		10.1074/jbc.273.33.20916	http://dx.doi.org/10.1074/jbc.273.33.20916			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694839	hybrid			2022-12-27	WOS:000075386100032
J	Sugimoto, R; Yae, Y; Akaiwa, M; Kitajima, S; Shibata, Y; Sato, H; Hirata, J; Okochi, K; Izuhara, K; Hamasaki, N				Sugimoto, R; Yae, Y; Akaiwa, M; Kitajima, S; Shibata, Y; Sato, H; Hirata, J; Okochi, K; Izuhara, K; Hamasaki, N			Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; MANNOSE-BINDING PROTEIN; MOLECULAR-CLONING; FIBRINOGEN-LIKE; BAND-3 PROTEIN; COLLAGEN-LIKE; COLLECTINS; DOMAINS; COMPLEMENT; FICOLINS	The Hakata antigen is a novel, thermolabile beta(2)-macro-glycoprotein that reacts with sera from patients suffering from systemic lupus erythematosus. In this study we present the structure and the function of the Hakata antigen. We have identified cDNA clones encoding the Hakata antigen and analyzed its function. The cDNA included a possible open reading frame of 897 nucleotides, encoding 299 amino acids. The Hakata antigen consisted of a collagen-like domain in the middle section and a fibrinogen-like domain in the COOH terminus, both of which are homologous to human ficolin-1 and opsonin P35, indicating that these three molecules form a distinct family, The molecular mass of the Hakata antigen expressed in transfected cells was 35 kDa under reduced conditions, and it formed ladder bands under nonreducing conditions compatible with the previous result that the Hakata antigen exists in serum as homopolymers, Purified Hakata antigen sustained lectin activity, showing affinity with GalNAc, GlcNAc, D-fucose as mono/oligosaccharide, and lipopolysaccharides from Salmonella typhimurium and Salmonella minnesota. These results suggest that the Hakata antigen, a new member of the ficolin/opsonin P35 family, plays a role in the serum exerting lectin activity under physiological conditions.	Kyushu Univ, Dept Clin Chem & Lab Med, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Dept Anat, Fac Med, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Hamasaki, N (corresponding author), Kyushu Univ, Dept Clin Chem & Lab Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hamasaki@cclm.med.kyushu-u.ac.jp						Davies EJ, 1997, J RHEUMATOL, V24, P485; EPSTEIN WV, 1973, ARTHRITIS RHEUM-US, V16, P43, DOI 10.1002/art.1780160107; Fukutomi T, 1996, CLIN CHIM ACTA, V255, P93, DOI 10.1016/0009-8981(96)06393-0; Hamasaki N, 1997, J BIOCHEM-TOKYO, V122, P577; HARUMIYA S, 1995, J BIOCHEM-TOKYO, V117, P1029, DOI 10.1093/oxfordjournals.jbchem.a124802; Harumiya S, 1996, J BIOCHEM-TOKYO, V120, P745; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; INABA S, 1990, Fukuoka Acta Medica, V81, P284; Inaba S., 1978, IGAKU AYUM, V107, P690; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; LU J, 1990, J IMMUNOL, V144, P2287; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; Matsushita M, 1996, J BIOL CHEM, V271, P2448, DOI 10.1074/jbc.271.5.2448; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Ohashi T, 1997, J BIOL CHEM, V272, P14220, DOI 10.1074/jbc.272.22.14220; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; THIEL S, 1992, IMMUNOPHARMACOLOGY, V24, P91, DOI 10.1016/0162-3109(92)90015-5; TURNER MW, 1994, BIOCHEM SOC T, V22, P88, DOI 10.1042/bst0220088; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; YAE Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P369, DOI 10.1016/0167-4838(91)90158-V	27	181	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20721	20727		10.1074/jbc.273.33.20721	http://dx.doi.org/10.1074/jbc.273.33.20721			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694814	hybrid			2022-12-27	WOS:000075386100007
J	Rapaport, D; Brunner, M; Neupert, W; Westermann, B				Rapaport, D; Brunner, M; Neupert, W; Westermann, B			Fzo1p is a mitochondrial outer membrane protein essential for the biogenesis of functional mitochondria in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST REQUIRES; INHERITANCE; DNA; MAINTENANCE; CHAPERONE; DYNAMIN; FUSION; GENE; SNAP	Fzo1p is a novel component required for the biogenesis of functional mitochondria in the yeast Saccharomyces cerevisiae. The protein is homologous to Drosophila Fzo, the first known protein mediator of mitochondrial fusion. Deletion of the FZO1 gene results in a petite phenotype, loss of mitochondrial DNA, and a fragmented mitochondrial morphology. Fzo1p is an integral protein of the mitochondrial outer membrane exposing its major part to the cytosol, It is imported into the outer membrane in a receptor-dependent manner. Fzo1p is part of a larger protein complex of 800 kDa, and presumably is the first identified component of the yeast mitochondrial fusion machinery.	Univ Munchen, Inst Physiol Chem Physikal Biochem & Zellbiol, D-80336 Munchen, Germany	University of Munich	Neupert, W (corresponding author), Univ Munchen, Inst Physiol Chem Physikal Biochem & Zellbiol, Goethestr 33, D-80336 Munchen, Germany.	neupert@bio.med.uni-muenchen.de	Westermann, Benedikt/H-7766-2013	Westermann, Benedikt/0000-0002-2991-1604; Brunner, Michael/0000-0001-9798-3047				Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; Berger KH, 1997, J CELL BIOL, V136, P545, DOI 10.1083/jcb.136.3.545; BURGESS SM, 1994, J CELL BIOL, V126, P1375, DOI 10.1083/jcb.126.6.1375; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GUAN KL, 1993, CURR GENET, V24, P141, DOI 10.1007/BF00324678; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HELM R, 1995, NATURE, V373, P663; Hermann GJ, 1997, J CELL BIOL, V137, P141, DOI 10.1083/jcb.137.1.141; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; HERRMANN JM, 1994, J CELL BIOL, V127, P893, DOI 10.1083/jcb.127.4.893; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCCONNELL SJ, 1993, SCIENCE, V260, P687, DOI 10.1126/science.8480179; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; PON L, 1991, MOL CELLULAR BIOL YE, P333; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Sambrook J., 2002, MOL CLONING LAB MANU; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; SOGO LF, 1994, J CELL BIOL, V126, P1361, DOI 10.1083/jcb.126.6.1361; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; STEWART LC, 1991, J CELL BIOL, V115, P1249, DOI 10.1083/jcb.115.5.1249; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Yaffe MP, 1997, CURR BIOL, V7, pR782, DOI 10.1016/S0960-9822(06)00404-0	33	285	295	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20150	20155		10.1074/jbc.273.32.20150	http://dx.doi.org/10.1074/jbc.273.32.20150			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685359	hybrid			2022-12-27	WOS:000075305400036
J	Sepp-Lorenzino, L; Rosen, N				Sepp-Lorenzino, L; Rosen, N			A farnesyl-protein transferase inhibitor induces p21 expression and G(1) block in p53 wild type tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; DNA-DAMAGE; FARNESYLTRANSFERASE INHIBITORS; NUCLEAR ANTIGEN; GROWTH; REPLICATION; MICE; PCNA; SUPPRESSION; RESISTANCE	Farnesylation is required for the membrane partition and function of several proteins, including Ras. Farnesyl-protein transferase inhibitors (FTIs) were developed to prevent Ras processing and thus to be effective agents for the treatment of cancers harboring mutated ras. However, FTIs inhibit the growth of most tumor cells and several xenograft models, irrespective of whether they possess mutated ras, Furthermore, the antiproliferative effect is not correlated with inhibition of Ki-Ras processing; tumors with wild type ras are inhibited, and FTIs are not particularly toxic. These data suggest that the mechanism of FTI action is complex and may involve other targets besides Ras, To begin to understand how FTIs work, we investigated the mechanism of growth inhibition. FTI causes G(1) arrest in a subset of sensitive lines. This is accomplished by transcriptional induction of p21, which mediates the inhibition of cyclin E-associated protein kinase activity, pRb hypophosphorylation and inhibition of DNA replication. Induction of p21 is p53-dependent; it does not occur in cells with mutant p53 or in cells expressing human papillomavirus E6, However, neither p53 nor p21 are required for inhibition of cell proliferation. FTI still blocks the growth of cells deficient in these proteins. In the absence of p21, G(1) block is relaxed, DNA replication is not affected, and cells become polyploid and undergo apoptosis. These results suggest that farnesylated protein(s) may be involved in regulating p53 function and in coordinating entrance into S, and that the consequences of FTI treatment are a function of the other mutations found in the tumor cell.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sepp-Lorenzino, L (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 333, New York, NY 10021 USA.	l-sepp@ski.mskcc.org	Rosen, Neal/ABF-2677-2020		NATIONAL CANCER INSTITUTE [P50CA068425] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA68425-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN X, 1995, CANCER RES, P4257; Coleman P S, 1997, Subcell Biochem, V28, P363; Cox AD, 1997, BBA-REV CANCER, V1333, pF51, DOI 10.1016/S0304-419X(97)00011-5; DelSal G, 1996, ONCOGENE, V12, P177; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GIARETTI W, 1994, METHOD CELL BIOL, V41, P389; Gibbs JB, 1996, BREAST CANCER RES TR, V38, P75, DOI 10.1007/BF01803786; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Li XS, 1996, CANCER RES, V56, P5055; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Miquel K, 1997, CANCER RES, V57, P1846; NUSSE M, 1990, CYTOMETRY, V11, P813, DOI 10.1002/cyto.990110707; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Prendergast GC, 1996, CANCER RES, V56, P2626; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SPITKOVSKY D, 1995, ONCOGENE, V10, P2421; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; VOJTESEK B, 1993, J CELL SCI, V105, P607; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; Zhang FL, 1997, J BIOL CHEM, V272, P10232; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	46	101	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20243	20251		10.1074/jbc.273.32.20243	http://dx.doi.org/10.1074/jbc.273.32.20243			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685373	hybrid			2022-12-27	WOS:000075305400050
J	Trocme, C; Gaudin, P; Berthier, S; Barro, C; Zaoui, P; Morel, F				Trocme, C; Gaudin, P; Berthier, S; Barro, C; Zaoui, P; Morel, F			Human B lymphocytes synthesize the 92-kDa gelatinase, matrix metalloproteinase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONONUCLEAR PHAGOCYTES; IV COLLAGENASE GELATINASE; HUMAN T-LYMPHOCYTES; IN-VITRO; NEUTROPHIL GELATINASE; CYTOKINE REGULATION; BASEMENT-MEMBRANE; TISSUE INHIBITOR; GENE-EXPRESSION; CELLS	Matrix metalloproteinases (MMPs) are involved in the remodeling of connective tissue as well as in disease states associated with acute and chronic inflammation or tumoral metastatic processes. Despite detailed and extensive studies of the mechanisms of lymphocyte extravasation, remarkably little is known about the expression and regulation of metalloproteinases involved in the migratory process. By using zymography and reverse transcription-polymerase chain reaction experiments, we have demonstrated that Epstein-Barr virus-immortalized B lymphocytes are able to secrete a 92-kDa metalloproteinase with gelatinolytic activity which has been purified and identified as being MMP-9. Moreover, the tissue inhibitor of metalloproteinase was shown to be constitutively expressed by the B cells. The expression of 92-kDa gelatinase is mediated by cytokines, growth factors, lipopolysaccharide, concanavalin A, and the tumor promotor phorbol 12-myristate 13-acetate. Time dependence activity increased rapidly up to 24 h of incubation with lipopolysaccharide or concanavalin A stimulation while it requires a delay and more time to have an optimum effect when cytokines were the stimulating agents; transforming growth factor-p abolished 92-kDa gelatinase production. Both staurosporine and wortmannin are inductive stimuli, and the level of MMP-9 secreted into the media is greater than that observed with other agents except concanavalin A. Elicitation of the chemotactic migration of B cells through a model basement membrane by lipopolysaccharide was shown to be correlated with gelatinase expression and inhibited by 7 mM captopril. Our study indicates that Epstein-Barr virus-B lymphocytes express 92-kDa gelatinase, the production of which can be modified by a variety of physiological and pharmacological signals which have been shown to differ according to the cell type.	CHU Albert Michallon, Enzymol Lab, UPR ES EA 2019, GREPI, F-38043 Grenoble 9, France; CHU Albert Michallon, Serv Rhumatol, F-38043 Grenoble 9, France; CHU Albert Michallon, Serv Nephrol, F-38043 Grenoble 9, France	CHU Grenoble Alpes; CHU Grenoble Alpes; CHU Grenoble Alpes	Morel, F (corresponding author), CHU Albert Michallon, Enzymol Lab, UPR ES EA 2019, GREPI, BP 217, F-38043 Grenoble 9, France.							AUMAILLEY M, 1993, M S-MED SCI, V9, P926, DOI 10.4267/10608/3013; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Buisson AC, 1996, J CELL PHYSIOL, V166, P413, DOI 10.1002/(SICI)1097-4652(199602)166:2<413::AID-JCP20>3.0.CO;2-A; BUSIEK DF, 1995, J IMMUNOL, V154, P6484; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHENTANUGI L, 1991, EUR J BIOCHEM, V202, P649, DOI 10.1111/j.1432-1033.1991.tb16419.x; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; FABRY Z, 1995, J IMMUNOL, V155, P325; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Houde M, 1996, BBA-MOL CELL RES, V1310, P193, DOI 10.1016/0167-4889(95)00167-0; ITOH Y, 1995, J BIOL CHEM, V270, P16518, DOI 10.1074/jbc.270.28.16518; LACRAZ S, 1994, J BIOL CHEM, V269, P22027; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEPPERT D, 1995, J IMMUNOL, V154, P4379; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MAINARDI CL, 1988, CONTROL TISSUE DAMAG, P139; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; MOREL F, 1993, BIOCHEM BIOPH RES CO, V191, P269, DOI 10.1006/bbrc.1993.1212; MOREL F, 1994, BBA-GEN SUBJECTS, V1201, P373, DOI 10.1016/0304-4165(94)90065-5; MURPHY G, 1995, METHOD ENZYMOL, V248, P470; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; POURMOTABBED T, 1994, BBA-PROTEIN STRUCT M, V1204, P97, DOI 10.1016/0167-4838(94)90038-8; Powell WC, 1996, CURR TOP MICROBIOL, V213, P1; RIES C, 1995, BIOL CHEM H-S, V376, P345; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; Sato T, 1996, FEBS LETT, V392, P175, DOI 10.1016/0014-5793(96)00808-3; SHOSHAN MC, 1992, J CELL BIOCHEM, V55, P496; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Smith WB, 1996, J IMMUNOL, V157, P360; SORBI D, 1993, KIDNEY INT, V44, P1266, DOI 10.1038/ki.1993.378; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; WEEKS BS, 1993, J CELL PHYSIOL, V157, P644, DOI 10.1002/jcp.1041570326; WERB Z, 1989, TXB RHEUMATOLOGY, P248; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINWOOD PJ, 1995, HEPATOLOGY, V22, P304; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WOESSNER JF, 1995, METHOD ENZYMOL, V248, P510; Xia MH, 1996, J IMMUNOL, V156, P160; Yao PM, 1996, J BIOL CHEM, V271, P15580, DOI 10.1074/jbc.271.26.15580; Zaoui P, 1996, BBA-GEN SUBJECTS, V1290, P101, DOI 10.1016/0304-4165(96)00008-6; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	51	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20677	20684		10.1074/jbc.273.32.20677	http://dx.doi.org/10.1074/jbc.273.32.20677			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685427	hybrid			2022-12-27	WOS:000075305400104
J	Mitoma, J; Kasama, T; Furuya, S; Hirabayashi, Y				Mitoma, J; Kasama, T; Furuya, S; Hirabayashi, Y			Occurrence of an unusual phospholipid, phosphatidyl-L-threonine, in cultured hippocampal neurons - Exogenous L-serine is required for the synthesis of neuronal phosphatidyl-L-serine and sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIN-LAYER CHROMATOGRAMS; HAMSTER OVARY CELLS; CEREBROSPINAL-FLUID; BIOSYNTHESIS; GROWTH; METABOLISM; REAGENT; ENZYME; BRAIN	We have recently reported that L-serine released hom astroglial cells supports the survival and neuritogenesis of hippocampal neurons under a serum- and glia-free culture condition (Mitoma, J., Furuya, S., and Hiraba-yashi, Y. (1998) Neurosci. Res. 30, 195-199). In this study, we show that exogenous L-serine is required for the synthesis of phosphatidyl-L-serine (PS) and sphingolipids in hippocampal neurons. When hippocampal neurons were maintained under an astroglial cell-fi ee condition, the levels of sphingolipids and phosphatidyl-L serine in the neurons were greatly reduced in the absence of external L-serine or glycine, Instead, a novel phospholipid appeared just ahead of PS on TLC. This novel lipid was determined to be phosphatidyl-L-threonine by TLC blotting/negative secondary ion mass spectrometry and amino acid analysis. Biochemical studies on rat brain microsomes have indicated that phosphatidyl-L-threonine is synthesized by the base exchange enzyme that is involved in PS synthesis with much lower affinity, that is, approximately 1/150 of L-serine. Addition of L-serine or glycine to the culture medium restored the synthesis of PS and sphingolipids in the neurons. These observations show that hippocampal neurons require exogenous L-serine for the synthesis of PS and sphingolipids in the absence of astroglial cells and suggested that astroglial cells contribute to neuronal lipid synthesis through the supply of L-serine.	RIKEN, Inst Phys & Chem Res, Lab Cellular Glycobiol, Frontier Res Program, Wako, Saitama 3510198, Japan; RIKEN, Inst Phys & Chem Res, Special Postdoctoral Researchers Program, Wako, Saitama 3510198, Japan; Tokyo Med & Dent Univ, Instrumental Anal Res Ctr Life Sci, Bunkyo Ku, Tokyo 1138510, Japan	RIKEN; RIKEN; Tokyo Medical & Dental University (TMDU)	Hirabayashi, Y (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cellular Glycobiol, Frontier Res Program, Wako, Saitama 3510198, Japan.	hirabaya@postman.riken.go.jp		Furuya, Shigeki/0000-0001-9020-3597; Hirabayashi, Yoshio/0000-0002-5774-7354				BELL RM, 1991, J BIOL CHEM, V266, P4661; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Furuya S, 1998, J NEUROCHEM, V71, P366; FURUYA S, 1995, J NEUROCHEM, V65, P1551; HANADA K, 1992, J BIOL CHEM, V267, P23527; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HIDARI KIPJ, 1993, BIOCHEM J, V296, P259, DOI 10.1042/bj2960259; HIRABAYASHI Y, 1986, BIOCHIM BIOPHYS ACTA, V876, P178; IGARASHI H, 1958, NATURE, V181, P1282, DOI 10.1038/1811282a0; Irie F., 1997, Society for Neuroscience Abstracts, V23, P1156; KANFER JN, 1992, METHOD ENZYMOL, V209, P341; KUGE O, 1986, J BIOL CHEM, V261, P5795; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P620; MARKMALCHOFF D, 1977, BIOCHEM BIOPH RES CO, V75, P589, DOI 10.1016/0006-291X(77)91513-3; MARKMALCHOFF D, 1978, BIOCHEMISTRY-US, V17, P2684, DOI 10.1021/bi00606a035; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.3.CO;2-Q; Mitoma J, 1998, NEUROSCI RES, V30, P195, DOI 10.1016/S0168-0102(97)00113-2; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; RYU EK, 1979, J LIPID RES, V20, P561; SASTRY PS, 1985, PROG LIPID RES, V24, P69, DOI 10.1016/0163-7827(85)90011-6; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; Skipski V.P., 1969, METHOD ENZYMOL, V14, P530; SNELL ME, 1986, J ASSOC PERS SEVERE, V11, P1; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; TAKI T, 1994, ANAL BIOCHEM, V223, P232, DOI 10.1006/abio.1994.1579; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	28	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19363	19366		10.1074/jbc.273.31.19363	http://dx.doi.org/10.1074/jbc.273.31.19363			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677350	hybrid			2022-12-27	WOS:000075125200002
J	Simpson, RU; O'Connell, TD; Pan, QT; Newhouse, J; Somerman, MJ				Simpson, RU; O'Connell, TD; Pan, QT; Newhouse, J; Somerman, MJ			Antisense oligonucleotides targeted against protein kinase CP and C beta II block 1,25-(OH)(2)D-3-induced differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; RAT OSTEOCALCIN GENE; D ENDOCRINE SYSTEM; TRANSCRIPTIONAL REGULATION; MYC PROTOONCOGENE; BINDING PROTEINS; EXPRESSION; 1,25-DIHYDROXYVITAMIN-D3; RECEPTORS; VITAMIN-D3	It is now recognized that protein kinase C (PKC) plays a critical role in 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3) promotion of HL-60 cell differentiation. In this study, the effects of phosphorothioate antisense oligonucleotides directed against PRC alpha, PKC beta, PKC beta I, and PKC beta II on HL-60 promyelocyte cell differentiation and proliferation were examined. Cellular differentiation was determined by nonspecific esterase activity, nitro blue tetrazolium reduction, and CD14 surface antigen expression. Differentiation promoted by 1,25-(OH)(2)D-3 (20 nM for 48 h) was inhibited similarly in cells treated with PKC beta antisense (30 mu M) 24 h prior to or at the same time as hormone treatment (86 +/- 9% inhibition; n = 4 versus 82 +/- 8% inhibition; n = 4 (mean +/- S.E.), respectively). In contrast, cells treated with PKC beta antisense 24 h after 1,25-(OH)(2)D-3 were unaffected and fully differentiated. PKC alpha antisense did not block 1,25-(OH)(2)D-3 promotion of HL-60 cell differentiation. Next, the ability of PKC beta I- and PKC beta II-specific antisense oligonucleotides to block 1,25-(OH)(2)D-3 promotion of cell differentiation was examined. PKC beta II antisense (30 mu M) completely blocked CD14 expression induced by 1,25-(OH)(2)D-3, whereas PRC beta I antisense had little effect. Interestingly, PKC beta II antisense blocked differentiation by 87 +/- 7% (n = 2, mean +/- S.D.) but had no effect on 1,25-(OH)(2)D-3 inhibition of cellular proliferation. These results indicate that the effects of 1,25-(OH)(2)D-3 on HL-60 cell differentiation and proliferation can be dissociated by blocking PKC beta II expression.	Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Periodont Prevent Geriatr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Simpson, RU (corresponding author), Univ Michigan, Dept Pharmacol, 2301D MSRB III, Ann Arbor, MI 48109 USA.		O'Connell, Timothy/D-5048-2013; Pan, Quintin/E-3808-2011		NIDCR NIH HHS [DE 10337] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010337] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BELLIDO T, 1991, VITAMIN D, P409; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRELVI ZS, 1986, LAB INVEST, V55, P269; Darwish HM, 1996, PROG NUCLEIC ACID RE, V53, P321, DOI 10.1016/S0079-6603(08)60149-X; DESAI RK, 1995, ENDOCRINOLOGY, V136, P5685, DOI 10.1210/en.136.12.5685; DEVALIA V, 1992, BLOOD, V80, P68; GAMARD CJ, 1994, CELL GROWTH DIFFER, V5, P405; HAUSSLER MR, 1995, BONE, V17, pS33, DOI 10.1016/8756-3282(95)00205-R; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOFFMANN J, 1997, FASEB J, V11, P649; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MANGELSDORF DJ, 1984, J CELL BIOL, V98, P391, DOI 10.1083/jcb.98.2.391; MARTELL RE, 1992, J BIOL CHEM, V267, P7511; MARTELL RE, 1987, J BIOL CHEM, V262, P5570; MARTELL RE, 1988, BIOCHEM PHARMACOL, V37, P635, DOI 10.1016/0006-2952(88)90136-0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORMAN AW, 1982, ENDOCR REV, V3, P331, DOI 10.1210/edrv-3-4-331; OBEID LM, 1990, J BIOL CHEM, V265, P2370; OCONNELL TD, ENDOCRINOLOGY, V136, P482; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Pan Q, 1997, BIOCHEM PHARMACOL, V54, P909, DOI 10.1016/S0006-2952(97)00286-4; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; SIMPSON RU, 1985, J BIOL CHEM, V260, P8882; SIMPSON RU, 1989, J BIOL CHEM, V264, P19710; SIMPSON RU, 1987, J BIOL CHEM, V262, P4104; SOLOMON DH, 1991, CELL GROWTH DIFFER, V2, P187; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; VANLEEUWEN JPTM, 1992, J BIOL CHEM, V267, P12562; WALI RK, 1990, J CLIN INVEST, V85, P1296, DOI 10.1172/JCI114567; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; WEAVER VM, 1992, CELL SIGNAL, V4, P293, DOI 10.1016/0898-6568(92)90069-K; YONEDA T, 1991, ENDOCRINOLOGY, V129, P683, DOI 10.1210/endo-129-2-683	36	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19587	19591		10.1074/jbc.273.31.19587	http://dx.doi.org/10.1074/jbc.273.31.19587			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677384	hybrid			2022-12-27	WOS:000075125200036
J	Baharians, Z; Schonthal, AH				Baharians, Z; Schonthal, AH			Autoregulation of protein phosphatase type 2A expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTER OKADAIC ACID; ELONGATION FACTOR-II; CATALYTIC SUBUNIT; CELL-CYCLE; GENE EXPRESSIONS; PHOSPHORYLATION; INITIATION; PROLIFERATION; SEQUENCE; ANTIGEN	Protein phosphatases are involved in many cellular processes. One of the most abundant of these enzymes, the serine/threonine-specific protein phosphatase type 2A (PP2A), is present in most eukaryotic cells and serves a variety of functions. However, the detailed study of its regulation and function has been hampered by the difficulty of manipulating its expression level in cell culture. By using a new mammalian expression vector to forcibly overexpress PP2A in the mouse fibroblast cell line NIH3T3, we now show that the catalytic subunit of PP2A is subject to a potent autoregulatory mechanism that adjusts PP2A protein to constant levels. This control is exerted at the translational level and does not involve regulation of transcription or RNA processing. Thus, our results demonstrate tight control of PP2A expression, and provide an explanation for the difficulty of increasing PP2A expression experimentally.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Southern California	Schonthal, AH (corresponding author), Univ So Calif, Dept Microbiol, HMR-405,2011 Zonal Ave, Los Angeles, CA 90033 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653	NCI NIH HHS [R29CA74278-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074278] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; Andjelkovic N, 1996, EMBO J, V15, P7156, DOI 10.1002/j.1460-2075.1996.tb01107.x; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRAUTIGAN DL, 1995, SEMIN CANCER BIOL, V6, P211, DOI 10.1006/scbi.1995.0028; BUSS WC, 1994, BIOCHEM PHARMACOL, V48, P1459, DOI 10.1016/0006-2952(94)90571-1; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Harlow E., 1988, ANTIBODIES LAB MANUA; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; KAKINOKI Y, 1992, BIOCHEM BIOPH RES CO, V185, P291, DOI 10.1016/S0006-291X(05)80989-1; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; Kikuchi K, 1997, CANCER DETECT PREV, V21, P36; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; LEE J, 1993, J BIOL CHEM, V268, P19192; LEE TH, 1995, SEMIN CANCER BIOL, V6, P203, DOI 10.1006/scbi.1995.0027; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAKAMURA K, 1992, BIOCHEM BIOPH RES CO, V187, P507, DOI 10.1016/S0006-291X(05)81523-2; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; RONNE H, 1991, MOL CELL BIOL, V11, P4876, DOI 10.1128/MCB.11.10.4876; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1992, NEW BIOL, V4, P16; SCHONTHAL AH, 1995, SEMIN CANCER BIOL, V6, P239, DOI 10.1006/scbi.1995.0031; SHEAY W, 1993, BIOTECHNIQUES, V15, P856; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; THOMAS G, 1977, EXP CELL RES, V108, P253, DOI 10.1016/S0014-4827(77)80032-3; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WELSH GI, 1994, BIOCHEM BIOPH RES CO, V201, P1279, DOI 10.1006/bbrc.1994.1843; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; XIE HY, 1994, J BIOL CHEM, V269, P1981; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	47	119	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19019	19024		10.1074/jbc.273.30.19019	http://dx.doi.org/10.1074/jbc.273.30.19019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668082	hybrid			2022-12-27	WOS:000074974700049
J	Spillmann, AA; Bandtlow, CE; Lottspeich, F; Keller, F; Schwab, ME				Spillmann, AA; Bandtlow, CE; Lottspeich, F; Keller, F; Schwab, ME			Identification and characterization of a bovine neurite growth inhibitor (bNI-220)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MYELIN-ASSOCIATED GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCAN; RAT SPINAL-CORD; CELL-ADHESION MOLECULES; CNS WHITE MATTER; OPTIC-NERVE; AXONAL REGENERATION; NEURONAL PLASTICITY; CORTICOSPINAL TRACT	The poor axonal regeneration that follows lesions of the central nervous system (CNS) is crucially influenced by the local CNS tissue environment through which neurites have to grow. In addition to an inhibitory role of the glial scar, inhibitory substrate effects of CNS myelin and oligodendrocytes have been demonstrated. Several proteins including NI-35/250, myelin-associated glycoprotein, tenascin-R, and NG-2 have been described to have neurite outgrowth inhibitory or repulsive properties in vitro. Antibodies raised against NI-35/250 (monoclonal antibody IN-1) were shown to partially neutralize the growth inhibitory effect of CNS myelin and oligodendrocytes, and to result in long distance! fiber regeneration in the lesioned adult mammalian CNS in vivo, We report here the purification of a myelin protein to apparent homogeneity from bovine spinal; cord which exerts a potent neurite outgrowth inhibitory effect on PC12 cells and chick dorsal root ganglion cells, induces collapse of growth cones of chick dorsal root ganglion cells, and also inhibits the spreading of 3T3 fibroblasts, These activities could be neutralized by the monoclonal antibody IN-1, The purification procedure includes detergent solubilization, anion exchange chromatography, gel filtration, and elution from high resolution SDS-polyacrylamide gel electrophoresis. The active protein has a molecular mass of 220 kDa and an isoelectric point between 5.9 and 6.2, Its inhibitory activity is sensitive to protease treatment and resists harsh treatments like 9 M urea or short heating, Glycosylation is, if present at all, not detectable. Microsequencing resulted ill six peptides and strongly suggests that this proteins is novel.	Univ Zurich, Brain Res Inst, CH-8029 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8029 Zurich, Switzerland; Genzentrum Martinsried, D-82152 Martinsried, Germany	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bandtlow, CE (corresponding author), Univ Zurich, Brain Res Inst, August Forelstr 1, CH-8029 Zurich, Switzerland.		Schwab, Martin E/B-6818-2016	Keller, Flavio/0000-0002-6449-6960				AMBERGER VR, 1994, CANCER RES, V54, P4017; AVELDANO MI, 1991, J NEUROCHEM, V57, P250, DOI 10.1111/j.1471-4159.1991.tb02122.x; Baka ID, 1996, MOL CELL NEUROSCI, V7, P289, DOI 10.1006/mcne.1996.0022; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; Bandtlow C, 1996, EUR J BIOCHEM, V241, P468, DOI 10.1111/j.1432-1033.1996.00468.x; BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; BARTSCH U, 1995, NEURON, V15, P1376; BASTMEYER M, 1991, J NEUROSCI, V11, P626; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BOXBERG YV, 1988, ANAL BIOCHEM, V169, P372, DOI 10.1016/0003-2697(88)90298-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; CARBONETTO S, 1987, J NEUROSCI, V7, P610; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen M. S., 1997, Society for Neuroscience Abstracts, V23, P1723; Clarke GA, 1997, EUR J NEUROSCI, V9, P334, DOI 10.1111/j.1460-9568.1997.tb01403.x; CLARKE GA, 1994, J CELL SCI, V107, P3393; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; CONN P, 1990, CELL CULTURE METHODS; CRUTCHER KA, 1989, ANN NEUROL, V26, P580, DOI 10.1002/ana.410260414; CRUTCHER KA, 1989, EXP NEUROL, V104, P39, DOI 10.1016/0014-4886(89)90007-1; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVID S, 1995, J NEUROSCI RES, V42, P594, DOI 10.1002/jnr.490420417; DOU CL, 1994, J NEUROSCI, V14, P7616; FAWCETT JW, 1989, J CELL SCI, V92, P93; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HASAN SJ, 1991, RESTOR NEUROL NEUROS, V2, P137, DOI 10.3233/RNN-1991-2303; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KAPFHAMMER JP, 1994, J COMP NEUROL, V340, P194, DOI 10.1002/cne.903400206; KAPFHAMMER JP, 1994, EUR J NEUROSCI, V6, P403, DOI 10.1111/j.1460-9568.1994.tb00283.x; KEIRSTEAD HS, 1992, P NATL ACAD SCI USA, V89, P11664, DOI 10.1073/pnas.89.24.11664; KOBAYASHI H, 1995, DEV BIOL, V168, P383, DOI 10.1006/dbio.1995.1088; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG DM, 1995, J NEUROSCI, V15, P99; Li M, 1996, J NEUROSCI RES, V46, P404, DOI 10.1002/(SICI)1097-4547(19961115)46:4<404::AID-JNR2>3.3.CO;2-W; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MEIRI KF, 1988, J NEUROSCI, V8, P2571; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Ng WP, 1996, BRAIN RES, V720, P17, DOI 10.1016/0006-8993(96)00062-5; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PAGANETTI PA, 1988, J CELL BIOL, V107, P2281, DOI 10.1083/jcb.107.6.2281; PERSSON H, 1990, ELECTROPHORESIS, V11, P642, DOI 10.1002/elps.1150110812; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; Rubin BP, 1995, EUR J NEUROSCI, V7, P2524, DOI 10.1111/j.1460-9568.1995.tb01052.x; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; SAVIO T, 1989, J NEUROSCI, V9, P1126; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, NEUROCHEM RES, V21, P755, DOI 10.1007/BF02532297; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SCHWEGLER G, 1995, J NEUROSCI, V15, P2756; Settles DL, 1997, J NEUROSCI RES, V47, P109; Small DH, 1996, J NEUROCHEM, V67, P889; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; Spillmann AA, 1997, EUR J NEUROSCI, V9, P549, DOI 10.1111/j.1460-9568.1997.tb01631.x; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Towbin H, 1979, 10 1073 PNAS 76 9 43, V76, P4350, DOI [10.1073/pnas.76.9.4350, DOI 10.1073/PNAS.76.9.4350]; TUTTLE R, 1991, J NEUROSCI METH, V39, P193, DOI 10.1016/0165-0270(91)90085-E; VARGA ZM, 1995, P NATL ACAD SCI USA, V92, P10959, DOI 10.1073/pnas.92.24.10959; WATANABE E, 1995, EUR J NEUROSCI, V7, P547, DOI 10.1111/j.1460-9568.1995.tb00659.x; WEHRLEHALLER B, 1993, J CELL SCI, V106, P597; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; Wilson DJA, 1996, J CELL SCI, V109, P3129; WINTERGERST ES, 1993, EUR J NEUROSCI, V5, P299, DOI 10.1111/j.1460-9568.1993.tb00497.x; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744	80	122	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19283	19293		10.1074/jbc.273.30.19283	http://dx.doi.org/10.1074/jbc.273.30.19283			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668118	hybrid			2022-12-27	WOS:000074974700085
J	Hesslinger, C; Kremmer, E; Hultner, L; Ueffing, M; Ziegler, I				Hesslinger, C; Kremmer, E; Hultner, L; Ueffing, M; Ziegler, I			Phosphorylation of GTP cyclohydrolase I and modulation of its activity in rodent mast cells - GTP cyclohydrolase I hyperphosphorylation is coupled to high affinity IgE receptor signaling and involves protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; TETRAHYDROBIOPTERIN SYNTHESIS; INTERFERON-GAMMA; IMMUNOGLOBULIN-E; SENSITIVE ASSAY; MESSENGER-RNA; RAT; ACTIVATION; EXPRESSION; SUBSTRATE	GTP cyclohydrolase I controls the de novo pathway for the synthesis of tetrahydrobiopterin, which is the essential cofactor for tryptophan 5-monooxygenase and thus, for serotonin production. In mouse bone marrow-derived mast cells, the kit Ligand selectively up-regulates GTP cyclohydrolase I activity (Ziegler, I., Hultner, L., Egger, D., Kempkes, B., Mailhammer, R., Gillis, S., and Rodl, W. (1993) J. Biol. Chem. 268, 12544-12551), Immunoblot analysis now confirms that this long term enhancement is caused by increased expression of the enzyme. Furthermore we show that GTP cyclohydrolase I is subject to modification at the post-translational level. In vivo labeling with [P-32]orthophosphate demonstrates that in primary mast cells and in transfected RBL-2H3 cells overexpressing GTP cyclohydrolase I, the enzyme exists in a phosphorylated form, Antigen binding to the high affinity receptor for IgE triggers an additional and transient phosphorylation of GTP cyclohydrolase I with a concomitant rise in its activity, and in consequence, cellular tetrahydrobiopterin levels increase, These events culminate 8 min after stimulation and call be mimicked by phorbol ester. The hyperphosphorylation is greatly reduced by the protein kinase C inhibitor Ro-31-8220. In vitro phosphorylation studies indicate that GTP cyclohydrolase I is a substrate for both casein kinase II and protein kinase C.	GSF, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany; GSF, Inst Immunol, D-81377 Munich, Germany; GSF, Inst Expt Hamatol, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Hesslinger, C (corresponding author), GSF, Inst Klin Mol Biol & Tumorgenet, Marchioninistr 25, D-81377 Munich, Germany.	hesslinger@gsf.de						ALBER G, 1992, J IMMUNOL, V149, P2428; BELL RM, 1991, J BIOL CHEM, V266, P4661; BENHAMOU M, 1997, IGE RECEPTOR FCERI F, P33; DAVIS MD, 1988, EUR J BIOCHEM, V173, P345, DOI 10.1111/j.1432-1033.1988.tb14004.x; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DUTCH DS, 1991, J NUTR BIOCH, V2, P411; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GERMANO P, 1994, J BIOL CHEM, V269, P23102; Gutlich M, 1996, BIOCHEM J, V314, P95; GUTLICH M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P133, DOI 10.1016/0167-4781(92)90112-D; GUTLICH M, 1994, BIOCHEM BIOPH RES CO, V203, P1675, DOI 10.1006/bbrc.1994.2379; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HendricksTaylor LR, 1997, J BIOL CHEM, V272, P1363, DOI 10.1074/jbc.272.2.1363; HULTNER L, 1989, IMMUNOLOGY, V67, P408; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; KAUFMAN S, 1972, OXYGENASES, P285; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KERLER F, 1989, BIOCHIM BIOPHYS ACTA, V990, P15, DOI 10.1016/S0304-4165(89)80005-4; KERLER F, 1990, J CELL PHYSIOL, V142, P268, DOI 10.1002/jcp.1041420208; Kieser A, 1996, GENE DEV, V10, P1455, DOI 10.1101/gad.10.12.1455; KIHARA H, 1994, J BIOL CHEM, V269, P22427; KREMMER E, 1995, VIROLOGY, V208, P336, DOI 10.1006/viro.1995.1157; KUHN DM, 1980, ARCH BIOCHEM BIOPHYS, V199, P355, DOI 10.1016/0003-9861(80)90291-X; KULCZYCKI A, 1974, J EXP MED, V139, P600, DOI 10.1084/jem.139.3.600; LEVENBERG B, 1959, J BIOL CHEM, V234, P955; MAIER J, 1995, BIOCHEM BIOPH RES CO, V212, P705, DOI 10.1006/bbrc.1995.2026; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; Nar H, 1995, P NATL ACAD SCI USA, V92, P12120, DOI 10.1073/pnas.92.26.12120; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; Pluss C, 1996, BIOCHEM J, V318, P665; REMBOLD H, 1969, BIOCHIM BIOPHYS ACTA, V184, P589, DOI 10.1016/0304-4165(69)90273-6; RIVERA J, 1997, IGE RECEPTOR FCERI F, P107; SAWADA M, 1986, ANAL BIOCHEM, V154, P361, DOI 10.1016/0003-2697(86)90537-3; SCHOEDON G, 1987, EUR J BIOCHEM, V166, P303, DOI 10.1111/j.1432-1033.1987.tb13515.x; SCHOTT K, 1992, EXP CELL RES, V200, P105, DOI 10.1016/S0014-4827(05)80077-1; SCHOTT K, 1993, J CELL PHYSIOL, V156, P12, DOI 10.1002/jcp.1041560103; SEIDL J, 1986, BIOCHEM BIOPH RES CO, V141, P494, DOI 10.1016/S0006-291X(86)80200-5; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WURSTER B, 1981, J BACTERIOL, V148, P183, DOI 10.1128/JB.148.1.183-192.1981; Yoneyama T, 1997, J BIOL CHEM, V272, P9690; ZANDOMENI R, 1984, J BIOL CHEM, V259, P4804; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZIEGLER I, 1990, J BIOL CHEM, V265, P17026; ZIEGLER I, 1985, J CELL BIOCHEM, V28, P197, DOI 10.1002/jcb.240280303; ZIEGLER I, 1993, ADV EXP MED BIOL, V338, P211; ZIEGLER I, 1993, J BIOL CHEM, V268, P12544; ZIEGLER I, 1992, FEBS LETT, V307, P147, DOI 10.1016/0014-5793(92)80755-6	49	47	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21616	21622		10.1074/jbc.273.34.21616	http://dx.doi.org/10.1074/jbc.273.34.21616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705293	hybrid			2022-12-27	WOS:000075492600027
J	Moss, J; Vaughan, M				Moss, J; Vaughan, M			Molecules in the ARF orbit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ADP-RIBOSYLATION FACTOR; GTPASE-ACTIVATING PROTEIN; NUCLEOTIDE-EXCHANGE PROTEIN; GUANINE-NUCLEOTIDE; FACTOR DOMAIN; BREFELDIN-A; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; SACCHAROMYCES-CEREVISIAE; HOMOLOGY DOMAINS; CHOLERA-TOXIN		NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vaughan, M (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Rm 5N-307,Bldg 10,10 Ctr Dr MSC 1434, Bethesda, MD 20892 USA.							AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Aoe T, 1998, P NATL ACAD SCI USA, V95, P1624, DOI 10.1073/pnas.95.4.1624; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CUKIERMAN E, 1995, SCIENCE, V270, P1944; Deitz SB, 1996, MOL CELL BIOL, V16, P3275; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; Emr SD, 1997, CURR OPIN CELL BIOL, V9, P475, DOI 10.1016/S0955-0674(97)80021-X; FRANCO M, 1995, FEBS LETT, V362, P286, DOI 10.1016/0014-5793(95)00258-B; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Hemmings BA, 1997, SCIENCE, V275, P1899, DOI 10.1126/science.275.5308.1899; Hong JX, 1998, J BIOL CHEM, V273, P15872, DOI 10.1074/jbc.273.25.15872; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; HONG JX, 1994, J BIOL CHEM, V269, P9743; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LEE FJS, 1994, J BIOL CHEM, V269, P20931; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sata M, 1998, P NATL ACAD SCI USA, V95, P4204, DOI 10.1073/pnas.95.8.4204; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; Vitale N, 1997, J BIOL CHEM, V272, P3897, DOI 10.1074/jbc.272.7.3897; Vitale N, 1997, J BIOL CHEM, V272, P25077, DOI 10.1074/jbc.272.40.25077; Vitale N, 1998, J BIOL CHEM, V273, P2553, DOI 10.1074/jbc.273.5.2553; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	57	294	296	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21431	21434		10.1074/jbc.273.34.21431	http://dx.doi.org/10.1074/jbc.273.34.21431			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705267	hybrid			2022-12-27	WOS:000075492600001
J	Bai, M; Trivedi, S; Lane, CR; Yang, YH; Quinn, SJ; Brown, EM				Bai, M; Trivedi, S; Lane, CR; Yang, YH; Quinn, SJ; Brown, EM			Protein kinase C phosphorylation of threonine at position 888 in Ca-0(2+)-sensing receptor (CaR) inhibits coupling to Ca2+ store release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PARATHYROID CELLS; FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; NEONATAL SEVERE HYPERPARATHYROIDISM; CA2+-SENSING RECEPTOR; HORMONE RELEASE; SENSING RECEPTOR; CALCIUM RECEPTOR; RAT HIPPOCAMPUS; ACTIVATION; SECRETION	Previous studies in parathyroid cells, which express the G protein-coupled, extracellular calcium-sensing receptor (CaR), showed that activation of protein kinase C (PKC) blunts high extracellular calcium (Ca-o(2+))-evoked stimulation of phospholipase C and the associated increases in cytosolic calcium (Ca-i(2+)), suggesting that PKC may directly modulate the coupling of the CaR to intracellular signaling systems, In this study, we examined the role of PKC in regulating the coupling of the CaR to Ca-i(2+) dynamics in fura-2-loaded human embryonic kidney cells (HEK293 cells) transiently transfected with the human parathyroid CaR, We demonstrate that several PKC activators exert inhibitory effects on CaR-mediated increases in Ca-i(2+) due to release of Ca2+ from intracellular stores. Consistent with the effect being mediated by activation of PKC, the inhibitory effect of PRC activators on Ca2+ release can be blocked by a PKC inhibitor. The use of site-directed mutagenesis reveals that threonine at amino acid position 888 is the major PKC site that mediates the inhibitory effect of PKC activators on Ca2+ mobilization, The effect of PKC activation can be maximally blocked by mutating three PKC sites (Thr(888), Ser(895), and Ser(915)) or all five PKC sites. In vitro phosphorylation shows that Thr(888) is readily phosphorylated by PKC, Our results suggest that phosphorylation of the CaR, is the molecular basis for the previously described effect of PKC activation on Ca-o(2+)-evoked changes in Ca-i(2+) dynamics in parathyroid cells.	Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiol, Res Lab, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Bai, M (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.				NIDDK NIH HHS [DK48330, DK09436, DK41415] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009436, R01DK048330, R01DK041415] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIDA K, 1995, J CLIN ENDOCR METAB, V80, P2594, DOI 10.1210/jc.80.9.2594; Bai M, 1997, J CLIN INVEST, V99, P1917, DOI 10.1172/JCI119359; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; CHANG WH, 1995, AM J PHYSIOL-ENDOC M, V269, pE864, DOI 10.1152/ajpendo.1995.269.5.E864; CLARKE BL, 1993, ENDOCRINOLOGY, V132, P1168, DOI 10.1210/en.132.3.1168; COLINO A, 1993, EUR J NEUROSCI, V5, P1198, DOI 10.1111/j.1460-9568.1993.tb00974.x; DUNCAN DB, 1955, BIOMETRICS, V11, P1, DOI 10.2307/3001478; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Gogusev J, 1997, KIDNEY INT, V51, P328, DOI 10.1038/ki.1997.41; GUERINEAU NC, 1995, J NEUROSCI, V15, P4395; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; ISHIZUKA T, 1987, ENDOCRINOL JAPON, V34, P965; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; KIFOR O, 1990, J BONE MINER RES, V5, P1003; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MacrezLepretre N, 1997, J BIOL CHEM, V272, P5261, DOI 10.1074/jbc.272.8.5261; MEMBRENO L, 1989, ENDOCRINOLOGY, V124, P789, DOI 10.1210/endo-124-2-789; MORRISSEY JJ, 1988, AM J PHYSIOL, V254, pE63, DOI 10.1152/ajpendo.1988.254.1.E63; MUFF R, 1988, ARCH BIOCHEM BIOPHYS, V265, P128, DOI 10.1016/0003-9861(88)90378-5; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P141, DOI 10.1113/jphysiol.1993.sp019764; RACKE FK, 1993, J PHYSIOL-LONDON, V468, P163, DOI 10.1113/jphysiol.1993.sp019765; RACKE FK, 1994, AM J PHYSIOL, V267, pE429, DOI 10.1152/ajpendo.1994.267.3.E429; Ribeiro CMP, 1996, J BIOL CHEM, V271, P21522, DOI 10.1074/jbc.271.35.21522; RIDEFELT P, 1992, ACTA ENDOCRINOL-COP, V126, P505, DOI 10.1530/acta.0.1260505; SAXE AW, 1987, SURGERY, V102, P932; SHOBACK DM, 1990, ENDOCRINOLOGY, V127, P141, DOI 10.1210/endo-127-1-141; SUN GY, 1988, NEUROCHEM INT, V12, P69, DOI 10.1016/0197-0186(88)90150-7; WATSON PH, 1992, J BONE MINER RES, V7, P667; WONGSURAWAT N, 1987, EXP GERONTOL, V22, P263, DOI 10.1016/0531-5565(87)90005-2; Ye CP, 1996, BIOCHEM BIOPH RES CO, V226, P572, DOI 10.1006/bbrc.1996.1396	37	119	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21267	21275		10.1074/jbc.273.33.21267	http://dx.doi.org/10.1074/jbc.273.33.21267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694886	hybrid			2022-12-27	WOS:000075386100079
J	Cao, LG; Zhang, L; Ruiz-Lozano, P; Yang, QC; Chien, KR; Graham, RM; Zhou, MD				Cao, LG; Zhang, L; Ruiz-Lozano, P; Yang, QC; Chien, KR; Graham, RM; Zhou, MD			A novel putative protein-tyrosine phosphatase contains a BRO1-like domain and suppresses Ha-ras-mediated transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PATHWAYS; CELL HYPERTROPHY; XENOPUS OOCYTES; PTP-PEST; GROWTH; EXPRESSION; CLONING; GENE; MYOCYTES; DIFFERENTIATION	To investigate a potential role of protein-tyrosine phosphatases (PTPases) in myocardial growth and signaling, a degenerate primer-based reverse transcription-polymerase chain reaction approach was used to isolate cDNAs for proteins that contain a PTPase catalytic domain. Among the 16 cDNA clones isolated by reverse transcription-polymerase chain reaction from total neonatal rat cardiomyocyte RNA, one, designated PTP-TD14, was unique. Subsequent isolation and sequencing of a full-length PTP-TD14 cDNA confirmed that it encodes a novel 164-kDa protein, p164(PTP-TD14) The C-terminal region contains the PTP-like domain, whereas the N-terminal region shows no homology to any known mammalian protein. However, this region is homologous to a yeast protein, BRO1, that is involved in the mitogen-activated protein kinase signaling pathway. Like BRO1, p164(PTP-TD14) contains a proline-rich region with two putative SH3-domain binding sites. By Northern blot analysis, PTP-TD14 is expressed as a 5.3-kilobase pair transcript, not only in neonatal heart but also in many adult rat tissues. When expressed in either COS-7 or NIH-3T3 cells, p164(PTP-TD14) localizes to the cytoplasm in association with vesicle-like structures. Expression of p164(PTP-TD14) in NIH-3T3 cells inhibits Ha ras-mediated transformation more than 3-fold. This inhibitory activity is localized to the C-terminal PTPase homology domain, since no inhibition of Ha-ras-mediated focus formation was observed with a PTP-TD14 mutant, in which the putative catalytic activity was presumably inactivated by a point mutation. These findings indicate that PTP-TD14 encodes a novel protein that may be critically involved in regulating Ha-ras-dependent cell growth.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Immusol Inc, San Diego, CA 92121 USA	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of New South Wales Sydney; University of California System; University of California San Diego	Zhou, MD (corresponding author), Victor Chang Cardiac Res Inst, 384 Victoria St,Level 6, Darlinghurst, NSW 2010, Australia.	m.zhou@victorchang.unsw.edu.au						AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BILSEN VM, 1993, CARDIVASC RES, V27, P1140; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; CHIEN KR, 1993, SCIENCE, V260, P916, DOI 10.1126/science.8493528; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HERTOG JD, 1992, BIOCHEM BIOPH RES CO, V184, P1241; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; HUNTER T, 1995, ANN REV BIOCH, V54, P897; KAMBAYASHI Y, 1995, BIOCHEM J, V306, P331, DOI 10.1042/bj3060331; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Liu QQ, 1996, CIRC RES, V79, P716, DOI 10.1161/01.RES.79.4.716; MCGILL CJ, 1995, CARDIOVASC RES, V30, P557, DOI 10.1016/S0008-6363(95)00113-1; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; SAITO H, 1992, BIOCHEM SOC T, V20, P165, DOI 10.1042/bst0200165; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; STONE RL, 1994, J BIOL CHEM, V269, P31323; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; THORBURN A, 1993, J BIOL CHEM, V268, P2244; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; UENO H, 1988, J CELL BIOL, V107, P1911, DOI 10.1083/jcb.107.5.1911; YANG Q, 1993, J BIOL CHEM, V268, P6622; ZAK R, 1974, CIRC RES, V35, P17; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU MD, 1995, P NATL ACAD SCI USA, V92, P7391, DOI 10.1073/pnas.92.16.7391	38	41	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21077	21083		10.1074/jbc.273.33.21077	http://dx.doi.org/10.1074/jbc.273.33.21077			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694860	hybrid			2022-12-27	WOS:000075386100053
J	Cuozzo, JW; Tao, K; Cygler, M; Mort, JS; Sahagian, GG				Cuozzo, JW; Tao, K; Cygler, M; Mort, JS; Sahagian, GG			Lysine-based structure responsible for selective mannose phosphorylation of cathepsin D and cathepsin L defines a common structural motif for lysosomal enzyme targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCAN; PROCATHEPSIN-D; 6-PHOSPHATE RECEPTOR; PORCINE PEPSINOGEN; CRYSTAL-STRUCTURES; PROTEIN STABILITY; 1.8-A RESOLUTION; GENETIC-ANALYSIS; MAMMALIAN-CELLS; ADHESION DOMAIN	Previous studies have shown that lysine residues on the surface of cathepsins and other lysosomal proteins are a shared component of the recognition structure involved in mannose phosphorylation, In this study, the involvement of specific lysine residues in mannose phosphorylation of cathepsin D was explored by site-directed mutagenesis, Mutation of two lysine residues in the mature portion of the protein, Lys-203 and Lys-293, cooperated to inhibit mannose phosphorylation by 70%. Other positively charged residues could not substitute for lysine at these positions, and comparison of thermal denaturation curves for the wild type and mutant proteins indicated that the inhibition could not be explained by alterations in protein folding. Structural comparisons of the two lysine residues with those required for phosphorylation of cathepsin L, using models generated from recently acquired crystal structures, revealed several relevant similarities. On both molecules, the lysine residues were positioned approximately 34 Angstrom apart (34.06 Angstrom for cathepsin D and 33.80 Angstrom for cathepsin L), When the lysine pairs were superimposed, N-linked glycosylation sites on the two proteins were found to be oriented so that oligosaccharides extending out from the sites could share a common region of space. Further similarities in the local environments of the critical lysines were also observed. These results provide details for a common lysosomal targeting structure based on a specific arrangement of lysine residues with respect to each other and to glycosylation sites on the surface of lysosomal proteins.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; Shriners Hosp Children, Joint Dis Lab, Montreal, PQ H3G 1A6, Canada	Tufts University; National Research Council Canada; McGill University	Sahagian, GG (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	gsahagia@opal.tufts.edu		Cuozzo, John/0000-0002-6229-0395				ALBER T, 1987, NATURE, V330, P41, DOI 10.1038/330041a0; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Bao M, 1996, J BIOL CHEM, V271, P31437, DOI 10.1074/jbc.271.49.31437; Bao M, 1996, J BIOL CHEM, V271, P31446, DOI 10.1074/jbc.271.49.31446; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6664, DOI 10.1021/bi00395a016; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6655, DOI 10.1021/bi00395a015; CUOZZO JW, 1994, J BIOL CHEM, V269, P14490; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; Dittmer F, 1997, J BIOL CHEM, V272, P852, DOI 10.1074/jbc.272.2.852; DONG JM, 1990, J BIOL CHEM, V265, P4210; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; FAUST PL, 1987, J CELL BIOL, V105, P1947, DOI 10.1083/jcb.105.5.1947; FAUST PL, 1985, P NATL ACAD SCI USA, V82, P4910, DOI 10.1073/pnas.82.15.4910; FERSHT A, 1977, ENZYME STRUCTURE MEC, P1; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GULNIK S, 1992, J MOL BIOL, V227, P265, DOI 10.1016/0022-2836(92)90696-H; HASILIK A, 1980, J BIOL CHEM, V255, P4946; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KOELSCH G, 1995, ADV EXP MED BIOL, V362, P273; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; Matthews BW, 1996, FASEB J, V10, P35, DOI 10.1096/fasebj.10.1.8566545; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nishikawa A, 1997, J BIOL CHEM, V272, P19408, DOI 10.1074/jbc.272.31.19408; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SCHOREY JS, 1995, J CELL SCI, V108, P2007; SIELECKI AR, 1990, J MOL BIOL, V214, P143, DOI 10.1016/0022-2836(90)90153-D; SIELECKI AR, 1991, J MOL BIOL, V219, P671, DOI 10.1016/0022-2836(91)90664-R; STEARNS NA, 1990, ARCH BIOCHEM BIOPHYS, V283, P447, DOI 10.1016/0003-9861(90)90666-M; TAO K, 1994, ARCH BIOCHEM BIOPHYS, V311, P19, DOI 10.1006/abbi.1994.1203; TONG PY, 1989, J BIOL CHEM, V264, P7962; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P8398; WOODS RJ, 1995, CURR OPIN STRUC BIOL, V5, P591, DOI 10.1016/0959-440X(95)80049-2; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; WYSS DF, 1995, BIOCHEMISTRY-US, V34, P1622, DOI 10.1021/bi00005a019	50	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21067	21076		10.1074/jbc.273.33.21067	http://dx.doi.org/10.1074/jbc.273.33.21067			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694859	hybrid			2022-12-27	WOS:000075386100052
J	Nass, R; Rao, R				Nass, R; Rao, R			Novel localization of a Na+/H+ exchanger in a late endosomal compartment of yeast - Implications for vacuole biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT RENAL-CORTEX; SACCHAROMYCES-CEREVISIAE; PREVACUOLAR COMPARTMENT; SYNTAXIN HOMOLOG; H+ EXCHANGE; PROTEIN; ANTIPORTER; MITOCHONDRIA; COMPONENTS; TRANSPORT	Na+/H+ exchangers catalyze the electrically silent countertransport of Na+ and H+, controlling the transmembrane movement of salt, water, and acid-base equivalents, and are therefore critical for Na+ tolerance, cell volume control, and pH regulation. In contrast to numerous well studied plasma membrane isoforms (NHE1-4), much less is known about intracellular Na+/H+ exchangers, and thus far no vertebrate isoform has been shown to have an exclusively endosomal distribution. In this context, me show that the yeast NHE homologue, Nhx1 (Nass, R., Cunningham, K. W., and Rao, R. (1997) J. Biol. Chem. 272, 26145-26152), localizes uniquely to prevacuolar compartments, equivalent to late endosomes of animal cells. In living yeast, we show that these compartments closely abut the vacuolar membrane in a striking bipolar distribution, suggesting that vacuole biogenesis occurs at distinct sites. Nhx1 is the founding member of a newly emergent cluster of exchanger homologues, from yeasts, worms, and humans that may share a common intracellular localization. By compartmentalizing Na+, intracellular exchangers play an important role in halotolerance; furthermore, we hypothesize that salt and water movement into vesicles may regulate vesicle volume and pH and thus contribute to vacuole biogenesis.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Johns Hopkins University	Rao, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St, Baltimore, MD 21205 USA.	rajini_rao@qmail.bs.jhu.edu						Anderie I, 1996, J MEMBRANE BIOL, V152, P195, DOI 10.1007/s002329900097; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; Barkla B J, 1994, Symp Soc Exp Biol, V48, P141; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dibrov P, 1997, FEBS LETT, V405, P119, DOI 10.1016/S0014-5793(97)00169-5; GARLID KD, 1991, J BIOL CHEM, V266, P6518; GARLID KD, 1978, BIOCHEM BIOPH RES CO, V83, P1450, DOI 10.1016/0006-291X(78)91383-9; GRIFFITHS G, 1989, J CELL BIOL, V90, P40; GRINSTEIN S, 1982, FEBS LETT, V148, P1, DOI 10.1016/0014-5793(82)81230-1; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GURICH RW, 1986, AM J PHYSIOL, V251, pF702, DOI 10.1152/ajprenal.1986.251.4.F702; HAIGH JR, 1989, BIOCHEM J, V257, P499, DOI 10.1042/bj2570499; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; HENSLEY CB, 1990, KIDNEY INT, V37, P707, DOI 10.1038/ki.1990.37; Hicke L, 1997, MOL BIOL CELL, V8, P13, DOI 10.1091/mbc.8.1.13; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; Nakamura N, 1997, J BIOL CHEM, V272, P11344; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SATIR B, 1973, J CELL BIOL, V56, P153, DOI 10.1083/jcb.56.1.153; SCHAEPER TJ, 1986, BRIT J EIGHTEENTH-C, V9, P1; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Sorin A, 1997, J BIOL CHEM, V272, P9895; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TSE CM, 1994, CELL PHYSIOL BIOCHEM, V4, P282, DOI 10.1159/000154731; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; Wada Y, 1997, J CELL SCI, V110, P1299; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WELIHINDA AA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P367, DOI 10.1016/0005-2728(93)90122-V	38	173	183	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21054	21060		10.1074/jbc.273.33.21054	http://dx.doi.org/10.1074/jbc.273.33.21054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694857	hybrid			2022-12-27	WOS:000075386100050
J	Srivastava, DK; Vande Berg, BJ; Prasad, R; Molina, JT; Beard, WA; Tomkinson, AE; Wilson, SH				Srivastava, DK; Vande Berg, BJ; Prasad, R; Molina, JT; Beard, WA; Tomkinson, AE; Wilson, SH			Mammalian abasic site base excision repair - Identification of the reaction sequence and rate-determining steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; DEOXYRIBOSE-PHOSPHATE RESIDUES; BOVINE TESTIS; LIGASE-III; XRCC1; RECONSTITUTION; PATHWAY; GENE; ENDONUCLEASE; REPLICATION	Base excision repair (BER) is one of the cellular defense mechanisms repairing damage to nucleoside 5'-monophosphate residues in genomic DNA. This repair pathway is initiated by spontaneous or enzymatic N-glycosidic bond cleavage creating an abasic or apurinic-apyrimidinic (AP) site in double-stranded DNA. Class II AP endonuclease, deoxyribonucleotide phosphate (dRP) lyase, DNA synthesis, and DNA ligase activities complete repair of the AP site. In mammalian cell nuclear extract, BER can be mediated by a macromolecular complex containing DNA polymerase beta (beta-pol) and DNA ligase I. These two enzymes are capable of contributing the latter three of the four BER enzymatic activities. In the present study, we found that AP site BER can be reconstituted in vitro using the following purified human proteins:AP endonuclease, beta-pol, and DNA ligase I. Examination of the individual enzymatic steps in BER allowed us to identify an ordered reaction pathway: subsequent to 5' "nicking" of the AP site-containing DNA strand by AP endonuclease, beta-pol performs DNA synthesis prior to removal of the 5'-dRP moiety in the gap. Removal of the (dRP flap is strictly required for DNA ligase I to seal the resulting nick, Additionally, the catalytic rate of the reconstituted BER system and the individual enzymatic activities was measured. The reconstituted BER system performs repair of AP site DNA at a rate that is slower than the respective rates of AP endonuclease, DNA synthesis, and ligation, suggesting that these steps are not rate-determining in the overall reconstituted BER system, Instead, the rate-limiting step in the reconstituted system was found to be removal of dRP tie. dRP lyase), catalyzed by the amino-terminal domain of beta-pol, This work is the first to measure the rate of BER in an in vitro reaction. The potential significance of the dRP-containing intermediate in the regulation of BER is discussed.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Hlth Sci Ctr, Ctr Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Health San Antonio	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, 111 Alexander Dr,Bldg 101,Rm B246, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Srivastava, Deo Kumar/P-2435-2017	Wilson, Samuel H/0000-0002-1702-5293; Srivastava, Deo Kumar/0000-0001-6693-8120				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; DIANOV G, 1994, NUCLEIC ACIDS RES, V22, P993, DOI 10.1093/nar/22.6.993; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DIMITRIADIS EK, 1998, IN PRESS J BIOL CHEM, V273; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; FROSINA G, 1994, BIOCHEM J, V304, P699, DOI 10.1042/bj3040699; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KLUNGLAND A, 1997, EMBO J, V16, P334; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; TERAOKA H, 1983, BIOCHIM BIOPHYS ACTA, V747, P117, DOI 10.1016/0167-4838(83)90129-2; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; WANG YCJ, 1994, J BIOL CHEM, V269, P31923; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	43	330	344	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21203	21209		10.1074/jbc.273.33.21203	http://dx.doi.org/10.1074/jbc.273.33.21203			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694877	hybrid			2022-12-27	WOS:000075386100070
J	Tsai, SC; Adamik, R; Hong, JX; Moss, J; Vaughan, M; Kanoh, H; Exton, JH				Tsai, SC; Adamik, R; Hong, JX; Moss, J; Vaughan, M; Kanoh, H; Exton, JH			Effects of arfaptin 1 on guanine nucleotide-dependent activation of phospholipase D and cholera toxin by ADP-ribosylation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE PROTEIN; BREFELDIN-A; BOVINE BRAIN; FACTOR ARF; GTP; GOLGI; PURIFICATION; STIMULATION; CONTAINS; DOMAINS	Arfaptin 1, a similar to 39-kDa protein based on the deduced amino acid sequence, had been initially identified in a yeast two-hybrid screen using dominant active ARF3 (Q71L) as bait with an HL-60 cDNA library. It was suggested that arfaptin 1 may be involved in Golgi functions, since the FLAG-tagged protein was associated with Golgi membranes when expressed in COS-7 cells and could be bound to Golgi in vitro in an ADP-ribosylation factor (ARF)- and GTP gamma S-dependent, brefeldin A-inhibited fashion. Arfaptin 2, found in the same two-hybrid screen as arfaptin 1, is 60% identical in amino acid sequence and may or may not have an analogous function. We now report some effects of arfaptin 1 on ARF activation of phospholipase D and cholera toxin ADP-ribosyltransferase, Arfaptin 1 inhibited activation of both enzymes in a concentration-dependent manner and was without effect in the absence of ARF. Two ARF1 mutants that activated the toxin, one lacking 13 N-terminal amino acids and the other, in which 73 residues at the N terminus were replaced with the analogous sequence from ARL1, were not inhibited by arfaptin, consistent with the conclusion that arfaptin interaction requires the N terminus of ARF. This region has also been implicated in phospholipase D activation, but whether the two proteins interact with the same structural elements in ARF remains to be determined, Arfaptin inhibition of the action of ARF5 and ARF6 was less than that of ARF1 and ARF3; its effects were less on nanmyristoylated than myristoylated ARFs. Arfaptin effects on guanine nucleotide binding by ARFs were minimal whether or not a purified ARF guanine nucleotide-exchange protein was present. These findings indicate that arfaptin acts as an inhibitor of ARF actions in vitro, raising the possibility that it has a similar role in vivo.	NHLBI, NIH, Pulm Crit Care Med Branch, Bethesda, MD 20892 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Physiol & Biophys & Pharmacol, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Howard Hughes Medical Institute; Vanderbilt University	Tsai, SC (corresponding author), NHLBI, NIH, Pulm Crit Care Med Branch, Rm 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.							BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HONG JX, 1994, J BIOL CHEM, V269, P9743; Kanoh H, 1997, J BIOL CHEM, V272, P5421, DOI 10.1074/jbc.272.9.5421; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; TAMKUN JW, 1991, P NATL ACAD SCI USA, V88, P3120, DOI 10.1073/pnas.88.8.3120; TSAI SC, 1988, J BIOL CHEM, V263, P1768; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; TSAI SC, 1993, J BIOL CHEM, V268, P10820; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	21	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20697	20701		10.1074/jbc.273.33.20697	http://dx.doi.org/10.1074/jbc.273.33.20697			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694811	hybrid			2022-12-27	WOS:000075386100004
J	Amendt, BA; Sutherland, LB; Semina, EV; Russo, AF				Amendt, BA; Sutherland, LB; Semina, EV; Russo, AF			The molecular basis of Rieger syndrome - Analysis of Pitx2 homeodomain protein activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HOMEOBOX GENES; TRANSCRIPTION; RECOGNITION; HELIX; ULTRABITHORAX; MUTATION; EMBRYO	Rieger syndrome is an autosomal-dominant developmental disorder that includes glaucoma and mild craniofacial dysmorphism in humans. Mutations in the Pitx2 homeobox gene have been linked to Rieger syndrome. We have characterized wild type and mutant Pitx2 activities using electrophoretic mobility shift assays, protein binding, and transient transfection assays. Pitx2 preferentially binds the bicoid homeodomain binding site and transactivates reporter genes containing this site. The combination of Pitx2 and another homeodomain protein, Pit-1, yielded a synergistic 55-fold activation of the prolactin promoter in transfection assays. Addition of Pit-1 increased Pitx2 binding to the bicoid element in electrophoretic mobility shift assays. Furthermore, we demonstrate specific binding of Pit-1 to Pitx2 in vitro. Thus, wild type Pitx2 DNA binding activity is modulated by protein-protein interactions. We next studied two Rieger mutants. A threonine to proline mutation (T68P) in the second helix of the homeodomain retained DNA binding activity with the same apparent K-D and only about a a-fold reduction in the B-max. However, this mutant did not transactivate reporter genes containing the bicoid site. The mutant Pitx2 protein binds Pit-1, but there was no detectable synergism on the prolactin promoter. A second mutation (L54Q) in a highly conserved residue in helix 1 of the homeodomain yielded an unstable protein. Our results provide insights into the potential mechanisms underlying the developmental defects in Rieger syndrome.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Amendt, BA (corresponding author), Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA.			Amendt, Brad A./0000-0001-6524-1006; Russo, Andrew/0000-0002-8156-5649	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE009170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007018, P30DK025295] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE09170] Funding Source: Medline; NIDDK NIH HHS [DK07018, DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEACHY PA, 1988, CELL, V55, P1069, DOI 10.1016/0092-8674(88)90251-6; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gage PJ, 1997, HUM MOL GENET, V6, P457, DOI 10.1093/hmg/6.3.457; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; Guichet A, 1997, NATURE, V385, P548, DOI 10.1038/385548a0; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hassan B, 1997, P NATL ACAD SCI USA, V94, P10991, DOI 10.1073/pnas.94.20.10991; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JIN YS, 1994, NATURE, V372, P780, DOI 10.1038/372780a0; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; KUMMAR J, 1997, GENE DEV, V11, P2023; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; Lanigan TM, 1997, J BIOL CHEM, V272, P18316, DOI 10.1074/jbc.272.29.18316; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; Ma L, 1996, HUM MOL GENET, V5, P1915, DOI 10.1093/hmg/5.12.1915; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Mucchielli ML, 1996, MOL CELL NEUROSCI, V8, P258, DOI 10.1006/mcne.1996.0062; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PERCIVALSMITH A, 1990, EMBO J, V9, P3967, DOI 10.1002/j.1460-2075.1990.tb07617.x; Rieger H, 1935, Z AUGENHEILKD, V86, P333; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; Semina EV, 1996, NAT GENET, V14, P392, DOI 10.1038/ng1296-392; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; STARK MR, 1994, NATURE, V371, P429, DOI 10.1038/371429a0; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; TREISMAN J, 1992, BIOESSAYS, V14, P145, DOI 10.1002/bies.950140302; TREISMAN J, 1989, CELL, V59, P553; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; Wilson DS, 1996, P NATL ACAD SCI USA, V93, P6886, DOI 10.1073/pnas.93.14.6886; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0	43	114	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20066	20072		10.1074/jbc.273.32.20066	http://dx.doi.org/10.1074/jbc.273.32.20066			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685346	hybrid			2022-12-27	WOS:000075305400023
J	Chen, CC; Wang, JK; Chen, WC; Lin, SB				Chen, CC; Wang, JK; Chen, WC; Lin, SB			Protein kinase C eta mediates lipopolysaccharide-induced nitric-oxide synthase expression in primary astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; GLIAL-CELLS; BINDING-PROTEIN; PHORBOL ESTERS; SUBTYPE-ALPHA; SOLUBLE CD14; INDUCTION; MECHANISMS; HEPATOCYTES; STIMULATION	The signaling pathway involved in protein kinase C (PRC) activation and role of PKC isoforms in lipopolysaccharide (LPS)-induced nitric oxide (NO) release were studied in primary cerebellar astrocytes. LPS caused a dose- and time-dependent increase in NO release and inducible NO synthase (iNOS) expression. The tyrosine kinase inhibitor, genestein, the phosphatidylcholine-phospholipase C inhibitor, D609, and the phosphatidate phosphodrolase inhibitor, propranolol, attenuated the LPS effects, whereas the PI-PLC inhibitor, U73122, had no effect. The PKC inhibitors (staurosporine, Po 31-8220, Go 6976, and calphostin C) also inhibited LPS-induced NO release and iNOS expression. However, long term (24 h) pretreatment of cells with 12-O-tetradecanoyl phorbol-13-acetate (TPA) did not affect the LPS response. Previous results have shown that TPA-induced translocation, but not down-regulation, of PKC eta occurs in astrocytes (Chen, C. C., and Chen, W. C. (1996) Glia 17, 63-71), suggesting possible involvement of PKC eta in LPS-mediated effects. Treatment with antisense oligonucleotides for PKC eta or delta, another isoform abundantly expressed in astrocytes, demonstrated the involvement of PKC eta, but not delta, in LPS-mediated effects. Stimulation of cells for 1 h with LPS caused activation of nuclear factor (NF)-kB in the nuclei as detected by the formation of a NF-kB-specific DNA-protein complex; this effect was inhibited by genestein, D609, propranolol, or Po 31-8220 or by PKC eta antisense oligonucleotides, but not by long term TPA treatment. These data suggest that in astrocytes, LPS might activate phosphatidylcholine-phospholipase C and phosphatidylcholine-phospholipase D through an upstream protein tyrosine kinase to induce PKC activation. Of the PKC isoforms present in these cells, only activation of PKC eta by LPS resulted in the stimulation of NF-kB-specific DNA-protein binding and then initiated the iNOS expression and NO release. This is further evidence demonstrating that different members of the PKC family within a single cell are involved in specific physiological responses.	Natl Taiwan Univ, Coll Med, Inst Pharmacol, Taipei 10018, Taiwan; Natl Taiwan Univ, Coll Med, Inst Med Technol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Pharmacol, 1 Jen Ai Rd,1st Sect, Taipei 10018, Taiwan.			CHEN, CHING-CHOW/0000-0002-7810-0939				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; BEATY CD, 1994, EUR J IMMUNOL, V24, P1278, DOI 10.1002/eji.1830240606; CHEN CC, 1995, MOL PHARMACOL, V48, P39; Chen CC, 1997, FEBS LETT, V412, P30, DOI 10.1016/S0014-5793(97)00697-2; Chen CC, 1996, GLIA, V17, P63; CHEN CC, 1998, IN PRESS J IMMUNOL; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Galea E, 1996, J NEUROIMMUNOL, V64, P19, DOI 10.1016/0165-5728(95)00143-3; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GROSS AH, 1994, J CLIN INVEST, V93, P2684; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAZIOT A, 1988, J IMMUNOL, V141, P547; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Kong LY, 1996, BRAIN RES, V729, P102, DOI 10.1016/0006-8993(96)00417-9; LIN RF, 1993, J EXP MED, V178, P643, DOI 10.1084/jem.178.2.643; LIN SB, 1995, J BIOCHEM-TOKYO, V117, P1100, DOI 10.1093/oxfordjournals.jbchem.a124813; LIN SB, 1993, BIOTECHNIQUES, V14, P795; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LYONS GR, 1992, J BIOL CHEM, V267, P6370; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; PAUL A, 1995, BRIT J PHARMACOL, V114, P482, DOI 10.1111/j.1476-5381.1995.tb13252.x; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SEVERN A, 1992, BIOCHEM BIOPH RES CO, V199, P461; SIMMONS ML, 1994, GLIA, V11, P227, DOI 10.1002/glia.440110303; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; XIE QW, 1994, J BIOL CHEM, V269, P4705	46	98	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19424	19430		10.1074/jbc.273.31.19424	http://dx.doi.org/10.1074/jbc.273.31.19424			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677361	hybrid			2022-12-27	WOS:000075125200013
J	Krishnan, K; Singh, B; Krolewski, JJ				Krishnan, K; Singh, B; Krolewski, JJ			Identification of amino acid residues critical for the Src-homology 2 domain-dependent docking of stat2 to the interferon alpha receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURES; REGULATORY REGION; BETA RECEPTOR; SH2 DOMAIN; IFN-ALPHA; SUBUNIT	The interaction between Src-homology 2 domains (SH2) domains and phosphorylated tyrosine residues serves a critical role in intracellular signaling. In addition to the phosphotyrosine, adjacent residues are critical mediators of the specificity of this interaction, Upon treatment of cells with interferon alpha (IFN alpha), the IFNaR1 subunit of the IFN alpha receptor becomes tyrosine phosphorylated at position 466, The region surrounding phosphorylated tyrosine 466 subsequently acts as a docking site for the SH2 domain of Stat2, facilitating phosphorylation of the latter and, thus, the transduction of the IFNa signal, In this report site-specific mutagenesis was employed to analyze the nature of the interaction between the SH2 domain of Stat2 and the region surrounding tyrosine 466 on IFNaR1. Mutation of the valine at the +1 position carboxyl-terminal to tyrosine 466 or of the serine at the +5 position inhibits the association of Stat2 with phosphorylated IFNaR1, Moreover, receptors mutated at either of these two positions act in a dominant manner to decrease IFN alpha signaling, as assayed by both Stat2 phosphorylation and expression of an IFN alpha-responsive reporter. The demonstration that these two residues are critical in mediating the interaction between Stat2 and IFNaR1 suggests that STAT proteins might utilize a structurally distinct subset of SH2 domains to mediate signal transduction from the cell surface to the nucleus.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Irving Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University	Krolewski, JJ (corresponding author), Univ Calif Irvine, Dept Pathol, Med Sci D-440, Irvine, CA 92717 USA.	jkrolews@uci.edu			NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; Gibbs VC, 1996, J BIOL CHEM, V271, P28710, DOI 10.1074/jbc.271.45.28710; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HELM MH, 1995, SCIENCE, V267, P1347; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; Krishnan K, 1996, ONCOGENE, V13, P125; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MARENGERE LEM, 1994, J CELL SCI, P97; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Pestka S, 1997, SEMIN ONCOL, V24, P918; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SOH JM, 1994, J BIOL CHEM, V269, P18102; SONG Y, 1994, PHYS PLASMAS, V1, P2777, DOI 10.1063/1.870513; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan H, 1996, MOL CELL BIOL, V16, P2074; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19495	19501		10.1074/jbc.273.31.19495	http://dx.doi.org/10.1074/jbc.273.31.19495			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677371	hybrid			2022-12-27	WOS:000075125200023
J	Okumura, K; Ohkura, N; Inoue, S; Ikeda, K; Hayashi, K				Okumura, K; Ohkura, N; Inoue, S; Ikeda, K; Hayashi, K			A novel phospholipase A(2) inhibitor with leucine-rich repeats from the blood plasma of Agkistrodon blomhoffii siniticus - Sequence homologies with human leucine-rich alpha(2)-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE RIBONUCLEASE INHIBITOR; CROTALUS-DURISSUS-TERRIFICUS; THAILAND COBRA; 2 SUBUNITS; PROTEINS; RECEPTOR; MECHANISM; CLONING; SERUM	The phospholipase A(2) (PLA(2)) inhibitor FLIP, purified from the blood plasma of Chinese mamushi snake (Agkistrodon blomhoffii siniticus), is a 160-kDa trimer with three 50-kDa subunits; and it inhibits specifically the enzymatic activity of the basic PLA, from its own venom (Ohkura, N., Okuhara, H., Inoue, S., Ikeda, a, and Hayashi, K. (1997) Biochem. J. 325, 527-531), In the present study, the 50-kDa subunit was found to be glycosylated with N-linked carbohydrate, and enzymatic deglycosylation decreased the molecular mass of the 50-kDa subunit to 39-kDa, One 160-kDa trimer of FLIP was found to form a stable complex with three basic PLA, molecules, indicating that one basic PLA, molecule would bind stoichiometrically to one subunit of FLIP. A cDNA encoding FLIP was isolated from a Chinese mamushi liver cDNA library by use of a probe prepared by a polymerase chain reaction on the basis of the partially determined amino acid sequence of the subunit. The cDNA contained an open reading frame encoding a 23-residue signal sequence followed by a 308-residue protein, which contained the sequences of all the peptides derived by lysyl endopeptidase digestion of the subunit. The molecular mass of the mature protein was calculated to be 34,594 Da, and the deduced amino acid sequence contained four potential N-glycosylation sites. The sequence of FLIP showed no significant homology with that of the known PLA, inhibitors. But, interestingly, it exhibited 33% identity with that of human leucine-rich alpha(2)-glycoprotein, a serum protein of unknown function. The most striking feature of the sequence is that it contained nine leucine-rich repeats (LRRs), each of 24 amino acid residues and thus encompassing over two-thirds of the molecule. LRRs in FLIP might be responsible for the specific binding to basic PLA(2), since LRRs are considered as the motifs involved in protein-protein interactions.	Osaka Univ Pharmaceut Sci, Dept Biochem, Takatsuki, Osaka 5691094, Japan	Osaka University of Pharmaceutical Sciences	Inoue, S (corresponding author), Osaka Univ Pharmaceut Sci, Dept Biochem, Takatsuki, Osaka 5691094, Japan.	inoue@oysun01.oups.ac.jp	Inoue, Seiji/E-5128-2010	Inoue, Seiji/0000-0003-0760-1047				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; CAVINS JF, 1970, ANAL BIOCHEM, V35, P489, DOI 10.1016/0003-2697(70)90211-3; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; EMMERT DB, 1994, NUCLEIC ACIDS RES, V22, P3445, DOI 10.1093/nar/22.17.3445; FORTESDIAS CL, 1994, J BIOL CHEM, V269, P15646; INOUE ES, 1997, BIOCHEM MOL BIOL INT, V41, P529; INOUE S, 1991, J BIOL CHEM, V266, P1001; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; KOGAKI H, 1989, J BIOCHEM-TOKYO, V106, P966, DOI 10.1093/oxfordjournals.jbchem.a122983; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; OHKURA N, 1993, J BIOCHEM-TOKYO, V113, P413, DOI 10.1093/oxfordjournals.jbchem.a124060; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V200, P784, DOI 10.1006/bbrc.1994.1519; Ohkura N, 1997, BIOCHEM J, V325, P527, DOI 10.1042/bj3250527; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V204, P1212, DOI 10.1006/bbrc.1994.2592; PERALES J, 1995, EUR J BIOCHEM, V227, P19, DOI 10.1111/j.1432-1033.1995.tb20355.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sambrook KJ, 1989, MOL CLONING LAB MANU; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5	28	44	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19469	19475		10.1074/jbc.273.31.19469	http://dx.doi.org/10.1074/jbc.273.31.19469			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677367	hybrid			2022-12-27	WOS:000075125200019
J	Chang, SH; Oh, CD; Yang, MS; Kang, SS; Lee, YS; Sonn, JK; Chun, JS				Chang, SH; Oh, CD; Yang, MS; Kang, SS; Lee, YS; Sonn, JK; Chun, JS			Protein kinase C regulates chondrogenesis of mesenchymes via mitogen-activated protein kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB BUD MESENCHYME; CARTILAGE DIFFERENTIATION; N-CADHERIN; IN-VITRO; PATTERN-FORMATION; GENE-EXPRESSION; MAP KINASE; CELL-SHAPE; CHONDROCYTES; REQUIREMENT	A possible regulatory mechanism of protein kinase C (PKC) in the chondrogenesis of chick limb bud mesenchymes has been investigated. Inhibition or down-regulation of PRC resulted in the activation of a mitogen-activated protein kinase subtype Erk-1 and the inhibition of chondrogenesis, On the other hand, inhibition of Erk-1 with PD98059 enhanced chondrogenesis and relieved PKC-induced blockage of chondrogenesis, Erk-1 inhibition, however, did not affect expression and subcellular distribution of PKC isoforms expressed in mesenchymes nor cell proliferation The results suggest that PHC regulates chondrogenesis by modulating Erk-1 activity. Inhibition or depletion of PKC inhibited proliferation of chondrogenic competent cells, and Erk-1 inhibition did not affect PKC modulation of cell proliferation. However, PKC-induced modulation of expression of cell adhesion molecules involved in precartilage condensation was reversed by the inhibition of Erk-1, Expression of N-cadherin was detected at the early period of chondrogenesis, Inhibition or depletion of PKC induced sustained expression of N-cadherin, and Erk-1 inhibition blocked the effects of PKC modulation, The expression of integrin alpha 5 beta 1 and fibronectin was found to be increased transiently during chondrogenesis, Depletion or inhibition of PKC caused a continuous increase of the expression of these molecules throughout the culture period, and Erk-1 inhibition abolished the modulating effects of PKC, Because reduction of the examined cell adhesion molecule expression is a prerequisite for the progression of chondrogenesis after cell condensation, our results indicate that PKC regulates chondrogenesis by modulating expression of these molecules via Erk-1 signaling.	Kyungpook Natl Univ, Coll Nat Sci, Dept Biol, Pook Gu, Taegu 702701, South Korea; Kyungpook Natl Univ, Coll Nat Sci, Dept Biochem, Taegu 702701, South Korea; Kyungpook Natl Univ, Coll Teachers, Taegu 702701, South Korea	Kyungpook National University; Kyungpook National University; Kyungpook National University	Chun, JS (corresponding author), Kyungpook Natl Univ, Coll Nat Sci, Dept Biol, Pook Gu, Taegu 702701, South Korea.	jschun@bh.kyungpook.ac.kr		Oh, Chundo/0000-0002-5419-8011				ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BOUAKKA M, 1988, BIOCHEM BIOPH RES CO, V153, P690, DOI 10.1016/S0006-291X(88)81150-1; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHOI B, 1995, BIOCHEM BIOPH RES CO, V216, P1034, DOI 10.1006/bbrc.1995.2724; Chun JS, 1996, J BIOL CHEM, V271, P13008, DOI 10.1074/jbc.271.22.13008; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DOWNIE SA, 1994, DEV BIOL, V162, P195, DOI 10.1006/dbio.1994.1078; Duprez DM, 1996, DEV BIOL, V174, P448, DOI 10.1006/dbio.1996.0087; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; GERSTENFELD LC, 1985, MOL CELL BIOL, V5, P1425, DOI 10.1128/MCB.5.6.1425; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GREGG BC, 1989, DEVELOPMENT, V105, P769; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V237, P336, DOI 10.1006/bbrc.1997.7061; Kulyk WM, 1996, EXP CELL RES, V223, P290, DOI 10.1006/excr.1996.0084; KULYK WM, 1991, DEV BIOL, V146, P38, DOI 10.1016/0012-1606(91)90444-8; MACKIE EJ, 1987, J CELL BIOL, V105, P2569, DOI 10.1083/jcb.105.6.2569; MAINI PK, 1991, INT REV CYTOL, V129, P91; Maleski MP, 1996, EXP CELL RES, V225, P55, DOI 10.1006/excr.1996.0156; MAMAJIWALLA SN, 1995, ONCOGENE, V11, P377; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; ROARK EF, 1994, DEV DYNAM, V200, P103, DOI 10.1002/aja.1002000203; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Solursh M, 1989, CURR OPIN CELL BIOL, V1, P989, DOI 10.1016/0955-0674(89)90070-7; SONN JK, 1993, DIFFERENTIATION, V53, P155, DOI 10.1111/j.1432-0436.1993.tb00704.x; TAKIGAWA M, 1983, CELL DIFFER DEV, V13, P283, DOI 10.1016/0045-6039(83)90038-6; Tavella S, 1997, J CELL SCI, V110, P2261; TAVELLA S, 1994, EXP CELL RES, V215, P354, DOI 10.1006/excr.1994.1352; TSONIS PA, 1994, EXP CELL RES, V213, P433, DOI 10.1006/excr.1994.1220; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; ZANETTI NC, 1986, DEV BIOL, V113, P110, DOI 10.1016/0012-1606(86)90113-2	40	83	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19213	19219		10.1074/jbc.273.30.19213	http://dx.doi.org/10.1074/jbc.273.30.19213			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668109	hybrid			2022-12-27	WOS:000074974700076
J	Karlsson, K; Carlsson, SR				Karlsson, K; Carlsson, SR			Sorting of lysosomal membrane glycoproteins lamp-1 and lamp-2 into vesicles distinct from mannose 6-phosphate receptor/gamma-adaptin vesicles at the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY INTERACTION; ADP-RIBOSYLATION FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYTOPLASMIC DOMAIN; ASSEMBLY PROTEINS; TARGETING SIGNAL; CELLS; BIOSYNTHESIS; LOCALIZATION; WORTMANNIN	Newly synthesized lysosomal membrane glycoproteins lamp-1 and lamp-2 are primarily sorted at the trans-Golgi network (TGN) by recognition of a tyrosine-based signal sequence in their cytoplasmic tails. It is presently unclear how this signal is recognized and what type of vesicle transports lamp-1 and lamp-2. Here, we describe a method to generate transport vesicles containing lamp proteins from the TGN in vitro. The method is based on incorporation of radioactive sialic acid in glycoproteins at the TGN by incubation of membranes with tritiated CMP-sialic acid. The generation of vesicles from labeled membranes required ATP and cytosol, and was temperature-dependent and brefeldin A-sensitive. Analysis on Nycodenz gradients revealed that lamp-vesicles were distinct from vesicles containing gamma-adaptin and mannose B-phosphate receptor (MPR), Moreover, both these types of vesicles migrated differently than vesicles containing proteins destined for the plasma membrane. The conclusion that lamps and MPRs are sorted into different vesicles was further strengthened by the finding that whereas wortmannin both in vitro and in vivo inhibited the production of gamma-adaptin/MPR-containing vesicles, this drug had no effect on the generation of lamp-vesicles and on the sorting of lamps. The results indicate that membrane proteins containing tyrosine-based motifs for sorting at the TGN are segregated from clathrin-coated vesicles containing MPRs.	Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden	Umea University	Carlsson, SR (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	sven.carlsson@medkem.umu.se		Carlsson, Sven R/0000-0001-5123-135X				Abeijon C, 1997, TRENDS BIOCHEM SCI, V22, P203, DOI 10.1016/S0968-0004(97)01053-0; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Brodsky FM, 1997, TRENDS CELL BIOL, V7, P175, DOI 10.1016/S0962-8924(97)01038-6; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CARLSSON SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P630, DOI 10.1016/0003-9861(92)90619-8; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Cieutat AM, 1998, BLOOD, V91, P1044, DOI 10.1182/blood.V91.3.1044.1044_1044_1058; COLLINS SJ, 1987, BLOOD, V70, P1233; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; DAHLGREN C, 1995, BIOCHEM J, V311, P667, DOI 10.1042/bj3110667; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Gaffet P, 1997, J BIOL CHEM, V272, P24170, DOI 10.1074/jbc.272.39.24170; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; GRAHAM JM, 1988, BIOCHEM J, V252, P437, DOI 10.1042/bj2520437; GREEN SA, 1987, J CELL BIOL, V105, P1227, DOI 10.1083/jcb.105.3.1227; GUARNIERI FG, 1993, J BIOL CHEM, V268, P1941; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Keller P, 1997, J CELL SCI, V110, P3001; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KOEFFLER HP, 1980, BLOOD, V56, P344; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kundra A, 1998, J BIOL CHEM, V273, P3848, DOI 10.1074/jbc.273.7.3848; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LeCabec V, 1997, BLOOD, V89, P2113, DOI 10.1182/blood.V89.6.2113; LEYTE A, 1992, EMBO J, V11, P4795, DOI 10.1002/j.1460-2075.1992.tb05585.x; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MARSH M, 1987, J CELL BIOL, V104, P875, DOI 10.1083/jcb.104.4.875; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Nakajima Y, 1997, MOL BIOL CELL, V8, P577, DOI 10.1091/mbc.8.4.577; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Reaves BJ, 1996, J CELL SCI, V109, P749; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; SCHACHTER H, 1983, METHOD ENZYMOL, V98, P98; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILSON AP, 1992, J IMMUNOL, V148, P1777; WimerMackin S, 1996, BIOCHEM BIOPH RES CO, V229, P472, DOI 10.1006/bbrc.1996.1828	62	70	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18966	18973		10.1074/jbc.273.30.18966	http://dx.doi.org/10.1074/jbc.273.30.18966			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668075	hybrid			2022-12-27	WOS:000074974700042
J	Rezzonico, R; Burger, D; Dayer, JM				Rezzonico, R; Burger, D; Dayer, JM			Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FIBRONECTIN GENE-EXPRESSION; PROCOLLAGEN MESSENGER-RNAS; GROWTH-FACTOR-BETA; INTERFERON-GAMMA; FACTOR-ALPHA; PRO-ALPHA-1(I) COLLAGEN; SYNOVIAL FIBROBLASTS; ADHESION MOLECULES; ENDOTHELIAL-CELLS	In many inflammatory diseases where tissue remodeling occurs, T cells are in close contact with mesenchymal cells. We investigated the effect of direct cell-cell contact between peripheral blood T lymphocytes or HUT-78 lymphoma cells and dermal fibroblasts or synoviocytes on the deposition of the major extracellular matrix components: types I and III collagen. Incubation of dermal fibroblasts and synoviocytes with plasma membrane preparations from resting T cells slightly increased the production of collagen I but did not significantly affect that of collagen III. Conversely, direct contact with either plasma membranes or fixed phytohemagglutinin/phorbol myristate acetate activated T cells markedly inhibited the synthesis of types I and III collagen by 60-70% in untreated dermal fibroblasts and synoviocytes and by 85% in transforming growth factor beta-stimulated fibroblasts. This decrease of collagen synthesis was abrogated when fixed T cells were separated physically hom fibroblasts, demonstrating that direct contact between the two cell types was necessary. This inhibition was associated with a marked decrease in steady-state levels of pro-alpha 1(I) and pro-alpha 1(III) collagen mRNAs. T cell contact decreased the transcription rate but did not significantly alter the stability of the alpha 1(I) and alpha 1(III) transcripts. Finally, using neutralizing antibodies or cytokine inhibitors we provide evidence that this inhibition of extracellular matrix production mediated by T cell contact was partially due to additive effects of T cell membrane-associated interferon gamma, tumor necrosis factor alpha, and interleukin-1 alpha.	Univ Geneva, Hop Cantonal, Unite Immunol Clin,Dept Internal Med, Div Immunol & Allergy,Hans Wilsdorf Lab, CH-1211 Geneva 14, Switzerland	University of Geneva	Rezzonico, R (corresponding author), Univ Geneva, Hop Cantonal, Unite Immunol Clin,Dept Internal Med, Div Immunol & Allergy,Hans Wilsdorf Lab, CH-1211 Geneva 14, Switzerland.		REZZONICO, Roger/N-9626-2016; Burger, Danielle/A-1996-2008	REZZONICO, Roger/0000-0002-8460-1641; 				ABRAHAM D, 1991, ARTHRITIS RHEUM, V34, P1164, DOI 10.1002/art.1780340913; Assenmacher M, 1996, EUR J IMMUNOL, V26, P263, DOI 10.1002/eji.1830260141; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BOMBARA MP, 1993, J LEUKOCYTE BIOL, V54, P399, DOI 10.1002/jlb.54.5.399; BURGER D, 1998, IN PRESS ARTHRITIS R; CHIZZOLINI C, 1988, IN PRESS ARTHRITIS R; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; CHU ML, 1985, J BIOL CHEM, V260, P4357; COLIGE AC, 1992, BIOCHEM J, V285, P215, DOI 10.1042/bj2850215; CZAJA MJ, 1987, J BIOL CHEM, V262, P13348; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; DHAWAN J, 1991, J BIOL CHEM, V266, P8470; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; DIAZ A, 1993, J BIOL CHEM, V268, P10364; Eckes B, 1996, BIOCHEM J, V315, P549, DOI 10.1042/bj3150549; ELIAS JA, 1990, ANN NY ACAD SCI, V580, P233, DOI 10.1111/j.1749-6632.1990.tb17932.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAZDAR AF, 1980, BLOOD, V55, P409; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOLDRING S R, 1981, Arthritis and Rheumatism, V24, pS106; GONZALEZAMARO R, 1988, CLIN IMMUNOL IMMUNOP, V46, P412, DOI 10.1016/0090-1229(88)90060-8; GRANSTEIN RD, 1990, J INVEST DERMATOL, V95, pS75, DOI 10.1111/1523-1747.ep12874789; HAYNES BF, 1988, ARTHRITIS RHEUM, V31, P947, DOI 10.1002/art.1780310802; HIBBS MS, 1983, J EXP MED, V157, P47, DOI 10.1084/jem.157.1.47; Ichiki Y, 1997, J RHEUMATOL, V24, P90; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; Korn J., 1997, TXB RHEUMATOLOGY, P199; KOVACS EJ, 1994, FASEB J, V8, P854, DOI 10.1096/fasebj.8.11.7520879; KRANE SM, 1984, EXTRACELLULAR MATRIX, P413; KRZESICKI RF, 1991, ARTHRITIS RHEUM-US, V34, P1245, DOI 10.1002/art.1780341007; KURTJONES EA, 1987, J IMMUNOL, V139, P2317; LAFEBER FPJG, 1992, AM J PATHOL, V140, P1421; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; Lou J, 1996, EUR J IMMUNOL, V26, P3107, DOI 10.1002/eji.1830261242; MAJORS AK, 1992, EXP CELL RES, V200, P168, DOI 10.1016/S0014-4827(05)80085-0; MAUVIEL A, 1991, J CELL BIOL, V113, P1455, DOI 10.1083/jcb.113.6.1455; MAUVIEL A, 1994, J BIOL CHEM, V269, P25; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MILTENBURG AMM, 1995, J IMMUNOL, V154, P2655; Nakatsuka K, 1997, J RHEUMATOL, V24, P458; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; Parry SL, 1997, J IMMUNOL, V158, P3673; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; POSTLETHWAITE AE, 1988, J CELL BIOL, V106, P311, DOI 10.1083/jcb.106.2.311; POSTLETHWAITE AE, 1993, DERMAL IMMUNE SYSTEM, P163; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; ROUX M, 1995, ARCH DERMATOL, V287, P401; Sebbag M, 1997, EUR J IMMUNOL, V27, P624, DOI 10.1002/eji.1830270308; Sporri B, 1996, CYTOKINE, V8, P631, DOI 10.1006/cyto.1996.0084; Tak PP, 1997, ARTHRITIS RHEUM, V40, P217, DOI 10.1002/art.1780400206; Unemori EN, 1996, J CLIN INVEST, V98, P2739, DOI 10.1172/JCI119099; VANDELOO FAJ, 1995, ARTHRITIS RHEUM, V38, P164; VARGA J, 1990, EUR J CLIN INVEST, V20, P487, DOI 10.1111/j.1365-2362.1990.tb01915.x; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; VEY E, 1992, J IMMUNOL, V149, P2040	58	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18720	18728		10.1074/jbc.273.30.18720	http://dx.doi.org/10.1074/jbc.273.30.18720			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668044	hybrid			2022-12-27	WOS:000074974700011
J	Thompson, SJ; Kim, SJ; Robinson, C				Thompson, SJ; Kim, SJ; Robinson, C			Sec-independent insertion of thylakoid membrane proteins - Analysis of insertion forces and identification of a loop intermediate involving the signal peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; INNER MEMBRANE; PROCESSING PEPTIDASE; PROCOAT PROTEIN; TRANSIT PEPTIDE; PHOTOSYSTEM-II; TRANSPORT; TRANSLOCATION; INTEGRATION; BACTERIOPHAGE-M13	A group of membrane proteins are synthesized with cleavable signal sequences but inserted into the thylakoid membrane by an unusual Sec/SRP-independent mechanism. In this report we describe a key intermediate in the insertion of one such protein, photosystem II subunit W (PSII-W). A single mutation in the terminal cleavage site partially blocks processing mid leads to the formation of an intermediate-size protein in the thylakoid membrane during chloroplast import assays. This protein is in the form of a loop structure: the N and C termini are exposed on the stromal face, whereas the cleavage site has been translocated into the lumen. In this respect the insertion of this protein resembles that of M13 procoat, which also adopts a loop structure during insertion, and we present preliminary evidence that a similar mechanism is used by another thylakoid protein, PSII-X. However, whereas the negative ly charged region of procoat is translocated by an apparently electrophoretic mechanism using the Delta mu H+, the corresponding region of PSII-W is equally acidic but insertion is Delta mu H+ independent, We furthermore show th.at neutralization of this region has no apparent effect on the insertion process. We propose that a central element in this insertion mechanism is a loop structure whose formation is driven by hydrophobic interactions.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.			Thompson, Simon/0000-0003-0769-8555				ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; BRASSILANA M, 1996, EMBO J, V15, P5202; CAO GQ, 1995, EMBO J, V14, P866, DOI 10.1002/j.1460-2075.1995.tb07068.x; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; DeGier JWL, 1997, FEBS LETT, V408, P1, DOI 10.1016/S0014-5793(97)00402-X; Fincher V, 1998, FEBS LETT, V423, P66, DOI 10.1016/S0014-5793(98)00066-0; GALLUSSER A, 1990, EMBO J, V9, P2723, DOI 10.1002/j.1460-2075.1990.tb07459.x; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GOUNARIS K, 1983, BIOCHIM BIOPHYS ACTA, V728, P129, DOI 10.1016/0005-2736(83)90445-5; HENRY R, 1994, J BIOL CHEM, V269, P10189; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; High S, 1997, J BIOL CHEM, V272, P11622; Kiefer D, 1997, EMBO J, V16, P2197, DOI 10.1093/emboj/16.9.2197; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; Kim SJ, 1996, FEBS LETT, V390, P175, DOI 10.1016/0014-5793(96)00658-8; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KUHN A, 1994, EUR J BIOCHEM, V226, P891, DOI 10.1111/j.1432-1033.1994.00891.x; KUHN A, 1990, EMBO J, V9, P2385, DOI 10.1002/j.1460-2075.1990.tb07413.x; KUHN A, 1995, FEMS MICROBIOL REV, V17, P185; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LI XX, 1995, P NATL ACAD SCI USA, V92, P3789, DOI 10.1073/pnas.92.9.3789; LORKOVIC ZJ, 1995, P NATL ACAD SCI USA, V92, P8930, DOI 10.1073/pnas.92.19.8930; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; ROBINSON C, 1994, EMBO J, V13, P279, DOI 10.1002/j.1460-2075.1994.tb06260.x; Robinson D, 1996, PLANT J, V10, P149, DOI 10.1046/j.1365-313X.1996.10010149.x; SAAF A, 1995, MOL MEMBR BIOL, V12, P209, DOI 10.3109/09687689509027509; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WOLFE PB, 1985, J BIOL CHEM, V260, P1836	34	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18979	18983		10.1074/jbc.273.30.18979	http://dx.doi.org/10.1074/jbc.273.30.18979			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668077	hybrid			2022-12-27	WOS:000074974700044
J	Yamaguchi, H; Hara, M; Strobeck, M; Fukasawa, K; Schwartz, A; Varadi, G				Yamaguchi, H; Hara, M; Strobeck, M; Fukasawa, K; Schwartz, A; Varadi, G			Multiple modulation pathways of calcium channel activity by a beta subunit - Direct evidence of beta subunit participation in membrane trafficking of the alpha(1c) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; XENOPUS OOCYTES; CHARGE MOVEMENT; IONIC CURRENT; HUMAN HEART; CELLS; INACTIVATION; EXPRESSION; CLONING; ALPHA(1)-SUBUNIT	In order to study the precise mechanisms of alpha(1) subunit modulation by an auxiliary beta subunit of voltage-dependent calcium channels, a recombinant beta(3) subunit fusion protein was produced and introduced into oocytes that express the human alpha(1C) subunit. Injection of the beta 3 subunit protein rapidly modulated the current kinetics and voltage dependence of activation, whereas massive augmentation of peak current amplitude occurred over a longer time scale. Consistent with the latter, a severalfold increase in the amount of the alpha(1C) subunit in the plasma membrane was detected by quantitative confocal laser-scanning microscopy after beta(3) subunit injection, Pretreatment of oocytes with bafilomycin A(1), a vacuolar type H+-ATPase inhibitor, abolished the increase of the alpha(1C) subunit in the plasma membrane, attenuated current increase, but did not affect the modulation of current kinetics and voltage dependence by the beta(3) subunit. These results provide clear evidence that the beta subunit modifies the calcium channel complex in a binary fashion; one is an allosteric modulation of the alpha(1) subunit function and the other is a chaperoning of the alpha(1) subunit to the plasma membrane.	Univ Cincinnati, Inst Mol Pharmacol & Biophys, Coll Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Varadi, G (corresponding author), Univ Cincinnati, Inst Mol Pharmacol & Biophys, Coll Med, 231 Bethesda Ave,POB 670828, Cincinnati, OH 45267 USA.	varadig@email.uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022619] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL22619-19] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; LORY P, 1993, FEBS LETT, V315, P167, DOI 10.1016/0014-5793(93)81156-T; MORI Y, 1991, NATURE, V350, P159; NEELY A, 1995, AM J PHYSIOL-CELL PH, V268, pC732, DOI 10.1152/ajpcell.1995.268.3.C732; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PEREZGARCIA MT, 1995, J GEN PHYSIOL, V105, P289, DOI 10.1085/jgp.105.2.289; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; UMATA T, 1990, J BIOL CHEM, V265, P21940; VARADI G, 1995, TRENDS PHARMACOL SCI, V16, P43, DOI 10.1016/S0165-6147(00)88977-4; VARADI G, 1991, NATURE, V352, P159, DOI 10.1038/352159a0; WAKAMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P1170, DOI 10.1006/bbrc.1993.2374; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	35	78	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19348	19356		10.1074/jbc.273.30.19348	http://dx.doi.org/10.1074/jbc.273.30.19348			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668125	hybrid			2022-12-27	WOS:000074974700092
J	Bolhuis, A; Broekhuizen, CP; Sorokin, A; van Roosmalen, ML; Venema, G; Bron, S; Quax, WJ; van Dijl, JM				Bolhuis, A; Broekhuizen, CP; Sorokin, A; van Roosmalen, ML; Venema, G; Bron, S; Quax, WJ; van Dijl, JM			SecDF of Bacillus subtilis, a molecular Siamese twin required for the efficient secretion of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL PEPTIDASE-I; TEMPORALLY CONTROLLED EXPRESSION; COLI INNER MEMBRANE; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCATION; EXPORT; GENE; ATP; INSERTION; HOMOLOG	In the present studies, we show that the SecD and SecF equivalents of the Gram-positive bacterium Bacillus subtilis are jointly present in one polypeptide, denoted SecDF, that is required to maintain a high capacity for protein secretion. Unlike the SecD subunit of the pre-protein translocase of Escherichia coli, SecDF of B. subtilis was not required for the release of a mature secretory protein from the membrane, indicating that SecDF is involved in earlier translocation steps. Strains lacking intact SecDF showed a cold-sensitive phenotype, which was exacerbated by high level production of secretory proteins, indicating that protein translocation in B. subtilis is intrinsically cold-sensitive. Comparison with SecD and SecF proteins from other organisms revealed the presence of 10 conserved regions in SecDF, some of which appear to be important for SecDF function. Interestingly, the SecDF protein of B. subtilis has 12 putative transmembrane domains. Thus, SecDF does not only show sequence similarity but also structural similarity to secondary solute transporters. Our data suggest that SecDF of B. subtilis represents a novel type of the SecD and SecF proteins, which seems to be present in at least two other organisms.	Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Genencor Int, NL-2288 GJ Rijswijk, Netherlands; INRA, Lab Genet Microbienne, F-78352 Jouy En Josas, France; Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Groningen	van Dijl, JM (corresponding author), Univ Groningen, Dept Genet, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	j.m.van.dijl@biol.rug.nl	Bolhuis, Albert/E-9932-2010; van Dijl, Jan Maarten/G-1205-2013; Quax, Wim/O-2875-2019; Quax, Wim/K-2802-2012; Sorokin, Alexei/AAV-4666-2020	Bolhuis, Albert/0000-0001-9307-0515; Quax, Wim/0000-0002-5162-9947; Quax, Wim/0000-0002-5162-9947; Sorokin, Alexei/0000-0002-8653-9896				ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; Bolhuis A, 1996, MOL MICROBIOL, V22, P605, DOI 10.1046/j.1365-2958.1996.d01-4676.x; Chambliss Glenn H., 1993, P213; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; DRIESSEN AJM, 1992, TRENDS BIOCHEM SCI, V17, P219, DOI 10.1016/0968-0004(92)90381-I; DRIESSEN AJM, 1996, HDB BIOL PHYS, V2, P759; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1997, EMBO J, V16, P2756, DOI 10.1093/emboj/16.10.2756; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Ferrari Eugenio, 1993, P917; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; JEONG SM, 1993, MOL MICROBIOL, V10, P133, DOI 10.1111/j.1365-2958.1993.tb00910.x; Kim L, 1996, GENE, V181, P71, DOI 10.1016/S0378-1119(96)00466-0; KIM YJ, 1994, CELL, V78, P845; KONTINEN VP, 1988, J GEN MICROBIOL, V134, P2333; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; PALVA I, 1982, GENE, V19, P81, DOI 10.1016/0378-1119(82)90191-3; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; POGLIANO KJ, 1993, GENETICS, V133, P763; POGLIANO KJ, 1994, J BACTERIOL, V176, P804, DOI 10.1128/jb.176.3.804-814.1994; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; REUTER K, 1991, J BACTERIOL, V173, P2256, DOI 10.1128/JB.173.7.2256-2264.1991; SADAIE Y, 1991, GENE, V98, P101; Sambrook F., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SUH JW, 1990, MOL MICROBIOL, V4, P305, DOI 10.1111/j.1365-2958.1990.tb00597.x; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; TJALSMA H, 1998, IN PRESS GENES DEV; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1991, J GEN MICROBIOL, V137, P2073, DOI 10.1099/00221287-137-9-2073; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; YANSURA DG, 1984, GENETICS BIOCH BACIL, P249	48	103	110	4	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21217	21224		10.1074/jbc.273.33.21217	http://dx.doi.org/10.1074/jbc.273.33.21217			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694879	Green Published, hybrid			2022-12-27	WOS:000075386100072
J	Eppink, MHM; Schreuder, HA; van Berkel, WJH				Eppink, MHM; Schreuder, HA; van Berkel, WJH			Interdomain binding of NADPH in p-hydroxybenzoate hydroxylase as suggested by kinetic, crystallographic and modeling studies of histidine 162 and arginine 269 variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-FLUORESCENS; CRYSTAL-STRUCTURE; ISOCITRATE DEHYDROGENASE; CHEMICAL MODIFICATION; 4-HYDROXYBENZOATE HYDROXYLASE; CIBACRON BLUE; ACTIVE-SITE; PURIFICATION; SEQUENCE; COMPLEX	The conserved residues His-162 and Arg-269 of the flavoprotein p-hydroxybenzoate hydroxylase (EC 1.14.13.2) are located at the entrance of the interdomain cleft that leads toward the active site. To study their putative role in NADPH binding, His-162 and Arg-269 were selectively changed by site-specific mutagenesis, The catalytic properties of H162R, H162Y, and R269K were similar to the wild-type enzyme. However, less conservative His-162 and Arg-269 replacements strongly impaired NADPH binding without affecting the conformation of the flavin ring and the efficiency of substrate hydroxylation, The crystal structures of H162R and R269T in complex with 4-hydroxybenzoate were solved at 3.0 and 2.0 Angstrom resolution, respectively. Both structures are virtually indistinguishable from the wild-type enzyme-substrate complex except for the substituted side chains, In contrast to wild-type p-hydroxybenzoate hydroxylase, H162R is not inactivated by diethyl pyrocarbonate, NADPH protects wild-type p-hydroxybenzoate hydroxylase from diethylpyrocarbonate inactivation, suggesting that His-162 is involved in NADPH binding, Based on these results and GRID calculations we propose that the side chains of His-162 and Arg-269 interact with the pyrophosphate moiety of NADPH, An interdomain binding mode for NADPH is proposed which takes a novel sequence motif (Eppink, M, H, M,, Schreuder, H, A., and van Berkel, W, J, H, (1997) Protein Sci, 6, 2454-2458) into account.	Agr Univ Wageningen, Biochem Lab, Dept Biomol Sci, NL-6703 HA Wageningen, Netherlands; Hoechst Marion Roussel, Core Res Funct, D-65926 Frankfurt, Germany	Wageningen University & Research; Sanofi-Aventis	van Berkel, WJH (corresponding author), Agr Univ Wageningen, Biochem Lab, Dept Biomol Sci, Dreijenlaan 3, NL-6703 HA Wageningen, Netherlands.	willem.vanberkel@fad.bc.wau.nl	Eppink, Michel/AAB-6866-2022; van Berkel, Willem J.H./O-2431-2014	Eppink, Michel/0000-0001-8297-9985; van Berkel, Willem J.H./0000-0002-6551-2782; Schreuder, Herman/0000-0003-2249-2782				Bell CE, 1997, PROTEIN SCI, V6, P2084; BREITER DR, 1994, PROTEIN SCI, V3, P2023, DOI 10.1002/pro.5560031115; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ENTSCH B, 1991, J BIOL CHEM, V266, P17341; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; ENTSCH B, 1990, METHOD ENZYMOL, V188, P138; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; EPPINK MHM, 1995, EUR J BIOCHEM, V231, P157, DOI 10.1111/j.1432-1033.1995.0157f.x; Eppink MHM, 1997, PROTEIN SCI, V6, P2454; Eppink MHM, 1998, EUR J BIOCHEM, V253, P194, DOI 10.1046/j.1432-1327.1998.2530194.x; EPPINK MHM, 1997, FLAVINS FLAVOPROTEIN, V12, P315; ESCHRICH K, 1993, EUR J BIOCHEM, V216, P137, DOI 10.1111/j.1432-1033.1993.tb18125.x; ESCHRICH K, 1990, FEBS LETT, V277, P197, DOI 10.1016/0014-5793(90)80843-8; FITA I, 1985, P NATL ACAD SCI USA, V82, P1604, DOI 10.1073/pnas.82.6.1604; GATTI DL, 1994, SCIENCE, V266, P110, DOI 10.1126/science.7939628; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MAS MT, 1984, BIOCHEMISTRY-US, V23, P1675, DOI 10.1021/bi00303a015; MULLER F, 1983, BIOCHEM INT, V7, P115; MULLER F, 1979, EUR J BIOCHEM, V101, P235, DOI 10.1111/j.1432-1033.1979.tb04236.x; MULLER F, 1982, EUR J BIOCHEM, V128, P21; Palfey BA, 1997, BIOCHEMISTRY-US, V36, P15713; PRESTERA T, 1992, BIOCHEMISTRY-US, V31, P824, DOI 10.1021/bi00118a027; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; Seibold B, 1996, EUR J BIOCHEM, V239, P469, DOI 10.1111/j.1432-1033.1996.0469u.x; SHUMAN B, 1993, J BIOL CHEM, V268, P17057; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; Stanier R Y, 1973, Adv Microb Physiol, V9, P89; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; STURA EA, 1983, J MOL BIOL, V170, P529, DOI 10.1016/S0022-2836(83)80160-0; SUBRAMANIAN S, 1984, CRC CR REV BIOCH MOL, V16, P169, DOI 10.3109/10409238409102302; SUZUKI K, 1995, J BIOCHEM-TOKYO, V117, P579, DOI 10.1093/oxfordjournals.jbchem.a124747; THOMPSON ST, 1976, P NATL ACAD SCI USA, V73, P361, DOI 10.1073/pnas.73.2.361; VANBERKEL W, 1992, EUR J BIOCHEM, V210, P411; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VANBERKEL WJH, 1987, EUR J BIOCHEM, V167, P35; VANBERKEL WJH, 1988, EUR J BIOCHEM, V176, P449; VANBERKEL WJH, 1994, PROTEIN SCI, V3, P2245, DOI 10.1002/pro.5560031210; VANBERKEL WJH, 1997, FLAVINS FLAVOPROTEIN, V12, P305; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WIJNANDS RA, 1982, BIOCHEMISTRY-US, V21, P6639, DOI 10.1021/bi00269a005; WIJNANDS RA, 1987, EUR J BIOCHEM, V163, P535, DOI 10.1111/j.1432-1033.1987.tb10901.x; WIJNANDS RA, 1984, EUR J BIOCHEM, V139, P637, DOI 10.1111/j.1432-1033.1984.tb08051.x; XIONG JP, 1994, NAT STRUCT BIOL, V1, P695, DOI 10.1038/nsb1094-695; YOU KS, 1985, CRC CR REV BIOCH MOL, V17, P313, DOI 10.3109/10409238509113625	58	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21031	21039		10.1074/jbc.273.33.21031	http://dx.doi.org/10.1074/jbc.273.33.21031			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694855	hybrid			2022-12-27	WOS:000075386100048
J	Nash, P; Whitty, A; Handwerker, J; Macen, J; McFadden, G				Nash, P; Whitty, A; Handwerker, J; Macen, J; McFadden, G			Inhibitory specificity of the anti-inflammatory myxoma virus serpin, SERP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; REACTIVE CENTER LOOP; KINETIC CHARACTERIZATION; PLASMINOGEN-ACTIVATOR; CONFORMATIONAL CHANGE; PROTEASE INHIBITORS; SUICIDE SUBSTRATE; FIBROMA VIRUS; MECHANISM; COMPLEX	SERP-1 is a myxoma virus-encoded serpin, secreted from infected cells, that is required for virulence and has anti-inflammatory activity. We report that purified recombinant SERP-1 forms SDS-stable complexes with urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator (tPA), plasmin, thrombin, and factor Xa, N-terminal sequencing confirmed Arg(319)-Asn(320) as the site of reaction. Mutation of these residues to Ala-Ala abolished inhibitory activity but had no effect on the specific cleavage at Thr(315)-Leu(316) Seen with elastase and with cathepsin G, Kinetic analysis of the reactions with uPA, tPA, plasmin, thrombin, Xa, and Cls showed second-order rate constants to vary over 3 logs, from k(inh) = 3 x 10(5) M(-1) s(-1) with thrombin to similar to 600 M(-1) s(-1) with Cls, while steady-state inhibition constants ranged from K(I) = 10 pM with thrombin to similar to 100 nM with C1s. Stoichiometries of inhibition varied between SI = 1.4 +/- 0.1 for uPA to SI = 13 +/- 3 for thrombin, Analysis of the variations in inhibition kinetics shows that when serpins act at ion: concentrations, comparable with the target protease or with K(I) (as appears likely for SERP-1 in vivo), inhibitory specificity becomes less dominated by It,, and is increasingly dependent on partitioning within the branched reaction mechanism and on the lifetime of the inhibited complex.	Robarts Res Inst, London, ON N6G 2V4, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Biogen Inc, Dept Prot Engn, Cambridge, MA 02142 USA; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6G 2V4, Canada	Western University (University of Western Ontario); University of Alberta; Biogen; Western University (University of Western Ontario)	McFadden, G (corresponding author), Robarts Res Inst, 1400 Western Rd,SDRI 133, London, ON N6G 2V4, Canada.							BLOCK W, 1985, VIROLOGY, V140, P113, DOI 10.1016/0042-6822(85)90450-7; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1987, COLD SPRING HARB SYM, V52, P527, DOI 10.1101/SQB.1987.052.01.060; CHRISTENSEN S, 1995, J BIOL CHEM, V270, P14859, DOI 10.1074/jbc.270.25.14859; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Fenner F., 1978, Viruses and environment, P539; FENNER F, 1965, MYXOMATOSIS; GETTINS P, 1993, BIOESSAYS, V15, P461, DOI 10.1002/bies.950150705; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; GHENDLER Y, 1994, EXP PARASITOL, V78, P121, DOI 10.1006/expr.1994.1013; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gils A, 1997, J BIOL CHEM, V272, P12662, DOI 10.1074/jbc.272.19.12662; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; JAMESON GW, 1973, BIOCHEM J, V131, P101; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LOMAS DA, 1993, J BIOL CHEM, V268, P516; Lucas A, 1996, CIRCULATION, V94, P2890, DOI 10.1161/01.CIR.94.11.2890; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; Maksymowych WP, 1996, J RHEUMATOL, V23, P878; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MCFADDEN G, 1995, J LEUKOCYTE BIOL, V57, P731, DOI 10.1002/jlb.57.5.731; MCFADDEN G, 1995, VIROCEPTORS VIROKINE; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MULDBJERG M, 1993, BLOOD COAGUL FIBRIN, V4, P47, DOI 10.1097/00001721-199304010-00008; Nash P, 1997, ADV EXP MED BIOL, V425, P195; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; PATSTON PA, 1991, BIOCHEMISTRY-US, V30, P8876, DOI 10.1021/bi00100a022; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; PATSTON PA, 1994, SEMIN THROMB HEMOST, V20, P410, DOI 10.1055/s-2007-1001929; Patston PA, 1996, FEBS LETT, V383, P87, DOI 10.1016/0014-5793(96)00231-1; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; Rubin H, 1996, NAT MED, V2, P632, DOI 10.1038/nm0696-632; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P100; Schechter NM, 1997, J BIOL CHEM, V272, P24499, DOI 10.1074/jbc.272.39.24499; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; Turner PC, 1995, VIROCEPTORS VIROKINE, P67; UPTON C, 1990, VIROLOGY, V179, P618, DOI 10.1016/0042-6822(90)90129-F; WILCZYNSKA M, 1995, J BIOL CHEM, V270, P29652; Wilczynska M, 1997, NAT STRUCT BIOL, V4, P354, DOI 10.1038/nsb0597-354; WRIGHT HT, 1994, PROTEIN-STRUCT FUNCT, V22, P210; YENBUTR P, 1995, INFECT IMMUN, V63, P1745, DOI 10.1128/IAI.63.5.1745-1753.1995; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	51	77	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20982	20991		10.1074/jbc.273.33.20982	http://dx.doi.org/10.1074/jbc.273.33.20982			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694848	hybrid			2022-12-27	WOS:000075386100041
J	Zhao, ZW; Weiner, JH				Zhao, ZW; Weiner, JH			Interaction of 2-n-heptyl-4-hydroxyquinoline-N-oxide with dimethyl sulfoxide reductase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR MOLYBDOENZYME; DIMETHYLSULFOXIDE REDUCTASE; LACTATE DEHYDROGENASE; SUBSTRATE-SPECIFICITY; FUMARATE REDUCTASE; BINDING; COMPLEX; SITE; TITRATION; MEMBRANE	colinWe have studied the interaction of the menaquinol analog 2-n-heptyl-4-hydroxyquinoline-N-oxide (HOQNO) with dimethyl sulfoxide reductase (DmsABC) and the effect of a mutation in the DmsC subunit (DmsABC(H65R)) using fluorescence titration and stopped-flow methods. The titration data show that the HOQNO fluorescence is quenched when HOQNO binds to DmsABC. The binding stoichiometry is determined to be about 1:1. The mutant DmsABCH65R blocks HOQNO binding to the protein. It is therefore proposed that there is one high-affinity HOQNO binding site per DmsABC molecule located in the DmsC subunit. Stopped-flow kinetic studies show that the interaction can be described by a two-step equilibrium model, a fast bimolecular step followed by a slow unimolecular step. The quenching of HOQNO fluorescence occurs in the bimolecular step. The rates for the forward and reverse reaction of the first equilibrium are determined to be k(1) = (3.9 +/- 0.3) x 10(5) M-1 s(-1) and k(2) = 0.10 +/- 0.01 s(-1) respectively. The dissociation constant for the first equilibrium, K-dI = k(2)/k(1) is calculated to be about 260 nM. The upper limit of the overall dissociation constant is estimated to be 6 nM.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Medical Research Council Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Weiner, JH (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	joel.weiner@ualberta.ca		Zhao, Zhongwei/0000-0003-4081-7077				BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRANDT U, 1991, EUR J BIOCHEM, V195, P163, DOI 10.1111/j.1432-1033.1991.tb15690.x; Buc J, 1995, EUR J BIOCHEM, V234, P766, DOI 10.1111/j.1432-1033.1995.766_a.x; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; CECCHINI G, 1995, J BACTERIOL, V177, P4587, DOI 10.1128/jb.177.16.4587-4592.1995; CORNFORTH JW, 1956, BIOCHEM J, V63, P124, DOI 10.1042/bj0630124; Giordani R, 1997, EUR J BIOCHEM, V250, P567, DOI 10.1111/j.1432-1033.1997.0567a.x; HALFORD SE, 1975, BIOCHEM J, V149, P411, DOI 10.1042/bj1490411; HAMMES GG, 1982, ENZYME CATALYSIS REG, P61; HIROMI K, 1979, KINETICS FAST ENZYME, P187; Holland LZ, 1997, BIOCHEMISTRY-US, V36, P3207, DOI 10.1021/bi962664k; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KOTIK M, 1992, BIOCHEMISTRY-US, V31, P7787, DOI 10.1021/bi00149a007; Magalon A, 1998, J BIOL CHEM, V273, P10851, DOI 10.1074/jbc.273.18.10851; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; PAULSEN KE, 1993, METHOD ENZYMOL, V227, P396; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; Rothery RA, 1998, EUR J BIOCHEM, V254, P588, DOI 10.1046/j.1432-1327.1998.2540588.x; ROY C, 1997, STRUCTURE LOND, V5, P1339; Sambrook J., 2002, MOL CLONING LAB MANU; SHIRAISHI F, 1992, J BIOL CHEM, V267, P22934; SimalaGrant JL, 1996, MICROBIOL-SGM, V142, P3231, DOI 10.1099/13500872-142-11-3231; TRIEBER CA, 1994, J BIOL CHEM, V269, P7103; VANARK G, 1977, BIOCHIM BIOPHYS ACTA, V459, P119, DOI 10.1016/0005-2728(77)90014-7; VanHellemond JJ, 1995, J BIOL CHEM, V270, P31065, DOI 10.1074/jbc.270.52.31065; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WEINER JH, 1993, J BIOL CHEM, V268, P3238; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	34	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20758	20763		10.1074/jbc.273.33.20758	http://dx.doi.org/10.1074/jbc.273.33.20758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694819	hybrid			2022-12-27	WOS:000075386100012
J	Edgerton, M; Koshlukova, SE; Lo, TE; Chrzan, BG; Straubinger, RM; Raj, PA				Edgerton, M; Koshlukova, SE; Lo, TE; Chrzan, BG; Straubinger, RM; Raj, PA			Candidacidal activity of salivary histatins - Identification of a histatin 5-binding protein on Candida albicans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH POLYPEPTIDES; HUMAN-PAROTID SECRETION; BLASTOSPORE VIABILITY; HELICAL CONFORMATION; ANTIFUNGAL ACTIVITY; FUNCTIONAL DOMAIN; HIV-INFECTION; ORAL CANDIDA; PEPTIDE; INHIBITION	Candida albicans is the predominant species of yeast isolated from patients with oral candidiasis, which is frequently a symptom of human immunodeficiency virus infection and is a criterion for staging and progression of AIDS, Salivary histatins (Hsts) are potent in vitro antifungal agents and have great promise as therapeutic agents in humans with oral candidiasis, The molecular mechanisms by which Hsts kill yeast cells are not known. We report here, that unlike other antimicrobial proteins, Hsts do not display lytic activities to lipid membranes, measured by release and dequenching of the fluorescent dye calcein, Analysis of the magnitude and time course of Hst-induced calcein release from C. albicans cells further showed that loss of cell integrity was a secondary effect following cell death, rather than the result of primary disruption of the yeast cell membrane. I-125-Hst 5 binding studies indicated that C. albicans expressed a class of saturable binding sites (K-D = 1 ELM), numbering 8.6 x 10(5) sites/cell. Both Hst 3 and Hst 4 competed for these binding sites with similar affinities, which is consistent with the micromolar concentration of Hsts required for candidacidal activity. Specific I-125-Hst 5 binding was not detected to C. albicans spheroplasts, which were 14-fold less susceptible to Hst 5 killing, compared with intact cells in candidacidal assays. in overlay experiments, I-125-Hst 5 bound to a 67-kDa protein detected in C, albicans whole cell lysates and crude membrane fractions, but not in the yeast cell wall fraction. Consistent with the overlay data, cross-linking of I-125-Hst 5 to C. albicans resulted in the appearance of a specific 73-kDa I-125-Hst B-containing complex that was not detected in the cell wall. I-125-Hst B-binding protein of similar size was also observed in susceptible S, cerevisiae strain TI#20, This is the first description of Hst 5 binding sites on C, albicans which mediate cell killing and identification of a 67-kDa yeast Hst 5-binding protein. The binding characteristics of Hst 5 are in agreement with the observed potency of its biological effect and provide crucial information to the use of Hst 5 as a therapeutic agent. The presence of a specific C. albicans Hst 5-binding protein provides further insight into the potential mechanism of yeast killing and suggests a basis for differential activity between yeast killing and the nontoxic nature of Hsts to humans.	SUNY Buffalo, Dept Oral Biol, Sch Dent Med, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Restorat Dent, Sch Dent Med, Buffalo, NY 14214 USA; SUNY Buffalo, Dept Pharmaceut, Buffalo, NY 14214 USA; MIT, Div Toxicol, Cambridge, MA 02139 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Massachusetts Institute of Technology (MIT)	Edgerton, M (corresponding author), SUNY Buffalo, Dept Oral Biol, Sch Dent Med, 310 Foster Hall,3435 Main St, Buffalo, NY 14214 USA.	mira_edgerton@sdm.buffalo.edu	RAJ, PROFESSORDES/AAA-1007-2020	RAJ, PROFESSORDES/0000-0002-4050-4778	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR027232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010641] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012159, R29DE010641, P50DE004898] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BEGGS WH, 1994, ANTIMICROB AGENTS CH, V38, P363, DOI 10.1128/AAC.38.2.363; Bolard J., 1991, Candida albicans. Cellular and molecular biology., P214; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; Bossche H. vanden, 1991, Candida albicans. Cellular and molecular biology., P239; BOUCHARA JP, 1990, INFECT IMMUN, V58, P48, DOI 10.1128/IAI.58.1.48-54.1990; BOURDINEAUD JP, 1990, MOL MICROBIOL, V4, P1737, DOI 10.1111/j.1365-2958.1990.tb00551.x; CALDERONE RA, 1988, INFECT IMMUN, V56, P252, DOI 10.1128/IAI.56.1.252-258.1988; CALDERONE RA, 1991, MICROBIOL REV, V55, P1; CANNON RD, 1995, J DENT RES, V74, P1152, DOI 10.1177/00220345950740050301; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; COLEMAN DC, 1993, CRIT REV MICROBIOL, V19, P61, DOI 10.3109/10408419309113523; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; Driscoll J, 1996, GENE, V177, P29, DOI 10.1016/0378-1119(96)00265-X; DUCLOHIER H, 1994, TOXICOLOGY, V87, P175, DOI 10.1016/0300-483X(94)90160-0; EDGERTON M, 1995, J BIOMED MATER RES, V29, P1277, DOI 10.1002/jbm.820291015; EDGERTON M, 1993, INFECT IMMUN, V61, P2644, DOI 10.1128/IAI.61.6.2644-2652.1993; Evans LJA, 1996, J MOL BIOL, V255, P559, DOI 10.1006/jmbi.1996.0047; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; GAZIT E, 1994, BIOCHEMISTRY-US, V33, P10681, DOI 10.1021/bi00201a016; GEORGOPAPADAKOU NH, 1994, SCIENCE, V264, P371, DOI 10.1126/science.8153622; GREENSPAN D, 1994, ORAL SURG ORAL MED O, V78, P211, DOI 10.1016/0030-4220(94)90149-X; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KITAMURA K, 1972, J GEN APPL MICROBIOL, V18, P57, DOI 10.2323/jgam.18.57; LAL K, 1992, J ACQ IMMUN DEF SYND, V5, P904; LAZDUNSKI CJ, 1995, MOL MICROBIOL, V16, P1059, DOI 10.1111/j.1365-2958.1995.tb02331.x; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; Lubkowitz MA, 1997, MICROBIOL-UK, V143, P387, DOI 10.1099/00221287-143-2-387; MACKAY BJ, 1984, INFECT IMMUN, V44, P695, DOI 10.1128/IAI.44.3.695-701.1984; MEITNER SW, 1990, INFECT IMMUN, V58, P2228, DOI 10.1128/IAI.58.7.2228-2236.1990; MURAKAMI Y, 1991, FEMS MICROBIOL LETT, V82, P253; NEGRE E, 1994, J BIOL CHEM, V269, P22039; OConnell BC, 1996, HUM GENE THER, V7, P2255, DOI 10.1089/hum.1996.7.18-2255; OPPENHEIM FG, 1988, J BIOL CHEM, V263, P7472; OPPENHEIM FG, 1986, J BIOL CHEM, V261, P1177; PARK NG, 1992, BIOCHEMISTRY-US, V31, P12241, DOI 10.1021/bi00163a038; POLLOCK JJ, 1984, INFECT IMMUN, V44, P702, DOI 10.1128/IAI.44.3.702-707.1984; RAJ PA, 1990, J BIOL CHEM, V265, P3898; RAJ PA, 1994, J BIOL CHEM, V269, P9610; Raj PA, 1998, BIOPOLYMERS, V45, P51, DOI 10.1002/(SICI)1097-0282(199801)45:1<51::AID-BIP5>3.0.CO;2-Y; Raj PA, 1996, BIOCHEMISTRY-US, V35, P4314, DOI 10.1021/bi951681r; Raj Periathamby Anthony, 1995, FEBS Letters, V368, P526, DOI 10.1016/0014-5793(95)00712-I; RUHR E, 1985, ANTIMICROB AGENTS CH, V27, P841, DOI 10.1128/AAC.27.5.841; SABATINI LM, 1989, BIOCHEM BIOPH RES CO, V160, P495, DOI 10.1016/0006-291X(89)92460-1; SANTARPIA RP, 1988, ARCH ORAL BIOL, V33, P567, DOI 10.1016/0003-9969(88)90131-8; SANTARPIA RP, 1990, ORAL MICROBIOL IMMUN, V5, P226, DOI 10.1111/j.1399-302X.1990.tb00651.x; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STRAHILEVITZ J, 1994, BIOCHEMISTRY-US, V33, P10951, DOI 10.1021/bi00202a014; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; TROXLER RF, 1990, J DENT RES, V69, P2, DOI 10.1177/00220345900690010101; Tsai H, 1997, ANTIMICROB AGENTS CH, V41, P2224, DOI 10.1128/AAC.41.10.2224; Tsai HY, 1996, INFECT IMMUN, V64, P5000, DOI 10.1128/IAI.64.12.5000-5007.1996; VANBELKUM MJ, 1991, J BACTERIOL, V173, P7934, DOI 10.1128/jb.173.24.7934-7941.1991; VANDENBOSSCHE H, 1987, CRIT REV MICROBIOL, V15, P57; XU L, 1993, ARCH ORAL BIOL, V38, P277, DOI 10.1016/0003-9969(93)90133-7; XU T, 1991, INFECT IMMUN, V59, P2549, DOI 10.1128/IAI.59.8.2549-2554.1991; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YPHANTIS DA, 1967, J BACTERIOL, V94, P1509, DOI 10.1128/JB.94.5.1509-1515.1967; ZUO Y, 1995, GENE, V161, P87, DOI 10.1016/0378-1119(95)00237-Z; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	71	159	165	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20438	20447		10.1074/jbc.273.32.20438	http://dx.doi.org/10.1074/jbc.273.32.20438			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685398	hybrid			2022-12-27	WOS:000075305400075
J	Escola, JM; Kleijmeer, MJ; Stoorvogel, W; Griffith, JM; Yoshie, O; Geuze, HJ				Escola, JM; Kleijmeer, MJ; Stoorvogel, W; Griffith, JM; Yoshie, O; Geuze, HJ			Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; SPAN-TRANSMEMBRANE PROTEIN; INVARIANT CHAIN COMPLEXES; GROWTH-FACTOR RECEPTOR; LEUKEMIA-VIRUS TYPE-1; T-CELL ACTIVATION; SYNCYTIUM FORMATION; HLA-DR; LYSOSOMAL COMPARTMENTS; LYMPHOBLASTOID CELLS	Association of major histocompatibility complex (MHC) class II molecules with peptides occurs in a series of endocytic vacuoles, termed MHC class II-enriched compartments (MIICs). Morphological criteria have defined several types of MIICs, including multivesicular MIICs, which are composed of 50-60-nm vesicles surrounded by a limiting membrane. Multivesicular MIICs can fuse with the plasma membrane, thereby releasing their internal vesicles into the extracellular space. The externalized vesicles, termed exosomes, carry MHC class II and can stimulate T-cells in, vitro. In this study, we show that exosomes are enriched in the co-stimulatory molecule CD86 and in several tetraspan proteins, including CD37, CD53, CD63, CD81, and CD82, Interestingly, subcellular localization of these molecules revealed that they were concentrated on the internal membranes of multivesicular MIICs, In contrast to the tetraspans, other membrane proteins of MIICs, such as HLA-DM, Lamp-1, and Lamp-a, were mainly localized to the limiting membrane and mere hardly detectable on the internal membranes of MIICs nor on exosomes, Because internal vesicles of multivesicular MIICs are thought to originate from inward budding of the limiting membrane, the differential distribution of membrane proteins on the internal and limiting membranes of MIICs has to be driven by active protein sorting.	Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Shionogi Inst Med Sci, Osaka 566, Japan	Utrecht University; Shionogi & Company Limited	Geuze, HJ (corresponding author), Univ Utrecht, Sch Med, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	H.J.Geuze@lab.azu.nl	Eckhardt, Erik/G-1567-2010	Yoshie, Osamu/0000-0003-4353-5809				ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; Cibotti R, 1997, IMMUNITY, V6, P245, DOI 10.1016/S1074-7613(00)80327-1; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GEUZE H, 1994, EUR J CELL BIOL, V64, P3; GEUZE HJ, 1981, J CELL BIOL, V89, P653, DOI 10.1083/jcb.89.3.653; Glickman JN, 1996, J CELL BIOL, V132, P769, DOI 10.1083/jcb.132.5.769; HAMMOND C, IN PRESS J IMMUNOL; HARDING CV, 1993, J IMMUNOL, V151, P3988; HARDING CV, 1992, J CELL BIOL, V119, P531, DOI 10.1083/jcb.119.3.531; IMAI T, 1992, J IMMUNOL, V149, P2879; IMAI T, 1993, J IMMUNOL, V151, P6470; IMAI T, 1995, J IMMUNOL, V155, P1229; JOHNSTONE RM, 1992, BIOCHEM CELL BIOL, V70, P179, DOI 10.1139/o92-028; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; Kleijmeer Monique J., 1996, Methods (Orlando), V10, P191, DOI 10.1006/meth.1996.0095; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAMB CA, 1992, J IMMUNOL, V148, P3478; Lazo PA, 1997, CELL IMMUNOL, V178, P132, DOI 10.1006/cimm.1997.1139; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Mannion BA, 1996, J IMMUNOL, V157, P2039; Morkowski S, 1997, EUR J IMMUNOL, V27, P609, DOI 10.1002/eji.1830270306; MORTON PA, 1995, J IMMUNOL, V154, P137; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; PATERSON DJ, 1987, J EXP MED, V165, P1, DOI 10.1084/jem.165.1.1; PATERSON DJ, 1987, J EXP MED, V166, P1603, DOI 10.1084/jem.166.5.1603; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; RAPOSO G, 1997, WEIRS HDB EXPT IMMUN; REILLY PL, 1995, J IMMUNOL, V155, P529; RENFREW CA, 1991, J BIOL CHEM, V266, P21265; RIBERDY JM, 1994, J CELL BIOL, V125, P1225, DOI 10.1083/jcb.125.6.1225; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sanderson F, 1996, IMMUNITY, V4, P87, DOI 10.1016/S1074-7613(00)80301-5; Sanderson F, 1995, CURR BIOL, V5, P1372, DOI 10.1016/S0960-9822(95)00274-0; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOT JW, 1988, METHOD MICROBIOL, V20, P211, DOI 10.1016/S0580-9517(08)70053-9; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; TOOTHILL VJ, 1990, J IMMUNOL, V145, P283; VANDEURS B, 1993, EUR J CELL BIOL, V61, P208; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; Wubbolts R, 1996, J CELL BIOL, V135, P611, DOI 10.1083/jcb.135.3.611	63	848	893	2	66	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20121	20127		10.1074/jbc.273.32.20121	http://dx.doi.org/10.1074/jbc.273.32.20121			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685355	hybrid			2022-12-27	WOS:000075305400032
J	Freeman, JLR; De La Cruz, EM; Pollard, TD; Lefkowitz, RJ; Pitcher, JA				Freeman, JLR; De La Cruz, EM; Pollard, TD; Lefkowitz, RJ; Pitcher, JA			Regulation of G protein-coupled receptor kinase 5 (GRK5) by actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; SKELETAL-MUSCLE; F-ACTIN; PURIFICATION; IDENTIFICATION; ACTIVATION; CALMODULIN; FAMILY; POLYMERIZATION; ASSOCIATION	Gr protein-coupled receptor kinases (GRKs) initiate pathways leading to the desensitization of agonist-occupied G-protein-coupled receptors (GPCRs), Here we report that the cytoskeletal protein actin binds and inhibits GRK5, Actin inhibits the kinase activity directly, reducing GRK5-mediated phosphorylation of both membrane-bound GPCRs and soluble substrates, GRK5 binds actin monomers with a K-d of 0.6 mu M and actin filaments with a K-d of 0.2 mu M. Mutation of 6 amino acids near the amino terminus of GRK5 eliminates actin-mediated inhibition of GRK5. Calmodulin has previously been shown to bind to the amino terminus of GRK5 (Pronin, A. N., and Benovic, J. L. (1997) J. Biol, Chem. 272, 3806-3812) and here we show calmodulin displaces GRK5 from actin. Calmodulin inhibits GRK5-mediated phosphorylation of GPCRs, but not soluble substrates such as casein. Thus in the presence of actin, calmodulin determines the substrate specificity of GRK5 by preferentially allowing phosphorylation of soluble substrates over membrane-bound substrates.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Salk Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Pitcher, Julie/ABH-2078-2020; Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL 16737] Funding Source: Medline; NIGMS NIH HHS [GM26338] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026338] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ARNOLD H, 1970, EUR J BIOCHEM, V15, P360, DOI 10.1111/j.1432-1033.1970.tb01016.x; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; Brown N G, 1993, Eur J Biochem, V212, P840; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; COOPER JA, 1985, BIOCHEMISTRY-US, V24, P793, DOI 10.1021/bi00324a039; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; FREEDMAN NJ, 1996, RECENT PROG HORM RES, V51, P352; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HITCHCOCKDEGREGORI SE, 1988, BIOCHEMISTRY-US, V27, P9182, DOI 10.1021/bi00426a016; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; Karino A, 1996, FEBS LETT, V398, P317, DOI 10.1016/S0014-5793(96)01266-5; KIM CM, 1993, RECEPTOR, V3, P39; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEISER M, 1986, J BIOL CHEM, V261, P1904; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; POLLARD TD, 1984, J CELL BIOL, V99, P1970, DOI 10.1083/jcb.99.6.1970; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Sallese M, 1997, J BIOL CHEM, V272, P10188; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WALSH TP, 1977, BIOCHEM J, V165, P165, DOI 10.1042/bj1650165	36	43	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20653	20657		10.1074/jbc.273.32.20653	http://dx.doi.org/10.1074/jbc.273.32.20653			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685424	hybrid			2022-12-27	WOS:000075305400101
J	Knudsen, KE; Arden, KC; Cavenee, KK				Knudsen, KE; Arden, KC; Cavenee, KK			Multiple G(1) regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; D-TYPE CYCLINS; CANCER-CELLS; PROTEIN FUNCTION; KINASE-ACTIVITY; ATPASE ACTIVITY; T-ANTIGEN; LNCAP; FIBROBLASTS; PHASE	Prostatic epithelial cells and most primary prostate tumors are dependent on androgen for growth, but how androgen regulates cellular proliferation remains unsolved. Using poorly understood mechanisms, recurrent tumor cells evade the androgen requirement. We utilized androgen-dependent prostatic tumor cells to demonstrate that androgen exerts its effect on the cell cycle by influencing specific aspects of G(1)-S progression. Androgen depletion of these cells results in early G(1) arrest, characterized by reduced cyclin dependent kinase activity, and underphosphorylated retinoblastoma tumor suppressor protein (RB), The reduction in kinase activity was partially attributed to reduction of specific G(1) cyclins and alternate regulation of cyclin-dependent kinase inhibitors, Using this information, we developed a reliable assay to assess the ability of specific G(1) regulatory proteins to circumvent these controls and promote androgen-independent growth. As expected, inactivation of RE was required for progression through the cell cycle. Surprisingly, overexpression of G(1) cyclins, which drives RE phosphorylation, was insufficient to promote androgen-independent cell cycle progression. Introduction of viral oncoproteins did promote G(1)-S progression in the absence of androgen, dependent on their ability to sequester RE and related proteins. These results provide the first evidence that multiple elements governing the G(1)-S transition dictate androgen-dependent growth, and the formation of androgen-independent prostatic tumors may be because of misregulation of these processes.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Cavenee, KK (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.			Knudsen, Karen/0000-0002-1301-890X				Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BERCHEM GJ, 1995, CANCER RES, V55, P735; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CARTER BS, 1990, P NATL ACAD SCI USA, V87, P8751, DOI 10.1073/pnas.87.22.8751; Chen Y, 1996, ONCOGENE, V13, P1765; Conzen SD, 1995, ONCOGENE, V11, P2295; Cunningham JM, 1996, CANCER RES, V56, P4475; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Denmeade SR, 1996, PROSTATE, V28, P251; ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; HERMAN JG, 1995, CANCER RES, V55, P4525; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, CANCER RES, V58, P2042; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1996, P NATL ACAD SCI USA, V93, P8278, DOI 10.1073/pnas.93.16.8278; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; MONTIE JE, 1994, UROLOGY, V43, P892, DOI 10.1016/0090-4295(94)90163-5; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Mymryk JS, 1996, ONCOGENE, V13, P1581; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEEPER DS, 1994, BBA-REV CANCER, V1198, P215, DOI 10.1016/0304-419X(94)90015-9; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAVENNA L, 1995, PROSTATE, V26, P290, DOI 10.1002/pros.2990260604; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAROFF J, 1980, ONCOLOGY-BASEL, V37, P46, DOI 10.1159/000225401; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Tsai J, 1996, J BIOL CHEM, V271, P9347, DOI 10.1074/jbc.271.16.9347; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WALL D, 1994, J BIOL CHEM, V269, P5446; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WENDEROTH UK, 1983, ENDOCRINOLOGY, V113, P569, DOI 10.1210/endo-113-2-569; WILDING G, 1995, CANCER SURV, V23, P43; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991	67	163	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20213	20222		10.1074/jbc.273.32.20213	http://dx.doi.org/10.1074/jbc.273.32.20213			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685369	hybrid			2022-12-27	WOS:000075305400046
J	McGinnis, KM; Whitton, MM; Gnegy, ME; Wang, KKW				McGinnis, KM; Whitton, MM; Gnegy, ME; Wang, KKW			Calcium/calmodulin-dependent protein kinase IV is cleaved by caspase-3 and calpain in SH-SY5Y human neuroblastoma cells undergoing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; HUMAN HEPATOMA-CELLS; POLY(ADP-RIBOSE) POLYMERASE; CYSTEINE PROTEASE; CA2+-ATPASE INHIBITOR; NEURONAL APOPTOSIS; MOLECULAR-CLONING; ACTIVATION; PHOSPHORYLATION; EXPRESSION	We have previously demonstrated cleavage of alpha-spectrin by caspase-3 and calpain during apoptosis in SH-SY5Y neuroblastoma cells (Nath, R, Raser, K, J., Stafford, D., Hajimohammadreza, I., Posner, A., Alien, H,, Talanian, R, V,, Yuen, P,, Gilbertsen, R. B,, and Wang, K, K, (1996) Biochem. J, 319, 683-690). We demonstrate here that calcium/calmodulin-dependent protein kinase IV (CaMK TV) is cleaved during apoptosis by caspase-3 and calpain, We challenged SH-SY5Y cells with the pro-apoptotic agent thapsigargin. Western blot analysis revealed major CaMK IV breakdown. products of 40, 38, and 33 kDa, Digestion of control SH-SY5Y lysate with purified caspase-3 produced a 38-kDa CaMK IV fragment; digestion with purified calpain produced a major fragment of 40 kDa, Pretreatment with carbobenzoxy-Asp-CH2OC(O)-2,6-dichlorobenzene or Z-Val-Ala-Asp-fluoromethylketone was able to block the caspase-3-mediated production of the 38-kDa fragment both in situ and in vitro. Calpain inhibitor II similarly blocked formation of the calpain-mediated 40-kDa fragment both in situ and in vitro. Digestion of recombinant CaMK TV by other caspase family members revealed that only caspase-3 produces a fragmentation pattern consistent to that seen in situ. The major caspase-3 and calpain cleavage sites are respectively identified as PAPD(176)*A and CG(201)*A, both within the CaMK TV catalytic domain. Furthermore, calmodulin-stimulated protein kinase activity decreases within 6 h in thapsigargin-treated SH-SY5Y, The loss of activity precedes cell death.	Warner Lambert Co, Dept Neurosci Therapeut, Lab Neurobiochem, Parke Davis Pharmaceut Res Div, Ann Arbor, MI 48105 USA; Warner Lambert Co, Dept Chem, Lab Neurobiochem, Parke Davis Pharmaceut Res Div, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	Pfizer; Pfizer; University of Michigan System; University of Michigan	Wang, KKW (corresponding author), Warner Lambert Co, Dept Neurosci Therapeut, Lab Neurobiochem, Parke Davis Pharmaceut Res Div, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.			Wang, Kevin/0000-0002-9343-6473	NIGMS NIH HHS [5T32GM07767] Funding Source: Medline; NIMH NIH HHS [MH36044] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH036044] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; Alevizopoulos A, 1997, J BIOL CHEM, V272, P23597, DOI 10.1074/jbc.272.38.23597; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Cain K, 1996, BIOCHEM J, V314, P27, DOI 10.1042/bj3140027; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; CHURN SB, 1995, J NEUROSCI, V15, P3200; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; EARNSHAW WC, 1987, J CELL BIOL, V105, P1479, DOI 10.1083/jcb.105.4.1479; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HARRIS AS, 1989, J BIOL CHEM, V264, P17401; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; Ho N, 1996, J EXP MED, V184, P101, DOI 10.1084/jem.184.1.101; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Ji RR, 1996, BRAIN RES, V721, P167, DOI 10.1016/0006-8993(95)01316-4; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; Kawamura KI, 1996, BIOCHEM PHARMACOL, V52, P1903, DOI 10.1016/S0006-2952(96)00692-2; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Posmantur R, 1997, J NEUROCHEM, V68, P2328; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Talanian RV, 1997, J BIOL CHEM, V272, P9677; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOMBES RM, 1995, CELL GROWTH DIFFER, V6, P1063; TSUKAMOTO A, 1993, CELL BIOL INT, V17, P969, DOI 10.1006/cbir.1993.1021; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wang KKW, 1996, BIOTECHNIQUES, V20, P662; Watanabe S, 1996, J BIOL CHEM, V271, P6903, DOI 10.1074/jbc.271.12.6903; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	70	87	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19993	20000		10.1074/jbc.273.32.19993	http://dx.doi.org/10.1074/jbc.273.32.19993			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685336	hybrid			2022-12-27	WOS:000075305400013
J	Bashour, AM; Bloom, GS				Bashour, AM; Bloom, GS			58K, a microtubule-binding golgi protein, is a formiminotransferase cyclodeaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST AXONAL-TRANSPORT; ALPHA-TUBULIN; MONOCLONAL-ANTIBODIES; KINESIN HEAVY; BREFELDIN-A; RAT-LIVER; APPARATUS; CELLS; IDENTIFICATION; SYSTEM	58K was previously identified as a rat liver protein that binds microtubules in vitro and is associated with the cytoplasmic surface of the Golgi apparatus in vivo (Bloom, G. S., and Brashear, T. A. (1989) J. Biol. Chem. 264, 16083-16092). We now report that 58K is a formiminotransferase cyclodeaminase (FTCD), a bifunctional enzyme that catalyzes two consecutive steps in the modification of tetrahydrofolate to 5,10-methenyl tetrahydrofolate. Comparative immunoblotting using several monoclonal antibodies made against 58K and a polyclonal antibody made against a chicken liver protein (p60) with similar properties (Hennig, D., Scales, S. J., Moreau, A., Murley, L. L., De Mey, J., and Kreis, T. E. (1998) J. Biol. Chem. 273, 19602-19611) demonstrated precise co purification of protein recognized by all antibodies through multiple fractionation steps, including gel filtration and ion exchange chromatography, and sucrose gradient ultracentrifugation. Eight peptides derived from 58K showed high sequence identity to amino acid sequences predicted by full length cDNA for p60 and porcine liver FTCD. Furthermore, purified 58K was associated with formiminotransferase and cyclodeaminase activities. Based on these collective results, 58K was concluded to be a rat liver version of FTCD. Microtubules assembled from brain tubulin, but not from liver tubulin, were able to bind rat liver FTCD. Binding to brain microtubules is suspected to occur via polyglutamates that are added post-translationally to tubulin in brain, which was shown to contain very low levels of FTCD, but not to tubulin in liver, which was determined to be the richest tissue source, by far, of FTCD. The physiologial significance of the microtubule binding activity of FTCD is thus called into question, but an association of FTCD with the Golgi apparatus has now been established.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bloom, GS (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.							ABERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BEAUDET R, 1976, BIOCHIM BIOPHYS ACTA, V453, P151, DOI 10.1016/0005-2795(76)90259-2; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BLOOM GS, 1985, BIOCHEMISTRY-US, V24, P4185, DOI 10.1021/bi00336a055; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BLOOM GS, 1985, P NATL ACAD SCI USA, V82, P5405; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; BULINSKI JC, 1979, P NATL ACAD SCI USA, V76, P293, DOI 10.1073/pnas.76.1.293; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; ELLURU RG, 1995, MOL BIOL CELL, V6, P21, DOI 10.1091/mbc.6.1.21; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; Hennig D, 1998, J BIOL CHEM, V273, P19602, DOI 10.1074/jbc.273.31.19602; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; KOTANI S, 1988, J BIOL CHEM, V263, P5385; KOTANI S, 1986, EUR J BIOCHEM, V156, P23, DOI 10.1111/j.1432-1033.1986.tb09543.x; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MOSKALEWSKI S, 1975, EXP CELL RES, V95, P440, DOI 10.1016/0014-4827(75)90569-8; MURLEY LL, 1993, J BIOL CHEM, V268, P22820; OLMSTED JB, 1981, J BIOL CHEM, V256, P3507; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; RAMBOURG A, 1974, AM J ANAT, V140, P27, DOI 10.1002/aja.1001400103; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; SCHOLEY JM, 1984, J BIOL CHEM, V259, P6516; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; TABOR H, 1959, J BIOL CHEM, V234, P1830; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1983, P NATL ACAD SCI-BIOL, V80, P6259, DOI 10.1073/pnas.80.20.6259; VOET D, 1990, BIOCHEMISTRY-US, P691; WEHLAND J, 1983, P NATL ACAD SCI-BIOL, V80, P4286, DOI 10.1073/pnas.80.14.4286; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WEITMAN S, 1994, VITAMIN RECPETORS VI, P259; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; ZAMIEROWSKI M, 1974, BIOCHEM BIOPH RES CO, P81	47	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19612	19617		10.1074/jbc.273.31.19612	http://dx.doi.org/10.1074/jbc.273.31.19612			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677387	hybrid			2022-12-27	WOS:000075125200039
J	Du, Q; Melnikova, IN; Gardner, PD				Du, Q; Melnikova, IN; Gardner, PD			Differential effects of heterogeneous nuclear ribonucleoprotein K on Sp1- and Sp3-mediated transcriptional activation of a neuronal nicotinic acetylcholine receptor promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SUBUNIT MESSENGER-RNAS; BINDING-PROTEIN; GENE PROMOTER; ALPHA-3 GENE; POU DOMAIN; RAT; DNA; BETA-4; BRAIN	The neuronal nicotinic acetylcholine receptor gene family consists of II members, alpha 2-alpha 9 and beta 2-beta 4, Three of the genes, those encoding the alpha 3, alpha 5, and beta 4 subunits, are clustered tightly within the genome. These three subunits constitute the predominant acetylcholine receptor subtype expressed in the peripheral nervous system. The genomic proximity of the three genes suggests a regulatory mechanism ensuring their coordinate expression. However, it is likely that gene-specific regulatory mechanisms are also functioning because the expression patterns of the three genes, although similar, are not identical. Previously we identified regulatory elements within the beta 4 promoter region and demonstrated that these elements interact specifically with nuclear proteins. One of these elements, E1, interacts with the regulatory factor Pur alpha as well as three other unidentified DNA-binding proteins with. molecular masses of 31, 65, and 114 kDa, Another element, E2, interacts with Spl and Sp3, Because El and E2 are immediately adjacent to one another, we postulated that the proteins that bind to the elements interact to regulate beta 4 gene expression. Here we report the identification of the 65-kDa El-binding protein as heterogeneous nuclear ribonucleoprotein K and demonstrate that it affects the transactivation of beta 4 promoter activity by Spl and Sp3 differentially.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Gardner, PD (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.	gardner@uthscsa.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030243] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30243, R01 NS030243] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMADOR M, 1995, J NEUROSCI, V15, P4525; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1996, J BIOL CHEM, V271, P32842, DOI 10.1074/jbc.271.51.32842; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BOULTER J, 1990, J BIOL CHEM, V265, P4472; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; CONROY WG, 1992, NEURON, V9, P679, DOI 10.1016/0896-6273(92)90031-8; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Criado M, 1997, J NEUROSCI, V17, P6554; DAUBAS P, 1993, P NATL ACAD SCI USA, V90, P2237, DOI 10.1073/pnas.90.6.2237; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINELEYMILLER K, 1992, MOL BRAIN RES, V16, P339, DOI 10.1016/0169-328X(92)90244-6; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Fornasari D, 1997, MOL PHARMACOL, V51, P250, DOI 10.1124/mol.51.2.250; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; Gerzanich V, 1997, MOL PHARMACOL, V51, P320, DOI 10.1124/mol.51.2.320; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAMMOND DN, 1990, BRAIN RES, V512, P190, DOI 10.1016/0006-8993(90)90626-M; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; HU MJ, 1995, J BIOL CHEM, V270, P4497, DOI 10.1074/jbc.270.19.11619; HU MJ, 1994, J NEUROCHEM, V62, P392; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; Lee MH, 1996, J BIOL CHEM, V271, P3420; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; MATTER JM, 1995, J NEUROSCI, V15, P5919; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McDonough J, 1997, J NEUROSCI, V17, P2273; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Melnikova IN, 1996, CELL GROWTH DIFFER, V7, P1067; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; PATRICK J, 1993, PROG BRAIN RES, V98, P113; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; WADA E, 1990, BRAIN RES, V526, P46; WinzerSerhan UH, 1997, J COMP NEUROL, V386, P540, DOI 10.1002/(SICI)1096-9861(19971006)386:4<540::AID-CNE2>3.0.CO;2-2; Wonnacott S, 1997, TRENDS NEUROSCI, V20, P92, DOI 10.1016/S0166-2236(96)10073-4; Yan GZ, 1997, J NEUROSCI, V17, P6122; YANG X, 1997, J NEUROBIOL, V28, P311; YANG XD, 1994, J BIOL CHEM, V269, P10252; YANG XD, 1995, J BIOL CHEM, V270, P8514, DOI 10.1074/jbc.270.15.8514; ZOLI M, 1995, J NEUROSCI, V15, P1912, DOI 10.1523/JNEUROSCI.15-03-01912.1995	62	70	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19877	19883		10.1074/jbc.273.31.19877	http://dx.doi.org/10.1074/jbc.273.31.19877			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677424	hybrid			2022-12-27	WOS:000075125200076
J	Hossain, A; Tsuchiya, S; Minegishi, M; Osada, M; Ikawa, S; Tezuka, F; Kaji, M; Konno, T; Watanabe, M; Kikuchi, H				Hossain, A; Tsuchiya, S; Minegishi, M; Osada, M; Ikawa, S; Tezuka, F; Kaji, M; Konno, T; Watanabe, M; Kikuchi, H			The Ah receptor is not involved in 2,3,7,8-tetrachlorodibenzo-p-dioxin-mediated apoptosis in human leukemic T cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON HYDROXYLASE; PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTOR; ICE/CED-3 PROTEASE; EXPRESSION; INDUCTION; ACTIVATION; TOXICITY; DEATH; GENES	2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a common environmental pollutant causing public concern. Its toxic effects include disruption of the immune, endocrine, and reproductive systems, impairment of fetal development, carcinogenicity, and lethality in rodents. Here, we report that TCDD induces apoptosis in two cultured human leukemic lymphoblastic T cell lines. This cell death was found not to be dependent on an aryl hydrocarbon receptor and to be inhibited by the inhibitor of tyrosine kinases and caspases. Apoptosis-linked c-Jun N-terminal kinase is rapidly activated in these cells by the treatment with TCDD. A dominant-negative mutant of c-Jun N-terminal kinase prevented cell death in the treatment with TCDD. Furthermore, TCDD decreases the Bcl-2 protein level in. these cell lines. These findings will help in the understanding of the molecular mechanism underlying TCDD-mediated immunotoxicity.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Pediat Oncol, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Pathol, Sendai, Miyagi 9808575, Japan; Natl Sendai Hosp, Dept Pathol, Miyagino Ku, Sendai, Miyagi 983, Japan	Tohoku University; Tohoku University; Tohoku University	Kikuchi, H (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.		井川, 俊太郎/L-5911-2015					Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BOMBICK DW, 1988, P NATL ACAD SCI USA, V85, P4128, DOI 10.1073/pnas.85.12.4128; Bronte V, 1996, BIOCHEM BIOPH RES CO, V218, P344, DOI 10.1006/bbrc.1996.0060; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVITO MJ, 1995, TOXICOLOGY, V102, P115, DOI 10.1016/0300-483X(95)03040-M; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; GARDIN K, 1994, J BIOL CHEM, V269, P23800; GASIEWICZ TA, 1984, MOL PHARMACOL, V26, P90; GREENLEE WF, 1985, TOXICOL APPL PHARM, V79, P112, DOI 10.1016/0041-008X(85)90373-4; HARRIS M, 1989, CANCER RES, V49, P4531; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hoffer A, 1996, TOXICOL APPL PHARM, V141, P238; HUFF J, 1994, ANNU REV PHARMACOL, V34, P343; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; KNUTSON JC, 1980, TOXICOL APPL PHARM, V54, P377, DOI 10.1016/0041-008X(80)90163-5; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lee DC, 1996, TOXICOL APPL PHARM, V137, P90, DOI 10.1006/taap.1996.0060; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; MA X, 1992, BIOCHEM BIOPH RES CO, V189, P5965; Martin Seamus J., 1993, Trends in Cell Biology, V3, P141, DOI 10.1016/0962-8924(93)90128-N; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; MCCABE MJ, 1993, BIOCHEM BIOPH RES CO, V194, P944, DOI 10.1006/bbrc.1993.1912; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MIGITA K, 1994, J IMMUNOL, V153, P3457; MINEGISHI M, 1995, LEUKEMIA RES, V19, P433, DOI 10.1016/0145-2126(95)00016-H; Morita S, 1996, LEUKEMIA, V10, P102; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; POLAND A, 1980, MOL PHARMACOL, V17, P86; POLAND A, 1977, MOL PHARMACOL, V13, P924; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rhile MJ, 1996, TOXICOLOGY, V110, P153, DOI 10.1016/0300-483X(96)83962-X; SILVERSTONE AE, 1994, TOXICOL APPL PHARM, V126, P248, DOI 10.1006/taap.1994.1114; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WHITLOCK JP, 1996, FASEB J, V10, P808; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	46	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19853	19858		10.1074/jbc.273.31.19853	http://dx.doi.org/10.1074/jbc.273.31.19853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677421	hybrid			2022-12-27	WOS:000075125200073
J	Wells, RD; Parniewski, P; Pluciennik, A; Bacolla, A; Gellibolian, R; Jaworski, A				Wells, RD; Parniewski, P; Pluciennik, A; Bacolla, A; Gellibolian, R; Jaworski, A			Small slipped register genetic instabilities in Escherichia coli in triplet repeat sequences associated with hereditary neurological diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X LOCI; MISMATCH REPAIR; MYOTONIC-DYSTROPHY; CELL-LINES; SACCHAROMYCES-CEREVISIAE; MOLECULAR-BASIS; DUPLEX DNA; REPLICATION; MUTATIONS; DELETION	Genetic instability investigations on three triplet repeat sequences (TRS) involved in human hereditary neurological diseases (CTG.CAG, CGG.CCG, and GAA.TTC) revealed a high frequency of small expansions or deletions in 3-base pair registers in Escherichia coli. The presence of G to A polymorphisms in the CTG.CAG sequences served as reporters for the size and location of these instabilities. For the other two repeat sequences, length determinations confirmed the conclusions found for CTG.CAG. These studies were conducted in strains deficient in methyl-directed mismatch repair or nucleotide excision repair in order to investigate the involvement of these postreplicative processes in the genetic instabilities of these TRS. The observation that small and large instabilities for (CTG.CAG)(175) fall into distinct size classes (1-8 repeats and approximate multiples of 41 repeats, respectively) leads to the conclusion that more than one DNA instability process is involved. The slippage of the complementary strands of the TRS is probably responsible for the small deletions and expansions in methyl-directed mismatch repair-deficient and nucleotide excision repair deficient cells. A model is proposed to explain the observed instabilities via strand misalignment, incision, or excision, followed by DNA synthesis and ligation. This slippage-repair mechanism may be responsible for the small expansions in type 1 hereditary neurological diseases involving polyglutamine expansions. Furthermore, these observations may relate to the high frequency of small deletions versus a lower frequency of large instabilities observed in lymphoblastoid cells from myotonic dystrophy patients.	Texas A&M Univ, Med Ctr, Dept Biochem & Biophys, Ctr Genome Res,Inst Biosci & Technol, Houston, TX 77030 USA; Polish Acad Sci, Ctr Microbiol & Virol, PL-93232 Lodz, Poland	Texas A&M University System; Polish Academy of Sciences	Wells, RD (corresponding author), Texas A&M Univ, Med Ctr, Dept Biochem & Biophys, Ctr Genome Res,Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NIGMS NIH HHS [GM52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Bowater RP, 1997, NUCLEIC ACIDS RES, V25, P2861, DOI 10.1093/nar/25.14.2861; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Harvey SC, 1997, BIOCHEMISTRY-US, V36, P3047, DOI 10.1021/bi962771e; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; Kang S, 1996, J MOL BIOL, V258, P543, DOI 10.1006/jmbi.1996.0266; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Kirkpatrick DT, 1997, NATURE, V387, P929, DOI 10.1038/43225; KORNBERG A, 1964, P NATL ACAD SCI USA, V51, P315, DOI 10.1073/pnas.51.2.315; Kramer PR, 1996, HUM GENET, V98, P151, DOI 10.1007/s004390050179; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; Leeflang EP, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P543; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Lovett ST, 1996, P NATL ACAD SCI USA, V93, P7120, DOI 10.1073/pnas.93.14.7120; MADSEN CS, 1993, P NATL ACAD SCI USA, V90, P7671, DOI 10.1073/pnas.90.16.7671; Mangiarini L, 1997, NAT GENET, V15, P197, DOI 10.1038/ng0297-197; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; Mortlock DP, 1996, NAT GENET, V13, P284, DOI 10.1038/ng0796-284; Muragaki Y, 1996, SCIENCE, V272, P548, DOI 10.1126/science.272.5261.548; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; Rosche WA, 1996, J BACTERIOL, V178, P5042, DOI 10.1128/jb.178.16.5042-5044.1996; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; Schweitzer JK, 1997, HUM MOL GENET, V6, P349, DOI 10.1093/hmg/6.3.349; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Steinbach P, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P509; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; TAUTZ D, 1994, CURR OPIN GENET DEV, V4, P832, DOI 10.1016/0959-437X(94)90067-1; Trottier Y, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P447; UMAR A, 1994, J BIOL CHEM, V269, P14367; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wells R.D., 1998, GENETIC INSTABILITIE; WELLS RD, 1965, J MOL BIOL, V14, P221, DOI 10.1016/S0022-2836(65)80242-X; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WELLS RD, 1993, GENOME ANAL, V7, P107; Yao M, 1996, J BIOL CHEM, V271, P30672, DOI 10.1074/jbc.271.48.30672; Zou Y, 1997, J BIOL CHEM, V272, P4820, DOI 10.1074/jbc.272.8.4820	71	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19532	19541		10.1074/jbc.273.31.19532	http://dx.doi.org/10.1074/jbc.273.31.19532			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677376	hybrid			2022-12-27	WOS:000075125200028
J	Li, SH; Hosseini, SH; Gutekunst, CA; Hersch, SM; Ferrante, RJ; Li, XJ				Li, SH; Hosseini, SH; Gutekunst, CA; Hersch, SM; Ferrante, RJ; Li, XJ			A human HAP1 homologue - Cloning, expression, and interaction with huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPANDED CAG REPEAT; DISEASE GENE; BRAIN; TRINUCLEOTIDE; EXPANSION; PROTEINS; LENGTH; IDENTIFICATION; INACTIVATION; PATHOGENESIS	Huntington's disease (HD) is caused by the expansion of a glutamine repeat in the protein huntingtin. The expanded glutamine repeat is thought to mediate a gain of function by causing huntingtin to abnormally interact with other proteins. We previously identified a rat huntingtin-associated protein (HAP1) that binds to huntingtin; HAP1 binds more tightly to huntingtin with an expanded glutamine repeat than to wild type huntingtin. Identification of the human homologue of HAP1 is necessary for investigation of the potential role of HAP1 in HD pathology. Here, we report the cloning of a human HAP1 homologue (hHAP) that shares 62% identity with rat HAP1 over its entire sequence and 82% amino acid identity in the putative huntingtin-binding region. The hHAP gene encodes a 4.1-kilobase transcript and a 75-kDa protein which are specifically expressed in human brain tissues. Its expression in Huntington's disease brains is reduced in parallel with a decreased expression of huntingtin. While two isoforms of rat HAP1 are expressed at similar levels in rat brain, only a single major form of hHAP is found in primate brains. In vitro binding, immunoprecipitation, and coexpression studies confirm the interaction of hHAP with huntingtin. The in vitro binding of hHAP to huntingtin is enhanced by lengthening the glutamine repeat. Despite similar binding properties of rat HAP1 and hHAP, differences in the sequences and expression of hHAP may contribute to a specific role for its interaction with huntingtin in humans.	Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Mol Med, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Boston Univ, Sch Med, Dept Neurol & Pathol, Bedford Vet Adm Med Ctr,Geriatr Res Educ & Clin C, Boston, MA 02115 USA	Emory University; Emory University; Emory University; Boston University; Geriatric Research Education & Clinical Center	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Genet, 1462 Clifton Rd NE, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS016375, R01NS036232, P50NS016375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36232, NS 16375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBIN RL, 1995, TRENDS NEUROSCI, V18, P11, DOI 10.1016/0166-2236(95)93943-R; AMBROSE CM, 1994, SOMAT CELL MOLEC GEN, V20, P27, DOI 10.1007/BF02257483; ANDREW SE, 1993, NAT GENET, V4, P398, DOI 10.1038/ng0893-398; Bao J, 1996, P NATL ACAD SCI USA, V93, P5037, DOI 10.1073/pnas.93.10.5037; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; DUYAO MP, 1993, HUM MOL GENET, V2, P673, DOI 10.1093/hmg/2.6.673; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Ferrante RJ, 1997, J NEUROSCI, V17, P3052; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Gutekunst Claire-Anne, 1997, Society for Neuroscience Abstracts, V23, P1911; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LI SH, 1993, GENOMICS, V16, P572, DOI 10.1006/geno.1993.1232; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; MacDonald ME, 1996, CURR OPIN NEUROBIOL, V6, P638, DOI 10.1016/S0959-4388(96)80097-3; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martin E. J., 1997, Society for Neuroscience Abstracts, V23, P1910; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; STINE OC, 1993, HUM MOL GENET, V2, P1547, DOI 10.1093/hmg/2.10.1547; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WANKER EE, 1997, HUM MOL GENET, V6, P47; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404	33	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19220	19227		10.1074/jbc.273.30.19220	http://dx.doi.org/10.1074/jbc.273.30.19220			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668110	hybrid			2022-12-27	WOS:000074974700077
J	Ling, YH; Tornos, C; Perez-Soler, R				Ling, YH; Tornos, C; Perez-Soler, R			Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; SIGNAL-TRANSDUCTION; PROTEIN; TAXOL; KINASE; RAF-1; ASSOCIATION; MECHANISM; REQUIRES; C-RAF-1	Phosphorylation of Bcl-2 protein is a post-translational modification of unclear functional consequences. We studied the correlation between Bcl-2 phosphorylation, mitotic arrest, and apoptosis induced by the antitubulin agent paclitaxel, Continuous exposure of human cervical carcinoma HeLa cells to 50 ng/ml paclitaxel resulted in mitotic arrest with a symmetrical bell-shaped curve over time. The number of mitotic cells was highest at 24 h (82%), then declined as arrested cells progressed into apoptosis, and barely no mitotic cells were present at 48-60 h. The time curves of paclitaxel-induced cyclin B1 accumulation and stimulation of Cdc2/cyclin B1 kinase activity were identical and superimposable to that of M phase arrest. In contrast, apoptosis was first detected at 12 h and steadily increased thereafter until the termination of the experiments at 48-60 h, when about 80-96% of cells were apoptotic. Bcl-2 phosphorylation was closely associated in time with M phase arrest, accumulation of cyclin B1, and activation of Cdc2/cyclin B1 kinase, but not with apoptosis. At 24 h, when about 82% of the cells were in mitosis, almost all Bcl-2 protein was phosphorylated, whereas at 48 h, when 70-90% of the cells were apoptotic, all Bcl-2 protein was unphosphorylated, Similar results were obtained with SKOV3 cells, indicating that the association of paclitaxel-induced M phase arrest and Bcl-2 phosphorylation is not restricted to HeLa cells, We used short exposure to nocodazole and double thymidine to synchronize HeLa cells and investigate the association of Bcl-2 phosphorylation with mitosis, These studies demonstrated that Bcl-2 phosphorylation occurs in tight association with the number of mitotic cells in experimental conditions that do not lead to apoptosis. However, a continuous exposure to nocodazole resulted in a pattern of Bcl-2 phosphorylation, M phase arrest, and apoptosis similar to that observed with paclitaxel, The phosphatase inhibitor okadaic acid was found to inhibit the dephosphorylation of phosphorylated Bcl-2 and to delay the progression of nocodazole M phase-arrested cells into interphase, In contrast, the serine/threonine kinase inhibitor staurosporine, but not the tyrosine kinase inhibitor genistein, led to rapid dephosphorylation of phosphorylated Bcl-2 and accelerated the progression of nocodazole M phase-arrested cells into interphase, Immune complex kinase assays in cell-free systems demonstrated that Bcl-2 protein can be a substrate of Cdc2/cyclin B1 kinase isolated from paclitaxel-treated cells arrested in M phase. Taken together, these studies suggest that Bcl-2 phosphorylation is tightly associated with mitotic arrest and fail to demonstrate that it is a determinant of progression into apoptosis after mitotic arrest induced by anti-tubulin agents.	Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Sect Expt Therapy, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Perez-Soler, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Thorac Head & Neck Med Oncol, Sect Expt Therapy, Box 080,1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA50270] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050270] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Chen CY, 1996, J BIOL CHEM, V271, P2376, DOI 10.1074/jbc.271.5.2376; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1997, CANCER RES, V57, P229; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Ibrado AM, 1997, CANCER RES, V57, P1109; Jordan MA, 1996, CANCER RES, V56, P816; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Ling YH, 1998, INT J CANCER, V75, P925, DOI 10.1002/(SICI)1097-0215(19980316)75:6<925::AID-IJC16>3.0.CO;2-1; LING YH, 1993, CANCER RES, V53, P1845; Ling YH, 1996, MOL PHARMACOL, V49, P832; LU QL, 1994, J CELL SCI, V107, P363; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MAY WS, 1994, J BIOL CHEM, V269, P26865; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; WANG HG, 1994, ONCOGENE, V9, P2751; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	27	218	225	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18984	18991		10.1074/jbc.273.30.18984	http://dx.doi.org/10.1074/jbc.273.30.18984			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668078	hybrid			2022-12-27	WOS:000074974700045
J	Zhao, R; Assaraf, YG; Goldman, ID				Zhao, R; Assaraf, YG; Goldman, ID			A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; L1210 LEUKEMIA-CELLS; DIHYDROFOLATE-REDUCTASE; MEDIATED TRANSPORT; SYSTEM; CDNA; SENSITIVITY; DEFICIENT; EXTENT; LINE	In an ongoing study of structure-function relationships of the murine reduced folate carrier 1 (RFC1), a glutamate to lysine mutation at amino acid 45 was identified in a methotrexate (MTX)-resistant L1210 clonal variant in which MTX and 5-formyltetrahydrofolate (5-CHO-THF) influx was markedly decreased. The characteristics of the mutated carrier, RFC1-E45K, were studied by cDNA transfection into the murine MTX(r)A line in which endogenous carrier is not functional. Folic acid influx doubled in the transfectant MTX(r)A-E45K as compared with L1210 or MTX(r)A cells; in contrast, MTX and 5-CHO-THF influx was only 14 and 27% that of L1210 cells, respectively. 5-CHO-THF influx in MTX(r)A-E45K cells was characterized by a 12- and 3.6-fold decrease in influx V-max and K-t respectively, relative to L1210 cells. The folic acid influx K-i in L1210 cells was more than 50-fold greater than that of MTX based upon inhibition of 5-CHO-THF influx. In comparison, the mutated carrier had comparable affinities for folic acid and MTX in MTX(r)A-E45K cells due to a 7-fold decrease in the folic acid influx K-i and 7-fold increase in the MTX influx K-i. Transport via native RFC1 is inhibited by a variety of anions in L1210 cells associated with an increase in influx K-i. However, influx of 5-CHO-THF in MTX(r)A-E45K cells in a HEPES buffer (9 mM chloride) was decreased by 70% due to a 3-fold fall in the V-max.In the complete absence of chloride (K+-HEPES-sucrose buffer) 5-CHO-THF influx was only 10% that in HBS buffer. 5-CHO-THF influx was restored by addition of chloride, fluoride, or nitrate but not by sulfate, phosphate, or ATP which were all inhibitory over a broad range of concentrations. The data suggest that substitution of a positive for a negative amino acid at position 45 results in the loss of RFC1 mobility in the absence of small inorganic anions that bind to, and neutralize the positive charge on, the lysine residue. Inhibition by higher charged anions may be due to interactions at another carrier site present in both the mutated and wild type carrier. This and other studies suggest that amino acids in the first predicted transmembrane domain play an important role in determining the spectrum of affinities for, and mobility of, RFC1 and is a cluster region for mutations; when cells are placed under selective pressure with antifolates that utilize RFC1 as the major route of entry into mammalian cells.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Goldman, ID (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Comprehens Canc Ctr, Chanin 2,1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39807] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; BUTTERWORTH CE, 1993, HLTH DIS, P165; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; DIXON KH, 1994, J BIOL CHEM, V269, P17; FRY DW, 1982, J BIOL CHEM, V257, P1890; GOLDMAN ID, 1971, BIOCHIM BIOPHYS ACTA, V233, P624, DOI 10.1016/0005-2736(71)90162-3; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GOLDMAN ID, 1986, MEMBRANE TRANSPORT A, P283; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1983, BIOCHEM INT, V6, P507; HENDERSON GB, 1980, ARCH BIOCHEM BIOPHYS, V200, P149, DOI 10.1016/0003-9861(80)90341-0; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; LEE GSF, 1992, J MOL BIOL, V223, P617, DOI 10.1016/0022-2836(92)90978-S; MATHERLY LH, 1995, BLOOD, V85, P500; MOSCOW JA, 1995, CANCER RES, V55, P3790; MULLERBERGER S, 1995, BIOCHEMISTRY-US, V34, P9325; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1985, CANCER RES, V45, P4732; SIROTNAK FM, 1986, MEMBRANE TRANSPORT A, P241; SIROTNAK FM, 1987, NCI MONOGRAPHS, V5, P27; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; Tse A., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P162; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; YANG CH, 1983, J MEMBRANE BIOL, V75, P11, DOI 10.1007/BF01870795; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207	37	64	64	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19065	19071		10.1074/jbc.273.30.19065	http://dx.doi.org/10.1074/jbc.273.30.19065			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668089	hybrid			2022-12-27	WOS:000074974700056
J	Knight, SAB; Sepuri, NBV; Pain, D; Dancis, A				Knight, SAB; Sepuri, NBV; Pain, D; Dancis, A			Mt-Hsp70 homolog, Ssc2p, required for maturation of yeast frataxin and mitochondrial iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-70; SACCHAROMYCES-CEREVISIAE; MEMBRANE; COMPLEX; TRANSLOCATION; TRANSPORT	Here we show that the yeast mitochondrial chaperone Ssc2p, a homolog of mt-Hsp70, plays a critical role in mitochondrial iron homeostasis. Yeast with ssc2-1 mutations were identified by a screen for altered iron-dependent gene regulation and mitochondrial dysfunction. These mutants exhibit increased cellular iron uptake, and the iron accumulates exclusively within mitochondria. Yfh1p is homologous to frataxin, the human protein implicated in the neurodegenerative disease, Friedreich's ataxia, Like mutants of yfh1, ssc2-1 mutants accumulate vast quantities of iron in mitochondria, Furthermore, using import studies with isolated mitochondria, we demonstrate a specific role for Ssc2p in the maturation of Yfh1p within this organelle. This function for a mitochondrial Hsp70 chaperone is likely to be conserved, implying that a human homolog of Ssc2p may be involved in iron homeostasis and in neurodegenerative disease.	Univ Penn, Dept Med, Div Hematol Oncol, Stellar Chance Labs 1009, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Dancis, A (corresponding author), Univ Penn, Dept Med, Div Hematol Oncol, Stellar Chance Labs 1009, 422 Curie Blvd, Philadelphia, PA 19104 USA.		Sepuri, Naresh/AAF-2704-2020	Knight, Simon/0000-0001-7407-3390				BACOCK M, 1997, SCIENCE, V276, P1709; BYERS B, 1991, P602; Cammack R, 1990, IRON TRANSPORT STORA, P17; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Goldstein J., 1981, SCANNING ELECT MICRO; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Koutnikova H, 1997, NAT GENET, V16, P345, DOI 10.1038/ng0897-345; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215; Schilke B, 1996, J CELL BIOL, V134, P603, DOI 10.1083/jcb.134.3.603; SCRIVER CR, 1995, METABOLIC MOL BASES, P2427; SCRIVER CR, 1995, METABOLIC MOL BASIS, P1860; SHERMAN F, 1991, P3; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x	26	145	148	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18389	18393		10.1074/jbc.273.29.18389	http://dx.doi.org/10.1074/jbc.273.29.18389			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660806	hybrid			2022-12-27	WOS:000074828500061
J	Matsushita, M; Nairn, AC				Matsushita, M; Nairn, AC			Characterization of the mechanism of regulation of Ca2+/calmodulin-dependent protein kinase I by calmodulin and by Ca2+/calmodulin-dependent protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; HIGH-AFFINITY INTERACTION; CRYSTAL-STRUCTURE; RAT-BRAIN; SUBSTRATE RECOGNITION; PEPTIDE SUBSTRATE; CATALYTIC SUBUNIT; SWITCH-LIKE; PHOSPHORYLATION; ACTIVATION	Ca2+/calmodulin-dependent protein kinase I (CaMKI) is maintained in an autoinhibited state by the interaction of a COOH-terminal helix-loop-helix (Ile(286)-Met(316)) regulatory domain with the catalytic core. Activation of the enzyme by calmodulin (CaM) also allows CaMKI to be phosphorylated and activated by a second enzyme, CaMK kinase (CaMKK). To more thoroughly characterize the regulation of CaMKI by CaM and its interrelationship with phosphorylation by CaMKK, we have carried out a detailed structure-function analysis using recombinant wild-type (WT) and mutant forms of CaMKI and CaMKK. CaMKI-WT, in the absence of CaM, or CaMKI-299 and CaMKI-298 were autoinhibited and could not be phosphorylated by CaMKK-433 (a truncated constitutively active form of CaMKK). Removal of Phe(298) (CaMK-297) generated a constitutively active form of CaMKI that was also phosphorylated by CaMKK-433. CaMKI-WT was essentially inactive in the absence of CaM (K-0.5 for activation by CaM similar to 30 nM). Mutation of Ile(294) and Phe(298) to alanine (CaMKI-2A) resulted in measurable basal enzyme activity. Additional mutation of Ile(286) and Val(290) to alanine (CaMKI-4A) increased this basal activity. Mutation of Trp(303) (CaMKI-W303S) resulted in a large increase in the K-0.5 for CaM (similar to 100 mu M), supporting a role for this residue as an initial target for CaM. Mutation of Phe(307) (CaMKI-F307A) resulted in increased basal enzyme activity, supporting a role for this residue in autoinhibition of CaMKI. Together these studies demonstrate the critical role of specific amino acids in the autoinhibition of CaMKI and also in its activation by CaM and phosphorylation by CaMKK.	Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Rockefeller University	Nairn, AC (corresponding author), Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA.			Nairn, Angus/0000-0002-7075-0195				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Chin D, 1997, J BIOL CHEM, V272, P31235, DOI 10.1074/jbc.272.50.31235; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cote GP, 1997, J BIOL CHEM, V272, P6846, DOI 10.1074/jbc.272.11.6846; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Ferrell JE, 1997, TRENDS BIOCHEM SCI, V22, P288, DOI 10.1016/S0968-0004(97)82217-7; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GRAND RJA, 1979, BIOCHEM J, V177, P521, DOI 10.1042/bj1770521; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hata Y, 1996, J NEUROSCI, V16, P2488; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1990, PEPTIDES PROTEIN PHO; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JC, 1994, P NATL ACAD SCI USA, V91, P6413, DOI 10.1073/pnas.91.14.6413; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAIRN AC, 1994, SEMIN CANCER BIOL, V5, P295; Okuno S, 1996, J BIOCHEM-TOKYO, V119, P1176; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1996, INTRACELLULAR SIGNAL, P251; Redpath NT, 1996, J BIOL CHEM, V271, P17547, DOI 10.1074/jbc.271.29.17547; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHACTER E, 1984, J BIOL CHEM, V259, P2252; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MK, 1992, J BIOL CHEM, V267, P1761; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	65	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21473	21481		10.1074/jbc.273.34.21473	http://dx.doi.org/10.1074/jbc.273.34.21473			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705275	hybrid			2022-12-27	WOS:000075492600009
J	Tripathi, S; Kloss, PS; Mankin, AS				Tripathi, S; Kloss, PS; Mankin, AS			Ketolide resistance conferred by short peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI; ERYTHROMYCIN RESISTANCE; TRANSLATION	Clones expressing pentapeptides conferring resistance to a ketolide antibiotic, HMR3004, were selected from a random pentapeptide mini-gene library. The pentapeptide MRFFV conferred the highest level of resistance and was encoded in three different mini-genes. Comparison of amino acid sequences of peptides conferring resistance to a ketolide with those conferring resistance to erythromycin reveals a correspondence between the peptide sequence and the chemical structure of macrolide antibiotic, indicating possible interaction between the peptide and the drag on the ribosome. Based on these observations, a "bottle brush" model of action of macrolide resistance peptides is proposed, in which newly translated peptide interacts with the macrolide molecule on the ribosome and actively displaces it from its binding site. Temporal "cleaning" of the ribosome from the bound antibiotic may be sufficient to allow continuation of protein synthesis even despite the presence of the drug in the medium.	Univ Illinois, Ctr Pharmaceut Biotechnol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Mankin, AS (corresponding author), Univ Illinois, Ctr Pharmaceut Biotechnol, M-C 870,900 S Ashland Ave, Chicago, IL 60607 USA.							Agouridas C, 1997, ANTIMICROB AGENTS CH, V41, P2149, DOI 10.1128/AAC.41.10.2149; CHITTUM HS, 1995, CURR MICROBIOL, V30, P273, DOI 10.1007/BF00295501; CHITTUM HS, 1994, J BACTERIOL, V176, P6192, DOI 10.1128/jb.176.20.6192-6198.1994; Cundliffe E., 1972, MOLECULAR BASIS ANTI, P278; Dam M, 1996, J MOL BIOL, V259, P1, DOI 10.1006/jmbi.1996.0296; ENDIE LM, 1997, ANTIMICROB AGENTS CH, V41, P1033; MENNINGER JR, 1994, MOL GEN GENET, V243, P225, DOI 10.1007/BF00280320; MENNINGER JR, 1982, ANTIMICROB AGENTS CH, V21, P810; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; OLEINICK NL, 1975, ANTIBIOTICS, V3, P396; OTAKA T, 1975, P NATL ACAD SCI USA, V72, P2649, DOI 10.1073/pnas.72.7.2649; PESTKA S, 1974, ANTIMICROB AGENTS CH, V5, P255, DOI 10.1128/AAC.5.3.255; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SIGMUND CD, 1982, P NATL ACAD SCI-BIOL, V79, P5602, DOI 10.1073/pnas.79.18.5602; Tenson T, 1995, BIOCHEM CELL BIOL, V73, P1061, DOI 10.1139/o95-114; Tenson T, 1997, J BIOL CHEM, V272, P17425, DOI 10.1074/jbc.272.28.17425; Tenson T, 1996, P NATL ACAD SCI USA, V93, P5641, DOI 10.1073/pnas.93.11.5641; TERAOKA H, 1978, J MOL BIOL, V126, P185, DOI 10.1016/0022-2836(78)90358-3; Vazquez D., 1975, ANTIBIOTICS MECHANIS, P459; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P577, DOI 10.1128/AAC.39.3.577; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	21	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20073	20077		10.1074/jbc.273.32.20073	http://dx.doi.org/10.1074/jbc.273.32.20073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685347	hybrid			2022-12-27	WOS:000075305400024
J	Vande Berg, BJ; Sancar, GB				Vande Berg, BJ; Sancar, GB			Evidence for dinucleotide flipping by DNA photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PHOTOLYASE; PYRIMIDINE DIMERS; CRYSTAL-STRUCTURE; CIS-SYN; SACCHAROMYCES-CEREVISIAE; ACTION MECHANISM; PHR1 PHOTOLYASE; THYMINE DIMERS; ENZYME; SUBSTRATE	DNA photolyases repair pyrimidine dimers via a reaction in which light energy drives electron donation from a catalytic chromophore, FADH(-), to the dimer. The crystal structure of Escherichia coli photolyase suggested that the pyrimidine dimer is flipped out of the DNA helix and into a cavity that leads from the surface of the enzyme to FADH-. We have tested this model using the Saccharomyces cerevisiae Phr1 photolyase which is >50% identical to E. coli photolyase over the region comprising the DNA binding domain. By using the bacterial photolyase as a starting point, we modeled the region encompassing amino acids 383-530 of the yeast enzyme. The model retained the cavity leading to FADH- as well as the band of positive electrostatic potential which defines the DNA binding surface. We found that alanine substitution mutations at sites within the cavity reduced both substrate binding and discrimination, providing direct support for the dinucleotide flip model. The roles of three residues predicted to interact with DNA flanking the dimer were also tested. Arg(452) was found to be particularly critical to substrate binding, discrimination, and photolysis, suggesting a role in establishing or maintaining the dimer in the flipped state. A structural model for photolyase-dimer interaction is presented.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Sancar, GB (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	gsancar.biochem@mhs.unc.edu			NIGMS NIH HHS [GM35123] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035123] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER M, 1989, MOL CELL BIOL, V9, P4777, DOI 10.1128/MCB.9.11.4777; BAER ME, 1993, J BIOL CHEM, V268, P16717; BRASH DE, 1985, J BIOL CHEM, V260, P1438; BROYDE S, 1980, BIOPOLYMERS, V19, P1695, DOI 10.1002/bip.1980.360190913; CADET J, 1985, BIOPOLYMERS, V24, P897, DOI 10.1002/bip.360240512; HAYES FN, 1971, J AM CHEM SOC, V93, P4940, DOI 10.1021/ja00748a065; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; HUSAIN I, 1987, NUCLEIC ACIDS RES, V15, P1109; KIENER A, 1989, J BIOL CHEM, V264, P13880; Kim Sang-Tae, 1993, Biochemistry, V32, P7065, DOI 10.1021/bi00079a001; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; KIM ST, 1992, P NATL ACAD SCI USA, V89, P900, DOI 10.1073/pnas.89.3.900; LI YF, 1990, BIOCHEMISTRY-US, V29, P5698, DOI 10.1021/bi00476a009; Maxam A M, 1980, Methods Enzymol, V65, P499; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; OGara M, 1996, J MOL BIOL, V261, P634, DOI 10.1006/jmbi.1996.0489; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SANCAR GB, 1985, NUCLEIC ACIDS RES, V13, P8231, DOI 10.1093/nar/13.22.8231; SANCAR GB, 1990, MUTAT RES, V236, P147, DOI 10.1016/0921-8777(90)90002-M; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; TAYLOR JS, 1987, J AM CHEM SOC, V109, P6735, DOI 10.1021/ja00256a030; Todo T, 1996, SCIENCE, V272, P109, DOI 10.1126/science.272.5258.109; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; Uchida N, 1997, PHOTOCHEM PHOTOBIOL, V65, P964, DOI 10.1111/j.1751-1097.1997.tb07955.x; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	39	56	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20276	20284		10.1074/jbc.273.32.20276	http://dx.doi.org/10.1074/jbc.273.32.20276			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685377	hybrid, Green Published			2022-12-27	WOS:000075305400054
J	Chang, S; Hu, T; Hsieh, TS				Chang, S; Hu, T; Hsieh, TS			Analysis of a core domain in Drosophila DNA topoisomerase II - Targeting of an antitumor agent ICRF-159	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; CLEAVAGE SITES; SACCHAROMYCES-CEREVISIAE; 2-GATE MECHANISM; PROTEIN CLAMP; ENZYME; YEAST; INHIBITION; DERIVATIVES; TRANSPORT	To investigate the biochemical properties of individual domains of eukaryotic topoisomerase (topo) II, two truncation mutants of Drosophila topo II were generated, ND406 and core domain. Both mutants lack the ATPase domain, corresponding to the N-terminal 406 amino acid residues in Drosophila protein. The core domain also lacks 240 amino acid residues of the hydrophilic C-terminal region. The mutant proteins have lost DNA strand passage activity while retaining the ability to cleave the DNA and the sequence preference in protein/DNA interaction, The cleavage experiments carried out in the presence of several topo II poisons suggest that the core domain is the key target for these drugs. We have used glass-fiber filter binding assay and CsCl density gradient ultracentrifugation to monitor the formation of a salt-stable, protein-clamp complex. Both truncation mutant proteins can form a clamp complex in the presence of an antitumor agent, ICRF-159, suggesting that the drug targets the core domain of the enzyme and promotes the intradimeric closure at the N-terminal interface of the core domain. Furthermore, the salt stability of the closed protein clamp induced by ICRF-159 depends on the presence and closure of the N-terminal ATPase domain.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711 DUMC, Durham, NC 27710 USA.		Hsieh, Tao-shih/G-9305-2012; Wu, Wan-lin/G-8937-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi N, 1997, NUCLEIC ACIDS RES, V25, P3135, DOI 10.1093/nar/25.15.3135; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; BOROS I, 1984, GENE, V30, P257, DOI 10.1016/0378-1119(84)90130-6; BROWN PO, 1979, P NATL ACAD SCI USA, V76, P6110, DOI 10.1073/pnas.76.12.6110; Caron P R, 1994, Adv Pharmacol, V29B, P271; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; COZZARELLI NR, 1980, CELL, V22, P327, DOI 10.1016/0092-8674(80)90341-4; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DEPEW RE, 1978, J BIOL CHEM, V253, P511; DRAKE FH, 1989, CANCER RES, V49, P2578; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GELLERT M, 1979, P NATL ACAD SCI USA, V83, P7152; HSIANG YH, 1989, MOL PHARMACOL, V36, P371; HSIEH T-S, 1992, Current Opinion in Cell Biology, V4, P396, DOI 10.1016/0955-0674(92)90004-V; HSIEH TS, 1983, METHOD ENZYMOL, V100, P161; Hu T, 1998, J BIOL CHEM, V273, P9586, DOI 10.1074/jbc.273.16.9586; Ishida R, 1996, ANTICANCER RES, V16, P2735; ISHIDA R, 1995, CANCER RES, V55, P2299; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; JENSEN PB, 1990, CANCER RES, V50, P3311; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MP, 1989, J BIOL CHEM, V264, P21779; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LEE MP, 1994, J MOL BIOL, V235, P436, DOI 10.1006/jmbi.1994.1004; Li W, 1997, J BIOL CHEM, V272, P31190, DOI 10.1074/jbc.272.49.31190; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; RIOU JF, 1986, BIOCHEM BIOPH RES CO, V137, P154, DOI 10.1016/0006-291X(86)91189-7; Roca J, 1996, P NATL ACAD SCI USA, V93, P4057, DOI 10.1073/pnas.93.9.4057; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; TANABE K, 1991, CANCER RES, V51, P4903; THOMAS CA, 1979, ANAL BIOCHEM, V93, P158, DOI 10.1016/S0003-2697(79)80130-X; UDVARDY A, 1985, CELL, V40, P933, DOI 10.1016/0092-8674(85)90353-8; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WIGLEY DB, 1995, ANNU REV BIOPH BIOM, V24, P185, DOI 10.1146/annurev.bb.24.060195.001153; WYCKOFF E, 1988, P NATL ACAD SCI USA, V85, P6272, DOI 10.1073/pnas.85.17.6272; YANG L, 1985, CELL, V41, P127, DOI 10.1016/0092-8674(85)90067-4	50	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19822	19828		10.1074/jbc.273.31.19822	http://dx.doi.org/10.1074/jbc.273.31.19822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677416	hybrid			2022-12-27	WOS:000075125200068
J	Hennig, D; Scales, SJ; Moreau, A; Murley, LL; De Mey, J; Kreis, TE				Hennig, D; Scales, SJ; Moreau, A; Murley, LL; De Mey, J; Kreis, TE			A formiminotransferase cyclodeaminase isoform is localized to the Golgi complex and can mediate interaction of trans-Golgi network-derived vesicles with microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDCK CELLS; PLASMA-MEMBRANE; KIDNEY-CELLS; HEAVY-CHAINS; PROTEIN; SEQUENCE; BINDING; IDENTIFICATION; PURIFICATION; ANTIBODIES	A protein of 60 kDa (p60) has been identified using a quantitative in vitro vesicle-microtubule binding assay. Purified p60 induces co-sedimentation with microtubules of trans-Golgi network-derived vesicles isolated from polarized, perforated Madin-Darby canine kidney cells. Sequencing of the cDNA coding for this protein revealed that it is the chicken homologue of formiminotransferase cyclodeaminase (FTCD), a liver specific enzyme involved in the histidine degradation pathway. Purified p60 from chicken liver has formiminotransferase activity, confirming that it is FTCD or an isoform of this enzyme. Isoforms of FTCD were identified in chicken hepatoma and HeLa cells, and immunolocalize to the region of the Golgi complex and vesicular structures in its vicinity. Furthermore, 58K, a previously identified microtubule-binding Golgi protein from rat liver (Bloom, G. S., and Brashear, T. A. (1989) J. Biol. Chem. 264, 16083-16092), is identical to FTCD. Both proteins co-purify with microtubules and co-localize with membranes of the Golgi complex. The capacity of FTCD to bind both to microtubules and Golgi-derived membranes may suggest that this protein, or one of its isoforms, might have in addition to its enzymatic activity, a second physiological function in mediating interaction of Golgi-derived membranes with microtubules.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland; Inst Jacques Monod, Dept Supramol & Cell Biol, F-75251 Paris, France; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	University of Geneva; UDICE-French Research Universities; Universite Paris Cite; McGill University	Kreis, TE (corresponding author), Univ Geneva, Dept Cell Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.		Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BAIROCH A, 1989, EMBL BIOCOMPUTING TE; Bashour AM, 1998, J BIOL CHEM, V273, P19612, DOI 10.1074/jbc.273.31.19612; BEAUDET R, 1976, BIOCHIM BIOPHYS ACTA, V453, P151, DOI 10.1016/0005-2795(76)90259-2; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P7398, DOI 10.1128/JB.176.23.7398-7404.1994; DANEELS G, 1986, J IMMUNOL METHODS, V89, P89, DOI 10.1016/0022-1759(86)90035-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRURY EJ, 1975, ARCH BIOCHEM BIOPHYS, V169, P662, DOI 10.1016/0003-9861(75)90210-6; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; FINDLAY WA, 1989, BIOCHIM BIOPHYS ACTA, V999, P52, DOI 10.1016/0167-4838(89)90029-0; FINDLAY WA, 1987, BIOCHEMISTRY-US, V26, P1948, DOI 10.1021/bi00381a024; FINDLAY WA, 1988, BIOCHEMISTRY-US, V27, P3404, DOI 10.1021/bi00409a042; GAUSEPOHL H, 1986, ADV METHODS PROTEIN, P149; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JACKSON RC, 1979, DEV BIOCHEM, V4, P665; Keller P, 1997, J CELL SCI, V110, P3001; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFONT F, 1994, NATURE, V372, P801; LANGLOIS AJ, 1974, CANCER RES, V34, P1457; MacKenzie R E, 1980, Methods Enzymol, V66, P626; MACKENZIE RE, 1980, BIOCHIM BIOPHYS ACTA, V611, P187, DOI 10.1016/0005-2744(80)90054-6; MACKENZIE RE, 1979, DEV BIOCHEM, V4, P443; MCCLAIN LD, 1975, J NEUROCHEM, V24, P719, DOI 10.1111/j.1471-4159.1975.tb03854.x; MURLEY LL, 1995, BIOCHEMISTRY-US, V34, P10358, DOI 10.1021/bi00033a006; MURLEY LL, 1993, J BIOL CHEM, V268, P22820; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; PAQUIN J, 1985, J BIOL CHEM, V260, P4925; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; RECHID R, 1989, COMPUT APPL BIOSCI, V5, P107; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; SHANE B, 1984, FOLATES PTERINS, V1, P433; Sheetz MP, 1996, SEMIN CELL DEV BIOL, V7, P329, DOI 10.1006/scdb.1996.0042; SHESTAKOVA E, 1998, IN PRESS EUR J CELL; SIBBALD PR, 1990, COMPUT APPL BIOSCI, V6, P279; TABOR H, 1959, J BIOL CHEM, V234, P1830; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	56	39	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19602	19611		10.1074/jbc.273.31.19602	http://dx.doi.org/10.1074/jbc.273.31.19602			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677386	hybrid			2022-12-27	WOS:000075125200038
J	Mark, BL; Wasney, GA; Salo, TJS; Khan, AR; Cao, ZM; Robbins, PW; James, MNG; Triggs-Raine, BL				Mark, BL; Wasney, GA; Salo, TJS; Khan, AR; Cao, ZM; Robbins, PW; James, MNG; Triggs-Raine, BL			Structural and functional characterization of Streptomyces plicatus beta-N-acetylhexosaminidase by comparative molecular modeling and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; AMINO-ACID-SEQUENCE; GLYCOSYL HYDROLASES; ALPHA-SUBUNIT; HEXOSAMINIDASE-A; ESCHERICHIA-COLI; HUMAN ENZYME; CLONING; CDNA; GENE	We have sequenced the Streptomyces plicatus beta-N-acetylhexosaminidase (SpHex) gene and identified the encoded protein as a member of family 20 glycosyl hydrolases, This family includes human beta-N-acetylhexosaminidases whose deficiency results in various forms of G(M2) gangliosidosis, Based upon the x-ray structure of Serratia marcescens chitobiase (SmChb), we generated a three-dimensional model of SpHex by comparative molecular modeling. The overall structure of the enzyme is very similar to homology modeling-derived structures of human beta-N-acetylhexosaminidases, with differences being confined mainly to loop regions. From previous studies of the human enzymes, sequence alignments of family 20 enzymes, and analysis of the SmChb x-ray structure, we selected and mutated putative SpHex active site residues. Arg(162) --> His mutation increased K-m 40-fold and reduced V-max 5-fold, providing the first biochemical evidence for this conserved Arg residue (Arg(178) in human beta-N-acetylhexosaminidase A (HexA) and Arg(349) in SmChb) as a substrate-binding residue in a family 20 enzyme, a finding consistent with our three-dimensional model of SpHex, Glu(314) --> Gln reduced V-max 296-fold, reduced K-m 7-fold, and altered the pH profile, consistent with it being the catalytic acid residue as suggested by our model and other studies. Asp(246) --> Asn reduced V-max 2-fold and increased K-m only 1.2-fold, suggesting that Asp(246) may play a lesser role in the catalytic mechanism of this enzyme. Taken together with the xray structure of SmChb, these studies suggest a common catalytic mechanism for family 20 glycosyl hydrolases.	Univ Manitoba, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Human Genet, Winnipeg, MB R3E 0W3, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	University of Manitoba; University of Manitoba; University of Alberta; Massachusetts Institute of Technology (MIT)	Triggs-Raine, BL (corresponding author), Univ Manitoba, Dept Biochem & Mol Biol, Winnipeg, MB R3E 0W3, Canada.		Triggs-Raine, Barbara/AAF-6209-2021	Triggs-Raine, Barbara/0000-0003-4719-6779; Mark, Brian/0000-0002-7344-1355; Robbins, Phillips/0000-0002-5121-1524; Khan, Amir/0000-0003-1176-6952				BAPAT B, 1988, FEBS LETT, V237, P191, DOI 10.1016/0014-5793(88)80199-6; BAYLERAN J, 1987, AM J HUM GENET, V41, P532; BEANAN MJ, 1995, J EUKARYOT MICROBIOL, V42, P632, DOI 10.1111/j.1550-7408.1995.tb05919.x; BEBENEK K, 1989, NUCLEIC ACIDS RES, V17, P5408, DOI 10.1093/nar/17.13.5408; BECCARI T, 1992, BIOCHEM J, V285, P593, DOI 10.1042/bj2850593; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CA, 1991, J BIOL CHEM, V266, P15855; BROWN CA, 1989, J BIOL CHEM, V264, P21705; BROWN CA, 1993, AM J HUM GENET, V53, P497; BRUNGER AT, 1993, XPLOR SYSTEM XRAY CR, P125; CANNON RD, 1994, J BACTERIOL, V176, P2640, DOI 10.1128/JB.176.9.2640-2647.1994; Cao ZM, 1997, J BIOL CHEM, V272, P14975, DOI 10.1074/jbc.272.23.14975; CARTER P, 1991, DIRECTED MUTAGENESIS, P1; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; Fernandes Maria, 1992, Human Molecular Genetics, V1, P759, DOI 10.1093/hmg/1.9.759; Fernandes MJG, 1997, J BIOL CHEM, V272, P814, DOI 10.1074/jbc.272.2.814; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; Gravel R. A., 1995, METABOLIC BASIS INHE, P1807; Henderson Peter J.F., 1993, P277; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOVATT A, 1994, MICROBIOL-UK, V140, P3399, DOI 10.1099/13500872-140-12-3399; MOSIMANN S, 1995, PROTEINS, V23, P301, DOI 10.1002/prot.340230305; MULDOON LL, 1994, AM J PATHOL, V144, P1109; MYEROWITZ R, 1985, P NATL ACAD SCI USA, V82, P7830, DOI 10.1073/pnas.82.23.7830; NAGAMATSU Y, 1995, BIOSCI BIOTECH BIOCH, V59, P219, DOI 10.1271/bbb.59.219; NISEN P, 1979, P NATL ACAD SCI USA, V76, P6240, DOI 10.1073/pnas.76.12.6240; ODOWD BF, 1985, P NATL ACAD SCI USA, V82, P7830; Pennybacker M, 1997, J BIOL CHEM, V272, P8002, DOI 10.1074/jbc.272.12.8002; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SOMERVILLE CC, 1993, P NATL ACAD SCI USA, V90, P6751, DOI 10.1073/pnas.90.14.6751; SOTOGIL RW, 1989, J BIOL CHEM, V264, P14778; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIBO H, 1995, APPL ENVIRON MICROB, V61, P804, DOI 10.1128/AEM.61.2.804-806.1995	47	59	59	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19618	19624		10.1074/jbc.273.31.19618	http://dx.doi.org/10.1074/jbc.273.31.19618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677388	hybrid			2022-12-27	WOS:000075125200040
J	Meredith, J; Mu, ZM; Saido, T; Du, XP				Meredith, J; Mu, ZM; Saido, T; Du, XP			Cleavage of the cytoplasmic domain of the integrin beta(3) subunit during endothelial cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; OUT SIGNAL-TRANSDUCTION; FOCAL ADHESION KINASE; PROTEASE INHIBITORS; NPXY MOTIF; CALPAIN; ACTIVATION; IDENTIFICATION; PP125(FAK); MUTATION	In this study, we report that the cytoplasmic domain of the integrin beta(3) subunit is a target for limited proteolysis during apoptosis of human umbilical vein endothelial cells, Calpain inhibitors inhibited the cleavage of the beta(3) cytoplasmic domain, indicating that calpain is required. Calpain-mediated proteolysis of fodrin was also detected, indicating that calpain is activated during endothelial cell apoptosis. A phosphatase inhibitor, sodium orthovanadate, inhibited endothelial cell apoptosis and cleavage beta(3), suggesting that protein dephosphorylation preceded integrin cleavage in the apoptosis signaling pathway. beta(3) cleavage was observed in cells that were viable, suggesting that it is an early event and not the consequence of post-death proteolysis. The extent of beta(3) cleavage correlated with a loss in the capacity of cells to reattach to matrix proteins. Loss of reattachment capacity during apoptosis was significantly retarded by a calpain inhibitor. As the beta(3) cytoplasmic domain is required for integrin signaling and interaction with the cytoskeleton, our results suggest that cleavage in the beta(3) cytoplasmic domain by calpain or a calpain-like protease negatively regulates integrin-mediated adhesion, signaling, and cytoskeleton association.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, Wako, Saitama 3510198, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Scripps Research Institute; RIKEN	Du, XP (corresponding author), Univ Illinois, Dept Pharmacol M C868, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL052547] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52547] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHEN YP, 1994, J BIOL CHEM, V269, P18307; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; DU XP, 1995, J BIOL CHEM, V270, P26146, DOI 10.1074/jbc.270.44.26146; FATH KR, 1989, J CELL SCI, V92, P67; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GEORGE JN, 1990, BLOOD, V75, P1383; Gressner AM, 1997, BIOCHEM BIOPH RES CO, V231, P457, DOI 10.1006/bbrc.1996.5777; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; LEONG L, 1995, J CELL SCI, V108, P3817; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lu Q, 1996, ARCH BIOCHEM BIOPHYS, V334, P175, DOI 10.1006/abbi.1996.0443; Maeda S, 1996, BIOCHEM MOL BIOL INT, V39, P447; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mellgren RL, 1996, J BIOL CHEM, V271, P15568, DOI 10.1074/jbc.271.26.15568; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ODA A, 1993, J BIOL CHEM, V268, P12603; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SARIN A, 1994, J IMMUNOL, V153, P862; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Tahiliani PD, 1997, J BIOL CHEM, V272, P7892, DOI 10.1074/jbc.272.12.7892; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Yang CL, 1996, CELL GROWTH DIFFER, V7, P161; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223; ZHU W, 1995, BIOCHEM BIOPH RES CO, V214, P1130, DOI 10.1006/bbrc.1995.2403; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	53	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19525	19531		10.1074/jbc.273.31.19525	http://dx.doi.org/10.1074/jbc.273.31.19525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677375	hybrid			2022-12-27	WOS:000075125200027
J	Blanchard, CZ; Waldrop, GL				Blanchard, CZ; Waldrop, GL			Overexpression and kinetic characterization of the carboxyltransferase component of acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOTIN CARBOXYLASE; PYRUVATE-CARBOXYLASE; SUBUNIT; GENES	Acetyl-CoA carboxylase catalyzes the first committed step in the biosynthesis of fatty acids. The Escherichia coli form of the enzyme consists of a biotin carboxylase protein, a biotin carboxyl carrier protein, and a carboxyltransferase protein. In this report the overexpression of the genes for the carboxyltransferase component is described. The steady-state kinetics of the recombinant carboxyltransferase are characterized in the reverse direction, in which malonyl-CoA reacts with biocytin to form acetyl-CoA and carboxybiocytin. The initial velocity patterns indicated that the kinetic mechanism is equilibrium-ordered with malonyl-CoA binding before biocytin and the binding of malonyl-CoA to carboxyltransferase at equilibrium. The biotin analogs, desthiobiotin and 2-imidazolidone, inhibited carboxyltransferase. Both analogs exhibited parabolic noncompetitive inhibition, which means that two molecules of inhibitor bind to the enzyme. The pH dependence for both the maximum velocity (V) and the (V/K)(biocytin) parameters decreased at low pH. A single ionizing group on the enzyme with a pK of 6.2 or lower in the (V/K)biocytin profile and 7.5 in the V profile must be unprotonated for catalysis. Carboxyltransferase was inactivated by N-ethylmaleimide, whereas malonyl-CoA protected against inactivation. This suggests that a thiol in or near the active site is needed for catalysis. The rate of inactivation of carboxyltransferase by N-ethylmaleimide decreased with decreasing pH and indicated that the pK of the sulfhydryl group had a pK value of 7.3. It is proposed that the thiolate ion of a cysteine acts as a catalytic base to remove the N1' proton of biocytin.	Louisiana State Univ, Dept Biochem, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Waldrop, GL (corresponding author), Louisiana State Univ, Dept Biochem, Rm 322 Choppin Hall, Baton Rouge, LA 70803 USA.				NIGMS NIH HHS [GM51261] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051261] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTWOOD PV, 1986, BIOCHEMISTRY-US, V25, P8197, DOI 10.1021/bi00373a012; BOGNAR AL, 1987, J BIOL CHEM, V262, P12337; Boyer P. D., 1970, ENZYMES, V2; Cleland W W, 1979, Methods Enzymol, V63, P103; CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; GRONWALD JW, 1994, BIOCHEM SOC T, V22, P616, DOI 10.1042/bst0220616; Guchhait R B, 1975, Methods Enzymol, V35, P32, DOI 10.1016/0076-6879(75)35135-5; GUCHHAIT RB, 1974, J BIOL CHEM, V249, P6633; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LI SJ, 1992, J BIOL CHEM, V267, P855; LI SJ, 1992, J BIOL CHEM, V267, P16841; MARAGOUDAKIS ME, 1971, J BIOL CHEM, V246, P348; Miles E W, 1977, Methods Enzymol, V47, P431; NONET ML, 1987, J BIOL CHEM, V262, P12209; POLAKIS SE, 1973, J BIOL CHEM, V248, P7957; POLAKIS SE, 1974, J BIOL CHEM, V249, P6657; TIPTON PA, 1988, BIOCHEMISTRY-US, V27, P4317, DOI 10.1021/bi00412a019; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WALDROP GL, 1994, BIOCHEMISTRY-US, V33, P10249, DOI 10.1021/bi00200a004; WERNEBURG BG, 1993, ARCH BIOCHEM BIOPHYS, V303, P214, DOI 10.1006/abbi.1993.1275; YANG YR, 1993, PROTEIN SCI, V2, P1013, DOI 10.1002/pro.5560020614	22	45	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19140	19145		10.1074/jbc.273.30.19140	http://dx.doi.org/10.1074/jbc.273.30.19140			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668099	hybrid			2022-12-27	WOS:000074974700066
J	Fujisawa, K; Madaule, P; Ishizaki, T; Watanabe, G; Bito, H; Saito, Y; Hall, A; Narumiya, S				Fujisawa, K; Madaule, P; Ishizaki, T; Watanabe, G; Bito, H; Saito, Y; Hall, A; Narumiya, S			Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS P21; ADP-RIBOSYLATION; PROTEIN-RHO; SERINE/THREONINE KINASE; GENE-PRODUCT; EFFECTOR REGION; COILED-COIL; DOMAIN; GTPASE; ACTIVATION	Based on their Rho binding motifs several Rho target molecules can be classified into three groups; class I includes the protein kinase PKN, rhophilin, and rhotekin, class II includes the protein kinases, Rho-associated coiled-coil containing protein kinases, ROCK-I and ROCK-II, and class III includes citron, Taking advantage of the selectivity in recognition by these targets between Rho and Rac, we examined the regions in Rho required for selective binding of each class of Rho target molecules, Yeast two-hybrid assays were performed using Rho/Rac chimeras and either rhophilin, ROCK-I, or citron, This study showed the existence of act least two distinct regions in Rho (amino acids 23-40 and 75-92) that are critical for the selective binding of these targets. The former was required for binding: to citron, whereas the latter was necessary for binding to rhophilin, On the other hand, either region showed affinity to ROCK-I. This was further confirmed by ligand overlay assay using both recombinant ROCK-I and ROCK-II proteins. Consistently, Rho/Rac chimeras containing either region can induce stress fibers in transfected HeLa cells, and this induction is suppressed by treatment with Y-27632, a specific inhibitor of ROCK kinases. These results suggest that the selective binding of different classes of Rho targets to Rho is determined by interaction between distinct Rho-binding motifs of the targets and different regions of Rho.	Univ London Univ Coll, MRC, Mol Cell Biol Lab, CRC Oncogene & Signal Transduct Grp, London WC1E 6BT, England; Univ London Univ Coll, Dept Biochem, London WC1E 6BT, England; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan	University of London; University College London; University of London; University College London; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Fujisawa K, 1996, J BIOL CHEM, V271, P23022, DOI 10.1074/jbc.271.38.23022; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; Hotta K, 1996, BIOCHEM BIOPH RES CO, V225, P69, DOI 10.1006/bbrc.1996.1132; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MATSUI T, EMBO J, V15, P2208; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORII N, 1993, J BIOL CHEM, V268, P27160; MORII N, 1992, J BIOL CHEM, V267, P20921; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Pal E.F., 1989, NATURE, V341, P209; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	45	102	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18943	18949		10.1074/jbc.273.30.18943	http://dx.doi.org/10.1074/jbc.273.30.18943			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668072	hybrid			2022-12-27	WOS:000074974700039
J	Tateno, H; Saneyoshi, A; Ogawa, T; Muramoto, K; Kamiya, H; Saneyoshi, M				Tateno, H; Saneyoshi, A; Ogawa, T; Muramoto, K; Kamiya, H; Saneyoshi, M			Isolation and characterization of rhamnose-binding lectins from eggs of steelhead trout (Oncorhynchus mykiss) homologous to low density lipoprotein receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ANTHOCIDARIS-CRASSISPINA EGGS; RAINBOW-TROUT; MOLECULAR CHARACTERIZATION; VITELLOGENIN RECEPTORS; CHICKEN OOCYTE; ANIMAL LECTINS; LIGAND-BINDING; YOLK PROTEINS; FAMILY	Two L-rhamnose-binding lectins named STL1 and STL2 were isolated from eggs of steelhead trout (Oncorhynchus mykiss) by affinity chromatography and ion exchange chromatography. The apparent molecular masses of purified STL1 and STL2 were estimated to be 84 and 68 kDa, respectively, by gel filtration chromatography. Sodium dodecyl sulfate polyacrylamide gel electrophoresis and matrix-assisted laser desorption ionization time of flight mass spectrometry of these lectins revealed that STL1 was composed of noncovalently linked trimer of 31.4-kDa subunits, and STL2 was noncovalently linked trimer of 21.5-kDa subunits. The minimum concentrations of STL1, a major component, and STL2, a minor component, needed to agglutinate rabbit erythrocytes were 9 and 0.2 mu g/ml, respectively. The most effective saccharide in the hemagglutination inhibition assay for both STL1 and STL2 was L-rhamnose. Saccharides possessing the same configuration of hydroxyl groups at C2 and C4 as that in L-rhamnose, such as L-arabinose and D-galactose, also inhibited. The amino acid sequence of STL2 was determined by analysis of peptides generated by digestion of the S-carboxamidomethylated protein with Achromobacter protease I or Staphylococcus aureus VS protease. The STL2 subunit of 195 amino acid residues proved to have a unique polypeptide architecture; that is, it was composed of two tandemly repeated homologous domains (STL2-N and STL2-C) with 52% internal homology. These two domains showed a sequence homology to the subunit (105 amino acid residues) of D-galactoside-specific sea urchin (Anthocidaris crassispina) egg lectin (37% for STL2-N and 46% for STL2-C, respectively). The N terminus of the STL1 subunit was blocked with an acetyl group. However, a partial amino acid sequence of the subunit showed a sequence similarity to STL2. Moreover, STL2 also showed a sequence homology to the ligand binding domain of the vitellogenin receptor. We have also employed surface plasmon resonance biosensor methodology to investigate the interactions between STL2 and major egg yolk proteins from steelhead trout, lipo-vitellin, and beta'-component, which are known as vitellogenin digests. Interestingly, STL2 showed distinct interactions with both egg yolk proteins. The estimated values for the affinity constant (K-alpha) of STL2 to lipo-vitellin and beta' component were 3.44 x 10(6) and 4.99 x 10(6), respectively. These results suggest that the fish egg lectins belong to a new family of animal lectin structurally related to the low density lipoprotein receptor superfamily.	Tohoku Univ, Grad Sch Agr, Dept Biol Resource Sci, Sendai, Miyagi 9818555, Japan; Kitasato Univ, Sch Fisheries Sci, Sanriku, Iwate 0220101, Japan; Teikyo Univ Sci & Technol, Dept Biol Sci, Yamanashi 4090193, Japan	Tohoku University; Kitasato University	Muramoto, K (corresponding author), Tohoku Univ, Grad Sch Agr, Dept Biol Resource Sci, Sendai, Miyagi 9818555, Japan.	muramoto@biochem.tohoku.ac.jp		Ogawa, Tomohisa/0000-0001-8700-6330				ANSTEE DJ, 1973, VOX SANG, V25, P347, DOI 10.1111/j.1423-0410.1973.tb04383.x; BARBER DL, 1991, J BIOL CHEM, V266, P18761; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FUJITA Y, 1975, BIOCHEMISTRY-US, V14, P4465, DOI 10.1021/bi00691a019; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Gheorghe MT, 1997, ANAL BIOCHEM, V254, P119, DOI 10.1006/abio.1997.2380; GINSBURG AS, 1961, J EMBRYOL EXP MORPH, V9, P173; GITT MA, 1992, J BIOL CHEM, V267, P10601; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HAKON L, 1997, GLYCOTECH, V9, P9; HARA A, 1978, COMP BIOCHEM PHYS B, V59, P339, DOI 10.1016/0305-0491(78)90011-1; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hiramatsu N, 1996, COMP BIOCHEM PHYS A, V115, P243, DOI 10.1016/0300-9629(96)00055-2; HOSONO M, 1992, BIOMED RES-TOKYO, V13, P443, DOI 10.2220/biomedres.13.443; HOSONO M, 1993, BIOL PHARM BULL, V16, P239; HOSONO M, 1993, TOHOKU YAKKA DAIGAKU, V40, P21; Iwasaki M., 1985, GLYCOCONJUGATE J, V2, P209, DOI [10.1007/BF01049269, DOI 10.1007/BF01049269]; KAMIYA H, 1990, NIPPON SUISAN GAKK, V56, P1139; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KRAJHANZL A, 1978, BIOCHIM BIOPHYS ACTA, V532, P215, DOI 10.1016/0005-2795(78)90575-5; Krajhanzl A, 1985, LECTINS BIOL BIOCH C, V4, P397; KRAJHANZL A, 1990, ADV LECTIN RES, V3, P83; KUBO T, 1993, DEV BIOL, V156, P381, DOI 10.1006/dbio.1993.1085; KUDO S, 1986, ZOOL SCI, V3, P323; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURAMOTO K, 1990, ANAL BIOCHEM, V189, P223, DOI 10.1016/0003-2697(90)90112-M; NOSEK J, 1983, HISTOCHEMISTRY, V79, P131, DOI 10.1007/BF00494350; ODA Y, 1993, J BIOL CHEM, V268, P5929; OZAKI H, 1983, DEV COMP IMMUNOL, V7, P77, DOI 10.1016/0145-305X(83)90057-5; OZEKI Y, 1991, BIOCHEMISTRY-US, V30, P2391, DOI 10.1021/bi00223a014; OZEKI Y, 1995, EXP CELL RES, V216, P318, DOI 10.1006/excr.1995.1040; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; Rodriguez JN, 1996, J EXP ZOOL, V274, P163, DOI 10.1002/(SICI)1097-010X(19960215)274:3&lt;163::AID-JEZ3&gt;3.0.CO;2-M; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sappington TW, 1996, P NATL ACAD SCI USA, V93, P8934, DOI 10.1073/pnas.93.17.8934; Schneider WJ, 1996, INT REV CYTOL, V166, P103, DOI 10.1016/S0074-7696(08)62507-3; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; Tyler CR, 1996, J COMP PHYSIOL B, V166, P11, DOI 10.1007/BF00264634; UHLENBRUCK G, 1967, VOX SANG, V12, P465, DOI 10.1111/j.1423-0410.1967.tb03376.x; VOSS EW, 1978, ARCH BIOCHEM BIOPHYS, V186, P25, DOI 10.1016/0003-9861(78)90459-9; YAMAZAKI M, 1984, J LEUKOCYTE BIOL, V35, P241; YOUSIF AN, 1994, DIS AQUAT ORGAN, V20, P127, DOI 10.3354/dao020127	49	102	111	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19190	19197		10.1074/jbc.273.30.19190	http://dx.doi.org/10.1074/jbc.273.30.19190			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668106	hybrid			2022-12-27	WOS:000074974700073
J	Lai, MM; Burnett, PE; Wolosker, H; Blackshaw, S; Snyder, SH				Lai, MM; Burnett, PE; Wolosker, H; Blackshaw, S; Snyder, SH			Cain, a novel physiologic protein inhibitor of calcineurin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; FK506 BINDING-PROTEIN; LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; CYCLOSPORINE-A; RYANODINE RECEPTOR; T-CELLS; PHOSPHATASE; BRAIN; IDENTIFICATION	Calcineurin is a widely distributed protein phosphatase regulated by calcium and calmodulin. It mediates the immunosuppressive actions of drugs such as cyclosporin and FK506, and has been implicated in a number of calcium-sensitive pathways in the nervous system, including regulation of neurotransmitter release and modulation of long-term changes in synaptic plasticity. Calcineurin associates physiologically with other proteins, including calmodulin, FKBP12 (FK506-binding protein), the ryanodine receptor, and the inositol 1,4,5-trisphosphate receptor. We now report the identification, molecular cloning, and functional characterization of a novel protein, cain (ca lcineurin inhibitor), that interacts with and inhibits calcineurin. The full-length cain cDNA predicts a 240-kDa protein with no significant homology to any known protein. Cain associates with calcineurin both in vitro and in vivo, leading to a non-competitive inhibition of calcineurin activity. The putative calcineurin-binding domain of cain, a 38-amino acid region defined by mutational analysis, is highly basic. Like calcineurin, cain has a prominent neuronal expression and a wide tissue distribution. Cain's expression pattern in the brain closely resembles that of calcineurin, indicating a physiologic association between the two proteins.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.			Wolosker, Herman/0000-0001-5508-9194	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABEL T, 1997, CELL, V88, P1; Blackshaw S, 1997, J NEUROSCI, V17, P8074; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; DECAMILLI P, 1996, NEURON, V16, P2479; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lu YF, 1996, NEUROSCI LETT, V205, P103, DOI 10.1016/0304-3940(96)12384-3; Luo C, 1996, MOL CELL BIOL, V16, P3955; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mayford M, 1997, CURR BIOL, V7, pR580, DOI 10.1016/S0960-9822(06)00287-9; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NICHOLS RA, 1994, J BIOL CHEM, V269, P23817; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHARP AH, 1993, J NEUROSCI, V13, P3051; SIHRA TS, 1995, BIOCHEM BIOPH RES CO, V212, P609, DOI 10.1006/bbrc.1995.2013; STEWART AA, 1982, FEBS LETT, V137, P80, DOI 10.1016/0014-5793(82)80319-0; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; Wang JH, 1997, J NEUROSCI, V17, P4600; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8	54	203	214	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18325	18331		10.1074/jbc.273.29.18325	http://dx.doi.org/10.1074/jbc.273.29.18325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660798	hybrid			2022-12-27	WOS:000074828500053
J	Oughtred, R; Bedard, N; Vrielink, A; Wing, SS				Oughtred, R; Bedard, N; Vrielink, A; Wing, SS			Identification of amino acid residues in a class I ubiquitin-conjugating enzyme involved in determining specificity of conjugation of ubiquitin to proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEASOME PATHWAY; ACTIVATING ENZYME; CARRIER PROTEIN; E6 ONCOPROTEIN; RAD6 PROTEIN; DEGRADATION; LIGASE; E6-AP; COMPLEX	The ubiquitin pathway is a major system for selective proteolysis in eukaryotes, However, the mechanisms underlying substrate selectivity by the ubiquitin system remain unclear. We previously identified isoforms of a rat ubiquitin-conjugating enzyme (E2) homologous to the Saccharomyces cerevisiae class I E2 genes, UBC4/ UBC5. Two isoforms, although 93% identical, show distinct features. UBC4-1 is expressed ubiquitously, whereas UBC4-testis is expressed in spermatids, Interestingly, although these isoforms interacted similarly with some ubiquitin-protein ligases (E3s) such as E6-AP and rat p100 and an E3 that conjugates ubiquitin to histone H2A, they also supported conjugation of ubiquitin to distinct subsets of testis proteins. UBC4-1 showed an Ii-fold greater ability to support conjugation of ubiquitin to endogenous substrates present in a testis nuclear fraction. Site-directed mutagenesis of the UBC4-testis isoform was undertaken to identify regions of the molecule responsible for the observed difference in substrate specificity. Four residues (Gln-15, Ala-49, Ser-107, and Gln-125) scattered on surfaces away from the active site appeared necessary and sufficient for UBC4-1-like conjugation. These four residues identify a large surface of the E2 core domain that may represent an area of binding to E3s or substrates, These findings demonstrate that a limited number of amino acid substitutions in E2s can dictate conjugation of ubiquitin to different proteins and indicate a mechanism by which small E2 molecules can encode a wide range of substrate specificities.	McGill Univ, Dept Med, Polypeptide Lab, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Joint Ctr Struct Biol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University	Wing, SS (corresponding author), McGill Univ, Dept Med, Polypeptide Lab, Strathcona Bldg,3640 Univ St,Suite W315, Montreal, PQ H3A 2B2, Canada.	cxwg@musica.mcgill.ca	Vrielink, Alice/D-3652-2013	Vrielink, Alice/0000-0001-8197-3725; Oughtred, Rose/0000-0002-6475-3373				Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GIROD PA, 1993, J BIOL CHEM, V268, P955; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; Haas AL, 1997, FASEB J, V11, P1257; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789; MORRISON A, 1988, MOL CELL BIOL, V8, P1179, DOI 10.1128/MCB.8.3.1179; MULLER D, 1992, NUCLEIC ACIDS RES, V20, P1471, DOI 10.1093/nar/20.7.1471; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; REISS Y, 1989, J BIOL CHEM, V264, P10378; Roest HP, 1996, CELL, V86, P799, DOI 10.1016/S0092-8674(00)80154-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wing SS, 1996, MOL CELL BIOL, V16, P4064; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125	46	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18435	18442		10.1074/jbc.273.29.18435	http://dx.doi.org/10.1074/jbc.273.29.18435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660812	hybrid			2022-12-27	WOS:000074828500067
J	Kamitani, H; Geller, M; Eling, T				Kamitani, H; Geller, M; Eling, T			Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLON-CANCER; HAMSTER EMBRYO FIBROBLASTS; SODIUM-BUTYRATE; NORDIHYDROGUAIARETIC ACID; ALVEOLAR MACROPHAGES; MOLECULAR-CLONING; EPITHELIAL-CELLS; ARACHIDONIC-ACID; SYNTHASE-2 GENE; PHORBOL ESTER	We studied arachidonic acid metabolism and the expression of cyclooxygenase(Cox) and 15-lipoxygenase (15-LO) in the human colorectal carcinoma cell line, Caco-2, which undergo apoptosis and cell differentiation in the presence of sodium butyrate (NaBT), Caco-2 cells expressed very low levels of Cox-1 but highly expressed Cox-a. NaBT treatment shifted the arachidonic acid metabolites by cell lysates from prostaglandins to 15-hydroxyeicosatetraenoic acid, indicating the presence of a 15-LO. Linoleic acid, an excellent substrate for 15-LO, was metabolized poorly by the Caco-2 cells, but NaBT treatment shifted metabolism to 15-LO metabolite, 13(S)-hydroxyoctadecadienoic acid. Caco-2 cells expressed a 15-LO but only after treatment with NaBT, as determined by Northern blotting. Immunoblotting with anti-human 15-LO antibody detected a 72-kDa band in NaBT-treated Caco-2 cells. Expression of 15-LO mRNA was dependent on the duration of NaBT treatment, with the highest expression observed between 10 and 24 h, Results from expression and metabolism studies with arachidonic and linoleic acid cells indicated Cox-a was responsible for the lipid metabolism in control cells, whereas 15-LO was the major enzyme responsible after NaBT induction of apoptosis and cell differentiation. The 15-LO in Caco-2 cells was characterized as human reticulocyte 15-LO by reverse transcription-polymerase chain reaction and restriction enzyme analysis. The expression of 15-LO and 15-hydroxyeicosatetraenoic acid or 13(S)-hydroxyoctadecadienoic acid formation correlates with cell differentiation or apoptosis in Caco-2 cells induced by NaBT, The addition of nordihydroguaiaretic acid, a lipoxygenase inhibitor, significantly increased NaBT-induced apoptosis, whereas the addition of indomethacin did not alter NaBT-induced apoptosis in the Caco-2 cells. However, indomethacin treatment decreased the expression of Cox-a in NaBT-treated cells and significantly increased the expression of 15-LO during NaBT treatment, These studies suggest a role for 15-LO, in addition to Cox-a, in modulating NaBT-induced apoptosis and cell differentiation in human colorectal carcinoma cells.	NIEHS, Eicosanoid Biochem Sect, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Eling, T (corresponding author), NIEHS, Eicosanoid Biochem Sect, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.							AUGERON C, 1984, CANCER RES, V44, P3961; Boolbol SK, 1996, CANCER RES, V56, P2556; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Glasgow WC, 1996, MOL PHARMACOL, V49, P1042; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; Glasgow WC, 1997, J BIOL CHEM, V272, P19269, DOI 10.1074/jbc.272.31.19269; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; HAGUE A, 1993, INT J CANCER, V55, P498, DOI 10.1002/ijc.2910550329; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; HENKE DC, 1984, ANAL BIOCHEM, V162, P156; Hill EM, 1998, AM J RESP CELL MOL, V18, P662, DOI 10.1165/ajrcmb.18.5.2985; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KARGMAN SL, 1995, CANCER RES, V55, P2556; KELLETT GL, 1993, BIOCHEM PHARMACOL, V45, P1932, DOI 10.1016/0006-2952(93)90454-5; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; MATSUMOTO H, 1990, GASTROENTEROLOGY, V98, P1199, DOI 10.1016/0016-5085(90)90334-W; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; Mirzoeva OK, 1996, FEBS LETT, V396, P266, DOI 10.1016/0014-5793(96)01111-8; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NASSAR GM, 1994, J BIOL CHEM, V269, P27631; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PAVANI M, 1994, BIOCHEM PHARMACOL, V48, P1935, DOI 10.1016/0006-2952(94)90592-4; PIAZZA GA, 1995, CANCER RES, V55, P3110; Piazza GA, 1997, CANCER RES, V57, P2452; PRESCOTT SM, 1996, CELL, V87, P159; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; SANO H, 1995, CANCER RES, V55, P3785; SHANNON VR, 1991, AM J PHYSIOL, V261, pL399, DOI 10.1152/ajplung.1991.261.6.L399; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; SIGAL E, 1992, AM J PHYSIOL, V262, pL392, DOI 10.1152/ajplung.1992.262.4.L392; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SIGAL E, 1990, J BIOL CHEM, V265, P5113; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SOBERMAN RJ, 1985, J BIOL CHEM, V260, P4508; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tang DG, 1997, J CELL PHYSIOL, V172, P155, DOI 10.1002/(SICI)1097-4652(199708)172:2<155::AID-JCP3>3.0.CO;2-N; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZHAO HL, 1995, J LIPID RES, V36, P2444	53	136	140	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21569	21577		10.1074/jbc.273.34.21569	http://dx.doi.org/10.1074/jbc.273.34.21569			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705287	hybrid			2022-12-27	WOS:000075492600021
J	Su, C; Sahlin, M; Oliw, EH				Su, C; Sahlin, M; Oliw, EH			A protein radical and ferryl intermediates are generated by linoleate diol synthase, a ferric hemeprotein with dioxygenase and hydroperoxide isomerase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	5th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Related Diseases	SEP 17-20, 1997	LA JOLLA, CALIFORNIA				PROSTAGLANDIN-H SYNTHASE; FUNGUS GAEUMANNOMYCES-GRAMINIS; HIGHER OXIDATION-STATES; COLI RIBONUCLEOTIDE REDUCTASE; TYROSYL RADICALS; PEROXIDASE REACTION; 5,8,11-EICOSATRIENOIC ACID; ENDOPEROXIDE SYNTHASE; ASPERGILLUS-NIDULANS; REACTION-MECHANISMS	Linoleate diol synthase (LDS) was isolated as a hemeprotein from the fungus Gaeumannomyces graminis, LDS converts linoleate sequentially to 8R-hydroperoxylinoleate (8-HPODE) through an 8-dioxygenase by insertion of molecular oxygen and to 7S,8S-dihydroxylinoleate through a hydroperoxide isomerase by intramolecular oxygen transfer. Light absorption and EPR spectra of LDS indicated that the heme iron was ferric and mainly high spin. Oxygen consumption during catalysis started after a short time lag which was reduced by 8-HPODE, Catalysis declined due to suicide inactivation. Stopped flow studies with LDS and 8-HPODE at 13 degrees C showed a rapid decrease in light absorption at 406 nm within 35 ms with a first order rate constant of 90-120 s(-1). Light absorption at 406 nm then increased at a rate of similar to 4 s(-1), whereas the absorption at 421 nm increased after a lag time of similar to 5 ms at a rate of similar to 70 s(-1). EPR spectra at 77 K of LDS both with linoleic acid and 8-HPODE showed a transient doublet when quenched after incubation on ice for 3 s (major hyperfine splitting 2.3 millitesla; g = 2.005), indicating a protein radical. The relaxation properties of the protein radical suggested interaction with a metal center. 8-HPODE generated about twice as much radical as linoleic acid, and the 8-HPODE-induced radical appeared to be stable. Our results suggest that LDS may form, in analogy with prostaglandin Ii synthases, ferryl intermediates and a protein radical during catalysis.	Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Sci, S-75124 Uppsala, Sweden; Stockholm Univ, Arrhenius Labs, Dept Mol Biol, S-10691 Stockholm, Sweden	Uppsala University; Stockholm University	Oliw, EH (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Pharmaceut Sci, POB 591, S-75124 Uppsala, Sweden.			Oliw, Ernst/0000-0002-7986-8130				ABELSON PH, 1995, SCIENCE, V269, P1027, DOI 10.1126/science.269.5227.1027; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN, P13; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODOWSKY ID, 1992, J BIOL CHEM, V267, P14738; CHAMPE SP, 1989, J BACTERIOL, V171, P3982, DOI 10.1128/jb.171.7.3982-3988.1989; CHAMULITRAT W, 1989, J BIOL CHEM, V264, P20968; Coves J, 1996, BIOCHEMISTRY-US, V35, P8595, DOI 10.1021/bi960355o; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; ELLIOTT WJ, 1986, J BIOL CHEM, V261, P6719; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; FUNK CD, 1993, PROG NUCLEIC ACID RE, V45, P67, DOI 10.1016/S0079-6603(08)60867-3; Hamberg M, 1997, ARCH BIOCHEM BIOPHYS, V344, P194, DOI 10.1006/abbi.1997.0194; HAMBERG M, 1994, ARCH BIOCHEM BIOPHYS, V309, P77, DOI 10.1006/abbi.1994.1087; Himo F, 1997, BIOPHYS J, V72, P1556, DOI 10.1016/S0006-3495(97)78803-9; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; HOLLENBERG PF, 1992, FASEB J, V6, P686, DOI 10.1096/fasebj.6.2.1537457; Ivancich A, 1996, J AM CHEM SOC, V118, P12852, DOI 10.1021/ja9628361; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; Licht S, 1996, SCIENCE, V271, P477, DOI 10.1126/science.271.5248.477; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Marnett Lawrence J., 1995, P49; MAZUR P, 1990, TETRAHEDRON LETT, V31, P3837, DOI 10.1016/S0040-4039(00)97482-3; OLIW EH, 1993, ARCH BIOCHEM BIOPHYS, V305, P288, DOI 10.1006/abbi.1993.1425; Oliw EH, 1997, J CHROMATOGR B, V690, P332, DOI 10.1016/S0378-4347(96)00372-6; OMalley PJ, 1995, BBA-BIOENERGETICS, V1232, P175, DOI 10.1016/0005-2728(95)00102-6; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SAHLIN M, 1995, J BIOL CHEM, V270, P12361, DOI 10.1074/jbc.270.21.12361; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SAHLIN M, 1994, J BIOL CHEM, V269, P11699; SCHENKMAN JB, 1982, HEPATIC CYTOCHROME P, P587; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Su C, 1996, J BIOL CHEM, V271, P14112, DOI 10.1074/jbc.271.24.14112; SU C, 1995, LIPIDS, V30, P43, DOI 10.1007/BF02537040; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; TSAI AL, 1993, J BIOL CHEM, V268, P8554; Tsai AL, 1997, J BIOL CHEM, V272, P8885; van der Ouderaa F J, 1980, Adv Prostaglandin Thromboxane Res, V6, P139; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u; Young P, 1996, J BIOL CHEM, V271, P20770, DOI 10.1074/jbc.271.34.20770	48	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20744	20751		10.1074/jbc.273.33.20744	http://dx.doi.org/10.1074/jbc.273.33.20744			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694817	hybrid			2022-12-27	WOS:000075386100010
J	Stephens, G; O'Luanaigh, N; Reilly, D; Harriott, P; Walker, B; Fitzgerald, D; Moran, N				Stephens, G; O'Luanaigh, N; Reilly, D; Harriott, P; Walker, B; Fitzgerald, D; Moran, N			A sequence within the cytoplasmic tail of GpIIb independently activates platelet aggregation and thromboxane synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; INTEGRIN-ALPHA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ALPHA(IIB)BETA(3); LIGAND; COMPLEX; SUBUNIT; DOMAIN; CALRETICULIN	All integrin alpha subunits contain a highly conserved KXGFFKR motifin their cytoplasmic domains that plays a crucial role in the regulation of integrin affinity for their ligands, We show that a lipid-modified peptide corresponding to the cytoplasmic region, 989-995, of the platelet integrin subunit glycoprotein GpIIb (alpha IIb), palmitoyl-KVGFFKR (Ppep; 10 mu m), but not a similarly modified scrambled peptide (palmitoyl-FKFVRGK), can specifically induce platelet activation and aggregation equivalent to that of strong agonists such as thrombin, Ppep-induced aggregation is also associated with indices of platelet activation including thromboxane A(2) (TXA(2)) synthesis (EC50 = 45 +/- 5 mu M), secretion of alpha-granules detected as enhanced surface expression of P-selectin (EC50 = 52 +/- 8 mu M), and conformational changes in GpIIb/IIIa measured by the monoclonal antibody, PAC-1 (EC50 = 3.7 +/- 1 mu M). The TXA(2) receptor antagonist, SQ29548, PGE(1), and the ADP scavenger, apyrase, differentially inhibit the aggregation response and TXA(2) synthesis in response to Ppep, Similarly, GpIIb/IIIa antagonists (RO-449883 and integrelin), which inhibit aggregation by greater than 90%, have little effect on peptide-induced TXA(2) synthesis, suggesting that this event is independent of fibrinogen binding to GpIIb/IIIa, Alanine-stepping of the Ppep sequence identifies GFFK(991-994) as the critical residues in all peptide-mediated events. We conclude that this peptide can imitate the cytoplasmic domain of GpIIb and initiate parallel but independent signaling pathways, one leading to ligand binding and platelet aggregation and the other to intracellular signaling events such as TXA(2) synthesis and secretion.	Royal Coll Surg Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, Dublin 2, Ireland; Queens Univ Belfast, Dept Biochem, Belfast BT9 7BL, Antrim, North Ireland	Royal College of Surgeons - Ireland; Trinity College Dublin; Queens University Belfast	Moran, N (corresponding author), Royal Coll Surg Ireland, Dept Clin Pharmacol, Ctr Cardiovasc Sci, St Stephens Green, Dublin 2, Ireland.		Walker, Brian/C-5263-2008; Moran, Niamh/F-4188-2012	Moran, Niamh/0000-0002-8614-3242	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRIESEWITZ R, 1993, MOL BIOL CELL, V4, P593, DOI 10.1091/mbc.4.6.593; BRUCHER KH, 1990, VIROLOGY, V178, P617, DOI 10.1016/0042-6822(90)90365-X; CHARO IF, 1992, CIRCULATION S1, V86, P1034; COLLER BS, 1995, THROMB HAEMOSTASIS, V74, P302; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DELANTY N, 1993, CIRCULATION, V88, pA1319; DU XP, 1993, J BIOL CHEM, V268, P23087; FitzGerald G A, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P87; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1994, ANN NY ACAD SCI, V714, P75, DOI 10.1111/j.1749-6632.1994.tb12032.x; Haas TA, 1996, J BIOL CHEM, V271, P6017, DOI 10.1074/jbc.271.11.6017; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; JONES CR, 1993, THROMB HAEMOSTASIS, V69, P560; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; LEONG L, 1995, J CELL SCI, V108, P3817; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Loh E, 1996, J BIOL CHEM, V271, P30233, DOI 10.1074/jbc.271.47.30233; MENDELSOHN ME, 1991, P NATL ACAD SCI USA, V88, P11212, DOI 10.1073/pnas.88.24.11212; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PERUTELLI P, 1992, Recenti Progressi in Medicina, V83, P100; Peter K, 1996, BLOOD COAGUL FIBRIN, V7, P233, DOI 10.1097/00001721-199603000-00031; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1986, BLOOD, V68, P1224; SONG A, 1992, CIRCULATION, V86, pA1410; STEINER B, 1993, THROMB HAEMOSTASIS, V69, P782; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; THIAGARAJAN P, 1987, BIOCHIM BIOPHYS ACTA, V924, P127, DOI 10.1016/0304-4165(87)90079-1; vanWilligen G, 1996, BIOCHEM J, V314, P769, DOI 10.1042/bj3140769; Weitzman JB, 1997, EUR J IMMUNOL, V27, P78, DOI 10.1002/eji.1830270112; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	41	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20317	20322		10.1074/jbc.273.32.20317	http://dx.doi.org/10.1074/jbc.273.32.20317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685382	hybrid			2022-12-27	WOS:000075305400059
J	Yuan, Y; Li, DM; Sun, H				Yuan, Y; Li, DM; Sun, H			PIR1, a novel phosphatase that exhibits high affinity to RNA ribonucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUAL-SPECIFICITY PHOSPHATASE; SPLICING FACTORS; MAP KINASE; IN-VIVO; PROTEIN; ENCODES	Protein tyrosine phosphatases are involved in the regulation of important cellular processes such as signal transduction, cell cycle progression, and tumor suppression. Here we report the cloning and characterization of PIR1, a novel member in the dual-specificity phosphatase subfamily of the protein tyrosine phosphatases. PIR1 also contains two stretches of arginine-rich sequences. We have shown that the recombinant PIR1 protein possessed an intrinsic phosphatase activity on phosphotyrosine-containing substrate. A unique feature of this phosphatase is that it binds directly to RNA in vitro with high affinity. In addition, we have found that PIR1 interacted with splicing factors 9G8 and SRp30C, possibly through an RNA intermediate during a yeast two-hybrid screen. PIR1 exhibited a nuclear-staining pattern that was sensitive to RNase A, but not to DNase I, suggesting that PIR1 in the cells are associated with RNA and/or ribonucleoprotein particles. Furthermore, a fraction of PIR1 showed a speckle-staining pattern that superimposed with that of the splicing factor, SC35. Taken together, our data suggest that PIR1 is a novel phosphatase that may participate in nuclear mRNA metabolism.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University	Sun, H (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.			Yuan, Yu/0000-0003-1075-1628				ALESSI DR, 1993, ONCOGENE, V8, P2015; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Dreyfuss G, 1996, CELL, V85, P963, DOI 10.1016/S0092-8674(00)81298-2; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; POLYAK K, 1994, CELL, V78, P56; SHENG ZQ, 1993, J BIOL CHEM, V268, P4728; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	25	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20347	20353		10.1074/jbc.273.32.20347	http://dx.doi.org/10.1074/jbc.273.32.20347			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685386	hybrid			2022-12-27	WOS:000075305400063
J	Liang, SH; Hong, D; Clarke, MF				Liang, SH; Hong, D; Clarke, MF			Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; GREEN FLUORESCENT PROTEIN; TUMOR-SUPPRESSOR PROTEIN; DNA-BINDING FUNCTION; CELL-CYCLE; BREAST-CANCER; NUCLEAR ACCUMULATION; GROWTH SUPPRESSION; GENE; OLIGOMERIZATION	Cytoplasmic sequestration of the p53 tumor suppresser protein has been proposed as a mechanism involved in abolishing p53 function. However, the mechanisms regulating p53 subcellular localization remain unclear. In this report, we analyzed the possible existence of cis-acting sequences involved in intracellular trafficking of the p53 protein. To study p53 trafficking, the jellyfish green fluorescent protein (GFP:) was fused to the wild-type or mutated p53 proteins for fast and sensitive analysis of protein localization in human MCF-7 breast cancer, RHO colon cancer, and SAOS-2 sarcoma cells. The wild-type p53/GFP fusion protein was localized in the cytoplasm, the nucleus, or both compartments in a subset of the cells. Mutagenesis analysis demonstrated that a single amino acid mutation of Lys-305 (mt p53) caused cytoplasmic sequestration of the p53 protein in the MCF-7 and RKO cells, whereas the fusion protein was distributed in both the cytoplasm and the nucleus of SAOS-2 cells, In SAOS-2 cells, the :mutant p53 was a less efficient inducer of p21/CIP1/WAF1 expression. Cytoplasmic sequestration of the mt p53 was dependent upon the C-terminal region (residues 326-355) of the protein. These results indicated the involvement of cis-acting sequences in the regulation of p53 subcellular localization. Lys-305 is needed for nuclear import of p53 protein, and amino acid residues 326-355 can sequester mt p53 in the cytoplasm.	Univ Michigan, Ctr Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Clarke, MF (corresponding author), Univ Michigan, Ctr Med, Dept Internal Med, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA67140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA067140, R01CA067140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOSARI S, 1995, AM J PATHOL, V147, P790; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CASEY G, 1991, ONCOGENE, V6, P1791; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DANG CV, 1989, J BIOL CHEM, V264, P18019; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1995, CANCER RES, V55, P1649; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liner D.I., 1979, CELL, V17, P43; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MIYASHITA T, 1995, CELL, V80, P293; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1995, ONCOGENE, V10, P1053; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZERRAHN J, 1992, ONCOGENE, V7, P1371	49	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19817	19821		10.1074/jbc.273.31.19817	http://dx.doi.org/10.1074/jbc.273.31.19817			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677415	hybrid			2022-12-27	WOS:000075125200067
J	Shapira, H; Amit, I; Revach, M; Oron, Y; Battey, JF				Shapira, H; Amit, I; Revach, M; Oron, Y; Battey, JF			G alpha(14) and G alpha(q) mediate the response to trypsin in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ALPHA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; THYROTROPIN-RELEASING-HORMONE; PHOSPHOLIPASE-C; LAEVIS OOCYTES; HUMAN PLATELETS; CELL-LINES; GQ FAMILY; RECEPTOR; EXPRESSION	Xenopus oocytes respond to trypsin with a characteristic chloride current, virtually indistinguishable from responses mediated by a large number of native and expressed G protein-coupled receptors. We studied the involvement of G proteins of the G alpha(q) family as possible mediators of this and other G protein-coupled receptor-mediated responses in Xenopus oocytes. We have cloned the third member of the G alpha(q) family, Xenopus G alpha(14), in addition to the previously cloned Xenopus G alpha(q) and Ga,, (Shapira, H., Way, J., Lipinsky, D., Oron, Y., and Battey, J. F. (1994) FEES Lett. 348, 89-92). Amphibian G alpha(14) is 354 amino acids long and is 93% identical to its mammalian counterpart. Based on the G alpha(14) cDNA sequence, we designed a specific antisense DNA oligonucleotide (antiG alpha(14)) that, together with antiG alpha(q) and antiG alpha(11), was used in antisense depletion experiments. 24 h after injection into oocytes, either antiG alpha(q) or antiG alpha(14) reduced the response to 1 mu g/ml trypsin by 70%, whereas antiG alpha(11) had no effect. A mixture of antiG alpha(q) and antiG alpha(14) virtually abolished the response. These data strongly suggest that G alpha(q) and G alpha(14) are the exclusive mediators of the trypsin-evoked response in Xenopus oocytes. Similar experiments with the expressed gastrin-releasing peptide receptor and muscarinic mi receptor revealed the coupling of G alpha(q) and G alpha(11) but not G alpha(14) to these receptors in oocytes. These results confirm the hypothesis that endogenous members of the Gag family discriminate among different native receptors in vivo.	Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; Natl Inst Deafness & Other Commun Disorders, NIH, Rockville, MD 20850 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Shapira, H (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	hshapira@post.tau.ac.il						AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARAGAY AM, 1992, J BIOL CHEM, V267, P24983; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CARROLL DJ, 1995, DEV BIOL, V170, P690, DOI 10.1006/dbio.1995.1247; DAVIS LG, 1986, BASIC METHODS MOL BI, P1; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; DURIEUX ME, 1994, FEBS LETT, V337, P235, DOI 10.1016/0014-5793(94)80198-3; Gallo CJ, 1996, DEV BIOL, V177, P300, DOI 10.1006/dbio.1996.0164; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HSEI KP, 1992, MOL ENDOCRINOL, V6, P1673; Kai H, 1996, MOL PHARMACOL, V49, P96; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Kuhn B, 1996, MOL ENDOCRINOL, V10, P1697, DOI 10.1210/me.10.12.1697; LIPINSKY D, 1992, FEBS LETT, V307, P237, DOI 10.1016/0014-5793(92)80775-C; MAREZLEPRETRE N, 1996, J BIOL CHEM, V272, P5261; MILLIGAN G, 1993, J NEUROCHEM, V61, P845, DOI 10.1111/j.1471-4159.1993.tb03595.x; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; Milligan G, 1996, TRENDS PHARMACOL SCI, V17, P235, DOI 10.1016/0165-6147(96)10026-2; MILLIGAN G, 1993, BIOCHIM BIOPHYS ACTA, V1179, P208, DOI 10.1016/0167-4889(93)90143-D; MITCHELL FM, 1993, BIOCHEM J, V293, P495, DOI 10.1042/bj2930495; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; OLATE J, 1989, FEBS LETT, V244, P188, DOI 10.1016/0014-5793(89)81190-1; PADRELL E, 1991, J BIOL CHEM, V266, P9771; PANG IH, 1990, J BIOL CHEM, V265, P18707; QUICK MW, 1994, J BIOL CHEM, V269, P30164; SAWAKI K, 1993, ARCH BIOCHEM BIOPHYS, V305, P546, DOI 10.1006/abbi.1993.1459; SHAH BH, 1995, P NATL ACAD SCI USA, V92, P1886, DOI 10.1073/pnas.92.6.1886; SHAPIRA H, 1994, FEBS LETT, V348, P89, DOI 10.1016/0014-5793(94)00570-2; SHAPIRA H, 1993, METHODS NEUROSCI, V13, P220; SHENKER A, 1991, J BIOL CHEM, V266, P9309; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; WESTERLO E, 1995, BIOCHEM J, V310, P559; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798	38	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19431	19436		10.1074/jbc.273.31.19431	http://dx.doi.org/10.1074/jbc.273.31.19431			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677362	hybrid			2022-12-27	WOS:000075125200014
J	Axelsson, MAB; Asker, N; Hansson, GC				Axelsson, MAB; Asker, N; Hansson, GC			O-glycosylated MUC2 monomer and dimer from LS 174T cells are water-soluble, whereas larger MUC2 species formed early during biosynthesis are insoluble and contain nonreducible intermolecular bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; VONWILLEBRAND-FACTOR; MOLECULAR-CLONING; GLYCOPROTEINS; APOPROTEIN; COMPLEX; MUCINS; REGION; CDNA	The MUC2 mucin is the major gel-forming mucin in the small and large intestine. Due to its sequence similarities with the von Willebrand factor, it has been suggested to dimerize in the endoplasmic reticulum and polymerize in the trans-Golgi network. Using an O-glycosylation-sensitive MUGS antiserum, a dimerization has been shown to occur in the endoplasmic reticulum of LS 174T cells (Asker, N., Axelsson, M. A. B., Olofsson, S.-O., and Hansson, G. C. (1998) J. Biol. Chem. 278, 18857-18863). Using an antiserum immunoprecipitating O-glycosylated MUGS mucin, monomers and dimers mere shown to occur in soluble form in the lysate of LS 174T cells. The amount of O-glycosylated dimer was small, and no larger species were found even after long chase periods. However, most of the labeled MUGS mucin was found in pelleted debris of the cell lysate. This insoluble MUC2 mucin was recovered by immunoprecipitation after reduction of disulfide bonds. Analysis by agarose gel electrophoresis revealed two bands, of which the smaller migrated as the O-glycosylated monomer and the larger migrated as the O-glycosylated dimer of the cell lysis supernatant. Mucins insoluble in 6 M guanidinium chloride could also be obtained from LS 174T cells. Such mucins have earlier been found in the small intestine (Carlstedt, I., Herrmann, A., Karlsson, H., Sheehan, J., Fransson, L.-A., and Hansson, G. C. (1993) J. Biol. Chem. 268, 18771-18781). Reduction of the mucins followed by purification by isopycnic density gradient ultracentrifugation and analysis by agarose gel electrophoresis revealed two bands reacting with an anti-MUC2 tandem repeat antibody after deglycosylation. These bands migrated identically to the bands shown by metabolic labeling, and they could also be separated by rate zonal ultracentrifugation. These results suggest that the MUC2 mucin is forming nonreducible intermolecular bonds early in biosynthesis, but after initial O-glycosylation.	Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Gothenburg	Hansson, GC (corresponding author), Gothenburg Univ, Dept Med Biochem, Med Gatan 9, S-41390 Gothenburg, Sweden.	gunnar.hansson@medkem.gu.se	Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019	Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869				Asker N, 1998, J BIOL CHEM, V273, P18857, DOI 10.1074/jbc.273.30.18857; ASKER N, 1995, BIOCHEM J, V308, P873, DOI 10.1042/bj3080873; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; AXELSSON MAB, 1998, IN PRESS GLYCOCONJ J; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARLSTEDT I, 1993, J BIOL CHEM, V268, P18771; CARLSTEDT I, 1983, BIOCHEM J, V213, P427, DOI 10.1042/bj2130427; CARLSTEDT I, 1983, BIOCHEM J, V211, P13, DOI 10.1042/bj2110013; CARLSTEDT I, 1982, ADV EXP MED BIOL, V144, P155; CARLSTEDT I, 1996, 4 INT WORKSH CARC AS; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; Forstner Janet F., 1994, P1255; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P604; Gipson IK, 1997, BIOL REPROD, V56, P999, DOI 10.1095/biolreprod56.4.999; GUM JR, 1992, J BIOL CHEM, V267, P21375; GUM JR, 1994, J BIOL CHEM, V269, P2440; HANSSON GC, 1994, BIOCHEM BIOPH RES CO, V198, P181, DOI 10.1006/bbrc.1994.1026; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; ROBERTON AM, 1989, BIOCHEM J, V261, P637, DOI 10.1042/bj2610637; SHEEHAN JK, 1984, BIOCHEM J, V217, P93, DOI 10.1042/bj2170093; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217; Xu GQ, 1996, GLYCOCONJUGATE J, V13, P81, DOI 10.1007/BF01049683; XU GQ, 1992, J BIOL CHEM, V267, P5401	27	78	80	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18864	18870		10.1074/jbc.273.30.18864	http://dx.doi.org/10.1074/jbc.273.30.18864			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668062	hybrid			2022-12-27	WOS:000074974700029
J	Burlacu-Miron, S; Perrier, V; Gilles, AM; Pistotnik, E; Craescu, CT				Burlacu-Miron, S; Perrier, V; Gilles, AM; Pistotnik, E; Craescu, CT			Structural and energetic factors of the increased thermal stability in a genetically engineered Escherichia coli adenylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; H-1-NMR SPECTRA; PROTEIN; SPECTROSCOPY; ASSIGNMENT; RESOLUTION; COMPLEX; DOMAIN	Several variants of Escherichia coli adenylate kinase, designed to bind a Zn2+ ion, were produced by site-directed mutagenesis. The metal binding and enzymatic properties of the engineered variants have been described (Perrier, V., Burlacu-Miron, S,, Bourgeois, S., Surewicz, W. K., and Gilles, A.-M. (1998) J. Biol, Chem. 273, 19097-19101), Here we report the structural properties and stability changes in a 4-Cys variant which binds a Zn2+ ion and has an increased thermal stability. CD studies indicate a very similar secondary structure content in the wild type and the engineered variant. NMR analysis revealed that the topology of the parallel P-sheet, belonging to the protein core, and of the peripheral antiparallel P-sheet are also conserved. The small local changes observed in the neighborhood of the substitution sites reflect a more compact state of the metal-binding domain. The Zn2+-bound quadruple mutant shows an increased thermal stability, reflected in a 9 degrees C increase of the mid-temperature of the first cooperative unfolding step. finding of a bisubstrate analog P-1,P-5-di(adenosine-5')-pentaphosphate increases, by about 7 degrees C, the midpoint of this transition in both wild type and modified variant. The NMR data suggest that the peripheral domains involved in substrate binding unfold during the first denaturation step. Urea denaturation experiments indicate an increased resistance against chemical unfolding of the Zn2+-binding variant. In contrast, the Gibbs free energy of unfolding (at physiologically relevant conditions) of the quadruple mutant is lower than that of the wild type.	Inst Curie Rech, INSERM, U350, Ctr Univ, F-91405 Orsay, France; Inst Pasteur, URA D1129, Lab Chim Struct Macromol, F-7524 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Craescu, CT (corresponding author), Inst Curie Rech, INSERM, U350, Ctr Univ, Bat 110-112, F-91405 Orsay, France.	craescu@curie.u-psud.fr	Miron, Simona/M-9223-2018; Perrier, Veronique/AAK-3594-2020	perrier, veronique/0000-0002-6570-7504				BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304; Bilderback T, 1996, BIOCHEMISTRY-US, V35, P6100, DOI 10.1021/bi951833i; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; GERSTEIN M, 1993, J MOL BIOL, V229, P494, DOI 10.1006/jmbi.1993.1048; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; JOHNSON CW, 1990, PROTEIN-STRUCT FUNCT, V7, P205; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MacedoRibeiro S, 1996, STRUCTURE, V4, P1291, DOI 10.1016/S0969-2126(96)00137-2; MIYOSHI K, 1990, J BIOCHEM-TOKYO, V108, P267, DOI 10.1093/oxfordjournals.jbchem.a123192; MONNOT M, 1987, J BIOL CHEM, V262, P2502; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; Pace C N, 1986, Methods Enzymol, V131, P266; Perrier V, 1998, J BIOL CHEM, V273, P19097, DOI 10.1074/jbc.273.30.19097; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC	22	22	22	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19102	19107		10.1074/jbc.273.30.19102	http://dx.doi.org/10.1074/jbc.273.30.19102			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668095	hybrid			2022-12-27	WOS:000074974700062
J	Harris, VK; Liaudet-Coopman, EDE; Boyle, BJ; Wellstein, A; Riegel, AT				Harris, VK; Liaudet-Coopman, EDE; Boyle, BJ; Wellstein, A; Riegel, AT			Phorbol ester-induced transcription of a fibroblast growth factor-binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; COLLAGENASE GENE; C/EBP FAMILY; ACTIVATION; NF-IL6; AP-1; FOS; EXPRESSION; DNA; INDUCTION	Earlier studies from our laboratory showed that a secreted binding protein for fibroblast growth factors (FGF-BP) is expressed at high levels in squamous cell carcinoma (SCC) cell lines. Overexpression studies or conversely reduced expression of FGF-BP by ribozyme targeting have elucidated a direct role of this protein in angiogenesis during tumor development. We have also observed a significant up-regulation of FGF-BP during TPA (12-O-tetradecanoylphorbol-13-acetate) promotion of skin cancer. Here we investigate the mechanism of TPA induction of FGF-BP gene expression in the human ME-180 SCC cell line. We found that TPA increased FGF-BP mRNA levels in a time- and dose-dependent manner mediated via the protein kinase C signal transduction pathway. Results from actinomycin D and cycloheximide experiments as well as nuclear transcription assays revealed that TPA up-regulated the steady-state levels of FGF-BP mRNA by increasing its rate of gene transcription independently of de novo protein synthesis. We isolated the human FGF-BP promoter and determined by deletion analysis that TPA regulatory elements were all contained in the first 118 base pairs upstream of the transcription start site. Further mutational analysis revealed that full TPA induction required interplay between several regulatory elements with homology to Ets, AP-1, and CAATT/enhancer binding protein C/EBP sites, In addition, deletion or mutation of a 10-base pair region juxtaposed to the AP-1 site dramatically increased TPA induced FGF-BP gene expression. This region represses the extent of the FGF-BP promoter response to TPA and contained sequences recognized by the family of E box helix-loop-helix transcription factors. Gel shift analysis showed specific and TPA-inducible protein binding to the Ets, AP-1, and C/EBP sites. Furthermore, distinct, specific, and TPA-inducible binding to the imperfect E box repressor element was also apparent. Overall, our data indicate that TPA effects on FGF-BP gene transcription are tightly controlled by a complex interplay of positive elements and a novel negative regulatory element.	Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University; Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Dept Pharmacol, Res Bldg,E307,3970 Reservoir Rd NW, Washington, DC 20007 USA.		Liaudet-Coopman, Emmanuelle/N-4744-2017	Liaudet-Coopman, Emmanuelle/0000-0001-9313-9690; Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [R01CA071508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K04DK002141] Funding Source: NIH RePORTER; NCI NIH HHS [CA71508] Funding Source: Medline; NIDDK NIH HHS [DK02141] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Combates NJ, 1997, CELL GROWTH DIFFER, V8, P213; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; CZUBAYKO F, 1994, J BIOL CHEM, V269, P28243; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Goppelt A, 1996, EMBO J, V15, P3105, DOI 10.1002/j.1460-2075.1996.tb00673.x; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HARVAT BL, 1995, CELL GROWTH DIFFER, V6, P955; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; Jenkins TD, 1997, J BIOL CHEM, V272, P24433, DOI 10.1074/jbc.272.39.24433; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KLAMPFER L, 1994, MOL CELL BIOL, V14, P6561, DOI 10.1128/MCB.14.10.6561; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kurtz A, 1997, ONCOGENE, V14, P2671, DOI 10.1038/sj.onc.1201117; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LiaudetCoopman EDE, 1996, BIOCHEM BIOPH RES CO, V229, P930, DOI 10.1006/bbrc.1996.1904; LiaudetCoopman EDE, 1997, CLIN CANCER RES, V3, P179; LiaudetCoopman EDE, 1996, J BIOL CHEM, V271, P21303, DOI 10.1074/jbc.271.35.21303; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PATERSON JM, 1995, NEUROSCI LETT, V191, P185, DOI 10.1016/0304-3940(95)11588-N; Rak J, 1997, NAT MED, V3, P1083, DOI 10.1038/nm1097-1083; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RIEGEL AT, 1991, MOL ENDOCRINOL, V5, P1973, DOI 10.1210/mend-5-12-1973; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; WU DQ, 1991, J BIOL CHEM, V266, P16778; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179	52	28	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19130	19139		10.1074/jbc.273.30.19130	http://dx.doi.org/10.1074/jbc.273.30.19130			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668098	hybrid			2022-12-27	WOS:000074974700065
J	Asano, K; Phan, L; Anderson, J; Hinnebusch, AG				Asano, K; Phan, L; Anderson, J; Hinnebusch, AG			Complex formation by all five homologues of mammalian translation initiation factor 3 subunits from yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SHUTTLE VECTORS; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; RABBIT RETICULOCYTES; RESTRICTION SITES; PRT1 PROTEIN; FACTOR EIF-3; GENE; DNA; SYSTEM	The PRT1, TIF34, GCD10, and SUI1 proteins of Saccharomyces cerevisiae were found previously to copurify with eukaryotic translation initiation factor 3 (eIF3) activity. Although TIF32, NIP1, and TIF35 are homologous to subunits of human eIF3, they were not known to be components of the yeast factor. We detected interactions between PRT1, TIF34, and TIF35 by the yeast two-hybrid assay and in vitro binding assays. Discrete segments (70-150 amino acids) of PRT1 and TIF35 were found to be responsible for their binding to TIF34, Temperature-sensitive mutations mapping in WD-repeat domains of TIF34 were isolated that decreased binding between TIF34 and TIF35 in vitro. The lethal effect of these mutations was suppressed by increasing TIF35 gene dosage, suggesting that the TIF34-TIF35 interaction is important for TIF34 function in translation. Pairwise in vitro interactions were also detected between PRT1 and TIF32, TIF32 and NIP1, and NIP1 and SUI1, Furthermore, PRT1, NIP1, TIF34, TIF35, and a polypeptide with the size of TIF32 were specifically coimmunoprecipitated from the ribosomal salt wash fraction. We propose that all five yeast proteins homologous to human eIF3 subunits are components of a stable heteromeric complex in vivo and may comprise the conserved core of yeast eIF3.	NICHHD, Lab Eukaryot Gene Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hinnebusch, AG (corresponding author), NICHHD, Lab Eukaryot Gene Regulat, Bethesda, MD 20892 USA.	ahinnebusch@nih.gov						ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BENNE R, 1978, J BIOL CHEM, V253, P3078; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOMMER UA, 1991, BIOCHIMIE, V73, P1007, DOI 10.1016/0300-9084(91)90142-N; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; Chaudhuri J, 1997, J BIOL CHEM, V272, P30975, DOI 10.1074/jbc.272.49.30975; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; Clapham DE, 1996, NATURE, V379, P297, DOI 10.1038/379297a0; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; EVANS DRH, 1995, MOL CELL BIOL, V15, P4525; FEINBERG B, 1982, J BIOL CHEM, V257, P846; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOX TD, 1996, TRANSLATIONAL CONTRO, P733; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JONSON KR, 1997, J BIOL CHEM, V272, P7106; KASPERAITIS MAM, 1995, FEBS LETT, V365, P47, DOI 10.1016/0014-5793(95)00427-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; Miller J. H, 1972, EXPT MOL GENETICS; Morley SJ, 1997, RNA, V3, P1085; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; Naranda T, 1997, MOL CELL BIOL, V17, P145, DOI 10.1128/MCB.17.1.145; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PHAN L, 1998, IN PRESS MOL CELL BI; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; SRIVASTAVA S, 1992, J MOL BIOL, V226, P301, DOI 10.1016/0022-2836(92)90946-H; Stagljar I, 1996, BIOTECHNIQUES, V21, P430; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRACHSEL H, 1979, BIOCHIM BIOPHYS ACTA, V565, P305, DOI 10.1016/0005-2787(79)90207-7; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; Verlhac MH, 1997, EMBO J, V16, P6812, DOI 10.1093/emboj/16.22.6812; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	56	130	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18573	18585		10.1074/jbc.273.29.18573	http://dx.doi.org/10.1074/jbc.273.29.18573			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660829	hybrid			2022-12-27	WOS:000074828500084
J	Blakesley, VA; Koval, AP; Stannard, BS; Scrimgeour, A; LeRoith, D				Blakesley, VA; Koval, AP; Stannard, BS; Scrimgeour, A; LeRoith, D			Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID COLORIMETRIC ASSAY; FOCAL ADHESION FORMATION; YEAST 2-HYBRID SYSTEM; MAP KINASE KINASE; IGF-I; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; RAT GLIOBLASTOMA; P85 SUBUNIT; PROTEIN	Insulin-like growth factor (IGF)-I signaling through the IGF-I receptor modulates cellular adhesion and proliferation and the transforming ability of cells overexpressing the IGF-I receptor. Tyrosine phosphorylation of intracellular proteins is essential for this transduction of the IGF-I-induced mitogenic and tumorigenic signals. IGF-I induces specific cytoskeletal structure and the phosphorylation of proteins in the associated focal adhesion complexes. The determination of the exact pathways emanating from the IGF-I receptor that are involved in mediating these signals will contribute greatly to the understanding of IGF-I action. We have previously shown that replacement of tyrosine residues 1250 and 1251 in the carboxyl terminus of the IGF-I receptor abrogates IGF-I-induced cellular proliferation and tumor formation in nude mice. In this study, replacement of either tyrosine 1250 or 1251 similarly re duces the cells ability to grow in an anchorage-independent manner. The actin cytoskeleton and cellular localization of vinculin are disrupted by replacement of tyrosine 1251, Tyrosine residues 1250 and 1251 are not essential for tyrosine phosphorylation of two known substrates; insulin receptor substrate-1 and SHC, nor association of known downstream adaptor proteins to these substrates. In addition, these mutant IGF-I receptors do not affect IGF-I-stimulated p42/p44 mitogen-activated protein kinase activation or phosphatidylinositol (PI) 3'-kinase activity. Thus, it appears that in fibroblasts expressing tyrosine 1250 and 1251 mutant IGF-I receptors, the signal transduction pathways impacting on mitogenesis and tumorigenesis do not occur exclusively through the PI 3'-kinase or mitogen-activated protein kinase pathways.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Bldg 10 Rm 8S235A,10 Ctr Dr MSC 1770, Bethesda, MD 20892 USA.	derek@helix.nih.gov	Scrimgeour, Angus/D-6794-2013					ALTSCHULER D, 1994, MOL ENDOCRINOL, V8, P1139, DOI 10.1210/me.8.9.1139; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Balaram SK, 1997, J VASC SURG, V25, P866, DOI 10.1016/S0741-5214(97)70216-7; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Berfield AK, 1997, J HISTOCHEM CYTOCHEM, V45, P583, DOI 10.1177/002215549704500410; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Blakesley Vicky A., 1996, P824; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLL JL, 1995, P NATL ACAD SCI USA, V92, P9161, DOI 10.1073/pnas.92.20.9161; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; Ezzell RM, 1997, EXP CELL RES, V231, P14, DOI 10.1006/excr.1996.3451; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; GANSLER T, 1989, AM J PATHOL, V135, P961; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Harder BA, 1996, J MOL CELL CARDIOL, V28, P19, DOI 10.1006/jmcc.1996.0003; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ito T, 1996, MOL CELL BIOL, V16, P943; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JOCKUSCH BM, 1981, P NATL ACAD SCI-BIOL, V78, P3005, DOI 10.1073/pnas.78.5.3005; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KALEBIC T, 1994, CANCER RES, V54, P5531; KATO H, 1994, MOL ENDOCRINOL, V8, P40, DOI 10.1210/me.8.1.40; KATO H, 1993, J BIOL CHEM, V268, P2655; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAMOTHE B, 1995, FEBS LETT, V373, P51, DOI 10.1016/0014-5793(95)01011-3; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Loeser RF, 1997, ARTHRITIS RHEUM, V40, P270, DOI 10.1002/art.1780400211; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, ONCOGENE, V8, P2773; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMUELSSON SJ, 1993, J CELL BIOL, V122, P485, DOI 10.1083/jcb.122.2.485; SANCHEZMARGALET V, 1995, MOL ENDOCRINOL, V9, P435, DOI 10.1210/me.9.4.435; Sasaoka T, 1996, ENDOCRINOLOGY, V137, P4427, DOI 10.1210/en.137.10.4427; SEGER R, 1992, J BIOL CHEM, V267, P14373; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sydor AM, 1996, J CELL BIOL, V134, P1197, DOI 10.1083/jcb.134.5.1197; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; TartareDeckert S, 1996, ENDOCRINOLOGY, V137, P1019, DOI 10.1210/en.137.3.1019; TOBE K, 1991, J BIOL CHEM, V266, P24793; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; VARNUMFINNEY B, 1994, J CELL BIOL, V127, P1071, DOI 10.1083/jcb.127.4.1071; VOLBERG T, 1995, J CELL SCI, V108, P2253; WESTMEYER A, 1990, EMBO J, V9, P2071, DOI 10.1002/j.1460-2075.1990.tb07374.x; WOODS A, 1992, J CELL SCI, V101, P277	80	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18411	18422		10.1074/jbc.273.29.18411	http://dx.doi.org/10.1074/jbc.273.29.18411			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660809	hybrid			2022-12-27	WOS:000074828500064
J	Gosling, M; Harley, SL; Turner, RJ; Carey, N; Powell, JT				Gosling, M; Harley, SL; Turner, RJ; Carey, N; Powell, JT			Human saphenous vein endothelial cells express a tetrodotoxin-resistant, voltage-gated sodium current	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; NA+ CURRENT; MUSCLE CELLS; PATCH-CLAMP; MEMBRANE; CALCIUM; HEART; ARTERY; LINE	Whole-cell patch-clamp electrophysiological investigation of endothelial cells cultured from human saphenous vein (HSVECs) has identified a voltage-gated Na+ current with a mean peak magnitude of -595 +/- 49 pA (n = 75). This current was inhibited by tetrodotoxin (TTX) in a concentration-dependent manner, with an IC50 value of 4.7 mu M, suggesting that it was of the TTX-resistant subtype, An antibody directed against the highly conserved intracellular linker region between domains III and IV of known Na+ channel alpha-subunits was able to retard current inactivation when applied intracellularly. This antibody identified a 245-kDa protein from membrane lysates on Western blotting and positively immunolabeled both cultured HSVECs and intact venous endothelium, HSVECs were also shown by reverse transcription-polymerase chain reaction to contain transcripts of the hH1 sodium channel gene. The expression of Na+ channels by HSVECs was shown using electrophysiology and cell-based enzyme-linked immunosorbent assay to be dependent on the concentration and source of human serum. Together, these results suggest that TTX-resistant Na+ channels of the hill isoform are expressed in human saphenous vein endothelium and that the presence of these channels is controlled by a serum factor.	Charing Cross Hosp, Imperial Coll, Dept Vasc Surg, Sch Med, London W6 8RF, England	Imperial College London	Gosling, M (corresponding author), Charing Cross Hosp, Imperial Coll, Dept Vasc Surg, Sch Med, Fulham Palace Rd, London W6 8RF, England.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; Beny JL, 1997, PFLUG ARCH EUR J PHY, V433, P364; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; BKAILY G, 1991, J MOL CELL CARDIOL, V23, P25, DOI 10.1016/0022-2828(91)90036-L; BOSSU JL, 1989, FEBS LETT, V255, P377, DOI 10.1016/0014-5793(89)81126-3; BOSSU JL, 1992, PFLUG ARCH EUR J PHY, V420, P200, DOI 10.1007/BF00374991; BROWN AM, 1981, J PHYSIOL-LONDON, V318, P479; Chahine M, 1996, AM J PHYSIOL-HEART C, V271, pH498, DOI 10.1152/ajpheart.1996.271.2.H498; Cohen S A, 1993, Int Rev Cytol, V137C, P55; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GORDIENKO DV, 1994, PFLUG ARCH EUR J PHY, V428, P91, DOI 10.1007/BF00374756; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JAFFE EA, 1985, ANN NY ACAD SCI, V454, P279, DOI 10.1111/j.1749-6632.1985.tb11868.x; KALLEN RG, 1990, NEURON, V4, P232; KOSTYUK PG, 1981, NEUROSCIENCE, V6, P2423, DOI 10.1016/0306-4522(81)90088-9; KUSAKA M, 1994, AM J PHYSIOL-CELL PH, V267, pC1288; MARSDEN PA, 1991, J AM SOC NEPHROL, V1, P931; Quignard JF, 1997, CIRC RES, V80, P377, DOI 10.1161/01.res.0000435853.85322.af; RENAUD JF, 1983, J BIOL CHEM, V258, P8799; REVEST PA, 1992, TRENDS PHARMACOL SCI, V13, P404, DOI 10.1016/0165-6147(92)90124-O; SAGE SO, 1991, J PHYSIOL-LONDON, V440, P569, DOI 10.1113/jphysiol.1991.sp018725; SCULPTOREANU A, 1992, AM J PHYSIOL, V262, pC724, DOI 10.1152/ajpcell.1992.262.3.C724; SONTHEIMER H, 1992, J NEUROPHYSIOL, V68, P1001, DOI 10.1152/jn.1992.68.4.1001; Sontheimer H, 1996, TRENDS NEUROSCI, V19, P325, DOI 10.1016/0166-2236(96)10039-4; VANHOUTTE PM, 1986, ANNU REV PHYSIOL, V48, P307; WATSKY MA, 1991, PFLUG ARCH EUR J PHY, V419, P454, DOI 10.1007/BF00370788; Ying XY, 1996, CIRC RES, V79, P898, DOI 10.1161/01.RES.79.4.898	31	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21084	21090		10.1074/jbc.273.33.21084	http://dx.doi.org/10.1074/jbc.273.33.21084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694861	hybrid			2022-12-27	WOS:000075386100054
J	Honsho, M; Mitoma, JY; Ito, A				Honsho, M; Mitoma, JY; Ito, A			Retention of cytochrome b(5) in the endoplasmic reticulum is transmembrane and luminal domain-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER PROTEINS; MEDIATED RETRIEVAL; SECRETORY PATHWAY; MEMBRANE-PROTEIN; GOLGI; YEAST; TRANSPORT; CLONING; SIGNAL; CDNA	Cytochrome b(5) (b5), a typical tail-anchored protein of the endoplasmic reticulum (ER) membrane, is composed of three functionally different domains: amino-terminal heme-containing catalytic, central hydrophobic membrane-anchoring, and carboxyl-terminal ER-targeting domains (Mitoma, J., and Ito, A. (1992) EMBO J. 11, 4197-4203), To analyze the potential retention signal of b5, mutant proteins were prepared to replace each domain with natural or artificial sequences, and subcellular localizations were examined using immunofluorescence microscopy and cell fractionation. The transmembrane domain functioned to retain the cytochrome in the ER, and the mutation of all or part of the transmembrane domain with an artificial hydrophobic sequence had practically no effect on intracellular distribution of the cytochrome. However, when the transmembrane domain was extended systematically, a substantial portion of the protein with the domain of over 22 amino acid residues leaked from the organelle, Thus, the transmembrane length functions as the retention signal. When cytochromes with mutations at the carboxyl-terminal end were overexpressed in cells, a substantial portion of the protein was transported to the plasma membrane, indicating that the carboxyl-terminal luminal domain also has a role in retention of b5 in the ER. Carbohydrate moiety of the glycosylatably-mutated b5 was sensitive to endoglycosidase H but resistant to endoglycosidase D. Therefore, both transmembrane and carboxyl-terminal portions seems to function as the static retention signal.	Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan	Kyushu University	Ito, A (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Higashi Ku, Fukuoka 8128581, Japan.			Honsho, Masanori/0000-0001-6165-4516				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; HABIG WH, 1974, J BIOL CHEM, V249, P7130; INOUE A, 1992, J BIOL CHEM, V267, P10613; ITO A, 1980, J BIOCHEM, V87, P63, DOI 10.1093/oxfordjournals.jbchem.a132753; ITO A, 1990, BIOCHEM INT, V22, P235; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; MIYAUCHI K, 1991, J BIOL CHEM, V266, P19536; MIZUOCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209, DOI 10.1093/oxfordjournals.jbchem.a134711; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON I, 1993, J BIOL CHEM, V268, P5798; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIKAWA S, 1993, P NATL ACAD SCI USA, V90, P8179, DOI 10.1073/pnas.90.17.8179; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; Pedrazzini E, 1996, P NATL ACAD SCI USA, V93, P4207, DOI 10.1073/pnas.93.9.4207; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Sato M, 1996, J CELL BIOL, V134, P279, DOI 10.1083/jcb.134.2.279; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SHIMER SB, 1990, P NATL ACAD SCI USA, V87, P5148; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247; VERGERES G, 1995, J BIOL CHEM, V270, P3414, DOI 10.1074/jbc.270.7.3414; Yang M, 1997, J BIOL CHEM, V272, P1970, DOI 10.1074/jbc.272.3.1970; ZHANG H, 1988, ARCH BIOCHEM BIOPHYS, V264, P343, DOI 10.1016/0003-9861(88)90603-0	40	51	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20860	20866		10.1074/jbc.273.33.20860	http://dx.doi.org/10.1074/jbc.273.33.20860			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694832	hybrid			2022-12-27	WOS:000075386100025
J	Maki, S; Hashimoto, K; Ohara, T; Sugino, A				Maki, S; Hashimoto, K; Ohara, T; Sugino, A			DNA polymerase II (epsilon) of Saccharomyces cerevisiae dissociates from the DNA template by sensing single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; CELL NUCLEAR ANTIGEN; ESCHERICHIA-COLI; S-PHASE; YEAST; CHECKPOINT; SUBUNIT; REPAIR; DELTA; RECONSTITUTION	Two forms of DNA polymerase II (epsilon) of Saccharomyces cerevisiae, Pol II* and Pol II, were purified to near homogeneity from yeast cells. Pol II* is a four-subunit complex containing a 256-kDa catalytic polypeptide, whereas Pol II consists solely of a 145-kDa polypeptide derived from the N-terminal half of the 256-kDa polypeptide of Pol II*. We show that Pol II* and Pol II are indistinguishable with respect to the processivity and rate of DNA-chain elongation. The equilibrium dissociation constants of the complexes of Pol II* and Pol II with the DNA template showed that the stability of these complexes is almost the same. However, when the rates of dissociation of the Pol II* and Pol II from the DNA template were measured using single-stranded DNA as a trap for the dissociated polymerase, Pol II* dissociated 75-fold faster than Pol II. Furthermore, the rate of dissociation of Pol II* from the DNA template became faster as the concentration of the single-stranded DNA was increased. These results indicate that the rapid dissociation of Pol II* from the DNA template is actively promoted by single-stranded DNA, The dissociation of Pol II from the DNA template was also shown to be promoted by single-stranded DNA, although at a much slower rate. These results suggest that the site for sensing single stranded DNA resides within the 145-kDa N-terminal portion of the catalytic subunit and that the efficiency for sensing single-stranded DNA by this site is positively modulated by either the C-terminal half of the catalytic subunit and/or the other subunits.	Osaka Univ, Microbial Dis Res Inst, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	Osaka University	Sugino, A (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Biochem & Mol Biol, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.							Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; EKI T, 1992, J BIOL CHEM, V267, P7284; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; Hashimoto K, 1998, NUCLEIC ACIDS RES, V26, P477, DOI 10.1093/nar/26.2.477; KESTI T, 1993, J BIOL CHEM, V268, P10238; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LEE SH, 1991, J BIOL CHEM, V266, P22707; MAGA G, 1995, BIOCHEMISTRY-US, V34, P891, DOI 10.1021/bi00003a023; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MORRISON A, 1993, PROG NUCLEIC ACID RE, V46, P93, DOI 10.1016/S0079-6603(08)61019-3; Mozzherin DJ, 1996, BIOCHEMISTRY-US, V35, P3572, DOI 10.1021/bi952142p; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; SANGER F, 1978, J MOL BIOL, V125, P225, DOI 10.1016/0022-2836(78)90346-7; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; Sugimoto K, 1996, P NATL ACAD SCI USA, V93, P7048, DOI 10.1073/pnas.93.14.7048; Sugimoto K, 1997, MOL CELL BIOL, V17, P5905, DOI 10.1128/MCB.17.10.5905; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; TUUSA J, 1995, NUCLEIC ACIDS RES, V23, P2178, DOI 10.1093/nar/23.12.2178; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG ZG, 1993, MOL CELL BIOL, V13, P1051, DOI 10.1128/MCB.13.2.1051; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; YODER BL, 1991, J BIOL CHEM, V266, P22689; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	40	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21332	21341		10.1074/jbc.273.33.21332	http://dx.doi.org/10.1074/jbc.273.33.21332			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694894	hybrid			2022-12-27	WOS:000075386100087
J	Murphy, GM; Yang, L; Cordell, B				Murphy, GM; Yang, L; Cordell, B			Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN FETAL ASTROCYTES; ALZHEIMERS-DISEASE; FACTOR-I; SCAVENGER RECEPTOR; CULTURED MICROGLIA; PLAQUE EVOLUTION; INTERFERON-GAMMA; GENE-EXPRESSION; FACTOR-ALPHA	In Alzheimer's disease (AD), a chronic cerebral inflammatory state is thought to lead to neuronal injury. Microglia, intrinsic cerebral immune effector cells, are likely to be key in the pathophysiology of this inflammatory state. We showed that macrophage colony-stimulating factor, a microglial activator found at increased levels in the central nervous system in AD, dramatically augments beta-amyloid peptide (beta AP)-induced microglial production of interleukin-l, interleukin-6, and nitric oxide. In contrast, granulocyte macrophage colony-stimulating factor, another hematopoietic cytokine found in the AD brain, did not augment beta AP-induced microglial secretory activity. These results indicate that increased macrophage colony-stimulating factor levels in AD could magnify beta AP-induced microglial inflammatory cytokine and nitric oxide production, which in turn could intensify the cerebral inflammatory state by activating astrocytes and additional microglia, as well as directly injuring neurons.	Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA; Scios Inc, Sunnyvale, CA 94086 USA	Stanford University; Scios	Murphy, GM (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Neurosci Res Labs, Stanford, CA 94305 USA.	greer.murphy@stanford.edu						AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; ARAUJO DM, 1992, BRAIN RES, V569, P141, DOI 10.1016/0006-8993(92)90380-R; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Bitting L, 1996, J BIOL CHEM, V271, P16084, DOI 10.1074/jbc.271.27.16084; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; CHUNG Y, 1994, J NEUROIMMUNOL, V52, P9; DERYUGINA EI, 1995, BLOOD, V86, P2568; DICKSON DW, 1991, LAB INVEST, V64, P135; Ding MZ, 1997, J BIOL CHEM, V272, P11327; ElKhoury J, 1996, NATURE, V382, P716; FUNG MC, 1992, J IMMUNOL METHODS, V149, P97, DOI 10.1016/S0022-1759(12)80053-6; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GOODWIN JL, 1995, BRAIN RES, V692, P207, DOI 10.1016/0006-8993(95)00646-8; GRIFFIN WST, 1995, J NEUROPATH EXP NEUR, V54, P276; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hamilton JA, 1997, IMMUNOL TODAY, V18, P313, DOI 10.1016/S0167-5699(97)01084-0; HAO C, 1990, J NEUROSCI RES, V27, P314, DOI 10.1002/jnr.490270310; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Ii M, 1996, BRAIN RES, V720, P93, DOI 10.1016/0006-8993(96)00156-4; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Kloss CUA, 1997, J NEUROSCI RES, V49, P248; LEE SC, 1993, J IMMUNOL, V150, P594; LEE SC, 1994, GLIA, V12, P309, DOI 10.1002/glia.440120407; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Lorton D, 1996, J NEUROIMMUNOL, V67, P21, DOI 10.1016/S0165-5728(96)00030-6; MARCINKIEWICZ J, 1995, EUR J IMMUNOL, V25, P947, DOI 10.1002/eji.1830250414; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MCMILLIAN M, 1995, BIOCHEM BIOPH RES CO, V215, P572, DOI 10.1006/bbrc.1995.2503; Meda L, 1996, J IMMUNOL, V157, P1213; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; MIYAJIMA A, 1993, BLOOD, V82, P1960; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; NOHAVA K, 1992, EUR J IMMUNOL, V22, P2539, DOI 10.1002/eji.1830221012; Paresce DM, 1996, NEURON, V17, P553, DOI 10.1016/S0896-6273(00)80187-7; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; Personett DA, 1996, J NEUROSCI METH, V65, P77, DOI 10.1016/0165-0270(95)00150-6; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Rogers J, 1996, NEUROBIOL AGING, V17, P681, DOI 10.1016/0197-4580(96)00115-7; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SEBIRE G, 1993, J IMMUNOL, V150, P1517; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SHADDUCK RK, 1993, EXP HEMATOL, V21, P515; SHAFITZAGARDO B, 1993, INT J DEV NEUROSCI, V11, P189, DOI 10.1016/0736-5748(93)90078-R; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Singh VK, 1997, J PSYCHIAT RES, V31, P657, DOI 10.1016/S0022-3956(97)00023-X; Smith MA, 1997, J NEUROSCI, V17, P2653; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; THERY C, 1992, J NEUROCHEM, V59, P1183, DOI 10.1111/j.1471-4159.1992.tb08366.x; VIGNE P, 1993, BRAIN RES, V606, P332, DOI 10.1016/0006-8993(93)91003-B; WALKER DG, 1995, J NEUROSCI RES, V40, P478, DOI 10.1002/jnr.490400407; Wishnok JS, 1996, METHOD ENZYMOL, V268, P130; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0	62	107	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20967	20971		10.1074/jbc.273.33.20967	http://dx.doi.org/10.1074/jbc.273.33.20967			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694846	hybrid			2022-12-27	WOS:000075386100039
J	Okkenhaug, K; Rottapel, R				Okkenhaug, K; Rottapel, R			Grb2 forms an inducible protein complex with CD28 through a Src homology 3 domain-proline interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; RECEPTOR TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE ASSOCIATION; GUANINE-NUCLEOTIDE EXCHANGE; LYMPHOCYTE SURFACE-RECEPTOR; C-CBL PROTOONCOGENE; SH3 DOMAIN; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; COSTIMULATORY RECEPTOR	CD28 provides a costimulatory signal that results in optimal activation of T cells. The signal transduction pathways necessary for CD28-mediated co-stimulation are presently unknown. Engagement of CD28 leads to its tyrosine phosphorylation and subsequent binding to Src homology 2 (SH2)-containing proteins including the p85 subunit of phosphatidylinositol 3'-kinase (PI3K); however, the contribution of PI3K to CD28-dependent costimulation remains controversial. Here we show that CD28 is capable of binding the Src homology 3 (SH3) domains of several proteins, including Grb2. The interaction between Grb2 and CD28 is mediated by the binding of Grb2-SH3 domains to the C-terminal diproline motif present in the cytoplasmic domain of CD28. While the affinity of the C-terminal SH3 domain of Grb2 for CD28 is greater than that of the N-terminal SH3 domain, optimal binding requires both SH3 domains. Ligation of CD28, but not tyrosine-phosphorylation, is required for the SH3-mediated binding of Grb2 to CD28. We propose a model whereby the association of Grb2 with CD28 occurs via an inducible SH3-mediated interaction and leads to the recruitment of tyrosine-phosphorylated proteins such as p52(shc) bound to the SH2 domain of Grb2. The inducible interaction of Grb2 to the C-terminal region of CD28 may form the basis for PI3K-independent signaling through CD28.	Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A2, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto	Okkenhaug, K (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Rottapel@oci.utoronto.ca	Okkenhaug, Klaus/H-3154-2019; Okkenhaug, Klaus/D-5149-2012	Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; Rottapel, Robert/0000-0002-6024-5558				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Boussiotis VA, 1996, J EXP MED, V184, P365, DOI 10.1084/jem.184.2.365; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CROOKS MEC, 1995, MOL CELL BIOL, V15, P6820; DEN HJ, 1996, EMBO J, V15, P3016; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; Gotoh N, 1997, MOL CELL BIOL, V17, P1824, DOI 10.1128/MCB.17.4.1824; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; Hutchcroft JE, 1996, J BIOL CHEM, V271, P13362, DOI 10.1074/jbc.271.23.13362; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Kim HH, 1998, J BIOL CHEM, V273, P296, DOI 10.1074/jbc.273.1.296; Klasen S, 1998, INT IMMUNOL, V10, P481, DOI 10.1093/intimm/10.4.481; LAHESMAA R, 1995, J IMMUNOL, V155, P3815; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LIU Y, 1992, P NATL ACAD SCI USA, V89, P3845, DOI 10.1073/pnas.89.9.3845; LU YL, 1992, J IMMUNOL, V149, P24; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; LU YL, 1994, EUR J IMMUNOL, V24, P2732, DOI 10.1002/eji.1830241124; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Marengere LEM, 1997, J IMMUNOL, V159, P3220; MAROC N, 1993, ONCOGENE, V8, P909; McGuire KL, 1997, J IMMUNOL, V159, P1319; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; Noel PJ, 1996, J IMMUNOL, V157, P636; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Pages F, 1996, J BIOL CHEM, V271, P9403, DOI 10.1074/jbc.271.16.9403; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Radvanyi LG, 1996, J IMMUNOL, V156, P1788; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHAPIROVS, 1997, MOL CELL BIOL, V17, P4051; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; Truitt KE, 1996, J IMMUNOL, V156, P4539; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; WARD SG, 1995, EUR J IMMUNOL, V25, P526, DOI 10.1002/eji.1830250233; WEISS A, 1986, J IMMUNOL, V137, P819; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	78	58	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21194	21202		10.1074/jbc.273.33.21194	http://dx.doi.org/10.1074/jbc.273.33.21194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694876	hybrid			2022-12-27	WOS:000075386100069
J	Strack, S; Colbran, RJ				Strack, S; Colbran, RJ			Autophosphorylation-dependent targeting of calcium/calmodulin-dependent protein kinase II by the NR2B subunit of the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; GLUTAMATE RECEPTORS; NMDA RECEPTORS; CALCIUM; PHOSPHORYLATION; EXPRESSION; SYNAPSES; IDENTIFICATION; PHOSPHATASE-1	Activation and Thr(286) autophosphorylation of calcium/calmodulindependent kinase II (CaMKII) following Ca2+ influx via N-methyl-D-aspartate (NMDA)-type glutamate receptors is essential for hippocampal long term potentiation (LTP), a widely investigated cellular model of learning and memory. Here, we show that NR2B, but not NR2A or NR1, subunits of NMDA receptors are responsible for autophosphorylation-dependent targeting of CaMKII. CaMKII and NMDA receptors colocalize in neuronal dendritic spines, and a CaMKII.NMDA receptor complex can be isolated from brain extracts. Autophosphorylation induces direct high-affinity binding of CaMKII to a 50 amino acid domain in the NR2B cytoplasmic tail; little or no binding is observed to NR2A and NR1 cytoplasmic tails. Specific colocalization of CaMKII with NR2B-containing NMDA receptors in transfected cells depends on receptor activation, Ca2+ influx, and Thr(286) autophosphorylation. Translocation of CaMKII because of interaction with the NMDA receptor Ca2+ channel may potentiate kinase activity and provide exquisite spatial and temporal control of postsynaptic substrate phosphorylation.	Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA.	roger.colbran@mcmail.vanderbilt.edu	Colbran, Roger/AAU-7708-2021	Colbran, Roger/0000-0001-7401-8244; Strack, Stefan/0000-0002-6175-7280	NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [GM47973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; Colbran RJ, 1997, J NEUROCHEM, V69, P920; DOSEMECI A, 1993, J NEUROCHEM, V61, P550; Flint AC, 1997, J NEUROSCI, V17, P2469; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Grant ER, 1997, J BIOL CHEM, V272, P647; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LOVINGER DM, 1995, J PHARMACOL EXP THER, V274, P164; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Otmakhov N, 1997, J NEUROSCI, V17, P5357; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Rema V, 1996, J COMP NEUROL, V368, P165; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Shi J, 1997, J NEUROSCI, V17, P6264; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	32	353	365	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20689	20692		10.1074/jbc.273.33.20689	http://dx.doi.org/10.1074/jbc.273.33.20689			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694809	hybrid			2022-12-27	WOS:000075386100002
J	Uhlik, M; Good, L; Xiao, GT; Harhaj, EW; Zandi, E; Karin, M; Sun, SC				Uhlik, M; Good, L; Xiao, GT; Harhaj, EW; Zandi, E; Karin, M; Sun, SC			NF-kappa B-inducing kinase and I kappa B kinase participate in human T-cell leukemia virus I tax-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HTLV-I; TRANSACTIVATOR TAX; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; 21-BASE-PAIR REPEATS; LYMPHOMA VIRUS; BZIP PROTEINS; ALPHA; TRANSFORMATION; DEGRADATION	The tax gene product of human T-cell leukemia virus I induces aberrant expression of various cellular genes, which contributes to transformation of host cells. Induction of many Tax target genes is mediated through transcription factor NF-kappa B. Here we show that Tax triggers activation of cellular protein kinases, I kappa B kinase alpha (IKK alpha) and IKK beta, which phosphorylate the NF-kappa B inhibitory protein I kappa B alpha, resulting in its degradation and NF-kappa B activation. Constitutive IKK activation occurs in both Tax-transfected and human T-cell leukemia virus I-infected T cells. We further demonstrate that Tax-mediated NF-kappa B signaling also requires the NF-kappa B-inducing kinase (NIK). Consistently, inactive forms of either IKKs or NIK. attenuate Tax-mediated NF-kappa B activation. Therefore, Tax activates NF-kappa B by targeting cellular signaling molecules, including both IKKs and NIK.	Penn State Univ, Coll Med, Dept Immunol & Microbiol, Hershey, PA 17033 USA; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of California System; University of California San Diego	Sun, SC (corresponding author), Penn State Univ, Coll Med, Dept Immunol & Microbiol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [F32CA071108, R01CA068471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006376] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA 71108-01A1, 1 R01 CA68471-03] Funding Source: Medline; NIEHS NIH HHS [ES06376-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GAZDAR AF, 1980, BLOOD, V55, P409; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRILLI M, 1993, INT REV CYTOL, V143, P1; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1995, J BIOL CHEM, V270, P11745, DOI 10.1074/jbc.270.20.11745; KOEFFLER HP, 1984, BLOOD, V64, P482; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MAGGIRWAR SB, 1995, ONCOGENE, V11, P993; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERL S, 1984, BLOOD, V64, P967; MIYOSHI I, 1981, GANN, V72, P978; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PERSAUD D, 1995, J VIROL, V69, P6297, DOI 10.1128/JVI.69.10.6297-6303.1995; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ressler S, 1996, FEMS MICROBIOL LETT, V140, P99, DOI 10.1016/0378-1097(96)00166-8; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1996, MOL CELL BIOL, V16, P1058; SUZUKI T, 1994, ONCOGENE, V9, P3099; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WORONICZ JD, 1997, SCIENCE, V278, P868; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	59	145	146	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21132	21136		10.1074/jbc.273.33.21132	http://dx.doi.org/10.1074/jbc.273.33.21132			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694868	hybrid			2022-12-27	WOS:000075386100061
J	Dumonteil, E; Laser, B; Constant, I; Philippe, J				Dumonteil, E; Laser, B; Constant, I; Philippe, J			Differential regulation of the glucagon and insulin I gene promoters by the basic helix-loop-helix transcription factors E47 and BETA2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; ENHANCER-BINDING PROTEINS; DNA-BINDING; E-BOX; ELEMENTS; COMPLEXES; SEQUENCES; MYOD; E2A; REGION	The insulin and glucagon genes are expressed in the beta and alpha cells of the islets of Langerhans, respectively, The factors controlling their cell- and islet-specific expression are poorly known. Insulin-enhancer factor-1 (IEF1) has previously been shown to interact with the E boxes of the rat insulin I and II genes and was proposed to play a critical role in beta cell-specific expression. BETA2, a recently identified basic helix-loop-helix (bHLH) protein, binds with high affinity and transactivates the rat insulin II gene upon dimerization with the ubiquitous bHLH protein E47, We show here that the heterodimer E47/BETA2 also binds and transactivates the rat insulin I and glucagon genes and exhibits the same characteristics as IEF1. In transfection experiments, the E boxes of the insulin I and glucagon genes confer transcriptional activity in both insulin- and glucagon-producing cells, which is increased by overexpression of E47 and BETA2, However, overexpression of E47 inhibits only E box-mediated glucagon gene expression, whereas it activates insulin gene transcription, indicating that the E boxes of the insulin and glucagon genes display gene-specific characteristics. We conclude that the heterodimer E47/BETA2 represents an islet-specific factor that controls both insulin and glucagon gene transcription and that the E47/BETA2 ratio may be important for regulated gene expression.	Ctr Med Univ, Unite Diabetol Clin, CH-1211 Geneva 4, Switzerland	University of Geneva	Philippe, J (corresponding author), Ctr Med Univ, Unite Diabetol Clin, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Philippe@cmu.unige.ch		Dumonteil, Eric/0000-0001-9376-0209				APONE S, 1995, J BIOL CHEM, V270, P21420, DOI 10.1074/jbc.270.36.21420; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; CORDIERBUSSAT M, 1995, MOL CELL BIOL, V15, P3904; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; DANDOYDRON F, 1991, NUCLEIC ACIDS RES, V19, P4925, DOI 10.1093/nar/19.18.4925; DRUCKER DJ, 1987, J BIOL CHEM, V262, P15659; DRUCKER DJ, 1987, T ASS AM PHYSICIAN C, P109; Dumonteil E, 1996, DIABETES METAB, V22, P164; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ERICKSON JW, 1993, GENE DEV, V7, P1688, DOI 10.1101/gad.7.9.1688; FISCHER F, 1992, EMBO J, V11, P4103; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; LASER B, 1997, ADV MOL CELLULAR END, V1, P203; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; PEYTON M, 1994, J BIOL CHEM, V269, P25936; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Sloan SR, 1996, MOL CELL BIOL, V16, P6900; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; VIERRA CA, 1995, MOL ENDOCRINOL, V9, P64, DOI 10.1210/me.9.1.64; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEINTRAUB H, 1994, GENE DEV, V8, P2203, DOI 10.1101/gad.8.18.2203; Wright WE, 1992, CURR OPIN GENET DEV, V2, P243, DOI 10.1016/S0959-437X(05)80280-1	40	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19945	19954		10.1074/jbc.273.32.19945	http://dx.doi.org/10.1074/jbc.273.32.19945			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685329	hybrid			2022-12-27	WOS:000075305400006
J	Itoh, T; Ijuin, T; Takenawa, T				Itoh, T; Ijuin, T; Takenawa, T			A novel phosphatidylinositol-5-phosphate 4-kinase (phosphatidylinositol-phosphate kinase II gamma) is phosphorylated in the endoplasmic reticulum in response to mitogenic signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-PHOSPHATE 5-KINASE; GTP ANALOGS; 4,5-BISPHOSPHATE; CELLS; POLYPHOSPHOINOSITIDES; PLATELETS; ISOFORMS; FAMILY; RHO	Here, we identify a novel rat phosphatidylinositol-5-phosphate 4-kinase, phosphatidylinositol-phosphate kinase II gamma (PIPKII gamma). PIPKII gamma comprises 420 amino acids with a molecular mass of 47,048 Ha, showing greater homology to the type II alpha and II beta isoforms (61.1 and 63.7% amino acid identities, respectively) of phosphatidylinositol-phosphate kinase than to the type I isoforms. It is predominantly expressed in kidney, with low expression in almost all other tissues. PIPKII gamma was found to have phosphatidylinositol-5-phosphate 4-kinase activity as demonstrated in other type II kinases such as PIPKII alpha. The PIPKII gamma that is present endogenously in rat fibroblasts, PC12 cells, and rat whole brain lysate or that is exogenously overexpressed in COS-7 cells shows a doublet migrating pattern on SDS-polyacrylamide gel electrophoresis. Alkaline phosphatase treatment and metabolic labeling in [P-32]orthophosphate experiments revealed that PIPKII gamma is phosphorylated in vivo, resulting in a shift in its electrophoretic mobility. Phosphorylation is induced by treatment of mitogens such as serum and epidermal growth factor. Immunostaining experiments and subcellular fractionation revealed that PIPKII gamma localizes dominantly in the endoplasmic reticulum (ER). Phosphorylation also occurs in the ER. Thus, PIPKII gamma may have an important role in the synthesis of phosphatidylinositol bisphosphate in the ER.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan	University of Tokyo	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan.	takenawa@ims.u-tokyo.ac.jp	Ijuin, Takeshi/H-7016-2017	Ijuin, Takeshi/0000-0002-0618-1776				BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HELMS JB, 1991, J BIOL CHEM, V266, P21368; Hinchliffe KA, 1996, EMBO J, V15, P6516, DOI 10.1002/j.1460-2075.1996.tb01042.x; Hinchliffe KA, 1998, BIOCHEM J, V329, P115; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; LUNDBERG GA, 1988, FEBS LETT, V240, P171, DOI 10.1016/0014-5793(88)80362-4; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MORRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1022, P339, DOI 10.1016/0005-2736(90)90283-T; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; SCHACHT J, 1978, J LIPID RES, V19, P1063; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SMITH CD, 1989, J BIOL CHEM, V264, P3206; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; URUMOW T, 1990, FEBS LETT, V264, P15; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	28	71	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20292	20299		10.1074/jbc.273.32.20292	http://dx.doi.org/10.1074/jbc.273.32.20292			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685379	hybrid			2022-12-27	WOS:000075305400056
J	Pap, M; Cooper, GM				Pap, M; Cooper, GM			Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EMBRYOS; GROWTH-FACTOR; INHIBITION; APOPTOSIS; INSULIN; REQUIREMENT; WORTMANNIN; ACTIVATION; EXPRESSION; PROTEASE	Growth factor-dependent survival of a variety of mammalian cells is dependent on the activation of phosphatidylinositol (PI) 3-kinase and its downstream effector, the protein kinase Akt. Glycogen synthase kinase-3 (GSK-3) has been previously identified as a physiological target of Akt, which is inhibited by phosphorylation, so we have investigated the role of GSK-3 in cell survival. Overexpression of catalytically active GSK-3 induced apoptosis of both Rat-1 and PC12 cells, whereas dominant-negative GSK-3 prevented apoptosis following inhibition of PI 3-kinase. GSK-3 thus plays a critical role in regulation of apoptosis and represents a key downstream target of the PI 3-kinase/Akt survival signaling pathway.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Cooper, GM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.	gmcooper@bio.bu.edu	Roszak, Joanna/F-4003-2010		NCI NIH HHS [R01 CA18689] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEMELLO SR, 1997, J NEUROSCI, V17, P1548; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hurel SJ, 1996, BIOCHEM J, V320, P871, DOI 10.1042/bj3200871; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Miller TM, 1997, J BIOL CHEM, V272, P9847; Minshall C, 1996, J IMMUNOL, V156, P939; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PESO LD, 1997, SCIENCE, V278, P687; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	35	922	965	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19929	19932		10.1074/jbc.273.32.19929	http://dx.doi.org/10.1074/jbc.273.32.19929			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685326	hybrid			2022-12-27	WOS:000075305400003
J	Thuerauf, DJ; Arnold, ND; Zechner, D; Hanford, DS; DeMartin, KM; McDonough, PM; Prywes, R; Glembotski, CC				Thuerauf, DJ; Arnold, ND; Zechner, D; Hanford, DS; DeMartin, KM; McDonough, PM; Prywes, R; Glembotski, CC			p38 mitogen-activated protein kinase mediates the transcriptional induction of the atrial natriuretic factor gene through a serum response element - a potential role for the transcription factor ATF6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN PROMOTER; DNA-BINDING ACTIVITY; MAP KINASE; TERNARY COMPLEX; GROWTH; PATHWAYS; SRF; EXPRESSION; STRESS; 3PK	In various cell types certain stresses can stimulate p38 mitogen-activated protein kinase (p38 MAPK), leading to the transcriptional activation of genes that contribute to appropriate compensatory responses, In this report the mechanism of p38-activated transcription was studied in cardiac myocytes where this MAPK is a key regulator of the cell growth and the cardiac-specific gene induction that occurs in response to potentially stressful stimuli. In the cardiac atrial natriuretic factor (ANF) gene, a promoter-proximal serum response element (SRE), which binds serum response factor (SRF), was shown to be critical for ANF induction in primary cardiac myocytes transfected with the selective p38 MAPK activator, MKK6 (Glu). This ANF SRE does not possess sequences typically required for the binding of the Ets-related ternary complex factors (TCFs), such as Elk-l, indicating that p38-mediated induction through this element may take place independently of such TCFs. Although p38 did not phosphorylate SRF in vitro, it efficiently phosphorylated ATF6, a newly discovered SRF-binding protein that is believed to serve as a coactivator of SRF-inducible transcription at SREs, Expression of an ATF6 antisense RNA blocked p38-mediated ANF induction through the ANF SRE. Moreover, when fused to the Gal4 DNA-binding domain, an N-terminal 273-amino acid fragment of ATF6 was sufficient to support trans-activation of Gal4/luciferase expression in response to p38 but not the other stress kinase, N-terminal Jun kinase (JNK); p38-activating cardiac growth promoters also stimulated ATF6 trans-activation. These results indicate that through ATF6, p38 can augment SRE-mediated transcription independently of Ets-related TCFs, representing a novel mechanism of SRF-dependent transcription by MAP kinases.	San Diego State Univ, Dept Biol, Inst Mol Biol, San Diego, CA 92182 USA	California State University System; San Diego State University	Glembotski, CC (corresponding author), San Diego State Univ, Dept Biol, Inst Mol Biol, San Diego, CA 92182 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056861, P01HL046345] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-46345, HL-56861] Funding Source: Medline; NINDS NIH HHS [NS/HL-25073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MOSS JB, 1994, J BIOL CHEM, V269, P12731; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Thuerauf DJ, 1997, J BIOL CHEM, V272, P7464, DOI 10.1074/jbc.272.11.7464; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	39	105	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20636	20643		10.1074/jbc.273.32.20636	http://dx.doi.org/10.1074/jbc.273.32.20636			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685422	hybrid			2022-12-27	WOS:000075305400099
J	Wang, JY; Frenzel, KE; Wen, DZ; Falls, DL				Wang, JY; Frenzel, KE; Wen, DZ; Falls, DL			Transmembrane neuregulins interact with LIM kinase 1, a cytoplasmic protein kinase implicated in development of visuospatial cognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEU DIFFERENTIATION FACTOR; GLIAL GROWTH-FACTOR; ZINC-FINGER; NERVOUS-SYSTEM; NEUROMUSCULAR-JUNCTIONS; WILLIAMS-SYNDROME; TGF-ALPHA; RECEPTOR; GENE; IDENTIFICATION	The neuregulins are receptor tyrosine kinase ligands that play a critical role in the development of the heart, nervous system, and breast, Unlike many extracellular signaling molecules, such as the neurotrophins, most neuregulins are synthesized as transmembrane proteins. To determine the functions of the highly conserved neuregulin cytoplasmic tail, a yeast two-hybrid screen was performed to identify proteins that interact with the 157-amino acid sequence common to the cytoplasmic tails of all transmembrane neuregulin isoforms, This screen revealed that the neuregulin cytoplasmic tail interacts with the LIM domain region of the nonreceptor protein kinase LIM kinase 1 (LLMK1). Interaction between the neuregulin cytoplasmic tail and full-length LIMK1 was demonstrated by in vitro binding and coimmunoprecipitation assays, Transmembrane neuregulins with each of the three known neuregulin cytoplasmic tail isoforms interacted with LIMK1. In contrast, the cytoplasmic tail of TGF-alpha did not interact with LIMK1. In vivo, neuregulin and LIMK1 are co-localized at the neuromuscular synapse, suggesting that LIMK1, like neuregulin, may play a role in synapse formation and maintenance. To our knowledge, LIMK1 is the first identified protein shown to interact with the cytoplasmic tail of a receptor tyrosine kinase ligand.	Emory Univ, Dept Biol, Atlanta, GA 30322 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	Emory University; Amgen	Falls, DL (corresponding author), Emory Univ, Dept Biol, Atlanta, GA 30322 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM056337] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 56337] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel P.L., 1993, CELLULAR INTERACTION; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Busfield SJ, 1997, MOL CELL BIOL, V17, P4007, DOI 10.1128/MCB.17.7.4007; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Carraway KL, 1996, BIOESSAYS, V18, P263, DOI 10.1002/bies.950180403; Carroll SL, 1997, J NEUROSCI, V17, P1642; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; CHENG AK, 1995, MECH DEVELOP, V52, P187, DOI 10.1016/0925-4773(95)00400-U; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Frangiskakis JM, 1996, CELL, V86, P59, DOI 10.1016/S0092-8674(00)80077-X; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GOODEARL ADJ, 1993, J BIOL CHEM, V268, P18095; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; Higuchi O, 1997, ONCOGENE, V14, P1819, DOI 10.1038/sj.onc.1201020; Hiraoka J, 1996, FEBS LETT, V399, P117, DOI 10.1016/S0014-5793(96)01303-8; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Kopp DM, 1997, J NEUROSCI, V17, P6697; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; LUPA MT, 1989, J NEUROSCI, V9, P3937; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUDAIRA P, 1993, PRACTICAL GUIDE PROT, P49; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIZUNO K, 1994, ONCOGENE, V9, P1605; Monaco AP, 1996, CURR BIOL, V6, P1396, DOI 10.1016/S0960-9822(96)00740-3; Mori T, 1997, MOL BRAIN RES, V45, P247, DOI 10.1016/S0169-328X(96)00257-4; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; Ng YP, 1997, MOL CELL NEUROSCI, V9, P132, DOI 10.1006/mcne.1997.0613; NUNOUE K, 1995, ONCOGENE, V11, P701; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PFEFFER S, 1985, NATURE, V313, P184, DOI 10.1038/313184a0; PROSCHEL C, 1995, ONCOGENE, V11, P1271; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Tassabehji M, 1996, NAT GENET, V13, P272, DOI 10.1038/ng0796-272; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Trachtenberg JT, 1997, J NEUROSCI, V17, P6243; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Yang X, 1998, NEURON, V20, P255, DOI 10.1016/S0896-6273(00)80454-7; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	71	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20525	20534		10.1074/jbc.273.32.20525	http://dx.doi.org/10.1074/jbc.273.32.20525			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685409	hybrid			2022-12-27	WOS:000075305400086
J	Chacko, G; Ling, Q; Hajjar, KA				Chacko, G; Ling, Q; Hajjar, KA			Induction of acute translational response genes by homocysteine - Elongation factors-1 alpha, -beta, and -delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-1-GAMMA MESSENGER-RNA; PROTEIN-C ACTIVATION; SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; PLASMINOGEN-ACTIVATOR; FACTOR EF-1-ALPHA; VASCULAR-DISEASE; ANNEXIN-II; ENDOPLASMIC-RETICULUM; DIFFERENTIAL DISPLAY	The thiol amino acid homocysteine (HC) accumulates in homocystinuria and homocyst(e)inemia, and is associated with a wide variety of clinical manifestations. To determine whether HC influences the cell's program of gene expression, vascular endothelial cells were treated with HC for 6-42 h and analyzed by differential display. We found a 3-7-fold, time-dependent induction of a 220-base pair fragment, which demonstrated complete sequence identity with elongation factor-1 delta (EF-1 delta), a member of the multimeric complex regulating mRNA translation. Fibroblasts from cystathionine beta-synthase -/- individuals also showed up to 3.0-fold increased levels of mRNA for EF-1 alpha, -beta, and -delta when compared with normal cells, and treatment of normal cells with the HC precursor, methionine, induced a 1.5-2.0-fold increase in EF-1 alpha, -beta, and -delta mRNA. This induction was completely inhibited by cycloheximide and reflected a doubling in the rate of gene transcription in nuclear run-on analyses. In HC-treated endothelial cells, pulse-chase studies revealed a doubling in the rate of synthesis of the thiol-containing protein, annexin II, but no change in synthesis of the cysteineless protein, plasminogen activator inhibitor-1. Thus, HC induces expression of a family of acute translational response genes through a protein synthesis-dependent transcriptional mechanism. This process may mediate accelerated synthesis of free thiol-containing proteins in response to HC-induced oxidative stress.	Cornell Univ, Coll Med, Dept Pediat, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, Div Hematol Oncol, New York, NY 10021 USA	Cornell University; Cornell University	Hajjar, KA (corresponding author), Cornell Univ, Coll Med, Dept Pediat, Div Hematol Oncol, 1300 York Ave,Box 45, New York, NY 10021 USA.	khajjar@mail.med.cornell.edu			NHLBI NIH HHS [HL 46403, HL 42493, HL 58981] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042493, P01HL046403, R01HL058981] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Blazquez M, 1996, J BIOL CHEM, V271, P18638, DOI 10.1074/jbc.271.31.18638; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; CAVALLIUS J, 1986, EXP GERONTOL, V21, P149, DOI 10.1016/0531-5565(86)90068-9; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; GOLDSTRAW P, 1992, DIAGN ONCOL, V2, P9; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; GRANT AG, 1992, INT J CANCER, V50, P740, DOI 10.1002/ijc.2910500513; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABBEN JE, 1995, P NATL ACAD SCI USA, V92, P8640, DOI 10.1073/pnas.92.19.8640; Hajjar KA, 1998, J BIOL CHEM, V273, P9987, DOI 10.1074/jbc.273.16.9987; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; HUANG LE, 1994, J BIOL CHEM, V269, P30718; JUNG M, 1994, CANCER RES, V54, P2541; Kato MV, 1997, BLOOD, V90, P1373, DOI 10.1182/blood.V90.4.1373.1373_1373_1378; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; KRAUS JP, 1994, J INHERIT METAB DIS, V17, P383, DOI 10.1007/BF00711354; LENTZ SR, 1993, BLOOD, V81, P683; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; MIMORI K, 1995, CANCER, V75, P1446, DOI 10.1002/1097-0142(19950315)75:6+<1446::AID-CNCR2820751509>3.0.CO;2-P; Mimori K, 1996, GUT, V38, P66, DOI 10.1136/gut.38.1.66; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1995, METABOLIC MOL BASES, V1, P1279; PATTON WF, 1995, J BIOL CHEM, V270, P21404, DOI 10.1074/jbc.270.36.21404; PROUD CG, 1994, MOL BIOL REP, V19, P161, DOI 10.1007/BF00986958; RATAN RR, 1994, J NEUROSCI, V14, P4385; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; RIJKEN DC, 1986, J BIOL CHEM, V261, P3098; RODGERS GM, 1990, BLOOD, V75, P895; SAMBROOK J, 1989, MOL CLONING, V1, P7; Sanders J, 1996, J CELL SCI, V109, P1113; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHEPHERD JCW, 1989, P NATL ACAD SCI USA, V86, P7520, DOI 10.1073/pnas.86.19.7520; SONG JM, 1989, MOL CELL BIOL, V9, P4571, DOI 10.1128/MCB.9.10.4571; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; Tsai JC, 1996, J CLIN INVEST, V97, P146, DOI 10.1172/JCI118383; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Voller A., 1976, AM SOC MICROBIOL, V17, P506; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; Wang H, 1997, J BIOL CHEM, V272, P25380, DOI 10.1074/jbc.272.40.25380	56	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19840	19846		10.1074/jbc.273.31.19840	http://dx.doi.org/10.1074/jbc.273.31.19840			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677419	hybrid			2022-12-27	WOS:000075125200071
J	Konig, J; Prenen, J; Nilius, B; Gerke, V				Konig, J; Prenen, J; Nilius, B; Gerke, V			The annexin II-p11 complex is involved in regulated exocytosis in bovine pulmonary artery endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PANCREATIC BETA-CELLS; DEPENDENT EXOCYTOSIS; INSULIN-SECRETION; CHROMAFFIN CELLS; CALPACTIN-I; CALCIUM; P36; PHOSPHORYLATION; SUBSTRATE	Annexin II is a member of a multigene family of Ca2+-regulated, membrane-binding proteins implicated through biochemical and perforated cell experiments in Ca2+-triggered secretion. Within most cells annexin II resides in a tight heterotetrameric complex with a cellular protein ligand, pll, and complex formation is mediated via the N-terminal 14 residues of annexin II including the N-terminal acetyl group. To analyze at the single cell level whether the annexin II-pll complex is involved in regulated secretion, we used membrane capacitance measurements to follow exocytotic fusion events in bovine aortic endothelial cells manipulated with respect to their annexin II-pll complex formation. Upon guanosine 5'-O-(thiotriphosphate) (GTP gamma S) stimulation, the endothelial cells show a significant increase in membrane capacitance which is generally preceded by a transient rise in intracellular Ca2+ and thus indicative of the occurrence of Ca2+-regulated secretion. The GTP gamma S-induced capacitance increase is markedly reduced in cells loaded with a synthetic peptide, Acl-14, which corresponds in sequence to the N-terminal 14 residues of annexin II in their correctly acetylated form and which is capable of disrupting preformed annexin II-pll complexes. The effect of the peptide is highly specific as the nonacetylated variant, N1-14, which is incapable of disrupting annexin II-pll, does not interfere with the GTP gamma S-induced increase in membrane capacitance, These data show that intact annexin II-p11 complexes are indispensable for regulated exocytosis to occur in an efficient manner in endothelial cells.	Univ Munster, Inst Med Biochem, D-48149 Munster, Germany; Catholic Univ Louvain, Physiol Lab, B-3000 Louvain, Belgium	University of Munster; Universite Catholique Louvain	Gerke, V (corresponding author), Univ Munster, Inst Med Biochem, Von Esmarch Str 56, D-48149 Munster, Germany.							ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; Celio MR, 1996, GUIDEBOOK CALCIUM BI; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Delouche B, 1997, J NEUROCHEM, V68, P1720; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Emeis JJ, 1997, J CELL BIOL, V139, P245, DOI 10.1083/jcb.139.1.245; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; Graham ME, 1997, MOL BIOL CELL, V8, P431, DOI 10.1091/mbc.8.3.431; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HARRISON VJ, 1995, P NATL ACAD SCI USA, V92, P6344, DOI 10.1073/pnas.92.14.6344; JOHNSSON N, 1988, EMBO J, V7, P2435, DOI 10.1002/j.1460-2075.1988.tb03089.x; JOHNSSON N, 1986, EMBO J, V5, P3455, DOI 10.1002/j.1460-2075.1986.tb04669.x; JOHNSSON N, 1986, FEBS LETT, V198, P361, DOI 10.1016/0014-5793(86)80437-9; JOHNSTONE SA, 1992, J BIOL CHEM, V267, P25976; Jost M, 1997, J CELL SCI, V110, P221; Jost M, 1996, BBA-MOL CELL RES, V1313, P283, DOI 10.1016/0167-4889(96)00101-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert O, 1997, J MOL BIOL, V272, P42, DOI 10.1006/jmbi.1997.1183; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; Oberhauser AF, 1996, BIOPHYS J, V71, P1131, DOI 10.1016/S0006-3495(96)79315-3; OSBORN M, 1988, EXP CELL RES, V175, P81, DOI 10.1016/0014-4827(88)90257-1; Proks P, 1996, J PHYSIOL-LONDON, V496, P255, DOI 10.1113/jphysiol.1996.sp021682; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; REGNOUF F, 1995, J BIOL CHEM, V270, P27143, DOI 10.1074/jbc.270.45.27143; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SARAFIAN T, 1991, J CELL BIOL, V114, P1135, DOI 10.1083/jcb.114.6.1135; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; THIEL C, 1992, J CELL SCI, V103, P733; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLAR L, 1987, J BIOL CHEM, V262, P5049; WAGNER DD, 1993, THROMB HAEMOSTASIS, V70, P105; WOLLHEIM CB, 1987, BIOSCIENCE REP, V7, P443, DOI 10.1007/BF01362507	43	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19679	19684		10.1074/jbc.273.31.19679	http://dx.doi.org/10.1074/jbc.273.31.19679			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677396	hybrid			2022-12-27	WOS:000075125200048
J	Frye, EB; Degenhardt, TP; Thorpe, SR; Baynes, JW				Frye, EB; Degenhardt, TP; Thorpe, SR; Baynes, JW			Role of the Maillard reaction in aging of tissue proteins - Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-ENZYMATIC GLYCOSYLATION; DIABETIC COMPLICATIONS; AMINO-ACIDS; NONENZYMATIC GLYCOSYLATION; SKIN COLLAGEN; GLYOXALASE SYSTEM; ALBUMIN INVIVO; SERUM-ALBUMIN; METHYLGLYOXAL; IDENTIFICATION	Dicarbonyl compounds such as glyoxal and methylglyoxal are reactive dicarbonyl intermediates in the nonenzymatic browning and cross-linking of proteins during the Maillard reaction. We describe here the quantification of glyoxal and methylglyoxal-derived imidazolium cross-links in tissue proteins. The imidazolium salt cross links, glyoxal-lysine dimer (GOLD) and methylglyoxal-lysine dimer (MOLD), were measured by liquid chromatography/mass spectrometry and were present in lens protein at concentrations of 0.02-0.2 and 0.1-0.8 mmol/mol of lysine, respectively. The lens concentrations of GOLD and MOLD correlated significantly with one another and also increased with lens age. GOLD and MOLD were present at significantly higher concentrations than the fluorescent cross-links pentosidine and dityrosine, identifying them as major Maillard reaction cross-links in lens proteins. Like the N-carboxy-alkyllysines N-epsilon-(carboxymethyl)lysine and N-epsilon-(carboxyethyl)lysine, these cross-links were also detected at lower concentrations in human skin collagen and increased with age in collagen. The presence of GOLD and MOLD in tissue proteins implicates methylglyoxal and glyoxal, either free or protein-bound, as important precursors of protein cross-links formed during Maillard reactions in vivo during aging and in disease.	Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA; Univ S Carolina, Dept Ophthalmol, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Baynes, JW (corresponding author), Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA.	baynes@psc.sc.edu			NIDDK NIH HHS [DK-19971] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; AHMED MU, 1986, J BIOL CHEM, V261, P4889; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRINKMANN E, 1995, J CHEM SOC P1, V1, P2817; BUCKINGHAM B, 1990, J CLIN INVEST, V86, P1046, DOI 10.1172/JCI114807; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9454; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; GARLICK RL, 1983, J BIOL CHEM, V258, P6142; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1965, DOI 10.1080/00021369.1986.10867692; HAYASHI T, 1986, AGR BIOL CHEM TOKYO, V50, P1959, DOI 10.1080/00021369.1986.10867691; Heath MM, 1996, BBA-MOL BASIS DIS, V1315, P176, DOI 10.1016/0925-4439(95)00120-4; HENLE T, 1994, Z LEBENSM UNTERS FOR, V199, P55, DOI 10.1007/BF01192954; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; HOFMANN K, 1960, J AM CHEM SOC, V82, P3727, DOI 10.1021/ja01499a064; IBERG N, 1986, J BIOL CHEM, V261, P3542; KONOSHI Y, 1994, BIOSCI BIOTECH BIOCH, V58, P1953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LO TWC, 1994, J BIOL CHEM, V269, P32299; LOIDLSTAHLHOFEN A, 1995, CHEM PHYS LIPIDS, V77, P113, DOI 10.1016/0009-3084(95)02459-V; MCLAUGHLIN JA, 1980, P NATL ACAD SCI-BIOL, V77, P949, DOI 10.1073/pnas.77.2.949; MCLELLAN AC, 1994, CLIN SCI, V87, P21, DOI 10.1042/cs0870021; MITCHEL REJ, 1977, ANAL BIOCHEM, V81, P47, DOI 10.1016/0003-2697(77)90597-8; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; PATRICK JS, 1990, J GERONTOL, V45, pB18, DOI 10.1093/geronj/45.1.B18; RAY M, 1987, J BIOL CHEM, V262, P5974; REICHARD GA, 1986, DIABETES, V35, P668, DOI 10.2337/diabetes.35.6.668; RICHARD JP, 1991, BIOCHEMISTRY-US, V30, P4581, DOI 10.1021/bi00232a031; SHAPIRO R, 1980, J BIOL CHEM, V255, P3120; SKOVSTED IC, 1997, P 6 INT MAILL S LOND, pA165; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Thornalley PJ, 1996, CLIN SCI, V91, P575, DOI 10.1042/cs0910575; THORNALLEY PJ, 1994, AMINO ACIDS, V6, P15, DOI 10.1007/BF00808119; THORNALLEY PJ, 1989, DIABETES RES CLIN PR, V7, P115, DOI 10.1016/0168-8227(89)90101-0; Thorpe SR, 1996, DRUG AGING, V9, P69, DOI 10.2165/00002512-199609020-00001; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; VLASSARA H, 1994, J LAB CLIN MED, V124, P19; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WATKINS NG, 1987, J BIOL CHEM, V262, P7207; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; WELLSKNECHT MC, 1993, J BIOL CHEM, V268, P12348; YIM HS, 1995, J BIOL CHEM, V270, P28228	47	273	289	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18714	18719		10.1074/jbc.273.30.18714	http://dx.doi.org/10.1074/jbc.273.30.18714			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668043	hybrid			2022-12-27	WOS:000074974700010
J	Huse, M; Eck, MJ; Harrison, SC				Huse, M; Eck, MJ; Harrison, SC			A Zn2+ ion links the cytoplasmic tail of CD4 and the N-terminal region of Lck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PROTEIN-KINASE; CELL ANTIGEN RECEPTOR; MICE LACKING P56(LCK); SIGNAL-TRANSDUCTION; T-CELLS; P56LCK; ASSOCIATION; COMPLEX; REQUIREMENT; ACTIVATION	Lck is a lymphoid-specific, Src family protein-tyrosine kinase that is known to interact with the T-cell coreceptors, CD4 and CD8. This interaction, which is critical for proper T-cell function, is mediated by the N-terminal unique region of Lck and the C-terminal cytoplasmic tail of the coreceptors. A pair of cysteines on each molecule is essential for association, suggesting that CD4 or CD8 may interact with Lck by jointly coordinating a metal ion. We describe here experiments in which a maltose-binding protein fusion protein bearing the CD4 tail has been coexpressed in Escherichia coli with an N-terminal fragment of Lck. The proteins associate in the expressing cells, forming a complex that can be affinity-purified. Formation of this complex, like the in vivo interaction, depends upon the two pairs of cysteines. Biochemical and biophysical experiments show that the complex dissociates in the presence of EDTA and that it contains a single Zn2+ ion. These results are consistent with the proposal that Lck and CD4 associate by thiol-mediated co-coordination of zinc.	Harvard Univ, Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Dept Cellular & Mol Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Harrison, SC (corresponding author), Harvard Univ, Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA.	harrison@crystal.harvard.edu						ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADAM D, 1993, J BIOL CHEM, V268, P19882; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BURGESS KE, 1991, EUR J IMMUNOL, V21, P1663, DOI 10.1002/eji.1830210712; Campbell KS, 1995, ANN NY ACAD SCI, V766, P89, DOI 10.1111/j.1749-6632.1995.tb26652.x; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; COLLINS TL, 1992, J IMMUNOL, V148, P2159; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; GASSMANN M, 1993, J RECEPTOR RES, V13, P711, DOI 10.3109/10799899309073688; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; KIM YJ, 1993, J IMMUNOL, V151, P1255; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; Lim GEK, 1998, EUR J IMMUNOL, V28, P745, DOI 10.1002/(SICI)1521-4141(199802)28:02<745::AID-IMMU745>3.0.CO;2-6; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MOLINA TJ, 1993, J IMMUNOL, V151, P699; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PENNINGER J, 1993, SCIENCE, V260, P358, DOI 10.1126/science.8469988; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RUDD CE, 1989, IMMUNOL REV, V111, P223; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	30	71	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18729	18733		10.1074/jbc.273.30.18729	http://dx.doi.org/10.1074/jbc.273.30.18729			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668045	hybrid			2022-12-27	WOS:000074974700012
J	Meyers, MB; Puri, TS; Chien, AJ; Gao, TY; Hsu, PH; Hosey, MM; Fishman, GI				Meyers, MB; Puri, TS; Chien, AJ; Gao, TY; Hsu, PH; Hosey, MM; Fishman, GI			Sorcin associates with the pore-forming subunit of voltage-dependent L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE RYANODINE-RECEPTOR; CALCIUM-RELEASE CHANNEL; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; CARDIAC-MUSCLE; RABBIT SKELETAL; ALPHA-1 SUBUNIT; PROTEIN-KINASE; CELL LINES; CONTRACTION	Intracellular Ca2+ release in muscle is governed by functional communication between the voltage-dependent L-type Ca2+ channel and the intracellular Ca2+ release channel by processes that are incompletely understood, We previously showed that sorcin binds to cardiac Ca2+ release channel/ryanodine receptors and decreases channel open probability in planar lipid bilayers. In addition, we showed that sorcin antibody immunoprecipitates ryanodine receptors from metabolically labeled cardiac myocytes along with a second protein having a molecular weight similar to that of the alpha(1) subunit of cardiac L-type Ca2+ channels. We now demonstrate that sorcin biochemically associates with cardiac and skeletal muscle L-type Ca2+ channels specifically within the cytoplasmically oriented C-terminal region of the alpha(1) subunits, providing evidence that the second protein recovered by sorcin antibody from cardiac myocytes was the 240-kDa L-type Ca2+ channel alpha(1) subunit, Anti-sorcin antibody immunoprecipitated full-length alpha(1) subunits from cardiac myocytes, C2C12 myotubes, and transfected non-muscle cells expressing alpha(1) subunits, In contrast, the anti-sorcin antibody did not immunoprecipitate C-terminal truncated forms of alpha(1) subunits that were detected in myotubes. Recombinant sorcin bound to cardiac and skeletal HIS6-tagged alpha(1) C termini immobilized on Ni2+ resin, Additionally, anti-sorcin antibody immunoprecipitated C-terminal fragments of the cardiac alpha(1) subunit exogenously expressed in mammalian cells. The results identified a putative sorcin binding domain within the C terminus of the alpha(1) subunit, These observations, along with the demonstration that sorcin accumulated substantially during physiological maturation of the excitation-contraction coupling apparatus in developing postnatal rat heart and differentiating C2C12 muscle cells, suggest that sorcin may mediate interchannel communication during excitation-contraction coupling in heart and skeletal muscle.	CUNY Mt Sinai Sch Med, Dept Med, Cardiovasc Inst, New York, NY 10029 USA; Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60611 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Northwestern University	Meyers, MB (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Cardiovasc Inst, Box 1030,1 Gustave L Levy Pl, New York, NY 10029 USA.	marian_meyers@smtplink.mssm.edu		Fishman, Glenn/0000-0002-2366-8527	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023306, R37HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010770] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23306] Funding Source: Medline; NIMH NIH HHS [1 F30-MH10770] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AIREY JA, 1991, DEV BIOL, V148, P365, DOI 10.1016/0012-1606(91)90344-3; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; ARAI M, 1992, AM J PHYSIOL, V262, P614; BASSANI JWM, 1994, CIRC RES, V74, P991, DOI 10.1161/01.RES.74.5.991; BEAM KG, 1992, NATURE, V360, P169, DOI 10.1038/360169a0; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Bers D.M., 1993, EXCITATION CONTRACTI; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRAWLEY RM, 1992, J BIOL CHEM, V267, P18218; BRILLANTES AMB, 1994, CIRC RES, V75, P503, DOI 10.1161/01.RES.75.3.503; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Cannell MB, 1997, BIOPHYS J, V73, P112, DOI 10.1016/S0006-3495(97)78052-4; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; Chavis P, 1996, NATURE, V382, P719, DOI 10.1038/382719a0; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; COHEN MM, 1998, J PHYSL, V406, P115; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; DEJONGH KS, 1991, P NATL ACAD SCI USA, V88, P10778, DOI 10.1073/pnas.88.23.10778; DIESSEROTH K, 1996, NEURON, V16, P89; Flucher BE, 1996, P NATL ACAD SCI USA, V93, P8101, DOI 10.1073/pnas.93.15.8101; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FUENTES O, 1994, CELL CALCIUM, V15, P305, DOI 10.1016/0143-4160(94)90070-1; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GYORKE S, 1993, SCIENCE, V260, P807, DOI 10.1126/science.8387229; Hosey MM, 1996, TRENDS CARDIOVAS MED, V6, P265, DOI 10.1016/S1050-1738(96)00109-0; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI FA, 1992, AM J PHYSIOL, V263, pC365, DOI 10.1152/ajpcell.1992.263.2.C365; LIGERONA JL, 1997, J MUSCLE RES CELL M, V18, P587; LIPP P, 1994, CIRC RES, V74, P979, DOI 10.1161/01.RES.74.5.979; LIU L, 1995, CIRCULATION, V92, P372; Lokuta AJ, 1997, J BIOL CHEM, V272, P25333, DOI 10.1074/jbc.272.40.25333; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Lovry O.H., 1951, J BIOL CHEM, V193, P265; MAYRLEITNER M, 1994, CELL CALCIUM, V15, P99, DOI 10.1016/0143-4160(94)90048-5; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; Meyers M B, 1989, Cancer Commun, V1, P233; Meyers M. B., 1991, NOVEL CALCIUM BINDIN, P385, DOI 10.1007/978-3-642-76150-8_22; MEYERS MB, 1995, J BIOL CHEM, V270, P26411, DOI 10.1074/jbc.270.44.26411; MEYERS MB, 1995, FEBS LETT, V357, P230, DOI 10.1016/0014-5793(94)01338-2; MEYERS MB, 1990, STIMULUS RESPONSE CO, P159; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLER JB, 1990, J CELL BIOL, V111, P1149, DOI 10.1083/jcb.111.3.1149; MORAD M, 1995, ADV EXP MED BIOL, V382, P89; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Pickel VM, 1997, J COMP NEUROL, V386, P625, DOI 10.1002/(SICI)1096-9861(19971006)386:4<625::AID-CNE8>3.0.CO;2-4; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; SELBERT S, 1995, J CELL SCI, V108, P85; SIPIDO KR, 1995, CIRC RES, V76, P102, DOI 10.1161/01.RES.76.1.102; TAKEKURA H, 1995, J MUSCLE RES CELL M, V16, P465, DOI 10.1007/BF00126431; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; VANDERBLIEK AM, 1986, EMBO J, V5, P3201, DOI 10.1002/j.1460-2075.1986.tb04630.x; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; Wier WG, 1997, CIRC RES, V81, P462, DOI 10.1161/01.RES.81.4.462; Xiao RP, 1997, J PHYSIOL-LONDON, V500, P343, DOI 10.1113/jphysiol.1997.sp022025; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zamparelli C, 1997, FEBS LETT, V409, P1, DOI 10.1016/S0014-5793(97)00464-X; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301	64	95	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18930	18935		10.1074/jbc.273.30.18930	http://dx.doi.org/10.1074/jbc.273.30.18930			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668070	hybrid			2022-12-27	WOS:000074974700037
J	Pepe, JC; Lory, S				Pepe, JC; Lory, S			Amino acid substitutions in PilD, a bifunctional enzyme of Pseudomonas aeruginosa - Effect on leader peptidase and N-methyltransferase activities in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPILIN PEPTIDASE; PROTEIN SECRETION; MEMBRANE-PROTEIN; SIGNAL PEPTIDASE; GENE; CLEAVAGE; METHYLATION; ADHERENCE; SEQUENCE; MUTAGENESIS	Subunits of type IV pill and a subset of proteins of the type II extracellular protein secretion apparatus undergo two consecutive post-translational modifications: leader peptide cleavage, followed by methylation of the newly created N-terminal amino acid. These two reactions are carried out by a single bifunctional enzyme encoded in Pseudomonas aeruginosa by the pilD gene. Properties of PilD mutants at positions Gly(95) and/or Lys(96) which were differentially affected in leader peptidase and N-methyltransferase function were characterized. None of the single amino acid substitutions showed a significant alteration in their ability to cleave the prepilin leader peptide; however, two double mutants did exhibit a modest reduction in the efficiency of cleavage. In contrast, a significant decrease of N-methyltransferase activity was detected in PilD having substitutions at Gly(95). Mutants with substitutions at position Lys(96) showed a variable effect on N-methyltransferase activity with an apparent requirement for any charged amino acid at this position. Absence of N-methyltransferase activity did not appear to interfere with the ability of P. aeruginosa to assemble functional pill. Moreover, pilin monomers isolated from P. aeruginosa expressing PilD with Gly(95) substitutions were not methylated. Although complete methylation does not appear to be absolutely required for pilus assembly in P. aeruginosa, this modification may be important for pilus function in its natural habitat.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Lory, S (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	guidos@u.washington.edu			NIAID NIH HHS [R0I AI 21451] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021451] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLY M, 1992, MOL MICROBIOL, V6, P1121, DOI 10.1111/j.1365-2958.1992.tb01550.x; BALLY M, 1991, J BACTERIOL, V173, P479, DOI 10.1128/jb.173.2.479-486.1991; BERKA RM, 1981, INFECT IMMUN, V34, P1071, DOI 10.1128/IAI.34.3.1071-1074.1981; BLAKE MS, 1989, J EXP MED, V170, P1727, DOI 10.1084/jem.170.5.1727; BLISS CI, 1970, STAT BIOL, P17; BODEY GP, 1983, REV INFECT DIS, V5, P279; CHATTERJEE S, 1995, J MOL BIOL, V245, P311, DOI 10.1006/jmbi.1994.0025; DALBEY RE, 1988, J BIOL CHEM, V263, P404; DEV IK, 1985, J BIOL CHEM, V260, P5891; DONNENBERG MS, 1992, MOL MICROBIOL, V6, P3427, DOI 10.1111/j.1365-2958.1992.tb02210.x; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GILBERT DG, 1989, ENZYME KINETICS; GREENE PJ, 1981, J BIOL CHEM, V256, P2143; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU PV, 1966, J INFECT DIS, V116, P112, DOI 10.1093/infdis/116.1.112; NUNN D, 1990, J BACTERIOL, V172, P2911, DOI 10.1128/jb.172.6.2911-2919.1990; NUNN DN, 1991, P NATL ACAD SCI USA, V88, P3281, DOI 10.1073/pnas.88.8.3281; NUNN DN, 1993, J BACTERIOL, V175, P4375, DOI 10.1128/JB.175.14.4375-4382.1993; NUNN DN, 1992, P NATL ACAD SCI USA, V89, P47, DOI 10.1073/pnas.89.1.47; PEPE JC, 1990, J BACTERIOL, V172, P3780, DOI 10.1128/jb.172.7.3780-3789.1990; Sambrook J, 1989, MOL CLONING LAB MANU, V1 and 3; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SIMPSON DA, 1992, INFECT IMMUN, V60, P3771, DOI 10.1128/IAI.60.9.3771-3779.1992; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; STROM MS, 1992, J BACTERIOL, V174, P7345, DOI 10.1128/jb.174.22.7345-7351.1992; STROM MS, 1991, J BIOL CHEM, V266, P1656; STROM MS, 1991, J BACTERIOL, V173, P1175, DOI 10.1128/jb.173.3.1175-1180.1991; STROM MS, 1993, J BIOL CHEM, V268, P15788; STROM MS, 1993, P NATL ACAD SCI USA, V90, P2404, DOI 10.1073/pnas.90.6.2404; WOODS DE, 1980, INFECT IMMUN, V30, P694	32	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19120	19129		10.1074/jbc.273.30.19120	http://dx.doi.org/10.1074/jbc.273.30.19120			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668097	hybrid			2022-12-27	WOS:000074974700064
J	Chu, BY; Zhong, R; Soncin, F; Stevenson, MA; Calderwood, SK				Chu, BY; Zhong, R; Soncin, F; Stevenson, MA; Calderwood, SK			Transcriptional activity of heat shock factor 1 at 37 degrees C is repressed through phosphorylation on two distinct serine residues by glycogen synthase kinase 3 alpha and protein kinases C alpha, and C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; GENE-EXPRESSION; MAP KINASE; BETA-CATENIN; HSP70 GENE; FACTOR-I; ACTIVATION; CELLS; STRESS; YEAST	Heat shock factor 1 (HSF1) is the key transcriptional regulator of the heat shock genes that protect cells from environmental stress. However, because heat shock gene expression is deleterious to growth and development, we have examined mechanisms for HSF1 repression at growth temperatures, focusing on the role of phosphorylation. Mitogen-activated protein kinases (MAPKs) of the ERR family phosphorylate HSF1 and represses transcriptional function. The mechanism of repression involves initial phosphorylation by MAP kinase on serine 307, which primes HSF1 for secondary phosphorylation by glycogen synthase kinase 3 on a key residue in repression (serine 303). In vivo expression of glycogen synthase kinase 3 (alpha or beta) thus represses HSF1 through phosphorylation of serine 303. HSF1 is also phosphorylated by MAPK in vitro on a second residue (serine 363) adjacent to activation domain 1, and this residue is additionally phosphorylated by protein kinase C. In vivo, HSF1 is repressed through phosphorylation of this residue by protein kinase C alpha or -zeta but not MAPK. Regulation at 37 degrees C, therefore, involves the action of three protein kinase cascades that repress HSF1 through phosphorylation of serine residues 303, 307, and 363 and may promote growth by suppressing the heat shock response.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Joint Ctr Radiat Therapy, Dept Adult Oncol, Boston, MA 02115 USA; Inst Pasteur, CNRS, EP 560, F-59021 Lille, France	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	stuart_calderwood@dfci.harvard.edu	SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673	NATIONAL CANCER INSTITUTE [R01CA050642, P01CA031303] Funding Source: NIH RePORTER; NCI NIH HHS [CA31303, CA4707, CA50642] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUCE JL, 1993, CANCER RES, V53, P12; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; Ding XZ, 1996, J INVEST MED, V44, P144; ENGELBERG D, 1994, MOL CELL BIOL, V14, P4929, DOI 10.1128/MCB.14.7.4929; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; Holmberg CI, 1997, J BIOL CHEM, V272, P6792, DOI 10.1074/jbc.272.10.6792; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Krebs RA, 1997, CELL STRESS CHAPERON, V2, P60, DOI 10.1379/1466-1268(1997)002<0060:DCOHOI>2.3.CO;2; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARUI N, 1991, BIOCHEM BIOPH RES CO, V179, P1662, DOI 10.1016/0006-291X(91)91766-6; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Newton EM, 1996, MOL CELL BIOL, V16, P839; NIKILOKAKI E, 1993, ONCOEGNE, V8, P833; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVIER AR, 1992, BIOCHEM SOC T, V20, P603, DOI 10.1042/bst0200603; PARKER PJ, 1994, PROTEIN KINASES, P68; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHILLER P, 1988, J MOL BIOL, V203, P97, DOI 10.1016/0022-2836(88)90094-0; Soncin F, 1997, PROTEIN EXPRES PURIF, V9, P27, DOI 10.1006/prep.1996.0672; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEVENSON MA, 1994, CANCER RES, V54, P12; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Woodgett JR, 1991, METHOD ENZYMOL, V200, P564; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094	51	144	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18640	18646		10.1074/jbc.273.29.18640	http://dx.doi.org/10.1074/jbc.273.29.18640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660838	hybrid			2022-12-27	WOS:000074828500093
J	Conrad, J; Sun, DH; Englund, N; Ofengand, J				Conrad, J; Sun, DH; Englund, N; Ofengand, J			The rluC gene of Escherichia coli codes for a pseudouridine synthase that is solely responsible for synthesis of pseudouridine at positions 955, 2504, and 2580 in 23 S ribosomal RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYLTRANSFERASE CENTER; 16S RNA; PURIFICATION; SUBUNIT; CLONING; RESIDUES; ENZYMES; BASE; LOOP; IV	Escherichia coli ribosomal RNA contains 10 pseudouridines, one in the 16 S RNA and nine in the 23 S RNA. Previously, the gene for the synthase responsible for the 16 S RNA pseudouridine was identified and cloned, as was a gene for a synthase that makes a single pseudouridine in 23 S RNA. The yceC open reading frame of E. coli is one of a set of genes homologous to these previously identified ribosomal RNA pseudouridine synthases. In this work, the gene was cloned, overexpressed, and shown to code for a pseudouridine synthase able to react with in vitro transcripts of 23 S ribosomal RNA. Deletion of the gene and analysis of the 23 S RNA from the deletion strain for the presence of pseudouridine at its nine known sites revealed that this synthase is solely responsible in Dice for the synthesis of three of the nine pseudouridine residues, at positions 955, 2504, and 2580, Therefore, this gene has been renamed rluC. Despite the absence of one-third of the normal complement of pseudouridines, there was no change in the exponential growth rate in either LB or M-9 medium at temperatures ranging from 24 to 42 degrees C. From this work and our previous studies, we have now identified three synthases that account for 50% of the pseudouridines in the E, coli ribosome.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Ofengand, J (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	jofengan@mednet.med.miami.edu						BAKIN A, 1994, NUCLEIC ACIDS RES, V22, P3681, DOI 10.1093/nar/22.18.3681; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13475, DOI 10.1021/bi00249a036; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BAKIN A, 1998, METHODS MOL BIOL PRO, pCH22; Becker HF, 1997, NUCLEIC ACIDS RES, V25, P4493, DOI 10.1093/nar/25.22.4493; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bocchetta M, 1998, P NATL ACAD SCI USA, V95, P3525, DOI 10.1073/pnas.95.7.3525; CUNNINGHAM PR, 1993, BIOCHEMISTRY-US, V32, P7172, DOI 10.1021/bi00079a014; CUNNINGHAM PR, 1992, BIOCHEMISTRY-US, V31, P12012, DOI 10.1021/bi00163a008; Dokudovskaya S, 1996, RNA, V2, P146; Grosjean H, 1997, BIOCHIMIE, V79, P293, DOI 10.1016/S0300-9084(97)83517-1; Gu J, 1998, NUCLEIC ACIDS RES, V26, P160, DOI 10.1093/nar/26.1.160; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; Hall BG, 1998, J BACTERIOL, V180, P2862, DOI 10.1128/JB.180.11.2862-2865.1998; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Kowalak JA, 1996, NUCLEIC ACIDS RES, V24, P688, DOI 10.1093/nar/24.4.688; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Massenet S., 1998, MODIFICATION EDITING, P201; Miller J. H., 1992, SHORT COURSE BACTERI, P357; NURSE K, 1995, RNA, V1, P102; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; Ofengand J., 1998, MODIFICATION EDITING, P229, DOI DOI 10.1128/9781555818296.CH12; SANTER M, 1993, BIOCHEMISTRY-US, V32, P5539, DOI 10.1021/bi00072a007; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; STOKER NG, 1982, GENE, V18, P3353; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; WEITZMANN CJ, 1990, NUCLEIC ACIDS RES, V18, P3515, DOI 10.1093/nar/18.12.3515; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437; ZYSKIND JW, 1992, RECOMBINANT DNA LAB, P187	35	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18562	18566		10.1074/jbc.273.29.18562	http://dx.doi.org/10.1074/jbc.273.29.18562			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660827	hybrid			2022-12-27	WOS:000074828500082
J	Crouse, JA; Elliott, GE; Burgess, TL; Chiu, L; Bennett, L; Moore, J; Nicolson, M; Pacifici, RE				Crouse, JA; Elliott, GE; Burgess, TL; Chiu, L; Bennett, L; Moore, J; Nicolson, M; Pacifici, RE			Altered cell surface expression and signaling of leptin receptors containing the fatty mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE GENE; OB-R; MISSENSE MUTATION; DIABETIC MICE; RAT FATTY; FA/FA RAT; CLONING; IDENTIFICATION; PROTEIN; SUBSTITUTION	Leptin and the leptin receptor are key players in the regulation of body weight. In an attempt to dissect the molecular mechanism of the Zucker fatty rat leptin receptor mutation (Gln(269) --> Pro) we analyzed the effects of this mutation on leptin receptor signaling and expression in three different expression systems: 1) 32D cells expressing leptin/erythropoietin receptor chimeras, 2) COS-7 cells expressing a leptin receptor short form, and 3) 293 cells expressing soluble receptor forms. To determine if the Gln(269) --> Pro mutation is critical for the observed phenotype, we made a similar Gln --> Pro mutation at a vicinal residue two amino acids upstream of the fatty mutation to see if it would have similar effects. Incorporation of either of the Gln --> Pro mutations into wild type receptor forms did not interfere with leptin binding, but it resulted in a signaling-incompetent receptor. In addition, the majority of the mutant receptor protein was localized intracellularly. Our results suggest that the obese phenotype resulting from the Gln(269) --> Pro mutation in the leptin receptor of the Zucker fatty rat may be due not only to a reduced cell surface expression of this form of the leptin receptor, but also to a post-leptin binding malfunction of the receptor that interferes with subsequent signal transduction.	Amgen Inc, Dept Computat Biol, Thousand Oaks, CA 91320 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mammalian Cell Mol Biol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Mol Genom, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Neurosci, Thousand Oaks, CA 91320 USA	Amgen; University of Southern California; Amgen; Amgen; Amgen; Amgen	Pacifici, RE (corresponding author), Amgen Inc, Dept Computat Biol, 1 Amgen Ctr Dr 14-1-D, Thousand Oaks, CA 91320 USA.							Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; BRIZZI MF, 1991, INT J CELL CLONING, V9, P274, DOI 10.1002/stem.5530090404; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; Chua SC, 1996, DIABETES, V45, P1141, DOI 10.2337/diabetes.45.8.1141; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; Devos R, 1997, J BIOL CHEM, V272, P18304, DOI 10.1074/jbc.272.29.18304; Devos R, 1996, P NATL ACAD SCI USA, V93, P5668, DOI 10.1073/pnas.93.11.5668; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; DUQUESNOY P, 1991, P NATL ACAD SCI USA, V88, P10272, DOI 10.1073/pnas.88.22.10272; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HIGUCHI R, 1989, PCR PROTOCOLS GUIDE, P177; Hoggard N, 1997, BIOCHEM BIOPH RES CO, V232, P383, DOI 10.1006/bbrc.1997.6245; IHLE JN, 1981, J IMMUNOL, V126, P2184; Iida M, 1996, BIOCHEM BIOPH RES CO, V222, P19, DOI 10.1006/bbrc.1996.0691; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LUCH SM, 1997, J MOL ENDOCRINOL, V18, P77; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Takaya K, 1996, BIOCHEM BIOPH RES CO, V225, P75, DOI 10.1006/bbrc.1996.1133; Takaya K, 1996, NAT GENET, V14, P130, DOI 10.1038/ng1096-130; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; White DW, 1997, P NATL ACAD SCI USA, V94, P10657, DOI 10.1073/pnas.94.20.10657; WuPeng XS, 1997, DIABETES, V46, P513, DOI 10.2337/diabetes.46.3.513; Yamashita T, 1997, DIABETES, V46, P1077, DOI 10.2337/diabetes.46.6.1077; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZUCKER LM, 1961, J HERED, V52, P275, DOI 10.1093/oxfordjournals.jhered.a107093; ZUCKER TF, 1963, J NUTR, V80, P6, DOI 10.1093/jn/80.1.6; ZUCKER TF, 1962, P SOC EXP BIOL MED, V110, P165, DOI 10.3181/00379727-110-27455	42	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18365	18373		10.1074/jbc.273.29.18365	http://dx.doi.org/10.1074/jbc.273.29.18365			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660803	hybrid			2022-12-27	WOS:000074828500058
J	Reczek, D; Bretscher, A				Reczek, D; Bretscher, A			The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-H+ EXCHANGER; PROTEIN; MOESIN; FAMILY; PHOSPHORYLATION; CYTOSKELETON; LOCALIZATION; INVOLVEMENT; ASSOCIATION; MECHANISM	EBP50 ((e) under bar zrin-radixin-moesin-(b) under bar inding (p) under bar hosphoprotein <(50)under bar>) was recently identified by affinity chromatography on the immobilized NH2-terminal domain of ezrin. Here we map and characterize the regions in EBP50 and ezrin necessary for this association. Using blot overlays and in solution binding assays, the COOH-terminal 30 residues of EBP50 were found to be sufficient for an association with residues 1-286 of ezrin. EBP50 did not bind to full-length (1-585) ezrin, indicating that the EBP50 binding site is masked in the full-length molecule. Ezrin contains two complementary self-association domains known as N- and C-ERMADs ((e) under bar zrin-(r) under bar adixin-(m) under bar oesin-(a) under bar ssociation (d) under bar omains), encompassing residues 1-296 and 479-585, respectively. An ezrin 1-583 construct lacking the two terminal residues necessary for this association was found to have an unmasked EBP50 binding site. Moreover, binding of EBP50 and the C-ERMAD to ezrin residues 1-296 was found to be mutually exclusive, with the C-ERMAD having a higher affinity. These results suggest that in full-length ezrin, the binding site for EBP50 is masked through an intramolecular N/C-ERMAD association, Based on these and additional results, we propose a model whereby dormant ezrin can be activated to bind EBP50 on its NH2-terminal end and F-actin on its COOH-terminal end. Since EBP50 is proposed to bind membrane proteins through its PDZ domains, this provides a molecular description of the regulated linkage of microfilaments to membranes in cell surface microvilli.	Cornell Univ, Biochem Mol & Cell Biol Sect, Ithaca, NY 14853 USA	Cornell University	Bretscher, A (corresponding author), Cornell Univ, Biochem Mol & Cell Biol Sect, Biotechnol Bldg, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM 36652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1997, J CELL SCI, V110, P3011; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, J CLIN INVEST, V92, P1781, DOI 10.1172/JCI116767; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010	30	173	174	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18452	18458		10.1074/jbc.273.29.18452	http://dx.doi.org/10.1074/jbc.273.29.18452			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660814	hybrid			2022-12-27	WOS:000074828500069
J	Sharma, MR; Penczek, P; Grassucci, R; Xin, HB; Fleischer, S; Wagenknecht, T				Sharma, MR; Penczek, P; Grassucci, R; Xin, HB; Fleischer, S; Wagenknecht, T			Cryoelectron microscopy and image analysis of the cardiac ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; MUSCLE SARCOPLASMIC-RETICULUM; FK506 BINDING-PROTEIN; SKELETAL-MUSCLE; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; MOLECULAR-CLONING; TILT SERIES; RECONSTITUTION; PURIFICATION	The three-dimensional structure of the cardiac muscle ryanodine receptor (RyR2) is described and compared with its skeletal muscle isoform (RyR1). Previously, structural studies of RyR2 have not been as informative as those for RyR1 because optimal conditions for electron microscopy, which require low levels of phospholipid, are destabilizing for RyR2. A simple procedure was devised for diluting RyR2 (in phospholipid-containing buffer) into a lipid-free buffer directly on the electron microscope grid, followed by freezing within a few seconds. Cryoelectron microscopy of RyR2 so prepared yielded images of sufficient quality for analysis by single particle image processing. Averaged projection images for RyR2, as well as for RyR1, prepared under the same conditions, were found to be nearly identical in overall dimensions and appearance at the resolution attained, approximate to 30 Angstrom. An initial three-dimensional reconstruction of RyR2 was determined (resolution approximate to 41 Angstrom ) and compared with previously reported reconstructions of RyR1, Although they looked similar, which is consistent with the similarity found for the projection images, and with expectations based on the 66% amino acid sequence identity of the two isoforms, structural differences near the corners of the cytoplasmic assembly were observed in both two- and three-dimensional studies.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12222 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Vanderbilt University	Sharma, MR (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA.				NHLBI NIH HHS [HL32711] Funding Source: Medline; NIAMS NIH HHS [AR40615] Funding Source: Medline; NIGMS NIH HHS [GM29169] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169, R37GM029169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON K, 1989, J BIOL CHEM, V264, P1329; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; Copello JA, 1997, BIOPHYS J, V73, P141, DOI 10.1016/S0006-3495(97)78055-X; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; INUI M, 1987, J BIOL CHEM, V262, P1740; INUI M, 1988, METHOD ENZYMOL, V157, P490; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LIU WP, 1995, J OPT SOC AM A, V12, P2615, DOI 10.1364/JOSAA.12.002615; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; RADERMACHER M, 1992, BIOPHYS J, V61, P936, DOI 10.1016/S0006-3495(92)81900-8; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; SERYSHEVA II, 1995, NAT STRUCT BIOL, V2, P18, DOI 10.1038/nsb0195-18; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; SORRENTINO V, 1995, RYANODINE RECEPTORS, P85; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIMERMAN AP, 1994, BIOCHEM BIOPH RES CO, V198, P701, DOI 10.1006/bbrc.1994.1101; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Tunwell REA, 1996, BIOCHEM J, V318, P477, DOI 10.1042/bj3180477; WAGENKNECHT T, 1994, BIOPHYS J, V67, P2286, DOI 10.1016/S0006-3495(94)80714-3; WAGENKNECHT T, 1995, FEBS LETT, V369, P43, DOI 10.1016/0014-5793(95)00581-S; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; Wagenknecht T, 1997, CURR OPIN STRUC BIOL, V7, P258, DOI 10.1016/S0959-440X(97)80034-6; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Yamazawa T, 1996, EMBO J, V15, P6172, DOI 10.1002/j.1460-2075.1996.tb01005.x; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	40	76	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18429	18434		10.1074/jbc.273.29.18429	http://dx.doi.org/10.1074/jbc.273.29.18429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660811	hybrid			2022-12-27	WOS:000074828500066
J	Witzenbichler, B; Maisonpierre, PC; Jones, P; Yancopoulos, GD; Isner, JM				Witzenbichler, B; Maisonpierre, PC; Jones, P; Yancopoulos, GD; Isner, JM			Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR; VASCULAR ENDOTHELIUM; ENHANCED EXPRESSION; TUMOR ANGIOGENESIS; GENE; TEK; NEOVASCULARIZATION; VASCULOGENESIS; PROLIFERATION	Angiopoietin-1 and its putative natural antagonist, angiopoietin-2, were recently isolated, and the critical role of angiopoietin-1 in embryogenic angiogenesis was demonstrated by targeted gene disruption. Specific biological effects of angiopoietin-1, however, have yet to be defined. in this study we demonstrate that angiopoietin-1, but not angiopoietin-2, is chemotactic for endothelial cells. In contrast, angiopoietin-1 as well as angiopoietin-2 exhibit no proliferative effect on endothelial cells. Excess soluble Tie2, but not Tiel receptor, abolish the chemotactic response of endothelial cells toward angiopoietin-1. Angiopoietin-2 dose-dependently blocks directed migration toward angiopoietin-1, consistent with the role of angiopoietin-2 as a naturally occurring inhibitor of angiopoietin-1. Fibroblasts stably transfected with Tie2 receptor exhibit chemotactic responses for both angiopoietin-1 and angiopoietin-2. Fibroblasts stably expressing a transfected chimeric receptor consisting of the ectodomain of TrkC fused to the cytoplasmic domain of Tie2 also exhibit a chemotactic response to neurotrophin 3 (NT-3), a specific Ligand for TrkC, Endothelial cells are shown to express angiopoietin-2 mRNA and protein, indicating the potential for autocrine activation of angiopoietin/Tie2, Finally, the demonstration that Tie2 as well as angiopoietin-1 are expressed in normal human arteries and veins suggests that the role of angiopoietin/Tie2 may extend beyond embryonic angiogenesis to maintaining integrity of the adult vasculature.	Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Dept Cardiovasc Res, Boston, MA 02135 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	St. Elizabeth's Medical Center; Tufts University; Regeneron	Isner, JM (corresponding author), Tufts Univ, Sch Med, St Elizabeths Med Ctr Boston, Dept Cardiovasc Res, 736 Cambridge St, Boston, MA 02135 USA.		Witzenbichler, Bernhard/ABC-2525-2021		NHLBI NIH HHS [HL 57516, HL 53354, HL 40518] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057516, R01HL040518, R37HL053354, R01HL053354] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Couffinhal T, 1997, AM J PATHOL, V150, P1673; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; HAIMOVITZFRIEDM.I, 1994, CANCER RES, V115, P245; Isner JM, 1996, LANCET, V348, P370, DOI 10.1016/S0140-6736(96)03361-2; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1994, CANCER RES, V54, P6571; KORHONEN J, 1992, BLOOD, V80, P2548; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MADER SL, 1992, J GERONTOL, V47, pB32, DOI 10.1093/geronj/47.2.B32; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PICKERING JG, 1992, J AM COLL CARDIOL, V20, P1430, DOI 10.1016/0735-1097(92)90259-P; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1989, MOL CLONING LAB MANU, P204; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHOLLEY MM, 1984, LAB INVEST, V51, P624; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; ZIEGLER SF, 1993, ONCOGENE, V8, P663	47	368	393	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18514	18521		10.1074/jbc.273.29.18514	http://dx.doi.org/10.1074/jbc.273.29.18514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660821	hybrid			2022-12-27	WOS:000074828500076
J	He, B; Gross, M; Roizman, B				He, B; Gross, M; Roizman, B			The gamma(1)34.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase I regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY RESPONSE GENE; AMINO-ACID-SEQUENCE; PREMATURE SHUTOFF; SKELETAL-MUSCLE; GROWTH ARREST; BRAIN-TUMORS; L-COMPONENT; DNA-DAMAGE; PHOSPHORYLATION; NEUROVIRULENCE	The carboxyl-terminal domain of the gamma(1)34.5 protein of the herpes simplex virus 1 binds to protein phosphatase 1 alpha (PP1) and is required to prevent the shut-off of protein synthesis resulting from phosphorylation of the alpha subunit of eIF-2 by the double-stranded RNA-activated protein kinase. The corresponding domain of the conserved GADD34 protein homologous to gamma(1)34.5 functionally substitutes for y(1)34.5, This report shows that y(1)34.5 and PPI form a complex in the infected cells, that fractions containing this complex specifically dephosphorylate eIF-2 alpha, and that both gamma(1)34.5 and GADD34 proteins contain the amino acid sequence motif common to subunits of PPI that is required for binding to the PPI catalytic subunit, An oligopeptide containing this motif competes with gamma(1)34.5 for binding to PPI, Substitution of Val(193) and Phe(195) in the PPI-binding motif abolished activity. These results suggest that the carboxyl-terminal domain of gamma(1)34.5 protein has the structural and functional attributes of a subunit of PP1 specific for eIF-2 alpha, that it has evolved to preclude shut-off of protein synthesis, and that GADD34 may have a similar function.	Univ Chicago, Marjorie B Kovler Viral Oncol Labs, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Roizman, B (corresponding author), Univ Chicago, Marjorie B Kovler Viral Oncol Labs, 910 E 58th St, Chicago, IL 60637 USA.	bernard@kovler.uchicago.edu			NATIONAL CANCER INSTITUTE [R35CA047451] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024009] Funding Source: NIH RePORTER; NCI NIH HHS [CA47451] Funding Source: Medline; NHLBI NIH HHS [HL30121] Funding Source: Medline; NIAID NIH HHS [AI24009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACKERMANN M, 1986, J VIROL, V58, P843, DOI 10.1128/JVI.58.3.843-850.1986; AITKEN A, 1982, FEBS LETT, V147, P54, DOI 10.1016/0014-5793(82)81010-7; Andreansky S, 1997, CANCER RES, V57, P1502; Andreansky SS, 1996, P NATL ACAD SCI USA, V93, P11313, DOI 10.1073/pnas.93.21.11313; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; CHOU J, 1986, J VIROL, V57, P629, DOI 10.1128/JVI.57.2.629-637.1986; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1992, P NATL ACAD SCI USA, V89, P3266, DOI 10.1073/pnas.89.8.3266; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CHOU J, 1990, J VIROL, V64, P1014, DOI 10.1128/JVI.64.3.1014-1020.1990; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOHERTY MJ, 1995, FEBS LETT, V375, P294, DOI 10.1016/0014-5793(95)01184-G; Doherty MJ, 1996, FEBS LETT, V399, P339, DOI 10.1016/S0014-5793(96)01357-9; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; EJERCITO PM, 1968, J GEN VIROL, V2, P357, DOI 10.1099/0022-1317-2-3-357; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GROSS M, 1987, J BIOL CHEM, V262, P6899; GROSS M, 1980, J BIOL CHEM, V255, P6270; GROSS M, 1973, BIOCHEM BIOPH RES CO, V50, P832, DOI 10.1016/0006-291X(73)91320-X; GROSS M, 1983, BIOCHIM BIOPHYS ACTA, V740, P255, DOI 10.1016/0167-4781(83)90134-3; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Helps NR, 1995, FEBS LETT, V377, P295, DOI 10.1016/0014-5793(95)01347-4; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; HIRANO K, 1995, J BIOL CHEM, V270, P19786, DOI 10.1074/jbc.270.34.19786; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LAGUNOFF M, 1995, J VIROL, V69, P3615, DOI 10.1128/JVI.69.6.3615-3623.1995; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; MCGEOCH DJ, 1991, J GEN VIROL, V72, P3057, DOI 10.1099/0022-1317-72-12-3057; MCGEOCH DJ, 1991, NATURE, V353, P609, DOI 10.1038/353609b0; POST LE, 1981, CELL, V25, P227, DOI 10.1016/0092-8674(81)90247-6; SHELDRICK P, 1974, COLD SPRING HARB SYM, V39, P667, DOI 10.1101/SQB.1974.039.01.080; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SUSSMAN MD, 1992, J VIROL, V66, P5586, DOI 10.1128/JVI.66.9.5586-5589.1992; TANG PM, 1991, J BIOL CHEM, V266, P15782; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; WADSWORTH S, 1975, J VIROL, V15, P1487, DOI 10.1128/JVI.15.6.1487-1497.1975; WHITLEY RJ, 1993, J CLIN INVEST, V91, P2837, DOI 10.1172/JCI116527; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	44	133	138	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20737	20743		10.1074/jbc.273.33.20737	http://dx.doi.org/10.1074/jbc.273.33.20737			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694816	hybrid			2022-12-27	WOS:000075386100009
J	Hirao, K; Hata, Y; Ide, N; Takeuchi, M; Irie, M; Yao, I; Deguchi, M; Toyoda, A; Sudhof, TC; Takai, Y				Hirao, K; Hata, Y; Ide, N; Takeuchi, M; Irie, M; Yao, I; Deguchi, M; Toyoda, A; Sudhof, TC; Takai, Y			A novel multiple PDZ domain-containing molecule interacting with N-methyl-D-aspartate receptors and neuronal cell adhesion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC DENSITY PROTEIN; TUMOR-SUPPRESSOR PROTEIN; GUANYLATE KINASE; WW DOMAIN; SEPTATE JUNCTIONS; PSD-95 FAMILY; HUMAN BRAIN; GENE; CHANNEL; HOMOLOG	At synaptic junctions, pre- and postsynaptic membranes are connected by cell adhesion and have distinct structures for specialized functions. The presynaptic membranes have a machinery for fast neurotransmitter release, and the postsynaptic membranes have clusters of neurotransmitter receptors, The molecular mechanism of the assembly of synaptic junctions is not yet clear. Pioneering studies identified postsynaptic density (PSD)-95/SAP90 as a prototypic synaptic scaffolding protein to maintain the structure of synaptic junctions. PSD-95/SAP90 belongs to a family of membrane-associated guanylate kinases and binds N-methyl-D-aspartate receptors, potassium channels, and neuroligins through the PDZ domains and GKAP/SAPAP/DAP through the guanylate kinase (GK) domain. We performed here a yeast two-hybrid screening for SAPAP-interacting molecules and identified a novel protein that has an inverse structure of membrane-associated guanylate kinases with an NH2-terminal GK-like domain followed by two WW and five PDZ domains. It binds SAPAP through the GH-like domain and NMDA receptors and neuroligins through the PDZ domains. We named this protein S-SCAM (synaptic scaffolding molecule) because S-SCAM may assemble receptors and cell adhesion proteins at synaptic junctions.	Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan; Univ Texas, SW Med Ctr, Dept Mol Genet, Howard Hughes Med Inst, Dallas, TX 75235 USA; JCR Pharmaceut Co Ltd, ERATO, Japan Sci & Technol Corp, Tokai Biotimer Project,Nishi Ku, Kobe, Hyogo 6512241, Japan	Osaka University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST)	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Biochem & Mol Biol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan.	ytakai@moIbio.med.osak-u.ac.jp	Toyoda, Atsushi/AAA-5885-2020	Toyoda, Atsushi/0000-0002-0245-3244				Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; DONG H, 1997, NATURE, V386, P379; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Hata Y, 1996, J NEUROSCI, V16, P2488; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kennedy M B, 1993, Curr Opin Neurobiol, V3, P732, DOI 10.1016/0959-4388(93)90145-O; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LA SA, 1991, NATURE, V352, P77; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Margolis RL, 1997, HUM GENET, V100, P114, DOI 10.1007/s004390050476; Margolis RL, 1996, MOL BRAIN RES, V36, P219, DOI 10.1016/0169-328X(95)00241-J; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Naisbitt S, 1997, J NEUROSCI, V17, P5687; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Niethammer M, 1996, J NEUROSCI, V16, P2157; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Satoh K, 1997, GENES CELLS, V2, P415, DOI 10.1046/j.1365-2443.1997.1310329.x; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; WOODS DF, 1993, MECH DEVELOP, V44, P85, DOI 10.1016/0925-4773(93)90059-7	44	243	258	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21105	21110		10.1074/jbc.273.33.21105	http://dx.doi.org/10.1074/jbc.273.33.21105			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694864	hybrid			2022-12-27	WOS:000075386100057
J	Linnik, KM; Herscovitz, H				Linnik, KM; Herscovitz, H			Multiple molecular chaperones interact with apolipoprotein B during its maturation - The network of endoplasmic reticulum-resident chaperones (ERp72, GRP94, calreticulin, and BiP) interacts with apolipoprotein B regardless of its lipidation state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; THIOL-DEPENDENT REDUCTASE; MAMMARY-DERIVED CELLS; STRESS PROTEINS; BETA-SUBUNIT; DEGRADATION; SECRETION; BINDING; LIPOPROTEINS; GLYCOPROTEINS	The present study was undertaken to identify and characterize molecular chaperones that assist in the folding of apolipoprotein (apo) B, a secretory protein that requires assembly with lipids (lipidation) for its secretion. Both HepG2 cells, normally secreting full-length apoB (apoB-100), and C127 cells transfected to secrete truncated forms of apoB, apoB-41, apoB-29, and apoB-17, respectively, were employed. C127 cells were used to determine whether chaperone binding is dependent on apoB lipidation as they secrete both unlipidated and lipidated apoB forms despite their lack of microsomal triglyceride transfer protein (MTP), which mediates lipidation of apoB in HepG2 cells. The endoplasmic reticulum (ER)-resident molecular chaperones GRP94, calreticulin, and ERp72 were co-immunoprecipitated with apoB-100 from HepG2 cell lysates following cross-linking of proteins in living cells. The same chaperones including BiP/GRP78 were also associated with all truncated forms of apoB. Sequential immunoprecipitation with antibodies to MTP and apoB revealed the presence of ternary complexes containing apoB-100, MTP, and ERp72. However, MTP is not obligatory for the binding of ERp72 as it was associated with all truncated forms of apoB in C127 cells that lack MTP. The interactions between apoB-100 and ERp72 or GRP94 persisted for at least 2 h following a 30-min pulse. Thus, BiP/GRP78, calreticulin, ERp72, and GRP94 may participate in critical steps in the folding of apoB before any substantial lipidation occurs. ERp72 and GRP94 may also mediate the folding of more advanced folding intermediates and/or target the misfolded underlipidated pool of apoB for degradation.	Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, Boston, MA 02118 USA	Boston University	Herscovitz, H (corresponding author), Boston Univ, Sch Med, Dept Biophys, Ctr Adv Biomed Res, 715 Albany St, Boston, MA 02118 USA.			Herscovitz, Haya/0000-0001-8067-6091	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058833, R01HL058833, P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58833-02, HL26335-18] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; Beggah A, 1996, J BIOL CHEM, V271, P20895, DOI 10.1074/jbc.271.34.20895; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Burch WL, 1996, CIRCULATION, V94, P867; Bush KT, 1997, J BIOL CHEM, V272, P9086; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; Feng WJ, 1996, J BIOL CHEM, V271, P18543, DOI 10.1074/jbc.271.31.18543; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Ginsberg HN, 1997, CLIN EXP PHARMACOL P, V24, pA29, DOI 10.1111/j.1440-1681.1997.tb03051.x; HAMMOND C, 1993, CURR BIOL, V3, P884, DOI 10.1016/0960-9822(93)90226-E; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; Huang XF, 1997, J BIOL CHEM, V272, P31872, DOI 10.1074/jbc.272.50.31872; KANE JP, 1983, METABOLIC BASIS INHE, P1139; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KNARR G, 1995, J BIOL CHEM, V270, P27589, DOI 10.1074/jbc.270.46.27589; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Luz J M, 1996, EXS, V77, P97; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; SCHAIFF WT, 1992, J EXP MED, V176, P657, DOI 10.1084/jem.176.3.657; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Shelness GS, 1996, J LIPID RES, V37, P408; Small DM, 1997, CIRCULATION, V96, P3; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Tran K, 1998, J BIOL CHEM, V273, P7244, DOI 10.1074/jbc.273.13.7244; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1993, J BIOL CHEM, V268, P22004; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; Yao ZM, 1997, J LIPID RES, V38, P1937; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220	58	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21368	21373		10.1074/jbc.273.33.21368	http://dx.doi.org/10.1074/jbc.273.33.21368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694898	hybrid			2022-12-27	WOS:000075386100091
J	Okamoto, K; Nakayama, K; Kadowaki, T; Abe, N; Ratnayake, DB; Yamamoto, K				Okamoto, K; Nakayama, K; Kadowaki, T; Abe, N; Ratnayake, DB; Yamamoto, K			Involvement of a lysine-specific cysteine proteinase in hemoglobin adsorption and heme accumulation by Porphyromonas gingivalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLACK-PIGMENTED BACTEROIDES; ARG-GINGIPAIN; COLLAGENOLYTIC ACTIVITY; BACTERICIDAL ACTIVITY; PERIODONTAL-DISEASE; MOLECULAR-CLONING; PURIFICATION; PROTEASE; VIRULENCE; COMPLEMENT	The oral anaerobic bacterium Porphyromonas gingivalis, a major pathogen of advanced adult periodontitis, produces a novel class of cysteine proteinases in both cell-associated and secretory forms. A lysine-specific cysteine proteinase (Lys-gingipain, KGP), as well as an arginine-specific cysteine proteinase (Arg-gingipain), is a major trypsin-like proteinase of the organism. Recent studies indicate that the secreted KGP is implicated in the destruction of periodontal tissue and the disruption of host defense mechanisms. In this study, we have constructed a KGP-deficient mutant to determine whether the cell-associated KGP is important for pathophysiology of the organism. Although the mutant retained the strong ability to disrupt the bactericidal activity of polymorphonuclear leukocytes, its hemagglutination activity was reduced to about one-half that observed with the wild-type strain. More important, the mutant did not form black-pigmented colonies on blood agar plates, indicating the defect of hemoglobin adsorption and heme accumulation. Immunoblot analysis showed that the expression of a 19-kDa hemoglobin receptor protein, which is thought to be responsible for hemoglobin binding by the organism, was greatly retarded in this mutant. The mutant also showed a marked decrease in the ability to degrade fibrinogen, These results suggest the possible involvement of RGP in the hemoglobin binding and heme accumulation of the organism and in the bleeding tendency in periodontal pockets.	Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Dent, Dept Pharmacol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Yamamoto, K (corresponding author), Kyushu Univ, Fac Dent, Dept Microbiol, Higashi Ku, Fukuoka 8128582, Japan.	kyama@dent.kyushu-u.ac.jp						Abe N, 1998, J BIOCHEM, V123, P305; BarkocyGallagher GA, 1996, J BACTERIOL, V178, P2734, DOI 10.1128/jb.178.10.2734-2741.1996; BEDI GS, 1994, J BIOL CHEM, V269, P599; BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; CHU L, 1991, INFECT IMMUN, V59, P1932, DOI 10.1128/IAI.59.6.1932-1940.1991; CIBOROWSKI P, 1994, J BACTERIOL, V176, P4549, DOI 10.1128/JB.176.15.4549-4557.1994; FRANDSEN EVG, 1987, INFECT IMMUN, V55, P631, DOI 10.1128/IAI.55.3.631-638.1987; Fujimura S, 1996, INFECT IMMUN, V64, P2339, DOI 10.1128/IAI.64.6.2339-2342.1996; Genco CA, 1996, TRENDS MICROBIOL, V4, P179, DOI 10.1016/0966-842X(96)10029-9; GIBBONS RJ, 1960, J BACTERIOL, V80, P164, DOI 10.1128/JB.80.2.164-170.1960; GRENIER D, 1989, ORAL MICROBIOL IMMUN, V4, P12, DOI 10.1111/j.1399-302X.1989.tb00400.x; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; Han NM, 1996, INFECT IMMUN, V64, P4000, DOI 10.1128/IAI.64.10.4000-4007.1996; HINODE D, 1992, ARCH ORAL BIOL, V37, P859, DOI 10.1016/0003-9969(92)90120-W; IMAMURA T, 1995, INFECT IMMUN, V63, P4877, DOI 10.1128/IAI.63.12.4877-4882.1995; IMAMURA T, 1994, J CLIN INVEST, V94, P361, DOI 10.1172/JCI117330; KADOWAKI T, 1994, J BIOL CHEM, V269, P21371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON DA, 1992, INFECT IMMUN, V60, P1524, DOI 10.1128/IAI.60.4.1524-1529.1992; Lee SW, 1996, INFECT IMMUN, V64, P4802, DOI 10.1128/IAI.64.11.4802-4810.1996; LINDEGREN CC, 1955, SCIENCE, V121, P605, DOI 10.1126/science.121.3147.605; LIPPKE JA, 1987, APPL ENVIRON MICROB, V53, P2588, DOI 10.1128/AEM.53.10.2588-2589.1987; MCKEE AS, 1988, J MED MICROBIOL, V27, P59, DOI 10.1099/00222615-27-1-59; Nakayama K, 1996, J BACTERIOL, V178, P2818, DOI 10.1128/jb.178.10.2818-2824.1996; NAKAYAMA K, 1995, J BIOL CHEM, V270, P23619, DOI 10.1074/jbc.270.40.23619; Nakayama K, 1997, MICROBIOL IMMUNOL, V41, P185, DOI 10.1111/j.1348-0421.1997.tb01189.x; Nakayama K, 1998, MOL MICROBIOL, V27, P51, DOI 10.1046/j.1365-2958.1998.00656.x; NIEKRASH CE, 1986, J PERIODONTAL RES, V21, P233; Okamoto K, 1996, J BIOCHEM-TOKYO, V120, P398; OKAMOTO K, 1995, ARCH BIOCHEM BIOPHYS, V316, P917, DOI 10.1006/abbi.1995.1123; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PAVLOFF N, 1995, J BIOL CHEM, V270, P1007, DOI 10.1074/jbc.270.3.1007; Pavloff N, 1997, J BIOL CHEM, V272, P1595, DOI 10.1074/jbc.272.3.1595; POTEMPA J, 1995, INFECT IMMUN, V63, P1176, DOI 10.1128/IAI.63.4.1176-1182.1995; SCHENKEIN HA, 1988, J PERIODONTAL RES, V23, P187, DOI 10.1111/j.1600-0765.1988.tb01356.x; SCOTT CF, 1993, J BIOL CHEM, V268, P7935; SHAH HN, 1989, FEMS MICROBIOL LETT, V61, P213, DOI 10.1016/0378-1097(89)90199-7; SHAH HN, 1979, BIOCHEM J, V180, P45, DOI 10.1042/bj1800045; SHAH HN, 1989, ORAL MICROBIOL IMMUN, V4, P19, DOI 10.1111/j.1399-302X.1989.tb00401.x; SOJAR HT, 1993, INFECT IMMUN, V61, P2369, DOI 10.1128/IAI.61.6.2369-2376.1993; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUNDQVIST G, 1988, ORAL MICROBIOL IMMUN, V3, P103, DOI 10.1111/j.1399-302X.1988.tb00093.x; SUNDQVIST G, 1987, J PERIODONTAL RES, V22, P300, DOI 10.1111/j.1600-0765.1987.tb01589.x; SUNDQVIST GK, 1984, SCAND J DENT RES, V92, P14; TODA K, 1984, J PERIODONTAL RES, V19, P372, DOI 10.1111/j.1600-0765.1984.tb01010.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Travis J, 1997, J PERIODONTAL RES, V32, P120, DOI 10.1111/j.1600-0765.1997.tb01392.x; UITTO VJ, 1989, INFECT IMMUN, V57, P213, DOI 10.1128/IAI.57.1.213-218.1989; Yamamoto K, 1997, BIOM HLTH R, V15, P139; YONEDA M, 1990, INFECT IMMUN, V58, P406, DOI 10.1128/IAI.58.2.406-411.1990	50	134	136	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21225	21231		10.1074/jbc.273.33.21225	http://dx.doi.org/10.1074/jbc.273.33.21225			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694880	hybrid			2022-12-27	WOS:000075386100073
J	Torrance, H; Giffin, W; Rodda, DJ; Pope, L; Hache, RJG				Torrance, H; Giffin, W; Rodda, DJ; Pope, L; Hache, RJG			Sequence-specific binding of Ku autoantigen to single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; LONG TERMINAL REPEAT; DEPENDENT PROTEIN-KINASE; MULTIPLE REGULATORY ELEMENTS; RNA POLYMERASE-II; ALPHA-ACTIN GENE; TRANSCRIPTION FACTOR; V(D)J RECOMBINATION; MMTV PROMOTER; MEDIATES INDUCTION	Glucocorticoid-induced transcription of mouse mammary tumor virus is repressed by Ku antigen/DNA-dependent protein kinase (DNA-PK) through a DNA sequence element (NRE1) in the viral long terminal repeat. Nuclear factors binding to the separated single strands of NRE1 have been identified that may also be important for transcriptional regulation through this element. We report the separation of the upper-stranded NRE1 binding activity in Jurkat T cell nuclear extracts into two components. One component was identified as Ku antigen. The DNA sequence preference for Ku binding to single-stranded DNA closely paralleled the sequence requirements of Ku for double-stranded DNA. Recombinant Ku bound the single, upper strand of NRE1 with an affinity that was 3-4-fold lower than its affinity for double-stranded NRE1, Sequence-specific single-stranded Ku binding occurred rapidly (t(1/2) on = 2.0 min) and was exceptionally stable, with an off rate of t(1/2) = 68 min. While Ku70 cross-linked to the upper strand of NRE1 when Ku was bound to double-stranded and single-stranded DNAs, the Ku80 subunit only crosslinked to single-stranded NRE1, Intriguingly, addition of Mg2+ and ATP, the cofactors required for Ku helicase activity, induced the cross-linking of Ku80 to a double-stranded NRE1-containing oligonucleotide, without completely unwinding the two strands.	Univ Ottawa, Dept Med, Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Grad Program Biochem, Ottawa Civic Hosp, Loeb Inst Med Res, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Univ Ottawa, Dept Med, Ottawa Civic Hosp, Loeb Inst Med Res, 1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada.	hache@civich.ottawa.on.ca						ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; BALL JK, 1988, J VIROL, V62, P2985, DOI 10.1128/JVI.62.8.2985-2993.1988; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; Cary RB, 1997, P NATL ACAD SCI USA, V94, P4267, DOI 10.1073/pnas.94.9.4267; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1988, CELL, V53, P371, DOI 10.1016/0092-8674(88)90157-2; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY JP, 1986, J VIROL, V57, P385, DOI 10.1128/JVI.57.1.385-388.1986; DVIR A, 1993, J BIOL CHEM, V268, P10440; FALZON M, 1993, J BIOL CHEM, V268, P10546; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GERSTLE JT, 1993, ELECTROPHORESIS, V14, P725, DOI 10.1002/elps.11501401115; GIFFIN W, 1994, J BIOL CHEM, V269, P1449; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GIFIN W, 1997, J BIOL CHEM, V272, P5647; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; HSU CLL, 1988, J VIROL, V62, P4644, DOI 10.1128/JVI.62.12.4644-4652.1988; JANSENDURR P, 1992, NUCLEIC ACIDS RES, V20, P1243, DOI 10.1093/nar/20.6.1243; Jin SF, 1997, EMBO J, V16, P6874, DOI 10.1093/emboj/16.22.6874; KADANOGA JT, 1986, P NATL ACAD SCI USA, V83, P5889; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; KIM MH, 1995, J VIROL, V69, P4717, DOI 10.1128/JVI.69.8.4717-4726.1995; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; KUSK P, 1995, MOL ENDOCRINOL, V9, P1180, DOI 10.1210/me.9.9.1180; Kusk P, 1996, J BIOL CHEM, V271, P31269, DOI 10.1074/jbc.271.49.31269; Laskowski M., 1971, HYDROLYSIS, V4, P289; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; LEE JW, 1991, J BIOL CHEM, V266, P24101; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; MAY G, 1991, J BIOL CHEM, V266, P3052; MCCORMICK L, 1992, J VIROL, V66, P3435, DOI 10.1128/JVI.66.6.3435-3447.1992; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MINK S, 1990, NUCLEIC ACIDS RES, V18, P2017, DOI 10.1093/nar/18.8.2017; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MOORE S, 1981, ENZYMES A, V14, P281; MORLEY KL, 1987, NUCLEIC ACIDS RES, V15, P6973, DOI 10.1093/nar/15.17.6973; MUKHERJEE R, 1993, NUCLEIC ACIDS RES, V21, P2655, DOI 10.1093/nar/21.11.2655; NORDSTROM LA, 1993, J BIOL CHEM, V268, P13193; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; OKUMURA K, 1994, FEBS LETT, V356, P94, DOI 10.1016/0014-5793(94)01243-1; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PINA B, 1990, MOL CELL BIOL, V10, P625, DOI 10.1128/MCB.10.2.625; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RODDA DJ, 1995, BIOCHEM BIOPH RES CO, V209, P379, DOI 10.1006/bbrc.1995.1514; Romero F, 1996, MOL CELL BIOL, V16, P37; Sakatsume O, 1996, J BIOL CHEM, V271, P31322, DOI 10.1074/jbc.271.49.31322; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STEWART TA, 1988, MOL CELL BIOL, V8, P473, DOI 10.1128/MCB.8.1.473; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SUCK D, 1986, NATURE, V321, P620, DOI 10.1038/321620a0; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; THEUNISSEN HJM, 1989, J VIROL, V63, P3466, DOI 10.1128/JVI.63.8.3466-3471.1989; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANOOYEN A, 1990, J VIROL, V64, P4043; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; YANAGAWA SI, 1993, J VIROL, V67, P112, DOI 10.1128/JVI.67.1.112-118.1993; YANAGAWA SI, 1990, J VIROL, V64, P2474, DOI 10.1128/JVI.64.6.2474-2483.1990; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	88	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20810	20819		10.1074/jbc.273.33.20810	http://dx.doi.org/10.1074/jbc.273.33.20810			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694826	hybrid			2022-12-27	WOS:000075386100019
J	Rim, JS; Atta, MG; Dahl, SC; Berry, GT; Handler, JS; Kwon, HM				Rim, JS; Atta, MG; Dahl, SC; Berry, GT; Handler, JS; Kwon, HM			Transcription of the sodium/myo-inositol cotransporter gene is regulated by multiple tonicity-responsive enhancers spread over 50 kilobase pairs in the 5 '-flanking region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERTONIC STRESS; ALDOSE REDUCTASE; OSMOTIC-STRESS; MESSENGER-RNA; RAT-KIDNEY; IN-VIVO; EXPRESSION; CELLS; DEHYDROGENASE; OSMOLYTES	The sodium/myo-inositol cotransporter is a plasma membrane protein responsible for concentrative cellular accumulation of myo-inositol in a variety of tissues. When cells in kidney and brain are exposed to a hyperosmolar salt condition (hypertonicity) due to the operation of urinary concentration mechanism and pathological conditions, respectively; they survive the stress of hypertonicity by raising the cellular concentration of myo-inositol. Transcription of the sodium/myo-inositol cotransporter gene is markedly stimulated in response to hypertonicity, leading to an increase in the activity of the cotransporter, which in turn drives the osmoprotective accumulation of myo-inositol. To understand the molecular mechanisms by which hypertonicity stimulates transcription, we analyzed the BI-flanking region of the cotransporter gene for cis-acting regulatory sequences. We identified five tonicity-responsive enhancers that are scattered over 50 kilobase pairs. All the enhancers are variations of the same type of enhancer interacting with the transcription factor named tonicity-responsive enhancer binding protein. In vivo methylation experiments demonstrated that exposure of cells to hypertonicity increases the binding of tonicity-responsive enhancer binding protein to the enhancer sites, indicating that all of these enhancers are involved in the transcriptional stimulation. We conclude that the sodium/myo-inositol cotransporter gene is regulated by a large region (similar to 50 kilobase pairs) upstream of the gene.	Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD 21205 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	Johns Hopkins University; University of Pennsylvania	Kwon, HM (corresponding author), 963 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Lee-Kwon, Whaseon/D-6021-2011	Berry, Gerard/0000-0001-5299-3313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042479, F32DK009469, T32DK007712] Funding Source: NIH RePORTER; NIDDK NIH HHS [F32 DK009469-01, F32 DK009469, DK42479, DK07712, DK09469] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Ferraris JD, 1996, AM J PHYSIOL-CELL PH, V270, pC650, DOI 10.1152/ajpcell.1996.270.2.C650; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; Ibsen L, 1996, AM J PHYSIOL-RENAL, V271, pF877, DOI 10.1152/ajprenal.1996.271.4.F877; ISHITANI M, 1995, PLANT MOL BIOL, V27, P307, DOI 10.1007/BF00020185; Kitamura H, 1998, KIDNEY INT, V53, P146, DOI 10.1046/j.1523-1755.1998.00747.x; Kitamura H, 1997, AM J PHYSIOL-RENAL, V272, pF267, DOI 10.1152/ajprenal.1997.272.2.F267; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; KWON HM, 1992, J BIOL CHEM, V267, P6297; KWON HM, 1995, CURR OPIN CELL BIOL, V7, P465, DOI 10.1016/0955-0674(95)80002-6; KWON HM, 1993, CELLULAR MOL PHYSL C, P383; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LUCHT JM, 1994, J BIOL CHEM, V269, P6578; Mallee JJ, 1997, GENOMICS, V46, P459, DOI 10.1006/geno.1997.5055; Minami Y, 1996, MOL BRAIN RES, V40, P64; Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753; Morimura H, 1996, MOL BRAIN RES, V35, P333, DOI 10.1016/0169-328X(95)00245-N; Rim JS, 1997, ARCH BIOCHEM BIOPHYS, V341, P193, DOI 10.1006/abbi.1997.9950; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1991, J CLIN INVEST, V88, P656, DOI 10.1172/JCI115350; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; YAMAUCHI A, 1995, J CLIN INVEST, V96, P1195, DOI 10.1172/JCI118151; YAMAUCHI A, 1994, J AM SOC NEPHROL, V5, P62; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; ZHOU C, 1997, EXP EYE RES, V35, P349	31	140	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20615	20621		10.1074/jbc.273.32.20615	http://dx.doi.org/10.1074/jbc.273.32.20615			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685419	hybrid, Green Accepted			2022-12-27	WOS:000075305400096
J	Seybold, J; Newton, R; Wright, L; Finney, PA; Suttorp, N; Barnes, PJ; Adcock, IM; Giembycz, MA				Seybold, J; Newton, R; Wright, L; Finney, PA; Suttorp, N; Barnes, PJ; Adcock, IM; Giembycz, MA			Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and G(s)-coupled receptor agonists - Potential role in beta(2)-adrenoreceptor desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP-PHOSPHODIESTERASE; CAMP-SPECIFIC PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; MESSENGER-RNA; NUCLEOTIDE PHOSPHODIESTERASE; MOLECULAR-CLONING; DROSOPHILA-MELANOGASTER; HORMONAL-REGULATION; ASTHMA; GENE	In this study, a potential mechanism of beta(2)-adrenoreceptor desensitization has been explored that is based upon the enhanced degradation of cAMP by phosphodiesterase (PDE), Pretreatment of Jurkat T-cells with 8-bromo cAMP (8-Br-cAMP) or prostaglandin E-2 increased PDE3 and PDE4 activity in an actinomycin D- and cycloheximide-sensitive manner. This effect was associated with increased expression of HSPDE3B, HSPDE4A4, HSPDE4D1, HSPDE4D2, and HSPDE4D3 mRNA transcripts. Western analysis reproducibly labeled a band of immunoreactivity in vehicle-treated cells that corresponded to HSPDE4A4 (125 kDa). Although the intensity of this band was unchanged in cells treated with 8-Br-cAMP, additional 68-72-kDa proteins (HSPDE4D2, HSPDE4D1) were labeled that were not detected after vehicle. Similar results were obtained with T-lymphocytes exposed to 8-Br-cAMP and fenoterol, However, in those experiments HSPDE4A4 and HSPDE4D1 appeared to be equally expressed in vehicle- and treated cells, whereas HSPDE4D2 (72 kDa) was detected only after 8-Br-cAMP. The up-regulation of PDE activity in Jurkat T-cells abolished the ability of isoproterenol to elevate cAMP, which was partially reversed by the non-selective PDE inhibitor, 3-isobutyl-1-methyl-xanthine, and by the PDE3 and PDE4 inhibitors, Org 9935 and rolipram, respectively. Collectively, these data suggest that chronic treatment of T-cells with cAMP-elevating agents compromises beta(2)-adrenoreceptor-mediated cAMP accumulation by increasing the expression of HSPDE3B and HSPDE4D gene products.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	Imperial College London	Giembycz, MA (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	m.giembycz@ic.ac.uk	Newton, Robert/C-6814-2012; Adcock, Ian/L-3217-2019	Newton, Robert/0000-0002-4919-8498; Adcock, Ian/0000-0003-2101-8843; Suttorp, Norbert/0000-0002-3958-1151; Barnes, Peter/0000-0002-5122-4018; Seybold, Joachim/0000-0003-1444-8976				ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; BAECKER PA, 1994, GENE, V138, P253, DOI 10.1016/0378-1119(94)90818-4; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; Bloom TJ, 1996, P NATL ACAD SCI USA, V93, P14188, DOI 10.1073/pnas.93.24.14188; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; CHERRY JA, 1995, J NEUROBIOL, V28, P102, DOI 10.1002/neu.480280109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DENT G, 1995, CLIN IMMUNOTHER, V3, P423, DOI 10.1007/BF03259062; ENGELS P, 1994, FEBS LETT, V350, P291, DOI 10.1016/0014-5793(94)00788-8; ENGELS P, 1995, FEBS LETT, V358, P305, DOI 10.1016/0014-5793(94)01460-I; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006, DOI 10.1164/ajrccm.150.4.7921429; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; Giembycz MA, 1996, BRIT J PHARMACOL, V118, P1945, DOI 10.1111/j.1476-5381.1996.tb15629.x; Giembycz MA, 1996, TRENDS PHARMACOL SCI, V17, P331, DOI 10.1016/0165-6147(96)10039-0; GIEMBYCZ MA, 1992, BIOCHEM PHARMACOL, V43, P2041, DOI 10.1016/0006-2952(92)90160-K; GIEMBYCZ MA, 1994, METHYLXANTHINES PHOS, P27; ICHIMURA M, 1993, BIOCHEM BIOPH RES CO, V193, P985, DOI 10.1006/bbrc.1993.1722; Kochetkova M, 1995, BIOCHEM PHARMACOL, V50, P2033, DOI 10.1016/0006-2952(95)02104-3; KOVALA T, 1994, J BIOL CHEM, V269, P8680; KUEHL FA, 1987, AM REV RESPIR DIS, V136, P210, DOI 10.1164/ajrccm/136.1.210; LIVI GP, 1990, MOL CELL BIOL, V10, P2678, DOI 10.1128/MCB.10.6.2678; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; Manning CD, 1996, J PHARMACOL EXP THER, V276, P810; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925, DOI 10.1164/ajrccm.151.6.7767541; MCLAUGHLIN MM, 1993, J BIOL CHEM, V268, P6470; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; Miki T, 1996, GENOMICS, V36, P476, DOI 10.1006/geno.1996.0493; Mirabet M, 1997, BRIT J PHARMACOL, V122, P1075, DOI 10.1038/sj.bjp.0701495; MONACO L, 1994, J BIOL CHEM, V269, P347; Nemoz G, 1996, FEBS LETT, V384, P97, DOI 10.1016/0014-5793(96)00300-6; OBERNOLTE R, 1993, GENE, V129, P239, DOI 10.1016/0378-1119(93)90274-7; PARSONS WJ, 1988, MOL PHARMACOL, V34, P37; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SETTE C, 1994, MOL CELL ENDOCRINOL, V100, P75, DOI 10.1016/0303-7207(94)90282-8; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAHID M, 1991, BRIT J PHARMACOL, V102, pP314; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SULLIVAN M, 1994, CELL SIGNAL, V6, P793, DOI 10.1016/0898-6568(94)00039-5; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; Taylor DR, 1996, MED CLIN N AM, V80, P719, DOI 10.1016/S0025-7125(05)70465-X; TENOR H, 1995, CLIN EXP ALLERGY, V25, P616, DOI 10.1111/j.1365-2222.1995.tb01109.x; TENOR H, 1995, J INVEST DERMATOL, V105, P70, DOI 10.1111/1523-1747.ep12313330; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; TORPHY TJ, 1991, THORAX, V46, P512, DOI 10.1136/thx.46.7.512; TORPHY TJ, 1994, ENVIRON HEALTH PERSP, V102, P79, DOI 10.2307/3432220; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164	61	88	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20575	20588		10.1074/jbc.273.32.20575	http://dx.doi.org/10.1074/jbc.273.32.20575			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685415	hybrid			2022-12-27	WOS:000075305400092
J	Waters, TR; Swann, PF				Waters, TR; Swann, PF			Kinetics of the action of thymine DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; MISMATCH REPAIR; CHROMATOGRAPHIC-SEPARATION; STRUCTURAL BASIS; HELA-CELLS; URACIL; PURIFICATION; EXTRACTS; O-6-METHYLGUANINE; SPECIFICITY	The time course of removal of thymine by thymine DNA glycosylase has been measured in vitro. Each molecule of thymine DNA glycosylase removes only one molecule of thymine from DNA containing a G.T mismatch because it binds tightly to the apurinic DNA site left after removal of thymine. The 5'-flanking base pair to G.T mismatches influences the rate of removal of thymine: k(cat) values with C.G, T.A, G.C, and A.T as the 5'-base pair were 0.91, 0.023, 0.0046, and 0.0013 min(-l), respectively. Thymine DNA glycosylase can also remove thymine from mismatches with S(6)-methylthioguanine, but, unlike G.T mismatches, a 5'-C.G does not have a striking effect on the rate: k(cat) values for removal of thymine from (SMe)G.T With C.G, T.A, G.C, and A.T as the 5'-base pair were 0.026, 0.018, 0.0017, and 0.0010 min(-l), respectively. Thymine removal is fastest when it is from a G.T mismatch with a 5'-flanking C.G pair, suggesting that the rapid reaction of this substrate involves contacts between the enzyme and oxygen 6 or the N-l hydrogen of the mismatched guanine as well as the 5'-flanking C.G pair. Disrupting either of these sets of contacts (i,e. replacing the 5'-flanking C.G base pair with a T.A or replacing the G.T mismatch with (SMe)G.T) has essentially the same effect on rate as disrupting both sets (i,e. replacing CpG.T with Tp(Sme)G.T), and so these contacts are probably cooperative. The glycosylase removes uracil from G.U, C.U, and T.U base pairs faster than it removes thymine from G.T. It can even remove uracil from A.U base pairs, although at a very much lower rate. Thus, thymine DNA glycosylase may play a backup role to the more efficient general uracil DNA glycosylase.	Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London	Waters, TR (corresponding author), Univ London Univ Coll, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	t.waters@biochem.ucl.ac.uk						AFEYAN NB, 1990, J CHROMATOGR, V519, P1, DOI 10.1016/0021-9673(90)85132-F; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Ceccotti S, 1996, CURR BIOL, V6, P1528, DOI 10.1016/S0960-9822(96)00758-0; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; KARRAN P, 1981, BIOCHEMISTRY-US, V20, P6092, DOI 10.1021/bi00524a027; Karran P, 1996, CHEM BIOL, V3, P875, DOI 10.1016/S1074-5521(96)90175-1; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Krokan HE, 1997, BIOCHEM J, V325, P1; MAXAM AM, 1977, P NATL ACAD SCI USA, V91, P1642; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; PEGG AE, 1990, CANCER RES, V50, P6119; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SIBGHATULLAH, 1995, BIOCHEMISTRY-US, V34, P6869, DOI 10.1021/bi00020a034; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; Singh J, 1996, J BIOL CHEM, V271, P28391, DOI 10.1074/jbc.271.45.28391; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Waters TR, 1997, BIOCHEMISTRY-US, V36, P2501, DOI 10.1021/bi9621573; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0; XU YZ, 1992, ANAL BIOCHEM, V204, P185, DOI 10.1016/0003-2697(92)90159-5	32	134	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20007	20014		10.1074/jbc.273.32.20007	http://dx.doi.org/10.1074/jbc.273.32.20007			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685338	hybrid			2022-12-27	WOS:000075305400015
J	Xu, SQ; Tang, DH; Chamberlain, S; Pronk, G; Masiarz, FR; Kaur, S; Prisco, M; Zanocco-Marani, T; Baserga, R				Xu, SQ; Tang, DH; Chamberlain, S; Pronk, G; Masiarz, FR; Kaur, S; Prisco, M; Zanocco-Marani, T; Baserga, R			The granulin/epithelin precursor abrogates the requirement for the insulin-like growth factor 1 receptor for growth in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM DNA TOPOISOMERASE; FACTOR-I RECEPTOR; GRANULIN PRECURSOR; POLYACRYLAMIDE GELS; EPITHELIN PRECURSOR; CELL-GROWTH; MAP KINASE; E-DOMAIN; GENE; PURIFICATION	3T3 cells null for the type 1 insulin-like growth factor receptor are refractory to stimulation by a variety of purified growth factors that are known to be required for the stimulation of other 3T3 cells. However, these cells, known as R- cells, grow in serum-supplemented medium and also in media conditioned by certain cell lines. We report here the purification of a growth factor that stimulates DNA synthesis (and growth) of R- cells. The growth factor, purified to homogeneity by SDS-polyacrylamide gel electrophoresis, was identified as the granulin/epithelin precursor by an accurate determination of the masses of endoproteinase Lys-C peptides using matrix-assisted laser desorption ionization mass spectrometry, followed by a data base search. The granulin/epithelin precursor is a little known growth factor, secreted by a variety of epithelial and hemopoietic cells. It is at present the only purified growth factor that can stimulate the growth of mouse embryo fibroblasts null for the type 1 insulin-like growth factor receptor.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calif San Francisco, Chiron Corp, San Francisco, CA 94608 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94608 USA	Jefferson University; Novartis; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.		Zanocco Marani, Tommaso/D-5801-2015	Zanocco Marani, Tommaso/0000-0002-9911-7078	NIA NIH HHS [AG 00378] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BABA T, 1993, FEBS LETT, V322, P89, DOI 10.1016/0014-5793(93)81544-A; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; Bhandari V, 1996, BIOCHEM J, V319, P441, DOI 10.1042/bj3190441; BHANDARI V, 1992, P NATL ACAD SCI USA, V89, P1715, DOI 10.1073/pnas.89.5.1715; BHANDARI V, 1992, BIOCHEM BIOPH RES CO, V188, P57, DOI 10.1016/0006-291X(92)92349-3; BHANDARI V, 1993, ENDOCRINOLOGY, V133, P2682, DOI 10.1210/en.133.6.2682; Bucan M, 1996, MAMM GENOME, V7, P704, DOI 10.1007/s003359900212; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P10458; DANGELIS T, 1995, J CELL PHYSL, V164, P214; DULAK NC, 1973, J CELL PHYSIOL, V81, P161, DOI 10.1002/jcp.1040810205; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; HYLKA VW, 1990, BIOCHIM BIOPHYS ACTA, V1051, P6, DOI 10.1016/0167-4889(90)90167-C; HYLKA VW, 1985, J BIOL CHEM, V260, P4417; ISHII K, 1983, J BIOL CHEM, V258, P2728; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Parnell PG, 1992, GROWTH FACTORS, V7, P65, DOI 10.3109/08977199209023938; PARNELL PG, 1995, J RECEPT SIGNAL TR R, V15, P747, DOI 10.3109/10799899509079904; PLOWMAN GD, 1992, J BIOL CHEM, V267, P13073; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Sparro G, 1997, PROTEIN EXPRES PURIF, V10, P169, DOI 10.1006/prep.1997.0726; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xu SQ, 1997, CELL PROLIFERAT, V30, P295; ZHOU J, 1993, J BIOL CHEM, V268, P10863; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	45	82	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20078	20083		10.1074/jbc.273.32.20078	http://dx.doi.org/10.1074/jbc.273.32.20078			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685348	hybrid, Green Published			2022-12-27	WOS:000075305400025
J	Yoneyama, T; Hatakeyama, K				Yoneyama, T; Hatakeyama, K			Decameric GTP cyclohydrolase I forms complexes with two pentameric GTP cyclohydrolase I feedback regulatory proteins in the presence of phenylalanine or of a combination of tetrahydrobiopterin and GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; PURIFICATION; DEFICIENCY; CLONING; ENZYME	The activity of GTP cyclohydrolase I is inhibited by (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and stimulated by phenylalanine through complex formation with GTP cyclohydrolase I feedback regulatory protein (GFRP). Gel filtration experiments as well as enzyme activity measurements showed that the number of subunits of GFRP in both the inhibitory and stimulatory complexes is equal to that of GTP cyclohydrolase I. Because GFRP is a pentamer and GTP cyclohydrolase I was shown here by cross-linking experiments to be a decamer, the results indicate that two molecules of a pentameric GFRP associate with one molecule of GTP cyclohydrolase I. Gel filtration analysis suggested that the complex has a radius of gyration similar to that of the enzyme itself. These observations support our model that one molecule of GFRP binds to each of the two outer faces of the torus-shaped GTP cyclohydrolase I. For formation of the inhibitory protein complex, both BH4, and GTP were required; the median effective concentrations of BH4 and GTP were 2 and 26 mu M, respectively. BH4 was the most potent of biopterins with different oxidative states. Among GTP analogues, dGTP as well as guanosine 5'-O-(3'-thiotriphosphate) exhibited similar inducibility compared with GTP, whereas other nucleotide triphosphates had no effect. On the other hand, phenylalanine alone was enough for formation of the stimulatory protein complex, and positive cooperativity was found for the phenylalanine-induced protein complex formation. Phenylalanine was the most potent of the aromatic amino acids.	Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hatakeyama, K (corresponding author), Univ Pittsburgh, Dept Surg, Kaufman Bldg,Suite 300,3471 5th Ave, Pittsburgh, PA 15213 USA.		Yoneyama, Tohru/ABG-2670-2020		NIDDK NIH HHS [DK51257] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051257] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENESADOUN A, 1976, ANAL BIOCHEM, V70, P241; DHONDT JL, 1983, EUR J PEDIATR, V141, P92, DOI 10.1007/BF00496797; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATAKEYAMA K, 1989, J BIOL CHEM, V264, P21660; HATAKEYAMA K, 1991, J BIOL CHEM, V266, P765; HATAKEYAMA K, 1997, METHOD MOL BIOL, V100, P267; KATZENMEIER G, 1991, BIOL CHEM H-S, V372, P991, DOI 10.1515/bchm3.1991.372.2.991; KAUFMAN S, 1985, BIOCHEM SOC T, V13, P433, DOI 10.1042/bst0130433; KAUFMAN S, 1978, NEW ENGL J MED, V299, P673, DOI 10.1056/NEJM197809282991301; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NEWMANN U, 1996, PROTEIN PROTOCOLS HD, P173; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; Weber K., 1975, PROTEINS, VI, P179; Yoneyama T, 1997, J BIOL CHEM, V272, P9690	18	60	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20102	20108		10.1074/jbc.273.32.20102	http://dx.doi.org/10.1074/jbc.273.32.20102			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685352	hybrid			2022-12-27	WOS:000075305400029
J	Busch, C; Hofmann, F; Selzer, J; Munro, S; Jeckel, D; Aktories, K				Busch, C; Hofmann, F; Selzer, J; Munro, S; Jeckel, D; Aktories, K			A common motif of eukaryotic glycosyltransferases is essential for the enzyme activity of large clostridial cytotoxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SORDELLII LETHAL TOXIN; NOVYI ALPHA-TOXIN; RHO-PROTEINS; DIFFICILE; GLUCOSYLATION; TRANSFERASE; RAS	A fragment of the N-terminal 546 amino acid residues of Clostridium sordellii lethal toxin possesses full enzyme activity and glucosylates Rho and Ras GTPases in vitro. Here we identified several amino acid residues in C. sordellii lethal toxin that are essential for the enzyme activity of the active toxin fragment. Exchange of aspartic acid at position 286 or 288 with alanine or asparagine decreased glucosyltransferase activity by about 5000-fold and completely blocked glucohydrolase activity. No enzyme activity was detected with the double mutant D286A/D288A. Whereas the wild-type fragment of C. sordellii lethal toxin was labeled by azido-UDP-glucose after UV irradiation, mutation of the DXD motif prevented radiolabeling. At high concentrations (10 mM) of manganese ions, the transferase activities of the D286A and D288A mutants but not that of wild-type fragment were increased by about 20-fold. The exchange of Asp(270) and Arg(273) reduced glucosyltransferase activity by about 200-fold and blocked glucohydrolase activity. The data indicate that the DXD motif, which is highly conserved in all large clostridial cytotoxins and also in a large number of glycosyltransferases, is functionally essential for the enzyme activity of the toxins and may participate in coordination of the divalent cation and/or in the binding of UDP-glucose.	Univ Freiburg, Inst Pharmakol & Toxikol, D-79104 Freiburg, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Zentrum Biochem, D-69120 Heidelberg, Germany	University of Freiburg; MRC Laboratory Molecular Biology; Ruprecht Karls University Heidelberg	Aktories, K (corresponding author), Univ Freiburg, Inst Pharmakol & Toxikol, Hermann Herder Str 5, D-79104 Freiburg, Germany.	aktories@ruf.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Munro, Sean/0000-0001-6160-5773				AKTORIES K, 1995, TRENDS CELL BIOL, V5, P441, DOI 10.1016/S0962-8924(00)89107-2; Aktories K, 1997, TRENDS MICROBIOL, V5, P282, DOI 10.1016/S0966-842X(97)01067-6; BARROSO LA, 1994, MICROB PATHOGENESIS, V16, P297, DOI 10.1006/mpat.1994.1030; BETTE P, 1991, TOXICON, V29, P877, DOI 10.1016/0041-0101(91)90224-F; BONGAERTS GPA, 1994, MICROB PATHOGENESIS, V17, P1, DOI 10.1006/mpat.1994.1047; Genth H, 1996, BIOCHEM BIOPH RES CO, V229, P370, DOI 10.1006/bbrc.1996.1812; HATHEWAY CL, 1990, CLIN MICROBIOL REV, V3, P66, DOI 10.1128/CMR.3.1.66-98.1990; HENDRICKSON TL, 1995, BIOCHEMISTRY-US, V34, P9444, DOI 10.1021/bi00029a020; Herrmann C, 1998, J BIOL CHEM, V273, P16134, DOI 10.1074/jbc.273.26.16134; Hofmann F, 1998, INFECT IMMUN, V66, P1076, DOI 10.1128/IAI.66.3.1076-1081.1998; Hofmann F, 1997, J BIOL CHEM, V272, P11074; Just I, 1996, J BIOL CHEM, V271, P10149, DOI 10.1074/jbc.271.17.10149; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; Lyerly David M., 1995, P867; MCGREGOR JA, 1989, AM J OBSTET GYNECOL, V161, P987, DOI 10.1016/0002-9378(89)90768-0; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Popoff MR, 1996, J BIOL CHEM, V271, P10217, DOI 10.1074/jbc.271.17.10217; Pothoulakis C, 1996, J CLIN INVEST, V98, P641, DOI 10.1172/JCI118835; Sehr P, 1998, BIOCHEMISTRY-US, V37, P5296, DOI 10.1021/bi972592c; Selzer J, 1996, J BIOL CHEM, V271, P25173, DOI 10.1074/jbc.271.41.25173; TAYLOR NS, 1981, INFECT IMMUN, V34, P1036, DOI 10.1128/IAI.34.3.1036-1043.1981; TSOPANAKIS AD, 1978, EUR J BIOCHEM, V83, P179, DOI 10.1111/j.1432-1033.1978.tb12082.x; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; WIGGINS CAR, 1998, IN PRESS P NATL ACAD	26	189	200	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19566	19572		10.1074/jbc.273.31.19566	http://dx.doi.org/10.1074/jbc.273.31.19566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677381	hybrid			2022-12-27	WOS:000075125200033
J	Kemper, C; Zipfel, PF; Gigli, I				Kemper, C; Zipfel, PF; Gigli, I			The complement cofactor protein (SBP1) from the barred sand bass (Paralabrax nebulifer) mediates overlapping regulatory activities of both human C4b binding protein and factor H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPONENT C4B-BINDING PROTEIN; HUMAN C4-BINDING PROTEIN; PATHWAY C-3 CONVERTASE; CLASSICAL PATHWAY; C3B INACTIVATOR; MOLECULAR-CLONING; SYSTEM; PURIFICATION; PHYLOGENY; PROTEOLYSIS	We have previously shown that serum of the teleost fish barred sand bass (Paralabrax nebulifer) cleaves the alpha'-chain of human C4b and C3b, The proteins that participate in these reactions were purified, and a specific protease and a single cofactor protein were identified. Functional characterization of the recombinantly expressed sand bass cofactor protein (SBP1) and truncated forms containing short consensus repeats (SCRs) 1-2, 1-3, 1-4, 1-5, and 12-17 revealed that SBP1 and SCRs 1-4 mediate the functional activities of the human plasma regulatory protein C4bp and factor Il, They form a complex with C4b, inhibit the formation, and accelerate the decay of the classical pathway C3 convertase and display cofactor activity for the cleavage of C4b, In contrast, the interaction of SBP1 and SCRs 1-4 with human C3b in all these activities was limited. This difference is due to species-specific incompatibilities between the cofactor protein and human C3b, SBP1 and SCRs 1-5 displayed full binding and cofactor activity for methylamine-treated C3 from trout, a species closely related to the sand bass. The presence of only one cofactor in the fish plasma that combines the functional activities of C4bp and factor Il demonstrates that the sand bass cofactor protein is the ancestral precursor to the two complement regulatory proteins in human plasma.	Univ Texas, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Bernhard Nocht Inst Trop Med, Dept Mol Parasitol, D-20359 Hamburg, Germany; Univ Hamburg, Dept Biol, Hamburg, Germany	University of Texas System; Bernhard Nocht Institut fur Tropenmedizin; University of Hamburg	Gigli, I (corresponding author), Univ Texas, Inst Mol Med Prevent Human Dis, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	igigli@imm2.imm.uth.tmc.edu	Kemper, Claudia/A-3673-2008; Kemper, Claudia/B-1502-2015	Kemper, Claudia/0000-0003-4196-1417	PHS HHS [A120067] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Accardo P, 1996, J IMMUNOL, V157, P4935; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG LP, 1985, BIOCHEM J, V230, P133, DOI 10.1042/bj2300133; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DAHMEN A, 1994, BIOCHEM J, V301, P391, DOI 10.1042/bj3010391; DAY NKB, 1970, J EXP MED, V132, P941, DOI 10.1084/jem.132.5.941; FARRIES TC, 1991, IMMUNOL TODAY, V12, P295, DOI 10.1016/0167-5699(91)90002-B; FEARON DT, 1973, J EXP MED, V138, P1305, DOI 10.1084/jem.138.6.1305; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1971, ANNU REV MICROBIOL, V25, P309, DOI 10.1146/annurev.mi.25.100171.001521; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; GIGLI I, 1981, J EXP MED, V154, P1, DOI 10.1084/jem.154.1.1; GORDON DL, 1995, J IMMUNOL, V155, P348; Hardig Y, 1997, BIOCHEM J, V323, P469; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; JANATOVA J, 1989, BIOCHEMISTRY-US, V28, P4754, DOI 10.1021/bi00437a036; KAI S, 1980, J IMMUNOL, V125, P2409; KAIDOH T, 1987, J IMMUNOL, V139, P194; KAIDOH T, 1989, J IMMUNOL, V142, P1605; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KRISTENSEN T, 1987, FASEB J, V46, P2463; KRUSHKAL J, 1998, IN PRESS J MOL EVOL; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; Kuroda N, 1996, IMMUNOGENETICS, V44, P459, DOI 10.1007/BF02602808; LAMBRIS JD, 1994, ANN NY ACAD SCI, V712, P354, DOI 10.1111/j.1749-6632.1994.tb33593.x; LAW S K, 1979, Journal of Immunology, V122, P759; LEE HH, 1978, J VIROL, V27, P754, DOI 10.1128/JVI.27.3.754-767.1978; MUELLEREBERHARD HJ, 1972, J EXP MED, V135, P1003; NAGASAWA S, 1977, IMMUNOCHEMISTRY, V14, P749, DOI 10.1016/0019-2791(77)90345-7; NAGASAWA S, 1980, J IMMUNOL, V125, P578; NAKAO M, 1988, FISH PATHOL, V23, P243, DOI 10.3147/jsfp.23.243; NONAKA M, 1984, J IMMUNOL, V133, P3242; OGATA RT, 1993, J IMMUNOL, V150, P2273; PANGBURN MK, 1984, SPRINGER SEMIN IMMUN, V7, P163, DOI 10.1007/BF01893019; POLLEY MJ, 1968, J EXP MED, V128, P533, DOI 10.1084/jem.128.3.533; REID KMB, 1989, IMMUNOL TODAY, V7, P230; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; Sambrook J, 1988, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Seeger A, 1996, MOL IMMUNOL, V33, P511, DOI 10.1016/0161-5890(96)00002-8; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; SITOMER G, 1966, IMMUNOCHEMISTRY, V3, P57, DOI 10.1016/0019-2791(66)90282-5; Smith LC, 1996, J IMMUNOL, V156, P593; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; Sunyer JO, 1997, BIOCHEM J, V326, P877, DOI 10.1042/bj3260877; Sunyer JO, 1996, P NATL ACAD SCI USA, V93, P8546, DOI 10.1073/pnas.93.16.8546; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; ZICCARDI RJ, 1983, J BIOL CHEM, V258, P6187	57	30	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19398	19404		10.1074/jbc.273.31.19398	http://dx.doi.org/10.1074/jbc.273.31.19398			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677357	hybrid			2022-12-27	WOS:000075125200009
J	Manning, JM; Dumoulin, A; Li, XF; Manning, LR				Manning, JM; Dumoulin, A; Li, XF; Manning, LR			Normal and abnormal protein subunit interactions in hemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							X-RAY-DIFFRACTION; SICKLE HEMOGLOBIN; STRUCTURAL BASIS; BINDING-SITE; AMINO-GROUPS; DEOXYHEMOGLOBIN; CYANATE; 2,3-DIPHOSPHOGLYCERATE; POLYMERIZATION; COOPERATIVITY		Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Northeastern University	Manning, JM (corresponding author), Northeastern Univ, Dept Biol, Mugar Life Sci Bldg,Rm 414,360 Huntington Ave, Boston, MA 02115 USA.	jmanning@lynx.neu.edu						ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ALBEN JO, 1967, J BIOL CHEM, V242, P1827; ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; BENESCH R, 1967, BIOCHEM BIOPH RES CO, V26, P162, DOI 10.1016/0006-291X(67)90228-8; BONAVENTURA J, 1976, J BIOL CHEM, V251, P7563; BOOKCHIN RM, 1971, J MOL BIOL, V60, P263, DOI 10.1016/0022-2836(71)90292-0; BRITTAIN T, 1987, COMP BIOCHEM PHYS B, V86, P473, DOI 10.1016/0305-0491(87)90434-2; Bunn HF, 1997, NEW ENGL J MED, V337, P762, DOI 10.1056/NEJM199709113371107; CERAMI A, 1971, P NATL ACAD SCI USA, V68, P1180, DOI 10.1073/pnas.68.6.1180; CHIANCONE E, 1972, J MOL BIOL, V70, P675, DOI 10.1016/0022-2836(72)90566-9; DIDONATO A, 1983, J BIOL CHEM, V258, P1890; Dumoulin A, 1997, J BIOL CHEM, V272, P31326, DOI 10.1074/jbc.272.50.31326; Eaton William A., 1994, P53; EDELSTEIN SJ, 1979, J MOL BIOL, V134, P851, DOI 10.1016/0022-2836(79)90491-1; FRIER JA, 1977, J MOL BIOL, V112, P97, DOI 10.1016/S0022-2836(77)80158-7; GACON G, 1977, FEBS LETT, V82, P243, DOI 10.1016/0014-5793(77)80593-0; GERSHEY EL, 1968, J BIOL CHEM, V243, P5018; GOLDBERG MA, 1977, J BIOL CHEM, V252, P3414; Harrington DJ, 1997, J MOL BIOL, V272, P398, DOI 10.1006/jmbi.1997.1253; Himanen JP, 1996, J BIOL CHEM, V271, P25152, DOI 10.1074/jbc.271.41.25152; HO C, 1992, ADV PROTEIN CHEM, V43, P154; ITO N, 1995, J MOL BIOL, V250, P648, DOI 10.1006/jmbi.1995.0405; LI X, 1997, BLOOD, V11, P4620; MANNING JM, 1994, METHOD ENZYMOL, V231, P225; Manning LR, 1996, PROTEIN SCI, V5, P775; MOOPENN WF, 1977, BIOCHEMISTRY-US, V16, P4872, DOI 10.1021/bi00641a019; Mylvaganam SE, 1996, NAT STRUCT BIOL, V3, P275, DOI 10.1038/nsb0396-275; NIGEN AM, 1976, J BIOL CHEM, V251, P7638; NIGEN AM, 1974, J BIOL CHEM, V249, P6611; ODONNELL S, 1979, J BIOL CHEM, V254, P2204; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PADLAN EA, 1985, J BIOL CHEM, V260, P8272; Pardanani A, 1997, J BIOL CHEM, V272, P13171, DOI 10.1074/jbc.272.20.13171; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; PERUTZ MF, 1982, NATURE, V299, P421, DOI 10.1038/299421a0; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PLATT OS, 1995, NAT MED, V1, P307, DOI 10.1038/nm0495-307; Rodgers GP, 1997, SEMIN HEMATOL, V34, P2; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; Schechter Alan N., 1994, P33; SCHEEPENS A, 1995, BIOCHEM J, V310, P597, DOI 10.1042/bj3100597; SCHROEDER WA, 1962, BIOCHIM BIOPHYS ACTA, V63, P532, DOI 10.1016/0006-3002(62)90125-7; UENO H, 1992, J PROTEIN CHEM, V11, P177, DOI 10.1007/BF01025223; WATOWICH SJ, 1989, J MOL BIOL, V209, P821, DOI 10.1016/0022-2836(89)90610-4; WIND M, 1976, BIOCHEMISTRY-US, V15, P5161, DOI 10.1021/bi00668a033; WOLD F, 1984, TRENDS BIOCHEM SCI, V9, P250; WYMAN J, 1967, J AM CHEM SOC, V89, P2202, DOI 10.1021/ja00985a037; YANASE H, 1994, PROTEIN SCI, V3, P1213, DOI 10.1002/pro.5560030807	48	38	38	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19359	19362		10.1074/jbc.273.31.19359	http://dx.doi.org/10.1074/jbc.273.31.19359			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677349	hybrid			2022-12-27	WOS:000075125200001
J	Oguro, A; Kakeshita, H; Nakamura, K; Yamane, K; Wang, W; Bechhofer, DH				Oguro, A; Kakeshita, H; Nakamura, K; Yamane, K; Wang, W; Bechhofer, DH			Bacillus subtilis RNase III cleaves both 5 '- and 3 '-sites of the small cytoplasmic RNA precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; ESCHERICHIA-COLI RIBONUCLEOPROTEIN; T7 EARLY RNAS; PROTEIN TRANSLOCATION; SEQUENCE RECOGNITION; RIBONUCLEASE-III; MESSENGER-RNA; 4.5S RNA; IN-VIVO; HOMOLOG	Bacillus subtilis small cytoplasmic RNA (scRNA) is a member of the signal recognition particle RNA family. It is transcribed as a 354-nucleotide primary transcript and processed to a 271-nucleotide mature scRNA, In the precursor, the 5'- and 3'-flanking regions form a stable double-stranded structure based on their complementary sequence. This structure is similar to those of substrates for the double-stranded RNA processing enzyme, RNase III. The B. subtilis enzyme that has similar activity to Escherichia coli RNase III has been purified and is designated Bs-RNase III. Recently, B, subtilis rncS has been shown to encode Bs-RNase III (Wang, W., and Bechhofer, D. H. (1997) J. Bacteriol. 179, 7379-7385). We show here that Bs-RNase III and the purified His-tagged product of rncS cleave pre-scRNA at both 5'- and 3'-sites to produce an intermediate scRNA (scRNA-275), although processing at the 3'-site is less efficient. The 5'-end of scRNA-275 was identical to that of the mature scRNA, whereas it contains four excess nucleotides at the 3'-end. Bs-RNase III cleavage yields a two-base S'-overhang, which is consistent with the manner in which E. coli RNase III cleaves, We also show that truncation of the rncS gene affected processing, and significant amounts of an intermediate scRNA (scRNA-275) were found to accumulate in the rncS-truncated mutant. It is concluded that Bs-RNase III is an enzyme that processes pre-scRNA.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan; Univ Tsukuba, Gene Expt Ctr, Tsukuba, Ibaraki 305, Japan; CUNY Mt Sinai Sch Med, Dept Biochem, New York, NY 10029 USA	University of Tsukuba; University of Tsukuba; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Yamane, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 305, Japan.	kyamane@sakura.cc.tsukuba.ac.jp						AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; AMBULOS NP, 1987, GENE, V51, P281, DOI 10.1016/0378-1119(87)90317-9; BARRY G, 1980, P NATL ACAD SCI-BIOL, V77, P3331, DOI 10.1073/pnas.77.6.3331; BERNSTEIN HD, 1989, NATURE, V340, P482, DOI 10.1038/340482a0; Bunai K, 1996, BIOCHEM BIOPH RES CO, V227, P762, DOI 10.1006/bbrc.1996.1582; COURT D, 1993, CONTROL MRNA STABILI, P70; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P1559, DOI 10.1073/pnas.70.5.1559; DUNN JJ, 1973, P NATL ACAD SCI USA, V70, P3296, DOI 10.1073/pnas.70.12.3296; HENNER DJ, 1990, METHOD ENZYMOL, V185, P223; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LOZERON HA, 1977, J MOL BIOL, V109, P359, DOI 10.1016/S0022-2836(77)80039-9; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MITRA S, 1994, J BIOL CHEM, V269, P31450; NAKAMURA K, 1994, BIOCHEM BIOPH RES CO, V199, P1394, DOI 10.1006/bbrc.1994.1385; Oguro A, 1995, DNA Res, V2, P95, DOI 10.1093/dnares/2.2.95; Oguro A, 1996, GENE, V172, P17, DOI 10.1016/0378-1119(96)00181-3; PANGANIBAN AT, 1983, CELL, V33, P907, DOI 10.1016/0092-8674(83)90033-8; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Rotondo G, 1996, NUCLEIC ACIDS RES, V24, P2377, DOI 10.1093/nar/24.12.2377; Shibata T, 1996, J BIOL CHEM, V271, P13162, DOI 10.1074/jbc.271.22.13162; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; STRUCK JCR, 1989, MOL GEN GENET, V215, P478, DOI 10.1007/BF00427046; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2719, DOI 10.1093/nar/16.6.2719; WALTER P, 1982, NATURE, V299, P691, DOI 10.1038/299691a0; Wang W, 1997, J BACTERIOL, V179, P7379, DOI 10.1128/jb.179.23.7379-7385.1997; YOUNG RA, 1978, P NATL ACAD SCI USA, V75, P3593, DOI 10.1073/pnas.75.8.3593	29	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19542	19547		10.1074/jbc.273.31.19542	http://dx.doi.org/10.1074/jbc.273.31.19542			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677377	hybrid			2022-12-27	WOS:000075125200029
J	Okamoto, T; Yamamoto, S; Watanabe, Y; Ohta, T; Hanaoka, F; Roeder, RG; Ohkuma, Y				Okamoto, T; Yamamoto, S; Watanabe, Y; Ohta, T; Hanaoka, F; Roeder, RG; Ohkuma, Y			Analysis of the role of TFIIE in transcriptional regulation through structure-function studies of the TFIIE beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INITIATION COMPLEX-FORMATION; BASAL TRANSCRIPTION; IMMEDIATELY UPSTREAM; PROMOTER CLEARANCE; HUMAN COACTIVATOR; TERMINAL DOMAIN; BINDING; SITE; ACTIVATION	The general transcription factor TFIIE plays important roles at two distinct but sequential steps in transcription as follows: preinitiation complex formation and activation (open complex formation), and the transition from initiation to elongation. The large subunit of human TFIIE (TFIIE alpha) binds to and facilitates the enzymatic functions of TFIIH, but TFIIE also functions independently from TFIIH. To determine functional roles of the small subunit of human TFIIE (TFIIE beta), deletion mutations were systematically introduced into putative structural motifs and characteristic sequences. Here we show that all of these structures that lie within the central 227-amino acid region of TFIIE beta are necessary and sufficient for both basal and activated transcription. We further demonstrate that two C-terminal basic regions are essential for physical interaction with both TFIIE alpha and single-stranded DNA, as well as with other transcription factors including the Drosophila transcriptional regulator Kruppel. In addition, we analyzed the effects of the TFIIE beta deletion mutations on TFIIH-dependent phosphorylation of the C-terminal domain of RNA polymerase II and on wild type TFIIE beta-driven basal transcription. Both responsible regions also mapped within the essential 227-amino acid region. Our results suggest that TFIIE engages in communication with both transcription factors and promoter DNA via the TFIIE beta subunit.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Rockefeller Univ, Biochem & Mol Biol Lab, New York, NY 10021 USA	Osaka University; Rockefeller University	Ohkuma, Y (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.	ohkumay@imeb.osaka-u.ac.jp			NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI37327] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037327] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bjorklund S, 1996, TRENDS BIOCHEM SCI, V21, P335, DOI 10.1016/0968-0004(96)10051-7; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHIANG CM, 1993, EMBO J, V12, P2749, DOI 10.1002/j.1460-2075.1993.tb05936.x; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HORIKOSHI M, 1990, CELL, V61, P1171, DOI 10.1016/0092-8674(90)90681-4; IMHOF A, 1997, CURR BIOL, V7, P889; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KIM TK, 1993, J BIOL CHEM, V268, P20866; Knaus R, 1996, EMBO J, V15, P1933, DOI 10.1002/j.1460-2075.1996.tb00544.x; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nikolov DB, 1997, P NATL ACAD SCI USA, V94, P15, DOI 10.1073/pnas.94.1.15; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; OHKUMA Y, 1992, NUCLEIC ACIDS RES, V20, P4363, DOI 10.1093/nar/20.16.4363; Ohkuma Y, 1997, J BIOCHEM-TOKYO, V122, P481; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAN GH, 1994, J BIOL CHEM, V269, P30101; PETERSON MG, 1991, NATURE, V354, P369; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TJIAN R, 1994, CELL, V77, P6; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479	52	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19866	19876		10.1074/jbc.273.31.19866	http://dx.doi.org/10.1074/jbc.273.31.19866			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677423	hybrid			2022-12-27	WOS:000075125200075
J	Teter, K; Chandy, G; Quinones, B; Pereyra, K; Machen, T; Moore, HPH				Teter, K; Chandy, G; Quinones, B; Pereyra, K; Machen, T; Moore, HPH			Cellubrevin-targeted fluorescence uncovers heterogeneity in the recycling endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETANUS-TOXIN; TRANSFERRIN RECEPTORS; ENDOCYTIC PATHWAY; LIVING CELLS; PH; ACIDIFICATION; TRANSPORT; CLEAVAGE; VESICLE; NA+,K+-ATPASE	The pH and trafficking of recycling endosomes have previously been studied using transferrin. We have used another approach, one in which the vesicle transport protein cellubrevin was appended with a luminal IgG epitope to allow targeting of fluorescein-5'-isothiocyanate (FITC)-labeled anti-IgG F(ab) antibodies to the recycling endosomes in living cells, FITC-F(ab) was specifically internalized by COS cells transfected with cellubrevin-Ig, which at steady state accumulated in a pericentriolar region similar to rhodamine-transferrin. Confocal microscopic analysis showed that endosome labeling by these two markers was heterogeneous. This differential distribution was not induced by the IgG tag, since endogenous Cb and Tf were also partitioned into separate endosomal populations. We used fluorescence ratio imaging of internalized FITC-F(ab) to measure the pH of cellubrevin-enriched recycling endosomes (pH(Cb)) and FITC-transferrin to measure the pH of transferrin-enriched recycling endosomes (pH(Tf)). In COS cells, cellubrevin endosomes (mean pH(Cb) 6.1 +/- 0.05; range, 5.2-6.6) were more acidic than transferrin endosomes (mean pH(Tf) 6.5 +/- 0.05; range, 5.6-7.2). Similar results were obtained in Chinese hamster ovary cells. Treatment with the vacuolar H+-ATPase inhibitor bafilomycin A(1) caused pH(Tf) to increase (Delta pH(Tf) = 1.2 pH units) to a greater extent than pH(Cb) (Delta pH(Cb) = 0.5 pH units). Furthermore, inhibition of the Na+/K+-ATPase by ouabain or acetylstrophanthidin caused pH(Tf) to decrease by 0.6 pH units but had no effect on pH(Cb). Based on the combination of these morphological and functional data, we suggest that the recycling endosomes are heterogeneous in their biochemical compositions, ion transport properties, and PEI values.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Moore, HPH (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 142 Life Sci Addit 3200, Berkeley, CA 94720 USA.			Quinones, Beatriz/0000-0001-5010-9889; Teter, Ken/0000-0003-4176-9361	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035239] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK95006] Funding Source: Medline; NIGMS NIH HHS [GM35239] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FUCHS R, 1989, J BIOL CHEM, V264, P2212; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; Johnson AO, 1996, J CELL BIOL, V135, P1749, DOI 10.1083/jcb.135.6.1749; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; LINK E, 1993, J BIOL CHEM, V268, P18423; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Nunez MT, 1997, J BIOL CHEM, V272, P19425, DOI 10.1074/jbc.272.31.19425; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Rybak SL, 1997, BIOPHYS J, V73, P674, DOI 10.1016/S0006-3495(97)78102-5; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SIPE DM, 1987, P NATL ACAD SCI USA, V84, P7119, DOI 10.1073/pnas.84.20.7119; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wei ML, 1998, J CELL BIOL, V140, P565, DOI 10.1083/jcb.140.3.565; Wilson JM, 1997, J CELL BIOL, V136, P319, DOI 10.1083/jcb.136.2.319; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	40	60	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19625	19633		10.1074/jbc.273.31.19625	http://dx.doi.org/10.1074/jbc.273.31.19625			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677389	hybrid			2022-12-27	WOS:000075125200041
J	Agati, JM; Yeagley, D; Quinn, PG				Agati, JM; Yeagley, D; Quinn, PG			Assessment of the roles of mitogen-activated protein kinase, phosphatidylinositol 3-kinase, protein kinase B, and protein kinase C in insulin inhibition of cAMP-induced phosphoenolpyruvate carboxykinase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; BINDING PROTEIN; CYCLIC-AMP; MULTIHORMONAL REGULATION; RECEPTOR SUBSTRATE-1; RAT ADIPOCYTES; INTACT RAT; MAP KINASE; PEPCK GENE; EXPRESSION	Transcription of the phosphoenolpyruvate carboxykinase (PEPCK) gene is induced by glucagon, acting through cAMP and protein kinase A, and this induction is inhibited by insulin. Conflicting reports have suggested that insulin inhibits induction by cAMP by activating the Ras/mitogen-activated protein kinase (MAPK) pathway or by activating the phosphatidylinositol 3-kinase (PI3-kinase), but not MAPK, pathway. Insulin activated PI3-kinase phosphorylates Lipids that activate protein kinase B (PKB) and Ca2+/diacylglycerol-insensitive forms of protein kinase C (PKC). We have assessed the roles of these pathways in insulin inhibition of cAMP/PKA-induced transcription of PEPCK by using dominant negative and dominant active forms of regulatory enzymes in the Ras/MAPK and PKB pathways and chemical inhibitors of PKC isoforms. Three independently acting inhibitory enzymes of the Ras/MAPK pathway, blocking SOS, Ras, and MAPK had no effect upon insulin inhibition. However, dominant active Ras prevented induction of PEPCK and also stimulated transcription mediated by Elk, a MAPK target. Insulin did not stimulate Elk-mediated transcription, indicating that insulin did not functionally activate the Ras/MAPK pathway. Inhibitors of PI3-kinase, LY294002 and wortmannin, abolished insulin inhibition of PEPCK gene transcription. However, inhibitors of PKC and mutated forms of PKB, both of which are known downstream targets of PI3-binase, had no effect upon insulin inhibition. Dominant negative forms of PKB did not interfere with insulin inhibition and a dominant active form of PKB did not prevent induction by PKA. Phorbol eater-mediated inhibition of PEPCK transcription was blocked by bisindole maleimide and by staurosporine, but insulin-mediated inhibition was unaffected. Thus, insulin inhibition of PKA-induced PEPCK expression does not require MAPK activation but does require activation of PI3-binase, although this signal. is not transmitted through the PKB or PKC pathways.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Quinn, PG (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049600] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49600] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1993, ONCOGENE, V8, P745; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; CHU DTW, 1986, J BIOL CHEM, V261, P6848; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CORBIN JD, 1998, MESSENGER PHOSPHOPRO, V21, P75; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FILLAT C, 1993, FEBS LETT, V318, P287, DOI 10.1016/0014-5793(93)80530-8; FOLLI F, 1992, J BIOL CHEM, V267, P22171; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOWARD P, 1991, J BIOL CHEM, V266, P10189; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; MYERS MG, 1993, DIABETES, V42, P643, DOI 10.2337/diabetes.42.5.643; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARK EA, 1990, MOL CELL BIOL, V10, P6264, DOI 10.1128/MCB.10.12.6264; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; QUINN PG, 1994, J BIOL CHEM, V269, P14375; QUINN PG, 1990, MOL CELL BIOL, V10, P3357, DOI 10.1128/MCB.10.7.3357; QUINN PG, 1993, J BIOL CHEM, V268, P16999; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; ROESLER WJ, 1993, J BIOL CHEM, V268, P3791; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; SASAKI K, 1984, J BIOL CHEM, V259, P5242; STANDAERT ML, 1995, BIOCHEM BIOPH RES CO, V209, P1082, DOI 10.1006/bbrc.1995.1608; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sutherland C, 1997, DIABETES, V46, P17, DOI 10.2337/diabetes.46.1.17; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sutherland C, 1998, J BIOL CHEM, V273, P3198, DOI 10.1074/jbc.273.6.3198; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOKER A, 1994, J BIOL CHEM, V269, P32358; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; Yeagley D, 1998, J BIOL CHEM, V273, P18743, DOI 10.1074/jbc.273.30.18743	65	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18751	18759		10.1074/jbc.273.30.18751	http://dx.doi.org/10.1074/jbc.273.30.18751			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668048	hybrid			2022-12-27	WOS:000074974700015
J	Sato, T; Konno, H; Tanaka, Y; Kataoka, T; Nagai, K; Wasserman, HH; Ohkuma, S				Sato, T; Konno, H; Tanaka, Y; Kataoka, T; Nagai, K; Wasserman, HH; Ohkuma, S			Prodigiosins as a new group of H+/Cl- symporters that uncouple proton translocators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; FLUORESCEIN ISOTHIOCYANATE-DEXTRAN; MEDIATED EXCHANGE DIFFUSION; H+-ATPASE; PHOSPHOLIPID-VESICLES; RAT-LIVER; 2.8-ANGSTROM RESOLUTION; TRIPHENYLTIN COMPOUNDS; GLUCOSE TRANSPORTER; HYDROXIDE EXCHANGE	We reported previously (Kataoka, T., Muroi, M., Ohkuma, S., Waritani, T., Magae, J., Takatsuki, A., Kondo, S., Yamasaki, M., and Nagai, K. (1995) FEES Lett. 359, 53-59) that prodigiosin 25-C uncoupled vacuolar H+-ATPase, inhibited vacuolar acidification, and affected glycoprotein processing. In the present study we show that prodigiosins (prodigiosin, metacycloprodigiosin and prodigiosin 25-C) inhibit the acidification activity of H+-ATPase chloride dependently, but not membrane potential formation or ATP hydrolysis activity, and suggest that they promote H+/Cl- symport (or OH-/Cl- exchange, in its equivalence) across vesicular membranes. In fact, prodigiosins displayed H+/Cl- symport activity on liposomal membranes. First of all, they decreased the internal pH of liposomes depending on the external chloride, and raised it depending on the internal chloride when external buffer was free from chloride. Second, their effect was electroneutral and not seriously affected by the application of an inside positive membrane potential generated by K+ and valinomycin, Finally, they promoted the uptake of [Cl-36] from external buffers with concomitant intraliposomal acidification when external pH was acidic relative to liposome interior. As prodisosins hardly inhibit the catalytic activity (ATP hydrolysis) unlike well known OH-/Cl- exchangers (for example, tributyltin chloride), they should provide powerful tools for the study of molecular machinery and cellular activities involving transport of protons and/or chloride.	Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cell Biol, Biochem Lab, Kanazawa, Ishikawa 9200934, Japan; Tokyo Inst Technol, Dept Bioengn, Midori Ku, Yokohama, Kanagawa 2260026, Japan; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Kanazawa University; Tokyo Institute of Technology; Yale University	Ohkuma, S (corresponding author), Kanazawa Univ, Fac Pharmaceut Sci, Dept Mol & Cell Biol, Biochem Lab, Takaramachi 13-1, Kanazawa, Ishikawa 9200934, Japan.	ohkuma@kenroku.kanazawa-u.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; [Anonymous], 1977, ADV PHYS ORG CHEM; ANTONENKO YN, 1990, J MEMBRANE BIOL, V113, P109, DOI 10.1007/BF01872884; ARAI K, 1991, J BIOCHEM, V110, P541, DOI 10.1093/oxfordjournals.jbchem.a123616; ARAI K, 1993, J BIOL CHEM, V268, P5649; ASH RP, 1977, J AM CHEM SOC, V99, P4471, DOI 10.1021/ja00455a043; BARRANCO J, 1981, BIOCHEM BIOPH RES CO, V100, P1402, DOI 10.1016/0006-291X(81)91980-X; BOGER DL, 1987, TETRAHEDRON LETT, V28, P2499, DOI 10.1016/S0040-4039(00)95451-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAIN K, 1977, BIOCHEM J, V162, P575, DOI 10.1042/bj1620575; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; CHANIOTAKIS NA, 1988, ANAL CHEM, V60, P185, DOI 10.1021/ac00153a020; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1534, DOI 10.1021/bi00509a019; DAlessio R, 1996, SYNLETT, P513; DIAZ RS, 1994, MOL PHARMACOL, V46, P1210; DIETRICH B, 1988, J CHEM SOC CHEM COMM, P691, DOI 10.1039/c39880000691; ElEtri M, 1996, AM J PHYSIOL-LUNG C, V270, pL386, DOI 10.1152/ajplung.1996.270.3.L386; EMANUEL EL, 1984, BIOCHIM BIOPHYS ACTA, V766, P209, DOI 10.1016/0005-2728(84)90233-0; FARROW BG, 1978, EUR J BIOCHEM, V86, P85, DOI 10.1111/j.1432-1033.1978.tb12287.x; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GOULD JM, 1976, EUR J BIOCHEM, V62, P567, DOI 10.1111/j.1432-1033.1976.tb10191.x; GRABE CG, 1983, ANAL BIOCHEM, V130, P287; HARASHIMA K, 1967, AGR BIOL CHEM TOKYO, V31, P481, DOI 10.1080/00021369.1967.10858824; HIGUTI T, 1993, NEW FUNCTIONALITY MA, P131; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; KALM G, 1995, J MOL BIOL, V253, P726; KANO K, 1978, BIOCHIM BIOPHYS ACTA, V509, P289, DOI 10.1016/0005-2736(78)90048-2; KARNISKI LP, 1992, J BIOL CHEM, V267, P19218; KASAHARA M, 1977, J BIOL CHEM, V252, P7384; KATAOKA T, 1992, J ANTIBIOT, V45, P1618, DOI 10.7164/antibiotics.45.1618; KATAOKA T, 1995, FEBS LETT, V359, P53, DOI 10.1016/0014-5793(94)01446-8; KONDO S, 1988, J ANTIBIOT, V41, P1196, DOI 10.7164/antibiotics.41.1196; KOVACIC H, 1993, J PHARMACOL EXP THER, V267, P1509; LEE MH, 1995, BIOSCI BIOTECH BIOCH, V59, P1417, DOI 10.1271/bbb.59.1417; Magae J, 1996, J ANTIBIOT, V49, P86, DOI 10.7164/antibiotics.49.86; MORIYAMA Y, 1984, J BIOCHEM-TOKYO, V95, P995, DOI 10.1093/oxfordjournals.jbchem.a134726; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1993, ARCH BIOCHEM BIOPHYS, V305, P278, DOI 10.1006/abbi.1993.1423; MUKOHATA Y, 1981, ARCH BIOCHEM BIOPHYS, V206, P72, DOI 10.1016/0003-9861(81)90067-9; NAKAMURA A, 1989, TRANSPLANTATION, V47, P1013, DOI 10.1097/00007890-198906000-00019; NAKAMURA A, 1986, J ANTIBIOT, V39, P1155, DOI 10.7164/antibiotics.39.1155; NAKAMURA K, 1970, CHEM COMMUN, P1135; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHKUMA S, 1983, J BIOCHEM, V94, P1935, DOI 10.1093/oxfordjournals.jbchem.a134547; OHKUMA S, 1982, P NATL ACAD SCI-BIOL, V79, P2758, DOI 10.1073/pnas.79.9.2758; Ohkuma S, 1997, CELL STRUCT FUNCT, V22, P253, DOI 10.1247/csf.22.253; OHKUMA S, 1989, METHOD ENZYMOL, V174, P131; OHKUMA S, 1996, JPN BIOENERG GROUP A, V22, P28; Rothmaier M, 1996, ANAL CHIM ACTA, V327, P17, DOI 10.1016/0003-2670(96)00055-4; SARTI P, 1995, BIOCHEM J, V312, P643, DOI 10.1042/bj3120643; SASAKI J, 1995, SCIENCE, V269, P73, DOI 10.1126/science.7604281; SASE S, 1982, J BIOL CHEM, V257, P1100; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SELWYN MJ, 1970, EUR J BIOCHEM, V14, P120, DOI 10.1111/j.1432-1033.1970.tb00268.x; SESSLER JL, 1991, J CHEM SOC CHEM COMM, P1733, DOI 10.1039/c39910001733; SINGH AP, 1986, BIOCHEM CELL BIOL, V64, P647, DOI 10.1139/o86-089; STARKS CM, 1985, ACS SYM SER, V326, P1; STOCKDAL.M, 1970, EUR J BIOCHEM, V15, P342, DOI 10.1111/j.1432-1033.1970.tb01013.x; TOSTESON MT, 1979, J GEN PHYSIOL, V73, P789, DOI 10.1085/jgp.73.6.789; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; UDAGAWA T, 1986, J BIOL CHEM, V261, P2616; USTA J, 1993, APPL ORGANOMET CHEM, V7, P193, DOI 10.1002/aoc.590070306; VERKMAN AS, 1989, BIOCHEMISTRY-US, V28, P4240, DOI 10.1021/bi00436a018; WASSERMAN HH, 1989, TETRAHEDRON LETT, V30, P1725, DOI 10.1016/S0040-4039(00)99566-2; WASSERMAN HH, 1984, TETRAHEDRON LETT, V25, P1387, DOI 10.1016/S0040-4039(01)80165-9; WASSERMAN HH, 1976, TETRAHEDRON, V32, P1867, DOI 10.1016/0040-4020(76)85188-5; WASSERMAN HH, 1966, TETRAHEDRON        S, V8, P647; WIETH JO, 1979, J GEN PHYSIOL, V73, P765, DOI 10.1085/jgp.73.6.765; Williams R.P., 1967, BIOSYNTHESIS, P410; Woo JT, 1997, BIOSCI BIOTECH BIOCH, V61, P400, DOI 10.1271/bbb.61.400; WULF RG, 1975, ARCH BIOCHEM BIOPHYS, V167, P176, DOI 10.1016/0003-9861(75)90454-3	72	135	136	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21455	21462		10.1074/jbc.273.34.21455	http://dx.doi.org/10.1074/jbc.273.34.21455			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705273	hybrid			2022-12-27	WOS:000075492600007
J	Trujillo, KM; Yuan, SSF; Lee, EYHP; Sung, P				Trujillo, KM; Yuan, SSF; Lee, EYHP; Sung, P			Nuclease activities in a complex of human recombination and DNA repair factors Rad50, Mre11, and p95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; MEIOSIS; GENES; ROLES	Genetic studies in yeast have indicated a role of the RAD50 and MRE11 genes in homologous recombination, telomere length maintenance, and DNA repair processes. Here, we purify from nuclear extract of Raji cells a complex consisting of human Rad50, Mre11, and another protein factor with a size of about 95 kDa (p95), which is likely to be Nibrin, the protein encoded by the gene mutated in Nijmegen breakage syndrome, We show that the Rad50-Mre11-p95 complex possesses manganese-dependent single-stranded DNA endonuclease and 3' to 5' exonuclease activities. These nuclease activities are likely to be important for recombination, repair, and genomic stability.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Sung, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA.	sung@uthscsa.edu		yuan, shyng-shiou/0000-0002-4753-788X	NCI NIH HHS [CA49649] Funding Source: Medline; NIEHS NIH HHS [ES07061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA049649, R29CA049649, R37CA049649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Connelly JC, 1996, GENES CELLS, V1, P285, DOI 10.1046/j.1365-2443.1996.23024.x; Cox MM, 1997, P NATL ACAD SCI USA, V94, P11764, DOI 10.1073/pnas.94.22.11764; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Kanaar R, 1998, NATURE, V391, P335, DOI 10.1038/34790; Klein HL, 1997, GENETICS, V147, P1533; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493, DOI 10.1128/MCB.14.7.4493; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Shinohara M, 1997, GENETICS, V147, P1545; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	18	312	327	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21447	21450		10.1074/jbc.273.34.21447	http://dx.doi.org/10.1074/jbc.273.34.21447			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705271	hybrid			2022-12-27	WOS:000075492600005
J	Deng, KP; Zhang, L; Kachurin, AM; Yu, L; Xia, D; Kim, H; Deisenhofer, J; Yu, CA				Deng, KP; Zhang, L; Kachurin, AM; Yu, L; Xia, D; Kim, H; Deisenhofer, J; Yu, CA			Activation of a matrix processing peptidase from the crystalline cytochrome bc(1) complex of bovine heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C OXIDOREDUCTASE COMPLEX; SACCHAROMYCES-CEREVISIAE; POTATO MITOCHONDRIA; ELECTRON-TRANSPORT; ENHANCING PROTEIN; SUBUNIT-II; UBIQUINOL; REDUCTASE; GENE; SEQUENCE	No mitochondrial processing peptidase (MPP) activity is detected in crystalline bovine heart mitochondrial cytochrome be, complex, which possesses full electron transfer activity. However, when the complex is treated with increasing concentrations of Triton X-100 at 37 degrees C, the electron transfer activity decreases, whereas peptidase activity increases. Maximum MPP activity is obtained when the electron transfer activity in the complex is completely inactivated with 1.5 mar of Triton X-100, This result supports our suggestion that the lack of MPP activity in the mammalian cytochrome be, complex is because of binding of an inhibitor polypeptide to the active site of MPP located at the interface of core subunits I and II. This suggestion is based on the three-dimensional structural information for the be, complex and the sequence homology between subunits of MPP and the core subunits of the beef complex. Triton X-100, at concentrations that disrupt the structural integrity of the be, complex as indicated by the loss of its electron transfer activity, weakens the binding of inhibitor polypeptide to the active site of MPP in core subunits, thus activating MPP, The Triton X-100-activated MPP is pH-, buffer system-, ionic strength-, and temperature-dependent. Maximum activity is observed with an assay mixture containing 15 mM Tris-HCl buffer at neutral pH (6.5-8.5) and at 37 degrees C, Activated MPP is completely inhibited by metal ion chelators such as EDTA and o-phenanthroline and partially inhibited by myxothiazol (58%), ferricyanide (28%), and dithiothreitol (81%). The metal ion chelator-inhibited activity can be partially restored by the addition of divalent cations such as Zn2+ (68%), Mg2+ (44%), Mn2+ (54%), Co2+ (62%), and Fe2+ (92%), indicating that metal ion is required for MPP activity. The cleavage site specificity of activated MPP depends more on the length of amino acid sequence from the mature protein portion and less on the presequence portion, when a synthetic peptide composed of NH2-terminal residues of a mature protein and the COOH-terminal residues of its presequence is used as a substrate.	Oklahoma State Univ, Stillwater, OK 74078 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, CA (corresponding author), Oklahoma State Univ, Stillwater, OK 74078 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY EA, 1992, J MOL BIOL, V224, P1161, DOI 10.1016/0022-2836(92)90476-Z; BRANDT U, 1993, J BIOL CHEM, V268, P8387; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; BRAUN HP, 1995, J BIOENERG BIOMEMBR, V27, P423, DOI 10.1007/BF02110005; DENG K, 1996, BIOPHYS J, V72, pA319; EMMERMANN M, 1993, PLANT PHYSIOL, V103, P615, DOI 10.1104/pp.103.2.615; EMMERMANN M, 1993, BIOCHIM BIOPHYS ACTA, V1142, P306, DOI 10.1016/0005-2728(93)90158-C; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; ERIKSSON AC, 1996, J BIOENERG BIOMEMBR, V28, P283; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; GLASER E, 1994, FEBS LETT, V346, P83, DOI 10.1016/0014-5793(94)00312-2; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; KIM H, 1998, IN PRESS P NATL ACAD; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; KUBOTA T, 1991, J MOL BIOL, V221, P379, DOI 10.1016/0022-2836(91)80059-4; MAARSE AC, 1988, EUR J BIOCHEM, V172, P179, DOI 10.1111/j.1432-1033.1988.tb13870.x; OU W, 1988, EMBO J, V8, P2605; OUDSHOORN P, 1987, EUR J BIOCHEM, V163, P97, DOI 10.1111/j.1432-1033.1987.tb10741.x; PHILLIPS JD, 1990, J BIOL CHEM, V265, P20813; RAWLINGS ND, 1991, BIOCHEM J, V275, P389, DOI 10.1042/bj2750389; SCHMITT ME, 1990, J BIOL CHEM, V265, P17005; SCHOPPINK PJ, 1989, BIOCHIM BIOPHYS ACTA, V974, P192, DOI 10.1016/S0005-2728(89)80372-X; Striebel HM, 1996, ARCH BIOCHEM BIOPHYS, V335, P211, DOI 10.1006/abbi.1996.0500; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; YANG XH, 1988, J BIOL CHEM, V263, P11962; YU CA, 1994, J MOL BIOL, V243, P802, DOI 10.1016/0022-2836(94)90051-5; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YUE WH, 1991, BIOCHEMISTRY-US, V30, P2303, DOI 10.1021/bi00223a002	34	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20752	20757		10.1074/jbc.273.33.20752	http://dx.doi.org/10.1074/jbc.273.33.20752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694818	hybrid			2022-12-27	WOS:000075386100011
J	Ekberg, M; Potsch, S; Sandin, E; Thunnissen, M; Nordlund, P; Sahlin, M; Sjoberg, BM				Ekberg, M; Potsch, S; Sandin, E; Thunnissen, M; Nordlund, P; Sahlin, M; Sjoberg, BM			Preserved catalytic activity in an engineered ribonucleotide reductase R2 protein with a nonphysiological radical transfer pathway - The importance of hydrogen bond connections between the participating residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; SITE-DIRECTED MUTAGENESIS; ELECTRON-TRANSFER COMPLEX; ESCHERICHIA-COLI; 2'-AZIDO-2'-DEOXYURIDINE 5'-DIPHOSPHATE; HYPOTHETICAL MODEL; PROMOTER SYSTEM; R1; MECHANISM; KINETICS	A hydrogen-bonded catalytic radical transfer pathway in Escherichia coli ribonucleotide reductase (RNR) is evident from the three-dimensional structures of the R1 and R2 proteins, phylogenetic studies, and site-directed mutagenesis experiments, Current knowledge of electron transfer processes is difficult to apply to the very long radical transfer pathway in RNR, To explore the importance of the hydrogen bonds between the participating residues, we converted the protein R2 residue Asp(237), one of the conserved residues along the radical transfer route, to an asparagine and a glutamate residue in two separate mutant proteins. In this study, me show that the D237E mutant is catalytically active and has hydrogen bond connections similar to that of the wild type protein. This is the first reported mutant protein that affects the radical transfer pathway while catalytic activity is preserved. The D237N mutant is catalytically inactive, and its tyrosyl radical is unstable, although the mutant can form a diferric-oxo iron center and a R1-R2 complex. The data strongly support our hypothesis that an absolute requirement for radical transfer during catalysis in ribonucleotide reductase is an intact hydrogen-bonded pathway between the radical site in protein R2 and the substrate binding site in R1, Our data thus strongly favor the idea that the electron transfer mechanism in RNR is coupled with proton transfer, i.e. a radical transfer mechanism.	Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden; Univ Stockholm, Dept Biophys, S-10691 Stockholm, Sweden	Stockholm University; Stockholm University	Sjoberg, BM (corresponding author), Univ Stockholm, Dept Mol Biol, S-10691 Stockholm, Sweden.	Britt-Marie.Sjoberg@molbio.su.se	Thunnissen, Marjolein MGM/B-9366-2011	Sjoberg, Britt-Marie/0000-0001-5953-3360				ABERG A, 1989, J BIOL CHEM, V264, P12249; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERATAN DN, 1991, SCIENCE, V252, P1285, DOI 10.1126/science.1656523; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8015, DOI 10.1021/ja00097a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; DEREGE PJF, 1995, SCIENCE, V269, P1409, DOI 10.1126/science.7660123; DOBELN UV, 1976, J BIOL CHEM, V251, P3616; Ekberg M, 1996, J BIOL CHEM, V271, P20655, DOI 10.1074/jbc.271.34.20655; Eriksson M, 1997, STRUCTURE, V5, P1077, DOI 10.1016/S0969-2126(97)00259-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HAZZARD JT, 1987, BIOCHEMISTRY-US, V26, P2836, DOI 10.1021/bi00384a027; HO PS, 1985, J AM CHEM SOC, V107, P1070, DOI 10.1021/ja00290a059; Katterle B, 1997, J BIOL CHEM, V272, P10414; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; LASSMANN G, 1992, BIOCHEM BIOPH RES CO, V188, P879, DOI 10.1016/0006-291X(92)91138-G; Logan DT, 1996, STRUCTURE, V4, P1053, DOI 10.1016/S0969-2126(96)00112-8; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; NORDLUND P, 1989, FEBS LETT, V258, P251, DOI 10.1016/0014-5793(89)81666-7; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Persson AL, 1997, J BIOL CHEM, V272, P31533, DOI 10.1074/jbc.272.50.31533; Persson BO, 1996, J BIOL INORG CHEM, V1, P247, DOI 10.1007/s007750050050; PERSSON BO, 1997, THESIS STOCKHOLM U S; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1980, J BIOL CHEM, V255, P322; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SAHLIN M, 1990, BIOCHEM BIOPH RES CO, V167, P813, DOI 10.1016/0006-291X(90)92098-K; SALOWE S, 1993, BIOCHEMISTRY-US, V32, P12749, DOI 10.1021/bi00210a026; SCHMIDT PP, 1998, IN PRESS J BIOL CHEM, V273; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1983, J BIOL CHEM, V258, P8060; SJOBERG BM, 1986, J BIOL CHEM, V261, P5658; Stubbe JA, 1995, CHEM BIOL, V2, P793, DOI 10.1016/1074-5521(95)90084-5; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Thelander L, 1978, Methods Enzymol, V51, P227; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; VANDERDONK WA, 1995, J AM CHEM SOC, V117, P8908, DOI 10.1021/ja00140a003; WALDMEYER B, 1982, J BIOL CHEM, V257, P6073; WANG JM, 1990, BIOCHEMISTRY-US, V29, P7160, DOI 10.1021/bi00483a003	50	64	65	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21003	21008		10.1074/jbc.273.33.21003	http://dx.doi.org/10.1074/jbc.273.33.21003			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694851	hybrid			2022-12-27	WOS:000075386100044
J	Furuchi, T; Anderson, RGW				Furuchi, T; Anderson, RGW			Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; DENSITY-LIPOPROTEIN RECEPTOR; PLASMA-MEMBRANE; MEDIATED TRANSPORT; MA104 CELLS; SR-BI; PROTEIN; GROWTH; COMPONENT; BINDING	Previously we showed that activation of Erk in quiescent cells occurs in the caveolae fraction isolated from fibroblasts. Since the structure and function of caveolae is sensitive to the amount of cholesterol in the membrane, it might be that a direct link exists between the concentration of membrane cholesterol and mitogen-activated protein (LAP) kinase activation. We acutely lowered the cholesterol level of the caveolae fraction by incubating Rat-1 cells in the presence of either cyclodextrin or progesterone, Cholesterol-depleted caveolae had a reduced amount of several key protein components of the MAP kinase complex, including Pas, GrbB, Erk2, and Src. Incubation of these cells in the presence of epidermal growth factor (EGF) caused a rapid loss of EGF receptor from the caveolae fraction, but the usual recruitment of c-Raf was markedly inhibited. Despite the reduced amount of c-Raf and Erk2 in the cholesterol-depleted caveolae fraction, EGF caused a hyperactivation of the remaining caveolae Erk isoenzymes. This was followed by an increase in the amount of active Erk in the cytoplasm, The increased amount of activated Erk produced under these conditions was linked to a 8-fold higher level of EGF-stimulated DNA synthesis. Even cholesterol depletion by itself stimulated Erk activation and DNA synthesis. These results suggest that the MAP kinase pathway can connect the cholesterol level of caveolae membrane to the control of cell division.	Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ANDERSON RGW, 1998, IN PRESS ANN REV BIO, V67; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Baorto DM, 1997, NATURE, V389, P636, DOI 10.1038/39376; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; GAMBLE W, 1978, J LIPID RES, V19, P1068; IALTABA AR, 1997, CELL, V90, P193; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Perrimon N, 1996, CELL, V86, P513, DOI 10.1016/S0092-8674(00)80124-5; Pomerantz KB, 1997, BIOCHEMISTRY-US, V36, P9523, DOI 10.1021/bi963069l; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554	38	327	332	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21099	21104		10.1074/jbc.273.33.21099	http://dx.doi.org/10.1074/jbc.273.33.21099			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694863	hybrid			2022-12-27	WOS:000075386100056
J	Liu, ST; Chang, WZ; Cao, HM; Hu, HL; Chen, ZH; Ni, FD; Lu, HF; Hong, GF				Liu, ST; Chang, WZ; Cao, HM; Hu, HL; Chen, ZH; Ni, FD; Lu, HF; Hong, GF			A HU-like protein binds to specific sites within nod promoters of Rhizobium leguminosarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-LIKE PROTEINS; ESCHERICHIA-COLI; GENE-EXPRESSION; RNA-POLYMERASE; LAC PROMOTER; DNA; NODULATION; COMPLEXES; MELILOTI; CHROMATOGRAPHY	Nodulation genes (nod) of rhizobia are essential for establishment of its symbiosis with specific legume hosts and are usually located on the Sym(biosis) megaplasmid, In this work we identified a new Sym plasmid independent protein in Rhizobium leguminosarum, Pr, by its ability to bind to nod promoters and induce DNA bending. Depending upon its concentrations relative to DNA templates, Pr could either stimulate or inhibit in vitro transcription of the major regulatory nodulation gene nodD. This may result from its property to bind to specific sites within nod promoters at lower concentration or in the presence of competitor calf thymus DNA but nonspecifically associate with DNA at higher levels or in the absence of competitors. Its binding sites within nodD and nodF promoters were determined by DNase I footprinting but showed no sequence consensus. N-terminal sequencing and Western blot revealed that Pr belongs to the HU class of prokaryotic histone-like proteins. Its binding feature and functioning mechanism were discussed in the Light of this discovery.	Chinese Acad Sci, Shanghai Inst Biochem, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Hong, GF (corresponding author), Chinese Acad Sci, Shanghai Inst Biochem, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Liu, Song-Tao/Y-4732-2019; chen, zehua/H-1260-2011	Liu, Song-Tao/0000-0002-9623-8579				Aki T, 1997, EMBO J, V16, P3666, DOI 10.1093/emboj/16.12.3666; BAGDASARIAN M, 1981, GENE, V16, P237, DOI 10.1016/0378-1119(81)90080-9; BIANCHI ME, 1994, MOL MICROBIOL, V14, P1, DOI 10.1111/j.1365-2958.1994.tb01261.x; BONNEFOY E, 1994, J MOL BIOL, V242, P116, DOI 10.1006/jmbi.1994.1563; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CAO HM, 1992, CHINESE SCI BULL, V37, P951; CASTAING B, 1995, J BIOL CHEM, V270, P10291, DOI 10.1074/jbc.270.17.10291; CHANG WZ, 1997, CHIN J BIOTECHNOL, V13, P83; CHANG WZ, 1996, THESIS CHINESE ACAD; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; FLASHNER Y, 1988, CELL, V54, P713, DOI 10.1016/S0092-8674(88)80016-3; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; KHANAKA H, 1985, EUR J BIOCHEM, V147, P343, DOI 10.1111/j.1432-1033.1985.tb08755.x; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; KONDOROSI E, 1989, EMBO J, V8, P1331, DOI 10.1002/j.1460-2075.1989.tb03513.x; KONDOROSI E, 1991, J MOL BIOL, V222, P885, DOI 10.1016/0022-2836(91)90583-R; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LAMB JW, 1985, GENE, V34, P235, DOI 10.1016/0378-1119(85)90132-5; LAVOIE BD, 1993, GENE DEV, V7, P2510, DOI 10.1101/gad.7.12b.2510; LI M, 1993, TRANSCRIPTION FACTOR, P49; MAVRIDOU A, 1995, MICROBIOL-UK, V141, P103, DOI 10.1099/00221287-141-1-103; OGAWA J, 1995, GENE DEV, V9, P714, DOI 10.1101/gad.9.6.714; PEREZMARTIN J, 1994, MICROBIOL REV, V58, P268; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; PREOBRAJENSKAYA O, 1994, MOL MICROBIOL, V13, P459, DOI 10.1111/j.1365-2958.1994.tb00440.x; Pueppke SG, 1996, CRIT REV BIOTECHNOL, V16, P1, DOI 10.3109/07388559609146599; ROSSEN L, 1985, EMBO J, V4, P3369, DOI 10.1002/j.1460-2075.1985.tb04092.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALLER H, 1972, EUR J BIOCHEM, V26, P474, DOI 10.1111/j.1432-1033.1972.tb01789.x; SCHLAMAN HRM, 1992, J BACTERIOL, V174, P5177, DOI 10.1128/JB.174.16.5177-5182.1992; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SERRANO M, 1993, TRENDS BIOCHEM SCI, V18, P202, DOI 10.1016/0968-0004(93)90187-R; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SHINDO H, 1992, NUCLEIC ACIDS RES, V20, P1553, DOI 10.1093/nar/20.7.1553; STERNBACH H, 1975, EUR J BIOCHEM, V60, P51, DOI 10.1111/j.1432-1033.1975.tb20974.x; TAGAMI H, 1995, NUCLEIC ACIDS RES, V23, P599, DOI 10.1093/nar/23.4.599; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; VANRHIJN P, 1995, MICROBIOL REV, V59, P124, DOI 10.1128/MMBR.59.1.124-142.1995; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Yasukawa H, 1997, MOL GEN GENET, V254, P548, DOI 10.1007/s004380050450; YELTON MM, 1987, J BACTERIOL, V169, P3094, DOI 10.1128/jb.169.7.3094-3098.1987	46	15	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20568	20574		10.1074/jbc.273.32.20568	http://dx.doi.org/10.1074/jbc.273.32.20568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685414	hybrid			2022-12-27	WOS:000075305400091
J	Sawaya, BE; Khalili, K; Mercer, WE; Denisova, L; Amini, S				Sawaya, BE; Khalili, K; Mercer, WE; Denisova, L; Amini, S			Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; WILD-TYPE P53; CELL-CYCLE; VIRION INCORPORATION; MUTATIONAL ANALYSIS; PROTEIN; ACTIVATION; ARRESTS; DOMAIN	Transcription of the human immunodeficiency virus type-1 (HIV-1) genome is controlled by cooperative interaction of viral encoded proteins and host regulatory proteins. In this study, we have examined the capacity of the viral auxiliary protein, Vpr, to modulate transcriptional activity of the HIV-1 promoter sequence located within the long terminal repeat (LTR), We demonstrate that ectopic expression of Vpr in human astrocytic cells, U-87MG, enhances the basal activity of the viral promoter in transfected cells and that the GC-rich sequences, spanning nucleotides -80 to -43, are important for this activity. Since this region serves as the target for p53-induced suppression of LTR activity and interacts with the ubiquitous transcription factor, Spl, we examined the cooperative activity of Vpr, p53, and Spl upon LTR transcription. Results from co-transfection studies indicated that overexpression of wild type p53, but not mutant p53, decreases the level of activation of the LTR by Vpr. Transcriptional activation of the LTR by Vpr required the presence of Spl since overexpression of Vpr in cells with no endogenous Spl failed to augment LTR activity. Results from protein-protein interaction studies indicated that Vpr is associated with both p53 and Spl in cells with ectopic expression of these proteins. Moreover, it was evident that p53 and Spl interact with each other in these cells. These functional and structural studies provided a working model on the cooperative interaction of Vpr with cellular proteins Spl and p53 and control of viral gene transcription at immediate early stage of infection prior to the participation of other viral regulatory proteins.	Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Drexel University; Jefferson University	Amini, S (corresponding author), Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, 245 N 15th St,Mailstop 406, Philadelphia, PA 19102 USA.	amini@auhs.edu						Agostini I, 1996, J MOL BIOL, V261, P599, DOI 10.1006/jmbi.1996.0485; ARRIGO SJ, 1990, J VIROL, V64, P4585, DOI 10.1128/JVI.64.9.4585-4588.1990; Ausubel FM, 1988, MOL REPROD DEV; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kundu M, 1997, J BIOL CHEM, V272, P29468, DOI 10.1074/jbc.272.47.29468; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; LEGROS Y, 1994, ONCOGENE, V9, P2071; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; MAHALINGAM S, 1995, VIROLOGY, V207, P297, DOI 10.1006/viro.1995.1081; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Serio D, 1997, P NATL ACAD SCI USA, V94, P3346, DOI 10.1073/pnas.94.7.3346; Shaw PH, 1996, PATHOL RES PRACT, V192, P669, DOI 10.1016/S0344-0338(96)80088-4; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; SUBLER MA, 1994, J VIROL, V68, P103, DOI 10.1128/JVI.68.1.103-110.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZEICHNER SL, 1991, J VIROL, V65, P2436, DOI 10.1128/JVI.65.5.2436-2444.1991; Zhao YQ, 1996, J VIROL, V70, P5821, DOI 10.1128/JVI.70.9.5821-5826.1996; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	46	84	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20052	20057		10.1074/jbc.273.32.20052	http://dx.doi.org/10.1074/jbc.273.32.20052			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685344	hybrid			2022-12-27	WOS:000075305400021
J	Steffensen, B; Bigg, HF; Overall, CM				Steffensen, B; Bigg, HF; Overall, CM			The involvement of the fibronectin type II-like modules of human gelatinase A in cell surface localization and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; IV COLLAGENASE; 72-KDA GELATINASE; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; PROGELATINASE-A; BINDING; EXPRESSION; METALLOPROTEINASES; 92-KDA	Recombinant collagen-binding domain (rCBD) comprising the three fibronectin type II-like modules of human gelatinase A was found to compete the zymogen form of this matrix metalloproteinase from the cell surface of normal human fibroblasts in culture. Upon concanavalin A treatment of cells, the induced cellular activation of gelatinase A was markedly elevated in the presence of the rCBD. Therefore, the mechanistic aspects of gelatinase A binding to cells by this domain were further studied using cell attachment assays. Fibroblasts attached to rCBD-coated microplate wells in a manner that was inhibited by soluble rCBD, blocking antibodies to the beta(1)-integrin subunit but not the cu,integrin subunit, and bacterial collagenase treatment. Addition of soluble collagen rescued the attachment of collagenase-treated cells to the rCBD. As a probe on ligand blots of octyl-beta-D-thioglucopyranoside-solubilized cell membrane extracts, the rCBD bound 140- and 160-kDa protein bands. Their identities were likely procollagen chains being both bacterial collagenase-sensitive and also converted upon pepsin digestion to 112- and 126-kDa bands that co-migrated with collagen arl(I) and alpha 2(I) chains. A rCBD mutant protein (Lys(263) --> Ala) with reduced collagen affinity showed less cell attachment, whereas a heparin-binding deficient mutant (Lys(357) --> Ala), heparinase treatment, or heparin addition did not alter attachment. Thus, a cell-binding mechanism for gelatinase A is revealed that does not involve the hemopexin COOH domain. Instead, an attachment complex comprising gelatinase A-native type I collagen-beta(1)-integrin forms as a result of interactions involving the collagen-binding domain of the enzyme. Moreover, this distinct pool of cell collagen-bound proenzyme appears recalcitrant to cellular activation.	Univ British Columbia, Fac Dent, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Fac Med, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Univ British Columbia, Fac Dent, 2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.							BANYAI L, 1991, FEBS LETT, V282, P23, DOI 10.1016/0014-5793(91)80436-7; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWN PD, 1990, CANCER RES, V50, P6184; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; EMONARD HP, 1992, CANCER RES, V52, P5845; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HEMLER ME, 1988, IMMUNOL TODAY, V9, P109, DOI 10.1016/0167-5699(88)91280-7; KEUNG W, 1989, ANAL BIOCHEM, V182, P16; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OVERALL CM, 1988, BIOCHEM J, V256, P965, DOI 10.1042/bj2560965; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; OVERALL CM, 1998, IN PRESS INHIBITORS; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; SEFTOR REB, 1993, CANCER RES, V53, P3411; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SODEK J, 1981, CALCIFIED TISSUE INT, V33, P255, DOI 10.1007/BF02409446; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	37	80	80	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20622	20628		10.1074/jbc.273.32.20622	http://dx.doi.org/10.1074/jbc.273.32.20622			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685420	hybrid			2022-12-27	WOS:000075305400097
J	Uchida, T; Ishikawa, H; Takahashi, S; Ishimori, K; Morishima, I; Ohkubo, K; Nakajima, H; Aono, S				Uchida, T; Ishikawa, H; Takahashi, S; Ishimori, K; Morishima, I; Ohkubo, K; Nakajima, H; Aono, S			Heme environmental structure of CooA is modulated by the target DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; CARBON-MONOXIDE DEHYDROGENASE; RESONANCE RAMAN-SCATTERING; RHODOSPIRILLUM-RUBRUM; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATOR; B-DNA; COMPLEX; DISTAL; HYDROGENASE	In order to investigate the gene activation mechanism triggered by the CO binding to CooA, a heme-containing transcriptional activator, the heme environmental structure and the dynamics of the CO rebinding and dissociation have been examined in the absence and presence of its target DNA. In the absence of DNA, the Fe-CO and C=O stretching Raman lines of the GO-bound CooA were observed at 487 and 1969 cm(-l), respectively, suggesting that a neutral histidine is an axial ligand trans to CO. The frequency of nu(Fe-CO) implies an open conformation of the distal heme pocket, indicating that the Ligand replaced by CO is located away from the bound CO. When the target DNA was added to GO-bound CooA, an appearance of a new nu(Fe-CO) line at 519 cm(-l) and narrowing of the main line at 486 cm(-1) were observed. Although the rate of the CO dissociation was insensitive to the additions of DNA, the CO rebinding was decelerated in the presence of the target DNA, but not in the presence of nonsense DNA. These observations demonstrate the structural alterations in the heme distal site in response to binding of the target DNA and support the activation mechanism proposed for CooA, which is triggered by the movement of the heme distal ligand to modify the conformation of the DNA binding domain.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan; Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan	Kyoto University; Japan Advanced Institute of Science & Technology (JAIST)	Morishima, I (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6068501, Japan.		Asano, Yasuhisa/K-5898-2016; Uchida, Takeshi/A-6455-2017; Aono, Shigetoshi/ABD-7618-2020; Ohkubo, Kei/L-5002-2019; Ishimori, Koichiro/S-1247-2016; Ishikawa, Haruto/B-1562-2012; Ohkubo, Kei/E-5127-2012; Ishimori, Koichiro/AAQ-4434-2021	Asano, Yasuhisa/0000-0003-3645-3952; Uchida, Takeshi/0000-0001-9270-8329; Aono, Shigetoshi/0000-0002-2870-3694; Ohkubo, Kei/0000-0001-8328-9249; Ishimori, Koichiro/0000-0002-5868-0462; Ishikawa, Haruto/0000-0001-6362-5719; Ohkubo, Kei/0000-0001-8328-9249; Ishimori, Koichiro/0000-0002-5868-0462				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; BONAM D, 1989, J BACTERIOL, V171, P3102, DOI 10.1128/jb.171.6.3102-3107.1989; DAWSON JH, 1983, J BIOL CHEM, V258, P3637; Fox JD, 1996, J BACTERIOL, V178, P1515, DOI 10.1128/jb.178.6.1515-1524.1996; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; JEWSBURY P, 1994, BIOPHYS J, V67, P2236, DOI 10.1016/S0006-3495(94)80708-8; KERBY RL, 1995, J BACTERIOL, V177, P2241, DOI 10.1128/jb.177.8.2241-2244.1995; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; Kerby RL, 1997, J BACTERIOL, V179, P2259, DOI 10.1128/jb.179.7.2259-2266.1997; KITAGAWA T, 1975, J BIOCHEM-TOKYO, V78, P719, DOI 10.1093/oxfordjournals.jbchem.a130960; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; LOU BS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P403, DOI 10.1016/0005-2728(93)90127-2; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; Millikan GA, 1936, PROC R SOC SER B-BIO, V120, P366, DOI 10.1098/rspb.1936.0041; MORIKIS D, 1989, BIOCHEMISTRY-US, V28, P4791, DOI 10.1021/bi00437a041; OLDFIELD E, 1991, J AM CHEM SOC, V113, P7537, DOI 10.1021/ja00020a014; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SMULEVICH G, 1994, INORG CHEM, V33, P4629, DOI 10.1021/ic00099a012; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; Uchida T, 1997, J BIOL CHEM, V272, P30108, DOI 10.1074/jbc.272.48.30108; UNO T, 1987, J BIOL CHEM, V262, P4549; WALLACE CJA, 1992, J BIOL CHEM, V267, P3852; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WITTENBERG BA, 1965, ARCH BIOCHEM BIOPHYS, V111, P576, DOI 10.1016/0003-9861(65)90237-7; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	37	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19988	19992		10.1074/jbc.273.32.19988	http://dx.doi.org/10.1074/jbc.273.32.19988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685335	hybrid			2022-12-27	WOS:000075305400012
J	Barbieri, MA; Kohn, AD; Roth, RA; Stahl, PD				Barbieri, MA; Kohn, AD; Roth, RA; Stahl, PD			Protein kinase B/akt and Rab5 mediate ras activation of endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASE RAB5; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; ENDOSOME FUSION; SER/THR KINASE; AKT; INHIBITION	Transient expression of oncogenic Ha-Ras (Ras:V12) stimulates endocytosis. Using NIH3T3 cells expressing constitutively active protein kinase B/akt (PKB/akt) or kinase-dead PKB/akt, we show that PKB/akt mediates the stimulatory effect of Ras on endocytosis. Fluid phase endocytosis of horseradish peroxidase in cells expressing the constitutively active form of PKB/akt was elevated and insensitive to phosphatidylinositol 3-kinase inhibitors. However, expression of dominant negative Rab5:N34 blocked endocytosis in cells expressing the constitutively active form of PKB/akt. Transient expression of either Rab5:wt or Rab5:L79, a GTPase deficient mutant of Rab5, in cells expressing constitutively activated PKB/akt further increased endocytic rate. However, in cells expressing kinase-dead PKB/akt, endocytic rate was not affected by transient expression of Rab5:wt, Rab5:L79, on the other hand, increased endocytosis in cells expressing kinase-dead PKB/akt. Similar results were obtained using an in vitro endosome fusion reconstitution assay with cytosol prepared from cells expressing the activated PKB/akt or kinase-dead PKB/akt. Both Rab5:wt and Rab5:L79 stimulated endosome fusion when assayed in cytosol containing the activated PKB/akt, whereas only Rab5:L79 activated fusion when the assay utilized cytosol from kinase-dead expressing cells. We conclude that Ras activation of endocytosis requires both PKB/akt and Rab5 and that active kinase is required for activation Rab5.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Palo Alto, CA 94305 USA	Washington University (WUSTL); Stanford University	Stahl, PD (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA.	pstahl@cellbio.wustl.edu	Stahl, Philip/D-6315-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034926, P30DK020579, P60DK020579, R01DK034926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20579, DK34926] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIAZ R, 1988, J BIOL CHEM, V263, P6093; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Jones AT, 1998, MOL BIOL CELL, V9, P323, DOI 10.1091/mbc.9.2.323; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; Li GP, 1997, J BIOL CHEM, V272, P10337; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOKER A, 1994, J BIOL CHEM, V269, P32358	31	68	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19367	19370		10.1074/jbc.273.31.19367	http://dx.doi.org/10.1074/jbc.273.31.19367			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677351	hybrid			2022-12-27	WOS:000075125200003
J	Lee, SK; Qing, WG; Mar, W; Luyengi, L; Mehta, RG; Kawanishi, K; Fong, HHS; Beecher, CWW; Kinghorn, AD; Pezzuto, JM				Lee, SK; Qing, WG; Mar, W; Luyengi, L; Mehta, RG; Kawanishi, K; Fong, HHS; Beecher, CWW; Kinghorn, AD; Pezzuto, JM			Angoline and chelerythrine, benzophenanthridine alkaloids that do not inhibit protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE ACTIVITY; MITOCHONDRIAL-FRACTION; PHORBOL ESTERS; RAT RETINA; CELLS; ACTIVATION; POTENT; PHOSPHORYLATION; INVOLVEMENT; EXPRESSION	Starting with an extract derived from the I;tem of Macleaya cordata (Papaveraceae) that was active in the process of inhibiting phorbol 12,13-dibutyrate binding to partially purified protein kinase C (PI(C), the benzophenanthridine alkaloid angoline was isolated and identified. This discovery appeared in context, as a related benzophenanthridine alkaloid, chelerythrine, has been reported to mediate a variety of biological activities, including potent and selective inhibition of protein kinase C (PKC). However, in our studies, angoline was not observed to function as a potent inhibitor of PHC. Moreover, we were unable to confirm the reported inhibitory activity of chelerythrine. In a comprehensive series of studies performed with various PKC isozymes derived from a variety of mammalian species, neither chelerythrine nor angoline inhibited activity with high potency. To the contrary, chelerythrine stimulated PKC activity in the cytosolic fractions of rat and mouse brain in concentrations up to 100 mu M. In addition, chelerythrine and angoline did not inhibit [H-3]phorbol 12,13-dibutyrate binding to the regulatory domain of PKC at concentrations up to 40 mu g/ml, and no significant; alteration of PKC-alpha, -beta, or -gamma translocation was observed with human leukemia (HL-60) cells in culture. Fur ther, chelerythrine did not inhibit 12-O-tetradecanoylphorbol 13-acetate-induced ornithine decarboxylase activity with cultured mouse 308 cells, but angoline was active in this capacity with an IC50 value of 1.0 mu g/ml. AI relatively large number of biological responses have been reported in studies conducted with chelerythrine, and alteration of PI(C activity has been considered as a potential mechanism of action. In light of the current report, mechanisms independent of PKC inhibition should be considered as responsible for these effects.	Univ Illinois, Coll Pharm, Program Collaborat Res Pharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Surg Oncol, Chicago, IL 60612 USA; Seoul Natl Univ, Inst Nat Prod Res, Seoul 110460, South Korea; Kobe Pharmaceut Univ, Kobe, Hyogo 658, Japan	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Seoul National University (SNU); Kobe Pharmaceutical University	Pezzuto, JM (corresponding author), Univ Illinois, Coll Pharm, Program Collaborat Res Pharmaceut Sci, M-C 877,833 S Wood St, Chicago, IL 60612 USA.			Kinghorn, A. Douglas/0000-0002-6647-8707	NATIONAL CANCER INSTITUTE [P01CA048112] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA48112] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COSTAGNA M, 1987, BIOL CELL, V59, P3; DASILVA C, 1990, CANCER RES, V50, P2081; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVRIES DJ, 1988, BIOCHEM PHARMACOL, V37, P4069, DOI 10.1016/0006-2952(88)90097-4; FONZES L, 1968, PHYTOCHEMISTRY, V7, P1889, DOI 10.1016/S0031-9422(00)86668-6; Gopalakrishna R., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P615; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HERBERT JM, 1993, THROMB RES, V71, P487, DOI 10.1016/0049-3848(93)90122-5; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; Hoelting T, 1997, CANCER LETT, V119, P1, DOI 10.1016/S0304-3835(97)00242-5; KO FN, 1990, BIOCHIM BIOPHYS ACTA, V1052, P360, DOI 10.1016/0167-4889(90)90144-3; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KRANE BD, 1984, J NAT PROD, V47, P1, DOI 10.1021/np50031a001; LARSEN AK, 1994, BBA-MOL CELL RES, V1222, P477, DOI 10.1016/0167-4889(94)90057-4; LENFELD J, 1981, PLANTA MED, V43, P161, DOI 10.1055/s-2007-971493; LICHTI U, 1982, J CELL PHYSIOL, V113, P433, DOI 10.1002/jcp.1041130312; Lombardini JB, 1996, BIOCHEM PHARMACOL, V52, P253, DOI 10.1016/0006-2952(96)00202-X; LOMBARDINI JB, 1995, BRAIN RES, V673, P194, DOI 10.1016/0006-8993(94)01369-S; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MCLEAN DB, 1969, CAN J CHEM, V47, P1951; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTTE AP, 1992, CELL, V68, P1021, DOI 10.1016/0092-8674(92)90074-M; SHARMA PN, 1979, INDIAN J CHEM B, V17, P299; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TSENG CP, 1994, CARCINOGENESIS, V15, P707, DOI 10.1093/carcin/15.4.707; VERMA AK, 1986, CANCER RES, V46, P6149; VONSTEBUT E, 1994, AGENTS ACTIONS, V41, pC56; WALTEROVA D, 1981, J MED CHEM, V24, P1103; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WOLFF J, 1993, BIOCHEMISTRY-US, V32, P13334, DOI 10.1021/bi00211a047; ZOUKHRI D, 1993, AM J PHYSIOL, V264, pC1045, DOI 10.1152/ajpcell.1993.264.4.C1045	37	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19829	19833		10.1074/jbc.273.31.19829	http://dx.doi.org/10.1074/jbc.273.31.19829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677417	hybrid			2022-12-27	WOS:000075125200069
J	Lelievre, V; Pineau, N; Du, J; Wen, CH; Nguyen, T; Janet, T; Muller, JM; Waschek, JA				Lelievre, V; Pineau, N; Du, J; Wen, CH; Nguyen, T; Janet, T; Muller, JM; Waschek, JA			Differential effects of peptide histidine isoleucine (PHI) and related peptides on stimulation and suppression of neuroblastoma cell proliferation - A novel VIP-independent action of PHI via map kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; 38-AMINO ACID FORM; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; PACAP RECEPTOR; FUNCTIONAL EXPRESSION; SELECTIVE INHIBITOR; MOLECULAR-CLONING; NEURITE OUTGROWTH	The growth rate of rodent embryonic neuroblasts and human neuroblastoma cell lines is regulated in part by autocrine or paracrine actions of neuropeptides of the family that includes vasoactive intestinal peptide (VIP), peptide histidine isoleucine (PHI), and pituitary adenylate cyclase-activating peptide (PACAP). These peptides act via seven transmembrane G-protein-linked receptors coupled to cAMP elevation, phospholipase C activation, intracellular Ca2+ release, and/or of mitogen-activated protein (MAP) kinase activation. Here we investigated the action of these peptides on the mouse neuroblastoma cell line Neuro2a PHI and VIP inhibited proliferation at concentrations as low as 10(-13) ns and 10(-10) M, respectively. In contrast, PACAP action was biphasic, with stimulation occurring at subnanomolar doses and inhibition at higher doses. Peptide actions were studied further by measuring cAMP and ERK1/2 MAP kinase activity and by assessing H-3-thymidine in corporation in conjunction with a panel of signal transduction pathways inhibitors. The data obtained indicated that the PHI-inhibitory and PACAP-stimulatory activities were mediated by corresponding changes in activity of the MAP kinase pathway and independent of protein kinase A (PRA) or protein kinase C (PKC). In contrast, the inhibitory actions of VIP and PACAP were specifically blocked by antagonists of PKA Northern blot analysis revealed gene expression for only the PACAP-preferring (PAC(1)) receptor. However, binding experiments using I-125-labeled PACAP27, PHI, and VIP, demonstrated the presence of PACAP-preferring sites, bivalent VIP/PACAP sites, and PHI-binding sites that did not interact with VIP. The studies demonstrate potent regulatory actions of PACAP, PHI, and VIP on neuroblastoma cell proliferation which al,pear to be mediated by multiple subsets of receptors which differentially couple to MAP kinase and PKA signaling pathways.	Univ Calif Los Angeles, Inst Neuropsychiat, Mental Retardat Res Ctr, Dept Psychiat, Los Angeles, CA 90024 USA; Univ Poitiers, UFR Sci, Lab Biol Interact Cellulaires, CNRS UMR 6558, F-86022 Poitiers, France	University of California System; University of California Los Angeles; Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers	Waschek, JA (corresponding author), Univ Calif Los Angeles, Inst Neuropsychiat, Mental Retardat Res Ctr, Dept Psychiat, 68-225 NPI,760 Westwood Plaza, Los Angeles, CA 90024 USA.	jwaschek@mednet.ucla.edu		Muller, Jean-Marc/0000-0001-6009-7471; Lelievre, Vincent/0000-0003-4150-8233	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD004612] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034475, P01HD006576] Funding Source: NIH RePORTER; NICHD NIH HHS [HD06576, HD04612, HD34475] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDER LD, 1995, NEUROPEPTIDES, V28, P167, DOI 10.1016/0143-4179(95)90112-4; Barrie AP, 1997, J BIOL CHEM, V272, P19666, DOI 10.1074/jbc.272.32.19666; Chatterjee TK, 1996, J BIOL CHEM, V271, P32226, DOI 10.1074/jbc.271.50.32226; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHISTOPHE J, 1993, BBRC, V1154, P183; DEUTSCH PJ, 1993, J NEUROSCI RES, V35, P312, DOI 10.1002/jnr.490350311; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; HANNIBAL J, 1995, REGUL PEPTIDES, V55, P133, DOI 10.1016/0167-0115(94)00099-J; HARMAR AJ, 1998, IN PRESS PHARM REV; HOSHINO M, 1993, NEUROSCI LETT, V159, P35, DOI 10.1016/0304-3940(93)90792-J; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ITOH N, 1983, NATURE, V304, P547, DOI 10.1038/304547a0; Jin JG, 1997, GASTROENTEROLOGY, V112, pA1159; JOURNOT L, 1995, BIOCHEM SOC T, V23, P133, DOI 10.1042/bst0230133; KOH SWM, 1991, BIOCHEM BIOPH RES CO, V174, P452, DOI 10.1016/0006-291X(91)91437-H; Lelievre V, 1996, NEUROPEPTIDES, V30, P313, DOI 10.1016/S0143-4179(96)90019-0; LUTZ EM, 1993, FEBS LETT, V334, P3, DOI 10.1016/0014-5793(93)81668-P; MULLER JM, 1989, J BIOL CHEM, V264, P3647; MULLER JM, 1995, MOL NEUROBIOL, V10, P115, DOI 10.1007/BF02740671; MURTHY KS, 1993, AM J PHYSIOL, V265, pG660, DOI 10.1152/ajpgi.1993.265.4.G660; ODORISIO MS, 1992, REGUL PEPTIDES, V37, P213; OHKUBO S, 1992, DNA CELL BIOL, V11, P21, DOI 10.1089/dna.1992.11.21; Pantaloni C, 1996, J BIOL CHEM, V271, P22146, DOI 10.1074/jbc.271.36.22146; PAUL S, 1987, LIFE SCI, V41, P2373, DOI 10.1016/0024-3205(87)90661-8; PENCE JC, 1993, ARCH SURG-CHICAGO, V128, P591; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Prins BA, 1996, J BIOL CHEM, V271, P14156, DOI 10.1074/jbc.271.24.14156; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; SAID SI, 1991, TRENDS ENDOCRIN MET, V2, P107, DOI 10.1016/S1043-2760(05)80006-2; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Straub SG, 1996, J BIOL CHEM, V271, P1660, DOI 10.1074/jbc.271.3.1660; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vertongen P, 1996, NEUROPEPTIDES, V30, P491, DOI 10.1016/S0143-4179(96)90015-3; Vertongen P, 1996, J CELL PHYSIOL, V167, P36, DOI 10.1002/(SICI)1097-4652(199604)167:1<36::AID-JCP4>3.0.CO;2-D; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; WASCHEK JA, 1995, CANCER LETT, V92, P143, DOI 10.1016/0304-3835(95)03768-R; Waschek JA, 1997, PEPTIDES, V18, P835, DOI 10.1016/S0196-9781(97)00015-6; WOLLMAN Y, 1993, BRAIN RES, V624, P339, DOI 10.1016/0006-8993(93)90100-2; Wray V, 1995, Biomed Pept Proteins Nucleic Acids, V1, P77; YAMAGUCHI K, 1992, BIOMED RES-TOKYO, V13, P279; YU D, ENDOCRINOLOGY, V131, P1188	42	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19685	19690		10.1074/jbc.273.31.19685	http://dx.doi.org/10.1074/jbc.273.31.19685			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677397	hybrid			2022-12-27	WOS:000075125200049
J	Tamori, Y; Kawanishi, M; Niki, T; Shinoda, H; Araki, S; Okazawa, H; Kasuga, M				Tamori, Y; Kawanishi, M; Niki, T; Shinoda, H; Araki, S; Okazawa, H; Kasuga, M			Inhibition of insulin-induced GLUT4 translocation by Munc18c through interaction with syntaxin4 in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE DOCKING; UNC-18 GENE ENCODES; RAT ADIPOSE CELL; GLUCOSE-TRANSPORT; GOLGI TRANSPORT; RECOMBINANT ADENOVIRUS; ENDOPLASMIC-RETICULUM; PLASMA-MEMBRANE; MAMMALIAN-CELLS; BINDING PROTEIN	Insulin induces the translocation of vesicles containing the glucose transporter GLUT4 from an intracellular compartment to the plasma membrane in adipocytes. SNARE proteins have been implicated in the docking and fusion of these vesicles with the cell membrane. The role of Munc18c, previously identified as an n-Sec1/Munc18 homolog in 3T3-L1 adipocytes, in insulin-regulated GLUT4 trafficking has now been investigated in 3T3-L1 adipocytes. In these cells, Munc18c was predominantly associated with syntaxin4, although it bound both syntaxin2 and syntaxin4 to similar extents in vitro. In addition, SNAP-23, an adipocyte homolog of SNAP-25, associated with both syntaxins 2 and 4 in 3T3-L1 adipocytes. Overexpression of Munc18c in 3T3-L1 adipocytes by adenovirus-mediated gene transfer resulted in inhibition of insulin-stimulated glucose transport in a virus dose-dependent manner (maximal effect, similar to 50%) as well as in inhibition of sorbitol-induced glucose transport (by similar to 35%), which is mediated by a pathway different from that used by insulin. In contrast, Munc18b, which is also expressed in adipocytes but which did not bind to syntaxin4, had no effect on glucose transport. Furthermore, overexpression of Munc18c resulted in inhibition of insulin-induced translocation of GLUT4, but not of that of GLUT1, to the plasma membrane. These results suggest that Munc18c is involved in the insulin-dependent trafficking of GLUT4 from the intracellular storage compartment to the plasma membrane in 3T3-L1 adipocytes by modulating the formation of a SNARE complex that includes syntaxin4.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 650, Japan	Kobe University	Tamori, Y (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.	gt@med.kobe-u.ac.jp	Okazawa, Hideki/C-3836-2011; Shinoda, Hiroyuki/Q-3230-2019; Okazawa, Hideki/E-3055-2010					AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COWLES CR, 1994, J CELL SCI, V107, P3449; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; DASCHER C, 1994, J BIOL CHEM, V269, P29363; FROST SC, 1985, J BIOL CHEM, V260, P2646; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HASHIRAMOTO M, 1992, J BIOL CHEM, V267, P17502; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Macaulay SL, 1997, BIOCHEM J, V324, P217, DOI 10.1042/bj3240217; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; OSSIG R, 1991, MOL CELL BIOL, V11, P2980, DOI 10.1128/MCB.11.6.2980; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; PIPER RC, 1991, AM J PHYSIOL, V260, P570; ROBINSON LJ, 1992, AM J PHYSIOL, V263, P383; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; YANG J, 1993, J BIOL CHEM, V268, P4600	60	128	129	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19740	19746		10.1074/jbc.273.31.19740	http://dx.doi.org/10.1074/jbc.273.31.19740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677404	hybrid			2022-12-27	WOS:000075125200056
J	Shuba, YM; Iwata, T; Naidenov, VG; Oz, M; Sandberg, K; Kraev, A; Carafoli, E; Morad, M				Shuba, YM; Iwata, T; Naidenov, VG; Oz, M; Sandberg, K; Kraev, A; Carafoli, E; Morad, M			A novel molecular determinant for cAMP-dependent regulation of the frog heart Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGER; FUNCTIONAL EXPRESSION; XENOPUS OOCYTES; ATP-BINDING; HELA-CELLS; CLONING; ISOFORMS; CONTRACTION; VENTRICLE; MUSCLE	Na+-Ca2+ exchanger is one of the major sarcolemmal Ca2+ transporters of cardiac myocytes, In frog ventricular myocytes the exchanger is regulated by isoproterenol via a beta-adrenoreceptor/adenylate-cyclase/cAMP-dependent signaling pathway providing a molecular mechanism for the relaxant effect of the hormone. Here, we report on the presence of a novel exon of 27-base pair insertion, which generates a nucleotide binding motif (P-loop) in the frog cardiac Na+-Ca2+ exchanger. To examine the functional role of this motif, we constructed a full-length frog heart Na+-Ca2+ exchanger cDNA (fNCX1a) containing this exon. The functional expression of fNCX1a in oocytes showed characteristic voltage dependence, divalent (Ni2+, Cd2+) inhibition, and sensitivity to cAMP in a manner similar to that of native exchanger in frog myocytes. In oocytes expressing the dog heart NCX1 or the frog mutant (Delta fNCX1a) lacking the 9-amino acid exon, cAMP failed to regulate Na+-dependent Ca2+ uptake. We suggest that this motif is responsible for the observed cAMP-dependent functional differences between the frog and the mammalian hearts.	Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; ETH Zurich, Biochem Lab, CH-8092 Zurich, Switzerland	Georgetown University; Georgetown University; ETH Zurich	Morad, M (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	moradm@gunet.georgetown.edu	Oz, Murat/E-2148-2012; Carafoli, Ernesto/K-5192-2016; Shuba, Yaroslav/AAT-6758-2021	Carafoli, Ernesto/0000-0002-7826-0094; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016152] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL16152-22] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; FABIATO A, 1998, METHOD ENZYMOL, V157, P358; Fan J, 1996, P NATL ACAD SCI USA, V93, P5527, DOI 10.1073/pnas.93.11.5527; FISCHMEISTER R, 1986, J PHYSIOL-LONDON, V376, P183, DOI 10.1113/jphysiol.1986.sp016148; Flesch M, 1996, CIRCULATION, V94, P992, DOI 10.1161/01.CIR.94.5.992; FURMAN I, 1993, FEBS LETT, V319, P105, DOI 10.1016/0014-5793(93)80046-W; HATEM SN, 1994, CIRC RES, V74, P253, DOI 10.1161/01.RES.74.2.253; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Iwata T, 1996, ANN NY ACAD SCI, V779, P37, DOI 10.1111/j.1749-6632.1996.tb44768.x; KOFUJI P, 1993, AM J PHYSIOL, V265, pF598, DOI 10.1152/ajprenal.1993.265.4.F598; KOMURO I, 1992, P NATL ACAD SCI USA, V89, P4769, DOI 10.1073/pnas.89.10.4769; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; Kraev A, 1996, ANN NY ACAD SCI, V779, P103, DOI 10.1111/j.1749-6632.1996.tb44774.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUREBAYASHI N, 1993, FOLIA PHARMACOL JPN, V102, pP46; KUREBAYASHI N, 1998, IN PRESS J MOL CELL; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1994, J BIOL CHEM, V269, P17434; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; LOW W, 1993, FEBS LETT, V316, P63, DOI 10.1016/0014-5793(93)81737-K; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; MORAD M, 1971, J PHYSIOL-LONDON, V219, P167, DOI 10.1113/jphysiol.1971.sp009656; Morad M., 1973, Progress Biophys Molec Biol, V27, P257, DOI 10.1016/0079-6107(73)90008-4; MORAD M, 1981, J PHYSL, V311, P168; NABAUER M, 1992, J PHYSIOL-LONDON, V457, P627; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Shuba YM, 1996, PFLUG ARCH EUR J PHY, V432, P562, DOI 10.1007/s004240050170; SMITH AA, 1987, FASEB J, V1, P380, DOI 10.1096/fasebj.1.5.2824269; VASSORT G, 1972, PFLUG ARCH EUR J PHY, V331, P191, DOI 10.1007/BF00589126; VILSEN B, 1992, FEBS LETT, V306, P213, DOI 10.1016/0014-5793(92)81003-5; WHITE MM, 1990, MOL PHARMACOL, V37, P720	37	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18819	18825		10.1074/jbc.273.30.18819	http://dx.doi.org/10.1074/jbc.273.30.18819			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668056	hybrid			2022-12-27	WOS:000074974700023
J	Ueda, A; Takeshita, F; Yamashiro, S; Yoshimura, T				Ueda, A; Takeshita, F; Yamashiro, S; Yoshimura, T			Positive regulation of the human macrophage stimulating protein gene transcription - Identification of a new hepatocyte nuclear factor-4 (HNF-4) binding element and evidence that indicates direct association between NF-Y and HNF-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR SUPERFAMILY; TYROSINE KINASE; MOLECULAR-CLONING; SEQUENCE IDENTITY; GROWTH-FACTOR; EXPRESSION; MEMBER; YEAST; PURIFICATION; DOMAIN	We previously reported that the transcription of the human macrophage stimulating protein (MSP) gene was positively regulated by the binding of NF-Y to the CAATT sequence in the promoter region of this gene. Here we confirmed our previous results and further characterized the MSP promoter. Luciferase assay with deletion constructs showed the importance of the region, +32 to +39, for the promoter activity in Hep3B cells. Two nuclear protein-DNA probe (+15 to +40) complexes, C1 and C2, were detected by electrophoretic mobility shift assay. C2 was specific to hepatoma cells and contained hepatocyte nuclear factor-4 (HNF-4). DNase I footprinting with recombinant HNF-4 located another HNF-4-binding site in the distal region, -89 to -54. Mutations in the CAATT or the proximal HNF-4-binding site significantly reduced the promoter activity in Hep3B cells and HNF-4-transfected HeLa cells, whereas mutations in the distal HNF-4-binding site had no effect. The close proximity between the CAATT and the proximal HNF-4-binding site suggested that a direct contact between NF-Y and HNF-4 might be important, Protein-protein interaction between the A-subunit of NF-Y and HNF-4 was detected by a yeast two-hybrid system. The binding of in vitro translated HNF-4 to immobilized NF-YA and in vitro translated NF-YA to immobilized HNF-4 was also detected. These results suggest the binding of HNF-4 to the proximal HNF-4-binding site directs the basal transcription of the MSP gene, and the maximal promoter activity may depend on the direct association between HNF-4 and NF-Y.	NCI, Immunopathol Sect, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Yokohama City Univ, Sch Med, Dept Internal Med 1, Yokohama, Kanagawa 236, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Yokohama City University	Yoshimura, T (corresponding author), NCI, Immunopathol Sect, Immunobiol Lab, Frederick Canc Res & Dev Ctr, Bldg 560,Rm 12-71, Frederick, MD 21702 USA.			Yoshimura, Teizo/0000-0002-3853-2075				BAOWEI C, 1994, BIOTECHNIQUES, V17, P657; Bartel P. L., 1993, CELLULAR INTERACTION, P153; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HARPER JW, 1993, CELL, V75, P805; IWABUCHI K, 1993, ONCOGENE, V8, P1693; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; Malik S, 1996, MOL CELL BIOL, V16, P1824; OGAMI K, 1991, J BIOL CHEM, V266, P9640; PINTO I, 1994, J BIOL CHEM, V269, P30569; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RONSIN C, 1993, ONCOGENE, V8, P1195; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKEEL A, 1994, J IMMUNOL, V152, P4618; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1996, J BIOL CHEM, V271, P20265, DOI 10.1074/jbc.271.34.20265; VUORIO T, 1990, J BIOL CHEM, V265, P22480; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	39	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19339	19347		10.1074/jbc.273.30.19339	http://dx.doi.org/10.1074/jbc.273.30.19339			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668124	hybrid			2022-12-27	WOS:000074974700091
J	McEnery, MW; Copeland, TD; Vance, CL				McEnery, MW; Copeland, TD; Vance, CL			Altered expression and assembly of N-type calcium channel alpha(1B) and beta subunits in epileptic lethargic (lh/lh) mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-CONOTOXIN GVIA; MUTANT MICE; ABSENCE SEIZURES; CA2+ CHANNELS; RAT-BRAIN; ATAXIA; HETEROGENEITY; RECEPTOR; CLONING; BINDING	Voltage-dependent calcium channels (VDCC) are multisubunit complexes whose expression and targeting require the assembly of the pore-forming alpha(1) with auxiliary beta and alpha(2)/delta subunits, The developmentally regulated expression and differential assembly of beta isoforms with the cu,, subunit to form N-type VDCC suggested a unique role for the beta 4 isoform in VDCC maturation (Vance, C. L., Begg, C. M., Lee, W.-L., Haase, H., Copeland, T. D., and McEnery, M. W. (1998) J, Biol. Chem, 273, 14495-14502), The focus of this study is the expression and assembly of alpha(1B) and beta isoforms in the epileptic mouse, lethargic (lh/lh), a mutant anticipated to produce a truncated beta 4 subunit (Burgess, D, L,, Jones, J, M., Meisler, M. H., and Noebels, J, L, (1997) Cell 88, 385-392), In this report, we demonstrate that neither full-length nor truncated beta 4 protein is expressed in lh/lh mice. The absence of beta 4 in lh/lh mice is associated with decreased expression of N-type VDCC in forebrain and cerebellum. The most surprising characteristic of the lh/lh mouse is increased expression of beta 1b protein. This result suggests a previously unidentified cellular mechanism wherein expression of the total pool of available beta subunits is under tight metabolic regulation. As a consequence of increased beta 1b expression, the beta 1b is increased in its incorporation into alpha(1B)/beta complexes relative to wild type. Thus, in striking similarity to the population of N-type VDCC present in immature rat brain, the population of N-type VDCC present in adult lh/lh mice is characterized by the absence of beta 4 with increased beta 1b expression and assembly into N-type VDCC, It is intriguing to speculate that the increased excitability and susceptibility to seizures observed in the lh/lh mouse arises from the inappropriate expression of an immature population of N-type VDCC throughout neuronal development.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA	Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	McEnery, MW (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	mwm4@po.cwru.edu						Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; COULTER DA, 1990, BRIT J PHARMACOL, V100, P800, DOI 10.1111/j.1476-5381.1990.tb14095.x; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Doyle J, 1997, MAMM GENOME, V8, P113, DOI 10.1007/s003359900369; DUNG HC, 1971, TEX REP BIOL MED, V29, P273; DUNG HC, 1972, TEX REP BIOL MED, V30, P23; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Hosford DA, 1997, EPILEPSIA, V38, P408, DOI 10.1111/j.1528-1157.1997.tb01729.x; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; LITZINGER MJ, 1994, J CHILD NEUROL, V9, P77, DOI 10.1177/088307389400900120; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; MAEDA N, 1989, BRAIN RES, V489, P21, DOI 10.1016/0006-8993(89)90004-8; MCENERY MW, 1991, P NATL ACAD SCI USA, V88, P11095, DOI 10.1073/pnas.88.24.11095; McEnery MW, 1997, FEBS LETT, V420, P74, DOI 10.1016/S0014-5793(97)01490-7; MCENERY MW, 1993, MOL CELLULAR BIOL PH, P3; MCENERY MW, 1998, IN PRESS J BIOENERG, V40; Noebels J L, 1986, Adv Neurol, V44, P97; PATIL P, 1998, NEURON, V20, P1; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Pichler M, 1997, J BIOL CHEM, V272, P13877, DOI 10.1074/jbc.272.21.13877; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Sander T, 1998, EPILEPSY RES, V29, P115, DOI 10.1016/S0920-1211(97)00073-9; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Smith SM, 1998, BIOPHYS J, V74, pA120; SNEAD OC, 1995, ANN NEUROL, V37, P146, DOI 10.1002/ana.410370204; Stevanin G, 1997, NEUROLOGY, V49, P1243, DOI 10.1212/WNL.49.5.1243; TANAKA O, 1995, MOL BRAIN RES, V30, P1, DOI 10.1016/0169-328X(94)00265-G; Vance CL, 1998, J BIOL CHEM, V273, P14495, DOI 10.1074/jbc.273.23.14495; VANCE CL, 1998, IN PRESS NEUROSCIENC; WAGNER JA, 1988, J NEUROSCI, V8, P3354; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	33	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21435	21438		10.1074/jbc.273.34.21435	http://dx.doi.org/10.1074/jbc.273.34.21435			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705268	hybrid			2022-12-27	WOS:000075492600002
J	Suzuki, T; Park, H; Kitajima, K; Lennarz, WJ				Suzuki, T; Park, H; Kitajima, K; Lennarz, WJ			Peptides glycosylated in the endoplasmic reticulum of yeast are subsequently deglycosylated by a soluble peptide: N-glycanase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; GLYCOPEPTIDE EXPORT; MOLECULAR-CLONING; QUALITY-CONTROL; ANIMAL-CELLS; IDENTIFICATION; REMODIFICATION; GLYCOAMIDASE; GLYCOSIDASE	Several lines of evidence suggest that soluble peptide: N-glycanase (PNGase) is involved in the quality control system for newly synthesized glycoproteins in mammalian cells. Here we report the occurrence of a soluble PNGase activity in Saccharomyces cerevisiae. The enzyme, which was recovered in the cytosolic fraction, has a neutral pH optimum, and dithiothreitol is required for activity. All of these properties were similar to those of earlier described for mammalian PNGases, Interestingly, the yeast enzyme activity was found to be present almost exclusively in cells in stationary phase; little activity was detected in logarithmic growth phase cells, Upon incubation of a glycosylatable peptide R-Asn-X-Thr-R' with permeabilized yeast spheroplasts, we detected formation of both,glycosylated peptide and the peptide product expected from PNGase-mediated deglycosylation of this glycopeptide, namely, R-Asp-X-Thr-R'. Recent findings that yeast have an active system for the retrograde transport of unfolded (glyco)proteins and glycopeptides out of the endoplasmic reticulum (ER) into the cytosol raise the possibility that this PNGase may participate in an early step in degradation of these molecules following their export from the ER.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 46401, Japan; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Nagoya University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Suzuki, Tadashi/AAX-5707-2021; Suzuki, Tadashi/I-4536-2014	Suzuki, Tadashi/0000-0003-1030-7631; 	NIGMS NIH HHS [GM33184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BELARD M, 1988, BIOCHEM J, V255, P235; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Chang T, 1997, FASEB J, V11, pA1247; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; DUNN B, 1990, CURRENT PROTOCOLS MO; Fan JQ, 1997, J BIOL CHEM, V272, P27058, DOI 10.1074/jbc.272.43.27058; FtouhiPaquin N, 1997, J BIOL CHEM, V272, P22960, DOI 10.1074/jbc.272.36.22960; HANOVER JA, 1982, J BIOL CHEM, V257, P2787; INOUE S, 1990, TRENDS GLYCOSCI GLYC, V2, P225; INOUE S, 1997, GLYCOPROTEINS, V2, P143; KITAJIMA K, 1995, ARCH BIOCHEM BIOPHYS, V319, P393, DOI 10.1006/abbi.1995.1309; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Ploegh HL, 1997, IMMUNOL TODAY, V18, P269, DOI 10.1016/S0167-5699(97)80021-7; ROMISCH K, 1992, P NATL ACAD SCI USA, V89, P7227, DOI 10.1073/pnas.89.15.7227; Romisch K, 1997, P NATL ACAD SCI USA, V94, P6730, DOI 10.1073/pnas.94.13.6730; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SEKO A, 1991, J BIOL CHEM, V266, P22110; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; SUZUKI T, 1995, GLYCOCONJUGATE J, V12, P183, DOI 10.1007/BF00731318; SUZUKI T, 1994, GLYCOCONJUGATE J, V11, P469, DOI 10.1007/BF00731283; SUZUKI T, 1995, J BIOL CHEM, V270, P15181, DOI 10.1074/jbc.270.25.15181; SUZUKI T, 1994, GLYCOBIOLOGY, V4, P777, DOI 10.1093/glycob/4.6.777; SUZUKI T, 1997, GLYCOSCIENCES STATUS, P121; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TAKAHASHI N, 1992, CRC HDB ENDOGLYCOSID, P183; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TARENTINO AL, 1993, TRENDS GLYCOSCI GLYC, V5, P163; Wang LX, 1997, J AM CHEM SOC, V119, P11137, DOI 10.1021/ja9712027; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655	37	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21526	21530		10.1074/jbc.273.34.21526	http://dx.doi.org/10.1074/jbc.273.34.21526			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705282	hybrid			2022-12-27	WOS:000075492600016
J	Grandori, R; Khalifah, P; Boice, JA; Fairman, R; Giovanielli, K; Carey, J				Grandori, R; Khalifah, P; Boice, JA; Fairman, R; Giovanielli, K; Carey, J			Biochemical characterization of WrbA, founding member of a new family of multimeric flavodoxin-like proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-SULFITE REDUCTASE; ESCHERICHIA-COLI; TRP REPRESSOR; CLONED GENES; DNA; SEQUENCE; FLAVOPROTEIN; YEAST	The protein WrbA had been identified as an Escherichia coli stationary-phase protein that copurified and coimmunoprecipitated with the tryptophan repressor. Sequences homologous to WrbA have been reported in several species of yeast and plants. We previously showed that this new family of proteins displays low but structurally significant sequence similarity with flavodoxins and that its members are predicted to share the alpha/beta core of the flavodoxin fold but with a short conserved insertion unique to the new family, which could account for reports that some family members may be dimeric in solution. The general sequence similarity to flavodoxins suggests that the members of the new family might bind FMN, but their wide evolutionary distribution indicates that, unlike the flavodoxins, these proteins may be ubiquitous. In this paper, we report the purification and biochemical characterization of WrbA, demonstrating that the protein binds FMN specifically and is a multimer in solution. The FMN binding constant is weaker than for many flavodoxins, being similar to 2 mu M at 25 degrees C in 0.1 mM sodium phosphate, pH 7.2, The protein participates in a dimer-tetramer equilibrium over a wide range of solution conditions, with a midpoint at approximately 1.4 mu M. One FMN binds per monomer and has no apparent effect on the multimerization equilibrium. WrbA has no effect on the affinity or mode of DNA binding by the tryptophan repressor; thus, its physiological role remains unclear. Although many proteins with flavodoxin-like domains are known to be multimers, WrbA is apparently the first characterized case in which multimerization is associated directly with the flavodoxin-like domain itself.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Princeton University; Bristol-Myers Squibb	Carey, J (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.			Khalifah, Peter/0000-0002-2216-0377	NIGMS NIH HHS [GM-43558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043558, R29GM043558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEDICT RC, 1981, BIOPHYS CHEM, V13, P245, DOI 10.1016/0301-4622(81)80006-3; BUJALOWSKI W, 1991, J BIOL CHEM, V266, P1616; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; ESCHENBRENNER M, 1995, FEBS LETT, V374, P82, DOI 10.1016/0014-5793(95)01081-O; Giebeler R, 1992, ANAL ULTRACENTRIFUGA, P16; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRANDORI R, 1994, PROTEIN SCI, V3, P2185, DOI 10.1002/pro.5560031204; GRANDORI R, 1994, TRENDS BIOCHEM SCI, V19, P72, DOI 10.1016/0968-0004(94)90037-X; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE TA, 1996, THESIS PRINCETON U; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; Mayhew S.G., 1975, ENZYMES, V12, P57; NICHOLS BP, 1983, METHOD ENZYMOL, V101, P155; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PALUH JL, 1986, NUCLEIC ACIDS RES, V14, P7851, DOI 10.1093/nar/14.20.7851; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Tollin G., 1980, METHOD ENZYMOL, V69, P392; VERVOORT J, 1994, METHOD ENZYMOL, V243, P188; WEBER G, 1994, PROTEIN INTERACTIONS, P16; WHITBY LG, 1953, BIOCHEM J, V54, P437, DOI 10.1042/bj0540437; Yang J, 1996, J MOL BIOL, V258, P37, DOI 10.1006/jmbi.1996.0232; YANG WP, 1993, P NATL ACAD SCI USA, V90, P5796, DOI 10.1073/pnas.90.12.5796	27	52	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20960	20966		10.1074/jbc.273.33.20960	http://dx.doi.org/10.1074/jbc.273.33.20960			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694845	hybrid			2022-12-27	WOS:000075386100038
J	Scantlebury, T; Maslowska, M; Cianflone, K				Scantlebury, T; Maslowska, M; Cianflone, K			Chylomicron-specific enhancement of acylation stimulating protein and precursor protein C3 production in differentiated human adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING PROTEIN; HUMAN ADIPOSE-TISSUE; LIPOPROTEIN-LIPASE; GENE-EXPRESSION; THYROID-HORMONE; 3T3-L1 ADIPOCYTES; MESSENGER-RNA; ACID; PATHWAY; ADIPSIN	Acylation stimulating protein (ASP) is a potent stimulator of adipocyte triacylglycerol storage. In vivo studies have shown that ASP production by adipocytes increases locally after a fat meal. Initial. in vitro studies demonstrated increased production of ASP in the presence of chylomicrons (CHYLO). The present aim was to define the CHYLO component responsible. None of the apoproteins tested (AT, AII, AIV, CI, CII, CIII, and E) were capable of stimulating C3 (the precursor protein) or ASP production. Rather, the active component is a nonlipid, loosely associated, trypsin-sensitive molecule. High pressure liquid chromatography fractionation of the CHYLO infranate proteins identified the critical protein as transthyretin (TTR), which binds retinol-binding protein and complexes thyroxine and retinol. Addition of TTR alone, with lipid emulsion, or with respun CHYLO to human differentiated adipocytes had little effect on C3 and ASP production. Ey contrast, when transthyretin was added to CHYLO, C3 and ASP production were substantially enhanced up to 75- and 7.5-fold respectively, compared with the effect of native CHYLO alone. Finally, a polyclonal antibody against TTR could inhibit stimulation of C3 and ASP production by CHYLO (by 98 and 100%, respectively) and by CHYLO infranate proteins (by 99 and 94%, respectively). We hypothesize that TTR. mediates the transfer of the active components from CHYLO to adipocytes, which then stimulates increased C3 and ASP production. Thus the CHYLO provides the physiologic trigger of the ASP pathway.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H3M 1M8, Canada	McGill University; Royal Victoria Hospital; Concordia University - Canada	Scantlebury, T (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Rm H7-35,687 Pine Ave, Montreal, PQ H3A 1A1, Canada.	mdkc@musica.mcgill.ca						AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; ANTRAS J, 1991, J BIOL CHEM, V266, P1157; ANTRASFERRY J, 1994, BIOCHEM J, V302, P943, DOI 10.1042/bj3020943; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BALDO A, 1995, J LIPID RES, V36, P1415; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASSIS LA, 1988, HYPERTENSION, V11, P591, DOI 10.1161/01.HYP.11.6.591; CHOY LN, 1992, J BIOL CHEM, V267, P12736; Cianflone K, 1997, CLIN BIOCHEM, V30, P301, DOI 10.1016/S0009-9120(97)00011-8; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; FLORESDELGADO G, 1987, MOL CELL BIOCHEM, V76, P35; GALTON DJ, 1991, HYPERLIPIDAEMIA PRAC, P1; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; HAUNER H, 1989, J CLIN INVEST, V84, P1663, DOI 10.1172/JCI114345; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hunter J, 1996, MOL CELL ENDOCRINOL, V116, P213, DOI 10.1016/0303-7207(95)03717-9; JIANG XC, 1991, J BIOL CHEM, V266, P4631; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kern PA, 1996, J LIPID RES, V37, P2332; LABRIE F, 1991, INT J OBESITY, V15, P91; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malpeli G, 1996, BBA-PROTEIN STRUCT M, V1294, P48, DOI 10.1016/0167-4838(95)00264-2; Maslowska M, 1997, INT J OBESITY, V21, P261, DOI 10.1038/sj.ijo.0800396; Maslowska M, 1997, J LIPID RES, V38, P1; OKUNO M, 1995, J LIPID RES, V36, P137; Peake PW, 1997, EUR J CLIN INVEST, V27, P922, DOI 10.1046/j.1365-2362.1997.2090759.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PETERSON J, 1990, P NATL ACAD SCI USA, V87, P909, DOI 10.1073/pnas.87.3.909; Saleh J, 1998, J LIPID RES, V39, P884; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Tao YH, 1997, BBA-LIPID LIPID MET, V1344, P221, DOI 10.1016/S0005-2760(96)00144-0; ZECHNER R, 1991, J BIOL CHEM, V266, P10583; ZOVICH DC, 1992, J BIOL CHEM, V267, P13884	36	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20903	20909		10.1074/jbc.273.33.20903	http://dx.doi.org/10.1074/jbc.273.33.20903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694837	hybrid			2022-12-27	WOS:000075386100030
J	Du, HS; Babitzke, P				Du, HS; Babitzke, P			trp RNA-binding attenuation protein-mediated long distance RNA refolding regulates translation of trpE in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 REGA PROTEIN; MESSENGER-RNA; SECONDARY STRUCTURE; ESCHERICHIA-COLI; LEADER RNA; TRAP; INITIATION; OPERON; EXPRESSION; SEQUENCE	Expression of the trpEDCFBA operon is regulated at both the transcriptional and translational levels by the trp RNA-binding attenuation protein (TRAP) of Bacillus subtilis, When cells contain sufficient levels of tryptophan to activate TRAP, the protein binds to trp operon transcripts as they are being synthesized, most often causing transcription termination. However, termination is never 100% efficient, and transcripts that escape termination are subject to translational control. We determined that TRAP-mediated translational control of trpE can occur via a novel RNA conformational switch mechanism. When TRAP binds to the 5'-untranslated leader segment of a trp operon read-through transcript, it can disrupt a large secondary structure containing a portion of the TRAP binding target. This promotes refolding of the RNA such that the trpE Shine-Dalgarno sequence, located more than 100 nucleotides downstream from the TRAP binding site, becomes sequestered in a stable RNA hairpin. Results from cell-free translation, ribosome toeprint, and RNA structure mapping experiments demonstrate that formation of this structure reduces TrpE synthesis by blocking ribosome access to the trpE ribosome binding site. The role of the Shine-Dalgarno blocking hairpin in controlling translation of trpE was confirmed by examining the effect of multiple nucleotide substitutions that abolish the structure without altering the Shine-Dalgarno sequence itself. The possibility of protein-mediated RNA refolding as a general mechanism in controlling gene expression is discussed.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Babitzke, P (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	pxb28@psu.edu	Babitzke, Paul/AAL-3048-2020	Babitzke, Paul/0000-0003-2481-1062	NIGMS NIH HHS [R01 GM052840, GM52840] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052840] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; ANTSON AA, 1994, J MOL BIOL, V244, P1, DOI 10.1006/jmbi.1994.1698; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; BABITZKE P, 1994, J BIOL CHEM, V269, P16597; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; BRUNEL C, 1995, J MOL BIOL, V253, P277, DOI 10.1006/jmbi.1995.0552; CHANG JHT, 1995, J BACTERIOL, V177, P6560, DOI 10.1128/jb.177.22.6560-6567.1995; CHRISTENSEN T, 1984, EMBO J, V3, P1609, DOI 10.1002/j.1460-2075.1984.tb02018.x; CLIMIE SC, 1988, J BIOL CHEM, V263, P15166; DESMIT MH, 1990, PROG NUCLEIC ACID RE, V38, P1; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; HATTMAN S, 1991, P NATL ACAD SCI USA, V88, P10027, DOI 10.1073/pnas.88.22.10027; Henner Dennis, 1993, P269; HENNER DJ, 1985, GENE, V34, P169, DOI 10.1016/0378-1119(85)90125-8; Hensold JO, 1997, NUCLEIC ACIDS RES, V25, P2869, DOI 10.1093/nar/25.14.2869; Hess MA, 1996, NUCLEIC ACIDS RES, V24, P2441, DOI 10.1093/nar/24.12.2441; Jackson RJ, 1997, CURR OPIN GENET DEV, V7, P233, DOI 10.1016/S0959-437X(97)80133-5; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; Kaminski A, 1994, Genet Eng (N Y), V16, P115; KANE JF, 1977, J BACTERIOL, V132, P419, DOI 10.1128/JB.132.2.419-425.1977; Klaff P, 1996, PLANT MOL BIOL, V32, P89, DOI 10.1007/BF00039379; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KURODA MI, 1988, J BACTERIOL, V170, P3080, DOI 10.1128/jb.170.7.3080-3088.1988; Lindahl L, 1992, CURR OPIN GENET DEV, V2, P720, DOI 10.1016/S0959-437X(05)80132-7; LOWMAN HB, 1986, J BIOL CHEM, V261, P5396; MA CK, 1994, MOL MICROBIOL, V14, P1033, DOI 10.1111/j.1365-2958.1994.tb01337.x; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; Miller J. H, 1972, EXPT MOL GENETICS; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; PANTOPOULOS K, 1994, PROG NUCLEIC ACID RE, V48, P181, DOI 10.1016/S0079-6603(08)60856-9; Perkins John B., 1993, P319; Poot RA, 1997, P NATL ACAD SCI USA, V94, P10110, DOI 10.1073/pnas.94.19.10110; SEKIGUCHI J, 1975, J BACTERIOL, V121, P688, DOI 10.1128/JB.121.2.688-694.1975; SHIMOTSU H, 1986, J BACTERIOL, V166, P461, DOI 10.1128/jb.166.2.461-471.1986; SLOCK J, 1990, J BACTERIOL, V172, P7211, DOI 10.1128/jb.172.12.7211-7226.1990; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; STEITZ JA, 1975, P NATL ACAD SCI USA, V72, P4734, DOI 10.1073/pnas.72.12.4734; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; UNNITHAN S, 1990, NUCLEIC ACIDS RES, V18, P7083, DOI 10.1093/nar/18.23.7083; WEBSTER KR, 1989, NUCLEIC ACIDS RES, V17, P10047, DOI 10.1093/nar/17.23.10047; WULCZYN FG, 1991, CELL, V65, P259, DOI 10.1016/0092-8674(91)90160-Z; Yang DC, 1997, VIROLOGY, V228, P63, DOI 10.1006/viro.1996.8366; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1	48	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20494	20503		10.1074/jbc.273.32.20494	http://dx.doi.org/10.1074/jbc.273.32.20494			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685405	hybrid			2022-12-27	WOS:000075305400082
J	Guo, HC; Xu, Q; Buckley, D; Guan, C				Guo, HC; Xu, Q; Buckley, D; Guan, C			Crystal structures of Flavobacterium glycosylasparaginase - An N-terminal nucleophile hydrolase activated by intramolecular proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME; LYSOSOMAL ASPARTYLGLUCOSAMINIDASE; MOLECULAR-CLONING; SUBUNITS; ASPARTYLGLYCOSAMINURIA; BIOCHEMISTRY; COMPLEX; SERINE	Glycosylasparaginase (GA) is a member of a novel family of N-terminal nucleophile hydrolases that catalytically use an N-terminal residue as both a polarizing base and a nucleophile. These enzymes are activated from a single chain precursor by intramolecular autoproteolysis to yield the N-terminal nucleophile. A deficiency of GA results in the human genetic disorder known as aspartylglycosaminuria. In this study, we report the crystal structure of recombinant GA from Flavobacterium meningosepticum, Similar to the human structure, the bacterial GA forms an alpha beta alpha sandwich. However, some significant differences are observed between the Flavobacterium and human structures. The active site of Flavobacterium glycosylasparaginase is in an open conformation when compared with the human structure. We also describe the structure of a mutant wherein the N-terminal nucleophile Thr(152) is, substituted by a cysteine. In the bacterial GA crystals, we observe a heterotetrameric structure similar to that found in the human structure, as well as that observed in solution for eukaryotic glycosylasparaginases. The results confirm the suitability of the bacterial enzyme as a model to study the consequences of mutations in aspartylglycosaminuria patients. They also suggest that further studies are necessary to understand the detail mechanism of this enzyme. The presence of the heterotetrameric structure in the crystals is significant because dimerization of precursors has been suggested in the human enzyme to be a prerequisite to trigger autoproteolysis.	Boston Univ, Sch Med, Dept Biophys, Boston, MA 02118 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Boston University	Guo, HC (corresponding author), Boston Univ, Sch Med, Dept Biophys, 715 Albany St, Boston, MA 02118 USA.							[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Aronson NN, 1996, GLYCOBIOLOGY, V6, P669, DOI 10.1093/glycob/6.7.669; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR MANUAL SYSTEM; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; FISHER KJ, 1993, FEBS LETT, V323, P271, DOI 10.1016/0014-5793(93)81355-4; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Guan CD, 1996, J BIOL CHEM, V271, P1732, DOI 10.1074/jbc.271.3.1732; HALILA R, 1991, BIOCHEM J, V276, P251, DOI 10.1042/bj2760251; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 1996, GLYCOBIOLOGY, V6, P527, DOI 10.1093/glycob/6.5.527; Liu Y, 1998, J BIOL CHEM, V273, P9688, DOI 10.1074/jbc.273.16.9688; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; MONONEN I, 1993, FASEB J, V7, P1247, DOI 10.1096/fasebj.7.13.8405810; MONONEN I, 1995, FASEB J, V9, P428, DOI 10.1096/fasebj.9.5.7896015; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Perler FB, 1998, CELL, V92, P1, DOI 10.1016/S0092-8674(00)80892-2; Riikonen A, 1996, J BIOL CHEM, V271, P21340, DOI 10.1074/jbc.271.35.21340; RIIKONEN A, 1995, J BIOL CHEM, V270, P4903, DOI 10.1074/jbc.270.9.4903; RISLEY JM, 1996, FASEB J, V10, P1104; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; TARENTINO AL, 1995, ARCH BIOCHEM BIOPHYS, V316, P399, DOI 10.1006/abbi.1995.1053; TOLLERSRUD OK, 1992, BIOCHEM J, V282, P891, DOI 10.1042/bj2820891; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8	39	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20205	20212		10.1074/jbc.273.32.20205	http://dx.doi.org/10.1074/jbc.273.32.20205			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685368	Green Submitted, hybrid			2022-12-27	WOS:000075305400045
J	Ivanovic, A; Reilander, H; Laube, B; Kuhse, J				Ivanovic, A; Reilander, H; Laube, B; Kuhse, J			Expression and initial characterization of a soluble glycine binding domain of the N-Methyl-D-aspartate receptor NR1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTORS; NMDA-RECEPTORS; H-3 MDL-105,519; PROTEINS; SITE; LIGAND; NEURONS; BRAIN; IDENTIFICATION; CHANNEL	Glycine is an essential co-agonist of the excitatory N-methyl-D-aspartate (NMDA) receptor, a subtype of the ionotropic glutamate receptor family. The glycine binding site of this hetero-oligomeric ion channel protein is formed by two distinct extracellular regions, S1 and S2, of the NR1 subunit, whereas the homologous domains of the NR2 subunit mediate glutamate binding. Here, segments SI and S2 of the NR1 polypeptide were fused via a linker peptide followed by N-. and C-terminally tagging with Flag and His, epitopes, respectively. Infection of High Five insect cells with a recombinant baculovirus containing this glycine binding site construct resulted in efficient secretion of a soluble fusion protein of about 53 kDa. After affinity purification to near-homogeneity, the fusion protein bound the competitive glycine site antagonist [H-3]MDL105,519 with high affinity (K-d = 5.22 +/- 0.13 nM) similar to that determined with rat brain membrane fractions. This high affinity binding could be competed by the glycine site antagonist 7-chlorokynurenic acid as well as the agonists glycine and D-serine but not by L-glutamate. This indicates that the S1 and S2 domains of the NR1 subunit are sufficient for the formation of a glycine binding site that displays pharmacological properties similar to those of the NMDA receptor in vivo.	Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany; Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60528 Frankfurt, Germany	Max Planck Society; Max Planck Society	Kuhse, J (corresponding author), Max Planck Inst Brain Res, Dept Neurochem, Deutschordenstr 46, D-60528 Frankfurt, Germany.	kuhse@mpih-frankfurt.mpg.de	Kuhse, Jochen/T-3864-2019					Anson LC, 1998, J NEUROSCI, V18, P581; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; Baron BM, 1996, J PHARMACOL EXP THER, V279, P62; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Everts I, 1997, MOL PHARMACOL, V52, P861, DOI 10.1124/mol.52.5.861; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; Grunewald S, 1996, BIOCHEMISTRY-US, V35, P15149, DOI 10.1021/bi9607564; HASEGAWA Y, 1994, STROKE, V25, P1241, DOI 10.1161/01.STR.25.6.1241; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuner T, 1996, NEURON, V17, P343, DOI 10.1016/S0896-6273(00)80165-8; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Lenhard T, 1996, GENE, V169, P187, DOI 10.1016/0378-1119(95)00831-4; LODGE D, 1994, NMDA RECEPTOR, P105; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OH BH, 1993, J BIOL CHEM, V268, P11348; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P124; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; SACK JS, 1989, J MOL BIOL, V206, P171, DOI 10.1016/0022-2836(89)90531-7; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Siegel BW, 1996, EUR J PHARMACOL, V312, P357, DOI 10.1016/0014-2999(96)00477-3; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; Wenzel A, 1995, NEUROREPORT, V7, P45, DOI 10.1097/00001756-199512290-00010	36	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19933	19937		10.1074/jbc.273.32.19933	http://dx.doi.org/10.1074/jbc.273.32.19933			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685327	hybrid			2022-12-27	WOS:000075305400004
J	Morrow, CS; Smitherman, PK; Diah, K; Schneider, E; Townsend, AJ				Morrow, CS; Smitherman, PK; Diah, K; Schneider, E; Townsend, AJ			Coordinated action of glutathione S-Transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification - Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CLASS; CANCER-CELLS; CONFERS RESISTANCE; ALKYLATING-AGENTS; LEUKOTRIENE C-4; EXPORT PUMP; PI-CLASS; GENE; EXPRESSION; SENSITIVITY	To examine the role of multidrug resistance protein 1 (MRP1) and glutathione S-transferases (GSTs) in cellular resistance to antineoplastic drugs, derivatives of MCF7 breast carcinoma cells were developed that express MRP1 in combination with one of three human cytosolic isozymes of GST, Expression of MRP1 alone confers resistance to several drugs representing the multidrug resistance phenotype, drugs including doxorubicin, vincristine, etoposide, and mitoxantrone. However, co-expression with MRP1 of any of the human GST isozymes Al-l, M1-1, or P1-1 failed to augment MRP1-associated resistance to these drugs. In contrast, combined expression of MRP1 and GST Al-l conferred similar to 4-fold resistance to the anticancer drug chlorambucil. Expression of MRP1 alone failed to confer resistance to chlorambucil, showing that the observed protection from chlorambucil cytotoxicity was absolutely dependent upon GST Al-l protein. Moreover, using inhibitors of GST (dicumarol) or MRP1 (sulfinpyrazone), it was shown that in MCF7 cells resistance to chlorambucil requires both intact MRP1-dependent efflux pump activity and, for full protection, GST Al-l catalytic activity. These results are the first demonstration that GST Al-l and MRP1 can act in synergy to protect cells from the cytotoxicity of a nitrogen mustard, chlorambucil.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wadsworth Ctr, Albany, NY 12201 USA	Wake Forest University; Wadsworth Center	Morrow, CS (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NCI NIH HHS [CA70338] Funding Source: Medline; NIEHS NIH HHS [ES06006] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R55ES006006, R01ES006006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMSTRONG DK, 1992, CANCER RES, V52, P1416; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Awasthi S, 1996, DRUG METAB DISPOS, V24, P371; Barnouin K, 1998, BRIT J CANCER, V77, P201, DOI 10.1038/bjc.1998.34; BERHANE K, 1993, CANCER RES, V53, P4257; BLACK SM, 1991, PHARMACOL THERAPEUT, V51, P139, DOI 10.1016/0163-7258(91)90044-M; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; BOLTON MG, 1991, CANCER RES, V51, P2410; BULLER AL, 1987, MOL PHARMACOL, V31, P575; Bunting KD, 1996, J BIOL CHEM, V271, P11884, DOI 10.1074/jbc.271.20.11884; CIACCIO PJ, 1991, BIOCHEM PHARMACOL, V42, P1504, DOI 10.1016/0006-2952(91)90468-K; CIACCIO PJ, 1990, CANCER COMMUN, V2, P279, DOI 10.3727/095535490820874263; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Davis LG, 1994, BASIC METHODS MOL BI; DIRVEN HAAM, 1995, CANCER RES, V55, P1701; DIRVEN HAAM, 1994, CANCER RES, V54, P6215; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HIPFNER DR, 1994, CANCER RES, V54, P5788; Jedlitschky G, 1996, CANCER RES, V56, P988; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; Kool M, 1997, CANCER RES, V57, P3537; LEIER I, 1994, J BIOL CHEM, V269, P27807; LEWIS AD, 1988, P NATL ACAD SCI USA, V85, P8511, DOI 10.1073/pnas.85.22.8511; LEYLANDJONES BR, 1991, CANCER RES, V51, P587; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MAYS JB, 1992, BIOCHEM PHARMACOL, V44, P921, DOI 10.1016/0006-2952(92)90124-2; MEWS K, 1993, CANCER RES, V53, P5135; MEYER DJ, 1993, XENOBIOTICA, V23, P823, DOI 10.3109/00498259309059411; MEYER DJ, 1992, BRIT J CANCER, V66, P433, DOI 10.1038/bjc.1992.292; Morrow CS, 1998, CARCINOGENESIS, V19, P109, DOI 10.1093/carcin/19.1.109; MORROW CS, 1990, CANCER CELL-MON REV, V2, P15; MOSCOW JA, 1989, MOL PHARMACOL, V36, P22; MOSCOW JA, 1988, P NATL ACAD SCI USA, V85, P6518, DOI 10.1073/pnas.85.17.6518; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PUCHALSKI RB, 1990, P NATL ACAD SCI USA, V87, P2443, DOI 10.1073/pnas.87.7.2443; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; SCHECTER RL, 1993, CANCER RES, V53, P4900; SCHNEIDER E, 1994, CANCER RES, V54, P152; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH MT, 1989, CANCER RES, V49, P2621; TEW KD, 1994, CANCER RES, V54, P4313; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TOWNSEND AJ, 1992, MOL PHARMACOL, V41, P230; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; WOLF CR, 1986, BIOCHEM PHARMACOL, V35, P1577, DOI 10.1016/0006-2952(86)90127-9; YANG WZ, 1992, MOL PHARMACOL, V41, P625	51	124	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20114	20120		10.1074/jbc.273.32.20114	http://dx.doi.org/10.1074/jbc.273.32.20114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685354	hybrid			2022-12-27	WOS:000075305400031
J	Savel'ev, AS; Novikova, LA; Kovaleva, IE; Luzikov, VN; Neupert, W; Langer, T				Savel'ev, AS; Novikova, LA; Kovaleva, IE; Luzikov, VN; Neupert, W; Langer, T			ATP-dependent proteolysis in mitochondria - m-AAA protease and PIM1 protease exert overlapping substrate specificities and cooperate with the mtHsp70 system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SIGMA(32); RAT-LIVER MITOCHONDRIA; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; SACCHAROMYCES-CEREVISIAE; INNER MEMBRANE; LON PROTEASE; CYTOCHROME-C; DNAJ HOMOLOG; DEGRADATION	To analyze protein degradation in mitochondria and the role of molecular chaperone proteins in this process, bovine apocytochrome P450scc was employed as a model protein. When imported into isolated yeast mitochondria, P450scc was mislocalized to the matrix and rapidly degraded. This proteolytic breakdown was mediated by the ATP-dependent PIM1 protease, a Lon-like protease in the mitochondrial matrix, in cooperation with the mtHsp70 system. In addition, a derivative of P450scc was studied to which a heterologous transmembrane region was fused at the amino terminus. This protein became anchored to the inner membrane upon import and was degraded by the membrane-embedded, ATP-dependent m-AAA protease, Again, degradation depended on the mtHsp70 system; it was inhibited at nonpermissive temperature in mitochondria carrying temperature-sensitive mutant forms of Ssc1p, Mdj1p, or Mge1p. These results demonstrate overlapping substrate specificities of PIM1 and the m-AAA protease, and they assign a central role to the mtHsp70 system during the degradation of misfolded polypeptides by both proteases.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	University of Munich; Lomonosov Moscow State University	Langer, T (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.	Langer@bio.med.uni-muenchen.de	Novikova, Ludmila A/A-3427-2014; Kovaleva, Irina/K-1217-2013	Saveliev, Alexander/0000-0003-0840-4774; Langer, Thomas/0000-0003-1250-1462				Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Beyer A, 1997, PROTEIN SCI, V6, P2043; BLASZCZAK A, 1995, EMBO J, V14, P5085, DOI 10.1002/j.1460-2075.1995.tb00190.x; Brodsky JL, 1996, TRENDS BIOCHEM SCI, V21, P122, DOI 10.1016/0968-0004(96)20010-6; Dekker PJT, 1997, J MOL BIOL, V270, P321, DOI 10.1006/jmbi.1997.1131; DESAUTELS M, 1982, J BIOL CHEM, V257, P1673; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Jubete Y, 1996, J BIOL CHEM, V271, P30798, DOI 10.1074/jbc.271.48.30798; KELLER JA, 1988, MOL MICROBIOL, V2, P31, DOI 10.1111/j.1365-2958.1988.tb00004.x; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; KUTEJOVA E, 1993, FEBS LETT, V329, P47, DOI 10.1016/0014-5793(93)80190-6; Langer T, 1996, EXPERIENTIA, V52, P1069, DOI 10.1007/BF01952104; LANGER T, 1994, BIOL HEAT SHOCK PROT, P53; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; NAKAI T, 1995, MOL CELL BIOL, V15, P4441; OMURA T, 1991, METHOD ENZYMOL, V206, P75; OU W, 1986, J BIOCHEM-TOKYO, V100, P1287, DOI 10.1093/oxfordjournals.jbchem.a121835; OU WJ, 1989, EMBO J, V8, P2605, DOI 10.1002/j.1460-2075.1989.tb08400.x; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; Rep M, 1996, CURR GENET, V30, P367, DOI 10.1007/s002940050145; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Savelev AS, 1997, BIOCHEMISTRY-MOSCOW+, V62, P779; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; SHERMAN MY, 1992, EMBO J, V11, P71; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; USANOV SA, 1990, FEBS LETT, V275, P33, DOI 10.1016/0014-5793(90)81432-N; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; Wagner I, 1997, EMBO J, V16, P7317, DOI 10.1093/emboj/16.24.7317; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; WESTERMANN B, 1995, EMBO J, V14, P3452, DOI 10.1002/j.1460-2075.1995.tb07351.x; Westermann B, 1996, MOL CELL BIOL, V16, P7063; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	70	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20596	20602		10.1074/jbc.273.32.20596	http://dx.doi.org/10.1074/jbc.273.32.20596			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685417	hybrid			2022-12-27	WOS:000075305400094
J	Vallet, VS; Casado, M; Henrion, AA; Bucchini, D; Raymondjean, M; Kahn, A; Vaulont, S				Vallet, VS; Casado, M; Henrion, AA; Bucchini, D; Raymondjean, M; Kahn, A; Vaulont, S			Differential roles of upstream stimulatory factors 1 and 2 in the transcriptional response of liver genes to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE; FACTOR USF; CARBOHYDRATE REGULATION; TRANSGENIC MICE; C-MYC; PROMOTER; PROTEINS; RAT; ORGANIZATION; EXPRESSION	USF1 and USF2 are ubiquitous transcription factors of the basic helix-loop-helix leucine zipper family. They form homo- and heterodimers and recognize a CACGTG motif termed E box. In the liver, USF binding activity is mainly accounted for by the USF1/USF2 heterodimer, which binds irt vitro the glucose/carbohydrate response elements (GlRE/ChoRE) of glucose-responsive genes. To assign a physiological role of USFs in vivo, we have undertaken the disruption of USF1 and USF2 genes in mice. We present here the generation of USF1-deficient mice. In the liver of these mice, we demonstrate that USFS remaining dimers can compensate for glucose responsiveness, even though the level of total USF binding activity is reduced by half as compared with wild type mice. The residual USF1 binding activity was similarly reduced in the previously reported USF2 -/- mice in which an impaired glucose responsiveness was observed (Vallet, V, S,, Henrion, A, A., Bucchini, D., Casado, M., Raymondjean, M., Kahn, A., and Vaulont, S. (1997) J. Biol. Chem. 272, 21944-21949). Taken together, these results clearly suggest differential transactivating efficiencies of USF1 and USF2 in promoting the glucose response. Furthermore, they support the view that USF2 is the functional transactivator of the glucose-responsive complex.	Universite Rene Descartes, INSERM, U129, Unite Rech Physiol & Pathol Genet & Mol, F-75014 Paris, France; Universite Rene Descartes, Inst Cochin Genet Mol, F-75014 Paris, France; Universite Rene Descartes, INSERM, U257, Lab Genet Cellulaire & Mol, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Vaulont, S (corresponding author), Universite Rene Descartes, INSERM, U129, Unite Rech Physiol & Pathol Genet & Mol, 24 Rue Faubourg, F-75014 Paris, France.	vaulont@cochin.inserm.fr	Vaulont, Sophie/O-6732-2017; Caude, Alexandra A Henrion/I-2778-2016; Casado, Marta/L-2078-2014	Caude, Alexandra A Henrion/0000-0002-8170-2260; Casado, Marta/0000-0001-6457-4650				Aperlo C, 1996, GENOMICS, V37, P337, DOI 10.1006/geno.1996.0568; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; CUIF MH, 1993, J BIOL CHEM, V268, P13769; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Joyner AL, 1993, GENE TARGETING PRACT; Kennedy HJ, 1997, J BIOL CHEM, V272, P20636, DOI 10.1074/jbc.272.33.20636; Kurschner C, 1997, BIOCHEM BIOPH RES CO, V231, P333, DOI 10.1006/bbrc.1997.6097; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LIAW CW, 1984, J BIOL CHEM, V259, P7253; LIN Q, 1994, J BIOL CHEM, V269, P23894; LITTLEWOOD TD, 1995, PROTEIN PROFILE, V2, P621; LONE YC, 1986, FEBS LETT, V195, P97, DOI 10.1016/0014-5793(86)80138-7; Lun Y, 1997, CELL GROWTH DIFFER, V8, P275; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; Pognonec P, 1997, ONCOGENE, V14, P2091, DOI 10.1038/sj.onc.1201046; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SHIH HM, 1992, J BIOL CHEM, V267, P13222; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; Takahashi Y, 1997, BIOCHEM BIOPH RES CO, V240, P293, DOI 10.1006/bbrc.1997.7651; Vallet VS, 1997, J BIOL CHEM, V272, P21944, DOI 10.1074/jbc.272.35.21944; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405	36	110	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20175	20179		10.1074/jbc.273.32.20175	http://dx.doi.org/10.1074/jbc.273.32.20175			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685363	hybrid			2022-12-27	WOS:000075305400040
J	Vecchi, M; Rudolph-Owen, LA; Brown, CL; Dempsey, PJ; Carpenter, G				Vecchi, M; Rudolph-Owen, LA; Brown, CL; Dempsey, PJ; Carpenter, G			Tyrosine phosphorylation and proteolysis - Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; KINASE-C-DELTA; NEU DIFFERENTIATION FACTOR; PHORBOL ESTER; CELL-SURFACE; FACTOR-ALPHA; T-CELLS; PROTEIN; ACTIVATION; LIGAND	Enhancement of tyrosine phosphorylation in cells by the application of pervanadate, an extremely potent phosphotyrosine phosphatase inhibitor, provokes the rapid metalloprotease-dependent cleavage of ErbB-4, a transmembrane receptor tyrosine kinase. The pervanadate-induced proteolysis occurs in NIH 3T3 cells expressing transfected human ErbB-4 and in several cell lines that express endogenous ErbB-4. One product of this proteolytic event is a membrane-anchored molecule of approximately 80 kDa, which is heavily tyrosine phosphorylated and which possesses tyrosine kinase catalytic activity toward an exogenous substrate in vitro. This response to pervanadate is not dependent on protein kinase C activation, which has previously been demonstrated to also activate ErbB-4 cleavage. Hence, the pervanadate and 12- O-tetradecanoylphorbol-13-acetate-induced proteolytic cleavage of ErbB-4 seem to proceed by different mechanisms, although both require metalloprotease activity. Moreover, pervanadate activation of ErbB-4 cleavage, but not that of 12-O-tetradecanoylphorbol-13-acetate, is blocked by the oxygen radical scavenger pyrrolidine dithiocarbomate. A second phosphotyrosine phosphatase inhibitor, phenylarsine oxide, also stimulates a similar cleavage of ErbB-4 but, unlike pervanadate, is not sensitive to pyrrolidine dithiocarbomate. Last, pervanadate is shown to stimulate the proteolytic cell surface processing of a second and unrelated transmembrane molecule: the precursor for amphiregulin, an epidermal growth factor-related molecule. Amphiregulin cleavage by pervanadate occurred in the absence of a cytoplasmic domain and:tyrosine phosphorylation of this substrate.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA.		Vecchi, Manuela/L-3502-2017	Vecchi, Manuela/0000-0002-2750-9160	NATIONAL CANCER INSTITUTE [R01CA046413, R01CA024071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007491] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA24071, R01 CA46413] Funding Source: Medline; NIAMS NIH HHS [T32 AR07491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; ARTEAGA CL, 1991, P NATL ACAD SCI USA, V88, P10435, DOI 10.1073/pnas.88.23.10435; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BRIZZI MF, 1994, ONCOGENE, V9, P1583; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GRASSMAN M, 1995, NATURE, V378, P390; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Kadotani M, 1997, J BIOCHEM-TOKYO, V121, P1047; Kamat Asha, 1997, Cytokine and Growth Factor Reviews, V8, P109, DOI 10.1016/S1359-6101(97)00003-8; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Krejsa CM, 1997, J BIOL CHEM, V272, P11541; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LIAO K, 1991, J BIOL CHEM, V266, P6544; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YEE NS, 1993, J BIOL CHEM, V268, P14189; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	61	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20589	20595		10.1074/jbc.273.32.20589	http://dx.doi.org/10.1074/jbc.273.32.20589			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685416	hybrid			2022-12-27	WOS:000075305400093
J	Leonard, AS; Davare, MA; Horne, MC; Garner, CC; Hell, JW				Leonard, AS; Davare, MA; Horne, MC; Garner, CC; Hell, JW			SAP97 is associated with the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CENTRAL NERVOUS-SYSTEM; GLUTAMATE-RECEPTOR; RAT-BRAIN; NMDA; LOCALIZATION; TOPOLOGY; PSD-95; SAP102; LIGHT	Rapid glutamatergic synaptic transmission is mediated by ionotropic glutamate receptors and depends on their precise localization at postsynaptic membranes opposing the presynaptic neurotransmitter release sites. Postsynaptic localization of N-methyl-D-aspartate-type glutamate receptors may be mediated by the synapse-associated proteins (SAPs) SAP90, SAP102, and chapsyn-110, SAPs contain three PDZ domains that can interact with the C termini of proteins such as N-methyl-D-aspartate receptor subunits that carry a serine or threonine at the -2 position and a valine, isoleucine, or leucine at the very C terminus (position 0), We now show that SAP97, a SAP whose function at the synapse has been unclear, is associated with alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-type glutamate receptors, AMPA receptors are probably tetramers and are formed by two or more of the four AMPA receptor subunits GluR1-4. GluR1 possesses a C-terminal consensus sequence for interactions with PDZ domains of SAPs, SAP97 was present in AMPA receptor complexes immunoprecipitated from detergent extracts of rat brain. After treatment of rat brain membrane fractions with the cross-linker dithiobis(succinimidylpropionate) and solubilization with sodium dodecylsulfate, SAP97 was associated with GluR1 but not GluR2 or GluR3. In vitro experiments with recombinant proteins indicate that SAP97 specifically associates with the C terminus of GluR1 but not other AMPA receptor subunits, Our findings suggest that SAP97 may be involved in localizing AMPA receptors at postsynaptic sites through its interaction with the GluR1 subunit.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Alabama Birmingham, Neurobiol Res Ctr, Birmingham, AL 35213 USA	University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham	Hell, JW (corresponding author), Univ Wisconsin, Dept Pharmacol, 3770 MSC,1300 Univ Ave, Madison, WI 53706 USA.	jwhell@facstaff.wisc.edu	Hell, Johannes W./P-5085-2019	Davare, Monika/0000-0003-1802-7597; Horne, Mary/0000-0002-2799-3212; Garner, Craig/0000-0003-1970-5417	NIA NIH HHS [AG12978] Funding Source: Medline; NINDS NIH HHS [R01-NS35563] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012978] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; Brenman JE, 1996, J NEUROSCI, V16, P7407; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; Garner CC, 1996, TRENDS CELL BIOL, V6, P429, DOI 10.1016/S0962-8924(96)10036-2; HELL JW, 1993, J BIOL CHEM, V268, P19451; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Leonard AS, 1997, J BIOL CHEM, V272, P12107, DOI 10.1074/jbc.272.18.12107; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Malenka RC, 1997, NATURE, V390, P552, DOI 10.1038/37472; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0	39	342	349	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19518	19524		10.1074/jbc.273.31.19518	http://dx.doi.org/10.1074/jbc.273.31.19518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677374	hybrid			2022-12-27	WOS:000075125200026
J	Ushio-Fukai, M; Griendling, KK; Akers, M; Lyons, PR; Alexander, RW				Ushio-Fukai, M; Griendling, KK; Akers, M; Lyons, PR; Alexander, RW			Temporal dispersion of activation of phospholipase C-beta 1 and -gamma isoforms by angiotensin II in vascular smooth muscle cells - Role of alpha(q/11), alpha(12), and beta gamma G protein subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; RECEPTOR; EXPRESSION; KINASE; G(12); ANTIBODIES; C-GAMMA-1; PATHWAY; CLONING; SIGNAL	Activation of phospholipase C (PLC) is one of the earliest events in angiotensin II (Ang II) type 1 (AT(1)) receptor (R)-mediated signal transduction in vascular smooth muscle cells (VSMCs). The coupling mechanisms of AT(1) Rs to PLC, however, are controversial, because both tyrosine phosphorylation of PLC-gamma and G protein-dependent PLC-beta activation pathways have been reported. The expression of PLC-beta 1, furthermore, has not been consistently demonstrated in VSMCs. Here we identified the PLC subtypes and subunits of heterotrimeric Gr proteins involved in AT(1) R-PLC coupling using cultured rat VSMCs. Western analysis revealed the expression of PLC-beta 1, -gamma 1, and -delta 1 in VSMCs. Ang II-stimulated inositol trisphosphate (IP3) formation measured at 15 s, which corresponds to the peak response, was significantly inhibited by electroporation of antibodies against PLC-beta 1, but not by anti-PLC-gamma and -delta antibodies. Electroporation of anti-G alpha(q/11), and -G alpha(12) antibodies also showed significant inhibition of the Ang II-induced IP3 generation at 15 s, while anti-G alpha(i) and G alpha(13) antibodies were ineffective. Furthermore, in VSMCs electroporated with anti-G beta antibody and cells stably transfected with the plasmid encoding the G beta gamma-binding region of the carboxyl terminus of beta-adrenergic receptor kinase1, the peak Ang II-stimulated PLC activity (at 15 s) was significantly inhibited. The tyrosine kinase inhibitor, genistein, had no effect on the peak. response to Ang II stimulation, but significantly inhibited IP3 production after 30 s, a time period which temporally correlated with PLC-gamma tyrosine phosphorylation in response to Ang II. Moreover, electroporation of anti-PLC-gamma antibody markedly inhibited the IP3 production measured at 30 s, indicating that tyrosine phosphorylation of PLC-gamma contributes mainly to the later phase of PLC activation. Thus, these results suggest that: 1) AT(1) receptors sequentially couple to PLC-beta 1 via a heterotrimeric G protein and to PLC-gamma via a downstream tyrosine kinase; 2) the initial AT(1) receptor-PLC-beta 1 coupling is mediated by G alpha(q/11)beta gamma and G alpha(q/11)beta gamma; 3) G beta gamma acts as a signal transducer for activation of PLC in VSMCs. The sequential coupling of AT(1) receptors to PLC-beta 1 and PLC-gamma, as well as dual coupling of AT(1) receptors to distinct Ga proteins, suggests a novel mechanism for a temporally controlled, highly organized and convergent Ang II-signaling network in VSMCs.	Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA	Emory University	Ushio-Fukai, M (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, 1639 Pierce Dr,Rm 319, Atlanta, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL47557] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047557] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BAHK YY, 1994, J BIOL CHEM, V269, P8240; Coso OA, 1996, J BIOL CHEM, V271, P3963; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; GRIENDLING KK, 1991, J BIOL CHEM, V266, P15498; GRIENDLING KK, 1989, J CARDIOVASC PHARM, V14, pS27, DOI 10.1097/00005344-198906146-00008; GRIENDLING KK, 1994, TXB HYPERTENSION, P244; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HOMMA Y, 1993, BIOCHEM J, V290, P649, DOI 10.1042/bj2900649; Kai H, 1996, MOL PHARMACOL, V49, P96; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KU CY, 1995, ENDOCRINOLOGY, V136, P1509, DOI 10.1210/en.136.4.1509; Macrez N, 1997, J BIOL CHEM, V272, P23180, DOI 10.1074/jbc.272.37.23180; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OKUDA K, 1996, AM J PHYSIOL, V271, pH595; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; Schelling JR, 1997, AM J PHYSIOL-CELL PH, V272, pC1558, DOI 10.1152/ajpcell.1997.272.5.C1558; Schelling JR, 1996, AM J PHYSIOL-RENAL, V270, pF682, DOI 10.1152/ajprenal.1996.270.4.F682; SOCORRO L, 1990, BIOCHEM J, V265, P799, DOI 10.1042/bj2650799; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; SU XL, 1994, J BIOL CHEM, V269, P12925; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZHANG BX, 1992, J BIOL CHEM, V267, P24387	30	97	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19772	19777		10.1074/jbc.273.31.19772	http://dx.doi.org/10.1074/jbc.273.31.19772			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677408	hybrid			2022-12-27	WOS:000075125200060
J	Bouvet, P; Diaz, JJ; Kindbeiter, K; Madjar, JJ; Amalric, F				Bouvet, P; Diaz, JJ; Kindbeiter, K; Madjar, JJ; Amalric, F			Nucleolin interacts with several ribosomal proteins through its RGG domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; RNA-BINDING PROTEINS; HAMSTER OVARY CELLS; TARGETING SEQUENCES; POLYACRYLAMIDE-GEL; RAT-LIVER; LOCALIZATION; GLYCINE; RICH; NG,NG-DIMETHYLARGININE	Nucleolin is one of the major nonribosomal proteins of the nucleolus, Through its four RNA-binding domains, nucleolin interacts specifically with pre-rRNA as soon as synthesis begins, but it is not found in mature cyto-plasmic ribosomes, Nucleolin is able to shuttle between the cytoplasm and the nucleus. These data suggest that nucleolin might be involved in the nucleolar import of cytoplasmic components and in the assembly of pre-ribosomal particles. Here we show, using two-dimensional blots in a ligand blotting assay, th at nucleolin interacts with 18 ribosomal proteins from rat (14 and 4 from the large and small subunit, respectively). The C-terminal domain of nucleolin (p50) interacts with 10 of these identified ribosomal proteins, In vitro binding assays show that the glycine-arginine rich, domain of nucleolin (RGG domain) is sufficient for the interaction with one of these proteins. Interestingly, most of the proteins that interact with p50 belong to the core ribosomal proteins, which are resistant to extraction with high salt concentration. These findings suggest that nucleolin might be involved in the nucleolar targeting of some ribosomal proteins and in their assembly within pre-ribosomal particles.	CNRS, Inst Biol Cellulaire & Genet, UPR 9006, Lab Biol Mol Eucaryote, F-31062 Toulouse, France; Fac Med Lyon, RTH Laennec, CNRS, UMR5537, F-69372 Lyon 08, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Bouvet, P (corresponding author), CNRS, Inst Biol Cellulaire & Genet, UPR 9006, Lab Biol Mol Eucaryote, 118 Route Narbonne, F-31062 Toulouse, France.		, Bouvet/AAC-8779-2020; DIAZ, Jean-Jacques/H-3018-2014; DIAZ, Jean-Jacques/AAT-3846-2021	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319; Bouvet, Philippe/0000-0003-4524-2233				BELENGUER P, 1990, MOL CELL BIOL, V10, P3607, DOI 10.1128/MCB.10.7.3607; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOURBON HM, 1983, MOL BIOL REP, V9, P39, DOI 10.1007/BF00777472; Bouvet P, 1997, EMBO J, V16, P5235, DOI 10.1093/emboj/16.17.5235; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAIZERGUESFERRER M, 1987, BIOCHEMISTRY-US, V26, P7876, DOI 10.1021/bi00398a051; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Chan YL, 1996, BIOCHEM BIOPH RES CO, V225, P952, DOI 10.1006/bbrc.1996.1277; CHOOI WY, 1981, P NATL ACAD SCI-BIOL, V78, P4823, DOI 10.1073/pnas.78.8.4823; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ERARD MS, 1988, EUR J BIOCHEM, V175, P525, DOI 10.1111/j.1432-1033.1988.tb14224.x; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GIRARD JP, 1994, J BIOL CHEM, V269, P18499; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPEYRE B, 1985, NUCLEIC ACIDS RES, V13, P5805, DOI 10.1093/nar/13.16.5805; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; MADJAR JJ, 1979, MOL GEN GENET, V171, P121, DOI 10.1007/BF00269998; MADJAR JJ, 1980, MOL GEN GENET, V179, P89, DOI 10.1007/BF00268450; MCCONKEY EH, 1979, MOL GEN GENET, V169, P1, DOI 10.1007/BF00267538; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; Quaye IKE, 1996, EUR J CELL BIOL, V69, P151; REBOUD JP, 1974, ACTA BIOL MED GER, V33, P661; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; RUSSO G, 1997, J BIOL CHEM, V272, P52229; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Serin G, 1996, BIOCHIMIE, V78, P530, DOI 10.1016/0300-9084(96)84759-6; Serin G, 1997, J BIOL CHEM, V272, P13109, DOI 10.1074/jbc.272.20.13109; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; WELFLE H, 1976, ACTA BIOL MED GER, V35, P401; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; Yaseen NR, 1997, P NATL ACAD SCI USA, V94, P4451, DOI 10.1073/pnas.94.9.4451	47	163	165	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19025	19029		10.1074/jbc.273.30.19025	http://dx.doi.org/10.1074/jbc.273.30.19025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668083	hybrid			2022-12-27	WOS:000074974700050
J	Franz, C; Durussel, I; Cox, JA; Schafer, BW; Heizmann, CW				Franz, C; Durussel, I; Cox, JA; Schafer, BW; Heizmann, CW			Binding of Ca2+ and Zn2+ to human nuclear S100A2 and mutant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; ZINC-BINDING; CA2+-BINDING PROTEINS; HIGH-AFFINITY; TROPONIN-C; FAMILY; EXPRESSION; CALCYCLIN; MEMBER; GENES	The Ca2+-binding protein S100A2 is an unusual member of the 5100 family, characterized by its nuclear localization and down-regulated expression in tumorigenic cells. In this study, we investigated the properties of human recombinant S100A2 (wtS100A2) and of two mutants in which the amino-terminal Ca2+-binding site I (N mutant) and in addition the carboxyl-terminal site II (NC mutant) were replaced by the canonical loop (EF-site) of cu-parvalbumin. Size exclusion chromatography and circular dichroism showed that, irrespective of the state of cation binding, wtS100A2 and mutants are dimers and rich in alpha-helical structure. Flow dialysis revealed that wtS100A2 binds four Ca2+ atoms per dimer with pronounced positive cooperativity. Both mutants also bind four Ca2+ atoms but with a higher affinity than wtS100A2 and with negative cooperativity. The binding of the first two Ca2+ ions to the N mutant occurred with 100-fold higher affinity than in wtS100A2 and a a-fold increase for the last two Ca2+ ions. A further 2-3-fold increase of affinity was observed for respective binding steps of the NC mutant. The Hummel-Dryer method demonstrated that the wild type and mutants bind four Zn2+ atoms per dimer with similar affinity. Fluorescence and difference spectrophotometry showed that the binding of Ca2+ and Zn2+ induces considerable conformational changes, mostly attributable to changes in the microenvironment of Tyr(76) located in site II. Fluorescence enhancement of 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid clearly indicated that Ca2+ and Zn2+ binding induce a hydrophobic patch at the surface of wtS100A2, which, as in calmodulin, may be instrumental for the regulatory role of S100A2 in the nucleus.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland	University of Geneva; University of Zurich	Cox, JA (corresponding author), Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland.	jos.cox@biochem.unige.ch		Schafer, Beat/0000-0001-5988-2915				Allen BG, 1996, BIOCHEM CELL BIOL, V74, P687, DOI 10.1139/o96-075; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DONATO R, 1991, CELL CALCIUM, V12, P713, DOI 10.1016/0143-4160(91)90040-L; Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226; Drohat AC, 1998, BIOCHEMISTRY-US, V37, P2729, DOI 10.1021/bi972635p; Durussel I, 1997, BBA-PROTEIN STRUCT M, V1343, P139, DOI 10.1016/S0167-4838(97)00106-4; ENGELKAMP D, 1993, P NATL ACAD SCI USA, V90, P6547, DOI 10.1073/pnas.90.14.6547; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FILIPEK A, 1990, FEBS LETT, V264, P263, DOI 10.1016/0014-5793(90)80263-I; Finkbeiner S, 1997, BIOESSAYS, V19, P657, DOI 10.1002/bies.950190803; FOHR UG, 1995, J BIOL CHEM, V270, P21056, DOI 10.1074/jbc.270.36.21056; FOHR UG, 1993, EUR J BIOCHEM, V215, P719, DOI 10.1111/j.1432-1033.1993.tb18084.x; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GLENNEY JR, 1989, J CELL BIOL, V108, P569, DOI 10.1083/jcb.108.2.569; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Heierhorst J, 1997, EUR J BIOCHEM, V249, P127, DOI 10.1111/j.1432-1033.1997.00127.x; Heizmann CW, 1996, MOL CELLS, V6, P629; HILT DC, 1991, NOVEL CALCIUM BINDIN, P65; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; JOHANSSON C, 1991, EUR J BIOCHEM, V202, P1283, DOI 10.1111/j.1432-1033.1991.tb16501.x; JOHANSSON C, 1993, BIOCHEMISTRY-US, V32, P8429, DOI 10.1021/bi00084a007; Kilby PM, 1996, STRUCTURE, V4, P1041, DOI 10.1016/S0969-2126(96)00111-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEUNG IKM, 1987, FEBS LETT, V214, P35, DOI 10.1016/0014-5793(87)80008-X; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; Matsumura H, 1998, STRUCTURE, V6, P233, DOI 10.1016/S0969-2126(98)00024-0; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; Pan BS, 1996, J BIOL CHEM, V271, P817, DOI 10.1074/jbc.271.2.817; PARKER C, 1994, DNA CELL BIOL, V13, P343, DOI 10.1089/dna.1994.13.343; PAULS TL, 1994, BIOCHEMISTRY-US, V33, P10393, DOI 10.1021/bi00200a021; PEDROCCHI M, 1994, BIOCHEMISTRY-US, V33, P6732, DOI 10.1021/bi00187a045; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; PerezTerzic C, 1997, BIOESSAYS, V19, P787, DOI 10.1002/bies.950190908; Potts BCM, 1996, PROTEIN SCI, V5, P2162, DOI 10.1002/pro.5560051103; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; Precheur B, 1996, FEBS LETT, V395, P89, DOI 10.1016/0014-5793(96)01007-1; Raftery MJ, 1996, BIOCHEM J, V316, P285, DOI 10.1042/bj3160285; Rhyner JA, 1996, BBA-MOL CELL RES, V1313, P179, DOI 10.1016/0167-4889(96)00087-0; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Sastry M, 1998, STRUCTURE, V6, P223, DOI 10.1016/S0969-2126(98)00023-9; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Smith SP, 1998, STRUCTURE, V6, P211, DOI 10.1016/S0969-2126(98)00022-7; Treves S, 1997, BIOCHEMISTRY-US, V36, P11496, DOI 10.1021/bi970160w; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1	57	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18826	18834		10.1074/jbc.273.30.18826	http://dx.doi.org/10.1074/jbc.273.30.18826			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668057	hybrid			2022-12-27	WOS:000074974700024
J	Duguay, SJ; Jin, Y; Stein, J; Duguay, AN; Gardner, P; Steiner, DF				Duguay, SJ; Jin, Y; Stein, J; Duguay, AN; Gardner, P; Steiner, DF			Post-translational processing of the insulin-like growth factor-2 precursor - Analysis of O-glycosylation and endoproteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; E-DOMAIN; TUMOR HYPOGLYCEMIA; IGF-II; SERUM; BIOSYNTHESIS; EXPRESSION; PROTEIN; MOUSE; CELLS	Insulin-like growth factor-2 (IGF-2) is expressed in most embryonic tissues and is required for normal development during gestation. After birth IGF-2 expression is extinguished in most tissues, but the gene is often reactivated during tumorigenesis. Tumors secrete high molecular weight forms of IGF-2 that result from aberrant post-translational processing of pro-IGF-2. As a first step toward understanding how high molecular weight IGF-P peptides might contribute to tumor progression, we have characterized the biosynthesis of IGF-P in a human embryonic cell line. We have found that pro-IGF-a can initially form two disulfide isomers that undergo rearrangement to a single conformation in vivo. The addition of N-acetylgalactosamine to Ser(71), Thr(72), Thr(75), and Thr(139) likely occurs in the cis-Golgi apparatus. Sialic acid addition begins in the trans Golgi apparatus, but IGF-2 peptides must reach the trans-Golgi network for oligosaccharide maturation to be completed. Endoproteolysis occurs concomitant to or slightly after oligosaccharide maturation. Cleavage was observed only at Arg(104), resulting in the secretion of IGF-2-(1-104) and free Et-peptide. Proteolysis required basic residues in the P1 (Arg(104)), and P4 (Arg(101)) positions, was completely blocked by a furin inhibitor, and was enhanced by coexpression with furin, PACE4, PC6A, PC6B, and LPC. These data suggest that members of the subtilisin-related proprotein convertase family mediate processing of pro-IGF-2 at Arg(104). We did not detect the IGF-S peptides that are most abundant in normal serum, mature IGF-S, and IGF-2-(1-87), in this expression system, which indicates that novel endoproteases are responsible for generating these products.	Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago	Duguay, SJ (corresponding author), Transkaryot Therapies Inc, 195 Albany St, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013914, P30DK020595, P60DK020595, R37DK013914] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20595, DK13914] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAUGHADAY WH, 1988, NEW ENGL J MED, V319, P1434, DOI 10.1056/NEJM198812013192202; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; DAUGHADAY WH, 1992, J CLIN ENDOCR METAB, V75, P641, DOI 10.1210/jc.75.2.641; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DUGUAY SJ, 1995, FEBS LETT, V371, P69, DOI 10.1016/0014-5793(95)00879-E; DUGUAY SJ, 1995, J BIOL CHEM, V270, P17566, DOI 10.1074/jbc.270.29.17566; Duguay SJ, 1997, J BIOL CHEM, V272, P6663, DOI 10.1074/jbc.272.10.6663; GOWAN LK, 1987, ENDOCRINOLOGY, V121, P449, DOI 10.1210/endo-121-2-449; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HOBER S, 1992, BIOCHEMISTRY-US, V31, P1749, DOI 10.1021/bi00121a024; HOBER S, 1994, BIOCHEMISTRY-US, V33, P6758, DOI 10.1021/bi00188a003; HOEFLICH A, 1995, EUR J BIOCHEM, V232, P172, DOI 10.1111/j.1432-1033.1995.tb20796.x; HOLTHUIZEN PE, 1993, REGUL PEPTIDES, V48, P77, DOI 10.1016/0167-0115(93)90337-8; Hounsell EF, 1996, GLYCOCONJUGATE J, V13, P19, DOI 10.1007/BF01049675; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; HYLKA VW, 1985, J BIOL CHEM, V260, P4417; Jespersen S, 1996, J MASS SPECTROM, V31, P893, DOI 10.1002/(SICI)1096-9888(199608)31:8<893::AID-JMS374>3.0.CO;2-S; LEE AV, 1994, MOL CELL ENDOCRINOL, V99, P211, DOI 10.1016/0303-7207(94)90010-8; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; NIELSEN FC, 1993, MOL CELL ENDOCRINOL, V93, P87, DOI 10.1016/0303-7207(93)90143-8; RINDERKNECHT E, 1978, FEBS LETT, V89, P283, DOI 10.1016/0014-5793(78)80237-3; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SHAPIRO ET, 1990, J CLIN INVEST, V85, P1672, DOI 10.1172/JCI114619; SHUI RPC, 1988, ENDOCRINOLOGY, V123, P1456; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; VALENZANO KJ, 1995, J BIOL CHEM, V270, P16441, DOI 10.1074/jbc.270.27.16441; Valenzano KJ, 1997, J BIOL CHEM, V272, P4804, DOI 10.1074/jbc.272.8.4804; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Yang CQ, 1996, ENDOCRINOLOGY, V137, P2766, DOI 10.1210/en.137.7.2766; YANG YWH, 1985, J BIOL CHEM, V260, P2570; ZAPF J, 1992, J CLIN INVEST, V90, P2574, DOI 10.1172/JCI116152; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	42	95	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18443	18451		10.1074/jbc.273.29.18443	http://dx.doi.org/10.1074/jbc.273.29.18443			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660813	hybrid			2022-12-27	WOS:000074828500068
J	Parker, AE; Van de Weyer, I; Laus, MC; Verhasselt, P; Luyten, WHML				Parker, AE; Van de Weyer, I; Laus, MC; Verhasselt, P; Luyten, WHML			Identification of a human homologue of the Schizosaccharomyces pombe rad17(+) checkpoint gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINT; WILD-TYPE P53; DNA POLYMERASE-DELTA; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; INSITU HYBRIDIZATION; ACCESSORY PROTEINS; 2-HYBRID SYSTEM; NUCLEAR ANTIGEN; DAMAGE	In the fission yeast Schizosaccharomyces pombe the rad17(+) gene is required for both the DNA damage-dependent and the DNA replication dependent cell cycle checkpoints, We have identified a human cDNA homologue of the S. pombe rad17(+) checkpoint gene, designated Hrad17. Hrad17 has 49% identity to the S. pombe rad17(+) sequence at the DNA level and 49% identity and 72% similarity at the amino acid level. Northern blot analysis indicates elevated levels of expression in testis and in cancer cell lines. Chromosomal localization by fluorescence in situ hybridization indicates that Hrad17 is located on chromosome 4q13.3-21.2. This region is subject to loss of heterozygosity in several human cancers. To begin to understand the protein-protein interactions of the human checkpoint machinery, Fee have used the yeast two-hybrid system to examine potential interactions between Hrad1, Hrad9, and Hrad17, We demonstrate a physical interaction between Hrad17 and Hrad1 but no interaction with Hrad9.	Janssen Res Fdn, Dept Expt Mol Biol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Appl Mol Biol, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson	Luyten, WHML (corresponding author), Janssen Res Fdn, Dept Expt Mol Biol, Turnhoutseweg 30, B-2340 Beerse, Belgium.	wluyten@janbe.jnj.com						ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CARR AM, 1994, INT J RAD BIOL S, V66, P133; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Heng H H, 1994, Methods Mol Biol, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Kaiser C., 1994, METHODS YEAST GENETI; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE SH, 1991, J BIOL CHEM, V266, P22707; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schwendel A, 1997, INT J CANCER, V74, P86, DOI 10.1002/(SICI)1097-0215(19970220)74:1<86::AID-IJC15>3.0.CO;2-G; Tirkkonen M, 1997, CANCER RES, V57, P1222; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; VERHAEGH GWCT, 1995, AM J HUM GENET, V57, P1095; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	47	69	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18340	18346		10.1074/jbc.273.29.18340	http://dx.doi.org/10.1074/jbc.273.29.18340			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660800	hybrid			2022-12-27	WOS:000074828500055
J	Sharma, PM; Egawa, K; Huang, Y; Martin, JL; Huvar, I; Boss, GR; Olefsky, JM				Sharma, PM; Egawa, K; Huang, Y; Martin, JL; Huvar, I; Boss, GR; Olefsky, JM			Inhibition of phosphatidylinositol 3-kinase activity by adenovirus-mediated gene transfer and its effect on insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE RELEASING-FACTOR; GLYCOGEN-SYNTHASE; 3T3-L1 ADIPOCYTES; GLUCOSE-TRANSPORT; RECEPTOR SUBSTRATE-1; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; DNA-SYNTHESIS; GROWTH-FACTOR; WILD-TYPE	Phosphatidylinositol 3-kinase (PI 3-K) is implicated in cellular events including glucose transport, glycogen synthesis, and protein synthesis. It is activated in insulin-stimulated cells by binding of the Src homology 2 (SH2) domains in its 85-kDa regulatory subunit to insulin receptor substrate-1 (IRS-1), and, others. We have previously she-con that IRS-l-associated PI 3-kinase activity is not essential for insulin-stimulated glucose transport in 3T3-L1 adipocytes, and that alternate pathways exist in these cells. We now show that adenovirus-mediated overexpression of the p85N-SH2 domain in these cells behaves in a dominant-negative manner, interfering with complex formation between endogenous PI 3-K and its SH2 binding targets. This not only inhibited insulin-stimulated IRS-l-associated PI 3-kinase activity, but also completely blocked anti-phosphotyrosine-associated PI 3-kinase activity, which would include the non-IRS-1-associated activity. This resulted in inhibition of insulin-stimulated glucose transport, glycogen synthase activity and DNA synthesis. Further, Ser/Thr phosphorylation of downstream molecules Akt and p70 S6 kinase was inhibited. However, co expression of a membrane-targeted p110(CAAX) With the p85N-SH2 protein rescued glucose transport, supporting our argument that the p85N-SH2 protein specifically blocks insulin-mediated PI 3-kinase activity, and, that the signaling pathways downstream of PI 3-kinase are intact. Unexpectedly, GTP-bound Pas was elevated in the basal state. Since p85 is known to interact with GTPase-activating protein in 3T3-L1 adipocytes, the overexpressed p85N-SH2 peptide could titrate out cellular GTPase-activating protein by direct association, such that it is unavailable to hydrolyze GTP-bound Pas. However, insulin-induced mitogen-activated protein kinase phosphorylation was inhibited. Thus, PI 3-kinase may be required for this action at a step independent of and downstream of Pas. We conclude that, in 3T3-L1 adipocytes, non-IRS-l-associated PI 3-kinase activity is crucial for insulin's metabolic signaling, and that overexpressed p85N-SH2 protein inhibits a variety of insulin's ultimate biological effects.	Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Inst Diabet & Endocrinol, La Jolla, CA 92093 USA; Vet Adm Res Serv, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Boss, Gerry/0000-0002-9758-8714	NIDDK NIH HHS [R01 DK 36651] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BALTENSPERGER K, 1994, J BIOL CHEM, V269, P28937; BENJAMIN WB, 1994, BIOCHEM J, V300, P477, DOI 10.1042/bj3000477; BERGER J, 1994, BIOCHEM BIOPH RES CO, V205, P570, DOI 10.1006/bbrc.1994.2703; Braselmann S, 1997, CURR BIOL, V7, pR470, DOI 10.1016/S0960-9822(06)00239-9; Carel K, 1996, J BIOL CHEM, V271, P30625, DOI 10.1074/jbc.271.48.30625; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Conricode KM, 1995, BIOCHEM MOL BIOL INT, V36, P835; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; Frevert EU, 1997, MOL CELL BIOL, V17, P190, DOI 10.1128/MCB.17.1.190; FRY MJ, 1994, BBA-MOL BASIS DIS, V1226, P237, DOI 10.1016/0925-4439(94)90036-1; Gluzman Y., 1982, EUKARYOTIC VIRAL VEC, P187; GUINOVART JJ, 1979, FEBS LETT, V106, P284, DOI 10.1016/0014-5793(79)80515-3; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Krook A, 1996, J BIOL CHEM, V271, P7134, DOI 10.1074/jbc.271.12.7134; LANGLOIS J, 1995, ENDOCRINE, V3, P475, DOI 10.1007/BF02738820; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lavan BE, 1997, J BIOL CHEM, V272, P21403, DOI 10.1074/jbc.272.34.21403; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LIU H, 1996, DIABETES S2, V45, pA119; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MARGALETSANCHEZ V, 1994, BIOCHEM BIOPH RES CO, V204, P446; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARKER PJ, 1983, EUR J BIOCHEM, V130, P227; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; SHARMA PM, 1994, P NATL ACAD SCI USA, V91, P9931, DOI 10.1073/pnas.91.21.9931; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; ZHANG WW, 1995, BIOTECHNIQUES, V18, P444	64	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18528	18537		10.1074/jbc.273.29.18528	http://dx.doi.org/10.1074/jbc.273.29.18528			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660823	hybrid			2022-12-27	WOS:000074828500078
J	Berhane, K; Ray, AA; Khanapure, SP; Rokach, J; Powell, WS				Berhane, K; Ray, AA; Khanapure, SP; Rokach, J; Powell, WS			Calcium/calmodulin-dependent conversion of 5-oxoeicosanoids to 6,7-dihydro metabolites by a cytosolic olefin reductase in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; LEUKOTRIENE B-4; 5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; PROSTAGLANDIN DEHYDROGENASE; ARACHIDONIC-ACID; DIHYDRO PRODUCTS; HUMAN MONOCYTES; FATTY-ACIDS; CELLS; PURIFICATION	We previously showed that 6-trans isomers of leukotriene B-4 but not leukotriene B-4 itself are converted to dihydro metabolites by human neutrophils. The first step in the formation of these metabolites is oxidation of the 5-hydroxyl group by 5-hydroxyeicosanoid dehydrogenase, The objective of the present investigation was to characterize the second step in the formation of the dihydro metabolites, reduction of an olefinic double bond. We found that the olefin reductase reduces the 6,7-double bond of 8-oxoeicosanoids, is localized in the cytosolic fraction of neutrophils, and requires NADPH as a cofactor. Neutrophil cytosol converts a variety of both 5-oxo- and 15-oxoeicosanoids to dihydro products. However, conversion of 5-oxoeicosanoids to their 6,7-dihydro metabolites is inhibited by EGTA and a calmodulin antagonist and stimulated by the addition of calcium and calmodulin, whereas the reduction of 15-oxoeicosanoids to their 13,14-dihydro metabolites is slightly inhibited by calcium. Furthermore, eicosanoid Delta(6)- and Delta(13)-reductases could be separated by chromatography on DEAE-Sepharose. 5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is converted by the Delta(6)-reductase to 6,7-dihydro-5-oxo-ETE, which is 1000 times less potent than 5-oxo-ETE in mobilizing calcium in neutrophils. We conclude that neutrophils contain both 5-oxo-eicosanoid Delta(6)-reductase and prostaglandin Delta(13)-reductase, Metabolism of 5-oxo-ETE by the Delta(6)-reductase results in loss of its biological activity.	McGill Univ, Dept Med, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA	McGill University; Florida Institute of Technology; Florida Institute of Technology	Powell, WS (corresponding author), McGill Univ, Dept Med, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	Bill@Meakins.LAN.McGill.ca	Powell, William/AAE-9000-2020	Powell, William/0000-0002-8507-4038; Rokach, Joshu/0000-0003-1814-7505	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044730] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44730] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGGARD E, 1971, ACTA PHYSIOL SCAND, V81, P396, DOI 10.1111/j.1748-1716.1971.tb04914.x; BERGHOLTE JM, 1987, ARCH BIOCHEM BIOPHYS, V257, P444, DOI 10.1016/0003-9861(87)90589-3; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAITHWAITE SS, 1975, J BIOL CHEM, V250, P2315; FILIPOVIC I, 1987, LIPIDS, V22, P261, DOI 10.1007/BF02533989; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; HAMBERG M, 1971, J BIOL CHEM, V246, P1073; KAEVER V, 1988, FEBS LETT, V231, P385, DOI 10.1016/0014-5793(88)80855-X; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; Khanapure SP, 1998, J ORG CHEM, V63, P4098, DOI 10.1021/jo980280p; Kitamura S, 1996, PROSTAGLANDINS, V52, P35, DOI 10.1016/0090-6980(96)00050-0; KUMLIN M, 1990, BIOCHEM BIOPH RES CO, V170, P23, DOI 10.1016/0006-291X(90)91235-K; MAAS RL, 1982, J BIOL CHEM, V257, P7056; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MASFERRER JL, 1991, EXP EYE RES, V52, P417, DOI 10.1016/0014-4835(91)90037-F; OFLAHERTY JT, 1993, BIOCHEM BIOPH RES CO, V192, P129, DOI 10.1006/bbrc.1993.1391; OFLAHERTY JT, 1994, BBA-GEN SUBJECTS, V1201, P505, DOI 10.1016/0304-4165(94)90083-3; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Okita RT, 1996, CRIT REV BIOCHEM MOL, V31, P101, DOI 10.3109/10409239609106581; Powell WS, 1996, J PHARMACOL EXP THER, V276, P728; POWELL WS, 1980, PROSTAGLANDINS, V20, P947, DOI 10.1016/0090-6980(80)90144-6; POWELL WS, 1993, J BIOL CHEM, V268, P9280; Powell WS, 1996, J IMMUNOL, V156, P336; POWELL WS, 1992, J BIOL CHEM, V267, P19233; POWELL WS, 1988, J BIOL CHEM, V263, P2170; POWELL WS, 1986, BIOCHEM BIOPH RES CO, V136, P707, DOI 10.1016/0006-291X(86)90497-3; POWELL WS, 1995, J IMMUNOL, V154, P4123; POWELL WS, 1987, ANAL BIOCHEM, V164, P117, DOI 10.1016/0003-2697(87)90375-7; SCHONFELD W, 1991, J LEUKOCYTE BIOL, V50, P303, DOI 10.1002/jlb.50.3.303; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; SHIMIZU T, 1990, METHOD ENZYMOL, V187, P296; SUN FF, 1974, PROSTAGLANDINS, V7, P327, DOI 10.1016/S0090-6980(74)80088-2; WAINWRIGHT S, 1990, BIOCHEMISTRY-US, V29, P10126, DOI 10.1021/bi00495a017; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WHEELAN P, 1995, J BIOL CHEM, V270, P19845, DOI 10.1074/jbc.270.34.19845; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128	38	14	14	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20951	20959		10.1074/jbc.273.33.20951	http://dx.doi.org/10.1074/jbc.273.33.20951			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694844	hybrid			2022-12-27	WOS:000075386100037
J	Bird, AJ; Turner-Cavet, JS; Lakey, JH; Robinson, NJ				Bird, AJ; Turner-Cavet, JS; Lakey, JH; Robinson, NJ			A carboxyl-terminal Cys/His(2)-type zinc-finger motif in DNA primase influences DNA content in Synechococcus PCC 7942	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR-SYNTHESIS OPERON; ESCHERICHIA-COLI PRIMASE; TRANSFER-RNA SYNTHETASE; TRANSCRIPTION FACTOR; REPLICATION FORK; METALLOTHIONEIN LOCUS; BINDING DOMAIN; METAL-BINDING; HELICASE; PROTEIN	The DNA primase gene, dnaG, has been isolated from the cyanobacterium Synechococcus PCC 7942, It is not part of a macromolecular synthesis operon but is cotranscribed with pheT and located adjacent to the metallothionein divergon, smt. At the carboxyl terminus of this DnaG is a Cys(2)/His(2) zinc-finger motif. The carboxyl-terminal 91 residues bound Zn-65 and 0.95 g atom of Zn2+ mol(-1) were detected with 4-(2-pyridylazo)resorcinol. Following exposure to Cd2+, 0.95 g atom of Cd2+ was displaced by 2 equivalents of p-(hydroxymercuri) phenylsulfonate mol(-1), while only 0.03 g atom of Cd2+ was displaced mol(-1) polypeptide missing the carboxyl-terminal (residue 592 onward) zinc-finger motif, Zn2+ caused an increase in intensity, and a reduction in wavelength, of Trp fluorescence at the tip of the predicted zinc-finger, while EDTA caused the converse. Cells containing a single chromosomal codon substitution (C597S), altering the zinc-finger, were generated by exploiting Zn2+-sensitive smt mutants and the proximity of dnaG to smt, Cells in which smt and dnaG(C597S) had integrated into the chromosome were selected via restored Zn2+ tolerance. Synechococcus PCC 7942 and its dnaG(C597S) mutant grew at equivalent rates, but the latter had a reduced number of chromosomes.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Robinson, NJ (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Robinson, Nigel J/J-6363-2012	Robinson, Nigel J/0000-0001-5586-1092; Cavet, Jennifer/0000-0001-5913-7157				AYROA S, 1997, MOL MICROBIOL, V23, P639; BERG JM, 1990, J BIOL CHEM, V265, P6513; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BINDER BJ, 1995, APPL ENVIRON MICROB, V61, P708, DOI 10.1128/AEM.61.2.708-717.1995; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; GRIEP A, 1997, BIOCHEMISTRY-US, V36, P544; Griep MA, 1996, BIOCHEMISTRY-US, V35, P8260, DOI 10.1021/bi952948p; GROMPE M, 1991, J BACTERIOL, V173, P1268, DOI 10.1128/jb.173.3.1268-1278.1991; HUCKLE JW, 1993, MOL MICROBIOL, V7, P177, DOI 10.1111/j.1365-2958.1993.tb01109.x; HUNT JB, 1984, J BIOL CHEM, V259, P4793; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; JEZOREK JR, 1979, ANAL CHEM, V51, P373, DOI 10.1021/ac50039a012; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; KLEMBA M, 1995, BIOCHEMISTRY-US, V34, P10094, DOI 10.1021/bi00031a034; Kusakabe T, 1996, J BIOL CHEM, V271, P19563, DOI 10.1074/jbc.271.32.19563; KUWAHARA J, 1990, BIOCHEMISTRY-US, V29, P8627, DOI 10.1021/bi00489a019; LANDRO JA, 1994, J BIOL CHEM, V269, P20217; LARK KG, 1972, NATURE-NEW BIOL, V240, P237, DOI 10.1038/newbio240237a0; LIU JH, 1995, J BIOL CHEM, V270, P15162, DOI 10.1074/jbc.270.25.15162; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; LUISI B, 1992, NATURE, V356, P379, DOI 10.1038/356379a0; LUPSKI JR, 1984, CELL, V39, P251, DOI 10.1016/0092-8674(84)90001-1; MANN N, 1974, J GEN MICROBIOL, V83, P399; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; MELY Y, 1993, BIOCHIM BIOPHYS ACTA, V1161, P6, DOI 10.1016/0167-4838(93)90189-X; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; METZGER R, 1994, GENE, V151, P161, DOI 10.1016/0378-1119(94)90649-1; MURPHY RC, 1990, J BACTERIOL, V172, P967, DOI 10.1128/jb.172.2.967-976.1990; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Poutney Dean L., 1997, Protein Science, V6, P892; ROSE PE, 1995, J VIROL, V69, P2842, DOI 10.1128/JVI.69.5.2842-2849.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YG, 1995, SCIENCE, V268, P282, DOI 10.1126/science.7536342; STAMFORD NPJ, 1992, BIOCHIM BIOPHYS ACTA, V1132, P17, DOI 10.1016/0167-4781(92)90047-4; TOMMEY AM, 1991, FEBS LETT, V292, P49; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; TSUJIKAWA K, 1991, FEBS LETT, V283, P239, DOI 10.1016/0014-5793(91)80597-V; TURNER JS, 1995, J IND MICROBIOL, V14, P259, DOI 10.1007/BF01569937; TURNER JS, 1993, J BIOL CHEM, V268, P4494; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; VANDERPLAS J, 1990, GENE, V95, P39, DOI 10.1016/0378-1119(90)90411-J; VERSALOVIC J, 1993, MOL MICROBIOL, V8, P343, DOI 10.1111/j.1365-2958.1993.tb01578.x; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; XU B, 1994, BIOCHEMISTRY-US, V29, P398; YU W, 1994, J BIOL CHEM, V269, P21010; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	52	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21246	21252		10.1074/jbc.273.33.21246	http://dx.doi.org/10.1074/jbc.273.33.21246			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694883	hybrid			2022-12-27	WOS:000075386100076
J	Vijapurkar, U; Cheng, KR; Koland, JG				Vijapurkar, U; Cheng, KR; Koland, JG			Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE BINDING; SIGNAL TRANSDUCTION; FUSION PROTEINS; EGF RECEPTOR; DOMAIN; PHOSPHORYLATION	The ErbB2 and ErbB3 proteins together constitute a functional coreceptor for heregulin (neuregulin). Heregulin stimulates the phosphorylation of both coreceptor constituents and initiates a variety of other signaling events, which include phosphorylation of the Shc protein. The role of Shc in heregulin-stimulated signal transduction through the ErbB2-.ErbB3 coreceptor was investigated here. Heregulin was found to promote ErbB3/Shc association in NIH-3T3 cells expressing endogenous ErbB2 and recombinant ErbB3. A mutant ErbB3 protein was generated in which Tyr-1325 in a consensus Shc phosphotyrosine-binding domain recognition site was mutated to Phe (ErbB3-Y/F). This mutation abolished the association of Shc with ErbB3 and blocked the activation of mitogen-activated protein kinase by heregulin. Whereas heregulin induced mitogenesis in NIH-3T3 cells transfected with wild-type ErbB3 cDNA, this mitogenic response was markedly attenuated in NIH-3T3 cells transfected with the ErbB3-Y/F cDNA. These results showed a specific interaction of Shc with the ErbB3 receptor protein and demonstrated the importance of this interaction in the activation of mitogenic responses by the ErbB2.ErbB3 heregulin coreceptor complex.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Koland, JG (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.			Koland, John/0000-0002-5028-4297	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044684, R01DK044684, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295, DK44684] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HORAN T, 1995, J BIOL CHEM, V270, P24604, DOI 10.1074/jbc.270.41.24604; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; KOLAND JG, 1990, BIOCHEM BIOPH RES CO, V166, P90, DOI 10.1016/0006-291X(90)91915-F; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; Laminet AA, 1996, J BIOL CHEM, V271, P264, DOI 10.1074/jbc.271.1.264; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; ROBBINS DJ, 1994, ADV CANCER RES, V63, P93, DOI 10.1016/S0065-230X(08)60399-1; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; Sierke SL, 1997, BIOCHEM J, V322, P757, DOI 10.1042/bj3220757; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20996	21002		10.1074/jbc.273.33.20996	http://dx.doi.org/10.1074/jbc.273.33.20996			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694850	hybrid			2022-12-27	WOS:000075386100043
J	Xie, LJ; Smith, JA; Gross, SS				Xie, LJ; Smith, JA; Gross, SS			GTP cyclohydrolase I inhibition by the prototypic inhibitor 2,4-diamino-6-hydroxypyrimidine - Mechanisms and unanticipated role of GTP cyclohydrolase I feedback regulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE GENERATION; VASCULAR SMOOTH-MUSCLE; MESSENGER-RNA; TETRAHYDROBIOPTERIN; PURIFICATION; SYNTHASE; CLONING; CELLS	2,4-Diamino-6-hydroxypyrimidine (DAHP) is considered to be a selective and direct-acting inhibitor of GTP cyclohydrolase I (GTPCH), the first and rate-limiting enzyme in the pathway for synthesis of tetrahydrobiopterin (BH4). Accordingly, DAHP has been widely employed to distinguish whether de novo BH4 synthesis is required in a given biological system. Although it has been assumed that DAHP inhibits GTPCH by direct competition with substrate GTP, this has never been formally demonstrated. In view of apparent structural homology between DAHP and BH4, we questioned whether DAHP may mimic BH4 in its inhibition of GTPCH by an indirect mechanism, involving interaction with a recently cloned 9.5-kDa protein termed GTPCH Feedback Regulatory Protein (GFRP). We show by reverse transcription-polymerase chain reaction that GFRP mRNA is constitutively expressed in rat aortic smooth muscle cells and further induced by treatment with immunostimulants. Moreover, functional GFRP is expressed and immunostimulant-induced BH4 accumulates in sufficient quantity to trigger feedback inhibition of GTPCH. Studies with DAHP reveal that GFRP is also essential to achieve potent inhibition of GTPCH. Indeed, DAHP inhibits GTPCH by dual mechanisms. At a relatively low concentration DAHP emulates BH4 and engages the GFRP-dependent feedback inhibitory system; at higher concentrations, DAHP competes directly for binding with GTP substrate. This knowledge predicts that DAHP would preferably target GTPCH in tissues with abundant GFRP.	Cornell Univ, Coll Med, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Coll Med, Program Biochem & Struct Biol, New York, NY 10021 USA	Cornell University; Cornell University	Gross, SS (corresponding author), Cornell Univ, Coll Med, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.				NHLBI NIH HHS [HL50656, HL 46403] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050656, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMOAHAPRAKU B, 1995, J AM SOC NEPHROL, V5, P1630; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KELLEY MR, 1993, ALCOHOL, V10, P185, DOI 10.1016/0741-8329(93)90033-K; LEEMING RJ, 1976, ARCH DIS CHILD, V51, P771, DOI 10.1136/adc.51.10.771; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; MUHL H, 1994, KIDNEY INT, V46, P1302, DOI 10.1038/ki.1994.398; NAR H, 1995, STRUCTURE, V3, P459, DOI 10.1016/S0969-2126(01)00179-4; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIEDERWIESER A, 1986, EUR J PEDIATR, V145, P176, DOI 10.1007/BF00446058; Oddis CV, 1996, AM J PHYSIOL-HEART C, V270, pH1864, DOI 10.1152/ajpheart.1996.270.5.H1864; OZELIUS LJ, 1994, NAT GENET, V8, P207, DOI 10.1038/ng1194-207; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; Werner-Felmayer G, 1996, METHODS NITRIC OXIDE, P271; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; Yoneyama T, 1997, J BIOL CHEM, V272, P9690	20	43	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21091	21098		10.1074/jbc.273.33.21091	http://dx.doi.org/10.1074/jbc.273.33.21091			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694862	hybrid			2022-12-27	WOS:000075386100055
J	Dickens, M; Svitek, CA; Culbert, AA; O'Brien, RM; Tavare, JM				Dickens, M; Svitek, CA; Culbert, AA; O'Brien, RM; Tavare, JM			Central role for phosphatidylinositide 3-kinase in the repression of glucose-6-phosphatase gene transcription by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; ACTIVATED PROTEIN-KINASE; FACTOR-BINDING PROTEIN-1; MAP KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PEPCK GENE; EXPRESSION; INHIBITION; RAPAMYCIN; RECEPTOR	Transcription of the gene encoding the catalytic subunit of glucose-6-phosphatase (G6Pase) is stimulated by glucocorticoids and strongly repressed by insulin. We have explored the signaling pathways by which insulin mediates the repression of G6Pase transcription in H4IIE cells. Wortmannin, a phosphatidylinositide 3-kinase (PtdIns 3-kinase) inhibitor blocked the repression of G6Pase mRNA expression by insulin. However, both rapamycin, which inhibits p70S6 kinase activation, and PD98059, an inhibitor of mitogen-activated protein kinase activation, were without effect. Insulin inhibited dexamethasone-induced luciferase expression from a transiently transfected plasmid that places the luciferase gene under the control of the G6Pase promoter. This effect of insulin was mimicked by the overexpression of a constitutively active PtdIns 3-kinase but not by a constitutively active protein kinase B. Taken together, these data demonstrate that PtdIns 3-kinase activation is both necessary and at least partly sufficient for the repression of G6Pase expression by insulin, but neither mitogen-activated protein kinase nor p70S6 kinase are involved. In addition, activation of protein kinase B alone is not sufficient for repression of the G6Pase gene. These results imply the existence of a novel signaling pathway downstream of PtdIns 3 kinase that is involved in the regulation of G6Pase expression by insulin.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of Bristol; Vanderbilt University	Tavare, JM (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England.	j.tavare@bristol.ac.uk	Dickens, Martin/B-2001-2012					Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FERRARI S, 1993, J BIOL CHEM, V268, P16091; GANSS R, 1994, MOL ENDOCRINOL, V8, P895, DOI 10.1210/me.8.7.895; GOSWAMI R, 1994, ENDOCRINOLOGY, V134, P736, DOI 10.1210/en.134.2.736; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Li WW, 1995, J CLIN INVEST, V96, P2601, DOI 10.1172/JCI118324; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; RUTTER GA, 1995, CURR BIOL, V5, P890, DOI 10.1016/S0960-9822(95)00179-5; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Welsh GI, 1997, ANAL BIOCHEM, V244, P16, DOI 10.1006/abio.1996.9838; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015	43	78	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20144	20149		10.1074/jbc.273.32.20144	http://dx.doi.org/10.1074/jbc.273.32.20144			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685358	hybrid			2022-12-27	WOS:000075305400035
J	Hess, JA; Ji, QS; Carpenter, G; Exton, JH				Hess, JA; Ji, QS; Carpenter, G; Exton, JH			Analysis of platelet-derived growth factor-induced phospholipase D activation in mouse embryo fibroblasts lacking phospholipase C-gamma 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL-LIPID HYDROLYSIS; SWISS 3T3 CELLS; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; PHOSPHATIDYLCHOLINE HYDROLYSIS; FACTOR INCREASES; KINASE-ACTIVITY; C ACTIVATION; STIMULATION; DIACYLGLYCEROL	Platelet-derived growth factor (PDGF) activates phospholipase D (PLD) in mouse embryo fibroblasts (MEFs). In order to investigate a role for phospholipase C-yl (PLC-gamma 1), we used targeted disruption of the Plcg1 gene in the mouse to develop Plcg1(+/+) and Plcg1(-/-) cell lines. Plcg1(+/+) MEFs treated with PDGF showed a time- and dose-dependent increase in the production of total inositol phosphates that was substantially reduced in Plcg1(-/-) cells, PLcg1(+/+) cells also showed a PDGF-induced increase in PLD activity that had a similar dose dependence to the PLC response but was down-regulated after 15 min. Phospholipase D activity, however, was markedly reduced in PLcg1(-/-) cells. The PDGF-induced inositol phosphate formation and the FLD activity that remained in the Plcg1(-/-) cells could be attributed to the presence of phospholipase C-gamma 2 (PLC-gamma S) in the Plcg1(-/-) cells, The PLC-gamma 2 expressed ire the Plcg1(-/-) cells was phosphorylated on tyrosine in response to PDGF treatment, and a small but significant fraction of the Plcg1(-/-) cells showed Ca2+ mobilization in response to PDGF, suggesting that the PLC-gamma 2 expressed in the Plcg1(-/-) cells was activated in response to PDGF. The inhibition of PDGF-induced phospholipid hydrolysis in Plcg1(-/-) cells was not due to differences in the level of PDGF receptor or in the ability of PDGF to cause autophosphorylation of the receptor. Upon treatment of the Plcg1(-/-) cells with oleoyalacetylglycerol and the Ca2+ ionophore ionomycin to mimic the effect of PLC-gamma 1, PLD activity was restored. The targeted disruption of Plcg1 did not result in universal changes in the cell signaling pathways of Plcg(1-/)- cells, because the phosphorylation of mitogen-activated protein kinase was similar in PLcg1(+/+) and Plcg1(-/-) cells. Because increased plasma membrane ruffles occurred in both Plcg1(+/+) and Pbcg1(-/-) cells following PDGF treatment, it is possible neither PLC nor PLD are necessary for this growth factor response. In summary, these data indicate that PLC-gamma is required for growth factor-induced activation of PLD in MEFs.	Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Dept Physiol & Mol Biophys, Sch Med, Nashville, TN 37232 USA.	john.exton@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA075195] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA75195] Funding Source: Medline; PHS HHS [T32KD07061-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BENAV P, 1993, EUR J BIOCHEM, V215, P455, DOI 10.1111/j.1432-1033.1993.tb18054.x; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOK SJ, 1992, BIOCHEM J, V285, P247, DOI 10.1042/bj2850247; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; delPeso L, 1997, BIOCHEM J, V322, P519; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; HA KS, 1993, J BIOL CHEM, V268, P10534; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; Heller M, 1978, Adv Lipid Res, V16, P267; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; Kim BY, 1996, BBA-MOL CELL RES, V1311, P33; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEVIN R, 1992, BIOCHEM J, V279, P559; Rani CSS, 1997, J BIOL CHEM, V272, P10777; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSOFF PM, 1988, CELL, V54, P73, DOI 10.1016/0092-8674(88)90181-X; SIMPSON CMF, 1987, NEUROCHEMISTRY PRACT, P193; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; TOTZKE F, 1992, FEBS LETT, V308, P125, DOI 10.1016/0014-5793(92)81258-N; vanDijk MCM, 1997, J BIOL CHEM, V272, P11011; WAKELAM MJO, 1993, BIOCHEM SOC T, V21, P873; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YEO EJ, 1994, J BIOL CHEM, V269, P27823	42	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20517	20524		10.1074/jbc.273.32.20517	http://dx.doi.org/10.1074/jbc.273.32.20517			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685408	hybrid			2022-12-27	WOS:000075305400085
J	Krueger, S; Gorshkova, I; Brown, J; Hoskins, J; McKenney, KH; Schwarz, FP				Krueger, S; Gorshkova, I; Brown, J; Hoskins, J; McKenney, KH; Schwarz, FP			Determination of the conformations of cAMP receptor protein and its T127L,S128A mutant with and without cAMP from small angle neutron scattering measurements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE BINDING; GENE ACTIVATOR PROTEIN; ESCHERICHIA-COLI; RESOLUTION; MECHANISM; MUTATIONS; DNA	Small angle neutron scattering (SANS) measurements were performed on solutions of cAMP receptor protein (CRP) and on solutions of the T127L,S128A double mutant of CRP (CRPQ*) in D2O K3PO4 buffer containing 0.5 M KCI, in the absence and presence of 3',5' cyclic adenosine monophosphate (cAMP). Energy-minimized structures of the CRP were calculated by minimization of the x-ray crystallographic structure of CRP in either the exclusively "closed" form where the alpha-helices of the carboxyl-terminal domain are folded close to the amino-terminal domain and in the exclusively "open" form where the alpha-helices of the carboxyl-terminal domain are folded away from the amino-terminal domain. Neutron scattering models show that the CRP SANS data follow closely the data curve predicted for unligated CRP in the open form, whereas the cAMP-ligated data are more in agreement with the data predicted for the minimized cAMP-ligated CRP structure in the closed form, Thus, it appears that CRP undergoes a conformational change from the open form to the closed form in solution upon ligation with cAMP. The SANS data from the CRP* and cAMP-ligated CRP*: are coincidental, which implies that there is very little structural difference between the two species of CRP*. This is in agreement with in vivo results, which show that whereas CRP activates transcription in the cell only in the presence of cAMP, CRP* activates transcription in the absence of cAMP, implying that CRP* is already in the correct conformation for the activation of transcription.	NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; NIST, Ctr Neutron Res, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA; National Institute of Standards & Technology (NIST) - USA	Schwarz, FP (corresponding author), NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.							CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; DEGRAZIA H, 1990, BIOCHEMISTRY-US, V29, P3557, DOI 10.1021/bi00466a019; Garcia AE, 1996, PROTEIN SCI, V5, P62; GARGES S, 1988, J BACTERIOL, V170, P1417, DOI 10.1128/jb.170.4.1417-1422.1988; GHOSAINI LR, 1988, BIOCHEMISTRY-US, V27, P5257, DOI 10.1021/bi00414a046; GLATTER O, 1977, J APPL CRYSTALLOGR, V10, P415, DOI 10.1107/S0021889877013879; GORSHKOVA I, 1995, J BIOL CHEM, V270, P21679, DOI 10.1074/jbc.270.37.21679; GRONENBORN AM, 1982, BIOCHEMISTRY-US, V21, P4040, DOI 10.1021/bi00260a020; GRUINIER A, 1955, SMALL ANGLE SCATTERI; HAMMOUDA B, 1993, J RES NATL INST STAN, V98, P31, DOI 10.6028/jres.098.003; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HINDS MG, 1992, BIOCHEM J, V287, P627, DOI 10.1042/bj2870627; KUMAR SA, 1980, FEBS LETT, V109, P121, DOI 10.1016/0014-5793(80)81324-X; KYPR J, 1985, BIOCHEM BIOPH RES CO, V131, P780, DOI 10.1016/0006-291X(85)91307-5; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; Moore JL, 1996, J BIOL CHEM, V271, P21273, DOI 10.1074/jbc.271.35.21273; MOORE JL, 1993, THESIS G WASHINGTON; PEDERSEN JS, 1990, J APPL CRYSTALLOGR, V23, P321, DOI 10.1107/S0021889890003946; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; TIMMINS PA, 1988, EUR BIOPHYS J BIOPHY, V15, P257, DOI 10.1007/BF00256476; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9	23	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20001	20006		10.1074/jbc.273.32.20001	http://dx.doi.org/10.1074/jbc.273.32.20001			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685337	hybrid			2022-12-27	WOS:000075305400014
J	Kato-Yamada, Y; Noji, H; Yasuda, R; Kinosita, K; Yoshida, M				Kato-Yamada, Y; Noji, H; Yasuda, R; Kinosita, K; Yoshida, M			Direct observation of the rotation of epsilon subunit in F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI F1 ATPASE; ESCHERICHIA-COLI; GAMMA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; F1-ATPASE; BINDING; SYNTHASE; COMPLEX; SITE	Rotation of the epsilon subunit in F-1-ATPase from thermophilic Bacillus strain PS3 (TF1) was observed under a fluorescence microscope by the method used for observation of the gamma subunit rotation (Noji, H., Yasuda, R., Yoshida, M., and Kinosita, K., Jr. (1997) Nature 386, 299-302). The alpha(3)beta(3)gamma epsilon complex of TF, was fixed to a solid surface, and fluorescently labeled actin filament was attached to the epsilon subunit through biotin-streptavidin. In the presence of ATP, the filament attached to epsilon subunit rotated in a unidirection. The direction of the rotation was the same as that observed for the gamma subunit. The rotational velocity was slightly slower than the filament attached to the gamma subunit, probably due to the experimental setup used. Thus, as suggested from biochemical studies (Aggeler, R., Ogilvie, I., and Capaldi, R. A. (1997) J. Biol. Chem. 272, 19621-19624), the epsilon subunit rotates with the gamma subunit in F-1-ATPase during catalysis.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 2268503, Japan; Keio Univ, Fac Sci & Technol, Dept Phys, Yokohama, Kanagawa 2238522, Japan; Teikyo Univ, Biotechnol Res Ctr 3F, Genet Programming Team 13, CREST, Kawasaki, Kanagawa 2160001, Japan	Tokyo Institute of Technology; Keio University; Japan Science & Technology Agency (JST); Teikyo University	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 1997, BBA-BIOENERGETICS, V1319, P177, DOI 10.1016/S0005-2728(96)00159-4; DUNN SD, 1982, J BIOL CHEM, V257, P7354; Hisabori T, 1997, EUR J BIOCHEM, V247, P1158, DOI 10.1111/j.1432-1033.1997.01158.x; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SMITH JB, 1977, BIOCHEMISTRY-US, V16, P306, DOI 10.1021/bi00621a023; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	32	161	165	5	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19375	19377		10.1074/jbc.273.31.19375	http://dx.doi.org/10.1074/jbc.273.31.19375			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677353	hybrid			2022-12-27	WOS:000075125200005
J	Tetaud, E; Manai, F; Barrett, MP; Nadeau, K; Walsh, CT; Fairlamb, AH				Tetaud, E; Manai, F; Barrett, MP; Nadeau, K; Walsh, CT; Fairlamb, AH			Cloning and characterization of the two enzymes responsible for trypanothione biosynthesis in Crithidia fasciculata	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GLUTATHIONYLSPERMIDINE METABOLISM; GLUTATHIONE-REDUCTASE; HYDROGEN-PEROXIDE; TRYPANOSOMA-CRUZI; PURIFICATION; POLYAMINES; DNA; SYNTHETASE; INHIBITORS	Protozoa of the order Kinetoplastida differ from other organisms in their ability to conjugate glutathione (gamma-Glu-Cys-Gly) and spermidine to form trypanothione (N-1,N-8-bis(glutathionyl)spermidine), which is involved in maintaining intracellular thiol redox and in defense against oxidants, In this study, the genes from Crithidia fasciculata, Cf-GSS and Cf-TRS, which encode, respectively, glutathionylspermidine synthetase (EC 6.3.1.8) and trypanothione synthetase (EC 6.3.1.9) have been cloned and expressed. The deduced amino acid sequence of both Cf-GSS and Cf-TRS share 50% sequence similarity with the Escherichia coli glutathionylspermidine synthetase/amidase. Both genes are present as single copies in the C. fasciculata genome. When expressed in E. coli and Saccharomyces cerevisiae, neither protein was present in an active soluble form. However, thiol analysis of S. cerevisiae demonstrated that cells transformed with the Cf-GSS gene contained substantial amounts of glutathionylspermidine, whereas cells expressing both the Cf-GSS and Cf-TRS genes contained glutathionylspermidine and trypanothione, confirming that these genes encode the functional glutathionylspermidine and trypanothione synthetases from C. fasciculata. The translation products of Cf-GSS and Cf-TRS show significant homology to the amidase domain present in E. coli glutathionylspermidine synthetase, which can catalyze both synthesis and degradation of glutathionylspermidine. Glutathionylspermidine synthetase isolated from C, fasciculata was found to possess a similar amidase activity.	Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	University of Dundee; Harvard University; Harvard Medical School	Fairlamb, AH (corresponding author), Univ Dundee, Dept Biochem, Wellcome Trust Bldg, Dundee DD1 4HN, Scotland.		Fairlamb, Alan/A-5272-2009	Fairlamb, Alan/0000-0001-5134-0329; Barrett, Mike/0000-0001-9447-3519	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AWAD S, 1992, INT J RADIAT BIOL, V62, P401, DOI 10.1080/09553009214552281; BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; Bey P., 1987, INHIBITION POLYAMINE, P1; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; BOVERIS A, 1980, BIOCHEM J, V188, P643, DOI 10.1042/bj1880643; BOVERIS A, 1977, EXPERIENTIA, V33, P1306, DOI 10.1007/BF01920148; BURLAND V, 1995, NUCLEIC ACIDS RES, V23, P2105, DOI 10.1093/nar/23.12.2105; Chen SJ, 1997, BIOORG MED CHEM LETT, V7, P505; Chen SJ, 1997, J MED CHEM, V40, P3842, DOI 10.1021/jm970414b; DUBIN DT, 1959, BIOCHEM BIOPH RES CO, V1, P26; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; ELSKENS MT, 1991, J GEN MICROBIOL, V137, P637, DOI 10.1099/00221287-137-3-637; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1985, MOL BIOCHEM PARASIT, V14, P187, DOI 10.1016/0166-6851(85)90037-4; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; FAIRLAMB AH, 1986, MOL BIOCHEM PARASIT, V21, P247, DOI 10.1016/0166-6851(86)90130-1; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; Koenig K, 1997, J BIOL CHEM, V272, P11908, DOI 10.1074/jbc.272.18.11908; Kwon DS, 1997, J BIOL CHEM, V272, P2429; Lin CH, 1997, CHEM BIOL, V4, P859, DOI 10.1016/S1074-5521(97)90118-6; LIN VH, 1997, BIOCHEMISTRY-US, V36, P14930; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1974, ENZYMES, V10, P699; Meister A., 1974, ENZYMES, V10, P671; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENKETH PG, 1987, FEBS LETT, V221, P427, DOI 10.1016/0014-5793(87)80968-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAMES SL, 1986, BIOCHEMISTRY-US, V25, P3519, DOI 10.1021/bi00360a007; SHIM H, 1988, J GEN MICROBIOL, V134, P807; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; SMITH K, 1995, BIOCHEM J, V312, P465, DOI 10.1042/bj3120465; Stadtman E.R., 1974, ENZYMES, V10, P755; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; STRAHERN JN, 1982, MOL BIOL YEAST SACCH; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1975, J BIOL CHEM, V250, P2648; Verbruggen C, 1996, BIOORG MED CHEM LETT, V6, P253, DOI 10.1016/0960-894X(96)00001-7; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; YANG TP, 1992, BIOCHIM BIOPHYS ACTA, V1130, P227, DOI 10.1016/0167-4781(92)90535-8; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328	44	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19383	19390		10.1074/jbc.273.31.19383	http://dx.doi.org/10.1074/jbc.273.31.19383			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677355	hybrid			2022-12-27	WOS:000075125200007
J	He, B; Kukarin, A; Temiakov, D; Chin-Bow, ST; Lyakhov, DL; Rong, MQ; Durbin, RK; McAllister, WT				He, B; Kukarin, A; Temiakov, D; Chin-Bow, ST; Lyakhov, DL; Rong, MQ; Durbin, RK; McAllister, WT			Characterization of an unusual, sequence-specific termination signal for T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION TERMINATION; DNA; BACTERIOPHAGE-T7; INITIATION; ELONGATION; PROMOTER; INVITRO; OPERON; VIRUS; SITE	We have characterized an unusual type of termination signal for T7 RNA polymerase that requires a conserved 7-base pair sequence in the DNA (ATCTGTT in the nontemplate strand). Each of the nucleotides within this sequence is critical for function, as any substitutions abolish termination. The primary site of termination occurs 7 nucleotides downstream from this sequence but is context-independent (that is, the sequence around the site of termination, and in particular the nucleotide at the site of termination, need not be conserved). Termination requires the presence of the conserved sequence and its complement in duplex DNA and is abolished or diminished if the signal is placed downstream of regions in which the non-template strand is missing or mismatched. Under the latter conditions, much of the RNA product remains associated with the template. The latter results suggest that proper resolution of the transcription bubble at its trailing edge and/or displacement of the RNA product are required for termination at this class of signal.	SUNY Hlth Sci Ctr, Morse Inst Mol Genet, Dept Immunol & Microbiol, Brooklyn, NY 11203 USA; Russian Acad Sci, Inst Mol Genet, Lab Mol Genet Microorganisms, Moscow 123182, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	McAllister, WT (corresponding author), SUNY Hlth Sci Ctr, Morse Inst Mol Genet, Dept Immunol & Microbiol, 450 Clarkson Ave,POB 44, Brooklyn, NY 11203 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38147, R01 GM038147-14, R01 GM038147] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHRISTIANSEN J, 1988, NUCLEIC ACIDS RES, V16, P7457, DOI 10.1093/nar/16.15.7457; DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; FODOR E, 1995, J VIROL, V69, P4012, DOI 10.1128/JVI.69.7.4012-4019.1995; Hartvig L, 1996, EMBO J, V15, P4767, DOI 10.1002/j.1460-2075.1996.tb00854.x; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; JENG ST, 1990, J BIOL CHEM, V265, P3823; JENG ST, 1992, J BIOL CHEM, V267, P19306; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; Lyakhov DL, 1997, J MOL BIOL, V269, P28, DOI 10.1006/jmbi.1997.1015; LYAKHOV DL, 1998, IN PRESS J MOL BIOL; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4281, DOI 10.1021/bi00067a017; MASLAK M, 1994, BIOCHEMISTRY-US, V33, P6918, DOI 10.1021/bi00188a022; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; PLATT T, 1996, RNA STRUCTURE FUNCTI, P541; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YB, 1988, J BIOL CHEM, V263, P527; STEEN R, 1986, EMBO J, V5, P1099, DOI 10.1002/j.1460-2075.1986.tb04328.x; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; TYAGARAJAN K, 1991, BIOCHEMISTRY-US, V30, P10920, DOI 10.1021/bi00109a016; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; Weston BF, 1997, J MOL BIOL, V272, P21, DOI 10.1006/jmbi.1997.1199; WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388; YOUNG RA, 1979, J BIOL CHEM, V254, P2725; ZHANG X, 1995, J MOL BIOL, V250, P156, DOI 10.1006/jmbi.1995.0367; Zhang X, 1997, J MOL BIOL, V269, P10, DOI 10.1006/jmbi.1997.1016	36	39	43	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18802	18811		10.1074/jbc.273.30.18802	http://dx.doi.org/10.1074/jbc.273.30.18802			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668054	hybrid			2022-12-27	WOS:000074974700021
J	Kozel, PJ; Friedman, RA; Erway, LC; Yamoah, EN; Liu, LH; Riddle, T; Duffy, JJ; Doetschman, T; Miller, ML; Cardell, EL; Shull, GE				Kozel, PJ; Friedman, RA; Erway, LC; Yamoah, EN; Liu, LH; Riddle, T; Duffy, JJ; Doetschman, T; Miller, ML; Cardell, EL; Shull, GE			Balance and hearing deficits in mice with a null mutation in the gene encoding plasma membrane Ca2+-ATPase isoform 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP ISOFORMS; MOLECULAR-CLONING; MESSENGER-RNAS; CA-2+-TRANSPORTING ATPASE; CA2+ PUMP; RAT-BRAIN; EXPRESSION; DOMAINS	Plasma membrane Ca2+-ATPase isoform 2 (PMCA2) exhibits a highly restricted tissue distribution, suggesting that it serves more specialized physiological functions than some of the other isoforms, A unique role in hearing is indicated by the high levels of PMCA2 expression in cochlear outer hair cells and spiral ganglion cells. To analyze the physiological role of PMCA2 we used gene targeting to produce PMCA2-deficient mice, Breeding of heterozygous mice yielded live homozygous mutant offspring. PMCA2-null mice grow more slowly than heterozygous and wild-type mice and exhibit an unsteady gait and difficulties in maintaining balance. Histological analysis of the cerebellum and inner ear of mutant and wild-type mice revealed that null mutants had slightly increased numbers of Purkinje neurons tin which PMCA2 is highly expressed), a decreased thickness of the molecular layer, an absence of otoconia in the vestibular system, and a range of abnormalities of the organ of Corti. Analysis of auditory evoked brainstem responses revealed that homozygous mutants were deaf and that heterozygous mice had a significant hearing loss. These data demonstrate that PMCA2 is required for both balance and hearing and suggest that it may be a major source of the calcium used in the formation and maintenance of otoconia.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol & Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Biol Sci, Cincinnati, OH 45221 USA; House Ear Inst, Los Angeles, CA 90057 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; House Research Institute	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Bethesda Ave,ML 524, Cincinnati, OH 45267 USA.				NHLBI NIH HHS [HL41496] Funding Source: Medline; NIDCD NIH HHS [K08 DC000119-06] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050594, R37DK050594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [K08DC000119] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Apicella S, 1997, NEUROSCIENCE, V79, P1145, DOI 10.1016/S0306-4522(97)00035-3; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; Crouch JJ, 1995, HEARING RES, V92, P112, DOI 10.1016/0378-5955(95)00201-4; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ERWAY LC, 1993, HEARING RES, V65, P125, DOI 10.1016/0378-5955(93)90207-H; Faddis BT, 1998, HEARING RES, V115, P6, DOI 10.1016/S0378-5955(97)00172-X; FURATA H, 1998, IN PRESS HEARING RES; GREEB J, 1989, J BIOL CHEM, V264, P18569; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; KAWAMATA S, 1995, ANAT RECORD, V242, P259, DOI 10.1002/ar.1092420216; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Liu LH, 1997, J BIOL CHEM, V272, P30538, DOI 10.1074/jbc.272.48.30538; MULLEN RJ, 1976, P NATL ACAD SCI USA, V73, P208, DOI 10.1073/pnas.73.1.208; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; Yamoah EN, 1998, J NEUROSCI, V18, P610	26	244	254	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18693	18696		10.1074/jbc.273.30.18693	http://dx.doi.org/10.1074/jbc.273.30.18693			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668038	hybrid			2022-12-27	WOS:000074974700005
J	Li, SS; Wang, GQ; Lin, HN; Huang, CH				Li, SS; Wang, GQ; Lin, HN; Huang, CH			Calorimetric studies of phosphatidylethanolamines with saturated sn-1 and dienoic sn-2 acyl chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE; DILAUROYLPHOSPHATIDYLETHANOLAMINE	We have semi-synthesized 18 species of mixed chain phosphatidylethanolamines (PE) in which the sn-l acyl chain is derived from stearic, arachidic, and behenic acids, and the sn-2 acyl chain is originated from cis,cis-octadecadienoic and cis,cis-eicosadienoic acids with the two methylene-interrupted double bonds loca.ted at various positions, These PEs constituting the bilayers in the aqueous dispersion were subjected to differential scanning calorimetric experiments. The T-m values associated with the gel-to-liquid crystalline phase transitions for these PEs are found to be significantly smaller than those of the saturated counterparts. Moreover, the magnitude of the T-m-lowering effect of acyl chain diun-saturation depends critically on the positions of the two methylene-interrupted cis double bonds in the sn-2 acyl chain. Specifically, if the sn-2 acyl chain is derived from cis,cis-octadecadienoic acid, the T-m-lowering effect has the following decreasing order: Delta(9,12) > Delta(6,9) > Delta(12,15). For cis,cis-eicosadienoyl acyl chain, the T-m-lowering effect is stronger in the order of Delta(10,13) > Delta(11,14) > Delta(8,11) > Delta(5,8) > Delta(14,17). Finally, a refined molecular model is presented that can adequately explain the T-m-lowering effect of sn-2 acyl chain diunsaturation, Moreover, this same refined molecular model can also be invoked, to better interpret the T-m-lowering effect observed for sn-l saturated/sn-2 monoenoic PE.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Huang, CH (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Biochem, Box 440, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017452] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-17452] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTA AK, 1984, J CHROMATOGR, V284, P257, DOI 10.1016/S0021-9673(01)87825-0; CHANG H, 1983, BIOCHIM BIOPHYS ACTA, V728, P319, DOI 10.1016/0005-2736(83)90501-1; Christie W.W., 1967, CHEM PHYS LIPIDS, V1, P407; HITCHCOCK PB, 1974, P NATL ACAD SCI USA, V71, P3036, DOI 10.1073/pnas.71.8.3036; HUANG C, 1994, BBA-BIOMEMBRANES, V1189, P7, DOI 10.1016/0005-2736(94)90273-9; HUANG C, 1998, CELL PHYSL SOURCE BO, P39; Huang CH, 1997, J BIOL CHEM, V272, P21917, DOI 10.1074/jbc.272.35.21917; Huang CH, 1996, ARCH BIOCHEM BIOPHYS, V334, P135, DOI 10.1006/abbi.1996.0438; KEOUGH KMW, 1990, BIOCHEM SOC T, V18, P835, DOI 10.1042/bst0180835; MANTSCH HH, 1983, BIOCHIM BIOPHYS ACTA, V728, P325, DOI 10.1016/0005-2736(83)90502-3; Mason JT, 1996, HDB NONMEDICAL APPL, V1, P195; SEDDON JM, 1983, J BIOL CHEM, V258, P3850; TAYLOR WR, 1950, J AM CHEM SOC, V72, P4623; Wang GQ, 1997, BIOPHYS J, V73, P283, DOI 10.1016/S0006-3495(97)78069-X; WANG ZQ, 1994, J BIOL CHEM, V269, P23491	15	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19009	19018		10.1074/jbc.273.30.19009	http://dx.doi.org/10.1074/jbc.273.30.19009			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668081	hybrid			2022-12-27	WOS:000074974700048
J	Ostrander, DB; O'Brien, DJ; Gorman, JA; Carman, GM				Ostrander, DB; O'Brien, DJ; Gorman, JA; Carman, GM			Effect of CTP synthetase regulation by CTP on phospholipid synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; HAMSTER OVARY CELLS; PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; TRANSFER PROTEIN; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; FUNCTIONAL COMPLEMENTATION; INOSITOL SYNTHESIS; GENE DISRUPTION; URA7 GENE	CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) activity in Saccharomyces cerevisiae is allosterically regulated by CTP product inhibition. Amino acid residue Glu(161) in the URA7-encoded and URA8-encoded CTP synthetases was identified as being involved in the regulation of these enzymes by CTP product inhibition. The specific activities of the URA7-encoded and URA8-encoded enzymes with a Glu(161) --> Lys (E161K) mutation were S-fold greater when compared with the wild-type enzymes. The E161K mutant URA7-encoded and URA8-encoded CTP synthetases were less sensitive to CTP product inhibition with inhibitor constants for CTP of 8.4- and 5-fold greater, respectively, than those of their wild-type counterparts. Cells expressing the E161K mutant enzymes on a multicopy plasmid exhibited an increase in resistance to the pyrimidine poison and cancer therapeutic drug cyclopentenylcytosine and accumulated elevated (6-15-fold) levels of CTP when compared with cells expressing the wild-type enzymes. Cells expressing the E161K mutation in the URA7 encoded CTP synthetase exhibited an increase (1.5-fold) in the utilization of the Kennedy pathway for phosphatidylcholine synthesis when compared with control cells. Cells bearing the mutation also exhibited an increase in the synthesis of phosphatidylcholine (1.5-fold), phosphatidylethanolamine (1.3-fold), and phosphatidate (2-fold) and a decrease in the synthesis of phosphatidylserine (1.7-fold). These alterations were accompanied by an inositol excretion phenotype due to the misregulation of the INO1 gene. Moreover, cells bearing the E161K mutation exhibited an increase (1.6-fold) in the ratio of total neutral lipids to phospholipids, an increase in triacylglycerol (1.4-fold), free fatty acids (1.7-fold), and ergosterol ester (1.8-fold), and a decrease in diacylglycerol (1.3-fold) when compared with control cells. These data indicated that the regulation of CTP synthetase activity by CTP plays an important role in the regulation of phospholipid synthesis.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08901 USA; Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Microbial Mol Biol, Princeton, NJ 08543 USA	Rutgers State University New Brunswick; Bristol-Myers Squibb	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ARONOW B, 1984, J BIOL CHEM, V259, P9035; ARONOW B, 1987, J BIOL CHEM, V262, P5106; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CARTER JR, 1966, J LIPID RES, V7, P678; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; CULBERTSON MR, 1975, GENETICS, V80, P23; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; ESKO JD, 1980, J BIOL CHEM, V255, P4474; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAID A, 1983, METHOD ENZYMOL, V96, P192; Henderson RJ, 1992, LIPID ANAL PRACTICAL, P65; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KANG GJ, 1989, J BIOL CHEM, V264, P713; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KIZAKI H, 1980, CANCER RES, V40, P3921; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; LIBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; ROSENBERG M, 1990, MICROBIAL CELL SURFA, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Shen H, 1996, J BIOL CHEM, V271, P29043, DOI 10.1074/jbc.271.46.29043; Shen HF, 1997, J BIOL CHEM, V272, P11215; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; SUMMERS EF, 1988, GENETICS, V120, P909; TAYLOR FR, 1978, J BACTERIOL, V136, P531, DOI 10.1128/JB.136.2.531-537.1978; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; VANCE DE, 1996, BIOCH LIPIDS LIPOPRO, P153; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; WEBER G, 1979, ADV ENZYME REGUL, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; WHELAN J, 1993, NAT GENET, V3, P317, DOI 10.1038/ng0493-317; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; ZHANG H, 1993, CANCER RES, V53, P5714; [No title captured]	85	97	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18992	19001		10.1074/jbc.273.30.18992	http://dx.doi.org/10.1074/jbc.273.30.18992			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668079	hybrid			2022-12-27	WOS:000074974700046
J	Pikas, DS; Li, JP; Vlodavsky, I; Lindahl, U				Pikas, DS; Li, JP; Vlodavsky, I; Lindahl, U			Substrate specificity of heparanases from human hepatoma and platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; ESCHERICHIA-COLI K5; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; CAPSULAR POLYSACCHARIDE; SULFATE PROTEOGLYCANS; MOUSE MASTOCYTOMA; MELANOMA-CELLS; CORE PROTEIN; HEPARIN; BIOSYNTHESIS	Heparan sulfate proteoglycans, attached to cell surfaces or in the extracellular matrix, interact with a multitude of proteins via their heparan sulfate side chains. Degradation of these chains by limited (endoglycosidic) heparanase cleavage is believed 60 affect a variety of biological processes. Although the occurrence of heparanase activity in mammalian tissues has been recognized for many years, the molecular characteristics and substrate recognition properties of the enzyme(s) have remained elusive. In the present study, the substrate specificity and cleavage site of heparanase from human hepatoma and platelets were investigated. Both enzyme preparations were found to cleave the single beta-D-glucuronidic Linkage of a heparin octasaccharide. A capsular polysaccharide from Escherichia coli K5, with the same (-GlcUA beta 1, 4-GlcNAc alpha 1,4-)(n) structure as the unmodified backbone of heparan sulfate, resisted heparanase degradation in its native state as well as after chemical N-deaeetylation/N-sulfation or partial enzymatic C-5 epimerization of beta-DGlcUA to alpha-L-IdceA By contrast, a chemically O-sulfated (but still N-acetylated) K5 derivative was susceptible to heparanase cleavage. O-Sulfate groups, but not N-sulfate or IdceA residues, thus are essential for substrate recognition by the heparanase(s). In particular, selective O-desulfation of the heparin octasaccharide implicated a 2-O-sulfate group on a hexuronic acid residue located two monosaccharide units from the cleavage site, toward the reducing end.	Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden; Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel	Uppsala University; Hebrew University of Jerusalem	Pikas, DS (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, Box 575, S-75123 Uppsala, Sweden.	Dagmar.Pikas@medkem.uu.se						Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bame KJ, 1997, J BIOL CHEM, V272, P2245; BAME KJ, 1993, J BIOL CHEM, V268, P19956; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; CASU B, 1994, CARBOHYD RES, V263, P271, DOI 10.1016/0008-6215(94)00172-3; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Graham LD, 1996, BIOCHEM MOL BIOL INT, V39, P563; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HOOK M, 1982, ANAL BIOCHEM, V119, P236, DOI 10.1016/0003-2697(82)90580-2; IRIMURA T, 1986, BIOCHEMISTRY-US, V25, P5322, DOI 10.1021/bi00366a050; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; KJELLEN L, 1985, J BIOL CHEM, V260, P8416; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V73, P569, DOI 10.1016/0006-291X(76)90848-2; KLEIN U, 1979, H-S Z PHYSIOL CHEM, V360, P1465, DOI 10.1515/bchm2.1979.360.2.1465; KLEIN U, 1976, BIOCHEM BIOPH RES CO, V69, P158, DOI 10.1016/S0006-291X(76)80286-0; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; Lapierre F, 1996, GLYCOBIOLOGY, V6, P355, DOI 10.1093/glycob/6.3.355; LEVY L, 1962, P SOC EXP BIOL MED, V109, P901; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; NAGASAWA K, 1977, CARBOHYD RES, V58, P47, DOI 10.1016/S0008-6215(00)83402-3; NAKAJIMA M, 1983, SCIENCE, V220, P611, DOI 10.1126/science.6220468; NAKAJIMA M, 1984, J BIOL CHEM, V259, P2283; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKAJIMA M, 1986, ANAL BIOCHEM, V157, P162, DOI 10.1016/0003-2697(86)90209-5; OGREN S, 1975, J BIOL CHEM, V250, P2690; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; OOSTA GM, 1982, J BIOL CHEM, V257, P1249; Pillarisetti S, 1997, J BIOL CHEM, V272, P15753, DOI 10.1074/jbc.272.25.15753; RAZI N, 1995, BIOCHEM J, V309, P465, DOI 10.1042/bj3090465; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Santini F, 1997, CARBOHYD RES, V302, P103, DOI 10.1016/S0008-6215(97)00111-0; SCHMIDTCHEN A, 1994, EUR J BIOCHEM, V223, P211, DOI 10.1111/j.1432-1033.1994.tb18985.x; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3935; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; Stringer SE, 1997, INT J BIOCHEM CELL B, V29, P709, DOI 10.1016/S1357-2725(96)00170-7; THUNBERG L, 1982, J BIOL CHEM, V257, P278; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9505	51	209	228	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18770	18777		10.1074/jbc.273.30.18770	http://dx.doi.org/10.1074/jbc.273.30.18770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668050	hybrid			2022-12-27	WOS:000074974700017
J	Rea, S; Martin, LB; McIntosh, S; Macaulay, SL; Ramsdale, T; Baldini, G; James, DE				Rea, S; Martin, LB; McIntosh, S; Macaulay, SL; Ramsdale, T; Baldini, G; James, DE			Syndet, an adipocyte target SNARE involved in the insulin-induced translocation of GLUT4 to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; GLUCOSE-TRANSPORTER; 3T3-L1 ADIPOCYTES; PROTEIN; VESICLES; LOCALIZATION; SPECIFICITY; TRAFFICKING; STIMULATION; CELLUBREVIN	In adipocytes, insulin stimulates the translocation of the glucose transporter, GLUT4, from an intracellular storage compartment to the cell surface. Substantial evidence exists to suggest that in the basal state GLUT4 resides in discrete storage vesicles. A direct interaction of GLUT I storage vesicles with the plasma membrane has been implicated because the v-SNARE, vesicle-associated membrane protein-2 (VAMP2), appears to be a specific component of these vesicles. In the present study we sought to identify the cognate target SNAREs for VAMPS in mouse 3T3-L1 adipocytes. Membrane fractions were isolated from adipocytes and probed by far Western blotting with the cytosolic portion of VAMPS fused to glutathione S-transferase. Two plasma membrane-enriched proteins, p25 and p35, were specifically labeled with this probe. By using a combination of immunoblotting, detergent extraction, and anion exchange chromatography, we identified p35 as Syntaxin- 4 and p25 as the recently identified murine SNAP-25 homologue, Syndet (mSNAP-23). By using surface plasmon resonance we show that VAMP2, Syntaxin-4, and Syndet form a ternary SDS-resistant SNARE complex. Microinjection of anti-Syndet antibodies into 3T3-L1 adipocytes, or incubation of permeabilized adipocytes with a synthetic peptide comprising the C-terminal 24 amino acids of Syndet, inhibited insulin-stimulated GLUT4 translocation to the cell surface by similar to 40%. GLUT1 trafficking remained unaffected by the presence of the peptide. Our data suggest that Syntaxin 4 and Syndet are important cell-surface target SNAREs within adipocytes that regulate docking and fusion of GLUT-4-containing vesicles with the plasma membrane in response to insulin.	Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Drug Design & Dev, St Lucia, Qld 4072, Australia; CSIRO, Div Mol Sci, Parkville, Vic 3052, Australia; Columbia Univ Coll Phys & Surg, Dept Anat & Cell Biol, New York, NY 10032 USA	University of Queensland; University of Queensland; University of Queensland; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Columbia University	James, DE (corresponding author), Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia.	D.James@cmcb.uq.edu.au	Martin, Laura/N-1789-2013; mcintosh, shane/AAL-4279-2021; Macaulay, Stuart Lance/A-6086-2008; Rea, Shane/F-4073-2014	Martin, Laura/0000-0002-4431-4381; Macaulay, Stuart Lance/0000-0001-5069-9516; James, David/0000-0001-5946-5257; mcintosh, shane/0000-0003-2835-7936				Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CALDERHEAD DM, 1990, J BIOL CHEM, V265, P13800; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; GOODYEAR LJ, 1990, AM J PHYSIOL, V258, pE667, DOI 10.1152/ajpendo.1990.258.4.E667; Holman GD, 1996, SEMIN CELL DEV BIOL, V7, P259, DOI 10.1006/scdb.1996.0034; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1993, J CELL SCI, V104, P607; Martin LB, 1998, J BIOL CHEM, V273, P1444, DOI 10.1074/jbc.273.3.1444; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; PLOUG T, 1987, AM J PHYSIOL, V253, pE12, DOI 10.1152/ajpendo.1987.253.1.E12; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; RAY P, 1993, J BIOL CHEM, V268, P11057; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; Wang GY, 1997, J CELL SCI, V110, P505	32	92	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18784	18792		10.1074/jbc.273.30.18784	http://dx.doi.org/10.1074/jbc.273.30.18784			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668052	hybrid			2022-12-27	WOS:000074974700019
J	Takagi, H; Shi, DS; Ha, Y; Allewell, NM; Theil, EC				Takagi, H; Shi, DS; Ha, Y; Allewell, NM; Theil, EC			Localized unfolding at the junction of three ferritin subunits - A mechanism for iron release?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; H-CHAIN FERRITIN; MAMMALIAN FERRITIN; CORE FORMATION; APOFERRITIN; OXIDATION; PROTEINS; CRYSTALLIZATION; RESOLUTION; KINETICS	How and where iron exits from ferritin for cellular use is unknown. Twenty-four protein subunits create a cavity in ferritin where iron is concentrated >10(11)-fold as a mineral. Proline substitution for conserved leucine 134 (L134P) allowed normal assembly but increased iron exit rates. X-ray crystallography of H-L134P ferritin revealed localized unfolding at the S-fold axis, also iron entry sites, consistent with shared use sites for iron exit and entry. The junction of three ferritin subunits appears to be a dynamic aperture with a "shutter" that cytoplasmic factors might open or close to regulate iron release in vivo.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA; Univ Minnesota, Dept Biochem, St Paul, MN 55108 USA	University of North Carolina; North Carolina State University; University of Minnesota System; University of Minnesota Twin Cities	Theil, EC (corresponding author), Childrens Hosp, Oakland Res Inst, 747 52nd St, Oakland, CA 94609 USA.			Shi, Dashuang/0000-0002-5491-1104	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020251, R01DK050727, R56DK020251, R37DK020251] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20251, DK50727] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANYARD SH, 1978, NATURE, V271, P282, DOI 10.1038/271282a0; BAUMINGER ER, 1993, BIOCHEM J, V296, P709, DOI 10.1042/bj2960709; Beard JL, 1996, J NUTR, V126, P154, DOI 10.1093/jn/126.1.154; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; Fetter J, 1997, J BIOL INORG CHEM, V2, P652, DOI 10.1007/s007750050180; Ha Y, 1997, ACTA CRYSTALLOGR D, V53, P513, DOI 10.1107/S0907444997003983; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hempstead PD, 1997, J MOL BIOL, V268, P424, DOI 10.1006/jmbi.1997.0970; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES T, 1978, BIOCHEMISTRY-US, V17, P4011, DOI 10.1021/bi00612a021; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; MERTZ JR, 1983, J BIOL CHEM, V258, P1719; Pereira AS, 1997, BIOCHEMISTRY-US, V36, P7917, DOI 10.1021/bi970348f; Proudhon D, 1996, J MOL EVOL, V42, P325, DOI 10.1007/BF02337543; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; Santambrogio P, 1997, BIOCHEM J, V322, P461, DOI 10.1042/bj3220461; SAUER UH, 1992, J BIOL CHEM, V267, P2393; STEFANINI S, 1989, BIOCHEMISTRY-US, V28, P378, DOI 10.1021/bi00427a052; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; THEIL EC, 1994, BIOCHEM J, V304, P1; TREFFRY A, 1993, BIOCHEM J, V296, P721, DOI 10.1042/bj2960721; TREFFRY A, 1995, BIOCHEMISTRY-US, V34, P15204, DOI 10.1021/bi00046a028; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; TRIKHA J, 1994, PROTEINS, V18, P107, DOI 10.1002/prot.340180204; Waldo G. S., 1996, COMPREHENSIVE SUPRAM, V5, P65; WALDO GS, 1993, SCIENCE, V259, P796, DOI 10.1126/science.8430332; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; WATT GD, 1988, P NATL ACAD SCI USA, V85, P7457, DOI 10.1073/pnas.85.20.7457; WATT GD, 1985, P NATL ACAD SCI USA, V82, P3640, DOI 10.1073/pnas.82.11.3640; WAUTERS M, 1978, FEBS LETT, V91, P276, DOI 10.1016/0014-5793(78)81191-0; YABLONSKI MJ, 1992, BIOCHEMISTRY-US, V31, P9680, DOI 10.1021/bi00155a022	37	113	117	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18685	18688		10.1074/jbc.273.30.18685	http://dx.doi.org/10.1074/jbc.273.30.18685			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668036	hybrid			2022-12-27	WOS:000074974700003
J	Gallardo-Madueno, R; Leal, JFM; Dorado, G; Holmgren, A; Lopez-Barea, J; Pueyo, C				Gallardo-Madueno, R; Leal, JFM; Dorado, G; Holmgren, A; Lopez-Barea, J; Pueyo, C			In vivo transcription of nrdAB operon and of grxA and fpg genes is triggered in Escherichia coli lacking both thioredoxin and glutaredoxin 1 or thioredoxin and glutathione, respectively	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; NEGATIVE MUTANTS; HYDROGEN DONOR; RNA; EXPRESSION; DNA; BIOSYNTHESIS; CONSTRUCTION; K12; FIS	We have previously described (1) that Escherichia coli maintains a balanced supply of deoxyribonucleotides by a regulatory, mechanism that up-regulates the levels of ribonucleotide reductase with the lack of its main hydrogen donors thioredoxin, glutaredoxin 1, and glutathione (GSH). By using a semi-quantitative reverse transcription/multiplex polymerase chain reaction fluorescent procedure that enables simultaneous analysis of up to seven mRNA species, we now demonstrate that regulation operates at the transcriptional level. Double mutant cells lacking both thioredoxin and glutaredoxin 1 had increased transcription of the nrdAB operon, as compared with the corresponding wild type parent (maximal induction of 10- and 9-fold for mRNA of nrdA and nrdB genes, respectively). Likewise, a dramatic increase of 36-fold in grxA mRNA was observed in bacteria simultaneously deficient in thioredoxin and GSH (the physiological reductant of all glutaredoxins). The increased expression of the grxA gene in trxA gshA double mutant bacteria was mimicked in trxA single mutant cells by depletion of GSH with diethylmaleate (DEM). This induction of grxA transcription was rapid since maximal increase was detected upon 10 min of DEM exposure. Like grxA expression, the basal level of fpg mRNA, encoding formamidopyrimidine-DNA glycosylase, was increased (about 4-fold) in a trxA gshA double mutant strain; this expression was also induced upon exposure to DEM (11-fold maximal induction). These results suggest that transcription of grxA might share common redox regulatory mechanism(s) with that of the fpg gene, involved in the repair of 8-oxoguanine in DNA.	Univ Cordoba, Dept Bioquim & Biol Mol, E-14071 Cordoba, Spain; Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Universidad de Cordoba; Karolinska Institutet	Pueyo, C (corresponding author), Univ Cordoba, Dept Bioquim & Biol Mol, Avda Medina Azahara S-N, E-14071 Cordoba, Spain.	bblpucuc@uco.es	Leal, Juan F Martinez/N-6328-2013; Pueyo, Carmen/B-4509-2016; Lopez-Barea, Juan/K-7258-2014	Leal, Juan F Martinez/0000-0002-7538-0875; Pueyo, Carmen/0000-0002-2624-2011; Lopez-Barea, Juan/0000-0002-2280-3379				APONTOWEIL P, 1975, MOL GEN GENET, V141, P91, DOI 10.1007/BF00267676; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; AUGUSTIN LB, 1994, J BACTERIOL, V176, P378, DOI 10.1128/JB.176.2.378-387.1994; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; CHARPENTIER B, 1994, J BACTERIOL, V176, P830, DOI 10.1128/jb.176.3.830-839.1994; DAVIS NK, 1982, J GEN MICROBIOL, V128, P1631; DellaSeta F, 1997, J BACTERIOL, V179, P5218, DOI 10.1128/jb.179.16.5218-5221.1997; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; GARDNER PR, 1987, J BIOL CHEM, V262, P17591; GILBERT I, 1990, Molecular and General Genetics, V220, P400; HANKE PD, 1983, J BACTERIOL, V156, P1192, DOI 10.1128/JB.156.3.1192-1197.1983; HANKE PD, 1983, J BACTERIOL, V154, P1040, DOI 10.1128/JB.154.3.1040-1045.1983; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; Jordan A, 1996, MOL MICROBIOL, V19, P777, DOI 10.1046/j.1365-2958.1996.424950.x; Jordan A, 1997, J BIOL CHEM, V272, P18044, DOI 10.1074/jbc.272.29.18044; Kim HS, 1996, MUTAT RES-DNA REPAIR, V363, P115, DOI 10.1016/0921-8777(96)00006-7; Kranendonk M, 1997, MUTAGENESIS, V12, P245, DOI 10.1093/mutage/12.4.245; MATA AM, 1984, Z NATURFORSCH C, V39, P908; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; MULDER GJ, 1988, GLUTATHIONE CONJUGAT, P357; PROVENCE DL, 1994, METHODS GEN MOL BACT, P343; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RYCHLIK W, 1993, METHODS MOL BIOL PCR, P31; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SUN L, 1994, J BACTERIOL, V176, P4617, DOI 10.1128/JB.176.15.4617-4626.1994; SUN L, 1992, MOL BIOL CELL, V3, P1095, DOI 10.1091/mbc.3.10.1095; SUN L, 1994, J BACTERIOL, V176, P2415, DOI 10.1128/JB.176.8.2415-2426.1994; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; WALLACE SS, 1997, OXIDATIVE STRESS MOL, P49; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	39	30	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18382	18388		10.1074/jbc.273.29.18382	http://dx.doi.org/10.1074/jbc.273.29.18382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660805	hybrid			2022-12-27	WOS:000074828500060
J	Manya, H; Aoki, J; Watanabe, M; Adachi, T; Asou, H; Inoue, Y; Arai, H; Inoue, K				Manya, H; Aoki, J; Watanabe, M; Adachi, T; Asou, H; Inoue, Y; Arai, H; Inoue, K			Switching of platelet-activating factor acetylhydrolase catalytic subunits in developing rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; NEURONAL MIGRATION; NUCLEAR MIGRATION; LIS-1 GENE; EXPRESSION; MESSENGER; CLONING; PURIFICATION; PRODUCT	In a previous study, we demonstrated that Platelet-activating Factor (PAF) acetylhydrolase purified from bovine brain cortical cytosol consists of two mutually homologous catalytic subunits (alpha 1 and alpha 2) and one putative regulatory beta subunit, The latter is a product of the LIS1 gene, which is defective in the Miller-Dieker syndrome, a form of lissencephaly. In this study, we examined the expression patterns of these three subunits in the developing rat brain. All three subunits were expressed in embryonic brain, whereas only alpha 2 and beta subunit were detected in the adult brain by Western blotting, Biochemical analyses revealed that the alpha 1/alpha 2 heterodimer and alpha 2/alpha 2 homodimer are major catalytic units of embryonic and adult brain PAF acetylhydrolases, respectively. The alpha 1 transcript and protein were detected predominantly in embryonic and postnatal neural tissues, such as the brain and spinal cord. Furthermore, we found using primary cultured cells isolated from neonatal rat brain that alpha 1 protein were expressed only in neurons but not in glial cells and fibroblasts. In contrast, alpha 2 and beta transcripts and proteins were detected both in neural and non-neural tissues, and their expression level was almost constant from fetal stages through adulthood, These results indicate that alpha 1 expression is restricted to actively migrating neurons in rats and that switching of catalytic subunits from the alpha 1/alpha 2 heterodimer to the alpha 2/alpha 2 homodimer occurred in these cells during brain development, suggesting that PAF acetylhydrolase plays a role(s) in neuronal migration.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 113, Japan; Hokkaido Univ, Grad Sch Med, Div Brain Sci, Lab Mol Neuroanat, Sapporo, Hokkaido 060, Japan; Tokyo Metropolitan Inst Gerontol, Dept Cell Biol, Itabashi Ku, Tokyo 173, Japan	University of Tokyo; Hokkaido University; Tokyo Metropolitan Institute of Gerontology	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.		Watanabe, Masahiko/S-3614-2019; WATANABE, Masahiko/A-4055-2012	Watanabe, Masahiko/0000-0001-5037-7138; WATANABE, Masahiko/0000-0001-5037-7138; Manya, Hiroshi/0000-0003-1573-9177; Aoki, Junken/0000-0001-9435-1896				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V214, P180, DOI 10.1006/bbrc.1995.2272; Adachi H, 1997, BIOCHEM BIOPH RES CO, V233, P10, DOI 10.1006/bbrc.1997.6383; Albrecht U, 1996, DEV BIOL, V180, P579, DOI 10.1006/dbio.1996.0330; AXTELL SM, 1995, MOL ENDOCRINOL, V9, P312, DOI 10.1210/me.9.3.312; BAZAN NG, 1995, NEUROCHEM INT, V26, P435, DOI 10.1016/0197-0186(94)00138-K; BOOK KJ, 1990, J COMP NEUROL, V297, P55, DOI 10.1002/cne.902970105; Gibbons IR, 1996, CELL STRUCT FUNCT, V21, P331, DOI 10.1247/csf.21.331; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Ho YS, 1997, NATURE, V385, P89, DOI 10.1038/385089a0; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; Morris SM, 1997, MOL ENDOCRINOL, V11, P229, DOI 10.1210/me.11.2.229; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; REINER O, 1995, J NEUROSCI, V15, P3730; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; WANG DS, 1995, BIOCHEM BIOPH RES CO, V209, P622, DOI 10.1006/bbrc.1995.1545; WATANABE M, 1997, BIOCHIM BIOPHYS ACTA, V1409, P73; Willins DA, 1997, MOL GEN GENET, V255, P194, DOI 10.1007/s004380050489; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YANOSHITA R, 1988, J BIOCHEM-TOKYO, V103, P815, DOI 10.1093/oxfordjournals.jbchem.a122352	28	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18567	18572		10.1074/jbc.273.29.18567	http://dx.doi.org/10.1074/jbc.273.29.18567			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660828	hybrid			2022-12-27	WOS:000074828500083
J	Bein, K; Ware, JA; Simons, M				Bein, K; Ware, JA; Simons, M			Myb-dependent regulation of thrombospondin 2 expression - Role of mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; C-MYB; MESSENGER-RNA; ONCOGENE PRODUCT; PROTO-ONCOGENE; DNA-BINDING; FIBROBLASTS; GENE; PROLIFERATION; PROTOONCOGENE	The nuclear transcription factor c-Myb, which is highly expressed in hematopoietic cells, has been shown to be functional in NIH 3T3 cells: cells that do not possess detectable levels of c-Myb, To identify endogenous target genes of c-Myb in fibroblasts, RNA isolated from NIH 3T3 cells stably transfected with a full-length or a dominant negative c-myb construct (GREMyb and GREMEn, respectively) was subjected to differential display analysis, 5'-Rapid amplification of cDNA ends of a selected band, sequencing, and a nucleotide homology search led to the identification of thrombospondin 2 (TSP 2) as the gene product repressed in GREMyb and induced in GREMEn cells. The pattern of TSP 2 expression during the cell cycle was consistent with c-myb-dependent regulation. The possibility that the identified transcript was TSP I, a homologous product known to be repressed by v-Src, c-Jun, and v-Myc, was ruled out by using a TSP 2-specific DNA probe and by showing a distinct pattern of regulation of TSP 1 and TSP 2 expression. Nuclear run-on and TSP 2 promoter-reporter (chloramphenicol acetyltransferase) assays showed similar transcriptional levels in GREMyb and NIH 3T3 cells. However, mRNA stability studies showed a much shorter TSP 2 mRNA half-life in GREMyb compared with wild type NIH 3T3 cells, suggesting that c-myb affects TSP 2 expression via a post-transcriptional mechanism. The implications of a protooncogene-mediated suppression of TSP expression are discussed.	Beth Israel Deaconess Med Ctr, Div Cardiovasc, Angiogenesis Res Ctr, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Simons, M (corresponding author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Angiogenesis Res Ctr, Dept Med, RW-453,330 Brookline Ave, Boston, MA 02215 USA.		Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Bein, Kiflai/0000-0002-5206-0801	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056993, R01HL047032, R01HL053793] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-47032, R01-HL-53793, P50-HL56993] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARLETTA C, 1992, European Journal of Gynaecological Oncology, V13, P53; Bein K, 1997, J CELL PHYSIOL, V173, P319, DOI 10.1002/(SICI)1097-4652(199712)173:3<319::AID-JCP3>3.0.CO;2-Q; BELASO J, 1993, EXPT APPROACHES STUD, P475; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BROWN KE, 1992, J BIOL CHEM, V267, P4625; CATRON KM, 1992, J IMMUNOL, V148, P934; CHEN H, 1994, J BIOL CHEM, V269, P32226; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUERIN M, 1990, ONCOGENE, V5, P131; Husain M, 1997, AM J PHYSIOL-CELL PH, V272, pC1947, DOI 10.1152/ajpcell.1997.272.6.C1947; Husain M, 1997, CIRC RES, V80, P617, DOI 10.1161/01.RES.80.5.617; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KU DH, 1993, J BIOL CHEM, V268, P2255; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAHERTY CD, 1992, J BIOL CHEM, V267, P3274; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lipsick JS, 1996, ONCOGENE, V13, P223; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; MIZUGUCHI G, 1995, J BIOL CHEM, V270, P9384, DOI 10.1074/jbc.270.16.9384; MUMBY SM, 1984, J CELL PHYSIOL, V120, P280, DOI 10.1002/jcp.1041200304; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHNER J, 1988, LEUKEMIA, V2, P749; SIMONS M, 1992, CIRC RES, V70, P835, DOI 10.1161/01.RES.70.4.835; SIMONS M, 1995, AM J PHYSIOL-CELL PH, V268, pC856, DOI 10.1152/ajpcell.1995.268.4.C856; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLACK JL, 1994, CELL GROWTH DIFFER, V5, P1373; SZCZYLIK C, 1993, J EXP MED, V178, P997, DOI 10.1084/jem.178.3.997; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TORELLI G, 1987, CANCER RES, V47, P5266; TRAVALI S, 1991, ONCOGENE, V6, P887; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; Weston K M, 1990, Semin Cancer Biol, V1, P371; WINQVIST R, 1985, CANCER GENET CYTOGEN, V18, P251, DOI 10.1016/0165-4608(85)90090-1; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	55	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21423	21429		10.1074/jbc.273.33.21423	http://dx.doi.org/10.1074/jbc.273.33.21423			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694906	hybrid			2022-12-27	WOS:000075386100099
J	Kovalsky, OI; Grossman, L				Kovalsky, OI; Grossman, L			Accessibility of epitopes on UvrB protein in intermediates generated during incision of UV-irradiated DNA by the Escherichia coli Uvr(A)BC endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; UVRABC ENDONUCLEASE; (A)BC EXCINUCLEASE; MONOCLONAL-ANTIBODIES; ENZYMATIC-PROPERTIES; PREINCISION COMPLEX; ATPASE ACTIVITY; DAMAGED DNA; BINDING; REGION	Structural intermediates generated during incision of damaged DNA by the Uvr(A)BC endonuclease were probed with monoclonal antibodies (mAbs) raised against the Escherichia coli UvrB protein. It was found that the epitope of B2C5 mAb, mapped at amino acids (aa) 171-278 of UvrB, is not accessible in any of the preformed Uvr intermediates. Preformed B2C5-UvrB immunocomplexes, however, inhibited formation of those intermediates. B2C5 mAb seems to interfere with the formation of the UvrA-UvrB complex due to overlapping of its epitope and the UvrA binding region of UvrB, Conversely, the epitope of B3C1 mAb (aa 1-7 and/or 62-170) was accessible in all Uvr intermediates. The epitope of B*2E3 mAb (aa 171-278) was not accessible in any of the nucleoprotein intermediates preceding UvrB-DNA preincision complex. However, B*2E3 was able to immunoprecipitate this complex and to inhibit overall incision. B2A1 mAb (aa 8-61) inhibited formation of those Uvr intermediates requiring ATP binding and/or hydrolysis by UvrB, B*2B9 mAb (aa 473-630) inhibited Uvr nucleoprotein complexes involving UvrB, B*2B9 seems to prevent the binding of the UvrA-UvrB complex to DNA, The epitope of the B*3E11 mAb (aa 379-472) was not accessible in Uvr complexes formed at damaged sites. These results are discussed in terms of structure-functional mapping of UvrB protein.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Grossman, L (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, 615 N Wolfe St, Baltimore, MD 21205 USA.	lg@welchlink.welch.jhu.edu			NIGMS NIH HHS [GM 22846] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022846, R01GM022846] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN B, 1995, THESIS J HOPKINS U; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1988, NUCLEIC ACIDS RES, V16, P10891, DOI 10.1093/nar/16.22.10891; GOLDBERG ME, 1991, TRENDS BIOCHEM SCI, V16, P358, DOI 10.1016/0968-0004(91)90148-O; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; Harlow E., 1988, ANTIBODIES LAB MANUA; HSU DS, 1995, J BIOL CHEM, V270, P8319, DOI 10.1074/jbc.270.14.8319; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KOVALSKY OI, 1994, J BIOL CHEM, V269, P27421; Kovalsky OI, 1998, BBA-GENE STRUCT EXPR, V1397, P91, DOI 10.1016/S0167-4781(98)00002-5; Lin CLG, 1997, NUCLEIC ACIDS RES, V25, P3151, DOI 10.1093/nar/25.15.3151; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; Moolenaar GF, 1995, J BIOL CHEM, V270, P30508, DOI 10.1074/jbc.270.51.30508; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; ORREN DK, 1989, P NATL ACAD SCI USA, V86, P5237, DOI 10.1073/pnas.86.14.5237; ORREN DK, 1990, J BIOL CHEM, V265, P15796; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SEELEY TW, 1990, J BIOL CHEM, V265, P7158; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; VANHOUTEN B, 1993, BIOESSAYS, V15, P51, DOI 10.1002/bies.950150108; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VISSE R, 1992, J BIOL CHEM, V267, P6736; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535; YEUNG AT, 1983, P NATL ACAD SCI-BIOL, V80, P6157, DOI 10.1073/pnas.80.20.6157	30	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21009	21014		10.1074/jbc.273.33.21009	http://dx.doi.org/10.1074/jbc.273.33.21009			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694852	hybrid			2022-12-27	WOS:000075386100045
J	Udalova, IA; Knight, JC; Vidal, V; Nedospasov, SA; Kwiatkowski, D				Udalova, IA; Knight, JC; Vidal, V; Nedospasov, SA; Kwiatkowski, D			Complex NF-kappa B interactions at the distal tumor necrosis factor promoter region in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA GENE; HUMAN TNF PROMOTER; IFN-BETA GENE; TRANSCRIPTIONAL ACTIVATION; VIRUS INDUCTION; CELL-LINE; LIPOPOLYSACCHARIDE; ELEMENT; MACROPHAGES; PROTEIN	We describe a dense cluster of DNA-protein interactions located 600 nucleotides upstream of the transcriptional start site of the human tumor necrosis factor (TNF) gene. This area was identified as being of potential importance for lipopolysaccharide-inducible TNF expression in the human monocyte cell line Mono Mac 6, based on reporter gene analysis of point mutations at a number of nuclear factor kappa B (NF-kappa B)-like motifs within the human TNF promoter region. The area contains two NF-kappa B sites, which are here shown by DNase I and methylation interference footprinting to flank a novel binding site. UV cross-linking studies reveal that the novel site can also bind NF-kappa B as well as an unknown protein(s) of approximately 40 kDa. We show that these three adjacent kappa B-binding sites differ markedly in their relative affinities for p50/p50, p65/p65, and p65/p50, yet this 39-nucleotide segment of DNA appears capable of binding up to three NF-kappa B heterodimers simultaneously. Reporter gene studies indicate that each element of the cluster contributes to lipopolysaccharide-induced transcriptional activation in Mono Mac 6 cells. These findings suggest that NF-kappa B acts in a complex manner to activate TNF transcription in human monocytes.	Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Dept Paediat, Oxford OX3 9DS, England; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow, Russia; Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow, Russia; SAIC Frederick, Intramural Res Support Program, Frederick, MD 21702 USA	University of Oxford; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Lomonosov Moscow State University; Science Applications International Corporation (SAIC); SAIC-Frederick	Udalova, IA (corresponding author), Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Dept Paediat, Oxford OX3 9DS, England.		Nedospasov, Sergei/C-3043-2018; Nedospasov, Sergei/L-1990-2015; Nedospasov, Sergei/J-5936-2013; Knight, Julian Charles/W-2399-2019; Knight, Julian/C-7242-2009; Nedospasov, Sergei/Q-7319-2016	Knight, Julian Charles/0000-0002-0377-5536; Knight, Julian/0000-0002-0377-5536; Udalova, Irina/0000-0002-6716-2528; Kwiatkowski, Dominic/0000-0002-5023-0176				BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO, P539; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRAMER B, 1995, J BIOL CHEM, V270, P6577; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUPRASH DV, 1995, ONCOGENE, V11, P97; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; POPE RM, 1994, J CLIN INVEST, V94, P1449, DOI 10.1172/JCI117482; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; SANDALTZOPOULOS R, 1994, NUCLEIC ACIDS RES, V22, P1511, DOI 10.1093/nar/22.8.1511; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; Stuber F, 1996, J INFLAMM, V46, P42; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P459; UDALOVA IA, 1995, DOKL AKAD NAUK+, V342, P413; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	33	115	123	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21178	21186		10.1074/jbc.273.33.21178	http://dx.doi.org/10.1074/jbc.273.33.21178			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694874	hybrid			2022-12-27	WOS:000075386100067
J	Viswanathan, A; Doetsch, PW				Viswanathan, A; Doetsch, PW			Effects of nonbulky DNA base damages on Escherichia coli RNA polymerase-mediated elongation and promoter clearance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCISION REPAIR; PYRBI OPERON EXPRESSION; TRANSCRIPTIONAL INITIATION; REITERATIVE TRANSCRIPTION; TEMPLATE DNA; STRAND; GENE; REPLICATION; MECHANISM; CLEAVAGE	DNA base damage products either formed spontaneously or as a result of exposure to various genotoxic agents were examined for their effects on Escherichia coli RNA polymerase-mediated transcription in vitro, Uracil, O-6-methylguanine (O-6-meG), and 8-oxoguanine (8-oxoG) were placed at specific sites downstream from the transcriptional start site on the transcribed strand of a duplex template under the control of the strong too promoter. In vitro, single-round transcription experiments carried out with purified E. coli RNA polymerase revealed efficient bypass at the three lesions examined and subsequent generation of full-length runoff transcripts. Transcript sequence analysis revealed that E, coli RNA polymerase inserted primarily adenine into the transcript opposite to uracil, uracil opposite to O-6-meG, and either adenine or cytosine opposite to 8-oxoG. Thus, a uracil in the DNA template resulted in a G-to-A transition mutation in the lesion bypass product whereas O-6-meG: produced a C-to-U transition mutation and 8-oxoG; generated either the correct transcriptional product or a C-to-A transversion mutation. When 8-oxoG was placed within close proximity to the transcriptional start site (within the region required for effective promoter clearance), a reduced of full-length, runoff transcript was observed, indicative of lower promoter clearance. Taken together, these results demonstrate that the DNA base damages studied here may exert significant in vivo effects on gene expression and DNA repair with respect to the production of mutant proteins (transcriptional mutagenesis), or decreased levels of expressed proteins.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Doetsch, PW (corresponding author), Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.	medpwd@ernory.edu			NATIONAL CANCER INSTITUTE [R01CA073041] Funding Source: NIH RePORTER; NCI NIH HHS [CA73041] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BOHR VA, 1987, CARCINOGENESIS, V8, P1333, DOI 10.1093/carcin/8.9.1333; BRIDGES BA, 1995, NATURE, V375, P741, DOI 10.1038/375741a0; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHEN YH, 1993, J BIOL CHEM, V268, P5849; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; ELLINGER T, 1994, J MOL BIOL, V239, P455, DOI 10.1006/jmbi.1994.1388; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hernandez VJ, 1996, J BIOL CHEM, V271, P18775, DOI 10.1074/jbc.271.31.18775; JACQUES JP, 1990, GENE DEV, V4, P1801, DOI 10.1101/gad.4.10.1801; Jin DJ, 1996, J BIOL CHEM, V271, P11659; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; LIU J, 1995, MOL CELL BIOL, V15, P6729; Liu J, 1998, NUCLEIC ACIDS RES, V26, P1707, DOI 10.1093/nar/26.7.1707; Liu J, 1996, BIOCHEMISTRY-US, V35, P14999, DOI 10.1021/bi961455x; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; Qi FX, 1996, METHOD ENZYMOL, V273, P71; QI FX, 1995, J MOL BIOL, V254, P552, DOI 10.1006/jmbi.1995.0638; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHI YB, 1988, J BIOL CHEM, V263, P527; SNOW ET, 1984, J BIOL CHEM, V259, P8095; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; ZHOU W, 1993, P NATL ACAD SCI USA, V90, P6601, DOI 10.1073/pnas.90.14.6601	28	96	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21276	21281		10.1074/jbc.273.33.21276	http://dx.doi.org/10.1074/jbc.273.33.21276			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694887	hybrid			2022-12-27	WOS:000075386100080
J	Zierath, JR; Tsao, TS; Stenbit, AE; Ryder, JW; Galuska, D; Charron, MJ				Zierath, JR; Tsao, TS; Stenbit, AE; Ryder, JW; Galuska, D; Charron, MJ			Restoration of hypoxia-stimulated glucose uptake in GLUT4-deficient muscles by muscle-specific GLUT4 transgenic complementation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; INSULIN-INDUCED TRANSLOCATION; CELL-SURFACE GLUT4; OVEREXPRESSING GLUT4; EXERCISE INCREASES; RESPONSIVE TISSUES; INTRACELLULAR POOL; TRANSPORT ACTIVITY; PLASMA-MEMBRANE; MICE	To investigate whether GLUT4 is required for exercise/hypoxia-induced glucose uptake, we assessed glucose uptake under hypoxia and normoxia in extensor digitorum longus (EDL) and soleus muscles from GLUT4-deficient mice. In EDL and soleus from wild type control mice, hypoxia increased a-deoxyglucose uptake 2-3 fold. Conversely, hypoxia did not alter a-deoxyglucose uptake in either EDL or soleus from either male or female GLUT4-null mice. Next we introduced the fast-twitch skeletal muscle-specific MLC-GLUT4 transgene into GLUT4-null mice to determine whether changes in the metabolic milieu accounted for the lack of hypoxia-mediated glucose transport. Transgenic complementation of GLUT4 in EDL was sufficient to restore hypoxia-mediated glucose uptake. Soleus muscles from MLC-GLUT4-null mice were transgene-negative, and hypoxia-stimulated a-deoxyglucose uptake was not restored. Although ablation of GLUT4 in EDL did not affect normoxic glycogen levels, restoration of GLUT4 to EDL led to an increase in glycogen under hypoxic conditions. Male GLUT4-null soleus displayed reduced normoxic glycogen stores, but female null soleus contained significantly more glycogen under normoxia and hypoxia, Reduced normoxic levels of ATP and phosphocreatine were measured in male GLUT4-null soleus but not in EDL, However, transgenic complementation of GLUT4 prevented the decrease in hypoxic ATP and phosphocreatine levels noted in male GLUT4-null and control EDL. In conclusion, we have demonstrated that GLUT4 plays an essential role in the regulation of muscle glucose uptake in response to hypoxia, Because hypoxia is a useful model for exercise, our results suggest that stimulation of glucose transport in response to exercise in skeletal muscle is totally dependent upon GLUT4, Furthermore, the compensatory glucose transport system that exists in GLUT4-null soleus muscle is not sensitive to hypoxia/muscle contraction.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden	Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Karolinska University Hospital	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Zierath, Juleen/0000-0001-6891-7497; Tsao, Tsu-Shuen/0000-0002-1041-9687	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58119] Funding Source: Medline; NIDDK NIH HHS [DK47425] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07491] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao SC, 1997, METABOLISM, V46, P1349, DOI 10.1016/S0026-0495(97)90243-2; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; Brozinick JT, 1997, BIOCHEM J, V321, P75, DOI 10.1042/bj3210075; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; CARTEE GD, 1990, AM J PHYSIOL, V258, pE390, DOI 10.1152/ajpendo.1990.258.2.E390; CARTEE GD, 1992, AM J PHYSIOL, V263, pR70, DOI 10.1152/ajpregu.1992.263.1.R70; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1996, BIOCHEM SOC T, V25, P963; CODERRE L, 1995, J BIOL CHEM, V270, P27584, DOI 10.1074/jbc.270.46.27584; DOUEN AG, 1990, FEBS LETT, V261, P256, DOI 10.1016/0014-5793(90)80566-2; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GAO JP, 1994, J APPL PHYSIOL, V77, P1597, DOI 10.1152/jappl.1994.77.4.1597; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSEN EJ, 1989, AM J PHYSIOL, V256, pE662, DOI 10.1152/ajpendo.1989.256.5.E662; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; HIRSHMAN MF, 1988, FEBS LETT, V238, P235, DOI 10.1016/0014-5793(88)80486-1; HOLLOSZY JO, 1965, J BIOL CHEM, V240, P3493; IDSTROM JP, 1986, BIOCHEM J, V233, P131, DOI 10.1042/bj2330131; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LUND S, 1994, AM J PHYSIOL, V267, pE461, DOI 10.1152/ajpendo.1994.267.3.E461; LUND S, 1993, FEBS LETT, V330, P312, DOI 10.1016/0014-5793(93)80895-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; Roy D, 1996, BIOCHEM BIOPH RES CO, V223, P147, DOI 10.1006/bbrc.1996.0860; Stenbit AE, 1996, J CLIN INVEST, V98, P629, DOI 10.1172/JCI118833; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; WALLBERGHENRIKS.H, 1987, ACTA PHYSL SCAND S, V131, P564; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WALLBERGHENRIKSSON H, 1988, J APPL PHYSIOL, V65, P909, DOI 10.1152/jappl.1988.65.2.909; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; YOUN JH, 1994, AM J PHYSIOL-REG I, V267, pR888, DOI 10.1152/ajpregu.1994.267.4.R888; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215	43	27	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20910	20915		10.1074/jbc.273.33.20910	http://dx.doi.org/10.1074/jbc.273.33.20910			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694838	hybrid			2022-12-27	WOS:000075386100031
J	Ishigami, M; Swertfeger, DK; Granholm, NA; Hui, DY				Ishigami, M; Swertfeger, DK; Granholm, NA; Hui, DY			Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL CORONARY ANGIOPLASTY; ACTIVATED PROTEIN-KINASE; CYCLIN D1 EXPRESSION; PLASMA-LIPOPROTEINS; DENSITY-LIPOPROTEIN; TRANSGENIC MICE; INTIMAL HYPERPLASIA; CHOLESTEROL EFFLUX; ALZHEIMER-DISEASE; RECEPTOR	The anti-atherogenic effects of apolipoprotein (apo) E have been attributed to its ability to reduce plasma cholesterol level and to limit foam cell formation. The purpose of this study was to ascertain if apoE also may have cytostatic functions that could attenuate vascular occlusive diseases. Purified apoE inhibited smooth muscle cell migration directed to platelet-derived growth factor (PDGF) or oxidized LDL (oxLDL) (p < 0.0001). The purified apoE also suppressed PDGF- and oxLDL-induced smooth muscle cell proliferation (p < 0.001). These apoE inhibitory effects were not because of suppression of PDGF binding to its receptors on the smooth muscle cells, but was correlated with a significant reduction in agonist-stimulated mitogen-activated protein kinase activity (p < 0.01), ApoE also inhibited PDGF-induced cyclin DI mRNA expression, suggesting that the apoE effect was mediated by growth arrest at the G(0) to G(1) phase. Taken together, these results suggest that apoE has cytostatic functions in the vessel wall and may protect against vascular diseases through inhibition of cell signaling events associated with growth factor-induced smooth muscle cell migration and proliferation.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Swertfeger, Debi/AAN-6490-2021	Swertfeger, Debi/0000-0002-0570-0271	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040917] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABIEU A, 1996, J CELL SCI, V109, P239; AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P369, DOI 10.1016/S0735-1097(85)80174-1; AUTRIO I, 1990, FEBS LETT, V277, P247; BIANCHI S, 1994, BIOCHEM BIOPH RES CO, V204, P691, DOI 10.1006/bbrc.1994.2515; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CHATTERJEE S, 1992, MOL CELL BIOCHEM, V111, P143; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COCKS BG, 1992, J BIOL CHEM, V267, P12307; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; DeGeest B, 1997, CIRCULATION, V96, P4349; DYER CA, 1988, J BIOL CHEM, V263, P10965; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIRALDO AA, 1985, ARCH PATHOL LAB MED, V109, P173; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; GROTENDORST GR, 1982, J CELL PHYSIOL, V113, P261, DOI 10.1002/jcp.1041130213; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HUI DY, 1980, J BIOL CHEM, V255, P1775; HUI DY, 1980, BIOCHEM J, V192, P91, DOI 10.1042/bj1920091; HUI DY, 1979, J BIOL CHEM, V254, P4666; JACKSON CL, 1993, ARTERIOSCLER THROMB, V13, P1218, DOI 10.1161/01.ATV.13.8.1218; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KRUTH HS, 1994, J BIOL CHEM, V269, P24511; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LaFerla FM, 1997, J CLIN INVEST, V100, P310, DOI 10.1172/JCI119536; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAJACK RA, 1988, J CELL BIOL, V107, P1207, DOI 10.1083/jcb.107.3.1207; Marques M, 1997, ALZHEIMER RES, V3, P1; MAZZONE T, 1994, J LIPID RES, V35, P1345; MISRA UK, 1994, J BIOL CHEM, V269, P18303; MISTRY MJ, 1995, CELL IMMUNOL, V160, P14, DOI 10.1016/0008-8749(95)80004-3; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1986, METHOD ENZYMOL, V128, P273; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; REYLAND ME, 1991, P NATL ACAD SCI USA, V88, P2375, DOI 10.1073/pnas.88.6.2375; Riddell DR, 1997, J BIOL CHEM, V272, P89; Russell PS, 1996, AM J PATHOL, V149, P91; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Seo HS, 1997, ARTERIOSCL THROM VAS, V17, P3593, DOI 10.1161/01.ATV.17.12.3593; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANBOCKXMEER FM, 1994, ATHEROSCLEROSIS, V110, P195, DOI 10.1016/0021-9150(94)90204-6; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; Yamamoto T, 1996, CURR OPIN LIPIDOL, V7, P298, DOI 10.1097/00041433-199610000-00007; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	63	125	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20156	20161		10.1074/jbc.273.32.20156	http://dx.doi.org/10.1074/jbc.273.32.20156			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685360	hybrid			2022-12-27	WOS:000075305400037
J	Matsuda, S; Hisatomi, O; Ishino, T; Kobayashi, Y; Tokunagati, F				Matsuda, S; Hisatomi, O; Ishino, T; Kobayashi, Y; Tokunagati, F			The role of calcium-binding sites in S-modulin function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSIN PHOSPHORYLATION; LIGHT ADAPTATION; RECOVERIN; RODS; TERMINUS; VISION	S-modulin controls rhodopsin phosphorylation in a calcium-dependent manner, and it has been suggested that it modulates the light sensitivity of the photoreceptor cell, S-modulin binds to the ROS membrane at high Ca2+ concentration, and N-terminal myristoylation is necessary for this property (the calcium-myristoyl switch). S-modulin has four EF-hand motifs, of which two (EF-2 and -3) are functional. Here, we report on the roles of EF-2 and -3 in S-modulin function (calcium binding, membrane association, and inhibition of rhodopsin phosphorylation) by site-directed mutants (E85M and E121M), Surprisingly, E121M, which has a mutation in EF-3, neither binds Ca2+ nor inhibits phosphorylation, In contrast, E85M binds one Ca2+ and has the same membrane affinity as wild-type S-modulin, but has lost the ability to inhibit rhodopsin phosphorylation, It is suggested that the binding of Ca2+ to EF-3 is probably required for EF-2 to be a functional Ca2+-binding site and to induce exposure of the myristoyl group; and that the binding of Ca2+ to EF-2 is important for the interaction with rhodopsin kinase.	Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650043, Japan	Osaka University	Tokunagati, F (corresponding author), Osaka Univ, Grad Sch Sci, Dept Earth & Space Sci, Machikaneyama Chyo 1-1, Toyonaka, Osaka 5600043, Japan.		Matsuda, Shinji/GRR-5226-2022; Matsuda, Shinji/L-4727-2013					AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; BABU A, 1992, J BIOL CHEM, V267, P15469; BLATT WF, 1968, ANAL BIOCHEM, V26, P151, DOI 10.1016/0003-2697(68)90039-0; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DIZHOOR AM, 1993, SCIENCE, V259, P829, DOI 10.1126/science.8430337; DIZHOOR AM, 1991, SCIENCE, V251, P915, DOI 10.1126/science.1672047; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Hisatomi O, 1997, BIOCHEM BIOPH RES CO, V234, P173, DOI 10.1006/bbrc.1997.6609; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATTHEWS HR, 1988, NATURE, V334, P67, DOI 10.1038/334067a0; MCNAUGHTON PA, 1986, NATURE, V322, P261, DOI 10.1038/322261a0; NAKATANI K, 1988, NATURE, V334, P69, DOI 10.1038/334069a0; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; SANADA K, 1995, J BIOL CHEM, V270, P15459, DOI 10.1074/jbc.270.26.15459; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; YAU KW, 1985, NATURE, V313, P579, DOI 10.1038/313579a0; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	24	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20223	20227		10.1074/jbc.273.32.20223	http://dx.doi.org/10.1074/jbc.273.32.20223			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685370	hybrid			2022-12-27	WOS:000075305400047
J	Menguy, T; Corre, F; Bouneau, L; Deschamps, S; Moller, JV; Champeil, P; le Maire, M; Falson, P				Menguy, T; Corre, F; Bouneau, L; Deschamps, S; Moller, JV; Champeil, P; le Maire, M; Falson, P			The cytoplasmic loop located between transmembrane segments 6 and 7 controls activation by Ca2+ of sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; CALCIUM-BINDING; AMINO-ACIDS; TRANSPORT SITES; ATPASE; CA-2+-ATPASE; CA-2+; PHOSPHORYLATION; DISSOCIATION	During active cation transport, sarcoplasmic reticulum Ca2+-ATPase, like other P-type ATPases, undergoes major conformational changes, some of which are dependent on Ca2+ binding to high affinity transport sites. me here report that, in addition to previously described residues of the transmembrane region (Clarke, D. M., Loo, T. W., Inesi, G., and MacLennan, D. H. (1989) Nature 339, 476-478), the region located in the cytosolic L6-7 loop connecting transmembrane segments M6 and M7 has a definite influence on the sensitivity of the Ca2+-ATPase to Ca2+, i.e. on the affinity of the ATPase for Ca2+. Cluster mutation of aspartic residues in this loop results in a strong reduction of the affinity for Ca2+, as shown by the Ca2+ dependence of ATPase phosphorylation from either ATP or P-i. The reduction in Ca2+ affinity for phosphorylation from P-i is observed both at acidic and neutral pH, suggesting that these mutations interfere with binding of the first Ca2+, as proposed for some of the intramembranous residues essential for Ca2+ binding (Andersen, J. P. (1995) Biosci. Rep. 15, 243-261). Treatment of the mutated Ca2+-ATPase with proteinase K, in the absence or presence of various Ca2+ concentrations, leads to Ca2+-dependent changes in the proteolytic degradation pattern similar to those in the wild type but observed only at higher Ca2+ concentrations. This implies that these effects are not due to changes in the conformational state of Ca2+-free ATPase but that changes affecting the proteolytic digestion pattern require higher Ca2+ concentrations. We conclude that aspartic residues in the L6-7 loop might interact with Ca2+ during the initial steps of Ca2+ binding.	CE Saclay, CEA, DBCM, Sect Biophys Proteines & Membranes, F-91191 Gif Sur Yvette, France; CE Saclay, CNRS URA 2096, F-91191 Gif Sur Yvette, France; Aarhus Univ, Dept Biophys, Danish Biomembrane Res Ctr, DK-8000 Aarhus, Denmark	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Aarhus University	Falson, P (corresponding author), CE Saclay, CEA, DBCM, Sect Biophys Proteines & Membranes, Bat 528, F-91191 Gif Sur Yvette, France.	falson@dsvidf.cea.fr		Falson, Pierre/0000-0002-9760-4577				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; ANDERSEN JP, 1985, J MEMBRANE BIOL, V88, P187, DOI 10.1007/BF01868432; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; Chen L, 1996, J BIOL CHEM, V271, P10745, DOI 10.1074/jbc.271.18.10745; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; COMBETTES L, 1993, CELL CALCIUM, V14, P279, DOI 10.1016/0143-4160(93)90049-C; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; ENOUF J, 1988, J BIOL CHEM, V263, P13922; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; FUJIMORI T, 1992, J BIOL CHEM, V267, P18475; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; HANEL AM, 1991, BIOCHEMISTRY-US, V30, P11320, DOI 10.1021/bi00111a019; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1980, J BIOL CHEM, V255, P3025; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LEVY D, 1990, J BIOL CHEM, V265, P19524; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUND S, 1988, J BIOL CHEM, V263, P1654; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; NAKAMURA Y, 1984, J BIOL CHEM, V259, P8183; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1988, J BIOL CHEM, V263, P17576; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P11331, DOI 10.1021/bi00111a020; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SKOU JC, 1992, J BIOENERG BIOMEMBR, V24, P249; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; TANFORD C, 1987, P NATL ACAD SCI USA, V84, P7094, DOI 10.1073/pnas.84.20.7094; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WATANABE T, 1981, BIOCHEMISTRY-US, V20, P6617, DOI 10.1021/bi00526a015; YAMADA S, 1986, J BIOCHEM-TOKYO, V100, P1329, DOI 10.1093/oxfordjournals.jbchem.a121839; YAMAGUCHI M, 1985, J BIOL CHEM, V260, P4896; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; [No title captured]	54	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20134	20143		10.1074/jbc.273.32.20134	http://dx.doi.org/10.1074/jbc.273.32.20134			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685357	hybrid			2022-12-27	WOS:000075305400034
J	Pacini, S; Ulivieri, C; Maddalena, M; Di Somma, MM; Isacchi, A; Lanfrancone', L; Pelicci, PG; Telford, JL; Baldari, CT				Pacini, S; Ulivieri, C; Maddalena, M; Di Somma, MM; Isacchi, A; Lanfrancone', L; Pelicci, PG; Telford, JL; Baldari, CT			Tyrosine 474 of ZAP-70 is required for association with the Shc adaptor and for T-cell antigen receptor-dependent gene activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; KINASE ZAP-70; ZETA-CHAIN; SIGNAL TRANSDUCTION; VAV PROTOONCOGENE; PROTEIN; PHOSPHORYLATION; DOMAIN; TCR; THYMOCYTES	The protein tyrosine kinase ZAP-70 plays a central role in T-cell activation. Following receptor engagement, ZAP-70 is recruited to the phosphorylated subunits of the T-cell antigen receptor (TCR). This event results in ZAP-70 activation and in association of ZAP-70 with a number of signaling proteins. Among these is the Shc adaptor, which couples the activated TCR to Ras, Shc interaction with ZAP-70 is mediated by the Shc PTB domain. The inhibitory effect of a Shc mutant containing the isolated PTB domain suggests that Shc interaction with ZAP-70 might be required for TCR signaling. Here, we show that a point mutation (Phe(474)) of the putative Shc binding site on ZAP-70, spanning tyrosine 474, prevented ZAP-70 interaction with Shc and the subsequent binding of Shc to phospho-zeta. Neither ZAP-70 catalytic activity nor the pattern of protein phosphorylation induced by TCR triggering was affected by this mutation. However expression of the phe(474) ZAP-70 mutant resulted in impaired TCR-dependent gene activation. ZAP-70 could effectively phosphorylate Shc in vitro. Only the CH domain, which contains the two Grb2 binding sites on Shc, was phosphorylated by ZAP-70. Both Grb2 binding sites were excellent substrates for ZAP-70, The data show that Tyr(474) On ZAP-70 is required for TCR signaling and suggest that Shc association with ZAP-70 and the resulting phosphorylation of Shc might be an obligatory step in linking the activated TCR to the Ras pathway.	Univ Siena, Dept Evolutionary Biol, I-53100 Siena, Italy; Pharmacia & Upjohn Inc, I-20014 Nerviano, Italy; European Inst Oncol, I-20141 Milan, Italy; Chiron SPA, I-53100 Siena, Italy	University of Siena; Pfizer; IRCCS European Institute of Oncology (IEO); Novartis	Baldari, CT (corresponding author), Univ Siena, Dept Evolutionary Biol, Via Mattioli 4, I-53100 Siena, Italy.	baldari@unisi.it	Lanfrancone, Luisa/AAC-8671-2019; Telford, John Laird/ABG-8144-2020; Ulivieri, Cristina/AAH-7543-2020; Pelicci, Pier Giuseppe/AAL-6572-2020	Lanfrancone, Luisa/0000-0002-4523-3815; Ulivieri, Cristina/0000-0002-1710-7977; Baldari, Cosima/0000-0002-4414-6744				ADAMS JM, 1992, ONCOGENE, V7, P611; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BALDARI CT, 1995, ONCOGENE, V10, P1141; BALDARI CT, 1998, IN PRESS BIOLOGICALS, V25; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; BORST J, 1990, HUM IMMUNOL, V29, P175, DOI 10.1016/0198-8859(90)90113-4; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Graef IA, 1997, EMBO J, V16, P5618, DOI 10.1093/emboj/16.18.5618; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Kong GH, 1996, MOL CELL BIOL, V16, P5026; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; Mege D, 1996, J BIOL CHEM, V271, P32644, DOI 10.1074/jbc.271.51.32644; Milia E, 1996, ONCOGENE, V13, P767; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; Wu J, 1997, J EXP MED, V185, P1877, DOI 10.1084/jem.185.10.1877; Yamasaki S, 1996, MOL CELL BIOL, V16, P7151; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhao QH, 1996, MOL CELL BIOL, V16, P6765	48	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20487	20493		10.1074/jbc.273.32.20487	http://dx.doi.org/10.1074/jbc.273.32.20487			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685404	hybrid			2022-12-27	WOS:000075305400081
J	Fang, TY; Alechina, O; Aleshin, AE; Fromm, HJ; Honzatko, RB				Fang, TY; Alechina, O; Aleshin, AE; Fromm, HJ; Honzatko, RB			Identification of a phosphate regulatory site and a low affinity binding site for glucose 6-phosphate in the N-terminal half of human brain hexokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; HALVES; MUTAGENESIS; RESIDUES; ENZYME; ATP	Crystal structures of human hexokinase I reveal identical binding sites for phosphate and the g-phosphoryl group of glucose B-phosphate in proximity to Gly(87), Ser(88), Thr(232), and Ser(415), a binding site for the pyranose moiety of glucose B-phosphate in proximity to Asp(84), Asp(413), and Ser(449), and a single salt link involving Arg(801) between the N- and C-terminal halves. Purified wildtype and mutant enzymes (Asp(84) --> Ala, Gly(87) --> Tyr, Ser(88) --> Ala, Th-232 --> Ala, Asp(413) --> Ala, Ser(415) --> Ala, Ser(449) --> Ala, and Arg(801) --> Ala) were studied by kinetics and circular dichroism spectroscopy. All eight mutant hexokinases have k(cat) and K-m values for substrates similar to those of wild-type hexokinase I. Inhibition of wild-type enzyme by 1,5-anhydroglucitol B-phosphate is consistent with a high affinity binding site (K-i = 50 mu M) and a second, low affinity binding site (K-ii = 0.7 mM), The mutations of Asp(84), Gly(87), and Thr232 listed above eliminate inhibition because of the low affinity site, but none of the eight mutations influence K-i of the high affinity site. Relief of 1,5-anhydroglucitol B-phosphate inhibition by phosphate for Asp(84) --> Ala, Ser(88) --> Ala, Ser(415) --> Ala, Ser(449) --> Ala and Arg(801) --> Ala mutant enzymes is substantially less than that of wild-type hexokinase and completely absent in the Gly(87) --> Tyr and Thr(232) --> Ala mutants. The results support several conclusions. (i) The phosphate regulatory site is at the N-terminal domain as identified in crystal structures. (ii) The glucose B-phosphate binding site at the N-terminal domain is a low affinity site and not the high affinity site associated with potent product inhibition. (iii) Arg(801) participates in the regulatory mechanism of hexokinase I.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA.				NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; ALESHIN AE, 1998, IN PRESS J MOL BIOL; ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BAIJAL M, 1995, ARCH BIOCHEM BIOPHYS, V321, P413, DOI 10.1006/abbi.1995.1412; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EASTERBY JS, 1973, EUR J BIOCHEM, V38, P201, DOI 10.1111/j.1432-1033.1973.tb03051.x; ELLISON WR, 1975, J BIOL CHEM, V250, P1864; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FROMM HJ, 1981, REGULATION CARBOHYDR, P45; HOLROYDE MJ, 1976, FEBS LETT, V62, P215, DOI 10.1016/0014-5793(76)80056-7; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU F, 1991, BIOCHEM BIOPH RES CO, V177, P305, DOI 10.1016/0006-291X(91)91983-J; LOWRY OH, 1964, J BIOL CHEM, V239, P31; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MANNING TA, 1984, BIOCHEM BIOPH RES CO, V118, P90, DOI 10.1016/0006-291X(84)91071-4; Rapoport S, 1968, Essays Biochem, V4, P69; TSAI HJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P206, DOI 10.1006/abbi.1995.1029; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; URETA T, 1975, ISOZYMES, V3, P575; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509; Zeng CB, 1998, J BIOL CHEM, V273, P700, DOI 10.1074/jbc.273.2.700	27	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19548	19553		10.1074/jbc.273.31.19548	http://dx.doi.org/10.1074/jbc.273.31.19548			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677378	hybrid			2022-12-27	WOS:000075125200030
J	Lin, HM; Hutchcroft, JE; Andoniou, CE; Kamoun, M; Band, H; Bierer, BE				Lin, HM; Hutchcroft, JE; Andoniou, CE; Kamoun, M; Band, H; Bierer, BE			Association of p59(fyn) with the T lymphocyte costimulatory receptor CD2 - Binding of the Fyn Src homology (SH) 3 domain is regulated by the Fyn SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; PROTEIN-TYROSINE KINASE; NATURAL-KILLER-CELLS; CYTOPLASMIC DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; ALTERNATIVE PATHWAY; PHOSPHATASE CD45; LIGAND AVIDITY; SURFACE LIGAND	Human CD2 is a 50-55-kDa cell surface receptor specifically expressed on the surface of T lymphocytes and NK cells. Stimulation of human peripheral blood T cells with mitogenic pairs of anti-CD2 monoclonal antibodies (mAbs) is sufficient to induce interleukin-a production and T cell proliferation in the absence of an antigen-specific signal through the T cell receptor. CD2 has been shown previously to associate physically with the Src family protein-tyrosine kinases p56(lck) and p59(fyn). We now report that stimulation of T cells with mitogenic pairs of anti-CD2 mAbs enhanced the association of the Fyn polypeptide with the CD2 complex, whereas stimulation with single anti-CD2 mAb had minimal effect. Using glutathione S-transferase (GST) fusion proteins, we found that CD2 bound to the Src homology (SH) 3 domain of Fyn. Interestingly, the CD2-Fyn association was negatively regulated by the Fyn SH2 domain; CD2 bound poorly to GST fusion proteins expressing both the SH2 and SH3 domains of Fyn. However, the inhibitory effect of the Fyn SH2 domain on binding of the Fyn SH3 domain to CD2 was relieved by peptides containing a phosphorylated YEEI sequence that bound directly to the Fyn SH2 domain. In addition, we found that the ability of the Fyn SH2 domain to precipitate tyrosine-phosphorylated proteins, including the CD3 zeta chain, was enhanced after T cell stimulation with mitogenic pairs of CD2 mAbs. Finally, overexpression of a mutated Fyn molecule, in which the ability of the Fyn SH2 domain to bind phosphotyrosine-containing proteins was abrogated, inhibited CD2-induced transcriptional activation of the nuclear factor of activated T cells (NFAT), suggesting a functional involvement of the Fyn SH2 domain in CD2-induced T cell signaling. We thus propose that stimulation through the CD2 receptor leads to the tyrosine phosphorylation of intracellular proteins, including CD3 zeta itself, which in turn bind to the Fyn-SH2 domain, allowing the direct association of the Fyn SH3 domain with CD2 and the initiation of downstream signaling events.	Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Med Sci, Comm Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Rheumatol & Immunol, Lymphocyte Biol Sect, Boston, MA 02115 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; University of Pennsylvania; Harvard University; Harvard Medical School	Bierer, BE (corresponding author), NHLBI, NIH, Bldg 10,Rm 5D49,10 Ctr Dr, Bethesda, MD 20892 USA.	biererb@nih.gov	Andoniou, Christopher/B-6296-2013	Bierer, Barbara/0000-0001-6448-8170; Andoniou, Christopher/0000-0003-0566-3180				ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; Bell GM, 1996, J EXP MED, V183, P169, DOI 10.1084/jem.183.1.169; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHANG SC, 1989, SENSORS COMPREHENSIV, V1, P169; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DECKERT M, 1992, EUR J IMMUNOL, V22, P2943, DOI 10.1002/eji.1830221128; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; GASSMANN M, 1994, EUR J IMMUNOL, V24, P139, DOI 10.1002/eji.1830240121; GOLLOB JA, 1995, J EXP MED, V182, P721, DOI 10.1084/jem.182.3.721; GUCKEL B, 1991, J EXP MED, V174, P957, DOI 10.1084/jem.174.5.957; HAHN WC, 1993, J EXP MED, V178, P1831, DOI 10.1084/jem.178.5.1831; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HAHN WC, 1992, SCIENCE, V256, P1805, DOI 10.1126/science.1377404; HOWARD FD, 1992, J EXP MED, V176, P139, DOI 10.1084/jem.176.1.139; Hubert P, 1996, J IMMUNOL, V157, P4322; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OFFRINGA R, 1993, J BIOL CHEM, V268, P4979; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; QUILL H, 1992, J IMMUNOL, V149, P2887; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANDRIN MS, 1993, J IMMUNOL, V151, P4606; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SCHRAVEN B, 1993, EUR J IMMUNOL, V23, P119, DOI 10.1002/eji.1830230119; SCHRAVEN B, 1994, J EXP MED, V180, P897, DOI 10.1084/jem.180.3.897; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; Shimizu Y, 1995, J CELL BIOL, V131, P1867, DOI 10.1083/jcb.131.6.1867; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Steeg C, 1997, EUR J IMMUNOL, V27, P2233, DOI 10.1002/eji.1830270917; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; Warren HS, 1996, J IMMUNOL, V156, P2866; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	65	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19914	19921		10.1074/jbc.273.31.19914	http://dx.doi.org/10.1074/jbc.273.31.19914			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677430	hybrid			2022-12-27	WOS:000075125200082
J	Tai, AW; Chuang, JZ; Sung, CH				Tai, AW; Chuang, JZ; Sung, CH			Localization of Tctex-1, a cytoplasmic dynein light chain, to the golgi apparatus and evidence for dynein complex heterogeneity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE T-COMPLEX; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTERMEDIATE CHAINS; SECRETORY PROTEINS; MEMBRANE-PROTEIN; OKADAIC ACID; HEAVY-CHAIN; HELA-CELLS; EXPRESSION	To date, much attention has been focused on the heavy and intermediate chains of the multisubunit cytoplasmic dynein complex; however, little is known about the localization or function of dynein light chains. In this study, we find that Tctex-1, a light chain of cytoplasmic dynein, localizes predominantly to the Golgi apparatus in interphase fibroblasts, Immunofluorescent staining reveals striking juxtanuclear staining characteristic of the Golgi apparatus as well as nuclear envelope and punctate cytoplasmic staining that often decorates microtubules, Tctex-1 colocalization with Golgi compartment markers, its distribution upon treatment with various pharmacological agents, and the cofractionation of Tctex-1-associated membranes with Golgi membranes are all consistent with a Golgi localization. The distribution of Tctex-1 in interphase cells only partially overlaps with the dynein intermediate chain and p150(Glued) upon immunofluorescence, but most of Tctex-1 is redistributed onto mitotic spindles along with other dynein/dynactin subunits, Using sequential immunoprecipitations, we demonstrate that there is a subset of Tctex-1 not associated with the intermediate chain at steady state; the converse also appears to be true, Distinct populations of dynein complexes are likely to exist, and such diversity may occur in part at the level of their light chain compositions.	Cornell Univ, Coll Med, Margaret M Dyson Vis Res Inst, Dept Cell Biol & Anat, New York, NY 10021 USA; Cornell Univ, Coll Med, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10021 USA	Cornell University; Cornell University	Sung, CH (corresponding author), Cornell Univ, Coll Med, Vis Res Inst, 1300 York Ave, New York, NY 10021 USA.	chsung@mail.med.cornell.edu	Tai, Andrew W./M-8380-2017	Tai, Andrew W./0000-0002-6877-450X	NEI NIH HHS [EY11307, EY07138, R01 EY011307] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011307, T32EY007138] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Benashski SE, 1997, J BIOL CHEM, V272, P20929, DOI 10.1074/jbc.272.33.20929; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BROWN WJ, 1987, P NATL ACAD SCI USA, V84, P9001, DOI 10.1073/pnas.84.24.9001; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; BURNS DM, 1982, J BIOL CHEM, V257, P9991; CAUGHEY B, 1983, BIOCHIM BIOPHYS ACTA, V757, P296, DOI 10.1016/0304-4165(83)90054-5; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DOOLITTLE MH, 1991, ANAL BIOCHEM, V195, P364, DOI 10.1016/0003-2697(91)90342-Q; DUNPHY WG, 1983, J CELL BIOL, V97, P270, DOI 10.1083/jcb.97.1.270; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; Fath KR, 1997, J CELL BIOL, V139, P1169, DOI 10.1083/jcb.139.5.1169; FEDDE KN, 1990, AM J HUM GENET, V47, P767; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; HO WC, 1989, EUR J CELL BIOL, V48, P250; HORN M, 1994, BIOCHEM J, V301, P69, DOI 10.1042/bj3010069; HUW LY, 1995, DEV BIOL, V170, P183, DOI 10.1006/dbio.1995.1206; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; KOONCE MP, 1990, CELL MOTIL CYTOSKEL, V15, P51, DOI 10.1002/cm.970150108; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; LIN SXH, 1993, J CELL SCI, V105, P579; LIN SXH, 1992, J CELL SCI, V101, P125; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; LYON MF, 1986, CELL, V44, P357, DOI 10.1016/0092-8674(86)90770-1; MARTINIUK F, 1981, BIOCHIM BIOPHYS ACTA, V658, P248, DOI 10.1016/0005-2744(81)90295-3; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; OLMSTED JB, 1986, METHOD ENZYMOL, V134, P467; PatelKing RS, 1997, J CELL BIOL, V137, P1081, DOI 10.1083/jcb.137.5.1081; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; Pfister KK, 1996, J BIOL CHEM, V271, P1687, DOI 10.1074/jbc.271.3.1687; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Reinsch S, 1997, CURR BIOL, V7, P211, DOI 10.1016/S0960-9822(97)70092-7; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; RON D, 1992, BIOTECHNIQUES, V13, P866; ROUX AF, 1994, HUM MOL GENET, V3, P257, DOI 10.1093/hmg/3.2.257; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SARASTE J, 1991, J CELL SCI, V100, P415; SAUNDERS WS, 1995, J CELL BIOL, V128, P617, DOI 10.1083/jcb.128.4.617; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SILVER LM, 1993, TRENDS GENET, V9, P250, DOI 10.1016/0168-9525(93)90090-5; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; VESLASCO A, 1993, J CELL BIOL, V122, P39; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; Watanabe TK, 1996, CYTOGENET CELL GENET, V73, P153, DOI 10.1159/000134329; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100; YOSHIDA T, 1994, J CELL SCI, V107, P625	76	68	71	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19639	19649		10.1074/jbc.273.31.19639	http://dx.doi.org/10.1074/jbc.273.31.19639			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677391	hybrid			2022-12-27	WOS:000075125200043
J	Zakharova, N; Hoffman, PS; Berg, DE; Severinov, K				Zakharova, N; Hoffman, PS; Berg, DE; Severinov, K			The largest subunits of RNA polymerase from gastric Helicobacters are tethered	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-NOV; PYLORI; GENOME; TRANSCRIPTION; DIVERSITY; SEQUENCE	The rpoB and rpoC genes of eubacteria and archaea, coding respectively for the beta- and beta'-like subunits of DNA-dependent RNA polymerase, are organized in an operon with rpoB always preceding rpoC. The genome sequence of the gastric pathogen Helicobacter pylori (strain 26695) revealed homologs of two genes in one continuous open reading frame that potentially could encode one 2890-amino acid-long beta-beta' fusion protein. Here, we show that this open reading frame does in fact encode a fused beta-beta' polypeptide. In addition, we establish by DNA sequencing that rpoB and rpoC are also fused in each of four other unrelated strains of H. pylori, as well as in Helicobacter felis, another member of the same genus. In contrast, the rpoB and rpoC genes are separate in two members of the related genus Campylobacter (Campylobacter jejuni and Campylobacter fetus) and encode separate RNA polymerase subunits. The Campylobacter genes are also unusual in overlapping one another rather than being separated by a spacer as in other Gramnegative bacteria. We propose that the unique organization of rpoB and rpoC in H. pylori may contribute to its ability to colonize the human gastric mucosa.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4H7, Canada; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Dalhousie University; Washington University (WUSTL); Washington University (WUSTL); Rutgers State University New Brunswick	Severinov, K (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.		Severinov, Konstantin/C-8545-2016		NHGRI NIH HHS [HG00820] Funding Source: Medline; NIAID NIH HHS [AI38166] Funding Source: Medline; NIDDK NIH HHS [DK48029] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R55HG000820, R01HG000820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048029] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P6221, DOI 10.1093/nar/20.23.6221; BORODIN AM, 1988, BIOORG KHIM+, V14, P1179; Buhler J.M., 1987, RNA POLYM REGULATION, P25; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Dykxhoorn DM, 1996, MOL MICROBIOL, V19, P483, DOI 10.1046/j.1365-2958.1996.384913.x; EATON KA, 1993, INT J SYST BACTERIOL, V43, P99, DOI 10.1099/00207713-43-1-99; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fox J G, 1997, Semin Gastrointest Dis, V8, P124; GARNER JA, 1995, J INFECT DIS, V172, P290, DOI 10.1093/infdis/172.1.290; GOODMAN TG, 1983, J CLIN MICROBIOL, V18, P825, DOI 10.1128/JCM.18.4.825-829.1983; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; MURRAY CL, 1981, J BIOL CHEM, V256, P5153; OVCHINNIKOV YA, 1981, EUR J BIOCHEM, V116, P621, DOI 10.1111/j.1432-1033.1981.tb05381.x; PASTER BJ, 1991, INT J SYST BACTERIOL, V41, P31, DOI 10.1099/00207713-41-1-31; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; Severinov K, 1997, J BIOL CHEM, V272, P24137, DOI 10.1074/jbc.272.39.24137; STETTER KO, 1974, EUR J BIOCHEM, V48, P527, DOI 10.1111/j.1432-1033.1974.tb03794.x; SUAREZ DL, 1997, J VET MICROBIOL, V57, P325; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; Xu Q, 1997, J BACTERIOL, V179, P6807, DOI 10.1128/jb.179.21.6807-6815.1997	24	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19371	19374		10.1074/jbc.273.31.19371	http://dx.doi.org/10.1074/jbc.273.31.19371			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677352	hybrid			2022-12-27	WOS:000075125200004
J	Murao, K; Wada, Y; Nakamura, T; Taylor, AH; Mooradian, AD; Wong, NCW				Murao, K; Wada, Y; Nakamura, T; Taylor, AH; Mooradian, AD; Wong, NCW			Effects of glucose and insulin on rat apolipoprotein A-I gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC-HEART-DISEASE; HIGH-DENSITY-LIPOPROTEIN; GROWTH-HORMONE GENE; PYRUVATE-KINASE; DIABETES-MELLITUS; MESSENGER-RNA; GLUCAGON GENE; 5'-FLANKING REGION; RESPONSE ELEMENT; RISK FACTOR	We have examined the regulation of apolipoprotein A-I (apoA-I) gene expression in response to glucose and insulin. In Hep G2 cells, endogenous apoA-I mRNA was suppressed by one-half or induced 2-fold following 48 h of exposure to high concentrations of glucose (22.4 mM) or insulin (100 microunits/ml), respectively, compared with control. Transcriptional activity of the rat apoA-I promoter (-474 to -7) in Hep G2 cells paralleled endogenous mRNA expression, and this activity was dependent on the dose of glucose or insulin. Deletional analysis showed that a 50-base pair fragment spanning -425 to -376 of the promoter mediated the effects of both insulin and glucose. Within this DNA fragment there is a motif (-411 to -404) that is homologous to a previously identified insulin response core element (IRCE). Mutation of this motif abolished not only the induction of the promoter by insulin but also abrogated its suppression by glucose. Electrophoretic mobility shift assay analysis of nuclear extracts from Hep G2 cells revealed IRCE binding activity that formed a duplex with radiolabeled probe. The IRCE binding activity correlated with insulin induction of apoA-I expression. In summary, our data show that glucose decreases and insulin increases apoA-I promoter activity. This effect appears to be mediated by a single cis-acting element.	Univ Calgary, Hlth Sci Ctr, Dept Med, Endocrine Res Grp,Fac Med, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Biochem Med, Endocrine Res Grp, Calgary, AB T2N 4N1, Canada; St Louis Univ, Dept Internal Med, Div Endocrinol, St Louis, MO 63104 USA; St Louis Vet Affairs Med Ctr, St Louis, MO 63104 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; Saint Louis University	Wong, NCW (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Med, Endocrine Res Grp,Fac Med, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	ncwwong@acs.ucalgary.ca		Taylor, Anthony/0000-0002-5746-9091				ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; ALEXANDERBRIDGES M, 1992, J CELL BIOCHEM, V48, P129, DOI 10.1002/jcb.240480204; ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; BARR DP, 1951, AM J MED, V11, P480, DOI 10.1016/0002-9343(51)90183-0; BarreraHernandez G, 1996, J BIOL CHEM, V271, P9969, DOI 10.1074/jbc.271.17.9969; BARRETTCONNOR E, 1987, AM J PREV MED, V3, P206; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BRESLOW JL, 1982, P NATL ACAD SCI USA, V7922, P6861; CHEN C, 1987, MOL CELL BIOL, V7, P27; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DYER RB, 1995, BIOTECHNIQUES, V19, P192; FLORESRIVEROS JR, 1993, BIOCHEM BIOPH RES CO, V194, P1148, DOI 10.1006/bbrc.1993.1942; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Guyton A.C., 2011, HALL TXB MED PHYSL; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HATADA EN, 1989, J BIOL CHEM, V264, P6741; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HICKEY DA, 1994, P NATL ACAD SCI USA, V91, P11109, DOI 10.1073/pnas.91.23.11109; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KELLER SA, 1990, GENE DEV, V4, P450; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; LAAKSO M, 1985, ARTERIOSCLEROSIS, V5, P653, DOI 10.1161/01.ATV.5.6.653; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MAGOULAS C, 1993, GENETICS, V134, P507; MEISLER MH, 1989, ANNU REV PHYSIOL, V51, P701, DOI 10.1146/annurev.physiol.51.1.701; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NASRIN N, 1990, P NATL ACAD SCI USA, V87, P5273, DOI 10.1073/pnas.87.14.5273; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; NOGUCHI T, 1985, J BIOL CHEM, V260, P4393; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OBRIEN RM, 1993, ADV SEC MESS PHOSPH, V28, P245; PHILIPPE J, 1989, J CLIN INVEST, V84, P672, DOI 10.1172/JCI114214; PHILIPPE J, 1991, P NATL ACAD SCI USA, V88, P7224, DOI 10.1073/pnas.88.16.7224; PRAGER D, 1988, J BIOL CHEM, V263, P16580; PRAGER D, 1990, J CLIN INVEST, V85, P1680, DOI 10.1172/JCI114620; REAVEN GM, 1991, DIABETES CARE, V14, P195, DOI 10.2337/diacare.14.3.195; ROMNEY JS, 1992, MOL ENDOCRINOL, V6, P943, DOI 10.1210/me.6.6.943; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SNIDERMAN A, 1992, J CLIN EPIDEMIOL, V45, P1357, DOI 10.1016/0895-4356(92)90197-U; SOLYMOSS BC, 1995, AM J CARDIOL, V76, P1152, DOI 10.1016/S0002-9149(99)80326-9; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STANLEY F, 1988, J BIOL CHEM, V263, P13444; Taylor AH, 1996, J LIPID RES, V37, P2232; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; WANKE IE, 1991, J BIOL CHEM, V266, P6068; WONG NCW, 1986, J BIOL CHEM, V261, P387; WONG NCW, 1989, J BIOL CHEM, V26, P4466	58	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18959	18965		10.1074/jbc.273.30.18959	http://dx.doi.org/10.1074/jbc.273.30.18959			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668074	hybrid			2022-12-27	WOS:000074974700041
J	Eggers, A; Siemann, G; Blume, R; Knepel, W				Eggers, A; Siemann, G; Blume, R; Knepel, W			Gene-specific transcriptional activity of the insulin cAMP-responsive element is conferred by NF-Y in combination with cAMP response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PANCREATIC BETA-CELLS; RNA POLYMERASE-II; RAT GLUCAGON GENE; CBF-DNA COMPLEX; REGULATORY ELEMENT; MEMBRANE DEPOLARIZATION; NEGATIVE REGULATION; FUNCTIONAL DOMAINS; NUCLEAR-PROTEIN	Cyclic AMP stimulates insulin gene transcription through a cAMP response element (CRE). In the present study the insulin CRE-binding proteins and their functions were investigated. A mutational analysis of nuclear protein binding in electrophoretic mobility shift assays in combination with specific antisera showed that in the CRE of the rat insulin I gene the imperfect CRE octamer-like sequence TGACGTCC interacts weakly with CREB and overlaps with two sequence motifs (TTGTTGAC and CCAAT) that bind winged helix-like proteins and the transcription factor NF-Y, respectively. Transient transfection of wild-type and mutant insulin CRE-reporter fusion genes and the inactivation of cellular CREB or NF-Y by overexpression of the dominant negative mutants KCREB or NF-YA29, respectively, indicate that cAMP inducibility of the insulin CRE is mediated by CREB or closely related proteins; however, NF-Y binding to the insulin CRE confers constitutive, basal activity and decreases the ability of CREB to mediate cAMP-stimulated transcription and calcium responsiveness. Results from these studies demonstrate that NF-Y binds to the insulin CRE and modulates the function of CREB. Together with the nonpalindromic sequence of the CRE octamer motif, the interaction of NF-Y with CREB may be responsible for the gene-specific transcriptional activity of the insulin CRE and explain why it has considerable basal activity but is less responsive to cAMP stimulation than others.	Univ Gottingen, Dept Mol Pharmacol, D-37070 Gottingen, Germany	University of Gottingen	Knepel, W (corresponding author), Univ Gottingen, Dept Mol Pharmacol, Robert Koch Str 40, D-37070 Gottingen, Germany.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; Alonso CR, 1996, J BIOL CHEM, V271, P22271, DOI 10.1074/jbc.271.36.22271; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; COCKELL M, 1995, MOL CELL BIOL, V15, P1933; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Diedrich T, 1997, BIOL CHEM, V378, P89, DOI 10.1515/bchm.1997.378.2.89; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; GEDRICH RW, 1995, J VIROL, V69, P2333, DOI 10.1128/JVI.69.4.2333-2340.1995; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUTIERREZHARTMANN A, 1994, MOL ENDOCRINOL, V8, P1447, DOI 10.1210/me.8.11.1447; HOCHHUTH C, 1994, ENDOCRINE, V2, P833; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; KENNEDY GC, 1990, J BIOL CHEM, V265, P6279; Kim IS, 1996, MOL CELL BIOL, V16, P4003; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KNEPEL W, 1990, J BIOL CHEM, V265, P8725; KNEPEL W, 1991, MOL ENDOCRINOL, V5, P1457, DOI 10.1210/mend-5-10-1457; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LI XY, 1992, J BIOL CHEM, V267, P8984; Liu XD, 1996, AM J PHYSIOL-RENAL, V271, pF347, DOI 10.1152/ajprenal.1996.271.2.F347; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILLER CP, 1993, MOL CELL BIOL, V13, P7080, DOI 10.1128/MCB.13.11.7080; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NITSCH D, 1993, P NATL ACAD SCI USA, V90, P5479, DOI 10.1073/pnas.90.12.5479; Nizielski SE, 1996, AM J PHYSIOL-REG I, V270, pR1005, DOI 10.1152/ajpregu.1996.270.5.R1005; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OETJEN E, 1994, J BIOL CHEM, V269, P27036; Osawa H, 1996, J BIOL CHEM, V271, P17296, DOI 10.1074/jbc.271.29.17296; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; PARK EA, 1993, J BIOL CHEM, V268, P613; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PHILIPPE J, 1990, J BIOL CHEM, V265, P1465; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; PHILIPPE J, 1994, MOL CELL BIOL, V14, P3514, DOI 10.1128/MCB.14.5.3514; PiseMasison CA, 1997, MOL CELL BIOL, V17, P1236, DOI 10.1128/MCB.17.3.1236; REED GE, 1995, BRAIN RES, V682, P1, DOI 10.1016/0006-8993(95)00284-W; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; Roy B, 1996, J BIOL CHEM, V271, P28995, DOI 10.1074/jbc.271.46.28995; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SCHWANINGER M, 1993, J BIOL CHEM, V268, P23111; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWANINGER M, 1993, J BIOL CHEM, V268, P5168; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALLEJO M, 1992, J BIOL CHEM, V267, P12876; VALLEJO M, 1994, J NEUROENDOCRINOL, V6, P587, DOI 10.1111/j.1365-2826.1994.tb00623.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Wrege Antje, 1995, Gene Expression, V4, P205; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147	81	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18499	18508		10.1074/jbc.273.29.18499	http://dx.doi.org/10.1074/jbc.273.29.18499			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660819	hybrid			2022-12-27	WOS:000074828500074
J	Pan, CQ; Dodge, TH; Baker, DL; Prince, WS; Sinicropi, DV; Lazarus, RA				Pan, CQ; Dodge, TH; Baker, DL; Prince, WS; Sinicropi, DV; Lazarus, RA			Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE; RESOLUTION; COMPLEX; PCR	The ability of recombinant human DNase I (DNase I) to degrade DNA to lower molecular weight fragments is the basis for its therapeutic use in cystic fibrosis (CF) patients and its potential use as a treatment for systemic lupus erythematosus (SLE), To increase the potency of human DNase I, we have generated and characterized three classes of mutants: (a) hyperactive variants, which have from one to six additional positively charged residues (+1 to +6) and digest DNA much more efficiently relative to wild type, (b) actin-resistant variants, which are no longer inhibited by G-actin, a potent inhibitor of DNase I, and (c) combination variants that are both hyperactive and actin-resistant. For DNA scission in CF sputum where the DNA concentration and length are large, we measured a similar to 20-fold increase in potency relative to wild type for the +3 hyperactive variant Q9R/E13R/N74K or the actin-resistant variant A114F; the hyperactive and actin-resistant combination variant was similar to 100-fold more potent than wild type DNase I. For digesting lower concentrations of DNA complexed to anti-DNA antibodies in human serum, we found a maximal enhancement of similar to 400-fold over wild type for the +2 variant E13R/N74K. The +3 enzymes have similar to 4000-fold enhancement for degrading moderate levels of exogenous DNA spiked into human serum, whereas the +6 enzyme has similar to 30,000-fold increased activity for digesting the extremely low levels of endogenous DNA found in serum. The actin resistance property of the combination mutants further enhances the degree of potency in human serum. Thus, the human DNase I variants we have engineered for improved biochemical and pharmacodynamic properties have greater therapeutic potential for treatment of both CF and SLE.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Lazarus, RA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	lazarus.bob@gene.com						BARON WF, 1998, IN PRESS GENE AMST; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; CAMPBELL VW, 1980, J BIOL CHEM, V255, P3726; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; Deininger PL, 1989, MOBILE DNA, P619; FROST P. G., 1968, CLIN EXP IMMUNOL, V3, P447; FUCHS HJ, 1994, NEW ENGL J MED, V331, P637, DOI 10.1056/NEJM199409083311003; GARDNER WD, 1979, J BIOL CHEM, V254, P5238; Hahn BH, 1997, DUBOIS LUPUS ERYTHEM, P69; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISSANE JM, 1958, J BIOL CHEM, V233, P184; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Macanovic M, 1996, CLIN EXP IMMUNOL, V106, P243, DOI 10.1046/j.1365-2249.1996.d01-839.x; MCCOUBREYHOYER A, 1984, AM J MED, V77, P23, DOI 10.1016/0002-9343(84)90431-5; MEJEAN C, 1987, J IMMUNOL METHODS, V99, P129; Pan CQ, 1998, J BIOL CHEM, V273, P11701, DOI 10.1074/jbc.273.19.11701; Pan CQ, 1997, BIOCHEMISTRY-US, V36, P6624, DOI 10.1021/bi962960x; Pan CQ, 1998, PROTEIN SCI, V7, P628, DOI 10.1002/pro.5560070312; PRINCE WS, 1998, IN PRESS CLIN EXP IM; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RAMSEY BW, 1993, AM REV RESPIR DIS, V148, P145, DOI 10.1164/ajrccm/148.1.145; Ramsey BW, 1996, NEW ENGL J MED, V335, P179, DOI 10.1056/NEJM199607183350307; Rodriguez AM, 1997, GENOMICS, V42, P507, DOI 10.1006/geno.1997.4748; STEINMAN CR, 1982, METHOD ENZYMOL, V84, P187; Ulmer JS, 1996, P NATL ACAD SCI USA, V93, P8225, DOI 10.1073/pnas.93.16.8225; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; WOLF E, 1995, PROTEIN ENG, V8, P79; WOODS VL, 1993, TXB RHEUMATOLOGY, V1, P999; Zeng ZZ, 1997, BIOCHEM BIOPH RES CO, V231, P499, DOI 10.1006/bbrc.1996.5923; [No title captured]	32	30	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18374	18381		10.1074/jbc.273.29.18374	http://dx.doi.org/10.1074/jbc.273.29.18374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660804	hybrid			2022-12-27	WOS:000074828500059
J	Khvotchev, M; Sudhof, TC				Khvotchev, M; Sudhof, TC			Newly synthesized phosphatidylinositol phosphates are required for synaptic norepinephrine but not glutamate or gamma-aminobutyric acid (GABA) release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-ACTIVATED SECRETION; PHOSPHOINOSITIDES; EXPRESSION; REGULATORS; EXOCYTOSIS; ISOFORMS; BINDING; DOMAINS; BRAIN	Newly synthesized phosphatidylinositol phosphates have been implicated in many membrane-trafficking reactions. They are essential for exocytosis of norepinephrine in PC12 cells and chromaffin cells, suggesting a function in membrane fusion. We have now studied the role of phosphatidylinositol phosphates in synaptic vesicle exocytosis using synaptosomes. Under conditions where phosphorylation of phosphatidylinositols is blocked, norepinephrine secretion was nearly abolished whereas glutamate and GABA release was still elicited. Thus phosphatidylinositides are essential only for some membrane fusion reactions, and exocytotic release mechanisms differ between neurotransmitters.	Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75235 USA.		Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549	PHS HHS [R01-50824] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FAIN JN, 1979, BIOCHEM J, V178, P45, DOI 10.1042/bj1780045; FYKSE EM, 1993, J NEUROSCI, V13, P4997; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HOKIN MR, 1954, J BIOL CHEM, V209, P549; Katz B., 1969, RELEASE NEURAL TRANS; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Mehrotra B, 1997, J BIOL CHEM, V272, P4237, DOI 10.1074/jbc.272.7.4237; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; SCHAEFER T, 1994, ANN NY ACAD SCI, V710, P356, DOI 10.1111/j.1749-6632.1994.tb26642.x; SCHELLER RH, 1995, NEURON, V14, P893; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; TURNER TJ, 1993, P NATL ACAD SCI USA, V90, P9518, DOI 10.1073/pnas.90.20.9518; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037	27	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21451	21454		10.1074/jbc.273.34.21451	http://dx.doi.org/10.1074/jbc.273.34.21451			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705272	hybrid			2022-12-27	WOS:000075492600006
J	Lohi, O; Poussu, A; Merilainen, J; Kellokumpu, S; Wasenius, VM; Lehto, VP				Lohi, O; Poussu, A; Merilainen, J; Kellokumpu, S; Wasenius, VM; Lehto, VP			EAST, an epidermal growth factor receptor- and Eps15-associated protein with Src homology 3 and tyrosine-based activation motif domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE SUBSTRATE EPS15; ZINC-FINGER DOMAIN; SIGNAL-TRANSDUCTION; BINDING DOMAIN; EGF RECEPTOR; SH2 DOMAINS; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; RECOGNITION	We describe the cloning and characterization of a new cytoplasmic protein designated epidermal growth factor receptor-associated protein with SH3- and TAM domains (EAST). It contains an Src homology 3 domain in its midregion and a tyrosine-based activation motif in its COOH terminus. Antibodies to EAST recognize a 68-kDa protein that is present in most chicken tissues. An epidermal growth factor (EGF) dependent association between the EGF receptor (EGFR) and EAST was shown by reciprocal immunoprecipitation/immunoblotting studies with specific antibodies. Activated EGFR catalyzed the tyrosine phosphorylation of EAST, as judged by an in vitro kinase assay with both immunoprecipitated and purified EGFR Immunoprecipitation/immunoblotting experiments also demonstrated an association between EAST and eps15, an EGFR substrate associated with clathrin-coated pits and vesicles, which is essential in the endocytotic pathway. The association between EAST and eps15 was not affected by EGF treatment. In immunofluorescence microscopy, EAST was shown to partially colocalize with clathrin. The sequence of the NH2-terminal portion of EAST shows a high degree of similarity with a group of proteins involved in endocytosis or vesicle trafficking. Thus, EAST is a novel signal transduction component probably involved in EGF signaling and in the endocytotic machinery.	Univ Oulu, Dept Pathol, FIN-90220 Oulu, Finland; Univ Oulu, Dept Anat, FIN-90220 Oulu, Finland; Univ Helsinki, Cent Hosp, Dept Radiotherapy & Oncol, FIN-00290 Helsinki, Finland	University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital	Lehto, VP (corresponding author), Univ Oulu, Dept Pathol, Kajaanintie 52 D, FIN-90220 Oulu, Finland.	lehto@csc.fi	Lohi, Olli/AAW-6157-2021	Lohi, Olli/0000-0001-9195-0797				ALVAREZ CV, 1995, J BIOL CHEM, V270, P16271, DOI 10.1074/jbc.270.27.16271; Bean AJ, 1997, NATURE, V385, P826, DOI 10.1038/385826a0; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Carbone R, 1997, CANCER RES, V57, P5498; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; REIZMAN H, 1997, CELL, V91, P731; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Seaman MNJ, 1996, CURR OPIN CELL BIOL, V8, P549, DOI 10.1016/S0955-0674(96)80034-2; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Takeshita T, 1996, BIOCHEM BIOPH RES CO, V225, P1035, DOI 10.1006/bbrc.1996.1290; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; YU JC, 1991, MOL CELL BIOL, V11, P3780, DOI 10.1128/MCB.11.7.3780; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	32	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21408	21415		10.1074/jbc.273.33.21408	http://dx.doi.org/10.1074/jbc.273.33.21408			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694904	hybrid			2022-12-27	WOS:000075386100097
J	Yu, JM; Wessling-Resnick, M				Yu, JM; Wessling-Resnick, M			Structural and functional analysis of SFT, a stimulator of Fe transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT IRON TRANSPORT; CELLS; EXPRESSION; PROTEIN; BINDING; SYSTEM	Previous studies demonstrated that SFT (Stimulator of Fe Transport) facilitates both transferrin and nontransferrin-bound iron uptake in HeLa cells (Yu, J,, and Wessling-Resnick, M, (1998) J, Biol. Chem, 273, 6909-6915), To further characterize the structure and function of SFT, we studied this human factor in rodent BHR cells. Kyte-Doolittle analysis suggests that SFT has six transmembrane-spanning segments. This transport protein also displays an REXXE motif resembling domains involved in iron binding by ferritin and in iron uptake mediated by the yeast transporter Ftr1, Using N- and C-terminal epitope tags, we have identified that modification of either protein terminus does not interfere with SFT function in nontransferrin-bound iron uptake. The N- and C-terminal domains are intracellularly disposed since antibodies against these epitopes fail to recognize expressed proteins unless BHK cells are solubilized with detergents. To define the topology of two large extramembranous loop domains, anti-peptide antibodies were employed; anti-loop 4 antibodies show no immunoreactivity unless cells are permeabilized but anti-loop 5 antibodies recognize and bind surface SFT. Thus, loop 4 must be intracellular while loop 5 is extracellular, These topological studies situate the putative iron-binding REXXE domain on the cytosolic face of the plasma membrane, However, Fe-55-binding studies reveal that the ability of SFT to bind and mediate transport of extracellular iron is defective in mutants with Glu --> Ala conversions in this motif, Curiously, we also find that depletion of intracellular iron by desferrioxamine impairs SFT transport and iron-binding functions. These observations lead to the speculation that the REXXE motif may play an important role in regulating SFT activity through interaction with intracellular iron and demonstrate that iron transport mediated by SFT is itself an iron-dependent process.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Wessling-Resnick, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.				NIDDK NIH HHS [DK52371] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052371] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Askwith C, 1997, J BIOL CHEM, V272, P401; BASSET P, 1986, CANCER RES, V46, P1644; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Gutierrez JA, 1997, J CELL BIOL, V139, P895, DOI 10.1083/jcb.139.4.895; INMAN RS, 1993, J BIOL CHEM, V268, P8521; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; Luo C, 1996, MOL CELL BIOL, V16, P3955; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STURROCK A, 1990, J BIOL CHEM, V265, P3139; TEICHMANN R, 1990, J CLIN INVEST, V86, P2145, DOI 10.1172/JCI114953; TRIKHA J, 1995, J MOL BIOL, V248, P949, DOI 10.1006/jmbi.1995.0274; Yu JM, 1998, J BIOL CHEM, V273, P6909, DOI 10.1074/jbc.273.12.6909	16	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21380	21385		10.1074/jbc.273.33.21380	http://dx.doi.org/10.1074/jbc.273.33.21380			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694900	hybrid			2022-12-27	WOS:000075386100093
J	Yuan, Y; Mead, D; Schroeder, BG; Zhu, YQ; Barry, CE				Yuan, Y; Mead, D; Schroeder, BG; Zhu, YQ; Barry, CE			The biosynthesis of mycolic acids in Mycobacterium tuberculosis - Enzymatic methyl(ene) transfer to acyl carrier protein bound meromycolic acid in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; FATTY-ACIDS; AURUM; WALL; IDENTIFICATION; CONDENSATION; SMEGMATIS; SYSTEM	A closely related family of enzymes from Mycobacterium tuberculosis has been shown by heterologous expression to catalyze the modification of mycolic acids through the addition of a methyl (or methylene) group derived from S-adenosyl-L-methionine (SAM). Overproduction of all six of these enzymes in Escherichia coli and subsequent in vitro reactions with heat-inactivated acceptor fractions derived from Mycobacterium smegmatis in the presence of [methyl-H-3]SAM demonstrated that the immediate substrate to which methyl group addition occurs was a family of very long-chain fatty acids. Inhibitors of methyl transfer, such as S-adenosyl-L-homocysteine and sinefungin, were shown to inhibit this reaction but had no effect on whole cells of either M. smegmatis or M. tuberculosis. Purified mycolic acids from M. tuberculosis were pyrolyzed, and the resulting meroaldehyde was oxidized and methylated to produce full-length methyl meromycolates. These esters were shown to comigrate with a fraction of the acceptor from the in vitro reactions, suggesting that methyl group addition occurs up to the level of the meromycolate, Protease and other treatments destroyed the activity of the acceptor fraction, which was also found to be extremely sensitive to basic pH. Antibody to the acyl carrier protein AcpM, which has recently been shown to be the carrier of full-length meromycolate produced by a unique type II fatty acid synthase system, inhibited the cell-free methyl(en)ation of these acids. These results suggest that mycolate modification reactions occur parallel with the synthesis of the AcpM-bound meromycolate chain.	NIAID, Rocky Mt Labs, TB Res Stn, Lab Intracellular Parasites,NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Barry, CE (corresponding author), NIAID, Rocky Mt Labs, TB Res Stn, Lab Intracellular Parasites,NIH, 903 S 4th St, Hamilton, MT 59840 USA.		Barry, Clifton E/ABE-7992-2020; Barry, III, Clifton/H-3839-2012	Barry, Clifton E/0000-0002-2927-270X; Barry, III, Clifton/0000-0002-2927-270X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000783] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 AI000783-11] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARRY CE, 1992, SCIENCE, V256, P377, DOI 10.1126/science.256.5055.377; BARRY CE, 1998, IN PRESS PROG LIPID; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Fersht A., 1985, ENZYME STRUCTURE MEC; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; HAMID ME, 1993, J GEN MICROBIOL, V139, P2203, DOI 10.1099/00221287-139-9-2203; KREMBEL J, 1966, TETRAHEDRON, V22, P1113, DOI 10.1016/0040-4020(66)80087-X; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1045, P58, DOI 10.1016/0005-2760(90)90203-A; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1042, P315, DOI 10.1016/0005-2760(90)90159-U; Lee RE, 1997, BBA-LIPID LIPID MET, V1346, P275, DOI 10.1016/S0005-2760(97)00051-9; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1998, MYCOBACTERIA MOL BIO, P1; LOPEZMARIN LM, 1991, BIOCHIM BIOPHYS ACTA, V1086, P22, DOI 10.1016/0005-2760(91)90150-G; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; PUGH CSG, 1982, BIOCHEMISTRY-US, V21, P1535, DOI 10.1021/bi00536a011; QURESHI N, 1984, J BACTERIOL, V157, P46, DOI 10.1128/JB.157.1.46-52.1984; QURESHI N, 1980, J BIOL CHEM, V255, P182; Ratledge C., 1982, BIOL MYCOBACTERIA, P53; Stodola FH, 1938, J BIOL CHEM, V126, P505; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKAYAMA K, 1978, LIPIDS, V13, P575, DOI 10.1007/BF02535818; TAKAYAMA K, 1978, AM REV RESPIR DIS, V118, P113; TAKAYAMA K, 1979, BIOL BIOMEDICAL APPL, P375; TAYLOR FR, 1979, BIOCHEMISTRY-US, V18, P3292, DOI 10.1021/bi00582a015; TRAGER W, 1980, EXP PARASITOL, V50, P83, DOI 10.1016/0014-4894(80)90010-7; WHEELER PR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P182, DOI 10.1016/0005-2760(93)90160-B; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828; Yuan Y, 1997, J BIOL CHEM, V272, P10041	31	58	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21282	21290		10.1074/jbc.273.33.21282	http://dx.doi.org/10.1074/jbc.273.33.21282			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694888	hybrid			2022-12-27	WOS:000075386100081
J	Dang, A; Frost, JA; Cobb, MH				Dang, A; Frost, JA; Cobb, MH			The MEK1 proline-rich insert is required for efficient activation of the mitogen-activated protein kinases ERK1 and ERK2 in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASES; MAP KINASE; PHOSPHORYLATION; IDENTIFICATION; RAF; TRANSFORMATION; CLONING; STE5	MEK1 and MEK2 contain a proline-rich insert not present in any other known MER. (MAP (mitogen-activated protein)/ERK (extracellular signal-regulated kinase) kinase) family members. We examined the effect of removing the MEK1 polyproline insert on MEK activity, its binding to Raf, and its ability to activate ERKs in cells. Deletion of the insert had no effect on either the activity of MEK1 or on its ability to bind to Raf-l. Both wild type and constitutively active MEK1 coimmunoprecipitated with Raf-l whether or not the insert was present. Deletion of the insert did not reduce activation of MEK1 by EGF or activated Raf in cells. The proline-rich insert enhanced the ability of an otherwise equally active MEK1 protein to regulate endogeneous ERKs in mammalian cells. Overexpression of either constitutively active MEK1 lacking the insert or ERK2 compensates for the weaker in vivo activity of the MEK1 deletion mutant. Expression of the insert in cells reduced activation of ERKs by EGF. We conclude that the proline-rich insert is not the site of the MEK-Raf interaction and that the polyproline insert is required for its efficient activation of downstream ERKs in cells.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Dang, A (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA.			Frost, Jeffrey/0000-0001-9722-1536; Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHIYING FH, 1996, P NATL ACAD SCI USA, V93, P10078; CHOI KY, 1994, CELL, V78, P499; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT A, 1995, J BIOL CHEM, V270, P24540, DOI 10.1074/jbc.270.41.24540; SEGER R, 1992, J BIOL CHEM, V267, P25628; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, J BIOL CHEM, V269, P19067; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	32	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19909	19913		10.1074/jbc.273.31.19909	http://dx.doi.org/10.1074/jbc.273.31.19909			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677429	hybrid			2022-12-27	WOS:000075125200081
J	Schroeder, SC; Weil, PA				Schroeder, SC; Weil, PA			Genetic tests of the role of Abf1p in driving transcription of the yeast TATA box bindng protein-encoding gene, SPT15	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL PREINITIATION COMPLEX; SACCHAROMYCES-CEREVISIAE; MULTISUBUNIT COMPLEX; SHUTTLE VECTORS; BINDING PROTEIN; QCR8 GENE; DNA; ACTIVATION; ELEMENTS; CIS	In this report we describe studies which utilized yeast strains bearing gain and loss of function alleles of ABF1 in order to attempt to directly implicate Abf1p in modulating transcription of the TBP-encoding gene, SPT15, in vivo. We found that overexpression of Abf1p in a yeast cell increased transcription of the TBP-encoding gene and that this stimulation depended upon the exact sequence of the Abf1p binding site (ABF1) present in the gene. Further, in a yeast strain expressing a temperature sensitive form of Abf1p, occupancy of the chromosomal ABF1 site in the TBP-encoding gene was immediately lost following a temperature shift. Both results suggest that Abf1p drives transcription of the TBP-encoding gene. Surprisingly though we found that continuous ABF1 cis-element occupancy by Abf1p was not acutely required for normal levels of transcription of either the TBP-encoding gene or other "Abf1p-driven" genes tested. We propose a model to explain these results and suggest mechanisms by which Abf1p could activate gene transcription.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	Weil, PA (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.				NIGMS NIH HHS [GM52461] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM052461, R01GM052461] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CHODER M, 1991, GENE DEV, V5, P2315, DOI 10.1101/gad.5.12a.2315; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DELLASETA F, 1990, MOL CELL BIOL, V10, P2437, DOI 10.1128/MCB.10.5.2437; DEWINDE JH, 1993, YEAST, V9, P847, DOI 10.1002/yea.320090805; DEWINDE JH, 1992, MOL CELL BIOL, V12, P2872, DOI 10.1128/MCB.12.6.2872; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FRANCESCONI SC, 1991, P NATL ACAD SCI USA, V88, P4089, DOI 10.1073/pnas.88.10.4089; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P398; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Holmes SG, 1996, GENE DEV, V10, P1021, DOI 10.1101/gad.10.8.1021; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; Klebanow ER, 1996, J BIOL CHEM, V271, P13706, DOI 10.1074/jbc.271.23.13706; LOO S, 1995, GENETICS, V141, P889; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16461; MIRKOVITCH J, 1992, MOL CELL BIOL, V12, P1; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; SCHROEDER SC, 1994, J BIOL CHEM, V269, P28335; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UPTON T, 1995, J BIOL CHEM, V270, P16153, DOI 10.1074/jbc.270.27.16153; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Werner MH, 1997, CELL, V88, P733, DOI 10.1016/S0092-8674(00)81917-0; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	44	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19884	19891		10.1074/jbc.273.31.19884	http://dx.doi.org/10.1074/jbc.273.31.19884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677425	hybrid			2022-12-27	WOS:000075125200077
J	Van Heek, M; Schmitt, D; Toren, P; Cathcart, MK; DiCorleto, PE				Van Heek, M; Schmitt, D; Toren, P; Cathcart, MK; DiCorleto, PE			Cholesteryl hydroperoxyoctadecadienoate from oxidized low density lipoprotein inactivates platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MOLECULES; POLAR STEROL ESTERS; FACTOR-LIKE PROTEIN; ENDOTHELIAL-CELLS; HUMAN ATHEROMA; LIPID-PEROXIDATION; 15-LIPOXYGENASE; ATHEROSCLEROSIS; PROLIFERATION; INHIBITION	Both oxidized low density lipoprotein (ox-LDL) and platelet-derived growth factor (PDGF) have been implicated in the genesis of various inflammatory responses, including atherosclerosis. We demonstrate here a novel interaction between specific oxidized lipids derived from ox-LDL and PDGF. The lipid moieties of ox-LDL caused concentration-dependent inactivation of PDGF as measured by loss of its mitogenic activity and its binding to high affinity receptors. Reverse-phase and normal-phase HPLC were used to purify the inactivating component in the lipid mixture. By fast atom bombardment mass spectrometry and infrared spectroscopy, we identified the inactivating lipids as the 9- and 13-hydroperoxy derivatives of cholesteryl linoleate, cholesteryl hydroperoxyoctadecadienoate. When a series of cholesteryl esters were subjected to oxidizing conditions, only those containing two or more double bonds caused inactivation of PDGF; the extent of inactivation increased with increased levels of oxidation. Exposing PDGF to cumene hydroperoxide, t-butyl hydroperoxide, or hydrogen peroxide did not affect the activity of the mitogen. The oxidized lipid had no effect on the mitogenic activity of epidermal growth factor but did abolish the mitogenic activity of basic fibroblast growth factor and the antiproliferative activity of transforming growth factor beta 1. The inactivation of PDGF and other cytokines by lipid hydroperoxides may occur in such processes as vascular disease, inflammation, and wound healing.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	DiCorleto, PE (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC10, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00080] Funding Source: Medline; NHLBI NIH HHS [HL-29582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; Belkner J, 1992, Agents Actions Suppl, V37, P78; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; BROOKS CJW, 1971, ATHEROSCLEROSIS, V13, P223, DOI 10.1016/0021-9150(71)90025-6; DICORLETO PE, 1985, J CLIN INVEST, V75, P1153, DOI 10.1172/JCI111810; EDELSTEIN C, 1986, BIOCH BIOL PLASMA LI, V11, P495; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FOLCIK VA, 1994, J LIPID RES, V35, P1570; FOLCIK VA, 1995, J CLIN INVEST, V96, P404; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FOX PL, 1987, J BIOL CHEM, V262, P6046; GAN QF, 1995, BIOCHEMISTRY-US, V34, P7069, DOI 10.1021/bi00021a019; GRANT MM, 1992, AM J PHYSIOL, V263, pL370, DOI 10.1152/ajplung.1992.263.3.L370; HARLAN JM, 1986, J CELL BIOL, V103, P1129, DOI 10.1083/jcb.103.3.1129; HARLAND WA, 1973, BIOCHIM BIOPHYS ACTA, V316, P378, DOI 10.1016/0005-2760(73)90076-3; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; KUHN H, 1992, EICOSANOIDS, V5, P17; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MOWRI H, 1986, BIOCHEM INT, V12, P347; RAINES EW, HDB EXPT PHARM, V951, P173; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SEIFERT RA, 1984, NATURE, V311, P669, DOI 10.1038/311669a0; Shen JH, 1996, J CLIN INVEST, V98, P2201, DOI 10.1172/JCI119029; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; WALKER LN, 1986, P NATL ACAD SCI USA, V83, P7311, DOI 10.1073/pnas.83.19.7311; YAMAMOTO Y, 1989, BIOCHEM BIOPH RES CO, V165, P988, DOI 10.1016/0006-291X(89)92700-9; ZAK B, 1954, ANAL CHEM, V26, P776, DOI 10.1021/ac60088a058	34	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19405	19410		10.1074/jbc.273.31.19405	http://dx.doi.org/10.1074/jbc.273.31.19405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677358	hybrid			2022-12-27	WOS:000075125200010
J	Yan, D; Swain, PK; Breuer, D; Tucker, RM; Wu, WP; Fujita, R; Rehemtulla, A; Burke, D; Swaroop, A				Yan, D; Swain, PK; Breuer, D; Tucker, RM; Wu, WP; Fujita, R; Rehemtulla, A; Burke, D; Swaroop, A			Biochemical characterization and subcellular localization of the mouse retinitis pigmentosa GTPase regulator (mRpgr)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; RETINAL DEGENERATION; BREFELDIN-A; PROTEIN; RHODOPSIN; TRANSPORT; GENE; RCC1; CHOROIDEREMIA; DEFICIENCY	The retinitis pigmentosa GTPase regulator (RPGR) gene encodes a protein homologous to the RCC1 guanine nucleotide exchange factor and is mutated in 20% of patients with X-linked retinitis pigmentosa. We have characterized the fall-length and variant cDNAs corresponding to the mouse homolog of the RPGR gene (mRpgr). Comparison with the human cDNA revealed sequence identity primarily in the region of RCC1 homology repeats. As in humans, the mRpgr gene maps within 50 kilobases from the 5'-end of the Otc gene. The mRpgr transcripts are detected as early as E7 during embryonic development and are expressed widely in the adult mice. Variant mRpgr isoforms are generated by alternative splicing and by utilizing two in-frame initiation codons. The products of mRpgr cDNAs migrate aberrantly in SDS-polyacrylamide gels because of a charged domain. In transfected COS cells, the mRpgr protein is isoprenylated and is localized in the Golgi complex. This subcellular distribution is not observed after treatments with brefeldin A or mevastatin and when the conserved isoprenylation sequence (CTIL) at the carboxyl terminus is deleted or mutagenized. These studies suggest a role for the mRpgr protein in Golgi transport and form the basis for investigating the mechanism of photoreceptor degeneration in X-linked retinitis pigmentosa.	Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Swaroop, A (corresponding author), Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol, 1000 Wall St, Ann Arbor, MI 48105 USA.	swaroop@umich.edu		Fujita, Ricardo/0000-0002-9617-5109; Burke, David/0000-0002-2564-7949; Swaroop, Anand/0000-0002-1975-1141	NCRR NIH HHS [M01-RR00042] Funding Source: Medline; NEI NIH HHS [R01 EY7961, EY07003] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY007961] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aldred MA, 1994, MOL GENETICS INHERIT, P259; Andreasson S, 1997, AM J OPHTHALMOL, V124, P95; ARVEILER B, 1991, Technique (Philadelphia), V3, P24; BIRD AC, 1975, BRIT J OPHTHALMOL, V59, P177, DOI 10.1136/bjo.59.4.177; BLAIR HJ, 1994, GENOMICS, V19, P215, DOI 10.1006/geno.1994.1050; Buraczynska M, 1997, AM J HUM GENET, V61, P1287, DOI 10.1086/301646; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Coligan JE, 1995, CURRENT PROTOCOLS PR; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; COULSON A, 1991, Technique (Philadelphia), V3, P17; DERETIC D, 1995, PROG RETIN EYE RES, V14, P249, DOI 10.1016/1350-9462(94)00004-3; Farber DB, 1997, CURR OPIN NEUROBIOL, V7, P666, DOI 10.1016/S0959-4388(97)80087-6; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fujita R, 1996, Mol Vis, V2, P4; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; HSIEH CL, 1990, SOMAT CELL MOLEC GEN, V16, P407, DOI 10.1007/BF01232469; HUNTER DG, 1988, ARCH OPHTHALMOL-CHIC, V106, P362; Jacobson SG, 1997, INVEST OPHTH VIS SCI, V38, P1983; Jilkina O, 1996, BBA-MOL CELL RES, V1314, P157, DOI 10.1016/S0167-4889(96)00073-0; Kaufman R. J., 1992, Gene amplification in mammalian cells: a comprehensive guide., P315; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MCCAFFERY JM, 1995, METHOD ENZYMOL, V257, P259; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Moore DD, 1995, GLOB MOB SURV; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ORCI L, 1991, CELL, V64, P1183; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; Seki T, 1996, J BIOCHEM, V120, P207; SUNG CH, 1994, J NEUROSCI, V14, P5818; SWAROOP A, 1993, CYTOGENET CELL GENET, V64, P292, DOI 10.1159/000133595; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39	42	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19656	19663		10.1074/jbc.273.31.19656	http://dx.doi.org/10.1074/jbc.273.31.19656			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677393	hybrid			2022-12-27	WOS:000075125200045
J	Dooley, CT; Ny, P; Bidlack, JM; Houghten, RA				Dooley, CT; Ny, P; Bidlack, JM; Houghten, RA			Selective ligands for the mu, delta, and Kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-PHASE SYNTHESIS; PEPTIDE LIGANDS; AMINO-ACIDS; BINDING; LEVEL; CELLS	A combinatorial library of 6,250,000 tetrapeptides in the mixture based positional scanning format was screened in binding assays for the three opioid receptors, mu, delta, and kappa, Three different binding profiles were found. Individual peptides were synthesized representing all possible combinations of the active amino acids identified from the screening data. New, highly active peptides selective for each of the three receptors were chosen. This study demonstrates the power of mixture-based combinatorial Libraries to identify distinctly different ligands for closely related receptors.	Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	Torrey Pines Institute for Molecular Studies, California; University of Rochester	Houghten, RA (corresponding author), Torrey Pines Inst Mol Studies, 3550 Gen Atom Ct, San Diego, CA 92121 USA.	houghten@tpims.org			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003742, R01DA009410] Funding Source: NIH RePORTER; NIDA NIH HHS [DA09410, DA03742] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARPENTIER S, 1991, BIOCHEM BIOPH RES CO, V179, P1161, DOI 10.1016/0006-291X(91)91693-7; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Dooley C. T., 1995, PEPTIDES 94, P805; DOOLEY CT, 1995, PEPTIDE RES, V8, P124; DOOLEY CT, 1993, P NATL ACAD SCI USA, V90, P10811, DOI 10.1073/pnas.90.22.10811; DOOLEY CT, 1993, LIFE SCI, V52, P1509, DOI 10.1016/0024-3205(93)90113-H; DOOLEY CT, 1994, SCIENCE, V266, P2019, DOI 10.1126/science.7801131; Eichler J, 1996, J PEPT SCI, V2, P240, DOI 10.1002/psc.310020402; Gear RW, 1996, NAT MED, V2, P1248, DOI 10.1038/nm1196-1248; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HOUGHTEN RA, 1993, BIOORG MED CHEM LETT, V3, P405, DOI 10.1016/S0960-894X(01)80222-5; HOUGHTEN RA, 1986, INT J PEPT PROT RES, V27, P673; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAW PY, 1983, MOL PHARMACOL, V23, P26; LAWERENCE DMP, 1993, J PHARMACOL EXP THER, V266, P1678; LAWRENCE DMP, 1995, BIOCHEM PHARMACOL, V49, P81, DOI 10.1016/0006-2952(94)00440-W; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; POKORNY V, 1994, INNOVATION PERSPECTI, P643; SCHILLER PW, 1989, J MED CHEM, V32, P698, DOI 10.1021/jm00123a035; TAM JP, 1983, J AM CHEM SOC, V105, P6442, DOI 10.1021/ja00359a014; TOVEY KC, 1974, CLIN CHIM ACTA, V56, P221, DOI 10.1016/0009-8981(74)90133-8; WALKER JS, 1995, LIFE SCI, V57, P371, DOI 10.1016/0024-3205(95)00296-I; YU VC, 1988, J PHARMACOL EXP THER, V245, P350; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	29	75	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18848	18856		10.1074/jbc.273.30.18848	http://dx.doi.org/10.1074/jbc.273.30.18848			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668060	hybrid			2022-12-27	WOS:000074974700027
J	Lundblad, JR; Kwok, RPS; Laurance, ME; Huang, MS; Richards, JP; Brennan, RG; Goodman, RH				Lundblad, JR; Kwok, RPS; Laurance, ME; Huang, MS; Richards, JP; Brennan, RG; Goodman, RH			The human T-cell leukemia virus-1 transcriptional activator Tax enhances cAMP-responsive element-binding protein (CREB) binding activity through interactions with the DNA minor groove	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; X-RAY STRUCTURE; HTLV-I; LEUCINE-ZIPPER; CYCLIC-AMP; 21-BASE-PAIR REPEATS; TRANSACTIVATOR TAX; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; ENERGY-TRANSFER	Tax-1, the transcriptional activation protein of human T-cell leukemia virus-1, increases transcription hom the human T-cell leukemia virus-1 long terminal repeat and specific cellular promoters through interactions with cellular DNA-binding proteins. The Tax response elements (TxREs) of the long terminal repeat resemble cAMP response elements (CREs), the target of cAMP-responsive element-binding protein (CREB). CREB binds the TxRE with reduced affinity; however, the interaction is specifically enhanced by Tax. Using a fluorescence quenching method, we determined that CREB dimerizes in the absence of DNA, and that Tax does not enhance dimerization. DNA footprinting of the TxRE with 1,10-phenanthroline-copper complex demonstrates that Tax contacts DNA and extends the footprint of CREB to GC-rich sequences Banking the core CRE-like element. The minor groove-binding drug chromomycin A,, but not distamycin A, disrupted Tax-enhanced CREB binding to the TxRE. Substitution of the guanine-rich sequences flanking the core of the TxRE with inosine residues also blocked the Tax effect. Finally, the IC-substituted TxRE binds CREB with increased affinity, suggesting Banking DNA influences the binding of CREB to the core CRE-like element. These data indicate that Tax does not regulate DNA binding of CREB by altering dimerization, but rather enhances DNA binding by additionally interacting with the minor groove of flanking DNA sequences.	Oregon Hlth Sci Univ, Dept Med, Div Mol Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Div Hematol Oncol, Dept Pediat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Lundblad, JR (corresponding author), Oregon Hlth Sci Univ, Dept Med, Div Mol Med, NRC-5, Portland, OR 97201 USA.			Brennan, Richard/0000-0001-7647-485X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051732] Funding Source: NIH RePORTER; NIDDK NIH HHS [R29 DK51732] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; ADYA N, 1994, P NATL ACAD SCI USA, V91, P5642, DOI 10.1073/pnas.91.12.5642; ANDERSON MG, 1994, NUCLEIC ACIDS RES, V22, P3194, DOI 10.1093/nar/22.15.3194; BAILLY C, 1995, EMBO J, V14, P2121, DOI 10.1002/j.1460-2075.1995.tb07204.x; Bantignies F, 1996, MOL CELL BIOL, V16, P2174; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Barnabas S, 1997, J BIOL CHEM, V272, P20684, DOI 10.1074/jbc.272.33.20684; BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; Chiang SY, 1996, J BIOL CHEM, V271, P23999, DOI 10.1074/jbc.271.39.23999; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GAO XL, 1989, BIOCHEMISTRY-US, V28, P751, DOI 10.1021/bi00428a051; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gitlin Scott D., 1993, P159; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LOW KG, 1994, MOL CELL BIOL, V14, P4958, DOI 10.1128/MCB.14.7.4958; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MARRIOTT SJ, 1990, MOL CELL BIOL, V10, P4192, DOI 10.1128/MCB.10.8.4192; Maxam A M, 1980, Methods Enzymol, V65, P499; Metallo SJ, 1997, NAT STRUCT BIOL, V4, P115, DOI 10.1038/nsb0297-115; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PAPAVASSILIOU AG, 1995, BIOCHEM J, V305, P345, DOI 10.1042/bj3050345; Park C, 1996, J AM CHEM SOC, V118, P4235, DOI 10.1021/ja950653t; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PERNELLE C, 1993, BIOCHEMISTRY-US, V32, P11682, DOI 10.1021/bi00094a026; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; SANTIAGORIVERA ZI, 1993, PROTEIN SCI, V2, P1461, DOI 10.1002/pro.5560020910; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; WILLIAMS JS, 1993, DNA CELL BIOL, V12, P183, DOI 10.1089/dna.1993.12.183; Yin MJ, 1996, J BIOL CHEM, V271, P4781, DOI 10.1074/jbc.271.9.4781; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; Yin MJ, 1996, J MOL BIOL, V264, P20, DOI 10.1006/jmbi.1996.0620; Yin MJ, 1996, MOL CELL BIOL, V16, P3156; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	66	62	62	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19251	19259		10.1074/jbc.273.30.19251	http://dx.doi.org/10.1074/jbc.273.30.19251			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668114	hybrid			2022-12-27	WOS:000074974700081
J	Sturm, NR; Fleischmann, J; Campbell, DA				Sturm, NR; Fleischmann, J; Campbell, DA			Efficient trans-splicing of mutated spliced leader exons in Leishmania tarentolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-EXON; TRYPANOSOMA-BRUCEI; IN-VIVO; LEPTOMONAS-COLLOSOMA; MESSENGER-RNAS; GENE; EXPRESSION; ELEMENTS; TRANSCRIPTION; METHYLATIONS	Every kinetoplastid mRNA receives a common, conserved leader sequence via the process of trans-splicing. In Leishmania tarentolae the precursor spliced leader RNA is 96 nucleotides, with a 39-nucleotide exon that is 7meG-capped and methylated on the first 4 nucleotides. trans-Splicing was inferred from the presence of tagged leader in the high molecular weight RNA population and confirmed for accuracy by cDNA cloning. Linker scan substitutions within the exon between positions 10 and 39 did not affect trans-splicing. The trans-splicing efficiency for three of the scan exons was proportional to the tagged:wild type ratio in the spliced leader precursor population. Two scan leader RNAs that were efficiently spliced showed reduced methylation. Longer exons showed reduced splicing, whereas 10- or 20-base pair deletions abolished splicing. These results indicate that size, but not content, of the exon is a constraint on the splicing process. These results, in combination with previous data eliminating a role in transcription initiation, suggest that translation may be the selective pressure on the leader content.	Univ Calif Los Angeles, Sch Med, Dept Immunol & Microbiol, Los Angeles, CA 90095 USA; W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Campbell, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Immunol & Microbiol, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007323, R01AI034536] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34536, 2-T32-AI-07323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGAMI R, 1994, NUCLEIC ACIDS RES, V22, P1959, DOI 10.1093/nar/22.11.1959; COOK GA, 1987, MOL BIOCHEM PARASIT, V25, P113, DOI 10.1016/0166-6851(87)90024-7; DELAFAILLE MAC, 1992, P NATL ACAD SCI USA, V89, P2703, DOI 10.1073/pnas.89.7.2703; Dungan JM, 1996, EMBO J, V15, P4016, DOI 10.1002/j.1460-2075.1996.tb00775.x; FERNANDES O, 1994, MOL BIOCHEM PARASIT, V66, P261, DOI 10.1016/0166-6851(94)90153-8; FLEISCHMANN J, 1994, GENE, V144, P45, DOI 10.1016/0378-1119(94)90201-1; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; Gunzl A, 1997, MOL BIOCHEM PARASIT, V85, P67, DOI 10.1016/S0166-6851(96)02816-2; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HARRIS KA, 1995, RNA, V1, P351; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; LECUYER KA, 1993, BIOCHEMISTRY-US, V32, P5301, DOI 10.1021/bi00071a004; LENARDO MJ, 1985, MOL CELL BIOL, V5, P2487, DOI 10.1128/MCB.5.9.2487; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; MARONEY PA, 1991, EMBO J, V10, P3869, DOI 10.1002/j.1460-2075.1991.tb04956.x; MASLOV DA, 1993, MOL BIOCHEM PARASIT, V61, P127, DOI 10.1016/0166-6851(93)90165-T; MCNALLY KP, 1992, MOL CELL BIOL, V12, P4844, DOI 10.1128/MCB.12.11.4844; MUHICH ML, 1987, NUCLEIC ACIDS RES, V15, P3141, DOI 10.1093/nar/15.7.3141; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Roberts TG, 1996, MOL BIOCHEM PARASIT, V83, P163, DOI 10.1016/S0166-6851(96)02762-4; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STURM NR, 1995, FEMS MICROBIOL LETT, V130, P177, DOI 10.1111/j.1574-6968.1995.tb07716.x; STURM NR, 1994, MOL CELL BIOL, V14, P6171, DOI 10.1128/MCB.14.9.6171; STURM NR, 1990, CELL, V61, P871, DOI 10.1016/0092-8674(90)90197-M; ULLU E, 1991, P NATL ACAD SCI USA, V88, P10074, DOI 10.1073/pnas.88.22.10074; ULLU E, 1993, J BIOL CHEM, V268, P13068; WATKINS KP, 1994, CELL, V76, P171, DOI 10.1016/0092-8674(94)90181-3; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091	29	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18689	18692		10.1074/jbc.273.30.18689	http://dx.doi.org/10.1074/jbc.273.30.18689			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668037	hybrid			2022-12-27	WOS:000074974700004
J	Hermsen, B; Stetzer, E; Thees, R; Heiermann, R; Schrattenholz, A; Ebbinghaus, U; Kretschmer, A; Methfessel, C; Reinhardt, S; Maelicke, A				Hermsen, B; Stetzer, E; Thees, R; Heiermann, R; Schrattenholz, A; Ebbinghaus, U; Kretschmer, A; Methfessel, C; Reinhardt, S; Maelicke, A			Neuronal nicotinic receptors in the locust Locusta migratoria - Cloning and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RAT HIPPOCAMPAL-NEURONS; ACETYLCHOLINE-RECEPTOR; MONOCLONAL-ANTIBODIES; ALPHA-BUNGAROTOXIN; BINDING-SITE; PATCH-CLAMP; SUBUNITS; DROSOPHILA; CELLS	We have identified five cDNA clones that encode nicotinic acetylcholine receptor (nAChR) subunits expressed in the nervous system of the locust Locusta migratoria. Four of the subunits are ligand-binding alpha subunits, and the other is a structural beta subunit. The existence of at least one more nAChR gene, probably encoding a beta subunit, is indicated. Based on Northern analysis and in situ hybridization, the five subunit genes are expressed. loc alpha 1, loc alpha 3, and loc beta 1 are the most abundant subunits and are expressed in similar areas of the head ganglia and retina of the adult locust. Because Loc alpha 3 binds alpha-bungarotoxin with high affinity, it may form a homomeric nAChR subtype such as the mammalian alpha 7 nAChR Loc alpha 1 and Loc beta 1 may then form the predominant heteromeric nAChR in the locust brain. loc alpha 4 is mainly expressed in optic lobe ganglionic cells and loc alpha 2 in peripherally located somata of mushroom body neurons. loc alpha 3 mRNA was additionally detected in cells interspersed in the somatogastric epithelium of the locust embryo, suggesting that this isoform may also be involved in functions other than neuronal excitability, Transcription of all nAChR subunit genes begins approximately 3 days before hatching and continues throughout adult life. Electrophysiological recordings from head ganglionic neurons also indicate the existence of more than one functionally distinct nAChR subtype, Our results suggest the existence of several nAChR subtypes, at least some of them heteromeric, in this insect species.	Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Mol Neurobiol Lab, D-55099 Mainz, Germany; Bayer AG, Cent Res Unit, D-5090 Leverkusen, Germany	Johannes Gutenberg University of Mainz; Bayer AG	Maelicke, A (corresponding author), Johannes Gutenberg Univ Mainz, Sch Med, Inst Physiol Chem & Pathobiochem, Mol Neurobiol Lab, 6 Duesbergweg, D-55099 Mainz, Germany.	alfred.maelicke@uni-mainz.de						Albuquerque EX, 1997, J RECEPT SIGNAL TR R, V17, P243, DOI 10.3109/10799899709036607; ALKONDON M, 1994, J PHARMACOL EXP THER, V271, P494; ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; Battey, 1986, BASIC METHODS MOL BI; BAUMANN A, 1990, NUCLEIC ACIDS RES, V18, P3640, DOI 10.1093/nar/18.12.3640; BENKE D, 1989, COMP BIOCHEM PHYS C, V94, P71, DOI 10.1016/0742-8413(89)90146-1; BENSON JA, 1993, COMP MOL NEUROBIOLOG, P390; BENSON JA, 1988, NATO ASI SERIES H, V25, P227; BERTRAND D, 1992, NEUROSCI LETT, V146, P87, DOI 10.1016/0304-3940(92)90179-B; BERTRAND D, 1994, EUR J NEUROSCI, V6, P869, DOI 10.1111/j.1460-9568.1994.tb00997.x; BERTRAND D, 1993, P NATL ACAD SCI USA, V90, P6971, DOI 10.1073/pnas.90.15.6971; BOSSY B, 1988, EMBO J, V7, P611, DOI 10.1002/j.1460-2075.1988.tb02854.x; BREER H, 1981, Neurochemistry International, V3, P43, DOI 10.1016/0197-0186(81)90048-6; BREER H, 1985, J NEUROSCI, V5, P3386; BREER H, 1987, J INSECT PHYSIOL, V33, P771, DOI 10.1016/0022-1910(87)90025-4; BULLER AL, 1990, J MEMBRANE BIOL, V115, P179, DOI 10.1007/BF01869456; CONROY WG, 1995, J BIOL CHEM, V270, P4424, DOI 10.1074/jbc.270.9.4424; CONTITRONCONI BM, 1990, BIOCHEMISTRY-US, V29, P6221, DOI 10.1021/bi00478a016; CONTITRONCONI BM, 1991, BIOCHEMISTRY-US, V30, P2575, DOI 10.1021/bi00224a003; COUTURIER S, 1990, J BIOL CHEM, V265, P17560; DENERIS ES, 1991, TRENDS PHARMACOL SCI, V12, P34, DOI 10.1016/0165-6147(91)90486-C; Eastham HM, 1998, EUR J NEUROSCI, V10, P879, DOI 10.1046/j.1460-9568.1998.00095.x; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; FELS G, 1986, J BIOL CHEM, V261, P5746; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; Forsayeth JR, 1997, J NEUROSCI, V17, P1531; GEHLE VM, 1991, MOL BRAIN RES, V11, P17, DOI 10.1016/0169-328X(91)90016-Q; GERSCHENFELD HM, 1973, PHYSIOL REV, V53, P1, DOI 10.1152/physrev.1973.53.1.1; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GRANDO SA, 1995, J INVEST DERMATOL, V105, P774, DOI 10.1111/1523-1747.ep12325606; GUNDELFINGER ED, 1992, BIOCHIM BIOPHYS ACTA, V1137, P299, DOI 10.1016/0167-4889(92)90150-A; HANKE W, 1986, NATURE, V321, P171, DOI 10.1038/321171a0; HERMANSBORGMEYER I, 1986, EMBO J, V5, P1503, DOI 10.1002/j.1460-2075.1986.tb04389.x; Lansdell SJ, 1997, J NEUROCHEM, V68, P1812; LEITCH B, 1993, J COMP NEUROL, V334, P47, DOI 10.1002/cne.903340104; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; Lindstrom J, 1996, Ion Channels, V4, P377; MAELICKE A, 1984, ANGEW CHEM INT EDIT, V23, P195, DOI 10.1002/anie.198401951; MARSHALL J, 1990, EMBO J, V9, P4391, DOI 10.1002/j.1460-2075.1990.tb07889.x; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; SAFRAN A, 1989, NATO ADV STUDY I CB, V32, P373; Sambrook J., 1989, MOL CLONING LAB MANU, V1; SATELLE DB, 1989, P R SOC LONDON B, V237, P501; SATELLE DB, 1980, ADV INSECT PHYSL, V15, P215; SCHRODER B, 1994, J BIOL CHEM, V269, P10407; Stetzer E, 1996, FEBS LETT, V397, P39, DOI 10.1016/S0014-5793(96)01115-5; Usherwood P.N.R., 1980, INSECT NEUROBIOLOGY, P115; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; WEBER H, 1938, COMPENDIUM ENTOMOLOG; ZWART R, 1994, PESTIC BIOCHEM PHYS, V48, P202, DOI 10.1006/pest.1994.1021	51	54	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18394	18404		10.1074/jbc.273.29.18394	http://dx.doi.org/10.1074/jbc.273.29.18394			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660807	hybrid			2022-12-27	WOS:000074828500062
J	Sells, MA; Barratt, JT; Caviston, J; Ottilie, S; Leberer, E; Chernoff, J				Sells, MA; Barratt, JT; Caviston, J; Ottilie, S; Leberer, E; Chernoff, J			Characterization of Pak2p, a pleckstrin homology domain-containing, p21-activated protein kinase from fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; ACTIN POLYMERIZATION; CELL-GROWTH; JUN KINASE; PH DOMAIN; PATHWAY; CDC42; STE20; ACTIVATION	p21-activated kinases (PAKs) bind to and are activated by Rho family GTPases such as Cdc42 and Rac. Since these GTPases play key roles in regulating cell polarity, stress responses, and cell cycle progression, the ability of PAK to affect these processes has been examined, me previously showed that fission yeast pak1(+) encodes an essential protein that affects mating and cell polarity. Here, we characterize a second pak gene (pak2(+)) from Schizosaccharomyces pombe. Like the Saccharomyces cerevisiae proteins Cla4p and Skm1p, fission yeast Pak2p contains an N-terminal pleckstrin homology domain in addition to a pal-binding domain and a protein kinase domain that are common to other members of the PAK family. Unlike pak1(+), pak2+ is not essential for vegetative growth or for mating in S. pombe. Overexpression of the wild-type pak2(+) allele suppresses the lethal growth defect associated with deletion of pak1(+), and this suppression requires both the pleckstrin homology- and the pll-binding domains of Pak2p, as well as kinase activity. A substantial fraction of Pak2p is associated with membranous components, an association mediated both by the pleckstrin homology- and by the pal-binding domains. These results show that S. pombe encodes at least two pak genes with distinct functions and suggest that the membrane localization of Pak2p, directed by its interactions with membrane lipids and Cdc42p, is critical to its biological activity.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Idun Pharmaceut, San Diego, CA 92121 USA; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Fox Chase Cancer Center; National Research Council Canada	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	J_Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014	Chernoff, Jonathan/0000-0002-4803-7836				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Benton BK, 1997, MOL CELL BIOL, V17, P5067, DOI 10.1128/MCB.17.9.5067; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Gutz H., 1974, HDB GENETICS, V1, P395; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEHRACH H, 1990, GENETIC PHYSICAL MAP, V1; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Rose M. D., 1990, METHODS YEAST GENETI, P155; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18490	18498		10.1074/jbc.273.29.18490	http://dx.doi.org/10.1074/jbc.273.29.18490			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660818	hybrid			2022-12-27	WOS:000074828500073
J	Tanikawa, M; Yamada, K; Tominaga, K; Morisaki, H; Kaneko, Y; Ikeda, K; Suzuki, M; Kiho, T; Tomokiyo, K; Furuta, K; Noyori, R; Nakanishi, M				Tanikawa, M; Yamada, K; Tominaga, K; Morisaki, H; Kaneko, Y; Ikeda, K; Suzuki, M; Kiho, T; Tomokiyo, K; Furuta, K; Noyori, R; Nakanishi, M			Potent prostaglandin A(1) analogs that suppress tumor cell growth through induction of p21 and reduction of cyclin E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; ANTINEOPLASTIC PROSTAGLANDINS; CDK6 INHIBITOR; LEUKEMIA-CELLS; DNA-DAMAGE; DIFFERENTIATION; EXPRESSION; ARREST; CANCER; MECHANISM	Although the cyclopentenone prostaglandin A(1) (PGA(1)) is known to arrest the cell cycle at the G(1) phase in vitro and to suppress tumor growth in vivo, its relatively weak activity limits its usefulness in cancer chemotherapy, In an attempt to develop antitumor drugs of greater potency and conspicuous biological specificity, we synthesized novel analogs based on the structure of PGA(1). Of the newly synthesized analogs, 15-epi Delta(7)-PGA(1), methyl ester (NAG-0092), 12-iso-Delta(7)-PGA(1), methyl ester (NAG-0093), and ent-Delta(7)-PGA(1), methyl ester (NAG-0022) possess a cross conjugated dienone structure around the five-member ring with unnatural configurations at C(12) and/or C(15) and were found to be far more potent than native PGA(1) in inhibiting cell growth and causing G(1) arrest in A172 human glioma cells. These three analogs induced the expression of p21 at both RNA and protein levels in a time- and dose-dependent fashion. Kinase assays with A172 cells treated with these analogs revealed that both cyclin A- and E-dependent kinase activities were markedly reduced, although cyclin D1-dependent kinase activity was unaffected. Immunoprecipitation-Western blot analysis showed that the decrease in cyclin A-dependent kinase activity was due to an increased association of p21 with cyclin A-cyclin-dependent kinase 2 complexes, whereas the decrease in cyclin E-dependent activity was due to a combined mechanism involving reduction in cyclin E protein itself and increased association of p21. Thus, these newly synthesized PGA(1) analogs may prove to be powerful tools in cancer chemotherapy as well as in investigations of the structural basis of the antiproliferative activity of A series prostaglandins.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 474, Japan; Nagoya City Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi 467, Japan; Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 50111, Japan; Nagoya Univ, Dept Chem, Chikusa Ku, Nagoya, Aichi 46401, Japan; Nagoya Univ, Mol Chiral Res Unit, Chikusa Ku, Nagoya, Aichi 46401, Japan	Nagoya City University; Gifu University; Nagoya University; Nagoya University	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo,Morioka Cho, Aichi 474, Japan.	mnakani@nils.go.jp	Tominaga, Kaoru/AAL-4250-2020	Tominaga, Kaoru/0000-0001-8799-528X				Akimaru K, 1997, ADV EXP MED BIOL, V407, P387; BREGMAN MD, 1986, CANCER RES, V46, P2740; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1994, ANN NY ACAD SCI, V744, P161, DOI 10.1111/j.1749-6632.1994.tb52733.x; FUKUSHIMA M, 1990, EICOSANOIDS, V3, P189; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1996, MOL CELL BIOL, V16, P762; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V74, P1009; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; JIANG HP, 1994, ONCOGENE, V9, P3397; KIKUCHI Y, 1992, J CANCER RES CLIN, V118, P453, DOI 10.1007/BF01629429; KIKUCHI Y, 1992, INT J IMMUNOPHARMACO, V14, P105; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NARUMIYA S, 1987, J PHARMACOL EXP THER, V242, P306; NARUMIYA S, 1986, J PHARMACOL EXP THER, V239, P500; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHNO K, 1986, BIOCHEM BIOPH RES CO, V139, P808, DOI 10.1016/S0006-291X(86)80062-6; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; SANTORO MG, 1986, CANCER RES, V46, P6073; SASAKI H, 1994, ANTI-CANCER DRUG, V5, P131, DOI 10.1097/00001813-199404000-00002; SASAKI H, 1991, GYNECOL ONCOL, V41, P36, DOI 10.1016/0090-8258(91)90251-Y; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Suzuki M, 1997, J AM CHEM SOC, V119, P2376, DOI 10.1021/ja9628359; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	50	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18522	18527		10.1074/jbc.273.29.18522	http://dx.doi.org/10.1074/jbc.273.29.18522			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660822	hybrid			2022-12-27	WOS:000074828500077
J	Wong, P; Burgess, WH				Wong, P; Burgess, WH			FGF2-heparin co-crystal complex-assisted design of mutants FGF1 and FGF7 with predictable heparin affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; SITE-DIRECTED MUTAGENESIS; FACTOR FAMILY; FACTOR-I; ENDOTHELIAL-CELLS; FACTOR RECEPTORS; ACIDIC FGF; BINDING; EXPRESSION; INVITRO	The co-crystal structures of FGF2 and heparin derived tetra- and hexasaccharides demonstrated the existence of high and low affinity contact residues that are likely to be involved in heparin binding (Faham, S., Hileman, R, E., Fromm, J. R., Linhardt, R. J., and Rees, D. C. (1996) Science 271, 1116-1120), To study the role of these putative contact residues, me chose three fibroblast growth factor family members with distinct heparin affinities for comparative mutagenesis studies. Only one amino acid significantly differed between FGF1 and FGF2 and was mutated, FGF1-31K. FGF7, also called keratinocyte growth factor, was mutated to mimic either FGF1 or FGF2 at two of the putative high contact points termed FGF7-1 and FGF7-2, respectively, FGF2 has higher apparent heparin affinity than FGF1 or FGF7, and FGF1 has higher heparin affinity than FGF7, All three mutants showed an increase in apparent heparin affinity compared with wild types, FGF7-1 has a lower apparent heparin affinity than FGF7-2, analogous to wild type FGF1 and FGF2, The FGF1-31K mutant showed no change in mitogenic activity, whereas the FGF7 mutants exhibited a decrease in activity, These results indicate that the co-crystal structure of the FGF2-heparin complexes can be used to design a rational approach to the generation of mutants with defined affinities for heparin or heparan sulfate proteoglycans.	Amer Red Cross, Jerome H Holland Lab, Dept Tissue Biol, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA	American Red Cross; George Washington University; George Washington University	Burgess, WH (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Tissue Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.							AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1994, MOL REPROD DEV, V39, P56, DOI 10.1002/mrd.1080390110; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fromm JR, 1997, ARCH BIOCHEM BIOPHYS, V346, P252, DOI 10.1006/abbi.1997.0299; FROMM JR, 1995, ARCH BIOCHEM BIOPHYS, V323, P279, DOI 10.1006/abbi.1995.9963; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HARPER JW, 1988, BIOCHEMISTRY-US, V27, P671, DOI 10.1021/bi00402a027; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KIMBALL ES, 1988, CELL IMMUNOL, V113, P341, DOI 10.1016/0008-8749(88)90032-9; Krufka A, 1996, BIOCHEMISTRY-US, V35, P11131, DOI 10.1021/bi960125+; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBB RR, 1988, BIOCHEMISTRY-US, V27, P2572, DOI 10.1021/bi00407a045; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MUELLER SN, 1989, J CELL PHYSIOL, V140, P439, DOI 10.1002/jcp.1041400306; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; RON D, 1993, J BIOL CHEM, V268, P2984; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	37	6	8	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18617	18622		10.1074/jbc.273.29.18617	http://dx.doi.org/10.1074/jbc.273.29.18617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660835	hybrid			2022-12-27	WOS:000074828500090
J	Zhang, JW; Parra, KJ; Liu, JZ; Kane, PM				Zhang, JW; Parra, KJ; Liu, JZ; Kane, PM			Characterization of a temperature-sensitive yeast vacuolar ATPase mutant with defects in actin distribution and bud morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; MEMBRANE H+-ATPASE; CELL-CYCLE CONTROL; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR PH; GENE ENCODES; NEUROSPORA-CRASSA; CDC24 GENE; SUBUNIT; CALCIUM	The 27-kDa E subunit, encoded by the VMA4 gene, is a peripheral membrane subunit of the yeast vacuolar H+ - ATPase. We hare randomly mutagenized the VMA4 gene in order to examine the structure and function of the 27-kDa subunit. Cells lacking a functional VMA4 gene are unable to grow at pH > 7 or in elevated concentrations of CaCl2. Plasmid-borne, mutagenized vma4 genes were screened for failure to complement these phenotypes. Mutants producing Vma4 proteins detectable by immunoblot were selected; one (vma4-1(ts)) is temperature conditional, exhibiting the Vma(-) phenotype only at elevated temperature (37 degrees C). Sequencing revealed that a single point mutation, D145G, was responsible for the phenotypes of the vma4-1(ts) allele. The unassembled 27-kDa subunit made in the vma4-1(ts) cells is rapidly degraded, particularly at 37 degrees C, but can be protected from degradation by prior assembly into the V-ATPase complex. In purified vacuolar resides from the mutant cells, the peripheral subunits are localized to the vacuolar membrane at decreased levels and a comparably decreased level of ATPase activity (14% of the activity in wild-type vesicles) is observed. When vma4-1(ts) mutant cells are shifted to pH 7.5 medium at 37 degrees C, the cells become enlarged and exhibit multiple large buds, elongated buds, and other abnormal morphologies, together with delocalization of actin and chitin, within 4 h. These phenotypes suggest connections between the vacuolar ATPase, bud morphology, and cytokinesis that had not been recognized previously.	SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Kane, PM (corresponding author), SUNY Hlth Sci Ctr, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.	kanepm@hscsyr.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050322] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM50322, R01 GM050322] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Bowman EJ, 1997, J BIOL CHEM, V272, P14776, DOI 10.1074/jbc.272.23.14776; BUSA WB, 1984, AM J PHYSIOL, V246, pR409, DOI 10.1152/ajpregu.1984.246.4.R409; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; Davies SA, 1996, J BIOL CHEM, V271, P30677, DOI 10.1074/jbc.271.48.30677; DENHOLLANDER JA, 1981, BIOCHEMISTRY-US, V20, P5871, DOI 10.1021/bi00523a034; Dietz KJ, 1996, BBA-BIOMEMBRANES, V1281, P134, DOI 10.1016/0005-2736(96)00044-2; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; EDMONDS BT, 1995, J BIOL CHEM, V270, P15222, DOI 10.1074/jbc.270.25.15222; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Ferea TL, 1996, GENETICS, V143, P147; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Forgac M, 1996, SOC GEN PHY, V51, P121; FOURY F, 1990, J BIOL CHEM, V265, P18554; GILLIES RJ, 1981, P NATL ACAD SCI-BIOL, V78, P2125, DOI 10.1073/pnas.78.4.2125; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; Greener A., 1994, STRATEGIES, V7, P32; GREER C, 1982, MOL CELL BIOL, V2, P1279, DOI 10.1128/MCB.2.10.1279; Guo YQ, 1996, BBA-BIOMEMBRANES, V1283, P4, DOI 10.1016/0005-2736(96)00103-4; HALACHMI D, 1993, FEBS LETT, V316, P73, DOI 10.1016/0014-5793(93)81739-M; HO MN, 1993, J BIOL CHEM, V268, P221; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; IIDA H, 1990, J BIOL CHEM, V265, P21216; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KANEKO R, 1991, ADV INFO STORAGE SYS, V1, P267; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4128, DOI 10.1021/bi00313a018; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; MORANO KA, 1994, J CELL SCI, V107, P2813; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OHYA Y, 1991, J BIOL CHEM, V266, P13971; Oluwatosin YE, 1998, MOL CELL BIOL, V18, P1534, DOI 10.1128/MCB.18.3.1534; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1982, METHODS YEAST GENETI, P177; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Temesvari LA, 1996, J CELL SCI, V109, P1479; VALLEJO CG, 1989, YEAST, V5, P307, DOI 10.1002/yea.320050411; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; White WH, 1997, GENETICS, V147, P43; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737	70	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18470	18480		10.1074/jbc.273.29.18470	http://dx.doi.org/10.1074/jbc.273.29.18470			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660816	hybrid			2022-12-27	WOS:000074828500071
J	Seidenbecher, CI; Langnaese, K; Sanmarti-Vila, L; Boeckers, TM; Smalla, KH; Sabel, BA; Garner, CC; Gundelfinger, ED; Kreutz, MR				Seidenbecher, CI; Langnaese, K; Sanmarti-Vila, L; Boeckers, TM; Smalla, KH; Sabel, BA; Garner, CC; Gundelfinger, ED; Kreutz, MR			Caldendrin, a novel neuronal calcium-binding protein confined to the somato-dendritic compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CAM KINASE-II; RAT-BRAIN; CA2+-BINDING PROTEINS; POSTSYNAPTIC DENSITY; CALMODULIN; PHOSPHATASE; VILIP; ALPHA; PARVALBUMIN	Using antibodies against synaptic protein preparations, we cloned the cDNA of a new Ca2+-binding protein. Its C-terminal portion displays significant similarity with calmodulin and contains two EF-hand motifs. The corresponding mRNA is highly expressed in rat brain, primarily in cerebral cortex, hippocampus, and cerebellum; its expression appears to be restricted to neurons. Transcript levels increase during postnatal development. A recombinant C-terminal protein fragment binds Ca2+ as indicated by a Ca2+-induced mobility shift in SDS-polyacrylamide gel electrophoresis. Antisera generated against the bacterial fusion protein recognize a brain-specific protein doublet with apparent molecular masses of 33 and 36 kDa, These data are confirmed by in vitro translation, which generates a single 36-kDa polypeptide, and by the heterologous expression in 293 cells, which yields a 33/36-kDa doublet comparable to that found in brain. On two-dimensional gels, the 33-kDa band separates into a chain of spots plausibly due to differential phosphorylation. This view is supported by in situ phosphorylation studies in hippocampal slices. Most of the immunoreactivity is detectable in cytoskeletal preparations with a further enrichment in the synapse-associated cytomatrix. These biochemical data, together with the ultra-structural localization in dendrites and the postsynaptic density, strongly suggest an association with the somato-dendritic cytoskeleton, Therefore, this novel Ca2+-binding protein was named caldendrin.	Otto Von Guericke Univ, Inst Med Psychol, AG Mol & Cellular Neurobiol, D-39120 Magdeburg, Germany; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Westfalische Wilhelms Universitat, Inst Anat, AG Mol Neuroendocrinol, D-48149 Munster, Germany; Otto Von Guericke Univ, Inst Pharmacol & Toxicol, D-39120 Magdeburg, Germany; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA	Otto von Guericke University; Leibniz Institut fur Neurobiologie (LIN); Otto von Guericke University; University of Alabama System; University of Alabama Birmingham	Kreutz, MR (corresponding author), Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, POB 1860, D-39008 Magdeburg, Germany.		Sabel, Bernhard A./E-6579-2013; Smalla, Dr. Karl-Heinz/C-3950-2012	Smalla, Dr. Karl-Heinz/0000-0002-0269-0311; Garner, Craig/0000-0003-1970-5417; Sabel, Bernhard/0000-0002-4472-5543; Seidenbecher, Constanze/0000-0002-7433-2716				BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; Bearer EL, 1996, P NATL ACAD SCI USA, V93, P6064, DOI 10.1073/pnas.93.12.6064; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; Braunewell KH, 1997, J NEUROCHEM, V68, P2129; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; CARLIN RK, 1983, J CELL BIOL, V96, P443, DOI 10.1083/jcb.96.2.443; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COOPER NGF, 1985, J CELL BIOL, V101, P1212, DOI 10.1083/jcb.101.4.1212; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Fukunaga K, 1996, NEUROCHEM INT, V28, P343, DOI 10.1016/0197-0186(95)00097-6; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; GARRISON JC, 1982, J BIOL CHEM, V257, P3135; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GRAB DJ, 1979, J BIOL CHEM, V254, P8690; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Heizmann C. W., 1995, CALCIUM REGULATION C; HENDRICKSON AE, 1991, J COMP NEUROL, V307, P626, DOI 10.1002/cne.903070409; JUNGBLUT P, 1993, ELECTROPHORESIS, V14, P638, DOI 10.1002/elps.1150140199; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KLAUCK TM, 1995, CELL SIGNAL, V7, P747, DOI 10.1016/0898-6568(95)02003-9; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langnaese K, 1996, MOL BRAIN RES, V42, P118, DOI 10.1016/S0169-328X(96)00147-7; Langnaese K, 1997, J BIOL CHEM, V272, P821, DOI 10.1074/jbc.272.2.821; Lenz SE, 1996, NEUROSCI LETT, V206, P133, DOI 10.1016/S0304-3940(96)12444-7; Lenz SE, 1996, BIOCHEM BIOPH RES CO, V225, P1078, DOI 10.1006/bbrc.1996.1298; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; MURACHI T, 1989, BIOCHEM INT, V18, P263; Pauls TL, 1996, BBA-GENE STRUCT EXPR, V1306, P39, DOI 10.1016/0167-4781(95)00221-9; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; SAITOH S, 1994, DEV BRAIN RES, V80, P199, DOI 10.1016/0165-3806(94)90105-8; SEIDENBECHER CI, 1995, J BIOL CHEM, V270, P27206, DOI 10.1074/jbc.270.45.27206; Seidenbecher CI, 1998, EUR J NEUROSCI, V10, P1621, DOI 10.1046/j.1460-9568.1998.00166.x; STAAK S, 1995, BRAIN RES, V682, P55, DOI 10.1016/0006-8993(95)00319-L; TRAVE G, 1995, EUR J BIOCHEM, V227, P35, DOI 10.1111/j.1432-1033.1995.tb20357.x; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	44	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21324	21331		10.1074/jbc.273.33.21324	http://dx.doi.org/10.1074/jbc.273.33.21324			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694893	hybrid			2022-12-27	WOS:000075386100086
J	Shahied-Milam, L; Soltaninassab, SR; Iyer, GV; LeStourgeon, WM				Shahied-Milam, L; Soltaninassab, SR; Iyer, GV; LeStourgeon, WM			The heterogeneous nuclear ribonucleoprotein C protein tetramer binds U1, U2, and U6 snRNAs through its high affinity RNA binding domain (the bZIP-like motif)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SINGLE-STRANDED-DNA; HNRNP PROTEINS; PREMESSENGER RNA; CROSS-LINKING; PARTICLES; COMPLEXES; PHOSPHORYLATION; PURIFICATION; SPECIFICITY	Eased on UV cross-linking experiments, it has been reported that the C protein tetramer of 40 S heterogeneous nuclear ribonucleoprotein complexes specifically interacts with stem-loop I of U2 small nuclear RNA (snRNA) (Temsamani, J., and Pederson, T. (1996) J. Biol. Chem. 271, 24922-24926), that C protein disrupts U4:U6 snRNA complexes (Forne, T., Rossi, F., Labourier, E., Antoine, E., Cathala, G., Brunel, C., and Tazi, J. (1995) J. Biol. Chem. 270, 16476-16481), that U6 snRNA may modulate C protein phosphorylation (Mayrand, S. H., Fung, P. A., and Pederson, T. (1996) Mol. Cel. Biol. 16, 1241-1246), and that hyperphosphorylated C protein lacks pre-mRNA binding activity. These findings suggest that snRNA-C protein interactions may function to recruit snRNA to, or displace C protein from, splice junctions. In this study, both equilibrium and non-equilibrium RNA binding assays reveal that purified native C protein binds U1, U2, and U6 snRNA with significant affinity (similar to 7.5-50 nM) although nonspecifically. Competition binding assays reveal that U2 snRNA (the highest affinity snRNA substrate) is ineffective in C protein displacement from branch-point/splice junctions or as a competitor of C protein's self-cooperative RNA binding mode. Additionally, C protein binds snRNA through its high affinity bZLM and mutations in the RNA recognition motif at suggested RNA binding sites primarily affect protein oligomerization.	Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA	Vanderbilt University	LeStourgeon, WM (corresponding author), Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37235 USA.	lestouwm@ctrvax.vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048567] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48567] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; AMRUTE SB, 1994, BIOCHEMISTRY-US, V33, P8282, DOI 10.1021/bi00193a015; BARNETT SF, 1988, J BIOCHEM BIOPH METH, V16, P87, DOI 10.1016/0165-022X(88)90106-6; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BUJALOWSKI W, 1988, J BIOL CHEM, V263, P4629; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHAMPIONARNAUD P, 1994, GENE DEV, V8, P1974, DOI 10.1101/gad.8.16.1974; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; FORNE T, 1995, J BIOL CHEM, V270, P16476, DOI 10.1074/jbc.270.27.16476; Fung PA, 1997, P NATL ACAD SCI USA, V94, P1064, DOI 10.1073/pnas.94.4.1064; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HUANG M, 1994, MOL CELL BIOL, V14, P518, DOI 10.1128/MCB.14.1.518; HUANG M, 1994, HDB CELL BIOL, V1; KANAAR R, 1995, EMBO J, V14, P4530, DOI 10.1002/j.1460-2075.1995.tb00132.x; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LU JR, 1995, J MOL BIOL, V247, P739, DOI 10.1016/S0022-2836(05)80152-4; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MAYRAND SH, 1990, NUCLEIC ACIDS RES, V18, P3307, DOI 10.1093/nar/18.11.3307; Mayrand SH, 1996, MOL CELL BIOL, V16, P1241; McAfee JG, 1996, RNA, V2, P1139; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P1212, DOI 10.1021/bi951974k; MCAFEE JG, 1997, PACKAGING PREMRNA FR, P68; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PU WT, 1991, P NATL ACAD SCI USA, V88, P6901, DOI 10.1073/pnas.88.16.6901; RECH JE, 1995, J STRUCT BIOL, V114, P77, DOI 10.1006/jsbi.1995.1007; RECH JE, 1996, J STRUCT BIOL, V114, P84; REVZIN A, 1991, GEL RETARDATION ASSA, P205; Sakashita E, 1996, J BIOCHEM, V120, P1028; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SMITH KC, 1969, BIOCHEM BIOPH RES CO, V34, P354, DOI 10.1016/0006-291X(69)90840-7; SMITH KC, 1968, BIOCHEMISTRY-US, V7, P1033, DOI 10.1021/bi00843a023; SOLTANINASSAB S, 1996, MOL BIOL; SOLTANINASSAB S, 1998, IN PRESS NUCL ACIDS; STEINER RF, 1973, BIOCHIM BIOPHYS ACTA, V294, P24, DOI 10.1016/0005-2787(73)90311-0; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; Temsamani J, 1996, J BIOL CHEM, V271, P24922, DOI 10.1074/jbc.271.40.24922; VONHIPPE PH, 1972, ANNU REV BIOCHEM, V41, P231, DOI 10.1146/annurev.bi.41.070172.001311; WILK HE, 1983, BIOCHEMISTRY-US, V22, P4592, DOI 10.1021/bi00288a038; WILUSZ J, 1990, MOL CELL BIOL, V10, P6397, DOI 10.1128/MCB.10.12.6397; WILUSZ J, 1988, MOL CELL BIOL, V8, P4477, DOI 10.1128/MCB.8.10.4477; WOOLEY J, 1986, BIOPHYS J, V49, P17, DOI 10.1016/S0006-3495(86)83575-5; [No title captured]	56	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21359	21367		10.1074/jbc.273.33.21359	http://dx.doi.org/10.1074/jbc.273.33.21359			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694897	hybrid			2022-12-27	WOS:000075386100090
J	Darnay, BG; Haridas, V; Ni, J; Moore, PA; Aggarwal, BB				Darnay, BG; Haridas, V; Ni, J; Moore, PA; Aggarwal, BB			Characterization of the intracellular domain of receptor activator of NF-kappa B (RANK) - Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappa B and c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CD40; PROTEIN; FAMILY	Various members of the tumor necrosis factor (TNF) receptor superfamily interact directly with signaling molecules of the TNF receptor-associated factor (TRAF) family to activate nuclear factor kappa B (NF-kappa B) and the c-Jun N-terminal kinase (JNK) pathway. The receptor activator of NF-kappa B (RANK), a recently described TNF receptor family member, and its ligand, RANKL, promote survival of dendritic cells and differentiation of osteoclasts. RANK contains 383 amino acids in its intracellular domain (residues 234-616), which contain three putative TRAF-binding domains (termed I, II, and III). In this study, we set out to identify the region of RANK needed for interaction with TRAF molecules and for stimulation of NF-kappa B and JNK activity. We constructed epitope-tagged RANK (F-RANK616) and three C-terminal truncations, F-RANK330, F-RANK427, and F-RANK530, lacking 85, 188, and 285 amino acids, respectively. From this deletion analysis, we determined that TRAF2, TRAF6, and TRAF6 interact with RANK at its C-terminal 85-amino acid tail; the binding affinity appeared to be in the order of TRAF2 > TRAF5 > TRAF6, Furthermore, overexpression of RANK stimulated JNK and NF-kappa B activation. When the C-terminal tail, which is necessary for TRAF binding, was deleted, the truncated RANK receptor was still capable of stimulating JNK activity but not NF-kappa B, suggesting that interaction with TRAFs is necessary for NF-kappa B activation but not necessary for activation of the JNK pathway.	Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Texas System; UTMD Anderson Cancer Center; GlaxoSmithKline; Human Genome Sciences Inc	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Cytokine Res Lab, Box 143,1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@audumla.mdacc.tmc.edu	Aggarwal, Bharat B/G-3388-2013					Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Haridas V, 1998, J IMMUNOL, V160, P3152; Hsu HL, 1997, J BIOL CHEM, V272, P13471, DOI 10.1074/jbc.272.21.13471; Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Miller WE, 1998, MOL CELL BIOL, V18, P2835, DOI 10.1128/MCB.18.5.2835; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	23	349	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20551	20555		10.1074/jbc.273.32.20551	http://dx.doi.org/10.1074/jbc.273.32.20551			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685412	hybrid			2022-12-27	WOS:000075305400089
J	Zhang, Q; Cox, D; Tseng, CC; Donaldson, JG; Greenberg, S				Zhang, Q; Cox, D; Tseng, CC; Donaldson, JG; Greenberg, S			A requirement for ARF6 in Fc gamma receptor-mediated phagocytosis in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PERIPHERAL MEMBRANE-PROTEIN; BREFELDIN-A; GOLGI MEMBRANES; NUCLEOTIDE-EXCHANGE; GUANINE-NUCLEOTIDE; MOUSE MACROPHAGES; CELLS; APPARATUS; BINDING	Phagocytosis requires extension of F-actin-rich pseudopods and is accompanied by membrane fusion events. Members of the ARF family of GTPases are essential for many aspects of membrane trafficking. To test a role for this family of proteins in Fc gamma receptor-mediated phagocytosis, we utilized the fungal metabolite brefeldin A (BFA). The addition of 100 mu M BFA to a subclone of RAW 264.7 macrophages disrupted the appearance and function of the Golgi apparatus as indicated by altered immunofluorescent distribution of P-COP and reduced efflux of BODIPY C-5-ceramide, a phospholipid that normally accumulates in the Gels apparatus. In contrast, BFA had no effect on phagocytosis of IgG-coated erythrocytes. These results suggested that activation of BFA-sensitive ARFs is not required for phagocytosis, ARF6 is unique among members of the ARF family in that its membrane association is unaffected by BFA. Expression of ARF6 mutants defective in either GTP hydrolysis (Q67L) or binding (T27N) inhibited phagocytosis of IgG-coated erythrocytes and attenuated the focal accumulation of F-actin beneath the test particles. These results indicate a requirement for ARF6 in Fc gamma receptor-mediated phagocytosis and suggest that ARF6 is an important mediator of cytoskeletal alterations after Fc gamma receptor activation.	Columbia Univ, Dept Med & Pharmacol, Coll Phys & Surg, New York, NY 10032 USA; NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Columbia University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Greenberg, S (corresponding author), Columbia Univ, Dept Med & Pharmacol, Coll Phys & Surg, PH8C,630 W 168th St, New York, NY 10032 USA.	greenberg@cuccfa.ccc.columbia.edu		Cox, Dianne/0000-0002-0591-9767				Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DSOUZASCHOREY C, 1997, EMBO J, V16, P5448; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KTISTAKIS NT, 1995, MOL BIOL CELL, V6, P135, DOI 10.1091/mbc.6.2.135; MICHL J, 1983, J EXP MED, V157, P1746, DOI 10.1084/jem.157.6.1746; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006	35	168	170	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					19977	19981		10.1074/jbc.273.32.19977	http://dx.doi.org/10.1074/jbc.273.32.19977			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685333	hybrid			2022-12-27	WOS:000075305400010
J	Adachi, S; Gottlieb, RA; Babior, BM				Adachi, S; Gottlieb, RA; Babior, BM			Lack of release of cytochrome c from mitochondria into cytosol early in the course of fas-mediated apoptosis of jurkat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2; MEMBRANE	Several groups have reported that during apoptosis, cytochrome c is released from the mitochondria into the cytosol, but we have found that in apoptotic cells the cytochrome appears to remain with the mitochondria. In hopes of reconciling these findings, we compared the results obtained from cells disrupted by our method (nitrogen cavitation) with those obtained using the cell-disruption method employed by others (homogenization). We observed that at 2 h, cytochrome c levels in apoptotic cytosols from homogenized cells exceeded control levels, whereas cytochrome c levels in apoptotic cytosols from cavitated cells were similar to control. Outer membranes of homogenized mitochondria appeared damaged because the mitochondria had become permeable to cytochrome c, whereas outer membranes of cavitated mitochondria excluded the cytochrome. 4 h after Fas ligation, both cavitated and homogenized mitochondria had released small amounts of cytochrome c into the cytosol, whereas after 6 h the cytochrome had disappeared from the cell lysate. We believe that the differences between our results and those reported by others were due to 1) our examining the cells after a short (2 h) incubation with the anti-Fas antibody, and 2) our use of nitrogen cavitation instead of homogenization to disrupt the cells.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Adachi, S (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.				NIAID NIH HHS [AI-01345] Funding Source: Medline; NIA NIH HHS [AG-13501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013501] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; DUKE RC, 1992, CURRENT PROTOCOLS IM; Errede B, 1978, Methods Enzymol, V53, P40; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; WANG HG, 1996, BLOOD, V88, P449; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	13	56	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19892	19894		10.1074/jbc.273.31.19892	http://dx.doi.org/10.1074/jbc.273.31.19892			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677426	hybrid			2022-12-27	WOS:000075125200078
J	Beitner-Johnson, D; Millhorn, DE				Beitner-Johnson, D; Millhorn, DE			Hypoxia induces phosphorylation of the cyclic AMP response element-binding protein by a novel signaling mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; C-FOS TRANSCRIPTION; MAPKAP KINASE-2; GROWTH-FACTOR; MEMBRANE DEPOLARIZATION; REGULATE CREB; EXPRESSION; ACTIVATION; STRESS; IDENTIFICATION	To investigate signaling mechanisms by which hypoxia regulates gene expression, we examined the effect of hypoxia on the cyclic AMP response element-binding protein (CREB) in PC12 cells. Exposure to physiological levels of hypoxia (5% O-2, similar to 50 mm Hg) rapidly induced a persistent phosphorylation of CREB on Ser(133), an event that is required for CREB-mediated transcriptional activation. Hypoxia-induced phosphorylation of CREB was more robust than that induced by any other stimulus tested, including forskolin, depolarization, and osmotic stress. Furthermore, this effect was not mediated by any of the previously known signaling pathways that lead to phosphorylation of CREB, including protein kinase A, calcium/calmodulin-dependent protein kinase, protein kinase C, ribosomal Se kinase-2, and mitogen-activated protein kinase-activated protein kinase-a. Hypoxic activation of a CRE-containing reporter (derived from the 5'-flanking region of the tyrosine hydroxylase gene) was attenuated markedly by mutation of the CRE. Thus, a physiological reduction in O-2 levels induces a functional phosphorylation of CREB at Ser(133) via a novel signaling pathway.	Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	University of Cincinnati	Beitner-Johnson, D (corresponding author), Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, POB 67-0576, Cincinnati, OH 45267 USA.	dana.johnson@uc.edu			PHS HHS [RH37 L 33831] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; Conforti L, 1997, J PHYSIOL-LONDON, V502, P293, DOI 10.1111/j.1469-7793.1997.293bk.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; CZYZYKKRZESKA MF, 1992, J NEUROCHEM, V58, P1538, DOI 10.1111/j.1471-4159.1992.tb11376.x; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GIBSON GE, 1981, AM J MED, V70, P1247, DOI 10.1016/0002-9343(81)90834-2; GINTY DD, 1991, J BIOL CHEM, V266, P15325; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gudi T, 1996, J BIOL CHEM, V271, P4597; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P933; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; KIM KS, 1993, J BIOL CHEM, V268, P15689; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; NagamotoCombs K, 1997, J BIOL CHEM, V272, P6051, DOI 10.1074/jbc.272.9.6051; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Pende M, 1997, J NEUROSCI, V17, P1291; Raymond R, 1997, KIDNEY INT, V51, P536, DOI 10.1038/ki.1997.74; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sato N, 1997, BIOCHEM BIOPH RES CO, V232, P637, DOI 10.1006/bbrc.1997.6341; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Sun PQ, 1996, J BIOL CHEM, V271, P3066, DOI 10.1074/jbc.271.6.3066; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Walton M, 1996, MOL BRAIN RES, V43, P21, DOI 10.1016/S0169-328X(96)00144-1; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; XIE HJ, 1995, J IMMUNOL, V154, P1717; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON SO, 1992, NEURON, V14, P241; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658	56	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19834	19839		10.1074/jbc.273.31.19834	http://dx.doi.org/10.1074/jbc.273.31.19834			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677418	hybrid			2022-12-27	WOS:000075125200070
J	Gerik, KJ; Li, XY; Pautz, A; Burgers, PMJ				Gerik, KJ; Li, XY; Pautz, A; Burgers, PMJ			Characterization of the two small subunits of Saccharomyces cerevisiae DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYACRYLAMIDE-GEL ELECTROPHORESIS; C-TERMINAL REGION; REPLICATION FORK; CDC2 GENE; YEAST; PROTEIN; REPAIR; BINDING; SEPARATION	Yeast DNA polymerase delta (Pol delta) has three subunits of 125, 58, and 55 kDa, The gene for the 125-kDa catalytic subunit (POL3) has been known for several years. Here we describe the cloning of the genes for the 58- and 55-kDa subunits using peptide sequence analysis and searching of the yeast genome data base, The 58-kDa subunit, encoded by the POL31 gene, shows 23-28% sequence similarity to the 48-kDa subunit of:human PoL delta and to S. pombe Cdc1. POL31 is allelic to HYS2 and SDP5. The 55-kDa subunit is encoded by the POL32 gene (ORF YJR043c in the yeast data base). Very limited sequence similarity was observed between Pol32p and Schizosaccharomyces pombe Cdc27, the functionally analogous subunit in S. pombe Pol delta. The POL32 gene is not essential, but a deletion mutant shows cold sensitivity for growth and is sensitive to hydroxyurea and DNA damaging agents. in addition, lethality was observed when the POL32 deletion mutation was combined with conditional mutations in either the POL3 or POL31 gene. Pol32 Delta strains are weak antimutators and are defective for damage-induced mutagenesis. The POL32 gene product binds proliferating cell nuclear antigen. A gel filtration analysis showed that Pol32p is a dimer in solution, When POL31 and POL32 were co-expressed in Escherichia coli, a tetrameric (Pol31p.Pol32p)(2) species was detected by gel filtration, indicating that the two subunits form a complex.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Burgers, PMJ (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.		Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUILERA A, 1988, GENETICS, V119, P779; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, J BIOL CHEM, V263, P917; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; BURGERS PMJ, 1988, J BIOL CHEM, V263, P925; Burgers PMJ, 1995, METHOD ENZYMOL, V262, P49; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; Cuesta R, 1998, GENETICS, V148, P1007; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gibbs E, 1997, J BIOL CHEM, V272, P2373; GIOT L, 1995, MOL GEN GENET, V246, P212, DOI 10.1007/BF00294684; Giot L, 1997, GENETICS, V146, P1239; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; Halas A, 1997, CURR GENET, V31, P292, DOI 10.1007/s002940050208; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Hindges R, 1997, BIOL CHEM, V378, P345; Kaiser C., 1994, METHODS YEAST GENETI; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KOBAYASHI M, 1985, ANAL BIOCHEM, V145, P351, DOI 10.1016/0003-2697(85)90373-2; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; MORRISON A, 1989, J BACTERIOL, V171, P5659, DOI 10.1128/jb.171.10.5659-5667.1989; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; PERCIVAL KJ, 1989, J BIOL CHEM, V264, P2593; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SITNEY KC, 1989, CELL, V56, P599, DOI 10.1016/0092-8674(89)90582-5; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SUGIMOTO K, 1995, NUCLEIC ACIDS RES, V23, P3493, DOI 10.1093/nar/23.17.3493; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONBORSTEL RC, 1993, MUTAT RES, V289, P97, DOI 10.1016/0027-5107(93)90135-3; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; Zhou JQ, 1997, NUCLEIC ACIDS RES, V25, P1094, DOI 10.1093/nar/25.6.1094; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zuo SJ, 1997, P NATL ACAD SCI USA, V94, P11244, DOI 10.1073/pnas.94.21.11244	55	179	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19747	19755		10.1074/jbc.273.31.19747	http://dx.doi.org/10.1074/jbc.273.31.19747			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677405	hybrid			2022-12-27	WOS:000075125200057
J	Wower, IK; Wower, J; Zimmermann, RA				Wower, IK; Wower, J; Zimmermann, RA			Ribosomal protein L27 participates in both 50 S subunit assembly and the peptidyl transferase reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA; CROSS-LINKING; A-SITE; PEPTIDYLTRANSFERASE ACTIVITY; PUROMYCIN REACTION; 23S RNA; 2-IMINOTHIOLANE; COMPONENTS; RECONSTITUTION	Protein L27 has been implicated as a constituent of the peptidyl transferase center of the Escherichia coli 50 S ribosomal subunit by a variety of experimental observations. To define better the functional role! of this protein, we constructed a strain in which the rpmA gene, which encodes L27, was replaced by a kanamycin resistance marker. The deletion mutant grows five to six times slower than the wild-type parent and is both cold-and temperature-sensitive. This phenotype is reversed when L27 is expressed from a plasmid-borne copy of the rpmA gene. Analysis of ribosomes from the L27-lacking strain revealed deficiencies in both the assembly and activity of the 50 S ribosomal subunits. Although functional 50 S subunits are formed in the mutant, an assembly "bottleneck" was evidenced by the accumulation of a prominent 40 S precursor to the 50 S subunit which was deficient in proteins Lie, L20, and L21, as web as L27. In addition, the peptidyl transferase activity of 70 S ribosomes containing mutant 50 S subunits was determined to be three to four times lower than for wild-type ribosomes, Ribosomes lacking L27 were found to be impaired in the enzymatic binding of Phe-tRNA(Phe) to the A site, although the interaction of N-acetyl-Phe-tRNA(Phe) with the P site was largely unperturbed. We therefore infer that L27 contributes to peptide bond formation by facilitating the proper placement of the acceptor end of the A-site tRNA at the peptidyl transferase center.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Zimmermann, RA (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.	zimmermann@biochem.umass.edu			NIGMS NIH HHS [GM22807] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022807] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN PN, 1991, CELL, V66, P141, DOI 10.1016/0092-8674(91)90146-P; AREVALO MA, 1989, J MED CHEM, V32, P2200, DOI 10.1021/jm00129a027; BISCHOF O, 1995, J BIOL CHEM, V270, P23060, DOI 10.1074/jbc.270.39.23060; CHEN R, 1975, FEBS LETT, V59, P96, DOI 10.1016/0014-5793(75)80349-8; COOPERMAN BS, 1988, METHOD ENZYMOL, V164, P341; DABBS ER, 1983, MOL GEN GENET, V192, P301, DOI 10.1007/BF00392166; GEYL D, 1981, MOL GEN GENET, V181, P309, DOI 10.1007/BF00425603; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GULLE H, 1988, NUCLEIC ACIDS RES, V16, P815, DOI 10.1093/nar/16.3.815; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HEROLD M, 1987, J BIOL CHEM, V262, P8826; JEONG JH, 1993, DNA SEQUENCE, V4, P59, DOI 10.3109/10425179309015624; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEDER P, 1966, BIOCHEM BIOPH RES CO, V25, P233, DOI 10.1016/0006-291X(66)90586-9; Mason TL, 1996, EXPERIENTIA, V52, P1148, DOI 10.1007/BF01952114; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; NICHOLSON AW, 1978, FEBS LETT, V90, P203, DOI 10.1016/0014-5793(78)80369-X; NIERHAUS KH, 1973, J MOL BIOL, V74, P587; NIRENBERG MW, 1964, SCIENCE, V145, P1399, DOI 10.1126/science.145.3639.1399; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OSSWALD M, 1990, NUCLEIC ACIDS RES, V18, P6755; Rappoport S, 1974, Methods Enzymol, V29, P685; RODNINA MV, 1992, J MOL BIOL, V228, P450, DOI 10.1016/0022-2836(92)90834-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SEMENKOV Y, 1992, FEBS LETT, V296, P207, DOI 10.1016/0014-5793(92)80380-Y; SEMENKOV YP, 1992, BIOCHIMIE, V74, P411, DOI 10.1016/0300-9084(92)90080-X; SONENBERG N, 1973, P NATL ACAD SCI USA, V70, P1423, DOI 10.1073/pnas.70.5.1423; STOFFLER G, 1986, STRUCTURE FUNCTION G, P28; SYLVERS LA, 1989, FEBS LETT, V245, P9, DOI 10.1016/0014-5793(89)80180-2; SZER W, 1972, BIOCHIM BIOPHYS ACTA, V259, P357, DOI 10.1016/0005-2787(72)90310-3; TEJEDOR F, 1985, BIOCHEMISTRY-US, V24, P467, DOI 10.1021/bi00323a033; TOTH MJ, 1986, J BIOL CHEM, V261, P6643; WALLECZEK J, 1989, J BIOL CHEM, V264, P4231; WALLECZEK J, 1989, BIOCHEMISTRY-US, V28, P4099, DOI 10.1021/bi00435a071; WOWER I, 1981, NUCLEIC ACIDS RES, V9, P4285, DOI 10.1093/nar/9.17.4285; WOWER J, 1988, BIOCHEMISTRY-US, V27, P8114, DOI 10.1021/bi00421a021; WOWER J, 1993, TRANSLATIONAL APPARATUS, P455; Wower J, 1995, BIOCHEM CELL BIOL, V73, P1041, DOI 10.1139/o95-111; WOWER J, 1993, EMBO J, V12, P617, DOI 10.1002/j.1460-2075.1993.tb05694.x; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135	45	62	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19847	19852		10.1074/jbc.273.31.19847	http://dx.doi.org/10.1074/jbc.273.31.19847			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677420	hybrid			2022-12-27	WOS:000075125200072
J	Lange, Y; Ye, J; Steck, TL				Lange, Y; Ye, J; Steck, TL			Circulation of cholesterol between lysosomes and the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPROTEIN-DERIVED CHOLESTEROL; CULTURED HUMAN-FIBROBLASTS; INTRACELLULAR-TRANSPORT; LDL CHOLESTEROL; CELLS; TRAFFICKING; STORAGE; SUPPRESSION; HOMEOSTASIS; ENDOCYTOSIS	The cholesterol in the lysosomes of cultured human fibroblasts was determined to constitute similar to 6% of the cell total. This pool was enlarged by as much as 10-fold in Niemann-Pick type C cells. Certain amphiphiles (e.g. U18666A, progesterone, and imipramine) caused lysosomal cholesterol to increase to similarly high levels at a rate of similar to 0.8% of cell cholesterol/h. Lysosomal cholesterol accumulated even in the absence of exogenous lipoproteins. Furthermore, nearly all of the lysosomal cholesterol in both of the two perturbed systems was shown to be derived from the plasma membrane. Oxysterols known to alter cholesterol movement and homeostasis blocked lysosomal cholesterol accretion in amphiphile-treated cells, suggesting that this process is regulated physiologically. Treating cells with amphiphiles slightly reduced the efflux of cholesterol from lysosomes and slightly increased the influx from the plasma membrane, causing the lysosomal cholesterol compartment to double in size in similar to 15 h. After more prolonged amphiphile treatments, a population of buoyant lysosomes appeared that exchanged cholesterol with the plasma membrane completely but slowly, Niemann-Pick type C lysosomes were similarly buoyant and sluggish. We conclude that cholesterol circulates bidirectionally between the plasma membrane and lysosomes. The massive accumulation of lysosomal cholesterol in the perturbed cells does not appear to reflect disabled lysosomal transport but rather the formation of lysosomes modified for lipid storage, i.e. lamellar bodies.	Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	Rush University; Rush University; University of Chicago	Lange, Y (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Pathol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Lange, Yvonne/A-7794-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL028448, R01HL028448] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL028448] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELSON M, 1995, J BIOL CHEM, V270, P15102, DOI 10.1074/jbc.270.25.15102; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Crawford JM, 1996, SEMIN LIVER DIS, V16, P169, DOI 10.1055/s-2007-1007230; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DRAYE JP, 1987, EUR J BIOCHEM, V170, P405, DOI 10.1111/j.1432-1033.1987.tb13714.x; DRAYE JP, 1988, J CELL BIOL, V107, P2109, DOI 10.1083/jcb.107.6.2109; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; FREEMAN DA, 1989, ENDOCRINOLOGY, V124, P2527, DOI 10.1210/endo-124-5-2527; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HRUBAN Z, 1984, ENVIRON HEALTH PERSP, V55, P53, DOI 10.2307/3429692; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; LANGE Y, 1988, J BIOL CHEM, V263, P9366; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1991, J BIOL CHEM, V266, P21439; Lange Y, 1996, TRENDS CELL BIOL, V6, P205, DOI 10.1016/0962-8924(96)20016-9; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; PADH H, 1993, J BIOL CHEM, V268, P6742; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; SANDHOFF K, 1994, FEBS LETT, V346, P103, DOI 10.1016/0014-5793(94)00282-7; SCHMITZ G, 1991, J LIPID RES, V32, P1539; SHANG TY, 1997, ANN REV BIOCH, V66, P613; SLOTTE JP, 1987, BIOCHEM J, V248, P237, DOI 10.1042/bj2480237; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THILO L, 1985, BIOCHIM BIOPHYS ACTA, V822, P243, DOI 10.1016/0304-4157(85)90010-3; TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Underwood KW, 1998, J BIOL CHEM, V273, P4266, DOI 10.1074/jbc.273.7.4266; VAN MEER G, 1989, ANNU REV CELL BIOL, V5, P247, DOI 10.1146/annurev.cellbio.5.1.247	47	105	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18915	18922		10.1074/jbc.273.30.18915	http://dx.doi.org/10.1074/jbc.273.30.18915			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668068	hybrid			2022-12-27	WOS:000074974700035
J	Perrier, V; Burlacu-Miron, S; Bourgeois, S; Surewicz, WK; Gilles, AM				Perrier, V; Burlacu-Miron, S; Bourgeois, S; Surewicz, WK; Gilles, AM			Genetically engineered zinc-chelating adenylate kinase from Escherichia coli with enhanced thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR ANALYSIS; BACILLUS-SUBTILIS; BINDING; PROTEINS; GENE; BACTERIOPHAGE-T4; CATALYSIS; SEQUENCE; CLONING; COMPLEX	In contrast with adenylate kinase from Gram-negative bacteria, the enzyme from Gram-positive organisms harbors a structural Zn2+ bound to 3 or 4 Cys residues in the structural motif Cys-X-2-Cys-X-16-Cys-X-2-Cys/Asp. Site-directed mutagenesis of His(126), Ser(129), Asp(146), and Thr(149) (corresponding to Cys(130), Cys(133), Cys(150), and Cys(153) in adenylate kinase from Bacillus stearothermophilus) in Escherichia coli adenylate kinase was undertaken for determining whether the presence of Cys residues is the only prerequisite to bind zinc or (possible) other cations. A number of variants of adenylate kinase from E. coli, containing 1-4 Cys residues were obtained, purified, and analyzed for metal content, structural integrity, activity, and thermodynamic stability. All mutants bearing 3 or 4 cysteine residues acquired zinc binding properties. Moreover, the quadruple mutant exhibited a remarkably high thermal stability as compared with the wild-type form with preservation of the kinetic parameters of the parent enzyme.	Inst Pasteur, Lab Chim Struct Macromol, F-75724 Paris 15, France; Inst Curie Rech, INSERM, U350, F-91405 Orsay, France; Inst Natl Agron, Ctr Grignon, Lab Sci Sols & Hydrol, F-78850 Thiverval Grignon, France; Univ Missouri, Dept Ophthalmol, Columbia, MO 65212 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; AgroParisTech; University of Missouri System; University of Missouri Columbia	Gilles, AM (corresponding author), Inst Pasteur, Lab Chim Struct Macromol, 28 Rue Dr Roux, F-75724 Paris 15, France.	amgilles@pasteur.fr	Miron, Simona/M-9223-2018; Perrier, Veronique/AAK-3594-2020	perrier, veronique/0000-0002-6570-7504				BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Boyer P.D, 1973, ENZYMES, P279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNE M, 1985, NUCLEIC ACIDS RES, V13, P7139, DOI 10.1093/nar/13.19.7139; Burlacu-Miron S, 1998, J BIOL CHEM, V273, P19102, DOI 10.1074/jbc.273.30.19102; Deligiannakis Y, 1997, BIOCHEMISTRY-US, V36, P9446, DOI 10.1021/bi970021e; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GILLES AM, 1993, EUR J BIOCHEM, V218, P921, DOI 10.1111/j.1432-1033.1993.tb18448.x; GILLES AM, 1994, J BACTERIOL, V176, P520, DOI 10.1128/JB.176.2.520-523.1994; GLASER P, 1992, BIOCHEMISTRY-US, V31, P3038, DOI 10.1021/bi00127a002; HAASE GHW, 1989, J MOL BIOL, V207, P151, DOI 10.1016/0022-2836(89)90446-4; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HUNT JB, 1984, J BIOL CHEM, V259, P4793; KLEMBA M, 1995, NAT STRUCT BIOL, V2, P368, DOI 10.1038/nsb0595-368; KOIVULA T, 1991, J GEN MICROBIOL, V137, P2595, DOI 10.1099/00221287-137-11-2595; KONRAD M, 1993, J BIOL CHEM, V268, P11326; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASKELL DJ, 1991, MOL MICROBIOL, V5, P1013, DOI 10.1111/j.1365-2958.1991.tb01874.x; Miller J.H., 1972, EXPT MOL GENETICS; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4; NAKAMURA K, 1990, J BIOCHEM-TOKYO, V107, P603; PERRIER V, 1994, BIOCHEMISTRY-US, V33, P9960, DOI 10.1021/bi00199a019; RALEIGH EA, 1989, CURRENT PROTOCOLS MO; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; SAINTGIRONS I, 1987, J BIOL CHEM, V262, P622; Schlauderer GJ, 1996, PROTEIN SCI, V5, P434; SCHULZ GE, 1990, J MOL BIOL, V213, P627, DOI 10.1016/S0022-2836(05)80250-5; SCHULZ GE, 1986, EUR J BIOCHEM, V161, P127, DOI 10.1111/j.1432-1033.1986.tb10132.x; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOMASSELLI AG, 1986, FEBS LETT, V202, P303, DOI 10.1016/0014-5793(86)80706-2; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1993, P NATL ACAD SCI USA, V90, P2715, DOI 10.1073/pnas.90.7.2715; VALLEE BL, 1993, BIOCHEMISTRY-US, V32, P6493, DOI 10.1021/bi00077a001; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2	41	23	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19097	19101		10.1074/jbc.273.30.19097	http://dx.doi.org/10.1074/jbc.273.30.19097			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668094	hybrid			2022-12-27	WOS:000074974700061
J	Favata, MF; Horiuchi, KY; Manos, EJ; Daulerio, AJ; Stradley, DA; Feeser, WS; Van Dyk, DE; Pitts, WJ; Earl, RA; Hobbs, F; Copeland, RA; Magolda, RL; Scherle, PA; Trzaskos, JM				Favata, MF; Horiuchi, KY; Manos, EJ; Daulerio, AJ; Stradley, DA; Feeser, WS; Van Dyk, DE; Pitts, WJ; Earl, RA; Hobbs, F; Copeland, RA; Magolda, RL; Scherle, PA; Trzaskos, JM			Identification of a novel inhibitor of mitogen-activated protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; GROWTH-FACTOR; IN-VITRO; MECHANISMS; CELLS; PATHWAYS; RECEPTOR; GLUCOCORTICOIDS; PROLIFERATION; TRANSCRIPTION	The compound U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene) was identified as an inhibitor of AP-1 transactivation in a cell-based reporter assay. U0126 was also shown to inhibit endogenous promoters containing AP-1 response elements but did not affect genes lacking an AP-1 response element in their promoters. These effects of U0126 result from direct inhibition of the mitogen-activated protein kinase kinase family members, MEK-1 and MEK-2. Inhibition is selective for MEK-1 and -2, as U0126 shows little, if any, effect on the kinase activities of protein kinase C, Abl, Raf, MEKK, ERK, JNK, MKK-3, MKK-4/SEK, MKK6, Cdk2, or Cdk4. Comparative kinetic analysis of U0126 and the MEK inhibitor PD098059 (Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci U. S. A. 92, 7686-7689) demonstrates that U0126 and PD098059 are noncompetitive inhibitors with respect to both MEK substrates, ATP and ERK. We further demonstrate that the two compounds bind to S218E/S222D MEK in a mutually exclusive fashion, suggesting that they may share a common or overlapping binding site(s). Quantitative evaluation of the steady state kinetics of MEK inhibition by these compounds reveals that U0126 has approximately 100-fold higher affinity for Delta N3-S218E/S222D MEK than does PD098059. We further tested the effects of these compounds on the activity of wild type MEK isolated after activation from stimulated cells. Surprisingly, we observe a significant diminution in affinity of both compounds for wild type MEK as compared with the Delta N3-S218E/S222D mutant enzyme. These results suggest that the affinity of both compounds is mediated by subtle conformational differences between the two activated MEK forms. The MEK affinity of U0126, its selectivity for MEK over other kinases, and its cellular efficacy suggest that this compound will serve as a powerful tool for in vitro and cellular investigations of mitogen-activated protein kinase-mediated signal transduction.	Dupont Merck Res Labs, Inflammatory Dis Res, Wilmington, DE 19880 USA; Dupont Merck Res Labs, Chem Enzymol, Wilmington, DE 19880 USA; Dupont Merck Res Labs, Chem & Phys Sci, Wilmington, DE 19880 USA		Trzaskos, JM (corresponding author), Dupont Merck Res Labs, Inflammatory Dis Res, POB 80400, Wilmington, DE 19880 USA.			Pitts, William/0000-0002-1034-6043				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; BAXTER JD, 1976, PHARMACOL THER PT B, V2, P605, DOI 10.1016/0306-039X(76)90010-6; BEHRENS TW, 1989, ARTHRITIS ALLIED CON, P604; BELL JE, 1988, PROTEINS ENZYMES, P378; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; Brattsand R, 1996, ALIMENT PHARM THERAP, V10, P81, DOI 10.1046/j.1365-2036.1996.22164025.x; BURT DW, 1989, J BIOL CHEM, V264, P7357; Carlson BA, 1996, CANCER RES, V56, P2973; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; CATO ACB, 1992, PROG NUCL ACID RES M, V43; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P187; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7868; Dumont FJ, 1998, J IMMUNOL, V160, P2579; FANGER GR, 1997, GENET DEV, V7, P67; FULLER PJ, 1991, FASEB J, V5, P3902; GEHRING U, 1987, TRENDS BIOCHEM SCI, V12, P399, DOI 10.1016/0968-0004(87)90195-2; Graf K, 1997, HYPERTENSION, V29, P334, DOI 10.1161/01.HYP.29.1.334; Granner D. K., 1970, METHODS ENZYMOL    A, V17, P633; HANDEL ML, 1993, AGENTS ACTIONS, V680, P219; HERRLICH P, 1994, TRENDS ENDOCRIN MET, V5, P341, DOI 10.1016/1043-2760(94)90164-3; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kuroki M, 1997, BIOCHEM BIOPH RES CO, V232, P474, DOI 10.1006/bbrc.1997.6296; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MANGELSDORF DJ, 1995, CELL, V83, P385; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MIDDLETON WJ, 1958, J AM CHEM SOC, V80, P2783, DOI 10.1021/ja01544a053; MIDDLETON WJ, 1958, J AM CHEM SOC, V80, P2822, DOI 10.1021/ja01544a058; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PARRILLO JE, 1979, ANNU REV PHARMACOL, V19, P179, DOI 10.1146/annurev.pa.19.040179.001143; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RINGOLD GM, 1985, ANNU REV PHARMACOL, V25, P529, DOI 10.1146/annurev.pa.25.040185.002525; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Simon C, 1996, CANCER RES, V56, P5369; Vincenti MP, 1996, CRIT REV EUKAR GENE, V6, P391, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.40; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9; ZHANG C, 1993, J BIOL CHEM, V268, P11435	49	2703	2769	3	126	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18623	18632		10.1074/jbc.273.29.18623	http://dx.doi.org/10.1074/jbc.273.29.18623			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660836	hybrid			2022-12-27	WOS:000074828500091
J	Schedlich, LJ; Young, TF; Firth, SM; Baxter, RC				Schedlich, LJ; Young, TF; Firth, SM; Baxter, RC			Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR A-CHAIN; CANCER CELLS; IGF-I; ENDOTHELIAL-CELLS; RETINOIC ACID; HUMAN-PLASMA; RECEPTORS; LOCALIZATION; FIBROBLASTS; INHIBITION	Insulin-like growth factor-binding proteins (IGFBPs) play an integral role in modifying insulin-like growth factor actions in a wide variety of cell types. Recent evidence suggests that IGFBP-3 and IGFBP-5 also have effects on cell growth that are insulin-like growth factor-independent. In investigating possible mechanisms for this effect, the intracellular trafficking of IGFBP-3 and IGFBP-5, both of which contain sequences with the potential for nuclear localization, was studied in T47D cells. Nuclear uptake of fluorescently labeled IGFBP-3 and IGFBP-5 was observed in a proportion of T47D cells that appeared to be rapidly dividing. IGFBP-1 and IGFBP-2, which do not possess the putative domain for nuclear translocation, were not transported to the nuclei of T47D cells. When T47D cells were preincubated with excess unlabeled IGFBP-3, nuclear localization of labeled IGFBP-3 or IGFBP-5 was not detected, indicating that their nuclear translocation involves a common pathway, Inhibition of receptor-mediated endocytosis did not affect nuclear uptake of IGFBP-3, suggesting that it uses an alternative non-classical import pathway for transport across the plasma membrane. In addition, a variant form of IGFBP-3 with a mutation in the putative nuclear localization sequence was unable to translocate to the nuclei of T47D cells, suggesting that nuclear translocation of IGFBP-3 was dependent on these carboxyl-terminal basic residues.	Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Sydney, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Schedlich, LJ (corresponding author), Royal N Shore Hosp, Kolling Inst Med Res, St Leonards, NSW 2065, Australia.		Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142				ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P423, DOI 10.1210/jcem-65-3-423; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; Baxter Robert C., 1995, Progress in Growth Factor Research, V6, P215, DOI 10.1016/0955-2235(95)00004-6; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; Gucev ZS, 1996, CANCER RES, V56, P1545; GUI GPH, 1995, BRIT J SURG, V82, P1192, DOI 10.1002/bjs.1800820914; GuiochonMantel A, 1996, J STEROID BIOCHEM, V56, P3, DOI 10.1016/0960-0760(95)00268-5; GURWELL JA, 1993, DEV BRAIN RES, V76, P293, DOI 10.1016/0165-3806(93)90222-V; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Ho PJ, 1997, CLIN ENDOCRINOL, V46, P333; IMAMURA T, 1994, EXP CELL RES, V215, P363, DOI 10.1006/excr.1994.1353; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JIN MJ, 1993, J BIOL CHEM, V268, P18390; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JOSEPH DR, 1996, ENDOCRINOLOGY, V137, P1318; Li WL, 1997, ENDOCRINOLOGY, V138, P1763, DOI 10.1210/en.138.4.1763; MAHER DW, 1989, MOL CELL BIOL, V9, P2251, DOI 10.1128/MCB.9.5.2251; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1995, ENDOCRINOLOGY, V136, P1219, DOI 10.1210/en.136.3.1219; MARTIN JL, 1992, ENDOCRINOLOGY, V131, P1703, DOI 10.1210/en.131.4.1703; MASSAGUE J, 1982, J BIOL CHEM, V257, P5038; MILLER DS, 1988, SCIENCE, V240, P506, DOI 10.1126/science.2451860; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; OH Y, 1993, J BIOL CHEM, V268, P26045; OH Y, 1995, J BIOL CHEM, V270, P13589, DOI 10.1074/jbc.270.23.13589; OH YM, 1993, J BIOL CHEM, V268, P14964; RADULESCU RT, 1994, TRENDS BIOCHEM SCI, V19, P278, DOI 10.1016/0968-0004(94)90004-3; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; SOLER AP, 1989, P NATL ACAD SCI USA, V86, P6640, DOI 10.1073/pnas.86.17.6640; SULLIVAN PM, 1993, MOL ENDOCRINOL, V7, P702, DOI 10.1210/me.7.5.702; TUREK JJ, 1993, J CELL SCI, V106, P423; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; WRAIGHT CJ, 1997, 4 INT S INS LIK GROW, P139	51	219	223	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18347	18352		10.1074/jbc.273.29.18347	http://dx.doi.org/10.1074/jbc.273.29.18347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660801	hybrid			2022-12-27	WOS:000074828500056
J	Reed, AL; Yamazaki, H; Kaufman, JD; Rubinstein, Y; Murphy, B; Johnson, AC				Reed, AL; Yamazaki, H; Kaufman, JD; Rubinstein, Y; Murphy, B; Johnson, AC			Molecular cloning and characterization of a transcription regulator with homology to GC-binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR GENE; PROTO-ONCOGENE; CELL-LINES; REPRESSES TRANSCRIPTION; MESSENGER-RNA; RETINOIC ACID; HUMAN P53; PROMOTER; IDENTIFICATION	GC-binding factor (GCF) represses transcription of certain genes and is encoded by a 3.0-kilobase mRNA (Kageyama, R., and Pastan, I. (1989) Cell 59, 815-825). The GCF cDNA hybridizes to two additional mRNA species, 4.2 and 1.2 kilobases. We have used differential hybridization to identify a cDNA clone (termed GCF2) for the 4.2-kilobase mRNA and find that it is highly expressed in HUT-102 cells. The open reading frame consists of 2256 nucleotides and encodes a protein of 752 amino acids with a calculated molecular mass of 83 kilodaltons. GCF2 expressed in vitro using reticulocyte lysates and Escherichia coli migrates as a 160-kilodalton protein in SDS-polyacrylamide gel electrophoresis but has a molecular mass of 83 kilodaltons as determined by mass spectrum analysis. GCF2 binds to epidermal growth factor receptor promoter fragments, and the major binding site is located between nucleotides -249 and -233. Cotransfection assays show that GCF2 acts to repress transcription from the epidermal growth factor receptor promoter in constructs containing the major GCF2 binding site and not when the site had been mutated. Thus, GCF2 is a newly identified transcriptional repressor with aberrant electrophoretic mobility.	NCI, Mol Biol Lab, DBS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Johnson, AC (corresponding author), NCI, Mol Biol Lab, DBS, NIH, Bldg 37,Rm 2D18,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAIROCH A, 1993, NUCLEIC ACIDS RES, V21, P3097, DOI 10.1093/nar/21.13.3097; BURTON Z, 1981, NUCLEIC ACIDS RES, V9, P2889, DOI 10.1093/nar/9.12.2889; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN LL, 1993, CELL GROWTH DIFFER, V4, P975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DEB SP, 1994, ONCOGENE, V9, P1341; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HOU XY, 1994, CELL GROWTH DIFFER, V5, P801; HOU XY, 1994, J BIOL CHEM, V269, P4307; Hudson L G, 1991, Genet Eng (N Y), V13, P137; HUDSON LG, 1990, P NATL ACAD SCI USA, V87, P7536, DOI 10.1073/pnas.87.19.7536; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JOHNSON AC, 1988, BIOCHEM BIOPH RES CO, V150, P412, DOI 10.1016/0006-291X(88)90536-0; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; JOHNSON AC, 1988, J BIOL CHEM, V263, P5693; JOHNSON AC, 1992, J BIOL CHEM, V267, P1689; Johnson AC, 1996, J BIOL CHEM, V271, P3033; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KING CR, 1985, NUCLEIC ACIDS RES, V13, P8477, DOI 10.1093/nar/13.23.8477; KITADAI Y, 1993, CELL GROWTH DIFFER, V4, P291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Merlino G T, 1990, Semin Cancer Biol, V1, P277; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; Shibutani M, 1998, J BIOL CHEM, V273, P6878, DOI 10.1074/jbc.273.12.6878; SUBLER MA, 1994, ONCOGENE, V9, P1351; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	45	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21594	21602		10.1074/jbc.273.34.21594	http://dx.doi.org/10.1074/jbc.273.34.21594			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705290	hybrid			2022-12-27	WOS:000075492600024
J	Godbout, R; Packer, M; Bie, WJ				Godbout, R; Packer, M; Bie, WJ			Overexpression of a DEAD box protein (DDX1) in neuroblastoma and retinoblastoma cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOGENEOUSLY STAINING REGIONS; DEPENDENT RNA HELICASE; N-MYC; AMPLIFICATION UNITS; MESSENGER-RNAS; GENE DDX1; COAMPLIFICATION; INITIATION; AMPLICON; ENCODES	The DEAD box gene, DDX1, is a putative RNA helicase that is co-amplified with MYCN in a subset of retinoblastoma (RE) and neuroblastoma (NB) tumors and cell lines. Although gene amplification usually involves hundreds to thousands of kilobase pairs of DNA, a number of studies suggest that co amplified genes are only overexpressed if they provide a selective advantage to the cells in which they are amplified. Here, we further characterize DDX1 by identifying its putative transcription and translation initiation sites. We analyze DDX1 protein levels in MYCN/DDX1-amplified NE and RE cell lines using polyclonal antibodies specific to DDX1 and show that there is a good correlation with DDXI gene copy number, DDXI transcript levels, and DDXI protein levels in all cell lines studied. DDXI protein is found in both the nucleus and cytoplasm of DDX1-amplified lines but is localized primarily to the nucleus of nonamplified cells. Our results indicate that DDX1 may be involved in either the formation or progression of a subset of NE and RE tumors and suggest that DDXI normally plays a role in the metabolism of RNAs located in the nucleus of the cell.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Edmonton, AB T6G 1Z2, Canada	University of Alberta; University of Alberta	Godbout, R (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.		Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				AKAO Y, 1992, CANCER RES, V52, P6083; AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; Arai Y, 1997, BLOOD, V89, P3936, DOI 10.1182/blood.V89.11.3936; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUELT MK, 1994, J BIOL CHEM, V269, P29367; COHN SL, 1991, PROG CLIN BIOL RES, V366, P21; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; DAN L, 1992, NUCLEIC ACIDS RES, V20, P1967, DOI 10.1093/nar/20.8.1967; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; Favaloro J, 1980, Methods Enzymol, V65, P718; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GODBOUT R, 1994, GENE, V138, P243, DOI 10.1016/0378-1119(94)90816-8; GODBOUT R, 1995, EXP EYE RES, V60, P645, DOI 10.1016/S0014-4835(05)80006-5; Graham J., 1984, CENTRIFUGATION PRACT, P161; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; JAMIESON DJ, 1991, NATURE, V349, P715, DOI 10.1038/349715a0; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuroda H, 1996, ONCOGENE, V13, P1561; LEROY P, 1989, CELL, V57, P549, DOI 10.1016/0092-8674(89)90125-6; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; Missel A, 1997, MOL CELL BIOL, V17, P4895, DOI 10.1128/MCB.17.9.4895; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; Pandita A, 1997, GENE CHROMOSOME CANC, V20, P243, DOI 10.1002/(SICI)1098-2264(199711)20:3<243::AID-GCC4>3.0.CO;2-2; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rafti F, 1996, GENE, V171, P225, DOI 10.1016/0378-1119(96)00034-0; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SQUIRE JA, 1995, ONCOGENE, V10, P1417; STRAUSS EJ, 1994, NUCLEIC ACIDS RES, V22, P3187, DOI 10.1093/nar/22.15.3187; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; ZEHNBAUER BA, 1988, MOL CELL BIOL, V8, P522, DOI 10.1128/MCB.8.2.522	56	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21161	21168		10.1074/jbc.273.33.21161	http://dx.doi.org/10.1074/jbc.273.33.21161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694872	hybrid			2022-12-27	WOS:000075386100065
J	Howe, L; Ranalli, TA; Allis, CD; Ausio, J				Howe, L; Ranalli, TA; Allis, CD; Ausio, J			Transcriptionally active Xenopus laevis somatic 5 S ribosomal RNA genes are packaged with hyperacetylated histone H4, whereas transcriptionally silent oocyte genes are net	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLATION; NUCLEOSOME; CHROMATIN	The relationship between histone acetylation and transcription of the Xenopus laevis oocyte and somatic 5 S ribosomal RNA genes was investigated, Chromatin fragments from a X. laevis kidney cell line were immunoprecipitated with an antibody specific for hyperacetylated histone H4. The DNA from the hyperacetylated chromatin was probed with both oocyte- and somatic gene-specific sequences, and the results showed that the upstream, nontranscribed region of the transcriptionally active somatic genes is packaged with acetylated histone H4. In contrast, the corresponding region of the transcriptionally silent oocyte genes is packaged with hypoacetylated histone H4 in this cells line. Further study also showed that this region of the oocyte genes was less sensitive to digestion with the enzyme, micrococcal nuclease, Together these results suggest that, as described for both RNA polymerase I and II transcribed genes, there is a correlation between histone acetylation and transcription of the RNA polymerase III transcribed 5 S ribosomal RNA genes in X. laevis.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Victoria; University of Rochester	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.							AUSIO J, 1992, J CELL SCI, V102, P1; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON AL, 1993, FEBS LETT, V336, P23, DOI 10.1016/0014-5793(93)81601-U; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; ENGELKE DR, 1990, NUCLEIC ACIDS RES, V18, P6031, DOI 10.1093/nar/18.20.6031; FORD PJ, 1976, NATURE, V261, P433, DOI 10.1038/261433a0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; Mutskov VJ, 1996, J BIOL CHEM, V271, P11852, DOI 10.1074/jbc.271.20.11852; PECK LJ, 1994, NUCLEIC ACIDS RES, V11, P443; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; REYNOLDS WF, 1982, CELL NUCLEUS, V11, P63; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; TURNER BM, 1991, J CELL SCI, V99, P13; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; WOLFFE AP, 1990, J BIOL CHEM, V265, P4592; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414; WORMINGTON WM, 1983, DEV BIOL, V99, P248, DOI 10.1016/0012-1606(83)90273-7	27	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20693	20696		10.1074/jbc.273.33.20693	http://dx.doi.org/10.1074/jbc.273.33.20693			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694810	hybrid			2022-12-27	WOS:000075386100003
J	Jonk, LJC; Itoh, S; Heldin, CH; ten Dijke, P; Kruijer, W				Jonk, LJC; Itoh, S; Heldin, CH; ten Dijke, P; Kruijer, W			Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; FAMILY; ACTIVATION; EXPRESSION; MEMBERS; ANTAGONIST; CELLS; GENE; SP1; BMP	Smad proteins have been identified as mediators of intracellular signal transduction by members of the transforming growth factor-beta (TGF-beta) superfamily, which affect cell proliferation, differentiation, as well as pattern formation during early vertebrate development. Following receptor activation, Smads are assembled into heteromeric complexes consisting of a pathway-restricted Smad and the common Smad4 that are subsequently translocated into the nucleus where they are thought to play an important role in gene transcription. Here we report the identification of Smad Binding Elements (SBEs) composed of the sequence CAGACA in the promoter of the JunB gene, an immediate early gene that is potently induced by TGF-beta, activin, and bone morphogenetic protein (BMP) 2, Two JunB SBEs are arranged as an inverted repeat that is transactivated in response to Smad3 and Smad4 co-overexpression and shows inducible binding of a Smad3- and Smad4-containing complex in nuclear extracts from TGF-beta-treated cells. Bacterial-expressed Smad proteins bind directly to the SEE. Multimerization of the SEE creates a powerful TGF-beta-inducible enhancer that is also responsive to activin and BMPs. The identification of the sequence CAGACA as a direct binding site for Smad proteins will facilitate the identification of regulatory elements in genes that are activated by members of the TGF-beta superfamily.	Groningen Biomol Sci & Biotechnol Inst, Dept Dev Genet, NL-9750 AA Haren, Netherlands; Ludwig Inst Canc Res, Biomed Ctr, S-7524 Uppsala, Sweden	University of Groningen; Ludwig Institute for Cancer Research	Kruijer, W (corresponding author), Groningen Biomol Sci & Biotechnol Inst, Dept Dev Genet, POB 14, NL-9750 AA Haren, Netherlands.	w.kruijer@biol.rug.nl	Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X; Itoh, Susumu/0000-0002-7967-0730				Alevizopoulos A, 1997, BIOESSAYS, V19, P581, DOI 10.1002/bies.950190709; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P128; BOER PH, 1990, BIOCHEM GENET, V28, P299, DOI 10.1007/BF02401419; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; LI L, 1990, J BIOL CHEM, V265, P1556; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Nishitoh H, 1996, J BIOL CHEM, V271, P21345, DOI 10.1074/jbc.271.35.21345; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; ROBERTS AB, 1996, PEPTIDE GROWTH FACTO, V95, P419; Schutte M, 1996, CANCER RES, V56, P2527; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	34	499	515	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21145	21152		10.1074/jbc.273.33.21145	http://dx.doi.org/10.1074/jbc.273.33.21145			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694870	hybrid			2022-12-27	WOS:000075386100063
J	Kenneth, KR; James, AA				Kenneth, KR; James, AA			Isolation and characterization of the gene encoding a novel factor Xa-directed anticoagulant from the yellow fever mosquito, Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; SALIVARY-GLANDS; INHIBITOR; PROTEINS; APYRASE; ALPHA-1-ANTITRYPSIN; CULICIDAE; SEQUENCE; SERPINS; DIPTERA	Mosquito salivary glands secrete a number of proteins that inhibit mammalian hemostasis and facilitate blood feeding, We have isolated the protein product and corresponding cDNA of a gene designated Anticoagulant-factor Xa (AFXa), that encodes the factor Xa (FXa)-directed anticoagulant of the yellow fever mosquito, Aedes aegypti. The protein was purified partially by cation exchange chromatography and shown by enzyme activity profiles and SDS polyacrylamide gel electrophoresis analysis to have an M-r = 54,000, The protein was purified further by preparative SDS-polyacrylamide gel electrophoresis and subjected to internal protein sequencing, and the sequence of five peptides was determined. Degenerate oligonucleotides were designed based on three of the peptide sequences, and these were used to screen an adult female salivary gland cDNA library from A. aegypti. A 1,8-kilobase pair cDNA was isolated and shown to encode a 415-amino acid conceptual translation product with a predicted molecular mass of 47.8 kDa that contains the five sequenced peptides. Hydrophobicity analysis predicts a 19-amino acid signal peptide typical for secreted proteins. Northern analysis demonstrated that AFXa is expressed only in female salivary glands, Baculovirus-expressed AFXa protein has the appropriate size and expected FXa-directed anticoagulant activity, Analysis of the primacy amino acid sequence shows that the AFXa gene product has similarities to the serpin superfamily of serine protease inhibitors and may represent a novel, highly diverged member of this family.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	James, AA (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Bio Sci 2,Rm 3205, Irvine, CA 92697 USA.			James, Anthony/0000-0001-5577-3308	NIAID NIH HHS [AI29746] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029746, R37AI029746] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ausubel FM, 1992, CURRENT PROTOCOLS MO; CHAMPAGNE DE, 1994, P NATL ACAD SCI USA, V91, P138, DOI 10.1073/pnas.91.1.138; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; Collins FH., 1996, SCI MED, V3, P52; CORNWALL J. W., 1914, Indian Journal of Medical Research, V2, P569; DUNWIDDIE C, 1984, J BIOL CHEM, V264, P1694; FRIEDRICH T, 1993, J BIOL CHEM, V268, P16216; Grossman G.L., 1993, Insect Molecular Biology, V1, P223, DOI 10.1111/j.1365-2583.1993.tb00095.x; Grossman GL, 1997, INSECT BIOCHEM MOLEC, V27, P769, DOI 10.1016/S0965-1748(97)00063-5; HOPKINS PCR, 1994, SCIENCE, V265, P1893; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Ibrahim MS, 1996, J MED ENTOMOL, V33, P955, DOI 10.1093/jmedent/33.6.955; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MARKWARDT F, 1991, HAEMOSTASIS, V21, P11; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Metcalf R. L., 1945, JOUR NATION MALARIA SOC, V4, P271; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; RIBEIRO JMC, 1992, J EXP BIOL, V165, P61; RIBIERO JMC, 1995, BIOCHEM J, V308, P243; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; Smartt CT, 1995, EXP PARASITOL, V81, P239, DOI 10.1006/expr.1995.1114; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; Stark KR, 1996, PARASITOL TODAY, V12, P430, DOI 10.1016/0169-4758(96)10064-8; Stark KR, 1996, J MED ENTOMOL, V33, P645, DOI 10.1093/jmedent/33.4.645; Stark KR, 1995, EXP PARASITOL, V81, P321, DOI 10.1006/expr.1995.1123; TITUS RG, 1990, PARASITOL TODAY, V6, P157, DOI 10.1016/0169-4758(90)90338-5; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YE RD, 1987, J BIOL CHEM, V262, P3718; YENBUTR P, 1995, INFECT IMMUN, V63, P1745, DOI 10.1128/IAI.63.5.1745-1753.1995	37	120	128	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20802	20809		10.1074/jbc.273.33.20802	http://dx.doi.org/10.1074/jbc.273.33.20802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694825	hybrid			2022-12-27	WOS:000075386100018
J	Mackay, DJG; Hall, A				Mackay, DJG; Hall, A			Rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACTIVATED PROTEIN-KINASE; ACTIN STRESS FIBERS; WISKOTT-ALDRICH SYNDROME; CELL-CYCLE PROGRESSION; FOCAL ADHESIONS; MAMMALIAN-CELLS; TERMINAL KINASE; RAC REGULATION; NADPH OXIDASE; CDC42 GTPASES		UCL, Canc Res Campaign, Oncogene & Signal Transduct Grp, London WC1E 6BT, England; UCL, Dept Biochem, London WC1E 6BT, England; UCL, Medical Research Council, Mol Cell Biol Lab, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Hall, A (corresponding author), UCL, Canc Res Campaign, Oncogene & Signal Transduct Grp, Gower St, London WC1E 6BT, England.	Alan.Hall@ucl.ac.uk	Mackay, Deborah JG/B-2879-2015	Mackay, Deborah JG/0000-0003-3088-4401				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Leung T, 1996, MOL CELL BIOL, V16, P5313; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	59	545	561	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20685	20688		10.1074/jbc.273.33.20685	http://dx.doi.org/10.1074/jbc.273.33.20685			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694808	hybrid			2022-12-27	WOS:000075386100001
J	Meijberg, W; Schuurman-Wolters, GK; Boer, H; Scheek, RM; Robillard, GT				Meijberg, W; Schuurman-Wolters, GK; Boer, H; Scheek, RM; Robillard, GT			The thermal stability and domain interactions of the mannitol permease of Escherichia coli - A differential scanning calorimetry study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHOTRANSFERASE SYSTEM; CYTOCHROME-C-OXIDASE; ENZYME-IIMTL; TRANSPORT PROTEIN; PHOSPHOENOLPYRUVATE; PHOSPHORYLATION; PURIFICATION; DENATURATION; TRANSITIONS; EXPRESSION	The thermal stability and domain interactions in the mannitol transporter from Escherichia coli, enzyme IImtl, have been studied by differential scanning calorimetry. To this end, the wild type enzyme, IICBA(mtl), as well as IICBmtl and IICmtl, were reconstituted into a dimyristoylphosphatidylcholine lipid bilayer, The changes in the gel to liquid crystalline transition of the lipid indicated that the protein was inserted into the membrane, disturbing a total of approximately 40 lipid molecules/protein molecule, The thermal unfolding profile of EIImtl exhibited three separate transitions, two of which were overlapping, that could be assigned to structural domains in the protein. Treatment with trypsin, resulting in the degradation of the water-soluble part of the enzyme while leaving the binding and translocation capability of the enzyme intact, resulted in a decrease of the T-m and enthalpy of unfolding of the membrane-embedded C domain. This effect was much more apparent in the presence of the substrate but only partly so in the presence of the substrate analog perseitol, These results are consistent with a recently proposed model (Meijberg, W., Schuurman-Wolters, G. K., and Robillard, G, T, (1998) J. Biol Chem. 273, 7949-7946), in which the B domain takes part in the conformational changes during the substrate binding process.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	G.T.Robillard@chem.rug.nl		Boer, Harry/0000-0002-1685-2270				BOER H, 1995, BIOCHEMISTRY-US, V34, P3239, DOI 10.1021/bi00010a013; BOER H, 1994, J BIOL CHEM, V269, P17863; BOER H, 1996, THESIS U GRONINGEN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; CONEJEROLARA F, 1991, BIOCHEMISTRY-US, V30, P2067, DOI 10.1021/bi00222a010; CORREAFREIRE MC, 1979, BIOCHEMISTRY-US, V18, P442, DOI 10.1021/bi00570a008; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GALISTEO ML, 1993, EUR BIOPHYS J BIOPHY, V22, P25, DOI 10.1007/BF00205809; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P309; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CA, 1983, J BIOL CHEM, V258, P761; LOLKEMA JS, 1990, BIOCHEMISTRY-US, V29, P10120, DOI 10.1021/bi00495a016; LOLKEMA JS, 1992, BIOCHEMISTRY-US, V31, P5514, DOI 10.1021/bi00139a013; LOLKEMA JS, 1991, BIOCHEMISTRY-US, V30, P6716, DOI 10.1021/bi00241a012; LOLKEMA JS, 1993, BIOCHEMISTRY-US, V32, P5848, DOI 10.1021/bi00073a018; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; MCELHANEY RN, 1986, BIOCHIM BIOPHYS ACTA, V864, P361, DOI 10.1016/0304-4157(86)90004-3; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Meijberg W, 1996, BIOCHEMISTRY-US, V35, P2759, DOI 10.1021/bi952567b; Meijberg W, 1998, J BIOL CHEM, V273, P7949, DOI 10.1074/jbc.273.14.7949; MORIN PE, 1990, BIOCHEMISTRY-US, V29, P781, DOI 10.1021/bi00455a028; MURPHY KP, 1992, J MOL BIOL, V227, P293, DOI 10.1016/0022-2836(92)90699-K; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RIGELL CW, 1987, BIOCHEMISTRY-US, V26, P4366, DOI 10.1021/bi00388a027; RIGELL CW, 1985, BIOCHEMISTRY-US, V24, P5638, DOI 10.1021/bi00341a053; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; ROBILLARD GT, 1993, BIOCHEMISTRY-US, V32, P9553, DOI 10.1021/bi00088a006; ROBILLARD GT, 1996, HDB BIOL PHYS, V2, P549; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUSTER R, 1988, J CHROMATOGR-BIOMED, V431, P271, DOI 10.1016/S0378-4347(00)83096-0; STEPHAN MM, 1986, BIOCHEMISTRY-US, V25, P8230, DOI 10.1021/bi00373a016; SUGIYAMA JE, 1991, P NATL ACAD SCI USA, V88, P9603, DOI 10.1073/pnas.88.21.9603; VANWEEGHEL RP, 1990, P NATL ACAD SCI USA, V87, P2613, DOI 10.1073/pnas.87.7.2613; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P9478, DOI 10.1021/bi00103a013; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1774, DOI 10.1021/bi00221a007	41	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20785	20794		10.1074/jbc.273.33.20785	http://dx.doi.org/10.1074/jbc.273.33.20785			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694823	Green Published, hybrid			2022-12-27	WOS:000075386100016
J	Orlandini, M; Semplici, F; Ferruzzi, R; Meggio, F; Pinna, LA; Oliviero, S				Orlandini, M; Semplici, F; Ferruzzi, R; Meggio, F; Pinna, LA; Oliviero, S			Protein kinase CK2 alpha ' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE THEILERIA-PARVA; II ALPHA-SUBUNIT; CASEIN KINASE-2; GROWTH-FACTOR; CELLULAR-REGULATION; C-MYC; ACTIVATION; PHOSPHORYLATION; INDUCTION; CLONING	Protein kinase CK2 is an ubiquitous and pleiotropic Ser/Thr protein kinase composed of two catalytic (alpha and/or alpha') and two noncatalytic (beta) subunits forming a heterotetrameric holoenzyme involved in-cell growth and differentiation. Here we report the identification, cloning, and oncogenic activity of the murine CK2 alpha' subunit. Serum treatment of quiescent mouse fibroblasts induces CK2 alpha' mRNA expression, which peaks at 4 h. The kinetics of CK2 alpha' expression correlate with increased kinase activity toward a specific CK2 holoenzyme peptide substrate. The ectopic expression of CK2 alpha' (or CK2 alpha) cooperates with Ha-ras in foci formation of rat primary embryo fibroblasts. Moreover; we observed that BALB/c 3T3 fibroblasts transformed with Ha-ras and CK2 alpha' show a faster growth rate than cells transformed with Ha-ras alone. In these cells the higher growth rate correlates with an increase in calmodulin phosphorylation, a protein substrate specifically affected by isolated CK2 catalytic subunits but not by CK2 holoenzyme, suggesting that unbalanced expression of a CK2 catalytic subunit synergizes with Ha-ras in cell transformation.	Univ Siena, Dipartimento Biol Mol, IRIS, I-53100 Siena, Italy; Univ Padua, Dipartimento Chim Biol, CNR, I-35121 Padua, Italy; Univ Padua, Ctr Studio Biomembrane, CNR, I-35121 Padua, Italy	Novartis; University of Siena; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Oliviero, S (corresponding author), Univ Siena, Dipartimento Biol Mol, IRIS, Via Fiorentina 1, I-53100 Siena, Italy.		Orlandini, Maurizio/AAF-8247-2020; oliviero, salvatore/R-6657-2019	Orlandini, Maurizio/0000-0002-6112-4889; oliviero, salvatore/0000-0002-3405-765X				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Antonelli M, 1996, EUR J BIOCHEM, V241, P272, DOI 10.1111/j.1432-1033.1996.0272t.x; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LOZEMAN FJ, 1990, BIOCHEMISTRY-US, V29, P8436, DOI 10.1021/bi00488a034; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MARAIS RM, 1992, EMBO J, V11, P97, DOI 10.1002/j.1460-2075.1992.tb05032.x; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Meisner H, 1991, CURR OPIN CELL BIOL, V3, P474, DOI 10.1016/0955-0674(91)90076-B; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OLEMOIYOI OK, 1995, SCIENCE, V267, P834, DOI 10.1126/science.7846527; OLEMOIYOI OK, 1993, EMBO J, V12, P1621, DOI 10.1002/j.1460-2075.1993.tb05807.x; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; OLIVIERO S, 1992, GENE DEV, V6, P1799, DOI 10.1101/gad.6.9.1799; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Sarno S, 1997, BIOCHEMISTRY-US, V36, P11717, DOI 10.1021/bi9705772; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532	39	105	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21291	21297		10.1074/jbc.273.33.21291	http://dx.doi.org/10.1074/jbc.273.33.21291			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694889	hybrid			2022-12-27	WOS:000075386100082
J	Ressad, F; Didry, D; Xia, GX; Hong, Y; Chua, NH; Pantaloni, D; Carlier, MF				Ressad, F; Didry, D; Xia, GX; Hong, Y; Chua, NH; Pantaloni, D; Carlier, MF			Kinetic analysis of the interaction of actin-depolymerizing factor (ADF)/cofilin with G- and F-actins - Comparison of plant and human ADFs and effect of phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT DYNAMICS; BOUND NUCLEOTIDE; STRUCTURAL BASIS; ATP HYDROLYSIS; YEAST COFILIN; POLYMERIZATION; PROTEIN; MYOSIN; COOPERATIVITY; ACANTHAMOEBA	The thermodynamics and kinetics of actin interaction with Arabidopsis thaliana actin-depolymerizing factor (ADF)(1), human ADF, and S6D mutant ADF(1) protein mimicking phosphorylated (inactive) ADF are examined comparatively. ADFs interact with ADP.G-actin in rapid equilibrium (k(+) = 155 mu M-1.s(-l) and k(-) = 16 s(-1) at 4 degrees C under physiological ionic conditions). The kinetics of interaction of plant and human ADFs with F-actin are slower and exhibit kinetic cooperativity, consistent with a scheme in which the initial binding of ADF to two adjacent subunits of the filament nucleates a structural change that propagates along the filament, allowing faster binding of ADF in a "zipper" mode. ADF binds in a non-cooperative faster process to gelsolin-capped filaments or to subtilisin-cleaved F-actin, which are structurally different from standard filaments (Orlova, A, Prochniewicz, E,, and Egelman, E, H. (1995) J. Mel. Biol. 245, 598-607), In contrast, the binding of phalloidin to F-actin cooperatively inhibits its interaction with ADF. The ADF-facilitated nucleation of ADP actin self-assembly indicates that ADF stabilizes lateral interactions in the filament, Plant and human ADFs cause only partial depolymerization of F-actin at pH 8, consistent with identical functions in enhancing F-actin dynamics, Phosphorylation does not affect ADF activity per se, but decreases its affinity for actin by 20-fold.	CNRS, LEBS, F-91198 Gif Sur Yvette, France; Natl Univ Singapore, Inst Mol Agrobiol, Lab Plant Cell Biol, Singapore 118240, Singapore; Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; National University of Singapore; Rockefeller University	Carlier, MF (corresponding author), CNRS, LEBS, F-91198 Gif Sur Yvette, France.	carlier@lebs.cnrs-gif.fr	Hong, Yan/D-5106-2014	Hong, Yan/0000-0002-2954-8788				ABE H, 1996, J CELL BIOL, V132, P335; AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; AIZAWA H, 1996, J CELL BIOL, V132, P871; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P1; BREMER A, 1991, J CELL BIOL, V115, P689, DOI 10.1083/jcb.115.3.689; BREMER A, 1992, Current Opinion in Cell Biology, V4, P20, DOI 10.1016/0955-0674(92)90054-G; BREMER A, 1994, J MOL BIOL, V242, P683, DOI 10.1006/jmbi.1994.1617; BRYAN J, 1984, J BIOL CHEM, V259, P7480; CARLIER MF, 1987, J BIOL CHEM, V262, P3052; CARLIER MF, 1984, J BIOL CHEM, V259, P9983; CARLIER MF, 1991, J BIOL CHEM, V266, P1; Carlier MF, 1998, CURR OPIN CELL BIOL, V10, P45, DOI 10.1016/S0955-0674(98)80085-9; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; DREWES G, 1993, EUR J BIOCHEM, V212, P247, DOI 10.1111/j.1432-1033.1993.tb17656.x; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; Fedorov AA, 1997, NAT STRUCT BIOL, V4, P366, DOI 10.1038/nsb0597-366; Feng L, 1997, J BIOL CHEM, V272, P16829, DOI 10.1074/jbc.272.27.16829; Fievez S, 1997, BIOCHEMISTRY-US, V36, P11837, DOI 10.1021/bi971205w; Hatanaka H, 1996, CELL, V85, P1047, DOI 10.1016/S0092-8674(00)81305-7; HAWKINS M, 1993, BIOCHEMISTRY-US, V32, P9985, DOI 10.1021/bi00089a014; HAYDEN SM, 1993, BIOCHEMISTRY-US, V32, P9994, DOI 10.1021/bi00089a015; ISAMBERT H, 1995, J BIOL CHEM, V270, P11437, DOI 10.1074/jbc.270.19.11437; LAL AA, 1984, J BIOL CHEM, V259, P3061; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Leonard SA, 1997, NAT STRUCT BIOL, V4, P369, DOI 10.1038/nsb0597-369; LEPAULT J, 1994, J STRUCT BIOL, V112, P79, DOI 10.1006/jsbi.1994.1009; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; Mogilner A, 1996, BIOPHYS J, V71, P3030, DOI 10.1016/S0006-3495(96)79496-1; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; OHTA Y, 1984, J BIOCHEM-TOKYO, V96, P1547, DOI 10.1093/oxfordjournals.jbchem.a134984; Oosawa F., 1972, COLD SPRING HARB SYM, V37, P277; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; PROCHNIEWICZ E, 1993, BIOPHYS J, V65, P113, DOI 10.1016/S0006-3495(93)81057-9; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SMALL JV, 1995, TRENDS CELL BIOL, V5, P52, DOI 10.1016/S0962-8924(00)88939-4; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WEGNER A, 1976, J MOL BIOL, V108, P139, DOI 10.1016/S0022-2836(76)80100-3	44	155	157	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20894	20902		10.1074/jbc.273.33.20894	http://dx.doi.org/10.1074/jbc.273.33.20894			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694836	hybrid			2022-12-27	WOS:000075386100029
J	Choi, KB; Wong, F; Harlan, JM; Chaudhary, PM; Hood, L; Karsan, A				Choi, KB; Wong, F; Harlan, JM; Chaudhary, PM; Hood, L; Karsan, A			Lipopolysaccharide mediates endothelial apoptosis by a FADD-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; NF-KAPPA-B; CELL-DEATH; BACTERIAL LIPOPOLYSACCHARIDE; CD95 FAS/APO-1; SOLUBLE CD14; FACTOR-ALPHA; ACTIVATION; ENDOTOXIN	Endothelial cells play a pivotal role in the inflammatory process by coordinating the recruitment of inflammatory cells to sites of tissue injury. Lipopolysaccharide (LPS) activates many of the proinflammatory and procoagulant responses of endothelial cells, and endothelial injury is thought to play a crucial role in the pathogenesis of septic shock due to Gram-negative bacteria. The receptor used by LPS to signal endothelial responses has not been identified. It is also not known how LPS induces endothelial injury/death. In this study, me demonstrate that LPS mediates endothelial apoptosis by a FADD-dependent pathway. FADD is a death domain-containing protein that binds to certain members of the tumor necrosis factor receptor family, namely TNFR1, Fas, and DR3. However, none of these receptors appear to be involved in LPS-mediated death, suggesting that LPS may utilize a novel death domain-containing protein to transduce a death signal.	St Pauls Hosp, McDonald Res Labs, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada; Univ Washington, Dept Mol Biotechnol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Karsan, A (corresponding author), St Pauls Hosp, McDonald Res Labs, 1081 Burrand St, Vancouver, BC V6Z 1Y6, Canada.		Chaudhary, Preet/E-1970-2018; Karsan, Aly/K-2067-2015					ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARDITI M, 1995, J IMMUNOL, V155, P3994; ARDITI M, 1993, INFECT IMMUN, V61, P3149, DOI 10.1128/IAI.61.8.3149-3156.1993; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CARMICHAEL J, 1987, CANCER RES, V47, P943; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CYBULSKY MI, 1988, LAB INVEST, V58, P365; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; EISSNER G, 1995, BLOOD, V86, P4184, DOI 10.1182/blood.V86.11.4184.bloodjournal86114184; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; INGALLS RR, 1995, J EXP MED, V181, P1473, DOI 10.1084/jem.181.4.1473; Ingalls RR, 1997, J IMMUNOL, V159, P433; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1998, TRENDS CARDIOVAS MED, V8, P19, DOI 10.1016/S1050-1738(97)00126-6; Karsan A, 1997, AM J PATHOL, V151, P1775; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; MEYRICK B, 1989, J CELL PHYSIOL, V138, P165, DOI 10.1002/jcp.1041380122; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; READ MA, 1993, P NATL ACAD SCI USA, V90, P9887, DOI 10.1073/pnas.90.21.9887; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; SATO I, 1995, MECH AGEING DEV, V81, P27, DOI 10.1016/0047-6374(94)01579-B; Thieblemont N, 1997, J EXP MED, V185, P2095, DOI 10.1084/jem.185.12.2095; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	40	135	140	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20185	20188		10.1074/jbc.273.32.20185	http://dx.doi.org/10.1074/jbc.273.32.20185			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685365	hybrid			2022-12-27	WOS:000075305400042
J	Engel, M; Seifert, M; Theisinger, B; Seyfert, U; Welter, C				Engel, M; Seifert, M; Theisinger, B; Seyfert, U; Welter, C			Glyceraldehyde-3-phosphate dehydrogenase and Nm23-H1/Nucleoside diphosphate kinase A - Two old enzymes combine for the novel Nm23 protein phosphotransferase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL DNA-GLYCOSYLASE; LYMPH-NODE METASTASIS; X-RAY STRUCTURE; ENZYMATIC-ACTIVITY; MELANOMA-CELLS; GROWTH-FACTOR; GENE-PRODUCT; EXPRESSION; DROSOPHILA; CARCINOMA	We have recently discovered an alternative function of the putative metastasis suppressor protein Nm23, which is identical to nucleoside diphosphate kinase, as a protein phosphotransferase in vitro, While purified native Nm23 protein did not phosphorylate other proteins, we could purify a Nm23-associated protein that activates the protein phosphotransferase function; it was identified as a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) isoenzyme. Go-expression and purification of (His)(6)-tagged GAPDH in combination with either Nm23-H1 or Nm23-H2 in baculovirus-infected Sf9 cells showed that only Nm23-H1, but not Nm23-H2, forms a stable complex with GAPDH. Protein phosphotransferase activity was confirmed for the recombinant GAPDH-Nm23-H1 complex but not for either of the enzymes alone, nor was this activity observed after simple mixing of the purified proteins in vitro. The molecular mass of the highly purified recombinant GAPDH Nm23-H1 complex suggests that a dimer of GAPDH interacts with a dimer of Nm23-H1. In contrast to the complex with GAPDH, co-expression of Nm23-H1 with antioxidant protein (MER-5) or creatine kinase did not activate the protein phosphotransferase function, indicating that this activation may specifically require GAPDH as a binding partner.	Univ Saarlandes, Inst Humangenet, Dept Human Genet, D-66421 Homburg, Germany; Univ Saarlandes, Dept Hemostaseol & Transfus Med, D-66421 Homburg, Germany	Saarland University; Saarland University	Engel, M (corresponding author), Univ Saarlandes, Inst Humangenet, Dept Human Genet, Geb 68, D-66421 Homburg, Germany.							Ann KS, 1996, J EUKARYOT MICROBIOL, V43, P365, DOI 10.1111/j.1550-7408.1996.tb05045.x; ARAI T, 1995, MODERN PATHOL, V8, P252; ASHMARINA LI, 1985, EUR J BIOCHEM, V149, P67, DOI 10.1111/j.1432-1033.1985.tb08894.x; Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; BAXI MD, 1995, BIOCHEMISTRY-US, V34, P9700, DOI 10.1021/bi00030a007; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHEREDNIKOVA TV, 1980, BIOCHIM BIOPHYS ACTA, V613, P292, DOI 10.1016/0005-2744(80)90084-4; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; De BP, 1996, J BIOL CHEM, V271, P24728, DOI 10.1074/jbc.271.40.24728; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; DUNBAR B, 1994, ANAL BIOCHEM, V216, P227, DOI 10.1006/abio.1994.1029; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; EPNER DE, 1993, CANCER RES, V53, P1995; Federici C, 1996, EUR J BIOCHEM, V238, P173, DOI 10.1111/j.1432-1033.1996.0173q.x; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; GOLDEN A, 1993, ONCOGENES TUMOR SUPP, P345; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; HILDEBRANDT M, 1995, NUCLEIC ACIDS RES, V23, P3858, DOI 10.1093/nar/23.19.3858; HSU S, 1994, CELL GROWTH DIFFER, V5, P909; Inoue H, 1996, BIOCHEM BIOPH RES CO, V218, P887, DOI 10.1006/bbrc.1996.0158; KANTOR JD, 1993, CANCER RES, V53, P1971; Karlsson A, 1996, J BIOL CHEM, V271, P19928, DOI 10.1074/jbc.271.33.19928; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KONISHI N, 1993, JPN J CANCER RES, V84, P1050, DOI 10.1111/j.1349-7006.1993.tb02800.x; LACOMBE ML, 1991, EUR J CANCER, V27, P1302, DOI 10.1016/0277-5379(91)90101-I; LASCU I, 1992, J BIOL CHEM, V267, P12775; Lebreton S, 1997, EUR J BIOCHEM, V246, P85, DOI 10.1111/j.1432-1033.1997.t01-2-00085.x; Lebreton S, 1997, EUR J BIOCHEM, V250, P286, DOI 10.1111/j.1432-1033.1997.0286a.x; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LEONE A, 1993, ONCOGENE, V8, P2325; Lu Q, 1996, J BIOL CHEM, V271, P32886, DOI 10.1074/jbc.271.51.32886; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; Mesnildrey S, 1997, FEBS LETT, V418, P53, DOI 10.1016/S0014-5793(97)01292-1; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Milon L, 1997, HUM GENET, V99, P550, DOI 10.1007/s004390050405; MORERA S, 1995, BIOCHEMISTRY-US, V34, P11062, DOI 10.1021/bi00035a011; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Mukhopadhyay S, 1997, J BIOL CHEM, V272, P17815, DOI 10.1074/jbc.272.28.17815; MURONETZ VI, 1983, BIOCHEM INT, V6, P443; MURONETZ VI, 1994, ARCH BIOCHEM BIOPHYS, V313, P253, DOI 10.1006/abbi.1994.1385; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAMORI S, 1993, CLIN EXP METASTAS, V11, P151, DOI 10.1007/BF00114973; Otero AD, 1997, J BIOL CHEM, V272, P14690, DOI 10.1074/jbc.272.23.14690; PARHAR RS, 1995, INT J CANCER, V60, P204; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROBINSON JB, 1981, J BIOL CHEM, V256, P769; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; Shankar S, 1997, MOL MICROBIOL, V24, P477, DOI 10.1046/j.1365-2958.1997.3491724.x; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Teng DHF, 1997, CANCER RES, V57, P4177; Timmons L, 1997, ADV GENET, V35, P207, DOI 10.1016/S0065-2660(08)60451-4; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; VENTURELLI D, 1995, P NATL ACAD SCI USA, V92, P7435, DOI 10.1073/pnas.92.16.7435; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wagner PD, 1997, P NATL ACAD SCI USA, V94, P9000, DOI 10.1073/pnas.94.17.9000; Xu J, 1996, DEV BIOL, V177, P544, DOI 10.1006/dbio.1996.0184; Xu Y, 1997, PROTEINS, V28, P150; YAMAGUCHI A, 1994, CANCER, V73, P2280, DOI 10.1002/1097-0142(19940501)73:9<2280::AID-CNCR2820730908>3.0.CO;2-3	63	112	125	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20058	20065		10.1074/jbc.273.32.20058	http://dx.doi.org/10.1074/jbc.273.32.20058			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685345	hybrid			2022-12-27	WOS:000075305400022
J	Barker, EL; Perlman, MA; Adkins, EM; Houlihan, WJ; Pristupa, ZB; Niznik, HB; Blakely, RD				Barker, EL; Perlman, MA; Adkins, EM; Houlihan, WJ; Pristupa, ZB; Niznik, HB; Blakely, RD			High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis - An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NOREPINEPHRINE TRANSPORTER; SINGLE AMINO-ACID; DOPAMINE TRANSPORTER; RAT-BRAIN; EXPRESSION CLONING; STRUCTURAL DOMAINS; OVERLAP EXTENSION; COCAINE BINDING; RNA-POLYMERASE; SITE	Human and Drosophila melanogaster serotonin (5-HT) transporters (SERTs) exhibit similar 5-HT transport kinetics and can be distinguished pharmacologically by many, but not all, biogenic amine transporter antagonists. By using human and Drosophila SERT chimeras, major determinants of potencies of two transporter antagonists, mazindol and citalopram, were tracked to the amino-terminal domains encompassing transmembrane domains I and II. Species-scanning mutagenesis, whereby amino acid substitutions are made switching residues from one species to another, was employed on the eight amino acids that differ between human and Drosophila SERTs in this region, and antagonist potencies were reassessed in 5-HT uptake assays. A single mutation in transmembrane domain I of human SERT, Y95F, shifted both citalopram and mazindol to Drosophila SERT-Iike potencies, Strikingly, these potency changes were in opposite directions suggesting Tyros contributes both positive and negative determinants of antagonist potency. To gain insight into how the Y95F mutant might influence mazindol potency, we determined how structural variants of mazindol responded to the mutation, Our studies demonstrate the importance of the hydroxyl group on the heterocyclic nucleus of mazindol for maintaining species-selective recognition of mazindol and suggest that transmembrane domain I participates in the formation of antagonist-binding sites for amine transporters.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; Purdue Univ, Sch Pharm, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Drew Univ, Charles A Dana Res Inst, Madison, NJ 07940 USA; Clarke Inst Psychiat, Dept Psychiat, Toronto, ON M5T 1RS, Canada; Clarke Inst Psychiat, Mol Neurobiol Lab, Toronto, ON M5T 1RS, Canada	Vanderbilt University; Vanderbilt University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Drew University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 412 MRB 2, Nashville, TN 37232 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R03DA008516, F32DA005679, R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA7390, F32-DA05679, R03-DA8516-02] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BARCZA S, 1975, J PHARM SCI, V64, P829, DOI 10.1002/jps.2600640522; Barker EL, 1996, MOL PHARMACOL, V50, P957; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BARKER EL, 1998, NEUROTRANSMITTER TRA; Barker Eric L., 1995, P321; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BRUSS M, 1995, J BIOL CHEM, V270, P9197; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Chang AS, 1996, MOL BRAIN RES, V43, P185, DOI 10.1016/S0169-328X(96)00172-6; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; CHEN JX, 1997, NEUR ABSTR, V23; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Clark JA, 1997, J BIOL CHEM, V272, P14695, DOI 10.1074/jbc.272.23.14695; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; DUGGER HA, 1976, DRUG METAB DISPOS, V4, P262; FONG TM, 1992, J BIOL CHEM, V267, P25668; FOZARD J, 1989, PERIPHERAL ACTIONS 5; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAOZZA CH, 1972, J HETEROCYCLIC CHEM, V9, P883, DOI 10.1002/jhet.5570090422; GIROS B, 1994, J BIOL CHEM, V269, P15985; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HALL JM, 1993, TRENDS PHARMACOL SCI, V14, P376, DOI 10.1016/0165-6147(93)90096-3; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HOULIHAN WJ, 1982, J ORG CHEM, V47, P5177, DOI 10.1021/jo00147a027; Houlihan WJ, 1996, J MED CHEM, V39, P4935, DOI 10.1021/jm960288w; HOULIHAN WJ, 1998, IN PRESS MED CHEM RE; KAO HT, 1992, FEBS LETT, V307, P324, DOI 10.1016/0014-5793(92)80705-L; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KOE BK, 1976, J PHARMACOL EXP THER, V199, P649; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; Melikian HE, 1996, MOL PHARMACOL, V50, P266; Meltesics W, 1975, Patent No. [US 3905994 A, 3905994]; MOORE KR, 1994, BIOTECHNIQUES, V17, P130; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Padbury JF, 1997, MOL BRAIN RES, V45, P163, DOI 10.1016/S0169-328X(96)00309-9; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; QIAN Y, 1995, J NEUROSCI, V15, P1261; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; TATE CG, 1994, J BIOL CHEM, V269, P26303; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; ZIFA E, 1992, PHARMACOL REV, V44, P401	54	126	128	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19459	19468		10.1074/jbc.273.31.19459	http://dx.doi.org/10.1074/jbc.273.31.19459			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677366	hybrid			2022-12-27	WOS:000075125200018
J	Hii, CST; Huang, ZH; Bilney, A; Costabile, M; Murray, AW; Rathjen, DA; Der, CJ; Ferrante, A				Hii, CST; Huang, ZH; Bilney, A; Costabile, M; Murray, AW; Rathjen, DA; Der, CJ; Ferrante, A			Stimulation of p38 phosphorylation and activity by arachidonic acid in HeLa cells, HL60 promyelocytic leukemic cells, and human neutrophils - Evidence for cell type-specific activation of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; GAP-JUNCTIONAL COMMUNICATION; NECROSIS-FACTOR-ALPHA; NADPH-OXIDASE; WB CELLS; SUPEROXIDE PRODUCTION; 2ND MESSENGER; PHORBOL ESTER; MAP KINASE; LONG-CHAIN	Although it is well appreciated that arachidonic acid, a second messenger molecule that is released by ligand-stimulated phospholipase A(2), stimulates a wide range of cell types, the mechanisms that mediate the actions of arachidonic acid are still poorly understood, We now report that arachidonic acid stimulated the appearance of dual-phosphorylated (active) p38 mitogen-activated protein kinase as detected by Western blotting in HeLa cells, HL60 cells, human neutrophils, and human umbilical vein endothelial cells but not Jurkat cells. An increase in p38 kinase activity caused by arachidonic acid was also observed. Further studies with neutrophils show that the stimulation of p38 dual phosphorylation by arachidonic acid was transient, peaking;at 5 min, and was concentration-dependent. The effect of arachidonic acid was not affected by either nordihydroguaiaretic acid, an inhibitor of the 5-, 12-, and 15-lipoxygenases or by indomethacin, an inhibitor of cyclooxygenase, Arachidonic acid also stimulated the phosphorylation and/or activity of the extracellular signal-regulated protein kinase and of c-jun N-terminal. kinase in a cell-type-specific manner. An examination of the mechanisms through which arachidonic acid stimulated the phosphorylation/activity of p38 and extracellular signal-regulated protein kinase in neutrophils revealed an involvement of protein kinase C, Thus, arachidonic acid stimulated the translocation of protein kinase C alpha; beta I, and beta II to a particulate fraction, and the effects of arachidonic acid on mitogen-activated protein kin;ase phosphorylation/activity were partially inhibited by GF109203X, an inhibitor of protein kinase C, This study Is the first to demonstrate that a polyunsaturated fatty acid causes the dual phosphorylation and activation of p38.	Womens & Childrens Hosp, Dept Immunopathol, N Adelaide, SA 5006, Australia; Flinders Univ S Australia, Sch Biol Sci, Bedford Pk, SA 5042, Australia; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA	Flinders University South Australia; University of North Carolina; University of North Carolina Chapel Hill	Hii, CST (corresponding author), Womens & Childrens Hosp, Dept Immunopathol, N Adelaide, SA 5006, Australia.		costabile, maurizio/AEN-4356-2022	costabile, maurizio/0000-0002-2162-6497; Der, Channing/0000-0002-7751-2747				ABRAMSON SB, 1991, J IMMUNOL, V147, P231; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANEL A, 1993, BIOCHEMISTRY-US, V32, P530, DOI 10.1021/bi00053a018; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAND AM, 1992, J MOL ENDOCRINOL, V8, P95, DOI 10.1677/jme.0.0080095; BATES EJ, 1995, ATHEROSCLEROSIS, V116, P247, DOI 10.1016/0021-9150(95)05553-9; BATES EJ, 1993, J LEUKOCYTE BIOL, V53, P420, DOI 10.1002/jlb.53.4.420; Berk PD, 1996, P SOC EXP BIOL MED, V212, P1; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; COREY SJ, 1991, J LAB CLIN MED, V118, P343; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DECOURSEY TE, 1993, BIOPHYS J, V65, P1590, DOI 10.1016/S0006-3495(93)81198-6; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; ElBenna J, 1996, ARCH BIOCHEM BIOPHYS, V334, P395; FERRANTE A, 1982, J IMMUNOL METHODS, V48, P81, DOI 10.1016/0022-1759(82)90212-5; FINSTAD HS, 1994, BLOOD, V84, P3799, DOI 10.1182/blood.V84.11.3799.bloodjournal84113799; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARDY SJ, 1995, BIOCHEM J, V311, P689, DOI 10.1042/bj3110689; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; HII CST, 1995, CARCINOGENESIS, V16, P1505, DOI 10.1093/carcin/16.7.1505; HII CST, 1991, J BIOL CHEM, V266, P20238; HII CST, 1994, BIOCHEM J, V303, P475, DOI 10.1042/bj3030475; Huang ZH, 1997, BIOCHEM J, V325, P553, DOI 10.1042/bj3250553; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LU Y, 1994, J IMMUNOL, V153, P1495; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; NICHOLS RC, 1990, J EXP MED, V171, P367, DOI 10.1084/jem.171.2.367; POULOS A, 1991, IMMUNOLOGY, V73, P102; RAO GN, 1994, J BIOL CHEM, V269, P32586; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; Robinson BS, 1997, IMMUNOLOGY, V91, P274, DOI 10.1046/j.1365-2567.1997.d01-2227.x; Robinson BS, 1996, J LIPID RES, V37, P1234; ROSE H, 1990, J MOL CELL CARDIOL, V22, P883, DOI 10.1016/0022-2828(90)90119-M; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; Smirnov SV, 1996, CIRC RES, V79, P20, DOI 10.1161/01.RES.79.1.20; STEINBECK MJ, 1991, J BIOL CHEM, V266, P16336; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VYSKA K, 1991, CIRC RES, V69, P857, DOI 10.1161/01.RES.69.3.857; Wieland SJ, 1996, J BIOL CHEM, V271, P19037, DOI 10.1074/jbc.271.32.19037; WOLF BA, 1986, J BIOL CHEM, V261, P3501; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	56	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19277	19282		10.1074/jbc.273.30.19277	http://dx.doi.org/10.1074/jbc.273.30.19277			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668117	hybrid			2022-12-27	WOS:000074974700084
J	Humpf, HU; Schmelz, EM; Meredith, FI; Vesper, H; Vales, TR; Wang, E; Menaldino, DS; Liotta, DC; Merrill, AH				Humpf, HU; Schmelz, EM; Meredith, FI; Vesper, H; Vales, TR; Wang, E; Menaldino, DS; Liotta, DC; Merrill, AH			Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase - Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP(1), and a new category of ceramide synthase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NOVO SPHINGOLIPID BIOSYNTHESIS; FUSARIUM-MONILIFORME; ESOPHAGEAL CANCER; SPHINGOSINE; CYTOTOXICITY; BASES; CELLS; CORN; SPHINGANINE; MYCOTOXINS	Fumonisin B-1 (FB1) is the predominant member of a family of mycotoxins produced by Fusarium moniliforme (Sheldon) and related fungi. Certain foods also contain the aminopentol backbone (AP(1)) that is formed upon base hydrolysis of the ester-linked tricarballylic acids of FB,. Both FB, and, to a lesser extent, AP(1) inhibit ceramide synthase due to structural similarities between fumonisins (as 1-deoxy-analogs of sphinganine) and sphingoid bases. To explore these structure-function relationships further, erythro- and threo-2-amino, 3-hydroxy- (and 3, 5-dihydroxy-) octadecanes were prepared by highly stereoselective syntheses. All of these analogs inhibit the acylation of sphingoid bases by ceramide synthase, and are themselves acylated with V-max/K-m of 40-125 for the erythro-isomers (compared with approximately 250 for D-erythro-sphinganine) and 4-6 for the threo-isomers. Ceramide synthase also acylates AP(1) (but not FB,, under the conditions tested) to N-palmitoyl-AP(1) (PAP(1)) with a V-max/K-m of approximately 1. The toxicity of PAP(1) was evaluated using HT29 cells, a human colonic cell line. PAP(1) was at least 10 times more toxic than FB, or AP(1) and caused sphinganine accumulation as an inhibitor of ceramide synthase. These studies demonstrate that: the 1-hydroxyl group is not required for sphingoid bases to be acylated; both erythro- and threo isomers are acylated with the highest apparent V-max/K-m for the erythro-analogs; and AP(1) is acylated to PAP(1), a new category of ceramide synthase inhibitor as well as a toxic metabolite that may play a role in the diseases caused by fumonisins.	Univ Wurzburg, Lehrstuhl Lebensmittelchem, D-97074 Wurzburg, Germany; Emory Univ, Sch Med, Dept Chem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; USDA ARS, Toxicol & Mycotoxin Res Unit, Athens, GA 30613 USA	University of Wurzburg; Emory University; Emory University; United States Department of Agriculture (USDA)	Humpf, HU (corresponding author), Univ Wurzburg, Lehrstuhl Lebensmittelchem, Hubland, D-97074 Wurzburg, Germany.	amerril@emory.edu	Schmelz, Eva M/E-6579-2012; Humpf, Hans-Ulrich/AAV-4845-2020	Merrill, Alfred/0000-0002-6673-968X; Humpf, Hans-Ulrich/0000-0003-3296-3058	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046368] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46368] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEZUIDENHOUT SC, 1988, J CHEM SOC CHEM COMM, P743, DOI 10.1039/c39880000743; Bhat RV, 1997, J TOXICOL-CLIN TOXIC, V35, P249, DOI 10.3109/15563659709001208; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Blackwell BA, 1996, ADV EXP MED BIOL, V392, P75; BRANHAM BE, 1993, J NAT PROD, V56, P1630, DOI 10.1021/np50099a030; CHU FS, 1994, APPL ENVIRON MICROB, V60, P847, DOI 10.1128/AEM.60.3.847-852.1994; Harrison L R, 1990, J Vet Diagn Invest, V2, P217; HENDRICH S, 1993, J AGR FOOD CHEM, V41, P1649, DOI 10.1021/jf00034a025; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; KARLSSON KA, 1970, LIPIDS, V5, P878, DOI 10.1007/BF02531119; KELLERMAN TS, 1990, ONDERSTEPOORT J VET, V57, P269; KRAUS GA, 1992, J AGR FOOD CHEM, V40, P2331, DOI 10.1021/jf00024a001; Marasas WFO, 1996, ADV EXP MED BIOL, V392, P1; MERRILL AH, 1993, ADV LIPID RES, V26, P215; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Nikolova-Karakashian M. N., 1997, SPHINGOLIPID MEDIATE, P159; OHTA H, 1995, CANCER RES, V55, P691; RHEEDER JP, 1992, PHYTOPATHOLOGY, V82, P353, DOI 10.1094/Phyto-82-353; Riley Ronald T., 1996, Natural Toxins, V4, P3, DOI 10.1002/19960401NT2; RILEY RT, 1993, TOXICOL APPL PHARM, V118, P105, DOI 10.1006/taap.1993.1015; SCHMELZ EM, 1994, J NUTR, V124, P702, DOI 10.1093/jn/124.5.702; Schmelz EM, 1998, TOXICOL APPL PHARM, V148, P252, DOI 10.1006/taap.1997.8356; Shephard Gordon S., 1995, Natural Toxins, V3, P145, DOI 10.1002/nt.2620030305; SHEPHARD GS, 1992, TOXICON, V30, P768, DOI 10.1016/0041-0101(92)90011-S; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P169, DOI 10.1515/bchm2.1973.354.1.169; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; SYDENHAM EW, 1990, J AGR FOOD CHEM, V38, P1900, DOI 10.1021/jf00100a004; Voss KA, 1998, ENVIRON TOXICOL PHAR, V5, P101, DOI 10.1016/S1382-6689(97)10009-6; Voss KA, 1996, FOOD CHEM TOXICOL, V34, P623, DOI 10.1016/0278-6915(96)00024-5; WANG E, 1992, J NUTR, V122, P1706, DOI 10.1093/jn/122.8.1706; WANG E, 1991, J BIOL CHEM, V266, P14486; Wilson T M, 1990, J Vet Diagn Invest, V2, P213; YOO HS, 1992, TOXICOL APPL PHARM, V114, P9, DOI 10.1016/0041-008X(92)90090-F; Yoo HS, 1996, TOXICOL APPL PHARM, V138, P211, DOI 10.1006/taap.1996.0119	38	133	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19060	19064		10.1074/jbc.273.30.19060	http://dx.doi.org/10.1074/jbc.273.30.19060			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668088	hybrid			2022-12-27	WOS:000074974700055
J	Li, XL; Matsuoka, Y; Bennett, V				Li, XL; Matsuoka, Y; Bennett, V			Adducin preferentially recruits spectrin to the fast growing ends of actin filaments in a complex requiring the MARCKS-related domain and a newly defined oligomerization domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN-ERYTHROCYTE MEMBRANE; GEL-SOL TRANSFORMATION; REGULATORY PROTEIN; BUNDLING PROTEIN; CROSS-LINKING; ATOMIC MODEL; BARBED ENDS; GELSOLIN; CALMODULIN	Adducin is a protein associated with spectrin and actin in membrane skeletons of erythrocytes sind possibly other cells, Adducin has activities in in vitro assays of association with the sides of actin filaments, capping the fast growing ends of actin filaments, and: recruiting spectrin to actin filaments, This study presents evidence that adducin exhibits a preference for the fast growing ends of actin filaments for recruiting spectrin to actin and for direct association with actin, beta-Adducin-(335-726) promoted recruitment of spectrin to gelsolin-sensitive sites at fast growing ends of actin filaments with half-maximal activity at 15 nM and to gelsolin-insensitive sites with half-maximal activity at 75 nM,. beta-Adducin(335-726) also exhibited a preference for actin filament ends in direct binding assays; the half-maximal concentration for binding of adducin to gelsolin-sensitive sites at filament ends was 60 nM, and the K-d for binding to lateral sites was 1.5 mu M. The concentration of beta-adducin(335-726) of 60 nM required for half-maximal binding to filament ends is in the same range as the concentration of 150 nM required for half-maximal actin capping activity. All interactions of adducin with actin require the myristoylated alanine-rich protein kinase substrate-related domain as well as a newly defined oligomerization site localized in the neck domain of adducin. Surprisingly, the head domain of adducin is not required for spectrin-actin interactions, although it could play a role in forming tetramers, The relative activities of adducin imply that an important role of adducin in cells is to form a complex with the fast growing ends of actin filaments that recruits spectrin and prevents addition or loss of actin subunits.	Duke Univ, Med Ctr, Dept Cell Biol & Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Bennett, V (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol & Biochem, Durham, NC 27710 USA.			Li, Xiaolin/0000-0001-9611-2434				BENNETT V, 1988, J BIOL CHEM, V263, P5860; BENNETT V, 1993, ANN REV CELL BIOL, V9, P7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DERICK LH, 1992, EUR J CELL BIOL, V57, P317; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; Fowler VM, 1996, CURR OPIN CELL BIOL, V8, P86, DOI 10.1016/S0955-0674(96)80052-4; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; Kuhlman PA, 1997, BIOCHEMISTRY-US, V36, P13461, DOI 10.1021/bi970601b; LAMB JA, 1993, J BIOL CHEM, V268, P8999; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; LIN DC, 1979, P NATL ACAD SCI USA, V76, P2345, DOI 10.1073/pnas.76.5.2345; LIN HF, 1994, DEVELOPMENT, V120, P947; LING E, 1986, J BIOL CHEM, V261, P13875; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; MATSUOKA Y, 1998, IN PRESS J CELL BIOL; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MISCHE SM, 1987, J CELL BIOL, V105, P2837, DOI 10.1083/jcb.105.6.2837; NEHLS V, 1991, BLOOD, V78, P1692; PARDEE JD, 1982, METHOD CELL BIOL, V24, P217; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; Schafer DA, 1996, J CELL BIOL, V135, P169, DOI 10.1083/jcb.135.1.169; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SIEGEL DL, 1985, J CELL BIOL, V100, P775, DOI 10.1083/jcb.100.3.775; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAYLOR KA, 1994, BIOPHYS J, V67, P1976, DOI 10.1016/S0006-3495(94)80680-0; WEBER A, 1987, BIOCHEMISTRY-US, V26, P2528, DOI 10.1021/bi00383a019; WEBER A, 1994, J CELL BIOL, V127, P1672; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; YIN HL, 1981, J BIOL CHEM, V256, P9693; YIN HL, 1981, J CELL BIOL, V91, P901, DOI 10.1083/jcb.91.3.901; YIN HL, 1987, BIOESSAYS, V7, P176, DOI 10.1002/bies.950070409	54	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19329	19338		10.1074/jbc.273.30.19329	http://dx.doi.org/10.1074/jbc.273.30.19329			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668123	hybrid			2022-12-27	WOS:000074974700090
J	Druey, KM; Sullivan, BM; Brown, D; Fischer, ER; Watson, N; Blumer, KJ; Gerfen, CR; Scheschonka, A; Kehrl, JH				Druey, KM; Sullivan, BM; Brown, D; Fischer, ER; Watson, N; Blumer, KJ; Gerfen, CR; Scheschonka, A; Kehrl, JH			Expression of GTPase-deficient G(i alpha 2) results in translocation of cytoplasmic RGS4 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; RECEPTORS; FAMILY; DOMAIN; CELLS; GAIP	The members of a recently identified protein family termed regulators of G-protein signaling (RGS) act as GTPase activating proteins for certain G(alpha) subunits in vitro, but their physiological effects in cells are uncertain in the face of similar biochemical activity and overlapping patterns of tissue expression. Consistent with its activity in in vitro GTPase-activating protein assays, RGS4 interacts efficiently with endogenous proteins of the G(i) and G(q) subclasses of G(alpha) subunits but not with G(12 alpha) or G(s alpha). Unlike other RGS proteins such as RGS9, RGS-GAIP, and Sst2p, which have been reported to be largely membrane-associated, a majority of cellular RGS4 is found as a soluble protein in the cytoplasm, However, the expression of a GTPase-deficient G(i alpha) subunit (G(i alpha 2)-Q204L) resulted in the translocation of both wild type RGS4 and a non-G(1 alpha)-binding mutant (L159F) to the plasma membrane. These data suggest that RGS4 may be recruited to the plasma membrane indirectly by G-protein activation and that multiple RGS proteins within a given cell might be differentially localized to determine a physiologic response to a G-protein-linked stimulus.	NIAID, Immunoregulat Lab, Rocky Mt Labs, NIH, Bethesda, MD 20892 USA; NIAID, Mol Biol Lab, Rocky Mt Labs, NIH, Bethesda, MD 20892 USA; NIMH, Neurophysiol Lab, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Harvard University; Massachusetts General Hospital; Washington University (WUSTL)	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, Rocky Mt Labs, NIH, Bldg 10,Rm 11B-13,10 Ctr Dr,MSC 1876, Bethesda, MD 20892 USA.		Blumer, Kendall J/C-5268-2012; Kehrl, John/AAE-6292-2019	Kehrl, John/0000-0002-6526-159X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038452] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38452] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Gold SJ, 1997, J NEUROSCI, V17, P8024; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; HUNT TW, 1996, NATURE, V383, P174; INOUE A, 1992, J BIOL CHEM, V267, P10613; KLEE WA, 1974, P NATL ACAD SCI USA, V71, P3474, DOI 10.1073/pnas.71.9.3474; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Scidmore MA, 1996, J CELL BIOL, V134, P363, DOI 10.1083/jcb.134.2.363; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; VILLARO MT, 1994, BRAIN RES MOL BRAIN, V21, P30; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	26	72	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18405	18410		10.1074/jbc.273.29.18405	http://dx.doi.org/10.1074/jbc.273.29.18405			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660808	hybrid			2022-12-27	WOS:000074828500063
J	Ramotar, D; Belanger, E; Brodeur, I; Masson, JY; Drobetsky, EA				Ramotar, D; Belanger, E; Brodeur, I; Masson, JY; Drobetsky, EA			A yeast homologue of the human phosphotyrosyl phosphatase activator PTPA is implicated in protection against oxidative DNA damage induced by the model carcinogen 4-nitroquinoline 1-oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; APURINIC APYRIMIDINIC SITES; XENOPUS-LAEVIS OOCYTES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN PHOSPHATASES; FPG PROTEIN; GENES; EXPRESSION; ENDONUCLEASE	The model carcinogen 4-nitroquinoline 1-oxide (4-NQO) has historically been characterized as "UV-mimetic" with respect to its genotoxic properties. However, recent evidence indicates that 4-NQO, unlike 254-nm UV light, may exert significant cytotoxic and/or mutagenic potential via the generation of reactive oxygen species. To elucidate the response of eukaryotic cells to 4-NQO-induced oxidative stress, we isolated Saccharomyces cerevisiae mutants exhibiting hypersensitivity to the cytotoxic effects of this mutagen. One such mutant, EBY1, was cross-sensitive to the oxidative agents UVA and diamide while retaining parental sensitivities to 254-nm UV light, methyl methanesulfonate, and ionizing radiation. A complementing gene (designated yPTPA1), restoring full UVA and 4-NQO resistance to EBY1 and encoding a protein that shares 40% identity with the human phosphotyrosyl phosphatase activator hPTPA, has been isolated. Targeted deletion of yPTPA1 in wild type yeast engendered the identical pattern of mutagen hypersensitivity as that manifested by EBY1, in addition to a spontaneous mutator phenotype that was markedly enhanced upon exposure to either UVA or 4-NQO but not to 254-nm UV or methyl methanesulfonate. Moreover, the yptpa1 deletion mutant exhibited a marked deficiency in the recovery of high molecular weight DNA following 4-NQO exposure, revealing a defect at the level of DNA repair. These data (i) strongly support a role for active oxygen intermediates in determining the genotoxic outcome of 4-NQO exposure and (ii) suggest a novel mechanism in yeast involving yPtpa1p-mediated activation of a phosphatase that participates in the repair of oxidative DNA damage, implying that hPTPA may exert a similar function in humans.	Univ Montreal, Ctr Rech, Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada	Universite de Montreal	Ramotar, D (corresponding author), Univ Montreal, Ctr Rech, Hop Maison Neuve Rosemont, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	dramotar@hmr.qc.ca		Masson, Jean Yves/0000-0002-4403-7169				Ariza RR, 1996, NUCLEIC ACIDS RES, V24, P433, DOI 10.1093/nar/24.3.433; ARMSTRONG JD, 1992, MUTAT RES, V268, P83, DOI 10.1016/0027-5107(92)90086-H; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; FELKNER C, 1968, J BACTERIOL, V96, P1448, DOI 10.1128/JB.96.4.1448-1449.1968; GALIEGUEZOUITINA S, 1986, CANCER RES, V46, P1858; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Guthrie C, 1991, METHODS ENZYMOL, V194; He CH, 1996, CAN J MICROBIOL, V42, P1263, DOI 10.1139/m96-164; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; KOHDA K, 1986, BIOCHEM BIOPH RES CO, V139, P626, DOI 10.1016/S0006-291X(86)80036-5; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Masson JY, 1996, MOL CELL BIOL, V16, P2091; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUNBY W, 1993, PHYSIOL REV, V73, P673; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; Ramotar D, 1997, BIOCHEM CELL BIOL, V75, P327, DOI 10.1139/bcb-75-4-327; RAMOTAR D, 1995, MOL CELL BIOCHEM, V145, P185, DOI 10.1007/BF00935491; Ramotar D, 1996, J BIOL CHEM, V271, P7368, DOI 10.1074/jbc.271.13.7368; RUIZLAGUNA J, 1994, CARCINOGENESIS, V15, P425, DOI 10.1093/carcin/15.3.425; Sander M, 1997, BIOCHEMISTRY-US, V36, P6100, DOI 10.1021/bi970048y; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Sherman F., 1983, METHODS YEAST GENETI; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; SUGIMURA T, 1966, CANCER RES, V26, P1717; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; TYRRELL RM, 1990, J PHOTOCH PHOTOBIO B, V4, P349, DOI 10.1016/1011-1344(90)85014-N; TYRRELL RM, 1989, PHOTOCHEM PHOTOBIOL, V49, P407, DOI 10.1111/j.1751-1097.1989.tb09187.x; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; YAMAMOTO K, 1993, CARCINOGENESIS, V14, P1397, DOI 10.1093/carcin/14.7.1397	43	49	51	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21489	21496		10.1074/jbc.273.34.21489	http://dx.doi.org/10.1074/jbc.273.34.21489			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705277	hybrid			2022-12-27	WOS:000075492600011
J	Lee, WNP; Lim, S; Bassilian, S; Bergner, EA; Edmond, J				Lee, WNP; Lim, S; Bassilian, S; Bergner, EA; Edmond, J			Fatty acid cycling in human hepatoma cells and the effects of troglitazone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; ISOTOPOMER; BIOSYNTHESIS; GLUCOSE; RATS	Fatty acid cycling by chain shortening/elongation in the peroxisomes is an important source of fatty acids for membrane lipid synthesis. Its role in the homeostasis of nonessential fatty acids is poorly understood. We report here a study on the cycling of saturated fatty acids and the effects of troglitazone in HepG2 cells in culture using [U-C-13]stearate or [U-C-13]oleate and mass isotopomer analysis. HepG2 cells were grown in the presence of 0.7 mmol/liter [U-C-13]stearate or [U-C-13]oleate, and in the presence and absence of 50 mu M troglitazone for 72 h. Fatty acids extracted from cell pellets after saponification were analyzed by gas chromatography/mass spectrometry. Peroxisomal beta-oxidation of uniformly C-13-labeled stearate (C18:0) and oleate (C18:1) resulted in chain shortening and produced uniformly labeled palmitate (C16:0) and palmitoleate (C16:1). In untreated cells, 16% of C16:0 was derived from C18:0 and 26% of C16:1 fi om C18:1 by chain shortening. Such contributions were significantly increased by troglitazone to 23.6 and 36.6%, respectively (p < 0.001). Desaturation of stearate contributed 67% of the oleate, while reduction of oleate contributed little to stearate (2%). The desaturation of C18:0 to C18:I was not affected by troglitazone. Our results demonstrated a high degree of recycling of C18:0 and C18:1 to C16:0 and C16:1 through chain shortening and desaturation. Chain shortening was accompanied by chain elongation in the synthesis of other long chain fatty acids. Troglitazone specifically increased recycling by peroxisomal beta-oxidation of C18 to C16 fatty acids, and the interconversion of long chain fatty acids was associated with reduced de novo lipogenesis.	Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90502 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lee, WNP (corresponding author), Harbor UCLA Res & Educ Inst, 1124 W Carson St, Torrance, CA 90502 USA.	lee@gcrc.humc.edu			NCI NIH HHS [P01-CA 42710] Funding Source: Medline; NCRR NIH HHS [MO1-RR 00425] Funding Source: Medline; NIDDK NIH HHS [R01-DK46353] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046353] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AJIE HO, 1995, AM J PHYSIOL-ENDOC M, V269, pE247, DOI 10.1152/ajpendo.1995.269.2.E247; ALLMANN DW, 1965, J LIPID RES, V6, P51; BLOM KF, 1988, ANAL CHEM, V60, P966, DOI 10.1021/ac00161a004; Clarke SD, 1996, LIPIDS, V31, pS7, DOI 10.1007/BF02637044; CLARKE SD, 1997, J NUTR, V10, P1170; Edmond J, 1998, J NEUROCHEM, V70, P1227; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Fulgencio JP, 1996, DIABETES, V45, P1556, DOI 10.2337/diabetes.45.11.1556; Hajra AK, 1996, ANN NY ACAD SCI, V804, P129, DOI 10.1111/j.1749-6632.1996.tb18613.x; Hashimoto T, 1996, ANN NY ACAD SCI, V804, P86, DOI 10.1111/j.1749-6632.1996.tb18610.x; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Inoue I, 1995, METABOLISM, V44, P1626, DOI 10.1016/0026-0495(95)90085-3; LEE WNP, 1992, BIOL MASS SPECTROM, V21, P114, DOI 10.1002/bms.1200210210; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; LEE WNP, 1995, ANAL BIOCHEM, V226, P100, DOI 10.1006/abio.1995.1197; LEE WNP, 1994, AM J PHYSIOL, V266, pE372, DOI 10.1152/ajpendo.1994.266.3.E372; LOWENSTEIN JM, 1975, METHOD ENZYMOL, V34, P279; POULOS A, 1995, LIPIDS, V30, P1, DOI 10.1007/BF02537036; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Sprecher H, 1995, J LIPID RES, V36, P2471	23	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20929	20934		10.1074/jbc.273.33.20929	http://dx.doi.org/10.1074/jbc.273.33.20929			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694841	hybrid			2022-12-27	WOS:000075386100034
J	Sepuri, NBV; Gordon, DM; Pain, D				Sepuri, NBV; Gordon, DM; Pain, D			A GTP-dependent "push" is generally required for efficient protein translocation across the mitochondrial inner membrane into the matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PRECURSOR PROTEIN; NUCLEOSIDE TRIPHOSPHATES; INTERMEMBRANE SPACE; CYTOPLASMIC CHAPERONES; CHLOROPLASTS REQUIRES; YEAST MITOCHONDRIA; IMPORT MACHINERY; ATP HYDROLYSIS; OUTER-MEMBRANE; HSP70	Mitochondrial biogenesis requires translocation of numerous preproteins across both outer and inner membranes into the matrix of the organelle, This translocation process requires a membrane potential (Delta psi) and ATP, We have recently demonstrated that the efficient import of a urea-denatured preprotein into the matrix requires GTP hydrolysis (Sepuri, N, B, V., Schulke, N,, and Pain, D. (1998) J. Biol, Chem. 273, 1420-1424), We now demonstrate that GTP is generally required for efficient import of various preproteins, both native and urea-denatured, The GTP participation is localized to a particular stage in the protein import process. In the presence of Delta psi but no added nucleoside triphosphates, the transmembrane movement of preproteins proceeds only to a point early in their translocation across the inner membrane. The completion of translocation into the matrix is independent of Delta psi but is dependent on a GTP-mediated "push," This push is Likely mediated by a membrane-bound GTPase on the cis side of the inner membrane. This conclusion is based on two observations: (i) GTP does not readily cross the inner membrane barrier and hence, primarily acts outside the inner membrane to stimulate import, and (ii) the GTP-dependent stage of import does not require soluble constituents of the intermembrane space and can be observed in isolated mitoplasts, Efficient import into the matrix, however, is achieved only through the coordinated action of a cis GTP-dependent push and a trans ATP-dependent "pull."	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pain, D (corresponding author), Univ Penn, Sch Med, Dept Physiol, D403 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Sepuri, Naresh/AAF-2704-2020					BECKER K, 1992, J BIOL CHEM, V267, P5637; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CRAIG EA, 1989, MOL CELL BIOL, V9, P3000, DOI 10.1128/MCB.9.7.3000; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FUKUCHI T, 1993, GENE, V129, P141; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Horst M, 1996, PROTEIN SCI, V5, P759; HWANG S, 1989, J CELL BIOL, V109, P487, DOI 10.1083/jcb.109.2.487; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; Majima E, 1998, BIOCHEMISTRY-US, V37, P424, DOI 10.1021/bi9710683; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; Millman JS, 1997, CELL, V89, P673, DOI 10.1016/S0092-8674(00)80248-2; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; OLSEN LJ, 1992, J BIOL CHEM, V267, P433; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; PFANNER N, 1990, J BIOL CHEM, V265, P16324; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RASSOW J, 1990, FEBS LETT, V275, P190, DOI 10.1016/0014-5793(90)81469-5; SCHEKMAN R, 1994, CELL, V78, P911, DOI 10.1016/0092-8674(94)90265-8; SCHLEYER M, 1985, CELL, V43, P339, DOI 10.1016/0092-8674(85)90039-X; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; Scott SV, 1996, J CELL BIOL, V132, P63, DOI 10.1083/jcb.132.1.63; Sepuri NBV, 1998, J BIOL CHEM, V273, P1420, DOI 10.1074/jbc.273.3.1420; SOLING HD, 1982, METABOLIC COMPARTMEN, P123; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; Tokatlidis K, 1996, NATURE, V384, P585, DOI 10.1038/384585a0; TZAGOLOFF A, 1982, CELL ORGANELLES SERI; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; ZIEGLER M, 1989, FEBS LETT, V248, P182, DOI 10.1016/0014-5793(89)80457-0	51	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20941	20950		10.1074/jbc.273.33.20941	http://dx.doi.org/10.1074/jbc.273.33.20941			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694843	hybrid			2022-12-27	WOS:000075386100036
J	Young, WJ; Lee, YF; Smith, SM; Chang, CS				Young, WJ; Lee, YF; Smith, SM; Chang, CS			A bidirectional regulation between the TR2/TR4 orphan receptors (TR2/TRA) and the ciliary neurotrophic factor (CNTF) signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; STEROID-RECEPTOR; TRANSCRIPTION FACTOR; THYROID-HORMONE; ALPHA COMPONENT; SUPERFAMILY; GENE; IDENTIFICATION; DEGENERATION; EXPRESSION	Previously, we reported that the nuclear orphan receptor TRA could induce transcriptional activity via the 5th intron of the ciliary neurotrophic factor (CNTF) alpha receptor gene (CNTFR-I5). Here we show CNTF could increase TR4 expression and enhance the DNA-binding capacity of TR4. Interestingly, the expression of TR2, a close family member of TR4, could also be induced by CNTF. In return, TR2 induced CNTFR alpha transcriptional activity through binding to a direct repeat response element of AGGTCA within CNTFR-I5. The possibility of this mutual influence between TR2 and the CNTF signaling was further strengthened by in situ hybridization. Similar expression patterns of TR2 and CNTFR alpha were observed in most of the developing neural structures such as the ganglia, neural epithelia, spinal cord, and the periventricular areas of brain. Together, our data suggest that an interaction between TR2/TR4 and the CNTF signaling pathway may occur, supporting the hypothesis that TR2/TR4 may play important roles in neurogenesis.	Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Biochem, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53792 USA	University of Rochester; University of Rochester; University of Rochester; University of Wisconsin System; University of Wisconsin Madison	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	chang@pathology.rochester.edu			NATIONAL CANCER INSTITUTE [T32CA009363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09363D, CA71570] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CEDARBAUM JM, 1995, CLIN NEUROPHARMACOL, V18, P515; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FORGER NG, 1995, J NEUROBIOL, V28, P354, DOI 10.1002/neu.480280308; GUPTA SK, 1993, EUR J NEUROSCI, V5, P977, DOI 10.1111/j.1460-9568.1993.tb00949.x; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; JONK LJC, 1994, MECH DEVELOP, V47, P81, DOI 10.1016/0925-4773(94)90098-1; LEE CH, 1995, GENOMICS, V30, P46, DOI 10.1006/geno.1995.0007; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1995, J BIOL CHEM, V270, P30129; Lin DL, 1998, ENDOCRINE, V8, P123, DOI 10.1385/ENDO:8:2:123; LIN TM, 1995, J BIOL CHEM, V270, P30121; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Lydon John P., 1992, Gene Expression, V2, P273; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1994, J NEUROBIOL, V25, P1437; VALENZUELA DM, 1995, GENOMICS, V25, P157, DOI 10.1016/0888-7543(95)80121-2; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Young WJ, 1997, J BIOL CHEM, V272, P3109, DOI 10.1074/jbc.272.5.3109	33	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					20877	20885		10.1074/jbc.273.33.20877	http://dx.doi.org/10.1074/jbc.273.33.20877			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694834	hybrid			2022-12-27	WOS:000075386100027
J	Zhang, Y; Cao, L; Yang, BL; Yang, BB				Zhang, Y; Cao, L; Yang, BL; Yang, BB			The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCANS; PG-M VERSICAN; SUBSTRATUM ADHESION; LINK PROTEIN; TENASCIN-R; GENE CSPG2; 3T3 CELLS; PHENOTYPE; RECEPTOR; TISSUES	Versican is a member of the large aggregating chondroitin sulfate proteoglycan family. We have expressed in NIH3T3 fibroblasts a recombinant versican mini-gene comprising the G1 and G3 domains and 15% of the CS domain. We observed that expression of the mini-versican gene stimulated cell proliferation as determined by cell counting and cell cycle analysis. Addition of exogenous mini-versican protein to cultured cells produced the same result. The effects of the mini-versican were greatly reduced when the G3 domain was deleted. Expression of the G3 domain alone promotes cell proliferation, and addition of purified G3 gene products to NIH3T3 fibroblasts and cultured chicken fibroblasts enhances cell growth. Further, deletion of the epidermal growth factor (EGF)-like motifs in the versican G3 domain reduced the effects of the mini-versican on cell proliferation. In the presence of the purified mini-versican protein, antisense oligonucleotides to the EGF receptor inhibited proliferation of NIH3T3 fibroblasts, compared with control sense oligonucleotides. Taken together, these results imply that versican enhances cell proliferation, and this effect is mediated, at least in part, by the action of versican EGF-like motifs on endogenous EGF receptor.	Univ Toronto, Sunnybrook Hlth Sci Ctr, Trauma Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Yang, BB (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Trauma Res Program, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BITTERMAN PB, 1983, J CELL BIOL, V97, P1925, DOI 10.1083/jcb.97.6.1925; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DONALD RGK, 1995, P NATL ACAD SCI USA, V92, P5749, DOI 10.1073/pnas.92.12.5749; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DUCROS DL, 1995, J INVEST DERMATOL, V105, P426, DOI 10.1111/1523-1747.ep12321131; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HAMADA H, 1995, BLOOD, V86, P225, DOI 10.1182/blood.V86.1.225.bloodjournal861225; IOZZO RV, 1992, GENOMICS, V14, P845, DOI 10.1016/S0888-7543(05)80103-X; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; NASO MF, 1994, J BIOL CHEM, V269, P32999; NASO MF, 1995, GENOMICS, V29, P297, DOI 10.1006/geno.1995.1251; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; Sambrook J., 2002, MOL CLONING LAB MANU; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; YAMAGATA M, 1993, J CELL SCI, V106, P55; YAMAGATA M, 1994, J CELL SCI, V107, P2581; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; YAMAGATA M, 1989, J BIOL CHEM, V264, P8012; YANG BB, 1997, MATRIX BIOL, V16, P541; YANG BH, 1994, J BIOL CHEM, V269, P4506; YAO LY, 1994, MATRIX BIOL, V14, P213, DOI 10.1016/0945-053X(94)90185-6; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	41	130	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21342	21351		10.1074/jbc.273.33.21342	http://dx.doi.org/10.1074/jbc.273.33.21342			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694895	hybrid			2022-12-27	WOS:000075386100088
J	Caamano, CA; Morano, MI; Dalman, FC; Pratt, WB; Akil, H				Caamano, CA; Morano, MI; Dalman, FC; Pratt, WB; Akil, H			A conserved proline in the hsp90 binding region of the glucocorticoid receptor is required for hsp90 heterocomplex stabilization and receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; GLUTATHIONE-S-TRANSFERASE; NON-DNA-BINDING; STEROID-RECEPTOR; HORMONE-BINDING; ESCHERICHIA-COLI; 90-KDA; TRANSFORMATION; COMMON; CELLS	Studies of hsp90 in yeast have supported the notion that this chaperone plays a critical role in signaling by steroid receptors. One limitation to these studies is that yeast expressing hsp90 mutants may also be deficient in fundamental cellular functions of the chaperone required for steroid-dependent induction of transcription. In this work, we have prepared mutants of the glucocorticoid receptor (GR) that permit analysis of hsp90 binding and transcriptional activity in cells with normal chaperone function. Our previous data supported a model in which hsp90 binds to the receptor steroid binding domain according to a two-site model. By amino acid mutagenesis of these two sites, we have now generated three receptor mutants and analyzed their function. Upon their translation in vitro, all three mutants interacted with hsp90 similarly to the wild-type receptor. However, one mutant, P643A (GRo), was of particular interest because, although it showed normal steroid binding and transformation to a glucocorticoid response element-specific DNA binding form, it was remarkably deficient in nuclear translocation and transcriptional function at 37 degrees C. Furthermore, GRo.hspSO heterocomplexes formed in vivo or assembled under cell-free conditions were much less stable than wild-type GR.hsp90 heterocomplexes. Our results demonstrate that Pro-643 plays a critical role in both stabilizing the receptor.hsp90 complex and in permitting an efficient nuclear translocation and, thus, support the concept that the chaperone is an integral component of the steroid-receptor signaling pathway.	Univ Michigan, Mental Hlth Res Inst, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pharmacol, Sch Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Caamano, CA (corresponding author), Univ Michigan, Mental Hlth Res Inst, Sch Med, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	ccaamano@umich.edu			NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034933] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIDDK NIH HHS [DK34933] Funding Source: Medline; NIMH NIH HHS [MH42251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bamberger CM, 1997, MOL CELL ENDOCRINOL, V131, P233, DOI 10.1016/S0303-7207(97)00115-9; BOHEN SP, 1993, P NATL ACAD SCI USA, V90, P11424, DOI 10.1073/pnas.90.23.11424; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAAMANO CA, 1994, ANN NY ACAD SCI, V746, P68; CAAMANO CA, 1993, BIOCHEMISTRY-US, V32, P8589, DOI 10.1021/bi00084a028; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOLBROOK NJ, 1983, J BIOL CHEM, V258, P6477; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCBLAIN WA, 1981, BIOCHEMISTRY-US, V20, P6790, DOI 10.1021/bi00527a008; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PRATT WB, 1988, J BIOL CHEM, V263, P267; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; SCHUH S, 1985, J BIOL CHEM, V260, P4292; Segnitz B, 1997, J BIOL CHEM, V272, P18694, DOI 10.1074/jbc.272.30.18694; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342	39	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20473	20480		10.1074/jbc.273.32.20473	http://dx.doi.org/10.1074/jbc.273.32.20473			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685402	hybrid			2022-12-27	WOS:000075305400079
J	Choi, SY; Goldberg, IJ; Curtiss, LK; Cooper, AD				Choi, SY; Goldberg, IJ; Curtiss, LK; Cooper, AD			Interaction between ApoB and hepatic lipase mediates the uptake of ApoB-containing lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; APOLIPOPROTEIN-B; CHYLOMICRON REMNANTS; RAT-LIVER; CHOLESTERYL ESTER; LDL RECEPTOR; BINDING; CELLS; PLASMA	Hepatic lipase (HL) on the surface of hepatocytes and endothelial cells lining hepatic sinusoids, the adrenal glands, and the ovary hydrolyzes triglycerides and phospholipids of circulating Lipoproteins. Its expression significantly enhances low density lipoprotein (LDL) uptake via the LDL receptor pathway. A specific interaction between LPL, a homologous molecule to HL, and apoB has been described (Choi, S. Y,, Sivaram, P,, Walker, D. E,, Curtiss, L, I,, Gretch, D, G,, Sturley, S. L,, Attie, A. D,, Deckelbaum, Il, J,, and Goldberg, I. J, (1995) J. Biol. Chem. 270, 8081-8086), The present studies tested the hypothesis that HL enhances the uptake of lipoproteins by a specific interaction of HL with apoB, On a ligand blot, HL bound to apoB26, 48, and 100 but not to apoE or apoAI, HL binding to LDL in a plate assay with LDL-coated plates was significantly greater than to bovine serum albumin-coated plates. Neither heat denatured HL nor bacterial fusion protein of HL bound to LDL in the plate assays. I-125-LDL bound to HL-saturated heparin-agarose gel with a K-d of 52 nM, and somewhat surprisingly, this binding was not inhibited by excess LPL, In cell culture experiments HL enhanced the uptake of I-125-LDL,at both 4 and 37 degrees C, The enhanced binding and uptake of LDL was significantly inhibited by monoclonal anti-apoB antibodies. In contrast to LPL, both amino- and carboxyl-terminal antibodies blocked the apoB interaction with HL to the same extent. Thus, we conclude that there is a unique interaction between HL and apoB that facilitates the uptake of apoB-containing lipoproteins by cells where HL is present.	Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Palo Alto Medical Foundation Research Institute; Columbia University; Stanford University; Scripps Research Institute	Choi, SY (corresponding author), Palo Alto Med Fdn, Res Inst, 860 Bryant St, Palo Alto, CA 94301 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL045095, R01HL045095, R29HL058034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038318] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45095, HL58034] Funding Source: Medline; NIDDK NIH HHS [DK38318] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVIRAM M, 1988, J BIOL CHEM, V263, P15416; BACH JF, 1978, ANTIGEN ANTIBODY REA, P248; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHOI SSY, 1994, J LIPID RES, V35, P848; Choi SY, 1997, J LIPID RES, V38, P77; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; COOPER AD, 1977, BIOCHIM BIOPHYS ACTA, V488, P464, DOI 10.1016/0005-2760(77)90204-1; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; deFaria E, 1996, J LIPID RES, V37, P197; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; GOLDBERG IJ, 1986, J CLIN INVEST, V78, P1523, DOI 10.1172/JCI112744; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P114; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HIDE WA, 1992, J LIPID RES, V33, P167; Ingram MF, 1997, J BIOL CHEM, V272, P10279; JANSEN H, 1981, BIOCHEM J, V196, P739, DOI 10.1042/bj1960739; JANSEN H, 1980, BIOCHIM BIOPHYS ACTA, V619, P119, DOI 10.1016/0005-2760(80)90248-9; JENSEN GL, 1980, J BIOL CHEM, V255, P1141; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; JI ZS, 1994, J BIOL CHEM, V269, P13429; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KOMAROMY MC, 1991, J LIPID RES, V32, P963; Krapp A, 1996, J LIPID RES, V37, P926; Kreuzer J, 1997, J LIPID RES, V38, P324; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURASE T, 1981, ATHEROSCLEROSIS, V39, P293, DOI 10.1016/0021-9150(81)90015-0; REDGRAVE TG, 1977, ATHEROSCLEROSIS, V28, P69, DOI 10.1016/0021-9150(77)90200-3; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAFI S, 1994, J LIPID RES, V35, P709; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035	40	25	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20456	20462		10.1074/jbc.273.32.20456	http://dx.doi.org/10.1074/jbc.273.32.20456			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685400	hybrid			2022-12-27	WOS:000075305400077
J	Engelman, JA; Lee, RJ; Karnezis, A; Bearss, DJ; Webster, M; Siegel, P; Muller, WJ; Windle, JJ; Pestell, RG; Lisanti, MP				Engelman, JA; Lee, RJ; Karnezis, A; Bearss, DJ; Webster, M; Siegel, P; Muller, WJ; Windle, JJ; Pestell, RG; Lisanti, MP			Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo - Implications for human breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; MAMMARY-TUMORS; GENE FAMILY; MEMBRANE; CELLS; INDUCTION; ONCOGENE; MUSCLE; IDENTIFICATION; PROTOONCOGENE	Neu (c-erbB2) is a proto-oncogene product that encodes an epidermal growth factor-like receptor tyrosine kinase, Amplification of wild-type c-Neu and mutational activation of Neu (Neu T) have been implicated in oncogenic transformation of cultured fibroblasts and mammary tumorigenesis in vivo. Here, we examine the relationship between Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Recent studies have suggested that caveolins may function as negative regulators of signal transduction, Our current results show that mutational activation of c-Neu down-regulates caveolin-1 protein expression, but not caveolin-2, in cultured NIH 3T3 and Rat 1 cells. Conversely, recombinant overexpression of caveolin-1 blocks Neu-mediated signal transduction in vice. These results suggest a reciprocal relationship between c-Neu tyrosine kinase activity and caveolin-1 protein expression. We next analyzed a variety of caveolin-1 deletion mutants to map this caveolin-1-dependent inhibitory activity to a given region of the caveolin-1 molecule. Results from this mutational analysis show that this functional in vivo inhibitory activity is contained within caveolin-1 residues 82-95, in accordance with these in vivo studies, a 20-amino acid peptide derived from this region (the caveolin-1 scaffolding domain) was sufficient to inhibit Neu autophosphorylation in an in vitro kinase assay. To further confirm or refute the relevance of our findings in vivo, we next examined the expression levels of caveolin-1 in mammary tumors derived from c-Neu transgenic mice. Our results indicate that dramatic reduction of caveolin-1 expression occurs in mammary tumors derived from c-Neu-expressing transgenic mice and other transgenic mice expressing downstream effecters of Neu-mediated signal transduction, such as Src and Ras, Taken together, our data suggest that a novel form of reciprocal negative regulation exists between c-Neu and caveolin-1.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; McMaster Univ, Dept Pathol, W Hamilton, ON L8S 4K1, Canada; Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; McMaster University; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Albert Einstein Canc Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Bearss, David/Q-9141-2019	Lisanti, Michael/0000-0003-2034-1382; Windle, Jolene/0000-0001-6690-385X; Bearss, David/0000-0002-4458-826X; Bearss, David/0000-0002-4280-5670	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443, T32GM007288] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA13330-26] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288, GM-50443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Brown D, 1996, HISTOCHEM CELL BIOL, V105, P261, DOI 10.1007/BF01463929; CACERES A, 1984, J NEUROSCI, V4, P394; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, TRENDS CARDIOVAS MED, V7, P103, DOI 10.1016/S1050-1738(97)00001-7; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hundley JE, 1997, CANCER RES, V57, P600; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Oka N, 1997, J BIOL CHEM, V272, P33416, DOI 10.1074/jbc.272.52.33416; PATERSON MC, 1991, CANCER RES, V51, P556; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; POLLARD JW, 1979, J CELL PHYSIOL, V98, P571, DOI 10.1002/jcp.1040980315; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; XIE YM, 1995, ONCOGENE, V10, P2409	43	190	200	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20448	20455		10.1074/jbc.273.32.20448	http://dx.doi.org/10.1074/jbc.273.32.20448			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685399	hybrid			2022-12-27	WOS:000075305400076
J	Negulescu, D; Leong, LEC; Chandy, KG; Semler, BL; Gutman, GA				Negulescu, D; Leong, LEC; Chandy, KG; Semler, BL; Gutman, GA			Translation initiation of a cardiac voltage-gated potassium channel by internal ribosome entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; ENCEPHALOMYOCARDITIS VIRUS-RNA; MESSENGER-RNA; POLIOVIRUS RNA; K+ CHANNELS; GENE; SEQUENCE; REGION; COMPLEX; INVITRO	The mammalian Kv1.4 voltage-gated potassium channel mRNA contains an unusually long (1.2 kilobases) 5'-untranslated region (UTR) and includes 18 AUG codons upstream of the authentic site of translation initiation. Computer-predicted secondary structures of this region reveal complex stem-loop structures that would serve as barriers to 5' --> 3' ribosomal scanning. These features suggested that translation initiation in Kv1.4 might occur by the mechanism of internal ribosome entry, a mode of initiation employed by a variety of RNA viruses but only a limited number of vertebrate genes. To test this possibility we introduced the 5'-UTR of mouse Kv1.4 mRNA into the intercistronic region of a bicistronic vector containing two tandem reporter genes, chloramphenicol acetyltransferase and luciferase, The control construct translated only the upstream chloramphenicol cistron in transiently transfected mammalian cells. In contrast, the construct containing the mKv1.4 UTR efficiently translated the luciferase cistron as well, demonstrating the presence of an internal ribosome entry segment. Progressive 5' --> 3' deletions localized the activity to a 3'-proximal 200-nucleotide fragment. Suppression of cap-dependent translation by extracts from poliovirus-infected HeLa cells in an in vitro translation assay eliminated translation of the upstream cistron while allowing translation of the downstream cistron, Our results indicate that the 8'-untranslated region of mKv1.4 contains a functional internal ribosome entry segment that may contribute to unusual and physiologically important modes of translation regulation for this and other potassium channel genes.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Gutman, GA (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.		Semler, Bert/AAV-8795-2020	Semler, Bert/0000-0002-2424-5155	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026765, R56AI026765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054872, R01GM054221] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26765] Funding Source: Medline; NIGMS NIH HHS [GMOD54872, GM54221] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI N, 1995, J VIROL, V69, P6367, DOI 10.1128/JVI.69.10.6367-6375.1995; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; Blyn LB, 1997, J VIROL, V71, P6243, DOI 10.1128/JVI.71.8.6243-6246.1997; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; deQuinto SL, 1997, J VIROL, V71, P4171; Ehrenfeld E, 1995, CURR TOP MICROBIOL, V203, P65; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GABELLE AP, 1996, TRANSLATIONAL CONTRO, P173; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Hille B., 1992, IONIC CHANNELS EXCIT; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Jackson RJ, 1995, RNA, V1, P985; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Kaminski A, 1995, RNA, V1, P924; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; Lee TE, 1996, J MEMBRANE BIOL, V151, P225, DOI 10.1007/s002329900073; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; MACEJAK DG, 1990, ENZYME, V44, P310, DOI 10.1159/000468767; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Nguyen A, 1996, MOL PHARMACOL, V50, P1672; Niepmann M, 1997, J VIROL, V71, P8330, DOI 10.1128/JVI.71.11.8330-8339.1997; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PALLANCK L, 1994, HUM MOL GENET, V3, P1239, DOI 10.1093/hmg/3.8.1239; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PESOLE G, 1994, GENE, V140, P219, DOI 10.1016/0378-1119(94)90547-9; Rijnbrand R, 1997, J VIROL, V71, P451, DOI 10.1128/JVI.71.1.451-457.1997; ROEHL HH, 1995, J VIROL, V69, P2954, DOI 10.1128/JVI.69.5.2954-2961.1995; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Stewart SR, 1997, SEMIN VIROL, V8, P242, DOI 10.1006/smvy.1997.0127; Tenenholz TC, 1997, BIOCHEMISTRY-US, V36, P2763, DOI 10.1021/bi9628432; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557	45	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20109	20113		10.1074/jbc.273.32.20109	http://dx.doi.org/10.1074/jbc.273.32.20109			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685353	hybrid			2022-12-27	WOS:000075305400030
J	Kolatkar, AR; Leung, AK; Isecke, R; Brossmer, R; Drickamer, K; Weis, WI				Kolatkar, AR; Leung, AK; Isecke, R; Brossmer, R; Drickamer, K; Weis, WI			Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MANNOSE-BINDING; SUGAR LIGANDS; PROTEIN; MACROPHAGES	The mammalian hepatic asialoglycoprotein receptor, a member of the C-type animal lectin family, displays preferential binding to N-acetylgalactosamine compared with galactose. The structural basis for selective binding to N-acetylgalactosamine has been investigated. Regions of the carbohydrate-recognition domain of the receptor believed to be important in preferential binding to N-acetylgalactosamine have been inserted into the homologous carbohydrate-recognition domain of a mannose-binding protein mutant that was previously altered to bind galactose, Introduction of a single histidine residue corresponding to residue 256 of the hepatic asialoglycoprotein receptor was found to cause a 14-fold increase in the relative affinity for N-acetylgalactosamine compared with galactose, The relative ability of various acyl derivatives of galactosamine 60 compete for binding to this modified carbohydrate-recognition domain suggest that it is a good model for the natural N-acetylgalactosamine binding site of the asialoglycoprotein receptor. Crystallographic analysis of this mutant carbohydrate-recognition domain in complex with N-acetylgalactosamine reveals a direct interaction between the inserted histidine residue and the methyl group of the N-acetyl substituent of the sugar. Evidence for the role of the side chain at position 208 of the receptor in positioning this key histidine residue was obtained from structural analysis and mutagenesis experiments. The corresponding serine residue in the modified carbohydrate-recognition domain of mannose-binding protein forms a hydrogen bond to the imidazole side chain. When this serine residue is changed to valine, loss in selectivity for N-acetylgalactosamine is observed, The structure of this mutant reveals that the beta-branched valine side chain interacts directly with the histidine side chain, resulting in an altered imidazole ring orientation.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Heidelberg Univ, Inst Biochem 2, D-69120 Heidelberg, Germany	Stanford University; University of Oxford; Ruprecht Karls University Heidelberg	Weis, WI (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	weis@fucose.stanford.edu	Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Leung, Anthony/0000-0001-5569-4036	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050565] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50565] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission)		BRUNGER AT, 1998, IN PRESS ACTA CRYS D; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DAVIDSON EA, 1966, METHOD ENZYMOL, V8, P52; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HORTON D, 1966, BIOCH PREP, V11, P1; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; IOBST ST, 1994, J BIOL CHEM, V269, P15505; ISECKE R, 1993, TETRAHEDRON, V49, P10009, DOI 10.1016/S0040-4020(01)80197-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWASAKI T, 1986, CARBOHYD RES, V151, P197, DOI 10.1016/S0008-6215(00)90340-9; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Maniatis T., 1982, MOL CLONING; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PERKINS SJ, 1980, BIOCHEMISTRY-US, V19, P245, DOI 10.1021/bi00543a001; SARKAR M, 1979, J BIOL CHEM, V254, P3170; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3	24	67	75	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19502	19508		10.1074/jbc.273.31.19502	http://dx.doi.org/10.1074/jbc.273.31.19502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677372	hybrid			2022-12-27	WOS:000075125200024
J	Quinn, SJ; Kifor, O; Trivedi, S; Diaz, R; Vassilev, P; Brown, E				Quinn, SJ; Kifor, O; Trivedi, S; Diaz, R; Vassilev, P; Brown, E			Sodium and ionic strength sensing by the calcium receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE RELEASE; BODY-FLUID HOMEOSTASIS; RAT SUBFORNICAL ORGAN; D-ASPARTATE RECEPTOR; EXTRACELLULAR CALCIUM; LAMINA-TERMINALIS; EXPRESSION; CELLS; CLONING; BOVINE	The calcium-sensing receptor (CaR) is activated by small changes in extracellular calcium [Ca2+](o)) in the physiological range, allowing the parathyroid gland to regulate serum [Ca2+](o); however, the CaR is also distributed in a number of other tissues where it may sense other endogenous agonists and modulators. CaR agonists are polycationic molecules, and charged residues in the extracellular domain of the CaR appear critical for receptor activation through electrostatic interactions, suggesting that ionic strength could modulate CaR activation by polycationic agonists, Changes in the concentration of external NaCl potently altered the activation of the CaR by external Ca2+ and spermine. Ionic strength had an inverse effect on the sensitivity of CaR to its agonists, with lowering of ionic strength rendering the receptor more sensitive to activation by [Ca2+](o) and raising of ionic strength producing the converse effect. Effects of osmolality could not account for the modulation seen with changes in NaCl, Other salts, which differed in the cationic or anionic species, showed shifts in the activation of the CaR by [Ca2+](o) similar to that elicited by NaCl, Parathyroid cells were potently modulated by ionic strength, with addition of 40 mM NaCl shifting the EC50 for [Ca2+](o) inhibition of parathyroid hormone by at least 0.5 mM, Several CaR-expressing tissues, including regions of the brain such as the subfornical organ and hypothalamus, could potentially use the CaR as a sensor for ionic strength and NaCl, The Journal guidelines state that the summary should be no longer than 200 words.	Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Quinn, SJ (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Dept Med, 221 Longwood Ave, Boston, MA 02115 USA.		Vehi, Josep/D-6602-2013	Vehi, Josep/0000-0001-6884-9789	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415, R01DK044588, R01DK048330] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41415, DK44588, DK48330] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; BATES RG, 1970, ANAL CHEM, V42, P867, DOI 10.1021/ac60290a006; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1995, CELL, V83, P679, DOI 10.1016/0092-8674(95)90180-9; BROWN EM, 1990, ENDOCRINOLOGY, V127, P1064, DOI 10.1210/endo-127-3-1064; BUTLER JN, 1968, BIOPHYS J, V8, P1426, DOI 10.1016/S0006-3495(68)86564-6; Denton DA, 1996, P NATL ACAD SCI USA, V93, P7397, DOI 10.1073/pnas.93.14.7397; Emanuel RL, 1996, MOL ENDOCRINOL, V10, P555, DOI 10.1210/me.10.5.555; Fitzsimons J T, 1989, Acta Physiol Scand Suppl, V583, P15; GARRETT JE, 1995, ENDOCRINOLOGY, V136, P5202, DOI 10.1210/en.136.11.5202; Hebert S C, 1996, Curr Opin Nephrol Hypertens, V5, P45, DOI 10.1097/00041552-199601000-00009; Johnson AK, 1996, CLIN EXP PHARMACOL P, V23, P183, DOI 10.1111/j.1440-1681.1996.tb02594.x; JOHNSON AK, 1993, FASEB J, V7, P678, DOI 10.1096/fasebj.7.8.8500693; LEBOFF MS, 1985, J CLIN INVEST, V75, P49, DOI 10.1172/JCI111696; LENG G, 1982, NEUROENDOCRINOLOGY, V34, P75, DOI 10.1159/000123280; LOBAUGH B, 1980, J NTUR, V111, P298; McKinley MJ, 1996, CLIN EXP PHARMACOL P, V23, P271, DOI 10.1111/j.1440-1681.1996.tb02823.x; OLDFIELD BJ, 1991, BRAIN RES, V561, P151, DOI 10.1016/0006-8993(91)90760-S; OLIET SHR, 1994, TRENDS NEUROSCI, V17, P340, DOI 10.1016/0166-2236(94)90177-5; PULLAN LM, 1992, J NEUROCHEM, V59, P2087; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; REYNOLDS IJ, 1988, EUR J PHARMACOL, V151, P103, DOI 10.1016/0014-2999(88)90697-8; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; Richter CP, 1937, ENDOCRINOLOGY, V21, P50, DOI 10.1210/endo-21-1-50; ROCK DM, 1995, ANNU REV PHARMACOL, V35, P463; Rogers KV, 1997, BRAIN RES, V744, P47, DOI 10.1016/S0006-8993(96)01070-0; ROMANO C, 1994, NEUROPHARMACOLOGY PO, P81; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SANDS JM, 1997, J CLIN INVEST, V99, P1917; SHAW GG, 1994, NEUROPHARMACOLOGY PO, P61; SIBBALD JR, 1988, BRAIN RES, V461, P205, DOI 10.1016/0006-8993(88)90251-X; SIGGAARDANDERSEN O, 1983, SCAND J CLIN LAB INV, V43, P11; SMITH DW, 1995, BRAIN RES, V698, P232, DOI 10.1016/0006-8993(95)00975-V; TARJAN E, 1984, PHYSL THIRST SODIUM, P473; THORNTON SN, 1984, PHYSL THIRST SODIUM, P103; THRASHER TN, 1980, AM J PHYSIOL, V238, pR333, DOI 10.1152/ajpregu.1980.238.5.R333; Tordoff MG, 1996, NEUROSCI BIOBEHAV R, V20, P89, DOI 10.1016/0149-7634(95)00051-F; TRAYNELIS SF, 1995, SCIENCE, V268, P873, DOI 10.1126/science.7754371; WEISINGER RS, 1984, PHYSL THIRST SODIUM, P485	40	113	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19579	19586		10.1074/jbc.273.31.19579	http://dx.doi.org/10.1074/jbc.273.31.19579			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677383	hybrid			2022-12-27	WOS:000075125200035
J	Zimmermann, G; Zhou, DM; Taussig, R				Zimmermann, G; Zhou, DM; Taussig, R			Mutations uncover a role for two magnesium ions in the catalytic mechanism of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROTEIN; PURIFICATION; EXPRESSION; ALPHA; SUBUNITS; BETA	The recent determination of the crystal structure of adenylyl cyclase has elucidated many structural features that determine the regulatory properties of the enzyme. In addition, the characterization of adenylyl cyclase by mutagenic techniques and the identification of the binding site for P-site inhibitors have led to modeling studies that describe the ATP-binding site. Despite these advances, the catalytic mechanism of adenylyl cyclase remains uncertain, especially with respect to the role that magnesium ions may play in this process. We have identified four mutant mammalian adenylyl cyclases defective in their metal dependence, allowing us to further characterize the function of metal ions in the catalytic mechanism of this enzyme. The wild-type adenylyl cyclase shows a biphasic Mg2+ dose-response curve in which the high-affinity component displays cooperativity (Hill coefficient of 1.4). Two mutations (C441R and Y442H) reduce the affinity of the adenylyl cyclase for Mg2+ dramatically without affecting the binding of MgATP, suggesting that there is a metal requirement in addition to the ATP-bound Mg2+. The results of this study thus demonstrate multiple metal requirements of adenylyl cyclase and support the existence of a Mg2+ ion essential for catalysis and distinct from the ATP-bound ion. We propose that adenylyl cyclase employs a catalytic mechanism analogous to that of DNA polymerase, in which two key magnesium ions facilitate the nucleophilic attack, of the S'-hydroxyl group and the subsequent elimination of pyrophosphate.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Taussig, R (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 3301E MSRB III, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053645] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53645] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; CASPERSON GF, 1985, P NATL ACAD SCI USA, V82, P5060, DOI 10.1073/pnas.82.15.5060; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; COOPER DMF, 1998, ADV 2 MESSENGERS PHO, V32, P1; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; LEE E, 1994, METHOD ENZYMOL, V237, P146; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MATSUMOTO K, 1981, MOL CELL BIOL, V1, P83, DOI 10.1128/MCB.1.2.83; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Segel I.H., 1975, ENZYME KINETICS BEHA, Vsecond, P100; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SOMKUTI SG, 1982, J BIOL CHEM, V257, P6387; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; VORHERR T, 1993, BIOCHEMISTRY-US, V32, P6081, DOI 10.1021/bi00074a020; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WU ZL, 1993, J BIOL CHEM, V268, P23766; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P18849, DOI 10.1074/jbc.272.30.18849; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0; Zimmermann G, 1998, J BIOL CHEM, V273, P6968, DOI 10.1074/jbc.273.12.6968	33	50	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19650	19655		10.1074/jbc.273.31.19650	http://dx.doi.org/10.1074/jbc.273.31.19650			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677392	hybrid			2022-12-27	WOS:000075125200044
J	Lee, KK; Murakawa, M; Takahashi, S; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S				Lee, KK; Murakawa, M; Takahashi, S; Tsubuki, S; Kawashima, S; Sakamaki, K; Yonehara, S			Purification, molecular cloning, and characterization of TRP32, a novel thioredoxin-related mammalian protein of 32 kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; NF-KAPPA-B; ESCHERICHIA-COLI; DISULFIDE-ISOMERASE; REDOX REGULATION; REDUCTION; CELL; ANTIOXIDANTS; ACTIVATION; RECEPTOR	We purified a protein of 32 kDa from human thymoma HPB-ALL cells that was co-purified with a catalytic fragment of MST (mammalian STE-20-like), a kinase of the STE20 family, which is proteolytically activated by caspase in apoptosis (Lee, K.-K., Murakawa, M., Nishida, E., Tsubuki, S., Kawashima, S., Sakamaki, K., and Yonehara, S. (1998) Oncogene 16, in press). Molecular cloning of the gene encoding this 32-kDa protein (TRP32) reveals that it is a novel protein of 289 amino acid residues and contains an NH2-terminal thioredoxin domain with a conserved thioredoxin active site. The human and mouse TRP32 proteins have 99% homology, and the thioredoxin domains are completely identical. The thioredoxin domain of TRP32 has thioredoxin-like reducing activity, which can reduce the interchain disulfide bridges of insulin in vitro. However, the thioredoxin domain of TRP32 is more sensitive to oxidation than human thioredoxin. Northern blot analysis showed that TRP32 is expressed in all human tissues. Expression of TRP32 was also confirmed in all mammalian cell lines tested by Western blot analysis using anti-TRP32 monoclonal antibody. Subcellular fractionation and immunostaining analysis showed TRP32 is cytoplasmic protein. These findings suggest that TRP32 is a novel cytoplasmic regulator of the redox state in higher eukaryotes.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Tokyo Metropolitan Inst Med Sci, Tokyo 1130021, Japan	Kyoto University; Tokyo Metropolitan Institute of Medical Science	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kawahara Cho, Kyoto 6068507, Japan.	syonehar@virus.kyoto-u.ac.jp		Sakamaki, Kazuhiro/0000-0002-7072-9628				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FORMANKAY JD, 1991, BIOCHEMISTRY-US, V30, P2685, DOI 10.1021/bi00224a017; FREEDMAN RB, 1988, BIOCHEM SOC T, V16, P96, DOI 10.1042/bst0160096; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; LEE KK, 1998, IN PRESS ONCOGENE, V16; LIM CJ, 1985, J BACTERIOL, V161, P799, DOI 10.1128/JB.161.2.799-802.1985; LOFERER H, 1994, TRENDS BIOCHEM SCI, V19, P169, DOI 10.1016/0968-0004(94)90279-8; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; NEWMAN GW, 1994, J EXP MED, V180, P359, DOI 10.1084/jem.180.1.359; OKAMOTO T, 1992, INT IMMUNOL, V4, P811, DOI 10.1093/intimm/4.7.811; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; RUSSEL M, 1985, P NATL ACAD SCI USA, V82, P29, DOI 10.1073/pnas.82.1.29; SCHALLREUTER KU, 1986, BIOCHEM BIOPH RES CO, V136, P630, DOI 10.1016/0006-291X(86)90487-0; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; TSANG MLS, 1976, J BACTERIOL, V125, P923, DOI 10.1128/JB.125.3.923-933.1976; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	41	78	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19160	19166		10.1074/jbc.273.30.19160	http://dx.doi.org/10.1074/jbc.273.30.19160			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668102	hybrid			2022-12-27	WOS:000074974700069
J	Scheenen, WJJM; Wollheim, CB; Pozzan, T; Fasolato, C				Scheenen, WJJM; Wollheim, CB; Pozzan, T; Fasolato, C			Ca2+ depletion from granules inhibits exocytosis - A study with insulin-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; CHROMAFFIN CELLS; RECEPTOR SUBTYPE-3; SYNAPTIC VESICLES; B-CELLS; CALCIUM; RELEASE; MITOCHONDRIAL; PHOSPHATE; ISLETS	The secretory compartment is characterized by low luminal pH and high Ca2+ content. Previous studies in several cell types have shown that the size of the acidic Ca2+ pool, of which secretory granules represent a major portion, could be estimated by applying first a Ca2+ ionophore followed by agents that collapse acidic pH gradients. In the present study we have employed this protocol in the insulin-secreting cell line Ins-1 to determine whether the Ca2+ trapped in the secretory granules plays a role in exocytosis. The results demonstrate that a high proportion of ionophore-mobilizable Ca2+ in Ins-1 cells resides in the acidic compartment. The latter pool, however, does not significantly contribute to the [Ca2+](i) changes elicited by thapsigargin and the inositol trisphosphate-producing agonist carbachol. By monitoring membrane capacitance at the single cell level or by measuring insulin release in cell populations, we show that Ca2+ mobilization from nonacidic Ca2+ pools causes a profound and long lasting increase in depolarization-induced secretion, whereas breakdown of granule pH had no significant effect. In contrast, releasing Ca2+ from the acidic pool markedly reduces secretion. It is suggested that a high Ca2+ concentration in the secretory compartment is needed to sustain optimal exocytosis.	Univ Padua, Dept Biomed Sci, Ctr Biomembranes, Consiglio Nazl Ric, I-35100 Padua, Italy; Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Geneva	Scheenen, WJJM (corresponding author), Univ Nijmegen, Dept Cellular Anim Physiol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	scheenen@sci.kun.nl	Scheenen, Wim/E-3674-2012; Fasolato, Cristina/AAE-6024-2019	Fasolato, Cristina/0000-0002-9816-7751				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; Austin CD, 1996, J BIOL CHEM, V271, P1194, DOI 10.1074/jbc.271.2.1194; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Calakos N, 1996, PHYSIOL REV, V76, P1; CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; Chilcoat ND, 1996, J CELL BIOL, V135, P1775, DOI 10.1083/jcb.135.6.1775; CHOW RH, 1994, P NATL ACAD SCI USA, V91, P12765, DOI 10.1073/pnas.91.26.12765; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Grohovaz F, 1996, P NATL ACAD SCI USA, V93, P4799, DOI 10.1073/pnas.93.10.4799; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; Helmchen F, 1997, BIOPHYS J, V72, P1458, DOI 10.1016/S0006-3495(97)78792-7; HORRIGAN FT, 1993, BIOPHYS J, V64, P101; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Innocenti B, 1996, J BIOL CHEM, V271, P8582, DOI 10.1074/jbc.271.15.8582; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; Lang IM, 1996, J BIOL CHEM, V271, P2754, DOI 10.1074/jbc.271.5.2754; LI GD, 1994, MOL BIOL CELL, V5, P1199, DOI 10.1091/mbc.5.11.1199; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Martin TFJ, 1997, TRENDS CELL BIOL, V7, P271, DOI 10.1016/S0962-8924(97)01060-X; Martinez JR, 1996, BIOCHEM J, V320, P627, DOI 10.1042/bj3200627; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; Petersen OH, 1996, TRENDS NEUROSCI, V19, P411; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; Ravazzola M, 1996, P NATL ACAD SCI USA, V93, P2745, DOI 10.1073/pnas.93.7.2745; Renstrom E, 1996, J PHYSIOL-LONDON, V494, P41, DOI 10.1113/jphysiol.1996.sp021474; SEKINE N, 1994, J BIOL CHEM, V269, P4895; Sekine N, 1997, DIABETES, V46, P1424, DOI 10.2337/diabetes.46.9.1424; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; Takahashi N, 1997, J CELL BIOL, V138, P55, DOI 10.1083/jcb.138.1.55; THIRION S, 1995, NEUROSCIENCE, V64, P125, DOI 10.1016/0306-4522(94)00414-Z; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; THOMASREETZ AC, 1994, FASEB J, V8, P209, DOI 10.1096/fasebj.8.2.7907072; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Yule DI, 1997, J BIOL CHEM, V272, P9093	40	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19002	19008		10.1074/jbc.273.30.19002	http://dx.doi.org/10.1074/jbc.273.30.19002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668080	hybrid			2022-12-27	WOS:000074974700047
J	Takeshita, A; Yen, PM; Ikeda, M; Cardona, GR; Liu, Y; Koibuchi, N; Norwitz, ER; Chin, WW				Takeshita, A; Yen, PM; Ikeda, M; Cardona, GR; Liu, Y; Koibuchi, N; Norwitz, ER; Chin, WW			Thyroid hormone response elements differentially modulate the interactions of thyroid hormone receptors with two receptor binding domains in the steroid receptor coactivator-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR TFIIB; ACTIVATION FUNCTION AF-2; VITAMIN-D RECEPTORS; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; TRANSACTIVATION DOMAIN; GENE-TRANSCRIPTION; CRYSTAL-STRUCTURE; RETINOIC ACID; CO-REPRESSOR	Ligand-dependent transcriptional activation by nuclear receptors is mediated by interactions with coactivators. Recently, a consensus interaction motif (LXXLL) has been identified in a number of coactivators such as steroid receptor coactivator-l (SRC-1). SRC-1 contains three such motifs in the central (nuclear receptor binding domain-1, NBD-1) and a single one in the C-terminal (NBD-S) regions. To define the nature and role of the two NBDs in SRC-1, interaction studies between the two NBDs and thyroid hormone receptor (TR) were performed. Although NBD-1 and NBD-S showed similar ligand- and AF-a dependent interactions with TR, in solution, these two NBDs possessed distinct interaction properties with TR when TR is bound to a thyroid hormone-response element (TRE). Both in vitro and in vivo interaction studies demonstrate that NBD-1, but not NBD-2, exhibits ligand-dependent interaction with TR in the presence of TREs. In addition, a natural isoform of SRC-1, SRC-1E, which lacks NBD-2, preserved TR as well as progesterone receptor-mediated coactivator function on reporter gene expression. Finally, we found that NBD-1 failed to interact with a TR and retinoid X receptor heterodimer complex on a transcriptionally inactive direct repeat +4 TRE in electrophoretic mobility shift assays. These observations indicate that DNA-induced, as well as ligand-induced, conformational change(s) of TR may influence the nature of its binding to SRC-1, and that the two NBDs of SRC-I may play different roles to regulate ligand-dependent transactivation of TRs.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Takeshita, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Genet, GW Thorn Res Bldg,Rm 1005,20 Shattuck St, Boston, MA 02115 USA.	takeshita@rascal.med.harvard.edu	Yen, Paul M/V-9857-2019	Koibuchi, Noriyuki/0000-0002-2247-9740; Yen, Paul/0000-0002-3790-8114				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Fondell JD, 1996, MOL CELL BIOL, V16, P281; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hayashi Y, 1997, BIOCHEM BIOPH RES CO, V236, P83, DOI 10.1006/bbrc.1997.6911; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; ING NH, 1992, J BIOL CHEM, V267, P17617; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liu Y, 1998, MOL ENDOCRINOL, V12, P34, DOI 10.1210/mend.12.1.0046; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; Monden T, 1997, J BIOL CHEM, V272, P29834, DOI 10.1074/jbc.272.47.29834; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RON D, 1992, BIOTECHNIQUES, V13, P866; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; SUEN CS, 1995, ENDOCRINOLOGY, V136, P2776, DOI 10.1210/en.136.6.2776; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONEY JH, 1993, BIOCHEMISTRY-US, V32, P2, DOI 10.1021/bi00052a001; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YEN PM, 1992, J BIOL CHEM, V267, P3565; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; YEN PM, 1992, J CLIN INVEST, V90, P1825, DOI 10.1172/JCI116058	52	58	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	1998	273	34					21554	21562		10.1074/jbc.273.34.21554	http://dx.doi.org/10.1074/jbc.273.34.21554			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	112JY	9705285	hybrid			2022-12-27	WOS:000075492600019
J	Atkinson, EA; Barry, M; Darmon, AJ; Shostak, I; Turner, PC; Moyer, RW; Bleackley, RC				Atkinson, EA; Barry, M; Darmon, AJ; Shostak, I; Turner, PC; Moyer, RW; Bleackley, RC			Cytotoxic T lymphocyte-assisted suicide - Caspase 3 activation is primarily the result of the direct action of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; FAS-MEDIATED APOPTOSIS; DNA FRAGMENTATION; SERINE PROTEASES; RAPID INDUCTION; FAMILY PROTEASE; TARGET-CELLS; SERPIN CRMA; DEATH; CPP32	Cytototoxic T lymphocyte-induced apoptosis can occur either through the directed exocytosis of granzyme B and perforin or via ligation of Fas. Both pathways involve the activation of a family of cysteine proteinases, the caspases, that cleave substrates at aspartic acid and are themselves activated by cleavage at internal aspartate residues. Fas recruits caspase 8, which initiates the death program through the subsequent activation of caspase 3, Granzyme B can process both caspase 8 and 3 in vitro, suggesting that both Fas and granzyme B access the apoptotic program in the same way. Here we demonstrate that although the two mechanisms are similar, the events that lead to activation of caspase 3 can be distinguished in, vivo on the basis of their sensitivities to both pharmacological and virus-encoded caspase inhibitors. In cytotoxic T lymphocytes-mediated death the initial cleavage event on caspase 3 is insensitive to benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone (zVAD-fmk) inhibition in both mouse and human systems. During Pas-mediated death, however, activation of caspase 3 is completely inhibited to zVAD-fmk, In addition, the viral serpin SPI-2, a homologue of cytokine response modifier A (crmA), is an effective inhibitor of the Pas but not the granzyme pathway. Our results demonstrate that whereas Fas-mediated activation of caspase 3 requires an upstream caspase activity that is zVAD-fmk-sensitive, the initial cleavage of caspase 3 during granule-mediated cell death is insensitive to zVAD-fmk, suggesting that caspase 3 is cleaved directly by granzyme B in vivo.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	University of Alberta; State University System of Florida; University of Florida	Bleackley, RC (corresponding author), Univ Alberta, Dept Biochem, 474 Med Sci Bldg, Edmonton, AB T6G 2H7, Canada.	chris.bleackley@ualberta.ca		Turner, Peter/0000-0002-7706-4593	NIAID NIH HHS [AI 25722] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI025722] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Atkinson EA, 1995, CRIT REV IMMUNOL, V15, P359, DOI 10.1615/CritRevImmunol.v15.i3-4.90; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; Chinnaiyan AM, 1996, CURR BIOL, V6, P897, DOI 10.1016/S0960-9822(02)00614-0; Darmon AJ, 1996, J BIOL CHEM, V271, P21699, DOI 10.1074/jbc.271.36.21699; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dobbelstein M, 1996, J VIROL, V70, P6479, DOI 10.1128/JVI.70.9.6479-6485.1996; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; Dubrez L, 1996, EMBO J, V15, P5504, DOI 10.1002/j.1460-2075.1996.tb00935.x; EBNET K, 1995, EMBO J, V14, P4230, DOI 10.1002/j.1460-2075.1995.tb00097.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; GARNER R, 1994, J IMMUNOL, V153, P5413; Gu Y, 1996, J BIOL CHEM, V271, P10816, DOI 10.1074/jbc.271.18.10816; Hasegawa J, 1996, CANCER RES, V56, P1713; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kettle S, 1997, J GEN VIROL, V78, P677, DOI 10.1099/0022-1317-78-3-677; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Macen JL, 1996, P NATL ACAD SCI USA, V93, P9108, DOI 10.1073/pnas.93.17.9108; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SHI L, 1996, J EXP MED, V175, P553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; SHRESTA S, 1995, IMMUNOL REV, V146, P211, DOI 10.1111/j.1600-065X.1995.tb00690.x; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	42	126	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21261	21266		10.1074/jbc.273.33.21261	http://dx.doi.org/10.1074/jbc.273.33.21261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694885	hybrid			2022-12-27	WOS:000075386100078
J	Naylor, DJ; Stines, AP; Hoogenraad, NJ; Hoj, PB				Naylor, DJ; Stines, AP; Hoogenraad, NJ; Hoj, PB			Evidence for the existence of distinct mammalian cytosolic, microsomal, and two mitochondrial GrpE-like proteins, the co-chaperones of specific Hsp70 members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; NUCLEOTIDE-EXCHANGE FACTOR; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; MESSENGER-RNA; HOMOLOG; SYSTEM; DNAK; PURIFICATION; ATPASE	We previously reported the cDNA cloning and characterization of a mammalian mitochondrial GrpE protein (similar to 21 kDa, mt-GrpE#l) and now provide evidence for the presence of distinct cytosolic (similar to 40 kDa), microsomal (similar to 50 kDa), and additional mitochondrial (similar to 22 kDa, mt-GrpE#2) GrpE-like members. While a cytosolic GrpE-like protein has recently been identified, the demonstration of both a microsomal and a second mitochondrial GrpE-like member represents the first in any biological system, Investigation of the microsomal and two mitochondrial. GrpE-like proteins revealed that they bound specifically to Escherichia coli DnaK, and the complexes formed were not disrupted in the presence of 0.5 M salt but were readily dissociated in the presence of 5 mM ATP. The functional integrity of mt-GrpE#l and #2 was verified by their ability to specifically interact with and stimulate the ATPase activity of mammalian mitochondrial Hsp70 (mt-Hsp70), Analysis of the cDNA sequences encoding the two mammalian mitochondrial GrpE-like proteins revealed similar to 47% positional identity at the amino acid level, the presence of a highly conserved mitochondrial leader sequence, and putative destabilization elements within the 3'-untranslated region of the mt-GrpE#2 transcript which are not present in the mt-GrpE#1 transcript. A constitutive expression of both mitochondrial GrpE-like transcripts in 22 distinct mouse tissues was observed but possible different posttranscriptional regulation of the mt-GrpE#l and #2 transcripts may confer a different expression pattern of the encoded proteins.	Univ Adelaide, Dept Hort Viticulture & Oenol, Dept Agron, Glen Osmond, SA 5064, Australia; Australian Wine Res Inst, Glen Osmond, SA, Australia; La Trobe Univ, Sch Biochem, Bundoora, Vic 3083, Australia	University of Adelaide; Australian Wine Research Institute; La Trobe University	Naylor, DJ (corresponding author), Univ Adelaide, Dept Hort Viticulture & Oenol, Dept Agron, Waite Campus,PMB1, Glen Osmond, SA 5064, Australia.		Hoogenraad, Nicholas J/C-7505-2011; Hoj, Peter B/E-8526-2011					Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gething MJ., 1997, GUIDEBOOK MOL CHAPER; Harlow E., 1988, ANTIBODIES LAB MANUA; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HARTMAN DJ, 1992, P NATL ACAD SCI USA, V89, P3394, DOI 10.1073/pnas.89.8.3394; HOHOFELD J, 1997, EMBO J, V16, P6209; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; IKEDA E, 1994, FEBS LETT, V339, P265, DOI 10.1016/0014-5793(94)80428-1; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LAROSA PC, 1992, PLANT PHYSIOL, V100, P409, DOI 10.1104/pp.100.1.409; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LEVY EJ, 1995, FEBS LETT, V368, P435, DOI 10.1016/0014-5793(95)00704-D; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MARTINUS RD, 1995, FASEB J, V9, P371, DOI 10.1096/fasebj.9.5.7896006; MEHTA AD, 1997, GUIDEBOOK MOL CHAPER, P141; NAKAI M, 1994, BIOCHEM BIOPH RES CO, V200, P435, DOI 10.1006/bbrc.1994.1468; NAYLOR DJ, 1995, BBA-PROTEIN STRUCT M, V1248, P75, DOI 10.1016/0167-4838(95)00007-H; Naylor DJ, 1996, FEBS LETT, V396, P181, DOI 10.1016/0014-5793(96)01100-3; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Rajagopalan LE, 1997, PROG NUCLEIC ACID RE, V56, P257, DOI 10.1016/S0079-6603(08)61007-7; RAKAYAMA S, 1997, EMBO J, V16, P4887; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; RYANMT, 1997, INT REV CYTOL, V174, P127; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlicher T, 1997, PLANT MOL BIOL, V33, P181, DOI 10.1023/A:1005784115363; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VOOS W, 1994, MOL CELL BIOL, V14, P6627, DOI 10.1128/MCB.14.10.6627; WEBSTER TJ, 1994, DNA CELL BIOL, V13, P1213, DOI 10.1089/dna.1994.13.1213; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; Wu B, 1996, EMBO J, V15, P4806, DOI 10.1002/j.1460-2075.1996.tb00861.x; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437	46	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 14	1998	273	33					21169	21177		10.1074/jbc.273.33.21169	http://dx.doi.org/10.1074/jbc.273.33.21169			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	110MZ	9694873	hybrid			2022-12-27	WOS:000075386100066
J	Carrasco-Serrano, C; Campos-Caro, A; Viniegra, S; Ballesta, JJ; Criado, M				Carrasco-Serrano, C; Campos-Caro, A; Viniegra, S; Ballesta, JJ; Criado, M			GC- and E-box motifs as regulatory elements in the proximal promoter region of the neuronal nicotinic receptor alpha 7 subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; ACETYLCHOLINE-RECEPTOR; CHROMAFFIN CELLS; MOLECULAR-CLONING; NERVOUS-SYSTEM; DNA-BINDING; POU DOMAIN; EGR-1; ACTIVATION; PROTEINS	The alpha 7 subunit is a component of alpha-bungarotoxin-sensitive nicotinic acetylcholine receptors expressed in bovine adrenomedullary chromaffin cells. The proximal promoter of the gene coding for this subunit contains several GC-boxes and one E-box, Deletion analysis and transient transfections showed that a 120-base pair region (-77 to +43) including all of these elements gave rise to similar to 70 and 95% of the maximal transcriptional activity observed in chromaffin and SHSY-5Y neuroblastoma cells, respectively. Site-directed mutagenesis of the different elements indicated that both GC and E motifs contribute to the activity of the alpha 7 gene in a very prominent way. Using electrophoretic mobility shift assays, the upstream stimulatory factor (USF) was shown to be a component of the complexes that interacted with the E-box when nuclear extracts from chromaffin and SHSY-5Y cells were used. Binding of the early growth response gene transcription factor (Egr-l) to three different GC-boxes was also demonstrated by shift assays and DNase I footprint analysis. Likewise, alpha 7 promoter activity increased by up to B-fold when alpha 7 constructs and an Egr-l expression vector were cotransfected into chromaffin cell cultures. Mutagenesis of individual GC-boxes had little effect on Egr-l activation. By contrast, pairwise suppression of GC-boxes abolished activation, especially when the most promoter-proximal of the Egr-l sites was removed. Taken together, these studies indicate that the alpha 7 gene is likely to be a target for multiple signaling pathways, in which various regulatory elements are involved.	Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain; Univ Miguel Hernandez, Dept Pharmacol, Alicante 03550, Spain; Univ Miguel Hernandez, Inst Neurociencias, Alicante, 03550, Spain	Universidad Miguel Hernandez de Elche; Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Criado, M (corresponding author), Univ Miguel Hernandez, Dept Neurochem, Alicante 03550, Spain.		Campos-Caro, Antonio/T-2807-2019; Viniegra, Salvador/K-5063-2014; Criado, Manuel/K-5109-2014	Campos-Caro, Antonio/0000-0001-8532-2153; Viniegra, Salvador/0000-0002-3892-8563; Criado, Manuel/0000-0002-3953-0346				BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BESSIS A, 1993, NUCLEIC ACIDS RES, V21, P2185, DOI 10.1093/nar/21.9.2185; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; BIGGER CB, 1996, J BIOL CHEM, V271, P23842; Boyd RT, 1996, NEUROSCI LETT, V208, P73, DOI 10.1016/0304-3940(96)12561-1; BOYD RT, 1994, J NEUROBIOL, V25, P960, DOI 10.1002/neu.480250806; CamposCaro A, 1997, J NEUROCHEM, V68, P488; CAO X, 1990, MOL CELL BIOL, V9, P1931; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CRIADO M, 1992, NEUROCHEM RES, V17, P281, DOI 10.1007/BF00966671; Criado M, 1997, J NEUROSCI, V17, P6554; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; Du Q, 1997, J BIOL CHEM, V272, P14990, DOI 10.1074/jbc.272.23.14990; DYODOROV D, 1998, J NEUROBIOL, V34, P151; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; Fyodorov D, 1996, MOL CELL BIOL, V16, P5004; GANDIA L, 1991, BRIT J PHARMACOL, V103, P1073, DOI 10.1111/j.1476-5381.1991.tb12302.x; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Gu HJ, 1996, J NEUROCHEM, V66, P1454; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HALLE JP, 1995, J BIOL CHEM, V272, P1753; HERNANDEZ MC, 1995, J BIOL CHEM, V270, P3224, DOI 10.1074/jbc.270.7.3224; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; LUKAS RJ, 1993, MOL CELL NEUROSCI, V4, P1, DOI 10.1006/mcne.1993.1001; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEGUELA P, 1993, J NEUROSCI, V13, P596; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; YANG XD, 1994, J BIOL CHEM, V269, P10252	48	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20021	20028		10.1074/jbc.273.32.20021	http://dx.doi.org/10.1074/jbc.273.32.20021			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685340	hybrid			2022-12-27	WOS:000075305400017
J	Hu, LA; King, SC				Hu, LA; King, SC			Functional significance of the "signature cysteine" in helix 8 of the Escherichia coli 4-aminobutyrate transporter from the amine-polyamine-choline superfamily - Restoration of Cys-300 to the Cys-less gabP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID TRANSPORTERS; LACTOSE PERMEASE; PROTEIN; SPECIFICITY; INHIBITORS; EVOLUTION; SITE	gab permease (GabP) is the exclusive mediator of 4-aminobutyrate (GABA) transport across the Escherichia coli plasma membrane. Helix 8 and a portion of the adjoining cytoplasmic region (loop 8-9) constitute the GabP "consensus amphipathic region" (CAR), a potential channel-forming domain that is found to be evolutionarily conserved within the APC (amine-polyamine-choline) transporter superfamily, Upon the polar surface of the CAR, all known gab permeases display a "signature cysteine" not found in other members of the APC superfamily, suggesting that discrete features within the CAR might play a role in imparting specificity (k(cat)/K-m) to the translocation reaction. Here we show that among the five cysteine residues in the E. coli GabP, only Cys-300, the signature cysteine, can restore wild type properties to the Cys-less GabP mutant. We conclude (i) from partial reaction studies (equilibrium exchange, counterflow) that rapid translocation of the GABA binding site from one side of the membrane to the other is greatly facilitated by Cys-300 and (ii) from pharmacological studies that loss of Cys-300 has little effect on the affinity that GabP exhibits for a structurally diverse array (kojic amine, 5-aminovaleric acid, GABA, nipecotic acid, and cis-4-aminocrotonic acid) of competitive ligands. These results raise the possibility that other GABA transporters might rely analogously upon conserved cysteine residues positioned within the amphipathic helix 8 and loop 8-9 regions.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	King, SC (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, 301 Univ Blvd, Galveston, TX 77555 USA.	steven.king@utmb.edu						Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Brechtel CE, 1996, J BIOL CHEM, V271, P783, DOI 10.1074/jbc.271.2.783; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; HU LA, 1998, BIOCHEM J, V300, P771; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; JessenMarshall AE, 1996, J BIOL CHEM, V271, P1400, DOI 10.1074/jbc.271.3.1400; JessenMarshall AE, 1997, J BACTERIOL, V179, P2616, DOI 10.1128/jb.179.8.2616-2622.1997; KING SC, 1995, J BIOL CHEM, V270, P19893, DOI 10.1074/jbc.270.34.19893; KING SC, 1995, J BACTERIOL, V177, P5381, DOI 10.1128/jb.177.18.5381-5382.1995; KING SC, 1997, HDB PSYCHIAT GENETIC, P163; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Miller J. H., 1972, EXPT MOL GENETICS, P398; Pazdernik NJ, 1997, J BIOL CHEM, V272, P26110, DOI 10.1074/jbc.272.42.26110; Pazdernik NJ, 1997, J BACTERIOL, V179, P735, DOI 10.1128/jb.179.3.735-741.1997; REIZER J, 1993, PROTEIN SCI, V2, P20, DOI 10.1002/pro.5560020103; ROSENBERG T, 1957, J GEN PHYSIOL, V41, P289, DOI 10.1085/jgp.41.2.289; SAIER MH, 1994, MICROBIOL REV, V58, P71, DOI 10.1128/MMBR.58.1.71-93.1994; SAIER MH, 1994, BIOESSAYS, V16, P23, DOI 10.1002/bies.950160104; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6	24	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20162	20167		10.1074/jbc.273.32.20162	http://dx.doi.org/10.1074/jbc.273.32.20162			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685361	hybrid			2022-12-27	WOS:000075305400038
J	MacLeod, RJ; Lembessis, P; James, S; Bennett, HPJ				MacLeod, RJ; Lembessis, P; James, S; Bennett, HPJ			Isolation of a member of the Neurotoxin/Cytotoxin peptide family from Xenopus laevis skin which activates dihydropyridine-sensetive Ca2+ channels in mammalian epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; REGULATORY VOLUME DECREASE; PROTEIN-KINASE-C; CALCIUM CHANNELS; P-GLYCOPROTEIN; DRUG TRANSPORT; RAT PITUITARY; MAJOR FORMS; FROG-SKIN; DOMAIN	We have used a sensitive bioassay of calcium-mediated volume changes in mammalian absorptive intestinal epithelial cells to screen extracts of the skin of the amphibian Xenopus laevis for the presence of factors affecting ion transport. A 66-residue peptide, purified using reversed-phase high performance liquid chromatography techniques, caused isotonic volume reduction of guinea pig jejunal villus cells in suspension. This volume reduction required extracellular Ca2+ and was prevented by the dihydropyridine-sensitive Ca2+ channel blocker niguldipine, Structural analysis demonstrated the presence of eight cysteines and a primary structure homologous to that of the neurotoxin/cytotoxin family found in the venom of certain poisonous snakes. The structure of the peptide was identical to that of xenoxin-1 purified from dorsal gland secretions of X. laevis (Kolbe, M., Huber A., Cordier, P., Rasmussen, U,, Bouchon, B,, Jaquinod, M,, Blasak, it,, Detot, E., and Kreil, G. (1993) J. Biol Chem, 268, 16458-16464), Xenoxin-l (10 nM) caused volume changes that required extracellular Ca2+ and were comparable in magnitude and direction to changes caused by BayK-8644 (100 nM), a dihydropyridine-sensitive Ca2+ channel agonist, The initial rate of dihydropyridine-sensitive Ca-45(2+) influx was substantially increased by xenoxin-l. Staurosporine (10 nM) prevented volume changes caused by ATP (250 mu M) but had no effect on volume changes caused by BayK-8644 or xenoxin-l. We conclude that xenoxin-l directly activated dihydropyridine-sensitive Ca2+ channels in villus cells and that a mammalian homologue to xenoxin-l may exist.	Royal Victoria Hosp, Endocrine Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada; McGill Univ, Fac Med, Montreal, PQ H3H 1P3, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University	Bennett, HPJ (corresponding author), Royal Victoria Hosp, Endocrine Lab, L2-05,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	bennett@pathology.lan.mcgill.ca		Lembessis, Panagiotis/0000-0001-8972-3499				BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; BENNETT HPJ, 1989, ANAL BIOCHEM, V179, P222, DOI 10.1016/0003-2697(89)90119-X; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BENNETT HPJ, 1983, ANAL BIOCHEM, V128, P121, DOI 10.1016/0003-2697(83)90352-4; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; Boer R, 1996, BIOCHEMISTRY-US, V35, P1387, DOI 10.1021/bi951912u; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; DONOWITZ M, 1989, J CLIN INVEST, V83, P1953, DOI 10.1172/JCI114104; DONOWITZ M, 1985, AM J PHYSIOL, V248, pC726; ERSPAMER V, 1971, ANNU REV PHARMACOLOG, V11, P327, DOI 10.1146/annurev.pa.11.040171.001551; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GRAZIADEI I, 1989, EUR J PHARM-MOLEC PH, V172, P329, DOI 10.1016/0922-4106(89)90013-8; Hamaguchi N, 1996, BIOCHEMISTRY-US, V35, P14312, DOI 10.1021/bi961024e; HOLLT V, 1992, BIOCHEM PHARMACOL, V43, P2601, DOI 10.1016/0006-2952(92)90149-D; HOMAIDAN FR, 1989, AM J PHYSIOL, V257, pG86, DOI 10.1152/ajpgi.1989.257.1.G86; KOLBE HVJ, 1993, J BIOL CHEM, V268, P16458; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG405, DOI 10.1152/ajpgi.1991.260.3.G405; MACLEOD RJ, 1994, AM J PHYSIOL, V267, pG387, DOI 10.1152/ajpgi.1994.267.3.G387; MACLEOD RJ, 1992, J MEMBRANE BIOL, V130, P23; MACLEOD RJ, 1990, AM J PHYSIOL, V258, pG665, DOI 10.1152/ajpgi.1990.258.5.G665; MACLEOD RJ, 1991, P NATL ACAD SCI USA, V88, P552, DOI 10.1073/pnas.88.2.552; MacLeod RJ, 1996, J BIOL CHEM, V271, P23138, DOI 10.1074/jbc.271.38.23138; MACLEOD RJ, 1992, AM J PHYSIOL, V262, pC950, DOI 10.1152/ajpcell.1992.262.4.C950; MASON MJ, 1991, J BIOL CHEM, V266, P20856; Palfree RGE, 1996, TISSUE ANTIGENS, V48, P71, DOI 10.1111/j.1399-0039.1996.tb02610.x; ROBINSON JP, 1990, BRIT J PHARMACOL, V100, P3, DOI 10.1111/j.1476-5381.1990.tb12041.x; ROMANIN C, 1992, PFLUG ARCH EUR J PHY, V420, P410, DOI 10.1007/BF00374478; SELSTED ME, 1987, IMMUNOLOGY, V155, P2281; SPEDDING M, 1992, PHARMACOL REV, V44, P363; SU CM, 1986, CAN J PHYSIOL PHARM, V64, P909, DOI 10.1139/y86-157; USSING HH, 1986, RENAL PHYSIOL BIOCH, V9, P38; USSING HH, 1949, ACTA PHYSIOL SCAND, V17, P1, DOI 10.1111/j.1748-1716.1949.tb00550.x; vanRhee AM, 1996, J MED CHEM, V39, P2980, DOI 10.1021/jm9600205	34	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 7	1998	273	32					20046	20051		10.1074/jbc.273.32.20046	http://dx.doi.org/10.1074/jbc.273.32.20046			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109DF	9685343	hybrid			2022-12-27	WOS:000075305400020
J	Gough, WH; VanOoteghem, S; Sint, T; Kedishvili, NY				Gough, WH; VanOoteghem, S; Sint, T; Kedishvili, NY			cDNA cloning and characterization of a new human microsomal NAD(+)-dependent dehydrogenase that oxidizes all-trans-retinol and 3 alpha-hydroxysteroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; ALCOHOL-DEHYDROGENASE; MESSENGER-RNA; MEMBRANE; LIVER; ACID; ACTIVATION; REDUCTION; INVITRO	We report the cDNA sequence and catalytic properties of a new member of the short chain dehydrogenase/reductase superfamily, The 1134-base pair cDNA isolated from the human liver cDNA library encodes a 317-amino acid protein, retinol dehydrogenase 4 (RoDH-4), which exhibits the strongest similarity with rat all-trans-retinol dehydrogenases RoDH-1, RoDH-2, and RoDH-3, and mouse cis-retinol/androgen dehydrogenase (less than or equal to 73% identity). The mRNA for RoDH-4 is abundant in adult liver, where it is translated into RoDH-4 protein, which is associated with microsomal membranes, as evidenced by Western blot analysis, Significant amounts of RoDH-4 message are detected in fetal liver and lung. Recombinant RoDH-4, expressed in microsomes of Sf9 insect cells using BacoluGold Baculovirus system, oxidizes all-trans retinol and 13-cis-retinol to corresponding aldehydes and oxidizes the 3 alpha-hydroxysteroids androstane-diol and androsterone to dihydrotestosterone and androstanedione, respectively. NAD(+) and NADH are the preferred cofactors, with apparent K-m values 250-1500 times lower than those for NADP(+) and NADPH. AU-trans-retinol and 13-cis-retinol inhibit RoDH-4 catalyzed oxidation of androsterone with apparent K-i values of 5.8 and 3.5 mu M, respectively. All-trans-retinol bound to cellular retinol-binding protein (type I) exhibits a similar K-i value of 3.6 mu M, Unliganded cellular retinol-binding protein has no effect on RoDH activity. Citral and acyclic isoprenoids also act as inhibitors of RoDH-4 activity. Ethanol is not inhibitory. Thus, we have identified and characterized a sterol/retinol-oxidizing short chain dehydrogenase/reductase that prefers NAD(+) and recognizes all-trans-retinol as substrate, RoDH-4 can potentially contribute to the biosynthesis of two powerful modulators of gene expression: retinoic acid from retinol and dihydrotestosterone from 3 alpha-androstane-diol.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Kedishvili, NY (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS 405, Indianapolis, IN 46202 USA.			Kedishvili, Natalia/0000-0001-6917-4891	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA002342, R01AA002342] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA00221, AA02342] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Burke YD, 1997, LIPIDS, V32, P151, DOI 10.1007/s11745-997-0019-y; CAO GQ, 1994, J BIOL CHEM, V269, P26898; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CROWELL PL, 1994, CANCER CHEMOTH PHARM, V35, P31, DOI 10.1007/s002800050189; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEO MA, 1987, ARCH BIOCHEM BIOPHYS, V259, P241, DOI 10.1016/0003-9861(87)90492-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mangelsdorf David J., 1994, P319; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; ONG DE, 1978, J BIOL CHEM, V253, P828; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; POSCH KC, 1992, BIOCHEM PHARMACOL, V43, P2296; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; SEGAL IH, 1975, ENZYME KINETICS, P18; SHERMAN DR, 1987, P NATL ACAD SCI USA, V84, P3209, DOI 10.1073/pnas.84.10.3209; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a	36	101	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19778	19785		10.1074/jbc.273.31.19778	http://dx.doi.org/10.1074/jbc.273.31.19778			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677409	hybrid			2022-12-27	WOS:000075125200061
J	Jin, SLC; Bushnik, T; Lan, L; Conti, M				Jin, SLC; Bushnik, T; Lan, L; Conti, M			Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases - Differential targeting and activation of the splicing variants derived from the PDE4D gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RAT SERTOLI-CELL; HORMONAL-REGULATION; ANCHORING PROTEINS; A-KINASE; IDENTIFICATION; INHIBITION; NEURONS; PHOSPHORYLATION; DROSOPHILA	Biochemical and immunofluorescence analyses revealed that phosphodiesterase variants encoded by the PDE4D gene are targeted to discrete subcellular structures. In quiescent FRTL-5 thyroid cells, the rolipram-sensitive phosphodiesterase (PDE) activity (cAMP-PDE) was recovered both in the soluble and particulate fractions of the homogenate, Although an immunoreactive 93-kDa PDE (PDE4D3) variant was recovered in both compartments, a 105-kDa variant with the properties of PDE4D4 was recovered mostly in the particulate fraction. The PDE4D3 form was readily solubilized with nonionic detergents. Conversely, the PDE4D4 form required buffers containing ionic detergents for extraction, suggesting that different mechanisms target these variants to insoluble structures. A 15-min stimulation with thyroid-stimulating hormone (TSH) led to an activation of the cAMP-PDE in both compartments and was correlated with a shift in electrophoretic mobility of the PDE4D3 polypeptide, Long term incubation with TSH caused an increase of the PDE activity in the soluble fraction and the appearance of a 68-kDa immunoreactive polypeptide with the properties of PDE4D2. Immunofluorescence analysis showed, in addition to diffuse staining, a signal localized on regions adjacent to the plasma membrane on cytoskeletal structures and in a perinuclear region of quiescent cells. Long term incubation with TSH caused an increase in the immunofluorescence signal in the soluble compartment. These data demonstrate that three PDE4D splicing variants are targeted to discrete subcellular compartments and that hormones cause the activation of these isoforms in a temporally and spatially dependent manner.	Stanford Univ, Med Ctr, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Med Ctr, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA.	marco.conti@forsythe.stanford.edu		Bushnik, Tamara/0000-0003-3328-257X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; CHERRY JA, 1995, J NEUROBIOL, V28, P102, DOI 10.1002/neu.480280109; COGHLAN VM, 1993, MOL CELL BIOCHEM, V128, P309, DOI 10.1007/BF01076780; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; JIN SLC, 1992, J BIOL CHEM, V267, P18929; JOHNSON BD, 1994, P NATL ACAD SCI USA, V91, P11492, DOI 10.1073/pnas.91.24.11492; Juilfs DM, 1997, P NATL ACAD SCI USA, V94, P3388, DOI 10.1073/pnas.94.7.3388; Kelly JJ, 1996, BIOCHEM J, V318, P425, DOI 10.1042/bj3180425; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; MACPHEE CH, 1986, P NATL ACAD SCI USA, V83, P6660, DOI 10.1073/pnas.83.17.6660; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; MONACO L, 1994, J BIOL CHEM, V269, P347; Naro F, 1996, ENDOCRINOLOGY, V137, P2464, DOI 10.1210/en.137.6.2464; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCHWABE U, 1976, MOL PHARMACOL, V12, P900; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SETTE C, 1994, MOL CELL ENDOCRINOL, V100, P75, DOI 10.1016/0303-7207(94)90282-8; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; SETTE C, 1994, J BIOL CHEM, V269, P18271; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SWINNEN JV, 1991, J BIOL CHEM, V266, P18370; SWINNEN JV, 1991, J BIOL CHEM, V266, P14383; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; Thompson W J, 1974, Methods Enzymol, V38, P205; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839	37	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19672	19678		10.1074/jbc.273.31.19672	http://dx.doi.org/10.1074/jbc.273.31.19672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677395	hybrid			2022-12-27	WOS:000075125200047
J	Kowalski, JM; Parekh, RN; Mao, J; Wittrup, KD				Kowalski, JM; Parekh, RN; Mao, J; Wittrup, KD			Protein folding stability can determine the efficiency of escape from endoplasmic reticulum quality control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; MOLECULAR CHAPERONES GROEL; SACCHAROMYCES-CEREVISIAE; THERMODYNAMIC STABILITIES; SECRETORY PATHWAY; ESCHERICHIA-COLI; MAMMALIAN-CELLS; T4 LYSOZYMES; CHO CELLS; YEAST	A fraction of each secreted protein is retained and degraded by the endoplasmic reticulum (ER) quality control apparatus that restricts export to correctly folded proteins. The intrinsic biophysical attributes that determine efficiency of escape from this proofreading process have been examined by expressing mutants of bovine pancreatic trypsin inhibitor (BPTI) in yeast. Secretion efficiency is strongly correlated with thermodynamic stability for a series of six point mutations of BPTI, No correlation of secretion efficiency with either oxidative folding or refolding rates in vitro is found; both the rapidly folded Y35L BPTI mutant and the slowly unfolded G36D BPTI mutant exhibit low secretion efficiency. Elimination of cysteines 14 and 38 by mutagenesis does not increase secretion efficiency, indicating that intramolecular thiol/disulfide rearrangements are not primarily responsible for retention and degradation of destabilized BPTI variants, Mutant yeast strains with diminished ER-associated degradation do not secrete BPTI more efficiently, indicating that retention and degradation are separable processes. These data support a model for ER quality control, wherein protein folding is functionally reversible and the relative rates of folding, unfolding, vesicular export, and retention determine secretion efficiency.	Univ Illinois, Dept Chem Engn, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Wittrup, KD (corresponding author), 600 S Mathews, Urbana, IL 61801 USA.	wittrup@uiuc.edu			NIGMS NIH HHS [GM50673] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050673, R21GM050673] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; ELLIOTT S, 1989, GENE, V79, P167, DOI 10.1016/0378-1119(89)90102-9; ElrodErickson MJ, 1996, MOL BIOL CELL, V7, P1043, DOI 10.1091/mbc.7.7.1043; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDENBERG DP, 1993, BIOCHEMISTRY-US, V32, P2835, DOI 10.1021/bi00062a015; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; INOUE I, 1994, J BIOL CHEM, V269, P29247; INOUE I, 1994, J BIOL CHEM, V269, P29241; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KIM PS, 1993, AM J PHYSIOL, V265, pC704, DOI 10.1152/ajpcell.1993.265.3.C704; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Kwon WS, 1996, PROTEIN ENG, V9, P1197, DOI 10.1093/protein/9.12.1197; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; Ma LC, 1997, BIOCHEMISTRY-US, V36, P3728, DOI 10.1021/bi962310t; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MENDOZA JA, 1994, BIOCHEMISTRY-US, V33, P1143, DOI 10.1021/bi00171a013; MOSES E, 1983, J MOL BIOL, V170, P765, DOI 10.1016/S0022-2836(83)80130-2; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; PAKULA AA, 1989, PROTEINS, V5, P202, DOI 10.1002/prot.340050303; PAREKH R, 1995, PROTEIN EXPRES PURIF, V6, P537, DOI 10.1006/prep.1995.1071; Parekh RN, 1997, BIOTECHNOL PROGR, V13, P117, DOI 10.1021/bp970009d; PENDSE GJ, 1992, BIOTECHNOL BIOENG, V40, P119, DOI 10.1002/bit.260400117; PUIG A, 1994, J BIOL CHEM, V269, P7764; Reff Mitchell E., 1993, Current Opinion in Biotechnology, V4, P573, DOI 10.1016/0958-1669(93)90079-C; Robinson AS, 1996, J BIOL CHEM, V271, P10017, DOI 10.1074/jbc.271.17.10017; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHULTZ LD, 1994, ANN NY ACAD SCI, V721, P148, DOI 10.1111/j.1749-6632.1994.tb47387.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Whiteley EM, 1997, J BIOL CHEM, V272, P22556, DOI 10.1074/jbc.272.36.22556; Wurm FM, 1996, ANN NY ACAD SCI, V782, P70, DOI 10.1111/j.1749-6632.1996.tb40548.x; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642; Zahn R, 1996, J MOL BIOL, V261, P43, DOI 10.1006/jmbi.1996.0440; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001	44	98	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19453	19458		10.1074/jbc.273.31.19453	http://dx.doi.org/10.1074/jbc.273.31.19453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677365	hybrid			2022-12-27	WOS:000075125200017
J	Prorok, M; Castellino, FJ				Prorok, M; Castellino, FJ			Thermodynamics of binding of calcium, magnesium, and zinc to the N-methyl-D-aspartate receptor ion channel peptidic inhibitors, conantokin-G and conantokin-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; PHOSPHOLIPID-BINDING; NMDA RESPONSES; PROTHROMBIN; NEURONS; TRANSITIONS; ANTAGONIST; RELEASE; BLOCK; SITE	The binding isotherms of the divalent metal cations, Ca2+, Mg2+, and Zn2+, to the synthetic gamma-carboxyglutamic acid-containing neuroactive peptides, conantokin-G (con-G) and conantokin-T (con-T), have been determined by isothermal titration calorimetry (ITC) at 25 degrees C and pH 6.5. We have previously shown by potentiometric measurements that con-G contains 2-3 equivalent Ca2+ sites with an average K-d value of 2800 mu M. With Mg2+, the ligand, two separate exothermic sites are obtained by ITC, one of K-d = 46 mu M and another of K-d = 311 mu M. Much tighter binding of Zn2+ is observed for these latter two sites (K-d values = 0.2 mu M and 1.1 mu M), and a third considerably weaker binding site is observed, characterized by a K-d value of 286 mu M and an endothermic enthalpy of binding, con-T possesses a single exothermic tight binding site for Ca2+, Mg2+, and Zn2+, with K-d values of 428 mu M, 10.2 mu M, and 0.5 mu M, respectively. Again, in the case of con-T, a weak (K-d = 410 mu M) endothermic binding site is observed for Zn2+, The binding of these cations to con-G and con-T result in an increase in the alpha-helical content of the peptides, However, this helix is somewhat destabilized in both cases by binding of Zn2+ to its weakest site. Since the differences observed in binding affinities of these three cations to the peptides are substantially greater than their comparative K-d values to malonate, we conclude that the structure of the peptide and, most likely, the steric and geometric properties imposed on the cation site as a result of peptide folding greatly influence the strength of the interaction of cations with con-G and con-T, Further, since the Zn2+ concentrations released in the synaptic cleft during excitatory synaptic activity are sufficiently high relative to the K-d of Zn2+ for con-G and con-T, this cation along with Mg2+, are most likely the most significant metal ion ligands of these peptides in neuronal cells.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu			NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANIKSZTEJN L, 1987, BRAIN RES, V404, P58, DOI 10.1016/0006-8993(87)91355-2; ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; Blandl T, 1997, BIOCHEM J, V328, P777, DOI 10.1042/bj3280777; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN HSV, 1992, J NEUROSCI, V12, P4427; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chen ZG, 1998, J BIOL CHEM, V273, P16248, DOI 10.1074/jbc.273.26.16248; CHRISTINE CW, 1990, J NEUROSCI, V10, P108; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAACK JA, 1990, J BIOL CHEM, V265, P6025; Kohn WD, 1998, J AM CHEM SOC, V120, P1124, DOI 10.1021/ja973673z; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MELDRUM BS, 1992, CURR OPIN NEUROL NEU, V5, P508; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1981, BIOCHEMISTRY-US, V20, P351, DOI 10.1021/bi00505a019; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P15677, DOI 10.1021/bi9718550; RIVIER J, 1987, BIOCHEMISTRY-US, V26, P8508, DOI 10.1021/bi00400a002; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; Warder SE, 1998, J BIOL CHEM, V273, P7512, DOI 10.1074/jbc.273.13.7512; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Zhou LM, 1996, J NEUROCHEM, V66, P620	30	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19573	19578		10.1074/jbc.273.31.19573	http://dx.doi.org/10.1074/jbc.273.31.19573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677382	hybrid			2022-12-27	WOS:000075125200034
J	Raab-Graham, KF; Vandenberg, CA				Raab-Graham, KF; Vandenberg, CA			Tetrameric subunit structure of the native brain inwardly rectifying potassium channel K-ir 2.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; MEMBRANE PROTEINS; MOLECULAR-CLONING; ION CHANNELS; SUBSTANCE-P; RAT-BRAIN; RECTIFIER; CONDUCTANCE; BINDING; SIZE	Strongly inwardly rectifying potassium channels of the K-ir 2 subfamily (IRK1, IRK2, and IRK3) are involved in maintenance and modulation of cell excitability in brain and heart, Electrophysiological studies of channels expressed in heterologous systems have suggested that the pore-conducting pathway contains four subunits. However, inferences from electrophysiological studies have not been tested on native channels and do not address the possibility of nonconducting: auxiliary subunits, Here, we investigate the subunit stoichiometry of endogenous inwardly rectifying potassium channel K-ir 2.2 (IRK2) from rat brain. Using: chemical cross-linking, immunoprecipitiation, and velocity sedimentation, we report physical evidence demonstrating the tetrameric organization of the native channel, K-ir 2.2 was sequentially cross-linked to produce bands on SDS-polyacrylamide gel electrophoresis corresponding in size to monomer, dimer, trimer, and three forms of tetramer. Fully cross-linked channel was present as a single band of tetrameric size. Immunoprecipitation of biotinylated membranes revealed a single band corresponding to K-ir 2,2, suggesting that the channel is composed of a single type of subunit. Hydrodynamic properties of 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonic acid-solubilized channel were used to calculate the molecular mass of the channel. Velocity sedimentation in H2O or D2O gave a sharp peak with a sedimentation coefficient of 17.3 S. Gel filtration yielded a Stokes radius of 5.92 nm, These data indicate a multisubunit protein with a molecular mass of 193 kDa, calculated to contain 3.98 subunit's. Together, these results demonstrate that K-ir 2.2 channels are formed by the homotetrameric association of K-ir 2.2 subunits and do not contain tightly associated auxiliary subunits, These studies suggest that K-ir 2.2 channels differ in structure from related heterooctomeric ATP-sensitive K channels and heterotetrameric G-protein-regulated inward rectifier K channels.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Vandenberg, CA (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	vandenbe@lifesci.lscf.ucsb.edu		Raab-Graham, Kimberly/0000-0001-6502-057X	NHLBI NIH HHS [HL41656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041656, R29HL041656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1967, J BIOL CHEM, V242, P3237; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CLARKE S, 1989, METHOD ENZYMOL, V172, P696; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Coligan JE, 1995, CURRENT PROTOCOLS PR; Corey S, 1998, J BIOL CHEM, V273, P5271, DOI 10.1074/jbc.273.9.5271; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; Fahlke C, 1997, J GEN PHYSIOL, V109, P93, DOI 10.1085/jgp.109.1.93; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Helenius A, 1979, Methods Enzymol, V56, P734; HJELMELAND LM, 1983, ANAL BIOCHEM, V130, P72, DOI 10.1016/0003-2697(83)90651-6; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; Inanobe A, 1995, BIOCHEM BIOPH RES CO, V217, P1238, DOI 10.1006/bbrc.1995.2901; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Jan LY, 1997, J PHYSIOL-LONDON, V505, P267, DOI 10.1111/j.1469-7793.1997.267bb.x; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUMAR KN, 1991, J BIOL CHEM, V266, P14947; LAI FA, 1989, J BIOL CHEM, V264, P16776; LAUE TM, 1990, METHOD ENZYMOL, V182, P566; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MARSHALL RC, 1986, PRACTICAL PROTEIN CH, P1; MILLER C, 1992, SCIENCE, V258, P240, DOI 10.1126/science.1384128; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; NEWMAN EA, 1993, J NEUROSCI, V13, P3333; Nichols CG, 1997, ANNU REV PHYSIOL, V59, P171, DOI 10.1146/annurev.physiol.59.1.171; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; Pessia M, 1996, EMBO J, V15, P2980, DOI 10.1002/j.1460-2075.1996.tb00661.x; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SHEN NV, 1993, NEURON, V11, P67; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SNYNG SL, 1997, J GEN PHYSIOL, V110, P655; SOBER MA, 1970, CRC HDB BIOCH MOL BI, pC10; TAKANO K, 1995, NEURON, V14, P999, DOI 10.1016/0896-6273(95)90338-0; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; TANFORD C, 1976, BIOCHIM BIOPHYS ACTA, V457, P133, DOI 10.1016/0304-4157(76)90009-5; Tinker A, 1996, CELL, V87, P857, DOI 10.1016/S0092-8674(00)81993-5; Tucker SJ, 1996, AM J PHYSIOL-HEART C, V271, pH379, DOI 10.1152/ajpheart.1996.271.1.H379; VANDENBERG CA, 1993, ION CHANNELS CARDIOV, P145; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5; YAMAGUCHI K, 1990, J PHYSIOL-LONDON, V426, P499, DOI 10.1113/jphysiol.1990.sp018151; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7	59	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19699	19707		10.1074/jbc.273.31.19699	http://dx.doi.org/10.1074/jbc.273.31.19699			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677399	hybrid			2022-12-27	WOS:000075125200051
J	Shimizu, N; Koyama, T; Ogura, K				Shimizu, N; Koyama, T; Ogura, K			Molecular cloning, expression, and purification of undecaprenyl diphosphate synthase - No sequence similarity between E- and Z-prenyl diphosphate synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HEXAPRENYL PYROPHOSPHATE SYNTHETASE; MICROCOCCUS-LUTEUS B-P-26; BACILLUS-STEAROTHERMOPHILUS; ESCHERICHIA-COLI; LACTOBACILLUS-PLANTARUM; CONSERVED ASPARTATE; DOMAIN-II; RESIDUES; IDENTIFICATION	Cloning of the gene for undecaprenyl diphosphate synthase was successful, providing the first primary structure for any prenyltransferase that catalyzes Z-prenyl chain elongation, A genomic DNA library of Micrococcus luteus B-P 26 was constructed in Escherichia coli, and the recombinant clones were grown on nylon membranes. The membrane was incubated directly by floating it on a reaction mixture containing radiolabeled isopentenyl diphosphate, nonlabeled farnesyl diphosphate, and Mg2+. Only the clones harboring plasmids encoding prenyltransferases could take up the substrates to synthesize and accumulate radiolabeled products inside the cells in amounts large enough to be detectable by autoradiography. Four positive colonies were found among about 4,000 bacterial colonies of the genomic DNA library. Two of them carried the gene for undecaprenyl diphosphate synthase, which catalyzes the Z-prenyl chain elongation, and the others carried the (all-E)-hexaprenyl diphosphate synthase genes (hers-a and hexs-b; Shimizu, N., Koyama, T., and Ogura, K, (1998) J. Bacteriol. 180, 1578-1581). The undecaprenyl diphosphate synthase, which had a predicted molecular mass of 28.9 kDa, was overproduced in E. coli cells by applying a soluble expression system, and it was purified to near homogeneity. The deduced primary structure of the Z-prenyl chain-elongating enzyme is totally different from those of E-prenyl chain-elongating enzymes, which have characteristic conserved regions, including aspartate-rich motifs.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Koyama, T (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan.	koyama@icrs.tohoku.ac.jp						ALLEN CM, 1976, ARCH BIOCHEM BIOPHYS, V175, P236, DOI 10.1016/0003-9861(76)90504-X; ASAI K, 1994, BIOCHEM BIOPH RES CO, V202, P340, DOI 10.1006/bbrc.1994.1933; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; CHEN AJ, 1994, PROTEIN SCI, V3, P600; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; FUJII H, 1982, J BIOL CHEM, V257, P4610; FUJII H, 1985, METHOD ENZYMOL, V110, P192; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; FUJISAKI S, 1984, BIOCHEM INT, V8, P779; ITO M, 1987, BIOCHEMISTRY-US, V26, P4745, DOI 10.1021/bi00389a022; JOLY A, 1993, J BIOL CHEM, V268, P26983; KOYAMA T, 1994, BIOCHEMISTRY-US, V33, P12644, DOI 10.1021/bi00208a015; KOYAMA T, 1995, BIOCHEM BIOPH RES CO, V212, P681, DOI 10.1006/bbrc.1995.2022; Koyama T, 1996, BIOCHEMISTRY-US, V35, P9533, DOI 10.1021/bi960137v; KOYAMA T, 1994, CAN J CHEM, V72, P75, DOI 10.1139/v94-012; KOYAMA T, 1993, J BIOCHEM-TOKYO, V113, P355, DOI 10.1093/oxfordjournals.jbchem.a124051; KOYAMA T, 1988, J BIOCHEM-TOKYO, V103, P867, DOI 10.1093/oxfordjournals.jbchem.a122363; MARRERO PF, 1992, J BIOL CHEM, V267, P21873; MUTH JD, 1984, ARCH BIOCHEM BIOPHYS, V230, P49, DOI 10.1016/0003-9861(84)90085-7; OGURA K, 1997, DYNAMIC ASPECTS NATU, P1; Ohnuma S, 1996, J BIOL CHEM, V271, P18831, DOI 10.1074/jbc.271.31.18831; Ohnuma S, 1996, J BIOL CHEM, V271, P30748, DOI 10.1074/jbc.271.48.30748; Ohnuma S, 1997, J BIOL CHEM, V272, P5192, DOI 10.1074/jbc.272.8.5192; Ohnuma SI, 1996, J BIOL CHEM, V271, P10087, DOI 10.1074/jbc.271.17.10087; RAETZ CRH, 1975, P NATL ACAD SCI USA, V72, P2274, DOI 10.1073/pnas.72.6.2274; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J., 2002, MOL CLONING LAB MANU; Shimizu N, 1998, J BACTERIOL, V180, P1578, DOI 10.1128/JB.180.6.1578-1581.1998; SONG LS, 1994, P NATL ACAD SCI USA, V91, P3044, DOI 10.1073/pnas.91.8.3044; TAKATSUJI H, 1983, BIOCHEM BIOPH RES CO, V110, P187, DOI 10.1016/0006-291X(83)91278-0; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Tarshis LC, 1996, P NATL ACAD SCI USA, V93, P15018, DOI 10.1073/pnas.93.26.15018	33	115	120	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19476	19481		10.1074/jbc.273.31.19476	http://dx.doi.org/10.1074/jbc.273.31.19476			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677368	hybrid			2022-12-27	WOS:000075125200020
J	Whitby, MC; Lloyd, RG				Whitby, MC; Lloyd, RG			Targeting Holliday junctions by the RecG branch migration protein of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY DNA JUNCTION; BACTERIOPHAGE-T7 ENDONUCLEASE-I; IMMOBILE JUNCTION; DRUG-BINDING; SELECTIVE INTERACTION; CRUCIFORM DNA; RECOMBINATION; RESOLUTION; COMPLEX; SEQUENCE	The RecG protein of Escherichia coli is a junction-specific DNA helicase that drives branch migration of Holliday intermediates in genetic recombination and DNA repair. The reaction was investigated using synthetic X-junctions. RecG dissociates X-junctions to flayed duplex products, although DNA unwinding of the heterologous arms is limited to less than or equal to 30 base pairs. Junction unwinding requires Mg2+ and the hydrolysis of ATP. X-junction DNA stimulates the ATPase activity of RecG;, ATPase activity is also stimulated by linear duplex DNA, although to a lesser extent than by X-DNA, but not by linear single-stranded DNA. In situ 1,10-phenanthroline-copper footprinting shows that RecG binds to the strand cross-over point at the center of the X-junction. Substrate recognition by RecG was investigated using DNAs that represented the various component parts of an X-junction. The minimal DNA structure that RecG forms a stable complex with is a flayed duplex, suggesting that this is the critical feature for junction recognition by RecG. Junction binding and unwinding also depend critically on the concentration of free Mg2+, excess free cation dramatically inhibiting both processes. These inhibitory effects are not mediated specifically by Mg2+; e.g. both Ca2+ and hexamminecobalt(III) chloride also inhibit X-junction binding and unwinding by RecG. The relative abilities of these cations to inhibit RecG-junction binding is correlated with their respective abilities to stack X-junction DNA From this we conclude that RecG is unable to bind or binds very poorly to fully stacked X-junctions.	Univ Oxford, Dept Biochem, Microbiol Unit, Oxford OX6 9FS, England; Univ Nottingham, Queens Med Ctr, Dept Genet, Nottingham NG7 2UH, England	University of Oxford; University of Nottingham	Whitby, MC (corresponding author), Univ Oxford, Dept Biochem, Microbiol Unit, S Parks Rd, Oxford OX6 9FS, England.	whitby@bioch.ox.ac.uk		Whitby, Matthew/0000-0003-0951-3374				AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; GiraudPanis MJE, 1996, J BIOL CHEM, V271, P33148, DOI 10.1074/jbc.271.51.33148; GRUBBS RD, 1987, MAGNESIUM, V6, P113; GUO Q, 1990, BIOCHEMISTRY-US, V29, P570, DOI 10.1021/bi00454a034; GUO Q, 1989, BIOCHEMISTRY-US, V28, P2355, DOI 10.1021/bi00432a001; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; HONG XK, 1995, EMBO J, V14, P2385, DOI 10.1002/j.1460-2075.1995.tb07233.x; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LLOYD RG, 1993, EMBO J, V12, P17, DOI 10.1002/j.1460-2075.1993.tb05627.x; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; LOHMAN TM, 1986, CRIT REV BIOCHEM MOL, V19, P191, DOI 10.3109/10409238609084656; LU M, 1990, BIOCHEMISTRY-US, V29, P1614, DOI 10.1021/bi00458a037; LU M, 1990, BIOCHEMISTRY-US, V29, P3407, DOI 10.1021/bi00465a038; Mahdi AA, 1997, NUCLEIC ACIDS RES, V25, P3875, DOI 10.1093/nar/25.19.3875; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; Miick SM, 1997, P NATL ACAD SCI USA, V94, P9080, DOI 10.1073/pnas.94.17.9080; MOLLEGAARD NE, 1994, EMBO J, V13, P1508; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; PANYUTIN IG, 1995, EMBO J, V14, P1819, DOI 10.1002/j.1460-2075.1995.tb07170.x; Parkinson MJ, 1997, J MOL BIOL, V270, P169, DOI 10.1006/jmbi.1997.1128; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; Pohler JRG, 1996, J MOL BIOL, V260, P678; PONTIGGIA A, 1993, MOL MICROBIOL, V7, P343, DOI 10.1111/j.1365-2958.1993.tb01126.x; PORSCHKE D, 1976, BIOPHYS CHEM, V4, P383, DOI 10.1016/0301-4622(76)80018-X; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; SHARPLES GJ, 1994, NUCLEIC ACIDS RES, V22, P308, DOI 10.1093/nar/22.3.308; SIGMAN DS, 1991, METHOD ENZYMOL, V208, P414; Vincent SD, 1996, J MOL BIOL, V264, P713, DOI 10.1006/jmbi.1996.0671; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671; West SC, 1996, J BACTERIOL, V178, P1237, DOI 10.1128/jb.178.5.1237-1241.1996; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WHITBY MC, 1995, EMBO J, V14, P3302, DOI 10.1002/j.1460-2075.1995.tb07337.x; WHITBY MC, 1993, CELL, V75, P341, DOI 10.1016/0092-8674(93)80075-P; WHITBY MC, 1994, EMBO J, V13, P5220, DOI 10.1002/j.1460-2075.1994.tb06853.x; Whitby MC, 1997, J MOL BIOL, V272, P509, DOI 10.1006/jmbi.1997.1286; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; White MF, 1997, J MOL BIOL, V266, P122, DOI 10.1006/jmbi.1996.0795	52	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 31	1998	273	31					19729	19739		10.1074/jbc.273.31.19729	http://dx.doi.org/10.1074/jbc.273.31.19729			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	106JB	9677403	hybrid			2022-12-27	WOS:000075125200055
J	Krebs, S; Lamas, JR; Poenaru, S; Folkers, G; de Castro, JAL; Seebach, D; Rognan, D				Krebs, S; Lamas, JR; Poenaru, S; Folkers, G; de Castro, JAL; Seebach, D; Rognan, D			Substituting nonpeptidic spacers for the T cell receptor-binding part of class I major histocompatibility complex-binding peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; MHC; MOLECULES; HLA-B27; ANTIGEN; ASSOCIATION; HLA-A2; HLA-B-ASTERISK-2705; BIOPOLYMERS; ANTAGONISTS	X-ray diffraction studies as well as structure-activity relationships indicate that the central part of class I major histocompatibility complex (MHC)-binding nonapeptides represents the main interaction site for a T cell receptor. In order to rationally manipulate T cell epitopes, three nonpeptidic spacers have been designed from the x-ray structure of a MHC-peptide complex and substituted for the T cell receptor-binding part of several antigenic peptides. The binding of the modified epitopes to the human leukocyte antigen-B*2705 protein was studied by an in vitro stabilization assay, and the thermal stability of all complexes was examined by circular dichroism spectroscopy. Depending on their chemical nature and length, the introduced spacers may be classified into two categories. Monofunctional spacers (11-amino undecanoate, (R)-3-hydroxybutyrate trimer) simply link two anchoring peptide positions (P3 and P9) but loosely contact the MHC binding groove and thus decrease more or less the affinity of the altered epitopes to human leukocyte antigen-B*2705, A bifunctional spacer ((R)-3-hydroxybutyrate tetramer) not only bridges the two distant anchoring amino acids but also strongly interacts with the binding cleft and leads to a 5-fold increase in binding to the MRC protein. To our knowledge, this is the first report of a nonpeptidic modification of T-cell receptor binding residues that significantly enhances the binding of altered peptide Ligands to their host MHC protein. The presented modified ligands constitute interesting tools for perturbing the T cell response to the parent antigenic peptide.	Swiss Fed Inst Technol, Dept Pharm, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Organ Chem Lab, CH-8092 Zurich, Switzerland; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, E-28049 Madrid, Spain	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Rognan, D (corresponding author), Swiss Fed Inst Technol, Dept Pharm, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	didier@pharma.ethz.ch	Rognan, Didier/B-9939-2014; Lamas, José Ramón/C-8318-2012	Lamas, José Ramón/0000-0003-1913-7261; Folkers, Gerd/0000-0002-3620-705X				BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Bouvier M, 1996, P NATL ACAD SCI USA, V93, P4583, DOI 10.1073/pnas.93.10.4583; BREWERTON DA, 1973, LANCET, V2, P994, DOI 10.1016/S0140-6736(73)91090-8; BROOKS JM, 1993, J EXP MED, V178, P879, DOI 10.1084/jem.178.3.879; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FALL K, 1991, NATURE, V351, P290; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fox T, 1997, J AM CHEM SOC, V119, P11571, DOI 10.1021/ja964315j; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia F, 1997, TISSUE ANTIGENS, V49, P215, DOI 10.1111/j.1399-0039.1997.tb02741.x; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P643; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HUET S, 1990, INT IMMUNOL, V2, P311, DOI 10.1093/intimm/2.4.311; ISHIOKA GY, 1994, J IMMUNOL, V152, P4310; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KINGSLEY G, 1993, IMMUNOL TODAY, V14, P387, DOI 10.1016/0167-5699(93)90139-C; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; MULLER HM, 1993, ANGEW CHEM INT EDIT, V32, P477, DOI 10.1002/anie.199304771; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NAGAI K, 1987, METHOD ENZYMOL, V131, P266; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PEARLMAN DA, 1995, AMBER 4 1; PLATTNER DA, 1993, HELV CHIM ACTA, V76, P2004, DOI 10.1002/hlca.19930760518; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; ROGNAN D, 1994, BIOCHEMISTRY-US, V33, P11476, DOI 10.1021/bi00204a009; Rognan D, 1997, J COMPUT AID MOL DES, V11, P463, DOI 10.1023/A:1007963901092; ROGNAN D, 1995, P NATL ACAD SCI USA, V92, P753, DOI 10.1073/pnas.92.3.753; ROTZSCHKE O, 1994, IMMUNOGENETICS, V39, P74; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; Schlegel HB., 2009, GAUSSIAN 09 REVISION; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Stryhn A, 1996, P NATL ACAD SCI USA, V93, P10338, DOI 10.1073/pnas.93.19.10338; Weiss GA, 1996, P NATL ACAD SCI USA, V93, P10945, DOI 10.1073/pnas.93.20.10945; WEISS GA, 1995, CHEM BIOL, V2, P401, DOI 10.1016/1074-5521(95)90221-X	51	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					19072	19079		10.1074/jbc.273.30.19072	http://dx.doi.org/10.1074/jbc.273.30.19072			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668090	hybrid			2022-12-27	WOS:000074974700057
J	Matoba, S; Ogrydziak, DM				Matoba, S; Ogrydziak, DM			Another factor besides hydrophobicity can affect signal peptide interaction with signal recognition particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; YEAST YARROWIA-LIPOLYTICA; EXTRACELLULAR PROTEASE; ENDOPLASMIC-RETICULUM; SECONDARY STRUCTURE; ESCHERICHIA-COLI; SEQUENCES; TRANSLOCATION; MUTATIONS; PLASMID	Translocation of alkaline extracellular protease (AEP) into the endoplasmic reticulum of Yarrowia lipolytica is cotranslational and signal recognition particle (SRP)dependent, whereas translocation of Firm AFP (proline to methionine at position 17, second amino acid in the pro-region) is posttranslational and SRP-independent. Firm signal peptide mutations that resulted in more rapid SRP-dependent translocation of AEP precursor were isolated. Most of these mutations significantly increased hydrophobicity, but the A12P/P17M mutation did not. The switch from SRP-dependent to SRP-independent translocation without a decrease in hydrophobicity (wild type to P17M) and restoration of SRP-dependent translocation without an increase in hydrophobicity (P17M to A12P/P17M) indicate that some factor(s) in addition to hydrophobicity determines selection of targeting pathway. Models of extended forms of wild type and A12P/P17M signal peptides are kinked, whereas the P17M signal peptide is relatively straight. Possibly the conformation/orientation of signal peptides at the ribosomal surface affects SRP binding and consequently the targeting route to the endoplasmic reticulum. Kinked signal peptides might approach SRP more closely more often. Most likely, these effects were only detectable because of the short length and low average hydrophobicity of the AEP signal peptide.	Univ Calif Davis, Inst Marine Resources, Davis, CA 95616 USA	University of California System; University of California Davis	Ogrydziak, DM (corresponding author), Univ Calif Davis, Inst Marine Resources, 1 Shields Ave, Davis, CA 95616 USA.	dmogrydziak@ucdavis.edu						BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BIRD P, 1990, J BIOL CHEM, V265, P8420; Brasseur R, 1997, TRENDS BIOCHEM SCI, V22, P167, DOI 10.1016/S0968-0004(97)01047-5; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ENDERLIN CS, 1994, YEAST, V10, P67, DOI 10.1002/yea.320100107; FIKES JD, 1987, J BACTERIOL, V169, P2345, DOI 10.1128/jb.169.6.2345-2351.1987; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; Lee IH, 1997, YEAST, V13, P499, DOI 10.1002/(SICI)1097-0061(199705)13:6<499::AID-YEA100>3.0.CO;2-M; Matoba S, 1997, MICROBIOL-UK, V143, P3263, DOI 10.1099/00221287-143-10-3263; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OGG SC, 1995, CELL, V81, P1075, DOI 10.1016/S0092-8674(05)80012-1; OGRYDZIAK DM, 1977, BIOCHIM BIOPHYS ACTA, V497, P525, DOI 10.1016/0304-4165(77)90209-4; Park CS, 1997, J BIOL CHEM, V272, P6876, DOI 10.1074/jbc.272.11.6876; RYAN JP, 1986, J BIOL CHEM, V261, P3389; Sambrook J., 2002, MOL CLONING LAB MANU; SHEEN J, 1993, CURRENT PROTOCOLS MO, V1; SIEGEL V, 1988, EMBO J, V7, P1769, DOI 10.1002/j.1460-2075.1988.tb03007.x; TOMILO M, 1994, J BIOL CHEM, V269, P32016; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WICKNER W, 1995, P NATL ACAD SCI USA, V92, P9433, DOI 10.1073/pnas.92.21.9433; XUAN JW, 1988, CURR GENET, V14, P15, DOI 10.1007/BF00405848; YAVER DS, 1992, J CELL BIOL, V116, P605, DOI 10.1083/jcb.116.3.605; Zheng N, 1996, CELL, V86, P849, DOI 10.1016/S0092-8674(00)80159-2	33	27	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 24	1998	273	30					18841	18847		10.1074/jbc.273.30.18841	http://dx.doi.org/10.1074/jbc.273.30.18841			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	103TV	9668059	hybrid			2022-12-27	WOS:000074974700026
J	Trybus, KM; Naroditskaya, V; Sweeney, HL				Trybus, KM; Naroditskaya, V; Sweeney, HL			The light chain-binding domain of the smooth muscle myosin heavy chain is not the only determinant of regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION-DEPENDENT REGULATION; SCALLOP MYOSIN; RESOLUTION; MEROMYOSIN; SEQUENCE; MOTOR	Interactions between the dephosphorylated regulatory light chains (RLCs) of smooth muscle myosin are involved in maintaining the enzymatically "off" state. Expressed chimeric smooth muscle heavy meromyosins containing skeletal muscle myosin heavy chain (HC) sequences were used to assess the relative importance of the light chain-binding domain (or "neck") to regulation. Surprisingly, regulation remained intact with a skeletal RLC-binding site. A chimera with the entire cu-helical neck composed of skeletal HC sequence showed a-fold regulation of motility and nearly 5-fold regulation of actin-activated ATPase activity. Complete activation of the dephosphorylated state (i.e. complete loss of regulation) occurred when skeletal HC sequence extended from the head/rod junction to the SH1-SH2 helix. Smooth muscle-specific sequences near the motor domain may therefore position the regulatory domain in a way that optimizes RLC-rod-head interactions, thus enabling a completely off state when the RLC is dephosphorylated. Conversely, a chimera that joins the motor domain from unconventional myosin V to the smooth muscle myosin neck and rod showed only a-fold regulation. The presence of the smooth muscle light chain-binding region and rod is therefore not sufficient to confer complete phosphorylation-dependent regulation upon all motor domains of the myosin family.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	Brandeis University; University of Pennsylvania	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, Given Bldg E207, Burlington, VT 05405 USA.		Sweeney, H Lee/F-1862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038113, R01HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035661] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38113] Funding Source: Medline; NIAMS NIH HHS [AR35661] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOLINA MI, 1987, J BIOL CHEM, V262, P6478; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Sata M, 1997, P NATL ACAD SCI USA, V94, P91, DOI 10.1073/pnas.94.1.91; SELLERS JR, 1985, J BIOL CHEM, V260, P5815; TRYBUS KM, 1989, J CELL BIOL, V109, P2879, DOI 10.1083/jcb.109.6.2879; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TRYBUS KM, 1997, P NATL ACAD SCI USA, V94, P46; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YANAGISAWA M, 1987, J MOL BIOL, V198, P143, DOI 10.1016/0022-2836(87)90302-0	19	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 17	1998	273	29					18423	18428		10.1074/jbc.273.29.18423	http://dx.doi.org/10.1074/jbc.273.29.18423			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	100RE	9660810	hybrid			2022-12-27	WOS:000074828500065
